<SEC-DOCUMENT>0001193125-20-010505.txt : 20200121
<SEC-HEADER>0001193125-20-010505.hdr.sgml : 20200121
<ACCEPTANCE-DATETIME>20200121062002
ACCESSION NUMBER:		0001193125-20-010505
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		49
FILED AS OF DATE:		20200121
DATE AS OF CHANGE:		20200121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-234363
		FILM NUMBER:		20534999

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d713200d424b4.htm
<DESCRIPTION>424(B)(4)
<TEXT>
<HTML><HEAD>
<TITLE>424(B)(4)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4) <BR>Registration No. 333-234363 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>7,407,400 American Depositary Shares </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g25k48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Representing 17,037,020 Ordinary Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">This is an initial
public offering of 7,407,400 American depositary shares (the &#147;ADSs&#148;), by <FONT STYLE="white-space:nowrap">I-Mab.</FONT> Each ten (10) ADSs represent twenty-three (23) of our ordinary shares, par value US$0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">Prior to this offering, there has been no public market for the ADSs or our shares. The ADSs have been approved for listing on the Nasdaq Global Market under the symbol
&#147;IMAB.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; under applicable U.S. federal securities laws and are eligible for reduced public company reporting
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">On November 4, 2019, we terminated the collaboration agreement with Everest Medicines Limited, or Everest, in order to retain full rights of TJ202 in
Greater China and maximum flexibility for product development towards commercialization. We will issue a total value of US$37.0 million of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing Everest&#146;s historical contribution
to our collaboration and the associated time cost. The CPP shares will be issued concurrently with, and subject to, the completion of this offering within 180 days from termination of the collaboration agreement, at a per share price equal to the
initial public offering price adjusted to reflect the ADS-to-ordinary share ratio. Based on the initial public offering price of US$14.00 per ADS (or US$6.09 per ordinary share), Everest will be issued 6,078,571 ordinary shares and become a minority
shareholder of our company upon the completion of this offering. See also &#147;The Offering&#151;Concurrent Private Placement&#148; for more details. Our issuance of ordinary shares to Everest is being made pursuant to an exemption from
registration with the U.S. Securities and Exchange Commission under Regulation S of the U.S. Securities Act of 1933. Everest has agreed not to, directly or indirectly, sell, transfer or dispose of any CPP Share for a period of 180 days after the
date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">Several existing shareholders have subscribed for and have been allocated by the underwriters an aggregate of 2,055,000 ADSs in this
offering (representing 27.7% of the ADSs being offered in this offering) at the initial public offering price and on the same terms as the other ADSs being offered, among which each of C-Bridge II Investment Thirteen Limited, an affiliate of one of
our principal shareholders, and Genexine Inc., has subscribed for and has been allocated 150,000 and 570,000 ADSs, respectively. The underwriters will receive the same underwriting discounts and commissions on any ADSs purchased by these parties as
they will on any other ADSs sold to the public in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL"><B>Investing in our ADSs involves risks. See &#147;<A HREF="#rom713200_4">Risk Factors</A>&#148;
beginning on page 19 for factors you should consider before buying the&nbsp;ADSs. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL"><B>Neither the United States Securities and Exchange Commission nor any other
regulatory body has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>PRICE US$14.00 PER ADS </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">14.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">103,703,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">0.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">7,259,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">13.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">96,444,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">For a description of compensation payable to the underwriters, see &#147;Underwriting.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">We have granted the underwriters an option to purchase up to an additional 1,111,110 ADSs within 30 days from the date of this prospectus at the initial public offering
price, less the underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">The underwriters expect to deliver the ADSs against payment in U.S. dollars in New York, New York on or
about January 22, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:19pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:18pt">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:19pt"><B>Jefferies</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>CICC</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.09em; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>China&nbsp;Renaissance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-right:8.00em; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Huatai&nbsp;Securities</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center">Prospectus dated January 16, 2020. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_3">SUMMARY CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_8">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_9">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_10">ENFORCEABILITY OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_11">CORPORATE HISTORY AND STRUCTURE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_12">SELECTED CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_13">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_14">INDUSTRY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_15">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_16">REGULATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_17">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_18">PRINCIPAL SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_19">RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_20">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_21">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_22">SHARES ELIGIBLE FOR FUTURE SALES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_23">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_24">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_25">EXPENSES RELATED TO THIS OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_26">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_27">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_28">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#rom713200_29">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should rely only on the information contained in this prospectus or in any related free writing prospectus. We
have not authorized anyone to provide you with information different from that contained in this prospectus or in any related free writing prospectus. We are offering to sell, and seeking offers to buy the ADSs, only in jurisdictions where offers
and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the&nbsp;ADSs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we have nor any of the underwriters has taken any action to permit a public offering of the ADSs outside the United&nbsp;States or to permit the possession or
distribution of this prospectus or any filed free writing prospectus outside the United&nbsp;States. Persons outside the United&nbsp;States who come into possession of this prospectus or any filed free writing prospectus must inform themselves about
and observe any restrictions relating to the offering of the ADSs and the distribution of this prospectus or any filed free writing prospectus outside the United&nbsp;States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Until February 10, 2020 (the 25th day after the date of this prospectus), all dealers that buy, sell or trade ADSs, whether or not participating in this offering,
may be required to deliver a prospectus. This is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial statements appearing
elsewhere in this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the risks of investing in our ADSs discussed under &#147;Risk Factors,&#148; before deciding whether to invest in our ADSs.
This prospectus contains information from an industry report commissioned by us and prepared by Frost&nbsp;&amp; Sullivan, an independent research firm, to provide information regarding our industry and our market position. We refer to this report
as the Frost&nbsp;&amp; Sullivan Report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical
stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were founded to capture the opportunities presented by the confluence of two major developments&#151;the emergence of an attractive and growing biologics market in
China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding
of China&#146;s biologics regulatory framework and our direct access to extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative pipeline of more than 10 clinical
and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage assets through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global pharmaceutical and biotech companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commercial Opportunities in China and Our Unique Position </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are fully
aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China, including need to raise significant capital, significant competition from global and other China-based biopharmaceutical
companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential implementation challenges and uncertainties of the recent government reform of the drug approval system. However, with these
challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional aspects of our drug development process to proactively deal with some of the regulatory challenges mentioned above.
Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel with the regulatory agencies to discuss and resolve various regulatory issues promptly and effectively. We see vast
opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence and mortality of cancers in China have been increasing in recent years and are outpacing those in the United States and the rest of the world.
Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States and Europe are not yet available in China. Third, the Chinese government has implemented new policies and regulations to simplify the review and
approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth, there has been a continuous and rapid increase in personal disposable income in China coupled with ongoing improvement in basic national health
insurance coverage, making innovative biologics more accessible to more Chinese patients. According to the Frost&nbsp;&amp; Sullivan Report, China&#146;s biologics market is growing faster than the global biologics market and is expected to reach
approximately RMB1.3 trillion (US$181.9 billion) by 2030 in terms of sales revenue. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe we are uniquely positioned as a China-based global player to tap
into these vast commercial opportunities. This is best demonstrated by our short journey in becoming one of the top clinical stage immunology companies in China. According to the Frost &amp; Sullivan Report, we are ranked as top clinical stage
China-based immunology companies as measured by the innovative quality and number of investigational </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
drugs and drug candidates under clinical and pre-clinical development in our pipeline, amount of pre-IPO financing raised (in excess of US$400 million in three years), pre-IPO valuation and
recognition and awards earned in the biotech industry. For example, in 2018 and 2019, we are the only China-based biotech company recognized by Genetic Engineering &amp; Biotechnology News (GEN) as a top 10 immuno-oncology start-up in the world. To
date, our research and development capabilities encompass discovery, translational medicine, biologics CMC development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical development with footprints in Shanghai, Beijing
and the United States. We are now at a critical juncture to transition from a clinical stage biotech company into a fully integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical
company in the next few years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Unique Business Model </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To achieve
our mission and capitalize on these commercial opportunities, we have developed a business model built on two pillars: a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy and a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> (proof of concept) global strategy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Strategy </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy focuses on seeking opportunities to <FONT STYLE="white-space:nowrap">in-license</FONT> the development and commercialization rights of
investigational drugs from global biopharmaceutical companies for Greater China. We only select investigational drugs that have the potential to become novel or highly differentiated medicines. Through our substantial
<FONT STYLE="white-space:nowrap">in-house</FONT> research and development efforts, we build additional data packages to meet the requirements of the National Medical Products Administration (the &#147;NMPA&#148;) to ensure programs are ready for
late-stage or registrational clinical development. Our internal development capabilities combined with our deep insight into China&#146;s regulatory framework and our clinical network enable us to efficiently navigate through the drug development
process to registration. To date, we have built an innovative China Portfolio consisting of five investigational drugs with an aim for near-term product launch. All of these investigational drugs have met the related pre-set safety and preliminary
efficacy endpoints in Phase 1 or Phase 2 clinical trials in Europe, the United States or elsewhere and are either in or ready for Phase 2 or Phase 3 clinical trials in China. TJ202 is undergoing two registrational trials, including a third-line
monotherapy trial and a second-line combination therapy trial, in multiple myeloma in Greater China. In addition, we submitted an IND application to the NMPA in October 2019 for a Phase 1b trial for TJ202 in systemic lupus erythematosus
(&#147;SLE&#148;). For TJ101, we are working towards submitting an IND application in 2020 for a Phase 3 registrational trial in China. For enoblituzumab, we expect to submit an IND application in 2020 for a registrational trial or a Phase 2 trial.
As a result, the investigational drugs in our China Portfolio are positioned for a series of new drug applications (NDAs) in China with the submission of the first NDA expected in 2021. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> Global Strategy </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy focuses on advancing our own novel or differentiated
biologics towards clinical validation in the United States. First, we seek PoC of these drug candidates in the United&nbsp;States by conducting early phase clinical trials with a set of safety and efficacy endpoints and leveraging the FDA&#146;s
streamlined regulatory system for innovative drug development, including a predictable timeline towards IND approval. Second, we will use the data generated to advance clinical development in China, which we believe confers several advantages,
including access to China&#146;s large patient pool, extensive clinical trial resources through collaborations with leading hospitals in China, and a regulatory pathway for fast-track approval of drugs supported by solid overseas clinical data.
Building on this approach, we may <FONT STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of these investigational drugs following clinical validation in the United States, while retaining the Greater China
rights for further development and commercialization. We believe this approach will allow Chinese patients to benefit from our most advanced treatments concurrently or soon after their market approvals elsewhere. To date, we have created a Global
Portfolio that consists of two molecular classes&#151;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, which are internally generated. They are highly innovative molecules compared to global competitor assets
in the same or related classes of drug candidates. Three investigational drugs in our Global Portfolio (TJM2, TJC4 and TJD5) are in Phase 1 trials in the United States. Having obtained IND approvals from the NMPA for TJC4, TJD5 and TJM2, we have
initiated a Phase 1 trial for TJC4 and expect to initiate Phase 1 trials for TJD5 and TJM2 in China in early 2020. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These two strategies and the resulting two portfolios complement each other. This enables us to achieve a balance
among our ambition to develop novel or highly differentiated drugs, our goal to efficiently advance our pipeline assets towards commercialization and the inherent development risks. With this goal in mind, we are also aware that the intended novelty
and key differentiation of our investigational drugs or drug candidates are subject to pivotal clinical validation and approval by the relevant regulatory authorities. There is no assurance that any such investigational drug or drug candidate will
receive regulatory approval. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Capabilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Innovative Discovery Expertise </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Built by an elite group of seasoned immunologists with extensive academic research and drug development experience, our discovery engine has generated a panel of
internally developed innovative drug molecules in a short span of four years. Among them, 11 innovative drug molecules have met our standard of novelty or high differentiation and have advanced toward further development. This achievement is a
testament to our discovery team&#146;s acumen and technical prowess in translating target biology into points of innovation or differentiation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The discovery of
TJC4 showcases our innovative research capabilities. Not settling on performing routine or traditional antibody screening, we set a specific goal to identify and select a unique CD47 antibody that is free from binding to red blood cells (RBC) from
all CD47 antibody leads. As a result, we selected by design, our proprietary CD47 antibody (TJC4) with a rare epitope that uniquely spares binding to RBCs as a differentiation point from other CD47 antibodies that typically cause inherent
hematologic side effects. Having confirmed the RBC-sparing property in a series of in vitro assays as well as multiple monkey studies, we are conducting a Phase 1 clinical trial for TJC4 in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Another example of our R&amp;D capability relates to our novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel that represents a new wave of oncology
drug candidates. We created novel biological properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies that are capable of enriching immune cells in tumors through dual targeting of
<FONT STYLE="white-space:nowrap">PD-L1</FONT> and immune cells for a synergistic anti-tumor effect. These <FONT STYLE="white-space:nowrap">bi-specific</FONT> drug candidates have been shown to exhibit unique properties that render tumors more
responsive to treatment. Our discovery expertise, when combined with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;fit-for-purpose&#148;</FONT></FONT> antibody engineering technology platforms, becomes a powerful engine
of innovation to create novel molecules. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fit-for-Purpose</FONT></FONT> Technology
Platforms </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our proprietary antibody engineering platforms enable us to accurately capture the biological properties of
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies and retain good manufacturability and druggability of the molecules. To date, we have created seven novel <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage <FONT
STYLE="white-space:nowrap">bi-specific</FONT> drug molecules. In addition to our own <FONT STYLE="white-space:nowrap">Ig-scFv</FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody platform, we partnered with ABL Bio and WuXi Biologics
to access their antibody engineering platforms in order to increase the probability of success, as different molecular configurations require different technologies. Furthermore, our proprietary antibody-cytokine technology has enabled another form
of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies such as <FONT STYLE="white-space:nowrap">TJ-L1I7</FONT> and <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> that link a tumor-engaging antibody with an immuno-modulatory cytokine.
Superior to monoclonal antibodies or cytokines alone, this class of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies has demonstrated unique properties capable of concentrating the drug molecules in tumors for a desired target effect
with reduced systemic toxicity of cytokines or creating biologic synergy that can potentially translate into better treatment outcome. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Biomarker-Enabled
Translational Medicine Capabilities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As we focus on developing innovative drug molecules, the ability to apply relevant biomarkers that link a drug response
to treatment effects is critical for early-stage clinical trials of our investigational drugs. This translational medicine capability requires cross-functional knowledge and unique skills to link the target biology of an investigational drug to
clinical responses. We have been developing tailor-made biomarkers for each of our investigational drugs, which are used to select potential responders, predict and measure target </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
engagement, support dose determination and enable timely informed decisions on advancing our assets to the next phase of clinical development. For example, for the development of TJD5, we intend
to use CD73 in tumor tissue in combination with other tumor biomarkers to stratify potential target patient populations in our clinical trial. To that end, we have developed assays to measure CD73 expression and activity in tumor tissues.
Furthermore, we have developed specialized assays to measure TJD5 drug concentrations in tumor tissues. By linking drug concentration with its activity in the same tumor location, these data help us determine appropriate dose selection for further
clinical studies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Clinical Development Capabilities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
clinical development is led by a global team of clinical scientists, industry physicians and experts in portfolio management, quantitative science, clinical operations, drug safety and quality control. Our clinical team accounts for approximately
80% of our entire R&amp;D organization&#146;s headcount and 80% of our budget allocation. The skillset of our clinical development team is highlighted by a combination of extensive global pharma, local drug development and operation experiences with
clinical networks in China and the United States. The team is driven by high ethical standards, with passion for improving the lives of patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team has the
ability to integrate internal core development functions to conduct global and local clinical trials. We also effectively leverage external resources, including clinical contract research organizations, academic clinical centers and/or networks, and
global pharmaceutical or biotech partnerships. Furthermore, we have established and implemented a robust internal clinical governance system and processes to safeguard patient safety and data integrity. Our current clinical development functions and
teams are strategically based in Shanghai, Beijing, and the United States to cover Phase 1 through Phase 3 clinical trials in China and early-stage clinical trials in the United&nbsp;States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical development capabilities are best demonstrated by the rapid implementation of eight ongoing clinical trials, including five Phase 1/2 and registrational
trials in Greater China and three Phase 1 trials in the United States within the past three years. To ensure regulatory approval and subsequent product launch as currently planned, we strive to reach the following critical clinical milestones by the
end of 2020: 11 active clinical programs consisting of two Phase 3 or registrational trials in China, two Phase 2 trials in China and seven Phase 1 trials in the United States and China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Global Strategic Collaborations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have established an excellent track
record of <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals with our global and regional partners. These <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals enable us to
acquire multiple innovative clinical stage assets with favorable clinical data packages. We have quickly built our China Portfolio through <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals with global biotech partners, including MorphoSys,
Genexine, MacroGenics and Ferring (as the sublicensee under our agreement with Ferring related to olamkicept TJ301). Over the past three years, we have established more than 10 global and regional partnerships with reputable pharma or biotech
companies. Our partners selected us among many China-based companies with the belief that we are an ideal partner in China given our strength in science and drug development capability, our outstanding track record of execution of rapidly
progressing drug development programs in China and the United States and our vision and network to tap into business opportunities and the growing pharmaceutical market in China. For example, MorphoSys, MacroGenics and Genexine all stated that we
are an ideal or the best partner in China in their press releases or public announcements. The <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals enable us to streamline our pipeline and focus our resources on the most valuable assets. In
addition, we seek <FONT STYLE="white-space:nowrap">co-development</FONT> opportunities to share development costs and risks and territorial commercial rights with our partners. In the past two years, we have
<FONT STYLE="white-space:nowrap">out-licensed</FONT> three <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets and initiated four <FONT STYLE="white-space:nowrap">co-development</FONT> programs with partners such as ABL Bio and WuXi
Biologics. The revenue from <FONT STYLE="white-space:nowrap">out-licensing</FONT> and <FONT STYLE="white-space:nowrap">co-development</FONT> deals is expected to continue to grow as our pipeline progresses. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Drug Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
chart below summarizes the development status of our drug pipeline. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g95n07.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman; " COLOR="#3d72ff"><FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#233;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">(i) For TJ202, it has two ongoing registrational trials, a monotherapy trial and a combination therapy trial in multiple myeloma in Greater China, and we expect to initiate a Phase 1b trial in systemic lupus
erythematosus (&#147;SLE&#148;) in 2020; (ii) for TJ101, we are working towards submitting an IND application in 2020 for a Phase 3 registrational trial in China; and (iii)&nbsp;for enoblituzumab, we expect to submit an IND application in 2020 for a
registrational trial or a Phase 2 trial. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We were collaborating with Everest Medicines Limited (&#147;Everest&#148;) to co-develop and commercialize TJ202 in Greater China for all indications in hematologic oncology. Everest was primarily responsible for
sharing with us, by the proportion of 75% for Everest and 25% for us, the development costs of TJ202. On November 4, 2019, we and Everest terminated the collaboration agreement (including all the supplements and amendments thereto) with respect to
the co-development and commercialization of TJ202 in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its commercialization. All intellectual
property rights in respect of TJ202 arising from its development under the collaboration agreement are vested and owned by us, and we hold all intellectual property rights and have maximum flexibility to further develop, manufacture and
commercialize TJ202 in Greater China. In consideration of the above arrangements, we will issue a total value of US$37.0 million of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing Everest&#146;s historical contribution to our
collaboration and the associated time cost. The CPP Shares will be issued concurrently with, and subject to, the completion of this offering within 180 days from termination of the collaboration agreement, at a per share price equal to the initial
public offering price adjusted to reflect the ADS-to-ordinary share ratio. In the event that this offering has not been completed within 180 days from the termination of the collaboration agreement, we will issue 4,762,751 ordinary shares to Everest
on the 181st day. See also &#147;The Offering&#151;Concurrent Private Placement&#148; for more details. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">**</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel consists of (i)&nbsp;four <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT>
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, including <FONT STYLE="white-space:nowrap">TJ-L1C4</FONT><B> </B><FONT STYLE="white-space:nowrap">(PD-L1</FONT> and CD47), <FONT STYLE="white-space:nowrap">TJ-L1H3</FONT> <FONT
STYLE="white-space:nowrap">(PD-L1</FONT> and <FONT STYLE="white-space:nowrap">B7-H3),</FONT> <FONT STYLE="white-space:nowrap">TJ-L14B</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> and <FONT STYLE="white-space:nowrap">4-1BB)</FONT> and
TJ-L1I7 (anti-PD-L1 and IL-7 cytokine fusion), <FONT STYLE="white-space:nowrap">(ii)&nbsp;TJ-C4GM</FONT> (anti-CD47 and <FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine fusion), and <FONT STYLE="white-space:nowrap">(iii)&nbsp;TJ-CLDN4B</FONT>
(Claudin 18.2 and <FONT STYLE="white-space:nowrap">4-1BB).</FONT> </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Highlights of Our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Portfolio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy is demonstrated by our China Portfolio, which consists of novel or highly differentiated investigational drugs. TJ202, TJ107, enoblituzumab
and TJ101 are the four anchor assets in our China Portfolio. While we have been diligently pursuing our fast-to-market China strategy, we are aware that there is no assurance that we will always be successful in commercializing any of our product
candidates in our </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
China Portfolio in an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ202 is a differentiated CD38 antibody originally developed by MorphoSys that meets the pre-set clinical safety and preliminary efficacy endpoints from a clinical
trial conducted in the European Union (EU). <FONT STYLE="white-space:nowrap">In-licensed</FONT> from MorphoSys, TJ202 is being developed to address the current unmet needs and commercial opportunities in China for multiple myeloma and potentially
autoimmune diseases, such as SLE. We own an exclusive license to develop TJ202 in Greater China. We believe TJ202, if approved, is potentially highly differentiated compared with the currently marketed CD38 antibody. First, under a similar <FONT
STYLE="white-space:nowrap">pre-medication</FONT> condition with dexamethasone, anti-pyretics and anti-histamines, TJ202 has demonstrated a significantly shorter infusion time and lower infusion reaction rate. Second, unlike the currently marketed
CD38 antibody, TJ202 does not down-regulate CD38 expression on the surface of bone marrow myeloma cells in vitro, maintaining sensitivity of myeloma cells to TJ202 for repeated treatments. TJ202 is undergoing a registrational trial as a third-line
monotherapy and a registrational trial in combination with lenalidomide as a second-line therapy, both in patients with multiple myeloma in Greater China. We aim to submit an NDA for TJ202 as a third-line monotherapy in 2021, followed by another NDA
submission for TJ202 as a second-line combination therapy. Moreover, we believe TJ202 has great market potential in the treatment of pathogenic antibody-mediated autoimmune diseases, such as SLE, where there is a significant unmet need for more
effective therapies. Additionally, we submitted an IND application to the NMPA in October 2019 for a Phase 1b trial for TJ202 in SLE. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ107 is the first
long-acting recombinant human IL-7 known to boost cancer-fighting T lymphocytes by increasing their number and function and is being developed as a potential oncology investigational drug. The clinical safety and effect of TJ107 on T cells have been
investigated in multiple previous and ongoing clinical trials in South Korea and the United States. TJ107 is being positioned to address a huge unmet medical need in oncology. First, TJ107 can be an oncology-care agent to treat cancer
treatment-related lymphopenia (low blood lymphocyte levels), a common condition that occurs in cancer patients who have received chemotherapy or radiation therapy, and there is no approved treatment for this condition. According to the
Frost&nbsp;&amp; Sullivan Report, in Greater China, the incidence of lymphopenia reached 1.5&nbsp;million in 2018 and is estimated to increase to 1.7&nbsp;million in 2023 and further to 2.0&nbsp;million in 2030. This condition causes further damage
to patients&#146; already compromised immune system and weakens its ability to fight cancers. Second, TJ107 has been shown to synergize with a PD-1 antibody in a tumor animal model potentially through increased T lymphocyte activation and
proliferation. We are conducting a Phase 1b trial in China to determine a suitable dose range for subsequent trials. We expect to start a Phase 2 trial in cancer patients in 2020. We are coordinating our study globally with Genexine, which is
conducting a Phase 2 clinical trial in South Korea and parallel clinical trials in the United States towards clinical PoC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enoblituzumab is a humanized antibody
directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> a member of the B7 family of T cell checkpoint regulators that is widely expressed across multiple tumor types and plays a key role in the regulation of immune response against cancers.
Similar to other inhibitors of the B7 family such as <FONT STYLE="white-space:nowrap">PD-L1,</FONT> targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> potentially provides a treatment option for a variety of cancers expressing <FONT
STYLE="white-space:nowrap">B7-H3.</FONT> Enoblituzumab was originally developed by MacroGenics, and we own the Greater China rights of this investigational drug. In multiple clinical trials conducted by MacroGenics, when combined with pembrolizumab
in recurrent or metastatic squamous cell carcinoma of the head and neck (&#147;SCCHN&#148;) and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;), enoblituzumab has shown favorable clinical results that warrant
further investigation. We expect to submit an IND application in 2020 for a registrational trial or a Phase 2 trial. Further clinical development is being planned together with MacroGenics to extend to other cancer indications in China and globally.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ101, if approved, is a potential highly differentiated long-acting human growth hormone that is being developed as a weekly treatment for pediatric growth
hormone deficiency as compared to currently available daily regimens of recombinant human growth hormone (rhGH). TJ101 was originally developed by Genexine, and we own the Greater China rights of this product, which has the potential to address an
important clinical </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
need and to cover a significant market gap in pediatric growth hormone deficiency. According to the Frost&nbsp;&amp; Sullivan Report, there are approximately 3.4&nbsp;million pediatric patients
with growth hormone deficiency in 2018 in Greater China, but only 3.7% of them receive growth hormone therapies, which are mostly daily regimens. In a previous Phase 2 trial conducted by Genexine in South Korea and the EU, both weekly and <FONT
STYLE="white-space:nowrap">bi-weekly</FONT> administration of TJ101 demonstrated similar therapeutic effects to daily injection of Genotropin, a short-acting rhGH. We are working towards submitting an IND application in 2020 for a Phase 3
registrational trial in China. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Highlights of Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> Global Portfolio
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy is demonstrated by our Global Portfolio,
which mainly consists of our internally developed novel or differentiated biologics. Our Global Portfolio focuses on two molecular classes&#150;&#150;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. While we
have been diligently pursuing our fast-to-PoC global strategy, we are aware that there is no assurance that we will always be successful in achieving PoC or pivotal development milestones for any of our product candidates in our Global Portfolio in
an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Monoclonal antibodies</I>&#151;Among the five monoclonal antibody drug candidates, TJM2, TJC4 and TJD5 are undergoing Phase 1 clinical trials in the United States.
Having obtained IND approvals from the NMPA for TJC4, TJD5 and TJM2, we have initiated a Phase 1 trial for TJC4 and expect to initiate Phase 1 trials for TJD5 and TJM2 in China in early 2020. In addition, we are collaborating with Shanghai Junshi
Biosciences Co., Ltd, or Junshi, to conduct clinical trials of the combination therapy of TJD5 and Junshi&#146;s PD-1 monoclonal antibody toripalimab in cancer patients with various types of solid tumors. We have not initiated any research and
development activities under such collaboration arrangement as of the date of this prospectus. TJ210 and TJX7 are at the CMC stage and are expected to be ready for IND submissions in 2020 for Phase 1 clinical trials in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJC4 is an internally discovered, fully human monoclonal antibody targeting CD47, which is one of the most promising immuno-oncology targets after <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1.</FONT></FONT> Blocking CD47 activates tumor-engulfing macrophages, a component of the innate immune system as an important cancer-fighting mechanism. CD47 antibodies are being
actively pursued in clinical trials by a few global companies. However, current development efforts on CD47 antibody drugs are hampered by hematologic side effects (such as anemia) due to binding to human RBCs. For example, at least two clinical
trials conducted by other companies have been suspended. Unlike competitor investigational drugs, TJC4 is a rare antibody originally selected, by design, to purposefully avoid or minimize binding to RBCs while maintaining a high antibody affinity
and tumor killing properties. TJC4&#146;s unique property of minimal RBC binding and no significant hematologic changes has been extensively validated in a whole series of robust in vitro assays and primate studies. In a GLP toxicology study
involving 40&nbsp;monkeys, no hematologic side-effects were seen even with repeated injections of 100 mg/kg doses. This unique property may enable TJC4 to be used safely in a broader patient population to explore its treatment potential in cancers,
differentiating it from other clinical stage CD47 investigational antibody drugs. TJC4 is being evaluated in a Phase 1 clinical trial with cancer patients in the United States. In parallel, leveraging the Phase 1 data generated in the United States,
we plan to begin a Phase 1 clinical trial of TJC4 in patients with hematologic malignancies, such as AML/MDS, by early 2020 in China. In addition, we are collaborating with Merck Sharp &amp; Dohme Corp, or MSD, in a Phase 1 clinical trial in the
United States for the combination therapy of TJC4 and MSD&#146;s PD-1 inhibitor KEYTRUDA (pembrolizumab) in cancer patients with several types of solid tumors. We have not initiated any research and development activities under such collaboration
arrangement as of the date of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibody panel</I>&#151;This novel antibody class represents
an emerging and fast-moving area of new drug discovery. <FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibodies are typically constructed to have a dual specificity of two selected antibodies or combined properties of an antibody linked with
a cytokine, previously called an immuno-cytokine. According to the Frost&nbsp;&amp; Sullivan Report, checkpoint inhibitors targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> had global sales of
US$16.3 billion in 2018 and are predicted to reach US$63.4 billion in global sales by 2030. However, despite the recent </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
success of checkpoint inhibitors, clinical efficacy of these drugs has been unsatisfactory. It is estimated that over 60% of cancer patients, including those with melanoma, renal cell cancer,
colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, urothelial cancer and head and neck squamous cell carcinoma, do not respond to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> monotherapies. In addition, some patients develop resistance after initial treatment with these therapies. As a result, the standard of care today leaves many
cancer patients underserved. There is consensus among cancer immunologists that tumors that do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment have poor immunologic features, such
as an absence or paucity of tumor-fighting immune cells or the presence of dysfunctional immune cells within the tumors, collectively known as &#147;cold tumors.&#148; We believe that
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> <FONT STYLE="white-space:nowrap">non-responders</FONT> can be better treated with novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. The
unique and superior properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies over <FONT STYLE="white-space:nowrap">PD-L1</FONT> inhibitors alone stem from a second targeting component attached to the <FONT
STYLE="white-space:nowrap">PD-L1</FONT> antibody moiety of the <FONT STYLE="white-space:nowrap">bi-specific</FONT> molecules, thereby enabling them to elicit a sufficient immune response and converting a &#147;cold tumor&#148; to an immune-active
&#147;hot tumor.&#148; Such unique properties of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies cannot be substituted by a combination of the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody with a selected second component
(either cytokine or antibody) in a free form. The underlying mechanism is such that the second component must be structurally integrated with the tumor-engaging <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody in order to concentrate and
function inside the tumor, which cannot be readily achieved by the two free agents used in combination. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have successfully generated a panel of four <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies in which our proprietary <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody acts as the backbone (the first signal) and is linked with various second components (the second signal)
including a <FONT STYLE="white-space:nowrap">4-1BB</FONT> agonist antibody <FONT STYLE="white-space:nowrap">(TJ-L14B),</FONT> a <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody <FONT STYLE="white-space:nowrap">(TJ-L1H3),</FONT> a CD47 antibody
<FONT STYLE="white-space:nowrap">(TJ-L1C4)</FONT> and an IL-7 cytokine (TJ-L1I7), which are shown to work synergistically with the <FONT STYLE="white-space:nowrap">PD-L1</FONT> backbone in various assays and cancer animal models. This unique panel
of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies is only made possible by our proprietary and partnered antibody engineering technologies and the availability of our proprietary monoclonal antibodies. Furthermore, we have generated
two other <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies <FONT STYLE="white-space:nowrap">(TJ-C4GM</FONT> and <FONT STYLE="white-space:nowrap">TJ-CLDN4B)</FONT> that are tailor-made to function as novel fortified antibodies by
linking TJC4 with an engineered <FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine for the treatment of solid tumors and by linking our <FONT STYLE="white-space:nowrap">Claudin-18.2</FONT> antibody with a
<FONT STYLE="white-space:nowrap">4-1BB</FONT> antibody as a unique gastric cancer treatment agent that only activates T cells conditionally upon tumor engagement. All <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies have been validated
in a series of robust <I>in vitro</I> and <I>in vivo</I> studies for biology <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> providing a solid basis for clinical validation in cancer patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to achieve our goal by pursuing the following
strategies: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rapidly advance our China Portfolio towards commercialization. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Expand our research and development capabilities and footprint in the United States to advance our Global Portfolio.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Build our manufacturing capabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Maximize the value of our pipeline. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Challenges </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Investing in our ADSs involves risks. If any of these risks
actually occurs, our business, financial condition or results of operations would likely be materially adversely affected. In such case, the trading price of our ADSs would likely decline, and you may lose all or part of your investment. The
following is a summary of some of the principal risks that we face: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have a limited operating history, which may make it difficult to evaluate our current business and predict our future
performance. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We recorded net cash outflow from operating activities since our inception. We may need to obtain additional financing to
fund our operations, and if we are unable to obtain such financing, we may be unable to complete the development and commercialization of our major drug candidates. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We depend substantially on the success of our investigational drugs and drug candidates, all of which are in clinical or
pre-clinical development, respectively, and our ability to identify additional investigational drugs and drug candidates. If we are unable to successfully identify new investigational drugs or drug candidates, complete clinical development, obtain
regulatory approval and commercialize them, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may not be able to identify, discover or <FONT STYLE="white-space:nowrap">in-license</FONT> new drug candidates, and
may allocate our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable, or for which there is a greater likelihood of success.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Even if we receive regulatory approval for our drug candidates, we will be subject to ongoing regulatory obligations and
continued regulatory review, which may result in significant additional expenses and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our drug candidates.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and
others in the medical community necessary for commercial success. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">As we rely on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical
trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and
our business could be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If we are unable to obtain and maintain patent and other intellectual property protection for our drug candidates, or if
the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, and our ability to successfully
commercialize any product or technology may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Changes in the political and economic policies of the PRC government may materially and adversely affect our business,
financial condition and results of operations and may result in our inability to sustain our growth and expansion strategies.</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Please see
&#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements&#148; and other information included in this prospectus for a discussion of these and other risks and uncertainties that we face. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate History and Structure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We commenced our operations in November
2014, when our predecessor Third Venture Biopharma (Nanjing) Co., Ltd (&#147;Third Venture&#148;) was established. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT>
was established in June 2016 under the laws of the Cayman Islands as our offshore holding company. In July 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> established <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited <FONT
STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hong Kong&#148;), as its intermediary holding company. In August 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong established a wholly-owned PRC subsidiary,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;). In September 2016, the assets and operations of Third Venture were consolidated into <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Shanghai. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired a controlling interest in <FONT
STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;), formerly known as Tasgen
<FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd., a company focused on CMC management of biologics in China. Through an internal corporate restructuring, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin became the 100% owner
of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai in September 2017 and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired the remaining interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018, becoming
the 100% owner of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong established in
Maryland, United States, a wholly-owned subsidiary <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> US&#148;), as the hub for the discovery and development of the drug candidates
in our Global Portfolio. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following diagram illustrates our corporate structure, including our principal subsidiaries, as of the date of
this prospectus: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g69u35.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implication of Being an Emerging Growth Company </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a company with less than
US$1.07&nbsp;billion in revenue for our last fiscal year, we qualify as an &#147;emerging growth company&#148; pursuant to the Jumpstart Our Business Startups Act of 2012, as amended (the &#147;JOBS Act&#148;). An emerging growth company may take
advantage of specified reduced reporting and other requirements compared to those that are otherwise applicable generally to public companies. These provisions include an exemption from the auditor attestation requirement under Section&nbsp;404 of
the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#146;s internal control over financial reporting. The JOBS Act also provides that an emerging growth company does not need to comply with any new or revised financial
accounting standards until such date that a private company is otherwise required to comply with such new or revised accounting standards. However, we have elected to &#147;opt out&#148; of this provision and, as a result, we will comply with new or
revised accounting standards as required when they are adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will remain an emerging growth company until the earliest of (a)&nbsp;the last day of the fiscal year during which we have total annual gross revenues of at least
US$1.07&nbsp;billion; (b)&nbsp;the last day of our fiscal year following the fifth anniversary of the completion of this offering; (c)&nbsp;the date on which we have, during the preceding three-year period, issued more than US$1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt; or (d)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; under the United States Securities Exchange Act of 1934, as amended, (the &#147;Exchange Act&#148;),
which would occur if the market value of our ADSs that are held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds US$700&nbsp;million as of the last business day of our most recently completed second fiscal quarter. Once we cease to
be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our principal executive offices are located at Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, People&#146;s Republic of China. Our
telephone number at this address is +86 <FONT STYLE="white-space:nowrap">21-6057-8000.</FONT> </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Our registered office in the Cayman Islands is located at Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman,
<FONT STYLE="white-space:nowrap">KY1-1205,</FONT> Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Investors should submit any inquiries to the address or through the telephone number of our principal executive offices. Our main website is <FONT
STYLE="white-space:nowrap">http://www.i-mabbiopharma.com/en/.</FONT> The information contained on our website is not a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conventions that
Apply to this Prospectus </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise indicated or the context otherwise requires, and for purposes of this prospectus only: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;ADRs&#148; refer to the American depositary receipts that evidence our ADSs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;ADSs&#148; refer to our American depositary shares, each ten (10) ADSs represent twenty-three (23) ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;China&#148; or &#147;the PRC&#148; refers to the People&#146;s Republic of China, excluding, for the purposes of
this prospectus only, Hong Kong, Macau and Taiwan, and &#147;Greater China&#148; does not exclude Hong Kong, Macau and Taiwan; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;China Portfolio&#148; refers to our investigational drugs of which we
<FONT STYLE="white-space:nowrap">in-license</FONT> Greater China rights from reputable global biopharmaceutical companies and rely on our own research and development capabilities to advance into pivotal clinical trials and commercialize in Greater
China with an aim for near-term product launch; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;Global Portfolio&#148; refers to our own proprietary novel or differentiated drug candidates that we are advancing
towards clinical validation in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">&#147;I-Mab,&#148;</FONT> &#147;we,&#148; &#147;us,&#148; &#147;our company&#148; and
&#147;our&#148; refer to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> a Cayman Islands exempted company, and its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;RMB&#148; refers to the legal currency of China; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;shares&#148; or &#147;ordinary shares&#148; refer to our ordinary shares, par value US$0.0001 per share; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;US$,&#148; &#147;U.S. dollars,&#148; &#147;$,&#148; and &#147;dollars&#148; refer to the legal currency of the
United States. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless the context indicates otherwise, all information in this prospectus assumes (i)&nbsp;no exercise by the underwriters of
their option to purchase additional ADSs and (ii) the conversion of each Series C-1 preferred share, each Series C preferred share, and each Series B-2 preferred share into 1.18, 1.11 and 1.08 ordinary shares of our company respectively immediately
prior to the completion of this offering, at an initial offering price of US$14.00 per ADS (or US$6.09 per ordinary share). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our reporting currency is RMB. This
prospectus also contains translations of certain foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations from RMB to U.S. dollars were made at a rate of RMB7.1477 to US$1.00, the
exchange rate in effect as of September 30, 2019 as set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System. We make no representation that any RMB or U.S. dollar amounts referred to in this prospectus could
have been or could be converted into U.S. dollars or RMB, as the case may be, at any particular rate, or at all. On January 10, 2020, the noon buying rate for RMB was RMB6.9178 to US$1.00. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Offering price </P></TD>
<TD>US$14.00 per ADS. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">ADSs offered by us </P></TD>
<TD>7,407,400 ADSs (or 8,518,510 ADSs if the underwriters exercise their option to purchase additional ADSs in full). </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">ADSs outstanding immediately after this offering </P></TD>
<TD>7,407,400 ADSs (or 8,518,510 ADSs if the underwriters exercise their option to purchase additional ADSs in full). </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Concurrent private placement </P></TD>
<TD>On November 4, 2019, we and Everest Medicines Limited, or Everest, terminated the collaboration agreement (including all the supplements and amendments thereto) with respect to the co-development and commercialization of TJ202 in Greater China.
Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its commercialization. All intellectual property rights in respect of TJ202 arising from its development under the
collaboration agreement are vested and owned by us, and we hold all intellectual property rights and have maximum flexibility to further develop, manufacture and commercialize TJ202 in Greater China. In consideration of the above arrangements, we
will issue a total value of US$37.0 million of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing Everest&#146;s historical contribution to our collaboration and the associated time cost. The CPP Shares will be issued concurrently
with, and subject to, the completion of this offering within 180 days from termination of the collaboration agreement, at a per share price equal to the initial public offering price adjusted to reflect the ADS-to-ordinary share ratio. The total
value of US$37.0 million was calculated based on the sum of (1) US$33.7 million, which equals cumulative paid-in contributions historically made by Everest under the collaboration agreement; and (2) a negotiated US$3.3 million time cost of the
foregoing historical contribution in light of our exclusive rights over the commercialization of TJ202 after this termination. Based on the initial public offering price of US$14.00 per ADS (or US$6.09 per ordinary share), Everest will be issued
6,078,571 ordinary shares and become a minority shareholder of our company upon the completion of this offering. In the event that this offering has not been completed within 180&nbsp;days from the termination of the collaboration agreement, we will
issue 4,762,751 ordinary shares (the &#147;Subject Shares&#148;) to Everest on the 181st day. Our issuance of ordinary shares to Everest is being made pursuant to an exemption from registration with the U.S. Securities and Exchange Commission under
Regulation S of the U.S. Securities Act of 1933, as amended, or the Securities Act. Everest has agreed not to, directly or indirectly, sell, transfer or dispose of (i) any CPP Shares for a period of 180 days after the date of this prospectus or
(ii)&nbsp;any Subject Shares for a period of 180 days after their issuance. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Anti-dilution adjustment </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Based on the initial public offering price of US$14.00 per ADS (or US$6.09 per ordinary share) and pursuant to our currently effective memorandum and articles of
association (as last amended on December 25, 2019), each Series C-1 preferred share, each Series C </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:9.5pt; font-family:ARIAL">
preferred share, and each Series B-2 preferred share will convert into 1.18, 1.11 and 1.08 ordinary shares of our company, respectively, and each preferred share of the other series will convert
into ordinary shares of our company on a one-for-one basis immediately prior to the completion of this offering. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Ordinary shares issued and outstanding immediately after this offering </P></TD>
<TD>131,239,439 (or&nbsp;133,794,992 ordinary shares if the underwriters exercise their option to purchase additional ADSs in full), excluding ordinary shares issuable upon the exercise of options outstanding under our share incentive plans as of
the date of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">The ADSs </P></TD>
<TD>Each ten (10) ADSs represent twenty-three (23) ordinary shares, par value US$0.0001 per share. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The depositary or its nominee will hold ordinary shares underlying your ADSs. You will have rights as provided in the deposit agreement among us, the depositary and all holders and beneficial owners of ADSs issued
thereunder. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We do not expect to pay dividends in the foreseeable future. If, however, we declare dividends on our ordinary shares, the depositary will pay you the cash dividends and other distributions it receives on our ordinary
shares after deducting its fees and expenses in accordance with the terms set forth in the deposit agreement. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">You may surrender your ADSs to the depositary in exchange for ordinary shares. The depositary will charge you fees for any such exchange. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may amend or terminate the deposit agreement without your consent. If you continue to hold your ADSs after an amendment to the deposit agreement, you agree to be bound by the deposit agreement as amended.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To better understand the terms of the ADSs, you should carefully read the &#147;Description of American Depositary Shares&#148; section of this prospectus. You should also read the deposit agreement, which is filed as
an exhibit to the registration statement that includes this prospectus. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Option to purchase additional shares </P></TD>
<TD>We have granted to the underwriters an option, exercisable within 30&nbsp;days from the date of this prospectus, to purchase up to an additional 1,111,110 ADSs. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We expect that we will receive net proceeds of approximately US$91.1 million from this offering, or approximately US$105.4 million if the underwriters exercise their option to purchase additional ADSs in full, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering to (i)&nbsp;research and development of our existing and future drug candidates, (ii)&nbsp;potential investments in the establishment of our own manufacturing
capacities and building research facilities in the United&nbsp;States, and (iii)&nbsp;general corporate purposes. See &#147;Use of Proceeds&#148; for more information. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Lock-up</FONT> </P></TD>
<TD>We, our directors and executive officers and our current shareholders have agreed with the underwriters not to sell, transfer or otherwise dispose of any ADSs, ordinary shares or similar securities for a period of 180 days after the date of this
prospectus, subject to certain exceptions. In addition, we will not authorize or permit Citibank, N.A., as depositary, to accept any deposit of any ordinary shares or issue any ADSs for 180 days after the date of this prospectus unless we expressly
consent to such deposit or issuance and we have agreed not to provide such consent without the prior written consent of the representatives on behalf of the underwriters. The foregoing does not affect the right of ADS holders to cancel their ADSs
and withdraw the underlying ordinary shares. See &#147;Shares Eligible for Future Sales&#148; and &#147;Underwriting.&#148; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Listing </P></TD>
<TD>The ADSs have been approved for listing on the Nasdaq Global Market under the symbol &#147;IMAB.&#148; Our ADSs and shares will not be listed on any other stock exchange or traded on any automated quotation system. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Payment and settlement </P></TD>
<TD>The underwriters expect to deliver the ADSs against payment therefor through the facilities of The Depository Trust Company on January&nbsp;22, 2020. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Depositary </P></TD>
<TD>Citibank, N.A. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following summary consolidated statements of comprehensive loss data for the years ended December&nbsp;31, 2017 and 2018, summary consolidated statements of
balance sheet data as of December&nbsp;31, 2017 and 2018 and summary consolidated statements of cash flow data for the years ended December&nbsp;31, 2017 and 2018 have been derived from our audited consolidated financial statements included
elsewhere in this prospectus. The following summary consolidated statements of comprehensive loss data for the nine months ended September 30, 2018 and 2019, summary consolidated balance sheet data as of September 30, 2019 and summary consolidated
statements of cash flow data for the nine months ended September 30, 2018 and 2019 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Our consolidated financial statements are
prepared and presented in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). Our historical results are not necessarily indicative of results expected for future periods. You should read
this Summary Consolidated Financial Data section together with our consolidated financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere
in this prospectus. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;YEAR&nbsp;ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;NINE&nbsp;MONTHS&nbsp;ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except for share and per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Summary Consolidated Statements of Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">11,556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">53,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">7,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">43,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">4,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(267,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(426,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(59,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(314,574<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(578,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(80,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(25,436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(66,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(9,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(40,912<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(582,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(81,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(280,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(438,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(61,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(312,095<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,131,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(158,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">4,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,438<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">22,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">3,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(5,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(11,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(10,575<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(2,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(16,780</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(2,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(16,985<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,758</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(14,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">61,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">8,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">60,484<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">5,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(298,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(401,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(56,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(277,733<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,103,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(154,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,722</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,635<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(298,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(402,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(56,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(279,368<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,103,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(154,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">5,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">53,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">7,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">60,101<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">66,254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">9,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Total comprehensive loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(292,322</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(349,144</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(48,848</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(219,267</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(1,037,126</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(145,099</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;YEAR&nbsp;ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;NINE&nbsp;MONTHS&nbsp;ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except for share and per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(298,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(402,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(56,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(279,368<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,103,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(154,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Weighted-average number of ordinary shares used in calculating net loss per shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">5,742,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6,529,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6,529,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6,397,663<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">7,184,086</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">7,184,086</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(51.93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(61.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(8.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(43.67<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(153.59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(21.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(51.93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(61.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(8.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(43.67<B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)<B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(153.59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(21.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Share-based compensation expenses were allocated as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:4%;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;YEAR&nbsp;ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;NINE&nbsp;MONTHS&nbsp;ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>493</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,970</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:4%;border-bottom:1px solid #000000">&nbsp;</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents our summary consolidated balance sheet data as of December&nbsp;31, 2017 and 2018 and
September&nbsp;30, 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Summary Consolidated Statements of Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,224,477</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>171,311</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>56,583</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>11,000</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contract assets<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Short-term investments<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>74,895</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>63,412</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,483,367</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>25,429</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease right-of-use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>13,255</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>148,844</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>162,574</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>332,407</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,839,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>257,375</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>309,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>415,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>58,156</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>549,622</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,894</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,015,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>407,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>407,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December 31, 2018 and
September&nbsp;30, 2019, 8,363,719 and 8,363,719 shares authorized, issued and outstanding as of December&nbsp;31, 2018 and September&nbsp;30, 2019, respectively)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>6</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>6</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Treasury stock<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(1</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(1</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional paid-in capital<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>52,369</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>366,885</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive income <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>5,691</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>125,634</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(357,860</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141,932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(2,117,869</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(296,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>(299,795</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>(955,104</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>(133,623</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>(1,625,345</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>(227,393</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>332,407</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,839,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>257,375</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents our summary consolidated statements of cash flow data for the years ended
December&nbsp;31, 2017 and 2018 and the nine months ended September&nbsp;30, 2018 and 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Summary Consolidated Statements of Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(651,993</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash (used in) generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,914<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>135,128</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>39,413</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>77,581</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419,782<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(399,871</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,680,931</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832,495<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,281,060</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An investment in our ADSs involves significant risks. You should carefully consider all of the information in this prospectus, including the risks and uncertainties
described below, before making an investment in our ADSs. Any of the following risks could have a material adverse effect on our business, financial condition and results of operations. In any such case, the market price of our ADSs could decline,
and you may lose all or part of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company with a limited operating history. Our operations to date have focused on organizing and staffing our operations,
business planning, raising capital, establishing our intellectual property portfolio and conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials of our drug candidates. We have not yet demonstrated an ability to
successfully manufacture, obtain marketing approvals for or commercialize our drug candidates. We have no products approved for commercial sale and have not generated any revenue from product sales. Consequently, any predictions about our future
success or viability may not be as accurate as they could be if we had a longer operating history. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are focused on the discovery and development of innovative
drugs for the treatment of various immuno-oncological and immuno-inflammatory diseases. Our limited operating history, particularly in light of the rapidly evolving drug research and development industry in which we operate and the changing
regulatory and market environments we encounter, may make it difficult to evaluate our prospects for future performance. As a result, any assessment of our future performance or viability is subject to significant uncertainty. We will encounter
risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields as we seek to transition to a company capable of supporting commercial activities. If we do not address these risks and difficulties successfully, our
business will suffer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have incurred net losses in each period since our inception and anticipate that we will continue to incur net losses for the
foreseeable future and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Investment in the development of biopharmaceutical products is highly speculative as it
entails substantial upfront capital expenditures and significant risks that a drug candidate may fail to demonstrate efficacy and/or safety to gain regulatory or marketing approvals or become commercially viable. To date, we have financed our
activities primarily through private placements. While we have generated revenue from licensing and collaboration deals, we have not generated any revenue from commercial product sales to date, and we continue to incur significant research and
development expenses and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses in each period since our inception. In 2017, 2018 and the nine months ended September&nbsp;30, 2019, our net
losses were RMB298.2&nbsp;million, RMB402.8&nbsp;million (US$56.4 million) and RMB1,103.4 million (US$154.4 million), respectively. Substantially all of our net losses have resulted from costs incurred in connection with our research and development
programs and from general and administrative costs associated with our operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to continue to incur net losses in the foreseeable future, and that
these net losses will increase as we carry out certain activities relating to our development, including, but not limited to, the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">conducting clinical trials of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacturing clinical trial materials through contract manufacturing organizations, or CMOs, in and out of China;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seeking regulatory approvals for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">commercializing our drug candidates for which we have obtained marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completing the construction of and maintaining our manufacturing facilities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hiring additional clinical, operational, financial, quality control and scientific personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing a sales, marketing and commercialization team for any future products that have obtained regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seeking to identify additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining, maintaining, expanding and protecting our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enforcing and defending any intellectual property-related claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> other drug candidates, intellectual property and
technologies. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Typically, it takes many years to develop one new drug from the time it is discovered to when it becomes available for treating
patients. During the process, we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend partially on the rate of the
future growth of our expenses, our ability to generate revenues and the timing and amount of milestone payments and other payments that we receive from or pay to third parties. If any of our drug candidates fails during clinical trials or does not
gain regulatory approval, or, even if approved, fails to achieve market acceptance, our business may not become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods thereafter.
Our prior losses and expected future losses have had, and will continue to have, an adverse effect on our working capital and shareholders&#146; equity. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We
recorded net cash outflow from operating activities since our inception. Even if we consummate this offering, we may need to obtain additional financing to fund our operations. If we are unable to obtain such financing, we may be unable to complete
the development and commercialization of our major drug candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, our operations have consumed substantial amounts of cash. We had
raised over US$400&nbsp;million in pre-IPO financing in the past three years. We spent RMB252.2&nbsp;million, RMB280.7&nbsp;million (US$39.3 million) and RMB652.0 million (US$91.2 million) in net cash to finance our operations in 2017, 2018 and the
nine months ended September 30, 2019, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect our expenses to increase significantly in connection with our ongoing activities, particularly as we
advance the clinical development of our clinical-stage drug candidates, continue the research and development of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates and initiate additional clinical trials of, and seek
regulatory approval for, these and other future drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if we obtain regulatory approvals for any of our drug candidates, we expect to incur
significant commercialization expenses relating to product manufacturing, marketing, sales and distribution and post-approval commitments to continue monitoring the efficacy and safety data of our future products on the market. In particular, costs
that may be required for the manufacture of any drug candidate that has received regulatory approval may be substantial as we may need to modify or increase our production capacity in the future at manufacturing facilities. We may also incur
expenses as we create additional infrastructure to support our operations as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations through public or private equity
offerings, debt financing, collaborations or licensing arrangements or other sources. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, limit, reduce or terminate our research and development programs
or any future commercialization efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to the interests to the holders of our ADSs and our shareholders,
restrict our operations or require us to relinquish rights to our technologies or drug candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may seek additional funding through a combination of
equity offerings, debt financings, collaborations, licensing arrangements, strategic alliances or partnerships and government grants or subsidies. To the extent that we raise additional capital through the sale of equity or convertible debt
securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a holder of our ADSs. The incurrence of additional indebtedness or the issuance of certain equity
securities could give rise to increased fixed payment obligations and also result in certain additional restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to
acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. In addition, the issuance of additional equity securities, or the possibility of such issuance, may
cause the market price of our ADSs to decline. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event we enter into collaborations or licensing arrangements in order to raise capital, we may be required to
accept unfavorable terms, including relinquishing or licensing to a third party our rights to technologies or drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
candidates on unfavorable terms, which we would have otherwise sought to develop or commercialize on our own or reserve for future potential arrangements when we are more likely to achieve more
favorable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Clinical Development of Our Drug Candidates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future
trial results. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. While our exclusive focus is to
develop drug candidates with potential to become novel or highly differentiated drugs in China and globally, we cannot guarantee that we are able to achieve this for any of our drug candidates. Failure can occur at any time during the clinical
development process. The results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage clinical trials. Drug candidates during later
stages of clinical trials may fail to show the desired results in safety and efficacy despite having progressed through <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and initial clinical trials and despite the level of scientific
rigor in the study, design and adequacy of execution. In some instances, there can be significant variability in safety and/or efficacy results among different trials of the same drug candidate due to numerous factors, including, but not limited to,
differences in individual patient conditions, including genetic differences, and other compounding factors, such as other medications or <FONT STYLE="white-space:nowrap">pre-existing</FONT> medical conditions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the case of any trials we conduct, results may differ from earlier trials due to the larger number of clinical trial sites and additional countries and languages
involved in such trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to a lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier
trials. We cannot guarantee that our future clinical trial results will be favorable based on currently available clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We depend substantially on the success of our drug candidates, all of which are in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development,
and our ability to identify additional drug candidates. If we are unable to successfully identify new drug candidates, complete clinical development, obtain regulatory approval and commercialize our drug candidates, or experience significant delays
in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business will depend on the successful development, regulatory approval and commercialization of
our drug candidates for the treatment of patients with our targeted indications, all of which are still in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development, and other new drug candidates that we may identify and develop.
As of the date of this prospectus, we have obtained IND approvals from the NMPA for six of our drug candidates, TJ202, TJ301, TJ107, TJC4, TJD5 and TJM2. In addition, we have obtained IND approvals from the FDA for three of our drug candidates,
TJC4, TJD5 and TJM2; from the Taiwan Food and Drug Administration (the &#147;TFDA&#148;) for two of our drug candidates, TJ202 and TJ301; and from the Korea Ministry of Food and Drug Safety (the &#147;MFDS&#148;) for TJ301. However, we cannot
guarantee that we are able to obtain regulatory approvals for our other existing drug candidates in a timely manner, or at all. In addition, none of our drug candidates has been approved for marketing in China or any other jurisdiction. Each of our
drug candidates will require additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and/or clinical development, regulatory approvals in multiple jurisdictions, development of manufacturing supply and capacity, substantial investment and
significant marketing efforts before we generate any revenue from product sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The success of our drug candidates will depend on several factors, including but
not limited to the successful completion of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and/or clinical trials or studies, receipt of regulatory approvals from applicable regulatory authorities for planned clinical trials, future clinical
trials or drug registrations, establishing adequate manufacturing capabilities and capacities, commercialization of our existing drug candidates, hiring sufficient technical experts to oversee all development and regulatory activities and license
renewal and meeting of the safety requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not achieve one or more of these in a timely manner or at all, we could experience significant delays in
our ability to obtain approval for our drug candidates, which would materially harm our business and we may not be able to generate sufficient revenues and cash flows to continue our operations. As a result, our financial condition, results of
operations and prospects will be materially and adversely harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to identify, discover or <FONT STYLE="white-space:nowrap">in-license</FONT> new drug
candidates, and may allocate our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable, or for which there is a greater likelihood of
success. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our
existing drug candidates, the success of our business depends in part upon our ability to identify, license, discover, develop, or commercialize additional drug candidates. Research programs to identify new drug candidates require substantial
technical, financial, and human resources. We may focus our efforts and resources on potential programs or drug candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to identify, discover or <FONT
STYLE="white-space:nowrap">in-license</FONT> new drug candidates for clinical development and commercialization for a number of reasons, including, without limitation, the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our research or business development methodology or search criteria and process may be unsuccessful in identifying
potential drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our potential drug candidates may be shown to have harmful side effects or may have other characteristics that may make
the products unmarketable or unlikely to receive marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it may take greater human and financial resources to identify additional therapeutic opportunities for our drug candidates
or to develop suitable potential drug candidates through internal research programs than we possess, thereby limiting our ability to diversify and expand our drug portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we have limited financial and managerial resources, we focus on research programs and drug candidates for specific indications. As a result, we may forgo or
delay pursuit of opportunities with other drug candidates or for other indications that later may prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on
viable commercial products or profitable market opportunities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic
opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs, which could materially adversely affect our future growth and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we encounter delays or difficulties enrolling patients in our clinical trials, our clinical development progress could be delayed or otherwise adversely
affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of
eligible patients to participate in these trials as required by the NMPA, the FDA, or similar regulatory authorities, or if there are delays in the enrollment of eligible patients as a result of the competitive clinical enrollment environment. The
inability to enroll a sufficient number of patients who meet the applicable criteria for our clinical trials would result in significant delays. As of the date of this prospectus, we have initiated clinical trials for TJ301 in South Korea and
Greater China, for TJ107 in China, for TJ202 in Greater China, for TJC4 in China and the United States, and for TJM2 and TJD5 in the United States. In addition, we expect to initiate clinical trials for TJM2 and TJD5 by early 2020 in China. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, some of our competitors have ongoing clinical trials for drug candidates that treat the same indications as our drug candidates, and patients who would
otherwise be eligible for our clinical trials may instead enroll in the clinical trials of our competitors&#146; drug candidates, which may further delay our clinical trial enrollments. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patient enrollment for our clinical trials may be affected by other factors, including but not limited to the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">total size and nature of the relevant patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">design and eligibility criteria for the clinical trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">perceived risks and benefits of the drug candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our resources to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">availability of competing therapies also undergoing clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our investigators&#146; or clinical trial sites&#146; efforts to screen and recruit eligible patients; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">proximity and availability of clinical trial sites for prospective patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased costs or may affect the
timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our drug candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce
positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining regulatory approval for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our drug
candidates in humans. We may experience numerous unexpected events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our drug candidates, including, without limitation:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulators, institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to
commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our inability to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacturing issues, including problems with manufacturing, supply quality, compliance with good manufacturing practice,
or GMP, or obtaining sufficient quantities of a drug candidate from third parties for use in a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide to conduct
additional clinical trials or abandon drug development programs, or regulators may require us to do so; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment
may be insufficient or slower than we anticipate or patients may drop out at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our third-party contractors, including clinical investigators, may fail to comply with regulatory requirements or meet
their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a finding of a
lack of clinical response or other unexpected characteristics or a finding that participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulators, IRBs or ethics committees may require that we or our investigators suspend or terminate clinical research or
not rely on the results of clinical research for various reasons, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of clinical trials of our drug candidates may be greater than we anticipate; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the supply or quality of our drug candidates, companion diagnostics or other materials necessary to conduct clinical
trials of our drug candidates may be insufficient or inadequate. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are required to conduct additional clinical trials or other testing of our
drug candidates beyond those that we currently plan, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if they
raise safety concerns, we may (i)&nbsp;be delayed in obtaining regulatory approval for our drug candidates; (ii)&nbsp;obtain approval for indications that are not as broad as intended; (iii)&nbsp;not obtain regulatory approval at all; (iv)&nbsp;have
the drug removed from the market after obtaining regulatory approval; (v)&nbsp;be subject to additional post-marketing testing requirements; (vi)&nbsp;be subject to restrictions on how the drug is distributed or used; or (vii)&nbsp;be unable to
obtain reimbursement for use of the drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Significant clinical trial delays may also increase our development costs and could shorten any periods during which we
have the exclusive right to commercialize our drug candidates or allow our competitors to bring drugs to market before we do. This could impair our ability to commercialize our drug candidates and may harm our business and results of operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Obtaining Regulatory Approval for Our Drug Candidates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>All material aspects of the research, development and commercialization of pharmaceutical products are heavily regulated. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All jurisdictions in which we intend to conduct our pharmaceutical-industry activities regulate these activities in great depth and detail. We intend to focus our
activities in the major markets of China and the United&nbsp;States. These jurisdictions strictly regulate the pharmaceutical industry, and in doing so they employ broadly similar regulatory strategies, including regulation of product development
and approval, manufacturing, and marketing, sales and distribution of products. However, there are differences in the regulatory regimes that make for a more complex and costly regulatory compliance burden for a company like us that plans to operate
in these regions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process of obtaining regulatory approvals and compliance with appropriate laws and regulations requires the expenditure of substantial time
and financial resources. Failure to comply with the applicable requirements at any time during the product development process and approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions
could include: refusal to approve pending applications; withdrawal of an approval; license revocation; clinical hold; voluntary or mandatory product recalls; product seizures; total or partial suspension of production or distribution; injunctions;
fines; refusals of government contracts; providing restitution; undergoing disgorgement; or other civil or criminal penalties. Failure to comply with these regulations could have a material adverse effect on our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The regulatory approval processes of the NMPA, the FDA and other comparable regulatory authorities are time-consuming and may evolve over time, and if we are
ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The time required to obtain the
approval of the NMPA, the FDA and other comparable regulatory authorities is inherently uncertain and depends on numerous factors, including the substantial discretion of the regulatory authorities. Generally, such approvals take many years to
obtain following the commencement of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, although they are typically provided within 12 to 18 months after clinical trials are completed. In addition, approval policies,
regulations or the type and amount of clinical data necessary to gain approval may change during the course of a drug candidate&#146;s clinical development and may vary among jurisdictions. As of the date of this prospectus, we have obtained IND
approvals from the NMPA for TJ202, TJ301, TJ107, TJC4, TJD5 and TJM2. In addition, we have obtained IND approvals from the FDA for TJC4, TJD5 and TJM2, from the TFDA for TJ202 and TJ301 and from the MFDS for TJ301. However, we cannot guarantee that
we are able to obtain regulatory approvals for our other existing drug candidates or any drug candidates we may discover, <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire and seek to develop in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our drug candidates could fail to receive the regulatory approval of the NMPA, the FDA or a comparable regulatory authority for many reasons, including, without
limitation: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disagreement with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to demonstrate that a drug candidate is safe and effective and potent for its proposed indication;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure of our clinical trial results to meet the level of statistical significance required for approval;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure of our clinical trial process to pass relevant good clinical practice (&#147;GCP&#148;) inspections;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to demonstrate that a drug candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disagreement with our interpretation of data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">insufficient data collected from the clinical trials of our drug candidates to support the submission and filing of a new
drug application, or NDA, or other submissions or to obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure of our drug candidates to pass current Good Manufacturing Practice (&#147;cGMP&#148;), inspections during the
regulatory review process or across the production cycle of our drug; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure of our clinical sites to pass audits carried out by the NMPA, the FDA or comparable regulatory authorities,
resulting in a potential invalidation of our research data; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">findings by the NMPA, the FDA or comparable regulatory authorities of deficiencies related to our manufacturing processes
or the facilities of third-party manufacturers with whom we contract for clinical and commercial supplies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in approval policies or regulations that render our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and
clinical data insufficient for approval; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure of our clinical trial process to keep up with any scientific or technological advancements required by approval
policies or regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The NMPA, the FDA or a comparable regulatory authority may require more information, including additional <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> or clinical data, to support approval, which may delay or prevent approval and our commercialization plans. Even if we were to obtain approval, regulatory authorities may approve any of our drug
candidates for fewer or more limited indications than we request, grant approval contingent on the performance of costly post-marketing clinical trials, or approve a drug candidate with an indication that is not desirable for the successful
commercialization of that drug candidate. Any of the foregoing scenarios could materially harm the commercial prospects of our drug candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The absence
of patent linkage, patent term extension and data and market exclusivity for NMPA-approved pharmaceutical products could increase the risk of early generic competition with our products in China. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the Federal Food, Drug and Cosmetic Act, as amended by the law generally referred to as &#147;Hatch-Waxman,&#148; provides the opportunity for
patent-term restoration, meaning a patent term extension of up to five years to reflect patent term lost during certain portions of product development and the FDA regulatory review process. Hatch-Waxman also has a process for patent linkage,
pursuant to which the FDA will stay approval of certain <FONT STYLE="white-space:nowrap">follow-on</FONT> applications during the pendency of litigation between the <FONT STYLE="white-space:nowrap">follow-on</FONT> applicant and the patent holder or
licensee, generally for a period of 30 months. Finally, Hatch-Waxman provides for statutory exclusivities that can prevent submission or approval of certain <FONT STYLE="white-space:nowrap">follow-on</FONT> marketing applications. For example,
federal law provides a five-year period of exclusivity within the United States to the first applicant to obtain approval of a new chemical entity and three years of exclusivity protecting certain innovations to previously approved active
ingredients where the applicant was required to conduct new clinical investigations to obtain approval for the modification. Similarly, the United States Orphan Drug Act provides seven years of market exclusivity for certain drugs to treat rare
diseases, where the FDA designates the drug candidate as an orphan drug and the drug is approved for the designated orphan indication. These provisions, designed to promote innovation, can prevent competing products from entering the market for a
certain period of time after the FDA grants marketing approval for the innovative product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending upon the timing, duration and specifics of any FDA marketing
approval process for any drug candidates we may develop, one or more of our U.S. patents, if issued, may be eligible for limited patent term extension under Hatch-Waxman. Hatch-Waxman permits a patent extension term of up to five years as
compensation for patent term lost during clinical trials and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval, only one patent may be
extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the
testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Furthermore, the applicable time period or
the scope of patent protection afforded could be less than we request. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In China, however, there is no currently effective law or regulation providing for patent
term extension, patent linkage, or data exclusivity (referred to as regulatory data protection). Therefore, a lower-cost generic drug can emerge onto the market much more quickly. Chinese regulators have set forth a framework for integrating patent
linkage and data exclusivity into the Chinese regulatory regime, as well as for establishing a pilot program for patent term extension. To be implemented, this framework will require adoption of regulations. To date, no regulations have been issued.
These factors result in weaker protection for us against generic competition in China than could be available to us in the United States. For instance, the patents we have in China are not yet eligible to be extended for patent term lost during
clinical trials and the regulatory review process. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration,
and our business, financial condition, results of operations, and prospects could be materially harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our drug candidates may cause undesirable adverse events or have other properties that could delay or prevent
their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Undesirable adverse events caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and may result in a more
restrictive label, a delay or denial of regulatory approval by the NMPA, the FDA or other comparable regulatory authorities, or a significant change in our clinical protocol or even our development plan. In particular, as is the case with drugs
treating cancers and auto-immune diseases, it is likely that there may be side effects, such as nausea, fatigue and infusion-related reactions, associated with the use of certain of our drug candidates. Results of our trials could reveal a high and
unacceptable severity or prevalence of certain adverse events. In such an event, our trials could be suspended or terminated and the NMPA, the FDA or other comparable regulatory authorities could order us to cease further development of, or deny
approval of, our drug candidates for any or all targeted indications. Adverse events related to our drug candidates may affect patient recruitment or the ability of enrolled subjects to complete the trial, and could result in potential liability
claims. Any of these occurrences may significantly harm our reputation, business, financial condition and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, if we or others identify
undesirable side effects caused by those of our existing drug candidates that have received regulatory approval, or our other drug candidates after having received regulatory approval, this may lead to potentially significant negative consequences
which include, but are not limited to, the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may suspend marketing of the drug candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities may withdraw their approvals of or revoke the licenses for the drug candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities may require additional warnings on the label; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA may require the establishment of a Risk Evaluation and Mitigation Strategy, or REMS, or the NMPA or a comparable
regulatory authority may require the establishment of a similar strategy that may, for instance, restrict distribution of our drugs and impose burdensome implementation requirements on us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be required to conduct specific post-marketing studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we could be subjected to litigation proceedings and held liable for harm caused to subjects or patients; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these events could prevent us from achieving or maintaining market acceptance of any particular drug candidate that is approved and could significantly harm our
business, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, combination therapy, such as using our wholly-owned drug candidates as well as third-party agents, may
involve unique adverse events that could be exacerbated compared with adverse events from monotherapies. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse events. These types of adverse events could be
caused by our drug candidates and could cause us or regulatory authorities to interrupt, delay or halt clinical trials and may result in a more restrictive indication or the delay or denial of regulatory approval by the NMPA, the FDA or other
comparable regulatory authority. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to obtain the NMPA approval for our drug candidates to be eligible for an expedited registration pathway as
innovative drug candidates, the time and cost we incur to obtain regulatory approvals may increase. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The NMPA has mechanisms in place for expedited review
and approval for drug candidates that are innovative drug applications, provided such drug or drug candidate has a new and clearly defined structure, pharmacological property and apparent clinical value and has not been marketed anywhere in the
world. However, there is no assurance that an innovative drug designation will be granted by the NMPA for any of our drug candidates. Moreover, an innovative drug designation, which is typically granted only towards the end of a drug&#146;s
developmental stage, does not increase the likelihood that our drug candidates will receive regulatory approval on a fast-track basis, or at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, there
have been recent regulatory initiatives in China in relation to clinical trial approvals, the evaluation and approval of certain drugs and medical devices and the simplification and acceleration of the clinical trial process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result, the regulatory process in China is evolving and subject to change. Any future policies, or changes to current polices might require us to change our
planned clinical study design or otherwise spend additional resources </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and effort to obtain approval of our drug candidates. In addition, policy changes may contain significant limitations related to use restrictions for certain age groups, warnings, precautions or
contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for our drug candidates in the PRC, or any approval contains significant limitations, we may not
be able to obtain sufficient funding or generate sufficient revenue to continue the development of our drug candidates or any other drug candidate that we may <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or develop in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we receive regulatory approval for our drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may
result in significant additional expenses and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our drug candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the NMPA, the FDA or a comparable regulatory authority approves any of our drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse
event reporting, storage, advertising, promotion and recordkeeping for the drug will be subject to extensive and ongoing regulatory requirements on pharmacovigilance. These requirements include submissions of safety and other post-marketing
information and reports, registration, random quality control testing, adherence to any chemistry, manufacturing, and controls (&#147;CMC&#148;), variations, continued compliance with current cGMPs, and GCPs and potential post-approval studies for
the purposes of license renewal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the approved indicated uses
for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 studies for the surveillance and monitoring of the safety and efficacy of the drug. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, once a drug is approved by the NMPA, the FDA or a comparable regulatory authority for marketing, it is possible that there could be a subsequent discovery
of previously unknown problems with the drug, including problems with third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements. If any of the foregoing occurs with respect to our drug products, it may
result in, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of the drug, withdrawal of the drug from the market, or voluntary or
mandatory drug recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, warning letters or holds on our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal by the NMPA, the FDA or comparable regulatory authorities to approve pending applications or supplements to
approved applications filed by us, or suspension or revocation of drug license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal by the NMPA, the FDA or comparable regulatory authorities to accept any of our other IND approvals, NDAs or BLAs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">drug seizure or detention, or refusal to permit the import or export of drugs; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions or the imposition of civil, administrative or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any government investigation of alleged violations of law could require us to expend significant time and resources and could generate negative publicity. Moreover,
regulatory policies may change or additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are not able to maintain regulatory compliance, we may lose the regulatory
approvals that we have already obtained and may not achieve or sustain profitability, which in turn could significantly harm our business, financial condition and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Illegal and/or parallel imports and counterfeit pharmaceutical products may reduce demand for our future approved drug candidates and could have a negative impact
on our reputation and business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The illegal importation of competing products from countries where government price controls or other market dynamics
result in lower prices may adversely affect the demand for our future approved drug candidates and, in turn, may adversely affect our sales and profitability in China and other countries where we commercialize our products. Unapproved foreign
imports of prescription drugs are illegal under the current laws of China. However, illegal imports may continue to occur or even increase as the ability of patients and other customers to obtain these lower priced imports continues to grow.
Furthermore, cross-border imports from lower-priced markets (which are known as parallel imports) into higher-priced markets could harm sales of our future drug products and exert </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
commercial pressure on pricing within one or more markets. In addition, competent government authorities may expand consumers&#146; ability to import lower priced versions of our future approved
products or competing products from outside China or other countries where we operate. Any future legislation or regulations that increase consumer access to lower priced medicines from outside China or other countries where we operate could have a
material adverse effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain products distributed or sold in the pharmaceutical market may be manufactured without proper licenses or
approvals, or be fraudulently mislabeled with respect to their content or manufacturers. These products are generally referred to as counterfeit pharmaceutical products. The counterfeit pharmaceutical product control and enforcement system,
particularly in developing markets such as China, may be inadequate to discourage or eliminate the manufacturing and sale of counterfeit pharmaceutical products imitating our products. Since counterfeit pharmaceutical products in many cases have
very similar appearances compared with the authentic pharmaceutical products but are generally sold at lower prices, counterfeits of our products could quickly erode the demand for our future approved drug candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, counterfeit pharmaceutical products are not expected to meet our or our collaborators&#146; rigorous manufacturing and testing standards. A patient who
receives a counterfeit pharmaceutical product may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit pharmaceutical products sold under our or our collaborators&#146;
brand name(s). In addition, thefts of inventory at warehouses, plants or while <FONT STYLE="white-space:nowrap">in-transit,</FONT> which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety,
our reputation and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Commercialization of Our Drug Candidates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary
for commercial success. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if our drug candidates receive regulatory approval, they may nonetheless fail to gain sufficient market acceptance by
physicians and patients and others in the medical community. Physicians and patients may prefer other drugs or drug candidates to ours. If our drug candidates do not achieve an adequate level of acceptance, we may not generate significant revenue
from sales of our drugs or drug candidates and may not become profitable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The degree of market acceptance of our drug candidates, if and only when they are
approved for commercial sale, will depend on a number of factors, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the clinical indications for which our drug candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">physicians, hospitals and patients considering our drug candidates as a safe and effective treatment;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether our drug candidates have achieved the perceived advantages of our drug candidates over alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product labeling or package insert requirements of the NMPA, the FDA or other comparable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limitations or warnings contained in the labeling approved by the NMPA, the FDA or other comparable regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">timing of market introduction of our drug candidates as well as competitive drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">availability of adequate coverage and reimbursement under the national and provincial reimbursement drug lists in the PRC,
or from third-party payors and government authorities in the United States or any other jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">willingness of patients to pay any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses in the absence of coverage and reimbursement by third-party payors and government authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">relative convenience and ease of administration, including as compared with alternative treatments and competitive
therapies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effectiveness of our sales and marketing efforts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our drug candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals or
others in the medical community, we will not be able to generate significant revenue or become profitable. Even if our drugs achieve market acceptance, we may not be able to maintain such market acceptance over time if new products or technologies
are introduced which are more favorably received than our drugs, are more cost effective or render our drugs obsolete. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We face intense competition and rapid
technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our
drug candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. While
our exclusive focus is to develop drug candidates with potential to become novel or highly differentiated drugs, we continue to face competition with respect to our current drug candidates, and will face competition with respect to any drug
candidates that we may seek to develop or commercialize in the future. Our competitors include major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. We are developing our drug candidates for the
treatment of cancer in competition with a number of large biopharmaceutical companies that currently market and sell drugs or are pursuing the development of drugs also for the treatment of cancer. Some of these competitive drugs and therapies are
based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. For details, see &#147;Business&#151;Our Drug Pipeline.&#148; Potential competitors further include academic
institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development staff and experienced marketing
and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory
approval from the NMPA, the FDA or other comparable regulatory authorities more rapidly than we are able to and may be more effective in selling and marketing their products as well. For example, the NMPA has recently accelerated market approval of
drugs for diseases with high unmet medical need. In particular, the NMPA may review and approve drugs that have gained regulatory market approval in the United States, the European Union or Japan in the recent ten years without requiring further
clinical trials in China. This may lead to potential increased competition from drugs which have already obtained approval in other jurisdictions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Smaller or
early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of
technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any drug candidate
that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration than we do. Additionally, technologies developed by our competitors may render our potential drug candidates
uneconomical or obsolete, and we may not be successful in marketing our drug candidates against competitors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The manufacture of biopharmaceutical products is
a complex process which requires significant expertise and capital investment, and if we encounter problems in establishing our manufacturing capabilities or manufacturing our future products, our business could suffer. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have limited experience in managing the manufacturing process. The manufacture of biopharmaceutical products is a complex process, in part due to strict regulatory
requirements. As of the date of this prospectus, we have no existing manufacturing infrastructure or capabilities. If we are unable to identify an appropriate production site or a suitable partner to develop our manufacturing infrastructure, or fail
to do so in a timely manner, this may lead to significant delays in the manufacturing of our drug candidates once regulatory and marketing approvals have been obtained. The investment for building a new biologics manufacturing facility that is
compliant with cGMP regulations may also be a significant upfront cost for us. In turn, this could materially harm our commercialization plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, problems may arise during the manufacturing process for a variety of reasons, including equipment
malfunction, failure to follow specific protocols and procedures, problems with raw materials, delays related to the construction of new facilities or expansion of any future manufacturing facilities, including changes in manufacturing production
sites and limits to manufacturing capacity due to regulatory requirements, changes in the types of products produced, increases in the prices of raw materials, physical limitations that could inhibit continuous supply,
<FONT STYLE="white-space:nowrap">man-made</FONT> or natural disasters and environmental factors. If problems arise during the production of a batch of future products, that batch of future products may have to be discarded and we may experience
product shortages or incur added expenses. This could, among other things, lead to increased costs, lost revenue, damage to customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with
respect to other batches or products. If problems are not discovered before such product is released to the market, recall and product liability costs may also be incurred. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have no experience in launching and marketing drug candidates. We may not be able to effectively build and manage our sales network, or benefit from
third-party collaborators&#146; sales network. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently have no sales, marketing or commercial product distribution capabilities and have no experience
in marketing drugs. We intend to develop an <FONT STYLE="white-space:nowrap">in-house</FONT> marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with
other biopharmaceutical companies to recruit, hire, train and retain marketing and sales personnel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable or decide not to establish internal sales,
marketing and commercial distribution capabilities for any or all of the drugs we develop, we will likely pursue collaborative arrangements regarding the sales and marketing of our drugs. However, there can be no assurance that we will be able to
establish or maintain such collaborative arrangements, or, if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend on the efforts of such third parties, which may not be successful. We may have little
or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our drug candidates ourselves. We will also face competition in our search for third parties to
assist us with the sales and marketing efforts of our drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There can be no assurance that we will be able to develop
<FONT STYLE="white-space:nowrap">in-house</FONT> sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product, and as a result, we may not be able to
generate product sales revenue. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we are able to commercialize any approved drug candidates, reimbursement may be limited or unavailable in certain
market segments for our drug candidates, and we may be subject to unfavorable pricing regulations, which could harm our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The regulations that
govern regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review
period begins after marketing or licensing approval is granted. In some <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is
granted. As a result, we might obtain regulatory approval for a drug in a particular country, but then be subject to price regulations that delay our commercial launch of the drug and negatively impact the revenues we are able to generate from the
sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain regulatory approval. For example, according to a statement, Opinions on
Reforming the Review and Approval Process for Pharmaceutical Products and Medical Devices, issued by the PRC State Council in August 2015, the enterprises applying for new drug approval will be required to undertake that the selling price of new
drug on PRC mainland market shall not be higher than the comparable market prices of the product in its country of origin or PRC&#146;s neighboring markets, as applicable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to commercialize any drugs successfully also will depend in part on the extent to which reimbursement for these drugs and related treatments will be
available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which
medications they will pay for and establish reimbursement levels. A primary trend in the global healthcare industry is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the
amount of reimbursement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for
medical products. We cannot be sure that reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any
drug for which we obtain regulatory approval. Obtaining reimbursement for our drugs may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. If reimbursement is not
available or is available only to limited levels, we may not be able to successfully commercialize any drug candidate that we successfully develop. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There may be
significant delays in obtaining reimbursement for approved drug candidates, and coverage may be more limited than the purposes for which the drug candidates are approved by the NMPA, the FDA or other comparable regulatory authorities. Moreover,
eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also
not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on payments allowed for lower cost drugs that are already
reimbursed, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws
that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any
future approved drug candidates and any new drugs that we develop could have a material adverse effect on our business, our operating results, and our overall financial condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect the
prices we may obtain. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States and certain other jurisdictions, there have been a number of legislative and regulatory changes and proposed
changes regarding the healthcare system that could prevent or delay marketing approval of our drug candidates, restrict post-approval activities and affect our ability to sell profitably any drug candidates for which we obtain marketing approval.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, became law. The
ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance
industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our drug candidates are the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic
products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government
investigative powers, and enhanced penalties for noncompliance; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">extension of manufacturers&#146; Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expansion of eligibility criteria for Medicaid programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expansion of the entities eligible for discounts under the Public Health Service Act&#146;s pharmaceutical pricing
program; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">new requirements to report to CMS financial arrangements with physicians and teaching hospitals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a new requirement to annually report to the FDA drug samples that manufacturers and distributors provide to physicians;
and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical
effectiveness research, along with funding for such research. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and
promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the
marketing approvals, if any, of our drug candidates may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent
product labeling and post-marketing conditions and other requirements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>As we <FONT STYLE="white-space:nowrap">out-license</FONT> some of our
commercialization rights and engage in other forms of collaboration worldwide, including conducting clinical trials abroad, we may be exposed to specific risks of conducting our business and operations in international markets. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Markets outside of China form an important component of our growth strategy, as we <FONT STYLE="white-space:nowrap">out-license</FONT> some of our commercialization
rights to third parties outside the PRC and conduct certain of our clinical trials abroad. If we fail to obtain applicable licenses or fail to enter into strategic collaboration arrangements with third parties in these markets, or if these
collaboration arrangements turn out unsuccessful, our revenue-generating growth potential will be adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, international business
relationships subject us to additional risks that may materially adversely affect our ability to attain or sustain profitable operations, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">efforts to enter into collaboration or licensing arrangements with third parties in connection with our international
sales, marketing and distribution efforts may increase our expenses or divert our management&#146;s attention from the acquisition or development of drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in a specific country&#146;s or region&#146;s political and cultural climate or economic condition;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">differing regulatory requirements for drug approvals and marketing internationally; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulty of effective enforcement of contractual provisions in local jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potentially reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential third-party patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">economic weakness, including inflation or political instability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">compliance with tax, employment, immigration and labor laws for employees traveling abroad; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effects of applicable <FONT STYLE="white-space:nowrap">non-PRC</FONT> tax structures and potentially adverse tax
consequences; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations
incidental to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">workforce uncertainty and labor unrest; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential for <FONT STYLE="white-space:nowrap">so-called</FONT> parallel importing, which is what happens when a local
seller, faced with high or higher local prices, opts to import goods from an international market with low or lower prices rather than buying them locally; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure of our employees and contracted third parties to comply with Office of Foreign Assets Control rules and
regulations and the Foreign Corrupt Practices Act of the United States, and other applicable rules and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and
terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These and other risks may materially
adversely affect our ability to attain or sustain revenue from international markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If safety, efficacy, or other issues arise with any medical product that is used in combination with our drug
candidates, we may be unable to market such drug candidate or may experience significant regulatory delays or supply shortages, and our business could be materially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to develop certain of our drug candidates for use as a combination therapy. If the NMPA, the FDA or another comparable regulatory agency revokes its approval of
another therapeutic we use in combination with our drug candidates, we will not be able to market our drug candidates in combination with such revoked therapeutic. If safety or efficacy issues arise with these or other therapeutics that we seek to
combine with our drug candidates in the future, we may experience significant regulatory delays, and we may be required to redesign or terminate the applicable clinical trials. In addition, if manufacturing or other issues result in a supply
shortage of any component of our combination drug candidates or if we cannot secure supply of any component of our drug candidates at commercially reasonable or acceptable prices, we may not be able to complete clinical development of our drug
candidates on our current timeline or within our current budget, or at all. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Lack of third-party combination drugs may materially and adversely affect demand
for our drugs. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our drug candidates may be administered in combination with drugs of other pharmaceutical companies as one regimen. In addition, we often
use such third-party drugs in our development and clinical trials as controls for our studies. As a result, both the results of our clinical trials and the sales of our drugs may be affected by the availability of these third-party drugs. If other
pharmaceutical companies discontinue these combination drugs, regimens that use these combination drugs may no longer be prescribed, and we may not be able to introduce or find an alternative drug to be used in combination with our drugs at all or
in a timely manner and on a cost-effective basis. As a result, demand for our drugs may be lowered, which would in turn materially and adversely affect our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>As we rely on third
parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected
deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have relied on and plan to continue to rely on third-party contract research organization (&#147;CROs&#148;) to monitor and manage data for some of our ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical programs. We rely on
these parties for the execution of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is
conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also rely on third parties to assist in conducting our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies in accordance with Good Laboratory Practices
(&#147;GLP&#148;). We and our CROs are required to comply with GCP, GLP and other regulatory regulations and guidelines enforced by the NMPA, the FDA and comparable foreign regulatory authorities for all of our drug candidates in clinical
development. Regulatory authorities enforce these GCP, GLP or other regulatory requirements through periodic inspections of trial sponsors, investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP, GLP or other
regulatory requirements, the relevant data generated in our clinical trials may be deemed unreliable and the NMPA, the FDA or other comparable regulatory authorities may require us to perform additional clinical studies before approving our
marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP requirements. In addition, our clinical trials must be
conducted with drug candidates or products produced under cGMP requirements. Failure to comply with these regulations may require us to repeat <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials, which would delay the regulatory
approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our CROs have the right to terminate their agreements with us in the event of an unrectified material breach. If any of our relationships with
our third-party CROs is terminated, we may not be able to (i)&nbsp;enter into arrangements with alternative CROs or do so on commercially reasonable terms or (ii)&nbsp;meet our desired clinical development timelines. In addition, there is a natural
transition period when a new CRO commences work, and the new CRO may not provide the same type or level of services as the original provider and data from our clinical trials may be compromised as a </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
result. There is also a need for relevant technology to be transferred to the new CRO, which may take time and further delay our development timelines. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except for remedies available to us under our agreements with our CROs, we cannot control whether or not our CROs devote sufficient time and resources to our ongoing
clinical, nonclinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data
they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or
successfully commercialize our drug candidates. As a result, our results of operations and the commercial prospects for our drug candidates would be harmed and our costs could increase. In turn, our ability to generate revenues could be delayed or
compromised. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we rely on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves certain risks that
third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these third
parties, which could increase the risk that such information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party service providers. To
the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no
assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect to rely on third parties to manufacture at least a portion of our drug candidate supplies, and we intend to rely on third parties for at least a portion
of the manufacturing process of our drug candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product or fail to do so at acceptable quality levels or prices. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we plan to either construct or acquire a facility that will be used as our clinical-scale manufacturing and processing facility, we intend to also partially
rely on third-party vendors to manufacture supplies and process our drug candidates. We have not yet manufactured or processed our drug candidates on a commercial scale and may not be able to do so for any of our drug candidates. We have limited
experience in managing the manufacturing process, and our process may be more difficult or expensive than the approaches currently in use. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our anticipated reliance
on third-party manufacturers exposes us to certain risks, including, but not limited to, the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is
limited and the NMPA, the FDA or other comparable regulatory authorities must approve any manufacturers as part of their regulatory oversight of our drug candidates. This approval would require new testing and cGMP-compliance inspections by the
NMPA, the FDA or other comparable regulatory authorities. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our contract manufacturers may have little or no experience with manufacturing our drug candidates, and therefore may
require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our contract manufacturers may have limited capacity or limited manufacturing slots, which may affect the timeline for the
production of our drugs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our contract manufacturers might be unable to timely manufacture our drug candidates or produce the quantity and quality
required to meet our clinical and commercial needs, if any; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">contract manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements
appropriately; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our drugs, or may not
remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our drugs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our contract manufacturers are subject to ongoing periodic unannounced inspections by the NMPA and the FDA to ensure
strict compliance with cGMP and other government regulations in the PRC and the United States, respectively, and by other comparable regulatory authorities for corresponding regulatory requirements. We do not have control over third-party
manufacturers&#146; compliance with these regulations and requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party
manufacturers in the manufacturing process for our drugs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our contract manufacturers could breach or terminate their agreements with us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our contract manufacturers may be unable to sustain their business and become bankrupt as a result; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">raw materials and components used in the manufacturing process, particularly those for which we have no other source or
supplier, may not be available or may not be suitable or acceptable for use due to material or component defects; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">products and components from our third-party manufacturers may be subject to additional customs and import charges, which
may cause us to incur delays or additional costs as a result; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural or <FONT
STYLE="white-space:nowrap">man-made</FONT> disasters; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our drug candidates by the NMPA, the
FDA or other comparable regulatory authorities, result in higher costs or adversely impact the commercialization of our drug candidates. In addition, we will rely on third parties to perform certain specification tests on our drug candidates prior
to delivery to patients. If these tests are not appropriately done and test data is not reliable, patients could be put at risk of serious harm and the NMPA, the FDA or other comparable regulatory authorities could place significant restrictions on
our company until deficiencies are remedied. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The manufacture of biopharmaceutical products is complex and requires significant expertise and capital investment,
including the development of advanced manufacturing techniques and process controls. Currently, our drug raw materials for our manufacturing activities are supplied by multiple source suppliers. We have agreements for the supply of drug materials
with manufacturers or suppliers that we believe have sufficient capacity to meet our demands. In addition, we believe that adequate alternative sources for such supplies exist. However, there is a risk that, if supplies are interrupted, our business
would be materially harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Manufacturers of biopharmaceutical products often encounter difficulties in production, particularly in scaling up or out, validating
the production process, and assuring high reliability of the manufacturing process, including the absence of contamination. These problems include logistics and shipping, difficulties with production costs and yields, quality control, including
stability of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced regulations in the PRC, the United States and other applicable jurisdictions. Further, if contaminants
are discovered in the supply of our drug candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time for us to investigate and remedy the contamination. There can be no assurance
that any stability failures or other issues relating to the manufacture of our drug candidates will not occur in the future. Additionally, our contract manufacturers may experience manufacturing difficulties due to resource constraints or as a
result of labor disputes or unstable political environment. If our contract manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our drug candidate to
patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials, increase the costs associated with maintaining clinical trial programs and,
depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have entered into collaborations and may form or seek collaborations or strategic alliances or enter into
additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may form or seek
strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our drug
candidates and any future drug candidates that we may develop. Any of these relationships may require us to incur recurring or <FONT STYLE="white-space:nowrap">non-recurring</FONT> expenses and other charges, increase our near and long-term
expenditures, issue securities that dilute the value of our ADSs, or disrupt our management and business. For example, we have entered into a license and collaboration agreement with MorphoSys AG (&#147;MorphoSys&#148;), pursuant to which we <FONT
STYLE="white-space:nowrap">in-licensed</FONT> from MorphoSys the development and commercialization rights of TJ202 in Greater China. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process
is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our drug candidates because they may be deemed to be at too early a stage of development for
collaborative effort and third parties may not view our drug candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for the development and commercialization of a drug
candidate, we can expect to relinquish some or all of the control over the future success of that drug candidate to the third party. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, collaborations
involving our drug candidates are subject to specific risks, which include, but are not limited to, the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a
collaboration; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may not pursue the development and commercialization of our drug candidates or may elect not to continue or
renew the development or commercialization programs based on clinical trial results, change in their strategic focus due to the acquisition of competitive drugs, availability of funding, or other external factors, such as a business combination that
diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, discontinue a clinical trial,
repeat or conduct new clinical trials, or require a new formulation of a drug candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with
our drug candidates or future drugs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators with marketing and distribution rights to one or more of our drug candidates or future drugs may not commit
sufficient resources to their marketing and distribution; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or
proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may not always be cooperative or responsive in providing their services in a clinical trial;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disputes may arise between us and a collaborator that cause a delay or termination of the research, development or
commercialization of our drug candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable drug candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our drug candidates
or future drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result, if we enter into collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the benefit of such transactions
if we are unable to successfully integrate these agreements or partnerships with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither can we be certain that, following a strategic transaction or license, we will be able to achieve the revenue or specific net income that justifies such
transaction. If we are unable to reach agreements with suitable collaborators </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug candidate, reduce or delay its development program or one or more of our other development
programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake
development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have
sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates or bring them to market and generate product sales revenue, which would harm our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to obtain and maintain patent and other intellectual property protection for our drug candidates, or if the scope of such intellectual property
rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, and our ability to successfully commercialize any product or technology
may be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success depends in large part on our ability to protect our proprietary technology and drug candidates from competition by
obtaining, maintaining, defending and enforcing our intellectual property rights, including patent rights. As of September 30, 2019, our owned patent portfolio consist of five patents and 156 patent applications primarily in connection with the drug
candidates in our Global Portfolio, including 17 Patent Cooperation Treaty (&#147;PCT&#148;) patent applications, 10 U.S. patent applications, 13 PRC patent applications and 116 patent applications in other jurisdictions. In addition, as of
September 30, 2019, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the Greater China and Korea rights relating to 20 issued patents and 24 pending patent applications primarily in connection with TJ202, TJ101, TJ301, enoblituzumab and TJ107.
We seek to protect the drug candidates and technology that we consider commercially important by filing patent applications in China, the United States and other countries or regions, relying on trade secrets or pharmaceutical regulatory protection
or employing a combination of these methods. This process is expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications in all jurisdictions at a reasonable cost or in a
timely manner. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years
been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which
protect our technology or drug candidates or which effectively prevent others from commercializing competitive technologies and drug candidates. The patent examination process may require us or our licensors to narrow the scope of the claims of our
or our licensors&#146; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure that all of the potentially relevant prior art relating to our patents and patent applications has
been found. If such prior art exists, it can invalidate a patent or prevent a patent application from being issued as a patent. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if patents do issue on any of
these applications, there can be no assurance that a third party will not challenge their validity, enforceability, or scope, which may result in the patent claims being narrowed or invalidated, or that we will obtain sufficient claim scope in those
patents to prevent a third party from competing successfully with our drug candidates. We may become involved in interference, <I>inter partes</I> review, post grant review, ex parte reexamination, derivation, opposition or similar other proceedings
challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drug candidates and
compete directly with us, or result in our inability to manufacture or commercialize drug candidates without infringing third-party patent rights. Thus, even if our patent applications issue as patents, they may not issue in a form that will provide
us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or drug
candidates in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent
offices in the United&nbsp;States and other countries. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or
commercializing similar or identical technology and drug candidates, or limit the duration of the patent protection of our technology and drug candidates. Given the amount of time required for the development, testing and regulatory review of new
drug candidates, patents protecting such assets might expire before or shortly after such assets are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drug candidates
similar or identical to ours. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the
value of our patents or narrow the scope of our patent protection. Under the America Invents Act (&#147;AIA&#148;) enacted in 2011, the United States moved to this
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> system in early 2013 from the previous system under which the first to make the claimed invention was entitled to the patent. Assuming the other
requirements for patentability are met, the first to file a patent application is entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States
and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or
that we were the first to file for patent protection of such inventions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We enjoy only limited geographical protection with respect to certain patents and
may not be able to protect our intellectual property rights throughout the world, including in the PRC. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing and prosecuting patent applications and
defending patents covering our drug candidates in all countries throughout the world could be prohibitively expensive. Competitors may use our and our licensors&#146; technologies in jurisdictions where we have not obtained patent protection to
develop their own drug candidates and, further, may export otherwise infringing drug candidates to territories, including the PRC, where we and our licensors have patent protection, but enforcement rights are not as strong as that in the United
States or Europe. These drug candidates may compete with our drug candidates, and our and our licensors&#146; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The laws of some jurisdictions, including the PRC, do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United
States and Europe, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the
enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing drug candidates in violation of our proprietary rights
generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being
invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies
awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop
or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to
market our drug candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our drug candidates in all of our
expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value
of these rights may be diminished and we may face additional competition from others in those jurisdictions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some countries also have compulsory licensing laws
under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In those countries, the patent owner may have
limited remedies, which could materially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
diminish the value of such patents. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may
be impaired. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance and annuity fees on any issued patent are due to be paid to the United States Patent and Trademark Office (&#147;USPTO&#148;) and foreign patent
agencies over the lifetime of a patent. In addition, the USPTO and other foreign patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an
inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which such <FONT
STYLE="white-space:nowrap">non-compliance</FONT> will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction.
<FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, and <FONT
STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our drug
candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to
successfully commercialize our drug candidates in any indication for which they are approved. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our owned and
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and other intellectual property may be subject to further priority disputes or to inventorship disputes and similar proceedings. If we or our licensors are unsuccessful in any of these
proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to modify or cease the development, manufacture and commercialization of one or more of the drug
candidates we may develop, which could have a material adverse impact on our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We or our licensors may be subject to claims that former employees,
collaborators or other third parties have an interest in our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> If we or our
licensors are unsuccessful in any interference proceedings or other priority or validity disputes (including any patent oppositions) to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more
patents owned or licensed or our owned or licensed patent claims may be narrowed, invalidated, or held unenforceable. In addition, if we or our licensors are unsuccessful in any inventorship disputes to which we or they are subject, we may lose
valuable intellectual property rights, such as exclusive ownership of, or the exclusive right to use, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents. If we or our licensors are unsuccessful in any interference proceeding or
other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be
available on commercially reasonable terms or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If we are unable to obtain and maintain such licenses, we may need to modify or cease the development, manufacture, and
commercialization of one or more of our drug candidates. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical drug products. Any of
the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects. Even if we are successful in an interference proceeding or other similar priority or inventorship disputes, it could
result in substantial costs and be a distraction to our management and other employees. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Claims that our drug candidates or the sale or use of our future
products infringe, misappropriate or otherwise violate the patents or other intellectual property rights of third parties could result in costly litigation or could require substantial time and money to resolve, even if litigation is avoided.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot guarantee that our drug candidates or the sale or use of our future products do not and will not in the future infringe, misappropriate or
otherwise violate third-party patents or other intellectual property rights. Third parties might allege that we are infringing their patent rights or that we have misappropriated their trade secrets, or that we are otherwise violating their
intellectual property rights, whether with respect to the manner in which we have conducted our research, or with respect to the use or manufacture of the compounds we have developed or are developing. Litigation relating to patents and other
intellectual property rights in the biopharmaceutical and pharmaceutical industries is common, including patent infringement lawsuits. The various markets in which we plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. Some claimants may have substantially greater resources than we have and may
be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. Third parties might resort to litigation against us or other parties we have agreed to indemnify, which
litigation could be based on either existing intellectual property or intellectual property that arises in the future. For example, we are aware of a third-party U.S. patent and its counterpart European patents that relate to the use of antibodies
having specificity to PD-L1 to treat cancer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is also possible that we failed to identify, or may in the future fail to identify, relevant patents or patent
applications held by third parties that cover our drug candidates. Publication of discoveries in the scientific or patent literature often lags behind actual discoveries. Therefore, we cannot be certain that we were the first to invent, or the first
to file patent applications on, our drug candidates or for their uses, or that our drug candidates will not infringe patents that are currently issued or that are issued in the future. In the event that a third party has also filed a patent
application covering one of our drug candidates or a similar invention, our patent application may be regarded as a competing application and may not be approved in the end. Additionally, pending patent applications that have been published can,
subject to certain limitations, be later amended in a manner that could cover our products or their use. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a third party were to assert claims of patent
infringement against us, even if we believe such third-party claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able
to block our ability to commercialize the applicable product unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were
held by a court of competent jurisdiction to cover aspects of our compositions, formulations, or methods of treatment, prevention, or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable
product unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In addition, defending such claims would cause us to incur substantial expenses and could cause us to pay substantial damages,
if we are found to be infringing a third party&#146;s patent rights. These damages potentially include increased damages and attorneys&#146; fees if we are found to have infringed such rights willfully. In order to avoid or settle potential claims
with respect to any patent or other intellectual property rights of third parties, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties or both, which could be substantial. These licenses
may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented
from commercializing a drug candidate, or be forced, by court order or otherwise, to modify or cease some or all aspects of our business operations, if, as a result of actual or threatened patent or other intellectual property claims, we are unable
to enter into licenses on acceptable terms. Further, we could be found liable for significant monetary damages as a result of claims of intellectual property infringement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Defending against claims of patent infringement, misappropriation of trade secrets or other violations of intellectual property rights could be costly and
time-consuming, regardless of the outcome. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by
disclosure during this type of litigation. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Issued patents covering one or more of our drug candidates could be found invalid or unenforceable if challenged in court. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite measures we take to obtain and maintain patent and other intellectual property rights with respect to our drug candidates, our intellectual property rights
could be challenged or invalidated. For example, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our drug candidates, the defendant could counterclaim that our patent is invalid and/or
unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an
unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, SIPO, or the applicable foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
counterpart, or made a misleading statement, during prosecution. Although we believe that we have conducted our patent prosecution in accordance with a duty of candor and in good faith, the
outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all,
of the patent protection on a drug candidate. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against
the defendant and others. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. In addition, if the
breadth or strength of protection provided by our patents is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize our current or future drug candidates. Any loss of patent protection could have a
material adverse impact on one or more of our drug candidates and our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enforcing our intellectual property rights against third parties may also cause
such third parties to file other counterclaims against us, which could be costly to defend and could require us to pay substantial damages, cease the sale of certain drugs or enter into a license agreement and pay royalties (which may not be
possible on commercially reasonable terms or at all). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property litigation may lead to unfavorable publicity which may harm our reputation and
cause the market price of our ADSs to decline, and any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our drug candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim
proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our drug candidates, future drugs, programs or intellectual property could be diminished. Accordingly, the market price
of our ADSs may decline. Such announcements could also harm our reputation or the market for our drug candidates, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of intellectual property litigation, there can be no assurance that we would prevail, even if the case against us is weak or flawed. If third parties
successfully assert their intellectual property rights against us, prohibitions against using certain technologies, or prohibitions against commercializing our drug candidates, could be imposed by a court or by a settlement agreement between us and
a plaintiff. In addition, if we are unsuccessful in defending against allegations that we have infringed, misappropriated or otherwise violated the patent or other intellectual property rights of others, we may be forced to pay substantial damage
awards to the plaintiff. Additionally, we may be required to obtain a license from the intellectual property owner in order to continue our research and development programs or to commercialize any resulting product. It is possible that the
necessary license will not be available to us on commercially acceptable terms, or at all. This may not be technically or commercially feasible, may render our products less competitive, or may delay or prevent the launch of our products to the
market. Any of the foregoing could limit our research and development activities, our ability to commercialize one or more drug candidates, or both. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Most of our
competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex intellectual property litigation longer than we could. In addition, the uncertainties associated with
litigation could have a material adverse effect on our ability to raise the funds necessary to conduct our clinical trials, continue our internal research programs, <FONT STYLE="white-space:nowrap">in-license</FONT> needed technology, or enter into
strategic partnerships that would help us bring our drug candidates to market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, any future intellectual property litigation, interference or other
administrative proceedings will result in additional expense and distraction of our personnel. An adverse outcome in such litigation or proceedings may expose us or any future strategic partners to loss of our proprietary position, expose us to
significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms, if at all, each of which could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect
our drug candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patent
rights. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time-consuming, and inherently uncertain. In addition, the United States has recently enacted and is
implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to
increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained, if any. Depending on decisions by the U.S. Congress, the
federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For
example, in a recent case, <I>Assoc. for Molecular Pathology v. Myriad Genetics,</I><I></I><I>&nbsp;Inc.</I>, the U.S. Supreme Court held that certain claims to naturally-occurring substances are not patentable. Although we do not believe that our
currently issued patents and any patents that may issue from our pending patent applications directed to our drug candidates if issued in their currently pending forms, as well as patent rights licensed by us, will be found invalid based on this
decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patent rights. There could be similar changes in the laws of foreign jurisdictions that may impact the value of our patent
rights or our other intellectual property rights. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position
would be harmed. We also may be subject to claims that our employees, consultants, or advisers have wrongfully used or disclosed alleged trade secrets of their former employers or claims asserting ownership of what we regard as our own intellectual
property. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to our issued patents and pending patent applications, we rely on trade secret and confidential information, including unpatented <FONT
STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position and to protect our drug candidates. We seek to protect this trade secret and confidential information, in part, by
entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties that have access to them, such as our employees, corporate collaborators, outside scientific collaborators, sponsored researchers,
contract manufacturers, consultants, advisers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, any of these parties may breach such agreements and
disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the
outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us
and our competitive position would be harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, many of our employees, consultants, and advisers, including our senior management, were previously
employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants, and advisers, including members of our senior management, executed proprietary rights, <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information
or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any
such individual&#146;s former employer. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but in the future litigation may be necessary to defend against such
claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management. In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such
intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, and furthermore, the assignment of intellectual property rights may not be
self-executing, or the assignment agreements may be breached, each of which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could
result in substantial costs, be a distraction to our management and scientific personnel and have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be successful in obtaining or maintaining necessary rights for our development pipeline through acquisitions and
<FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because our programs may involve additional drug candidates that may require the use of proprietary
rights held by third parties, the growth of our business may depend in part on our ability to acquire and maintain licenses or other rights to use these proprietary rights. We may be unable to acquire or
<FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, or other intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a
competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive
advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be
unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual
property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or drug candidate, which could have a material adverse effect on our business, financial condition, results of
operations and prospects for growth. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our rights to develop and commercialize our drug candidates are subject, in part, to the terms and conditions of
licenses granted to us by others. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely on licenses to certain patent rights and other intellectual property from third parties that are important or
necessary to the development of our drug candidates. These and other licenses may not provide exclusive rights to use such intellectual property in all relevant fields of use and in all territories in which we may wish to develop or commercialize
our drug products. As a result, we may not be able to prevent competitors from developing and commercializing competitive drug products in territories included in all of our licenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the drug
candidates that we license from third parties. Moreover, we have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights that we jointly own with certain
of our licensors and <FONT STYLE="white-space:nowrap">sub-licensors.</FONT> Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent
with the best interests of our business. If our licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right
to develop and commercialize any of our drugs that are subject of such licensed rights could be adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the terms of the license agreements
with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity or unenforceability of these patents. Even if we are permitted to pursue the enforcement or
defense of our licensed patents, we will require the cooperation of our licensors and any applicable patent owners and such cooperation may not be provided to us. We cannot be certain that our licensors will allocate sufficient resources or
prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us
from continuing to license intellectual property that we may need to operate our business. If we lose any of our licensed intellectual property, our right to develop and commercialize any of our drug candidates that are subject of such licensed
rights could be adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our licensors may have relied on third party consultants or collaborators or on funds from third parties such that
our licensors are not the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license.</FONT> This could have a material adverse effect on our competitive position, business, financial conditions, results of operations,
and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements
and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize drug products covered by these license agreements. If such licenses are terminated, we may be required seek alternative <FONT
STYLE="white-space:nowrap">in-license</FONT> arrangements, which may not be available on commercially reasonable terms or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If these
<FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the underlying patents fail to provide the intended exclusivity, we may need to modify or cease the development, manufacture, and commercialization of one or more of our drug
candidates and competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses,
we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the
intellectual property that is subject to our existing licenses. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience
disruptions to our business relationships with our licensors, we could be required to pay monetary damages or could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business relies, in large part, on our ability to develop and commercialize drug candidates we have licensed from third parties, and we have entered into license
agreements with third parties providing us with rights to various third-party intellectual property, including rights in patents and patent applications. Our licenses may not encumber all intellectual property rights owned or controlled by the
affiliates of our licensors and relevant to our drug candidates, and we may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of drug candidates we may develop. In such case,
we may need to obtain additional licenses which may not be available on an exclusive basis, on commercially reasonable terms or at a reasonable cost, if at all. In that event, we may be required to expend significant time and resources to redesign
our drug candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize
the affected drug candidates, which could harm our business, financial condition, results of operations, and prospects significantly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if our licensors
breach the license agreements, we may not be able to enforce such agreements against our licensors&#146; parent entity or affiliates. Under each of our license and intellectual property-related agreements, in exchange for licensing or sublicensing
us the right to develop and commercialize the applicable drug candidates, our licensors will be eligible to receive from us milestone payments, tiered royalties from commercial sales of such drug candidates, assuming relevant approvals from
government authorities are obtained, or other payments. Our license and intellectual property-related agreements also require us to comply with other obligations including development and diligence obligations, providing certain information
regarding our activities with respect to such drug candidates and/or maintaining the confidentiality of information we receive from our licensors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to
comply with our obligations under our current or future license agreements, our counterparties may have the right to terminate these agreements and, upon the effective date of such termination, have the right to
<FONT STYLE="white-space:nowrap">re-obtain</FONT> the licensed and <FONT STYLE="white-space:nowrap">sub-licensed</FONT> technology and intellectual property. If any of our licensors terminate any of our licenses, we might not be able to develop,
manufacture or market any drug or drug candidate that is covered by the licenses provided for under these agreements and other third parties may be able to market drug candidates similar or identical to ours. In such case, we may have to negotiate
new or reinstated agreements with less favorable terms, and may be required to provide a grant back license to the licensors under our own intellectual property with respect to the terminated products. We may also face claims for monetary damages or
other penalties under these agreements. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the intellectual property rights licensed
and sublicensed to us, we may not be able to do so in a timely manner, at an acceptable cost or at all. In particular, some of the milestone payments are payable upon our drug candidates reaching development milestones before we have commercialized,
or received any revenue from, sales of such drug candidate, and we cannot guarantee that we will have sufficient resources to make such milestone payments. Any uncured, material breach under the license agreements could result in our loss of
exclusive rights and may lead to a complete termination of our rights to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
applicable drug candidate. Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. Certain of our license agreements also
require us to meet development thresholds to maintain the license, including establishing a set timeline for developing and commercializing products. Disputes may arise regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which our technology and processes infringe, misappropriate or violate intellectual property of the licensor
that is not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the sublicensing of patent and other rights under our collaborative development relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be
susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we
believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual
property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug candidates, which could have a
material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily protect us
from all potential threats to our competitive advantage. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is
uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may be able to make compounds that are similar to our drug candidates but that are not covered by the claims of the
patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we might not have been the first to make the inventions covered by the issued patents or pending patent applications that
we own or may in the future exclusively license, which could result in the patents applied for not being issued or being invalidated after issuing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we might not have been the first to file patent applications covering certain of our inventions, which could result in the
patents applied for not being issued or being invalidated after issuing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held
invalid or unenforceable, as a result of legal challenges by our competitors or other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may obtain patents for certain compounds many years before we receive regulatory approval for drugs containing such
compounds, and because patents have a limited life, which may begin to run prior to the commercial sale of the related drugs, the commercial value of our patents may be limited; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then
use the information learned from such activities to develop competitive drugs for commercialization in our major markets; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may fail to develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we operate;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">third parties may gain unauthorized access to our intellectual property due to potential lapses in our information
systems; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the patents of others may have an adverse effect on our business, for example by preventing us from commercializing one or
more of our drug candidates for one or more indications. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of the aforementioned threats to our competitive advantage could have a material
adverse effect on our business and future prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not adequately protected, we may not be able to build name
recognition in our markets of interest and our competitive position may be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We own registered trademarks. We may not be able to obtain
trademark protection in territories that we consider of significant importance to us. In addition, any of our trademarks or trade names, whether registered or unregistered, may be challenged, opposed, infringed, cancelled, circumvented or declared
generic, or determined to be infringing on other marks, as applicable. We may not be able to protect our rights to these trademarks and trade names, which we will need to build name recognition by potential collaborators or customers in our markets
of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Terms of our future patents may not be sufficient to effectively protect our drug candidates and business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In many countries where we file applications for patents, the term of an issued patent is generally 20 years from the earliest claimed filing date of a <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent application in the applicable country. Although various extensions may be available, the life of a patent and the protection it affords are limited. Even if we obtain patents covering our drug
candidates, we may still be open to competition from other companies, as well as generic medications once the patent life has expired for a drug. While there are patent regulations in the PRC in respect of regulatory data protection of new drugs
containing new chemical components, there are currently no other clear mechanisms providing patent term extension or patent linkages for other drugs in the PRC. Therefore, it is possible that a lower-cost generic drug can emerge onto the market much
more quickly. PRC regulators have set out a framework for integrating patent linkage and data exclusivity into the PRC regulatory regime, as well as for establishing a pilot program for patent term extension. This framework will require adoption of
regulations to be implemented, although no such regulations have been issued to date. These factors may result in weaker protection for us against generic competition in the PRC than could be available to us in other jurisdictions, such as the
United States. In addition, patents which we expect to obtain in the PRC may not be eligible to be extended for patent terms lost during clinical trials and the regulatory review process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable to obtain patent term extensions or if such extensions are less than requested for, our competitors may obtain approval of competing products following
our patent expirations and our business, financial condition, results of operations and prospects could be materially harmed as a result. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we do not obtain
additional protection under the Hatch-Waxman Amendments and similar legislation in other countries extending the terms of our patents, if issued, relating to our drug candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending upon the timing, duration and specifics of FDA regulatory approval for our drug candidates, one or more of our U.S. patents, if issued, may be eligible for
limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#147;Hatch-Waxman Amendments&#148;). The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for
patent term lost during drug development and the FDA regulatory review process. Patent term extensions, however, cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of drug approval by the FDA, and only one
patent can be extended for a particular drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The application for patent term extension is subject to approval by the USPTO, in conjunction with the FDA. We may
not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period
or the scope of patent protection afforded could be less than we request. If we are unable to obtain a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patent term extension for a given patent or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our drug will be shortened
and our competitors may obtain earlier approval of competing drugs, and our ability to generate revenues could be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related
to Our Industry, Business and Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our future success depends on our ability to attract, retain and motivate senior management and qualified
scientific employees. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are highly dependent on the expertise of the members of our research and development team, as well as the principal members of our
management. We have entered into employment agreements with our executive officers, but each of them may terminate their employment with us at any time with prior written notice. In addition, we currently do not have
<FONT STYLE="white-space:nowrap">&#147;key-man&#148;</FONT> insurance for any of our executive officers or other key personnel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recruiting, retaining and
motivating qualified management, scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of
our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Further, replacing executive officers and key employees may be difficult and may take an extended period of
time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs. Competition to hire from this limited pool is intense,
and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous biopharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific and
clinical personnel from universities and research institutions. In addition, our management will be required to devote significant time to new compliance initiatives from our status as a public company, which may require us to recruit more
management personnel. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to experience significant growth in the number of our employees and consultants and the scope of our operations, particularly in the areas of
clinical development, regulatory affairs and business development. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit
and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead
to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations, and have a material adverse effect on our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The data and information that we gather in our research and development process could be inaccurate or incomplete, which could harm our business, reputation,
financial condition and results of operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We collect, aggregate, process, and analyze data and information from our
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, manufacturing technology development programs and clinical programs. We also engage in substantial information gathering following the identification of a promising drug candidate.
Because data in the healthcare industry is fragmented in origin, inconsistent in format, and often incomplete, the overall quality of data collected or accessed in the healthcare industry is often subject to challenge, the degree or amount of data
which is knowingly or unknowingly absent or omitted can be material, and we often discover data issues and errors when monitoring and auditing the quality of our data. If we make mistakes in the capture, input, or analysis of these data, our ability
to advance the development of our drug candidates may be materially harmed and our business, prospects and reputation may suffer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also engage in the procurement
of regulatory approvals necessary for the development and commercialization of our products under development, for which we manage and submit data to governmental entities. These processes and submissions are governed by complex data processing and
validation policies and regulations. Notwithstanding such policies and regulations, interim, <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary data from our clinical trials that we announce or publish from time to time may change as
more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, in which case we may be exposed to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
liability to a customer, court or government agency that concludes that our storage, handling, submission, delivery, or display of health information or other data was wrongful or erroneous.
Although we maintain insurance coverage for clinical trials, this coverage may prove to be inadequate or could cease to be available to us on acceptable terms, if at all. Even unsuccessful claims could result in substantial costs and diversion of
management time, attention, and resources. A claim brought against us that is uninsured or under-insured could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we rely on CROs, our partners and other third parties to monitor and manage data for some of our ongoing
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical programs and control only certain aspects of their activities. If any of our CROs, our partners or other third parties does not perform to our standards in terms of data accuracy or
completeness, data from those <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials may be compromised as a result, and our reliance on these parties does not relieve us of our regulatory responsibilities. For a detailed
discussion, see &#147;&#151;Risks Related to Our Reliance on Third Parties&#151;As we rely on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, if we lose our relationships with these
third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially
harmed&#148; above. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to liability lawsuits arising from our clinical trials. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently carry liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a
court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or which is in excess of the limits of our insurance coverage. Our insurance policies also contain various exclusions, and we may be subject to
particular liability claims for which we have no coverage. We will have to pay any amount awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able
to obtain, sufficient capital to pay such amounts. In addition, if we cannot successfully defend ourselves against such claims, we may incur substantial liabilities and be required to suspend or delay our ongoing clinical trials. Even a successful
defense would require significant financial and management resources. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regardless of the merits or eventual outcome, liability claims may result in significant
negative consequences to our business and prospects, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">decreased demand for our drug candidates or any resulting products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injury to our reputation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of other clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a diversion of our management&#146;s time and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inability to commercialize our drug candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a decline in the market price of our ADSs. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have limited insurance coverage, and any claims beyond our insurance coverage may result in our incurring substantial costs and a diversion of resources.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain insurance policies that are required under PRC laws and regulations as well as insurance based on our assessment of our operational needs and
industry practice. We also maintain liability insurance covering our clinical trials. In line with industry practice in the PRC, we have elected not to maintain certain types of insurances, such as business interruption insurance or <FONT
STYLE="white-space:nowrap">key-man</FONT> insurance. Our insurance coverage may be insufficient to cover any claim for product liability, damage to our fixed assets or employee injuries. Any liability or damage to, or caused by, our facilities or
our personnel beyond our insurance coverage may result in our incurring substantial costs and a diversion of resources. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Disruptions in the financial markets
and economic conditions could affect our ability to raise capital. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Global economies could suffer dramatic downturns as the result of a deterioration in the
credit markets and related financial crisis as well as a variety of other factors including, extreme volatility in security prices, severely diminished liquidity and credit availability, ratings downgrades of certain investments and declining
valuations of others. In the past, governments have taken unprecedented actions in an attempt to address and rectify these extreme market and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
economic conditions by providing liquidity and stability to the financial markets. If these actions are not successful, the return of adverse economic conditions may cause a significant impact on
our ability to raise capital, if needed, on a timely basis and on acceptable terms or at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, there is considerable uncertainty over the long-term
effects of the expansionary monetary and fiscal policies adopted by the central banks and financial authorities of some of the world&#146;s leading economies, including the United States and China. There have been concerns over unrest and terrorist
threats in the Middle East, Europe and Africa and over the conflicts involving Ukraine, Syria and North Korea. There have also been concerns on the relationship among China and other Asian countries, which may result in or intensify potential
conflicts in relation to territorial disputes or the trade related disputes between the United States and China. In addition, the U.K. held a referendum on June&nbsp;23, 2016 on its membership in the European Union, in which a majority of voters in
the U.K. voted to exit the European Union (commonly referred to as &#147;Brexit&#148;). The U.K.&#146;s departure from the European Union remains uncertain. Brexit could adversely affect European and worldwide economic and market conditions and
could contribute to instability in global financial and foreign exchange markets. It is unclear whether these challenges and uncertainties will be contained or resolved, and what effects they may have on the global political and economic conditions
in the long term. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities,
including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are exposed to the risk of fraud,
misconduct or other illegal activities by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">comply with the laws of the NMPA, the FDA and other comparable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide true, complete and accurate information to the NMPA, the FDA and other comparable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">comply with manufacturing standards we have established; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">comply with healthcare fraud and abuse laws in the PRC, the United States and similar fraudulent misconduct laws in other
applicable jurisdictions; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">report financial information or data accurately or to disclose unauthorized activities to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, our founder, Dr.&nbsp;Jingwu Zhang Zang, was the corresponding author of a research paper prepared by scientists at GSK China&#146;s research center and
published in Nature Medicine in 2010. The paper was retracted in 2013 as a result of misrepresentation of certain data for which Dr.&nbsp;Zang admitted his management oversight, accepted the responsibility as the corresponding author and coordinated
the retraction of the paper. In addition, Dr.&nbsp;Zang received a warning letter from the FDA in March 1999 relating to the lack of IND approval before the initiation of a clinical research study in human subjects. For details, please see
&#147;Management&#151;Certain Past Incidents.&#148; We cannot assure you that there will not be any inquiries, investigations or other actions against Dr.&nbsp;Zang by any regulatory or government authorities or any negative publicity against
Dr.&nbsp;Zang or us regarding these incidents, any of which could distract Dr.&nbsp;Zang and our management&#146;s attention and negatively affect our business and results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we obtain approval of any of our drug candidates and begin commercializing those drugs in the PRC, the United States or other applicable jurisdictions, our potential
exposure under the laws of such jurisdictions will increase significantly and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal
investigators and research patients, as well as future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry,
are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and
commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which
could result in regulatory sanctions and cause serious harm to our reputation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is not always possible to identify and deter misconduct by employees and other parties, and the precautions we
take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or
regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or
other sanctions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute the value of your
investment in our ADSs, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may evaluate various acquisitions and
strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including, but not limited to:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the assumption of additional indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the issuance of our equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated
with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the diversion of our management&#146;s attention from our existing product programs and initiatives in pursuing such a
strategic merger or acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">risks and uncertainties associated with the assimilation of operations, corporate culture and personnel of the acquired
business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and
its existing drugs or drug candidates and regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in
undertaking the acquisition or even to offset the associated acquisition and maintenance costs; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in accounting principles relating to recognition and measurement of our investments that may have a significant
impact on our financial results. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations,
incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this
inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to
comply with applicable anti-bribery laws, our reputation may be harmed and we could be subject to penalties and significant expenses that have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to anti-bribery laws in China that generally prohibit companies and their intermediaries from making payments to government officials for the purpose of
obtaining or retaining business or securing any other improper advantage. In addition, although currently our primary operating business is in China, we are subject to the Foreign Corrupt Practices Act (the &#147;FCPA&#148;). The FCPA generally
prohibits us from making improper payments to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> officials for the purpose of obtaining or retaining business. Although we have policies and procedures designed to ensure that we, our employees and our
agents comply with anti-bribery laws, there is no assurance that such policies or procedures will prevent our agents, employees and intermediaries from engaging in bribery activities. Failure to comply with anti-bribery laws could disrupt our
business and lead to severe criminal and civil penalties, including imprisonment, criminal and civil fines, loss of our export licenses, suspension of our ability to do business with the government, denial of government reimbursement for our
products and/or exclusion from participation in government healthcare programs. Other remedial measures could include further changes or enhancements to our procedures, policies, and controls and potential personnel changes and/or disciplinary
actions, any of which could have a material adverse effect on our business, financial condition, results of operations and liquidity. We could also be adversely affected by any allegation that we violated such laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any failure to comply with applicable regulations and industry standards or obtain various licenses and permits
could harm our reputation and our business, results of operations and prospects. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A number of governmental agencies or industry regulatory bodies in the
PRC, the United States and other applicable jurisdictions impose strict rules, regulations and industry standards governing biopharmaceutical research and development activities, which apply to us. Our or our CROs&#146; failure to comply with such
regulations could result in the termination of ongoing research, administrative penalties imposed by regulatory bodies or the disqualification of data for submission to regulatory authorities. This could harm our business, reputation, prospects for
future work and results of operations. For example, if we or our CROs were to treat research animals inhumanely or in violation of international standards set out by the Association for Assessment and Accreditation of Laboratory Animal Care, it
could revoke any such accreditation and the accuracy of our animal research data could be questioned. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we or our CROs or other contractors or consultants
fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and third parties, such as our CROs or other contractors or consultants, are subject to numerous environmental, health and safety laws and regulations, including
those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and radioactive and biological
materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of
contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and
penalties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of or exposure to hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in
connection with our storage, use or disposal of biological, hazardous or radioactive materials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may be required to incur substantial costs to
comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may
result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we face allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with laws and
encounter sanctions, our reputation, revenues and liquidity may suffer, and our drug candidates and future drugs could be subject to restrictions or withdrawal from the market. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any government investigation of alleged violations of laws could require us to expend significant time and resources in response, and could generate negative publicity.
Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues from our drugs. If regulatory sanctions are applied or if regulatory approval is withdrawn, the
value of our company and our operating results will be adversely affected. Additionally, if we are unable to generate revenues from our product sales, our potential for achieving profitability will be diminished and the capital necessary to fund our
operations will be increased. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security
breaches. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although to our knowledge we have not experienced any material system failure or security breach to date, if such an event were to occur and
cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in
our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we partially rely on our third-party research institution collaborators for research and development of our drug candidates and other
third parties for the manufacture of our drug candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or
applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our drug candidates could be delayed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could
include civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use or
adoption, and could otherwise negatively affect our operating results and business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The regulatory framework for the collection, use, safeguarding,
sharing, transfer and other processing of personal information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Regulatory authorities in virtually every jurisdiction in which we operate have implemented
and are considering a number of legislative and regulatory proposals concerning personal data protection. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory authorities in China have implemented and are
considering a number of legislative and regulatory proposals concerning data protection. For example, China&#146;s Cyber Security Law, which became effective in June 2017, created China&#146;s first national-level data protection for &#147;network
operators,&#148; which may include all organizations in China that provide services over the internet or another information network. Numerous regulations, guidelines and other measures are expected to be adopted under the umbrella of the Cyber
Security Law. Drafts of some of these measures have now been published, including the draft rules on cross-border transfers published by the China Cyberspace Administration in 2017, which may, upon enactment, require security review before
transferring human health-related data out of China. In addition, certain industry-specific laws and regulations affect the collection and transfer of personal data in China. For example, the PRC State Council promulgated Regulations on the
Administration of Human Genetic Resources (effective in July 2019), which require approval from the Science and Technology Administration Department of the State Council where human genetic resources, or HGR, are involved in any international
collaborative project and additional approval for any export or cross-border transfer of the HGR samples or associated data. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices,
potentially resulting in confiscation of HGR samples and associated data and administrative fines. In addition, the interpretation and application of data protection laws in China and elsewhere are often uncertain and in flux. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, we are subject to laws and regulations that address privacy, personal information protection and data security at both the federal and state
levels. Numerous laws and regulations, including security breach notification laws, health information privacy laws, and consumer protection laws, govern the collection, use, disclosure and protection of health-related and other personal
information. Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all measures required by regulators or courts in their
interpretation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory authorities in Europe have implemented and are considering a number of legislative and regulatory proposals concerning data protection.
For example, the General Data Protection Regulation (EU) 2016/679, or GDPR, which became effective in May 2018, imposes a broad range of strict requirements on companies subject to the GDPR, such as us, including, but not limited to, requirements
relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside the European Economic Area (including to the United States), providing details to those individuals
regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#146; requests to exercise their rights in
respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, and recordkeeping. The GDPR substantially increases the penalties to which we
could be subject in the event of any <FONT STYLE="white-space:nowrap">non-compliance,</FONT> including fines of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to 20,000,000
Euros or up to 4% of our total worldwide annual turnover for more serious offenses. Given the new law, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all measures required by
data protection authorities or courts in interpretation of the new law. National laws of member states of the European Union are in the process of being adapted to the requirements under the GDPR. Because the GDPR
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
specifically gives member states flexibility with respect to certain matters, national laws may partially deviate from the GDPR and impose different obligations from country to country, leading
to additional complexity and uncertainty. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that we will continue to face uncertainty as to whether our efforts to comply with evolving obligations under
global data protection, privacy and security laws will be sufficient. Any failure or perceived failure by us to comply with applicable laws and regulations could result in reputational damage or proceedings or actions against us by governmental
entities, individuals or others. These proceedings or actions could subject us to significant civil or criminal penalties and negative publicity, result in the delayed or halted transfer or confiscation of certain personal information, require us to
change our business practices, increase our costs and materially harm our business, prospects, financial condition and results of operations. In addition, our current and future relationships with customers, vendors, pharmaceutical partners and
other third parties could be negatively affected by any proceedings or actions against us or current or future data protection obligations imposed on them under applicable law, including the GDPR. In addition, a data breach affecting personal
information, including health information, could result in significant legal and financial exposure and reputational damage that could potentially have an adverse effect on our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Natural disasters, acts of war or terrorism or other factors beyond our control may adversely affect the economy, infrastructure and livelihood of the people in the
regions where we conduct our business. Our operations may be under the threat of floods, earthquakes, sandstorms, snowstorms, fire or drought, power, water or fuel shortages, failures, malfunction and breakdown of information management systems,
unexpected maintenance or technical problems, or may be susceptible to potential wars or terrorist attacks. Serious natural disasters may result in loss of lives, injury, destruction of assets and disruption of our business and operations. Acts of
war or terrorism may also injure our employees, cause loss of lives, disrupt our business network and destroy our markets. Any of these factors and other factors beyond our control could have an adverse effect on the overall business sentiment and
environment, cause uncertainties in the regions where we conduct business, cause our business to suffer in ways that we cannot predict and materially and adversely impact our business, financial conditions and results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have identified two material weaknesses in our internal controls, and if we fail to implement and maintain an effective system of internal controls to
remediate our material weaknesses over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, we have been a private company with limited accounting personnel and other resources with which to address our internal controls. In the course
of auditing our consolidated financial statements, we and our independent registered public accounting firm identified two material weaknesses and control deficiencies in our internal control over financial reporting. As defined in the standards
established by the U.S. Public Company Accounting Oversight Board, a &#147;material weakness&#148; is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a
material misstatement of the company&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The material weaknesses
that have been identified relate to (i)&nbsp;our lack of sufficient and competent financial reporting and accounting personnel with appropriate knowledge of U.S. GAAP and the reporting and compliance requirements of the United States Securities and
Exchange Commission, or the SEC, to formalize key controls over financial reporting and to prepare consolidated financial statements and related disclosures; and (ii)&nbsp;our lack of sufficient documented financial closing policies and procedures,
specifically those related to (a)&nbsp;accounting for licensing and collaboration agreements and (b)&nbsp;period end expenses <FONT STYLE="white-space:nowrap">cut-off</FONT> and accruals. These material weaknesses, if not timely remedied, may lead
to significant misstatements in our consolidated financial statements in the future. Following the identification of the material weaknesses and other control deficiencies, we have taken measures and plan to continue to take measures to remediate
these deficiencies. See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Internal Control over Financial Reporting.&#148; However, the implementation of those measures may not fully remediate the
material weaknesses in a timely manner. Our failure to correct these deficiencies or our failure to discover and address any other deficiencies could result in inaccuracies in our financial statements and impair our ability to comply with applicable
financial reporting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
requirements and related regulatory filings on a timely basis. Moreover, ineffective internal control over financial reporting could significantly hinder our ability to prevent fraud. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, we will become subject to the Sarbanes-Oxley Act of 2002. Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404,
requires that we include a report from management on the effectiveness of our internal control over financial reporting in our annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> beginning with our annual report for the fiscal year
ending December&nbsp;31, 2020. In addition, once we cease to be an &#147;emerging growth company&#148; as defined in the JOBS Act, our independent registered public accounting firm must attest to and report on the effectiveness of our internal
control over financial reporting. Our management may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our
independent registered public accounting firm, after conducting its own independent testing, may issue an adverse report if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated or
reviewed, or if it interprets the relevant requirements differently from us. In addition, once we have become a public company, our reporting obligations may place a significant strain on our management, operational and financial resources and
systems for the foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the course of documenting and
testing our internal control procedures, in order to satisfy the requirements of Section&nbsp;404, we may identify other weaknesses and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain the adequacy
of our internal control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in
accordance with Section&nbsp;404. If we fail to establish and maintain adequate internal controls, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to
lose confidence in our reported financial information. This could limit our access to capital markets, adversely affect our results of operations and lead to a decline in the trading price of the ADSs. Additionally, ineffective internal controls
could expose us to an increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list or to other regulatory investigations and civil or criminal sanctions. We could also be
required to restate our historical financial statements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our auditor, like other independent registered public accounting firms operating in China, is not
permitted to be subject to inspection by Public Company Accounting Oversight Board, and consequently investors may be deprived of the benefits of such inspection. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our auditor, the independent registered public accounting firm that issued the audit report included elsewhere in this registration statement, as an auditor of
companies that are traded publicly in the United States and a firm registered with the Public Company Accounting Oversight Board (United States), or PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular
inspections to assess its compliance with applicable professional standards. Our auditor is located in, and organized under the laws of, the PRC, which is a jurisdiction where the PCAOB, has been unable to conduct inspections without the approval of
the Chinese authorities. In May 2013, PCAOB announced that it had entered into a Memorandum of Understanding on Enforcement Cooperation with the CSRC and the PRC Ministry of Finance, which establishes a cooperative framework between the parties for
the production and exchange of audit documents relevant to investigations undertaken by PCAOB, the CSRC or the PRC Ministry of Finance in the United States and the PRC, respectively. PCAOB continues to be in discussions with the China Securities
Regulatory Commission, or CSRC, and the PRC Ministry of Finance to permit joint inspections in China of audit firms that are registered with PCAOB and audit Chinese companies that trade on U.S. exchanges. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December 7, 2018, the SEC and the PCAOB issued a joint statement highlighting continued challenges faced by the U.S. regulators in their oversight of financial
statement audits of U.S.-listed companies with significant operations in China. However, it remains unclear what further actions, if any, the SEC and PCAOB will take to address the problem. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This lack of PCAOB inspections in China prevents the PCAOB from fully evaluating audits and quality control procedures of our independent registered public accounting
firm. As a result, we and investors in our ordinary shares are deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in China makes it more difficult to evaluate the effectiveness of our
independent registered public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
accounting firm&#146;s audit procedures or quality control procedures as compared to auditors outside of China that are subject to PCAOB inspections, which could cause investors and potential
investors in our stock to lose confidence in our audit procedures and reported financial information and the quality of our financial statements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Proceedings
instituted by the SEC against &#147;big four&#148; PRC-based accounting firms, including our independent registered public accounting firm, could result in financial statements being determined to not be in compliance with the requirements of the
Exchange Act. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Starting in 2011 &#147;big four&#148; PRC-based accounting firms, including our independent registered public accounting firm, were affected
by a conflict between U.S. and Chinese law. Specifically, for certain U.S.-listed companies operating and audited in mainland China, the SEC and the PCAOB sought to obtain from the Chinese firms access to their audit work papers and related
documents. The firms were, however, advised and directed that under Chinese law, they could not respond directly to the U.S. regulators on those requests, and that requests by foreign regulators for access to such papers in China had to be channeled
through the CSRC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In late 2012, this impasse led the SEC to commence administrative proceedings under Rule 102(e) of its Rules of Practice and also under the
Sarbanes-Oxley Act of 2002 against the Chinese accounting firms, including our independent registered public accounting firm. A first instance trial of the proceedings in July 2013 in the SEC&#146;s internal administrative court resulted in an
adverse judgment against the firms. The administrative law judge proposed penalties on the firms including a temporary suspension of their right to practice before the SEC, although that proposed penalty did not take effect pending review by the
Commissioners of the SEC. On February 6, 2015, before a review by the Commissioner had taken place, the firms reached a settlement with the SEC. Under the settlement, the SEC accepted that future requests by the SEC for the production of documents
will normally be made to the CSRC. The firms were to receive matching Section 106 requests, and were required to abide by a detailed set of procedures with respect to such requests, which in substance require them to facilitate production via the
CSRC. If they failed to meet specified criteria, the SEC retained authority to impose a variety of additional remedial measures on the firms depending on the nature of the failure. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the settlement, the underlying proceeding against the four China-based accounting firms was deemed dismissed with prejudice four years after entry of
the settlement. The four-year mark occurred on February 6, 2019. While we cannot predict if the SEC will further challenge the four China-based accounting firms&#146; compliance with U.S. law in connection with U.S. regulatory requests for audit
work papers or if the results of such a challenge would result in the SEC imposing penalties such as suspensions. If additional remedial measures are imposed on the &#147;big four&#148; PRC-based accounting firms, including our independent
registered public accounting firm, we could be unable to timely file future financial statements in compliance with the requirements of the Exchange Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the
event the &#147;big four&#148; PRC-based accounting firms become subject to additional legal challenges by the SEC or PCAOB, depending upon the final outcome, listed companies in the United States with major PRC operations may find it difficult or
impossible to retain auditors in respect of their operations in China, which could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act, including possible delisting. Moreover, any
negative news about any such future proceedings against these audit firms may cause investor uncertainty regarding China-based, U.S.-listed companies and the market price of our common stock may be adversely affected. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our independent registered public accounting firm was denied, even temporarily, the ability to practice before the SEC and we were unable to timely find another
registered public accounting firm to audit and issue an opinion on our financial statements, our financial statements could be determined not to be in compliance with the requirements of the Exchange Act. Such a determination could ultimately lead
to the delisting of the ADSs from the Nasdaq Global Market or deregistration from the SEC, or both, which would substantially reduce or effectively terminate the trading of the ADSs in the United States. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our reputation is important to our business success. Negative publicity may adversely affect our reputation and business prospects. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any negative publicity concerning us, our affiliates or any entity that shares the <FONT STYLE="white-space:nowrap">&#147;I-Mab&#148;</FONT> name, even if untrue, could
adversely affect our reputation and business prospects. There can be no assurance that negative publicity about us </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
or any of our affiliates or any entity that shares the <FONT STYLE="white-space:nowrap">&#147;I-Mab&#148;</FONT> name would not damage our brand image or have a material adverse effect on our
business, results of operations and financial condition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Negative publicity with respect to us, our management, employees, business partners, affiliates, or
our industry, may materially and adversely affect our reputation, business, results of operations and prospect. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our reputation is vulnerable to many
threats that can be difficult or impossible to control, and costly or impossible to remediate. Negative publicity about us, such as alleged misconduct or improper activities, or negative rumors relating to us, our management, employees, business
partners or affiliates, can harm our business and results of operations, even if they are unsubstantiated or are satisfactorily addressed. For example, a number of media reported that our founder, Dr.&nbsp;Jingwu Zhang Zang, was involved in
misrepresentation of certain data in a research paper prepared by scientists at GSK China&#146;s research center and published in Nature Medicine in 2010, for which Dr.&nbsp;Zang was the corresponding author, and consequently Dr.&nbsp;Zang was
dismissed by GSK in 2013. In addition, Dr.&nbsp;Zang received a warning letter from the FDA in March 1999 relating to the lack of IND approval before the initiation of a clinical research study in human subjects. For details, please see
&#147;Management&#151;Certain Past Incidents.&#148; To the best of our knowledge, Dr.&nbsp;Zang was not and is not subject to any legal or regulatory charges, proceedings or disciplinary actions in connection with these incidents or by relevant
parties involved in the incidents. However, we cannot assure you that there will not be any inquiries, investigations or other actions against Dr.&nbsp;Zang by any regulatory or government authorities in the future. Any regulatory inquiries or
investigations or other actions against Dr.&nbsp;Zang or our other management, any perceived unethical, fraudulent, or inappropriate business conduct by us or perceived wrong doing by any key member of our management team or other employees, our
business partners or our affiliates, could harm our reputation and materially adversely affect our business. Regardless of the merits or final outcome of any such regulatory inquiries or investigations or other actions, our reputation may be
substantially damaged, which may impede our ability to attract and retain talents and business partners and grow our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, any negative media
publicity about the biopharmaceutical industry in general or product or service quality problems of other companies in the industry, including our peers, may also negatively impact our reputation. If we are unable to maintain a good reputation, our
ability to attract and retain key employees and business partners could be harmed which in turn may materially and adversely affect our business, results of operations and prospect. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Change in business prospects of acquisitions may result in impairment to our goodwill, which could negatively affect our reported results of operations.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired a controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in July 2017 and the remaining interest in <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018. In connection with our acquisition of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we identified RMB148.8&nbsp;million of intangible assets and RMB162.6&nbsp;million of goodwill
of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin attributable to core technology and synergy effects expected from combining the operations of the discovery and development of innovative biologics and the development of clinical stage
biologics. We are required to test our goodwill annually, or more frequently if events or changes in circumstances indicate that it might be impaired. Goodwill is allocated to cash-generating units or groups of cash-generating units for the purpose
of impairment testing. An impairment loss of goodwill is recognized for the amount by which the relevant cash-generating unit&#146;s or group of cash-generating unit&#146;s carrying amount exceeds its recoverable amount, and we would be required to
write down the carrying value of our goodwill during the period in which it is determined to be impaired, which would materially and adversely affect our results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the
risk of <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are or will be subject to rules and regulations by various governing bodies, including,
for example, once we have become a public company, the SEC, which is charged with the protection of investors and the oversight of companies whose securities are publicly traded, and the various regulatory authorities in China and the Cayman
Islands, and to new and evolving regulatory measures under applicable law. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a
diversion of management time and attention from revenue-generating activities to compliance activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, because these laws, regulations and standards are
subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and comply with these regulations
and any subsequent changes, we may be subject to penalty and our business may be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Doing Business in China </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The pharmaceutical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of our drugs.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our research and development operations and manufacturing facilities are in China, which we believe confers clinical, commercial and regulatory advantages.
The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. See &#147;Regulation&#148; for a
discussion of the regulatory requirements that are applicable to our current and planned business activities in China. In recent years, the regulatory framework in China regarding the pharmaceutical industry has undergone significant changes, and we
expect that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful development or commercialization of our drug candidates
in China and reduce the current benefits we believe are available to us from developing and manufacturing drugs in China. PRC authorities have become increasingly vigilant in enforcing laws in the pharmaceutical industry and any failure by us or our
partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities in China. We believe our strategy and approach are
aligned with the PRC government&#146;s regulatory policies, but we cannot ensure that our strategy and approach will continue to be aligned. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in the
political and economic policies of the PRC government may materially and adversely affect our business, financial condition and results of operations and may result in our inability to sustain our growth and expansion strategies.</I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A significant portion of our operations are in China. Our financial condition and results of operations are affected to a large extent by economic, political and legal
developments in China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The PRC economy differs from the economies of most developed countries in many respects, including the extent of government involvement,
level of development, growth rate, control of foreign exchange and allocation of resources. Although the PRC government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of
productive assets, and the establishment of improved corporate governance in business enterprises, a substantial portion of productive assets in China is still owned by the government. In addition, the PRC government continues to play a significant
role in regulating industrial development by imposing industrial policies. The PRC government also exercises significant control over China&#146;s economic growth by allocating resources, controlling payment of foreign currency-denominated
obligations, setting monetary policy, regulating financial services and institutions and providing preferential treatment to particular industries or companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While the PRC economy has experienced significant growth in the past four decades, growth has been uneven, both geographically and among various sectors of the economy.
The PRC government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall PRC economy, but may also have a negative effect on us. Our business, financial
condition and results of operations could be materially and adversely affected by government control over capital investments or changes in tax regulations that are applicable to us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the PRC government had, in the past, implemented certain measures, including interest rate increases, to control the pace of economic growth. These
measures may cause decreased economic activity in China, which may adversely affect our business and results of operations. More generally, if the business environment in China deteriorates from the perspective of domestic or international
investment, our business in China may also be adversely affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and
regulations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our primary business is governed by PRC laws and regulations. Our primary business operation is supervised by relevant regulatory authorities
in China. The PRC legal system is a civil law system based on written statutes and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
unlike the common law system, prior court decisions can only be cited as reference and have limited precedential value. Additionally, written statutes in the PRC are often principle-oriented and
require detailed interpretations by the enforcement bodies to further apply and enforce such laws. Since 1979, the PRC government has developed a comprehensive system of laws, rules and regulations in relation to economic matters, such as foreign
investment, corporate organization and governance, commerce, taxation and trade. However, the interpretation and enforcement of these laws, rules and regulations involve uncertainties and may not be as consistent or predictable as in other more
developed jurisdictions. As these laws and regulations are continually evolving in response to changing economic and other conditions, and because of the limited volume of published cases and their <FONT STYLE="white-space:nowrap">non-binding</FONT>
nature, any particular interpretation of PRC laws and regulations may not be definitive. Moreover, we cannot predict the effect of future developments in the PRC legal system and regulatory structure. Such unpredictability towards our contractual,
property and procedural rights as well as our rights licensed, approved or granted by the competent regulatory authority could adversely affect our business and impede our ability to continue our operations. In addition, the PRC legal system is
based in part on government policies and internal rules, some of which are not published on a timely basis, if at all, and which may have a retroactive effect. Hence, we may not be aware of violation of these policies and rules until after such
violation has occurred. Further, the legal protections available to us and our investors under these laws, rules and regulations may be limited. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, any
administrative or court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since PRC administrative and court authorities have significant discretion in interpreting and
implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. These uncertainties may impede
our ability to enforce various contracts we have entered into and could materially and adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against us or our management named
in the prospectus based on foreign laws. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a company incorporated under the laws of the Cayman Islands, we conduct substantially all of our operations
in China and substantially all of our assets are located in China. In addition, all our senior executive officers reside within China for a significant portion of the time and some of them are PRC nationals. As a result, it may be difficult for you
to effect service of process upon us or those persons inside China. It may also be difficult for you to enforce in U.S. courts judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us
and our officers and directors as none of them currently resides in the United States or has substantial assets located in the United States. In addition, there is uncertainty as to whether the courts of the Cayman Islands or the PRC would recognize
or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws of the United States or any state. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in
accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any treaties or other forms
of written arrangement with the United States that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law, the PRC courts will not enforce a foreign judgment against us or
our directors and officers if they decide that the judgment violates the basic principles of PRC laws or national sovereignty, security or the public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a
judgment rendered by a court in the United States. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be restricted from transferring our scientific data abroad. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;17, 2018, the General Office of the PRC State Council promulgated the Measures for the Management of Scientific Data, or the Scientific Data Measures,
which provide a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in China must seek governmental approval before any scientific data involving a
state secret may be transferred abroad or to foreign parties. Further, any researcher conducting research funded, at least in part, by the PRC government is required to submit relevant scientific data for management by the entity to which such
researcher is affiliated before such data may be published in any foreign academic journal. Currently, as the term &#147;state secret&#148; is not clearly defined, there </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
is no assurance that we can always obtain relevant approvals for sending scientific data (such as the results of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical
trials conducted within China) abroad, or to our foreign partners in China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable to obtain the necessary approvals in a timely manner, or at all, our
research and development of drug candidates may be hindered, which may materially and adversely affect our business, results of operations, financial conditions and prospects. If relevant government authorities consider the transmission of our
scientific data to be in violation of the requirements under the Scientific Data Measures, we may be subject to specific administrative penalties imposed by those government authorities. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in U.S. and international trade policies, particularly with regard to China, may adversely impact our business and operating results. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. government has recently made statements and taken certain actions that may lead to potential changes to U.S. and international trade policies, including
imposing several rounds of tariffs affecting certain products manufactured in China. In March 2018, U.S. President Donald J. Trump announced the imposition of tariffs on steel and aluminum entering the United States and in June 2018 announced
further tariffs targeting goods imported from China. It is unknown whether and to what extent tariffs (or other new laws or regulations) will be adopted, or the effect that any such actions would have on us or our industry. While we have not started
commercialization of drug candidates, any unfavorable government policies on international trade, such as capital controls or tariffs, may affect the demand for our drug products, the competitive position of our drug products, the hiring of
scientists and other research and development personnel, and import or export of raw materials in relation to drug development, or prevent us from selling our drug products in certain countries. If any new tariffs, legislation and/or regulations are
implemented, or if existing trade agreements are renegotiated or, in particular, if the U.S. government takes retaliatory trade actions due to the recent U.S.-China trade tension, such changes could have an adverse effect on our business, financial
condition and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in
unfavorable tax consequences to us and our <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders or ADS holders. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the PRC Enterprise Income Tax
Law and its implementation rules, an enterprise established outside of the PRC with &#147;de facto management body&#148; within China is considered a &#147;resident enterprise&#148; and will be subject to the enterprise income tax on its global
income at the rate of 25%. The implementation rules define the term &#147;de facto management body&#148; as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and
properties of an enterprise. In 2009, the SAT issued the Circular of the State Administration of Taxation on Issues Relating to Identification of <FONT STYLE="white-space:nowrap">PRC-Controlled</FONT> Overseas Registered Enterprises as Resident
Enterprises in Accordance With the De Facto Standards of Organizational Management, or Circular 82, which provides certain specific criteria for determining whether the &#147;de facto management body&#148; of a
<FONT STYLE="white-space:nowrap">PRC-controlled</FONT> enterprise that is incorporated offshore is located in China. Although this Circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those
controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the SAT&#146;s general position on how the &#147;de facto management body&#148; text should be applied in determining the tax resident status of all
offshore enterprises. According to Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its &#147;de facto management body&#148; in China
and will be subject to PRC enterprise income tax on its global income if all of the following conditions are met: (i)&nbsp;the primary location of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
operational management is in China; (ii)&nbsp;decisions relating to the enterprise&#146;s financial and human resource matters are made or are subject to approval by organizations or personnel in China; (iii)&nbsp;the enterprise&#146;s primary
assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in China; and (iv)&nbsp;at least 50% of voting board members or senior executives habitually reside in China. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our PRC counsel, JunHe LLP, has advised us that, based on its understanding of the current PRC Laws and Regulations, I-Mab should not be considered as a PRC resident
enterprise for PRC tax income purposes. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#147;de facto management
body.&#148; If the PRC tax authorities determine that we are a PRC resident enterprise for enterprise income tax purposes, we could be subject to PRC tax at a rate of 25% on our worldwide income, which could materially reduce our net income, and we
may be required to withhold a 10% withholding tax from dividends we pay to our shareholders that are <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprises </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
(including the holders of our ADSs). In addition, <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise shareholders (including our ADS holders) may be subject to PRC tax at a rate of
10% on gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within China. Furthermore, if we are deemed a PRC resident enterprise, dividends payable to our <FONT
STYLE="white-space:nowrap">non-PRC</FONT> individual shareholders (including our ADS holders) and any gain realized on the transfer of ADSs or ordinary shares by such shareholders may be subject to PRC tax at a rate of 20% in the case of <FONT
STYLE="white-space:nowrap">non-PRC</FONT> individuals (which in the case of dividends may be withheld at source) unless a reduced rate is available under an applicable tax treaty. It is unclear whether <FONT STYLE="white-space:nowrap">non-PRC</FONT>
shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. Any such tax may reduce the returns on your
investment in the ADSs or ordinary shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Failure to renew our current leases or locate desirable alternatives for our leased properties could materially
and adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We lease properties for our offices and laboratories. We may not be able to successfully extend or renew such leases
upon expiration of the current term on commercially reasonable terms or at all, and may therefore be forced to relocate our affected operations. This could disrupt our operations and result in significant relocation expenses, which could adversely
affect our business, financial condition and results of operations. In addition, we compete with other businesses for premises at certain locations or of desirable sizes. As a result, even though we could extend or renew our leases, rental payments
may significantly increase as a result of the high demand for the leased properties. In addition, we may not be able to locate desirable alternative sites for our current leased properties as our business continues to grow and failure in relocating
our affected operations could adversely affect our business and operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Certain of our leasehold interests in leased properties have not been registered
with the relevant PRC governmental authorities as required by relevant PRC laws. The failure to register leasehold interests may expose us to potential fines. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not registered certain of our lease agreements with the relevant government authorities. Under the relevant PRC laws and regulations, we may be required to
register and file with the relevant government authority executed leases. The failure to register the lease agreements for our leased properties will not affect the validity of these lease agreements, but the competent housing authorities may order
us to register the lease agreements in a prescribed period of time and impose a fine ranging from RMB1,000 to RMB10,000 for each non-registered lease if we fail to complete the registration within the prescribed timeframe. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have granted, and may continue to grant, options and other types of awards under our share incentive plans, which may result in increased share-based
compensation expenses. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted the Second Amended and Restated 2017 Employee Stock Option Plan (the &#147;2017 Plan&#148;), the Second Amended and
Restated 2018 Employee Stock Option Plan (the &#147;2018 Plan&#148;) and the 2019 Share Incentive Plan (the &#147;2019 Plan&#148;), for the purpose of granting share-based compensation awards to employees, directors and consultants to incentivize
their performance and align their interests with ours. The 2019 Plan will become effective immediately prior to the completion of this offering. We recognize expenses in our consolidated financial statements in accordance with U.S. GAAP. As of the
date of this prospectus, options to purchase a total of 9,450,315 ordinary shares and 10,991,671 ordinary shares have been granted and outstanding under the 2017 Plan and 2018 Plan, respectively. As of the date of this prospectus, no award has been
granted or outstanding under the 2019 Plan. See &#147;Management&#151;Share Incentive Plans.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe the granting of share-based compensation is of
significant importance to our ability to attract and retain key personnel and employees, and we will continue to grant share-based compensation to employees in the future. As a result, our expenses associated with share-based compensation may
increase, which may have an adverse effect on our results of operations. We <FONT STYLE="white-space:nowrap">may&nbsp;re-evaluate&nbsp;the</FONT> vesting <FONT STYLE="white-space:nowrap">schedules,&nbsp;lock-up&nbsp;period,</FONT> exercise price or
other key terms applicable to the grants under our currently effective share incentive plans from time to time. If we choose to do so, we may experience substantial change in our share-based compensation charges in the reporting periods following
this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fluctuations in exchange rates could have a material and adverse effect on our results of operations and the value of your investment.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The value of RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic
conditions in China and by China&#146;s foreign exchange policies. On July&nbsp;21, 2005, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the PRC government changed its <FONT STYLE="white-space:nowrap">decade-old</FONT> policy of pegging the value of RMB to the U.S. dollar, and RMB appreciated more than 20% against the U.S. dollar
over the following three years. Between July 2008 and June 2010, this appreciation halted and the exchange rate between RMB and the U.S. dollar remained within a narrow band. Since June 2010, RMB has fluctuated against the U.S. dollar, at times
significantly and unpredictably. On November&nbsp;30, 2015, the Executive Board of the International Monetary Fund completed the regular five-year review of the basket of currencies that make up the Special Drawing Right, or the SDR, and decided
that with effect from October&nbsp;1, 2016, RMB is determined to be a freely usable currency and will be included in the SDR basket as a fifth currency, along with the U.S. dollar, the Euro, the Japanese yen and the British pound. In the fourth
quarter of 2016, RMB has depreciated significantly in the backdrop of a surging U.S. dollar and persistent capital outflows of China. This depreciation halted in 2017, and RMB appreciated approximately 7% against the U.S. dollar during this <FONT
STYLE="white-space:nowrap">one-year</FONT> period. With the development of the foreign exchange market and progress towards interest rate liberalization and RMB internationalization, the PRC government may in the future announce further changes to
the exchange rate system, and we cannot assure you that RMB will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces or PRC or U.S. government policy may impact the
exchange rate between RMB and the U.S. dollar in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Significant revaluation of RMB may have a material and adverse effect on your investment. For example,
to the extent that we need to convert U.S. dollars we receive from this offering into RMB for our operations, appreciation of RMB against the U.S. dollar would have an adverse effect on the RMB amount we would receive from the conversion.
Conversely, if we decide to convert our RMB into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar against RMB would have a negative effect on
the U.S. dollar amount available to us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have
not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited
and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert RMB into foreign currency. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the PRC government imposes controls on the convertibility of RMB into foreign currencies and, in certain cases, the remittance of currency out of China. We
receive substantially all of our revenues in RMB. Under our current corporate structure, our Cayman Islands holding company primarily relies on dividend payments from our PRC subsidiary to fund any cash and financing requirements we may have. Under
existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval of
the State Administration of Foreign Exchange, or SAFE, by complying with certain procedural requirements. Specifically, under the existing exchange restrictions, without prior approval of SAFE, cash generated from the operations of our PRC
subsidiaries in China may be used to pay dividends to our company. However, approval from or registration with appropriate government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital
expenses, such as the repayment of loans denominated in foreign currencies. As a result, we need to obtain SAFE approval to use cash generated from the operations of our PRC subsidiaries to pay off their respective debt in a currency other than RMB
owed to entities outside China, or to make other capital expenditure payments outside China in a currency other than RMB. In light of the flood of capital outflows of China, the PRC government may from time to time impose more restrictive foreign
exchange policies and step up scrutiny of major outbound capital movement. More restrictions and a substantial vetting process may be required by SAFE or other government authorities to regulate cross-border transactions falling under the capital
account. The PRC government may at its discretion restrict access to foreign currencies for current account transactions in the future. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our
foreign currency demands, we may not be able to pay dividends in foreign currencies to our shareholders, including holders of our ADSs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Certain PRC
regulations may make it more difficult for us to pursue growth through acquisitions. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Regulations on Mergers and Acquisitions of Domestic Enterprises by
Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies in 2006 and amended in 2009, established additional procedures and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex. Such regulation requires, among other things, that the Ministry of Commerce,
or MOFCOM, be notified in advance of any change of control transaction in which a foreign investor acquires control of a PRC domestic enterprise and involves any of the following circumstances: (i)&nbsp;any important industry is concerned;
(ii)&nbsp;such transaction involves factors that impact or may impact national economic security; or (iii)&nbsp;such transaction will lead to a change in control of a domestic enterprise which holds a famous trademark or PRC time-honored brand. We
do not expect that this offering will trigger MOFCOM <FONT STYLE="white-space:nowrap">pre-notification</FONT> under each of the above-mentioned circumstances or any review by other PRC government authorities, except as disclosed below in
&#147;&#151;The approval of the CSRC may be required in connection with this offering, and, if required, we cannot predict whether we will be able to obtain such approval.&#148; Moreover, the Anti-Monopoly Law promulgated by the Standing Committee
of National People&#146;s Congress which became effective in 2008 requires that transactions which are deemed concentrations and involve parties with specified turnover thresholds must be cleared by State Administration for Market Regulation (the
&#147;SAMR&#148;), the successive authority of MOFCOM, before they can be completed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may rely on dividends and other distributions on equity paid by our
PRC subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a Cayman Islands holding company and we may rely on dividends and other distributions on equity paid by our PRC subsidiaries for our cash and financing
requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders and service any debt we may incur. If any of our PRC subsidiaries incur debt on its own behalf in the future, the instruments governing the
debt may restrict their ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiaries, each of which is a wholly foreign-owned enterprise may pay dividends only out of its respective accumulated
profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its <FONT STYLE="white-space:nowrap">after-tax</FONT> profits each year, if
any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its
<FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to a staff welfare and bonus fund. The reserve fund and staff welfare and bonus fund cannot be distributed to us as dividends. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our PRC subsidiaries generate primarily all of their revenue in RMB, which is not freely convertible into other currencies. As result, any restriction on currency
exchange may limit the ability of our PRC subsidiaries to use their RMB revenues to pay dividends to us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The PRC government may continue to strengthen its capital
controls, and more restrictions and a substantial vetting process may be put forward by SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation on the ability of our PRC subsidiaries to pay
dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the PRC Enterprise Income Tax Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by
PRC companies to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-PRC-resident</FONT></FONT> enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and
governments of other countries or regions where the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-PRC-resident</FONT></FONT> enterprises are incorporated. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries&#146; ability to change their registered capital or
distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC laws. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2014, SAFE
promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore Investment and Financing and Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 requires
PRC residents (including PRC individuals and PRC corporate entities as well as foreign individuals that are deemed as PRC residents for foreign exchange administration purpose) to register with SAFE or its local branches in connection with their
direct or indirect offshore investment activities. SAFE Circular 37 further requires amendment to the SAFE registrations in the event of any changes with respect to the basic information of the offshore special purpose vehicle, such as changes of a
PRC individual shareholder, name and operation term, or any significant changes with respect to the offshore special purpose vehicle, such as increase or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
decrease of capital contribution, share transfer or exchange, or mergers or divisions. SAFE Circular 37 is applicable to our shareholders who are PRC residents. If our shareholders who are PRC
residents fail to make the required registration or to update the previously filed registration, our PRC subsidiaries may be prohibited from distributing their profits or the proceeds from any capital reduction, share transfer or liquidation to us,
and we may also be prohibited from making additional capital contributions into our PRC subsidiaries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2015, SAFE promulgated a Notice on Further
Simplifying and Improving Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, effective June 2015. Under SAFE Notice 13, applications for foreign exchange registration of inbound foreign direct investments and outbound
overseas direct investments, including those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE. The qualified banks will directly examine the applications and accept registrations under the supervision of SAFE. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our shareholders who we are aware of being subject to the SAFE regulations have completed the initial registrations with the local SAFE branch or qualified banks
as required by SAFE Circular 37. However, we may not be informed of the identities of all the PRC residents holding direct or indirect interests in our company, and we cannot provide any assurance that these PRC residents will comply with our
request to make or obtain any applicable registrations or continuously comply with all requirements under SAFE Circular 37 or other related rules. The failure or inability of the relevant shareholders to comply with the registration procedures set
forth in these regulations may subject us to fines and legal sanctions, such as restrictions on our cross-border investment activities, on the ability of our wholly foreign-owned subsidiaries in China to distribute dividends and the proceeds from
any reduction in capital, share transfer or liquidation to us. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable foreign
exchange restrictions. As a result, our business operations and our ability to distribute profits could be materially and adversely affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any failure to
comply with PRC regulations regarding our employee equity incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and our directors, executive officers and other employees who are PRC citizens or who have resided in China for a continuous period of not less than one year and who
will be granted restricted shares or options are subject to the Notice on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plan of Overseas Publicly Listed Company, issued by SAFE in
February 2012, according to which, employees, directors, supervisors and other management members participating in any share incentive plan of an overseas publicly listed company who are PRC citizens or who are
<FONT STYLE="white-space:nowrap">non-PRC</FONT> citizens residing in China for a continuous period of not less than one year, subject to limited exceptions, are required to register with SAFE through a domestic qualified agent, which could be a PRC
subsidiary of such overseas listed company, and complete certain other procedures. In addition, an overseas entrusted institution must be retained to handle matters in connection with the exercise or sale of stock options and the purchase or sale of
shares and interests. Failure to complete the SAFE registrations may subject them to fines and legal sanctions and may also limit our ability to make payments under our equity incentive plans or receive dividends or sales proceeds related thereto,
or our ability to contribute additional capital into our wholly foreign-owned enterprises in China and limit our wholly foreign-owned enterprises&#146; ability to distribute dividends to us. We also face regulatory uncertainties that could restrict
our ability to adopt additional equity incentive plans for our directors and employees under PRC law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the SAT has issued circulars concerning employee
share options or restricted shares. Under these circulars, employees working in China who exercise share options, or whose restricted shares vest, will be subject to PRC individual income tax. The PRC subsidiaries of an overseas listed company have
obligations to file documents related to employee share options or restricted shares with relevant tax authorities and to withhold individual income taxes of those employees related to their share options or restricted shares. If the employees fail
to pay, or the PRC subsidiaries fail to withhold applicable income taxes, the PRC subsidiaries may face sanctions imposed by the tax authorities or other PRC government authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental
control of currency conversion may delay or prevent us from using the proceeds of this offering to make loans to our PRC subsidiaries in China, which could materially and adversely affect our liquidity and our ability to fund and expand our
business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an offshore holding company conducting our operations in China through our PRC subsidiaries. We may make loans to our PRC subsidiaries
subject to the approval from governmental authorities and limitation on the available loan amount, or we may make additional capital contributions to our wholly foreign-owned subsidiaries in China. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any loans to our wholly foreign-owned subsidiaries in China, which are treated as foreign-invested enterprises under PRC law, are subject to PRC regulations and foreign
exchange loan registrations. For example, loans by us to our wholly foreign-owned subsidiaries in China to finance their activities cannot exceed statutory limits and must be registered with the local counterpart of SAFE. In addition, a
foreign-invested enterprise shall use its capital pursuant to the principle of authenticity and <FONT STYLE="white-space:nowrap">self-use</FONT> within its business scope. The capital of a foreign-invested enterprise shall not be used for the
following purposes: (i)&nbsp;directly or indirectly used for payment beyond the business scope of the enterprises or the payment prohibited by relevant laws and regulations; (ii)&nbsp;directly or indirectly used for investment in securities or
investments other than banks&#146; principal-secured products unless otherwise provided by relevant laws and regulations; (iii)&nbsp;the granting of loans to <FONT STYLE="white-space:nowrap">non-affiliated</FONT> enterprises, except where it is
expressly permitted in the business license; and (iv)&nbsp;paying the expenses related to the purchase of real estate that is not for <FONT STYLE="white-space:nowrap">self-use</FONT> (except for the foreign-invested real estate enterprises). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming the Administration of Foreign Exchange Settlement of Capital of
Foreign-invested Enterprises, or SAFE Circular 19, effective June 2015, in replacement of the Circular on the Relevant Operating Issues Concerning the Improvement of the Administration of the Payment and Settlement of Foreign Currency Capital of
Foreign-Invested Enterprises, the Notice from the State Administration of Foreign Exchange on Relevant Issues Concerning Strengthening the Administration of Foreign Exchange Businesses, and the Circular on Further Clarification and Regulation of the
Issues Concerning the Administration of Certain Capital Account Foreign Exchange Businesses. According to SAFE Circular 19, the flow and use of RMB capital converted from foreign currency-denominated registered capital of a foreign-invested company
is regulated such that RMB capital may not be used for the issuance of RMB entrusted loans, the repayment of inter-enterprise loans or the repayment of banks loans that have been transferred to a third party. Although SAFE Circular 19 allows RMB
capital converted from foreign currency-denominated registered capital of a foreign-invested enterprise to be used for equity investments within China, it also reiterates the principle that RMB converted from the foreign currency-denominated capital
of a foreign-invested company may not be directly or indirectly used for purposes beyond its business scope. Thus, it is unclear whether SAFE will permit such capital to be used for equity investments in China in actual practice. SAFE promulgated
the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange Settlement Management Policy of Capital Account, or SAFE Circular 16, effective on June&nbsp;9, 2016, which reiterates some of the rules
set forth in SAFE Circular 19, but changes the prohibition against using RMB capital converted from foreign currency-denominated registered capital of a foreign-invested company to issue RMB entrusted loans to a prohibition against using such
capital to issue loans to <FONT STYLE="white-space:nowrap">non-associated</FONT> enterprises. Violations of SAFE Circular 19 and SAFE Circular 16 could result in administrative penalties. SAFE Circular 19 and SAFE Circular 16&nbsp;may significantly
limit our ability to transfer any foreign currency we hold, including the net proceeds from this offering, to our PRC subsidiaries, which may adversely affect our liquidity and our ability to fund and expand our business in China. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, we cannot assure you
that we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans to our PRC subsidiaries or future capital contributions by us to our
wholly foreign-owned subsidiaries in China. As a result, uncertainties exist as to our ability to provide prompt financial support to our PRC subsidiaries when needed. If we fail to complete such registrations or obtain such approvals, our ability
to use the proceeds we expect to receive from this offering and to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We and our shareholders face uncertainties with respect to indirect transfers of equity interests in PRC
resident enterprises or other assets attributable to a PRC establishment of a <FONT STYLE="white-space:nowrap">non-PRC</FONT> company. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;3,
2015, the SAT issued the Bulletin on Issues of Enterprise Income Tax and Indirect Transfers of Assets by <FONT STYLE="white-space:nowrap">Non-PRC</FONT> Resident Enterprises, or Bulletin 7. Pursuant to this Bulletin, an &#147;indirect transfer&#148;
of &#147;PRC taxable assets,&#148; including equity interests in a PRC resident enterprise, by <FONT STYLE="white-space:nowrap">non-PRC</FONT> resident enterprises may be recharacterized and treated as a direct transfer of PRC taxable assets, if
such arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax.
When determining whether there is a &#147;reasonable commercial purpose&#148; of the transaction arrangement, factors to be taken into consideration include: whether the main value of the equity interest of the relevant offshore enterprise derives
from PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consist of direct or indirect investment in China or if its income mainly derives from China; whether the offshore enterprise and its subsidiaries directly or
indirectly holding PRC taxable assets have real commercial nature which is evidenced by their actual function and risk exposure; the duration of existence of the business model and organizational structure; the replicability of the transaction by
direct transfer of PRC taxable assets; and the tax situation of such indirect transfer and applicable tax treaties or similar arrangements. On October&nbsp;17, 2017, the SAT issued the Announcement of the State Administration of Taxation on Issues
Concerning the Withholding of <FONT STYLE="white-space:nowrap">Non-resident</FONT> Enterprise Income Tax at Source, or Bulletin 37, which came into effect on December&nbsp;1, 2017. Bulletin 37 further clarifies the practice and procedure of the
withholding of non-resident enterprise income tax. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Late payment of applicable tax will subject the transferor to default interest. Gains derived from the sale of
shares by investors are not subject to the PRC enterprise income tax pursuant to Bulletin 7 where such shares were acquired in a transaction through a public stock exchange. However, the sale of ADSs or ordinary shares by a <FONT
STYLE="white-space:nowrap">non-PRC</FONT> resident enterprise outside a public stock exchange may be subject to PRC enterprise income tax under Bulletin 7. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There
are uncertainties as to the application of Bulletin 7. Bulletin 7&nbsp;may be determined by the tax authorities to be applicable to the sale of the shares of our offshore subsidiaries or investments where PRC taxable assets are involved. The
transferors and transferees may be subject to the tax filing and withholding or tax payment obligation, while our PRC subsidiaries may be requested to assist in the filing. Furthermore, we, our <FONT STYLE="white-space:nowrap">non-resident</FONT>
enterprises and PRC subsidiaries may be required to spend valuable resources to comply with Bulletin 7 or to establish that we and our <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprises should not be taxed under Bulletin 7, for our
previous and future restructuring or disposal of shares of our offshore subsidiaries, which may have a material adverse effect on our financial condition and results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The PRC tax authorities have the discretion under Bulletin 7 to make adjustments to the taxable capital gains based on the difference between the fair value of the
taxable assets transferred and the cost of investment. If the PRC tax authorities make adjustments to the taxable income of the transactions under Bulletin 7 / Bulletin 37, our income tax costs associated with such potential acquisitions or
disposals will increase, which may have an adverse effect on our financial condition and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The approval of the CSRC may be required in
connection with this offering, and, if required, we cannot predict whether we will be able to obtain such approval. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The M&amp;A Rules require overseas
special purpose vehicles that are controlled by PRC companies or individuals and formed for the purpose of seeking a public listing on an overseas stock exchange through acquisitions of PRC domestic companies using shares of such special purpose
vehicles or held by its shareholders as consideration to obtain the approval of the CSRC, prior to the listing and trading of such special purpose vehicle&#146;s securities on an overseas stock exchange. However, the application of the M&amp;A Rules
remains unclear. If CSRC approval is required, it is uncertain whether it would be possible for us to obtain the approval, and any failure to obtain or delay in obtaining CSRC approval for this offering would subject us to sanctions imposed by the
CSRC and other PRC regulatory agencies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our PRC counsel has advised us based on their understanding of the current PRC laws, rules and regulations that the
CSRC&#146;s approval may not be required for the listing and trading of our ADSs on the Nasdaq Stock Market in the context of this offering, given that: (i)&nbsp;the CSRC currently has not issued any definitive rule or interpretation concerning
whether offerings like ours in this prospectus are subject to this regulation, <FONT STYLE="white-space:nowrap">(ii)&nbsp;I-Mab</FONT> Tianjin was not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
acquired by a connected merger or by acquisition of equity interest or assets of a PRC domestic company owned by PRC companies or individuals as defined under the M&amp;A Rules and <FONT
STYLE="white-space:nowrap">(iii)&nbsp;I-Mab</FONT> Shanghai was incorporated as a wholly foreign-owned enterprise by means of direct investment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, our PRC
counsel has further advised us that there remain some uncertainties as to how the M&amp;A Rules will be interpreted or implemented in the context of an overseas offering and its opinions summarized above are subject to any new laws, rules and
regulations or detailed implementations and interpretations in any form relating to the M&amp;A Rules. We cannot assure you that relevant PRC government agencies, including the CSRC, would reach the same conclusion as we do. If it is determined that
CSRC approval is required for this offering, we may face sanctions by the CSRC or other PRC regulatory agencies for failure to seek CSRC approval for this offering. These sanctions may include fines and penalties on our operations in China,
limitations on our operating privileges in China, delays in or restrictions on the repatriation of the proceeds from this offering into the PRC, restrictions on or prohibition of the payments or remittance of dividends by our subsidiaries in China,
or other actions that could have a material and adverse effect on our business, financial condition, results of operations, reputation and prospects, as well as the trading price of our ADSs. The CSRC or other PRC regulatory agencies may also take
actions requiring us, or making it advisable for us, to halt this offering before the settlement and delivery of the ADSs that we are offering. Consequently, if you engage in market trading or other activities in anticipation of and prior to the
settlement and delivery of the ADSs we are offering, you would be doing so at the risk that the settlement and delivery may not occur. In addition, if the CSRC or other regulatory agencies later promulgate new rules or explanations requiring that we
obtain their approvals for this offering, we may be unable to obtain a waiver of such approval requirements, if and when procedures are established to obtain such a waiver. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recent litigation and negative publicity surrounding China-based companies listed in the U.S. may result in increased regulatory scrutiny of us and negatively
impact the trading price of the ADSs and could have a material adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that litigation and negative publicity surrounding companies with operations in China that are listed in the U.S. have negatively impacted stock prices for
such companies. Various equity-based research organizations have published reports on China-based companies after examining, among other things, their corporate governance practices, related party transactions, sales practices and financial
statements that have led to special investigations and stock suspensions on national exchanges. Any similar scrutiny of us, regardless of its lack of merit, could result in a diversion of management resources and energy, potential costs to defend
ourselves against rumors, decreases and volatility in the ADS trading price, and increased directors and officers insurance premiums and could have a material adverse effect upon our business, including our results of operations, financial
condition, cash flows and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our ADSs and This Offering </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>There has been no public market for our shares or ADSs prior to this offering, and you may not be able to resell our ADSs at or above the price you paid, or at
all. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this initial public offering, there has been no public market for our shares or ADSs. The ADSs have been approved for listing on the Nasdaq
Stock Market. Our shares will not be listed on any exchange or quoted for trading on any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> trading system. If an active trading market for our ADSs does
not develop after this offering, the market price and liquidity of our ADSs will be materially and adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Negotiations with the underwriters will
determine the initial public offering price for our ADSs which may bear no relationship to their market price after the initial public offering. We cannot assure you that an active trading market for our ADSs will develop or that the market price of
our ADSs will not decline below the initial public offering price. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The trading price of our ADSs may be volatile, which could result in substantial losses to
you. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading price of our ADSs can be volatile and fluctuate widely in response to a variety of factors, many of which are beyond our control. In
addition, the performance and fluctuation of the market prices of other companies with business operations located mainly in the PRC that have listed their securities in the United&nbsp;States may affect the volatility in the price of and trading
volumes for our ADSs. Some of these companies have experienced significant volatility. The trading performances of these PRC companies&#146; securities may affect the overall investor sentiment towards other PRC companies listed in the United States
and consequently may impact the trading performance of our ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to market and industry factors, the price and trading volume for our ADSs may be highly volatile for
specific business reasons, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements of regulatory approval or a complete response letter, or specific label indications or patient populations
for a drug&#146;s use, or changes or delays in the regulatory review process; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements of therapeutic innovations, new products, acquisitions, strategic relationships, joint ventures or capital
commitments by us or our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and
marketing activities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any adverse changes to our relationship with manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the results of our testing and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the results of our efforts to acquire or license additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variations in the level of expenses related to our existing drugs and drug candidates or
<FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical development and commercialization programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any intellectual property infringement actions in which we may become involved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements concerning our competitors or the pharmaceutical industry in general; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fluctuations in product revenue, sales and marketing expenses and profitability; manufacture, supply or distribution
shortages; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variations in our results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements about our results of operations that are not in line with analyst expectations, the risk of which is
enhanced because it is our policy not to give guidance on results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publication of operating or industry metrics by third parties, including government statistical agencies, that differ from
expectations of industry or financial analysts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in financial estimates by securities research analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">media reports, whether or not true, about our business, our competitors or our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additions to or departures of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fluctuations of exchange rates between the RMB and the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">release or expiry of <FONT STYLE="white-space:nowrap">lock-up</FONT> or other transfer restrictions on our outstanding
ordinary shares or ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sales or perceived potential sales of additional ordinary shares or ADSs by us, our executive officers and directors or
our shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general economic and market conditions and overall fluctuations in the U.S. equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in accounting principles; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes or developments in the PRC or global regulatory environment. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the stock market, in general, and pharmaceutical and biotechnology companies have experienced extreme price and volume fluctuations that have often been
unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our ADSs, regardless of our actual operating performance. Further, the current volatility in
the financial markets and related factors beyond our control may cause the market price of our ADSs to decline rapidly and unexpectedly. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>After the completion
of this offering, we may face an increased risk of securities class action litigation. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Historically, securities class action litigation has often been
brought against a company following a significant decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant share price volatilities in
recent years. If we were to face lawsuits, it could lead to substantial costs and a distraction of management&#146;s attention and resources, which could harm our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, or if they adversely change their
recommendations regarding our ADSs, the market price for our ADSs and trading volume could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our ADSs will depend in part on
the research and reports that securities or industry analysts publish about us or our business. If research analysts do not establish and maintain adequate research coverage or if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
one or more of the analysts who covers us downgrades our ADSs or publishes inaccurate or unfavorable research about our business, the market price for our ADSs would likely decline. If one or
more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our ADSs to decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because our initial public offering price is substantially higher than our net tangible book value per share, you will experience immediate and substantial
dilution. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase ADSs in this offering, you will pay more for your ADSs than the amount paid by our existing shareholders for their ordinary
shares on a per ADS basis. As a result, you will experience immediate and substantial dilution of US$8.94 per ADS (assuming that no outstanding options to acquire ordinary shares are exercised), representing the difference between (i) the initial
public offering price of US$14.00 per ADS, and (ii) our pro&nbsp;forma net tangible book value adjusted per ADS as of September 30, 2019, after giving effect to our sale of the ADSs offered in this offering. In addition, you may experience further
dilution to the extent that our ordinary shares are issued upon the exercise of share options. See &#147;Dilution&#148; for a more complete description of how the value of your investment in the ADSs will be diluted upon completion of
this&nbsp;offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because we do not expect to pay dividends in the foreseeable future after this offering, you must rely on price appreciation of our ADSs
for return on your investment. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently intend to retain most, if not all, of our available funds and any future earnings after this offering to fund
the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in our ADSs as a source for any future dividend income. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has complete discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. In addition, our
shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law, a Cayman Islands company may pay a dividend out of either profit or share premium account of
the company, provided that in no circumstances may a dividend be paid out of share premium if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides
to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our
subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in our ADSs will likely depend entirely upon any future price appreciation of our
ADSs. There is no guarantee that our ADSs will appreciate in value after this offering or even maintain the price at which you purchased the ADSs. You may not realize a return on your investment in our ADSs and you may even lose your entire
investment in our ADSs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Substantial future sales or perceived potential sales of our ADSs in the public market could cause the price of our ADSs to decline.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of our ADSs in the public market after this offering, or the perception that these sales could occur, could cause the market price of our ADSs to
decline. Upon completion of this offering, we will have 131,239,439 ordinary shares issued and outstanding, including 17,037,020 ordinary shares represented by ADSs, assuming the underwriters do not exercise their over-allotment option. All ADSs
sold in this offering will be freely transferable without restriction or additional registration under the United States Securities Act of 1933, as amended, or the Securities Act. The remaining ordinary shares issued and outstanding after this
offering will be available for sale, upon the expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period beginning from the date of this prospectus, subject to volume and other
restrictions as applicable under Rules 144 and 701 under the Securities Act. Any or all of these shares may be released prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period at the discretion of the representatives of
the underwriters of this offering. To the extent shares are released before the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period and sold into the market, the market price of our ADSs could decline. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After completion of this offering, certain holders of our ordinary shares may cause us to register under the Securities Act the sale of their shares, subject to the <FONT
STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period in connection with this offering. Registration of these shares under the Securities Act would result in ADSs representing these shares becoming freely
tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. Sales of these registered shares in the form of ADSs in the public market could cause the price of our ADSs to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able
to exercise the same rights as our shareholders. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of ADSs do not have the same rights as our shareholders. As a holder of our ADSs, you will not
have any direct right to attend general meetings of our shareholders or to cast any votes at such meetings. As an ADS holder, you will only be able to exercise the voting rights carried by the underlying ordinary shares indirectly by giving voting
instructions to the depositary in accordance with the provisions of the deposit agreement. Under the deposit agreement, you may vote only by giving voting instructions to the depositary. Upon receipt of your voting instructions, the depositary will
try, as far as is practicable, to vote the ordinary shares underlying your ADSs in accordance with your instructions. If we ask for your instructions, then upon receipt of your voting instructions, the depositary will try to vote the underlying
ordinary shares in accordance with these instructions. If we do not instruct the depositary to ask for your instructions, the depositary may still vote in accordance with instructions you give, but it is not required to do so. You will not be able
to directly exercise your right to vote with respect to the underlying ordinary shares unless you withdraw the shares, and become the registered holder of such shares prior to the record date for the general meeting. When a general meeting is
convened, you may not receive sufficient advance notice of the meeting to withdraw the shares underlying your ADSs and become the registered holder of such shares to allow you to attend the general meeting and to vote directly with respect to any
specific matter or resolution to be considered and voted upon at the general meeting. In addition, under our post-offering memorandum and articles of association that will become effective prior to completion of this offering, for the purposes of
determining those shareholders who are entitled to attend and vote at any general meeting, our directors may close our register of members and/or fix in advance a record date for such meeting, and such closure of our register of members or the
setting of such a record date may prevent you from withdrawing the ordinary shares underlying your ADSs and becoming the registered holder of such shares prior to the record date, so that you would not be able to attend the general meeting or to
vote directly. If we ask for your instructions, the depositary will notify you of the upcoming vote and will arrange to deliver our voting materials to you. We have agreed to give the depositary notice of shareholder meetings sufficiently in advance
of such meetings. Nevertheless, we cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the underlying ordinary shares represented by your ADSs. In addition, the depositary and
its agents are not responsible for failing to carry out voting instructions or for their manner of carrying out your voting instructions. This means that you may not be able to exercise your right to direct how the shares underlying your ADSs are
voted and you may have no legal remedy if the shares underlying your ADSs are not voted as you requested. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders&#146; meeting. Except in limited circumstances, the
depositary for our ADSs will give us a discretionary proxy to vote the ordinary shares underlying your ADSs if you do not vote at shareholders&#146; meetings, which could adversely affect your interests. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the deposit agreement for the ADSs, if you do not vote, the depositary will give us a discretionary proxy to vote the ordinary shares underlying your ADSs at
shareholders&#146; meetings unless: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we have instructed the depositary that we do not wish a discretionary proxy to be given; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we have informed the depositary that there is substantial opposition as to a matter to be voted on at the meeting;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a matter to be voted on at the meeting would have an adverse impact on shareholders; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the voting at the meeting is to be made on a show of hands. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The effect of this discretionary proxy is that you cannot prevent our ordinary shares underlying your ADSs from being voted, except under the circumstances described
above. This may make it more difficult for shareholders to influence the management of our company. Holders of our ordinary shares are not subject to this discretionary proxy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make rights available to you in the
United States unless we register both the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. Under the deposit agreement, the depositary will not make rights
available to you unless both the rights and the underlying securities to be distributed to ADS holders are either registered under the Securities Act or exempt from registration under the Securities Act. We are under no obligation to file a
registration statement with respect to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
such rights or securities or to endeavor to cause such a registration statement to be declared effective and we may not be able to establish a necessary exemption from registration under the
Securities Act. Accordingly, you may be unable to participate in our rights offerings and may experience dilution in your holdings. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You may not receive cash
dividends if the depositary decides it is impractical to make them available to you. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The depositary will pay cash dividends on the ADSs only to the extent
that we decide to distribute dividends on our ordinary shares or other deposited securities, and we do not have any present plan to pay any cash dividends on our ordinary shares in the foreseeable future. To the extent that there is a distribution,
the depositary of our ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses pursuant to the deposit agreement.
You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary may, at its discretion, decide that it is inequitable or impractical to make a distribution available to any holders of
ADSs. For example, the depositary may determine that it is not practicable to distribute certain property through the mail, or that the value of certain distributions may be less than the cost of mailing them. In these cases, the depositary may
decide not to distribute such property to you. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You may be subject to limitations on transfer of your ADSs. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient
in connection with the performance of its duties. The depositary may close its books from time to time for a number of reasons, including in connection with corporate events such as a rights offering, during which time the depositary needs to
maintain an exact number of ADS holders on its books for a specified period. The depositary may also close its books in emergencies, and on weekends and public holidays. In addition, the depositary may refuse to deliver, transfer or register
transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any
provision of the deposit agreement, or for any other reason. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Certain judgments obtained against us by our shareholders may not be enforceable. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an exempted company incorporated under the laws of the Cayman Islands. We conduct our operations in China and substantially all of our assets are located in
China. In addition, our directors and executive officers, and some of the experts named in this prospectus, reside within China, and most of the assets of these persons are located within China. As a result, it may be difficult or impossible for you
to bring an action against us or against these individuals in the United States in the event that you believe that your rights have been infringed under the U.S. federal securities laws or otherwise. Even if you are successful in bringing an action
of this kind, the laws of the Cayman Islands and of the PRC may render you unable to enforce a judgment against our assets or the assets of our directors and officers. For more information regarding the relevant laws of the Cayman Islands and China,
see &#147;Enforceability of Civil Liabilities.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit
agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The deposit agreement governing the ADSs representing our
ordinary shares provides that, subject to the depositary&#146;s right to require a claim to be submitted to the federal or state courts in the City of New&nbsp;York have jurisdiction to hear and determine claims arising under the deposit agreement
and in that regard, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including
any claim under the U.S. federal securities laws. Also, we may amend or terminate the deposit agreement without your consent. If you continue to hold your ADSs after an amendment to the deposit agreement, you agree to be bound by the deposit
agreement as amended. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we or the depositary were to oppose a jury trial demand based on such waiver, the court would determine whether the waiver was enforceable
in the facts and circumstances of that case in accordance with applicable state and federal law, including whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. The waiver to right to a jury trial of the deposit
agreement is not intended to be deemed a waiver by any holder or beneficial owner of ADSs of our or the depositary&#146;s compliance with the U.S. federal securities laws and the rules and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection
with matters arising under the deposit agreement or the ADSs, including claims under U.S. federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the
effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, in which
the trial would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Nevertheless, if this jury trial waiver provision is not enforced, to the extent a court action proceeds, it would proceed under the terms of the deposit agreement with
a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities
laws and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You may face difficulties in protecting your interests, and your ability to protect your rights
through U.S. courts may be limited, because we are incorporated under Cayman Islands law. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an exempted company incorporated under the laws of the
Cayman Islands with limited liability. Our corporate affairs are governed by our memorandum and articles of association, the Companies Law (2018 Revision) of the Cayman Islands, which we refer to as the Companies Law, and the common law of the
Cayman Islands. The rights of shareholders to take action against our directors, actions by our minority shareholders and the fiduciary duties of our directors to us under Cayman Islands law are to a large extent governed by the common law of the
Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common law of England, the decisions of whose courts are of persuasive authority, but are
not binding, on a court in the Cayman Islands. The rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedent in some
jurisdictions in the United States. In particular, the Cayman Islands has a less developed body of securities laws than the United States. Some U.S. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate
law than the Cayman Islands. In addition, Cayman Islands companies may not have standing to initiate a shareholder derivative action in a federal court of the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to obtain copies of lists of
shareholders of these companies. Our directors have discretion under our post-offering articles of association that will become effective immediately prior to completion of this offering to determine whether or not, and under what conditions, our
corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder
motion or to solicit proxies from other shareholders in connection with a proxy contest. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of all of the above, our public shareholders may have more
difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a company incorporated in the United States. For a
discussion of significant differences between the provisions of the Companies Law and the laws applicable to companies incorporated in the United States and their shareholders, see &#147;Description of Share Capital&#151;Differences in Corporate
Law.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have not determined a specific use for a portion of the net proceeds from this offering and we may use these proceeds in ways with which you
may not agree. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not determined a specific use for a portion of the net proceeds of this offering, and our management will have considerable
discretion in deciding how to apply these proceeds. You will not have the opportunity to assess whether the proceeds are being used appropriately before you make your investment decision. You must rely on the judgment of our management regarding the
application of the net proceeds of this offering. We cannot assure you that the net proceeds will be used in a manner that would improve our results of operations or increase our ADS price, nor that these net proceeds will be placed only in
investments that generate income or appreciate in value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The post-offering memorandum and articles of association that will become effective immediately prior to the
completion of this offering will contain anti-takeover provisions that could discourage a third party from acquiring us and adversely affect the rights of holders of our ordinary shares and the ADSs. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted an amended and restated memorandum and articles of association that will become effective immediately prior to the completion of this offering, which we
refer to as the post-offering memorandum and articles of association. Our post-offering memorandum and articles of association will contain provisions to limit the ability of others to acquire control of our company or cause us to engage in change
of control transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium over prevailing market prices by discouraging third parties from seeking to obtain control of our
company in a tender offer or similar transaction. Our board of directors has the authority to issue preferred shares in one or more series and to fix their designations, powers, preferences, privileges, and relative participating, optional or
special rights and the qualifications, limitations or restrictions, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights associated with our
ordinary shares, in the form of ADS or otherwise. Preferred shares could be issued with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. If our board of directors decides to issue
preferred shares, the price of our ADSs may fall and the voting and other rights of the holders of our ordinary shares and ADSs may be materially and adversely affected. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an &#147;emerging growth company,&#148; as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of certain
exemptions from various requirements applicable to other public companies that are not emerging growth companies including, most significantly, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of
Sarbanes-Oxley Act of 2002 for so long as we are an emerging growth company. As a result, if we elect not to comply with such auditor attestation requirements, our investors may not have access to certain information they may deem important. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The JOBS Act also provides that an emerging growth company does not need to comply with any new or revised financial accounting standards until such date that a private
company is otherwise required to comply with such new or revised accounting standards. However, we have elected to &#147;opt out&#148; of this provision and, as a result, we will comply with new or revised accounting standards as required when they
are adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are a foreign private
issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions applicable to U.S. domestic public companies. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the securities rules and regulations in the United
States that are applicable to U.S. domestic issuers, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> or current reports on Form <FONT STYLE="white-space:nowrap">8-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect of a
security registered under the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities
and liability for insiders who profit from trades made in a short period of time; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the selective disclosure rules by issuers of material nonpublic information under Regulation FD promulgated by SEC.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will be required to file an annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> within four months of the end of each fiscal
year. In addition, we intend to publish our results on a quarterly basis as press releases, distributed pursuant to the rules and regulations of the Nasdaq Stock Market. Press releases relating to financial results and material events will also be
furnished to the SEC on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> However, the information we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S.
domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>As an exempted company incorporated in the Cayman Islands, we are permitted to adopt certain home country
practices in relation to corporate governance matters that differ significantly from the Nasdaq Stock Market&#146;s corporate governance requirements; these practices may afford less protection to shareholders than they would enjoy if we complied
fully with the Nasdaq Stock Market&#146;s corporate governance requirements. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a Cayman Islands company listed on the Nasdaq Stock Market, we are subject
to the Nasdaq Stock Market&#146;s corporate governance requirements. However, the Nasdaq Stock Market rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance
practices in the Cayman Islands, which is our home country, may differ significantly from the Nasdaq Stock Market&#146;s corporate governance requirements. For example, neither the Companies Law nor our post-offering memorandum and articles of
association that will become effective immediately prior to the completion of this offering requires a majority of our directors to be independent and we could include <FONT STYLE="white-space:nowrap">non-independent</FONT> directors as members of
our compensation committee and nominating committee, and our independent directors would not necessarily hold regularly scheduled meetings at which only independent directors are present. Currently, we do not plan to rely on home country practice
with respect to our corporate governance after we complete this offering. However, if we choose to follow home country practice in the future, our shareholders may be afforded less protection than they otherwise would under the Nasdaq Stock
Market&#146;s corporate governance requirements applicable to U.S. domestic issuers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>There can be no assurance that we will not be classified as a passive
foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable year, which could subject U.S. investors in our ADSs or ordinary shares to significant adverse U.S. income tax consequences. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will be a passive foreign investment company, or PFIC, for any taxable year if either (i)&nbsp;75% or more of our gross income for such year consists of certain
types of &#147;passive&#148; income or (ii) 50% or more of the average quarterly value of our assets (as determined on the basis of fair market value) during such year produce or are held for the production of passive income (the &#147;asset
test&#148;). No assurance can be given with respect to our PFIC status for the current taxable year or any future taxable year. The determination of whether we are or will become a PFIC is uncertain because it is a fact-intensive inquiry made on an
annual basis that will depend, in part, on the composition of our income and assets. Fluctuations in the market price of our ADSs may cause us to be a PFIC for the current or subsequent taxable years because the value of our assets for purposes of
the asset test may be determined by reference to the market price of our ADSs from time to time (which may be volatile for biopharmaceutical companies, such as ours, that have not yet achieved commercialization with respect to any of their
products). The composition of our income and assets may also be affected by how, and how quickly, we use our liquid assets and the cash raised in this offering. Under circumstances where our revenue from activities that produce passive income
increases relative to our revenue from activities that produce non-passive income, or where we determine not to deploy cash for active purposes, our risk of being a PFIC will substantially increase. Because there are uncertainties in the application
of the relevant rules, it is possible that the IRS may challenge our classification or valuation of certain income and assets, each of which may result in our being or becoming a PFIC for the current or subsequent taxable years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are a PFIC in any taxable year, a U.S. Holder (as defined in &#147;Taxation&#151;United States Federal Income Tax Considerations&#148;) may incur significantly
increased U.S. income tax on gain recognized on the sale or other disposition of the ADSs or ordinary shares and on the receipt of distributions on the ADSs or ordinary shares to the extent such gain or distribution is treated as an &#147;excess
distribution&#148; under the U.S. federal income tax rules and such holder may be subject to burdensome reporting requirements. Further, if we are a PFIC for any year during which a U.S. holder holds our ADSs or ordinary shares, we generally will
continue to be treated as a PFIC for all succeeding years during which such U.S. holder holds our ADSs or ordinary shares. For more information see &#147;Taxation&#151;United States Federal Income Tax Considerations&#151;Passive Foreign Investment
Company Considerations.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will incur increased costs and become subject to additional rules and regulations as a result of being a public company,
particularly after we cease to qualify as an &#147;emerging growth company.&#148; </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a public company, we expect to incur significant legal, accounting and
other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, as well as rules&nbsp;subsequently implemented by the SEC and the Nasdaq Global Market, impose various requirements on the corporate governance practices of
public companies. As a company with less than US$1.07&nbsp;billion in net revenues for our last fiscal year, we qualify as an &#147;emerging growth company&#148; pursuant to the JOBS Act. An emerging growth company may take advantage of specified
reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
include exemption from the auditor attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#146;s internal control over
financial reporting and permission to delay adopting new or revised accounting standards until such time as those standards apply to private companies. However, we have elected to &#147;opt out&#148; of the provision that allows us to delay adopting
new or revised accounting standards and, as a result, we will comply with new or revised accounting standards as required when they are adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is
irrevocable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect these rules&nbsp;and regulations to increase our legal and financial compliance costs and to make some corporate activities more
time-consuming and costly. After we are no longer an &#147;emerging growth company,&#148; we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002 and the other rules&nbsp;and regulations of the SEC. We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be
required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In addition, we will incur additional costs associated with our public company reporting requirements. It may also be
more difficult for us to find qualified persons to serve on our board of directors or as executive officers. We are currently evaluating and monitoring developments with respect to these rules&nbsp;and regulations, and we cannot predict or estimate
with any degree of certainty the amount of additional costs we may incur or the timing of such costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the past, shareholders of a public company often brought
securities class action suits against the company following periods of instability in the market price of that company&#146;s securities. If we were involved in a class action suit, it could divert a significant amount of our management&#146;s
attention and other resources from our business and operations, which could harm our results of operations and require us to incur significant expenses to defend the suit. Any such class action suit, whether or not successful, could harm our
reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and
results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains forward-looking statements that reflect our current expectations and views of future events. The forward-looking statements are contained
principally in the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business.&#148; Known and unknown risks,
uncertainties and other factors, including those listed under &#147;Risk Factors,&#148; may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You can identify some of these forward-looking statements by words or phrases such as &#147;may,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148;
&#147;aim,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;is/are likely to,&#148; &#147;potential,&#148; &#147;continue&#148; or other similar expressions. We have based these forward-looking statements
largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include statements relating
to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of initiation and completion, and the progress of our drug discovery and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to advance our drug candidates into drugs, and the successful completion of clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the approval, pricing and reimbursement of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the commercialization of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the market opportunities and competitive landscape of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the payment, receipt and timing of any milestone payments in relation to the licensing agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to attract and retain senior management and key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our future business development, financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">future developments, trends, conditions and competitive landscape in the industry and markets in which we operate;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our strategies, plans, objectives and goals and our ability to successfully implement these strategies, plans, objectives
and goals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to continue to maintain our market position in China&#146;s biopharmaceutical and biotechnology industries;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to identify and integrate suitable acquisition targets; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes to regulatory and operating conditions in our industry and markets. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These forward-looking statements involve various risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are
reasonable, our expectations may later be found to be incorrect. Our actual results could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our expectations
are generally set forth in &#147;Prospectus Summary&#151;Our Challenges,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Business,&#148;
&#147;Regulation&#148; and other sections in this prospectus. You should read thoroughly this prospectus and the documents that we refer to with the understanding that our actual future results may be materially different from and worse than what we
expect. We qualify all of our forward-looking statements by these cautionary statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains certain data and information that we obtained
from various government and private publications. Statistical data in these publications also include projections based on a number of assumptions. The biopharmaceutical industry may not grow at the rate projected by market data, or at all. Failure
of this market to grow at the projected rate may have a material and adverse effect on our business and the market price of our ADSs. In addition, the rapidly evolving nature of the biopharmaceutical industry results in significant uncertainties for
any projections or estimates relating to the growth prospects or future condition of our market. Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the
projections based on these assumptions. You should not place undue reliance on these forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The forward-looking statements made in this prospectus relate only to events or information as of the date on which
the statements are made in this prospectus. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on
which the statements are made or to reflect the occurrence of unanticipated events. You should read this prospectus and the documents that we refer to in this prospectus and have filed as exhibits to the registration statement, of which this
prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that we will receive net proceeds from this offering of approximately US$91.1 million, or approximately US$105.4 million if the underwriters exercise their
option to purchase additional ADSs in full, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
primary purposes of this offering are to create a public market for our shares for the benefit of all shareholders, retain talented employees by providing them with equity incentives, and obtain additional capital. We plan to use the net proceeds of
this offering as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately US$50.0 million for research and development of our existing and future drug candidates, including:
</P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">approximately US$15.0 million to fund the ongoing two registrational trials, as well as a planned exploratory trial in
SLE, for TJ202; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">approximately US$4.0 million to fund the planned registrational trial&nbsp;for enoblituzumab and the milestone payments
in connection with development of enoblituzumab; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">approximately US$8.0 million to fund the planned registrational trial for TJ101; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">approximately US$4.0 million to fund the ongoing Phase 2 trial for TJ301 and the milestone payments in connection with
development of TJ301; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">approximately US$4.0 million to fund the ongoing Phase 1b trial and planned phase 2 trial for TJ107 and the milestone
payments in connection with development of TJ107; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">approximately US$8.0 million to fund the Phase 1 trials both in the United States and China for TJC4;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">approximately US$5.0 million to fund the ongoing Phase 1 trial in the United States and the planned Phase 1 trial in
China for TJD5; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">approximately US$2.0 million to fund the planned Phase 1b trial in China for TJM2; </P></TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately US$18.4 million for potential investments in the establishment of our own manufacturing capacities,
including the construction of our manufacturing facility in China and for expanding our U.S. presence by building research facilities, including a translational medicine laboratory, in the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately US$22.7 million&nbsp;for general corporate purposes (including working capital needs), potential strategic
alliances, investments or acquisitions, although we have not identified any specific alliances, investment or acquisition opportunities as of the date of this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foregoing represents our current intentions based upon our present plans and business conditions to use and allocate the net proceeds of this offering. Our
management, however, will have significant flexibility and discretion to apply the net proceeds of this offering. If an unforeseen event occurs or business conditions change, we may use the proceeds of this offering differently than as described in
this prospectus. See &#147;Risk Factors&#151;Risks Related to Our ADSs and This Offering&#151;We have not determined a specific use for a portion of the net proceeds from this offering and we may use these proceeds in ways with which you may not
agree.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending any use described above, we plan to invest the net proceeds from this offering in short-term, interest-bearing, debt instruments or demand
deposits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has complete discretion on whether to pay dividends, subject to certain requirements of Cayman Islands law. Even if our board of directors
decides to pay dividends on our ordinary shares, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that our
board of directors may deem relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have any present plan to pay any cash dividends on our ordinary shares in the foreseeable future after this
offering. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a holding
company incorporated in the Cayman Islands. We may rely on dividends from our subsidiaries in China for our cash requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiaries
to pay dividends to us. See &#147;Regulation&#151;PRC Regulation&#151;Regulations Relating to Foreign Exchange and the Dividend Distribution.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we pay any
dividends on our ordinary shares, we will pay those dividends which are payable in respect of the ordinary shares underlying our ADSs to the depositary, as the registered holder of such ordinary shares, and the depositary then will pay such amounts
to our ADS holders in proportion to the ordinary shares underlying the ADSs held by such ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. See &#147;Description of American Depositary
Shares.&#148; Cash dividends on our ordinary shares, if any, will be paid in U.S. dollars. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our capitalization as of September 30, 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma basis to reflect (i) the automatic conversion of all of our issued and outstanding convertible preferred
shares into 95,222,315 ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (except for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-to-1.08</FONT></FONT> for
Series&nbsp;B-2 convertible preferred shares and 1-to-1.11 for Series C convertible preferred shares) immediately prior to the completion of this offering and (ii) the increase of our authorized share capital to US$80,000 immediately prior to the
completion of this offering, which will be divided into 800,000,000 ordinary shares of a par value of US$0.0001 each; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma as adjusted basis to reflect (i)&nbsp;the automatic conversion of all of our issued and outstanding
convertible preferred shares into 99,760,129 ordinary shares (including Series C-1 convertible preferred shares issued in October and November 2019) on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT>
basis (except for 1-to-1.08 for Series B-2 convertible preferred shares, 1-to-1.11 for Series C convertible preferred shares and 1-to-1.18 for Series C-1 convertible preferred shares) immediately upon the completion of this offering; (ii) the
increase of our authorized share capital to US$80,000 immediately prior to the completion of this offering, which will be divided into 800,000,000 ordinary shares of a par value of US$0.0001 each; (iii) vesting of 1,179,633 restricted shares on
October&nbsp;18, 2019; (iv) the issuance of 6,078,571 ordinary shares to Everest Medicines Limited (&#147;Everest&#148;) upon the completion of this offering in connection with the termination of the collaboration agreement between our company and
Everest; and (v) the sale of 17,037,020 ordinary shares represented by ADSs by us in this offering after deducting underwriting discounts and commissions, underwriting incentive fees and estimated offering expenses payable by us, assuming the
underwriters do not exercise the over-allotment option. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should read this table together with our consolidated financial statements and the
related notes included elsewhere in this prospectus and the information under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER 30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO FORMA<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS&nbsp;ADJUSTED<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Convertible promissory notes<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Consideration received in advance from a preferred shares investor</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Series A convertible preferred shares (US$0.0001 par value, 30,227,056 shares authorized, issued and
outstanding on an actual basis; and nil outstanding on a pro forma and pro forma as adjusted basis as of September 30, 2019)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>687,482</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER 30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO FORMA<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS&nbsp;ADJUSTED<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Series B convertible preferred shares (US$0.0001 par value, 30,305,212 shares authorized, issued and
outstanding on an actual basis; and nil outstanding on a pro forma and pro forma as adjusted basis as of September 30, 2019)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>921,243</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued and
outstanding on an actual basis; and nil outstanding on a pro forma and pro forma as adjusted basis as of September 30, 2019)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,306,633</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>407,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized on an actual basis, 800,000,000 shares
authorized on a pro forma and pro forma as adjusted basis as of September 30, 2019; 8,363,719 shares issued and outstanding as of September 30, 2019; 103,586,034 shares issued and outstanding on a pro forma basis as of September 30, 2019; and
131,239,439 shares issued and outstanding on a pro forma as adjusted basis as of September&nbsp;30, 2019)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>6</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Treasury stock<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(1</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Additional paid-in capital<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,282,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,392,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">614,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Accumulated other comprehensive<BR>income <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Accumulated deficit<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,117,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(296,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,117,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(296,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,141,758</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(299,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,625,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(227,393</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,290,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>180,481</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,376,661</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>332,508</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Total mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,290,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>180,481</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,290,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>180,481</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,376,661</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>332,508</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Total capitalization</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,431,075</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>200,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,431,075</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>200,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,446,994</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>342,348</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The unaudited pro forma presentation does not include (i) Series C-1 convertible preferred shares issued in October and November 2019; (ii) the vesting 1,179,633 restricted shares on October 18, 2019; (iii) our
share-based awards that shall be vested and exercisable upon the completion of this offering; or (iv) the issuance of ordinary shares to Everest upon the completion of this offering in connection with the termination of the collaboration agreement
between our company and Everest. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted information assumes no exercise of any stock options outstanding as of the date of this prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted information assumes no conversion of the Company&#146;s convertible promissory notes into the Company&#146;s convertible preferred shares upon the completion of this offering.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The unaudited pro forma and pro forma as adjusted presentations do not include the accounting impacts of the amendments made to the Company&#146;s convertible preferred shares on December 25, 2019. See &#147;Description
of Share Capital.&#148; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_9"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our ADSs, your interest will be diluted to the extent of the difference between the initial public offering price per ADS and our net tangible book
value per ADS after this offering. Dilution results from the fact that the initial public offering price per ordinary share is substantially in excess of the book value per ordinary share attributable to the existing shareholders for our presently
outstanding ordinary shares, and holders of our vested restricted shares and convertible preferred shares which will automatically convert into our ordinary shares upon the completion of this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our net tangible book value as of September 30, 2019 was approximately US$136.42 million. Net tangible book value represents the amount of our total consolidated
tangible assets, less the amount of our total consolidated liabilities. Dilution is determined by subtracting net tangible book value per ordinary share, after giving effect to (i)&nbsp;the conversion of all our outstanding convertible preferred
shares (including Series C-1 convertible preferred shares issued in October and November 2019) into ordinary shares immediately prior to the completion of this offering; (ii) the increase of our authorized share capital to US$80,000 immediately
prior to the completion of this offering, which will be divided into 800,000,000 ordinary shares of a par value of US$0.0001 each; (iii)&nbsp;vesting of 1,179,633 restricted shares on October 18, 2019; (iv)&nbsp;the issuance of 6,078,571 ordinary
shares to Everest upon the completion of this offering in connection with the termination of the collaboration agreement between our company and Everest; and (v) the additional proceeds we will receive from this offering after deducting underwriting
discounts and commissions, underwriting incentive fees and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Without taking into account any other changes in net tangible
book value after September&nbsp;30, 2019, other than to give effect to (i) the conversion of all our outstanding convertible preferred shares (including Series C-1 convertible preferred shares issued in October and November 2019) into ordinary
shares immediately upon the completion of this offering; (ii) the increase of our authorized share capital to US$80,000 immediately prior to the completion of this offering, which will be divided into 800,000,000 ordinary shares of a par value of
US$0.0001 each; (iii) vesting of 1,179,633 restricted shares on October 18, 2019; (iv)&nbsp;the issuance of 6,078,571 ordinary shares to Everest upon the completion of this offering in connection with the termination of the collaboration agreement
between our company and Everest; and (v) our sale of the ADSs in this offering after deduction of the underwriting discounts and commissions, underwriting incentive fees and estimated offering expenses payable by us, our pro forma as adjusted net
tangible book value as of September 30, 2019 would have been US$288.45 million, or US$2.20 per ordinary share and US$5.06 per ADS. This represents an immediate increase in net tangible book value of US$0.87 per ordinary share and US$2.00 per ADS to
the existing shareholders (including preferred shareholders) and an immediate dilution in net tangible book value of US$3.89 per ordinary share and US$8.94 per ADS to investors purchasing ADSs in this offering. The following table illustrates such
dilution: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;ORDINARY&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">14.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net tangible book value per share after giving effect to the conversion of our convertible
preferred shares into ordinary shares on a one-for-one basis (except for 1-to-1.08 for Series B-2 convertible preferred shares and 1-to-1.11 for Series C convertible preferred shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">1.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">3.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after giving effect to (i) the conversion of our
convertible preferred shares into ordinary shares on a one-for-one basis (except for 1-to-1.08 for Series B-2 convertible preferred shares, 1-to-1.11 for Series C convertible preferred shares and 1-to-1.18 for Series C-1 convertible preferred
shares), (ii) vesting of 1,179,633 restricted shares on October 18, 2019, (iii) the issuance of 6,078,571 ordinary shares to Everest, and (iv) this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">2.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">5.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;ORDINARY&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in net tangible book value per share attributable to new investors in this offering after giving
effect to (i) the conversion of our Series C-1 convertible preferred shares into ordinary shares, (ii) vesting of 1,179,633 restricted shares on October 18, 2019 and (iii) the issuance of 6,078,571 ordinary shares to Everest.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">0.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Amount of dilution in net tangible book value per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">3.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">8.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes, on a pro forma as adjusted basis as of September 30, 2019, the differences between existing shareholders and the new investors with
respect to the number of ordinary shares (represented by ADSs or shares) purchased from us, the total consideration paid and the average price per ordinary share and per ADS paid in this offering before deducting the underwriting discounts and
commissions, underwriting incentive fees and estimated offering expenses. The total number of ordinary shares does not include ordinary shares underlying the ADSs issuable upon the exercise of the over-allotment option granted to the underwriters.
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY&nbsp;SHARES&nbsp;PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL&nbsp;CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AVERAGE<BR>PRICE&nbsp;PER<BR>ORDINARY<BR>SHARE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AVERAGE<BR>PRICE&nbsp;PER<BR>ADS</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(US$ million)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,202,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">4.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$9.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,037,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$14.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,239,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pro forma as adjusted information discussed above is illustrative only. Our net tangible book value following the completion of this offering is subject to
adjustment based on the actual initial public offering price of our ADSs and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The discussion and tables above
assume no exercise of any stock options outstanding as of the date of this prospectus and no conversion of our company&#146;s convertible promissory notes into our company&#146;s convertible preferred shares upon the completion of this offering. As
of the date of this prospectus, there are 20,441,986 ordinary shares issuable upon exercise of outstanding stock options at a weighted average exercise price of US$0.97&nbsp;per share (taking into account of impacts of adjustments to our
company&#146;s 2017 Plan and 2018 Plan. See &#147;Management&#151;Share Incentive Plans.&#148;), and there are 172,986 ordinary shares available for future issuance upon the exercise of future grants under our stock incentive plans. If any of these
options are exercised, there will be further dilution to new investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_10"></A>ENFORCEABILITY OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are incorporated under the laws of the Cayman Islands as an exempted company with limited liability. We are incorporated in the Cayman Islands because of certain
benefits associated with being a Cayman Islands exempted company, such as political and economic stability, an effective judicial system, a favorable tax system, the absence of foreign exchange control or currency restrictions and the availability
of professional and support services. However, the Cayman Islands has a less developed body of securities laws than the United&nbsp;States and provides less protection for investors. In addition, Cayman Islands companies do not have standing to sue
before the federal courts of the United&nbsp;States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Most of our assets are located outside the United&nbsp;States. In addition, most of our directors and officers
are nationals or residents of jurisdictions other than the United&nbsp;States and all or a substantial portion of their assets are located outside the United&nbsp;States. As a result, it may be difficult for investors to effect service of process
within the United&nbsp;States upon us or these persons, or to enforce judgments obtained in U.S.&nbsp;courts against us or them, including judgments predicated upon the civil liability provisions of the securities laws of the United&nbsp;States or
any state in the United&nbsp;States. It may also be difficult for you to enforce judgments obtained in U.S.&nbsp;courts based on the civil liability provisions of the U.S.&nbsp;federal securities laws against us and our officers and&nbsp;directors.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have appointed Cogency Global Inc. as our agent to receive service of process with respect to any action brought against us in the U.S.&nbsp;District Court for
the Southern District of New&nbsp;York in connection with this offering under the federal securities laws of the United&nbsp;States or the securities laws of any state in the United&nbsp;States or any action brought against us in the Supreme Court
of the State of New&nbsp;York in the County of New&nbsp;York in connection with this offering under the securities laws of the State of New&nbsp;York. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Conyers
Dill&nbsp;&amp; Pearman, our counsel as to Cayman Islands law, has advised us that there is uncertainty as to whether the courts of the Cayman Islands would (1)&nbsp;recognize or enforce judgments of U.S.&nbsp;courts obtained against us or our
directors or officers that are predicated upon the civil liability provisions of the federal securities laws of the United&nbsp;States or the securities laws of any state in the United&nbsp;States, or (2)&nbsp;entertain original actions brought in
the Cayman Islands against us or our directors or officers that are predicated upon the federal securities laws of the United&nbsp;States or the securities laws of any state in the United&nbsp;States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Conyers Dill&nbsp;&amp; Pearman has informed us that the uncertainty with regard to Cayman Islands law relates to whether a judgment obtained from the U.S. courts under
civil liability provisions of the securities law will be determined by the courts of the Cayman Islands as penal or punitive in nature. The courts of the Cayman Islands may not recognize or enforce such judgments against a Cayman company, and
because such a determination has not yet been made by a court of the Cayman Islands, it is uncertain whether such civil liability judgments from U.S. courts would be enforceable in the Cayman Islands. Conyers Dill&nbsp;&amp; Pearman has further
advised us that the courts of the Cayman Islands would recognize as a valid judgment, a final and conclusive judgment in personam obtained in the federal or state courts of the United States under which a sum of money is payable (other than a sum of
money payable in respect of multiple damages, taxes or other charges of a like nature or in respect of a fine or other penalty) or, in certain circumstances, an in personam judgment for <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief,
and would give a judgment based thereon provided that (a)&nbsp;such courts had proper jurisdiction over the parties subject to such judgment; (b)&nbsp;such courts did not contravene the rules of natural justice of the Cayman Islands; (c)&nbsp;such
judgment was not obtained by fraud; (d)&nbsp;the enforcement of the judgment would not be contrary to the public policy of the Cayman Islands; (e)&nbsp;no new admissible evidence relevant to the action is submitted prior to the rendering of the
judgment by the courts of the Cayman Islands; and (f)&nbsp;there is due compliance with the correct procedures under the laws of the Cayman Islands. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">JunHe LLP, our
counsel as to PRC law, has advised us that there is uncertainty as to whether the courts of China would (1)&nbsp;recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil
liability provisions of the securities laws of the United States or any state in the United States, or (2)&nbsp;entertain original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities
laws of the United States or any state in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">JunHe LLP has further advised us that the recognition and enforcement of foreign judgments are
provided for under the PRC Civil Procedures Law. The PRC courts may recognize and enforce foreign judgments in accordance with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on principles of reciprocity between jurisdictions. China does
not have any treaties or other form of reciprocal arrangements with the United States or the Cayman Islands that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law,
courts in China will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC law or national sovereignty, security or public interest. As a result, it is uncertain
whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States or in the Cayman Islands. Under the PRC Civil Procedures Law, foreign shareholders may initiate actions based on PRC law before a PRC court
against a company for disputes, if the plaintiff can establish a sufficient contact with China for a PRC court to exercise jurisdiction and has a direct interest, cause of action and a concrete claim. The action may be initiated by a shareholder
through filing a complaint with the PRC court. The PRC court will determine whether to accept the complaint in accordance with the PRC Civil Procedures Law. The shareholder may participate in the action by itself or entrust any other person or PRC
legal counsel to participate on behalf of such shareholder. In addition, it will be difficult for U.S. shareholders to originate actions against us in China in accordance with PRC laws because we are incorporated under the laws of the Cayman Islands
and it will be difficult for U.S. shareholders, by virtue only of holding our ADSs or ordinary shares, to establish a connection to China for a PRC court to have jurisdiction as required under the PRC Civil Procedures Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_11"></A>CORPORATE HISTORY AND STRUCTURE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We commenced our operations in November 2014, when our predecessor Third Venture Biopharma (Nanjing) Co., Ltd (&#147;Third Venture&#148;) was established. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> was established in June 2016 under the laws of the Cayman Islands as our offshore holding company. In July 2016, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> established <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hong Kong&#148;), as its intermediary holding company. In August 2016,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong established a wholly-owned PRC subsidiary, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;). In
September 2016, the assets and operations of Third Venture were consolidated into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2017, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired a controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd.
<FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;), formerly known as Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd., a company focused on CMC management of biologics in China. Through an internal
corporate restructuring, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin became the 100% owner of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai in September 2017 and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired the
remaining interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018, becoming the 100% owner of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong established in Maryland, United States, a wholly-owned subsidiary <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> US&#148;), as the hub for the discovery and development of the drug candidates in our Global Portfolio. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following diagram illustrates our corporate structure, including our principal subsidiaries, as of the date of this prospectus: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g69u35.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_12"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following selected consolidated statements of comprehensive loss data for the years ended December&nbsp;31, 2017 and 2018, selected consolidated balance sheet data
as of December&nbsp;31, 2017 and 2018 and selected consolidated statements of cash flow data for the years ended December&nbsp;31, 2017 and 2018 have been derived from our audited consolidated financial statements included elsewhere in this
prospectus. The following selected consolidated statements of comprehensive loss data for the nine months ended September&nbsp;30, 2018 and 2019, selected consolidated balance sheet data as of September&nbsp;30, 2019 and selected consolidated
statements of cash flow data for the nine months ended September&nbsp;30, 2018 and 2019 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Our consolidated financial statements
are prepared and presented in accordance with accounting principles generally accepted in the U.S. GAAP. Our historical results are not necessarily indicative of results expected for future periods. You should read this Selected Consolidated
Financial Data section together with our consolidated financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere in this prospectus. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Selected Consolidated Statements of Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(314,574<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(578,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,918</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,912<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(438,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(312,095<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,131,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,438<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,575<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,985<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,484<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(401,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(277,733<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,635<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279,368<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,101<B></B> <B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total comprehensive loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,848</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(219,267</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,037,126</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(145,099</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(56,359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(279,368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(154,368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except for share and per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Weighted-average number of ordinary shares used in calculating net loss per shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,397,663<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43.67<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B> <B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43.67<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B> <B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Share-based compensation expenses were allocated as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;YEAR&nbsp;ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE NINE MONTHS<BR>ENDED SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">4,927</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">2,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">2,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">514,726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">72,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>493</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,970</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents our selected consolidated statements of balance sheet data as of December&nbsp;31, 2017 and 2018 and September 30, 2019: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Selected Consolidated Statements of Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">307,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">1,588,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">222,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">1,224,477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">171,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">104,783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">92,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">12,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">56,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">7,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contract assets<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Short-term investments<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">12,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">88,972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">12,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">74,895</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">10,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">266,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">255,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">35,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">63,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">8,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>691,591</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>2,036,861</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>284,968</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>1,483,367</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>207,531</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">22,336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">27,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">3,870</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">25,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">3,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease right-of-use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">13,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">1,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">148,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">148,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">20,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">148,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">20,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">162,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">162,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">22,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">162,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">22,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>1,025,345</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>2,375,938</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>332,407</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>1,839,635</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>257,375</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>309,151</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>415,684</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>58,156</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>549,622</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>76,894</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>1,015,989</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>2,915,358</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>407,874</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>2,915,358</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>407,874</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December 31, 2018 and September
30, 2019, 8,363,719 and 8,363,719 shares authorized, issued and outstanding as of December&nbsp;31, 2018 and September 30, 2019, respectively)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B></B>6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Treasury stock<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B></B>(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B></B>)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional paid-in capital<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B></B>52,369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">366,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">51,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive income <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B></B>5,691</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">59,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">8,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">125,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">17,758</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B></B>(357,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B></B>)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1,014,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(141,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(2,117,869</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(296,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>(299,795</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>(955,104</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>(133,623</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>(1,625,345</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>(227,393</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>1,025,345</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>2,375,938</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>332,407</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>1,839,635</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><B>257,375</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents our selected consolidated statements of cash flow data for the years ended December&nbsp;31, 2017 and 2018 and the nine months ended
September 30, 2018 and 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED</B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Selected Consolidated Statements of Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(651,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash (used in) generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,281,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_13"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should
read the following discussion and analysis of our financial condition and results of operations in conjunction with the section entitled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and the consolidated
financial statements of <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;) and the related notes included elsewhere
in this prospectus. This discussion contains forward-looking statements that reflect our current expectations and views of future events, which may involve risks and uncertainties. Our actual results and the timing of selected events could differ
materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#147;Risk Factors&#148; and elsewhere in this prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired a controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin on July&nbsp;15, 2017 and have consolidated the results of operations of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries since July&nbsp;15, 2017. In this section, when discussing historical facts and operating results for the period before July&nbsp;15, 2017, &#147;we,&#148; &#147;us,&#148;
&#147;our company&#148; and &#147;our&#148; refer to <FONT STYLE="white-space:nowrap">I-Mab</FONT> and its then subsidiaries, and do not include <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin or its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company committed to the
discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were founded to capture the opportunities presented by the confluence of two major developments&#151;the emergence of an attractive and growing biologics market in
China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding
of China&#146;s biologics regulatory framework and our direct access to extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative pipeline of more than 10 clinical
and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage assets through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global pharmaceutical and biotech companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are fully aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China, including need to raise
significant capital, significant competition from global and other China-based biopharmaceutical companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential implementation challenges
and uncertainties of the recent government reform of the drug approval system. However, with these challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional aspects of our drug
development process to proactively deal with some of the regulatory challenges mentioned above. Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel with the regulatory
agencies to discuss and resolve various regulatory issues promptly and effectively. We see vast opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence and mortality of cancers in China have been
increasing in recent years and are outpacing those in the United States and the rest of the world. Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States and Europe are not yet available in China.
Third, the Chinese government has implemented new policies and regulations to simplify the review and approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth, there has been a continuous and rapid
increase in personal disposable income in China coupled with ongoing improvement in basic national health insurance coverage, making innovative biologics more accessible to more Chinese patients. According to the Frost&nbsp;&amp; Sullivan Report,
China&#146;s biologics market is growing faster than the global biologics market and is expected to reach approximately RMB1.3 trillion (US$181.9 billion) by 2030 in terms of sales revenue. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe we are uniquely positioned as a China-based global player to tap into these vast commercial opportunities. This is best demonstrated by our short journey in
becoming one of the top clinical stage immunology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
companies in China. According to the Frost &amp; Sullivan Report, we are ranked as top clinical stage China-based immunology companies as measured by the innovative quality and number of
investigational drugs and drug candidates under clinical and pre-clinical development in our pipeline, amount of pre-IPO financing raised (in excess of US$400 million in three years), pre-IPO valuation and recognition and awards earned in the
biotech industry. For example, in 2018 and 2019, we are the only China-based biotech company recognized by Genetic Engineering &amp; Biotechnology News (GEN) as a top 10 immuno-oncology start-up in the world. To date, our research and development
capabilities encompass discovery, translational medicine, biologics CMC development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical development with footprints in Shanghai, Beijing and the United States. We are now at
a critical juncture to transition from a clinical stage biotech company into a fully integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company in the next few years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since the commencement of our operation in 2014, we have devoted most of our efforts and financial resources to organize and staff our operations, business planning,
raise capital, establish our intellectual property portfolio and conduct pre-clinical and clinical trials of our drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We had raised in excess of
US$400&nbsp;million in pre-IPO financing in the past three years. We have not generated any revenue from product sales, and as a result, we have never been profitable and have incurred net losses since the commencement of our operations. In 2017,
2018 and the nine months ended September 30, 2019, our net losses were RMB298.2&nbsp;million, RMB402.8&nbsp;million (US$56.4 million) and RMB1,103.4 million (US$154.4 million), respectively. We do not expect to generate product revenue unless and
until we obtain marketing approval for and commercialize a drug candidate, and we cannot assure you that we will ever generate significant revenue or profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Key Factors Affecting Our Results of Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our results of operations,
financial condition, and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> comparability of our financial results have been, and are expected to continue to be, principally affected by the below
factors: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cost and Expenses Structure </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our results of operations
are significantly affected by our cost structure, which primarily consists of research and development expenses and administrative expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and
development activities are central to our business model. We believe our ability to successfully develop drug candidates will be the primary factor affecting our long-term competitiveness, as well as our future growth and development. Developing
high-quality drug candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. Since our inception, we have focused our resources
on our research and development activities, including conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, and activities related to regulatory filings for our drug candidates. Our research and development
expenses primarily include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to development of our pipeline assets under all stages including discovery, pre-clinical testing or clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">patent license fees and other fees under the licensing, collaboration and development agreements with respect to our
in-licensed drug candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">employee salaries and related benefit costs, including share-based compensation expenses, for research and development
personnel. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At this time, we are unable to predict when, if ever, we will be able to achieve profitability. Even if we achieve profitability in
the future, we may not be able to sustain profitability in subsequent periods thereafter. This is due to the numerous risks and uncertainties associated with developing such drug candidates, including the uncertainty of: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing an appropriate safety profile; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">commercializing the drug candidates, if and when approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continued acceptable safety profiles of the products following approval; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">retention of key research and development personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any change in the outcome of any of these variables with respect to the development of any of our drug candidates would significantly change the costs, timing and
viability associated with the development of that drug candidate. We expect research and development costs to continue to increase for the foreseeable future as we expand our operations and our development programs progress, including as we continue
to support and advance the clinical trials of our drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our administrative expenses consist primarily of employee salaries and related benefit costs.
Other administrative expenses include professional fees for consulting and auditing as well as other direct and allocated expenses for rental expenses for our facilities, travel costs and other supplies used in administrative activities. We expect
our administrative expenses to increase in the future to support our pipeline assets and research and development efforts, and the commercialization of our drug candidates once approval is obtained. We also anticipate that our administrative
expenses will increase as we operate as a public company following the completion of this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue from
<FONT STYLE="white-space:nowrap">Out-Licensing</FONT> Agreements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We continue to seek <FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities
for our <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets to streamline our pipeline. In 2017 and 2018 and for the nine months ended September 30, 2019, our revenue consisted primarily of payments from granting licenses to use and
otherwise exploit certain of our intellectual properties linked to our <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets. See &#147;Business&#151;Licensing and Collaboration Arrangements&#148; for more information on the existing <FONT
STYLE="white-space:nowrap">out-licensing</FONT> arrangements. In addition, after validating clinical safety and preliminary efficacy of a drug candidate in our Global Portfolio in clinical trials in the United States, we may elect to <FONT
STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of such drug candidate, while retaining the Greater China rights for further development and commercialization. But we may also choose to retain these rights
for the United States or other countries or regions as we may deem fit. Before the commercialization of one or more of our drug candidates, we expect that the majority of our revenue will continue to be generated from
<FONT STYLE="white-space:nowrap">out-licensing</FONT> our intellectual properties. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Funding for Our Operations </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the periods presented, we funded our operations primarily from financing through the issuance and sale of preferred shares and convertible promissory notes in
private placement transactions. Going forward, in the event of successful commercialization of one or more of our drug candidates, we expect to fund our operations in part with revenue generated from sales of our commercialized drug products.
However, with the continuing expansion of our business and our product pipeline, we may require further funding through public or private offerings, debt financing, collaboration, and licensing arrangements or other sources. Any fluctuation in our
ability to fund our operations will impact our cash flow plan and our results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Ability to Commercialize Our Drug Candidates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business and results of operations depend on our ability to commercialize our drug candidates, once and if those candidates are approved for marketing by the
respective health authority. Currently, our pipeline consists of more than ten drug candidates ranging in development status from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> to late-stage clinical programs. Although we currently do not have
any product approved for commercial sale and have not generated any revenue from product sales, we expect to generate revenue from sales of a drug candidate after we complete the clinical development, obtain regulatory approval, and successfully
commercialize such drug candidate. Our late-stage investigational drugs at or potentially near pivotal trials are TJ202, TJ101, TJ301 and enoblituzumab. See &#147;Business&#151;Our Drug Pipeline&#148; for more information on the development status
of our various drug candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Effect of Our Acquisition of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired a controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin on July&nbsp;15, 2017 and the remaining interest in <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018. Since our acquisition of the controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin on July&nbsp;15, 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin has
been consolidated into our results of operations. Shortly after we acquired the controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we integrated the operations of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin into
our operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin did not generate any external revenue from July&nbsp;15, 2017 to September 30, 2019. In
connection with our acquisition of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we identified RMB148.8&nbsp;million of intangible assets and RMB162.6&nbsp;million of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
goodwill of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. Goodwill is not amortized, but impairment of goodwill assessment is performed on an least an annual basis on December&nbsp;31 or
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. No impairment was identified as of December&nbsp;31, 2017 and 2018 and September 30, 2019. Impairment charges could substantially
affect our results of operations in the periods of such charges. In addition, impairment charges would negatively impact our financial ratios and could limit our ability to obtain financing in the future. See &#147;Risk Factors&#151;Risks Related to
Our Industry, Business and Operations&#151;Change in business prospects of acquisitions may result in impairment to our goodwill, which could negatively affect our reported results of operations.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Key Components of Results of Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenues </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future before the
successful commercialization of one or more of our drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We generated substantially all of our revenues for the years ended December&nbsp;31, 2017 and
2018 and the nine&nbsp;months ended September 30, 2019 from granting licenses to use and otherwise exploit certain of our intellectual properties in connection with our <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses
primarily consist of: (i)&nbsp;payroll and other related expenses of research and development personnel, (ii)&nbsp;fees associated with the exclusive development rights of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> drug candidates,
(iii)&nbsp;fees for services provided by contract research organizations, investigators and clinical trial sites that conduct our clinical studies, and (iv)&nbsp;expenses relating to the development of our drug candidates, including raw materials
and supplies, product testing, depreciation, and facility related expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our current research and development activities primarily relate to the clinical
development of the following investigational drugs: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">TJ202, a potential highly differentiated CD38 antibody for multiple myeloma and autoimmune diseases, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">TJ107, the first long-acting recombinant human IL-7 with the potential for cancer treatment-related lymphopenia and cancer
immunotherapy, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">TJ101, a potential highly differentiated long-acting growth hormone for growth hormone deficiency, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">TJ301, a potential highly differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for ulcerative colitis and
other autoimmune diseases, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Enoblituzumab, the most advanced clinical stage humanized B7-H3 antibody as a potential immuno-oncology treatment, if
approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">TJC4, a potential highly differentiated CD47 monoclonal antibody with unique
<FONT STYLE="white-space:nowrap">RBC-sparing</FONT> differentiation, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">TJD5, a potential highly differentiated CD73 antibody for immuno-oncology, if approved; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">TJM2, a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> monoclonal antibody for rheumatoid arthritis and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CAR-T-related</FONT></FONT> therapies, if approved. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We incurred research and
development expenses of RMB267.1&nbsp;million and RMB426.0&nbsp;million (US$59.6 million) for the years ended December&nbsp;31, 2017 and 2018, respectively, representing 91.3% and 86.5% of our total research and development and administrative
expenses for the corresponding periods. We incurred research and development expenses of RMB578.4&nbsp;million (US$80.9&nbsp;million) for the nine months ended September 30, 2019. We expect our research and development expenses to continue to
increase for the foreseeable future, as we continue to expand our operations and to advance our pipeline and our drug candidates toward later stages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Administrative expenses primarily consist of salaries and related benefit costs, including share-based compensation, for employees engaged in managerial and
administrative positions or involved in general corporate functions, professional fees for consulting and auditing as well as other direct and allocated expenses for rental expenses for our facilities, travel costs and other supplies used in
administrative activities. For the years ended December&nbsp;31, 2017 and 2018 and the nine months ended September 30, 2019, our administrative expenses amounted to RMB25.4&nbsp;million, RMB66.4&nbsp;million (US$9.3 million) and RMB582.7 million
(US$81.5 million), respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest
expense consist primarily of interest expenses on our (i)&nbsp;short-term bank borrowings and (ii)&nbsp;convertible promissory notes issued to certain investors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest Income </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest income consists primarily of interest
income derived from our term deposit and restricted cash pledged as collateral for a working capital loan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Income (Expenses), Net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other income consists primarily of income from other financial assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other
expenses consist primarily of the net loss resulting from the conversion of a portion of our convertible promissory notes. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value Change of Warrants
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fair value change of warrants consists primarily of the <FONT STYLE="white-space:nowrap">non-cash</FONT> items incurred in connection with changes in the
fair value of our warrant liabilities that we issued to certain investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Taxation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cayman Islands </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab,</FONT> our
holding entity, is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, <FONT STYLE="white-space:nowrap">I-Mab</FONT> is not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a
withholding tax on payments of dividends to shareholders. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong
profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate is 16.5% in Hong Kong. For the years ended December&nbsp;31, 2017
and 2018 and the nine months ended September 30, 2019, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong&nbsp;Kong Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings
in Hong Kong for any of the periods presented. Under the Hong Kong tax law, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong&nbsp;Kong Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes
in Hong Kong on remittance of dividends. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United States </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. is incorporated in Maryland and is subject to U.S. federal corporate income tax at a rate of 21%. It is also subject to state income tax in Maryland at a rate of 8.25%. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. has no taxable income for all periods presented and therefore no provision for income taxes is required. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>China </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;16, 2007, the National People&#146;s Congress of
PRC enacted a new Corporate Income Tax Law (&#147;new CIT law&#148;), under which Foreign Investment Enterprises (&#147;FIEs&#148;) and domestic companies would be subject to corporate income tax at a uniform rate of 25%. The new CIT law became
effective on January&nbsp;1, 2008. Under the new CIT law, preferential tax treatments will continue to be granted to entities which conduct businesses in certain encouraged sectors and to entities otherwise classified as &#147;High and New
Technology Enterprises.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai has been qualified as a &#147;High and New Technology Enterprise&#148; and
enjoys a preferential income tax rate of 15% from 2018 to 2020. No provision for income taxes has been accrued because all of our PRC subsidiaries are in cumulative loss positions for all the periods presented.
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin is subject to the statutory income tax at a rate of 25%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than
not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, we evaluate a variety of positive and negative factors including our operating history, accumulated deficit, the
existence of taxable temporary differences and reversal periods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred net accumulated operating losses for income tax purposes since our inception. We
believe that it is more likely than not that these net accumulated operating losses will not be utilized in the future. Therefore, we have provided full valuation allowances for the deferred tax assets as of December&nbsp;31, 2017 and 2018 and
September 30, 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We evaluate each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and
measure the unrecognized benefits associated with the tax positions. As of December&nbsp;31, 2017 and 2018 and September 30, 2019, we did not have any significant unrecognized uncertain tax positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth a summary of our
consolidated results of operations for the periods indicated. This information should be read together with our consolidated financial statements and related notes included elsewhere in this prospectus. The operating results in any period are not
necessarily indicative of the results that may be expected for any future period. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE NINE MONTHS ENDED<BR>SEPTEMBER 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(314,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(578,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,918</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(438,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(312,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,131,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(401,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(277,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Share-based compensation expenses were allocated as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE NINE MONTHS ENDED<BR>SEPTEMBER 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>493</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,970</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Comparison of Nine Months Ended September 30, 2019 and 2018 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenues </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our revenues generated from licensing and collaboration
decreased by 30.9% from RMB43.4 million for the nine&nbsp;months ended September 30, 2018 to RMB30.0 million (US$4.2 million) for the nine months ended September&nbsp;30, 2019. Our revenues generated in the nine months ended September 30, 2018
consisted of (i)&nbsp;RMB26.2 million we recognized pursuant to our out-licensing arrangement with HDYM and (ii) RMB17.2 million of upfront payment to us pursuant to our out-licensing arrangement with ABL Bio. Our revenues generated in the nine
months ended September 30, 2019 solely consisted of CSPC entity&#146;s upfront and milestone payments to us pursuant to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangement with CSPC entity. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth a
breakdown of the major components of our research and development expenses in absolute amounts and as a percentage of our total research and development expenses for the periods indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE NINE MONTHS ENDED SEPTEMBER 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">CRO service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">In-licensed patent right fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee benefit expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Material costs for drug candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our research and development expenses increased by 83.9% from RMB314.6 million for the nine months ended September 30, 2018 to RMB578.4 million (US$80.9 million) for
the nine months ended September 30, 2019, primarily attributable to (i) an increase in the CRO service fees from RMB172.3 million for the nine months ended September 30, 2018 to RMB316.6 million (US$44.3 million) for the nine months ended September
30, 2019, as we initiated a few more research and development programs and advanced some of our existing investigational drugs into more advanced clinical development stages; (ii) an increase in in-licensed patent right fees from RMB78.5 million for
the nine months ended September 30, 2018 to RMB160.4 million (US$22.4 million) for the nine&nbsp;months ended September 30, 2019, mainly due to upfront fees paid to MacroGenics; and (iii) an increase in employee benefit expenses of employees
involved in research and development from RMB34.4 million for the nine&nbsp;months ended September 30, 2018 to RMB72.1 million (US$10.1&nbsp;million) for the nine months ended September&nbsp;30, 2019, due to an increase in the headcount. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the nine months ended September 30, 2019, 90.3% and 9.7% of our total research and development expenses were attributable to clinical programs and preclinical
programs, respectively. In the nine months ended September&nbsp;30, 2018, 78.4% and 21.6% of our total research and development expenses were attributable to clinical programs and preclinical programs, respectively. For the nine months ended
September 30, 2019, TJ202 represented approximately 50.1% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. For the nine months ended September 30, 2018, TJ107 represented
approximately 30.3% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. No other programs represented a significant amount of research and development expenses in the nine months
ended September 30, 2019 and 2018. Though we manage our external research and development expenses by program, we do not allocate our internal research and development expenses by program because our employees and internal resources may be engaged
in projects for multiple programs at any time. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our administrative expenses increased from RMB40.9 million for the nine months ended September 30, 2018 to RMB582.7 million (US$81.5 million) for the nine months ended
September 30, 2019, primarily attributable to (i)&nbsp;stock options granted to a director of our company under the 2018 Plan, (ii) repurchase of share awards held by a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
director of our company, (iii) the increase in employee benefit expenses due to headcount increase, and (iv) the increase in third-party professional expenses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest Income </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We recorded RMB1.4 million of interest income for
the nine months ended September 30, 2018 and RMB22.8 million (US$3.2 million) of interest income for the nine months ended September 30, 2019. The change was primarily attributable to the interest income derived from bank deposits. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We recorded RMB10.6 million of interest expense for
the nine months ended September 30, 2018 and RMB2.5 million (US$0.3 million) of interest expense for the nine months ended September 30, 2019. The change was primarily attributable to the interest expense related to our convertible promissory notes,
which were converted in June and July 2018. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Income (Expenses), Net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We recorded RMB17.0 million of other expenses for the nine months ended September 30, 2018 and RMB1.8 million (US$0.2 million) of other income for the nine months ended
September 30, 2019. The change was primarily attributable to the conversion of our convertible promissory notes and onshore convertible loans during the nine months ended September&nbsp;30, 2019. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value Change of Warrants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We recorded a gain from change in the
fair value of warrant liability of RMB60.5 million for the nine months ended September 30, 2018 and RMB5.6 million (US$0.8 million) for the nine months ended September&nbsp;30, 2019. The change was primarily attributable to (i) the change in fair
value of warrants due to the increase in the valuation of our company, and (ii) the modification in 2018 that added certain forfeiture conditions to the warrants, which increased the possibility of forfeiture of the warrants and therefore resulted
in a reduction in our warrant liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Comparison of Twelve Months Ended December&nbsp;31, 2018 and 2017 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenues </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our revenues generated from licensing and collaboration
increased by 365.4% from RMB11.6&nbsp;million for the year ended December&nbsp;31, 2017 to RMB53.8&nbsp;million (US$7.5 million) for the year ended December&nbsp;31, 2018. Our revenues generated for the year ended December 31, 2017 consisted solely
of HDYM&#146;s milestone payment to us pursuant to our out-licensing arrangement with it. Our revenues generated for the year ended December 31, 2018 consisted of both HDYM&#146;s milestone payment and ABL Bio&#146;s upfront payment to us pursuant
to our out-licensing arrangements with them, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a percentage of our total
research and development expenses for the periods indicated: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">CRO service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-licensed</FONT> patent right fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employment benefit expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Material costs for drug candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our research and development expenses increased by 59.5% from RMB267.1&nbsp;million for the year ended December&nbsp;31, 2017 to RMB426.0&nbsp;million (US$59.6 million)
for the year ended December&nbsp;31, 2018, primarily attributable to (i)&nbsp;an increase in the CRO service fees from RMB83.0&nbsp;million in 2017 to RMB212.3&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
(US$29.7 million) in 2018, as we initiated a few more research and development programs and advanced some of our existing investigational drugs into more advanced clinical development stages; and
(ii)&nbsp;an increase in employee benefit expenses of employees involved in research and development from RMB26.8&nbsp;million in 2017 to RMB56.6&nbsp;million (US$7.9 million) in 2018, due to an increase in the headcount. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2018, 72.3% and 27.7% of our total research and development expenses were attributable to clinical programs and pre-clinical programs, respectively. In 2017, 77.5%
and 22.5% of our total research and development expenses were attributable to clinical programs and pre-clinical programs, respectively. In 2018, TJ107 and TJ202 represented approximately 25.0% and 9.9% of our external research and development
expenses, which primarily included licensing fees and payments to CROs and CMOs. In 2017, TJ202 represented approximately 59.1% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs.
No other programs represented a significant amount of research and development expenses in 2018 and 2017. Though we manage our external research and development expenses by program we do not allocate our internal research and development expenses by
program because our employees and internal resources may be engaged in projects for multiple programs at any time. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our administrative expenses increased from RMB25.4&nbsp;million for the year ended December&nbsp;31, 2017 to RMB66.4&nbsp;million (US$9.3 million) for the year ended
December&nbsp;31, 2018, primarily attributable to (i) the increase in employee benefit expenses due to headcount increase, and (ii) the increase in third-party professional expenses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest Income </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We recorded RMB0.9 million of interest income for
the year ended December 31, 2017 and RMB4.6 million (US$0.6 million) of interest income for the year ended December 31, 2018. The change was primarily attributable to the interest income derived from our bank deposits. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We recorded RMB5.6 million of interest expense for
the year ended December 31, 2017 and RMB11.7 million (US$1.6 million) of interest expense for the year ended December 31, 2018. The change was primarily attributable to (i) the interest expense accrued on the one-year bank borrowing facilities we
entered into in the third quarter of 2017 and 2018, respectively; and (ii) the interest expense related to our convertible promissory notes, which were converted in June and July 2018. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Income (Expenses), Net </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We recorded RMB1.5&nbsp;million of
other income for the year ended December&nbsp;31, 2017 and RMB16.8&nbsp;million (US$2.4 million) of other expenses for the year ended December&nbsp;31, 2018. The change was primarily attributable to the net loss resulting from the conversion of a
portion of our convertible promissory notes, partially offset by an increase in the income from the other financial assets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value Change of Warrants
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We recorded a loss from change in the fair value of warrant liability of RMB14.0&nbsp;million for the year ended December&nbsp;31, 2017, and a gain from
change in the fair value of warrant liability of RMB61.4&nbsp;million (US$8.6 million) for the year ended December&nbsp;31, 2018. The change was primarily attributable to (i)&nbsp;the change in fair value of warrants due to the increase in the
valuation of our company, and (ii)&nbsp;the modification in 2018 that added certain forfeiture conditions to the warrants, which increased the possibility of forfeiture of the warrants and therefore resulted in a reduction in our warrant
liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since inception, we have
incurred net losses and negative cash flows from our operations. Substantially all of our losses have resulted from funding our research and development programs and administrative costs associated with our operations. We incurred net losses of
RMB298.2&nbsp;million, RMB402.8&nbsp;million (US$56.4&nbsp;million) and RMB1,103.4 million (US$154.4 million) for the years ended December&nbsp;31, 2017 and 2018 and the nine months ended September&nbsp;30, 2019, respectively. Our primary use of
cash is to fund our research and development activities. We used RMB252.2&nbsp;million, RMB280.7&nbsp;million (US$39.3 million) and RMB652.0 million (US$91.2&nbsp;million) in cash for our operating activities for the years ended December&nbsp;31,
2017 and 2018 and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
nine months ended September&nbsp;30, 2019, respectively. Historically, we have financed our operations principally through proceeds from the issuance and sale of preferred shares and convertible
promissory notes in private placement transactions. For more information of our equity financing, see &#147;Description of Share Capital&#151;History of Securities Issuances.&#148; As of September&nbsp;30, 2019, we had cash, cash equivalents and
restricted cash of RMB1,281.1&nbsp;million (US$179.2 million). Our cash, cash equivalents and restricted cash consist primarily of cash in bank and on hand. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
following table sets forth a summary of our cash flows for the periods presented: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(651,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash (used in) generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>39,413</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(399,871</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,680,931</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,281,060</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or future drug
candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our drug candidates and begin to commercialize
any approved products. Upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our drug candidates, we expect to incur
significant commercialization expenses for product sales, marketing and manufacturing. Accordingly, we anticipate that we will need substantial additional funding in connection with our continuing operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on our current operating plan, we believe that our current cash and cash equivalents and proceeds from this offering will be sufficient to meet our current and
anticipated working capital requirements and capital expenditures for at least the next 12 months. In that time, we expect that our expenses will increase substantially as we fund new and ongoing research and development activities and working
capital needs. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and
commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After this offering, we may decide to enhance our liquidity position or increase our cash reserve for future operations and investments through additional financing.
The issuance and sale of additional equity would result in further dilution to our shareholders and ADS holders, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as an ADS holder. The
incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations, which could potentially dilute your interest. If we raise additional funds through collaborations,
strategic alliances or licensing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or research programs or to grant licenses on terms that may not be favorable
to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and
market products or drug candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September 30, 2019, 7.9% of our cash and cash equivalents
were denominated in RMB and held in China. In utilizing the proceeds we expect to receive from this offering, we may make additional capital contributions to our PRC subsidiaries, establish new PRC subsidiaries and make capital contributions to
these new PRC subsidiaries, make loans to our PRC subsidiaries, or acquire offshore entities with business operations in China in offshore transactions. However, most of these uses are subject to PRC regulations and approvals. See &#147;Risk
Factors&#151;Risks Related to Doing Business in China&#151;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds
of this offering to make loans to our PRC subsidiaries in China, which could materially and adversely affect our liquidity and our ability to fund and expand our business&#148; and &#147;Use of Proceeds&#148; for more information on the related PRC
rules and regulations on the use of proceeds. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that the majority of our future revenues will be denominated in RMB. Under existing PRC foreign exchange
regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior SAFE approval as long as certain routine
procedural requirements are fulfilled. Therefore, our PRC subsidiaries are allowed to pay dividends in foreign currencies to us without prior SAFE approval by following certain routine procedural requirements. However, approval from or registration
with competent government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may at its
discretion restrict access to foreign currencies for current account transactions in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities for the nine months ended September&nbsp;30, 2019 was RMB652.0 million (US$91.2 million). Our net loss was RMB1,103.4 million
(US$154.4 million) for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain non-cash expenses or gains, including share-based compensation of RMB366.9 million
(US$51.3 million), and changes in certain working capital items, including an increase in the research and development funding of RMB52.2 million (US$7.3 million), and an increase in the accruals and other payables of RMB32.2 million (US$4.5
million), partially offset by an decrease in advance from customers of RMB14.2 million (US$2.0 million). The change in share-based compensation was attributable to the grant of stock options to a director of our company under the 2018 Plan. The
change in fair value of warrant liabilities was attributable to the increase in the valuation of our company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities for the year
ended December&nbsp;31, 2018 was RMB280.7&nbsp;million (US$39.3 million). Our net loss was RMB402.8&nbsp;million (US$56.4 million) for the same period. The difference between our net loss and our net cash used in operating activities was primarily
attributable to certain <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses or gains, including fair value gains of warrants of RMB61.4&nbsp;million (US$8.6 million), and changes in certain working capital items, including (i)&nbsp;an increase
in the research and development funding of RMB178.7&nbsp;million (US$25.0 million) and (ii)&nbsp;an increase in accruals and other payables of RMB55.6&nbsp;million (US$7.8 million), partially offset by an increase in prepayments and other
receivables of RMB76.3&nbsp;million (US$10.7 million). The accruals and other payables principally consist of accrued external research and development activities related expenses and staff salaries and welfare payables. The change in fair value of
warrant liabilities was attributable to the exercise of part of the warrants issued in 2017 and the modification in 2018 that added certain forfeiture conditions to the warrants. Prepayments and other receivables primarily consist of our prepayment
to CRO partners and value-added tax recoverable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities for the year ended December&nbsp;31, 2017 was RMB252.2&nbsp;million. Our net
loss was RMB298.2&nbsp;million. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses or gains, including the fair value loss
of warrant liabilities of RMB14.0&nbsp;million, and changes in certain working capital items, including (i)&nbsp;an increase in contract liabilities of RMB15.8&nbsp;million and (ii)&nbsp;a decrease in prepayments and other receivables of
RMB8.8&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash generated from investing activities for the nine months ended September 30, 2019 was RMB135.1 million (US$18.9 million). The net cash increase was primarily
attributable to RMB192.4 million (US$26.9 million) of the cash received from disposal of other financial assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash generated from investing activities for
the year ended December&nbsp;31, 2018 was RMB9.5&nbsp;million (US$1.3 million). The net cash increase was primarily attributable to RMB40.0&nbsp;million (US$5.6 million) of the cash received from disposal of other financial assets, partially offset
by RMB30.0&nbsp;million (US$4.2 million) of the cash used in other financial assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities for the year ended December&nbsp;31,
2017 was RMB157.7&nbsp;million. The net cash decrease was primarily attributable to RMB369.0&nbsp;million of investments in other financial assets, partially offset by RMB133.0&nbsp;million of proceeds from disposal of other financial assets and
RMB93.3&nbsp;million of cash acquired from acquisition of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash generated from financing activities for the nine months ended September 30, 2019 was RMB39.4 million (US$5.5 million), primarily attributable to the repayment
of bank borrowings of RMB80.0 million (US$11.2 million), partially offset by the proceeds of bank borrowings of RMB50.0 million (US$7.0 million) and consideration received in advance from a preferred shares investor of RMB70.7 million (US$9.9
million). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash generated from financing activities in the year ended December&nbsp;31, 2018 was RMB1,479.7&nbsp;million (US$207.0 million), primarily
attributable to (i)&nbsp;proceeds from issuance of RMB1,306.6&nbsp;million (US$182.8 million) convertible preferred shares and (ii)&nbsp;receipt of RMB132.3&nbsp;million (US$18.5 million) resulting from the exercise of warrants by investors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash generated from financing activities in the year ended December&nbsp;31, 2017 was RMB758.6&nbsp;million, primarily attributable to proceeds of our issuance of
RMB346.5&nbsp;million convertible preferred shares, RMB161.2&nbsp;million redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and RMB99.0&nbsp;million proceeds from bank borrowings. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Capital Expenditures </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our capital expenditures were incurred for
purposes of purchasing property, equipment and software. Our capital expenditures were RMB20.3&nbsp;million, RMB14.4&nbsp;million (US$2.0 million) and RMB4.6 million (US$0.6 million) in the years ended December&nbsp;31, 2017 and 2018 and the nine
months ended September 30, 2019, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that our capital expenditures in 2019 will primarily consist of purchase of intangible assets and the
costs relating to construction of our manufacturing facility in China. We intend to fund our future capital expenditures with our existing cash and proceeds from this offering. We will continue to make capital expenditures to meet the expected
growth of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table
sets forth our contractual obligations as of December&nbsp;31, 2018: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN<BR>1&nbsp;YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">1-3</FONT> YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">3-5</FONT> YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MORE&nbsp;THAN<BR>5&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our operating lease commitments relate to leases for our office premises pursuant to <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating lease agreements.
Other than as shown above, we did not have any significant capital and other commitments, long-term obligations or guarantees as of December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Commitments and Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. In addition, we have not entered into
any derivative contracts that are indexed to our shares and classified as shareholder&#146;s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets
transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us
or engages in leasing, hedging or product development services with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, we have been a private company with limited accounting personnel and other resources with which to address our internal control over financial
reporting. In connection with the audits of our consolidated financial statements included in this prospectus, we and our independent registered public accounting firm identified the following material weaknesses and other control deficiencies in
our internal control over financial reporting. As defined in the standards established by the U.S. Public Company Accounting Oversight Board, a &#147;material weakness&#148; is a deficiency, or combination of deficiencies, in internal control over
financial reporting, such that there is a reasonable possibility that a material misstatement of the company&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The material weaknesses that have been identified relate to (i)&nbsp;our lack of sufficient and competent financial reporting and accounting personnel with appropriate
knowledge of U.S. GAAP and SEC reporting and compliance requirements, to formalize key controls over financial reporting and to prepare consolidated financial statements and related disclosures; and (ii)&nbsp;our lack of sufficient documented
financial closing policies and procedures, specifically those related to (a)&nbsp;accounting for licensing and collaboration agreements and (b)&nbsp;period end expenses <FONT STYLE="white-space:nowrap">cut-off</FONT> and accruals. These material
weaknesses, if not timely remedied, may lead to significant misstatements in our consolidated financial statements in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have implemented and plan to
implement a number of measures to address the material weaknesses that have been identified in connection with the audits of our consolidated financial statements as of and for the years ended December&nbsp;31, 2017 and 2018 and the review of the
consolidated financial statements as of and for the nine months ended September 30, 2019. We have hired additional qualified financial and accounting staff with working experience of U.S. GAAP and SEC reporting requirements, and plan to continue
such hiring efforts. We intend to conduct regular and continuous U.S. GAAP accounting and financial reporting training programs for our financial reporting and accounting personnel. We further intend to establish sufficient and formal financial
closing policies and procedures, specifically those related to accounting for licensing and collaboration arrangements and period end <FONT STYLE="white-space:nowrap">cut-off</FONT> and accruals. We plan to, as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">work-in-progress,</FONT></FONT> engage an external consulting firm to assist us to assess Sarbanes-Oxley Act compliance requirements and improve our overall internal controls. Furthermore, we plan to prepare more detailed
guidance on accounting policies, manuals and closing procedures to improve the quality and accuracy of our period end financing closing process. We will continue to implement these and other measures to remediate our internal control deficiencies.
We may incur significant costs in the implementation of such measures. However, the implementation of these measures may not fully address the deficiencies in our internal control over financial reporting, and we cannot assure you that all of these
measures will be sufficient to remediate our material weakness in time, or at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a company with less than US$1.07&nbsp;billion in revenue for our last fiscal
year, we qualify as an &#147;emerging growth company&#148; pursuant to the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies.
These provisions include exemption from the auditor attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Inflation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, inflation in China has not materially affected our
results of operations. According to the National Bureau of Statistics of China, the year-over-year percent changes in the consumer price index for January&nbsp;2017, 2018 and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
2019 were increases of 2.5%, 1.5% and 1.7%, respectively. Although we have not been materially affected by inflation in the past, we may be affected if China experiences higher rates of inflation
in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Holding Company Structure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a holding company with
no material operations of its own. We currently conduct our operations primarily through our PRC subsidiaries. As a result, our ability to pay dividends depends upon dividends paid by our PRC subsidiaries. If our existing PRC subsidiaries or any
newly formed ones incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us. In addition, our wholly foreign-owned subsidiaries in China are permitted to pay dividends to us
only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. Under PRC law, each of our subsidiaries and their subsidiaries in China is required to set aside at least 10% of its <FONT
STYLE="white-space:nowrap">after-tax</FONT> profits each year, if any, to fund certain statutory reserve funds until such reserve funds reach 50% of their registered capital. In addition, our wholly foreign-owned subsidiaries in China may allocate a
portion of their <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to enterprise expansion funds and staff bonus and welfare funds at their discretion, and their subsidiaries may allocate a portion of their <FONT
STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to a surplus fund at their discretion. The statutory reserve funds and the discretionary funds are not distributable as cash dividends. Remittance of dividends by
a wholly foreign-owned company out of China is subject to examination by the banks designated by SAFE. Our PRC subsidiaries have not paid dividends and will not be able to pay dividends until they generate accumulated profits and meet the
requirements for statutory reserve funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest and Credit Risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We had cash, cash equivalents and
restricted cash of RMB412.7&nbsp;million, RMB1,680.9&nbsp;million (US$235.2 million) and RMB1,281.1 million (US$179.2 million) as of December&nbsp;31, 2017 and 2018 and September&nbsp;30, 2019, respectively. Our exposure to interest rate risk
primarily relates to the interest income generated by excess cash, which is mostly held in interest-bearing bank deposits. Interest-earning instruments carry a degree of interest rate risk. We have not been exposed to material risks due to changes
in interest rates, and we have not used any derivative financial instruments to manage our interest risk exposure. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our credit risk is primarily attributable to the
carrying amounts of cash and cash equivalents. The carrying amounts of cash and cash equivalents represent the maximum amount of loss due to credit risk. We mainly place or invest cash and cash equivalents with state-owned or reputable financial
institutions in the PRC, and reputable financial institutions outside of the PRC. We do not believe that our cash and cash equivalents have significant risk of default or illiquidity, and we will continually monitor the credit worthiness of these
financial institutions. While we believe our cash and cash equivalents do not contain excessive risk, future investments may be subject to adverse changes in market value. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Foreign Exchange Risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Most of our revenues and expenses are
denominated in RMB. Our management considers that the business is not exposed to any significant foreign exchange risk and we have not used any derivative financial instruments to hedge exposure to such risk. Although our exposure to foreign
exchange risks should be limited in general, the value of your investment in our ADSs will be affected by the exchange rate between U.S. dollar and RMB because the value of our business is effectively denominated in RMB, while our ADSs will be
traded in U.S. dollars. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RMB is not freely convertible into foreign currencies for capital account transactions. The value of RMB against the U.S. dollar and other
currencies is affected by, among other things, changes in China&#146;s political and economic conditions and China&#146;s foreign exchange prices. On July&nbsp;21, 2005, the PRC government changed its policy of pegging the value of the RMB to the
U.S. dollar. Following the removal of the U.S. dollar peg, the RMB appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted and the exchange rate between the RMB and
the U.S. dollar remained within a narrow band. Since June 2010, the PRC government has allowed the RMB to appreciate slowly against the U.S. dollar again, and it has appreciated more than 10% since June 2010. On August&nbsp;11, 2015, the
People&#146;s Bank of China announced plans to improve the central parity rate of the RMB against the U.S. dollar by authorizing market-makers to provide parity to the China Foreign Exchange Trading Center operated by the People&#146;s Bank of China
with reference to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
interbank foreign exchange market closing rate of the previous day, the supply and demand for foreign currencies as well as changes in exchange rates of major international currencies. Effective
from October&nbsp;1, 2016, the International Monetary Fund added RMB to its Special Drawing Rights currency basket. Such change and additional future changes may increase volatility in the trading value of the RMB against foreign currencies. The PRC
government may adopt further reforms of its exchange rate system, including making the RMB freely convertible in the future. Accordingly, it is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate
between RMB and the U.S. dollar in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that we need to convert U.S. dollars into RMB for our operations, appreciation of RMB against the
U.S.&nbsp;dollar would reduce the RMB amount we receive from the conversion. Conversely, if we decide to convert RMB into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs, servicing our outstanding debt,
or for other business purposes, appreciation of the U.S. dollar against the RMB would reduce the U.S. dollar amounts available to us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September 30, 2019, we
had <FONT STYLE="white-space:nowrap">RMB-denominated</FONT> cash, cash equivalents and restricted cash of RMB101.3&nbsp;million (US$14.2 million). A 10% depreciation of RMB against U.S. dollar based on the foreign exchange rate on September 30, 2019
would result in a decrease of US$1.4&nbsp;million in cash and cash equivalents. A 10% appreciation of RMB against U.S. dollar based on the foreign exchange rate on September 30, 2019 would result in an increase of US$1.4&nbsp;million in cash and
cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S.
GAAP. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and
liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including
initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as useful lives of property, plant and equipment,
write-down of inventories, allowance for doubtful accounts, share-based compensation, impairment of long-lived assets, impairment of other intangible asset and goodwill, taxes on income, tax valuation allowances and revenues from research and
development projects. Actual results could differ from those estimates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We adopted Accounting Standard Codification (&#147;ASC&#148;) 606, Revenue from Contracts with Customers (Topic 606) (&#147;ASC 606&#148;) for all periods presented.
Consistent with the criteria of Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or
services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&nbsp;identify
the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the transaction price to the performance
obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration to which it is
entitled in exchange for the goods or services it transfers to the customer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once a contract is determined to be within the scope of ASC 606 at contract inception,
we review the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation
when that performance obligation is satisfied or as it is satisfied. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Collaboration Revenue </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC&nbsp;808, Collaborative Arrangements (&#147;ASC
808&#148;) to determine whether such arrangements involve joint operating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For
collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and
therefore within the scope of ASC&nbsp;606. For the collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights,
agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, we must develop assumptions that
require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a performance obligation, we consider competitor pricing for a similar or
identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied
either by delivering a good or providing a service, limited to the consideration that is not constrained. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When the timing of the delivery of product is different
from the timing of payments made by the customers, we recognizes either a contract asset (performance precedes the contractual due date) or a contract liability (customer payment precedes performance). Our contractual payment terms are typically due
in no more than 30&nbsp;days from invoicing. In limited situations, certain customer contractual payment terms require us to bill in arrears; thus, we satisfy some or all of our performance obligations before we are contractually entitled to bill
the customer. In these situations, billing occurs subsequent to revenue recognition, which results in a contract asset. For example, certain of the contractual arrangements do not permit us to bill until the completion of the production of the
samples. In other limited situations, certain customer contractual payment terms allow us to bill in advance; thus, we receive customer cash payment before satisfying some or all of its performance obligations. In these situations, billing occurs in
advance of revenue recognition, which results in contract liabilities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Licenses of Intellectual Property </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing our intellectual property are evaluated to determine if the license is distinct
from the other performance obligations identified in the arrangement. For licenses determined to be distinct, we recognize revenues from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees
allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Services </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The portion of the transaction
price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Milestone Payments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the inception of each arrangement that
includes development, commercialization, and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future
periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize
revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the probability of achieving such development milestones and any
related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the
period of adjustment. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Royalties </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For arrangements that include
sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i)&nbsp;when the related sales occur, or
(ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Elements of research and development expenses primarily include: (1)&nbsp;payroll and other related expenses of personnel engaged in research and development
activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to us, (3)&nbsp;expenses related to <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing of our
technologies under development and clinical trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct our clinical studies, (4)&nbsp;costs to develop the drug candidates,
including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures
relate to our research and development services and have no alternative future uses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have acquired rights to develop and commercialize drug candidates. Upfront
payments that relate to the acquisition of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research
and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined under U.S. GAAP, the drug has not achieved regulatory
approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be capitalized as intangible assets and amortized over the
estimated remaining useful life of the related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We grant restricted shares and stock
options to eligible employees and account for share-based compensation in accordance with ASC 718, <I>Compensation</I>&#151;<I>Stock Compensation.</I> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Employees&#146; share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses (i) immediately at the grant date if
no vesting conditions are required; (ii) for share-based awards granted with only service conditions, using the graded vesting method net of estimated forfeitures over the vesting period; or (iii) for share-based awards granted with service
conditions and the occurrence of an initial public offering as performance condition cumulative share-based compensation expenses for the options that have satisfied the service condition should be recorded upon the completion of the initial public
offering using the graded vesting method. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. We
calculate incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, we
recognize incremental compensation cost in the period when the modification occurs. For awards not being fully vested, we recognize the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original
awards over the remaining requisite service period after modification. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Share-based compensation in relation to the restricted shares is measured based on the fair
market value of our ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of our ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and
subjective variables, including discount rate, and subjective judgments regarding our projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the
grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of our ordinary shares as well as
the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. The fair value of these awards was determined with the
assistance from an independent valuation firm. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted ordinary shares </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31, 2016, we issued 4,019,554 ordinary shares to Mr. Zang Jingwu Zhang, Ms.&nbsp;Qian Lili, Mr. Wang Zhengyi and Mr. Fang Lei
(collectively the &#147;Founders&#148;), and we recorded share-based compensation expense of RMB18.7&nbsp;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2016, the Founders entered into an arrangement with our other investors, and the 87,441 ordinary shares
issued to the Founders in June 2016 were cancelled, and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to service vesting conditions, that shall vest 20%, 20% and 30% over the next three years,
respectively. By October 2019, all the restricted shares were vested. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred share-based compensation was measured for the restricted shares using the estimated
fair value of our ordinary shares of US$0.77 at the date of imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3&nbsp;years.
The following table summarizes our Founders&#146; restricted shares activities for the years ended December&nbsp;31, 2017 and 2018 and the nine months ended September 30, 2018 and 2019: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBERS<BR>OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>GRANT&nbsp;DATE<BR>FAIR&nbsp;VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,752,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2017 and September 30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2018 and September 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shared-based compensation expense in relation to the restricted ordinary shares recognized in the years ended December&nbsp;31, 2017 and 2018 and the nine months
ended September 30, 2018 and 2019 was RMB7,039&nbsp;thousand and RMB3,520 thousand, RMB2,970 thousand and RMB1,556 thousand, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shared-based
compensation expenses relating to restricted shares were included in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS</B><br><B>ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Second Amended and Restated 2017 Employee Stock Option Plan (the &#147;2017 Plan&#148;) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2017, we adopted the 2017 Plan (as last amended and restated on December 25, 2019). Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that
may be issued pursuant to all awards granted were approved. Notwithstanding the foregoing, solely in connection with offering, the maximum aggregate number of shares that may be issued pursuant to all awards under the 2017 Plan may be adjusted in
accordance with a formula pre-approved by our shareholders. See &#147;Management&#151;Share Incentive Plans&#151;Second Amended and Restated 2017 Employee Stock Option Plan.&#148; Stock options granted to an employee under the 2017 Plan will be
exercisable upon the completion of a listing and the employee renders service to us in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. Employees are generally subject to a three-year service
schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second&nbsp;anniversary of the grant date, a vesting of the remaining fifty percent 50% on the third anniversary of the applicable grant date. The
stock options under the 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We granted 11,051,230, 1,470,000, 1,470,000 and 640,000 stock options to employees, all with an exercise price of US$1, for the years ended December&nbsp;31, 2017 and
2018 and for the nine months ended September&nbsp;30, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
2018 and 2019, respectively. No options are exercisable as of December&nbsp;31, 2017 and 2018, September 30, 2018 and 2019 and prior to the completion of a listing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the stock options activities for the periods presented: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED</B><br><B>AVERAGE</B><br><B>EXERCISE</B><br><B>PRICE</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED</B><br><B>AVERAGE</B><br><B>REMAINING</B><br><B>CONTRACTUAL</B><br><B>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE</B><br><B>INTRINSIC</B><br><B>VALUE</B><br><B>US$&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,051,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other addition (note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,761,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,005,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercisable as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(351,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,435,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of September 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,859,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercisable as of September 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="right">Note:</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Other addition represented the modified share options that originally granted to two senior management employees in October 2016 (see &#147;&#151;other share-based compensation&#148;). </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">62.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><FONT STYLE="white-space:nowrap">61.32%-62.13</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><FONT STYLE="white-space:nowrap">61.32%-62.13</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">54.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">2.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><FONT STYLE="white-space:nowrap">2.81%-3.06</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"><FONT STYLE="white-space:nowrap">2.81%-3.06</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">2.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of our
options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our options in effect at the option valuation date. The expected exercise
multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As we did not have sufficient information of past employee exercise history, it was
estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as we have never declared or paid any cash dividends on its shares, and we do not anticipate any dividend payments in the foreseeable
future. Expected term is the contract life of the option. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There were 640,000 stock options granted to employees under 2017 Plan for the nine months ended
September&nbsp;30, 2019. Since the exercisability is dependent upon the listing, and it is not probable that this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
performance condition can be achieved until a listing is effective, no share-based compensation expense relating to the 2017 Plan was recorded for the years ended December&nbsp;31, 2017 and 2018
and the nine months ended September&nbsp;30, 2018 and 2019. We will recognize compensation expenses relating to options vested cumulatively upon the completion of our listing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Second Amended and Restated 2018 Employee Stock Option Plan (the &#147;2018 Plan&#148;) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;22, 2019, our company adopted the 2018 Plan (as last amended and restated on December&nbsp;25, 2019). Under the 2018 Plan, the maximum aggregate number
of ordinary shares which may be issued pursuant to all awards is 14,005,745, subject to further amendment. Notwithstanding the foregoing, solely in connection with offering, the maximum aggregate number of shares that may be issued pursuant to all
awards under the 2018 Plan may be adjusted in accordance with a formula pre-approved by our shareholders. See &#147;Management&#151;Share Incentive Plans&#151;Second Amended and Restated 2018 Employee Stock Option Plan.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock options granted to an employee under the 2018 Plan will be generally exercisable when our company completes a listing and the employee renders service to our
company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. Employees are generally subject to a two-year vesting schedule consisting of a cliff vesting of 50% of the stock options on the first
anniversary of the applicable vesting commencement date and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date. If a listing occurs at any time prior to any stock option granted under the 2018 Plan
becoming fully vested, to the extent such stock option has been granted and is outstanding, any such stock option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the Board of Directors, any vested portion
of the stock options shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however, that in each case, no stock option of an employee shall become exercisable until the third
anniversary of such employee&#146;s employment commencement date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the 2018 Plan, the 10,893,028 stock options granted to a director of our company
under the 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of these 10,893,028 stock options, 454,940 stock options have been repurchased by our company in February 2019 (see Note 17 (d) to our unaudited interim
condensed consolidated financial statements for further details). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amounts of shared-based compensation expense in relation to the stock options (except for
those repurchased by a director of our company as described in Note 17 (d) to our unaudited interim condensed consolidated financial statements) recognized in the nine months ended September 30, 2019 was RMB365,329, which were allocated to our
administrative expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the stock options activities for the nine months ended September 30, 2019: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED</B><br><B>AVERAGE</B><br><B>EXERCISE</B><br><B>PRICE</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED</B><br><B>AVERAGE</B><br><B>REMAINING</B><br><B>CONTRACTUAL</B><br><B>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE</B><br><B>INTRINSIC</B><br><B>VALUE</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,991,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Repurchased (Note 17 (d))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(454,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,536,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercisable as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,438,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option
Pricing Model with the following assumptions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">54.64%-56.31%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.15%-2.75%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of our
company&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our company&#146;s options in effect at the option valuation
date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As our company did not have sufficient information of past
employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as our company has never declared or paid any cash dividends on its shares, and our company does not
anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Repurchase of share awards held by a director
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of our company, pursuant to which only
the 3,435,215 stock options held by a director of our company under the 2017 equity incentive plan became fully vested and exercisable on February&nbsp;22, 2019. As a result of the performance condition being waived, the shares held by a director of
our company were accounted for as a Type III modification where a condition that our company expects will not be satisfied is changed to a condition that our company expects will be satisfied. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, on the same day, our company repurchased such 3,435,215 stock options under the amendment and restated 2017 equity incentive plan that was held by a
director of our company along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902 (equivalent to approximately RMB148,308)
at an average share price of US$5.63 per share. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our company recorded the total payment of US$21,902 (equivalent to approximately RMB148,308) as share-based
compensation costs in the condensed statement of comprehensive loss. There was no impact to the overall stockholder&#146;s equity balance as the amended shares vested immediately and were repurchased. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other share-based compensation </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the year ended December&nbsp;31, 2016,
we recorded share-based compensation expense of RMB3.3&nbsp;million for issuance and grant of 710,366 stock options to two senior management employees in October 2016, as rewards for their services they had performed in the past and in exchange for
their full-time devotion and professional expertise. Stock options granted to the two employees were exercisable once granted, with an exercise price of US$0.06. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2017, in connection with the adoption of the 2017 Plan, we amended the stock option agreement with the two aforementioned employees, under which the stock
options would become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control that defined in the stock option agreements. As the modification of terms and conditions of share-based compensation were
not beneficial to its employees, no further accounting impact was resulting from it. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Fair Value of Ordinary Shares&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are required to estimate the fair value of the ordinary shares on grant dates of share-based compensation awards/share option to our employees and the issuance of
financial instruments to investors. Therefore, our board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
directors has estimated the fair value of our ordinary shares on various dates, with inputs from management, considering the third-party valuations. The valuations of our ordinary shares were
performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Audit and Accounting Practice Aid Series: Valuation of Privately-Held-Company Equity Securities Issued as Compensation,
or the AICPA Practice Guide. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our board of directors considered various objective and subjective factors, along with inputs from management and the
independent third-party valuation firm, to determine the fair value of our ordinary shares, including: external market conditions affecting the biopharmaceutical industry, trends within the biopharmaceutical industry, the prices at which we sold
convertible preferred shares, the superior rights and preference of the convertible preferred shares or other senior securities relative to our ordinary shares at the time of each grant and the likelihood of achieving a liquidity event such as an
initial public offering. The option-pricing method was used to allocate the enterprise&#146;s value to preferred shares or other senior securities and ordinary shares, taking into account the guidance prescribed by the AICPA Practice Guide. This
method treats ordinary shares and convertible preferred shares or other senior securities as call options on the enterprise&#146;s value, with exercise prices based on their respective payoffs upon a liquidity event. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining the enterprise&#146;s value, we applied the market approach/backsolve method based on pricing from recent transactions in our own securities. The basis
for application of this method is our transactions in equity securities with unrelated parties or among unrelated parties themselves. No evidence is observed to indicate these transactions are not
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors determined the fair value of our share options and the restricted
shares as of the dates of grant, taking into consideration the various objective and subjective factors described above, including the conclusion of valuation of our ordinary shares as of dates close to the grant dates of our share options and the
restricted shares. We computed the per share estimated fair value for share options based on the binomial option pricing model and the per share estimated fair value for restricted shares based on per share estimated fair value of ordinary shares as
of the date of grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once public trading market of the ADSs has been established in connection with the completion of this offering, it will no longer be
necessary for our board of directors to estimate the fair value of our ordinary shares in connection with our accounting for granted share options and restricted shares. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Fair Value Measurements&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our financial assets and
liabilities primarily comprise of cash and cash equivalents, restricted cash, other financial assets, contract assets, other receivables, short-term borrowings, accruals and other payables and warrant liabilities. As of December&nbsp;31, 2017 and
2018, and September 30, 2019, except for other financial assets and warrants liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. We report other
financial assets and warrant liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We measure our financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs
other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3 includes unobservable inputs that reflect the management&#146;s assumptions about the assumptions that market participants would use in pricing the
asset. The management develops these inputs based on the best information available, including the own data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We measured our short-term investments at fair value on a recurring basis. As our other financial assets and
derivative liabilities are not traded in an active market with readily observable prices, we use significant unobservable inputs to measure the fair value of other financial assets, and derivatives liabilities. These instruments are categorized in
the Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A list of recently issued accounting pronouncements that are relevant to us is included in note 2 &#147;Principal Accounting Policies&#151;2.24 Recent
Accounting Pronouncements&#148; of our consolidated financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_14"></A>INDUSTRY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We see vast commercial opportunities for immuno-oncology and autoimmune biologics therapies. In 2018, approximately 60.8% of the antibody-based biologics in terms of
global sales revenue targeted conditions in these areas, according to the Frost&nbsp;&amp; Sullivan Report. In China, the need for efficacious drugs to treat cancer and autoimmune diseases is rising due to limited availability of such medicines and
delayed access to global innovative medicines. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The figure below illustrates the historical and projected market sizes of immune-oncology therapies and autoimmune
disease treatment globally and in China. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g07g87.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The figure below illustrates the unmet medical need for autoimmune diseases globally and in China. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g78p43.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g02t31.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite the recent success of checkpoint inhibitors, such as <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT STYLE="white-space:nowrap">PD-L1,</FONT> clinical
efficacy of these drugs has not lived up to expectations. The Frost&nbsp;&amp; Sullivan Report estimates that more than 60% of cancer patients, including those with melanoma, renal cell cancer, colorectal cancer,
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, urothelial cancer and head and neck squamous cell carcinoma, do not respond to PD-1/PD-L1 monotherapies. Even for the tumor type with a high tumor mutational burden (i.e., the total
number of mutations with coding region of a tumor cell genome) the ORR rarely exceeds 30% for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. Similar findings are observed using <FONT
STYLE="white-space:nowrap">PD-L1</FONT> as a biomarker in the treatment of NSCLC with pembrolizumab: the average ORR is 41% for PD-L1 positive tumor and 13% for PD-L1 negative tumor. The immuno-oncology field has been diligently seeking a more
efficacious therapy with treatment agent(s) that works synergistically with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. Such a novel combination therapy may provide an effective treatment
option for those who do not respond to current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. For example, our investigational drugs, including TJ107, enoblituzumab, TJC4, and TJD5, are intended
to work as combination therapies with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> regimens to address unmet medical needs in oncology. Currently, our target indications in the area of immuno-oncology
cover a variety of hematologic malignancies, such as multiple myeloma, lymphoma and solid tumors, such as head and neck cancer, and cancer treatment-related lymphopenia. For autoimmune diseases, our target indications include systemic lupus
erythematosus, ulcerative colitis, rheumatoid arthritis and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-6-implicated</FONT></FONT> autoimmune diseases. The discussion below provides (i)&nbsp;an overview of the market
trends and growth drivers in China&#146;s biologics market and (ii)&nbsp;an overview of the competitive landscape and key segments with respect to our most advanced clinical stage product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Trends and Growth Drivers of Biologics Market in China </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the
Frost&nbsp;&amp; Sullivan Report, the growth of China&#146;s biologics market is attributable, in particular, to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Large and Growing Oncology and Autoimmune Disease Patient Populations</I>&#151;China&#146;s oncology patient
population, especially treatment-naive patients, has been increasing over the years. New cases of cancers in China reached 4.3&nbsp;million in 2018 and are projected to reach 4.9&nbsp;million in 2023. China also has a large autoimmune disease
population. In 2018, systemic lupus erythematosus, ulcerative colitis and rheumatoid arthritis affected approximately 1.0&nbsp;million, 0.4&nbsp;million and 5.9&nbsp;million patients in China, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Unmet Demands for Innovative Biologics Therapies Targeting Oncology</I>&#151;Many biologics, especially monoclonal
antibodies, have proved to have superior efficacy and less side effects for treating cancer. However, many antibody drugs approved to treat cancer in the United States are not available in China. From 1997 to 2018, 37 therapeutic antibodies were
launched globally, but only seven of them are marketed in China. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Unmet Demands for Effective Therapies Targeting Autoimmune Diseases</I>&#151;To date, there are no curative therapies
for many autoimmune diseases. Targeted biologics that aim to improve physical functioning and prevent irreversible tissue or organ damage offer a promising trajectory. This class of biologics is expected to stimulate the biologics market that
targets autoimmune diseases in China. The sales revenue of this market was RMB2.5 billion in 2018 and is projected to increase to RMB87.8 billion in 2030, representing a compound annual growth rate (&#147;CAGR&#148;) of 34.6%. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Increasing Cost Burden of Autoimmune Diseases</I>&#151;Autoimmune diseases have been reported to be on the rise in
China, making this poorly understood category of diseases a public health issue at levels comparable </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
to heart disease and cancer. Because of a lack of effective treatment and awareness amongst the general public and medical practitioners, the associated cost of autoimmune diseases accounts for a
significant portion of the rising cost of healthcare burden in China. Innovative biologic treatments, as a means of reducing healthcare spending while ensuring improved public health, can help address the mounting pressure surrounding autoimmune
diseases. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Increasing Investment in Biologics</I>&#151;Research and development in innovative biologics therapies is the key to
industry growth. Discovery and development of new biologics is a long, difficult and expensive process. Research and development investment for biologics in China is expected to continue rising in the future, leading to more new products entering
the market. The continuous launch of new products will further drive the growth of China&#146;s biologics industry. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Favorable Environment for Clinical Trials</I>&#151;With nearly a <FONT STYLE="white-space:nowrap">one-fourth</FONT> of
the world&#146;s cancer patient population, China provides an excellent opportunity to access a large patient pool and clinical resources for oncology drug development and market demands. The Chinese government has taken initiatives to address
regulatory challenges that previously caused a lag in clinical trial applications of therapeutic biologics. Notably, in October 2017, the General Office of the CPC Central Committee and the General Office of the State Council issued the Opinions on
Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices, which aims to improve the regulatory approval process and encourage technological innovation for new drugs. In addition, in July
2018, the NMPA implemented Technical Guidelines for Accepting Data from Overseas Clinical Trials of Drugs, which significantly shortens the registration process and provides potential clinical trial exemptions for drugs that have robust clinical
data from trials conducted overseas. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Increasing Affordability</I>&#151;The average disposable income of the Chinese population is expected to continue
growing rapidly, increasing the willingness and ability of patients to pay for medications. In 2019, households with an annual disposable income of over US$30,000 accounted for 38.1% of the total households in China and are expected to increase to
56.5% of the total households in China by 2023. As more Chinese households increase their spending power, they can afford more expensive medical treatments, particularly for life-threatening diseases. In addition, inclusion of a drug in the National
Reimbursement Drug List (&#147;NRDL&#148;) typically results in a much higher sales volume and significant sales growth despite a reduction in price. Such inclusion is expected to be implemented for innovative biologics on a regular basis,
suggesting that more biologics are expected to be covered by the NRDL in the future, further increasing the affordability of biologics in China. As biologics become increasingly affordable to the general public, they will be used more commonly as a
treatment for oncology and autoimmune diseases. As a result, the market size of the biologics industry in China is expected to continue to grow. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Multiple Myeloma </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Overview </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Multiple myeloma (&#147;MM&#148;) is a type of blood cancer that starts in the bone marrow and is characterized by excessive proliferation of malignant plasma cells
that accumulate in the bone marrow, where they displace and suppress healthy blood progenitor cell populations, cause destructive lytic bone lesions (rounded, <FONT STYLE="white-space:nowrap">punched-out</FONT> areas of the bone), diffuse
osteoporosis, bone pain, and produce abnormal proteins that accumulate in the urine, and anemia. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In Greater China, new cases of MM reached approximately 20,500 in
2018 and is expected to increase to approximately 23,700 in 2023, representing a CAGR of 2.9%, according to the Frost&nbsp;&amp; Sullivan Report. MM is primarily a disease of the elderly, and this population of patients 65 years and older continues
to grow at a fast clip in China. In fact, the new incidence of MM in China is projected to reach approximately 28,300 in 2030, representing a CAGR of 2.6% from 2023 to 2030. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of MM </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MM treatment is individualized but generally
includes small molecules drugs and biologics. The primary treatment regimens are cytoreductive chemotherapies, in combination with stem cell transplants, aimed at achieving a cure, if possible. In addition, MM patients require substantial supportive
therapy aimed at managing complications of the disease (such as bone damage) and ameliorating the side effects of treatment. There are a number of drug classes for MM treatment, including monoclonal antibodies, immunomodulatory drugs, proteasome
inhibitors, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
chemotherapy, histone deacetylase inhibitors, and steroids. A patient&#146;s individual treatment plan is based on factors such as age and general health, results of laboratory and cytogenetic
(genomic) tests, symptoms and disease complications, prior myeloma treatment as well as the patient&#146;s lifestyle, goals, views on quality of life, and personal preferences. In addition, many cancer centers have developed their own guidelines for
treating MM. In China, drugs approved for treating relapsed or refractory MM (&#147;RRMM&#148;) include daratumumab (Darzalex from Janssen), lenalidomide (Revlimid from Celgene), thalidomide (Thalomid from Celgene), bortezomib (Velcade from Takeda),
and ixazomib (Ninlaro from Takeda). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unmet Medical Need </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, there is no curative treatment for RRMM. Although the currently marketed CD38 antibody product is efficacious, it takes a long time to be administered by IV
infusion (up to six hours) and causes a high infusion reaction rate (&#147;IRR&#148;). In clinical trials, approximately half of all patients experience an infusion reaction, which may include fever, chills, nausea, bronchospasm, hypoxia, dyspnea,
hypertension, laryngeal edema and pulmonary edema. Thus, there is a need for a safer and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">convenient-to-use</FONT></FONT> drug. Such a drug may be combined with other therapeutic
agents for better treatment effects in RRMM. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Competitive Landscape </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are various monotherapy agents and combination treatments currently under clinical development targeting different lines of MM therapies. Our TJ202, if approved,
is a potentially highly differentiated CD38 monoclonal antibody and could be the second antibody therapy for MM to launch in China. The following tables illustrate the competitive landscape of biologic MM therapies targeting CD38 antibody in China
and the rest of the world. (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Marketed CD38 Antibody Drug for Treating MM </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>PRODUCT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>COMPANY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FDA<BR>APPROVAL<BR>TIME</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NMPA<BR>APPROVAL<BR>TIME</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PATENT</B><br><B>EXPIRY&nbsp;IN&nbsp;THE<BR>U.S.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>GLOBAL&nbsp;SALES&nbsp;REVENUE&nbsp;IN<BR>2018 (IN BN, US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Daratumumab IV</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Johnson&nbsp;&amp; Johnson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investigational CD38 Antibody Drugs for Treating MM </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>INVESTIGATIONAL DRUGS<SUP STYLE="font-size:85%; vertical-align:top">
(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>COMPANY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>GLOBAL&nbsp;STATUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CHINA&nbsp;STATUS</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Daratumumab SC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Johnson&nbsp;&amp;&nbsp;Johnson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Isatuximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ImmunoGen&nbsp;and&nbsp;Sanofi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">BLA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TJ202<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>N/A</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Phase 3</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">TAK-079</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Takeda</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 1/2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Investigational drugs prior to Phase 2 clinical trials are not included in this table. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In November 2017, we and MorphoSys entered into an exclusive regional licensing agreement to develop and commercialize MOR202, which we refer to as TJ202 in this prospectus, in Greater China (including Taiwan, Hong Kong
and Macao). TJ202 is currently undergoing two registrational clinical trials in multiple myeloma in Greater China. We aim to submit a new drug application (&#147;NDA&#148;) to the NMPA for TJ202 as a monotherapy in 2021. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Historical and Forecast Market Size of MM Therapeutics Globally and in China </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following diagrams illustrate the market size of all MM therapeutics in terms of sales revenue globally and in China. (<I>Source: Frost</I><I></I><I>&nbsp;&amp;
Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Global MM Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g90r82.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>China MM Therapeutics Market Size (2014-2030E) </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g94p77.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Head and Neck Cancer </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Overview </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Head and neck cancers occur in various parts of the head and neck, including the mouth, nose, throat, larynx,&nbsp;sinuses, and salivary glands. More than 90% of head
and neck cancers are classified as squamous cell carcinomas (&#147;SCCHN&#148;), which begins in the squamous cells that line the moist, mucosal surfaces inside the head and neck. Symptoms of head and neck cancers may include a lump or sore that
does not heal, a sore throat that does not go away, difficulty swallowing or breathing, a change or hoarseness in the voice,&nbsp;unusual bleeding, and facial swelling. According to the Frost&nbsp;&amp; Sullivan Report, in Greater China, new cases
of head and neck cancer reached approximately 140,200 in 2018 and are predicted to increase to approximately 155,300 in 2023, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
representing a CAGR of 2.1%, and new cases of head and neck cancers in China are projected to grow, reaching approximately 173,400 in 2030 with a CAGR of 1.6% from 2023 to 2030. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of Head and Neck Cancer </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The treatment principles and
regimens for head and neck cancer in China are similar to those in the rest of the world. Treatment strategies often depend on the location and stage of the cancer, the patient&#146;s physical status, and response to prior treatments. Early-stage
disease is primarily treated with surgical resection, while patients with locally advanced, recurrent or metastatic disease are typically treated with drug therapy. The combination of surgery and drug therapy, with or without radiation therapy, is
the current standard of care for Stage 3 SCCHN patients with locally advanced disease. Platinum-based chemotherapy regimens are widely used as first-line therapies for Stage 4 and distant relapse patients. Erbitux (cetuximab from Eli Lilly and Merck
KGaA) was approved in 2006 as a first-line treatment of locally advanced SCCHN in combination with radiation therapy. Regimens containing Erbitux, platinum-based chemotherapy, and <FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> known as
EXTREME, are often considered as the standard of care for first-line treatment of distant relapse SCCHN. Second-line therapy is highly varied, including single-agent docetaxel or paclitaxel, Erbitux monotherapy, or Erbitux/paclitaxel combination
therapy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2016, <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors were approved globally as a second-line therapy and more recently, Keytruda
(pembrolizumab from Merck&nbsp;&amp; Co), as a single agent or in combination with chemotherapy, was approved by the FDA as a first-line therapy for metastatic or unresectable recurrent SCCHN. In October 2019, the NMPA approved a PD-1 inhibitor,
Opdivo (nivolumab from Bristol-Myers Squibb), for use in patients with SCCHN that has progressed during chemotherapy with a platinum-based drug or that has recurred or metastasized after platinum-based chemotherapy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unmet Medical Need </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to Datamonitor Healthcare&#146;s
epidemiology forecast (2016-2036), 76% of all actively treated patients with SCCHN have Stage 3, Stage 4, local relapse or distant relapse disease, but efficacious treatment options are limited for these patients. For example, only about 35% of all
patients with distant relapse SCCHN respond to EXTREME, and the resulting overall median survival is only 10.1 months. In addition, about half of the patients on first-line therapies need later line therapies. In addition, the average ORR for
second-line <FONT STYLE="white-space:nowrap">PD-1</FONT> therapies has been less than 15%. As such, SCCHN patients, especially those with late stage or relapsed disease, need more efficacious treatments with fewer side effects, which represents a
significant unmet medical need. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Competitive Landscape </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
enoblituzumab is the only conventional <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody in clinical development globally. The following table illustrates the competitive landscape of investigational
<FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody drugs in China and the rest of the world. (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investigational <FONT STYLE="white-space:nowrap">B7-H3</FONT> Antibody Drugs </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>INVESTIGATIONAL<BR>DRUGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DRUG FORM</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>COMPANY</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>INDICATIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>GLOBAL STATUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CHINA&nbsp;STATUS</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top">131</SUP><FONT STYLE="white-space:nowrap">I-Omburtamab</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Radio-labeled</FONT> antibody</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Y-mAbs</FONT> Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">CNS/leptomeningeal metastases of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">neuroblastoma</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pivotal&nbsp;Phase&nbsp;2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Enoblituzumab<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Monoclonal antibody</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>MacroGenics <FONT STYLE="white-space:nowrap">I-Mab</FONT><SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Solid tumors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phase 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">MGC-018</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Antibody-Drug</FONT> Conjugate</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">MacroGenics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Solid tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1/2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top">124</SUP><FONT STYLE="white-space:nowrap">I-Omburtamab</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Radio-labeled antibody</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Y-mAbs</FONT> Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Glioma</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">ABBV-155</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Antibody-Drug Conjugate</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AbbVie</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Solid tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have the development and commercialization rights for enoblituzumab in Greater China pursuant to a partnership agreement with MacroGenics. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Historical and Forecast Market Size of Head and Neck Cancer Therapeutics Globally and in China </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following diagrams illustrate the size of the head and neck cancer drug market in terms of sales revenue in global and China markets. (<I>Source:
Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Global Head and Neck Cancer Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g31m68.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>China Head and Neck Cancer Therapeutics Market Size (2014-2030E) </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g86o18.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cancer Treatment-Related Lymphopenia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Overview </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Lymphopenia is a decrease in lymphocyte cell count that is lower than the <FONT STYLE="white-space:nowrap">age-appropriate</FONT> reference level. Cancer patients who
undergo chemotherapy and/or radiation therapy often develop severe lymphopenia (&lt;500&nbsp;cells/mm3), which further damages their already compromised immune systems and their ability to fight against cancers. According to the Frost&nbsp;&amp;
Sullivan Report, more than 85% of cancer patients receive chemotherapy or radiation therapy, and approximately 43% of them develop lymphopenia. Furthermore, there is a <FONT STYLE="white-space:nowrap">two-fold</FONT> increase in the risk of early
cancer death associated with severe lymphopenia. Currently no drug is available for cancer treatment-related lymphopenia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In Greater China, according to the Frost&nbsp;&amp; Sullivan Report, the incidence of lymphopenia reached
1.5&nbsp;million in 2018 and is estimated to increase to 1.7&nbsp;million in 2023 and further to 2.0&nbsp;million in 2030. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Treatment of Cancer Treatment-Related
Lymphopenia </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is currently no guideline and no specific or effective treatment for cancer treatment-related lymphopenia. Most patients with cancer
treatment-related lymphopenia are clinically monitored without specific treatment both globally and in China. Proleukin is a recombinant human <FONT STYLE="white-space:nowrap">IL-2</FONT> that has shown some therapeutic effect in promoting overall
T&nbsp;cell populations in cancers, which also include tumor-protecting T regulatory (Treg) cells. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Unmet Medical Need </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug for cancer treatment-related lymphopenia. There remains a substantial need for an
effective treatment for lymphopenia as prolonged lymphopenia often correlates with shortened survival time as reported in the medical literature (Grossman et al., J Natl Compr Canc Netw. 2015 October ; 13(10): 1225&#150;1231). Proleukin has a
limited effect on lymphopenia with serious side effects. There are global research and development efforts to find effective T cell cytokines capable of selectively promoting proliferation of tumor-fighting T cells but not tumor-protecting Treg
cells. These efforts include <FONT STYLE="white-space:nowrap">IL-7,</FONT> <FONT STYLE="white-space:nowrap">IL-12</FONT> and <FONT STYLE="white-space:nowrap">IL-15,</FONT> all of which are in early stages of development. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Competitive Landscape </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are only two <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">IL-7-based</FONT></FONT> investigational drugs, TJ107 (efineptakin) and <FONT STYLE="white-space:nowrap">CYT-107.</FONT> (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investigational Drugs of Recombinant Human <FONT STYLE="white-space:nowrap">IL-7</FONT> </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>INVESTIGATIONAL DRUGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DRUG FORM</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>COMPANY</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>INDICATIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>GLOBAL&nbsp;STATUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CHINA&nbsp;STATUS</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Efineptakin<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Long-acting&nbsp;rhIL-7</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Lymphopenia and cancer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phase&nbsp;1b/2a</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Efineptakin<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Long-acting&nbsp;rhIL-7</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Genexine&nbsp;Inc. (KOSDAQ: 095700)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Solid tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">CYT-107</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Glycosylated&nbsp;rhIL-7</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Revimmune</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Sepsis and septic shock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have the development and commercialization rights for efineptakin in Greater China pursuant to a partnership agreement with Genexine. We are conducting clinical trials in China as part of the coordinated global
clinical development plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Forecast Market Size of Potential Cancer Treatment-Related Lymphopenia Globally and in China </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the Frost&nbsp;&amp; Sullivan Report, since most patients with cancer treatment-related lymphopenia are not actively treated, there is currently no such
drug market globally or in China. However, there is a huge market potential as the following diagrams illustrate the forecast size of the market when an effective drug for treatment-related lymphopenia becomes available. (<I>Source:
Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Global Cancer Treatment-Related Lymphopenia Market Size (2023E-2030E) </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g83v20.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>China Cancer Treatment-Related Lymphopenia Market Size (2023E-2030E) </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g43c34.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Systemic Lupus Erythematosus </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Overview </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Systemic lupus erythematosus (&#147;SLE&#148;) is a chronic, multi-system and incurable autoimmune disease that can potentially lead to serious organ damage, systemic
complications and even death. Patients with SLE have aberrant production of auto-antibodies (antibodies against self-antigens) by CD38-positive plasma cells, and dysregulated CD38-positive pathogenic B cells. As part of the disease mechanism, immune
complexes induced by auto-antibodies are formed and deposit in the kidneys and cause tissue damage. Common symptoms of SLE include painful and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
swollen joints, unexplained fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, extreme fatigue, and red rashes that most commonly appear on the face, and these symptoms vary widely
among patients and fluctuate unpredictably over time as the disease progresses. More importantly, at the advanced stage of the disease, patients can develop renal damage and renal failure. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the Frost&nbsp;&amp; Sullivan Report, SLE had an estimated prevalence of approximately 1.04&nbsp;million in 2018 in Greater China, which is projected to
increase to 1.08&nbsp;million in 2023, representing a CAGR of 0.8%. Cases of SLE in China are projected to increase to 1.11 million in 2030. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of
Systemic Lupus Erythematosus </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, there is a significant unmet medical need for more effective therapies for SLE. Since SLE is a chronic disease,
current treatments aim to manage symptoms and reduce the frequency of disease flares. Patients with mild SLE are often managed by <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drugs, while more severe patients may need
corticosteroids or immunosuppressants. Combination treatments can also be used as disease-modifying treatment regimens, aiming to control the disease and prevent chronic tissue damage. Approved by the FDA in 2011 and by the NMPA in July 2019,
Benlysta (belimumab), a <FONT STYLE="white-space:nowrap">B-lymphocyte</FONT> stimulator (BLyS)-specific inhibitor developed by GSK, is currently the world&#146;s only biologic approved to treat SLE. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unmet Medical Need </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The effect of symptomatic treatments for SLE,
including <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drugs, is short-lived and often very limited. The therapeutic role of corticosteroids or immunosuppressants in the long-term management of SLE is hampered by severe
drug-related side effects and lack of a disease-modifying effect. As auto-antibodies and resulting immune complexes produced by CD38-positive B cells and plasma cells act at the core of the pathogenesis of SLE, direct inhibition and selective
depletion of pathogenic B cells and plasma cells are believed to offer better treatment options. TJ202 has the potential to offer such a <FONT STYLE="white-space:nowrap">disease-modifying</FONT> treatment option. In addition, the advantages of TJ202
include convenience of use and a lower IRR, making it a more favorable treatment agent in the long-term clinical management of SLE if approved. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Competitive
Landscape </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables illustrate the competitive landscape of the biologics treating SLE in China and the rest of the world. (<I>Source:
Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Marketed Biological Products for SLE </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>PRODUCT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TARGET</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMPANY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FDA<BR>APPROVAL<BR>TIME</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NMPA<BR>APPROVAL<BR>TIME</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PATENT<BR>EXPIRY&nbsp;IN<BR>THE U.S.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>GLOBAL&nbsp;SALES&nbsp;REVENUE&nbsp;IN<BR>2018 (IN BN, US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Belimumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BLyS</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">GSK</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investigational Drugs for SLE in China </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>INVESTIGATIONAL DRUGS<SUP STYLE="font-size:85%; vertical-align:top">
(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>TARGET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DRUG FORM</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>COMPANY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>GLOBAL&nbsp;STATUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CHINA&nbsp;STATUS</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">RCT-18</FONT> (telitacicept)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:9.5pt">BLyS/APRIL</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:9.5pt">Antibody&nbsp;fusion protein</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:9.5pt">Rong Chang</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:9.5pt">N/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">BLA filed</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ustekinumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">IL-12/23</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Monoclonal antibody</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Johnson&nbsp;&amp; Johnson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TJ202</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>CD38</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Monoclonal antibody</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>IND</B></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Competing investigational biologics that are prior to Phase 3 clinical trials are not included in this table. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Historical and Forecast Market Size of SLE Therapeutics Globally and in China </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following diagrams illustrate the size of the SLE drug market in terms of sales revenue in the global and China markets. (<I>Source: Frost</I><I></I><I>&nbsp;&amp;
Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Global SLE Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g85v78.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>China SLE Therapeutics Market Size (2014-2030E) </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g67b87.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Ulcerative Colitis </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Overview </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ulcerative colitis (&#147;UC&#148;) is an inflammatory bowel disease (&#147;IBD&#148;) that causes chronic and often relapsing inflammation and ulceration of the colon
and rectum, in which the lining of the colon and rectum become inflamed and develop tiny open sores, or ulcers, which produce pus and mucous. This combination of inflammation and ulceration can cause abdominal discomfort and frequent emptying of the
colon. UC patients experience recurrent flares of abdominal pain and bloody diarrhea. Other UC symptoms include fatigue, weight loss, and fever. Disease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
complications may include megacolon, inflammation of the eye, joints, or liver, and colon cancer. According to the Frost&nbsp;&amp; Sullivan Report, in Greater China, UC affected approximately
370,100 patients in 2018, which is predicted to increase to approximately 543,700 cases in 2023, representing a CAGR of 8.0%. Greater China has a relatively lower UC incidence and prevalence compared to those in Western countries, but the absolute
number of patients is predicted to increase to approximately 918,300 in 2030 with a CAGR of 7.8% from 2023 to 2030, as a result of the increasingly westernized lifestyle in Greater China. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of UC </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, there is no curative treatment for UC.
Most of the approved biologics for UC are <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> inhibitors. Vedolizumab (Entyvio), an integrin <FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>4&szlig;7 antibody that blocks lymphocytes from accumulating in the intestinal wall, is currently the only <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-anti-TNF-</FONT></FONT></FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> biologic approved for UC. Vedolizumab is also in a Phase 3
trial in China. In May 2018, tofacitinib (Xeljanz), which is a small molecule Jak1/3 kinase inhibitor, became the first oral medication approved for chronic use in moderate to severe UC in the United States. In China,
<FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drugs, such as <FONT STYLE="white-space:nowrap">5-aminosalicylic</FONT> acids <FONT STYLE="white-space:nowrap">(&#147;5-ASAs&#148;),</FONT> and corticosteroids or other
immunosuppressants, including azathioprine, mercaptopurine and cyclosporine, are often used as an initial treatment and throughout the course of clinical management with limited treatment efficacy. Approved by the NMPA in 2019, infliximab
(Remicade), which is a <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> inhibitor, is currently the only biologic approved to treat UC in China. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unmet Medical Need </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The incidence of UC is increasing rapidly, but UC
patients, especially those with a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> disease, have few treatment options, which have limited treatment efficacy and considerable side-effects. For
example, Jak1/3 kinase inhibitors can carry the risk of serious infections and malignancies. <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> inhibitors also
have inherent side effects and do not work in all patients. According to the Frost&nbsp;&amp; Sullivan Report, approximately 45% patients are considered treatment <FONT STYLE="white-space:nowrap">non-responders</FONT> to <FONT
STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> drugs among all autoimmune diseases. Thus, there is a substantial unmet medical need in UC for a treatment agent(s)
that is efficacious and safe through pathways beyond the traditional drug targets. TJ301 is believed to potentially fulfill such a product profile as it works through the <FONT STYLE="white-space:nowrap">IL-6</FONT> trans-signaling pathway. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Competitive Landscape </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our TJ301 is the only clinical stage selective
<FONT STYLE="white-space:nowrap">interleukin-6</FONT> <FONT STYLE="white-space:nowrap">(&#147;IL-6&#148;)</FONT> inhibitor that works through the trans-signaling mechanism. It is a potential highly differentiated
<FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for UC, if approved. The following table illustrates the competitive landscape of investigational biologics for treating UC that are in late-stage development in China and the rest of the world.
(<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>PRODUCT<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TARGET</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMPANY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>GLOBAL&nbsp;STATUS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHINA&nbsp;STATUS</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vedolizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>4&szlig;7&nbsp;integrin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Takeda</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Approved</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase&nbsp;3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ustekinumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-12/IL-23</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Johnson&nbsp;&amp;&nbsp;Johnson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">NDA&nbsp;filed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risankizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">IL-23</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AbbVie</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase&nbsp;3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mirikizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">IL-23</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Eli Lilly</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Etrolizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&szlig;7 integrin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Roche</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ontamalimab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">MAdCAM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Takeda/Shire</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Spesolimab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">IL-36</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Boehringer<BR>Ingelheim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase<BR>2/3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Olamkicept (TJ301<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP>)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">IL-6</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phase 2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phase&nbsp;2</B></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Competing investigational biologics that are prior to Phase 3 clinical trials are not included in this table. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have the development and commercialization rights for olamkicept in Greater China pursuant to a partnership agreement with Ferring Pharmaceuticals. A regional multi-center Phase 2 trial in Greater China and South
Korea sponsored by <FONT STYLE="white-space:nowrap">I-Mab</FONT> is ongoing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Historical and Forecast Market Size of UC Therapeutics Globally and in China </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following diagrams illustrate the size of the UC drug market in terms of sales revenue in the global and China markets. (<I>Source: Frost</I><I></I><I>&nbsp;&amp;
Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Global Ulcerative Colitis Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g93x36.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>China Ulcerative Colitis Therapeutics Market Size (2014-2030E) </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g22d25.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Growth Hormone Deficiency </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Overview </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Growth hormone deficiency (&#147;GHD&#148;) is an endocrine disorder that occurs when the production of growth hormone, normally secreted by the pituitary gland, is
disrupted. Since growth hormone plays a critical role in stimulating body growth and development and is involved in the production of muscle protein and the breakdown of fats, deficiency in growth hormone affects numerous physiological processes,
resulting in short stature in children and other physical ailments in both children (&#147;PGHD&#148;) and adults (&#147;AGHD&#148;). According to the Frost&nbsp;&amp; Sullivan Report, PGHD affected approximately 3.4&nbsp;million patients in 2018 in
Greater China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of PGHD </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The widely adopted treatment for PGHD is patient-specific growth hormone replacement therapy, which is given in a calculated weight-based dosing regimen. Currently,
short-acting recombinant human growth hormone (&#147;rhGH&#148;) is commonly used for the long-term treatment of children and adults with inadequate endogenous growth hormone secretion. There are certain safety concerns related to long-term use of
pegylated drugs, such as potential renal toxicity, cellular vacuolation and formation of anti-polyethylene glycol antibodies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Approved by the NMPA in 2014,
Jintrolong (developed by GeneScience) is currently the only long-acting pegylated rhGH in China. Other companies in China currently developing long-acting rhGH include Anhui Anke Biotechnology, Xiamen Amoytop Biotech, Generon Pharmaceutical
Technology and Visen Pharmaceuticals. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unmet Medical Need </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the Frost&nbsp;&amp; Sullivan Report, only 3.7% of all PGHD patients in China were receiving growth hormone replacement therapy in 2018, which consists of
daily injections of rhGH before sleep. This dosing regimen puts a substantial burden on pediatric patients and their families because it requires drug preparation and needle injection every day, which is painful and extremely inconvenient, often
resulting in poor patient compliance. More importantly, studies have shown that skipping just one or two doses in a week can significantly reduce the efficacy of the treatment. Therefore, there is a substantial medical need for long-acting growth
hormone therapies that are similarly efficacious but with reduced injection frequency, and the market potential for such a long-acting rhGH in China is largely untapped. In addition, recombinant human growth hormone therapy has been included in the
National Reimbursement Drug List (NRDL) in China. Inclusion of a drug in the NRDL typically results in a much higher sales volume and significant sales growth despite a reduction in price. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Competitive Landscape </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our TJ101 is the only <FONT
STYLE="white-space:nowrap">Fc-based</FONT> long-acting rhGH ready for a Phase 3 clinical trial in China. The following tables illustrate the competitive landscape of long-acting growth hormone products and product candidates in China and the rest of
the world. (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Marketed Products of Long-acting GH </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>PRODUCT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DRUG FORM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMPANY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FDA<BR>APPROVAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NMPA<BR>APPROVAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PATENT<BR>EXPIRY&nbsp;IN<BR>CHINA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>GLOBAL&nbsp;SALES&nbsp;REVENUE&nbsp;IN<BR>2018 (IN BN, RMB)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jintrolong</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">PEGylated&nbsp;GH</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">GeneScience</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investigational Drugs of Long-acting rhGH </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>INVESTIGATIONAL DRUG<SUP STYLE="font-size:85%; vertical-align:top">
(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DRUG FORM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMPANY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>GLOBAL&nbsp;STATUS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHINA&nbsp;STATUS</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">NNC0195-0092</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">PEGylated&nbsp;hGH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Novo&nbsp;Nordisk</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lonapegsomatropin (ACP-001)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">TransCon hGH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ascendis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase&nbsp;3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Visen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase&nbsp;3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Eftansomatropin (TJ101)</B><SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Hy-Fc</FONT></B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>(Fc&nbsp;fusion&nbsp;protein)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phase&nbsp;3&nbsp;ready</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Eftansomatropin
<FONT STYLE="white-space:nowrap">(GX-H9</FONT><SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Genexine</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase&nbsp;3&nbsp;ready</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PEG-rhGH</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">PEGylated GH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Anhui Anke</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase&nbsp;2/3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Y-shaped pegylated somatropin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">PEGylated hGH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Xiamen<BR>Amoytop</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase&nbsp;2/3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Somatrogon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">hGH-CTP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">OPKO/Pfizer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase&nbsp;3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Competing investigational biologics that are prior to Phase 2 clinical trials are not included in this table. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TJ101 and <FONT STYLE="white-space:nowrap">GX-H9</FONT> are the same investigational drug. We have the development and commercialization rights for TJ101 in Greater China pursuant to a partnership agreement with
Genexine. We plan to submit an IND application in 2020 for a Phase 3 clinical trial (pending the NPMA&#146;s approval) in China. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Historical and Forecast Market Size of PGHD Therapeutics Globally and in China </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following diagram illustrates the size of the PGHD drug market in terms of sales revenue in the global and China markets. (<I>Source: Frost</I><I></I><I>&nbsp;&amp;
Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Global PGHD Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g11t09.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>China PGHD Therapeutics Market Size (2014-2030E) </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g49s71.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_15"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company committed to the
discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were founded to capture the opportunities presented by the confluence of two major developments&#151;the emergence of an attractive and growing biologics market in
China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding
of China&#146;s biologics regulatory framework and our direct access to extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative pipeline of more than 10 clinical
and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage assets through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global pharmaceutical and biotech companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commercial Opportunities in China and Our Unique Position </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are fully
aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China, including need to raise significant capital, significant competition from global and other China-based biopharmaceutical
companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential implementation challenges and uncertainties of the recent government reform of the drug approval system. However, with these
challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional aspects of our drug development process to proactively deal with some of the regulatory challenges mentioned above.
Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel with the regulatory agencies to discuss and resolve various regulatory issues promptly and effectively. We see vast
opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence and mortality of cancers in China have been increasing in recent years and are outpacing those in the United States and the rest of the world.
Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States and Europe are not yet available in China. Third, the Chinese government has implemented new policies and regulations to simplify the review and
approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth, there has been a continuous and rapid increase in personal disposable income in China coupled with ongoing improvement in basic national health
insurance coverage, making innovative biologics more accessible to more Chinese patients. According to the Frost&nbsp;&amp; Sullivan Report, China&#146;s biologics market is growing faster than the global biologics market and is expected to reach
approximately RMB1.3 trillion (US$181.9 billion) by 2030 in terms of sales revenue. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe we are uniquely positioned as a China-based global player to tap
into these vast commercial opportunities. This is best demonstrated by our short journey in becoming one of the top clinical stage immunology companies in China. According to the Frost &amp; Sullivan Report, we are ranked as top clinical stage
China-based immunology companies as measured by the innovative quality and number of investigational drugs and drug candidates under clinical and pre-clinical development in our pipeline, amount of pre-IPO financing raised (in excess of US$400
million in three years), pre-IPO valuation and recognition and awards earned in the biotech industry. For example, in 2018 and 2019, we are the only China-based biotech company recognized by Genetic Engineering &amp; Biotechnology News (GEN) as a
top 10 immuno-oncology start-up in the world. To date, our research and development capabilities encompass discovery, translational medicine, biologics CMC development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical
development with footprints in Shanghai, Beijing and the United States. We are now at a critical juncture to transition from a clinical stage biotech company into a fully integrated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company in the next few years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Unique
Business Model </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To achieve our mission and capitalize on these commercial opportunities, we have developed a business model built on two pillars: a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> (proof of concept) global strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Strategy
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy focuses on seeking opportunities to <FONT
STYLE="white-space:nowrap">in-license</FONT> the development and commercialization rights of investigational drugs from global biopharmaceutical companies for Greater China. We only select investigational drugs that have the potential to become
novel or highly differentiated medicines. Through our substantial <FONT STYLE="white-space:nowrap">in-house</FONT> research and development efforts, we build additional data packages to meet the requirements of the National Medical Products
Administration (the &#147;NMPA&#148;) to ensure programs are ready for late-stage or registrational clinical development. Our internal development capabilities combined with our deep insight into China&#146;s regulatory framework and our clinical
network enable us to efficiently navigate through the drug development process to registration. To date, we have built an innovative China Portfolio consisting of five investigational drugs with an aim for near-term product launch. All of these
investigational drugs have met the related pre-set safety and preliminary efficacy endpoints in Phase 1 or Phase 2 clinical trials in Europe, the United States or elsewhere and are either in or ready for Phase 2 or Phase 3 clinical trials in China.
TJ202 is undergoing two registrational trials, including a third-line monotherapy trial and a second-line combination therapy trial, in multiple myeloma in Greater China. In addition, we submitted an IND application to the NMPA in October 2019 for a
Phase 1b trial for TJ202 in systemic lupus erythematosus (&#147;SLE&#148;). For TJ101, we are working towards submitting an IND application in 2020 for a Phase 3 registrational trial in China. For enoblituzumab, we expect to submit an IND
application in 2020 for a registrational trial or a Phase 2 trial. As a result, the investigational drugs in our China Portfolio are positioned for a series of new drug applications (NDAs) in China with the submission of the first NDA expected in
2021. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> Global Strategy </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy focuses on advancing our own novel or differentiated
biologics towards clinical validation in the United States. First, we seek PoC of these drug candidates in the United States by conducting early phase clinical trials with a set of safety and efficacy endpoints and leveraging the FDA&#146;s
streamlined regulatory system for innovative drug development, including a predictable timeline towards IND approval. Second, we will use the data generated to advance clinical development in China, which we believe confers several advantages,
including access to China&#146;s large patient pool, extensive clinical trial resources through collaborations with leading hospitals in China, and a regulatory pathway for fast-track approval of drugs supported by solid overseas clinical data.
Building on this approach, we may <FONT STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of these investigational drugs following clinical validation in the United States, while retaining the Greater China
rights for further development and commercialization. We believe this approach will allow Chinese patients to benefit from our most advanced treatments concurrently or soon after their market approvals elsewhere. To date, we have created a Global
Portfolio that consists of two molecular classes&#151;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, which are internally generated. They are highly innovative molecules compared to global competitor assets
in the same or related classes of drug candidates. Three investigational drugs in our Global Portfolio (TJM2, TJC4 and TJD5) are in Phase 1 trials in the United States. Having obtained IND approvals from the NMPA for TJC4, TJD5 and TJM2, we have
initiated a Phase 1 trial for TJC4 and expect to initiate Phase 1 trials for TJD5 and TJM2 in China in early 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These two strategies and the resulting two
portfolios complement each other. This enables us to achieve a balance among our ambition to develop novel or highly differentiated drugs, our goal to efficiently advance our pipeline assets towards commercialization and the inherent development
risks. With this goal in mind, we are also aware that the intended novelty and key differentiation of our investigational drugs or drug candidates are subject to pivotal clinical validation and approval by the relevant regulatory authorities. There
is no assurance that any such investigational drug or drug candidate will receive regulatory approval. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Capabilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Innovative Discovery Expertise </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Built by an elite group of seasoned immunologists with extensive academic research and drug development experience, our discovery engine has generated a panel of
internally developed innovative drug molecules in a short span of four years. Among them, 11 innovative drug molecules have met our standard of novelty or high differentiation and have advanced toward further development. This achievement is a
testament to our discovery team&#146;s acumen and technical prowess in translating target biology into points of innovation or differentiation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The discovery of TJC4 showcases our innovative research capabilities. Not settling on performing routine or
traditional antibody screening, we set a specific goal to identify and select a unique CD47 antibody that is free from binding to red blood cells (RBC) from all CD47 antibody leads. As a result, we selected by design, our proprietary CD47 antibody
(TJC4) with a rare epitope that uniquely spares binding to RBCs as a differentiation point from other CD47 antibodies that typically cause inherent hematologic side effects. Having confirmed the RBC-sparing property in a series of in vitro assays as
well as multiple monkey studies, we are conducting a Phase 1 clinical trial for TJC4 in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Another example of our R&amp;D capability relates to our
novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel that represents a new wave of oncology drug candidates. We created novel biological properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies that are
capable of enriching immune cells in tumors through dual targeting of <FONT STYLE="white-space:nowrap">PD-L1</FONT> and immune cells for a synergistic anti-tumor effect. These <FONT STYLE="white-space:nowrap">bi-specific</FONT> drug candidates have
been shown to exhibit unique properties that render tumors more responsive to treatment. Our discovery expertise, when combined with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;fit-for-purpose&#148;</FONT></FONT>
antibody engineering technology platforms, becomes a powerful engine of innovation to create novel molecules. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Fit-for-Purpose</FONT></FONT> Technology Platforms </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our proprietary antibody engineering platforms enable us to accurately
capture the biological properties of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies and retain good manufacturability and druggability of the molecules. To date, we have created seven novel
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage <FONT STYLE="white-space:nowrap">bi-specific</FONT> drug molecules. In addition to our own <FONT STYLE="white-space:nowrap">Ig-scFv</FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT>
antibody platform, we partnered with ABL Bio and WuXi Biologics to access their antibody engineering platforms in order to increase the probability of success, as different molecular configurations require different technologies. Furthermore, our
proprietary antibody-cytokine technology has enabled another form of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies such as <FONT STYLE="white-space:nowrap">TJ-L1I7</FONT> and <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> that link
a tumor-engaging antibody with an immuno-modulatory cytokine. Superior to monoclonal antibodies or cytokines alone, this class of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies has demonstrated unique properties capable of
concentrating the drug molecules in tumors for a desired target effect with reduced systemic toxicity of cytokines or creating biologic synergy that can potentially translate into better treatment outcome. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Biomarker-Enabled Translational Medicine Capabilities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As we
focus on developing innovative drug molecules, the ability to apply relevant biomarkers that link a drug response to treatment effects is critical for early-stage clinical trials of our investigational drugs. This translational medicine capability
requires cross-functional knowledge and unique skills to link the target biology of an investigational drug to clinical responses. We have been developing tailor-made biomarkers for each of our investigational drugs, which are used to select
potential responders, predict and measure target engagement, support dose determination and enable timely informed decisions on advancing our assets to the next phase of clinical development. For example, for the development of TJD5, we intend to
use CD73 in tumor tissue in combination with other tumor biomarkers to stratify potential target patient populations in our clinical trial. To that end, we have developed assays to measure CD73 expression and activity in tumor tissues. Furthermore,
we have developed specialized assays to measure TJD5 drug concentrations in tumor tissues. By linking drug concentration with its activity in the same tumor location, these data help us determine appropriate dose selection for further clinical
studies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Clinical Development Capabilities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical
development is led by a global team of clinical scientists, industry physicians and experts in portfolio management, quantitative science, clinical operations, drug safety and quality control. Our clinical team accounts for approximately 80% of our
entire R&amp;D organization&#146;s headcount and 80% of our budget allocation. The skillset of our clinical development team is highlighted by a combination of extensive global pharma, local drug development and operation experiences with clinical
networks in China and the United States. The team is driven by high ethical standards, with passion for improving the lives of patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team has the ability
to integrate internal core development functions to conduct global and local clinical trials. We also effectively leverage external resources, including clinical contract research organizations, academic clinical centers and/or networks, and global
pharmaceutical or biotech partnerships. Furthermore, we have established and implemented a robust internal clinical governance system and processes to safeguard patient safety and data integrity. Our current clinical development functions and teams
are strategically based in Shanghai, Beijing, and the United States to cover Phase 1 through Phase 3 clinical trials in China and early-stage clinical trials in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical development capabilities are best demonstrated by the rapid implementation of eight ongoing clinical
trials, including five Phase 1/2 and registrational trials in Greater China and three Phase 1 trials in the United States within the past three years. To ensure regulatory approval and subsequent product launch as currently planned, we strive to
reach the following critical clinical milestones by the end of 2020: 11 active clinical programs consisting of two Phase 3 or registrational trials in China, two Phase 2 trials in China and seven Phase 1 trials in the United States and China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Global Strategic Collaborations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have established an excellent track
record of <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals with our global and regional partners. These <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals enable us to
acquire multiple innovative clinical stage assets with favorable clinical data packages. We have quickly built our China Portfolio through <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals with global biotech partners, including MorphoSys,
Genexine, MacroGenics and Ferring (as the sublicensee under our agreement with Ferring related to olamkicept TJ301). Over the past three years, we have established more than 10 global and regional partnerships with reputable pharma or biotech
companies. Our partners selected us among many China-based companies with the belief that we are an ideal partner in China given our strength in science and drug development capability, our outstanding track record of execution of rapidly
progressing drug development programs in China and the United States and our vision and network to tap into business opportunities and the growing pharmaceutical market in China. For example, MorphoSys, MacroGenics and Genexine all stated that we
are an ideal or the best partner in China in their press releases or public announcements. The <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals enable us to streamline our pipeline and focus our resources on the most valuable assets. In
addition, we seek <FONT STYLE="white-space:nowrap">co-development</FONT> opportunities to share development costs and risks and territorial commercial rights with our partners. In the past two years, we have
<FONT STYLE="white-space:nowrap">out-licensed</FONT> three <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets and initiated four <FONT STYLE="white-space:nowrap">co-development</FONT> programs with partners such as ABL Bio and WuXi
Biologics. The revenue from <FONT STYLE="white-space:nowrap">out-licensing</FONT> and <FONT STYLE="white-space:nowrap">co-development</FONT> deals is expected to continue to grow as our pipeline progresses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Drug Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The chart below summarizes the development status of our
drug pipeline. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g95n07.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman; " COLOR="#3d72ff"><FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#233;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">(i) For TJ202, it has two ongoing registrational trials, a monotherapy trial and a combination therapy trial in multiple myeloma in Greater China, and we expect to initiate a Phase 1b trial in systemic lupus
erythematosus (&#147;SLE&#148;) in 2020; (ii) for TJ101, we are working towards submitting an IND application in 2020 for a Phase 3 registrational trial in China; and (iii)&nbsp;for enoblituzumab, we expect to submit an IND application in 2020 for a
registrational trial or a Phase 2 trial. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#3d72ff">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We were collaborating with Everest Medicines Limited (&#147;Everest&#148;) to co-develop and commercialize TJ202 in Greater China for all indications in hematologic oncology. Everest was primarily responsible for
sharing with us, by the proportion of 75% for Everest and 25% for us, the development costs of TJ202. On November&nbsp;4, 2019, we and Everest terminated the collaboration agreement (including all the supplements and amendments thereto) with respect
to the co-development and commercialization of TJ202 in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its commercialization. All intellectual
property rights in respect of TJ202 arising from its development under the collaboration agreement are vested and owned by us, and we hold all intellectual property rights and have maximum flexibility to further develop, manufacture and
commercialize TJ202 in Greater China. In consideration of the above arrangements, we will issue a total value of US$37.0 million of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing Everest&#146;s historical contribution to our
collaboration and the associated time cost. The CPP Shares will be issued concurrently with, and subject to, the completion of this offering within 180 days from termination of the collaboration agreement, at a per share price equal to the initial
public offering price adjusted to reflect the ADS-to-ordinary share ratio. In the event that this offering has not been completed within 180 days from the termination of the collaboration agreement, we will issue 4,762,751 ordinary shares to Everest
on the 181st day. See also &#147;The Offering&#151;Concurrent Private Placement&#148; for more details. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#3d72ff">**</FONT></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel consists of (i)&nbsp;four <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT>
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, including <FONT STYLE="white-space:nowrap">TJ-L1C4</FONT><B> </B><FONT STYLE="white-space:nowrap">(PD-L1</FONT> and CD47), <FONT STYLE="white-space:nowrap">TJ-L1H3</FONT> <FONT
STYLE="white-space:nowrap">(PD-L1</FONT> and <FONT STYLE="white-space:nowrap">B7-H3),</FONT> <FONT STYLE="white-space:nowrap">TJ-L14B</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> and <FONT STYLE="white-space:nowrap">4-1BB)</FONT> and
TJ-L1I7 (anti-PD-L1 and IL-7 cytokine fusion), <FONT STYLE="white-space:nowrap">(ii)&nbsp;TJ-C4GM</FONT> (anti-CD47 and <FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine fusion), and <FONT STYLE="white-space:nowrap">(iii)&nbsp;TJ-CLDN4B</FONT>
(Claudin 18.2 and <FONT STYLE="white-space:nowrap">4-1BB).</FONT> </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Highlights of Our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Portfolio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy is demonstrated by our China Portfolio, which consists of novel or highly differentiated investigational drugs. TJ202, TJ107, enoblituzumab
and TJ101 are the four anchor assets in our China Portfolio. While we have been diligently pursuing our fast-to-market China strategy, we are aware that there is no assurance that we will always be successful in commercializing any of our product
candidates in our China Portfolio in an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ202 is a differentiated CD38 antibody originally developed by MorphoSys that meets the pre-set clinical safety and preliminary efficacy endpoints from a clinical
trial conducted in the European Union (EU). <FONT STYLE="white-space:nowrap">In-licensed</FONT> from MorphoSys, TJ202 is being developed to address the current unmet needs and commercial opportunities in China for multiple myeloma and potentially
autoimmune diseases, such as SLE. We own an exclusive license to develop TJ202 in Greater China. We believe TJ202, if approved, is potentially highly differentiated compared with the currently marketed CD38 antibody. First, under a similar <FONT
STYLE="white-space:nowrap">pre-medication</FONT> condition with dexamethasone, anti-pyretics and anti-histamines, TJ202 has demonstrated a significantly shorter infusion time and lower infusion reaction rate. Second, unlike the currently marketed
CD38 antibody, TJ202 does not down-regulate CD38 expression on the surface of bone marrow myeloma cells in vitro, maintaining sensitivity of myeloma cells to TJ202 for repeated treatments. TJ202 is undergoing a registrational trial as a third-line
monotherapy and a registrational trial in combination with lenalidomide as a second-line therapy, both in patients with multiple myeloma in Greater China. We aim to submit an NDA for TJ202 as a third-line monotherapy in 2021, followed by another NDA
submission for TJ202 as a second-line combination therapy. Moreover, we believe TJ202 has great market potential in the treatment of pathogenic antibody-mediated autoimmune diseases, such as SLE, where there is a significant unmet need for more
effective therapies. Additionally, we submitted an IND application to the NMPA in October 2019 for a Phase 1b trial for TJ202 in SLE. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ107 is the first
long-acting recombinant human IL-7 known to boost cancer-fighting T lymphocytes by increasing their number and function and is being developed as a potential oncology investigational drug. The clinical safety and effect of TJ107 on T cells have been
investigated in multiple previous and ongoing clinical trials in South Korea and the United States. TJ107 is being positioned to address a huge unmet medical need in oncology. First, TJ107 can be an oncology-care agent to treat cancer
treatment-related lymphopenia (low blood lymphocyte levels), a common condition that occurs in cancer patients who have received chemotherapy or radiation therapy, and there is no approved treatment for this condition. According to the
Frost&nbsp;&amp; Sullivan Report, in Greater China, the incidence of lymphopenia reached 1.5&nbsp;million in 2018 and is estimated to increase to 1.7&nbsp;million in 2023 and further to 2.0&nbsp;million in 2030. This condition causes further damage
to patients&#146; already compromised immune system and weakens its ability to fight cancers. Second, TJ107 has been shown to synergize with a PD-1 antibody in a tumor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
animal model potentially through increased T&nbsp;lymphocyte activation and proliferation. We are conducting a Phase 1b trial in China to determine a suitable dose range for subsequent trials. We
expect to start a Phase 2 trial in cancer patients in 2020. We are coordinating our study globally with Genexine, which is conducting a Phase 2 clinical trial in South Korea and parallel clinical trials in the United States towards clinical PoC.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enoblituzumab is a humanized antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> a member of the B7 family of T cell checkpoint regulators that is
widely expressed across multiple tumor types and plays a key role in the regulation of immune response against cancers. Similar to other inhibitors of the B7 family such as <FONT STYLE="white-space:nowrap">PD-L1,</FONT> targeting <FONT
STYLE="white-space:nowrap">B7-H3</FONT> potentially provides a treatment option for a variety of cancers expressing <FONT STYLE="white-space:nowrap">B7-H3.</FONT> Enoblituzumab was originally developed by MacroGenics, and we own the Greater China
rights of this investigational drug. In multiple clinical trials conducted by MacroGenics, when combined with pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (&#147;SCCHN&#148;) and <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;), enoblituzumab has shown favorable clinical results that warrant further investigation. We expect to submit an IND application in 2020 for a registrational trial or a
Phase 2 trial. Further clinical development is being planned together with MacroGenics to extend to other cancer indications in China and globally. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ101, if
approved, is a potential highly differentiated long-acting human growth hormone that is being developed as a weekly treatment for pediatric growth hormone deficiency as compared to currently available daily regimens of recombinant human growth
hormone (rhGH). TJ101 was originally developed by Genexine, and we own the Greater China rights of this product, which has the potential to address an important clinical need and to cover a significant market gap in pediatric growth hormone
deficiency. According to the Frost&nbsp;&amp; Sullivan Report, there are approximately 3.4&nbsp;million pediatric patients with growth hormone deficiency in 2018 in Greater China, but only 3.7% of them receive growth hormone therapies, which are
mostly daily regimens. In a previous Phase 2 trial conducted by Genexine in South Korea and the EU, both weekly and <FONT STYLE="white-space:nowrap">bi-weekly</FONT> administration of TJ101 demonstrated similar therapeutic effects to daily injection
of Genotropin, a short-acting rhGH. We are working towards submitting an IND application in 2020 for a Phase 3 registrational trial in China. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Highlights of
Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> Global Portfolio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy is demonstrated by our Global Portfolio, which mainly consists of our internally developed novel or differentiated biologics. Our Global Portfolio focuses on two molecular
classes&#151;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. While we have been diligently pursuing our fast-to-PoC global strategy, we are aware that there is no assurance that we will always be successful
in achieving PoC or pivotal development milestones for any of our product candidates in our Global Portfolio in an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and
commercialization of our drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Monoclonal antibodies</I>&#151;Among the five monoclonal antibody drug candidates, TJM2, TJC4 and TJD5 are undergoing
Phase 1 clinical trials in the United States. Having obtained IND approvals from the NMPA for TJC4, TJD5 and TJM2, we have initiated a Phase 1 trial for TJC4 and expect to initiate Phase 1 trials for TJD5 and TJM2 in China in early 2020. In
addition, we are collaborating with Shanghai Junshi Biosciences Co., Ltd, or Junshi, to conduct clinical trials of the combination therapy of TJD5 and Junshi&#146;s PD-1 monoclonal antibody toripalimab in cancer patients with various types of solid
tumors. We have not initiated any research and development activities under such collaboration arrangement as of the date of this prospectus. TJ210 and TJX7 are at the CMC stage and are expected to be ready for IND submissions in 2020 for Phase 1
clinical trials in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJC4 is an internally discovered, fully human monoclonal antibody targeting CD47, which is one of the most promising
immuno-oncology targets after <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1.</FONT></FONT> Blocking CD47 activates tumor-engulfing macrophages, a component of the innate immune system as an important cancer-fighting
mechanism. CD47 antibodies are being actively pursued in clinical trials by a few global companies. However, current development efforts on CD47 antibody drugs are hampered by hematologic side effects (such as anemia) due to binding to human RBCs.
For example, at least two clinical trials conducted by other companies have been suspended. Unlike competitor investigational drugs, TJC4 is a rare antibody originally selected, by design, to purposefully avoid or minimize binding to RBCs while
maintaining a high antibody affinity and tumor killing properties. TJC4&#146;s unique property of minimal RBC binding and no significant hematologic changes has been extensively validated in a whole series of robust in vitro assays and primate
studies. In a GLP toxicology study involving 40 monkeys, no hematologic side-effects were seen even with repeated injections of 100 mg/kg doses. This unique property may enable TJC4 to be used safely in a broader
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patient population to explore its treatment potential in cancers, differentiating it from other clinical stage CD47 investigational antibody drugs. TJC4 is being evaluated in a Phase 1 clinical
trial with cancer patients in the United States. In parallel, leveraging the Phase 1 data generated in the United States, we plan to begin a Phase 1 clinical trial of TJC4 in patients with hematologic malignancies, such as AML/MDS, by early 2020 in
China. In addition, we are collaborating with Merck Sharp &amp; Dohme Corp, or MSD, in a Phase 1 clinical trial in the United States for the combination therapy of TJC4 and MSD&#146;s PD-1 inhibitor KEYTRUDA (pembrolizumab) in cancer patients with
several types of solid tumors. We have not initiated any research and development activities under such collaboration arrangement as of the date of this prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibody panel</I>&#151;This novel antibody class represents an emerging and fast-moving area of new drug
discovery. <FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibodies are typically constructed to have a dual specificity of two selected antibodies or combined properties of an antibody linked with a cytokine, previously called an
immuno-cytokine. According to the Frost&nbsp;&amp; Sullivan Report, checkpoint inhibitors targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> had global sales of US$16.3&nbsp;billion in 2018 and are
predicted to reach US$63.4&nbsp;billion in global sales by 2030. However, despite the recent success of checkpoint inhibitors, clinical efficacy of these drugs has been unsatisfactory. It is estimated that over 60% of cancer patients, including
those with melanoma, renal cell cancer, colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, urothelial cancer and head and neck squamous cell carcinoma, do not respond to PD-1/PD-L1 monotherapies. In addition, some
patients develop resistance after initial treatment with these therapies. As a result, the standard of care today leaves many cancer patients underserved. There is consensus among cancer immunologists that tumors that do not respond to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment have poor immunologic features, such as an absence or paucity of tumor-fighting immune cells or the presence of dysfunctional immune cells within the
tumors, collectively known as &#147;cold tumors.&#148; We believe that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> <FONT STYLE="white-space:nowrap">non-responders</FONT> can be better treated with novel
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. The unique and superior properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies over <FONT STYLE="white-space:nowrap">PD-L1</FONT> inhibitors alone stem from
a second targeting component attached to the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody moiety of the <FONT STYLE="white-space:nowrap">bi-specific</FONT> molecules, thereby enabling them to elicit a sufficient immune response and
converting a &#147;cold tumor&#148; to an immune-active &#147;hot tumor.&#148; Such unique properties of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies cannot be substituted by a combination of the
<FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody with a selected second component (either cytokine or antibody) in a free form. The underlying mechanism is such that the second component must be structurally integrated with the tumor-engaging <FONT
STYLE="white-space:nowrap">PD-L1</FONT> antibody in order to concentrate and function inside the tumor, which cannot be readily achieved by the two free agents used in combination. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have successfully generated a panel of four <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies in which our proprietary
<FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody acts as the backbone (the first signal) and is linked with various second components (the second signal) including a <FONT STYLE="white-space:nowrap">4-1BB</FONT> agonist antibody <FONT
STYLE="white-space:nowrap">(TJ-L14B),</FONT> a <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody <FONT STYLE="white-space:nowrap">(TJ-L1H3),</FONT> a CD47 antibody <FONT STYLE="white-space:nowrap">(TJ-L1C4)</FONT> and an IL-7 cytokine
(TJ-L1I7), which are shown to work synergistically with the <FONT STYLE="white-space:nowrap">PD-L1</FONT> backbone in various assays and cancer animal models. This unique panel of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies is
only made possible by our proprietary and partnered antibody engineering technologies and the availability of our proprietary monoclonal antibodies. Furthermore, we have generated two other <FONT STYLE="white-space:nowrap">bi-specific</FONT>
antibodies <FONT STYLE="white-space:nowrap">(TJ-C4GM</FONT> and <FONT STYLE="white-space:nowrap">TJ-CLDN4B)</FONT> that are tailor-made to function as novel fortified antibodies by linking TJC4 with an engineered
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine for the treatment of solid tumors and by linking our <FONT STYLE="white-space:nowrap">Claudin-18.2</FONT> antibody with a <FONT STYLE="white-space:nowrap">4-1BB</FONT> antibody as a unique
gastric cancer treatment agent that only activates T cells conditionally upon tumor engagement. All <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies have been validated in a series of robust <I>in vitro</I> and <I>in vivo</I> studies
for biology <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> providing a solid basis for clinical validation in cancer patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moving forward, we strive to become a fully integrated <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company whose capabilities encompass drug discovery, GMP manufacturing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical
development and commercialization. To achieve this goal, we intend to pursue the following strategies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rapidly advance our China Portfolio towards
commercialization </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to pursue the most efficient pathway to NDA approval for the investigational drugs in our China Portfolio. In the next 12
months, we expect to make significant advances with our China Portfolio. All of the clinical assets of our China Portfolio are expected to undergo Phase 2, Phase 3 or registrational clinical trials in 2020. We plan to submit NDAs to the NMPA for
these products in sequence from 2021 to 2024. With respect to commercialization capabilities, we plan to initially partner with a specialty pharmaceutical company that has existing commercial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
capabilities and infrastructure in China to jointly market our leading products. Once we have acquired commercial experience and developed a distribution network, we plan to build a robust
internal sales and marketing platform. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expand our research and development capabilities and footprint in the United States to advance our Global Portfolio
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of our global strategy, we plan to expand our research and development capabilities in the United States to include regulatory affairs,
translational medicine, drug formulation and clinical operations. These specific research and development functions in the United States are complementary to and an integral part of our overall research and development capabilities to support
clinical development of our Global Portfolio. Currently, three of our investigational antibody drugs (TJM2, TJC4 and TJD5) are in clinical trials in the United States. We aim to continue advancing the ongoing clinical trials to Phase 2 for clinical
validation and to initiate multiple new clinical programs by the end of 2020 or early 2021 in the United States. In addition, we intend to expand our operational footprint in the United States to create an independent multi-functional business
entity covering global business development, investor relations and corporate communications and other operational capabilities. We are in the process of assembling an integrated management team with global experience and extensive track record
dedicated to overseeing our operations in the United States. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Build our manufacturing capabilities </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe it is advantageous that we own and control our GMP manufacturing process in order to ensure quality and secure production slots for clinical trial materials
and commercial supplies. We plan to commence a joint effort to build a comprehensive biologics manufacturing facility in 2020 in China. At this planned manufacturing facility, we intend to produce drug substance and drug product for clinical use as
well as future commercial use. We envisage this facility to include a pilot GMP manufacturing plant with two <FONT STYLE="white-space:nowrap">500-liter</FONT> and two <FONT STYLE="white-space:nowrap">2,000-liter</FONT> single-use bioreactors, and
upon completion of the construction, a commercial scale manufacturing plant with eight more <FONT STYLE="white-space:nowrap">2,000-liter</FONT> single-use bioreactors with filling and finishing lines. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Maximize the value of our pipeline </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to our successful <FONT
STYLE="white-space:nowrap">in-licensing</FONT> efforts, we have established a good track record of <FONT STYLE="white-space:nowrap">out-licensing</FONT> collaborations and <FONT STYLE="white-space:nowrap">co-development</FONT> partnerships. For the
years ended December&nbsp;31, 2017 and 2018 and the nine months ended September 30, 2019, we recorded revenues of RMB11.6&nbsp;million, RMB53.8&nbsp;million (US$7.5 million) and RMB30.0 million (US$4.2 million) from upfront and milestone payments
through three <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals, respectively. We have reached cost-sharing <FONT STYLE="white-space:nowrap">co-development</FONT> deals for some of our drug candidates with multiple global and regional
partners. These achievements have not only demonstrated our ability to optimize our pipeline but also provided a sustainable revenue stream. Going forward, we plan to enhance our <FONT STYLE="white-space:nowrap">out-licensing</FONT> efforts. We
expect that the revenue generated from <FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities will continue to increase and will account for the majority of our net revenue before the commercialization of our marketed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Drug Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>China Portfolio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>TJ202: A Potential Highly Differentiated CD38 Antibody for Multiple Myeloma and Autoimmune Diseases </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ202 (MOR202) is a fully human, highly
differentiated monoclonal antibody directed against CD38. TJ202, if approved, is positioned as a potential highly differentiated anti-CD38 therapy for multiple myeloma (&#147;MM&#148;), either as a monotherapy or as a combination therapy with other
anti-cancer agents. We aim to demonstrate the advantages of TJ202, including its short infusion time, low infusion reaction rate (&#147;IRR&#148;) and potentially sustained efficacy, in our ongoing clinical trials in China. Additionally, as
pathogenic CD38-positive B cells and plasma cells are strongly implicated in the disease progression of pathogenic antibody-mediated autoimmune diseases, we believe the therapeutic value of TJ202 can be extended to these diseases that have
significant unmet medical needs. We have begun to explore its therapeutic application in systemic lupus erythematosus (&#147;SLE&#148;) and later in other autoimmune diseases. In November 2017, we obtained an exclusive license from MorphoSys to
develop TJ202 in Greater China. The development of TJ202 is driven by a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> strategy. We have started registrational trials for a third-line monotherapy and a
second-line treatment trial in combination with lenalidomide, both in patients with MM in Greater China. We aim to submit an NDA for TJ202 as a third-line monotherapy in 2021, followed by another NDA submission for TJ202 as a second-line combination
therapy. Additionally, we submitted an IND application to the NMPA in October 2019 and expect to initiate a clinical trial for TJ202 in SLE patients in 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Therapeutic Options and Current Development&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Multiple Myeloma (MM) </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The treatment options and
investigational drugs under development in China include: (i)&nbsp;for small molecule drugs, two or three approved drugs known as doublets or triplets are used. VRD triplet (Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone) has
recently been approved for overseas frontline treatment and is recommended in China in the 2017 version of treatment guideline. VCD triplet (Velcade, cyclophosphamide and dexamethasone) is the most widely adopted first-line treatment in China due to
its lower cost. In 2017, lenalidomide and bortezomib were included in the National Reimbursement Drug List in China; (ii)&nbsp;with respect to CD38 antibody therapy, daratumumab (from Johnson&nbsp;&amp; Johnson) received conditional NDA approval
from the NMPA in July 2019, and isatuximab (from Sanofi) is in a Phase 3 trial in China; and (iii)&nbsp;for <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy, several Phase 1 or 2 clinical trials are ongoing in China. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, there is no curative treatment for MM. Although the currently marketed CD38 antibody in China is efficacious, it takes a long time to be administered by IV
infusion (up to six hours) and causes a high infusion reaction rate (&#147;IRR&#148;). In clinical trials, approximately half of all patients experience an infusion reaction, symptoms of which may include fever, chills, nausea, bronchospasm,
hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Thus, there is a need for a safer and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">convenient-to-use</FONT></FONT> drug. Such a drug may be combined with other
therapeutic agents for better treatment effects in MM. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Systemic Lupus Erythematosus (SLE) </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients with mild SLE are often given <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drugs, while more severe patients may need
corticosteroids or immunosuppressants. Approved by the FDA in 2011 and by the NMPA in July 2019, Benlysta (belimumab), a <FONT STYLE="white-space:nowrap">B-lymphocyte</FONT> stimulator (BLyS)-specific inhibitor developed by GSK, is currently the
world&#146;s only biologic approved to treat SLE. However, there remains a significant unmet medical need beyond belimumab for SLE in China and the rest of the world. As dysregulated CD38-positive B cells and auto-antibodies produced by
CD38-positive plasma cells and resulting immune complexes are at the core of the pathogenesis of SLE, direct inhibition and selective depletion of pathogenic B cells and plasma cells are believed to offer better treatment options. Our TJ202 has the
potential to offer such a disease-modifying treatment option. In addition, as described below, the advantages of our TJ202 include convenience of use and a lower IRR, making it a more favorable treatment agent in the long-term clinical management of
SLE if approved. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Advantages of TJ202&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ202, if
approved, is a potentially highly differentiated CD38 monoclonal antibody and could be the second antibody therapy for MM to launch in China. A Phase 2a trial of TJ202 in MM showed a level of treatment effects comparable to that observed in trials
of the currently marketed CD38 antibody. However, available trial data from MorphoSys and Johnson &amp; Johnson indicate that with similar <FONT STYLE="white-space:nowrap">pre-medications</FONT> of dexamethasone, anti-pyretics and anti-histamines,
TJ202 required only a short infusion time of 0.5 to 2 hours, compared to 3.5 to 6.5 hours for the currently marketed CD38 antibody at the first infusion. Moreover, the IRR was as low as 7% for TJ202, compared to 48% for the currently marketed CD38
antibody. The advantages of TJ202 associated with infusion may be attributed to its lack of antibody CDC activity and are likely to translate into clinical benefits in terms of tolerability and convenience of use as well as economic benefits due to
the cost and length of hospital stay. In addition, unlike the currently marketed CD38 antibody, TJ202 treatment does not down-regulate CD38 expression on the surface of bone marrow myeloma cells in vitro, maintaining sensitivity of malignant myeloma
cells to repeated TJ202 treatments. As TJ202 is being considered for long-term treatment management of autoimmune diseases, we believe such clinical differentiation is critical. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For autoimmune diseases, TJ202 has advantages over other B cell-targeting therapies such as CD20 antibodies, as it specifically targets malfunctioned CD38<SUP
STYLE="font-size:85%; vertical-align:top">high</SUP> B cells and pathogenic plasma cells involved in autoimmune diseases while CD20 antibodies target most B cells, including those involved in normal immune functions and regulatory functions, but not
plasma cells producing pathogenic antibodies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Mechanism of Action&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ202 binds to CD38 overexpressed on the surface of target cells and kills them by inducing antibody-dependent cellular cytotoxicity (&#147;ADCC&#148;) and
antibody-dependent cellular phagocytosis (&#147;ADCP&#148;). The target cells are the malignant plasma cells in MM and a group of dysregulated CD38<SUP STYLE="font-size:85%; vertical-align:top">high</SUP> B cells and plasma cells that produce
pathogenic antibodies in autoimmune conditions such as SLE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g63r89.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>TJ202 kills CD38-bearing tumor cells by inducing ADCC and ADCP.</I></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary of Clinical Results&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MorphoSys has conducted a Phase 1/2a study in adult patients with relapsed or refractory MM in Austria and Germany. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Study Design</I>. The open-label, multicenter, dose-escalation study was designed to characterize the safety profile and preliminary efficacy of TJ202 in adults with
relapsed or refractory MM. A 3+3 dose escalation design was used to establish the maximum tolerated dose (&#147;MTD&#148;), recommended dose and dosing regimen of TJ202 as monotherapy, weekly or <FONT STYLE="white-space:nowrap">bi-weekly,</FONT>
with or without dexamethasone (&#147;DEX&#148;), and in combination with pomalidomide (&#147;POM&#148;) and DEX or lenalidomide (&#147;LEN&#148;) and DEX standard regimens. The MTD and recommended dose and dosing regimens were to be confirmed in
three confirmation cohorts of at least six evaluable subjects each. TJ202 dose levels in this study ranged from 0.01 mg/kg to 16.0 mg/kg, administered by intravenous (&#147;IV&#148;) infusion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical study results as of the data cutoff date, December&nbsp;31, 2017, are summarized as follows. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety</I>. TJ202 was well tolerated in patients with RRMM, as a single agent and in combination with DEX, or with POM/DEX, or with LEN/DEX. The MTD of TJ202 was not
reached. In the 56 patients from three groups receiving combination regimens, grade <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>3 adverse events (&#147;AEs&#148;) were mainly in the hematological
system reflected by a decrease of various blood cells. This was as expected, because of decreased bone marrow function due to the presence of myeloma as well as the expression of CD38 on various cell lineages of the myeloid and lymphoid
compartments. Most of the hematological adverse events were transient and generally manageable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ202 was administered as a
<FONT STYLE="white-space:nowrap">two-hour</FONT> IV infusion at first dose and infusion time could be reduced to as short as 30 minutes at subsequent doses without obvious safety concerns. Among all cohorts, infusion-related reactions, including
tachycardia, pyrexia and hypersensitivity, occurred in 18 of 91 patients (19.8%) and were mostly mild to moderate. In the combination cohorts containing DEX, a very low IRR (4 out of 56 patients (7%)) was observed. These results compared favorably
with the historical data of the currently marketed CD38 antibody. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Clinical Efficacy</I>. Preliminary efficacy results were based on 56 patients from three
groups treated with TJ202 combination therapies. No responses were observed for the monotherapy groups which were primarily serving for dose escalation. TJ202 in combination with low dose DEX, POM/DEX or LEN/DEX demonstrated an overall response rate
(&#147;ORR&#148;) of 28%, 48% and 65%, respectively. Durable responses were observed as median progression-free survival (&#147;PFS&#148;) was of 8.4 months and 17.5 months for the DEX and the POM/DEX combination groups, respectively, and PFS levels
were not reached for the LEN/DEX combination group, as there were not sufficient events of progression recorded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g95p44.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Best overall response and ORR. Patients were treated with TJ202 (MOR202) in combination with low dose of DEX (40 mg for 75 years old and younger, or 20 mg for older than 75 years old), POM (4 mg) /Dex or LEN (25 mg)/Dex. Dex:
dexamethasone; POM: pomalidomide; LEN: lenalidomide; ITT: intent to treat; NE: not evaluable; PD: progressive disease; SD: stable disease; MR: minimal response; PR: partial response; VGPR: very good partial response; CR: complete response; sCR:
stringent complete response; ORR: overall response rate. (Source: MorphoSys)</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The definitions of PD, SD, MR, PR, VGPR, CR and sCR and how these responses were measured for multiple myeloma are set forth in the
table below. <I>(Source: International Myeloma Working Group Uniform Response Criteria (2006) and European Group for Blood and Marrow Transplantation Criteria)</I> </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>RESPONSE SUBCATEGORY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CRITERIA<SUP STYLE="font-size:85%; vertical-align:top">
A</SUP></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">sCR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;CR as
defined below plus<BR>Normal free light chain ratio (FLC) and<BR>Absence of clonal cells in bone marrow<SUP STYLE="font-size:85%; vertical-align:top">b</SUP> by immunohistochemistry or
immunofluorescence<SUP STYLE="font-size:85%; vertical-align:top">c</SUP></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">CR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Negative
immunofixation on the serum and urine and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Disappearance of any soft tissue
plasmacytomas and</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;&lt;5% plasma
cells in bone marrow<SUP STYLE="font-size:85%; vertical-align:top">b</SUP></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">VGPR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Serum and
urine M-protein detectable by immunofixation but not electrophoresis or</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>90% reduction in serum M-protein plus urine M-protein level &lt;100
mg/24&nbsp;hours</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">PR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>50% reduction of serum M-protein and reduction in 24-hour urinary <FONT STYLE="white-space:nowrap">M-protein</FONT> by
<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>90% or to &lt;200&nbsp;mg/24&nbsp;hours</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;If the serum and urine M-protein
were unmeasurable, a&nbsp;<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>50% decrease in the difference between levels of involved and uninvolved free-light-chains instead of the M-protein
criteria</P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>RESPONSE SUBCATEGORY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CRITERIA<SUP STYLE="font-size:85%; vertical-align:top">
A</SUP></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;In addition
to the above-listed criteria, if present at baseline, a <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>50% reduction in the size of soft tissue plasmacytomas was also required</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">MR<SUP STYLE="font-size:85%; vertical-align:top"> d,e</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;25&#150;49%
reduction in level of serum M-protein</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;50&#150;89% reduction in 24-hour
urinary M-protein, which still exceeds 200 mg/24 hours. If present at baseline, 25&#150;49% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;No increase in the size or number
of lytic bone lesions (development of a compression fracture did not exclude response)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SD<SUP STYLE="font-size:85%; vertical-align:top"> f</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Not meeting
criteria for CR, VGPR, PR, MR, or PD</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">PD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">NOTE: Required any 1 or more of the following:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Increase of <FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>25% from nadir in</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Serum M-component and/or (absolute increase <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>0.5&nbsp;g/dL)<SUP
STYLE="font-size:85%; vertical-align:top">g</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Urine M-component and/or (absolute
increase <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>200&nbsp;mg/24&nbsp;hours)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Only in subjects without measurable
serum and urine M-protein levels: the difference between involved and uninvolved FLC levels. Absolute increase &gt;10&nbsp;mg/dL.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Bone marrow plasma cell percentage:
absolute % <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>&nbsp;10%<SUP STYLE="font-size:85%; vertical-align:top">h</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Definite development of new bone
lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Development of hypercalcemia
(corrected serum calcium &gt;11.5 mg/dL or 2.65&nbsp;mmol/L) that could be attributed solely to the plasma cell proliferative disorder</P></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:8pt; font-family:ARIAL">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">a</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All response categories required 2&nbsp;consecutive assessments made at any time before the institution of any new therapy; all categories also required no known evidence of progressive or new bone lesions if
radiographic studies were performed. Radiographic studies were not required to satisfy these response requirements. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">b</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Confirmation with repeat bone marrow biopsy not needed. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">c</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Presence/absence of clonal cells was based upon the <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT></FONT>/<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#108;</FONT></FONT> ratio. An abnormal
<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT></FONT>/<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#108;</FONT></FONT> ratio by immunohistochemistry and/or immunofluorescence
required a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT></FONT>/<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#108;</FONT></FONT> of &gt;4:1 or &lt;1:2. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">d</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MR also included subjects in whom some, but not all, the criteria for PR were fulfilled, provided the remaining criteria satisfied the requirements for MR. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">e</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The response criterion MR did not apply to subjects who presented with serum FLCs only. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">f</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Per the International Myeloma Working Group Uniform Response Criteria, stable disease was not recommended for use as an indicator of response; stability of disease is best described by providing the time to progression
estimates. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">g</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For progressive disease, serum M-component increases of <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>1&nbsp;g/dL were sufficient to define relapse if starting
M-component was <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>5&nbsp;g/dL. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">h</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Relapse from CR has the 5% cut-off versus 10% for other categories of relapse. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacodynamics</I>. As a
pharmacodynamic marker, serum myeloma (M)&nbsp;protein levels were used to evaluate severity and clinical response. The median relative change in M protein levels from baseline to post-baseline nadir for TJ202 in combination with low doses of DEX,
POM/DEX or LEN/DEX was <FONT STYLE="white-space:nowrap">-13%,</FONT> <FONT STYLE="white-space:nowrap">-58%</FONT> and <FONT STYLE="white-space:nowrap">-81%,</FONT> respectively. The data below show strong effects of TJ202 in reducing M protein
levels. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g36d33.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>The relative change in M protein levels from baseline to post-baseline nadir. Patients were treated with TJ202 (MOR202) in combination with low doses of DEX, POM/DEX or LEN/DEX. S: serum sample; U:&nbsp;urine sample. (Source:
MorphoSys)</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacokinetics (&#147;PK&#148;)</I>. The PK of TJ202 in humans was well characterized by a
<FONT STYLE="white-space:nowrap">two-compartment</FONT> model at dose levels greater than 4 mg/kg. At these doses, stable or even increasing trough levels could be observed over time suggesting the potential for full target occupancy, especially at
the highest dose level (16&nbsp;mg/kg). For most subjects, steady state at 16 mg/kg was observed after the fourth infusion. Terminal half-life at high-dose levels
(<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT> 4 mg/kg) was at approximately two weeks. Pharmacokinetics of TJ202 were generally consistent across different individuals and dosing days and not
affected by the <FONT STYLE="white-space:nowrap">co-medications.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Immunogenicity</I>. No anti-drug antibody (&#147;ADA&#148;) against TJ202 was observed
as of the <FONT STYLE="white-space:nowrap">cut-off</FONT> date. Thus, risk of ADA induction for TJ202 in humans is considered low. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Clinical
Development Plan&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately after <FONT STYLE="white-space:nowrap">in-licensing</FONT> TJ202, we formulated a robust clinical development strategy with
an aim for an NDA submission by 2021. With an approved IND, we have started a <FONT STYLE="white-space:nowrap">single-arm</FONT> registrational trial with TJ202 and DEX as a third-line therapy for MM patients in Greater China using ORR as the
primary endpoint (NCT03860038). Dosing of the first patient took place in March 2019. Data from this <FONT STYLE="white-space:nowrap">82-patient</FONT> study are expected to be the major package supporting registrational filing for conditional
approval in 2021. In parallel, we started a registrational trial combining TJ202 with LEN and DEX as a second-line combination therapy in MM patients (NCT03952091). We plan to enroll 291 patients for full approval. Dosing of the first patient took
place in Taiwan in April 2019. We have recruited a total of 19 patients for both registrational trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical development plan for SLE starts with a Phase
1b clinical trial to explore dose range, clinical safety and tolerability as well as TJ202&#146;s profiles of PK and pharmacodynamics (&#147;PD&#148;) in SLE patients. Additionally, we submitted an IND application to the NMPA in October 2019. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>TJ107 (Efineptakin): The First Long-acting Recombinant Human IL-7 with the Potential for Cancer Treatment-related Lymphopenia and Cancer Immunotherapy </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ107 (International Nonproprietary Name
(&#147;INN&#148;): efineptakin) is the world&#146;s first and only long-acting recombinant human <FONT STYLE="white-space:nowrap">interleukin-7</FONT> <FONT STYLE="white-space:nowrap">(&#147;rhIL-7&#148;),</FONT> which is being developed as a T
lymphocyte-booster for cancer-related immunotherapy. Due to its advantages in terms of selective immune functions, improved stability, developability, and extended half-life, TJ107 is differentiated from an earlier generation of short-acting <FONT
STYLE="white-space:nowrap">rhIL-7</FONT> and T cell growth factor <FONT STYLE="white-space:nowrap">(interleukin-2).</FONT> In December 2017, we acquired exclusive rights from Genexine to develop and commercialize TJ107 in Greater China. We plan to
position TJ107 first as a monotherapy or an oncology care product for cancer patients with cancer treatment-related lymphopenia (low blood lymphocyte levels) induced by chemotherapy or radiation therapy. This target indication covers a large
population of cancer patients who develop cancer treatment-related lymphopenia, a condition that weakens the ability to receive continued chemotherapy or radiation therapy and leads to worsened disease prognosis and clinical outcome. Currently,
there is no treatment available for this condition. Second, TJ107 is expected to show a therapeutic effect as a combination therapy with immune checkpoint inhibitors, i.e.,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies, due to its inherent selective T cell-boosting properties. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies have indicated that TJ107
exerted additional anti-tumor effect when combined with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. If proven efficacious in clinical studies, we believe such a combination therapy, can
potentially treat a large </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
population of cancer patients who do not respond or respond poorly to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. We are conducting a
Phase 1b study in China to determine a suitable dose range for subsequent trials. We expect to start a Phase 2 trial in cancer patients in 2020. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Therapeutic Options and Current Development&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">One of
the target therapeutic indications of TJ107 is cancer treatment-related lymphopenia. Cancer patients who undergo chemotherapy and/or radiation therapy often develop cancer treatment-related lymphopenia, which further damages their already
compromised immune systems and their ability to fight against cancers. According to the Frost&nbsp;&amp; Sullivan Report, more than 85% of all cancer patients receive chemotherapy or radiation therapy, and 43% of these patients develop lymphopenia,
which represents a significant unmet medical need, as currently no drug is available for the treatment of lymphopenia. Advanced solid tumor is another indication of TJ107 as a combination therapy with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatments. As more than 60% cancer patients either do not respond or respond poorly to current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies,
there are intense attempts to identify an effective agent that can work synergistically with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies to increase the probability of treatment success. TJ107
is believed to provide such a treatment option, which is supported by <FONT STYLE="white-space:nowrap">pre-clinical</FONT> reports that <FONT STYLE="white-space:nowrap">IL-7</FONT> exhibits a synergistic effect with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> antibodies in the treatment of cancers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Advantages of TJ107&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ107 has an advantage over other T lymphocyte cytokines with therapeutic potential in oncology. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> and clinical
results generated so far indicate that TJ107 has a favorable immune function profile over recombinant human <FONT STYLE="white-space:nowrap">interleukin-2</FONT> <FONT STYLE="white-space:nowrap">(&#147;rhIL-2&#148;)</FONT> in that TJ107 activates
and expands tumor-fighting CD4, CD8 and natural killer T cells but spares tumor-protecting Treg cells. By contrast, <FONT STYLE="white-space:nowrap">rhIL-2</FONT> is a well-known inducer of Tregs, which suppresses tumor-fighting effector T cells.
Furthermore, <FONT STYLE="white-space:nowrap">rhIL-2</FONT> has a narrow therapeutic window and causes serious side effects such as capillary leak syndrome, breathing problems, serious infections, and seizures. A polyethylene glycol (PEG)-conjugated
<FONT STYLE="white-space:nowrap">IL-2</FONT> variant recently developed by Nektar Therapeutics has yielded mixed results, indicating the complexity associated with using <FONT STYLE="white-space:nowrap">IL-2</FONT> as a cancer treatment. Owing to
its preferred immune function and molecular profiles demonstrated in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and Phase 1/2 clinical trials, we believe that TJ107 is a superior T cell cytokine investigational drug for cancer
treatment-related lymphopenia and cancer immunotherapy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ107, as an engineered <FONT STYLE="white-space:nowrap">rhIL-7,</FONT> has the advantages of improved
stability and half-life extension through Genexine&#146;s proprietary hybrid fragment crystallizable region (&#147;hyFc&#148;). Introducing a few hydrophilic amino acid residues to the <FONT STYLE="white-space:nowrap">N-terminus</FONT> of <FONT
STYLE="white-space:nowrap">IL-7</FONT> overcomes stability issues that hampered the development of previous <FONT STYLE="white-space:nowrap">rhIL-7</FONT> drug candidates. Furthermore, application of the hyFc technology enhances <FONT
STYLE="white-space:nowrap">IL-7&#146;s</FONT> function, increases its half-life (from 48 to 112 hours after a single subcutaneous (&#147;SC&#148;) dose in clinical studies), and allows for a robust purification process. By contrast, the half-life of
first-generation <FONT STYLE="white-space:nowrap">rhIL-7</FONT> was reported to be about 12 hours after SC dosing in human subjects. The hyFc in TJ107 is also <FONT STYLE="white-space:nowrap">non-cytolytic,</FONT> so it will not damage the T cells
to which it binds. Unlike TJ107, the previous <FONT STYLE="white-space:nowrap">rhIL-7</FONT> drug candidates adopt <FONT STYLE="white-space:nowrap">non-glycosylated</FONT> (CYT <FONT STYLE="white-space:nowrap">99-007)</FONT> or glycosylated <FONT
STYLE="white-space:nowrap">(CYT-107)</FONT> forms of short-acting <FONT STYLE="white-space:nowrap">rhIL-7</FONT> and were developed by Revimmune Inc (formerly known as Cytheris SA). These molecules had low stability, low production yield, and a
short half-life because <FONT STYLE="white-space:nowrap">IL-7</FONT> protein is intrinsically unstable and prone to aggregation. However, the preliminary clinical results from Phase 1 and Phase 2 trials in patients with AIDS did show an increase of
T lymphocytes following treatment with CYT-107 (Thiebaut R et al., PLoS Comput Biol., 2014). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Mechanism of Action&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">IL-7</FONT> is a cytokine essential for the survival and homeostatic proliferation of naive and memory T cells (see figure below). <FONT
STYLE="white-space:nowrap">IL-7</FONT> is critically involved in restoring T cells to normal levels in the event of lymphopenia by stimulating T cell proliferation. <FONT STYLE="white-space:nowrap">IL-7</FONT> exerts its functions by binding to and
activating the <FONT STYLE="white-space:nowrap">IL-7</FONT> receptor, which is expressed primarily on lymphocytes, including the lymphoid precursors, developing T and B cells, naive T cells, and memory T cells, but not on tumor-protecting Tregs.
TJ107 as a monotherapy may enhance anti-tumor immunity by augmenting the number and functionality of T&nbsp;cells, whereas TJ107 in combination with an immune checkpoint inhibitor, cancer vaccine or <FONT STYLE="white-space:nowrap">CAR-T</FONT> may
improve the anti-tumor response by restoring T cell numbers, reconstituting T cell pools and reinvigorating exhausted T cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g59k87.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Role of <FONT STYLE="white-space:nowrap">IL-7</FONT> in T cell maintenance and proliferation.</I></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary of Clinical Results&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 trial has been conducted by Genexine in South Korea. This was a
randomized, double-blind, placebo-controlled, single ascending dose study, to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of 20 or 60 &micro;g/kg TJ107 via SC or intramuscular (&#147;IM&#148;) administration in
healthy volunteers. Each dose group consisted of 10 subjects, eight of whom were administered TJ107 and two were given placebo via the same route of administration. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety</I>. TJ107 was well-tolerated in all 30 subjects without serious adverse events. The most common adverse events were transient Grade 1 or 2 injection site
skin reactions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacodynamics (&#147;PD&#148;)</I>. Because <FONT STYLE="white-space:nowrap">IL-7</FONT> promotes the survival and proliferation of T cells,
absolute lymphocyte count (&#147;ALC&#148;) in the peripheral blood was used as a reliable and convenient PD marker for TJ107 (see figure below). ALC initially decreased transiently in all TJ107 groups. This effect is often termed margination, which
is a physiological phenomenon common to many cytokines as a result of increased adherence of cytokine-stimulated white blood cells to the blood vessels and subsequent trafficking to tissues and lymphoid organs. ALC recovered in approximately seven
days, reaching a maximum value at close to 21 days, before gradually declining. This result indicated that a single dose of TJ107 had a long-lasting effect of increasing lymphocyte levels. Overall, a greater increase in ALC was observed in Cohort 2
compared with Cohort 1, demonstrating a dose-dependent response. Additionally, a higher increase in ALC was observed in Cohort 3 compared with Cohort 2, which was consistent with the results of an animal study, where IM injection induced a more
effective increase in lymphocytes than SC injection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g27s64.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Median fold changes of ALC following a single dose of TJ107 in humans. Cohort 1: 20 &micro;g/kg, SC; Cohort 2: 60 &micro;g/kg, SC; and Cohort 3: 60 &micro;g/kg, IM. (Source: Genexine)</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ107 treatment resulted in a substantial increase in the number of CD4 and CD8 T cells, natural killer T&nbsp;cells, naive T cells,
central memory, effector memory, and terminally differentiated effector memory T cells, without affecting the number of B cells, natural killer cells, monocytes or Tregs. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g95b62.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g99a02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Median fold changes of T cells and subsets following a single dose of TJ107 in human subjects. Cohort 1: 20 &micro;g/kg, SC; Cohort 2: 60 &micro;g/kg, SC; Cohort 3: 60 &micro;g/kg, IM. (A)&nbsp;CD3+T cells, (B)&nbsp;CD4+T
cells, (C)CD8 + T cells, (D)&nbsp;Natural Killer T cells, and (E)&nbsp;regulatory T cells (Treg). (Source: Genexine)</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacokinetics</I>. TJ107 was slowly absorbed, particularly after SC administration, and was slowly removed, resulting in a
half-life of 48 to 112 hours, longer than that reported for the first generation <FONT STYLE="white-space:nowrap">rhIL-7</FONT> (about 12 hours). Intramuscular TJ107 showed approximately <FONT STYLE="white-space:nowrap">two-fold</FONT> greater
exposure than SC administration at the same dose level of 60 &micro;g/kg. The higher plasma exposure of TJ107 after IM administration was well-correlated with a more robust PD effect on ALC in Cohort 3. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Immunogenicity</I>. ADAs were detected in 22 of 24 subjects treated with TJ107. One subject in Cohort 3 was positive for ADAs before treatment. Neutralizing
antibodies were observed in 42% and 46% of the subjects within one to two months following administration, respectively, but only one person still harbored neutralizing ADAs five months after administration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical relevance of ADA was evaluated during long-term <FONT STYLE="white-space:nowrap">follow-up</FONT>
monitoring. ALC levels were maintained above the baseline values, endogenous <FONT STYLE="white-space:nowrap">IL-7</FONT> was maintained at normal levels, and no specific adverse events associated with ADAs were observed. These results are
consistent with well-documented reports that a normal individual can harbor <FONT STYLE="white-space:nowrap">pre-existing</FONT> auto-antibodies for cytokines such as <FONT STYLE="white-space:nowrap">IL-2,</FONT>
<FONT STYLE="white-space:nowrap">IL-3,</FONT> <FONT STYLE="white-space:nowrap">IL-4,</FONT> and <FONT STYLE="white-space:nowrap">IL-7,</FONT> and that these anti-cytokine antibodies tend to serve as a reservoir and carrier of the cytokines in the
blood, extending the half-life of these cytokines and preserving their functions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Clinical Development Plan&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By leveraging the results of Genexine&#146;s ongoing clinical trials in South Korea and the United States, we aim to rapidly advance the clinical development of TJ107
for approval in Greater China. Currently, a Phase 1b trial in China is ongoing to investigate the safety, tolerability and PK/PD response of TJ107 in patients with advanced solid cancers. The clinical trial (NCT04001075) is designed to include:
(i)&nbsp;dose escalation of TJ107 using a conventional &#147;3 + 3&#148; study design to identify a safe and active dose range and (ii)&nbsp;dose expansion to confirm the safety and obtain preliminary evidence of efficacy. We have finished dose
escalation for the first two patient cohorts, and the safety and tolerability profile as well as the PK/PD response are consistent with other ongoing studies of TJ107. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After determining the recommended Phase 2 dose (&#147;RP2D&#148;) in the Phase 1b trial, we expect to start a Phase&nbsp;2 trial in cancer patients in 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Genexine has initiated a dose-finding trial in combination with checkpoint inhibitors in patients with solid tumors. Meanwhile, Genexine is also sponsoring additional
early-stage clinical trials in advanced solid tumors, including glioblastoma and high-risk skin cancer, in the United States and South Korea. The safety, pharmacology and preliminary efficacy data from these ongoing studies are expected to
significantly facilitate our clinical development of TJ107 in Greater China. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>TJ101: A Potential Highly Differentiated Long-Acting Growth Hormone for Growth
Hormone Deficiency </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ101, if
approved, is a potential highly differentiated long-acting recombinant human growth hormone (&#147;rhGH&#148;) (INN: eftansomatropin) being developed as a more convenient and effective therapy for growth hormone deficiency (&#147;GHD&#148;), for
which there is substantial unmet medical need in China. TJ101 met the pre-set safety endpoints in three multi-regional clinical trials conducted in Europe and Asia and preliminary efficacy endpoints in
<FONT STYLE="white-space:nowrap">pre-pubertal</FONT> growth hormone naive pediatric growth hormone deficient (&#147;PGHD&#148;) patients. In contrast to marketed short-acting rhGH such as Genotropin, TJ101 showed similar efficacy results in a weekly
(vs. daily) regimen. Furthermore, TJ101 has not shown the safety concerns typically associated with approved pegylated drugs. We <FONT STYLE="white-space:nowrap">in-licensed</FONT> the China rights to TJ101 from Genexine and are positioning TJ101 as
a highly differentiated growth hormone replacement therapy because of its advantages over a daily regimen in terms of injection frequency (weekly vs. daily) and safety profile (natural protein-based vs. pegylated long-acting rhGH), especially in
pediatric patients. We are preparing for a registrational Phase 3 trial in China to validate the efficacy, safety, pharmacodynamics, and pharmacokinetics of TJ101 in PGHD, with a plan for IND submission in 2020. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Therapeutic Options and Current Development&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
current therapeutic indication is PGHD. The widely adopted treatment for PGHD is patient-specific growth hormone replacement therapy, which is given in a calculated weight-based dosing regimen. Currently, short-acting recombinant human growth
hormone (&#147;rhGH&#148;) is commonly used for the long-term treatment of children and adults with inadequate endogenous growth hormone secretion. There are certain safety concerns related to long-term use of pegylated drugs, such as potential
renal toxicity, cellular vacuolation and formation of anti-polyethylene glycol antibodies. Approved by the NMPA in 2014, Jintrolong (developed by GeneScience) is currently the only marketed long-acting pegylated rhGH in China, according to the Frost
&amp; Sullivan Report. Other companies in China currently developing long-acting rhGH include Anhui Anke Biotechnology, Xiamen Amoytop Biotech, Generon Pharmaceutical Technology and Visen Pharmaceuticals. Our TJ101 is the only <FONT
STYLE="white-space:nowrap">Fc-based</FONT> long-acting rhGH ready for a Phase 3 clinical trial in China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the Frost&nbsp;&amp; Sullivan Report, only
3.7% of all PGHD patients in China were receiving growth hormone replacement therapy in 2018, which primarily consists of daily injections of rhGH before sleep. This dosing regimen puts a substantial burden on pediatric patients and their families
because it requires drug preparation and needle injection every day, which is painful and extremely inconvenient, often resulting in poor patient compliance. More importantly, studies have shown that skipping just one or two doses in a week can
markedly reduce the efficacy of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the treatment. Therefore, there is a substantial unmet medical need for long-acting growth hormone therapies that are similarly efficacious but with reduced injection frequency, and the market
potential for such a long-acting rhGH in China is largely untapped. In addition, recombinant human growth hormone therapy has been included in the National Reimbursement Drug List (NRDL) in China. Inclusion of a drug in the NRDL typically results in
a much higher sales volume and significant sales growth despite a reduction in price. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Advantages of TJ101&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that TJ101 has the following advantages: (i)&nbsp;when compared to the daily regimen of rhGH, TJ101 is expected to be a more convenient therapy with better
patient compliance due to a reduced dosing frequency to either weekly or twice-monthly administration, while maintaining similar efficacy; and (ii)&nbsp;TJ101 has not shown safety concerns typically associated with pegylated drugs, such as potential
renal toxicity, <FONT STYLE="white-space:nowrap">pre-existing</FONT> or treatment-induced <FONT STYLE="white-space:nowrap">anti-PEG</FONT> antibodies, and cellular vacuolation in macrophages, renal tubule cells and the choroid plexus epithelial
cells. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Mechanism of Action&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Like endogenous
growth hormone, TJ101 stimulates the production of insulin-like growth factor 1 <FONT STYLE="white-space:nowrap">(&#147;IGF-1&#148;)</FONT> in the liver, which has growth-stimulating effects on a variety of tissues, including osteoblast and
chondrocyte activities that stimulate bone growth. Thus, <FONT STYLE="white-space:nowrap">IGF-1</FONT> is a reliable pharmacodynamic marker and more importantly, the key mediator of TJ101&#146;s growth-promoting activity. TJ101 is based on
Genexine&#146;s patented hyFc technology. The hyFc part consists of a portion of human immunoglobulin D (&#147;IgD&#148;) and G<SUB STYLE="font-size:85%; vertical-align:bottom">4</SUB>
(&#147;IgG<SUB STYLE="font-size:85%; vertical-align:bottom">4</SUB>&#148;). The former contains a flexible hinge, and the latter is responsible for half-life extension through neonatal Fc receptor (&#147;FcRn&#148;)-mediated recycling. Additionally,
TJ101&#146;s increased molecular weight (103 kilodalton) is expected to reduce renal clearance. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g31j43.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Schematic presentation of the structure of TJ101. CH2 &amp; CH3: Constant regions 2 &amp; 3 of antibody heavy chains, respectively; hGH: human growth hormone. (Source: Genexine)</I></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary of Clinical Results&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Genexine has completed three clinical trials with TJ101, including one Phase 1 trial in healthy adult volunteers, one Phase 1b/2 multi-regional trial in adults with
GHD, and one Phase 2 multi-regional trial in PGHD in Europe, altogether involving 32 healthy subjects and 99 patients with GHD and PGHD. Overall, TJ101 was shown to be well-tolerated, and clinical efficacy endpoint achieved by weekly or
twice-monthly TJ101 administration was comparable to that of daily administration of Genotropin. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Phase 1 Clinical Trial&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial of TJ101 was a randomized, double-blind, placebo-controlled
single dose-ascending study in four groups of healthy subjects. A total of 32 subjects were enrolled, and 31 completed the study. TJ101 was shown to be well-tolerated at all dose levels studied (0.2&#150;1.6 mg/kg). TJ101 was detectable in the blood
until Day 7 for the 0.2 mg/kg dose group, Day 14 for the 0.4 and 0.8 mg/kg dose groups, and Day 21 for the 1.6 mg/kg dose group. A single subcutaneous (&#147;SC&#148;) injection of TJ101 at dose levels of 0.4 mg/kg and higher increased <FONT
STYLE="white-space:nowrap">IGF-1</FONT> and <FONT STYLE="white-space:nowrap">IGF-binding</FONT> <FONT STYLE="white-space:nowrap">protein-3</FONT> <FONT STYLE="white-space:nowrap">(&#147;IGFBP-3&#148;)</FONT> levels for at least one week. No safety
concerns were identified. TJ101 showed a half-life ranging from 69.2 to 138 hours. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Phase 2 Clinical Trial in PGHD&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Study Design. </I>The Phase 2 trial in PGHD was a randomized, open-label, active-controlled study to assess the safety, tolerability, efficacy, pharmacokinetics, and
pharmacodynamics of weekly and twice-monthly doses of TJ101, as compared to a daily injection of Genotropin, which is currently the standard of care for PGHD. Subjects were randomly assigned to receive one of three doses of TJ101 (0.8 mg/kg/weekly,
1.2 mg/kg/weekly or 2.4 mg/kg/twice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
monthly) or 0.03 mg/kg/daily of Genotropin for up to 24 months. The primary clinical endpoint was annualized height velocity (aHV) in centimeters (cm)&nbsp;per year (equivalent to annual growth
rate), measured at six months. A total of 56 subjects were randomized at 27 centers in nine European countries and South Korea. Fifty two subjects completed the six-month treatment (through Visit 7), meeting the primary endpoint. Two subjects
withdrew from the study before first drug administration, and two subjects discontinued due to treatment-related adverse events (&#147;AEs&#148;). Genexine and its <FONT STYLE="white-space:nowrap">co-developer</FONT> Handok presented the latest
interim results of the Phase 2 clinical trial for PGHD in March 2018 at the Endocrine Society&#146;s annual meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety. </I>No study drug-related serious
adverse events (&#147;SAEs&#148;) or death were observed. The tolerability of TJ101 was consistent with known properties of marketed products. The AE incidence rate was generally similar across the TJ101 cohorts treated with three different dose
levels (ranging between 69.2% and 84.6%) and the Genotropin cohort (57.1%). A total of two (14.3%), three (23.1%), two (15.4%), and zero subjects experienced treatment-related AEs in the 0.8 mg/kg/week, 1.2 mg/kg/week, and 2.4&nbsp;mg/kg/twice
monthly TJ101 groups, and the 0.03 mg/kg/daily Genotropin group, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Two subjects withdrew from the study due to treatment-related AEs. One subject from
Cohort 2 (1.2 mg/kg/week of TJ101) discontinued due to retinal vascular disorder. The Data and Safety Monitoring Board (&#147;DSMB&#148;) reviewed this case independently, concluding that the retinal finding was more likely to be of completely
different etiology than treatment-induced intracranial hypertension. One subject from Cohort 3 (2.4 mg/kg/twice monthly of TJ101) discontinued due to pseudopapilloedema (optic disc drusen), which was assessed by the principal investigator to be mild
with continuous frequency and possibly related to the study drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Injection site reactions (&#147;ISRs&#148;) were reported by 13 out of 40 subjects (32.5%) in the
TJ101 cohorts. Pain was the most prominent and common symptom observed in 10 subjects. Also, six subjects reported redness, four reported itching, and one reported bruising, swelling and warmness. With respect to the Genotropin cohort, pain was the
only ISR reported in 683 cases by 11 out of 14 subjects (78.5%). None of the ISRs led to discontinuation of treatment, and most of the reported ISRs posed no issue for the subjects and were resolved quickly. No safety signal was detected in
laboratory parameters or vital signs for either TJ101 or Genotropin. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacokinetics.</I> Half-life of TJ101 was 77.75&#150;141.95 hours after a single dose
and 43.92&#150;55.66 hours (compared to 5.27 hours for Genotropin) after three months of multiple-dose administration. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Immunogenicity. </I>Formation of
treatment-emergent ADA with neutralizing property was reported in two subjects (one from Cohort 2 and one from Cohort 3) out of a total of 40 subjects randomized and dosed with TJ101. With respect to the Genotropin cohort, the presence of
treatment-emergent ADA with neutralizing property was not observed in any subject. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Clinical Efficacy. </I>Subcutaneous administration of TJ101 over the dose
range of 0.8 mg/kg/week&#150;2.4 mg/kg/twice monthly resulted in an increase in aHV over the <FONT STYLE="white-space:nowrap">six-month</FONT> study period.<I> </I>Subjects who<I> </I>received TJ101 at 0.8 mg/kg weekly, 1.2 mg/kg weekly, and 2.4
mg/kg twice monthly showed growth rates of 11.50, 11.54, and 11.86 cm/year, respectively, while the growth rate in the control group treated with Genotropin was approximately 11.24 cm/year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g29v69.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>The aHV at six months indicated comparable growth rates between all doses of TJ101 (both weekly and twice-monthly treatment) and the active comparator, Genotropin. (Source: Genexine)</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacodynamics.</I> The growth-promoting effect of TJ101 was accompanied by elevated serum
<FONT STYLE="white-space:nowrap">IGF-1</FONT> levels. This hormone is an important biomarker, which mediates growth hormone&#146;s biological effects. The Standard Deviation Score (&#147;SDS&#148;), which is a calculated score with reference to the
normal <FONT STYLE="white-space:nowrap">age-</FONT> and <FONT STYLE="white-space:nowrap">sex-matched</FONT> <FONT STYLE="white-space:nowrap">IGF-1</FONT> levels, is a standardized parameter to compare <FONT STYLE="white-space:nowrap">IGF-1</FONT>
levels across laboratories and populations. Mean <FONT STYLE="white-space:nowrap">IGF-1</FONT> SDS at the beginning of the study was below the lower limit of the normal range in all treatment arms. Following initiation of treatment, the <FONT
STYLE="white-space:nowrap">IGF-1</FONT> SDS values quickly normalized by five days (Visit&nbsp;2) and three weeks (Visit 3) after the initial treatment, respectively, for the TJ101 treatment arms and the Genotropin treatment arm. <FONT
STYLE="white-space:nowrap">IGF-1</FONT> responses were maintained throughout the intended dosing interval, supporting both the weekly and twice monthly treatment regimens. <FONT STYLE="white-space:nowrap">IGF-1</FONT> mean peak levels were mostly
within the upper limit of the physiologic range, which is considered safe in clinical practice. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Clinical Development Plan&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on Genexine&#146;s Phase 2 study in PGHD, we are preparing to conduct a registrational Phase 3, randomized, active-controlled, and multi-center study in China to
assess the efficacy, safety, and pharmacokinetics of TJ101 in PGHD. The primary objective is to demonstrate <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of 1.2 mg/kg/week of TJ101 administered SC, based on aHV after 26 weeks of treatment,
compared to the active control Jintropin, a daily rhGH marketed in China. We have finalized the study design with key opinion leaders, and our development plan and study design have been discussed with the NMPA through a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting. We are working towards submitting an IND application in 2020. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>TJ301: A Potential Highly Differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> Blocker for Ulcerative Colitis and other Autoimmune Diseases </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ301 (INN: olamkicept) is the only clinical
stage selective <FONT STYLE="white-space:nowrap">interleukin-6</FONT> <FONT STYLE="white-space:nowrap">(&#147;IL-6&#148;)</FONT> inhibitor that works through the trans-signaling mechanism. <FONT STYLE="white-space:nowrap">IL-6</FONT> is an important
cytokine driver in the propagation and maintenance of chronic inflammation in autoimmune diseases. Compared to the approved antibody drugs that directly block <FONT STYLE="white-space:nowrap">IL-6</FONT> or
<FONT STYLE="white-space:nowrap">IL-6</FONT> receptor <FONT STYLE="white-space:nowrap">(&#147;IL-6R&#148;),</FONT> TJ301 is expected to provide a novel alternative for the treatment of <FONT STYLE="white-space:nowrap">IL-6</FONT> mediated
inflammation without affecting some of the normal physiological functions of <FONT STYLE="white-space:nowrap">IL-6,</FONT> e.g., acute immune response against infection and metabolic regulation. TJ301 demonstrated therapeutic effects in pre-clinical
animal models of autoimmune diseases, including inflammatory colitis. Moreover, the safety and tolerability profile of TJ301 was studied in three clinical trials in Germany involving 128 subjects. We believe that TJ301 has the potential to become a
highly differentiated therapy to target autoimmune diseases. We acquired an exclusive license from Ferring Pharmaceuticals to develop and commercialize TJ301 in Greater China and South Korea with an option of licensing worldwide rights. As part of
our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> strategy for TJ301, we are conducting a Phase 2 clinical trial in ulcerative colitis (&#147;UC&#148;) for the following reasons: (i)&nbsp;TJ301 was
shown to be effective in animal models of colitis; (ii)&nbsp;an exploratory Phase&nbsp;2a biomarker trial showed promising interim treatment effects of TJ301 in UC patients; and (iii)&nbsp;even though UC incidence is increasing rapidly, innovative
biologic treatments for this disease are lacking in China. We expect to obtain preliminary data from this Phase 2 clinical trial by the second half of 2020. After clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
efficacy and differentiation are validated for UC, we plan to develop TJ301 in other inflammatory indications, in which IL-6 plays a role. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Therapeutic Options and Current Development&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
current therapeutic indication for development is UC. UC and Crohn&#146;s disease (&#147;CD&#148;) are the main types of inflammatory bowel disease (&#147;IBD&#148;), which cause chronic and often relapsing inflammation of the large and small
intestines, respectively. Anti-inflammatory drugs, such as <FONT STYLE="white-space:nowrap">5-aminosalicylic</FONT> acids <FONT STYLE="white-space:nowrap">(&#147;5-ASAs&#148;)</FONT> and corticosteroids, are often used as initial treatment for UC.
Immune system suppressors are also used to control inflammation in patients with UC, including azathioprine, mercaptopurine, and cyclosporine. Biologics that inhibit tumor necrosis factor alpha <FONT STYLE="white-space:nowrap">(TNF-</FONT><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>), including infliximab (Remicade), adalimumab (Humira), and golimumab (Simponi), are efficacious in some UC patients who fail to respond to conventional
therapies. Entyvio, an integrin <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><SUB STYLE="font-size:85%; vertical-align:bottom">4</SUB>&szlig;<SUB STYLE="font-size:85%; vertical-align:bottom">7
</SUB>antibody that blocks lymphocytes from accumulating in the intestinal wall, is the first and, to date, the only
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-anti-TNF-</FONT></FONT></FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> biologics approved
for UC. In China, Remicade is currently the only biologic approved for treatment of UC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is a substantial unmet medical need in UC for a treatment agent(s)
that is efficacious and safe through pathways beyond the traditional drug targets. The incidence of UC is increasing rapidly, but UC patients, especially those with a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> disease, have few treatment options, which have limited efficacy and considerable side-effects. For example, Jak1/3 kinase inhibitors can carry the
risk of serious infections and malignancies. <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> inhibitors also have inherent side effects and do not work in
all patients. According to the Frost&nbsp;&amp; Sullivan Report, approximately 45% patients with autoimmune diseases are considered treatment <FONT STYLE="white-space:nowrap">non-responders</FONT> to <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> drugs and less than one third the UC patients taking <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> drugs achieve drug free remission. Thus, as the only clinical stage selective <FONT STYLE="white-space:nowrap">interleukin-6</FONT> <FONT STYLE="white-space:nowrap">(&#147;IL-6&#148;)</FONT> inhibitor
that works through the trans-signaling mechanism, we believe TJ301 has the potential to become a highly differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for UC, if approved. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Advantages of TJ301&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The existing <FONT
STYLE="white-space:nowrap">IL-6</FONT> or <FONT STYLE="white-space:nowrap">IL-6R</FONT> blockers cause total inhibition of <FONT STYLE="white-space:nowrap">IL-6</FONT> signaling and are associated with significant adverse events in the clinic, such
as infection, gastrointestinal perforation, metabolic disturbances, and insulin resistance. TJ301 is expected to provide a novel alternative as it works through a different mechanism, the trans-signaling pathway. This key advantage has been
demonstrated in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and three clinical trials conducted in Germany. The results indicated that TJ301 has no side effects on lipid, glucose or bone metabolism, and it has no agonistic
activities that could activate receptors or trigger detrimental immune cascades. We expect that selective inhibition of <FONT STYLE="white-space:nowrap">IL-6</FONT> trans-signaling is an effective and safer approach to the treatment of chronic
inflammation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Mechanism of Action&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ301 is a
homodimer of a fusion protein consisting of the extracellular domains of human glycoprotein130 (&#147;gp130&#148;) and the fragment crystallizable (Fc) domain of human IgG<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>. Mimicking the
function of endogenous soluble gp130, TJ301 works as a decoy by binding to a complex consisting of <FONT STYLE="white-space:nowrap">IL-6</FONT> and soluble <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor
<FONT STYLE="white-space:nowrap">(&#147;sIL-6R&#148;),</FONT> thereby preventing TJ301 from stimulating the trans-signaling pathway in cells that do not express <FONT STYLE="white-space:nowrap">IL-6R.</FONT> The gp130 part selectively binds the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-6/sIL-6R</FONT></FONT> complex with high affinity (Kd=130 pM), whereas the Fc part initiates dimerization and offers longer half-life for the molecule. TJ301 is not expected to affect
the beneficial effects of <FONT STYLE="white-space:nowrap">IL-6,</FONT> such as the acute immune response against infection mediated by the classical pathway. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g75i90.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Classical signaling and trans-signaling pathways of <FONT STYLE="white-space:nowrap">IL-6.</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-IL-6R</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-IL-6</FONT></FONT> block both pathways, whereas TJ301 blocks only trans-signaling. <FONT STYLE="white-space:nowrap">IL-6R:</FONT> <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor;
<FONT STYLE="white-space:nowrap">sIL-6R:</FONT> Soluble <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor.</I></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary of Clinical Results&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ferring Pharmaceuticals has completed two Phase 1 trials to evaluate TJ301&#146;s preliminary safety and clinical pharmacology. TJ301 was shown to be well-tolerated
based on the clinical results collected from a total of 112 subjects exposed to the drug. In addition, a Phase 2a biomarker study in active IBD (known as the FUTURE study) has been completed in Germany with promising pharmacodynamic and clinical
responses observed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Phase 1 Clinical Trial: Single Dose Ascending Trial </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Study Design. </I>The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial of TJ301 was a single dose,
placebo-controlled, single-blind, randomized within dose, and parallel group dose-escalating trial. The trial recruited both healthy subjects and patients with Crohn&#146;s Disease (&#147;CD&#148;) in clinical remission. The primary objective was to
examine the safety, tolerability and pharmacokinetics after a single dose of TJ301. Several dose levels were tested, ranging from 0.75&nbsp;mg to 750 mg, with each dose level including six subjects receiving TJ301 and two receiving placebo. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacokinetics. </I>In healthy subjects and CD patients, TJ301 showed similar terminal half-life of 4.3 to 5.1 days. The maximum concentration (C<SUB
STYLE="font-size:85%; vertical-align:bottom">max</SUB>) in plasma and the area under curve (&#147;AUC&#148;) of the plasma drug concentration-time curve were dose proportional. For SC administration of TJ301 (60 mg), the C<SUB
STYLE="font-size:85%; vertical-align:bottom">max</SUB> was approximately 1.0 &micro;g/mL at 2.3 days, and the bioavailability was approximately 48%. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g19d04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Single dose pharmacokinetic profile of TJ301. Left, healthy subjects (colored lines) and IBD patients in remission (gray lines) received a single IV infusion at 75 mg (blue lines), 300 mg (magenta lines) or 600&nbsp;mg (red
lines) fixed doses. Right, healthy subjects received a single SC injection at 60 mg. LLOQ: lower limit of quantitation. (Source: Ferring Pharmaceuticals)</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety. </I>TJ301 was well-tolerated when administered as a single IV dose at up to 750 mg and as a single SC dose at 60 mg. No
apparent dose-related AE was observed. Infusion was discontinued in two subjects due to mild to moderate infusion-related reactions, with skin symptoms such as urticaria and swelling, which were rapidly resolved.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Only one healthy subject in the 300 mg group showed <FONT STYLE="white-space:nowrap">non-neutralizing</FONT> treatment-emergent ADAs at the <FONT STYLE="white-space:nowrap">follow-up</FONT> visit
five to six weeks after administration. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Phase 1 Clinical Trial: Multiple Dose Ascending Trial </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Study Design. </I>This trial was a placebo-controlled, double-blind, and randomized dose-escalating trial in healthy subjects. A total of 24 healthy subjects were
randomized into three dose groups and received four weekly infusions of TJ301 at 75 mg, 300 mg or 600 mg. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacokinetics</I>. PK characteristics were similar
on the first and last treatment days of the multiple dose-ascending trial and were similar to results in the single dose-ascending study. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g61j34.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Multiple dose pharmacokinetic profile of TJ301. Healthy subjects received weekly IV infusions at 75 mg (blue lines), 300 mg (magenta lines) or 600 mg (gray lines) fixed doses. LLOQ, lower limit of quantitation. (Source:
Ferring Pharmaceuticals)</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety. </I>There were only a few mild or moderate AEs reported across all treatment groups. One subject from the 600&nbsp;mg group
withdrew due to mild infusion-related reactions with urticaria and pruritus 30 minutes after administrating the first dose. No apparent dose-related trends or treatment-related change in vital signs, electrocardiogram or clinical chemistry
parameters were observed. No ADAs were reported by any subject. Overall, TJ301 was well-tolerated when administered by IV at up to 600 mg once weekly for four weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Overall Summary of Treatment-Emergent Adverse Events </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>75&nbsp;mg<BR>(N = 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>300 mg<BR>(N = 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>600 mg<BR>(N = 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo<BR>(N = 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Active<BR>(N = 18)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n&nbsp;(%)&nbsp;E</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n&nbsp;(%)&nbsp;E</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n&nbsp;(%)&nbsp;E</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n&nbsp;(%)&nbsp;E</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n&nbsp;(%)&nbsp;E</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Any TEAE<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(100)&nbsp;13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(33)&nbsp;5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4&nbsp;(67)&nbsp;6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(100)&nbsp;14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;(67)&nbsp;24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Serious TEAEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adverse Drug Reactions<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(100)&nbsp;11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(33)&nbsp;2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;(50)&nbsp;5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4&nbsp;(67)&nbsp;6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11&nbsp;(61)&nbsp;18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">TEAEs Leading to Withdrawal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(17)&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(6)&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deaths</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Source: Ferring Pharmaceuticals </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1%; font-size:8pt; font-family:ARIAL">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reasonably possibly related to treatment; N: number of subjects exposed; n: number of subjects with AE; %: n/N*100; E: number of AEs </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Phase 2a Biomarker Study in Active IBD (FUTURE Study) </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Study Design. </I>This was an open-label exploratory study to assess the mechanisms of molecular activity (effects on biomarkers), safety and tolerability of TJ301
in adult patients with active IBD. Nine UC patients and seven CD patients were dosed with TJ301 (600 mg, IV, q2w) for up to 12 weeks followed by 42 days of safety <FONT STYLE="white-space:nowrap">follow-up.</FONT> Patients enrolled had moderately to
severe active UC or ileocolonic CD with median disease duration of 5.3 (UC) and 6.9 (CD) years and with immunologically active inflammation <FONT STYLE="white-space:nowrap">(C-reactive</FONT> protein &gt;5 mg/l), who had failed conventional
therapies and had no prior biologics treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The primary endpoint was the proportion of patients with reduced mucosal expression of a predefined set of
inflammation-relevant genes (TNFA, IL1A, REG1A, IL8, IL1B and LILRA) as a composite score. Objective assessments included centrally read endoscopies, histology readings, and various explorative molecular parameters and inflammatory biomarkers. The
trial was sponsored and conducted by the University Hospital Schleswig Holstein and Paul-Ehrlich Institute <FONT STYLE="white-space:nowrap">(EUDRA-CT</FONT> <FONT STYLE="white-space:nowrap">2016-000205-36),</FONT> with financial and material support
from Ferring Pharmaceuticals. The study has been completed, and the abstract of the results was presented at the United European Gastroenterology Week meeting in October 2019. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety.</I> TJ301 was well-tolerated. Reported AEs were unspecific in nature and showed no signs of immune suppression. Five SAEs were observed, none of which were
life-threatening or deemed to be related to TJ301. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacokinetics.</I> After single and repeated IV administration of TJ301 (600 mg, Q2W) to patients with UC
and CD, similar serum exposure was observed after the first and last dosing events, with respect to Cmax and total exposure over 14 days. Maximal serum drug concentration after each dosing was reached at the end of infusion. The mean terminal
half-life of TJ301 after the last administration was approximately 5.1 days. Circulating biological activity of TJ301 was confirmed by whole-blood STAT3 phosphorylation assays in all patients. A minimal and transient ADA production was observed in
three patients. ADAs were only detected at week 12 and week 15, but no longer detectable at week 18. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g37e21.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Time course of the mean serum concentration of TJ301.</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacodynamics.</I> In the assessment of the primary endpoint, it was observed that clinical remission was associated with a
significant reduction of <FONT STYLE="white-space:nowrap">IL-1B,</FONT> <FONT STYLE="white-space:nowrap">IL-8</FONT> and REG1A gene expression in the intestinal mucosa. Pathway analysis of blood transcriptome signatures showed an early molecular
anti-inflammatory signature as early as four hours after treatment in all patients, irrespective of treatment outcome, which indicated a thorough inhibitory effect of <FONT STYLE="white-space:nowrap">IL-6</FONT> trans-signaling blockade on
inflammatory pathways. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Clinical Efficacy</I>. A preliminary clinical response was observed in both UC and CD patients, which appeared to be stronger in patients
with UC than those with CD. Overall, 55% of UC patients (5/9) responded to TJ301, with 22% (2/9) reaching clinical remission, whereas 29% of CD patients (2/7) responded to TJ301, with 14% (1/7) reaching clinical remission. All three patients in
clinical remission showed a fast and thorough induction of clinical, endoscopic, and immunologic remission within the first four weeks. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Clinical
Development Plan&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are positioning TJ301 as a differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for a number of autoimmune diseases.
The first target indication is active stage UC that is not well-controlled by conventional therapies such as mesalazine. We have initiated a multi-regional Phase 2 clinical trial in Greater China and South Korea to assess the pharmacokinetics,
safety, and efficacy of TJ301 in patients with active UC (NCT03235752). This is a randomized, double-blind, and placebo-controlled clinical trial with three treatment arms. We plan to enroll 90 patients. A total of 58 patients have been dosed. We
expect to obtain preliminary data from this Phase 2 clinical trial by the second half of 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Besides UC, we are evaluating the possibility of extending TJ301 to other autoimmune conditions where there is significant unmet medical need in China. We expect to initiate a second clinical
trial for a chronic inflammatory disorder, such as systemic sclerosis and Castleman&#146;s disease, in which <FONT STYLE="white-space:nowrap">IL-6</FONT> is implicated as a key pathogenic cytokine. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Enoblituzumab: The Most Advanced Clinical Stage Humanized B7-H3 Antibody as a Potential Immuno-oncology Treatment </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enoblituzumab is a humanized antibody
directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> a member of the B7 family of T cell checkpoint regulators. <FONT STYLE="white-space:nowrap">B7-H3</FONT> is a promising immuno-oncology drug target as it is widely expressed across multiple
tumor types and plays a key role in regulating immune response against cancers. Increasing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical evidence suggests that antibodies targeting the two T cell checkpoint <FONT
STYLE="white-space:nowrap">molecules&#150;&#150;B7-H3</FONT> and <FONT STYLE="white-space:nowrap">PD-1&#150;&#150;work</FONT> synergistically in treating cancer. Given <FONT STYLE="white-space:nowrap">B7-H3&#146;s</FONT> critical role, enoblituzumab
has a wide range of cancer applications as either a monotherapy or in combination with <FONT STYLE="white-space:nowrap">PD-1</FONT> therapies. At the molecular level, enoblituzumab is engineered to possess an enhanced anti-tumor ADCC function and is
at the forefront in global clinical development. Originally developed by MacroGenics, enoblituzumab has been evaluated in multiple clinical trials as a monotherapy or in combination with CTLA-4 or PD-1 therapies in patients with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B7-H3-expressing</FONT></FONT> cancers. Enoblituzumab is also being evaluated in a neoadjuvant Phase 2 study as a single agent in patients with intermediate and high-risk localized prostate
cancer. The clinical studies so far have shown that enoblituzumab is well-tolerated, and it increased CD8 T cell infiltration in tumors with more focused T cell repertoires in patients treated with enoblituzumab as a monotherapy. Recent clinical
studies conducted by MacroGenics indicate that combination therapy with enoblituzumab and pembrolizumab correlates with preliminary anti-tumor effects in recurrent or metastatic squamous cell carcinoma of the head and neck (&#147;SCCHN&#148;) and <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;). We recently acquired the development and commercial rights of enoblituzumab from MacroGenics for Greater China. We expect to submit an IND application in 2020 for a
registrational trial or a Phase 2 trial. As more clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data become available, further clinical trials will be planned together with MacroGenics to extend enoblituzumab to other cancer
indications in China and globally. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Therapeutic Options and Current Development&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our initial therapeutic indication is head and neck cancer. Head and neck cancers occur in various parts of the head and neck, including the mouth, nose, throat and
salivary glands. More than 90% of head and neck cancers are classified as SCCHN, which begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck. The treatment principles and regimens for head and neck cancer in
China are similar to those in the rest of the world. Treatment strategies often depend on the location and stage of the cancer, the patient&#146;s physical status, and response to prior treatments. Early-stage disease is primarily treated with
surgical resection, while patients with locally advanced, recurrent or metastatic disease are typically treated with drug therapy. The combination of surgery and drug therapy, with or without radiation therapy, is the current standard of care for
Stage 3 SCCHN patients with locally advanced disease. Platinum-based chemotherapy regimens are widely used as first-line therapies for Stage 4 and distant relapse patients. Erbitux (cetuximab from Eli Lilly and Merck KGaA) was approved in 2006 as a
first-line treatment of locally advanced SCCHN in combination with radiation therapy. Regimens containing Erbitux, platinum-based chemotherapy, and <FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> known as EXTREME, are often considered as the
standard of care for first-line treatment of distant relapse SCCHN. However, only about 35% of patients respond to EXTREME, and the resulting overall median survival is only 10.1 months. Furthermore, about half of the patients on first-line
therapies need later-line therapies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, even second-line therapy is highly varied, including single-agent docetaxel or paclitaxel, Erbitux monotherapy,
and Erbitux and paclitaxel combination therapy. In 2016, <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors were approved globally as second-line therapies. Recently, Keytruda (pembrolizumab from Merck&nbsp;&amp; Co), used as a single agent or
in combination with chemotherapy, was approved by the FDA as first-line therapy for patients with metastatic or unresectable recurrent SCCHN. The average ORR for second-line therapies has been less than 15%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As such, we believe that SCCHN patients, especially those with late stage or relapsed disease, need more efficacious treatments with fewer side effects, which
represents a significant unmet medical need for immunotherapy and targeted therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Advantages of Enoblituzumab&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enoblituzumab is the most advanced clinical stage humanized B7-H3 antibody as a potential immuno-oncology treatment. The foregoing statement applies only to
conventional therapeutic <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibodies and does not include radio-labeled <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibodies in development by <FONT STYLE="white-space:nowrap">Y-mabs</FONT>
Therapeutics. Targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> offers several advantages over other target options within the class of T cell checkpoint molecules. First, <FONT STYLE="white-space:nowrap">B7-H3</FONT> is a tumor-associated
antigen that is over-expressed in a variety of solid tumors while its expression in normal tissues is rather limited, enabling the tumor killing mechanism of enoblituzumab. Second, <FONT STYLE="white-space:nowrap">B7-H3</FONT> is a unique checkpoint
whose expression in tumors is associated with disease prognosis. For example, biomarker analysis of more than 400 NSCLC patients revealed that among all the elevated immune checkpoint inhibitors, including <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1,</FONT></FONT> <FONT STYLE="white-space:nowrap">PD-L2,</FONT> <FONT STYLE="white-space:nowrap">B7-H3,</FONT> <FONT STYLE="white-space:nowrap">TIM-3,</FONT> BTLA and CTLA4, only
<FONT STYLE="white-space:nowrap">B7-H3</FONT> is negatively correlated with clinical efficacies of neoadjuvant treatments (Lou et al., Clinical Cancer Research, 2016). Furthermore, recent studies have shown that when combined with a <FONT
STYLE="white-space:nowrap">PD-1</FONT> antibody, a blockade of <FONT STYLE="white-space:nowrap">B7-H3</FONT> results in superior treatment effects in relevant cancer animal models while another study indicates that
<FONT STYLE="white-space:nowrap">B7-H3</FONT> expression correlates with a lack of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> response (Yonesaka et al., Clinical Cancer Research, 2018). The advantages
summarized above make <FONT STYLE="white-space:nowrap">B7-H3</FONT> a favorable tumor target for immuno-therapeutic intervention. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Mechanism of
Action&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enoblituzumab (MGA271) is an investigational humanized immunoglobulin (IgG1/kappa monoclonal antibody) that binds to B7 homolog 3 <FONT
STYLE="white-space:nowrap">(B7-H3).</FONT> This antibody consists of an engineered human IgG1 fragment crystallizable (Fc) domain that imparts increased affinity for the human activating Fc gamma receptor
(Fc<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>R) IIIA (CD16A) and decreased affinity for the human inhibitory
Fc<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>RIIB (CD32B). The engineered Fc domain confers enoblituzumab with enhanced target-specific antibody-dependent cellular cytotoxicity (&#147;ADCC&#148;)
in vitro and anti-tumor activity in preclinical studies. Therefore, enhanced cytolysis of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B7-H3-expressing</FONT></FONT> tumor cells is a mechanism that supports the development of
this molecule as an antineoplastic agent. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, data suggest that enoblituzumab impacts <FONT STYLE="white-space:nowrap">T-cell</FONT> homeostasis in vivo.
Cancer patients display a more narrowly focused <FONT STYLE="white-space:nowrap">T-cell</FONT> repertoire following enoblituzumab treatment compared to their baseline repertoire distribution. Moreover, enhanced local
<FONT STYLE="white-space:nowrap">T-cell</FONT> infiltration has been observed in prostate cancer patients treated with enoblituzumab. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These data are consistent
with the notion that enoblituzumab is capable of engaging both innate and adaptive immunity as mediators of its anti-tumor activity. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g93a29.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Enoblituzumab contributes to the coordination and engagement of innate and adaptive immunity to mediate tumor regression. Enoblituzumab binds to tumor cells, activates innate immune cells such as natural killer cells (NK
cells) to kill cancer cells through ADCC. The released tumor antigens may then be presented by antigen-presenting cells, such as macrophages, which, in concert with <FONT STYLE="white-space:nowrap">PD-1</FONT> blockade, can promote tumor-specific <FONT
STYLE="white-space:nowrap">T-cell</FONT> immunity. (Source: MacroGenics)</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary of Clinical Results&#151; </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Phase 1 Study of Enoblituzumab Monotherapy </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Study
Design.</I> This was an open-label, multi-dose, <FONT STYLE="white-space:nowrap">single-arm,</FONT> multi-center, and dose-escalation study to define safety, tolerability, maximum tolerated dose (&#147;MTD&#148;), PK, immunogenicity, and potential
anti-tumor activity of enoblituzumab in patients with refractory cancers that express <FONT STYLE="white-space:nowrap">B7-H3</FONT> conducted by MacroGenics. In the dose escalation segment of the study, six doses (0.15&#150;15 mg/kg QW) were
evaluated in a conventional &#147;3+3&#148; design. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No MTD or dose-limiting toxicity (&#147;DLT&#148;) was observed in the dose escalation phase, so the highest
administered dose, 15 mg/kg, was used in the cohort expansion, in which patients received weekly infusions of enoblituzumab in eight-week cycles for up to 12 cycles. Tumor evaluation was carried out by both Response Evaluation Criteria in Solid
Tumors (&#147;RECIST&#148;) and immune-related response criteria (&#147;irRC&#148;) with an initial response assessment after eight weeks. This entailed seven tumor-specific cohorts, including melanoma (post-checkpoint inhibitor failure, n=31), head
and neck cancer (n=19), prostate cancer (n=34), triple-negative breast cancer (n=17), renal cell carcinoma (n=16), NSCLC (n=8), and bladder cancer (n=12). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety.</I> Interim data analysis as of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date of April&nbsp;13, 2017, indicates that enoblituzumab is
well-tolerated. Treatment-related AEs (per investigator assessment) were experienced by 134 out of 170 (78.8%) patients, most of which were infusion-related reactions (n=62, 36.5%), fatigue (n=54, 31.8%), nausea (n=32, 18.8%), and chills (n=24,
14.1%). Only three out of 179 patients (1.7%) had a treatment-related discontinuation, and 13 (7.3%) patients experienced treatment-related Grade 3 or higher AEs (fatigue, infusion-related reactions, and nausea), assessed based on Common Terminology
Criteria for Adverse Events (CTCAE) criteria version 4.0. Mild to moderate infusion-related reactions were managed with low dose steroids or a decrease of the infusion rate. No severe immune-mediated toxicity was observed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacokinetics.</I> Preliminary analysis and population PK modeling based on 18 patients dosed at 15&nbsp;mg/kg indicate that PK of enoblituzumab was
characterized primarily by target-mediated drug disposition and was consistent with a typical human IgG1 with near-linear PK. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Efficacy.</I> Evidence of
decreased size of target and <FONT STYLE="white-space:nowrap">non-target</FONT> lesions as well as extended time to progression were observed across a broad range of tumors, including heavily pretreated cancers. Three patients achieved PR (partial
responses) by RECIST out of a total of approximately 71 patients being evaluated. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Phase 1 Study of Enoblituzumab in Combination with
Pembrolizumab </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Study Design.</I> This is an open-label, dose escalation, cohort expansion, and efficacy <FONT STYLE="white-space:nowrap">follow-up</FONT>
study of enoblituzumab in combination with pembrolizumab conducted by MacroGenics. The dose escalation phase is designed to characterize the safety and tolerability of the combination and to define the maximum tolerated or maximum administered dose.
Three dose levels of enoblituzumab (3, 10, 15 mg/kg, IV, QW) have been evaluated in combination with pembrolizumab (2 mg/kg, IV, Q3W). No MTD has been identified, and so the maximum administered dose of enoblituzumab (15 mg/kg) in combination with
pembrolizumab was given to additional cohorts of patients enrolled during the cohort expansion phase. The efficacy <FONT STYLE="white-space:nowrap">follow-up</FONT> period consists of the <FONT STYLE="white-space:nowrap">two-year</FONT> period after
administering the final dose of the study drug. All tumor evaluations are carried out by both RECIST and irRC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A total of 133 patients with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B7-H3-expressing</FONT></FONT> melanoma, squamous cell carcinoma of the head and neck (SCCHN), <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;), and
urothelial cancer have been treated in the study. The interim results as of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date, October&nbsp;12, 2018, were presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer
(SITC), which showed an ORR (overall response rate) that compared favorably with historical experience with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> naive patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety.</I> The combination of enoblituzumab
and pembrolizumab demonstrated acceptable tolerability in patients treated to date. Grade 3 or higher AEs, assessed based on Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0, occurred in 27.1% of all patients. Drug-related
AEs of all grades included infusion-related reactions (n=73, 54.9%), fatigue (n=37, 27.8%), rash (n=14, 10.5%), and nausea (n=12, 9.0%). The incidence of immune-related AEs in the study was comparable to that observed in patients who received anti <FONT
STYLE="white-space:nowrap">PD-1</FONT> monotherapy. Nine patients experienced drug-related AEs leading to treatment discontinuation. Drug-related AEs and immune-related AEs of special interest are summarized in the table below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Drug-Related and Immune-Related Adverse Events </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>During Combination Treatment with Enoblituzumab and Pembrolizumab </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NO.&nbsp;(%)&nbsp;OF&nbsp;PATIENTS</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>DRUG-RELATED AES (</B><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><B></B><B>5% OF PATIENTS)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL&nbsp;GRADES&nbsp;TOTAL<BR>(N=133)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B></B><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><B></B><B>&nbsp;GRADE&nbsp;3</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(N=133)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Any adverse event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115&nbsp;(86.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36&nbsp;(27.1)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Infusion-related reaction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73&nbsp;(54.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9&nbsp;(6.8)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fatigue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37&nbsp;(27.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(1.5)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14&nbsp;(10.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Nausea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;(9.0</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pyrexia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;(9.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lipase increased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11&nbsp;(8.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8&nbsp;(6.0)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arthralgia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;(7.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Decreased appetite</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9&nbsp;(6.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(1.5)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Diarrhea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9&nbsp;(6.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Hypothyroidism</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8&nbsp;(6.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Anemia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;(5.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pneumonitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;(5.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(1.5)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;(5.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NO. (%) OF PATIENTS</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>IMMUNE-RELATED ADVERSE EVENTS OF SPECIAL INTEREST (AESI)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL&nbsp;GRADES&nbsp;TOTAL<BR>(N=133)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B></B><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><B></B><B>&nbsp;GRADE&nbsp;3</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(N=133)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pneumonitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5&nbsp;(3.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(1.5)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Myocarditis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(1.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Diarrhea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adrenal insufficiency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Colitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Drug-related AEs: </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Leading to treatment discontinuation: 6.8% (9 patients) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Leading to death: 0.8% (1 patient with pneumonitis) </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Nature of events consistent with enoblituzumab or pembrolizumab alone </P></TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>Source: MacroGenics. </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Clinical Efficacy.</I> As of October&nbsp;12, 2018,
the <FONT STYLE="white-space:nowrap">cut-off</FONT> date of the most recent data analysis, preliminary results indicated that among the 18 response-evaluable SCCHN patients who had not previously received <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies, six patients (33.3%) had confirmed partial responses (&#147;PRs&#148;). Among the subset of patients with 10% or higher <FONT STYLE="white-space:nowrap">B7-H3</FONT> tumor expression,
six out of 15 (40.0%) had confirmed PRs (see figure below) compared to previously reported SCCHN patients treated with <FONT STYLE="white-space:nowrap">PD-1</FONT> monotherapy, which achieved ORRs ranging from 13% to 16%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Anti-tumor Activity in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1/PD-L1-Naive</FONT></FONT></FONT></FONT> SCCHN Patients </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g27e81.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>Source: MacroGenics </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Among 14 response-evaluable NSCLC patients who had not
previously received <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies and were <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative, i.e., <FONT STYLE="white-space:nowrap">PD-L1</FONT> less or
equal to 1%, five patients (35.7%) had confirmed PRs (see figure below). Objective response rates ranging from 8% to 17% were reported in <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative NSCLC patients treated with <FONT
STYLE="white-space:nowrap">PD-1</FONT> monotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Anti-tumor Activity in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1-Naive</FONT></FONT> NSCLC Patients Who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> Negative <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &lt; 1%) </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor Volume Change from Baseline (%) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g05c03.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>Source: MacroGenics </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the two figures above, CR (complete response) means the disappearance of all target lesions, with the reduction of
all pathological lymph nodes to &lt;10 mm; PR (partial response) means at least a 30% decrease in the sum of the target lesions, in comparison to the baseline sum diameter; PD (progressive disease) means a 20% increase in the sum of the diameters in
comparison to the smallest sum of diameters with an absolute increase of at least 5 mm, provided that any new lesion is considered progressive disease; and SD (stable disease) means meeting neither the criteria for partial response nor for
progressive disease, in comparison to the smallest sum of diameters. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Clinical Development Plan&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to develop enoblituzumab as a second-line combination therapy with a <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody in a registrational clinical trial
(pending regulatory approval by the NMPA) or a Phase 2 trial in patients with recurrent or metastatic SCCHN. We expect to submit an IND application in 2020 for a registrational trial or a Phase 2 trial. The primary efficacy endpoint of this study
will be objective response rate (ORR) performed by central review. In addition, we are planning to explore enoblituzumab development in a variety of <FONT STYLE="white-space:nowrap">B7-H3</FONT> expressing solid tumors. MacroGenics plans to combine
enoblituzumab and a <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody with and without chemotherapy in a <FONT STYLE="white-space:nowrap">two-part</FONT> Phase 2/3 study for first-line treatment of patients with recurrent or metastatic SCCHN not
curable by localized therapy. We expect to participate in the Phase 3 global study if initiated. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Global Portfolio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>TJM2: A <FONT STYLE="white-space:nowrap">GM-CSF</FONT> Monoclonal Antibody for Rheumatoid Arthritis and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">CAR-T-related</FONT></FONT> Therapies </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJM2 is an internally discovered neutralizing antibody against human granulocyte-macrophage colony-stimulating factor
<FONT STYLE="white-space:nowrap">(&#147;GM-CSF&#148;),</FONT> an important cytokine that plays a critical role in chronic inflammation and destruction in autoimmune diseases such as rheumatoid arthritis (&#147;RA&#148;). TJM2 is expected to be the
first clinical stage GM-CSF monoclonal antibody in China. TJM2 is a humanized IgG1 that displays high affinity binding to <FONT STYLE="white-space:nowrap">GM-CSF</FONT> and blocks its signaling and downstream effects. TJM2 is being developed for the
treatment of autoimmune and inflammatory diseases, including RA, cytokine release syndrome (&#147;CRS&#148;) and neuroinflammation from <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. We have completed a single-dose first-in-human study in
healthy volunteers in the United States. We have received IND approval from the NMPA for a multiple-dose Phase 1b study in Chinese patients with RA and may expand to other autoimmune and inflammatory indications with high unmet medical need, where <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> is known as a pathogenic cytokine in disease activity and progression. TJM2 is expected to be the first compound of its class to enter clinical trial in China in early 2020. If approved, it is expected to
provide an effective treatment option as a disease-modifying anti-rheumatic drug (&#147;DMARD&#148;) therapy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Therapeutic Options and Current
Development&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our current therapeutic indication is RA, a systemic chronic inflammatory disease considered to be one of the most prevalent immune-mediated
inflammatory diseases. RA is nearly always polyarticular and causes joint destruction, deformity, and loss of function. Extra-articular manifestations include cardiopulmonary diseases, eye diseases, Sjogren&#146;s syndrome, rheumatoid vasculitis and
neurological diseases. Current therapies for RA in China include traditional Chinese medicine, corticosteroids, and DMARDs, including immunosuppressants and targeted therapies such as TNF inhibitors. Although the market for RA has become more
competitive in China, new medicines targeting different pathways with greater clinical efficacy and safety remain a significant unmet need. Our <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody targets an entirely different disease pathway and
has these desired characteristics to treat RA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical evidence supporting the role of a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody in RA is
highlighted in a few recent global studies. For example, both otilimab (MOR103), a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody from MorphoSys and GSK, and mavrilimumab, a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> receptor antibody
from Medimmune, have shown an early onset of clinical responses in Phase 2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trials with RA patients. In addition to RA, attempts to develop a <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> antibody for treating other autoimmune diseases, such as ankylosing spondylitis, are being studied by Amgen and Takeda. These autoimmune conditions involve the same autoimmune cell types, including
macrophages, and neutrophils and the same connective tissues such as bones, joints, and tendons. Given the large patient population affected and the burden of these diseases, we are keen to explore the therapeutic role of TJM2 in treating these
diseases, if initial studies in RA patients meet primary end-points. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The therapeutic role of TJM2 goes beyond autoimmune diseases. A recent study indicates that <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> plays a critical role in serious side effects associated with chimeric antigen receptor <FONT STYLE="white-space:nowrap">(CAR)-T</FONT> therapy, such as cytokine release syndrome (&#147;CRS&#148;) and
neurotoxicity. As <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy has become an effective treatment option for certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
cancer types, finding a treatment solution for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CAR-T-related</FONT></FONT> toxicities that occur frequently and can turn into a
serious and potentially fatal condition becomes an urgent need. These severe toxicities add to the morbidity and mortality of <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. CRS is caused by a massive release of circulating cytokines by
expanding <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells, and <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is one of the key cytokines of CRS. Currently, there are no effective therapies to prevent CRS or neurotoxicity. Tocilizumab, an <FONT
STYLE="white-space:nowrap">IL-6</FONT> receptor antagonist, is approved for severe CRS with limited therapeutic coverage. Recent studies indicate that neutralizing <FONT STYLE="white-space:nowrap">GM-CSF</FONT> <I>in vivo</I> may ameliorate and
potentially prevent CRS and neuroinflammation without affecting <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell activity. Humanigen recently teamed up with Kite to evaluate lenzilumab, a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody, as
a preventive or treatment agent in association with Yescarta, an approved CD19-directed <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. In parallel with an RA clinical trial, we are seeking opportunities to co-develop TJM2 as a treatment
option for CRS associated with CAR-T therapy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Advantages of TJM2&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on reported clinical findings with front-runner <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibodies compared to other RA biologics that are clinically used,
we have the following expectations: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Fast onset of therapeutic effect</I>. Because <FONT STYLE="white-space:nowrap">GM-CSF</FONT> acts at a relatively early
stage in the inflammatory cascade, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> blockade is expected to take effect after just a few initial doses and provide quick symptomatic relief to patients. This fast onset of clinical responses in RA has
been shown in Phase 2 clinical trials on otilimab and mavrilimumab (NCT01023256 and NCT01050998); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Convenience and increased patient compliance</I>. Given the favorable development profile (high affinity, excellent PK,
clean immunogenicity and concentrated formulation) exhibited by TJM2 thus far, the clinically active dose for TJM2 is expected to be low, which is advantageous for chronic maintenance of the disease by subcutaneous administration. This provides
convenience to the patients and will likely increase patient compliance; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Analgesic effect on inflammatory pain</I>. Because the <FONT STYLE="white-space:nowrap">GM-CSF</FONT> receptor is also
expressed on sensory neurons and is involved in <FONT STYLE="white-space:nowrap">RA-associated</FONT> inflammatory pain, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> blockade is expected to provide relief for inflammatory pain, which provides
additional clinical benefits to patients. This analgesic effect has been shown in a Phase 2 clinical trial on mavrilimumab (NCT01706926). </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Mechanism of Action&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">GM-CSF</FONT> is a central driver cytokine in orchestrating an innate immune response during inflammation. It is responsible for
myeloid cell proliferation and functions, such as chemotaxis, adhesion, phagocytosis, and microbial killing. Importantly, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> can polarize macrophages into a
<FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> M1 phenotype and is known to induce an inflammatory cascade involving other <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines such as TNF,
<FONT STYLE="white-space:nowrap">IL-1,</FONT> <FONT STYLE="white-space:nowrap">IL-6,</FONT> <FONT STYLE="white-space:nowrap">IL-12,</FONT> and <FONT STYLE="white-space:nowrap">IL-23.</FONT> It is evident that
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> plays a crucial role in the pathogenesis and disease progression of multiple autoimmune conditions. The action of <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is mediated by binding of its cognate
receptor on target cells and subsequent phosphorylation of signal transducer and activator of transcription 5 (&#147;STAT5&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJM2 specifically binds to human
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> with high affinity and can block <FONT STYLE="white-space:nowrap">GM-CSF</FONT> from binding to its receptor, thereby preventing downstream signaling and target cell activation. As a result, it can
effectively inhibit inflammatory responses mediated by macrophages, neutrophils, and dendritic cells, leading to reduced tissue inflammation and damage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g93q99.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>Figure:&nbsp;&nbsp;&nbsp;&nbsp;Role of <FONT STYLE="white-space:nowrap">GM-CSF</FONT> in orchestrating coordinated immune response. </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary of <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Results&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A series of nonclinical studies have been conducted to evaluate the pharmacology, PK, and toxicology profiles of TJM2. TJM2 could potently bind to human and monkey
GM-CSF but not rodent GM-CSF. TJM2 neutralized GM-CSF in a number of pharmacological studies <I>in vitro</I> and <I>in vivo</I>. TJM2 demonstrated linear PK behavior in single dose IV and SC studies in monkeys with a half-life characteristic of IgG
and a low ADA potential. Weekly TJM2 treatment significantly reduced arthritis score and clinical symptoms in monkeys with established collagen-induced arthritis (a&nbsp;model of RA). In a <FONT STYLE="white-space:nowrap">GLP-compliant</FONT>
multilevel four-week repeat-dose general toxicology study in cynomolgus monkeys, the no observed adverse effect level (&#147;NOAEL&#148;) was considered to be 60&nbsp;mg/kg. The nonclinical studies performed to date have demonstrated an acceptable
pharmacological profile to allow TJM2 to progress to clinical studies in healthy volunteers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Pharmacokinetics in Cynomolgus Monkeys </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The systemic exposure in monkeys after a single IV injection of TJM2 appeared to increase proportionally with doses from 5, 25 to 50 mg/kg. The mean half-life (T<SUB
STYLE="font-size:85%; vertical-align:bottom">1/2</SUB>) was 217&#150;241 hours, the mean maximum observed concentration (C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB>) ranged 112&#150;1220 &micro;g/mL, and the mean exposure (AUC<SUB
STYLE="font-size:85%; vertical-align:bottom"><FONT STYLE="white-space:nowrap">0-last</FONT></SUB>) ranged 14800&#150;124000 &micro;g*h/mL. TJM2 also exhibited linear PK behavior following a single subcutaneous (&#147;SC&#148;) injection from 5, 25
to 50 mg/kg, with the mean T<SUB STYLE="font-size:85%; vertical-align:bottom">1/2</SUB> being 215&#150;242 hours and the mean bioavailability ranging from 73 to 79%. No apparent sex difference was observed. The elimination rate of TJM2 was
independent of the dose route. ADAs were of low titers and detected only in one animal before dosing and on Day 42 <FONT STYLE="white-space:nowrap">post-IV</FONT> dose, which did not affect the PK profile. ADA was clean for the SC administration.
These results indicate that TJM2 is not a strong immunogen to cynomolgus monkeys. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Pharmacodynamics in Cynomolgus Monkeys </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Type II collagen-induced arthritis (&#147;CIA&#148;) is a recognized animal model for RA, and drugs approved for RA have shown efficacy in this model. Monkeys were
immunized with collagen to induce the disease. Once the animals exhibited signs of disease (joint swelling), weekly injections of vehicle control or 40 mg/kg TJM2 were initiated. TJM2 significantly decreased the severity of CIA as measured by
arthritis score over the entire treatment period, which correlated with the decrease in STAT5 phosphorylation in PBMCs 24 hours after treatment. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Repeat-Dose Toxicology Study in Cynomolgus Monkeys </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A <FONT
STYLE="white-space:nowrap">GLP-compliant</FONT> four-week repeat-dose toxicology study with a <FONT STYLE="white-space:nowrap">30-day</FONT> recovery was conducted in cynomolgus monkeys via weekly IV administrations at 20, 60 or 200 mg/kg. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The TK parameters were similar following the first and fourth dose, indicating no apparent accumulation after repeat administration. No apparent sex difference was
observed. All samples were detected as <FONT STYLE="white-space:nowrap">ADA-negative</FONT> throughout the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
study period. No TJM2-related death or moribund sacrifices occurred. Possible TJM2-related observation was limited to pulmonary granulomas observed in one male animal given 200 mg/kg dose.
Minimal congestion and alveolar protein observed in one male animal given 20 mg/kg dose during the recovery period had uncertain relation to TJM2 and was not considered adverse. No other TJM2-related findings were noted. The NOAEL was considered to
be 60&nbsp;mg/kg, with corresponding mean C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> and AUC<SUB STYLE="font-size:85%; vertical-align:bottom"><FONT STYLE="white-space:nowrap">0-t</FONT></SUB> following the fourth dose of 2010
&micro;g/mL and 117000 &micro;g*h/mL for males, and 1930 &micro;g/mL and 119000 &micro;g*h/mL for females, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary of Clinical
Results&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the pre-clinical results, we initiated a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT>
study in healthy volunteers in the United States (NCT03794180). This study has now been completed with a clinical study report (CSR) available. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Study
design.</I> This randomized, double-blind, placebo-controlled, and single dose-ascending study was designed to assess the safety, tolerability, PK/PD, and immunogenicity of TJM2 (referred to as TJ003234) in healthy volunteers. We have enrolled and
completed dosing of four planned cohorts at 0.3, 1, 3 and 10 mg/kg dose levels, with each cohort consisting of eight subjects randomized into six receiving TJM2 and two receiving placebo IV infusions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety. </I>TJM2 was well tolerated following a single IV dose up to 10 mg/kg in healthy subjects with no MTD reached. There were no interruptions in dosing or early
withdrawals. Fourteen males and 18 females participated in the study. The majority of AEs were mild to moderate in nature. No serious adverse events were reported during the study. Overall, 8 of the 24 subjects who received TJM2 and 3 of the 8
subjects on placebo reported treatment-related treatment-emergent adverse events (TEAEs). The most common AEs experienced by subjects dosed with TJM2 were headache (25%) and protein urine (25%). These AEs were also the most common AEs reported by
subjects receiving placebo (37.5% and 37.5%, respectively). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacokinetics. </I>Serum concentrations of TJM2 (TJ003234) were determined by anti-idiotypic
antibody capture immunoassay and PK parameters were analyzed by noncompartmental analysis. Results showed that over the dose range of 0.3 mg/kg to 10 mg/kg, both C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> and exposure increased in
an approximately dose-proportional manner, with C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> increased from 5.75 &micro;g/mL to 260 &micro;g/mL and AUC<SUB STYLE="font-size:85%; vertical-align:bottom">0-last</SUB> increased from 90.5
day*&micro;g/mL to 3780 day*&micro;g/mL (see <I>Figure</I> below). In addition, t<SUB STYLE="font-size:85%; vertical-align:bottom">1/2</SUB> was approximately 3 weeks across the tested dose range. Clearance of TJM2 decreased with increasing dose.
Volume of distribution decreased slightly with increasing dose. In terms of immunogenicity, two subjects in the 3 mg/kg TJM2 cohort and 1 placebo subject were positive for ADA. No subject in the 10 mg/kg dose level was positive for ADA. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g02s93.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>Figure: Mean&plusmn;SD concentration-time plots of serum TJM2 (TJ003234) levels. Linear scale, left; semi-log scale, right. LLOQ, lower limit of quantitation. </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacodynamics</I>. Four hours after dosing, the induction of pSTAT5 by <I>ex vivo</I> GM-CSF stimulation in the monocyte population was inhibited by at least 70%
compared to the placebo following a single dose of TJM2 for all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
dose groups. TJM2 inhibited GM-CSF-stimulated pSTAT5 levels by more than 90% in subjects in the 3&nbsp;mg/kg and 10 mg/kg cohorts at 4 h to up to 2 weeks after dosing, suggesting the saturation
of the pSTAT5 inhibition by the treatment at doses of 3 mg/kg and above. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Clinical Development Plan&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Data from this first-in-human study support continued development of TJM2. We have received IND approval from the NMPA for a multiple-dose Phase 1b study in patients
with RA to be initiated in the first half of 2020. We also intend to investigate the efficacy of TJM2 in reducing or preventing CRS and neurotoxicity associated with <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy through collaborations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>TJC4: A Potential Highly Differentiated CD47 Antibody for Immuno-Oncology </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJC4 is a fully human CD47 monoclonal
antibody that we have discovered and developed internally for cancer immunotherapy. CD47 has emerged as one of the most promising immuno-oncology targets. Unlike other immuno-oncology targets being explored, the CD47-SIRP<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> pathway is involved in tumor progression by delivering a &#147;don&#146;t eat me&#148; signal to tumor-engulfing macrophages, thereby protecting tumors from
natural attacks by macrophages. Blockade of this pathway by CD47 antibody represents one of the most effective tumor killing mechanisms. However, due to the inherent epitope sharing between tumor cells and normal red blood cells (&#147;RBCs&#148;),
the first-wave of clinical stage CD47 antibodies were found in clinical trials to bind to RBCs and cause significant hematologic adverse effects, such as severe anemia, which has hampered the development of these CD47 antibodies as a potential
cancer therapy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We developed TJC4 by design to possess a unique property or differentiation, to minimize binding to RBCs while retaining anti-tumor activities in
line with other antibodies of the same class. This key differentiation is achieved through additional RBC counter-screening to select rare antibody clones that bind to CD47 with high affinity but do not bind to or bind minimally to RBCs. The
proportion of RBC-sparing CD47 antibody leads among all CD47 antibody leads we identified after screening was 0.5%. TJC4 has been validated in a series of <I>in vitro</I> and <I>in vivo</I> <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
studies, which have consistently shown a unique <FONT STYLE="white-space:nowrap">RBC-sparing</FONT> profile comprised of minimal RBC binding, lack of hemagglutination and no significant adverse hematologic changes in cynomolgus monkeys even when
used at a high dose (100 mg/kg). Our pre-clinical data thus far indicate that TJC4, if approved, is a potentially highly differentiated anti-tumor CD47 antibody with the advantage of minimizing hematologic side effects. We have obtained the IND
approval from the FDA and the NMPA, respectively. We have initiated a Phase 1 clinical trial in the United States to study the safety profile, especially the hematologic profile, of TJC4 and to assess its pharmacokinetics, pharmacodynamics and early
anti-tumor signals in cancer patients. We expect to obtain single-agent safety data of TJC4 in mid-2020. In parallel, we have initiated a Phase 1 clinical trial of TJC4 in China in patients with AML/MDS. In addition, we are collaborating with Merck
Sharp &amp; Dohme Corp, or MSD, in a Phase 1 clinical trial in the United States for the combination therapy of TJC4 and MSD&#146;s PD-1 inhibitor KEYTRUDA (pembrolizumab) of multiple types of solid tumors. We have not initiated any research and
development activities under such collaboration arrangement as of the date of this prospectus. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Therapeutic Options and Current Development&#151;
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to evaluate the therapeutic role of TJC4 in a variety of solid tumors, such as cancers of the ovary, lung, liver, pancreas, breast and colon, and
hematological malignancies such as AML/MDS, lymphoblastic leukemia, and NHL. Although <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies represent a new paradigm in cancer treatment, less than 40% of
cancer patients have a clinically meaningful response to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment. As a result, targeting other immune components or cells involved in the immune
system&#146;s anti-tumor mechanism has become an area of active pursuit in the field of immuno-oncology. TJC4 is one such innovative and promising therapeutic antibody, which is capable of mobilizing macrophage functions for effective and direct
tumor-killing. Currently, a number of CD47 antibodies are in clinical development by biotech companies including Forty-Seven, Inc., Celgene, Surface Oncology and Arch Oncology. The most advanced asset, 5F9 from Forty-Seven, Inc., is in Phase 2
clinical studies for multiple cancer indications. However, almost all clinical trials with CD47 antibodies so far have shown significant hematologic adverse effects, likely due to inherent <FONT STYLE="white-space:nowrap">RBC-binding</FONT>
properties of generic CD47 antibodies, and as a result, some clinical studies had to be either terminated or managed with extra cautions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Advantages of TJC4&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJC4 has similar sub-nanomolar binding affinity as other CD47 antibodies and exhibits comparable anti-tumor activity. The key advantage of TJC4 is its minimal binding
to RBCs, thus potentially avoiding or minimizing inherent hematologic adverse effects typically seen in other CD47 antibodies in clinical trials. This differentiated property of TJC4 is due to its unique epitope interaction as revealed by
crystallography, which appears different from those recognized by other CD47 antibodies currently in clinical development based on publicly available information. The differentiation of TJC4 is highlighted in a series of <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies summarized as the following: (i)&nbsp;TJC4 displays only minimal <FONT STYLE="white-space:nowrap">RBC-binding</FONT> even at high antibody concentrations by flow cytometry; (ii)&nbsp;TJC4 does
not induce RBC agglutination even in a high dose range; and (iii)&nbsp;most importantly, TJC4 does not cause significant hematologic changes or systemic toxicologic effects even at high doses in multiple cynomolgus monkey studies, including a
pivotal <FONT STYLE="white-space:nowrap">4-week</FONT> GLP toxicity study. Taken together, TJC4 has a potentially better clinical safety profile and may be used in a broader patient population doses to explore its anti-tumor potential compared to
other clinical stage competitor molecules. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g57c81.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><I>Table:</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Differentiated product profile of TJC4. (Sources for comparator antibodies: American Society of Hematology publication, PLOS One publication, World Intellectual Property Organization and company data)</I></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Mechanism of Action&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJC4 blocks the interaction between CD47 expressed on cancer cells and
SIRP<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> expressed on macrophages, leading to increased phagocytosis of cancer cells by macrophages. Blockade of CD47 by TJC4 may also promote the development
of anti-tumor T cell responses, resulting from increased tumor antigen presentation by professional antigen-presenting cells such as macrophages and dendritic cells. In addition to stimulating the phagocytosis of cancer cells, CD47 blockade was
shown to involve other anti-tumor mechanisms, such as the enhancement of ADCC, direct induction of apoptosis (programmed cell death) of cancer cells, induction of differentiation of cancer stem cells, and inhibition of metastasis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g21v73.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Targeting the CD47/SIRP</I><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><I></I><I> myeloid-specific immune checkpoint. CD47 is highly expressed on many different types of cancers.
SIRP</I><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><I></I><I> is an inhibitory receptor expressed on macrophages and other myeloid immune cells. When CD47 binds to SIRP</I><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><I></I><I>, it causes the inhibition of phagocytosis. CD47 antibodies disrupt the CD47/SIRP</I><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><I></I><I> axis and enable the phagocytosis of cancer cells.</I></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary of <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Results&#151; </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>CD47-related In Vitro and In Vivo Anti-tumor Activities </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJC4 exhibits high-affinity binding to human CD47 protein and CD47-expressing tumor cells at the nanomolar level and effectively blocks interaction of CD47 with its
receptor SIRP<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>. As compared with other CD47 antibodies currently under clinical development, TJC4 demonstrated comparable potency in the enhanced
macrophage-mediated phagocytosis of Raji tumor cells (see Figure A below) and comparable anti-tumor activity in the <FONT STYLE="white-space:nowrap">HL-60</FONT> leukemia and Raji xenograft models (see Figure B below). Moreover, when combined with
rituximab, TJC4 exhibited a markedly enhanced inhibition on tumor growth in a diffuse large B cell lymphoma (DLBCL) animal model, through the synergistic effect of both agents (see Figure C below). </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g30a67.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>In vitro and in vivo anti-tumor activity of TJC4. (A) In vitro phagocytosis of Raji cells by primary human macrophages in the presence of different doses of TJC4 or comparator CD47 antibodies. (B)&nbsp;In vivo anti-tumor activity
of TJC4 mono-treatment in Raji xenograft model. (C)&nbsp;In vivo anti-tumor activity of TJC4 (5 mg/kg, BIW) in combination with Rituximab (5 mg/kg, BIW) in the DLBCL model.</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Assessment of Potential CD47-related In Vitro and In Vivo Hematologic Effects&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">First, in a representative flow cytometric analysis (see Figure A below), TJC4 showed minimal binding to human RBCs compared to comparator CD47 antibodies used at the
same concentration (1 &micro;g/ml). The minimal binding of TJC4 to RBCs was confirmed when compared with other CD47 antibodies across multiple concentrations in another flow cytometric experiment (see Figure B below). </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g99f98.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Binding of CD47 monoclonal antibodies to RBCs. (A)&nbsp;Representative graph of the staining of human RBCs with CD47 monoclonal antibodies or control IgG (1 &micro;g/ml); (B) Dose dependent binding of CD47 monoclonal antibodies
with human RBCs from different healthy donors (n = 3). MFI: mean fluorescence intensity.</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Second, as CD47 is expressed on normal RBCs, binding of CD47 antibodies to the surface of RBCs could cross-link the RBCs into lattices
and prevent them from precipitating into compact pellets, which is a phenomenon termed hemagglutination. Our results showed that TJC4 did not induce RBC agglutination across a wide range of antibody concentrations, while a comparator antibody caused
significant hemagglutination starting at a concentration of 0.3 &micro;g/ml. Results from a representative experiment are shown below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g11b01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Hemagglutination by CD47 monoclonal antibodies. Left: representative graph of hemagglutination (haze appearance) or lack thereof (precipitate) by different concentrations of control IgG, TJC4, and comparator antibodies. Right:
quantification through an index determined by the area of RBC occupation in the presence of the test antibodies, normalized to that of IgG control.</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Thirdly, <I>in vivo</I> safety studies were performed in cynomolgus monkeys to assess the effects of TJC4 on the
hematology parameters. Whereas a single bolus IV injection of the comparator antibody caused a significant drop in the number of RBCs and hemoglobin (&#147;HGB&#148;) levels, treatment with TJC4 at a dose of 10 mg/kg did not significantly affect the
number of RBCs, HGB levels or reticulocyte or platelet counts (see figure below). </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g61p76.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Hematological parameters in <FONT STYLE="white-space:nowrap">non-human</FONT> primates treated with a single dose of CD47 antibodies. On Day 0, naive cynomolgus monkeys were IV injected with PBS control (n=2), TJC4 (n=2, 10
mg/kg) or a comparator antibody (n=2, 10 mg/kg). Blood cells were counted, twice before drug injection (baseline) and at 3, 6, 10, 14 and 21 days post-injection.</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, in a four-week GLP toxicology study, TJC4 treatment did not induce significant overall toxicologic changes. Only mild
decreases in the number of RBCs, HGB and hematocrit were found, which reached nadir at Day 4 post-first administration and then gradually recovered to the normal range following administration. The changes were not dose-dependent. Compared with the
placebo control, the average decrease of RBCs in the treated animals was approximately 6% to 9% with only one animal showing an 18% drop at a dose of 30&nbsp;mg/kg. No <FONT STYLE="white-space:nowrap">RBC-associated</FONT> changes were noted in
histopathologic examinations or in bone marrow smears (including erythrocytic series). Therefore, NOAEL was defined at 100 mg/kg. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Four-week GLP Toxicology Study in Monkeys
</B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g61w04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>No anemia in non-human primates (male) at a high dose range.</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key preclinical data from above have been published as a poster presentation (#4063) at American Society of Hematology 2019 Annual
Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Clinical Development Plan&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have recently initiated a Phase 1 clinical trial in patients with advanced cancer in the United States. The clinical trial (NCT03934814) is designed to assess the
safety of TJC4, in particular, the hematologic safety profile, including changes in hemoglobin levels and RBC counts. The clinical trial includes typical dose escalation schemes up to 30&nbsp;mg/kg and cohort expansions in cancer patients. We
expected to obtain single-agent safety data of TJC4 in mid-2020. In the same clinical trial, we also intend to evaluate the pharmacokinetics, pharmacodynamics and preliminary efficacy signals of TJC4 as a single agent and in combination with a <FONT
STYLE="white-space:nowrap">PD-1</FONT> inhibitor or rituximab in patients with advanced solid tumors and relapsed or refractory lymphoma. The first cohort of four patients has been enrolled and dosed at 1 mg/kg. Preliminary data showed that the
average reduction in hemoglobin levels after treatment was less than 10%. In parallel, we have initiated a Phase 1 clinical trial of TJC4 in China in patients with AML/MDS. In addition, we are collaborating with Merck Sharp &amp; Dohme Corp, or MSD,
in the same Phase&nbsp;1 clinical trial in the United States for the combination therapy of TJC4 and MSD&#146;s PD-1 inhibitor KEYTRUDA (pembrolizumab) under a collaboration agreement in cancer patients with several types of solid tumors after
completing a single-agent dose escalation. We have not initiated any research and development activities under such collaboration arrangement as of the date of this prospectus. The goals of our global and China clinical development plans are to
(i)&nbsp;advance clinical development of TJC4 in hematologic malignancies towards registration, and (ii)&nbsp;explore TJC4&#146;s treatment efficacy in various solid tumors in combination with <FONT STYLE="white-space:nowrap">PD-1</FONT> therapies,
including but not limited to ovarian cancer, gastric cancer, hepatocellular carcinoma, renal cell carcinoma, NSCLC and urothelial carcinoma, in which CD47 is highly expressed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>TJD5: A Potential Highly Differentiated CD73 Antibody for Cancer Treatment </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJD5 is an internally developed, humanized
inhibitory antibody against human CD73. CD73 is a homodimeric enzyme expressed in tumors and plays a critical role in suppressing immune cells in tumor micro-environment. TJD5 displays <FONT STYLE="white-space:nowrap">sub-nanomolar</FONT> binding
affinity to CD73 and inhibits its nucleotidase activity. <I>In vitro</I>, TJD5 completely reversed the <FONT STYLE="white-space:nowrap">AMP-</FONT> or tumor cell-mediated suppression of T cells. <I>In vivo</I>, when combined with a <FONT
STYLE="white-space:nowrap">PD-L1</FONT> antibody, TJD5 exhibited a superior or synergistic inhibitory effect on tumor growth. The key differentiation of TJD5 when compared to some of the other clinical stage antibodies of the same class, is related
to its novel epitope, which works through a unique intra-dimer binding mode, resulting in a complete inhibition of the enzymatic activity and avoiding the aberrant pharmacological property known as the &#147;hook effect.&#148; With this particular
mode of action, TJD5, if approved, has the potential to become a highly differentiated CD73 antibody. We have initiated a Phase 1 clinical trial in cancer patients in partnership with TRACON Pharmaceuticals in the United States. Safety data from
dose escalation cohorts of TJD5 in combination with atezolizumab (a PD-L1 inhibitor) provided by Roche under a clinical supply agreement among Roche, TRACON and us, are expected in 2020. We obtained IND approval from the NMPA for TJD5 in September
2019. In China, we will collaborate with Shanghai Junshi Biosciences Co., Ltd, or Junshi, for the combination therapy of TJD5 with Junshi&#146;s PD-1 monoclonal antibody toripalimab in cancer patients with various types of solid tumors. We have not
initiated any research and development activities under such collaboration arrangement as of the date of this prospectus. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Therapeutic Options
and Current Development&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite recent breakthroughs with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT>
therapies, clinical <FONT STYLE="white-space:nowrap">non-response</FONT> rates to such treatments remains high in cancer patients (exceeding 60%). This <FONT STYLE="white-space:nowrap">non-responsiveness</FONT> to these standard treatments is partly
due to the fact that T cells within an inhibitory tumor environment are suppressed and fail to respond to stimulation induced by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. CD73, which
converts extracellular adenosine monophosphate (&#147;AMP&#148;) to adenosine, is implicated in one of the protective mechanisms of tumors that evade immune attack by creating an adenosine-rich microenvironment inhibitory to immune cells. <FONT
STYLE="white-space:nowrap">Pre-clinical</FONT> studies have indicated that the inhibition of CD73 renders T cells more responsive to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies by altering the
tumor micro-environment, resulting in a superior anti-tumor effect. As CD73 is widely expressed in various cancers, a combination therapy of TJD5 with a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT>
antibody may increase the likelihood of treatment success in cancer patients who do not respond to standard <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. The potential cancer indications of
TJD5 include thyroid cancer, lung cancer, colorectal cancer, stomach cancer, urothelial cancer, endometrial cancer, head and neck cancer, breast cancer, ovarian cancer, and melanoma, in which CD73 is widely expressed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A number of global companies are running active clinical development programs with CD73 antibodies. MEDI-9447 from Medimmune and
<FONT STYLE="white-space:nowrap">BMS-986179</FONT> from Bristol-Myers Squibb are the two most advanced CD73 antibodies, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
are in Phase 1/2 clinical trials. <FONT STYLE="white-space:nowrap">BMS-986179</FONT> is being studied as a single agent and in combination with nivolumab (a
<FONT STYLE="white-space:nowrap">PD-1</FONT> antibody) for the treatment of advanced colorectal, esophageal, gastric, ovarian, and pancreatic cancers. MedImmune is testing MEDI-9447 for the treatment of solid tumors as a single agent or in
combination with durvalumab (a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody) or chemotherapy. <FONT STYLE="white-space:nowrap">NZV-930</FONT> (from Novartis) and <FONT STYLE="white-space:nowrap">CPI-006</FONT> (from Corvus) have entered
Phase 1 clinical trials for the treatment of solid tumors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Advantages of TJD5&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Extracellular AMP can be generated from ATP, cyclic AMP and nicotinamide adenine dinucleotide (&#147;NAD&#148;) through separate biochemical pathways, all of which
converge to CD73 to generate adenosine. Thus, CD73 antibody is expected to block adenosine generation more completely than other related targets. Further, CD73 antibody works through a substrate non-competitive fashion and has advantages over small
molecule inhibitors targeting the adenosine pathway through a substrate competing fashion. More importantly, TJD5, if approved, is potentially highly differentiated among the clinical stage CD73 antibodies as it binds to a novel epitope in the <FONT
STYLE="white-space:nowrap">C-terminal</FONT> domain of CD73 without causing a &#147;hook effect.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJD5 has the following key advantages: (i)&nbsp;TJD5
exhibits a typical dose-response curve without the &#147;hook effect&#148; and with a complete inhibition of both soluble and surface-bound CD73 and (ii)&nbsp;TJD5 has a non-competitive inhibitory effect that is not blunted by high levels of CD73
enzyme substrates, which would be expected for small-molecule competitive blockers. These pharmacological properties may translate into efficient target inhibition in tumors and superior anti-tumor activity, especially in an adenosine-rich
micro-environment. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Mechanism of Action&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Adenosine
is a potent immunosuppressive signaling molecule abundant in the tumor microenvironment. CD73 is the rate-limiting enzyme that generates adenosine from extracellular AMP. TJD5 allosterically inhibits the CD73 enzyme by preventing the inactive CD73
dimer from changing into the active conformation in a substrate non-competitive manner. This results in a decrease in adenosine production in the tumor micro-environment, increasing T cell anti-tumor activity. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g53f99.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Schematic diagram of CD73-catalyzed adenosine (Ado) generation and immunosuppression by Ado in the tumor microenvironment.</I></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Summary of <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Results&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Inhibition of CD73 by TJD5. </I>As shown in the figure below, TJD5 displayed complete inhibition of soluble CD73 enzymatic activity (IC<SUB
STYLE="font-size:85%; vertical-align:bottom">50</SUB>= 0.22 n<I>M</I>) without the &#147;hook effect&#148; in contrast to the comparator molecule, which at higher concentrations caused a paradoxical rebound of enzymatic activity presumably due to
its inter-dimer binding mode. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g00i34.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>Figure: Inhibition of soluble CD73 enzymatic activity by CD73 antibodies. </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restoration of T Cell Activity by TJD5 In Vitro. </I>We observed that AMP inhibited interferon gamma <FONT STYLE="white-space:nowrap">(IFN-</FONT><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>) production by CD4 or CD8 T cells through adenosine generation, mimicking the suppressive tumor microenvironment where AMP is abundantly produced. However,
this suppression could be reversed by TJD5 in a concentration-dependent manner. Moreover, in an experimental system where CD73<SUP STYLE="font-size:85%; vertical-align:top">high</SUP> human ovarian cell line <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SK-OV-3</FONT></FONT> and human T cells were <FONT STYLE="white-space:nowrap">co-cultured,</FONT> addition of TJD5 restored T cell activity as measured by IFN<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> production in a concentration-dependent manner. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>In Vivo Anti-tumor Activity of TJD5. </I>TJD5 monotherapy showed
a moderate anti-tumor effect in a mouse xenograft model bearing A375 melanoma cells. To examine whether TJD5 can enhance the anti-tumor activity of the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody, we evaluated the therapeutic effects of
TJD5 used as a single agent and in combination with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody in the same A375 melanoma model. The combination treatment group resulted in 68% inhibition of tumor growth which is significantly better
than the vehicle and TJD5 monotherapy. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g01c14.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>In vivo anti-tumor activity of TJD5 and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> in A375 melanoma xenograft model. Mice were treated with PBS control, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> (10 mg/kg), TJD5 (5 mg/kg) or a combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> and TJD5 twice a week for
three weeks. Tumor volumes as percentages relative to baseline (day 0) for each treated group (n=7 per group) (left) and for each individual mouse (right) were plotted.</I></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmacokinetics of TJD5 in Cynomolgus Monkeys</I>. Following a single IV injection of TJD5 at 5, 25 and 50&nbsp;mg/kg, the mean Cmax
ranged dose-proportionally from 136 to 1430 &micro;g/mL, and the systemic exposure indicated by the AUC0-last increased in a <FONT STYLE="white-space:nowrap">non-linear</FONT> manner, ranging from 4020 to 135000 hr*&micro;g/mL. Mean half-life was
44.9 hours, 61.5 hours and 104 hours, respectively, reflecting decreased clearance of TJD5 with increasing dose. No apparent sex difference was observed in the main PK parameters. Positive ADAs against TJD5 were detected in the majority of the
animals, without an apparent impact on systemic exposure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g93m30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>Figure: Concentration-time profile of TJD5 in cynomolgus monkeys. </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Repeat-dose Toxicology Study of TJD5 in Cynomolgus Monkeys. </I>A four-week GLP toxicity study was conducted in cynomolgus monkeys followed by a <FONT
STYLE="white-space:nowrap">six-week</FONT> recovery period to evaluate the potential toxicity of TJD5. Forty cynomolgus monkeys were randomly assigned into four groups (5/sex/group) and given five weekly doses of TJD5 at 20, 60 or 200 mg/kg via IV
injection. Systemic exposures (Cmax and AUC<SUB STYLE="font-size:85%; vertical-align:bottom"><FONT STYLE="white-space:nowrap">0-t</FONT></SUB>) generally increased dose-proportionately, and the Day 22 values were generally higher than those on Day
1, with mean accumulation ratios (AR) ranging between 1.65 and 2.19. No apparent sex difference was observed. Positive TJD5 antibodies were detected in the majority of animals following repeat administration at all doses, while no significant impact
was observed on the TK profiles. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The only TJD5-related effect was decreased monocyte chemoattractant protein 1 <FONT STYLE="white-space:nowrap">(MCP-1)</FONT> on
Day 1 (24 or 48 hours post-dosing) in treated animals. Due to a lack of corresponding findings or impact on the well-being of the animals, this effect was not considered adverse. No abnormality was observed in other study endpoints, including safety
pharmacology parameters and immunotoxicity. The no observed adverse effect level (NOAEL) was defined at 200&nbsp;mg/kg. This dose level corresponded to the mean C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> and AUC values of
6890&nbsp;&micro;g/mL and 594000 &micro;g*hr/mL in males, respectively, and 6450 &micro;g/mL and 501000 &micro;g*hr/mL in females, respectively, on Day 22 of the dosing phase. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Clinical Development Plan&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The current clinical
development plan is to develop TJD5 in the United States and China in parallel. In the United States, we have initiated a Phase 1 clinical trial of TJD5 in combination with atezolizumab (a PD-L1 inhibitor) provided by Roche under a clinical supply
agreement among Roche, TRACON and us, in patients with advanced solid tumors in partnership with TRACON Pharmaceuticals, Inc., which will be responsible for conducting the current Phase 1 clinical trial in the United States (TJD5 is referred to as
TJ004309, NCT03835949). Seven patients have been dosed so far. Safety data of TJD5 from dose escalation cohorts are expected in 2020. In China, we have obtained the IND approval from NMPA and plan to begin a clinical trial to evaluate the safety,
tolerability, PK/PD, and potential efficacy primarily in patients with solid tumors, including lung cancer. We are collaborating with Shanghai Junshi Biosciences Co., Ltd, or Junshi, for the combination therapy of TJD5 with Junshi&#146;s PD-1
monoclonal antibody toripalimab in cancer patients with various types of solid tumors. We have not initiated any research and development activities under such collaboration arrangement as of the date of this prospectus. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Assets (Monoclonal antibodies) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ210 and TJX7 are monoclonal antibodies currently at the CMC stage, moving towards IND submission in the United States by 2020. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>TJ210: A Potential Highly Differentiated Antibody Targeting Myeloid Derived Suppressor Cells in Cancers and Autoimmune Diseases&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJ210 is a fully human, high affinity antibody against human C5aR1 for the treatment of cancers and potentially autoimmune diseases. Tumors produce large amounts of
complement factor C5a to attract C5aR1-expressing myeloid derived suppressor cells (&#147;MDSCs&#148;), M2 macrophages and neutrophils. These myeloid cells critically contribute to an immunosuppressive microenvironment as part of the evading
mechanism of tumors and are associated with poor prognosis and resistance to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies in many cancers. Inhibition of C5a or its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
receptor C5aR in mice leads to markedly reduced MDSCs and has an inhibitory effect on tumor growth in various tumor-bearing animal models. The C5aR-blocking antibody has been shown to have
significant therapeutic activity when combined with <FONT STYLE="white-space:nowrap">PD-1</FONT> therapies in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1-resistant</FONT></FONT> tumor models. TJ210 exerts strong anti-tumor
activity by blocking the activation and migration of C5aR1-expressing myeloid cells and has a highly differentiated potential, if approved, as it binds to a novel epitope and possesses superior functional properties. Compared to the only competitor
antibody from Innate Pharma, TJ210 shows a more potent anti-tumor effect, especially when C5a concentrations are high, and binds to C5a receptors in both humans and monkeys, making <FONT STYLE="white-space:nowrap">pre-clinical</FONT> safety
assessment possible. In addition, TJ210 has therapeutic potential in multiple inflammatory and autoimmune indications, in which the role of the C5a/C5aR axis has been validated. We partnered with the original developer of TJ210, MorphoSys, for
Greater China rights and shared global rights. TJ210 is progressing towards IND submission by 2020 in the United States, and we plan to work jointly with MorphoSys to develop this asset. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>TJX7: A Novel CXCL13 Antibody for Autoimmune Diseases&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TJX7 is an internally discovered novel humanized neutralizing antibody targeting the CXCL13 chemokine. CXCL13, through its receptor CXCR5, plays a key role in forming
germinal centers, which are critical for immune response. The role of CXCL13 in forming germinal centers is to guide the migration of germinal center B cells and follicular T&nbsp;cells within the lymphoid organs and facilitate their interaction,
maturation and function. One of the key pathogenic features in autoimmune diseases is related to the aberrant formation of ectopic germinal centers formed in affected organs, contributing to chronic inflammation and tissue destruction. Elevated
serum CXCL13 levels, CXCR5-expressing T cells and pathogenic germinal center B cells and even ectopic germinal center formation are found in multiple autoimmune diseases, including Sj&ouml;gren&#146;s syndrome, RA, multiple sclerosis, and SLE. TJX7
is being developed for the treatment of autoimmune disorders and has been shown to bind to CXCL13 with <FONT STYLE="white-space:nowrap">sub-nanomolar</FONT> affinity, effectively blocking the interaction between CXCL13 and CXCR5 and the downstream
signaling. TJX7 has been shown to completely inhibit the migration of primary human tonsil B cells. Pharmacodynamic studies in mice and cynomolgus monkeys have confirmed TJX7&#146;s inhibitory effects on germinal center formation and antibody
production. Results generated so far indicate that TJX7 may provide a new therapeutic angle in the treatment of autoimmune diseases as it acts uniquely at the core of tissue pathologies. TJX7 is currently under CMC and
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> development. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Assets
<FONT STYLE="white-space:nowrap">(Bi-Specific</FONT> Antibody Panel) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> <FONT STYLE="white-space:nowrap">Bi-specific</FONT> Antibodies</I>. As
previously discussed, this panel of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies is designed according to the scientific rationale that a <FONT
STYLE="white-space:nowrap">PD-L1</FONT> antibody, when engineered with a selected second immune component such as a cytokine or another antibody, is able to convert &#147;cold tumors,&#148; which typically do not respond to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> inhibitors, to &#147;hot tumors,&#148; which are more sensitive to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT>
therapies. Such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies are expected to increase the probability of treatment success in patients who
do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment. Based on this concept, we have generated a panel of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies using our
proprietary <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody sequence as the backbone (the first signal), linked to a second component (the second signal) of selected immune properties. The second signals for this panel of <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies include <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine (expanding T effector cells), <FONT STYLE="white-space:nowrap">4-1BB</FONT> and <FONT STYLE="white-space:nowrap">B7-H3</FONT>
antibodies (activating T cells synergistically with <FONT STYLE="white-space:nowrap">PD-L1)</FONT> and CD47 antibody (adding the macrophage killing mechanism). We strive to validate all bi-specific antibodies through a series of robust <I>in
vitro</I> and <I>in vivo</I> studies for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> thus providing a solid basis for further development. Collectively, we have demonstrated that the second
paired component must be structurally integrated with the tumor-engaging <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> backbone to concentrate and function effectively inside tumors, which cannot be
achieved by simply combining two free agents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>&#147;Fortified&#148; <FONT STYLE="white-space:nowrap">Bi-specific</FONT> Antibodies for Specific Cancer
Therapeutic Purposes. </I><FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> is a &#147;fortified&#148; version of the CD47 antibody, which is specifically designed for the treatment of solid tumors through the
<FONT STYLE="white-space:nowrap">CD47-mediated</FONT> macrophage killing mechanism. As the majority of tumor-associated macrophages adopt an anti-inflammatory and tumor-promoting M2 phenotype rather than a
<FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> M1 phenotype, they are less efficient in phagocytosis in response to CD47 blockade. Thus, treatment of solid tumors with the CD47 antibody may exhibit limited efficacy. <FONT
STYLE="white-space:nowrap">TJ-C4GM</FONT> is a novel molecule composed of TJC4 with an engineered <FONT STYLE="white-space:nowrap">GM-CSF</FONT> moiety fused at the <FONT STYLE="white-space:nowrap">C-terminus</FONT> of the antibody heavy chain.
GM-CSF is a potent cytokine known to convert tumor-resident M2 macrophages into tumor-engulfing M1 macrophages, which enables TJ-C4GM to exert a better phagocytic effect in solid tumors. These unique functional properties of <FONT
STYLE="white-space:nowrap">TJ-C4GM</FONT> are confirmed in a series of <I>in vitro</I> and <I>in vivo</I> tumor animal models, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
which <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> exerts superior anti-tumor activity against solid tumors, which cannot be achieved by TJC4 or <FONT STYLE="white-space:nowrap">GM-CSF</FONT>
used either alone or in combination. <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> is currently at the CMC and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development stage. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> is a <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody targeting both Claudin18.2 (CLDN18.2), a tumor
antigen preferentially expressed in gastric and pancreatic cancers, and <FONT STYLE="white-space:nowrap">4-1BB,</FONT> a co-stimulatory molecule on T cells. CLDN18.2 is a tight junction molecule normally expressed only on epithelial cells of the
gastric mucosa, which is inaccessible by antibodies under normal conditions, making it a highly attractive tumor target. Although a CLDN18.2 monoclonal antibody (claudiximab) was active in a Phase 2 trial, only the CLDN18.2 high-expressing tumors
seemed to be susceptible. In collaboration with ABL Bio, we developed a <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody, <FONT STYLE="white-space:nowrap">TJ-CLDN4B,</FONT> which provides two key advantages over current CLDN18.2
antibodies and <FONT STYLE="white-space:nowrap">4-1BB</FONT> agonistic antibodies. First, <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> is capable of binding to tumor cells even with low levels of CLDN18.2 expression, making it more suitable for
a broader patient population. Second, only upon tumor cell engagement by <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> are T cells activated. In contrast, other <FONT STYLE="white-space:nowrap">pan-activating</FONT> <FONT
STYLE="white-space:nowrap">4-1BB</FONT> antibodies that activate T cells regardless of tumor engagement are prone to liver toxicity as seen in clinical studies. In a humanized mouse model, <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> suppressed
tumor growth to a greater extent than anti-CLDN18.2 or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-4-1BB</FONT></FONT> alone or in combination. <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> is currently at the CMC and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development stage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Licensing and Collaboration Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with MorphoSys (MOR202/TJ202) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2017, we
entered into a license and collaboration agreement with MorphoSys AG (&#147;MorphoSys&#148;) with respect to the development and commercialization of MOR202/TJ202, MorphoSys&acute;s proprietary investigational antibody against CD38 (the &#147;CD38
product&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under this agreement, MorphoSys granted to us an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human
therapeutic or diagnostic purpose in the licensed territory, namely Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to this agreement, we granted to MorphoSys an exclusive license to our
rights in any inventions that we make while exploiting MOR202/TJ202 under this agreement, solely to exploit MOR202/TJ202 outside of Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also received
the right to sublicense to affiliates and third parties acting as contract manufacturers, contract research organizations, distributors or wholesalers without prior written consent, as well as the right to sublicense to other third parties with the
prior written consent of MorphoSys, not to be unreasonably withheld, delayed or conditioned. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are solely responsible for the development and commercialization of
MOR202/TJ202 in Greater China, and must use commercially reasonable efforts as we develop and commercialize MOR202/TJ202. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to this agreement, we paid to
MorphoSys an upfront license fee of US$20.0&nbsp;million. We also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate amount of
US$98.5&nbsp;million. Such milestones include first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess of a certain amount. As of the date of this prospectus, we
have made milestone payments of US$8.0 million to MorphoSys. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we are required to pay tiered low-teens royalties to MorphoSys on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis during the term, commencing with the first
commercial sale of a relevant licensed product in Greater China. The end of the royalty term is linked to (i)&nbsp;the expiration, invalidation or abandonment of relevant patent claims, (ii)&nbsp;10 years from the date of first commercial sale of
such CD38 product, and (iii)&nbsp;marketing exclusivity for such relevant licensed product. To date, we have not paid any royalties to MorphoSys. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect
until the expiration of our last payment obligation under the agreement. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. In addition, we have the right to terminate the
agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
for convenience at any time after a certain specified time period upon a notice period that varies based upon the stage of development. MorphoSys has the right to terminate the agreement if we
challenge its patents. To the extent that we terminate for convenience or MorphoSys terminates for our material breach, bankruptcy, insolvency or patent challenge, among other things, all licenses and rights granted by MorphoSys to us will
automatically terminate and the licenses and rights granted by us to MorphoSys will survive. In the event of such termination, we must also grant to MorphoSys an exclusive, royalty-bearing, sublicensable license under certain of our intellectual
property relating to the licensed product to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in Greater China. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Assignment and License
Agreement with Genexine (TJ101) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2015, <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> Tianjin Co.,
Ltd., known as Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. at the time (which subsequently became our subsidiary following the Acquisition) <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;), entered
into an intellectual property assignment and license agreement with Genexine, Inc. (&#147;Genexine&#148;), further amended in December 2017, with respect to four licensed products, namely <FONT STYLE="white-space:nowrap">GX-H9</FONT> (TJ101), <FONT
STYLE="white-space:nowrap">GX-G3</FONT> (TJ102), <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-P2</FONT> and one assigned product, <FONT STYLE="white-space:nowrap">GX-G6</FONT> (TJ103). Under this agreement,
Genexine (i)&nbsp;granted to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin an exclusive, <FONT STYLE="white-space:nowrap">non-transferable,</FONT> sublicensable license to use and otherwise exploit certain intellectual property to engage in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of the above-mentioned licensed products for (A)&nbsp;the treatment of any disease with respect to
<FONT STYLE="white-space:nowrap">GX-H9</FONT> and <FONT STYLE="white-space:nowrap">GX-G3</FONT> in China (which, for clarity excludes, Hong Kong, Macau and Taiwan), (B) the treatment of chemically induced diarrhea, with respect to <FONT
STYLE="white-space:nowrap">GX-G8</FONT> anywhere in the world and (C)&nbsp;the treatment of rheumatoid arthritis and lupus (not including psoriasis) with respect to <FONT STYLE="white-space:nowrap">GX-P2</FONT> anywhere in the world and further
(ii)&nbsp;assigned to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin a certain Chinese patent and related <FONT STYLE="white-space:nowrap">know-how</FONT> related to the assigned product (TJ103) and granted
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin an exclusive license to exploit the assigned intellectual property to engage in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution
of the assigned product (TJ103) for the treatment of any disease in China (which, for clarity, excludes Hong Kong, Macau and Taiwan). <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin will also receive an exclusive license to any improvements
that Genexine develops or acquires related to any of the aforementioned products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under this agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin paid
an aggregate upfront license fee of US$13.0&nbsp;million in relation to the patents, patent applications, <FONT STYLE="white-space:nowrap">know-how,</FONT> data and information in connection with the four licensed products and a purchase fee of
US$7.0&nbsp;million in connection with the assigned product (TJ103). <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin also agreed to make certain milestone payments, including milestone payments in the aggregate amount of US$40.0&nbsp;million
for <FONT STYLE="white-space:nowrap">GX-H9,</FONT> US$25.0&nbsp;million for TJ103 and US$15.0&nbsp;million for <FONT STYLE="white-space:nowrap">GX-G3,</FONT> conditioned upon the achievement of certain net sales targets. As of the date of this
prospectus, I-Mab Shanghai has made upfront license payment of US$0.1 million and milestone payments of US$0.5 million to Genexine. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term of this agreement is
30 years unless terminated earlier in accordance with the terms thereof. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency, in the event of force majeure or a PRC regulatory
requirement to make material alteration or modification to the contractual rights or obligations of this agreement which has the effect of preventing the parties from achieving their business objectives, or upon the termination of a certain
subscription agreement or a certain joint venture agreement entered into by I-Mab Tianjin and Genexine in October 2015 (provided that the termination of such subscription agreement or joint venture agreement was not due to the material breach of the
party electing to terminate this agreement). Genexine has the right to terminate the agreement if we fail to use commercially reasonable efforts to obtain regulatory approvals for commercializing the licensed product in the agreed period due to our
own fault or if we cease to pursue clinical development or product registration or to conduct licensed activities on a reasonable scale as approved by our board of directors. During the term of this agreement, if
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin develops or acquires any improvement, modification or alteration to the licensed products, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin will become the sole legal owner of such
improvements, modifications and alterations and has full power, right and authority to grant licenses or transfer ownership of the same. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin is required to promptly notify Genexine in writing giving
details of any such improvements, modifications or alterations and provide Genexine with such explanations or trainings to enable Genexine to legally and effectively use the same. Additionally, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin
shall grant to Genexine a fully paid up, royalty-free, exclusive license to use any such improvements, modifications and alterations anywhere outside of the territory for which <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin is licensed under
this agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with Genexine (GX-I7/TJ107) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2017, we entered into an intellectual property license agreement with Genexine with respect to <FONT STYLE="white-space:nowrap">GX-I7,</FONT> a long-acting <FONT
STYLE="white-space:nowrap">IL-7</FONT> cytokine. Under this agreement, Genexine granted to us an exclusive, sublicensable and transferable license to use and otherwise exploit certain intellectual property (including improvements subsequently
developed or acquired by Genexine) in connection with the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of <FONT STYLE="white-space:nowrap">GX-I7</FONT> to treat cancers in the
field of oncology in China, Hong Kong, Macau and Taiwan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under this agreement, we paid an upfront license fee of US$12.0&nbsp;million to Genexine. We also agreed
to make milestone payments in the aggregate amount of US$23.0&nbsp;million, conditioned upon the achievement of certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and NDA or BLA approval in any of China,
Hong Kong, Macau or Taiwan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, we agreed to make milestone payments in the aggregate amount of US$525.0&nbsp;million, conditioned upon the achievement of
certain cumulative net sales of <FONT STYLE="white-space:nowrap">GX-I7</FONT> up to US$2,000 million. We also are required to pay Genexine a <FONT STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty in respect of the total annual
net sales of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> The aforesaid milestones and royalties (other than the upfront payment) will be reduced by 50% following the entry of a generic version of <FONT STYLE="white-space:nowrap">GX-I7</FONT> in
China, Hong Kong, Macau and Taiwan without the consent or authorization of us or any of our sublicensees. As of the date of this prospectus, no milestone payments or royalties are due under this agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&nbsp;the expiry of the last to expire patent
of the licensed intellectual property that includes a valid claim for China, Hong Kong, Macau or Taiwan. and that covers the composition of <FONT STYLE="white-space:nowrap">GX-I7;</FONT> and (ii) 15 years from the date of the first commercial sale
of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency, in the event of force majeure or regulatory requirement to make material
alteration or modification to the contractual rights or obligations of this agreement which has the effect of preventing the parties from achieving their business objectives, or by mutual agreement of both parties. Genexine has the right to
terminate the agreement if we fail to use commercially reasonable efforts to obtain regulatory approvals or other registrations necessary for commercializing the licensed product in the agreed period due to our fault or if we cease to pursue
clinical development or product registration or to conduct licensed activities on a reasonable scale as agreed (&#147;Development and Commercialization Termination Events&#148;). Such Development and Commercialization Termination Events expressly
include our failure to reach certain development milestones or commercially launch the licensed product in the agreed period. To the extent that we terminate as a result of a regulatory requirement to make material alteration or modification to the
contractual rights or obligations of this agreement or Genexine terminates for our material breach, bankruptcy or insolvency, force majeure, or the Development and Commercialization Termination Events, we cannot develop, manufacture, market,
promote, sell, offer for sale, distribute or otherwise make available any competing product for a certain period after such termination. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the term of this
agreement, if we develop or acquire any improvement, modification or alteration to the licensed product, we will own such improvements, modifications or alterations and provide Genexine details thereof, whether patentable or not. Additionally, we
shall grant to Genexine a fully paid up, royalty-free. exclusive license (with a right to sublicense) to use any such improvements, modifications or alterations anywhere outside of China, Hong Kong, Macau and Taiwan. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with Ferring (TJ301) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2016, we entered into
a license and sublicense agreement with Ferring International Center SA (&#147;Ferring&#148;) with respect to (i)&nbsp;FE301, an <FONT STYLE="white-space:nowrap">interleukin-6</FONT> inhibitor, and (ii)&nbsp;all pharmaceutical formulations in
finished packaged form containing FE301 covered by certain patents or patent applications. Under this agreement, Ferring granted to us an exclusive, sublicensable license (excluding any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license
that Ferring granted to Conaris Research Institute AG under a licensing agreement entered into in November 2008) under certain Ferring intellectual property to research, develop, make, have made, import, use, sell and offer to sell FE301 (and the
licensed products containing FE301) in China, Hong Kong, Macau, Taiwan and South Korea. We also have an option to receive an exclusive, sublicensable license under certain Ferring intellectual property to research, develop, make, have made, import,
use, sell and offer to sell FE301 (and the licensed products containing FE301) in the countries in North America, the European Union and Japan that are mutually agreed upon by the parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are required to use commercially reasonable efforts to obtain approval of FE301 and to promote, market, distribute
and sell it in China, Hong Kong, Macau, Taiwan, and South Korea. Such activities are to be at our own cost and expense. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under this agreement, we paid to Ferring an
upfront license fee of US$2.0&nbsp;million. We also agreed to make milestone payments to Ferring, in the aggregate amount of US$14.5&nbsp;million, conditioned on the achievement of certain development milestones in the licensed territory, including
completion of Phase 1b and Phase 2a clinical studies and the submission and approval of the new drug application. Further, if we exercise our option to receive a license in any of the mutually agreed upon countries in North America, the European
Union and Japan, we are required to pay to Ferring an additional US$3.0&nbsp;million as an upfront license fee (upon the exercise of the option), and milestone fees up to the aggregate amount of US$30.0&nbsp;million, conditioned upon the licensed
product achieving certain development milestones in certain countries in the option territory. As of the date of this prospectus, no milestone payments are due under this agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we agreed to pay Ferring tiered royalties ranging from the <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> to high-single-digit percentages of
annual net sales for countries in China, Hong Kong, Macau, Taiwan, and South Korea, and from the high-single-digits to 10% of annual net sales for the mutually agreed upon countries in North America, the European Union and Japan. To date, we have
not paid any royalties to Ferring. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The royalty term commences with the first commercial sale of the licensed product in the relevant country and ends upon the
later of (i) 15 years from the date of launch, and (ii)&nbsp;the expiry of the last to expire patent of Ferring that includes a valid claim covering the development, making, using or selling of the licensed compound or licensed product in the
licensed territory and/or option territory. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of the expiry of the royalty term, and the first date on which we are not conducting any
necessary and outstanding clinical study with respect to the licensed product or seeking to obtain any necessary and pending regulatory approval for the licensed product, if applicable. This agreement may be terminated by either party for the other
party&#146;s uncured material breach, bankruptcy or insolvency. In addition, in the event that the original licensor terminates its license to Ferring governing any of the intellectual property sublicensed to us under this agreement, Ferring has the
right to terminate this agreement with respect to such sublicenses in which case both parties will discuss in good faith how to resolve and mitigate to mutual satisfaction. To the extent that Ferring terminates for our material breach, bankruptcy or
insolvency, among other things, all licenses and rights granted by Ferring to us will automatically terminate and the licenses and rights we granted to Ferring will survive and automatically become irrevocable with the right to sublicense. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the term of the licensing agreement, if we develop or acquire any improvement, modification, enhancement or addition to the licensed product, we will own and
retain all rights, title and interest therein, and grant to Ferring a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> fully paid, royalty-free, worldwide license thereto. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>License and Collaboration Agreement with MacroGenics (enoblituzumab) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
July 2019, we entered into a license and collaboration agreement with MacroGenics, Inc. for development and commercialization of an <FONT STYLE="white-space:nowrap">Fc-optimized</FONT> antibody known as enoblituzumab that targets <FONT
STYLE="white-space:nowrap">B7-H3,</FONT> including in combination with other agents, such as the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody known as MGA012, in the People&#146;s Republic of
China, Hong Kong, Macau and Taiwan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under this agreement, MacroGenics granted to us an exclusive, sublicensable, royalty-bearing license to MacroGenics&#146;
patents and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In exchange for these rights, in addition to certain financial consideration, we grant to MacroGenics a royalty-free, sublicensable, license outside of Greater China,
to our patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the enoblituzumab product or a product containing MGA012, and
combinations thereof. The license is <FONT STYLE="white-space:nowrap">(i)&nbsp;non-exclusive</FONT> with respect to the enoblituzumab product, and (ii)&nbsp;exclusive with regard to MGA012. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless prohibited by applicable laws and regulations, which include all international, national, federal, state, regional, provincial, municipal and local government
laws, rules, and regulations that apply to either us or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
MacroGenics or to the conduct of the collaboration under this agreement (including Good Manufacturing Practice, Good Clinical Practices, General Biological Products Standards, and the laws, rules
and regulations of the International Conference on Harmonisation, the United States, China, Hong Kong, Macau, and Taiwan, each as may be then in effect, as applicable and amended from time to time), we will
<FONT STYLE="white-space:nowrap">co-own</FONT> all clinical data generated pursuant to this agreement in any clinical trial conducted solely in Greater China, and, to the extent that such joint ownership is not legally permitted, MacroGenics will be
the sole and exclusive owner of such clinical data. MacroGenics will solely and exclusively own all other clinical data generated pursuant to this agreement. We are not aware of any applicable laws or regulations that would prohibit us from jointly
owning such clinical data and, to our knowledge, we currently qualify for such joint ownership with MacroGenics under this agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to this agreement,
we paid MacroGenics an upfront payment of US$15.0 million. We also agreed to pay MacroGenics development and regulatory milestone fees of up to US$135.0 million and tiered double-digit royalties (ranging from
<FONT STYLE="white-space:nowrap">mid-teens</FONT> to twenty percent) based on annual net sales in the territories. As of the date of this prospectus, no milestone payments or royalties are due under this agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are responsible for, and must use commercially reasonable efforts, to develop and commercialize the enoblituzumab product (which includes the enoblituzumab product
in combination with MGA012) in Greater China. This includes conducting all clinical studies required for approval, participating in a planned, global Phase 3 trial (or another mutually agreeable global clinical trial) of the enoblituzumab
combination product, the conduct of at least two Phase 2 or Phase 3 trials each targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> expressing patient populations, and submissions to regulatory authorities in Greater China. MacroGenics is
responsible for, and must use commercially reasonable efforts to, develop and commercialize the enoblituzumab product (which includes the enoblituzumab product in combination with MGA012) in the rest of the world. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are responsible for all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world, except that we are
responsible for 20% of the costs incurred in (i)&nbsp;activities supporting global clinical trials in which we participate, (ii)&nbsp;certain CMC activities for material intended to be used in clinical trials in Greater China, and
(iii)&nbsp;companion diagnostic development and validation for indications being studied in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless terminated earlier in accordance with the terms
thereof, this agreement will remain in effect, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis, until the later of (i)&nbsp;the twelfth (12th) anniversary of the first commercial sale of an enoblituzumab product in such country or region,
(ii)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> MacroGenics patent licensed under this agreement, which will occur in October 2036, and (iii)&nbsp;the expiration of the
latest data exclusivity period for the enoblituzumab product in such country or region. Since there is currently no data exclusivity protection period in China, Hong Kong, Macau or Taiwan, this agreement will remain in effect until the later of
clauses (i) and (ii). This agreement may be terminated by either party for the other party&#146;s uncured material breach, safety reasons or force majeure. In addition, we have the right to terminate the agreement for convenience at any time after a
certain specified time period upon advance notice to MacroGenics. MacroGenics has the right to terminate the agreement if we challenge its patents. To the extent that we terminate for convenience or MacroGenics terminates for our material breach,
patent challenge or safety reasons, all licenses and rights granted by MacroGenics to us will automatically terminate and the licenses and rights granted by us to MacroGenics will survive and automatically become exclusive and worldwide. To the
extent that we terminate for MacroGenics&#146; material breach or safety reasons, among other things, all licenses and rights granted by MacroGenics to us will automatically terminate. The licenses and rights granted by us to MacroGenics will also
automatically terminate to the extent we terminate for MacroGenics&#146; material breach. To the extent we terminate for safety reasons, such licenses and rights will terminate only with respect to the licensed territory and will otherwise survive
outside the licensed territory. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2018, we entered into a license and collaboration agreement with MorphoSys for MorphoSys&#146;s proprietary antibody (MOR210/TJ210) directed against C5aR
(the &#147;C5aR Agreement&#148;). Under this agreement, MorphoSys granted to us an exclusive, royalty-bearing license to explore, develop and commercialize MOR210/TJ210 in Greater China and South Korea. <FONT STYLE="white-space:nowrap">I-Mab</FONT>
will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and South Korea, including all relevant clinical trials </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
(including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. As of the date of this prospectus, we
have made an upfront payment of US$3.5 million to MorphoSys and no milestone payments or royalties are due under this agreement. MorphoSys retains rights in respect of development and commercialization of MOR210/TJ210 in the rest of the world.
Additionally, MorphoSys maintains the right to conduct activities in Greater China and South Korea that enable MorphoSys to exploit MOR210/TJ210 outside of those countries. Pursuant to the C5aR Agreement, we are required to use commercially
reasonable efforts as we develop and commercialize MOR210/TJ210 in Greater China and South Korea. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. In addition, we have the
right to terminate the agreement for convenience at any time after a certain specified time period upon a notice period that varies based upon the stage of development and for safety reasons. MorphoSys has the right to terminate the agreement if we
challenge its patents. To the extent that we terminate for convenience or MorphoSys terminates for our material breach, bankruptcy, insolvency or patent challenge, among other things, all licenses and rights granted by MorphoSys to us will
automatically terminate and the licenses and rights granted by us to MorphoSys will survive. In the event of such termination, in addition to other obligations, we must grant to MorphoSys an exclusive, royalty-bearing, sublicensable license under
certain of our intellectual property relating to the licensed product to exploit MOR210/TJ210 in Greater China and South Korea. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>B. <FONT
STYLE="white-space:nowrap">Out-Licensing</FONT> Arrangements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with ABL Bio </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2018, we entered into a license and collaboration agreement with ABL Bio (the &#147;ABL Bio License&#148;). Under the ABL Bio License, we granted to ABL Bio
exclusive, worldwide (excluding Greater China, royalty-bearing rights to develop and commercialize a bispecific antibody (the &#147;BsAb&#148;) using certain of our monoclonal antibody sequences. ABL Bio has developed expertise in the area of
bispecific antibodies for cancer treatment and has developed proprietary intellectual property around the BsAb technology, and the license allows ABL Bio to further develop and commercialize the BsAb based on monoclonal antibodies licensed from us
under the ABL Bio License. ABL Bio granted to us an exclusive, royalty-free, sublicensable license under its interest in the BsAb and related <FONT STYLE="white-space:nowrap">know-how</FONT> (including improvements thereto) to exploit the licensed
BsAb in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the ABL Bio License, we and ABL Bio each are responsible for using commercially reasonable efforts to develop the licensed products
through the completion of in vivo studies, and ABL Bio is responsible for using commercially reasonable efforts thereafter. We agreed to split costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible
for all costs and activities following that time. ABL Bio is responsible for all development and commercialization activities, subject to our input through a joint committee comprised of an equal number of our and ABL Bio&#146;s representatives
(though ABL Bio has final decision-making authority). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In consideration of the license, ABL Bio paid us an upfront fee of US$2.5&nbsp;million and agrees to make
milestone payments in the aggregate amount of US$97.5&nbsp;million conditioned upon achieving certain research, clinical development and sales milestones. Further, ABL Bio agreed to pay us royalties at
<FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentages in respect of the total annual net sales of the licensed BsAb product.<B><I> </I></B> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition, ABL Bio granted to us an exclusive, royalty-free, sublicensable license to use its BsAb technology solely to exploit the licensed BsAb product for all indications in Greater China. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also agreed that, during the term of the ABL Bio License, neither we nor ABL Bio would develop independently from the other a bispecific antibody that uses the same
pair of antibodies as the bispecific antibody molecules created under the ABL Bio License. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ABL Bio License will continue to be in effect until expiration of
the last payment obligation thereunder, unless earlier terminated according to its terms. The ABL Bio License may be terminated by either party for the other party&#146;s uncured material breach or in the event that the other party challenges its
patents. In addition, after a certain specified time period, ABL Bio may terminate the ABL Bio License upon a notice period that varies based upon the stage of development. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon expiration (but not termination) of the ABL Bio License, we and ABL Bio will each retain our respective licenses granted under the ABL Bio License. If the ABL Bio
License is terminated pursuant to ABL Bio&#146;s right to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
terminate at will or due to ABL Bio&#146;s material breach, all rights and obligations (including all licenses granted) shall terminate and upon our request, we and ABL Bio will negotiate in good
faith regarding our takeover of the exploitation of the BsAb product outside of Greater China in exchange for reasonable compensation. Such negotiation will include, among other things, ABL Bio&#146;s assignment of assets related to the licensed
BsAb product and the continuation of the licenses granted to us under the ABL Bio License. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with CSPC Entity </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2018, we entered into a product development agreement (the &#147;CSPC Agreement&#148;) with an entity controlled by CSPC Pharmaceutical Group Limited
(01093.HK) (&#147;CSPC entity&#148;). Under the CSPC Agreement, we granted to CSPC entity exclusive, <FONT STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-irrevocable</FONT> and sublicensable rights under our
patent rights in China to develop and commercialize TJ103 for treating type 2 diabetes mellitus and any other potential therapeutic applications. CSPC entity&#146;s right to sublicense is conditioned on our prior written consent, which we cannot
unreasonably withhold, other than sublicense to CSPC entity&#146;s affiliates. CSPC entity is a comprehensive pharmaceutical and drug manufacturing company, with an increasing focus on its research and development of new products focusing the
therapeutic area of oncology, among others. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the CSPC Agreement, CSPC entity is responsible for using commercially reasonable efforts to develop, obtain
market approval and commercialize the licensed products, while we are responsible for using commercially reasonable efforts to transfer the manufacturing technology of the licensed products to CSPC entity and assist or guide CSPC entity in the
continued optimization of such manufacturing technology thereafter. CSPC entity has final decision-making authority with respect to product development (though the research plan shall be jointly developed by both parties and any changes to the plan
shall be discussed and approved by the joint development committee) and commercialization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also agreed that, during the term of the CSPC Agreement, we shall not
develop, either for ourselves or for third parties, any other hyFc platform technology-based long-acting recombinant <FONT STYLE="white-space:nowrap">GLP-1</FONT> Fc fusion proteins that may be in a competitive position with TJ103. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In consideration of the license, CSPC entity paid us an upfront fee of RMB15.0&nbsp;million and agreed to make milestone payments in an aggregate amount of
RMB135.0&nbsp;million conditioned upon achieving certain clinical development and regulatory approval milestones, including completion of Phase 2 and Phase 3 clinical studies and obtaining NDA approval or market approval. Further, we will also be
entitled to tiered royalties ranging from mid-single-digit percentages to 10 percent in respect of the total annual net sales of the products after their commercialization in China. The royalty term shall terminate at the later of: (i)&nbsp;the
expiry date of the underlying patents of the licensed products with application numbers 201410851771.1 and 201580071643.8 (final grant of rights requested relating to <FONT STYLE="white-space:nowrap">GLP-1)</FONT> in China, whichever is later; and
(ii)&nbsp;the <FONT STYLE="white-space:nowrap">ten-year</FONT> anniversary of the initial commercialization of the product developed under the CSPC Agreement. We expect any patents that may issue under the aforementioned patent application numbers
201410851771.1 and 201580071643.8 will expire between 2034 and 2035, before taking into account any extension that may be obtained through patent term extensions or adjustments, or term reduction due to filing of terminal disclaimers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless terminated earlier in accordance with the terms thereof, the CSPC Agreement will remain in effect until the termination of the royalty term. This agreement may
be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency or force majeure. We have the right to terminate the agreement if CSPC entity fails to use commercially reasonable efforts to obtain
regulatory approvals for commercializing the licensed product in the period stipulated by its board of directors due to its own fault or if CSPC entity ceases to pursue clinical development or product registration as determined by its board of
directors. CSPC entity has the right to terminate the agreement if we fail to resolve certain intellectual property disputes relating to TJ103 within six months after signing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the term of the CSPC Agreement, CSPC entity shall have exclusive, royalty-free rights in China to any work product generated by us, and be responsible for any
patent application and maintenance costs of such work product. CSPC entity shall have all rights to any work product generated by itself under the CSPC Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> Arrangements </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2017, our subsidiary <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai entered into a technology transfer agreement (the &#147;HDYM License&#148;) with
Ningbo Hou De Yi Min Information Technology Co., Ltd. (&#147;HDYM&#148;) and Hangzhou HealSun Biopharm Co., Ltd. (&#147;HealSun&#148;) with respect to <FONT STYLE="white-space:nowrap">PD-L1</FONT> humanized monoclonal antibodies. HealSun is a
portfolio company of Lepu Biotech (


<IMG SRC="g713200g84s38.jpg" ALT="LOGO">
). Under the HDYM License, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai agreed to grant to HDYM exclusive (even to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai itself), worldwide and sublicensable
rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <FONT STYLE="white-space:nowrap">PD-L1</FONT> related patents, patent applications, know-hows, data and information of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, relevant cell lines as well as any <FONT STYLE="white-space:nowrap">PD-L1</FONT> monoclonal antibody arising from such cell lines for the treatment of diseases. Further, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and its cooperative party HealSun agreed to provide subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative <FONT
STYLE="white-space:nowrap">PD-L1</FONT> humanized monoclonal antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples, toxicological and
pharmacological testing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmaceutical experiment report drafting, and application for and registration of clinical trials. If any party breaches the agreement and fails to cure, the
non-breaching parties may terminate this agreement. In addition, in the event that the development of the licensed product encounters insurmountable technical difficulties, this agreement may be terminated by mutual agreement of all parties. To the
extent that the agreement is terminated for HDYM&#146;s breach, all licenses and rights granted by us to HDYM will automatically terminate and be re-assigned to us. To the extent that the agreement is terminated due to material difficulty, HDYM will
have all rights to dispose of any development data and technology held by HealSun and us under this agreement and neither HealSun or us may use such development data and technology without HDYM&#146;s consent. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>C. Collaboration Arrangements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Collaboration Agreement with
Everest </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2018, we entered into a collaboration agreement with Everest whereby both parties agreed to collaborate to
<FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary CD38 antibody (TJ202 or the CD38 product) and commercialize the CD38 product in Greater China for all indications in hematologic oncology. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the agreement, we and Everest established a joint steering committee with equal representation from each party to, among other things, coordinate and oversee the
development and commercialization regarding the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. We have final decision-making authority on matters related to the development of the CD38 product, provided
that Everest has the right to opt out of sharing of development cost increases for new work or clinical trials added to the initial development plan and budget. Everest has final decision-making authority on matters related to the commercialization
of the CD38 product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the agreement, we are primarily responsible for using commercially reasonable efforts to carry out the development, manufacture and
supply of the CD38 product, and we are also responsible for seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing with us, by the proportion of 75% for Everest and 25% for us, the development costs of the CD38
product, including payments due to MorphoSys under the License and Collaboration Agreement, dated November&nbsp;30, 2017, between us and MorphoSys. We are not required to make any upfront, milestone or royalty payments to Everest under this
agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The joint steering committee will decide whether we or Everest shall be responsible for conducting the commercialization of the CD38 product pursuant to
the commercialization plan approved by the committee. If Everest is selected to be responsible for commercialization, we shall grant an exclusive royalty-free license to Everest to commercialize the CD38 product for all indications in hematologic
oncology in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and Everest will share the CD38 product&#146;s profit and loss in proportion to the costs that each of us incur in developing the
product. The parties will also split <FONT STYLE="white-space:nowrap">out-license</FONT> revenue according to the proportion of development costs incurred, with us getting an additional five percent (5%) share and Everest receiving five percent (5%)
less. Everest cannot share in any profit from the commercialization of CD38 product until it has fulfilled its payment obligations under this agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we want to develop the CD38 product for indications other than hematologic oncology in Greater China, we must
first provide notice of such intent to Everest and, at their election, negotiate with them in good faith regarding such rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The agreement shall continue as
effective so long as we and Everest continue to develop the CD38 product for any indications in hematologic oncology in Greater China. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or
insolvency. In addition, if we fail to initiate or conduct any material development activities in relation to any therapeutic, prophylactic or palliative CD38 product for a period of three months (other than as a result of a regulatory requirement),
Everest will have the right to terminate this agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon any termination of the agreement, the terminating party has the right to continue the development and
commercialization of CD38 product. If Everest is the rightful terminating party, we shall reasonably cooperate with Everest to, among other things, (i)&nbsp;assign the MorphoSys license to Everest (subject to the terms and conditions of such
license); (ii) grant to Everest an exclusive license to all intellectual property rights we own or control to further develop, manufacture, and commercialize the CD38 product; and (iii)&nbsp;transfer the development, manufacture and
commercialization of the CD38 product to Everest, including providing reasonable technical assistance and assigning to Everest any agreement with third party vendors pertaining to the development, manufacture and commercialization of the CD38
product. In addition, the terminating party that elects to continue the development and commercialization of the CD38 product shall be solely responsible for the cost and expense of such development and commercialization after termination. In the
event that such continuing party successfully develops and commercializes the CD38 product, it shall pay to the other party a percentage of the product profit and <FONT STYLE="white-space:nowrap">out-license</FONT> income generated therefrom in
accordance with the terms of this agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November&nbsp;4, 2019, we and Everest Medicines Limited, or Everest, terminated the collaboration agreement
(including all the supplements and amendments thereto) with respect to the co-development and commercialization of TJ202 in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or
any economic interest in its commercialization. All intellectual property rights in respect of TJ202 arising from its development under the collaboration agreement are vested and owned by us, and we hold all intellectual property rights and have
maximum flexibility to further develop, manufacture and commercialize TJ202 in Greater China. In consideration of the above arrangements, we will issue a total value of US$37.0 million of ordinary shares (the &#147;CPP Shares&#148;) to Everest,
representing Everest&#146;s historical contribution to our collaboration and the associated time cost. The CPP Shares will be issued concurrently with, and subject to, the completion of this offering within 180 days from termination of the
collaboration agreement, at a per share price equal to the initial public offering price adjusted to reflect the ADS-to-ordinary share ratio. The total value of US$37.0 million was calculated based on the sum of (1) US$33.7 million, which equals
cumulative paid-in contributions historically made by Everest under the collaboration agreement; and (2) a negotiated US$3.3 million time cost of the foregoing historical contribution in light of our exclusive rights over the commercialization of
TJ202 after this termination. At an initial offering price of US$14.00 per ADS (or US$6.09 per ordinary share), Everest will be issued 6,078,571 ordinary shares and become a minority shareholder of our company upon the completion of this offering.
In the event that this offering has not been completed within 180 days from the termination of the collaboration agreement, we will issue 4,762,751 ordinary shares (the &#147;Subject Shares&#148;) to Everest on the 181st&nbsp;day. Our issuance of
ordinary shares to Everest is being made pursuant to an exemption from registration with the U.S. Securities and Exchange Commission under Regulation S of the U.S. Securities Act of 1933, as amended, or the Securities Act. Everest has agreed not to,
directly or indirectly, sell, transfer or dispose of (i) any CPP Shares for a period of 180 days after the date of this prospectus or (ii)&nbsp;any Subject Shares for a period of 180 days after their issuance. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Collaboration Arrangements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2018, we entered into a
collaboration agreement with ABL Bio whereby both parties agreed to collaborate to develop three <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> bispecific antibodies by using ABL Bio&#146;s proprietary
BsAb technology and commercialize them in their respective territories, which, collectively, include the PRC, Hong Kong, Macau, Taiwan and South Korea, and other territories throughout the rest of the world if both parties agree to do so in such
other territories during the performance of the agreement. This agreement may be terminated by either party for the other party&#146;s uncured material breach or in the event that the other party challenges its patents. Also, if a party encounters
insurmountable technical difficulties and risks, which cannot be resolved by such party within a certain period </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
thereafter despite all reasonable efforts, such party will have the right to terminate this agreement and will no longer have the right to develop the licensed product. As of the date of this
prospectus, ABL Bio has not made any upfront, milestone or royalty payments to us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In September 2018, we entered into a collaboration and platform technology
license agreement with WuXi Biologics Ireland Limited (&#147;WuXi Biologics&#148;), whereby both parties agreed to collaborate in the research and development of at least three bispecific antibodies for our company to commercialize them worldwide.
Such bispecific antibodies shall be created using our proprietary monoclonal antibodies and WuXi Biologics&#146; proprietary WuXiBody platform technology for generating bispecific antibodies, shall be developed and manufactured through the exclusive
service of WuXi Biologics. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. WuXi Biologics has the right to terminate this agreement if we challenge its patents. We have
the right to terminate this agreement if we decide to end the development and commercialization of the licensed product in the licensed territory due to scientific, technical, or commercial reasons. As of the date of this prospectus, we have made an
up-front payment of US$0.9 million to Wuxi Biologics and no milestone payments or royalties are due under this agreement. In April 2019, we extended our existing partnership with WuXi Biologics (Shanghai) Co., Ltd. (&#147;WuXi Biologics
Shanghai&#148;). We entered into a long-term, strategic collaboration agreement with WuXi Biologics Shanghai to facilitate the CMC development and GMP manufacturing of both clinical and commercial supplies of certain of our monoclonal and bispecific
antibodies and fusion products, leveraging WuXi Biologics&#146; and its affiliates&#146; expertise in this area and supporting our <FONT STYLE="white-space:nowrap">pre-existing</FONT> collaboration and platform technology license agreement with WuXi
Biologics. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2018, we entered into collaboration agreements with TRACON Pharmaceuticals, Inc. (&#147;TRACON&#148;), whereby we and TRACON agreed to
(1)&nbsp;collaborate to <FONT STYLE="white-space:nowrap">co-develop</FONT> our proprietary CD73 antibody, TJD5 and (2)&nbsp;collaborate to <FONT STYLE="white-space:nowrap">co-develop</FONT> up to five BsAbs. Both agreements may be terminated by
either party for the other party&#146;s uncured material breach, bankruptcy or insolvency or for safety reasons. In addition, the agreement in respect of TJD5 may be terminated by us: (i) for convenience within a certain period upon completing
different clinical stages subject to certain payments and royalties, based on the clinical stage, that would be owed to TRACON upon the exercise of such termination for convenience; (ii) in the event that TRACON causes the Phase 1 study timeline to
be delayed beyond the agreed extension periods; or (iii) if we decide to end the development of the collaborative product prior to its first commercial sale. Further, prior to the first commercial sale, TRACON may deem this agreement to be
terminated by us if it reasonably believes that we have discontinued all meaningful development of the collaborative product for at least 12 months and certain other conditions are met. As of the date of this prospectus, no payments or royalties are
due under this agreement. Additionally, in March 2019, we agreed with TRACON and F. Hoffmann-La Roche Ltd (&#147;Roche&#148;) on a clinical supply agreement for Roche to supply atezolizumab for use in clinical studies under the collaboration
agreement with TRACON. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success will depend
significantly on our ability to obtain and maintain patent and other proprietary protection for our drug candidates and other commercially important products, technologies, inventions and <FONT STYLE="white-space:nowrap">know-how,</FONT> as well as
on our ability to defend and enforce our patents including any patent that we have or may issue from our patent applications, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and
proprietary rights of other parties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September 30, 2019, our owned patent portfolio consist of (i) five issued patents, including two issued in the U.S., one
issued in the PRC and two issued in Korea; and (ii) 156 pending patent applications, including 17 PCT patent applications, 10 U.S. patent applications, 13 PRC patent applications and 116 patent applications in other jurisdictions. Our owned patents
and patent applications primarily relate to the drug candidates in our Global Portfolio. Furthermore, as of September 30, 2019, we in-licensed the Greater China and Korea rights relating to (i)&nbsp;20 issued patents, including 12 issued in the PRC,
one issued in Korea, five issued in Hong Kong and two issued in Taiwan; and (ii) 24 pending patent applications, including three PCT patent applications, 10 PRC patent applications, seven Hong Kong patent applications, three Taiwan patent
applications and one Korean patent application. The in-licensed patents and patent applications primarily relate to TJ202, TJ101, TJ301, enoblituzumab and TJ107. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><U>TJ202</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">As of September 30, 2019, we exclusively licensed from MorphoSys eight issued patents (including five issued in the PRC, two issued in Hong Kong and one issued in Taiwan) and six pending patent applications (including three in
the PRC and three in Hong Kong) relating to TJ202. The licensed patents include composition of matter patents in China, Hong Kong and Taiwan. The patents (including patent applications if issued) in this portfolio are expected to expire between 2025
and 2037, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><U>TJ101</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September 30, 2019, we (i) exclusively licensed from Genexine two pending PRC patent applications directly relating to TJ101 and (ii) exclusively licensed from Genexine three issued patents in the PRC relating to a hyFc
platform that develops TJ101. The licensed patents include composition of matter patents in China. The patents (including patent applications if issued) in this portfolio are expected to expire between 2028 and 2037, before taking into account any
extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><U>TJ301</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September 30, 2019, we exclusively licensed from Ferring two issued patents in the PRC and Korea relating to TJ301. The licensed patents include composition of matter patents. These patents are expected to expire in 2027,
before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><U>Enoblituzumab</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September 30, 2019, we exclusively licensed from MacroGenics six issued patents (including two issued in the PRC, three issued in Hong Kong and one issued in Taiwan) and eight pending patent applications (including two in the
PRC, four in Hong Kong and two in Taiwan) relating to enoblituzumab. The patents (including patent applications if issued) in this portfolio are expected to expire between 2023 and 2036, before taking into account any extension that may be obtained
through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><U>TJ107</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September 30, 2019, we (i) exclusively licensed from Genexine one pending PRC patent application directly relating to TJ107 and (ii) exclusively license from Genexine three issued patents in the PRC relating to a hyFc platform
that develops TJ107. The patents (including patent applications if issued) in this portfolio are expected to expire between 2028 and 2036, before taking into account any extension that may be obtained through patent term extension or adjustment, or
term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><U>TJM2</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September 30, 2019, we owned one pending PCT patent application that relates to TJM2 and it has entered national phases in China, the United States and 22 other jurisdictions. We expect that any patent that may issue under
this application will expire in 2037, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><U>TJC4 </U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September 30, 2019, we owned two pending PCT patent applications and one of them has entered national phases in the PRC, the United States and 22 other jurisdictions. We expect that any patents that may issue under these
applications will expire between 2037 and 2038, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><U>TJD5</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September 30, 2019, we owned one pending PCT patent application and it has entered national phases in the PRC, the United States, and 23 other jurisdictions. We expect that any patent that may issue under this application will
expire in 2038, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term of a patent depends upon the laws of the country in which it is issued. In most jurisdictions, a patent term is 20 years from
the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. Under the PRC Patent Law, the term </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of patent protection starts from the date of application. Patents relating to inventions are effective for twenty years, and utility models and designs are effective for ten years from the date
of application. There are no patent term adjustments or patent term extensions available in the PRC for issued patents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to patents, we rely upon
unpatented trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can
be difficult to protect. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our partners, collaborators, scientific advisors, employees, consultants and other third parties, and invention assignment
agreements with our consultants and employees. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our
proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee that
we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes or that these agreements will afford us adequate protection of our intellectual property and
proprietary information rights. If any of the partners, collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements or otherwise discloses our
proprietary information, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, as of
September 30, 2019, we had (i)&nbsp;three registered trademarks in Hong Kong, four registered trademarks in the PRC, eight trademark applications in the PRC and six trademark applications in the United States; (ii)&nbsp;nine domain names in the PRC,
including <I><FONT STYLE="white-space:nowrap">www.i-mabbiopharma.com</FONT></I>, four domain names in Hong Kong and two domain names in the United States and (iii) 12 software copyrights in the PRC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For more information on these and other risks related to intellectual property, see &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing and Supply </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our manufacturing strategy for our drug candidates
consists of two progressive steps, involving (i) using contract development and manufacturing organizations (&#147;CDMOs&#148;) and (ii) establishing our own capabilities and infrastructure, including a manufacturing facility. We believe that
development of our own manufacturing facility will provide us with enhanced control of material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes and help us achieve better long-term
margins. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently outsource the manufacturing of clinical trial material for our internally developed, IND enabling projects to leading CDMOs in China such as
WuXi Biologics, and the manufacturing of clinical trial material for clinical stage projects which were <FONT STYLE="white-space:nowrap">in-licensed</FONT> from our global partners to reputable global CDMOs, which have established track records for
both clinical trial material supply and commercial material supply. We have assembled a seasoned internal team with deep experience in this area to drive and monitor this process. For contingency planning purposes, we have also established
relationships with other CDMOs. We expect to continue our outsourcing relationships with contract manufacturers to meet the ongoing needs for the development of our drug candidates. We have framework agreements with these external service providers,
under which they provide services to us on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">project-by-project</FONT></FONT> basis. We also monitor the manufacturing activities of clinical trial material at CDMO to ensure the
compliance with local and international cGMP and applicable regulations. Currently, our contract manufacturers obtain raw materials and supplies for the manufacturing activities from multiple suppliers who we believe have sufficient capacity to meet
our demands. We typically order materials and services on a purchase order basis. We also enter into long-term capacity or minimum supply arrangements with them. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe it is advantageous that we own and control our GMP manufacturing process in order to ensure quality and secure production slots for clinical trial materials
and commercial supplies. We plan to commence the construction of our own state-of-the-art biologics manufacturing facility in China in 2020. At this manufacturing facility, we plan to produce drug substance and drug product for clinical or, in the
future, commercial use. We expect this facility to include a pilot GMP manufacturing plant with two <FONT STYLE="white-space:nowrap">500-liter</FONT> and two <FONT STYLE="white-space:nowrap">2,000-liter</FONT> single-use bioreactors, and upon
completion of the construction, a commercial scale manufacturing plant with eight more <FONT STYLE="white-space:nowrap">2,000-liter</FONT> single-use bioreactors with filling and finishing lines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Manufacturing is subject to extensive regulations governing quality management systems, manufacturing processes and
controls, personnel training, and operating procedures. The CDMOs will be required to operate under cGMP conditions. These cGMP conditions are regulatory requirements for the production of pharmaceuticals for human use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>R&amp;D Governance </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have established robust governance regime for all
stages of our research and development activities, through our internal discovery, CMC, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development programs, and through product acquisition and
<FONT STYLE="white-space:nowrap">in-licensing</FONT> strategies. The research and development governance regime has enabled our senior management to continuously oversee and monitor our company&#146;s research and development activities for
complying with applicable laws, regulations, rules, guidelines and internal policies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have established various governance and decision-making committees,
composed of senior representatives from the respective functional units to review, discuss and determine, for instance, whether a drug candidate molecule is qualified to move forward into the next stage or not, what data package is considered
appropriate and compliant to be submitted to regulatory agencies and how clinical safety of our investigational drugs will be monitored and reported. These committees make decisions over the critical &#147;checkpoints&#148; of our research and
development activities and include our (i)&nbsp;Science Committee, (ii)&nbsp;IND Scientific Advisory Committee, (iii)&nbsp;R&amp;D Project/Program/Portfolio Governance, (iv)&nbsp;Medical Safety Council, (v)&nbsp;Safety Management Team, and (vi)
Quality Committees. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Science Committee for Early Stage Research of Drug Candidates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our Science Committee is composed of selected functional heads and members of the leadership, including Dr.&nbsp;Taylor B. Guo, Dr. Zheru Zhang, Dr. Joan Huaqiong Shen,
Dr. Jane Meng, Yuan Meng, Dr. Weimin Tang, Dr.&nbsp;Chao Zhang and Dr. Zhengyi Wang, chaired by Dr.&nbsp;Taylor&nbsp;B. Guo. The Science Committee will collaborate with the management team to enhance our company&#146;s research practices and assist
management in evaluating scientific aspects of potential <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities, collaborations and new technologies that may bolster our pipeline and research and development capabilities. The Science
Committee&#146;s responsibilities include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approving the target review package submitted by our discovery group; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">providing governance on the quality and integrity of drug candidates, before entering into CMC process development;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">examining the experimental data and scientific evidence supporting the drug candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations on our company&#146;s resource allocation in further development; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">setting the direction for scientific and technical review of potential
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, our Corporate Compliance Function led by Mr.&nbsp;Thomas Song
has taken a number of steps to review the integrity and reliability of the experimental data submitted with the selected drug candidate. The design, operation and monitoring of this data integrity program is integral to our quality control and
assurance system, and is independent with respect to our research and development unit and Science Committee, to ensure the compliance with the principles of scientific data integrity, including controls over changes to, and deletions of source of
data. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>IND Scientific Advisory Committee for Drug Candidates Entering into Clinical Development Stage </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our IND Scientific Advisory Committee is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang, Dr.&nbsp;Jane Meng and Rebecca Zhang. The IND Scientific
Advisory Committee is accountable for our IND application strategy and the data quality of our IND registration dossier before submission to the FDA, the NMPA and other comparable authorities. Our IND Scientific Advisory Committee advises the
project team on policy matters and provides overall direction of new drug studies, and to that extent serves as a standing modality committee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>R&amp;D
Project/Program/Portfolio Governance (&#147;IP3 Governance&#148;) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our IP3 Governance is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang and
Dr.&nbsp;Chao Zhang, with Dr. Joan Huaqiong Shen serving as the chair. Our IP3 Governance is a decision-making body that assesses and approves research and development portfolio strategy and execution proposals from a multi-discipline perspective,
with an integrated approach incorporating scientific, clinical and commercial considerations. Our IP3 Governance aims to ensure that the project, program and/or portfolio-related decisions are logical, robust and repeatable and that our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
investments in research and development activities is aligned with our vision and strategy. The IP3 Governance responsibilities include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and determining the <FONT STYLE="white-space:nowrap">in-licensing</FONT> and
<FONT STYLE="white-space:nowrap">out-licensing</FONT> strategic plan; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing reviews on critical research and development stage gates, including clinical asset selection, GLP pharmacology
and toxicology studies, FIH studies, clinical development and regulatory submission; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing product development strategy and monitoring project timeline and costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Medical Safety Council (&#147;MSC&#148;) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our MSC is composed of
selected research and development functional heads and Subject Matter Experts, including Yuan Meng, Dr. Joan Huaqiong Shen, Michelle Yang, Rebecca Zhang, Dr. Taylor B. Guo, Dr. Jane Meng, Dr. Claire Xu and Zhengsong Zhang, chaired by Yuan Meng, Head
of Medical Office. Our MSC is the highest medical safety governance body engaged in setting standards for protecting the medical safety of patients and users of our products, and providing strategic direction in product vigilance and patient or user
safety. The MSC&#146;s responsibilities include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing standards and policies, and identifying best practices related to medical safety; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">providing oversight of all medical safety relevant activities, and overseeing the implementation of our company&#146;s
medical safety standard, as well as the outcomes of the periodic audits; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">addressing safety information that could result in a significant change in the benefit-risk profile of our products; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving FIH studies and any other issues with respect to the safety of human exposure during early
development stage. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Safety Management Teams (&#147;SMT&#148;) for Product-Related Safety System </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our SMT is composed of representatives from each research and development function, including Yuan Meng, program lead, clinical physician (on program level),
representatives of regulatory affairs (on program level), representatives of project management (on project level), external business partner (if applicable) and representatives of medical affairs (if applicable), chaired by Yuan Meng. The SMT is a
product-based, cross-functional collaborative team responsible for the review and evaluation of medical safety data arising from any source throughout the product lifecycle. Our SMT performs assessments to identify changes in safety profiles or
potential safety signals. Based on these safety evaluations, the SMT will determine the appropriate safety-related actions to be taken with respect to the product based on its benefit-risk profile for subjects in clinical trials and for patients
treated with the marketed product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our SMT works closely with and escalates safety issues, as appropriate, to the MSC to fulfill our medical safety obligations.
Our SMT is responsible for reviewing available safety information from multiple sources on a regular basis and make final decisions on safety in a timely manner with appropriate cross-functional input. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Quality Committees </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have formed two Quality Committees, namely,
I-Mab Biopharma Quality Management Review and R&amp;D Quality Council. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">I-Mab Biopharma Quality Management Review (&#147;I-Mab QMR&#148;) is composed of Dr. Joan
Huaqiong Shen, Dr. Zheru Zhang, Yuan Meng, Thomas Song and Rebecca Zhang, co-chaired by R&amp;D Quality Assurance officer Yuan Meng and CMC Quality Assurance officer Jack Qin. I-Mab QMR is a company-level cross-functional senior leadership meeting
to provide management oversight of our company&#146;s Quality Management System (&#147;QMS&#148;) and the compliance status of our company&#146;s regulated activities with applicable laws, regulations, policies and procedures, focusing on R&amp;D
and CMC GXP activities. To ensure our Corporate Quality Plan is set, key QMS elements are established and maintained, quality requirements are met, and trends, changes and risks are identified and addressed proactively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">R&amp;D Quality Council is composed of representatives from each research and development function, including Dr.&nbsp;Joan Huaqiong Shen, Niri Wu, Yuan Meng, Michelle
Yang, Dr. Claire Xu, Dr. Jane Meng, Rebecca Zhang and heads of therapeutic areas (in China and the United States), chaired by Dr. Joan Huaqiong Shen. R&amp;D Quality Council is a governance body that oversees the performance of the QMS and serves as
the final decision-making </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
body for critical quality issues that affect subject and patient safety, data integrity and compliance with global and local regulatory authorities. The QMS encompasses the structure,
responsibilities and procedures that enable the organization to identify, measure, control and enhance core regulated processes and activities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Code of
Conduct </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted a Code of Conduct that is applicable to many aspects of our business operation, such as business ethics, responsible research and
development activities, IP and data protection, workplace ethics and other corporate governance topics, as well as implementing high ethical standards that are mandatory for our employees. In addition, we have adopted an employee handbook which
describes the compliance management system implemented at <FONT STYLE="white-space:nowrap">I-Mab</FONT> to ensure compliance with applicable legal and regulatory requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quality Control and Assurance </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the research and development
governance regime described above, we have established an independent quality control and assurance system and devote significant attention to quality control for the designing, manufacturing and testing of our drug candidates. Our Assurance Board
is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang and Thomas Song. Our senior management is firmly committed to delivering our quality performance, actively involved in allocating sufficient resources to quality management system and
setting quality governance mechanism. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials, the overall quality management outlines the
implementation of our business policies and procedures in order to consistently comply with the regulatory requirements, including Good Laboratory Practices, or GLP; Good Clinical Practices, or GCP; Good Pharmacovigilance Practice, or GVP and other
applicable regulatory requirements in the performance of the trials. This includes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">predefined policies and procedures to manage <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical studies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">dedicated resources and personnel with well delineated roles and responsibilities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">quality risk management across the product lifecycle; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continuous quality management system improvement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">non-conformance</FONT> management via quality issue management process;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">development and execution of quality audit program; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory inspection readiness. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For CMC, we have established a quality management system to oversee the process development and API and drug production at the CDMOs. This system takes a holistic
approach bringing senior management, quality assurance team and company policies together to create an efficient and agile quality culture.&nbsp;Our CMC quality commitment includes, but not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">ensure that the product manufacturing, releasing, packaging, storage, and shipment meets all specifications and the
requirements of the FDA and/or NMPA&#146;s quality system regulations, cGMP or other applicable laws and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">review of process deviations and changes, root cause analysis, impact assessment, corrective and preventative actions, and
validation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">ensure the consistency of key quality practices with our CDMOs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">proactive quality system review based on audits, process data analysis, equipment condition, and periodic review of
internal and external sources of data; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">assessment of regulatory guidance and ensure readiness for regulatory inspections. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We had 59, 134
and 185 employees as of December&nbsp;31, 2017, 2018 and 2019, respectively. As of December&nbsp;31, 2019, 166 employees were located in China and 19 were located outside China. The table below sets forth our employees by function as of December 31,
2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chemistry, manufacturing and controls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Business and corporate development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We recruit our employees primarily through recruitment websites, recruiters, internal referrals and job fairs. We recruit our employees based on their qualification and
potential. We promote culture diversity, and our employees come from the United States, Taiwan and South Korea, in addition to China. The remuneration package of our employees includes salary, benefits and bonus. Our compensation programs are
designed to remunerate our employees based on their performance, measured against specified objective criteria. We are required to make contributions to social insurance and housing provident funds in accordance with PRC laws and regulations from
time to time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We provide new hire training to our employees and periodic <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">on-the-job</FONT></FONT>
training to enhance the skills and knowledge of our employees. We have not established a labor union. We have not experienced any material labor disputes or strikes that may have a material and adverse effect on our business, financial condition or
results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We enter into standard confidentiality and employment agreements with all of our key management and research staff. The contracts with our
key personnel typically include a standard <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement that prohibits the employee from competing with us, directly or indirectly, during his or her employment and for one year after the termination
of his or her employment. The contracts also typically include undertakings regarding assignment of innovations and discoveries made during the course of his or her employment. For further details regarding the terms of confidentiality and
employment agreements with our key management, see &#147;Management.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our headquarter is located in Shanghai, China, where we lease and occupy approximately 2,679 square meters as office space and laboratories. We currently lease
approximately 435 square meters of office space in Beijing, approximately 54 square meters of office space in Tianjin, approximately 49 square meters of office space in Chengdu, approximately 105 square meters of office space and laboratories in
Hong Kong, and approximately 441 square meters of office space and laboratories in Maryland. The terms of these leases range from one year to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal
Proceedings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not
presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. Regardless of the outcome,
litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal Control and
Risk Management </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have implemented various risk management policies and measures to identify, assess and manage risks arising from our operations. In
addition, we have codified risk categories identified by our management, internal and external reporting mechanisms, remedial measures and contingency management as part of our policies. For details on major risks identified by our management, see
&#147;Risk Factors&#148; in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To monitor the ongoing implementation of our risk management policies and corporate governance measures following
this offering, we have adopted or will adopt, among other things, the following risk management and internal control measures: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the establishment of an audit committee responsible for overseeing our financial records, internal control procedures and
risk management systems. See &#147;Management&#151;Committees of the Board of Directors&#148; in this prospectus for information of our audit committee members and detailed description of the responsibility of our audit committee; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the engagement of external legal advisors to advise us on compliance with relevant regulatory requirements and applicable
laws to which we will be subject to as a public company, where necessary. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, we have adopted or will adopt before this offering, various
internal regulations against corrupt and fraudulent activities, including measures against bribery and the misuse of company assets. Key measures and procedures to implement such regulations include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">authorizing our compliance department to assume responsibility for our anti-corruption and anti-fraud measures, including
handling complaints, conducting internal investigations and ensuring protection for whistleblowers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">providing anti-corruption compliance training to our senior management and employees on a periodic basis to enhance their
knowledge and compliance with applicable laws and regulations, including relevant policies and prohibitions against <FONT STYLE="white-space:nowrap">non-compliance</FONT> set out in our employee handbook; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">evaluating and undertaking rectification measures with respect to any identified corrupt or fraudulent activity, including
proposing and establishing preventative measures to avoid future <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will continue to
implement and enforce these measures and procedures to ensure ongoing compliance with all applicable laws and regulations, including the prevention of our employees from engaging in corruption, bribery or other improper conduct. During the periods
presented, we were not subject to any government investigation or litigation with respect to claims or allegations relating to monetary and <FONT STYLE="white-space:nowrap">non-monetary</FONT> bribery activities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also designated responsible personnel to monitor our ongoing compliance with relevant laws and regulations that govern our business operations, and to oversee
the implementation of any necessary measures. Meanwhile, we plan to provide our directors, senior management and relevant employees with continuing training programs and updates regarding relevant laws and regulations on a regular basis, with a view
to proactively identifying concerns or issues relating to any potential <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_16"></A>REGULATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRC Regulation </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to a variety of PRC laws, rules and
regulations affecting many aspects of our business. This section summarizes the principal PRC laws, rules and regulations that we believe are relevant to our business and operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulations on Company Establishment and Foreign Investment </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Company Law </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The establishment, operation and management of companies in
China is governed by the PRC Company Law, which was passed by the Standing Committee of the National People&#146;s Congress (the &#147;NPC&#148;), on December&nbsp;29, 1993 and came into effect on July&nbsp;1, 1994 and was latest revised or amended
on October&nbsp;26, 2018, respectively. In light of the PRC Company Law, companies established in the PRC are either in the form of a limited liability company or a joint stock company. The PRC Company Law applies to both PRC domestic companies and
foreign-invested companies, unless otherwise provided in the relevant foreign investment laws and regulations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Foreign Investment Law </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;15, 2019, the NPC approved the PRC Foreign Investment Law, which became effective on January&nbsp;1, 2020 and replaced the three old rules on foreign
investment in China, namely, the PRC Equity Joint Venture Law, the PRC Cooperation Joint Venture Law and the Wholly Foreign-Owned Enterprise Law, together with their implementation rules and ancillary regulations. The Foreign Investment Law
establishes the basic framework for the access to, and the promotion, protection and administration of foreign investments in view of investment protection and fair competition. According to the Foreign Investment Law, &#147;foreign investment&#148;
refer to investment activities directly or indirectly conducted by one or more natural persons, business entities, or other organizations of a foreign country (collectively referred to as &#147;foreign investor&#148;) within China, and
&#147;investment activities&#148; include the following activities: (i)&nbsp;a foreign investor, individually or together with other investors, establishes a foreign-invested enterprise within China; (ii)&nbsp;a foreign investor acquires stock
shares, equity shares, shares in assets, or other similar rights and interests of an enterprise within China; (iii)&nbsp;a foreign investor, individually or together with other investors, invests in a new construction project within China; and
(iv)&nbsp;investments in other means as provided by the laws, administrative regulations or the State Council. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Regulations Relating to Foreign Investment
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December 26, 2019, the State Council promulgated the Implementation Rules to the Foreign Investment Law, which became effective on January 1, 2020. The
implementation rules further clarified that the state encourages and promotes foreign investment, protects the lawful rights and interests of foreign investors, regulates foreign investment administration, continues to optimize foreign investment
environment, and advances a higher-level opening. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, <FONT STYLE="white-space:nowrap">PRC-based</FONT> investments by foreign investors shall also be
regulated by the Catalogue for the Guidance of Foreign Investment Industries (2017 Revision) issued on June&nbsp;28, 2017 and effective from July&nbsp;28, 2017, and the Special Management Measures (Negative List) for the Access of Foreign Investment
(2018)&nbsp;issued on June&nbsp;28, 2018 and effective from July&nbsp;28, 2018. According to the aforesaid catalogue and management measures, foreign-invested industries fall into four categories, namely, &#147;encouraged,&#148;
&#147;permitted,&#148; &#147;restricted&#148; and &#147;prohibited,&#148; and certain ownership requirements, requirements for senior executives and other special management measures shall apply to foreign investors with regard to the access of
foreign investments in certain categories. The Special Management Measures (Negative List) for the Access of Foreign Investment (2019) and the Catalogue of Industries for Encouraging Foreign Investment (2019 Version), which became effective on
July&nbsp;30, 2019, further reduce restrictions on the foreign investment and replaced the Special Management Measures (Negative List) for the Access of Foreign Investment (2018). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December 30, 2019, the MOFCOM and SAMR jointly promulgated Measures for Information Reporting on Foreign Investment, which became effective on January 1, 2020.
Pursuant to the Measures for Information Reporting on Foreign Investment, where a foreign investor carries out investment activities in China directly or indirectly, the foreign investor or the foreign-invested enterprise shall submit the investment
information to the competent commerce department. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>M&amp;A Rules </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According
to the Provisions on the Merger or Acquisition of Domestic Enterprises by Foreign Investors jointly issued by the MOFCOM, the State Assets Supervision and Administration Commission of the State Council, the State Administration of Taxation (the
&#147;SAT&#148;), the State Administration for Industry and Commerce (now known as the State Administration for Market Regulation), the China Securities Regulatory Commission and the State Administration of Foreign Exchange (the &#147;SAFE&#148;),
on August&nbsp;8, 2006 and amended by the MOFCOM on June&nbsp;22, 2009, among other things, (i)&nbsp;the purchase of an equity interest or subscription to the increase in the registered capital of
<FONT STYLE="white-space:nowrap">non-foreign-invested</FONT> enterprises, (ii)&nbsp;the establishment of foreign-invested enterprises to purchase and operate the assets of <FONT STYLE="white-space:nowrap">non-foreign-invested</FONT> enterprises, or
(iii)&nbsp;the purchase of the assets of <FONT STYLE="white-space:nowrap">non-foreign-invested</FONT> enterprises and the use of such assets to establish foreign-invested enterprises to operate such assets, in each case, by foreign investors shall
be subject to the Provisions on the Merger or Acquisition of Domestic Enterprises by Foreign Investors. Particularly, application shall be made for examination and approval of the acquisition of any company in China affiliating to a domestic
company, enterprise or natural person, which is made in the name of an oversea company established or controlled by such domestic company, enterprise or natural person. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>PRC Drug Regulation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Drug Administration Law of the PRC
promulgated by the Standing Committee of the NPC on September&nbsp;20, 1984 and effective from July&nbsp;1, 1985 and amended on February&nbsp;28, 2001, December&nbsp;28, 2013, April&nbsp;24, 2015 and August 26, 2019, respectively, and the
Implementing Measures of the Drug Administration Law promulgated by the State Council on August&nbsp;4, 2002 and effective from September&nbsp;15, 2002 and amended on February&nbsp;6, 2016 and March&nbsp;2, 2019, respectively, have jointly
established the legal framework for the administration of pharmaceutical products in China, including the research, development and manufacturing of new drugs. The Drug Administration Law applies to entities and individuals engaged in the
development, production, trade, application, supervision and administration of pharmaceutical products, which regulates and provides for a framework for the administration of pharmaceutical manufacturers, pharmaceutical trading companies and
medicinal preparations of medical institutions, and the development, research, manufacturing, distribution, packaging, pricing and advertisements of pharmaceutical products. The Implementing Measures of the Drug Administration Law, on the other
hand, provides detailed implementation regulations for the Drug Administration Law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The newly amended Drug Administration Law, which became effective on December
1, 2019, brought a series of changes to the drug supervision and administration system, including but not limited to the clarification of the drug marketing authorization holder system, pursuant to which the marketing authorization holder shall
assume responsibilities for non-clinical studies, clinical trials, manufacturing and marketing, post-marketing studies, monitoring, reporting and handling of adverse reactions of the drug. The amendment also stipulates that the State supports the
innovation of drugs with clinical value and specific or special effects on human diseases, encourages the development of drugs with new therapeutic mechanisms and have multi-targeted, systematic regulatory and intervention functions on human body
and promotes the technological advancement of drugs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are required to follow the above-mentioned regulations in respect of our
<FONT STYLE="white-space:nowrap">non-clinical</FONT> research, clinical trials and production of new drugs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Regulatory Authorities and Recent Government
Reorganization </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pharmaceutical products and medical devices and equipment in China are monitored and supervised on a national scale by the NMPA (formerly known
as the China Food and Drug Administration, or the &#147;CFDA&#148;), while the local provincial medical products administrative authorities are responsible for the supervision and administration of drugs within their respective administrative
regions. Pursuant to the Decision of the First Session of the Thirteenth National People&#146;s Congress on the State Council Institutional Reform Proposal made by the NPC on March&nbsp;17, 2018, the NMPA is no longer an independent agency and its
duties shall be performed by the newly established State Administration for Market Regulation, into which the various agencies responsible for, among other areas, consumer protection, advertising, anticorruption, pricing, fair competition and
intellectual property, have been merged. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The NMPA is still the chief drug regulatory agency and implements the same laws, regulations, rules, and guidelines as the
CFDA, and the NMPA regulates almost all of the key stages of the life cycle of pharmaceutical products, including <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, clinical trials, marketing approvals, manufacturing, advertising and
promotion, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
distribution, and pharmacovigilance (i.e., post-marketing safety reporting obligations). The Center for Drug Evaluation (the &#147;CDE&#148;), which remains under the NMPA, conducts the technical
evaluation of each drug and biologic application for safety and effectiveness. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Formed on March&nbsp;2018, the National Health Commission (the &#147;NHC&#148;)
(formerly known as the Ministry of Health (&#147;MOH&#148;) and the National Health and Family Planning Commission (&#147;NHFPC&#148;)) is China&#146;s chief healthcare regulator. It is primarily responsible for overseeing the operation of medical
institutions, which also serve as clinical trial sites, and regulating the licensure of hospitals and medical personnel. The NHC plays a significant role in drug reimbursement. Furthermore, the NHC and its local counterparts at or below
provincial-level local governments also oversee and organize public medical institutions&#146; centralized bidding and procurement process for pharmaceutical products, which is the chief means through which public hospitals and their internal
pharmacies acquire drugs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also, as part of its 2018 reorganization, the PRC government formed a new State Medical Insurance Bureau (the &#147;SMIB&#148;), which
focuses on regulating reimbursement under the state-sponsored insurance plans. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Clinical</FONT> Research </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August 4, 2003, the NMPA promulgated the Administrative Measures for Good Laboratories Practice of <FONT STYLE="white-space:nowrap">Non-clinical</FONT> Laboratory,
which was revised on July&nbsp;27, 2017, to improve the quality of <FONT STYLE="white-space:nowrap">non-clinical</FONT> research, and began to conduct the Good Laboratories Practice. Pursuant to the Circular on Administrative Measures for
Certification of Good Laboratory Practice for <FONT STYLE="white-space:nowrap">Non-clinical</FONT> Laboratory issued by the NMPA on April&nbsp;16, 2007, the NMPA is responsible for the certification of
<FONT STYLE="white-space:nowrap">non-clinical</FONT> research institutions nationwide and local provincial medical products administrative authorities is in charge of the daily supervision of non-clinical research institution. The NMPA decides
whether an institution is qualified for undertaking pharmaceutical <FONT STYLE="white-space:nowrap">non-clinical</FONT> research by evaluating such institution&#146;s organizational administration, its research personnel, its equipment and
facilities, and its operation and management of <FONT STYLE="white-space:nowrap">non-clinical</FONT> pharmaceutical projects. A Good Laboratory Practice Certification will be issued by the NMPA if all the relevant requirements are satisfied, which
will also be published on the NMPA&#146;s website. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Regulations for the Administration of Affairs Concerning Experimental Animals promulgated by the
State Science and Technology Commission on November&nbsp;14, 1988 and amended on January&nbsp;8, 2011, July&nbsp;18, 2013 and March&nbsp;1, 2017, respectively, by the State Council, the Administrative Measures on Good Practice of Experimental
Animals jointly promulgated by the State Science and Technology Commission and the State Bureau of Quality and Technical Supervision on December&nbsp;11, 1997, and the Administrative Measures on the Certificate for Experimental Animals (Trial)
promulgated by the State Science and Technology Commission and other regulatory authorities on December&nbsp;5, 2001, a Certificate for Use of Laboratory Animals is required for performing experimentation on animals. Applicants must satisfy the
following conditions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Laboratory animals must be qualified and sourced from institutions that have Certificates for Production of Laboratory
Animals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The environment and facilities for the animals&#146; living and propagating must meet national requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The animals&#146; feed and water must meet national requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The animals&#146; feeding and experimentation must be conducted by professionals, specialized and skilled workers, or
other trained personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The management systems must be effective and efficient; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The applicable entity must follow other requirements as stipulated by Chinese laws and regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> and Clinical Development </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The NMPA requires supporting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data for the registration applications for imported and domestic drugs. <FONT
STYLE="white-space:nowrap">Pre-clinical</FONT> work, including pharmacology and toxicology studies, must satisfy the requirements of the Administrative Measures for Good Laboratories Practice of <FONT STYLE="white-space:nowrap">Non-clinical</FONT>
Laboratory. No approval is required from the NMPA to conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">189 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Clinical Trials and Registration of New Drugs </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Categories&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Administrative Measures
for Drug Registration promulgated by the NMPA on July&nbsp;10, 2007 and effective from October&nbsp;1, 2007, which provides the standards and requirements for clinical trials and drug registration applications, drug registration applications are
divided into three different types, namely, New Drug Application, Generic Drug Application, and Imported Drug Application. Drugs are categorized based on their working mechanism, including chemical medicine, biological product or traditional Chinese
or natural medicine. As provided in the Administrative Measures for Drug Registration, the Drug Administration Law and Implementing Measures of the Drug Administration Law, upon completion of <FONT STYLE="white-space:nowrap">non-clinical</FONT>
research, clinical trials shall be conducted for the application of new drug registration, upon approval from NMPA or authorized institutions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to engaging
with the NMPA on research and development approval, an applicant shall determine the registration category for its drug candidate (subject to ultimate confirmation by the NMPA), which will determine the requirements for its clinical trial and
marketing application. There are five categories for small molecule drugs: Category 1 (&#147;innovative drugs&#148;) refers to drugs with a new chemical entity that have not been marketed anywhere in the world; Category 2 (&#147;improved new
drugs&#148;) refers to drugs with a new indication, dosage form, route of administration, combination, or certain formulation changes not previously approved anywhere in the world; Categories 3 and 4 refer to generic drugs that reference an
innovator drug (or certain well-known generic drugs) marketed either abroad or in China, respectively; and Category 5 refers to innovative or generic drugs that have already been marketed abroad but are not yet approved in China (i.e., various
imported drugs). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Approval&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All clinical trials
conducted in China for new drug development must be approved and conducted at pharmaceutical clinical trial institution which shall be under filing administration. For imported drugs, proof of foreign approval is required prior to the trial, unless
the drug has never been approved anywhere in the world. In addition to a standalone trial in China, imported drug applicants may establish a site in China as part of an international multi-center trial (the &#147;IMCT&#148;) at the outset of the
global trial. Domestically manufactured drugs are not subject to foreign approval requirements, and by contrast to prior practice, the NMPA has recently decided to also permit such drugs to be tested and developed through an IMCT. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the NMPA has adopted a notification system for clinical trials of new drugs. Pursuant to the Opinions on Deepening the Reform of the Evaluation and
Approval Systems and Encouraging Innovation on Drugs and Medical Devices (the &#147;Innovation Opinion&#148;) and the Announcement on Adjusting the Evaluation and Approval Procedure of Drug Clinical Trial, clinical trials may be commenced as long as
the applicant has not received any objections from the CDE within 60 business days of application filing, as opposed to the lengthier prior clinical trial <FONT STYLE="white-space:nowrap">pre-approval</FONT> process, in which an affirmative approval
from the NMPA must be obtained to commence clinical trials. The number of trial sites in China may increase due to the shortening of the accreditation timeline resulting from the replacement of the
<FONT STYLE="white-space:nowrap">pre-approval</FONT> procedure with the notification procedure. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Drug Clinical Trial Registration </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Administrative Measures for Drug Registration, upon obtaining the clinical trial approval and before commencing a clinical trial, the applicant shall
file a registration with the NMPA containing various details of the clinical trial, including the clinical study protocol, the name of the principal researcher of the leading institution, names of participating institutions and researchers, an
approval letter from the ethics committee, and a sample of the Informed Consent Form, with a copy sent to the competent provincial administration departments where the trial institutions will be located. On September&nbsp;6, 2013, the NMPA released
the Announcement on Drug Clinical Trial Information Platform, providing that for all clinical trials approved by the NMPA and conducted in China, instead of the aforementioned registration filed with the NMPA, clinical trial registration shall be
completed and trial information shall be published through the Drug Clinical Trial Information Platform. The applicant shall complete trial <FONT STYLE="white-space:nowrap">pre-registration</FONT> within one month after obtaining the clinical trial
approval to obtain the trial&#146;s unique registration number and shall complete registration of certain <FONT STYLE="white-space:nowrap">follow-up</FONT> information before the first subject&#146;s enrollment in the trial. If approval of the
foregoing <FONT STYLE="white-space:nowrap">pre-registration</FONT> and registration is not obtained within one year after obtaining the clinical trial approval, the applicant shall submit an explanation, and if the procedure is not completed within
three years, the clinical trial approval shall automatically expire. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">190 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Human Genetic Resources Approval&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;10, 1998, the Ministry of Science and Technology and the MOH jointly established the rules for protecting and utilizing human genetic resources in China.
On July&nbsp;2, 2015, the Ministry of Science and Technology issued the Service Guide for Administrative Licensing Items concerning Examination and Approval of Sampling, Collecting, Trading, Exporting Human Genetic Resources, or Taking Such
Resources out of the PRC, which provides that foreign-invested sponsors that sample and collect human genetic resources in clinical trials shall be required to file with the China Human Genetic Resources Management Office through its online system.
On October&nbsp;26, 2017, the Ministry of Science and Technology issued the Circular on Optimizing the Administrative Examination and Approval of Human Genetic Resources, which simplified the approval for sampling and collecting human genetic
resources for the purpose of commercializing a drug in the PRC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;10, 2019, the State Council of PRC issued the National Regulations on the Management
of Human Genetic Resources, which formalized the approval requirements pertinent to research collaborations between Chinese and foreign-owned entities. Pursuant to this new rule, a new notification system (as opposed to the advance approval approach
originally in place) is put in place for clinical trials using China&#146;s human genetic resources at clinical institutions without involving the export of human genetic resources outside of China. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Trial Exemptions and Acceptance of Foreign Data&#151; </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
NMPA may reduce its requirements for clinical trials and data, depending on the drug and the existing data. The NMPA has granted waivers for all or part of trials and has stated that it will accept data generated abroad (even if not as part of a
global study), including early phase data, that meets its requirements. On July&nbsp;6, 2018, the NMPA issued the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data (the &#147;Guidance Principles&#148;) as one of the
implementing rules for the Innovation Opinion. According to the Guidance Principles, the data of foreign clinical trials must meet the authenticity, completeness, accuracy and traceability requirements, and such data must be obtained in consistency
with the relevant requirements under the Good Clinical Trial Practice (GCP) of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (the &#147;ICH&#148;). Clinical trial sponsors
must be attentive to potentially meaningful ethnic differences in the subject population. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The NMPA now officially permits, and its predecessor agencies have
permitted on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis in the past, drugs approved outside of China to be approved in China on a conditional basis without
<FONT STYLE="white-space:nowrap">pre-approval</FONT> clinical trials being conducted in China. Specifically, in 2018, the NMPA issued the Procedures for Reviewing and Approval of Clinical Urgently Needed Overseas New Drugs, permitting drugs that
have been approved within the last ten years in the United States, the European Union or Japan and that prevent or treat orphan diseases or prevent or treat serious life-threatening illnesses for which there is either no effective therapy in China
or for which the foreign-approved drug would have clear clinical advantages. Applicants will be required to establish a risk mitigation plan and may be required to complete trials in China after the drug has been marketed. The CDE has developed a
list of qualifying drugs that meet the foregoing criteria. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Clinical Trial Process and Good Clinical Practices&#151; </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Typically, drug clinical trials in China have four phases. Phase 1 refers to the initial clinical pharmacology and human safety evaluation studies. Phase 2 refers to
the preliminary evaluation of a drug candidate&#146;s therapeutic efficacy and safety for target indication(s) in patients. Phase 3 (often the pivotal study) refers to clinical trials that further verify the drug candidate&#146;s therapeutic
efficacy and safety on patients with target indication(s) and ultimately provide sufficient evidence for the review of a drug registration application. Phase 4 refers to a new drug&#146;s post-marketing study to assess therapeutic effectiveness and
adverse reactions when the drug is widely used, to evaluate overall benefit-risk relationships of the drug when used among the general population or specific groups and to adjust the administration dose, etc. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;6, 2003, the NMPA promulgated the Administration of Quality of Drug Clinical Practice (the &#147;GCP&#148;) to improve the quality of clinical trials.
Pursuant to the newly amended Drug Administrative Law, and the Regulations on the Administration of Drug Clinical Trial Institution jointly promulgated by NMPA and NHC on November 29, 2019 and effective from December 1, 2019, drug clinical trial
institutions shall be under filing administration. Clinical trial institutions that only conduct analysis of biological samples related to clinical trials of drugs do not need to be filed. Pursuant to the Circular on Measures for Certification of
Good Laboratory Practice for Non-clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">191 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Laboratory, a Good Laboratory Practice Certification will be issued by the NMPA if all the relevant requirements are satisfied, which will also be published on the NMPA&#146;s website. Pursuant
to the Opinions on Deepening the Reform of the Evaluation and Approval System and Inspiring Innovation of Drugs and Medical Devices and Equipment, the accreditation of the institutions for drug clinical trials shall be subject to record-filing
administration. The conduct of clinical trials must adhere to the Good Laboratory Practice, and the protocols must be approved by the ethics committees of each study site. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Reform of Evaluation and Approval System for Drugs </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;9, 2015,
the State Council promulgated the Opinions on the Reform of Evaluation and Approval System for Drugs and Medical Devices and Equipment, which establishes the reform framework of the evaluation and approval system for drugs, medical devices and
equipment, indicating the enhancement of the standard of approval for drug registration and accelerating the evaluation and approval process for innovative drugs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November&nbsp;11, 2015, the NMPA issued the Circular Concerning Several Policies on Drug Registration Review and Approval, which further clarifies the measures and
policies with regard to the simplification and acceleration of the approval process for drugs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the Decision of the NMPA on Adjusting the Approval
Procedures under the Administrative Approval Items for Certain Drugs made on March&nbsp;17, 2017 and effective from May&nbsp;1, 2017, the approval for a clinical trial application can be directly issued by the CDE under the NMPA on behalf of the
NMPA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;8, 2017, the General Office of the State Council promulgated the Innovation Opinions, which further promotes the structural adjustment to and
technical innovations of drugs, medical devices and equipment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December&nbsp;21, 2017, the NMPA promulgated the Opinions on Encouraging the Prioritized
Evaluation and Approval for Drug Innovations, replacing the Opinions on Priority Review and Approval for Resolving Drug Registration Applications Backlog promulgated on February&nbsp;24, 2016, which provides for fast track clinical trial approval or
drug registration pathway to innovative drugs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On May&nbsp;23, 2018, the NMPA and the NHC jointly issued the Circular on Issues Concerning Optimizing Drug
Registration Review and Approval, which further simplifies and accelerates the clinical trial approval process. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Special Examination and Fast Track Approval for
Innovative Drugs under Current Reform Frame </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Provisions on the Administration of Special Examination and Approval of Registration of New Drugs
promulgated by the NMPA on January&nbsp;7, 2009, the NMPA conducts special examination and approval for new drug registration applications when, among others, (1)&nbsp;the effective constituent of a drug extracted from plants, animals, minerals,
etc., as well as the preparations thereof, have never been marketed in China, or the material medicines and the preparations thereof are newly discovered; (2)&nbsp;the chemical raw material medicines as well as the preparations thereof and the
biological product have not been approved for marketing anywhere in the world; (3)&nbsp;the new drugs are for treating AIDS, malignant tumors and rare diseases, etc., and have obvious advantages in clinical treatment; or (4)&nbsp;the new drugs are
for treating diseases with no effective methods of treatment. The Provisions on the Administration of Special Examination and Approval of Registration of New Drugs provides that the applicant may file for special examination and approval at the
clinical trial application stage if the drug candidate falls within items (1)&nbsp;or (2). The provisions provide that for drug candidates that fall within items (3)&nbsp;or (4), the application for special examination and approval cannot be made
until filing for production. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Circular Concerning Several Policies on Drug Registration Review and Approval issued on November&nbsp;11, 2015 further clarifies
the above-mentioned policy, potentially simplifying and accelerating the approval process of clinical trials: (x)&nbsp;a <FONT STYLE="white-space:nowrap">one-time</FONT> umbrella approval procedure allowing the overall approval of all phases of a
new drug&#146;s clinical trials, replacing the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">phase-by-phase</FONT></FONT> application and approval procedure, will be adopted for new drugs&#146; clinical trial
applications; and (y)&nbsp;a fast track drug registration or clinical trial approval pathway for the following applications: (i)&nbsp;registration of innovative new drugs treating AIDS, malignant tumors, serious infectious diseases and rare
diseases; (ii)&nbsp;registration of pediatric drugs; (iii)&nbsp;registration of drugs treating specific or prevalent diseases in elders; (iv)&nbsp;registration of drugs listed in national major science and technology projects or national key
research and development plan; (v)&nbsp;registration of innovative drugs using advanced technology, using innovative treatment methods, or having distinctive clinical benefits; (vi)&nbsp;registration of foreign innovative drugs to be manufactured
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">192 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
locally in China; (vii)&nbsp;concurrent applications for new drug clinical trials which are already approved in the United States or the European Union or concurrent drug registration
applications for drugs which have applied to the competent drug approval authorities for marketing authorization and passed such authorities&#146; onsite inspections in the United States or European Union and are manufactured using the same
production line in China; and (viii)&nbsp;clinical trial approval for drugs with urgent clinical need and patent expiry within three years, and manufacturing authorization applications for drugs with urgent clinical need and patent expiry within one
year. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Opinions on Encouraging the Prioritized Evaluation and Approval for Drug Innovations promulgated on December&nbsp;21, 2017 provides that a fast track
clinical trial approval or drug registration pathway will be available to both innovative drugs with distinctive clinical benefits, which have not been sold within or outside China, and drugs using advanced technology, innovative treatment methods
or having distinctive treatment advantages. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Opinions on the Reform of Evaluation and Approval System for Drugs and Medical Devices and Equipment promulgated on
August&nbsp;9, 2015 provides that the composition of the examiner team of the CDE shall be strengthened by, among other actions, (1)&nbsp;recruiting professional evaluation talent from the public, (2)&nbsp;engaging relevant experts to participate in
technological examination and evaluation, and (3)&nbsp;establishing a system of chief professional positions. Additionally, the Opinions on Encouraging the Prioritized Evaluation and Approval for Drug Innovations emphasizes the improvement of the
examination and evaluation system, which requires the establishment of a new drug examination and evaluation team comprising professionals specialized in clinical medicine, pharmaceutical sciences, pharmacology, toxicology and statistics. As a
result, since 2015, the NMPA and the CDE have started a large-scale expansion of examiners, which could greatly accelerate the new drug approval process in China. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Manufacturing and Distribution </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the Drug Administration Law,
all facilities that manufacture drugs in China must receive a drug manufacturing license from the local drug regulatory authority. Each drug manufacturing license issued to a pharmaceutical manufacturing enterprise is effective for a period of five
years. Any enterprise holding a drug manufacturing license is subject to review by the relevant regulatory authorities on an annual basis. A separate certification of compliance with Good Manufacturing Practice (the &#147;GMP&#148;) is also
required. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, to conduct sales, importation, shipping and storage (collectively, the &#147;distribution activities&#148;), a company must obtain a Drug
Distribution License from the local drug regulatory authority, subject to renewal every five years. A separate certification of compliance with the NMPA&#146;s drug good supply practice (the &#147;GSP&#148;), is also required. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">China has implemented a <FONT STYLE="white-space:nowrap">&#147;Two-Invoice</FONT> System&#148; to control the distribution of prescription drugs. The <FONT
STYLE="white-space:nowrap">&#147;Two-Invoice</FONT> System&#148; generally requires that no more than two invoices be issued throughout the distribution chain: one from the manufacturer to a distributor and another from the distributor to the <FONT
STYLE="white-space:nowrap">end-user</FONT> hospital. This excludes the sale of products invoiced from the manufacturer to its wholly-owned or controlled distributors, or for imported drugs, to its exclusive distributor, or from a distributor to its
wholly-owned or controlled subsidiary (or between its wholly-owned or controlled subsidiaries). However, the system still significantly limits the options for companies to use multiple distributors to reach a larger geographic area in China.
Compliance with the <FONT STYLE="white-space:nowrap">Two-Invoice</FONT> System is a prerequisite for pharmaceutical companies to participate in the procurement processes of public hospitals, which currently provide most of China&#146;s healthcare
services. Manufacturers and distributors that fail to implement the <FONT STYLE="white-space:nowrap">Two-Invoice</FONT> System may lose their qualifications to participate in the bidding process. <FONT STYLE="white-space:nowrap">Non-compliant</FONT>
manufacturers may also be blacklisted from engaging in drug sales to public hospitals in a locality. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">Two-Invoice</FONT> System
was first implemented in 11 provinces involved in pilot comprehensive medical reforms, and the program has been expanded to nearly all provinces, each with its own individual rules for the program. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>New Drug Application </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Administrative Measures for Drug
Registration, when Phases 1, 2 and 3 clinical trials have been completed, the applicant may apply to the NMPA for approval of a new drug application. The NMPA shall then determine whether to approve the application according to the comprehensive
evaluation opinion provided by the CDE of the NMPA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">193 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>International Multi-center Clinical Trials Regulations </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;30, 2015, the NMPA promulgated the Notice on Issuing the International Multi-Center Clinical Trial Guidelines (Trial), effective as of March&nbsp;1,
2015, to provide guidance on the regulation of the application, implementation and administration of international multi-center clinical trials in China. Pursuant to the Notice on Issuing the International Multi-Center Clinical Trial Guidelines
(Trial), international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicant plans to make use of the data derived from the international
multi-center clinical trials for its application to the NMPA for approval of a new drug application, such international multi-center clinical trials shall satisfy, in addition to the requirements set forth in the Drug Administration Law and its
implementation measures, the Administrative Measures for Drug Registration and other relevant laws and regulations, the following requirements: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The applicant shall first conduct an overall evaluation on the global clinical trial data and further make trend analysis
of the Asian and Chinese clinical trial data. In the analysis of Chinese clinical trial data, the applicant shall consider the representativeness of the research subjects, i.e., the participating patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The applicant shall analyze whether the amount of Chinese research subjects is sufficient to assess and adjudicate the
safety and effectiveness of the drug under clinical trial, and satisfy the statistical and relevant legal requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The onshore and offshore international multi-center clinical trial research centers shall be subject to <FONT
STYLE="white-space:nowrap">on-site</FONT> inspections by competent PRC governmental agencies. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">International multi-center clinical trials shall
follow international prevailing GCP principles and ethics requirements. Applications shall ensure the truthfulness, reliability and trustworthiness of clinical trials results; the researchers shall have the qualification and capability to perform
relevant clinical trials; and an ethics committee shall continuously review the trials and protect the subjects&#146; interests, benefits and safety. Before the performance of the international multi-center clinical trial, applicants shall obtain
clinical trial approvals or complete filings pursuant to requirements under the local regulations where clinical trials are conducted, and register and disclose the information of all major researchers and clinical trial organizations on the NMPA
drug clinical trial information platform. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Opinions on Deepening the Reform of the Evaluation and Approval System and Inspiring Innovation of Drugs
and Medical Devices and Equipment, clinical trial data obtained from foreign centers may be used to apply for registration in China as long as such data meet the relevant requirements for the registration of drugs and medical devices in China. When
using international multi-center clinical trial data to support new drug applications in China, applicants shall submit the completed global clinical trial report, statistical analysis report and database, along with relevant supporting data in
accordance with <FONT STYLE="white-space:nowrap">ICH-CTD</FONT> (International Conference on Harmonization-Common Technical Document) content and format requirements; subgroup research results summary and comparative analysis shall also be conducted
concurrently. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Marketing Authorization Holder System </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the
Opinions on the Reform of Evaluation and Approval System for Drugs and Medical Devices and Equipment promulgated on August&nbsp;9, 2015, the State Council published the policy for carrying out a pilot plan for the drug marketing authorization holder
mechanism. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the newly amended Drug Administrative Law, under the drug marketing authorization holder mechanism, an enterprise obtained drug registration
certificate and a research and development institution are eligible to be a pharmaceutical marketing authorization holder and the drug marketing authorization holder shall be responsible for nonclinical laboratory studies, clinical trials,
production and distribution, post-market studies, and the monitoring, reporting, and handling of adverse reactions in connection with pharmaceuticals in accordance with the provisions of the Drug Administrative Law. The pharmaceutical marketing
authorization holder may engage contract manufacturers for manufacturing, provided that the contract manufacturers are licensed and may engage pharmaceutical distribution enterprises with drug distribution license for the distribution activities.
Upon the approval of the medical products administrative department under the State Council, a drug marketing authorization holder may transfer the drug marketing license and the transferee shall have the capability of quality management, risk
prevention and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">194 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
control, and liability compensation to ensure the safety, effectiveness and quality controllability of drugs, and fulfill the obligations of the drug marketing license holder. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Administrative Observation Periods for New Drugs </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the
Implementing Measures of the Drug Administration Law, the NMPA may, for the purposes of protecting public health, set an administrative observation period of not more than five years for a new drug produced by a drug manufacturer. During the
administrative observation period, no approval shall be given to any other manufacturer to produce or import the said drug. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Inferiority</FONT> Standard </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In China,
a drug may receive regulatory approval without showing superiority in its primary endpoint. Rather, a drug may be approved for use if it shows <FONT STYLE="white-space:nowrap">non-inferiority</FONT> in its primary endpoint and superiority in one of
its secondary endpoints. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Packaging of Pharmaceutical Products </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant
to the Administration of Quality of Drug Clinical Practice, the applicant shall be responsible for proper packaging and labeling of drugs for clinical trials, and in double-blinded clinical trials, the test drug shall be consistent with the control
drug or placebo in appearance, odor, packaging, labeling, and certain other features. According to the Measures for the Administration of Pharmaceutical Packaging promulgated on February&nbsp;12, 1988 and effective from September&nbsp;1, 1988,
pharmaceutical packaging must comply with national and professional standards. If there is no national or professional standard available, an applicant may formulate and implement its own standards after obtaining the approval of the provincial
administration or bureau of standards. The applicant must reapply if it needs to change its own packaging standards. Drugs that have not been developed and approved for packaging standards must not be sold or marketed in the PRC (except for drugs
for the military). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>National List of Essential Drugs </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;18,
2009, the MOH and eight other ministries and commissions in the PRC issued the Provisional Measures on the Administration of the National List of Essential Drugs which was revised on February&nbsp;13, 2015 aim to promote essential medicines sold to
consumers at fair prices in the PRC and ensure that the general public in the PRC has equal access to the drugs contained in the National List of Essential Drugs. The MOH promulgated the National List of Essential Drugs on March&nbsp;13, 2013 and on
September 30, 2018. According to these regulations, basic healthcare institutions funded by the government shall store up and use drugs listed in the National List of Essential Drugs. The drugs listed in the National List of Essential Drugs shall be
purchased by centralized tender process and shall be subject to the price control by the National Development and Reform Commission (the &#147;NDRC&#148;). Remedial drugs in the National List of Essential Drugs are all listed in the NRDL and the
purchase price of such drugs is entitled to reimbursement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Government Price Controls </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Chinese government has abolished the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">15-year-old</FONT></FONT>
<FONT STYLE="white-space:nowrap">government-led</FONT> pricing system for drugs. On May&nbsp;4, 2015, the NDRC and six other ministries and commissions in the PRC issued the Opinion on Promoting Drug Pricing Reform, which lifted the
government-prescribed maximum retail price for most drugs, except for narcotic drugs and Class&nbsp;I psychotropic drugs. The government regulates drug prices mainly by establishing a consolidated procurement mechanism, restructuring medical
insurance reimbursement standards and strengthening the regulation of medical and pricing practices as discussed below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Centralized Procurement and Tenders
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the current regulations, public medical institutions owned by the government or owned by State-owned or controlled enterprises are required to purchase
pharmaceutical products through centralized online procurement processes. There are exceptions for drugs on the National List of Essential Drugs, which have their own procurement rules, and for certain drugs subject to the central government&#146;s
special control, such as toxic, radioactive and narcotic drugs and traditional Chinese medicines. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The centralized procurement process takes the form of public
tenders operated by provincial or municipal-level government agencies. The centralized tender process is typically conducted once every year. The bids are assessed by a committee randomly selected from a database of experts. The committee members
assess the bids based on a number of factors, including, but not limited to, bid price, product quality, clinical effectiveness, product safety, level of technology, qualifications and reputation of the manufacturer, after-sale services and
innovation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">195 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The State Council approved state-run centralized medicine procurement and 11 pilot cities for the program in a
circular issued on January 17, 2019. It is an effort to deepen reform of the medical and health sector and optimize the pricing system of drugs. According to the circular, in the 11 pilot cities drugs will be selected from generic brands for
centralized medicine procurement. The selected drugs must pass the consistency evaluation on quality and effectiveness. The policy is aimed at lowering drug costs for patients, reducing transaction costs for enterprises, regulating drug use of
institutions, and improving the centralized medicine procurement and pricing system. The centralized procurement is open to all approved enterprises that can produce drugs on the procurement list in China. Clinical effects, adverse reactions, and
batch stability of the drugs will be considered, and their consistency will be the main criteria for evaluation, while production capacity and stability of the supplier will also be considered. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Commercial Insurance </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;25, 2016, the State Council issued the
Plan for Healthy China 2030. According to the Plan, the country will establish a multi-level medical security system built around basic medical insurance, with other forms of insurance supplementing the basic medical insurance, including serious
illness insurance for urban and rural residents, commercial health insurance and medical assistance. Furthermore, the Plan encourages enterprises and individuals to participate in commercial health insurance and various forms of supplementary
insurance. The evolving medical insurance system makes innovative drugs more affordable and universally available to the Chinese population, which renders greater opportunities to drug manufacturers that focus on the research and development of
innovative drugs, such as high-cost cancer therapeutics. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Healthcare System Reform </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The PRC government recently promulgated several healthcare reform policies and regulations to reform the healthcare system. On March&nbsp;17, 2009, the State Council
issued the Guidelines on Strengthening the Reform of Healthcare System. On December&nbsp;27, 2016, the State Council issued the Notice on the Issuance of the 13th Five-year Plan on Strengthening the Reform of Healthcare System. On April&nbsp;25,
2017, the General Office of the State Council issued the Notice on the Main Tasks of Strengthening the Reform of Healthcare System in 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Highlights of the
aforementioned healthcare reform policies and regulations include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">One of the main objectives of the reform is to establish a basic healthcare system that covers both urban and rural
residents and provides Chinese citizens with safe, effective, convenient and affordable healthcare services. By 2020, a basic healthcare system covering both urban and rural residents shall be established. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Another main objective of the reform is to improve the healthcare system through the development of a graded hierarchical
healthcare system, modern hospital management, basic medical insurance, drug supply support and comprehensive supervision. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The reforms aimed to promote orderly market competition and improve the efficiency and quality of the healthcare system to
meet the various medical need of the Chinese population. From 2009, basic public healthcare services such as preventive healthcare, maternal and child healthcare and health education have been provided to urban and rural residents. In the meantime,
the reforms also encourage innovations by pharmaceutical companies to eliminate pharmaceutical products that fail to demonstrate reliable efficacy and positive risk-benefit ratio. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The key tasks of the reform were as follows: (1)&nbsp;to deepen the reform of public hospitals; (2)&nbsp;to accelerate the
development of a graded diagnosis and treatment system; (3)&nbsp;to consolidate and improve the universal medical insurance system; (4)&nbsp;to guarantee drug supply; (5)&nbsp;to establish and improve a comprehensive supervision system; (6)&nbsp;to
cultivate talented health-care practitioners; (7)&nbsp;to stabilize and perfect the basic public health service equalization system; (8)&nbsp;to advance the construction of health information technology; (9)&nbsp;to accelerate the development of the
health services industry generally and (10)&nbsp;to strengthen organization and implementation. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Chronic Diseases Prevention and Treatment
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Guiding Opinion of the General Office of the State Council on Promoting the Construction of the Hierarchical Healthcare System issued by the
General Office of the State Council on September&nbsp;8, 2015 and the Notice on Promoting Pilot Work for Hierarchical Healthcare System jointly promulgated by the NHFPC and the State Administration of Traditional Chinese Medicine on August&nbsp;19,
2016, the hierarchical healthcare system is expected to be gradually improved, and the framework for division and coordination among medical and health institutions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">196 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
shall be substantially established by 2017, and a diagnosis and treatment model featuring objectives, such as initial diagnosis of common diseases and frequent diseases at primary hospitals and
separate treatment of acute and chronic diseases, are expected to be gradually established. According to the Guiding Opinion of the General Office of the State Council on Promoting the Construction of the Hierarchical Healthcare System, several
chronic diseases, including hypertension, diabetes, cancer and cardiovascular and cerebrovascular diseases, are pilot diseases under the hierarchical healthcare system. Primary healthcare institutions, rehabilitation hospitals and nursing
institutions may provide treatment, rehabilitation and nursing services for patients with chronic diseases, patients in stable conditions, elderly patients, and advanced cancer patients who have clear diagnosis and stable disease conditions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;22, 2017, the General Office of the State Council issued the Notice on the Medium and Long-Term Plan for Chronic Disease Prevention and Treatment in
China (2017-2025), which sets up the objectives of the management of diabetes patients, targeting the involvement of 35&nbsp;million diabetic patients by 2020 and 40&nbsp;million by 2025 in chronic disease management. The Notice on the Medium and
Long-Term Plan for Chronic Disease Prevention and Treatment in China (2017-2025) reaffirms that the hierarchical healthcare system of chronic diseases such as diabetes shall be promoted and encourages the initial diagnosis of common diseases and
frequent diseases at primary hospitals. In addition, social participation in regional medical services, health management and chronic disease prevention services, as well as investments in the field of chronic disease prevention by social capital,
are encouraged. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual Property Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">China became a
member of the World Trade Organization and a party to the Agreement on Trade-Related Aspects of Intellectual Property Rights on December&nbsp;11, 2001. China has also entered into several international conventions on intellectual property rights,
including, but not limited to, the Paris Convention for the Protection of Industrial Property, the Madrid Agreement Concerning the International Registration of Marks, and the Patent Cooperation Treaty. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Patents </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the PRC Patent Law promulgated by the Standing
Committee of the NPC on March&nbsp;12, 1984 and amended on September&nbsp;4, 1992, August&nbsp;25, 2000 and December&nbsp;27, 2008, respectively, and effective from October&nbsp;1, 2009, and the Implementation Rules of the Patent Law of the PRC
promulgated by the State Council on June&nbsp;15, 2001 and amended on December&nbsp;28, 2002 and January&nbsp;9, 2010, respectively, patents in China fall into three categories: invention, utility model and design. An invention patent is granted to
a new technical solution proposed in respect of a product or method or an improvement of a product or method. A utility model is granted to a new technical solution that is practicable for application and proposed in respect of the shape, structure
or a combination of both of a product. A design patent is granted to the new design of a certain product in shape, pattern or a combination of both and in color, shape and pattern combinations aesthetically suitable for industrial application. Under
the PRC Patent Law, the term of patent protection starts from the date of application. Patents relating to invention are effective for twenty years, and utility models and designs are effective for ten years from the date of application. The PRC
Patent Law adopts the principle of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, which provides that where more than one person files a patent application for the same invention, a
patent will be granted to the person who files the application first. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Existing patents can become narrowed, invalid or unenforceable due to a variety of grounds,
including lack of novelty, creativity, and deficiencies in patent application. In China, a patent must have novelty, creativity and practical applicability. Under the PRC Patent Law, novelty means that before a patent application is filed, no
identical invention or utility model has been publicly disclosed in any publication in China or overseas or has been publicly used or made known to the public by any other means, whether in or outside of China, nor has any other person filed with
the patent authority an application that describes an identical invention or utility model and is recorded in patent application documents or patent documents published after the filing date. Creativity means that, compared with existing technology,
an invention has prominent substantial features and represents notable progress, and a utility model has substantial features and represents any progress. Practical applicability means an invention or utility model can be manufactured or used and
may produce positive results. Patents in China are filed with the State Intellectual Property Office (the &#147;SIPO&#148;). Normally, the SIPO publishes an application for an invention patent within 18 months after the filing date, which may be
shortened at the request of applicant. The applicant must apply to the SIPO for a substantive examination within three years from the date of application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">197 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Article 20 of the PRC Patent Law provides that, for an invention or utility model completed in China, any applicant
(not just Chinese companies and individuals), before filing a patent application outside of China, must first submit it to the SIPO for a confidential examination. Failure to comply with this requirement will result in the denial of any Chinese
patent for the relevant invention. This added requirement of confidential examination by the SIPO has raised concerns by foreign companies who conduct research and development activities in China or outsource research and development activities to
service providers in China. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Patent Enforcement </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unauthorized use of
patents without consent from owners of patents, forgery of the patents belonging to other persons, or engagement in other patent infringement acts, will subject the infringers to infringement liability. Serious offenses such as forgery of patents
may be subject to criminal penalties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When a dispute arises out of infringement of the patent owner&#146;s patent right, Chinese law requires that the parties
first attempt to settle the dispute through mutual consultation. However, if the dispute cannot be settled through mutual consultation, the patent owner, or an interested party who believes the patent is being infringed, may either file a civil
legal suit or file an administrative complaint with the relevant patent administration authority. A Chinese court may issue a preliminary injunction upon the patent owner&#146;s or an interested party&#146;s request before instituting any legal
proceedings or during the proceedings. Damages for infringement are calculated as the loss suffered by the patent holder arising from the infringement, and if the loss suffered by the patent holder arising from the infringement cannot be determined,
the damages for infringement shall be calculated as the benefit gained by the infringer from the infringement. If it is difficult to ascertain damages in this manner, damages may be determined by using a reasonable multiple of the license fee under
a contractual license. Statutory damages may be awarded in the circumstances where the damages cannot be determined by the above-mentioned calculation standards. The damage calculation methods shall be applied in the aforementioned order. Generally,
the patent owner has the burden of proving that the patent is being infringed. However, if the owner of an invention patent for manufacturing process of a new product alleges infringement of its patent, the alleged infringer has the burden of proof.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Medical Patent Compulsory License </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the PRC Patent Law, for
the purpose of public health, the SIPO may grant a compulsory license for manufacturing patented drugs and exporting them to countries or regions covered under relevant international treaties to which the PRC has acceded. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Trade Secrets </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the PRC Anti-Unfair Competition Law promulgated
by the Standing Committee of the NPC on September&nbsp;2, 1993 and amended on November&nbsp;4, 2017 and April&nbsp;23, 2019, respectively, the term &#147;trade secrets&#148; refers to technical and business information that is unknown to the public,
has utility, may create business interests or profits for its legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing
others&#146; trade secrets by (1)&nbsp;obtaining the trade secrets from the legal owners or holders by any unfair methods, such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means; (2)&nbsp;disclosing, using or
permitting others to use the trade secrets obtained illegally under item (1)&nbsp;above; (3)&nbsp;disclosing, using or permitting others to use the trade secrets, in violation of any contractual agreements or any requirements of the legal owners or
holders to keep such trade secrets in confidence; or (4) instigating, inducing or assisting others to disclose, use or permit others to use the trade secrets, in violation of any contractual agreements or any requirement of the legal owners or
holders to keep such trade secret in confidence. If a third party knows or should have known of the above-mentioned illegal conduct but nevertheless obtains, uses or discloses trade secrets of others, the third party may be deemed to have committed
a misappropriation of the others&#146; trade secrets. The parties whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities may terminate any illegal activities and impose fines on the
infringing parties. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Trademarks </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Trademark Law of the
PRC promulgated by the Standing Committee of the NPC on August&nbsp;23, 1982 and amended on February&nbsp;22, 1993, October&nbsp;27, 2001 and August&nbsp;30, 2013, respectively, and effective from May&nbsp;1, 2014, which has been amended on
April&nbsp;23, 2019 and became effective from November&nbsp;1, 2019, the period of validity for a registered trademark is ten years, commencing from the date of registration. The registrant shall go through the formalities for renewal within twelve
months prior to the expiry date of the trademark if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">198 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
continued use is intended. Where the registrant fails to do so, a grace period of six months may be granted. The validity period for each renewal of registration is ten years, commencing from the
day immediately after the expiry of the preceding period of validity for the trademark. In the absence of a renewal upon expiry, the registered trademark shall be cancelled. Industrial and commercial administrative authorities have the authority to
investigate any behavior in infringement of the exclusive right under a registered trademark in accordance with the law. In case of a suspected criminal offense, the case shall be timely referred to a judicial authority and decided according to the
law. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Domain Names </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Domain names are protected under the Measures on
Administration of Domain Names for the Chinese Internet promulgated by the Ministry of Industry and Information Technology, on November&nbsp;5, 2004 and effective from December&nbsp;20, 2004, which was replaced by the Administrative Measures on the
Internet Domain Names issued by the Ministry of Industry and Information Technology on August&nbsp;24, 2017 and effective from November&nbsp;1, 2017, and the Implementing Rules on Registration of Domain Names issued by China Internet Network
Information Center on May&nbsp;28, 2012, which became effective on May&nbsp;29, 2012. The Ministry of Industry and Information Technology is the main regulatory body responsible for the administration of PRC internet domain names. Domain name
registrations are handled through domain name service agencies established under the relevant regulations, and the applicants become domain name holders upon successful registration. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Product Liability </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Product Quality Law of the PRC promulgated by
the Standing Committee of the NPC on February&nbsp;22, 1993 and amended on July&nbsp;8, 2000, August&nbsp;27, 2009 and December&nbsp;29, 2018, respectively, is the principal governing law relating to the supervision and administration of product
quality. According to the Product Quality Law, manufacturers shall be liable for the quality of products produced by them, and sellers shall take measures to ensure the quality of the products sold by them. A manufacturer shall be liable for
compensating for any bodily injuries or property damages, other than the defective product itself, resulting from the defects in the product, unless the manufacturer is able to prove that: (1)&nbsp;the product has never been distributed;
(2)&nbsp;the defects causing injuries or damages did not exist at the time when the product was distributed; or (3)&nbsp;the science and technology at the time when the product was distributed was at a level incapable of detecting the defects. A
seller shall be liable for compensating for any bodily injuries or property damages of others caused by the defects in the product if such defects are attributable to the seller. A seller shall pay compensation if it fails to indicate either the
manufacturer or the supplier of the defective product. A person who is injured or whose property is damaged by the defects in the product may claim for compensation from the manufacturer or the seller. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the General Principles of the Civil Law of the PRC promulgated by the NPC on April&nbsp;12, 1986 and amended on August&nbsp;27, 2009, both manufacturers and
sellers shall be held liable where the defective products result in property damages or bodily injuries to others. Pursuant to the Tort Liability Law of the PRC promulgated by the Standing Committee of the NPC on December&nbsp;26, 2009 and effective
from July&nbsp;1, 2010, manufacturers shall assume tort liabilities where the defects in products cause damages to others. Sellers shall assume tort liabilities where the defects in products that have caused damages to others are attributable to the
sellers. The aggrieved party may claim for compensation from the manufacturer or the seller of the defected product that has caused damage. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulation of
Commercial Bribery </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pharmaceutical companies involved in a criminal investigation or administrative proceedings related to bribery are listed in the Adverse
Records of Commercial Briberies by their respective provincial health and family planning administrative department. Pursuant to the Provisions on the Establishment of Adverse Records of Commercial Briberies in the Medicine Purchase and Sales
Industry which became effective on March&nbsp;1, 2014, provincial health and family planning administrative departments formulate the implementing measures for establishment of Adverse Records of Commercial Briberies. Where a pharmaceutical company
or its agent is listed in the Adverse Records of Commercial Briberies on one occasion, it will be prohibited from participating in the procurement bidding process or selling its products to public medical institutions located in the local
provincial-level region for two years from the publication of the adverse records. The evaluation points of such pharmaceutical company or agent in respect of the procurement bidding process and procurement by public medical institutions must be
credited by public medical institutions in the other provincial-level regions for two years from the publication of the adverse records. Where a pharmaceutical company or its agent is listed in the Adverse Records of Commercial Briberies on two or
more occasions within five years, it will be prohibited from participating in the procurement bidding process or selling its products to all public medical institutions in the PRC for two years from the publication of these adverse records. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">199 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulations Relating to Employee Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February&nbsp;2012, the SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock
Incentive Plans of Overseas Publicly Listed Companies (the &#147;Stock Option Rules&#148;), which replaced the Application Procedures of Foreign Exchange Administration for Domestic Individuals Participating in Employee Stock Ownership Plans or
Stock Option Plans of Overseas Publicly Listed Companies issued by the SAFE on March&nbsp;28, 2007. In accordance with the Stock Option Rules and relevant rules and regulations, PRC citizens or <FONT STYLE="white-space:nowrap">non-PRC</FONT>
citizens residing in China for a continuous period of not less than one year, who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with the SAFE through a domestic
qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain procedures. We and our employees who are PRC citizens or who reside in China for a continuous period of not less than one year and who participate
in our stock incentive plan will be subject to such regulation. In addition, the SAT has issued circulars concerning employee share options or restricted shares. Under these circulars, employees working in the PRC who exercise share options, or
whose restricted shares vest, will be subject to PRC individual income tax (the &#147;IIT&#148;). The PRC subsidiaries of an overseas listed company have obligations to file documents related to employee share options or restricted shares with
relevant tax authorities and to withhold IIT of those employees related to their share options or restricted shares. If the employees fail to pay, or the PRC subsidiaries fail to withhold, their IIT according to relevant laws, rules and regulations,
the PRC subsidiaries may face sanctions imposed by the tax authorities or other PRC government authorities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulations Relating to Foreign Exchange and the
Dividend Distribution </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Foreign Exchange Control </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The State
Council promulgated the PRC Regulation for the Foreign Exchange on January&nbsp;29, 1996, which was amended on January&nbsp;14, 1997 and August&nbsp;5, 2008, respectively. On June&nbsp;20, 1996, the People&#146;s Bank of China promulgated the
Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment, which came into effect on July&nbsp;1, 1996. Pursuant to the above-mentioned regulations, foreign exchanges required for distribution of profits and payment of
dividends may be purchased from designated foreign exchange banks in the PRC upon presentation of a board resolution authorizing the distribution of profits or payment of dividends. The Regulation on the Administration of the Foreign Exchange
Settlement, Sales and Payment removed the previous restrictions on convertibility of foreign exchange in respect of current account items, including the distribution of dividends, interest and royalty payments, trade and service-related foreign
exchange transactions, while foreign exchange transactions in respect of capital account items, such as direct investment, loan, securities investment and repatriation of investment, remain subject to the approval of the SAFE. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November&nbsp;19, 2012, the SAFE issued the Operating Rules for Foreign Exchange Issues with Regard to Direct Investment under Capital Account as an appendix to the
Circular of the SAFE on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment, which was issued on November&nbsp;19, 2012 and amended on May&nbsp;4, 2015. According to the Circular of the SAFE on Further Improving and
Adjusting the Foreign Exchange Policies on Direct Investment, (i)&nbsp;the opening of and payment into foreign exchange accounts under direct investment accounts are no longer subject to approval by the SAFE; (ii)&nbsp;reinvestment with the legal
income of foreign investors in China is no longer subject to approval by the SAFE; (iii)&nbsp;the procedures for capital verification and confirmation that foreign-funded enterprises need to go through are simplified; (iv)&nbsp;the purchase and
external payment of foreign exchange under direct investment accounts are no longer subject to approval by the SAFE; (v)&nbsp;domestic transfer of foreign exchange under direct investment accounts is no longer subject to approval by the SAFE; and
(vi)&nbsp;the administration over the conversion of foreign exchange capital of foreign-funded enterprises is improved. On February&nbsp;13, 2015, the SAFE issued the Circular on Further Simplifying and Improving Foreign Exchange Administration
Policies in Respect of Direct Investment, which came into effect on June&nbsp;1, 2015, providing that the banks, instead of the SAFE, can directly handle the foreign exchange registration and approval under foreign direct investment, while the SAFE
and its branches indirectly supervise the foreign exchange registration and approval under foreign direct investment through the banks. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On May&nbsp;11, 2013, the
SAFE promulgated the Provisions on the Administration of Foreign Exchange in Foreign Direct Investments by Foreign Investors, which became effective on May&nbsp;13, 2013, and relevant supporting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">200 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
documents that regulate and clarify the administration over foreign exchange administration in foreign direct investments. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;30, 2015, the SAFE released the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested
Enterprises, which came into effect on June&nbsp;1, 2015 and superseded the Notice on the Relevant Operating Issues Concerning the Improvement of the Administration of Payment and Settlement of Foreign Currency Capital of Foreign-funded Enterprises
issued by the SAFE on August&nbsp;29, 2008. The Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises has made certain adjustments to some regulatory requirements on the
settlement of foreign exchange capital of foreign-invested enterprises, and some foreign exchange restrictions provided in the Notice on the Relevant Operating Issues Concerning the Improvement of the Administration of Payment and Settlement of
Foreign Currency Capital of Foreign-funded Enterprises. On June&nbsp;9, 2016, the SAFE issued the Circular on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects. Under the Circular on the Reform and
Standardization of the Management Policy of the Settlement of Capital Projects and the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises, the settlement of foreign exchange
by foreign-invested enterprises shall be governed by the policy of foreign exchange settlement on a discretionary basis. However, the aforementioned circulars also reiterate that the settlement of foreign exchange shall only be used for its own
operation purposes within the business scope of the foreign-invested enterprises and following the principles of authenticity. Considering that these circulars are relatively new, it is unclear how they will be implemented, and there exist great
uncertainties with respect to their interpretation and implementation by the authorities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The SAFE promulgated the Circular on Relevant Issues Concerning Foreign
Exchange Control on Domestic Residents&#146; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles on July 4, 2014, which requires PRC residents to register with local branches of the SAFE in connection with
their direct establishment or indirect control of an offshore entity for the purpose of overseas investment and financing, with such PRC residents&#146; legally owned assets or equity interests in domestic enterprises or offshore assets or interests
as a &#147;special purpose vehicle&#148; as defined therein. The aforesaid circular further requires amendment to the registration in the event of any significant changes with respect to the special purpose vehicle. Failure to comply with the SAFE
registration requirements under the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles could result in liabilities
under PRC law for evasion of foreign exchange controls. The Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, provides that local banks, instead of the SAFE, can directly handle
the initial foreign exchange registration and amendment registration under the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore Investment and Financing and Roundtrip Investment through Special
Purpose Vehicles. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dividend Distribution </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the PRC Company
Law, the Wholly Foreign-Owned Enterprise Law of the PRC and the Detailed Implementing Rules for the Wholly Foreign-Owned Enterprise Law of the People&#146;s Republic China, foreign-invested enterprises in the PRC may pay dividends only out of their
accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a foreign-invested enterprise is required to set aside at least 10% of its accumulated profits each year to fund certain reserve funds, until
the accumulative amount of such fund reaches 50% of its registered capital. These wholly foreign-owned companies may also allocate a portion of their <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to
employee welfare and bonus funds. Amounts allocated to these reserve funds and employee welfare and bonus funds reduce the amount distributable as cash dividends. Upon approval of the competent governmental authorities, foreign investors may utilize
RMB dividends to invest or <FONT STYLE="white-space:nowrap">re-invest</FONT> in enterprises established in China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;26, 2017, the SAFE issued the
Notice on Improving the Check of Authenticity and Compliance to Further Promote Foreign Exchange Control, which stipulates several capital control measures with respect to outbound remittance of profits from domestic entities to offshore entities,
including the following: (i)&nbsp;under the principle of genuine transaction, banks shall check board resolutions regarding profit distribution, the original version of tax filing records and audited financial statements; and (ii)&nbsp;domestic
entities shall hold income to account for previous years&#146; losses before remitting the profits. Moreover, domestic entities shall provide detailed explanations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">201 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of the sources of capital and the utilization arrangements and board resolutions, contracts and other proof when completing the registration procedures in connection with an outbound investment.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulations Relating to Labor </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Labor Law and Labor Contract
Law </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the PRC Labor Law promulgated by the Standing Committee of the NPC on July&nbsp;5, 1994 and effective from January&nbsp;1, 1995 and amended on
August&nbsp;27, 2009 and December&nbsp;29, 2018, respectively, the PRC Labor Contract Law promulgated by the Standing Committee of the NPC on June&nbsp;29, 2007 and effective from January&nbsp;1, 2008 and amended on December&nbsp;28, 2012 and
effective from July&nbsp;1, 2013, and the Implementing Regulations of the Employment Contracts Law of the PRC promulgated by the State Council on September&nbsp;18, 2008, labor contracts in written form shall be executed to establish labor
relationships between employers and employees. Wages cannot be lower than the local minimum wage. The employer must establish a system for labor safety and sanitation, strictly abide by the state rules and standards, provide education regarding
labor safety and sanitation to its employees, provide employees with labor safety and sanitary conditions and necessary protection materials in compliance with the state rules and standards, and carry out regular health examinations for employees
engaged in work involving occupational hazards. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Social Insurance and Housing Provident Funds </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under applicable PRC laws, including the Social Insurance Law of the PRC which became effective on July&nbsp;1, 2011 and was amended on December&nbsp;19, 2018, the
Interim Regulations on the Collection and Payment of Social Security Funds promulgated by the State Council on January&nbsp;22, 1999 and amended on March&nbsp;24, 2019, and the Regulations on the Administration of Housing Provident Funds promulgated
by the State Council on April&nbsp;3, 1999 and amended on March&nbsp;24, 2002 and March&nbsp;24, 2019, respectively, employers are required to contribute, on behalf of their employees, to a number of social security funds, including funds for basic
pension insurance, unemployment insurance, basic medical insurance, occupational injury insurance, maternity insurance and housing provident funds. These payments are made to local administrative authorities, and any employer who fails to contribute
may be fined and ordered to pay the deficit amount within a stipulated time limit. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulations Relating to Enterprise Income Tax </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Enterprise Income Tax Law of the PRC effective as of January&nbsp;1, 2008 and as amended on February&nbsp;24, 2017 and December&nbsp;29, 2018,
respectively, the income tax rate for both domestic and foreign-invested enterprises is 25% with certain exceptions. To clarify certain provisions in the Enterprise Income Tax Law, the State Council promulgated the Implementation Rules of the
Enterprise Income Tax Law on December&nbsp;6, 2007, which was amended and became effective on April 23, 2019. Under the Enterprise Income Tax Law and the Implementation Rules of the Enterprise Income Tax Law, enterprises are classified as either
&#147;resident enterprises&#148; or <FONT STYLE="white-space:nowrap">&#147;non-resident</FONT> enterprises.&#148; Besides enterprises established within the PRC, enterprises established outside of China whose &#147;de facto management bodies&#148;
are located in China are considered &#147;resident enterprises&#148; and subject to the uniform 25% enterprise income tax rate for their global income. In addition, the Enterprise Income Tax Law provides that a
<FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise refers to an entity established under foreign law whose &#147;de facto management bodies&#148; are not within the PRC, but has an establishment or place of business in the PRC, or does
not have an establishment or place of business in the PRC but has income sourced within the PRC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Implementation Rules of the Enterprise Income Tax Law provide
that since January&nbsp;1, 2008, an income tax rate of 10% shall normally be applicable to dividends declared to <FONT STYLE="white-space:nowrap">non-PRC</FONT> resident enterprise investors that do not have an establishment or place of business in
the PRC, or have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived from sources within the PRC. The income tax on the
dividends may be reduced pursuant to a tax treaty between China and the jurisdictions in which the <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders reside. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other PRC National- and Provincial-Level Laws and Regulations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are
subject to changing regulations under many other laws and regulations administered by governmental authorities at the national, provincial and municipal levels, some of which are or may become applicable to our business. For example, regulations
control the confidentiality of patients&#146; medical information and the circumstances under which patient medical information may be released for inclusion in our databases, or released by us to third parties. These laws and regulations governing
both the disclosure and the use of confidential patient medical information may become more restrictive in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">202 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also comply with numerous additional national and provincial laws relating to matters such as safe working
conditions, manufacturing practices, environmental protection and fire hazard control. We believe that we are currently in compliance with these laws and regulations; however, we may be required to incur significant costs to comply with these laws
and regulations in the future. Unanticipated changes in existing regulatory requirements or adoption of new requirements could therefore have a material adverse effect on our business, results of operations and financial condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>U.S. Regulation </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Government Regulation and Product Approval in the
United States </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and other regulatory authorities in the United States at federal, state and local levels, as well as in foreign countries,
extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion,
marketing, post-approval monitoring and post-approval reporting of biological products. Along with third-party contractors, we will be required to navigate the various <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical and commercial
approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our drug candidates. The processes for obtaining regulatory approvals in the United States and in
foreign jurisdictions, along with subsequent compliance with applicable laws and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Government policies may change and additional government regulations may be enacted that could prevent or delay further development or regulatory approval of any of our
drug candidates, or anticipated manufacturing processes, disease indications, or labeling. We cannot predict the likelihood, nature or extent of government regulation that might arise from future legislative or administrative action. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Review and Approval for Licensing Biologics in the United States </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
the United States, the FDA regulates our current drug candidates as biological products, or biologics, under the Federal Food, Drug, and Cosmetic Act (the &#147;FDCA&#148;), the Public Health Service Act and associated implementing regulations.
Biologics, like other drugs, are used for the treatment, prevention or cure of disease in humans. In contrast to chemically synthesized small molecular weight drugs, which have a well-defined structure and can be thoroughly characterized, biologics
are generally derived from living material (human, animal, or microorganism) and are complex in structure, and thus are usually not fully characterized. Biologics include immunomedicines for cancer and other diseases. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biologics are also subject to other federal, state and local statutes and regulations. The failure to comply with applicable statutory and regulatory requirements at
any time during the product development process, approval process or after approval may subject a sponsor or applicant to administrative or judicial enforcement actions. These actions could include the suspension or termination of clinical trials by
the FDA, the FDA&#146;s refusal to approve pending applications or supplemental applications, withdrawal of an approval, &#147;Warning Letters&#148; (official messages from the FDA to a manufacturer or other organization that it has violated some
rule in a federally regulated activity) or &#147;Untitled Letters&#148; (initial correspondences from the FDA with a regulated industry that cite violations that do not meet the threshold of regulatory significance for a Warning Letter and request
correction of the violation), product recalls, product seizures, total or partial suspension of production or distribution, import detention, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or
criminal investigations and penalties brought by the FDA, the Department of Justice (the &#147;DOJ&#148;), or other governmental entities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An applicant seeking
approval to market and distribute a biologic in the United States typically must undertake the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completion of <FONT STYLE="white-space:nowrap">non-clinical</FONT> laboratory tests and animal studies performed in
accordance with the FDA&#146;s good laboratory practice (the &#147;GLP&#148;), regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the FDA of an application for an Investigational New Drug (&#147;IND&#148;), which must become effective
before clinical trials may begin and must be updated annually or when significant changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacture, labeling and distribution of an investigational drug in compliance with current good manufacturing practice
(the &#147;cGMP&#148;); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">203 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approval by an independent institutional review board (the &#147;IRB&#148;), or ethics committee at each clinical site
before each clinical trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#146;s current Good Clinical
Practices requirements (the &#147;cGCP&#148;), to establish the safety, purity and potency of the proposed biological drug candidate for its intended purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparation of and submission to the FDA of a biologics license application (&#147;BLA&#148;), after completion of all
pivotal clinical trials requesting marketing approval for one or more proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of an FDA Advisory Committee review, where appropriate or if applicable, as may be requested by
the FDA to assist with its review; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the proposed
product, or components thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#146;s identity, safety, quality, purity and
potency; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of FDA audits of selected clinical investigation sites to assure compliance with cGCP requirements
and the integrity of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">payment of user fees under the Prescription Drug User Fee Act (the &#147;PDUFA&#148;), for the relevant year;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining FDA review and approval of the BLA to permit commercial marketing of the licensed biologic for particular
indications for use in the United States; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and
Mitigation Strategy (the &#147;REMS&#148;), and the potential requirement to conduct post-approval studies. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The testing and approval process
requires substantial time, effort and financial resources and we cannot be certain that any approvals for our drug candidates will be granted on a timely basis, if at all. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, legislation is drafted, introduced and passed in the Congress of the United States that could significantly change the statutory provisions governing
the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and
our drug candidates. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> and Clinical Development in the United States </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before a BLA applicant can begin testing the potential asset in human subjects, the applicant must first conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
studies. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as in vitro and animal studies to assess the potential safety and activity of the biologic
for initial testing in humans and to establish a rationale for therapeutic use. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies are subject to federal regulations and requirements, including GLP regulations. The results of an
applicant&#146;s <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies are submitted to the FDA as part of an IND. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An IND is a request for authorization
from the FDA to administer an investigational new drug product to humans. An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial. Such authorization must
be secured prior to interstate shipment. In support of a request for an IND, applicants must submit a range of information, including <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data, manufacturing information and a detailed protocol for
each clinical trial. Any subsequent protocol amendments must be submitted to the FDA as part of the IND. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Human clinical trials may not begin until an IND is
effective. The IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless the FDA raises safety concerns or questions about the proposed clinical trial within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period. In
such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to
begin a clinical trial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may also place a clinical hold or partial clinical hold on such trial following commencement of a clinical trial under an IND. A
clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">204 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol
or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor with a written explanation of the basis for the
hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the
sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials involve the administration
of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP regulations, which include the requirement that all research subjects provide their informed consent for their participation in
any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the
existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A sponsor may choose,
but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the
sponsor must ensure that the study complies with cGCP regulations in order to use the study as support for an IND or application for marketing approval, including review and approval by an independent ethics committee and informed consent from
subjects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its
informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the
subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some trials also include oversight by an
independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board (the &#147;DSMB&#148;). DSMBs provide authorization for whether or not a trial may move forward at designated check points based
on access to certain data from the trial and may halt the clinical trial if a DSMB determines that there is an unacceptable safety risk for subjects or based on other grounds, such as no demonstration of efficacy. Other grounds for suspension or
termination may be made based on evolving business objectives and/or competitive climate. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical Trials </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of BLA approval, clinical trials are
typically conducted in the following sequential phases that may overlap or be combined: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 1: The investigational product is initially introduced into a small number of healthy human subjects or patients
with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses. These
trials may also yield early evidence of effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product is suspected or known to be unavoidably toxic, the initial human testing may be conducted in
patients. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 2: The investigational product is administered to a limited patient population with a specified disease or condition
to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more
expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3: The investigational product is administered to an expanded patient population generally at multiple
geographically dispersed clinical trial sites to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety. These clinical trials are intended to generate sufficient data to
statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval by the FDA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">205 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product
is approved to gain more information about the product, referred to as Phase 4 trials. Such post-approval trials, when applicable, are conducted following initial approval, typically to develop additional data and information relating to the
biological characteristics of the product and treatment of patients in the intended therapeutic indication. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Progress reports detailing the results of the clinical
trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: suspected serious and unexpected adverse reactions;
findings from epidemiological studies, pooled analysis of multiple studies, animal or in vitro testing, or other clinical studies, whether or not conducted under an IND, and whether or not conducted by the sponsor, that suggest a significant risk in
humans exposed to the drug; and any clinically important increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure, which is a comprehensive document summarizing the body of
information about an investigational product obtained during clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of Phase 1, Phase 2 and
Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research
patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with
the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with cGCP and the integrity of the clinical data submitted. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient-reported outcomes
(the &#147;PROs&#148;), and observer-reported outcomes (the &#147;OROs&#148;), the process typically is an iterative one. The FDA has issued guidance on the framework it uses to evaluate PRO instruments. Although the agency may offer advice on
optimizing PRO and ORO instruments during the clinical development process, the FDA usually reserves final judgment until it reviews the BLA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with
clinical trials, companies often complete additional animal studies, and develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in
accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity and
potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>BLA Submission and Review </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming successful completion of all
required clinical testing in accordance with all applicable regulatory requirements, an applicant may submit a BLA requesting licensing to market the biologic for one or more indications in the United States. The BLA must include the results of
product development, <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials; detailed information on the product&#146;s chemistry, manufacture and controls; and proposed labeling. Under the Prescription Drug User Fee
Amendments, a BLA submission is subject to an application user fee, unless a waiver or exemption applies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA will initially review the BLA for completeness
before accepting it for filing. Under the FDA&#146;s procedures, the agency has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing and substantive review. If the agency determines that the application
does not meet this initial threshold standard, the FDA may refuse to file the application and request additional information, in which case the application must be resubmitted with the requested information and review of the application delayed.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With certain exceptions, BLAs must include a pediatric assessment, generally based on clinical trial data, of the safety and effectiveness of the biologic in
relevant pediatric populations. Under certain circumstances, the FDA may waive or defer the requirement for a pediatric assessment, either at the sponsor&#146;s request or by the agency&#146;s initiative. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the BLA is accepted for filing, the FDA reviews the BLA to determine, among other things, whether a product is safe, pure and potent and if the facility in which
it is manufactured, processed, packed or held meets standards </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">206 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
designed to assure the product&#146;s continued identity, strength, quality, safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application
review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities
comply with cGMP and are adequate to assure consistent production of the product within required specifications. In addition, the FDA expects that all data be reliable and accurate, and requires sponsors to implement meaningful and effective
strategies to manage data integrity risks. Data integrity is an important component of the sponsor&#146;s responsibility to ensure the safety, efficacy and quality of its product or products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA will typically inspect one or more clinical sites to assure compliance with cGCP regulations before approving a BLA. If the FDA determines that the application,
manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FDA performance goals generally provide for
action on a BLA within ten months of filing, which (as discussed above) typically occurs within 60 days of submission, but that deadline is extended in certain circumstances. Furthermore, the review process is often significantly extended by FDA
requests for additional information or clarification. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may refer applications for novel products or products that present difficult questions of safety or
efficacy to an advisory committee. Typically, an advisory committee consists of a panel that includes clinicians and other experts who will review, evaluate and provide a recommendation as to whether the application should be approved and, if so,
under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components will be produced, the FDA may
issue an approval letter or a Complete Response Letter (the &#147;CRL&#148;). An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A CRL will describe all of the
deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing
submitted product lots and/or reviewing proposed labeling. If and when the deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. In issuing the CRL, the FDA may recommend
actions that the applicant might take to place the BLA in condition for approval, including requests for additional data, information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not
satisfied, and may require additional testing or information and/or require post-marketing studies and clinical trials. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the
regulatory criteria for approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the approval process, the FDA will determine whether a REMS is necessary to assure the safe use of the biologic. A REMS is
a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans
or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes that a REMS is needed, the BLA sponsor must submit a proposed REMS and the FDA will not approve the
BLA without a REMS that the agency has determined is acceptable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, under the Pediatric Research Equity Act of 2003 (the &#147;PREA&#148;), as amended
and reauthorized, certain applications or supplements must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and
administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of
the product for use in adults, or full or partial waivers from the pediatric data requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the FDA approves a product, it may limit the approved
indications for use for the product, or require that contraindications, warnings or precautions be included in the product labeling. The FDA may also require that post-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">207 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#146;s safety after approval. The FDA may prevent or limit further marketing of a product based on the
results of post-marketing studies or surveillance programs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may also require testing and surveillance programs to monitor the product after
commercialization. For biologics, such testing may include official lot release, which requires the manufacturer to perform certain tests on each lot of the product before it is released for distribution. The manufacturer then typically must submit
samples of each lot of product to the FDA, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain
confirmatory tests on lots of some products itself, before releasing the lots for distribution by the manufacturer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After approval, many types of changes to the
approved product, such as adding new indications, manufacturing changes and additional labeling claims, are often subject to further testing requirements and FDA review and approval, depending on the nature of the post-approval change. The FDA may
withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any products manufactured or distributed
pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations and adverse experiences, product
sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and approval. There also are continuing
user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their third-party contractors are required to register their establishments with the FDA and certain
state agencies. These establishments are subject to routine and periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and data integrity requirements, which impose certain procedural and documentation
requirements to assure quality of manufacturing and product. The FDA has increasingly observed cGMP violations involving data integrity during site inspections and investigating compliance with data integrity requirements is a significant focus of
its oversight. Requirements with respect to data integrity include, among other things, controls to ensure data are complete and secure; activities documented at the time of performance; audit trail functionality; authorized access and limitations;
validated computer systems; and review of records for accuracy, completeness and compliance with established standards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Post-approval changes to the manufacturing
process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting
requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP, data
integrity, pharmacovigilance (i.e., post-marketing safety reporting obligations) and other aspects of regulatory compliance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may withdraw a product
approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-approval studies or clinical trials to
assess new safety risks; or imposition of distribution or other restrictions under a REMS. Other potential consequences include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product
recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, Warning Letters, Untitled Letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of
existing product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure or detention, or refusal of the FDA to permit the import or export of products that it believes present
safety problems by issuing an Import Alert; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">208 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">permanent injunctions and consent decrees, including the imposition of civil or criminal penalties; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">voluntary product recall. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. A company can make only those claims
relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA&#146;s regulation includes, among other things, standards and regulations for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the
Internet and social media. Promotional claims relating to a product&#146;s safety or effectiveness are prohibited before the drug is approved. After approval, a product generally may not be promoted for uses that are not approved by the FDA, as
reflected in the product&#146;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the drug&#146;s labeling, known as
<FONT STYLE="white-space:nowrap">off-label</FONT> uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#146; communications, prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in <FONT STYLE="white-space:nowrap">non-promotional,</FONT>
<FONT STYLE="white-space:nowrap">non-misleading</FONT> communication regarding <FONT STYLE="white-space:nowrap">off-label</FONT> information, such as distributing scientific or medical journal information. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a company is found to have promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, it may become subject to adverse public relations and administrative and
judicial enforcement by the FDA, the DOJ or the Office of the Inspector General of the Department of Health and Human Services, as well as other federal and state authorities. This could subject a company to a range of penalties that could have a
significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products. The federal government has levied large civil and criminal fines against
companies for alleged improper promotion, and has also requested that companies enter into consent decrees and permanent injunctions under which specified promotional conduct is changed or curtailed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of prescription drugs and biologics are subject to the Drug Supply Chain Security Act (the &#147;DSCSA&#148;), which requires manufacturers and other
stakeholders to comply with product identification, tracing, verification, detection and response, notification and licensing requirements. In addition, the Prescription Drug Marketing Act (the &#147;PDMA&#148;), and its implementing regulations,
and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove prescription drug and biological products that may be
counterfeit, stolen, contaminated, or otherwise harmful from the market. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After approval, owners of relevant drug or biological product patents may apply for up to a five-year patent extension to restore a portion of patent term lost during
product development and FDA review of a BLA if approval of the application is the first permitted commercial marketing or use of a biologic containing the active ingredient under the Drug Price Competition and Patent Term Restoration Act of 1984,
referred to as the Hatch-Waxman Act. The allowable patent term extension is calculated as <FONT STYLE="white-space:nowrap">one-half</FONT> of the product&#146;s testing phase, which is the time between IND and BLA submission, and all of the review
phase, which is the time between BLA submission and approval, up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may
not exceed more than 14 years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60 days of approval. The United States
Patent and Trademark Office (the &#147;USPTO&#148;), in consultation with the FDA, reviews and approves the application for patent term restoration. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For patents
that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension
granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug candidate covered by the patent for which a patent extension is being sought is likely. Interim patent extensions
are not available for a drug candidate for which a BLA has not been submitted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">209 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA is required to facilitate the development and expedite the review of pharmaceutical products that are intended for the treatment of a serious or
life-threatening condition for which there is no effective treatment and which demonstrate the potential to address unmet medical need for the condition. Under the fast track program, the sponsor of a new drug candidate may request the FDA to
designate the product for a specific indication as a fast track product concurrent with or after the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60 days after
receipt of the sponsor&#146;s request. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to other benefits, such as the ability to have more frequent interactions with the FDA, the agency may initiate
review of sections of a fast track product&#146;s BLA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant
pays applicable user fees. However, the FDA&#146;s PDUFA review period for a fast track application does not begin until the last section of the BLA is submitted. In addition, the fast track designation may be withdrawn by the FDA if the agency
believes that the designation is no longer supported by data emerging in the clinical trial process. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Healthcare Regulation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pharmaceutical Coverage and Reimbursement </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Significant uncertainty exists as
to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the
availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. Third-party payors establish the coverage and
reimbursement policies for pharmaceutical products, and the marketability of any products for which we may receive regulatory approval for commercial sale depends on those payors&#146; coverage policies and reimbursement rates. Third-party payors
may limit coverage to specific products on an approved list, or formulary, which might not include one or more of our drug candidates, if approved. Third-party payors, together with regulators and others, are increasingly challenging the prices
charged for pharmaceutical products and health services, in addition to their cost-effectiveness, safety and efficacy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, no uniform policy for coverage
and reimbursement exists in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval process apart
from Medicare determinations. Therefore, coverage and reimbursement rates can vary significantly from payor to payor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, obtaining coverage and adequate
reimbursement is a time-consuming and costly process. We may be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval will be obtained, and we may need to
conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. We cannot be certain that our drug candidates will be considered cost-effective by third-party payors. This process could delay the market
acceptance of any drug candidates for which we may receive approval and could have a negative effect on our future revenues and operating results. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other U.S.
Healthcare Laws and Compliance Requirements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, our business may be subject to healthcare fraud and abuse regulation and enforcement by both
the federal government and the states in which we conduct our business, particularly once third-party reimbursement becomes available for one or more of our products. The healthcare fraud and abuse laws and regulations that may affect our ability to
operate include, but are not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving,
offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or
recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs, or other federal healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, or
FCA, which prohibits, among other things, knowingly presenting, or causing to be presented, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">210 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
claims for payment of government funds that are false or fraudulent, or knowingly making, or using or causing to be made or used, a false record or statement material to a false or fraudulent
claim to avoid, decrease, or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal Health Insurance Portability and Accountability Act of 1996 (the &#147;HIPAA&#148;), which, among other
things, prohibits executing a scheme to defraud any healthcare benefit program, including private third-party payors, and prohibits (i)&nbsp;knowingly and willfully falsifying, concealing or covering up a material fact or making any materially
false, fictitious or fraudulent statement or representation and (ii)&nbsp;making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of
or payment for healthcare benefits, items or services; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (the
&#147;HITECH&#148;), and their respective implementing regulations, which impose requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, including health plans,
healthcare clearinghouses and certain healthcare providers, and their business associates, individuals or entities that perform certain services on behalf of a covered entity that involve the use or disclosure of individually identifiable health
information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or
injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal Physician Payments Sunshine Act, being implemented as the Open Payments Program, which requires manufacturers
of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and Medicaid Services
(the &#147;CMS&#148;), information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in a company by physicians and their immediate family
members. Beginning in 2022, applicable manufacturers will also be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse
anesthetists and certified nurse-midwives; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. state and local laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or
marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; state laws that require pharmaceutical companies to
comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that
restrict the ability of manufacturers to offer <FONT STYLE="white-space:nowrap">co-pay</FONT> support to patients for certain prescription drugs; state laws that require drug manufacturers to report information related to clinical trials, or
information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require drug manufacturers to report information on the pricing of certain drugs; state laws and
local ordinances that require identification or licensing of sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often
are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will be required to spend substantial time and money to ensure that our
business arrangements with third parties comply with applicable healthcare laws and regulations. Even then, governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws and regulations. If governmental authorities find that our operations violate any of these laws or any other governmental regulations that may apply to us, we may be subject to
significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and additional reporting obligations and oversight
if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and we may be required to curtail or restructure our operations. Moreover,
we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our operations and business. In addition, the approval and commercialization of any drug candidate we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">211 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. The extent to which future legislation or
regulations, if any, relating to health care fraud and abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on our business remains uncertain. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Healthcare Reform </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States there have been, and continue to be,
several legislative and regulatory changes and proposed reforms of the healthcare system to contain costs, improve quality and expand access to care. In the United States, there have been and continue to be a number of healthcare-related legislative
initiatives that have significantly affected the pharmaceutical industry. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#147;ACA&#148;), was
passed in March 2010, substantially changing the way healthcare is financed by both governmental and private insurers and significantly impacting the U.S. pharmaceutical industry. Among other things, the ACA subjects biologics to potential
competition by lower-cost biosimilars; addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increases the
minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; establishes annual fees and taxes on manufacturers of certain
branded prescription drugs; and creates a new Medicare Part D coverage gap discount program in which, as a condition of coverage of its products under Medicare Part D, manufacturers must now agree to offer 70% <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. In addition,
there have been efforts by the Trump Administration to repeal or replace certain aspects of the ACA and to alter the implementation of the ACA and related laws. For example, Congress has considered legislation that would repeal or repeal and replace
all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 (the &#147;Tax Act&#148;),
includes a provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or
part of a year commonly referred to as the &#147;individual mandate.&#148; On January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain <FONT
STYLE="white-space:nowrap">ACA-mandated</FONT> fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain high cost
employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. The Bipartisan Budget Act
of 2018 (the &#147;BBA&#148;), among other things, amends the ACA, effective January&nbsp;1, 2019, to reduce the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; In addition, in July 2018, the CMS issued
a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the
method CMS uses to determine this risk adjustment. Additional legislative changes or regulatory changes related to the ACA remain possible. In December 2018, a United States District Court Judge for the Northern District of Texas ruled that the
entire ACA is unconstitutional because the tax penalty associated with the &#147;individual mandate&#148; was repealed by Congress as part of the Tax Act. This ruling is under appeal and stayed pending appeal. While the United States District Court
Judge for the Northern District of Texas, as well as the Trump Administration and the CMS, have stated that the ruling will have no effect while this appeal is pending, it is unclear how this decision, subsequent appeals and other efforts to
invalidate the ACA, regulations promulgated under the ACA or portions thereof, will impact the ACA and its implementation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, there has been increasing
legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to drug pricing; reduce the cost of prescription drugs under Medicare; review the relationship between pricing and manufacturer patient programs; and reform government program reimbursement methodologies
for drugs. For example, the Trump Administration released a &#147;Blueprint&#148; to lower drug prices and reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">212 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list
price of their products and reduce the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of drug products paid by consumers. On January&nbsp;31, 2019, Office of the Inspector General of the
Department of Health and Human Services proposed modifications to the federal Anti-Kickback Statute discount safe harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will remove safe
harbor protection from rebates paid by manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations. Although a number of these, and other proposed measures may require
additional authorization to become effective, Congress and the Trump Administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have
also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement limitations, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding
procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, on
May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are
undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for
a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">213 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_17"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directors and Executive Officers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information
regarding our directors and executive officers as of the date of this prospectus. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>DIRECTORS AND EXECUTIVE OFFICERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>POSITION/TITLE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jingwu Zhang Zang, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Founder, Honorary Chairman and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Joan Huaqiong Shen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Zheru Zhang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director and President</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director and Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Wei Fu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mengjiao Jiang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jie Yu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lin Li, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chun Kwok Alan Au</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Conor Chia-hung Yang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pamela M. Klein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lili Qian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President of Operations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weimin Tang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Vice President of Global Business Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Yunhan Lin, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President of Corporate Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Neil Warma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Manager of I-Mab US</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Jingwu Zhang Zang</I>, M.D., Ph.D., is our founder, honorary chairman and director. Dr. Zang served as our chief executive officer from our inception to October
2019. Prior to founding our company, Dr. Zang served as the chief scientific officer and president of Simcere Pharmaceutical Group and Bioscikin Co., Ltd. from September 2013 to April 2016. Dr.&nbsp;Zang held senior management positions at
GlaxoSmithKline (GSK), as the global senior vice president and head of GSK&#146;s Research and Development in China from April 2007 to June 2013. The academic career of Dr. Zang started in Dr. Willems Institute and University of Limburg in Belgium.
Dr. Zang became a professor at Baylor College of Medicine in Houston and later joined the Chinese Academy of Sciences as the founding director of the Institute of Health Sciences and as a co-director of Institute Pasteur Shanghai, an independent <FONT
STYLE="white-space:nowrap">non-profit</FONT> life science institute to address public health problems in China, where he served as its director from October 2004 to September 2006. Dr.&nbsp;Zang also served as a director of Shanghai Institute of
Immunology from June 2002 to April 2007. Dr.&nbsp;Zang received his M.D. from Shanghai Second Medical University (now part of Shanghai Jiaotong University) in 1984, and his Ph.D. in neuroimmunology from the University of Brussels in 1990.
Dr.&nbsp;Zang conducted his post-doctoral work at Harvard Medical School in 1992, and obtained his U.S. medical license from the Texas Medical Board through a clinical residency at Baylor College of Medicine in Houston. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Joan Huaqiong Shen</I>, M.D., Ph.D., has served as our head of discovery and clinical development since September 2017, as our director since July 2019 and as our
chief executive officer since October 2019. Prior to joining our company, Dr.&nbsp;Shen served as the vice president and development head of Janssen Pharmaceutical Companies of Johnson&nbsp;&amp; Johnson from September 2015 to September 2017.
Dr.&nbsp;Shen was the chief medical officer and vice president in Jiangsu Hengrui Medicine, Co., Ltd. (SHA: 600276) from May 2013 to August 2015. Dr.&nbsp;Shen served as the head of the China clinical department and a senior director at Pfizer
(China) Research and Development Co., Ltd. from August 2011 to May 2013. Prior to that, Dr.&nbsp;Shen worked as a senior medical director at Pfizer Inc. (NYSE:&nbsp;PFE) from November 2009 to August 2011. From August 2005 to November 2009,
Dr.&nbsp;Shen was the medical director at Wyeth Research, a leading pharmaceutical company. Dr.&nbsp;Shen worked as a clinical research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">214 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
physician at Eli Lilly and Company (NYSE: LLY) from September 2003 to August 2005. Dr. Shen served as an adjunctive assistant professor in the department of psychiatry of the Indiana University
School of Medicine from October 2003 to October 2005. She has also been a guest professor of Beijing University Clinical Research Institute since March 2018. Dr. Shen completed three fellowships in the Indiana University School of Medicine, one in
endocrinology from August 1996 to July 1998, one in psychopharmacology and one in clinical pharmacology, both from January 2002 to September 2003. Dr. Shen obtained her U.S. medical license from the Indiana University School of Medicine through a
clinical residency. Dr.&nbsp;Shen received her M.D. from Southeast University Medical College in 1983, master&#146;s degree in anatomy from West China University of Medical Sciences, currently Sichuan University School of Medicine in 1989, and her
Ph.D. in anatomy/neuroscience from the Indiana University School of Medicine in 1996. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Zheru Zhang</I>, Ph.D., has served as our director and president since
September 2017. Prior to joining our company, Dr.&nbsp;Zhang served as the president at Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. from November 2015 to April 2017, as the chief executive officer at Shanghai <FONT
STYLE="white-space:nowrap">JMT-Bio</FONT> Co., Ltd. from October 2012 to October 2015, as a vice president, research and development at Celltrion Inc. from March 2008 to October 2012, as a group leader for the development of analytics and drug
products at Johnson&nbsp;&amp; Johnson (NYSE: JNJ) from January 2006 to March 2008, and as a research investigator at Bristol-Myers Squibb Company from May 2000 to January 2006, focusing on bioanalytical development and protein therapeutics
development, respectively. Dr.&nbsp;Zhang received his master&#146;s degree in chemistry from Suzhou University in 1991, and his Ph.D. in chemistry from University of Alberta in Canada in 2000. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Jielun Zhu</I> has served as our chief financial officer since August 2018 and as our director since July 2019. Prior to joining our company, Mr.&nbsp;Zhu held
positions as a managing director and the head of healthcare investment banking, Asia, at Jefferies Hong Kong Limited from December 2015 to July 2018, advising biotechnology and healthcare clients globally on initial public offerings, mergers and
acquisitions and other strategic transactions. From August 2008 to December 2015, Mr.&nbsp;Zhu worked at the Deutsche Bank Group in its Hong Kong branch, with his last position being a director in the corporate finance division. He worked as an
investment banker at UBS Investment Bank in Hong Kong from July 2007 to July 2008. Mr.&nbsp;Zhu received his bachelor&#146;s degree of arts with honors in mathematics-economics from Wesleyan University in May 2000 and master&#146;s degree in
business administration from the Harvard Business School with Distinction in June 2007. Mr.&nbsp;Zhu was awarded the Chartered Financial Analyst (CFA) charter by the CFA Institute in January 2012. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Wei Fu</I> has served as our director since June 2018. Mr.&nbsp;Fu was appointed by the <FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities pursuant to our
shareholders agreement dated July&nbsp;6, 2018. Mr.&nbsp;Fu has served as the chief executive officer and a managing partner of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital Investment Management, Ltd. since April 2014. Mr.&nbsp;Fu
currently also serves on the board of several private companies. From August 2011 to December 2013, Mr.&nbsp;Fu served as the general manager of the investment department at Far East Horizon International, a financial services organization.
Mr.&nbsp;Fu served as a partner and the head of the Beijing office of Themes Investment Management Ltd, a private equity firm specializing in healthcare and environmental businesses, from July 2010 to July 2011. From March 2008 to April 2010,
Mr.&nbsp;Fu worked as an associate director of the private equity department at Standard Chartered Business Consulting (Beijing) Co., Ltd, where he was mainly responsible for private equity investment in relation to infrastructure projects.
Mr.&nbsp;Fu received his bachelor&#146;s degree in electrical engineering and business administration from Nanyang Technological University in Singapore in February 2005. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Mengjiao Jiang</I> has served as our director since September 2017. Ms.&nbsp;Jiang was appointed by the <FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities
pursuant to our shareholders agreement dated July&nbsp;6, 2018. Ms.&nbsp;Jiang is a managing director of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital Investment Management, Ltd., a healthcare-dedicated private equity firm, and has served
as a partner and a managing director since January 2014. Ms.&nbsp;Jiang currently also serves on the board of several private companies. Ms.&nbsp;Jiang served as a director at International Far East Horizon International, a financial services
organization, from March 2012 to December 2013. Prior to that, Ms.&nbsp;Jiang served at ARC China Inc. as a managing director from May 2008 to June 2011. Ms.&nbsp;Jiang received her bachelor&#146;s degree in economics with a political science double
major from Wellesley College in Massachusetts in May 2003. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Jie Yu</I> has served as our director since July 2019. Mr.&nbsp;Yu was appointed by the Tasly
entities pursuant to our shareholders agreement dated July&nbsp;6, 2018. Mr.&nbsp;Yu has served as the secretary of the board at Tasly Pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">215 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Group Co., Ltd. since November 2016. Prior to that, Mr.&nbsp;Yu was a director of brand management office at China Minsheng Investment Co., Ltd., an international private capital investment
group, from March 2015 to October 2016. Mr.&nbsp;Yu worked as the head of the brand management department and the head of Chinese media affairs department at Huawei Technologies Co., Ltd. from April 2001 to March 2015. Mr.&nbsp;Yu received his
bachelor&#146;s degree in management from Harbin Normal University in 1998 and master&#146;s degree in management from Northeast Forestry University in 2001. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Lin</I> <I>Li</I>, Ph.D. has served as our director since July 2018. Dr.&nbsp;Li was appointed by the Hony entity pursuant to our shareholders agreement dated
July&nbsp;6, 2018. Dr.&nbsp;Li has served as an investment director at Hony Capital since December 2016. Dr.&nbsp;Li worked as an associate at Snow Lake Capital (HK) Limited from November 2014 to November 2016. Dr.&nbsp;Li served as a senior
investment manager in the cross-border investment group at Hony Capital from April 2012 to October 2014. Prior to that, he worked as an associate in the corporate finance department of Goldman Sachs Gao Hua Securities Company Limited in Beijing from
July 2010 to April 2012. Dr.&nbsp;Li received his bachelor&#146;s degree in biology from Peking University in July 2000, Ph.D. in biology from Boston University in 2006, and master&#146;s degree in business administration from the Harvard Business
School in 2010. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Mr. Chun Kwok Alan Au </I>has served as our director since January 2020. Mr. Au is the founder of GT Healthcare Group, a private equity platform
focusing on cross border healthcare investments, and has served as the managing partner of GT Healthcare Group since September 2015. Mr. Au has served as a director of Cellular BioMedicine Group (Nasdaq: CBMG), a clinical-stage biopharmaceutical
firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, since November 2014. Mr. Au also has served as a panel member for the Entrepreneur Support Scheme (ESS Program) of the Innovation and
Technology Fund of the Hong Kong SAR Government since 2014. Mr. Au was an advisor to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE: SCR, privatized in December 2013, when Mr. Au served as chairman
of the special committee on the board of directors). Mr. Au was also a member of the board of China Nepstar Chain Drugstore Ltd. (NYSE: NPD, privatized in September 2016) from March 2013 to August 2016. Mr. Au served as the head of the Asia
Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&amp;A in the region from April 2011 to December 2012. Prior to that, Mr. Au served as the executive director at JAFCO Asia Investment Group, responsible for
healthcare investments in China from 2008 to 2010. Mr.&nbsp;Au worked at Morningside Group as a director in charge of healthcare investments in Asia from 2000 to 2005. Mr. Au received his bachelor&#146;s degree in psychology from Chinese University
of Hong Kong in 1995 and his master&#146;s degree in management from Columbia Business School in New York in 2007. Mr. Au is a certified public accountant (CPA) in the U.S. and a chartered financial analyst (CFA). He is an associate member of the
Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Mr. Conor Chia-hung Yang </I>has served as our
director since January 2020. Mr. Yang is a co-founder of Black Fish Group Limited and has served as the president of Black Fish Group Limited since November 2017. Prior to that, Mr.&nbsp;Yang was the chief financial officer of Tuniu Corporation
(Nasdaq: TOUR) from January 2013 to November 2017, the chief financial officer of E-Commerce China Dangdang Inc. from March 2010 to July 2012 and the chief financial officer of AirMedia Group Inc., currently known as AirNet Technology Inc., (Nasdaq:
ANTE) from March 2007 to March 2010. Mr. Yang was the chief executive officer of Rock Mobile Corporation from 2004 to February 2007. From 1999 to 2004, Mr. Yang served as the chief financial officer of the Asia Pacific region for CellStar Asia
Corporation. Mr. Yang was an executive director of Goldman Sachs (Asia) L.L.C. from 1997 to 1999. Prior to that, Mr. Yang was a vice president of Lehman Brothers Asia Limited from 1994 to 1996 and an associate at Morgan Stanley Asia Limited from
1992 to 1994. Mr. Yang currently serves as an independent director and chairman of the audit committee of each of China Online Education Group (NYSE: COE) and Ehang Holdings Limited (Nasdaq: EH). Mr. Yang received a master&#146;s degree of business
administration from University of California, Los Angeles in 1992. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dr. Pamela M. Klein</I> has served as our director since January 2020. Dr. Klein currently
serves a director of Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) since July 2019, a director of argenx SE (Nasdaq: ARGX) since April 2016 and a director of Patrys Limited (ASX: PAB) since October 2019. In addition, Dr. Klein has served as the
president at PMK BioResearch since 2008, offering consultancy in Oncology Drug Development to Biotech, Pharma and the Investment Community. Previously, Dr. Klein served as Chief Medical Officer for successful biotech start-ups and prior to that,
Vice President, Genentech, Development. Dr. Klein received her bachelor&#146;s degree in cell and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">216 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
molecular biology from California State University in 1985 and an M.D. from Stritch School of Medicine, Loyola University Chicago in 1992 followed by an internal medicine residency at Cedars
Sinai, Los Angeles. Dr. Klein spent seven years at the National Cancer Institute of the NIH in Bethesda, Maryland in medical oncology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Lili Qian</I>, Ph.D., has
served as the vice president of operations since June 2016 and our director from September 2017 to July 2019. Dr.&nbsp;Qian worked at Bioscikin Biopharma Technology Co., Ltd. from January 2016 to May 2016, serving as the secretary to the board of
directors and president office manager. Prior to that, Dr.&nbsp;Qian held various positions at Simcere Pharmaceutical Group as the president assistant and a project management manager from October 2013 to December 2015, and as a business development
manager from July 2013 to October 2013. She was the project leader of the national key laboratory of protein and plant genetic engineering at Peking University from September 2007 to June 2013. Dr.&nbsp;Qian received her bachelor&#146;s degree in
biochemistry from University of British Columbia in 2005 and her Ph.D. in biochemistry and molecular biology from Peking University in 2013. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Weiming Tang</I>,
Ph.D., has served as our executive vice president of global business development since April 2018. Prior to joining our company, Dr.&nbsp;Tang served as an executive director and a business director at Hengrui Therapeutics, Inc. from July 2015 to
April 2018. Dr.&nbsp;Tang served as the vice president and a business director at Crown Bioscience Inc., a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> contract research organization, from July 2011 to July 2015. Prior to that, Dr.&nbsp;Tang
served as the vice president and a business director at ShanghaiBio Corporation Shanghai Biotechnology Cooperation, a biotech company based in Shanghai, from October 2010 to July 2011. Dr.&nbsp;Tang received his bachelor&#146;s degree in plant
pathology from Zhejiang University in 1986, master&#146;s degree in microbiology from Chinese Academy of Sciences in 1989, and Ph.D. in biochemistry from Rutgers University, New Jersey in 1997. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Yunhan Lin</I>, Ph.D., has served as our vice president of corporate development since September 2017. Prior to joining our Company, Dr.&nbsp;Lin served as the head
of business development at Mycenax Biotech Inc., a Taiwan-based public pharmaceutical company, from January 2016 to September 2017. Prior to that, Dr.&nbsp;Lin served as the head of business development at SynCore Biotechnology Co., Ltd, a
Taiwan-based public biopharmaceutical company, from February 2012 to December 2015. Dr.&nbsp;Lin worked as a science project deputy manager at Sinphar Pharmaceutical Co, Ltd., a Taiwan-based pharmaceutical company, from September 2001 to January
2012. Dr.&nbsp;Lin received his bachelor&#146;s degree in applied chemistry from Providence University, Taiwan in 2000, master&#146;s degree in chemistry from Fu Jen Catholic University, Taiwan in 2003, and Ph.D. in chemistry from Tamkang
University, Taiwan in 2008. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Neil Warma</I> has served as the general manager of I-Mab US since September 2019. Mr. Warma is currently an advisor to several
companies and serves on the board of directors of several biotechnology companies and BioHouston, a non-profit tax-exempt 501(c)(3) corporation founded by Houston area academic/research institutions. Prior to joining our Company, Mr. Warma served as
the president and chief executive officer of Opexa Therapeutics, currently Acer Therapeutics Inc. (Nasdaq: OPXA), from June 2008 to September 2017, and as its director from September 2008 to September 2017. At Opexa Therapeutics, he also served as
acting chief financial officer from March 2016 to September 2017, and previously served in such role from March 2009 to August 2012. From July 2004 to September 2007, Mr. Warma served as president and chief executive officer of Viron Therapeutics
Inc., a privately-held clinical stage biopharmaceutical company. Mr.&nbsp;Warma co-founded MedExact USA, Inc., an Internet company providing clinical information and services to physicians and pharmaceutical companies in 2000 and served as president
until 2003. From 1992 to 2000, Mr. Warma held senior positions of increasing responsibility at Novartis Pharmaceuticals (previously Ciba-Geigy Ltd.) at its corporate headquarters in Basel, Switzerland. While at Novartis, Mr. Warma served as the Head
of International Pharma Policy &amp; Advocacy and in senior management within global marketing where he worked on the international launch of a gastrointestinal product. Mr. Warma obtained an honors degree specializing in neuroscience from the
University of Toronto in 1984 and an International M.B.A. from the Schulich School of Management at York University in Toronto in 1992. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Scientific Advisory
Board </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The members of our scientific advisory board provide scientific, portfolio and project strategy advice to us, including the evaluation of research and
development strategies. The members of our scientific advisory board receive cash compensation for their services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Howard Weiner</I>, M.D., has served on our
scientific advisory board since July 2019. Dr. Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director of the Partners Multiple Sclerosis (&#147;MS&#148;) Center and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">217 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Co-Director of Center for Neurologic Diseases at Brigham &amp; Women&#146;s Hospital in Boston. The Partners MS Center is the first integrated MS Center that combines clinical care, MRI imaging
and immune monitoring to the MS patient as part of the 2000 patient CLIMB cohort study. Dr. Weiner has pioneered immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer&#146;s disease,
amyotrophic lateral sclerosis, stroke and brain tumors. Dr. Weiner has also pioneered the investigation of the mucosal immune system for the treatment of autoimmune and other diseases and the use of anti-CD3 to induce regulatory T cells for the
treatment of these diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Eric K. Rowinsky</I>, M.D., has served on our scientific advisory board since June 2019. Dr.&nbsp;Rowinsky is an independent
consultant and/or board member of various public and private companies and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> efforts. Since 2017, Dr.&nbsp;Rowinsky has served as an advisor to <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> Capital and the U.S. Chief Medical Officer for Everest Medicines, Inc. Since 2015, Dr.&nbsp;Rowinsky has served as an Executive Director and President at Rgenix Inc. and as the Chief Scientific Officer of
Clearpath Development Co. From 2005 to 2015, Dr.&nbsp;Rowinsky held various positions with various biotechnology companies. At ImClone Systems (now a wholly-owned subsidiary of Eli Lilly), Dr.&nbsp;Rowinsky and his team developed and registered
cetuximab (Erbitux) and ramucirumab in five indications and two other monoclonal antibodies in North America and elsewhere. Dr.&nbsp;Rowinsky has been an Adjunct Professor of Medicine at New York University School of Medicine since 2005. From 1987
to 2005, Dr.&nbsp;Rowinsky held various academic and research positions with various universities and research institutions including the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio, where he held the SBC
Endowed Chair for Early Drug Development, and the Johns Hopkins University School of Medicine. Dr.&nbsp;Rowinsky received his B.A. degree from New York University and his M.D. from the Vanderbilt University School of Medicine and completed
fellowship training at the Johns Hopkins University School of Medicine. Dr.&nbsp;Rowinsky received the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award. He has also served on the Board of Scientific
Counselors of the NCI. Dr.&nbsp;Rowinsky is the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Editor-in-Chief</FONT></FONT> of Investigational New Drugs, an Editorial Board Member of Cancer Research and several other oncology
journals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Patricia LoRusso</I>, D.O., M.A., Ph.D., has served on our scientific advisory board since July 2019. Dr.&nbsp;LoRusso is currently a professor of
medicine and a clinical scholar in medical oncology and Associate Director of Innovative Medicine at Yale Cancer Center in New Haven, Connecticut, USA, where she is also Director of Early Therapeutics Disease-Aligned Team. Dr. LoRusso&#146;s
expertise is in testing new treatments on patient volunteers with advanced-stage cancer. She heads the early clinical trials program at Yale Cancer Center. She has served as the co-leader of the Stand Up To Cancer/Melanoma Research
Alliance&#150;funded Melanoma Dream Team, a Komen Promise grant <FONT STYLE="white-space:nowrap">co-Principal</FONT> Investigator, and has been a Principal Investigator of the National Cancer Institute Phase 1/early phase clinical trials program
grant in excess of 20 years. She is currently primary investigator or <FONT STYLE="white-space:nowrap">co-investigator</FONT> of numerous clinical trials. Prior to joining Yale in August 2014, Dr.&nbsp;LoRusso served in numerous leadership roles at
Wayne State University&#146;s Barbara Karmanos Cancer Institute for more than 25 years, most recently as director of the Phase 1 Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics. Dr.&nbsp;LoRusso also worked as a
director in Karmanos Cancer Institute, a cancer research and provider network, from 1997 to 2014. Dr.&nbsp;LoRusso received her B.A. degree of science in religion/religious studies and biology, her master&#146;s degree at Yale University, her D.O.
and Ph.D. from Michigan State University, and completed fellowship training at Wayne State University. Dr.&nbsp;LuRosso served as co-chair of the National Cancer Institute Cancer Therapy Evaluation Program (NCI CTEP) Investigational Drug Steering
Committee, a prior parent member of the NCI&#146;s Quick Trials Clinical Subcommittee, and has served as either an ad hoc or an appointed member on multiple study sections and has reviewed for Komen Promise grants, numerous SPORE and P01 study
sections, and translational research grants. She has served on the education and scientific committees of the American Society of Clinical Oncology, the Scientific Committee of the American Association for Cancer Research as well as a Vice-Chair for
the 2019 AACR annual meeting. She is a member of the NCI Board of Scientific Council and has served on the Board of Directors for the American Association for Cancer Research. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Yi-Long Wu</I>, M.D., FACS, has served on our scientific advisory board since August 2019. Yi-Long Wu is a tenured professor of Guangdong General Hospital, Guangdong
Academy of Medical Sciences and Guangdong Lung Cancer Institute. He is the former President of Chinese Society of Clinical Oncology (CSCO), the Chief of the WUJIEPING Oncology Medical Foundation, the vice-director of the Precision Medicine of the
Chinese Medical Doctor Association, the President of Chinese Thoracic Oncology Group (C-TONG), the President of International Chinese Society of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">218 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Thoracic Surgery (ICSTS), a Fellow of the American College of Surgeons, a Member of Board of Directors of the International Association Study of Lung Cancer (IASLC), the Chairman of European
Society for Medical Oncology (ESMO) in China, the Chairman of Federation of Asia Clinical Oncology (FACO), a past Member of the International Affairs Committee of American Society of Clinical Oncology (ASCO), and a former Member of staging committee
of the IASLC. He graduated from Sun Yat-sen University of Medical Sciences in 1982 and completed his thoracic surgery training in Germany in 1989. His main research interests are the multidisciplinary synthetic therapy on lung cancer in translation
medicine and evidence-based medicine in oncology. He is leading the Chinese lung cancer research field and has been the Principal Investigator or Co-PI of more than 120 international or national multicenter clinical trials. He has contributed 20
books on cancer and has published more than 300 articles in peer-reviewed journals including<I> J Clin Oncol, Lancet Oncol, New Engl J Med, Cancer Cell and J Thorac Oncol</I>. He also serves on the editorial boards of <I>Cancer Letters, Annals of
Surgical Oncology, Lung Cancer Management, International Journal of Biological Marker and General Thoracic and Cardiovascular Surgery</I>. He is Editor-in-Chief of <I>Journal of Evidence-based Medicine, Journal of Thoracic Oncology (Chinese
Edition), and The Oncologist (Chinese Edition)</I><I> </I>etc. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Timothy Yap</I>, M.D., Ph.D., has served on our scientific advisory board since August 2019. Dr.
Yap is a medical oncologist and physician-scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of
Thoracic/Head and Neck Medical Oncology. Dr. Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the
Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his
current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK. Dr. Yap gained his BSc
degree with First Class Honors in Immunology and Infectious Diseases at Imperial College London, UK, and was awarded the Huggett Memorial Prize. His BSc laboratory research involved an immunogenetics study under the supervision of Professor Charles
Bangham. He subsequently went on to attain his Medical degree from Imperial College London, UK, before completing general medical training in Oxford. Dr. Yap&#146;s main research focuses on the first-in-human and combinatorial development of
molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. Dr. Yap leads immuno-oncology clinical and associated translational studies, including novel
agents targeting PD-1/PD-L1, ICOS, IDO, LAG3, TIM3, STING, TGFbeta, adenosine A2A receptor and fucosylation. He was previously the UK Chief Investigator for the CheckMate 331 Phase III trial in relapsed small cell lung cancer and the KEYNOTE-158
Phase II biomarker study in advanced solid tumors and multiple novel immunotherapy combination phase I trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Roy S. Herbst, MD, PhD</I>, has served on our
scientific advisory board since July 2019. Dr. Roy S. Herbst is an Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology, the Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital, and an Associate Cancer
Center Director for Translational Research, Yale Cancer Center in New Haven, CT. Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics
and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies. Prior to his appointment at Yale, Dr. Herbst was the Barnhart Distinguished Professor and
Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center (UT-MDACC) in Houston, Texas. He also served as Professor in the Department of
Cancer Biology and Co-Director of the Phase I Clinical Trials Program. He has led the Phase I development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and
bevacizumab. More recently, he participated in the successful registration of pembrolizumab for the treatment of advanced non-small cell lung cancer, following the successful Yale-led KEYNOTE 10 study of the immune therapy drug commonly used to
treat other cancers. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program, and served as a Co-program Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr.
Herbst&#146;s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he
has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">219 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led.
After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training
included an internship and residency in medicine at Brigham and Women&#146;s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women&#146;s
Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts. Dr. Herbst is an author or co-author of more than 275 publications, including
peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. Dr.
Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco
Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the
communications committee for ASCO and the International Association for the Study of Lung Cancer. He is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the
SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Certain Past Incidents </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From June 2007 to June 2013, Dr.&nbsp;Jingwu Zhang Zang worked and held senior management positions at GlaxoSmithKline (&#147;GSK&#148;), as a global senior vice
president, and head of GSK&#146;s Research and Development in China. Dr.&nbsp;Zang was dismissed by GSK in June 2013 after GSK became aware of misrepresentation of certain data in a research paper entitled &#147;Crucial role of <FONT
STYLE="white-space:nowrap">interleukin-7</FONT> in T helper type 17 survival and expansion in autoimmune disease,&#148; which was prepared by scientists at GSK China&#146;s research center and published in Nature Medicine in 2010. Dr.&nbsp;Zang was
the corresponding author of the paper, primarily handling manuscript editing and communications with editors and reviewers of the paper, which are the general responsibility of a corresponding author. According to Dr.&nbsp;Zang and the first author
of the paper, Dr.&nbsp;Zang, as the head of GSK China&#146;s research center and a member of GSK&#146;s global senior management, was neither involved in nor aware of the mislabeled samples relating to the misrepresented data referenced in the paper
at the time when the paper was prepared and published. Nonetheless, Dr.&nbsp;Zang admitted his management oversight and accepted the responsibility as the corresponding author. He later coordinated the retraction of the paper in September 2013. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From 1996 to 2002, Dr.&nbsp;Zang was employed by Baylor College of Medicine in Houston, Texas initially as an associate professor and was later promoted to full
professor. At that time, Dr.&nbsp;Zang&#146;s team was conducting a clinical study on <FONT STYLE="white-space:nowrap">T-cell</FONT> vaccination for the treatment of multiple sclerosis after approval by Baylor&#146;s Institutional Review Board
(&#147;IRB&#148;). Dr.&nbsp;Zang was led to believe that such clinical research would not require FDA approval. In March 1999, the Food and Drug Administration, or the FDA, issued a warning letter to Dr.&nbsp;Zang stating that the clinical study did
require IND approval from the FDA in addition to the approval from the IRB and requested the study to be suspended. The study was suspended and later <FONT STYLE="white-space:nowrap">re-initiated</FONT> and successfully completed after the IND
approval was obtained. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the best of our knowledge, Dr.&nbsp;Zang was not and is not subject to any legal or regulatory charges, proceedings or disciplinary
actions in connection with the above incidents or by relevant parties involved in the incidents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since the incident, Dr. Zang continues to be recognized by his
peers and institutions, given his longstanding scientific achievements. For example, he was approved by the Ministry of Science and Technology of PRC in 2015 through a peer review process, to serve as the director of China National Key Laboratory of
Translational Medicine and Innovative Medicine. Since 2016, Dr. Zang successfully led all financing rounds of our company from high caliber investors prior to this IPO. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For risks related to the above incidents, please see &#147;Risk Factors&#151;Risks Related to Our Industry, Business and Operations&#151;Negative publicity with respect
to us, our management, employees, business partners, affiliates, or our industry, may materially and adversely affect our reputation, business, results of operations and prospect.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">220 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the measures and systems we have in place to ensure the integrity and legal compliance of our R&amp;D process and
business operations, please see &#147;Business&#151;R&amp;D Governance&#148; and &#147;Business&#151;Quality Control and Assurance.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board of Directors
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors consists of 11 directors. A director is not required to hold any shares in our company by way of qualification. Subject to the Nasdaq
Global Market rules and disqualification by the chairman of the relevant board meeting, a director may vote with respect to any contract, proposed contract or arrangement in which he is interested. A director who is interested in a contract,
proposed contract or arrangement shall declare the nature of his or her interest at the earliest meeting of the board at which it is practicable for him or her to do so, either specifically or by way of a general notice. The directors may exercise
all the powers of our company to borrow money, mortgage its undertaking, property and uncalled capital, and issue debentures or other securities whenever money is borrowed or as security for any obligation of our company or of any third party. None
of our directors who are not our executive officers has a service contract with us that provides for benefits upon termination of service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Committees of the
Board of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will establish three committees under the board of directors immediately upon the effectiveness of our registration statement on Form <FONT
STYLE="white-space:nowrap">F-1,</FONT> of which this prospectus forms a part: an audit committee, a compensation committee and a nominating and corporate governance committee. We have adopted a charter for each of the three committees. Each
committee&#146;s members and functions are described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Audit Committee</I>. Our audit committee consists of Mr. Conor Chia-hung Yang, Mr. Chun Kwok Alan Au
and Mr. Lin Li. Mr. Conor Chia-hung Yang is the chairman of our audit committee. We have determined that each of Mr. Conor Chia-hung Yang, Mr. Chun Kwok Alan Au and Mr. Lin Li satisfies the &#147;independence&#148; requirements of Rule 5605(c)(2) of
the Nasdaq Stock Market Rules and meets the independence standards under Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. We have determined that Mr. Conor Chia-hung Yang qualifies as an &#147;audit committee financial
expert.&#148; The audit committee will oversee our accounting and financial reporting processes and the audits of the financial statements of our company. The audit committee is responsible for, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appointing the independent auditors and <FONT STYLE="white-space:nowrap">pre-approving</FONT> all auditing and <FONT
STYLE="white-space:nowrap">non-auditing</FONT> services permitted to be performed by the independent auditors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing with the independent auditors any audit problems or difficulties and management&#146;s response;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">discussing the annual audited financial statements with management and the independent auditors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any steps
taken to monitor and control major financial risk exposures; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving all proposed related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">meeting separately and periodically with management and the independent auditors; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of
our procedures to ensure proper compliance. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Compensation Committee</I>. Our compensation committee consists of Dr. Jingwu Zhang Zang, Mr. Chun
Kwok Alan Au and Dr. Pamela M. Klein. Dr. Jingwu Zhang Zang is the chairman of our compensation committee. We have determined that each of Mr. Chun Kwok Alan Au and Dr. Pamela M. Klein satisfies the &#147;independence&#148; requirements of Rule
5605(a)(2) of the Nasdaq Stock Market Rules. The compensation committee will assist the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers. Our chief
executive officer may not be present at any committee meeting during which his compensation is deliberated. The compensation committee is responsible for, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving, or recommending to the board for its approval, the compensation for our chief executive officer
and other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and recommending to the board for determination with respect to the compensation of our directors who are not
our employees; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">221 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing periodically and approving any incentive compensation or equity plans, programs or similar arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">selecting compensation consultant, legal counsel or other adviser only after taking into consideration all factors
relevant to that person&#146;s independence from management. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Nominating and Corporate Governance Committee</I>. Our nominating and corporate
governance committee consists of Mr. Wei Fu, Mr. Chun Kwok Alan Au and Mr. Conor Chia-hung Yang. Mr. Wei Fu is the chairman of our nominating and corporate governance committee. We have determined that each of Mr. Chun Kwok Alan Au and Mr. Conor
Chia-hung Yang satisfies the &#147;independence&#148; requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules. The nominating and corporate governance committee will assist the board of directors in selecting individuals qualified to become
our directors and in determining the composition of the board and its committees. The nominating and corporate governance committee is responsible for, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">selecting and recommending to the board nominees for election by the shareholders or appointment by the board;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing annually with the board the current composition of the board with regards to characteristics such as
independence, knowledge, skills, experience and diversity; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">making recommendations on the frequency and structure of board meetings and monitoring the functioning of the committees
of the board; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">advising the board periodically with regards to significant developments in the law and practice of corporate governance
as well as our compliance with applicable laws and regulations, and making recommendations to the board on all matters of corporate governance and on any corrective action to be taken. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Duties of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Cayman Islands law, our directors owe fiduciary
duties to our company, including a duty of loyalty, a duty to act honestly, and a duty to act in what they consider in good faith to be in our best interests. Our directors must also exercise their powers only for a proper purpose. Our directors
also have a duty to exercise skills they actually possess and with such care and diligence that a reasonably prudent person would exercise in comparable circumstances. It was previously considered that a director need not exhibit in the performance
of his or her duties a greater degree of skill than what may reasonably be expected from a person of his or her knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required
skill and care, and these authorities are likely to be followed in the Cayman Islands. In fulfilling their duty of care to us, our directors must ensure compliance with our memorandum and articles of association, as amended from time to time, and
the class rights vested thereunder in the holders of the shares. Our company has the right to seek damages if a duty owed by our directors is breached. A shareholder may in certain limited circumstances have the right to seek damages in our name if
a duty owed by the directors is breached. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has all the powers necessary for managing, and for directing and supervising, our business
affairs. The functions and powers of our board of directors include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">convening shareholders&#146; annual general meetings and reporting its work to shareholders at such meetings;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">declaring dividends and other distributions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appointing officers and determining the term of office of the officers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">exercising the borrowing powers of our company and mortgaging the property of our company; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approving the transfer of shares in our company, including the registration of such shares in our share register.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Terms of Directors and Officers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our directors may be
elected by an ordinary resolution of our shareholders. Alternatively, our board of directors may, by the affirmative vote of a simple majority of the directors present and voting at a board meeting appoint any person as a director to fill a casual
vacancy on our board or as an addition to the existing board. Our directors (other than independent directors) are not automatically subject to a term of office and hold office until such time as they are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">222 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
removed from office by an ordinary resolution of our shareholders. Our independent directors hold office until the earlier of (i) the date on which the independent director ceases to be a member
of the board for any reason; (ii) the date of termination of an independent director&#146;s director agreement, which may be terminated by either the independent director or by us with a 30-day advance written notice or such other shorter period as
mutually agreed; or (iii) three years from the effective date of the director agreement, subject to the terms of the then-current memorandum and articles of association of our company. In addition, a director will cease to be a director if he or she
(i)&nbsp;becomes bankrupt or makes any arrangement or composition with his or her creditors; (ii)&nbsp;dies or is found to be or becomes of unsound mind; (iii)&nbsp;resigns his or her office by notice in writing; (iv)&nbsp;without special leave of
absence from our board, is absent from meetings of our board for three consecutive meetings and our board resolves that his or her office be vacated; or (v)&nbsp;is removed from office pursuant to any other provision of our articles of association.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our officers are appointed by and serve at the discretion of the board of directors, and may be removed by our board of directors. Under our post-offering articles
of association, the board of directors may appoint one or more of their number to the office of managing director upon like terms, but any such appointment shall ipso facto terminate if any managing director ceases for any cause to be a director, or
if our company by ordinary resolution of shareholders resolves that his tenure of office be terminated. In addition, the board of directors may appoint any natural person or corporation to be a secretary (and if need be an assistant secretary or
assistant secretaries) who shall hold office for such term, at such remuneration and upon such conditions and with such powers as they think fit. Any secretary or assistant secretary so appointed by the board of directors may be removed by the board
of directors or by ordinary resolution of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Agreements and Indemnification Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into employment agreements with all of our executive officers. Under these agreements, each of our executive officers is employed for a specified time
period. We may terminate employment for cause, at any time, for certain acts of the executive officer, such as continued failure to satisfactorily perform, willful misconduct or gross negligence in the performance of agreed duties, conviction or
nolo contendere plea of guilty to any felony or any misdemeanor involving moral turpitude, or dishonest act that result in material harm to our detriment, or material breach by the executive officer of the employment agreement. We may also terminate
an executive officer&#146;s employment without cause upon a 60-day prior written notice. In such case of termination by us, we will provide severance payments to the executive officer as may be agreed between the executive officer and us. The
executive officer may resign at any time with a 60-day prior written notice. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under these agreements, each executive officer has agreed to hold, both during and
after the termination or expiry of his or her employment agreement, in strict confidence and not to use, except as required in the performance of his or her duties in connection with the employment or pursuant to applicable law, any of our
confidential information or trade secrets, any confidential information or trade secrets of our clients or prospective clients, or the confidential or proprietary information of any third party received by us and for which we have confidential
obligations. The executive officers have also agreed to disclose in confidence to us all inventions, designs and trade secrets which they conceive, develop or reduce to practice during the executive officer&#146;s employment with us and to assign
all right, title and interest in them to us, and assist us in obtaining and enforcing patents, copyrights and other legal rights for these inventions, designs and trade secrets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, under these agreements, each executive officer has agreed to be bound by <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> restrictions during the term of his or her employment and typically for one year following the last date of employment. Specifically, each executive officer has agreed not to (i)&nbsp;approach our
suppliers, clients, direct or end customers or contacts or other persons or entities introduced to the executive officer in his or her capacity as a representative of us for the purpose of doing business with such persons or entities that will harm
our business relationships with these persons or entities; (ii)&nbsp;assume employment with or provide services to any of our competitors, or engage, whether as principal, partner, licensor or otherwise, any of our competitors, without our express
consent; or (iii)&nbsp;seek directly or indirectly, to solicit the services of any of our employees who is employed by us on or after the date of the executive officer&#146;s termination, or in the year preceding such termination, without our
express consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">223 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also entered into indemnification agreements with each of our directors and executive officers. Under these
agreements, we agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or officer of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation of Directors and Executive Officers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the fiscal year ended
December&nbsp;31, 2019, we paid an aggregate of approximately RMB175.7&nbsp;million (US$24.6 million) in cash to our executive officers including the repurchase of 3,890,155 options held by a director of our company at the total consideration of
US$21.9 million, and we did not pay any compensation to our directors who are not our executive officers. We have not set aside or accrued any amount to provide pension, retirement or other similar benefits to our executive officers and directors.
Our PRC subsidiaries are required by law to make contributions equal to certain percentages of each employee&#146;s salary for his or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a housing
provident fund. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Share Incentive Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Second Amended and
Restated 2017 Employee Stock Option Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2017, we adopted an equity incentive plan (as last amended and restated in December 2019), which we
refer to as the 2017 Plan, to secure and retain the services of valuable employees, directors or consultants, and provide incentives for such persons to exert their best efforts for the success of our business. Upon the completion of this offering,
the maximum aggregate number of ordinary shares which may be issued pursuant to all awards under the 2017 Plan is 9,609,084, subject to certain adjustments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
the date of this prospectus, awards to purchase 9,450,315 ordinary shares under the 2017 Plan have been granted and outstanding, excluding awards that were forfeited or cancelled after the relevant grant dates. Immediately prior to the completion of
this offering, certain grantees under the 2017 Plan will surrender a portion of their unvested options, if vested, to purchase a total of 332,566 ordinary shares of our company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following paragraphs describe the principal terms of the 2017 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Types
of awards</I>. The 2017 Plan permits the awards of options. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan administration</I>. Our board of directors will administer the 2017 Plan. The board of
directors will determine, among other things, the participants to receive options, the number and subscription price of options to be granted to each participant, and the terms and conditions of each option granted. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Offer letter</I>. Options granted under the 2017 Plan are evidenced by an offer letter that sets forth terms, conditions and limitations for each option, which may
include the term of the option, and the provisions applicable in the event that the grantee&#146;s employment or service terminates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Eligible participants</I>.
We may grant awards to employees, officers, directors, contractors, advisors and consultants of our company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Vesting schedule</I>. Unless otherwise approved by
the board of directors and set forth in an offer letter, the vesting schedule shall be a three-year vesting schedule consisting of a cliff vesting 50% on the second anniversary of the applicable vesting commencement date, and a vesting of the
remaining 50% on the third anniversary of the applicable vesting commencement date. Except as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of a listing or the occurrence of a change
in control. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Exercise of options</I>. The board of directors determines the subscription price for each option, which is stated in the offer letter. The vested
portion of each option will expire if not exercised prior to the time as the board of directors determines at the time of its grant. However, the maximum exercisable term is ten years from the applicable vesting commencement date or such shorter
period specified in the award agreement. Further, an option will lapse upon the earliest of, among other circumstances, two years after the date when the option becomes exercisable upon the listing or the occurrence of a change in control, and a
violation in transfer restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">224 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transfer restrictions</I>. Options may not be transferred in any manner by the participant other than in
accordance with the exceptions provided in the 2017 Plan or the relevant offer letter or otherwise determined by the board of directors, such as transfers by will or the laws of descent and distribution. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Termination and amendment of the 2017 Plan</I>. Unless terminated earlier, the 2017 Plan has a term of ten years. The board of directors has the authority to amend,
suspend or terminate the plan, subject to the limitations of applicable laws. No amendment, suspension or termination may adversely affect in any material way any awards previously granted pursuant to the 2017 Plan unless agreed to by the
participant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes, as of the date of this prospectus, the number of ordinary shares under our outstanding options that we granted under
the 2017 Plan to several of our directors and executive officers, excluding awards that were forfeited or cancelled after the relevant grant dates. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY&nbsp;SHARES<BR>UNDERLYING<BR>OUTSTANDING<BR>OPTIONS&nbsp;GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXERCISE&nbsp;PRICE<BR>(US$/SHARE)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DATE OF GRANT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DATE OF<BR>EXPIRATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Zheru Zhang </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,421,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1,&nbsp;2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Joan Huaqiong Shen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,505,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">August 1, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;2, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Yunhan Lin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lili Qian </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other grantees </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4,670,593</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2017<BR>to&nbsp;July 25,<BR>2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9,450,315</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:8pt; font-family:ARIAL">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less than 1% of our total outstanding shares. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Second Amended and Restated 2018 Employee Stock Option Plan
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2019, we adopted an equity incentive plan (as last amended and restated in December 2019), which we refer to as the 2018 Plan, to secure and
retain the services of valuable employees, directors or consultants, and provide incentives for such persons to exert their best efforts for the success of our business. Upon the completion of this offering, the maximum aggregate number of ordinary
shares which may be issued pursuant to all awards under the 2018 Plan is 11,005,888, subject to certain adjustments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of the date of this prospectus, awards to
purchase 10,991,671 ordinary shares under the 2018 Plan have been granted and outstanding, excluding awards that were forfeited or cancelled after the relevant grant dates. Immediately prior to the completion of this offering, Dr. Zang will
surrender a portion of his vested options to purchase 2,544,917 ordinary shares of our company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following paragraphs describe the principal terms of the 2018
Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Types of awards</I>. The 2018 Plan permits the awards of options. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan administration</I>. Our board of directors will administer the 2018 Plan. The board of directors will determine, among other things, the participants to receive
options, the number and subscription price of options to be granted to each participant, and the terms and conditions of each option granted. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Offer letter</I>.
Options granted under the 2018 Plan are evidenced by an offer letter that sets forth terms, conditions and limitations for each option, which may include the term of the option, and the provisions applicable in the event that the grantee&#146;s
employment or service terminates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Eligible participants</I>. We may grant awards to employees or if approved by the board, designee of any employee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">225 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Vesting schedule</I>. Unless otherwise approved by the board of directors and set forth in an offer letter, the
vesting schedule shall be a two-year vesting schedule consisting of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the second anniversary of the applicable vesting
commencement date. Notwithstanding the foregoing, if a listing occurs at anytime prior to any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding, any such option shall vest in full
with immediate effect upon the listing. Except as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided,
however that in each case, no option of an employee shall become exercisable until the third anniversary of such employee&#146;s employment commencement date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Exercise of options</I>. The board of directors determines the subscription price for each option, which is stated in the offer letter. The vested portion of each
option will expire if not exercised prior to the time as the board of directors determines at the time of its grant. However, the maximum exercisable term is ten years from the applicable vesting commencement date or such shorter period specified in
the award agreement. Further, an option will lapse upon the earliest of, among other circumstances, two years after the date when the option becomes exercisable upon the listing or the occurrence of a change in control, and a violation in transfer
restrictions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transfer restrictions</I>. Options may not be transferred in any manner by the participant other than in accordance with the exceptions provided
in the 2018 Plan or the relevant offer letter or otherwise determined by the board of directors, such as transfers by will or the laws of descent and distribution. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Termination and amendment of the 2018 Plan</I>. Unless terminated earlier, the 2018 Plan has a term of ten years. The board of directors has the authority to amend,
suspend or terminate the plan, subject to the limitations of applicable laws. No amendment, suspension or termination may adversely affect in any material way any awards previously granted pursuant to the 2018 Plan unless agreed to by the
participant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes, as of the date of this prospectus, the number of ordinary shares underlying our outstanding options that we granted
under the 2018 Plan, excluding awards that were forfeited or cancelled after the relevant grant dates. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY SHARES<BR>UNDERLYING<BR>OUTSTANDING<BR>OPTIONS&nbsp;GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXERCISE&nbsp;PRICE<BR>(US$/SHARE)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DATE OF GRANT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DATE&nbsp;OF&nbsp;EXPIRATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jingwu Zhang Zang </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,893,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February&nbsp;22,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February&nbsp;22,&nbsp;2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Zheru Zhang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Joan Huaqiong Shen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Yunhan Lin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lili Qian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other grantees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,110,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,991,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:8pt; font-family:ARIAL">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less than 1% of our total outstanding shares. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2019 Share Incentive Plan </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To promote the success and enhance the value of our company, in October 2019, our shareholders and board of directors approved the 2019 Share Incentive Plan (the
&#147;2019 Plan&#148;), which will become effective immediately prior to the completion of this offering. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance shall initially be 100,000. As of the date of this
prospectus, no award has been granted or outstanding under the 2019 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">226 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following paragraphs describe the principal terms of the 2019 Plan: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Type of Awards</I>. The plan permits the awards of options, restricted shares, restricted share units or other types of awards approved by the board of directors or
a committee of one or more members of the board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Administration</I>. Our board of directors or a committee of one or more members of the board
of directors will administer the plan. The committee or the board of directors, as applicable, will determine the participants to receive awards, the type and number of awards to be granted to each participant, and the terms and conditions of each
grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Award Agreement</I>. Awards granted under the plan are evidenced by an award agreement that sets forth the terms, conditions and limitations for each
award, which may include the term of the award, the provisions applicable in the event that the grantee&#146;s employment or service terminates, and our authority to unilaterally or bilaterally amend, modify, suspend, cancel or rescind the award.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Eligibility</I>. We may grant awards to our independent directors, as determined by a committee of one or more members of the board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Vesting Schedule.</I> In general, the plan administrator determines the vesting schedule, which is specified in the relevant award agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Exercise of Options</I>. The plan administrator determines the exercise price for each award, which is stated in the relevant award agreement. Options that are
vested and exercisable will terminate if they are not exercised prior to the time as the plan administrator determines at the time of grant. However, the maximum exercisable term is ten years from the date of grant. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transfer Restrictions</I>. Awards may not be transferred in any manner by the participant other than in accordance with the exceptions provided in the plan or the
relevant award agreement or otherwise determined by the plan administrator, such as transfers by will or the laws of descent and distribution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Termination and
Amendment of the Plan</I>. Our board of directors has the authority to terminate, amend, suspend or modify the plan in accordance with our articles of association. However, without the prior written consent of the participant, no such action may
adversely affect in any material way any award previously granted pursuant to the plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Biomaster Trust </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biomaster Trust was established under the trust deed dated October 23, 2019, between us and TMF Trust (HK) Limited, or TMF Trust, as the trustee of the Biomaster Trust.
As of the date of this prospectus, all participants in Biomaster Trust are our employees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Participants in Biomaster Trust transfer their equity awards granted
under the 2017 Plan and the 2018 Plan to TMF Trust for their benefit. Upon satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards
to the relevant grant recipients with the consent of the advisory committee. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by our
company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">227 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_18"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as specifically noted, the following table sets forth information with respect to the beneficial ownership of our ordinary shares on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis as of the date of this prospectus by: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of our directors and executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each person known to us to own beneficially 5% or more of our ordinary shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The calculations in the table below are based on 103,799,490 ordinary shares on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis outstanding as of the date
of this prospectus, and 131,239,439 ordinary shares outstanding immediately after the completion of this offering, assuming (i) the underwriters do not exercise their over-allotment option and (ii) each Series C-1 preferred share, each Series C
preferred share, and each Series B-2 preferred share will convert into 1.18, 1.11 and 1.08 ordinary shares of our company immediately prior to the completion of this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Several existing shareholders have subscribed for and have been allocated by the underwriters an aggregate of 2,055,000 ADSs in this offering (representing 27.7% of the
ADSs being offered in this offering) at the initial public offering price and on the same terms as the other ADSs being offered, among which each of C-Bridge II Investment Thirteen Limited, an affiliate of one of our principal shareholders, and
Genexine Inc., has subscribed for and has been allocated 150,000 and 570,000 ADSs, respectively. The underwriters will receive the same underwriting discounts and commissions on any ADSs purchased by these parties as they will on any other ADSs sold
to the public in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares
beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant or other right or the conversion of
any other security. These shares, however, are not included in the computation of the percentage ownership of any other person. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY&nbsp;SHARES</B><br><B>BENEFICIALLY<BR>OWNED&nbsp;PRIOR&nbsp;TO&nbsp;THIS&nbsp;OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY SHARES</B><br><B>BENEFICIALLY OWNED<BR>IMMEDIATELY AFTER THIS<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Directors and Executive Officers **:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Jingwu Zhang Zang<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,370,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,825,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Joan Huaqiong Shen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Zheru Zhang<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Wei Fu<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">39,464,599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">38.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">46,645,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">35.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Mengjiao Jiang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Jie Yu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Lin Li</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Chun Kwok Alan Au ***</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Conor Chia-hung Yang ***</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Pamela M. Klein ***</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Lili Qian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Yunhan Lin </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Neil Warma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All Directors and Executive Officers as a Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">55,992,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">48.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">60,629,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">42.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">228 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>



<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY&nbsp;SHARES</B><br><B>BENEFICIALLY<BR>OWNED&nbsp;PRIOR&nbsp;TO&nbsp;THIS&nbsp;OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY SHARES</B><br><B>BENEFICIALLY OWNED<BR>IMMEDIATELY AFTER THIS<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Principal Shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities<SUP STYLE="font-size:85%; vertical-align:top">
(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,464,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,645,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tasly entities<SUP STYLE="font-size:85%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,495,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,664,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Hony entity<SUP STYLE="font-size:85%; vertical-align:top"> (5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,537,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,465,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Genexine<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,261,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,572,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1%; font-size:8pt; font-family:ARIAL">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less than 1% of our total ordinary shares on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis outstanding as of the date of this prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">**</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Except as otherwise indicated below, the business address of our directors and executive officers is Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China. The business address of Wei Fu
and Mengjiao Jiang is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong. The business address of Jie Yu is Tianshili Great Health City, No. 2, East Puji River Road, Beichen District, Tianjin, China. The business address of
Lin Li is 6F, South Tower C, Raycom Info Tech Park, No.2, Kexueyuan South Road, Haidian District, Beijing, China. The business address of Chun Kwok Alan Au is 22 Pottinger Street, Central, Hong Kong. The business address of Conor Chia-hung Yang is 7<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Building C, Luneng International Center, No. 209 Guoyao Road, Pudong New Area, Shanghai, China. The business address of Dr. Pamela M. Klein is 231 Fort Mason, San Francisco, California 94123,
the United States. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">***</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of Mr. Chun Kwok Alan Au, Mr. Conor Chia-hung Yang and Dr. Pamela M. Klein has accepted the appointment as our independent director, effective upon the SEC&#146;s declaration of effectiveness of our registration
statement on Form F-1, of which this prospectus is a part. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The number of ordinary shares beneficially owned by Dr. Zang prior to this offering is 14,370,201 ordinary shares issuable upon the conversion of (i) 3,932,113 ordinary shares directly held by Mabcore Limited, a British
Virgin Islands company and (ii) 10,438,088 ordinary shares issuable upon exercise of options exercisable within 60 days after the date of this prospectus held by Dr.&nbsp;Zang, assuming Dr. Zang will not surrender any of his vested options at the
pricing of this offering. Dr.&nbsp;Zang, through himself and The Jingwu Zhang Zang 2018 Retained Annuity Trust, owns a 55.6% equity interest in Mabcore Limited. Dr. Lili Qian and two other individuals own the remaining equity interest in Mabcore
Limited. Dr.&nbsp;Zang is the sole director of Mabcore Limited. The Jingwu Zhang Zang 2018 Retained Annuity Trust was established under the laws of New York and is managed by Dr.&nbsp;Zang, as the trustee, the settlor and the sole beneficiary.
Pursuant to the currently effective memorandum and articles of association of Mabcore Limited, Dr.&nbsp;Zang, as the sole director, has the power to direct the actions of Mabcore Limited, including the voting and disposal of Mabcore Limited&#146;s
shares in <FONT STYLE="white-space:nowrap">I-Mab.</FONT> Accordingly, Dr.&nbsp;Zang is deemed to indirectly own all of the 3,932,113 ordinary shares held by Mabcore Limited, while Dr.&nbsp;Qian and the other two individuals are only entitled to
their respective <FONT STYLE="white-space:nowrap">pro-rata</FONT> economic interest in Mabcore Limited. Immediately prior to the completion of this offering, Dr. Zang will surrender a portion of his vested options to purchase 2,544,917 ordinary
shares of our company. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents 1,025,232 ordinary shares issuable upon exercise of options exercisable within 60 days after the date of this prospectus held by Gorgeous Sino Limited, a British Virgin Islands company. Dr. Zhang is the sole
shareholder and the sole director of Gorgeous Sino Limited. The registered office of Gorgeous Sino Limited is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The number of ordinary shares beneficially owned by the C-Bridge entities prior to this offering is 39,464,599 ordinary shares issuable upon the conversion of (i) 4,629,231 Series
<FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares and 512,356 Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares held by IBC Investment Seven Limited, a Hong Kong limited liability company, (ii) 8,361,823 Series <FONT
STYLE="white-space:nowrap">A-3</FONT> preferred shares held by CBC SPVII LIMITED, a Hong&nbsp;Kong limited liability company, (iii) 14,089,714 Series B preferred shares, 2,247,321 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares,
and 1,997,618 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares held by CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, a British Virgin Islands limited liability company, and (iv) 1,804,880 Series B preferred
shares, 287,880 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares, and 255,894 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares held by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited,
a British Virgin Islands limited liability company, and (v) 5,277,882 Series C preferred shares directly held by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Seven Limited, a British Virgin Islands limited liability company, each
at a conversion ratio of 1:1. IBC Investment Seven Limited, CBC SPVII LIMITED, CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited and <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Seven Limited are collectively referred to as the <FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities. CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Seven Limited are controlled by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Healthcare Fund II, L.P., whose
general partner is <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Healthcare Fund GP II, L.P., and its general partner is <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. CBC SPVII Limited and IBC Investment Seven Limited are
controlled by <FONT STYLE="white-space:nowrap">I-Bridge</FONT> Healthcare Fund, L.P., whose general partner is <FONT STYLE="white-space:nowrap">I-Bridge</FONT> Healthcare GP, L.P., and its general partner is
<FONT STYLE="white-space:nowrap">I-Bridge</FONT> Capital GP, Ltd., which is indirectly controlled by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. Wei Fu is the sole director of <FONT STYLE="white-space:nowrap">C-Bridge</FONT>
Capital GP, Ltd. The business address of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong. All the preferred shares held by the C-Bridge entities will be
converted into ordinary shares immediately prior to the completion of this offering. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:ARIAL">The number of ordinary shares beneficially owned
by the C-Bridge entities immediately after this offering is 46,645,757 consisting of (i) 31,933,205 ordinary shares converted from all the Series A-1 preferred shares, the Series A-2 preferred shares, the Series A-3 preferred shares, the Series B
preferred shares and the Series B-1 preferred shares beneficially owned by the applicable C-Bridge </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">229 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:ARIAL">
entities at a conversion ratio of 1:1; (ii)&nbsp;8,288,981 ordinary shares converted from all the Series C preferred shares and the Series B-2 preferred shares beneficially owned by the
applicable C-Bridge entities at a conversion ratio of 1:1.11 and 1:1.08, respectively; (iii) 6,078,571 CPP Shares issued to Everest concurrently with the completion of this offering, and (iv) 150,000 ADSs purchased in this offering by C-Bridge II
Investment Thirteen Limited. The CPP Shares issued to Everest are deemed to be beneficially owned by the <FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities as Everest is controlled by funds which are under common control of the C-Bridge
entities that are indirectly controlled by Wei Fu. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The number of ordinary shares beneficially owned by the Tasly entities prior to this offering is 14,495,315 ordinary shares issuable upon the conversion of (i) 8,361,823 Series
<FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares and 4,581,174 Series B preferred shares held by Tasly Biopharm Limited, a British Virgin Islands limited liability company, and (ii) 1,552,318 Series C preferred shares directly held by
Tasly International BioInv One Limited, each at a conversion ratio of 1:1. Tasly Biopharm Limited and Tasly International BioInv One Limited are collectively referred to as the Tasly entities. Tasly International BioInv One Limited is wholly-owned
by Tasly International Capital Limited, whose sole shareholder is Tasly Holding Group Co., Ltd. Tasly Biopharm Limited&#146;s sole shareholder is Tasly Biopharmaceuticals Co., Ltd., which is controlled by Tasly Pharmaceutical Group Co., Ltd., which
is in turn controlled by Tasly Holding Group Co., Ltd. Tasly Holding Group Co., Ltd. is controlled by Tianjin Tasly Health Industry Investment Group Co., Ltd., which is in turn controlled by Tianjin Fuhuade Science&nbsp;&amp; Technology Development
Co., Ltd. Kaijing Yan is the controlling shareholder of Tianjin Fuhuade Science&nbsp;&amp; Technology Development Co., Ltd. and the ultimate beneficial owner of Tasly Biopharm Limited. The registered address of Tasly Biopharm Limited is P.O. Box
957, Offshore Incorporation Centre, Road Town, Tortola, British Virgin Islands. The registered address of Tasly International BioInv One Limited is 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman
Islands. All the preferred shares held by the Tasly entities will be converted into ordinary shares immediately prior to the completion of this offering. </TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:ARIAL">The number of ordinary shares beneficially owned by the Tasly entities immediately after this offering is 14,664,020, consisting of (i) 12,942,997
ordinary shares converted from all the Series A-3 preferred shares and the Series B preferred shares beneficially owned by the applicable Tasly entities at a conversion ratio of 1:1; and (ii) 1,721,023 ordinary shares converted from all the Series C
preferred shares beneficially owned by the applicable Tasly entities at a conversion ratio of 1:1.11. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The number of ordinary shares beneficially owned by the Hony entity prior to this offering is 8,537,749 ordinary shares issuable upon the conversion of 8,537,749 Series C preferred shares at a conversion ratio of 1:1
held by Fortune Eight Jogging Limited, a British Virgin Islands limited liability company, which we refer to as the Hony entity. Fortune Eight Jogging Limited is wholly-owned by Hony Hongling (Shanghai) Investment Center, a PRC limited partnership,
whose general partner is Hony Capital (Shanghai) Ltd. The sole shareholder of Hony Capital (Shanghai) Ltd is Beijing Hony Hezhong Management Ltd. Each of Yonggang Cao, Minsheng Xu and Lijie Wang holds 33.3% equity interests in Beijing Hony Hezhong
Management Ltd. The registered address of Fortune Eight Jogging Limited is Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands. All the preferred shares held by the Hony entity will be converted into ordinary shares immediately
prior to the completion of this offering. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:ARIAL">The number of ordinary shares beneficially owned by the Hony entity immediately after this
offering is 9,465,631, which are converted from all the Series C preferred shares beneficially owned by the Hony entity at a conversion ratio of 1:1.11. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents 10,572,823 ordinary shares issuable upon the conversion of (i) 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares directly held by Genexine, Inc. (Genexine), (ii) 900,000 preferred
shares issuable to Genexine upon the full conversion of the US$9.0&nbsp;million interest-free convertible promissory note based on a conversion price of US$10 per share, and (iii) 570,000 ADSs purchased in this offering. Genexine is a Korean public
company. The registered address of Genexine is 700 <FONT STYLE="white-space:nowrap">Daewangpangyo-ro,</FONT> Korea Bio Park, Bldg. B4F, <FONT STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT
STYLE="white-space:nowrap">Gyeonggi-do,</FONT> Korea. All the preferred shares held by Genexine will be converted into ordinary shares immediately prior to the completion of this offering. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of the date of this prospectus, none of our ordinary shares outstanding is held by any record holders in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ADSs that we issue in this offering will represent ordinary shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are not
aware of any arrangement that may, at a subsequent date, result in a change of control of our company. See &#147;Description of Share Capital&#151;History of Securities Issuances&#148; for historical changes in our shareholding structure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">230 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_19"></A>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Private Placements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See &#147;Description of Share Capital&#151;History of
Securities Issuances.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Shareholders Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See
&#147;Description of Share Capital&#151;History of Securities Issuances&#151;Shareholders Agreement.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Agreements and Indemnification Agreements
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See &#147;Management&#151;Employment Agreements and Indemnification Agreements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Share Incentive Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See &#147;Management&#151;Share Incentive
Plans.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Related Party Transactions with Our Shareholders and Affiliates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;25, 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai entered into a loan
agreement with each of Qianhai Equity Investment Fund (Limited Partnership) (&#147;Qianhai Fund&#148;), Shanghai Tasly Pharmaceutical Co., Ltd. (&#147;Shanghai Tasly&#148;), and Tianjin Kangshijing Biopharmaceutical Technology Partnership (Limited
Partnership) (&#147;CBC RMB Fund&#148;), pursuant to which each of Qianhai Fund, Shanghai Tasly and CBC RMB Fund made a loan to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin to fund its business operations in an aggregate principal amount in
RMB equivalent to US$1.3&nbsp;million, US$5.1&nbsp;million and US$1.6&nbsp;million, respectively. Each of these loans bears an annual compound interest rate of 8%. Pursuant to these loan agreements, each of Qianhai Fund, Shanghai Tasly and CBC RMB
Fund has the right to contribute its interest in the respective loan to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in exchange for <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s equity interests. We fully repaid the loans
made by Qianhai Fund and Shanghai Tasly in 2018, and neither of these lenders exercised such right. The loan agreement with CBC RMB Fund was not performed by CBC RMB Fund and was mutually terminated on September&nbsp;25, 2017. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2018, we entered into a collaboration agreement with Everest, an affiliate of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital Investment Management,
Ltd., whereby both parties agreed to collaborate on programs to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary CD38 antibody for all indications in hematologic oncology and commercialize the CD38 product in China,
Hong Kong, Macau and Taiwan. For a detailed description of this collaboration agreement, see &#147;Business&#151;Licensing and Collaboration Arrangements&#151;C. Collaboration Arrangements.&#148; As of September 30, 2019, we recorded
RMB238.1&nbsp;million (US$33.3 million) of research and development funding received from Everest. Everest had paid us prepayments of RMB170.2 million and RMB52.2 million (US$7.3 million) for the nine months ended September 30, 2018 and 2019,
respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 4, 2019, we and Everest Medicines Limited, or Everest, terminated the collaboration agreement (including all the supplements and
amendments thereto) with respect to the co-development and commercialization of TJ202 in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its
commercialization. All intellectual property rights in respect of TJ202 arising from its development under the collaboration agreement are vested and owned by us, and we hold all intellectual property rights and have maximum flexibility to further
develop, manufacture and commercialize TJ202 in Greater China. In consideration of the above arrangements, we will issue a total value of US$37.0 million of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing Everest&#146;s
historical contribution to our collaboration and the associated time cost. The CPP Shares will be issued concurrently with, and subject to, the completion of this offering within 180 days from termination of the collaboration agreement, at a per
share price equal to the initial public offering price adjusted to reflect the ADS-to-ordinary share ratio. The total value of US$37.0 million was calculated based on the sum of (1) US$33.7 million, which equals cumulative paid-in contributions
historically made by Everest under the collaboration agreement; and (2) a negotiated US$3.3 million time cost of the foregoing historical contribution in light of our exclusive rights over the commercialization of TJ202 after this termination.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">231 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Based on the initial public offering price of US$14.00 per ADS (or US$6.09 per ordinary share), Everest will be issued 6,078,571 ordinary shares and become a minority shareholder of our company
upon the completion of this offering. In the event that this offering has not been completed within 180 days from the termination of the collaboration agreement, we will issue 4,762,751 ordinary shares (the &#147;Subject Shares&#148;) to Everest on
the 181st day. Our issuance of ordinary shares to Everest is being made pursuant to an exemption from registration with the U.S. Securities and Exchange Commission under Regulation S of the U.S. Securities Act of 1933, as amended, or the Securities
Act. Everest has agreed not to, directly or indirectly, sell, transfer or dispose of (i) any CPP Shares for a period of 180 days after the date of this prospectus or (ii)&nbsp;any Subject Shares for a period of 180 days after their issuance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2018, we entered into a biologics master services agreement with CMAB Biopharma (Suzhou) Inc. (&#147;CMAB&#148;), an affiliate of Bridge Capital Partners LLC.
In July 2018, we entered into Service Proposal: CMC Development of A Monoclonal Antibody with this entity. Pursuant to these two agreements, CMAB will provide us with CMC services in connection with the preparation of the IND filings to the FDA and
the NMPA in a period of 18 to 22 months for US$3.6&nbsp;million. We had paid CMAB RMB2.8&nbsp;million (US$0.4 million) for the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In September 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin entered into a CRO agreement with Tasly Pharmaceutical Group Co., Ltd. (&#147;Tasly&#148;) and
three ancillary agreements to this CRO agreement in November 2016, May 2017 and June 2017, respectively. Pursuant to these agreements, Tasly Pharmaceutical Group Co., Ltd. will provide <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin with CRO
services in connection with <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">G-CSF-HyFc</FONT></FONT> fusion protein. All of these agreements were terminated on
December&nbsp;10, 2018. We had paid Tasly RMB0.8&nbsp;million, nil and RMB5.6 million (US$0.8 million) for the year ended December&nbsp;31, 2017 and 2018 and the nine months ended September&nbsp;30, 2019, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">232 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_20"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a Cayman Islands exempted company with limited liability and our affairs are governed by our memorandum and articles of association, the Companies Law, Cap. 22
(Law 3 of 1961, as consolidated and revised), as amended, of the Cayman Islands, which is referred to as the Companies Law below, and the common law of the Cayman Islands. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of the date of this prospectus, our authorized share capital is US$50,000 divided into: (i) 398,069,815 voting ordinary shares of a nominal or par value of US$0.0001
each, (ii) 4,629,231 voting redeemable Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares of a nominal or par value of US$0.0001 each, (iii) 512,356 voting redeemable Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred
shares of a nominal or par value of US$0.0001 each, (iv) 25,085,469 voting redeemable Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares of a nominal or par value of US$0.0001 each, (v) 23,288,783 voting redeemable Series B
preferred shares a nominal or par value of US$0.0001 each, (vi) 3,714,580 voting redeemable Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares of a nominal or par value of US$0.0001 each, (vii) 8,254,622 voting redeemable Series <FONT
STYLE="white-space:nowrap">B-2</FONT> preferred shares of a nominal or par value of US$0.0001 each, (viii) 31,718,409 voting redeemable Series C preferred shares of a nominal or par value of US$0.0001 each, and (ix) 4,726,735 voting redeemable
Series C-1 preferred shares of a nominal or par value of US$0.0001 each. As of the date of this prospectus, 8,363,719 ordinary shares, 4,629,231 Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares, 512,356 Series <FONT
STYLE="white-space:nowrap">A-2</FONT> preferred shares, 25,085,469 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares, 23,288,783 Series B preferred shares, 3,714,580 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred
shares, 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, 31,046,360 Series C preferred shares and 3,857,143 Series C-1 preferred shares are issued and outstanding. All of our issued and outstanding ordinary and
preferred shares are fully paid. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately prior to the completion of this offering, our authorized share capital will become US$80,000 divided into 800,000,000
ordinary shares of a par value of US$0.0001 each. Based on the initial public offering price of US$14.00 per ADS (or US$6.09 per ordinary share, immediately prior to the completion of this offering, each Series C-1 preferred share, each Series C
preferred share, and each Series B-2 preferred share will convert into 1.18, 1.11 and 1.08 ordinary shares of our company, respectively. Each preferred share of the other series will convert into one ordinary share of our company. Immediately after
the completion of this offering, there will be 131,239,439 ordinary shares issued and outstanding (or 133,794,992 ordinary shares if the option to purchase additional shares is exercised in full by the underwriters), including a total of 99,760,129
ordinary shares resulting from the automatic conversion of all of our outstanding preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Post-Offering Memorandum and Articles </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted an amended and restated memorandum and articles of association, which will become effective and replace our current amended and restated memorandum and
articles of association in its entirety immediately prior to the completion of this offering. We refer to this amended and restated memorandum and articles of association as our post-offering memorandum and articles of association. The following is
a summary of the material provisions of the post-offering memorandum and articles of association and of the Companies Law, insofar as they relate to the material terms of our ordinary shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Objects of Our Company</I>. Under our post-offering memorandum and articles of association, the objects of our company are unrestricted and we have the full power
and authority to carry out any object not prohibited by the laws of the Cayman Islands. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Ordinary Shares</I>. Our ordinary shares are issued in registered form
and are issued when registered in our register of members. We may not issue shares to bearers. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote their shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dividends</I>. Our directors may from time to time declare dividends (including interim dividends) and other distributions on our shares in issue and authorize
payment of the same out of the funds of our company lawfully available therefor. In addition, our shareholders may declare dividends by ordinary resolution, but no dividend shall exceed the amount recommended by our directors. Our post-offering
memorandum and articles of association provide that dividends may be declared and paid out of the funds of our company lawfully available therefor. Under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">233 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the laws of the Cayman Islands, our company may pay a dividend out of either profit or the credit standing in our share premium account; provided that in no circumstances may a dividend be paid
out of the share premium account if this would result in our company being unable to pay its debts as they fall due in the ordinary course of business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Voting
Rights</I>. Voting at any meeting of shareholders is by show of hands unless a poll is demanded. A poll may be demanded by the chairman of such meeting or any one shareholder or shareholders collectively holding not less than 5% of the votes
attaching to the shares present in person or by proxy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a
simple majority of the votes attaching to the ordinary shares cast at a meeting, while a special resolution requires the affirmative vote of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes attaching to the ordinary
shares cast at a meeting. A special resolution will be required for important matters such as a change of name or making changes to our post-offering memorandum and articles of association. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Alternation of Share Capital </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may from time to time by ordinary
resolution of shareholders: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">increase our share capital by new shares of such amount as it thinks expedient; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">consolidate and divide all or any of our share capital into shares of a larger amount than its existing shares;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">subdivide our shares, or any of them, into shares of an amount smaller than that fixed by the memorandum of association,
provided that in the subdivision the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">cancel any shares that, at the date of the passing of the resolution, have not been taken or agreed to be taken by any
person and diminish the amount of its share capital by the amount of the shares so cancelled. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may by special resolution, subject to any
confirmation or consent required by the Companies Law, reduce our share capital and any capital redemption reserve in any manner authorized by law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General
Meetings of Shareholders</I>. As a Cayman Islands exempted company, we are not obliged by the Companies Law to call shareholders&#146; annual general meetings. Our post-offering memorandum and articles of association provide that we may (but are not
obliged to) in each year hold a general meeting as our annual general meeting in which case we shall specify the meeting as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined by
our directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shareholders&#146; general meetings may be convened by our directors (acting by a resolution of our board). Advance notice of at least 14 calendar
days is required for the convening of our annual general shareholders&#146; meeting (if any) and any other general meeting of our shareholders. A quorum required for any general meeting of shareholders consists of, at the time when the meeting
proceeds to business, one or more of our shareholders holding shares which carry in aggregate (or representing by proxy) not less than <FONT STYLE="white-space:nowrap">one-third</FONT> of all votes attaching to all of our shares in issue and
entitled to vote at such general meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Companies Law does not provide shareholders with any right to requisition a general meeting, nor any right to put any
proposal before a general meeting. However, these rights may be provided in a company&#146;s articles of association. Our post-offering articles of association allow our shareholders holding in aggregate not less than one-tenth of all votes
attaching to the issued and outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our board is obliged to convene an extraordinary general meeting
and to put the resolutions so requisitioned to a vote at such meeting. However, our post-offering memorandum and articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or
extraordinary general meetings not called by such shareholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transfer of Ordinary Shares</I>. Subject to the restrictions set out below, any of our
shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">234 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share which
is not fully paid up or on which we have a lien. Our board of directors may also decline to register any transfer of any ordinary share unless: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates
and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the instrument of transfer is in respect of only one class of shares; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the instrument of transfer is properly stamped, if required; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be transferred
does not exceed four; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a fee of such maximum sum as the Nasdaq Global Market may determine to be payable or such lesser sum as our directors may
from time to time require is paid to us in respect thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our directors refuse to register a transfer, they shall, within three calendar
months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The registration of
transfers may, on ten calendar days&#146; notice being given by advertisement in such one or more newspapers, by electronic means or by any other means in accordance with the rules of the Nasdaq Global Market be suspended and the register closed at
such times and for such periods as our board of directors may from time to time determine; provided, however, that the registration of transfers shall not be suspended nor the register closed for more than 30 calendar days in any year. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Liquidation</I>. On the winding up of our company, if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole
of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those
shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay all of the <FONT STYLE="white-space:nowrap">paid-up</FONT>
capital, such assets will be distributed so that, as nearly as may be, the losses are borne by our shareholders in proportion to the par value of the shares held by them. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Calls on Shares and Forfeiture of Shares</I>. Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their shares in a
notice served to such shareholders at least 14 calendar days prior to the specified time and place of payment. The shares that have been called upon and remain unpaid are subject to forfeiture. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Redemption, Repurchase and Surrender of Shares</I>. We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the
holders of these shares, on such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by our shareholders by a special resolution. Our company may also repurchase any of our shares on such
terms and in such manner as have been approved by our board of directors or by an ordinary resolution of our shareholders. Under Cayman Islands law, any redemption or repurchase of shares by our company may be made out of profits of our company, out
of our company&#146;s share premium account or out of the proceeds of a fresh issue of shares made for the purpose of the repurchase or, if so authorized by the articles of association and subject to provisions of the Companies Law, out of capital.
Any premium payable on a redemption or repurchase over the par value of the shares to be repurchased or redeemed must be provided for out of profits of our company or from sums standing to the credit of the share premium account of our company or,
if authorized by the articles of association and subject to the provisions of the Companies Law, out of capital. At no time may a company redeem or repurchase its shares unless they are fully paid. A company may not redeem or repurchase any of its
shares if, as a result of the redemption or repurchase, there would no longer be any issued shares of the company other than shares held as treasury shares. In addition, our company may accept the surrender of any fully paid share for no
consideration. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Variations of Rights of Shares</I>. Whenever the capital of our company is divided into different classes the rights attached to any such class
may, subject to any rights or restrictions for the time being attached to any class, only be varied with the consent in writing of the holders of all of the issued shares of that class or with the sanction of a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">235 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
special resolution passed at a separate meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares of any class issued with preferred or other rights
shall not, subject to any rights or restrictions for the time being attached to the shares of that class, be deemed to be varied by the creation, allotment or issue of further shares ranking <I>pari passu</I> with or subsequent to them or the
redemption or purchase of any shares of any class by our company. The rights of the holders of shares shall not be deemed to be varied by the creation or issue of shares with preferred or other rights including, without limitation, the creation of
shares with enhanced or weighted voting rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Issuance of Additional Shares</I>. Our post-offering memorandum and articles of association authorize our board
of directors to issue additional ordinary shares from time to time as our board of directors shall determine. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our post-offering memorandum and articles of
association also authorize our board of directors to issue from time to time one or more series of preference shares and to determine, with respect to any series of preference shares, the terms and rights of that series, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the designation of the series; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of shares of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the dividend rights, dividend rates, conversion rights, voting rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the rights and terms of redemption and liquidation preferences. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Issuance of these shares may dilute the voting power of holders of ordinary shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Inspection of Books and Records</I>. The notice of registered office is a matter of public record. A list of the names of the current directors and alternate
directors (if applicable) are made available by the Registrar of Companies of the Cayman Islands for inspection by any person on payment of a fee. The register of mortgages is open to inspection by creditors and shareholders. Shareholders have no
general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, we intend to provide our shareholders with annual audited financial statements. See &#147;Where You Can Find Additional
Information.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Anti-Takeover Provisions</I>. Some provisions of our post-offering memorandum and articles of association may discourage, delay or prevent a
change of control of our company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue preference shares in one or more series and to designate the price, rights, preferences,
privileges and restrictions of such preference shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, under Cayman Islands law, our directors may only exercise the rights and powers granted to them
under our post-offering memorandum and articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Exempted Company. We are an exempted company with limited liability under the Companies Law. The Companies Law distinguishes between ordinary resident companies and
exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same
as for an ordinary company except that an exempted company: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">does not have to file an annual return of its shareholders with the Registrar of Companies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">is not required to open its register of members for inspection; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">does not have to hold an annual general meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may issue negotiable or bearer shares or shares with no par value; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years
in the first instance); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may register as a limited duration company; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may register as a segregated portfolio company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">236 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Limited liability&#148; means that the liability of each shareholder is limited to the amount unpaid by the
shareholder on the shares of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Differences in Corporate Law </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Companies Law is modeled after that of England but does not follow recent English statutory enactments and differs from laws applicable to U.S. corporations and
their shareholders. Set forth below is a summary of the significant differences between the provisions of the Companies Law applicable to us and the laws applicable to companies incorporated in the United States and their shareholders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Mergers and Similar Arrangements</I>. The Companies Law permits mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and <FONT
STYLE="white-space:nowrap">non-Cayman</FONT> Islands companies. For these purposes, (a) &#147;merger&#148; means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies
as the surviving company, and (b)&nbsp;a &#147;consolidation&#148; means the combination of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the
consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must then be authorized by (a)&nbsp;a special resolution of the
shareholders of each constituent company, and (b)&nbsp;such other authorization, if any, as may be specified in such constituent company&#146;s articles of association. The plan of merger or consolidation must be filed with the Registrar of
Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a statement of the assets and liabilities of each constituent company and an undertaking that a copy of the certificate of
merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is not required for a merger or
consolidation which is effected in compliance with these statutory procedures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A merger between a Cayman parent company and its Cayman subsidiary or subsidiaries
does not require authorization by a resolution of shareholders if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member agrees otherwise. For this purpose a company is a &#147;parent&#148; of
a subsidiary if it holds issued shares that together represent at least ninety percent (90%) of the votes at a general meeting of the subsidiary. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The consent of
each holder of a fixed or floating security interest over a constituent company is required unless this requirement is waived by a court in the Cayman Islands. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Save in certain limited circumstances, a shareholder of a Cayman constituent company who dissents from the merger or consolidation is entitled to payment of the fair
value of his or her shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) upon dissenting to the merger or consolidation, provided that the dissenting shareholder complies strictly with the procedures set
out in the Companies Law. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, save for the right to seek relief on
the grounds that the merger or consolidation is void or unlawful. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Separate from the statutory provisions relating to mergers and consolidations, the Companies Law
also contains statutory provisions that facilitate the reconstruction and amalgamation of companies by way of schemes of arrangement, provided that the arrangement is approved by a majority in number of each class of shareholders and creditors with
whom the arrangement is to be made, and who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or meetings,
convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction
ought not to be approved, the court can be expected to approve the arrangement if it determines that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the statutory provisions as to the required majority vote have been met; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the shareholders have been fairly represented at the meeting in question and the statutory majority are acting bona fide
without coercion of the minority to promote interests adverse to those of the class; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">237 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the arrangement is such that may be reasonably approved by an intelligent and honest man or woman of that class acting in
respect of his interest; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Law.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When a takeover offer is made and accepted by holders of 90% of the shares within four months, the offeror may, within a <FONT
STYLE="white-space:nowrap">two-month</FONT> period commencing on the expiration of such four-month period, require the holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can be made to the
Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If an arrangement and reconstruction is thus approved, or if a takeover offer is made and accepted, a dissenting shareholder would have no rights comparable to
appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Shareholders&#146; Suits</I>. In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be brought by a minority
shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely the rule in Foss v.
Harbottle and the exceptions thereto) which may permit a minority shareholder to commence a class action against, or derivative actions in the name of, our company to challenge: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an act which is ultra vires or illegal and is therefore incapable of ratification by the shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an act which constitutes a fraud against the minority where the wrongdoers are themselves in control of the company; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an act which requires a resolution with a qualified (or special) majority (i.e., more than a simple majority) which has
not been obtained. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Indemnification of Directors and Executive Officers and Limitation of Liability</I>. Cayman Islands law does not limit the
extent to which a company&#146;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such
as to provide indemnification against civil fraud or the consequences of committing a crime. Our post-offering memorandum and articles of association permit indemnification of officers and directors for losses, damages, costs and expenses incurred
in their capacities as such unless such losses, damages, costs and expenses arise from dishonesty, wilful default or fraud of such directors or officers. This standard of conduct is generally the same as permitted under the Delaware General
Corporation Law for a Delaware corporation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we have entered into indemnification agreements with our directors and executive officers that provide
such persons with additional indemnification beyond that provided in our post-offering memorandum and articles of association. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as indemnification for
liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy as
expressed in the Securities Act and is therefore unenforceable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Directors&#146; Fiduciary Duties</I>. Under Delaware corporate law, a director of a Delaware
corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent
person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that
a director acts in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and
mandates that the best interests of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">238 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption
may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, the director must prove the procedural fairness of the transaction, and that the transaction was of
fair value to the corporation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the
company and therefore it is considered that he or she owes the following duties to the company&#151;a duty to act in good faith in the best interests of the company, a duty not to make a personal profit based on his or her position as director
(unless the company permits him or her to do so), a duty not to put himself or herself in a position where the interests of the company conflict with his or her personal interest or his or her duty to a third party and a duty to exercise powers for
the purpose for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his or her duties a
greater degree of skill than may reasonably be expected from a person of his or her knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these
authorities are likely to be followed in the Cayman Islands. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Shareholder Action by Written Consent</I>. Under the Delaware General Corporation Law, a
corporation may eliminate the right of shareholders to act by written consent by amendment to its certificate of incorporation. Cayman Islands law and our post-offering articles of association provide that shareholders may approve corporate matters
by way of a unanimous written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Shareholder Proposals</I>. Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders,
provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling
special meetings. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Companies Law does not provide shareholders with any right to requisition a general meeting, nor any right to put any proposal before a
general meeting. However, these rights may be provided in a company&#146;s articles of association. Our post-offering articles of association allow our shareholders holding in aggregate not less than <FONT STYLE="white-space:nowrap">one-tenth</FONT>
of all votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our board is obliged to convene an extraordinary
general meeting and to put the resolutions so requisitioned to a vote at such meeting. Other than this right to requisition a shareholders&#146; meeting, our post-offering articles of association do not provide our shareholders with any other right
to put proposals before annual general meetings or extraordinary general meetings. As an exempted Cayman Islands company, we are not obliged by law to call shareholders&#146; annual general meetings. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Cumulative Voting</I>. Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&#146;s
certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the
shareholder is entitled on a single director, which increases the shareholder&#146;s voting power with respect to electing such director. There are no prohibitions in relation to cumulative voting under the laws of the Cayman Islands but our
post-offering articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Removal of Directors</I>. Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed only for cause with the
approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our post-offering articles of association, subject to certain restrictions as contained therein, directors may be
removed with or without cause, by an ordinary resolution of our shareholders. A director shall hold office until the expiration of his or her term or his or her successor shall have been elected and qualified, or until his or her office is otherwise
vacated. In addition, a director&#146;s office shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">239 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
be vacated if the director (i)&nbsp;becomes bankrupt or makes any arrangement or composition with his or her creditors; (ii)&nbsp;is found to be or becomes of unsound mind or dies;
(iii)&nbsp;resigns his or her office by notice in writing to the company; (iv)&nbsp;without special leave of absence from our board of directors, is absent from three consecutive meetings of the board and the board resolves that his or her office be
vacated; (v)&nbsp;is prohibited by law from being a director; or (vi)&nbsp;is removed from office pursuant to any other provisions of our post-offering memorandum and articles of association. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transactions with Interested Shareholders</I>. The Delaware General Corporation Law contains a business combination statute applicable to Delaware corporations
whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in certain business combinations with an &#147;interested shareholder&#148;
for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target&#146;s outstanding voting share within the past
three years. This has the effect of limiting the ability of a potential acquirer to make a <FONT STYLE="white-space:nowrap">two-tiered</FONT> bid for the target in which all shareholders would not be treated equally. The statute does not apply if,
among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested shareholder.
This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target&#146;s board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute.
However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such transactions must be entered into bona fide in the best interests of the company and not with the
effect of constituting a fraud on the minority shareholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dissolution; Winding up</I>. Under the Delaware General Corporation Law, unless the board of
directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple
majority of the corporation&#146;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its members or, if the company
is unable to pay its debts as they fall due, by an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do
so. Under the Companies Law and our post-offering articles of association, our company may be dissolved, liquidated or wound up by a special resolution of our shareholders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Variation of Rights of Shares</I>. Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority
of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under our post-offering articles of association, if our share capital is divided into more than one class of shares, we may vary the rights attached
to any class with the written consent of the holders of all of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Amendment of Governing Documents</I>. Under the Delaware General Corporation Law, a corporation&#146;s governing documents may be amended with the approval of a
majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. As permitted by Cayman Islands law, our post-offering memorandum and articles of association may only be amended with a special
resolution of our shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">240 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>History of Securities Issuances </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of our securities issuances in the past three years. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ordinary Shares </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;30, 2016, we issued (i) 1 ordinary
share to Offshore Incorporations (Cayman) Limited which was immediately transferred to Mabcore Limited for a purchase price of US$0.0001 and (ii) 4,019,553 ordinary shares to Mabcore Limited for a purchase price of US$401.9553. Dr.&nbsp;Zang,
through himself and The Jingwu Zhang Zang 2018 Retained Annuity Trust, owns a 55.6% equity interest in Mabcore Limited. Lili Qian and two other individuals own the remaining equity interest in Mabcore Limited. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;18, 2016, we repurchased and cancelled 87,441 ordinary shares from Mabcore Limited. The remaining 3,932,113 ordinary shares held by Mabcore Limited have
been designated as restricted ordinary shares pursuant to the restricted share agreement, dated as of October&nbsp;18, 2016, by and among <FONT STYLE="white-space:nowrap">I-Mab,</FONT> Mabcore Limited and certain other parties thereto. None of these
restricted shares may be sold, transferred, pledged, hypothecated, or otherwise disposed of, directly or indirectly, by any shareholder of Mabcore Limited or Mabcore Limited prior to the termination of our repurchase right unless consented to by IBC
Investment Seven Limited, an affiliate of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital Investment Management, Ltd. As of the date of this prospectus, our repurchase right with respect to 70% of these restricted shares has already lapsed,
and our repurchase right with respect to the remaining 30% of the restricted shares shall lapse on October&nbsp;18, 2019. However, such repurchase right may be terminated earlier upon the completion of: (i)&nbsp;a change of control of our company;
(ii)&nbsp;the consummation of a firm underwritten public offering of the ordinary shares of our company on the Shenzhen or Shanghai Stock Exchange, the NEEQ (which is the National Equities Exchange and Quotations Co., Ltd., a Chinese <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> system for trading the shares of a public limited company that is not listed on either the Shenzhen or Shanghai Stock Exchange) or other recognized regional
or national securities exchange, with an offering price that reflects a market capitalization of not less than US$200&nbsp;million (exclusive of underwriting commissions and expenses) and gross proceeds to our company of at least US$40&nbsp;million
(prior to any underwriters&#146; commissions and expenses), or (iii)&nbsp;the termination of employment or consultancy of any of these shareholders of Mabcore Limited with us without cause. Prior to the termination of our repurchase right, we have
the right to repurchase, from Mabcore Limited, all of the restricted shares ultimately held by any of these shareholders of Mabcore Limited, at a repurchase price equal to the equivalent amount of US$ of RMB0.5385 per share, plus a 12% interest
compounded annual interest accruing from October&nbsp;18, 2016, upon (x)&nbsp;the voluntary termination by a shareholder of Mabcore Limited of his/her employment or consultancy with us, or (y)&nbsp;the termination by us of such person&#146;s
employment or consultancy with us for cause. To exercise our repurchase right, we shall deliver a written notice to Mabcore Limited and the applicable shareholder of Mabcore Limited within 60 days after the termination of the employment or
consultancy of such shareholder. We have no obligation to repurchase any restricted shares. We may not assign any repurchase right to any party without the prior written consent of IBC Investment Seven Limited. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;18, 2016, we issued an aggregate of 4,431,606 ordinary shares to BioScikin Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd for an aggregate purchase
price of approximately RMB16.0&nbsp;million. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preferred Shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;18, 2016, we issued 4,629,231 Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares and 512,356 Series
<FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares to IBC Investment Seven Limited for an aggregate purchase price of approximately US$4.6&nbsp;million and US$8.4&nbsp;million, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;6, 2017, we issued an aggregate of 16,723,646 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares to CBC SPVII LIMITED and Genexine
for an aggregate purchase price of US$30.0&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;22, 2017, we issued 14,089,714 Series B preferred shares to CBC Investment <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Limited for an aggregate purchase price of US$48.4&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;9, 2018, we issued 1,804,880 Series B
preferred shares to <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited for an aggregate purchase price of US$6.2&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
June&nbsp;29, 2018, we issued an aggregate of 2,535,201 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-MAB</FONT> Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT>
II Investment Ten Limited for an aggregate purchase price of approximately US$13.7&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">241 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
as a result of the conversion by these two entities of the convertible promissory notes issued to them on September&nbsp;25, 2017 and February&nbsp;9, 2018, respectively. On the same date, we
issued an aggregate of 2,253,512 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-MAB</FONT> Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten
Limited for an aggregate purchase price of approximately US$13.7&nbsp;million as a result of the exercise of the warrants granted to them on September&nbsp;25, 2017. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;29, 2018, we issued 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares, 5,938,640 Series B preferred shares, and 947,218 Series <FONT
STYLE="white-space:nowrap">B-1</FONT> preferred shares to Tasly Biopharma Limited in exchange for Tasly Biopharma Limited&#146;s equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;6, 2018, Tasly Biopharma Limited transferred to Rainbow Horizon Limited 947,218 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares and the
warrant in part to purchase 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares for a total purchase price of US$6.0&nbsp;million. On the same date, we issued 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT>
preferred shares to Rainbow Horizon Limited as a result of the exercise of the warrant by Rainbow Horizon for an aggregate purchase price of US$5.1&nbsp;million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;6, 2018, we issued to Qianhai Ark (Cayman) Investment Co. Limited (&#147;Qianhai Ark Cayman&#148;), (i) 1,455,549 Series B preferred shares for a purchase
price of approximately US$2.0&nbsp;million, (ii) 232,161 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares for an aggregate purchase price of US$1.25&nbsp;million as a result of the conversion of a convertible promissory note
issued to Qianhai Ark Cayman on July&nbsp;6, 2018, and (iii) 206,366 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares for an aggregate purchase price of US$1.25&nbsp;million as a result of the exercise of warrant granted to
Qianhai Ark Cayman on September&nbsp;25, 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;6, 2018, we issued an aggregate of 31,046,360 Series C preferred shares to Fortune Eight Jogging
Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Seven Limited, HH IMB Holdings Limited, Ally Bridge LB Precision Limited, Marvey Investment Company Limited, Mab Health Limited, Casiority H Limited, Southern Creation Limited
(formerly known as Ally Bridge <FONT STYLE="white-space:nowrap">LB-Sunshine</FONT> Limited), Tasly International Capital Limited, and Parkway Limited for an aggregate purchase price of US$200.0&nbsp;million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July 25, 2019, we entered into a share purchase agreement with Caesar Pro Holdings Limited, WuXi Biologics HealthCare Venture, and Hongkong Tigermed Co., Limited.
Pursuant to the share purchase agreement, these investors will subscribe for an aggregate of 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shares of <FONT STYLE="white-space:nowrap">I-Mab</FONT> for an aggregate purchase
price of US$27.0 million. On October 17, 2019, we issued 1,428,571 Series C-1 preferred shares to Wuxi Biologics HealthCare Venture. On November 6, 2019, we issued an aggregate of 2,428,572 Series C-1 preferred shares to Hong Kong Tigermed Co.,
Limited and Caesar Pro Holdings Limited. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible Promissory Notes </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;25, 2017, we issued a US$12.1&nbsp;million convertible promissory note due September 2020 to CBC Investment
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited. On June&nbsp;29, 2018, CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited converted this note to 2,247,321 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;5, 2018, we issued a US$9.0&nbsp;million convertible promissory note due February 2021 to Genexine. Genexine can at any time prior to
February&nbsp;5, 2021 convert this note into preferred shares of <FONT STYLE="white-space:nowrap">I-Mab</FONT> at US$10 per share, subject to certain price adjustments. As of the date of this prospectus, Genexine has not converted this note. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;9, 2018, we issued a US$1.6&nbsp;million convertible promissory note due September 2020 to <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II
Investment Ten Limited. On June&nbsp;29, 2018, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited converted this note into 287,880 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;6, 2018, we issued a US$1.3&nbsp;million convertible promissory note due July 2021 to Qianhai Ark Cayman. On July&nbsp;6, 2018, Qianhai Ark Cayman
converted this note into 232,161 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Options and Warrants </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;18, 2016, we granted IBC Investment Seven Limited a warrant to purchase up to 2,246,744 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred
shares. The warrant was cancelled on September&nbsp;6, 2017 pursuant to a termination agreement between us and IBC Investment Seven Limited, who had not exercised the warrant prior to the termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">242 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;6, 2017, we granted Shanghai Tasly an option to purchase up to 8,361,823 Series <FONT
STYLE="white-space:nowrap">A-3</FONT> preferred shares. On September&nbsp;25, 2017, we granted Shanghai Tasly an additional option to purchase up to 5,938,640 Series B preferred shares and 947,218 Series <FONT STYLE="white-space:nowrap">B-1</FONT>
preferred shares. On June&nbsp;29, 2018, Tasly Biopharma Limited, as Shanghai Tasly&#146;s permitted assign, exercised these options in full. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;25,
2017, we granted (i)&nbsp;Qianhai Fund an option to purchase up to 1,455,549 Series B preferred shares and up to 232,161 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares, and (ii)&nbsp;CBC RMB Fund an option to purchase up to
1,804,880 Series B preferred shares and up to 287,880 additional Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred Shares. The option granted to Qianhai Fund was exercised in full on July&nbsp;6, 2018. The option granted to CMC RMB Fund
was terminated on February&nbsp;9, 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;25, 2017, we granted a warrant to each of CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Limited, Shanghai Tasly, Qianhai Fund and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited to purchase up to 4,994,046 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, up to 2,104,928 Series <FONT
STYLE="white-space:nowrap">B-2</FONT> preferred shares, up to 515,914 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares and up to 639,734 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, respectively. On
July&nbsp;6, 2018, these investors exercised their warrants in part and purchased 1,997,618 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, 206,366
Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares and 255,894 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, for an aggregate purchase price of US$20.0&nbsp;million. These investors have waived and cancelled
their rights under the rest of the warrants. On September&nbsp;25, 2017, we also granted a warrant to CBC RMB Fund to purchase up to 639,734 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, which was terminated on the same date.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;6, 2018, Tasly Biopharm Limited, as Shanghai Tasly&#146;s permitted assign, transferred to Rainbow Horizon Limited the warrant in part to purchase
841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares. On the same date, Rainbow Horizon Limited exercised this warrant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted
options to purchase our ordinary shares to certain of our directors, executive officers and&nbsp;employees. See &#147;Management&#151;Share Incentive Plans.&#148; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shareholders Agreement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2019, we entered into our fourth
amended and restated shareholders agreement with our shareholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shareholders agreement provides for certain special rights, including right of first
refusal, <FONT STYLE="white-space:nowrap">co-sale</FONT> rights, preemptive rights and contains provisions governing the board of directors and other corporate governance matters. Unless specifically noted, those special rights, as well as the
corporate governance provisions, will automatically terminate upon the completion of this offering. Each series of our preferred shares will be automatically converted to ordinary shares on a one-for-one basis immediately prior to the completion of
this offering, provided that in the event that the initial offering price per ordinary share is lower than the original issue price for a particular series of preferred shares, the holders of that series of preferred shares is entitled to
anti-dilution protection pursuant to our currently effective memorandum and articles of association (as last amended on December 25, 2019). At an initial offering price of US$14.00 per ADS (or US$6.09 per ordinary share), each Series C-1 preferred
share, each Series C preferred share, and each Series B-2 preferred share will convert into 1.18, 1.11 and 1.08 ordinary shares of our company respectively immediately prior to the completion of this offering. For additional details on the effect of
this change on the related conversion ratios, see &#147;Dilution,&#148; &#147;Capitalization&#148; and &#147;Principal Shareholders.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deed of
Undertaking </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2019, a deed of undertaking was made by our company and a few shareholders of our company, each as a warrantor, to the other
shareholders of our company (other than the shareholder warrantors), each as a warrantee, pursuant to which each warrantor represents and warrants to each warrantee that it has provided each warrantee with all information and documents in connection
with this offering that has the effect of establishing rights or otherwise benefiting any shareholder in a manner more favorable than the corresponding terms applicable to the relevant warrantee in relation to this offering (collectively, the
&#147;More Favorable Arrangements&#148;). Pursuant to the deed of undertaking, until the fifth anniversary of the completion of this offering, we will not directly or indirectly enter into any agreements or arrangements or modify, amend or waive any
existing agreements or arrangements of any kind that would have the effect of establishing the More Favorable Arrangements; provided that it shall be allowed to adopt or modify any employee incentive plans and grant options to the management or any
employee of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">243 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
our company after this offering pursuant to such plans and in accordance with the then effective memorandum and articles of association and the applicable listing rules for the purpose of
rewarding their bona fide services. The deed of undertaking will terminate immediately and all obligations thereunder will cease if this offering is not consummated on or before March&nbsp;31, 2020 or if this offering is cancelled by way of
resolutions of the shareholders of our company, whichever occurs earlier. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Registration Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to our shareholders agreement, we have granted certain registration rights to our shareholders. Set forth below is a description of the registration rights
granted under the agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Demand Registration Rights</I>. At any time after the earlier of (i)&nbsp;December&nbsp;31, 2020, or (ii)&nbsp;six months following
the effectiveness of a registration statement for a firm underwritten public offering of our ordinary shares on The Stock Exchange of Hong Kong Limited, the New York Stock Exchange, the Nasdaq Stock Market or other internationally recognized
securities exchange, with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$1.0&nbsp;billion, the holders of a majority of the
registrable securities then issued and outstanding may request in writing that we file a registration statement covering the registration of at least 20% of the registrable securities (or any lesser percentage if the anticipated gross receipts from
the offering are to exceed US$5.0 million). Upon such a request, we shall, within ten business days of the receipt of such written request, give written notice of such request to all holders, and use our best efforts to effect, as soon as
practicable, the registration of all registrable securities that the holders request to be registered and included in such registration by written notice given by such holders to us within 20 days after receipt of the request notice. We have the
right to defer filing of a registration statement for a period of not more than 90 days after receipt of the request of the initiating holders if our board of directors determines in good faith that filing of such registration statement at such time
will be materially detrimental to us or our shareholders, but we cannot exercise the deferral right more than once during any twelve-month period and cannot register any other securities during such twelve-month period. We are not obligated to
effect any such registration if we have, within the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date of such request, already effected a registration. We are not obligated to effect more than three demand registrations.
This demand registration right is subject to the customary exclusion right of the underwriters. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Registration on Form
<FONT STYLE="white-space:nowrap">F-3</FONT></I>. If we qualify for registration on Form <FONT STYLE="white-space:nowrap">F-3,</FONT> any holder or holders of a majority of all registrable securities then issued and outstanding may request in writing
that we effect a registration on <FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> (or an equivalent registration in a jurisdiction outside of the U.S.). We shall promptly give written notice of the proposed registration and as soon as
practicable, effect such registration within 20 days after we provide the aforesaid written notice. The holders are entitled to an unlimited number of registrations on Form <FONT STYLE="white-space:nowrap">F-3</FONT> so long as such registration
offerings are in excess of US$500,000. We are not obligated to effect any such registration if we have, within the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date of such request, already effected a registration other
than a registration from which registrable securities of the holders have been excluded, or if we would be required to qualify to do business&nbsp;or to execute a general consent to service of process in effecting such registration in any particular
jurisdiction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Piggyback Registration Rights</I>. If we propose to register for a public offering of our securities (other than registration statements relating
to demand registration, Form <FONT STYLE="white-space:nowrap">F-3</FONT> registration, any employee benefit plan or a corporate reorganization), we shall give written notice of such registration to all holders of registrable securities at least 30
days prior to filing any registration statement and afford each such holder an opportunity to be included in such registration. If a holder decides not to include all of its registrable securities in any registration statement thereafter filed by
us, such holder shall nevertheless continue to have the right to include any registrable securities in any subsequent registration statement or registration statements as may be filed by us, subject to certain limitations. This piggyback
registration right is subject to the customary exclusion right of the underwriters. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expenses of Registration</I>. We will bear all registration expenses. Each
holder, however, should bear its proportionate share of all of the underwriting discounts and selling commissions applicable to the sale of registrable securities or other amounts payable to underwriter(s) or brokers in connection with such offering
by the holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">244 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Termination of Obligations</I>. Our obligations to effect any demand,
<FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> or piggyback registration shall terminate upon the earlier of (i) the tenth anniversary of this offering (ii) after listing, the date on which such shareholder is eligible to sell all of the
registrable securities held by it under Rule 144 within any 90-day period without volume limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">245 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_21"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citibank, N.A. has agreed to act as the depositary for the American Depositary Shares. Citibank&#146;s depositary offices are located at 388 Greenwich Street, New
York, New York 10013. American Depositary Shares are frequently referred to as &#147;ADSs&#148; and represent ownership interests in securities that are on deposit with the depositary. ADSs may be<B> </B>represented by certificates that are commonly
known as &#147;American Depositary Receipts&#148; or &#147;ADRs.&#148; The depositary typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A.&#151;Hong Kong, located at 9/F, Citi Tower, One
Bay East, 83 Hon Hai Road, Kwun Tong, Kowloon, Hong Kong. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have appointed Citibank as depositary pursuant to a deposit agreement. A copy of the deposit agreement
is on file with the SEC under cover of a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> You may obtain a copy of the deposit agreement from the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C.
20549 and from the SEC&#146;s website (<U>www.sec.gov</U>). Please refer to Registration Number <FONT STYLE="white-space:nowrap">333-234363</FONT> when retrieving such copy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by
their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge you to review the deposit
agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each ten (10) ADSs represent the right to receive, and to exercise the beneficial ownership interests in, twenty-three (23) ordinary shares that are on deposit with the
depositary and/or the custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary or the custodian on behalf of the owner of the ADS but that has not been
distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary may agree to change the <FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT> shares ratio by amending the deposit agreement. This
amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The
deposited property does not constitute the proprietary assets of the depositary, the custodian or their nominees. <B></B>Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners
of the ADSs. The depositary, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. <B></B>A beneficial
owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders
of the ADSs (on behalf of the applicable ADS owners) only through the depositary, and the depositary (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon
the terms of the deposit agreement.<B></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms
and to the terms of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary. As an ADS holder you appoint the
depositary to act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of the Cayman Islands,
which may be different from the laws in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, applicable laws and regulations may require you to satisfy reporting requirements and
obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary, the custodian, us or any of their or our respective agents or
affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary will hold on your behalf the
shareholder rights attached to the ordinary shares underlying your ADSs.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">246 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<I>As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary only to the extent contemplated in the deposit
agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder.</I> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The manner in which you own the ADSs (e.g., in a brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may affect your
rights and obligations, and the manner in which, and extent to which, the depositary&#146;s services are made available to you. As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or
safekeeping account, or through an account established by the depositary in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary (commonly referred to as the &#147;direct registration system&#148; or
&#147;DRS&#148;). The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the
depositary to the holders of the ADSs. The direct registration system includes automated transfers between the depositary and The Depository Trust Company (&#147;DTC&#148;), the central book-entry clearing and settlement system for equity securities
in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the
ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions
concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as
such, we will refer to you as the &#147;holder.&#148; When we refer to &#147;you,&#148; we assume the reader owns ADSs and will own ADSs at the relevant time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
registration of the ordinary shares in the name of the depositary or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary or the custodian the record ownership in the applicable ordinary shares with the
beneficial ownership rights and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary or the custodian shall at all times be entitled to exercise the
beneficial ownership rights in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Dividends and Distributions </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a holder of ADSs, you generally have
the right to receive the distributions we make on the securities deposited with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such
distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of the specified record date, after deduction of the applicable fees, taxes and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Distributions of Cash </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Whenever we make a cash distribution for the
securities on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary will arrange for the funds received in a currency other than U.S. dollars to
be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to the laws and regulations of the Cayman Islands. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary will apply the same method for distributing the proceeds of the sale of any property (such as
undistributed rights) held by the custodian in respect of securities on deposit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of cash will be made net of the fees, expenses, taxes and
governmental charges payable by holders under the terms of the deposit agreement. The depositary will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for the benefit of the
applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">247 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Distributions of Shares </U></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Whenever we make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with
the custodian. Upon receipt of confirmation of such deposit, the depositary will <U>either</U> distribute to holders new ADSs representing the ordinary shares deposited <U>or</U> modify the <FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT>
shares ratio, in which case each ADS you hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be
distributed as in the case of a cash distribution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of new ADSs or the modification of the <FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT>
shares ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the
depositary may sell all or a portion of the new ordinary shares so distributed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No such distribution of new ADSs will be made if it would violate a law
(<I>e.g.</I>, the U.S. securities laws) or if it is not operationally practicable. If the depositary does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will
distribute the proceeds of the sale as in the case of a distribution of cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Distributions of Rights </U></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary and we will assist the depositary in
determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The depositary will establish
procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the
documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your
rights. The depositary is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The depositary will <I>not</I> distribute the rights to you if: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We do not timely request that the rights be distributed to you or we request that the rights not be distributed to you; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We fail to deliver satisfactory documents to the depositary; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">It is not reasonably practicable to distribute the rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The depositary will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be
distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Elective
Distributions </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give
prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary in determining whether such distribution is lawful and reasonably
practicable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The depositary will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation
contemplated in the deposit agreement. In such case, the depositary will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in the Cayman Islands would receive upon
failing to make an election, as more fully described in the deposit agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">248 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Other Distributions </U></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Whenever we intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will notify the depositary in
advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary in determining whether such distribution to holders is lawful and reasonably practicable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If it is reasonably practicable to distribute such property to you and if we provide to the depositary all of the documentation contemplated in the deposit agreement,
the depositary will distribute the property to the holders in a manner it deems practicable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution will be made net of fees, expenses, taxes and
governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary may sell all or a portion of the property received. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The depositary will <I>not</I> distribute the property to you and will sell the property if: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We do not request that the property be distributed to you or if we request that the property not be distributed to you; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We do not deliver satisfactory documents to the depositary; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The depositary determines that all or a portion of the distribution to you is not reasonably practicable.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Redemption </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Whenever we decide to redeem any of the securities on
deposit with the custodian, we will notify the depositary in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary will provide notice of the redemption to the holders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary will convert into U.S.
dollars upon the terms of the deposit agreement the redemption funds received in a currency other than U.S. dollars and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the
depositary. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a <I>pro rata</I> basis, as the
depositary may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Changes Affecting Ordinary Shares </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, <FONT STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or any other reclassification of
such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of the Company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any such change were to occur, your ADSs
would, to the extent permitted by law and the deposit agreement, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver new ADSs to you,
amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form <FONT STYLE="white-space:nowrap">F-6,</FONT> call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to
reflect as to the ADSs the change affecting the ordinary shares. If the depositary may not lawfully distribute such property to you, the depositary may sell such property and distribute the net proceeds to you as in the case of a cash distribution.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Issuance of ADSs upon Deposit of Ordinary Shares </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon
completion of this offering, the ordinary shares being offered pursuant to this prospectus will be deposited by us with the custodian.&nbsp;Upon receipt of confirmation of such deposit, the depositary will issue ADSs to the underwriters named in
this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">249 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the closing of this offering, the depositary may create ADSs on your behalf if you or your broker deposit
ordinary shares with the custodian. The depositary will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your
ability to deposit ordinary shares and receive ADSs may be limited by U.S. and Cayman Islands legal considerations applicable at the time of deposit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The issuance
of ADSs may be delayed until the depositary or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary will only issue ADSs in a
denomination of ten (10) ADSs or any whole multiple of ten (10) ADSs. No fractional ADSs will be issued and no fractional share will be accepted for deposit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When
you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the depositary. As such, you will be deemed to represent and warrant that: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The ordinary shares are duly authorized, validly issued, fully paid,
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and legally obtained. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or exercised.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">You are duly authorized to deposit the ordinary shares. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage
or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The ordinary shares presented for deposit have not been stripped of any rights or entitlements. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of the representations or warranties are incorrect in any way, we and the depositary may, at your cost and expense, take any and all actions necessary to correct
the consequences of the misrepresentations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Transfer, Combination and Split Up of ADRs </U></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you will have to surrender the
ADRs to be transferred to the depositary and also must: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide such proof of identity and genuineness of signatures as the depositary deems appropriate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide any transfer stamps required by the State of New York or the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the
terms of the deposit agreement, upon the transfer of ADRs. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To have your ADRs either combined or split up, you must surrender the ADRs in question
to the depositary with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Withdrawal of Ordinary Shares Upon Cancellation of ADSs </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a holder,
you will be entitled to present your ADSs to the depositary for cancellation and then receive the corresponding number of underlying ordinary shares at the custodian&#146;s offices. Your ability to withdraw the ordinary shares held in respect of the
ADSs may be limited by U.S. and Cayman Islands law considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary the fees for cancellation of
ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you hold ADSs registered in your name, the depositary may ask you to provide proof of identity and genuineness of any signature and such other documents as the
depositary may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary receives satisfactory evidence of compliance with all applicable laws and
regulations. Please keep in mind that the depositary will only accept a number of ADSs for cancellation that represent a whole number of securities on deposit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">250 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You will have the right to withdraw the securities represented by your ADSs at any time except for: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed, or
(ii)&nbsp;ordinary shares are immobilized on account of a shareholders&#146; meeting or a payment of dividends. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Obligations to pay fees, taxes and similar charges. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to comply with
mandatory provisions of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Voting Rights </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a holder, you
generally have the right under the deposit agreement to instruct the depositary to exercise the voting rights for the ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in &#147;Description of
Share Capital.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At our request, the depositary will distribute to you any notice of shareholders&#146; meeting received from us together with information
explaining how to instruct the depositary to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary may distribute to holders of ADSs instructions on how to retrieve such materials
upon request. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the depositary timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy)
represented by the holder&#146;s ADSs as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>In the event of voting by show of hands</I>, the depositary will vote (or cause the custodian to vote) all ordinary
shares held on deposit at that time in accordance with the voting instructions received from a majority of holders of ADSs who provide timely voting instructions. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>In the event of voting by poll</I>, the depositary will vote (or cause the Custodian to vote) the ordinary shares held
on deposit in accordance with the voting instructions received from the holders of ADSs. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities for which no voting instructions have been
received will not be voted (except as otherwise contemplated in the deposit agreement).<B> </B>Please note that the ability of the depositary to carry out voting instructions may be limited by practical and legal limitations and the terms of the
securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Fees and Charges </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an ADS holder, you will be required to pay the
following fees under the terms of the deposit agreement: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SERVICE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>FEES</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Issuance of
ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares, upon a change in the <FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT> shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of
ordinary shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS issued</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Cancellation of
ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the <FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT> shares ratio, or for any other reason)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS cancelled</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Distribution of
cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Distribution of
ADSs pursuant to (i)&nbsp;stock dividends or other free stock distributions, or (ii)&nbsp;exercise of rights to purchase additional ADSs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Distribution of
securities other than ADSs or rights to purchase additional ADSs (e.g., upon a <FONT STYLE="white-space:nowrap">spin-off)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR></TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">251 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SERVICE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>FEES</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;ADS
Services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held on the applicable record date(s) established by the depositary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Registration of
ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and <I>vice versa</I>, or for any other reason)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) transferred</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.32em; text-indent:-1.89em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8201;&#8202;Conversion of
ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely transferable ADSs, and <I>vice
versa</I>).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) converted</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an ADS holder you will also be responsible to pay certain charges such as: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">taxes (including applicable interest and penalties) and other governmental charges; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register
and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain cable, telex and facsimile transmission and delivery expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the fees, expenses, spreads, taxes and other charges of the depositary and/or service providers (which may be a division,
branch or affiliate of the depositary) in the conversion of foreign currency; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the reasonable and customary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses incurred by the depositary in connection with compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs and ADRs; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the fees, charges, costs and expenses incurred by the depositary, the custodian, or any nominee in connection with the ADR
program. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ADS fees and charges for (i)&nbsp;the issuance of ADSs, and (ii)&nbsp;the cancellation of ADSs are charged to the person for whom the
ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary into DTC, the ADS issuance and cancellation fees and charges may be
deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will
be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the ADS
service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i)&nbsp;distributions
other than cash and (ii)&nbsp;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held
through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices
prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs. In the case of (i)&nbsp;registration of ADS transfers, the ADS transfer fee will be payable by the
ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii)&nbsp;conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the Holder whose ADSs are converted
or by the person to whom the converted ADSs are delivered. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of refusal to pay the depositary fees, the depositary may, under the terms of the deposit
agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder. Certain depositary fees and charges (such as the ADS services fee) may become
payable shortly after the closing of the ADS offering.<B><I> </I></B>Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary. You will receive prior notice of such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">252 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
changes. The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or
otherwise, upon such terms and conditions as we and the depositary agree from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Amendments and Termination </U></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may agree with the depositary to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days&#146; prior notice of any
modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary
for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior
notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You will be bound by the modifications to
the deposit agreement if you continue to hold your ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except
as permitted by law). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have the right to direct the depositary to terminate the deposit agreement. Similarly, the depositary may in certain circumstances on its
own initiative terminate the deposit agreement. In either case, the depositary must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be unaffected. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After termination, the depositary will continue to collect distributions received (but will not distribute any such property until you request the cancellation of your
ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account.
At that point, the depositary will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with any termination of the deposit agreement, the depositary may make available to owners of ADSs a means to withdraw the ordinary shares represented by
ADSs and to direct the depositary of such ordinary shares into an unsponsored American depositary share program established by the depositary. The ability to receive unsponsored American depositary shares upon termination of the deposit agreement
would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored American depositary shares and the payment of applicable depositary fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Books of Depositary </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The depositary will maintain ADS holder records
at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The depositary will maintain in New York facilities to record and process the issuance, cancellation, combination, <FONT STYLE="white-space:nowrap">split-up</FONT>
and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Limitations on Obligations and Liabilities
</U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The deposit agreement limits our obligations and the depositary&#146;s obligations to you. Please note the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We and the depositary are obligated only to take the actions specifically stated in the deposit agreement without
negligence or bad faith. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is
cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The depositary disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the
content of any document forwarded to you on our behalf or for the accuracy of any translation of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">253 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for any tax consequences that result from the ownership
of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give notice. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the deposit
agreement. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We and the depositary disclaim any liability if we or the depositary are prevented or forbidden from or subject to any
civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of present
or future provision of any provision of our post-offering memorandum and articles of association, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided
for in the deposit agreement or in our post-offering memorandum and articles of association or in any provisions of or governing the securities on deposit. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or information
received from legal counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or
information. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We and the depositary also disclaim liability for the inability by a holder to benefit from any distribution, offering,
right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We and the depositary may rely without any liability upon any written notice, request or other document believed to be
genuine and to have been signed or presented by the proper parties. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the terms of the
deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary relationship,
among us, the depositary and you as ADS holder. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which parties
adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to account for
any payment received as part of those transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Taxes </U></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary and the
custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the
sale proceeds do not cover the taxes that are due. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The depositary may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities
on deposit until all taxes and charges are paid by the applicable holder. The depositary and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However,
you may be required to provide to the depositary and to the custodian proof of taxpayer status and residence and such other information as the depositary and the custodian may require to fulfill legal obligations. You are required to indemnify us,
the depositary and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">254 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Foreign Currency Conversion </U></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The depositary will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S.
dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental
requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or
within a reasonable period, the depositary may take the following actions in its discretion: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom
the conversion and distribution is lawful and practical. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Distribute the foreign currency to holders for whom the distribution is lawful and practical. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Hold the foreign currency (without liability for interest) for the applicable holders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Governing Law/Waiver of Jury Trial </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The deposit agreement, the ADRs
and the ADSs will be interpreted in accordance with the laws of the State of New&nbsp;York. The rights of holders of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of the Cayman Islands. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an owner of ADSs, you irrevocably agree that any legal action arising out of the Deposit Agreement, the ADSs or the ADRs, involving the Company or the Depositary,
may only be instituted in a state or federal court in the city of&nbsp;New York. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>AS A PARTY TO THE DEPOSIT AGREEMENT, YOU IRREVOCABLY WAIVE, TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW, YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND/OR THE DEPOSITARY. </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the
depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would
determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the
depositary&#146;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">255 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_22"></A>SHARES ELIGIBLE FOR FUTURE SALES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, we will have 7,407,400 ADSs outstanding, representing approximately 13.0% of our outstanding ordinary shares, assuming the
underwriters do not exercise their over-allotment option. All of the ADSs sold in this offering will be freely transferable by persons other than by our &#147;affiliates&#148; without restriction or further registration under the Securities Act.
Sales of substantial amounts of our ADSs in the public market could adversely affect prevailing market prices of our ADSs. Prior to this offering, there has been no public market for our ordinary shares or the ADSs. The ADSs have been approved for
listing on the Nasdaq Global Market, but we cannot assure you that a regular trading market will develop in the ADSs. We do not expect that a trading market will develop for our ordinary shares not represented by the ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our
officers, directors and our current shareholders have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell or offer to sell any ADSs, ordinary shares or similar securities currently or hereafter owned either of record or
beneficially (as defined in Rule 13d-3 under the Exchange Act), </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into any swap, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and
sale of any ADSs, ordinary shares or similar securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly announce any intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than this offering, we are not aware of any plans by any significant shareholders to dispose of significant numbers of our ADSs or ordinary shares. However, one
or more existing shareholders or owners of securities convertible or exchangeable into or exercisable for our ADSs or ordinary shares may dispose of significant numbers of our ADSs or ordinary shares in the future. We cannot predict what effect, if
any, future sales of our ADSs or ordinary shares, or the availability of ADSs or ordinary shares for future sale, will have on the trading price of our ADSs from time to time. Sales of substantial amounts of our ADSs or ordinary shares in the public
market, or the perception that these sales could occur, could adversely affect the trading price of our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our ordinary shares that will be outstanding upon the completion of this offering, other than those ordinary shares underlying the ADSs sold in this offering,
are &#147;restricted securities&#148; as that term is defined in Rule 144 under the Securities Act and may be sold publicly in the United States only if they are subject to an effective registration statement under the Securities Act or pursuant to
an exemption from the registration requirement such as those provided by Rule 144 and Rule 701 promulgated under the Securities Act. In general, beginning 90 days after the date of this prospectus, a person (or persons whose shares are aggregated)
who at the time of a sale is not, and has not been during the three months preceding the sale, an affiliate of ours and has beneficially owned our restricted securities for at least six months will be entitled to sell the restricted securities
without registration under the Securities Act, subject only to the availability of current public information about us, and will be entitled to sell restricted securities beneficially owned for at least one year without restriction. Persons who are
our affiliates and have beneficially owned our restricted securities for at least six months may sell a number of restricted securities within any three-month period that does not exceed the greater of the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1% of the then outstanding ordinary shares of the same class, represented by ADSs or otherwise, which immediately after
this offering will equal 1,312,394 ordinary shares, assuming the underwriters do not exercise their option to purchase additional ADSs; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the average weekly trading volume of our ordinary shares of the same class, represented by ADSs or otherwise, during the
four calendar weeks preceding the date on which notice of the sale is filed with the SEC. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">256 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales by our affiliates under Rule 144 are also subject to certain requirements relating to manner of sale, notice
and the availability of current public information about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule 701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in
connection with a compensatory stock plan or other written agreement executed prior to the completion of this offering is eligible to resell those ordinary shares in reliance on Rule&nbsp;144, but without compliance with some of the restrictions,
including the holding period, contained in Rule&nbsp;144. However, the Rule 701 shares would remain subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> arrangements and would only become eligible for sale when the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period expires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">257 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_23"></A>TAXATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following summary of the material Cayman Islands, PRC and U.S. federal income tax consequences of an investment in our ADSs or ordinary shares is based upon laws
and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change. This summary does not deal with all possible tax consequences relating to an investment in our ADSs or ordinary shares, such as the
tax consequences under U.S. state and local tax laws or under the tax laws of jurisdictions other than the Cayman Islands, China and the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cayman
Islands Taxation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no
taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied by the government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or brought
within the jurisdiction of the Cayman Islands. The Cayman Islands are a party to a double tax treaty entered into with the United Kingdom in 2010 but otherwise is not party to any double tax treaties. There are no exchange control regulations or
currency restrictions in the Cayman Islands. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments of dividends and capital in respect of our shares will not be subject to taxation in the Cayman Islands and
no withholding will be required on the payment of a dividend or capital to any holder of the shares, nor will gains derived from the disposal of our shares be subject to Cayman Islands income or corporation tax. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No stamp duty is payable in respect of the issue of shares by our Company and no stamp duty is payable on transfers of shares of our Company provided our Company does
not hold any interest in land in the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRC Taxation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside China with &#147;de facto management body&#148; within China is
considered as a Tax Resident Enterprise for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. The implementation rules define the term &#147;de facto management
body&#148; as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties of an enterprise. In April 2009, the State Administration of Taxation issued Circular 82,
which provides certain specific criteria for determining whether the &#147;de facto management body&#148; of a <FONT STYLE="white-space:nowrap">PRC-controlled</FONT> enterprise that is incorporated offshore is located in China. Although this
circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the State Administration of
Taxation&#146;s general position on how the &#147;de facto management body&#148; text should be applied in determining the tax resident status of all offshore enterprises. According to Circular 82, an offshore incorporated enterprise controlled by a
PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its &#147;de facto management body&#148; in China if all of the following conditions are met: (i)&nbsp;the primary location of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operational management is in China; (ii)&nbsp;decisions relating to the enterprise&#146;s financial and human resource matters are made or are subject to approval
by organizations or personnel located in China; (iii)&nbsp;the enterprise&#146;s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in China; and (iv)&nbsp;at least 50% of
voting board members or senior executives habitually reside in China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our PRC counsel, JunHe LLP, is of the opinion that, based on its understanding of the current
PRC Laws and Regulations, <FONT STYLE="white-space:nowrap">I-Mab</FONT> should not be considered as a PRC resident enterprise for PRC income tax purposes because <FONT STYLE="white-space:nowrap">I-Mab</FONT> does not meet all of the above
conditions. <FONT STYLE="white-space:nowrap">I-Mab</FONT> is incorporated outside of China and it is not controlled by a PRC enterprise or PRC enterprise group. We have structured a clear management guideline in place to segregate the policy set up
and business operating execution responsibilities in order to differentiate the effective control from our headquarter office and subsidiaries including record keeping and offshore work location plan. <FONT STYLE="white-space:nowrap">I-Mab</FONT> is
a company incorporated outside the PRC. As a holding company, its key assets are its ownership interests in its subsidiaries, and its key assets are located, and its records (including the resolutions of its board of directors and the resolutions of
its shareholders) are maintained, outside China. However, the tax resident status of an enterprise is subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">258 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#147;de facto management body.&#148; However, we cannot guarantee you that PRC
tax authorities will not take a different view. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the PRC tax authorities determine that <FONT STYLE="white-space:nowrap">I-Mab</FONT> is a PRC resident
enterprise for enterprise income tax purposes, our worldwide income could be subject to 25% enterprise income tax; and any dividends payable to non-resident enterprise holders of our common shares or ADSs may be treated as income derived from
sources within China and therefore, subject to a 10% withholding tax (or 20% in the case of non-resident individual holders) unless an applicable income tax treaty provides otherwise. In addition, capital gains realized by non-resident enterprise
shareholders (including our ADS holders) upon the disposition of our common shares or ADSs may be treated as income derived from sources within PRC and therefore, subject to 10% income tax (or 20% in the case of non-resident individual shareholders
or ADS holders) unless an applicable income tax treaty provides otherwise. It is unclear whether non-PRC shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the
event that we are treated as a PRC resident enterprise. See &#147;Risk Factors&#151;Risks Related to Doing Business in China&#151;If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in
unfavorable tax consequences to us and our <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders or ADS holders.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>United States Federal Income Tax
Considerations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion is a summary of U.S. federal income tax considerations relating to the ownership and disposition of our ADSs or
ordinary shares by a U.S. Holder (as defined below) that acquires our ADSs in this offering and holds our ADSs as &#147;capital assets&#148; (generally, property held for investment) under the U.S. Internal Revenue Code of 1986, as amended, or the
Code. This discussion is based upon existing U.S. federal tax law, which is subject to differing interpretations or change, possibly with retroactive effect. No ruling has been sought from the U.S. Internal Revenue Service, or the IRS, with respect
to any U.S. federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This discussion does not address the U.S. federal estate, gift, Medicare, and alternative minimum
tax considerations, certain information reporting requirements pursuant to section 1471 through 1474 of the Code, or any state, local, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax considerations, relating to the ownership or disposition
of our ADSs or ordinary shares. This discussion, moreover, does not discuss all aspects of U.S. federal income taxation that may be important to particular investors in light of their individual investment circumstances or to investors subject to
special tax situations such as: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">banks and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cooperatives; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">real estate investment trusts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">broker-dealers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">traders in securities that elect to use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain former U.S. citizens or long-term residents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities (including private foundations); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">investors who are not U.S. Holders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">investors who own (directly, indirectly or constructively) 10% or more of our stock (by vote or value);
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">investors who acquire their ADSs or ordinary shares pursuant to any employee share option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">investors that will hold their ADSs or ordinary shares as part of a straddle, hedge, conversion, constructive sale or
other integrated transaction for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">investors required to accelerate the recognition of any item of gross income with respect to our ADSs or ordinary shares
as a result of such income being recognized on an applicable financial statement; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">investors that have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">259 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">all of whom may be subject to tax rules that differ significantly from those discussed below. Each U.S. Holder is
urged to consult its tax advisor regarding the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income and other tax considerations of an investment in our ADSs or ordinary shares. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, a &#147;U.S. Holder&#148;
is a beneficial owner of our ADSs or ordinary shares that is, for U.S. federal income tax purposes, (i)&nbsp;an individual who is a citizen or resident of the United States, (ii)&nbsp;a corporation (or other entity treated as a corporation for U.S.
federal income tax purposes) created in, or organized under the law of, the United States or any state thereof or the District of Columbia, (iii)&nbsp;an estate the income of which is includible in gross income for U.S. federal income tax purposes
regardless of its source, or (iv)&nbsp;a trust (A)&nbsp;the administration of which is subject to the primary supervision of a U.S. court and which has one or more U.S. persons who have the authority to control all substantial decisions of the trust
or (B)&nbsp;that has otherwise validly elected to be treated as a U.S. person under the Code. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a partnership (or other entity treated as a partnership for U.S.
federal income tax purposes) is a beneficial owner of our ADSs or ordinary shares, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partner and the partnership.
Partnerships holding our ADSs or ordinary shares and their partners are urged to consult their tax advisors regarding an investment in our ADSs or ordinary shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For U.S. federal income tax purposes, it is generally expected that a U.S. Holder of ADSs will be treated as the beneficial owner of the underlying shares represented
by the ADSs. The remainder of this discussion assumes that a U.S. Holder of our ADSs will be treated as the beneficial owner of the underlying shares represented by the ADSs. Accordingly, deposits or withdrawals of ordinary shares for ADSs will
generally not be subject to U.S. federal income tax. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Passive Foreign Investment Company Considerations </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation, such as our company, will be classified as a passive foreign investment company, or, or PFIC, for U.S.
federal income tax purposes for any taxable year if either (i) 75% or more of its gross income for such year consists of certain types of &#147;passive&#148; income or (ii) 50% or more of the value of its assets (determined on the basis of a
quarterly average) during such year is attributable to assets that produce or are held for the production of passive income. For this purpose, cash and assets readily convertible into cash are each categorized as a passive asset and the
company&#146;s goodwill and other unbooked intangibles are taken into account. Passive income generally includes, among other things, dividends, interest, rents, royalties, and gains from the disposition of passive assets. We will be treated as
owning a proportionate share of the assets and earning a proportionate share of the income of any other corporation in which we own, directly or indirectly, 25% or more (by value) of the stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No assurance can be given with respect to our PFIC status for the current taxable year or any future taxable year. The determination of whether we are or will become a
PFIC is uncertain, because it is a fact-intensive inquiry made on an annual basis that depends, in part, on the composition of our income and assets. Fluctuations in the market price of our ADSs may cause us to become a PFIC for the current or
subsequent taxable years because the value of our assets for the purpose of the asset test may be determined by reference to the market price of our ADSs from time to time (which may be volatile for biopharmaceutical companies, such as ours, that
have not yet achieved commercialization with respect to any of their products). The composition of our income and assets may also be affected by how, and how quickly, we use our liquid assets and the cash raised in this offering. Under circumstances
where our revenue from activities that produce passive income increases relative to our revenue from activities that produce non-passive income, or where we determine not to deploy cash for active purposes, our risk of becoming classified as a PFIC
will substantially increase. In addition, because there are uncertainties in the application of the relevant rules, it is possible that the IRS may challenge our classification of certain income and assets as non-passive or our valuation of our
tangible and intangible assets, each of which may result in our being or becoming a PFIC for the current or subsequent taxable years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The discussion below under
&#147;&#151;Dividends&#148; and &#147;&#151;Sale or Other Disposition of ADSs or Ordinary Shares&#148; is written on the basis that we will not be classified as a PFIC for U.S. federal income tax purposes. The U.S. federal income tax rules that
apply if we are treated as a PFIC are generally discussed below under &#147;&#151;Passive Foreign Investment Company Rules.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">260 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject
to the discussion below under &#147;&#151;Passive Foreign Investment Company Rules,&#148; any cash distributions (including the amount of any tax withheld) paid on our ADSs or ordinary shares out of our current or accumulated earnings and profits,
as determined under U.S. federal income tax principles, will generally be includible in the gross income of a U.S. Holder as dividend income on the day actually or constructively received by the U.S. Holder. Because we do not intend to determine our
earnings and profits on the basis of U.S. federal income tax principles, any distribution we pay will generally be reported as a &#147;dividend&#148; for U.S. federal income tax purposes. Dividends received on our ADSs or ordinary shares will not be
eligible for the dividends received deduction allowed to corporations in respect of dividends received from U.S. corporations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder will generally be subject to tax on dividend income from a &#147;qualified foreign corporation&#148; at a lower applicable capital gains rate rather than the marginal tax rates
generally applicable to ordinary income provided that certain conditions are satisfied, including that (1)&nbsp;our ADSs or ordinary shares on which the dividends are paid are readily tradable on an established securities market in the United
States, or in the event that we are deemed to be a PRC resident enterprise under the PRC tax law, we are eligible for the benefits of the United <FONT STYLE="white-space:nowrap">States-PRC</FONT> income tax treaty (the &#147;Treaty&#148;); (2) we
are neither a PFIC nor treated as such with respect to a U.S. Holder for the taxable year in which the dividend is paid and the preceding taxable year, and (3)&nbsp;certain holding period requirements are met. The ADSs have been approved for listing
on the Nasdaq Global Market. Provided the listing is approved, we believe that the ADSs will be readily tradable on an established securities market in the United States, and that we will be a qualified foreign corporation with respect to dividends
paid on the ADSs. Since we do not expect that our ordinary shares will be listed on an established securities market, we do not believe that dividends that we pay on our ordinary shares that are not represented by ADSs will meet the conditions
required for the reduced tax rate. There can be no assurance, however, that our ADSs will continue to be considered readily tradable on an established securities market in later years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that we are deemed to be a PRC resident enterprise under the PRC Enterprise Income Tax Law, we may be eligible for the benefits of Treaty and in that case
we would be treated as a qualified foreign corporation with respect to dividends paid on our ordinary shares or ADSs. Each <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder is advised to consult its tax advisors regarding the
availability of the reduced tax rate applicable to qualified dividend income for any dividends we pay with respect to our ADSs or ordinary shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Dividends will
generally be treated as income from foreign sources for U.S. foreign tax credit purposes and will generally constitute passive category income. In the event that we are deemed to be a PRC resident enterprise under the PRC Enterprise Income Tax Law,
a U.S. Holder may be subject to PRC withholding taxes on dividends paid on our ADSs or ordinary shares. See &#147;&#151;PRC Taxation&#148; above. In that case, depending on the U.S. Holder&#146;s individual facts and circumstances, a U.S. Holder may
be eligible, subject to a number of complex limitations, to claim a foreign tax credit not in excess of any applicable treaty rate in respect of any foreign withholding taxes imposed on dividends received on our ADSs or ordinary shares. A U.S.
Holder who does not elect to claim a foreign tax credit for foreign tax withheld may instead claim a deduction, for U.S. federal income tax purposes, in respect of such withholding, but only for a year in which such holder elects to do so for all
creditable foreign income taxes. The rules governing the foreign tax credit are complex and their outcome depends in large part on the U.S. Holder&#146;s individual facts and circumstances. Accordingly, U.S. Holders are urged to consult their tax
advisors regarding the availability of the foreign tax credit under their particular circumstances. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sale or Other Disposition of ADSs or Ordinary Shares
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion below under &#147;&#150;&#150;Passive Foreign Investment Company Rules,&#148; a U.S. Holder will generally recognize capital gain
or loss upon the sale or other disposition of ADSs or ordinary shares in an amount equal to the difference between the amount realized upon the disposition and the holder&#146;s adjusted tax basis in such ADSs or ordinary shares. Any capital gain or
loss will be long-term if the ADSs or ordinary shares have been held for more than one year and will generally be U.S. source gain or loss for U.S. foreign tax credit purposes. Long-term capital gain of
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders is generally eligible for a reduced rate of taxation. The deductibility of a capital loss may be subject to limitations. In the event that we are treated as a PRC resident enterprise
under the Enterprise Income Tax Law and gain from the disposition of the ADSs or ordinary shares is subject to tax in China, a U.S. Holder that is eligible for the benefits of the Treaty may elect to treat the gain as PRC source income. If a U.S.
Holder is not eligible for the benefits of the Treaty or fails to make the election to treat any gain as foreign source, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">261 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
then such U.S. Holder may not be able to use the foreign tax credit arising from any PRC tax imposed on the disposition of the ADSs or ordinary shares unless such credit can be applied (subject
to applicable limitations) against U.S. federal income tax due on other income derived from foreign sources in the same income category (generally, the passive category). U.S. Holders are urged to consult their tax advisors regarding the tax
consequences if a foreign tax is imposed on a disposition of our ADSs or ordinary shares, including the availability of the foreign tax credit under their particular circumstances and the election to treat any gain as PRC source income. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Passive Foreign Investment Company Rules </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are classified as a
PFIC for any taxable year during which a U.S. Holder holds our ADSs or ordinary shares, and unless the U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election (as described below),
the U.S. Holder will generally be subject to special tax rules that have a penalizing effect, regardless of whether we remain a PFIC, on (i)&nbsp;any excess distribution that we make to the U.S. Holder (which generally means any distribution paid
during a taxable year to a U.S. Holder that is greater than 125&nbsp;percent of the average annual distributions paid in the three preceding taxable years or, if shorter, the U.S. Holder&#146;s holding period for the ADSs or ordinary shares), and
(ii)&nbsp;any gain realized on the sale or other disposition (including, under certain circumstances, a pledge) of ADSs or ordinary shares. Under the PFIC rules: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the excess distribution or gain will be allocated ratably over the U.S. Holder&#146;s holding period for the ADSs or
ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the amount allocated to the current taxable year and any taxable years in the U.S. Holder&#146;s holding period prior to
the first taxable year in which we are classified as a PFIC (each, a <FONT STYLE="white-space:nowrap">&#147;pre-PFIC</FONT> year&#148;), will be taxable as ordinary income; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the amount allocated to each prior taxable year, other than a <FONT STYLE="white-space:nowrap">pre-PFIC</FONT> year, will
be subject to tax at the highest tax rate in effect for individuals or corporations, as appropriate, for that year, increased by an additional tax equal to the interest on the resulting tax deemed deferred with respect to each such taxable year.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs or ordinary shares and any of our subsidiaries is also a PFIC,
such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes of the application of these rules. U.S. Holders are urged to consult their tax advisors regarding the application of the
PFIC rules to any of our subsidiaries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an alternative to the foregoing rules, a U.S. Holder of &#147;marketable stock&#148; (as defined below) in a PFIC may
make a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to such stock. If a U.S. Holder makes this election, the holder will generally (i)&nbsp;include as ordinary income for each
taxable year that we are a PFIC the excess, if any, of the fair market value of ADSs held at the end of the taxable year over the adjusted tax basis of such ADSs and (ii)&nbsp;deduct as an ordinary loss the excess, if any, of the adjusted tax basis
of the ADSs over the fair market value of such ADSs held at the end of the taxable year, but such deduction will only be allowed to the extent of the amount previously included in income as a result of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. The U.S. Holder&#146;s adjusted tax basis in the ADSs would be adjusted to reflect any income or loss resulting from the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. If a U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election in respect of a corporation classified as a PFIC and
such corporation ceases to be classified as a PFIC, the holder will not be required to take into account the gain or loss described above during any period that such corporation is not classified as a PFIC. If a U.S. Holder makes a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, any gain such U.S. Holder recognizes upon the sale or other disposition of our ADSs in a year when we are a PFIC will be treated as ordinary income
and any loss will be treated as ordinary loss, but such loss will only be treated as ordinary loss to the extent of the net amount previously included in income as a result of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. If a U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election it will be
effective for the taxable year for which the election is made and all subsequent taxable years unless the ADSs are no longer treated as marketable stock or the IRS consents to the revocation of the election. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only for &#147;marketable stock,&#148; which is
stock that is regularly traded on a qualified exchange or other market, as defined in applicable United States Treasury Regulations. We expect that our ADSs, but not our ordinary shares, will be treated as marketable stock upon their listing on the
Nasdaq Global Market. However, we cannot guarantee that, once listed, our ADSs will continue to be listed and traded on the Nasdaq Global Market. Furthermore, while we anticipate that our ADSs should qualify as being regularly traded, but no
assurances may be given in this regard. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">262 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election
cannot be made for any lower-tier PFICs that we may own, a U.S. Holder may continue to be subject to the PFIC rules with respect to such U.S. Holder&#146;s indirect interest in any investments held by us that are treated as an equity interest in a
PFIC for U.S. federal income tax purposes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not intend to provide information necessary for U.S. Holders to make qualified electing fund elections which, if
available, would result in tax treatment different from the general tax treatment for PFICs described above. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a U.S. Holder owns our ADSs or ordinary shares
during any taxable year that we are a PFIC, the holder must generally file an annual IRS Form 8621. Each U.S. Holder is urged to consult its tax advisor concerning the U.S. federal income tax consequences of purchasing, holding and disposing ADSs or
ordinary shares if we are or become a PFIC, including the possibility of making a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">263 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_24"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and the underwriters named below have entered into an underwriting agreement with respect to the ADSs being offered. Subject to certain conditions, each underwriter
has severally agreed to purchase the number of ADSs indicated in the following table. Jefferies LLC and China International Capital Corporation Hong Kong Securities Limited are acting as the book-running managers of this offering and as the
representatives of the underwriters. The address of Jefferies LLC is 520 Madison Avenue, New York, New York 10022, United States. The address of China International Capital Corporation Hong Kong Securities Limited is 29th Floor, One International
Finance Centre, 1&nbsp;Harbour View Street Central, Hong Kong. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>UNDERWRITERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,444,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">China International Capital Corporation Hong Kong Securities Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,222,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">China Renaissance Securities (Hong Kong) Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">518,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Huatai Securities (USA), Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,407,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the ADSs subject to their acceptance of the ADSs from us and subject to prior sale. The underwriting agreement provides that the
obligations of the several underwriters to pay for and accept delivery of the ADSs offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated,
severally and not jointly, to take and pay for all of the ADSs offered by this prospectus if any such ADSs are taken, other than the ADSs covered by the underwriters&#146; option to purchase additional ADSs described below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Several existing shareholders have subscribed for and have been allocated by the underwriters an aggregate of 2,055,000 ADSs in this offering (representing 27.7% of the
ADSs being offered in this offering) at the initial public offering price and on the same terms as the other ADSs being offered, among which each of C-Bridge II Investment Thirteen Limited, an affiliate of one of our principal shareholders, and
Genexine Inc., has subscribed for and has been allocated 150,000 and 570,000 ADSs, respectively. The underwriters will receive the same underwriting discounts and commissions on any ADSs purchased by these parties as they will on any other ADSs sold
to the public in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters initially propose to offer part of the ADSs directly to the public at the public offering price listed on the
cover of this prospectus and part of the ADSs to certain dealers at a price that represents a concession not in excess of US$0.588 per ADS under the public offering price. After the initial offering of the ADSs, the offering price and other selling
terms may from time to time be varied by the underwriters. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of the underwriters are not broker-dealers registered with the SEC. Therefore, to the extent
they intend to make any offers or sales of ADSs in the United States, they will do so only through one or more registered broker-dealers in compliance with applicable securities law and regulations, and FINRA rules. China International Capital
Corporation Hong Kong Securities Limited is not a broker-dealer registered with the SEC and, to the extent that its conduct may be deemed to involve participation in offers or sales of ADSs in the United States, those offers or sales will be made
through one or more <FONT STYLE="white-space:nowrap">SEC-registered</FONT> broker-dealers in compliance with applicable laws and regulations. China Renaissance Securities (Hong Kong) Limited is not a broker-dealer registered with the SEC and will
offer ADSs in the United States through its registered broker-dealer affiliate in the United States, China Renaissance Securities (US) Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase
Additional ADSs </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to an aggregate of
1,111,110 additional ADSs from us at the offering price listed on the cover of this prospectus, less underwriting discounts and commissions. To the extent the option is exercised, each underwriter will become
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">264 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
severally obligated, subject to certain conditions, to purchase additional ADSs approximately proportionate to each underwriter&#146;s initial amount reflected in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commissions and Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total underwriting discounts and commissions to be
paid to the underwriters represent 7.0% of the total amount of the offering. The following table shows the per ADS and total underwriting discounts and commissions to be paid to the underwriters by us. Such amounts are shown assuming both no
exercise and full exercise of the underwriters&#146; option to purchase additional ADSs. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NO&nbsp;EXERCISE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FULL&nbsp;EXERCISE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">0.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">7,259,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">8,348,139.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have agreed to pay all fees and expenses that we occur in connection with the offering. We have agreed to reimburse the US and non-US underwriters for certain
expenses in an amount not to exceed US$302,000. We have also agreed to pay the US and non-US underwriters an incentive fee of 1% of the gross proceeds from the offering. In no event will the U.S. underwriters receive aggregate underwriting
compensation in excess of 9% of gross offering proceeds. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to an engagement letter between us and one of the underwriters, during the term of the engagement
letter and for a period of 24 months following the termination of the engagement letter, such underwriter has the right to participate in the distribution of our future financings and financial advisory services. FINRA deems this to be an
underwriting compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers, directors and our current shareholders have agreed, subject to specified exceptions, not to directly or indirectly: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell or offer to sell any ADSs, ordinary shares or similar securities currently or hereafter owned either of record or
beneficially (as defined in Rule 13d-3 under the Exchange Act), </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into any swap, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and
sale of any ADSs, ordinary shares or similar securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly announce any intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close of trading of the ADSs on and including the 180<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of
this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The representatives of the underwriters may, in their sole discretion and at any time or from time to time before the termination of the 180-day
period, release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our shareholders who will execute a lock-up agreement, providing consent to the sale of ADSs or
ordinary shares prior to the expiration of the lock-up period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, through a letter agreement, we will instruct Citibank, N.A., as depositary, not to
accept any deposit of any ordinary shares or deliver any ADSs until after 180 days following the date of this prospectus unless we consent to such deposit or issuance. We will not provide such consent without the prior written consent of the
representatives of the underwriters. The foregoing does not affect the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nasdaq Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ADSs have been approved for listing on the Nasdaq Global
Market under the symbol &#147;IMAB.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the offering, the underwriters may purchase and sell ADSs in the open market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">265 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These transactions may include short sales, stabilizing transactions and purchases to cover positions created by
short sales. Short sales involve the sale by the underwriters of a greater number of ADSs than they are required to purchase in the offering. &#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option
to purchase additional ADSs in the offering. The underwriter may close out any covered short position by either exercising their option to purchase additional ADSs or purchasing ADSs in the open market. In determining the source of ADSs to close out
the covered short position, the underwriters will consider, among other things, the price of ADSs available for purchase in the open market as compared to the price at which they may purchase additional ADSs pursuant to the option granted to them.
&#147;Naked&#148; short sales are any sales in excess of such option. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters must close out any naked short position by purchasing ADSs in the open
market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs in the open market after pricing that could adversely affect investors who purchase in the
offering. Stabilizing transactions consist of various bids for, or purchases of, ADSs made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discounts received by
it because the representatives have repurchased ADSs sold by, or for the account of, such underwriter in stabilizing or short covering transactions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Purchases to
cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of the ADSs, and together with the imposition of
the penalty bid, may stabilize, maintain or otherwise affect the market price of the ADSs. As a result, the price of the ADSs may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in
these activities, and if these activities are commenced, they are required to be conducted in accordance with applicable laws and regulations, and any of these activities may be discontinued at any time. These transactions may be effected on the
Nasdaq, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus in electronic format will be made available on the websites maintained by one or more of the underwriters or one or more securities dealers. One
or more of the underwriters may distribute prospectuses electronically. The underwriters may agree to allocate a number of ADSs for sale to their online brokerage account holders. ADSs to be sold pursuant to an internet distribution will be
allocated on the same basis as other allocations. In addition, ADSs may be sold by the underwriters to securities dealers who resell ADSs to online brokerage account holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Relationships </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial
and investment banking, financial advisory, investment management, principal investment, hedging, financing, investment research, market making, brokerage and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and
services. Certain of the underwriters and their respective affiliates may have, from time to time, performed, and may in the future perform, various financial advisory, commercial and investment banking services and other services for us and to
persons and entities with relationships with us, for which they received or will receive customary fees and commissions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in the ordinary course of
their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including
bank loans) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">266 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and securities activities may involve securities and instruments of us and/or persons and entities with relationships with us. The underwriters and their respective affiliates may also make or
communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they
should acquire, long and/or short positions in such assets, securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has been no public market for our ordinary shares or the ADSs. The initial public offering price was determined by negotiations between us
and the representatives of the underwriters. Among the factors to be considered in determining the initial public offering price of the ADSs, in addition to prevailing market conditions, will be our historical performance, estimates of our business
potential and earnings prospects, an assessment of our management and the consideration of the above factors in relation to market valuation of companies in related businesses. An active trading market for the ADSs may not develop. It is also
possible that after the offering the ADSs will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No action has been taken in any jurisdiction (except in the United States) that would permit a public offering of the ADSs, or the possession, circulation or
distribution of this prospectus or any other material relating to us or the ADSs in any jurisdiction where action for that purpose is required. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, the
ADSs may not be offered or sold, directly or indirectly, and neither this prospectus nor any other material or advertisements in connection with the ADSs may be distributed or published, in or from any country or jurisdiction except in compliance
with any applicable laws, rules and regulations of any such country or jurisdiction. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Australia </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">does not constitute a product disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth)
(the &#147;Corporations Act&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission (&#147;ASIC&#148;), as a
disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document under Chapter 6D.2 of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">does not constitute or involve a recommendation to acquire, an offer or invitation for issue or sale, an offer or
invitation to arrange the issue or sale, or an issue or sale, of interests to a &#147;retail client&#148; (as defined in section 761G of the Corporations Act and applicable regulations) in Australia; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the
categories of investors, or Exempt Investors, available under section 708 of the Corporations Act. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ADSs may not be directly or indirectly
offered for subscription or purchased or sold, and no invitations to subscribe for or buy the ADSs may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any ADSs may be distributed in
Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the ADSs, you represent and
warrant to us that you are an Exempt Investor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As any offer of ADSs under this prospectus will be made without disclosure in Australia under Chapter 6D.2 of the
Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that
resale. By applying for the ADSs you undertake to us that you will not, for a period of 12 months from the date of issue of the ADSs, offer, transfer, assign or otherwise alienate those securities to investors in Australia except in circumstances
where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">267 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains general information only and does not take account of the investment objectives, financial
situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is
appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Canada </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ADSs may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT
STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration
Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the ADSs must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any
amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The
purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts, or NI
<FONT STYLE="white-space:nowrap">33-105,</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cayman Islands </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus does not constitute a
public offer of the ADSs or ordinary shares, whether by way of sale or subscription, in the Cayman Islands. ADSs or ordinary shares have not been offered or sold, and will not be offered or sold, directly or indirectly, in the Cayman Islands. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dubai International Finance Center </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus relates to an
Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority (the &#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must
not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the
information set forth herein and has no responsibility for this prospectus. The securities to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should
conduct their own due diligence on the securities. If you do not understand the contents of this prospectus you should consult an authorized financial advisor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
relation to its use in the DIFC, this prospectus is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or
used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>European Economic
Area </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation to each Member State of the European Economic Area (each a &#147;Member State&#148;), no ADSs have been offered or will be offered
pursuant to this offering to the public in that Member State prior to the publication of a prospectus in relation to the ADSs which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member
State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of ADSs may be made to the public in that Member State at any time under the following exemptions under the
Prospectus Regulation: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation),
subject to obtaining the prior consent of the representatives of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">268 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of ADSs shall require us or any underwriter to publish a prospectus pursuant to Article 3
of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression an
&#147;offer to the public&#148; in relation to any ADSs in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ADSs to be offered so as to enable an investor to decide to
purchase or subscribe for any ADSs, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ADSs may not be offered or sold by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of
the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules
made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32, Laws of Hong Kong), and no
advertisement, invitation or document relating to the ADSs may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely
to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to ADSs which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional
investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indonesia
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus does not, and is not intended to, constitute a public offering in Indonesia under Law Number 8 of 1995 regarding Capital Market. This
prospectus may not be distributed in the Republic of Indonesia and the ADSs may not be offered or sold in the Republic of Indonesia or to Indonesian citizens wherever they are domiciled, or to Indonesia residents, in a manner which constitutes a
public offering under the laws of the Republic of Indonesia. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Israel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the State of Israel, the ADSs offered hereby may not be offered to any person or entity other than the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a fund for joint investments in trust (i.e., mutual fund), as such term is defined in the Law for Joint Investments in
Trust, 5754-1994, or a management company of such a fund; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a provident fund as defined in Section&nbsp;47(a)(2) of the Income Tax Ordinance of the State of Israel, or a management
company of such a fund; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an insurer, as defined in the Law for Oversight of Insurance Transactions, 5741-1981, a banking entity or satellite
entity, as such terms are defined in the Banking Law (Licensing), 5741-1981, other than a joint services company, acting for their own account or for the account of investors of the type listed in Section&nbsp;15A(b) of the Securities Law 1968;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a company that is licensed as a portfolio manager, as such term is defined in Section&nbsp;8(b) of the Law for the
Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account or for the account of investors of the type listed in Section&nbsp;15A(b) of the Securities Law 1968; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a company that is licensed as an investment advisor, as such term is defined in Section&nbsp;7(c) of the Law for the
Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a company that is a member of the Tel Aviv Stock Exchange, acting on its own account or for the account of investors of
the type listed in Section&nbsp;15A(b) of the Securities Law 1968; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an underwriter fulfilling the conditions of Section&nbsp;56(c) of the Securities Law, 5728-1968; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a venture capital fund (defined as an entity primarily involved in investments in companies which, at the time of
investment, (i)&nbsp;are primarily engaged in research and development or manufacture of new technological products or processes and (ii)&nbsp;involve above-average risk); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an entity primarily engaged in capital markets activities in which all of the equity owners meet one or more of the above
criteria; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an entity, other than an entity formed for the purpose of purchasing the ADSs in this offering, in which the shareholders
equity (including pursuant to foreign accounting rules, international accounting regulations </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">269 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
and U.S. generally accepted accounting rules, as defined in the Securities Law Regulations (Preparation of Annual Financial Statements), 1993) is in excess of NIS 250&nbsp;million.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any offeree of the ADSs offered hereby in the State of Israel shall be required to submit written confirmation that it falls within the scope of
one of the above criteria. This prospectus will not be distributed or directed to investors in the State of Israel who do not fall within one of the above criteria. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ADSs have not been and will not be registered under the
Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended) and, accordingly, will not be offered or sold directly or indirectly in Japan or to, or for the benefit of any Japanese person or to others, for reoffering or <FONT
STYLE="white-space:nowrap">re-sale</FONT> directly or indirectly in Japan or to any Japanese person, except in each case pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Securities and Exchange
Law of Japan and any other applicable laws, rules and regulations of Japan. For purposes of this paragraph, &#147;Japanese person&#148; means any person resident in Japan, including any corporation or other entity organized under the laws of Japan.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Korea </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ADSs may not be offered, sold and delivered directly
or indirectly, or offered or sold to any person for reoffering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the Korea Securities and Exchange Act
and the Foreign Exchange Transaction Law and the decrees and regulations thereunder. The ADSs have not been registered with the Financial Services Commission of Korea for public offering in Korea. Furthermore, the ADSs may not be resold to Korean
residents unless the purchaser of the ADSs complies with all applicable regulatory requirements (including but not limited to government approval requirements under the Foreign Exchange Transaction Law and its subordinate decrees and regulations) in
connection with the purchase of the ADSs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Kuwait </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless all
necessary approvals from the Kuwait Ministry of Commerce and Industry required by Law No.&nbsp;31/1990 &#147;Regulating the Negotiation of Securities and Establishment of Investment Funds,&#148; its Executive Regulations and the various Ministerial
Orders issued pursuant thereto or in connection therewith, have been given in relation to the marketing and sale of the ADSs, these may not be marketed, offered for sale, nor sold in the State of Kuwait. Neither this prospectus (including any
related document), nor any of the information contained therein is intended to lead to the conclusion of any contract of whatsoever nature within Kuwait. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Malaysia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No prospectus or other offering material or document in
connection with the offer and sale of the ADSs has been or will be registered with the Securities Commission of Malaysia (the &#147;Commission&#148;) for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007.
Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the ADSs may not be circulated or distributed, nor may the ADSs be offered or sold, or be made the
subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services License; (iii)&nbsp;a
person who acquires the ADSs, as principal, if the offer is on terms that the ADSs may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total
net personal assets or total net joint assets with his or her spouse exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual
income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign
currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total
net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as
defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the ADSs is made by
a holder of a Capital Markets Services Licence who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">270 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the
registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>People&#146;s Republic of China </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus may not be circulated or distributed in the PRC and the ADSs may not be offered or sold, and will not offer or sell to any person for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any resident of the PRC except pursuant to applicable laws, rules and regulations of the PRC. For the purpose of this paragraph only, the PRC does not include Taiwan
and the special administrative regions of Hong Kong and Macau. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Philippines </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>THE ADSS BEING OFFERED OR SOLD HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE PHILIPPINE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES REGULATION CODE
OF THE PHILIPPINES, OR THE SRC. ANY FUTURE OFFER OR SALE OF THE ADSS WITHIN THE PHILIPPINES IS SUBJECT TO THE REGISTRATION REQUIREMENTS UNDER THE SRC UNLESS SUCH OFFER OR SALE QUALIFIES AS A TRANSACTION EXEMPT FROM THE REGISTRATION UNDER THE SRC.
</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, this prospectus, and any other document or material in connection with the offer or sale, or invitation for subscription or purchase of the ADSs,
may not be circulated or distributed in the Philippines, and the ADSs may not be offered or sold, or be made the subject of an invitation for subscription or purchase, to persons in the Philippines, other than (i)&nbsp;to qualified investors in
transactions that are exempt from the registration requirements of the SRC; and (ii)&nbsp;by persons licensed to make such offers or sales in the Philippines. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Qatar </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the State of Qatar, the offer contained herein is made on
an exclusive basis to the specifically intended recipient thereof, upon that person&#146;s request and initiative, for personal use only and shall in no way be construed as a general offer for the sale of securities to the public or an attempt to do
business as a bank, an investment company or otherwise in the State of Qatar. This prospectus and the underlying securities have not been approved or licensed by the Qatar Central Bank or the Qatar Financial Centre Regulatory Authority or any other
regulator in the State of Qatar. The information contained in this prospectus shall only be shared with any third parties in Qatar on a need to know basis for the purpose of evaluating the contained offer. Any distribution of this prospectus by the
recipient to third parties in Qatar beyond the terms hereof is not permitted and shall be at the liability of such recipient. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Saudi Arabia </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations issued by the
Capital Market Authority. The Capital Market Authority does not make any representation as to the accuracy or completeness of this prospectus, and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon,
any part of this prospectus. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this prospectus you
should consult an authorized financial adviser. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Singapore </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each
underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented, warranted and agreed that it has not offered or sold any ADSs or
caused the ADSs to be made the subject of an invitation for subscription or purchase and will not offer or sell any ADSs or cause the ADSs to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed,
nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the ADSs, whether directly or indirectly, to any persons in Singapore other
than (i) to an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter 289 of Singapore), as modified or amended from time to time (the &#147;SFA&#148;) pursuant to Section 274 of the SFA, (ii) to a relevant
person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA, or (iii) otherwise pursuant to,
and in accordance with the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the ADSs are subscribed or purchased under Section 275 of the SFA by a
relevant person which is: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">271 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is
to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">securities or securities-based derivatives contracts (each term as defined in
Section 2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the ADSs pursuant to an
offer made under Section 275 of the SFA except: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section 276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as specified in Section 276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based
Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ADSs will not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading
facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under
art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to our company or the ADSs have been or
will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of the ADSs will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of the ADSs
has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (the &#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend
to acquirers of the ADSs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taiwan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ADSs have not been and
will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an
offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding
or otherwise intermediate the offering and sale of the ADSs in Taiwan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Thailand </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus does not, and is not intended to, constitute a public offering in Thailand. The ADSs may not be offered or sold to persons in Thailand, unless such
offering is made under the exemptions from approval and filing requirements under applicable laws, or under circumstances which do not constitute an offer for sale of the shares to the public for the purposes of the Securities and Exchange Act of
1992 of Thailand, nor require approval from the Office of the Securities and Exchange Commission of Thailand. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United Arab Emirates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ADSs have not been offered or sold, and will not be offered or sold, directly or indirectly, in the United Arab Emirates, except: (i)&nbsp;in compliance with all
applicable laws and regulations of the United Arab Emirates; and (ii)&nbsp;through persons or corporate entities authorized and licensed to provide investment advice and/or engage in brokerage activity and/or trade in respect of foreign securities
in the United Arab Emirates. The information contained in this prospectus does not constitute a public offer of securities in the United Arab Emirates in accordance with the Commercial Companies Law (Federal Law No.&nbsp;8 of 1984 (as amended)) or
otherwise and is not intended to be a public offer and is addressed only to persons who are sophisticated investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">272 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been approved by an authorized person in the United Kingdom and is for distribution only to persons who (i) have professional experience in
matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Financial Promotion Order&#148;), (ii) are persons falling within Article 49(2)(a) to
(d) (high net worth companies, unincorporated associations, etc.) of the Financial Promotion Order, (iii) are outside the United Kingdom or (iv)&nbsp;are persons to whom an invitation or inducement to engage in investment activity (within the
meaning of section 21 of the Financial Services and Markets Act 2000 (the &#147;FSMA&#148;)) in connection with the issue or sale of any ADSs may otherwise lawfully be communicated or caused to be communicated pursuant to the Financial Promotion
Order (all such persons together being referred to as &#147;relevant persons&#148;). This prospectus is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment
activity to which this prospectus relates is available only to relevant persons and will be engaged in only with relevant persons. No person may communicate or cause to be communicated any invitation or inducement to engage in investment activity
(within the meaning of section 21 of the FSMA) received by it in connection with the issue or sale of the securities other than in circumstances in which Section 21(1) of the FSMA does not apply to us. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vietnam </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ADSs have not been and will not be registered with the
State Securities Commission of Vietnam under the Law on Securities of Vietnam and its guiding decrees and circulars. The ADSs will not be offered or sold in Vietnam through a public offering and will not be offered or sold to Vietnamese persons
other than those who are licensed to invest in offshore securities under the Law on Investment of Vietnam. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">273 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_25"></A>EXPENSES RELATED TO THIS OFFERING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Set forth below is an itemization of the total expenses, excluding underwriting discounts and commissions, that we expect to incur in connection with this offering.
With the exception of the SEC registration fee, the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;), filing fee, and the Nasdaq market entry and listing fee, all amounts are&nbsp;estimates. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SEC Registration Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">16,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FINRA Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">19,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Nasdaq Market Entry and Listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Printing and Engraving Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">326,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">2,040,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounting Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">610,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">1,140,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>US$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,302,807</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">274 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_26"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are being represented by Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP with respect to certain legal matters as to United States federal securities and New York
State law. The underwriters are being represented by Davis Polk&nbsp;&amp; Wardwell LLP with respect to certain legal matters as to United States federal securities and New York State law. The validity of the ordinary shares represented by the ADSs
to be sold in this offering will be passed upon for us by Conyers Dill&nbsp;&amp; Pearman. Certain legal matters as to PRC law will be passed upon for us by JunHe LLP and for the underwriters by King&nbsp;&amp; Wood Mallesons. Skadden, Arps, Slate,
Meagher&nbsp;&amp; Flom LLP may rely upon Conyers Dill&nbsp;&amp; Pearman with respect to matters governed by Cayman Islands law and JunHe LLP with respect to matters governed by PRC law. Davis Polk&nbsp;&amp; Wardwell LLP may rely upon
King&nbsp;&amp; Wood Mallesons with respect to matters governed by PRC law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">275 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_27"></A>EXPERTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements as of December&nbsp;31, 2017 and 2018 and for each of the two years in the period ended December&nbsp;31, 2018 included in this prospectus
have been so included in reliance on the report of PricewaterhouseCoopers Zhong Tian LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The office of PricewaterhouseCoopers Zhong Tian LLP is located at 11th Floor, PricewaterhouseCoopers Center, Link Square 2, 202 Hu Bin Road, Shanghai, the People&#146;s
Republic of China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">276 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom713200_28"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed a registration statement, including relevant exhibits, with the SEC on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under the Securities Act with
respect to the underlying ordinary shares represented by the ADSs to be sold in this offering. We have also filed a related registration statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> with the SEC to register the ADSs. This
prospectus, which constitutes a part of the registration statement on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> does not contain all of the information contained in the registration statement. You should read our registration statements and
their exhibits and schedules for further information with respect to us and our ADSs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately upon the effectiveness of the registration statement on Form <FONT
STYLE="white-space:nowrap">F-1</FONT> of which this prospectus forms a part, we will become subject to periodic reporting and other informational requirements of the Exchange Act as applicable to foreign private issuers. Accordingly, we will be
required to file reports, including annual reports on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> and other information with the SEC. The SEC maintains an internet site at http://www.sec.gov that contains reports, proxy and information
statements, and other information regarding issuers that file electronically with the SEC. We maintain our website at <FONT STYLE="white-space:nowrap">http://www.i-mabbiopharma.com/en/.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and
our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we will not be required under the Exchange Act to
file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we intend to furnish the depositary with our annual reports, which will
include a review of operations and annual audited consolidated financial statements prepared in conformity with U.S. GAAP, and all notices of shareholders&#146; meetings and other reports and communications that are made generally available to our
shareholders. The depositary will make such notices, reports and communications available to holders of ADSs and, if we so request, will mail to all record holders of ADSs the information contained in any notice of a shareholders&#146; meeting
received by the depositary from us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">277 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="index"></A><A NAME="rom713200_29"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Consolidated Financial Statements for the Years Ended December&nbsp;31, 2017 and 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_2">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_3">Consolidated Balance Sheets as of December&nbsp;31, 2017 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_4">Consolidated Statements of Comprehensive Loss for the Years Ended December&nbsp;
31, 2017 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_5">Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) for the Years
 Ended December&nbsp;31, 2017 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_6">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2017 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_7">Notes to the Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin)
Co., Ltd. (previously known as &#147;Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd.&#148;) (Note)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Consolidated Financial Statements for the Period from January&nbsp;1, 2017 to July&nbsp;15,
2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_10">Report of Independent Auditors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_11">Consolidated Balance Sheet as of July&nbsp;15, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_12">Consolidated Statement of Comprehensive Loss for the Period from January&nbsp;
1, 2017 to July&nbsp;15, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_13">Consolidated Statement of Changes in Shareholders&#146; Equity for the Period from January&nbsp;1,
 2017 to July&nbsp;15, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_14">Consolidated Statement of Cash Flows for the Period from January&nbsp;
1, 2017 to July&nbsp;15, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_15">Notes to the Consolidated Financial Statements for the Period from January&nbsp;
1, 2017 to July&nbsp;15, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>I-Mab</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Unaudited Interim Condensed Consolidated Financial Statements for the Nine Months Ended
September&nbsp;30, 2018 and 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_16">Unaudited Interim Condensed Consolidated Balance Sheets as of December 31, 2018 and September&nbsp;30,
2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_17">Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Nine
 Months Ended September&nbsp;30, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_18">Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders&#146; Equity
 (Deficit) for the Nine Months Ended September&nbsp;30, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_19">Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Nine Months
 Ended September&nbsp;30, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin713200_20">Notes to the Unaudited Interim Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective July&nbsp;15, 2017, the registrant acquired 66.67% equity
interest of <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. (referred to as &#147;Tasgen Group&#148;) for approximately US$63,802,000 by issuance of convertible preferred shares (the
&#147;Acquisition&#148;). Under Rule <FONT STYLE="white-space:nowrap">3-05</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> when comparing Tasgen Group&#146;s total assets with registrant&#146;s total assets, the Acquisition was
determined to be greater than 50% to the registrant on the basis of the most recent <FONT STYLE="white-space:nowrap">pre-Acquisition</FONT> annual financial statements (being the year ended December&nbsp;31, 2016), and the net revenue reported by
Tasgen Group in its most recent fiscal year (being the year ended December&nbsp;31, 2018) was less than US$100.0&nbsp;million, hence requiring 2 years of audited financial statements for Tasgen Group to be provided in connection with any public
offering of securities by the registrant. To meet the <FONT STYLE="white-space:nowrap">two-year</FONT> audited financial statements requirement, the registrant is filing the <FONT STYLE="white-space:nowrap">pre-Acquisition</FONT> financial
statements for Tasgen Group from January&nbsp;1, 2017 (the first day of Tasgen Group&#146;s fiscal year) through July&nbsp;15, 2017 (the Acquisition&#146;s effective date), so as to provide potential investors with 2 years of financial statements
for Tasgen Group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_2"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the Board of Directors and Shareholders of I-Mab </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial
Statements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying consolidated balance sheets of I-Mab and its subsidiaries (the &#147;Company&#148;) as of December 31, 2018 and
2017, and the related consolidated statements of comprehensive loss, of changes in shareholders&#146; equity (deficit) and of cash flows for the years then ended, including the related notes (collectively referred to as the &#147;consolidated
financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows
for the years then ended in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audits of
these consolidated financial statements in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audits included
performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ PricewaterhouseCoopers Zhong Tian LLP </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shanghai, the People&#146;s Republic of China </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">July 29, 2019 </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_3"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>As of December&nbsp;31, 2017 and 2018 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All
amounts in thousands, except for share and per share data, unless otherwise noted) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4,&nbsp;5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>332,407</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Short-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4,&nbsp;15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>309,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>415,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>58,156</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A convertible preferred shares (US$0.0001 par value, 21,865,233 and 30,227,056 shares authorized,
issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B convertible preferred shares (US$0.0001 par value, 15,894,594 and 30,305,212 shares authorized,
issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued and
outstanding as of December&nbsp;31, 2018)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,015,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>407,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2017 and 2018,
8,363,719 shares authorized, issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141,932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(133,623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>332,407</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_4"></A>Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(438,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(401,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total comprehensive loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,848</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average number of ordinary shares used in calculating net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_5"></A>Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY&nbsp;SHARE&nbsp;(NOTE&nbsp;12)<BR>(US$0.001&nbsp;PAR&nbsp;VALUE)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TREASURY<BR>STOCK</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL<BR><FONT STYLE="white-space:nowrap">PAID-IN</FONT><BR>CAPITAL</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>OTHER<BR>COMPREHENSIVE<BR>INCOME</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>SHAREHOLDERS&#146;<BR>EQUITY&nbsp;(DEFICIT)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(299,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Transaction with redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests
(Note&nbsp;16)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253,796</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(309,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(955,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_6"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Adjustments to reconcile net loss to net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on disposal of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expenses of convertible promissory notes and onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,591</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from conversion of onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from issuance of 2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash acquired from acquisition of a subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash paid for investments in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash received from disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash received on income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash (used in) generated from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of convertible preferred shares, net of issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Repayment of bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Effect of exchange rate changes on cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net increase in cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents, and restricted cash, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents, and restricted cash, end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Supplemental cash flow disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payables for purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payables for <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible preferred shares issued for business combination (Note&nbsp;3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_7"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. PRINCIPAL ACTIVITIES AND ORGANIZATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) was incorporated in the Cayman Islands on June&nbsp;30, 2016 as an exempted company with limited
liability under the Companies Law of the Cayman Islands. The Company and its subsidiaries (together the &#147;Group&#148;) are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and
immuno-inflammation diseases in the People&#146;s Republic of China (the &#147;PRC&#148;) and other countries and regions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the incorporation of the
Company, the Group carried out its operation in the PRC since November 2014 mainly through Third Venture Biopharma (Nanjing) Co., Ltd. (&#147;Third Venture&#148;), which was incorporated on November&nbsp;17, 2014 in the PRC. For the purpose of
introduction of overseas investors and in preparation for a listing of the Company&#146;s shares on the overseas capital markets, the Group underwent a reorganization (the &#147;Reorganization&#148;) in 2016. The Reorganization was approved by the
Board of Directors and a restructuring framework agreement was entered into by Third Venture, the Company, and the shareholders of the Company based on Reorganization framework agreement, pursuant to which on July&nbsp;7, 2016, Third Venture
transferred all of its assets and operations to the Company&#146;s wholly owned subsidiary, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;), which was a
transaction in which shareholders had identical ownership interests before and after the transaction and was accounted for in a manner similar to a common control transaction. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Reorganization, as described above has been accounted for at historical cost. That Reorganization was reverse merger of Third Venture and Third Venture is the
predecessor of the Company. As such, the assets and liabilities of Third Venture are consolidated in the Company&#146;s financial statements at historical cost. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As
of December&nbsp;31, 2018, the Company&#146;s principal subsidiaries are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>SUBSIDIARIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PLACE OF<BR>INCORPORATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DATE OF<BR>INCORPORATION&nbsp;OR<BR>ACQUISITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE<BR>OF DIRECT<BR>OR INDIRECT<BR>OWNERSHIP<BR>BY THE<BR>COMPANY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRINCIPAL&nbsp;ACTIVITIES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Hong&nbsp;Kong</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;8, 2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Investment&nbsp;holding</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">PRC</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">August&nbsp;24,&nbsp;2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR><BR><BR></TD>
<TD VALIGN="top" ALIGN="right">Research and<BR>development of<BR>innovative<BR>medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin)
Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="right">PRC</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="right">July&nbsp;15, 2017</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="right">100</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">%&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;<BR><BR><BR></P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="right">Research and<BR>development of<BR>innovative<BR>medicines</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">U.S.</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">February&nbsp;28,&nbsp;2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR><BR><BR></TD>
<TD VALIGN="top" ALIGN="right">Research and<BR>development of<BR>innovative<BR>medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. PRINCIPAL ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.1 Basis of presentation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying consolidated financial
statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#147;U.S. GAAP&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Significant accounting policies followed by the Group in the preparation of its accompanying consolidated financial
statements are summarized below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.2 Basis of consolidation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.3 Use of estimates </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preparation of the consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and
liabilities and other intangible assets. Additionally, estimates are used in determining items such as useful lives of property, equipment and software, impairment of contract assets and other receivables, impairment of long-lived assets and
goodwill, share-based compensation, tax valuation allowances and revenues from licensing and collaboration arrangements. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be
reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.4 Fair value measurements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial assets and liabilities of the
Group primarily comprise of cash and cash equivalents, restricted cash, other financial assets, contract assets, other receivables, short-term borrowings, accruals and other payables and warrants liabilities. As of December&nbsp;31, 2017 and 2018,
except for other financial assets and warrant liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports other financial assets and warrant
liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group
measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs
other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3 includes unobservable inputs that reflect the management&#146;s assumptions about the assumptions that market participants would use in pricing the
asset. The management develops these inputs based on the best information available, including the own data.</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Assets and liabilities measured at fair value on a
recurring basis </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group measured its other financial assets and warrant liabilities at fair value on a recurring basis. As the Group&#146;s other financial
assets and warrant liabilities are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of other financial assets and warrant liabilities. These instruments are
categorized in the Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the Group&#146;s financial assets and liabilities measured and recorded at fair value
on a recurring basis as of December&nbsp;31, 2017 and 2018: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTIVE&nbsp;MARKET<BR>(LEVEL&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OBSERVABLE&nbsp;INPUT<BR>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">NON-OBSERVABLE&nbsp;INPUT</FONT><BR>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTIVE&nbsp;MARKET<BR>(LEVEL&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OBSERVABLE&nbsp;INPUT<BR>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">NON-OBSERVABLE&nbsp;INPUT</FONT><BR>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The roll forward of major Level&nbsp;3 financial asset and financial liability are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OTHER&nbsp;FINANCIAL<BR>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WARRANT&nbsp;LIABILITIES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of Level&nbsp;3 financial asset and liability as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,931</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Business combination (Note 3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investment in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of warrants to investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income received from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of Level&nbsp;3 financial asset and liability as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investment in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income received from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of Level&nbsp;3 financial assets and financial as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Refer to Note 15 for additional information about Level&nbsp;3 warrant liabilities measured at fair value on a recurring basis for the years ended December&nbsp;31,
2017 and 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.5 Foreign currency translation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group uses Chinese Renminbi (&#147;RMB&#148;) as its reporting currency. The United States Dollar (&#147;US$&#148;) is the functional currency of the Group&#146;s
entities incorporated in the Cayman Islands, the United States of America (&#147;U.S.&#148;) and Hong Kong, the Australia Dollar (&#147;AUD&#148;) is the functional currency of the Group&#146;s entity incorporated in Australia and the RMB is the
functional currency of the Company&#146;s PRC subsidiaries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Transactions denominated in other than the functional currencies are translated into the functional
currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting exchange differences
are recorded in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The consolidated financial statements of the Group are translated from the functional currency
to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are translated at the average exchange rates prevailing for the
year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive income. The exchange rates used for translation on December&nbsp;31, 2017 and 2018 were US$1.00&nbsp;=&nbsp;RMB6.5342 and
RMB6.8632, respectively, representing the index rates stipulated by the People&#146;s Bank of China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Translations of balances in the consolidated balance sheets,
consolidated statements of comprehensive loss, consolidated statements of changes in shareholders&#146; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the year ended December&nbsp;31, 2018 are solely for
the convenience of the readers and were calculated at the rate of US$1.00=RMB7.1477, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on
September 30, 2019. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on September 30, 2019, or at any other rate. The US$ convenience translation is not required under
U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.6 Cash and cash equivalents
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers all highly
liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.7 Restricted cash </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Restricted cash consists of the guarantee deposits held in a designated bank account as security deposits under bank borrowing agreements. Such restricted cash will be
released when the Group repays the related bank borrowings. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.8 Property, equipment and software </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line
method over the following estimated useful lives, taking into account any estimated residual value: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3&nbsp;to&nbsp;5&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2 to 5 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lesser&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease&nbsp;term</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group recognized the gain or loss on the disposal of property, equipment and software in the consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.9 Intangible assets </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Intangible assets with definite useful lives
are amortized to their estimated residual values over their estimated useful lives and reviewed for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Amortization is
initiated for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
(IPR&amp;D) intangible assets that are acquired from business combination when their useful lives have been determined. IPR&amp;D intangible assets which are determined to have an impairment in
their fair value are adjusted downward and an expense recognized in research and development in the consolidated statements of comprehensive loss. These IPR&amp;D intangible assets are tested at least an annual basis on December&nbsp;31 or when a
triggering event occurs that could indicate a potential impairment. (see Note 7). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.10 Impairment of <FONT STYLE="white-space:nowrap">long-lived</FONT>
assets </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived
assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell. For the years ended
December&nbsp;31, 2017 and 2018, there was no impairment of the value of the Group&#146;s long-lived assets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.11 Goodwill </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and
separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair
value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment of goodwill assessment is performed on at least an annual basis on December&nbsp;31 or whenever events or changes
in circumstances indicate that the carrying value of the asset may not be recoverable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group has elected to first assess qualitative factors to determine
whether it is more likely than not that the fair value of the Group&#146;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#146;s evaluation of relevant events and circumstances
affecting the Group&#146;s single reporting unit, including macroeconomic, industry, market conditions and the Group&#146;s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group&#146;s
reporting unit&#146;s fair value is less than its carrying amount, then the Group will perform the quantitative impairment test by comparing the reporting unit&#146;s carrying amount, including goodwill, to its fair value. If the carrying amount of
the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess. For the years ended December&nbsp;31, 2017 and 2018, the Group determined that there were no indicators of impairment of the
goodwill. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.12 Deferred subsidy income </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred subsidy income
consists of deferred income from government grants. Government grants consist of cash subsidies received by the Group&#146;s subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with
government specified performance obligations are recognized when all the obligations have been fulfilled. If such obligations are not satisfied, the Group may be required to refund the subsidy. Cash grants of RMB2,500 was recorded in deferred
subsidy income as of December&nbsp;31, 2018, which will be recognized when the government specified performance obligation is satisfied, which is expected to be more than 12 months after December&nbsp;31, 2018. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.13 Revenue recognition </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group adopted Accounting Standard
Codification (&#147;ASC&#148;) 606, <I>Revenue from Contracts with Customers</I> (Topic&nbsp;606) (&#147;ASC 606&#148;) for all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of
promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the
entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&nbsp;identify the
contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the transaction price to the performance
obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect the consideration to
which it is entitled in exchange for the goods or services it transfers to the customer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Group reviews the contract
to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that
performance obligation is satisfied or as it is satisfied. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Collaboration revenue </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At contract inception, the Group analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,<I>&nbsp;Collaborative
Arrangements</I>&nbsp;(&#147;ASC 808&#148;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on
the commercial success of such activities.&nbsp;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines if the collaboration is deemed to be within the scope of ASC 808 and those that are
more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For the collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group&#146;s collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property
rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Group must develop
assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&nbsp;In developing the stand-alone selling price for a performance obligation, the Group considers competitor
pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective
obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When the timing of the delivery
of product is different from the timing of payments made by the customers, the Group recognizes either a contract asset (performance precedes the contractual due date) or a contract liability (customer payment precedes performance). The Group&#146;s
contractual payment terms are typically due in no more than 30 days from invoicing. In limited situations, certain customer contractual payment terms require the Group to bill in arrears; thus, the Group satisfies some or all of the performance
obligations before the Group is contractually entitled to bill the customer. In these situations, billing occurs subsequent to revenue recognition, which results in a contract asset. For example, certain of the contractual arrangements do not permit
the Group to bill until the completion of the production of the samples. In other limited situations, certain customer contractual payment terms allow the Group to bill in advance; thus, the Group receives customer cash payment before satisfying
some or all of its performance obligations. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licenses of Intellectual Property</I>: Upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing the Group&#146;s intellectual property
are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from
<FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit
from the license.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Services</I>: The portion of the transaction price allocated to research and development services performance
obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Milestone Payments</I>: At the
inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of
cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone
selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the
probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Royalties</I>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the
predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been
satisfied (or partially satisfied). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.14 <FONT STYLE="white-space:nowrap">Value-added-tax</FONT> (&#147;VAT&#148;) recoverable and surcharges </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Value added tax recoverable represent amounts paid by the Group for purchases. The surcharges (i.e., Urban construction and maintenance tax, educational surtax, local
educational surtax), vary from 6% to 17% of the <FONT STYLE="white-space:nowrap">value-added-tax</FONT> depending on the <FONT STYLE="white-space:nowrap">tax-payer&#146;s</FONT> location. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.15 Research and development expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Elements of research and
development expenses primarily include (1)&nbsp;payroll and other related expenses of personnel engaged in research and development activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development
rights of drugs granted to the Group, (3)&nbsp;expenses related to preclinical testing of the Group&#146;s technologies and clinical trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites
that conduct the clinical studies (4)&nbsp;expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, (5)&nbsp;other research and development expenses. Research and
development expenses are charged to expense as incurred when these expenditures relate to the Group&#146;s research and development services and have no alternative future uses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <FONT
STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development in the period in which they are incurred, provided that the new
drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established
alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. The conditions enabling
capitalization of development expenses as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.16 Leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Leases are classified at the inception date as either a
capital lease or an operating lease. the Group assesses a lease to be a capital lease if any of the following conditions exist: (1)&nbsp;ownership is transferred to the lessee by the end of the lease term, (2)&nbsp;there is a bargain purchase
option, (3)&nbsp;the lease term is at least 75% of the property&#146;s estimated remaining economic life or (4)&nbsp;the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased
property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an incurrence of an obligation at the inception of the lease. The Group has no capital leases for the years presented. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All other leases are accounted for as operating leases wherein rental payments are expensed on a straight-line basis over the periods of their respective lease terms.
Certain of the lease agreements contain rent holidays. Rent holidays are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial possession of the lease property for
purposes of recognizing lease expense on straight-line basis over the term of the lease. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.17 Comprehensive loss </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions
resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, <I>Comprehensive Income</I>, requires that all items that are required to be recognized under current accounting standards as components of
comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#146;s comprehensive loss includes net loss and foreign currency
translation adjustments, which are presented in the consolidated statements of comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.18 Share-based compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company grants restricted shares and stock options to eligible employees and accounts for share-based compensation in accordance with ASC 718,
<I>Compensation</I>&#151;<I>Stock Compensation</I>. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Employees&#146; share-based compensation awards are measured at the grant date fair value of the awards and
recognized as expenses a) immediately at the grant date if no vesting conditions are required; or b) for share-based awards granted with only service conditions, using the graded vesting method net of estimated forfeitures over the vesting period;
or c) for share-based awards granted with service conditions and the occurrence of an initial public offering (&#147;IPO&#148;) as performance condition cumulative share-based compensation expenses for the options that have satisfied the service
condition should be recorded upon the completion of the IPO using the graded vesting method. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A change in any of the terms or conditions of share-based awards is
accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are
modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation
expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Share-based
compensation in relation to the restricted shares is measured based on the fair market value of the Group&#146;s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#146;s ordinary shares
involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding the Group&#146;s projected financial and operating results,
its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model.
The determination of the fair value of share options is affected by the share price of the Group&#146;s ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility,
risk-free interest rate, exercise multiple and expected dividend yield. The fair value of these awards was determined with the assistance from an independent valuation firm. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.19 Income taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group accounts for income taxes under the
liability method. Under the liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the tax income
rates that will be in effect when the differences are expected to reverse. A valuation allowance is recorded if it is more likely than not that some portion or all of a deferred income tax assets will not be realized in the foreseeable future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group evaluates its uncertain tax positions using the provisions of ASC 740-10, <I>Income Taxes</I>, which prescribes a recognition threshold that a tax position is
required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the benefit of a tax position which is &#145;&#145;more likely than not&#146;&#146; to be sustained under examination based solely
on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax
benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#146;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.20 Borrowings </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Borrowings are recognized initially at fair value,
net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net&nbsp;of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss
over the period of the borrowings using the effective interest method. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.21 Business combination </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group accounts for its business combinations using the acquisition method of accounting in accordance with ASC topic 805, <I>Business Combinations</I> (&#147;ASC
805&#148;). The acquisition method of accounting requires all of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
following steps: (i)&nbsp;identifying the acquirer, (ii)&nbsp;determining the acquisition date, (iii)&nbsp;recognizing and measuring the identifiable assets acquired, the liabilities assumed, and
any noncontrolling interest in the acquiree, and (iv)&nbsp;recognizing and measuring goodwill or a gain from a bargain purchase. The consideration transferred in a business combination is measured as the aggregate of the fair values at the date of
exchange of the assets given, liabilities incurred, and equity instruments issued as well as the contingent considerations and all contractual contingencies as of the acquisition date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their
estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and
assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets may include, but are not limited to, future expected cash flows from acquired assets, timing and probability of success of clinical
events and regulatory approvals, and assumptions on useful lives of the patents and discount rates. Management&#146;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable
and, as a result, actual results may differ from estimates. Additional information, such as that related to income tax and other contingencies, existing as of the acquisition date but unknown to us may become known during the remainder of the
measurement period, not to exceed one year from the acquisition date, which may result in changes to the amounts and allocations recorded. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Acquisitions that do not
meet the accounting definition of a business combination are accounted for as asset acquisitions. For transactions determined to be asset acquisitions, the Group allocates the total cost of the acquisition, including transaction costs, to the net
assets acquired based on their relative fair values. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.22 Segment information </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with ASC 280, <I>Segment Reporting</I>, the Group&#146;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results
when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose of internal
reporting. As the Group&#146;s long-lived assets are substantially located in and derived from the PRC, no geographical segments are presented. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.23 Loss per
share </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares
outstanding during the period using the <FONT STYLE="white-space:nowrap">two-class</FONT> method. Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, the net loss is allocated between ordinary shares and other participating
securities based on their participating rights. Net loss is not allocated to other participating securities if based on their contractual terms they are not obligated to share in the loss. Diluted loss per share is calculated by dividing net loss
attributable to ordinary shareholders by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of the preferred shares
using the <FONT STYLE="white-space:nowrap">if-converted</FONT> method, shares issuable upon the exercise of share options using the treasury stock method, shares issuable upon the conversion of the convertible promissory notes using the <FONT
STYLE="white-space:nowrap">if-converted</FONT> method, and shares issuable upon the exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of the diluted loss per share calculation when
inclusion of such shares would be anti-dilutive. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.24 Recent accounting pronouncements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases (Topic 842) (&#147;ASU
<FONT STYLE="white-space:nowrap">2016-02&#148;).</FONT> Under this guidance, an entity is required to recognize <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities on its balance
sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative
information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-11,</FONT>
Leases (Topic 842): Targeted Improvements (&#147;ASU <FONT STYLE="white-space:nowrap">2018-11&#148;),</FONT> which provides entities the option to initially apply ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> at the adoption date and recognize
a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> and ASU <FONT STYLE="white-space:nowrap">2018-11</FONT> are effective for the annual reporting
period beginning after December&nbsp;15, 2018, including interim periods within that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reporting period. The Group adopted the new leasing standards on January&nbsp;1, 2019, using a modified retrospective transition approach to be applied to leases existing as of, or entered into
after, January&nbsp;1, 2019. The Group have reviewed the existing lease contracts and the impact of the new leasing standards on the consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards,
the Group expect to recognize a lease liability and related <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset on the consolidated balance sheets of approximately RMB11,333 and RMB13,100, respectively.
The impact of adoption of the new leasing standards will have an immaterial impact to the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2016, the FASB
issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> Financial Instruments &#150; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;).</FONT> This
guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and
supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-19,</FONT> Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#147;ASU <FONT
STYLE="white-space:nowrap">2018-19&#148;),</FONT> which clarifies certain topics included within ASU <FONT STYLE="white-space:nowrap">2016-13.</FONT> ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> and ASU
<FONT STYLE="white-space:nowrap">2018-19</FONT> are effective for the annual reporting period beginning after December&nbsp;15, 2019, including interim periods within that reporting period. The Group is currently evaluating the impact on the
consolidated financial statements upon the adoption of this guidance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-15,</FONT>
Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments. ASU <FONT STYLE="white-space:nowrap">2016-15</FONT> provides guidance for targeted changes with respect to how cash receipts and cash payments are
classified in the statements of cash flows, with the objective of reducing diversity in practice. The amendments in this update are effective for public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods
within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. The impact of this ASU to the consolidated
financial statements is immaterial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT> Statement of Cash Flows (Topic 230)
(&#147;ASU <FONT STYLE="white-space:nowrap">2016-18&#148;).</FONT> This ASU affects all entities that have restricted cash or restricted cash equivalents and are required to present a statement of cash flows under Topic 230. ASU <FONT
STYLE="white-space:nowrap">2016-18</FONT> requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This
update was required to be adopted for fiscal years beginning after December&nbsp;15, 2018, and interim periods within fiscal years beginning after December&nbsp;15, 2019, and early adoption is permitted in any interim or annual period. The Group
elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. BUSINESS COMBINATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2017, the Group acquired 66.67% of the equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries including Chengdu Tasgen <FONT
STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. and Shanghai Tianyunjian <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. (together the &#147;Tasgen Group&#148;) by issuing convertible preferred shares to the then equity holders of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. The acquisition date was determined as July&nbsp;15, 2017 when the Group controlled the board and business of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin from July&nbsp;15, 2017 accordingly.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries are principally engaged in the research and development of innovative medicines. The
Group acquired <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries for its research team, technical experience, and pipeline assets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and
separately recognized. The Company allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the
fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized but is tested for impairment at least annually or more frequently if events or changes in circumstances would indicate a
potential impairment. None of the goodwill recognized is expected to be deductible for income tax purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group completed the valuations necessary to assess the fair values of the tangible assets acquired and
liabilities assumed, resulting from which the amount of goodwill was determined and recognized as of the date of acquisition. The following table summarizes the estimated aggregate fair values of the assets acquired and liabilities assumed as of the
date of acquisition: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF JULY&nbsp;15, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible preferred shares to be issued (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other financial assets (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Intangible assets <SUP STYLE="font-size:85%; vertical-align:top">(</SUP>*<SUP
STYLE="font-size:85%; vertical-align:top">)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of net assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests (Note 16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The intangible assets acquired in the business combination were IPR&amp;D intangible assets, which represented the fair value assigned to research and development assets that the Group acquired. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The acquired business did not contribute any revenues and contributed net loss of RMB14,750 to the Group for the period from July&nbsp;15, 2017 to December&nbsp;31,
2017. Unaudited pro forma operating results for the Group, assuming the acquisition of Tasgen Group occurred on January&nbsp;1, 2017 is as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED<BR>DECEMBER&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(314,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following summarizes the business combination as presented on the consolidated statement of cash flows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED<BR>DECEMBER&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash acquired for acquisition of a subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible preferred shares issued for business combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. PREPAYMENTS AND OTHER RECEIVABLES </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepayments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">&#151;Prepayments to CRO vendors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">&#151;Prepayments for other services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Value-added tax recoverable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rental deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. OTHER FINANCIAL ASSETS </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Financial asset at fair value through profit or loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Note receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group placed the principal amount for short-term investments through a contractual arrangement with a third party for the period from June&nbsp;30, 2017 to
June&nbsp;30, 2020 (&#147;Principal Amount&#148;). The Principal Amount can be redeemed from the third party at the discretion of the Group from time to time whereby the Group is expecting to earn an income on the Principal Amount with an average
yield in the range from 4.50% to 5.25% per annum. The Group initially records these assets at cost, which approximates its fair value at inception and subsequently records these assets at fair value. Changes in the fair value are reflected in the
consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subsequent to December&nbsp;31, 2018, the Group entered into an agreement with the relevant party involved for early
termination of the contractual arrangement with effect from June&nbsp;22, 2019 (&#147;Termination Agreement&#148;). Pursuant to the Termination Agreement, the Group shall receive cash with an amount of RMB95,056 and commercial bills with a total
face value of RMB160,944 (including those commercial bills redeemed during the year ended December&nbsp;31, 2018 with a face value of RMB40,387). No material gain or loss was arising from such termination. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Up to the issuance of these consolidated financial statements, cash of RMB80,000 was received and an amount of RMB85,374 cash was received upon the maturities of
certain commercial bills. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. PROPERTY, EQUIPMENT AND SOFTWARE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property, equipment and software consist of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,390</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The total amounts charged to the consolidated statements of comprehensive loss for depreciation and amortization expenses amounted to approximately RMB1,634 and
RMB6,740 for the years ended December&nbsp;31, 2017 and 2018, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. INTANGIBLE ASSETS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Intangible assets as of December&nbsp;31, 2017 and 2018 are summarized as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">IPR&amp;D represents the fair value assigned to research and development assets that we acquired from business combination of Tasgen Group in 2017 and had not reached
technological feasibility at the date of acquisition. Upon commercialization, the Group will determine the estimated useful life and amortize these amounts based upon an economic consumption method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. GOODWILL </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The goodwill of RMB162,574 (US$22,745) as of December&nbsp;31,
2017 and 2018 represented the goodwill generated from the acquisition of Tasgen Group in 2017 (Note 3). The business of Tasgen Group was fully integrated into the Company post acquisition. As of December&nbsp;31, 2017 and 2018, the Group performed a
qualitative assessment by evaluating relevant events and circumstances that would affect the Group&#146;s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Group&#146;s reporting unit is
less than its carrying amount, and therefore the Group&#146;s goodwill was not impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. SHORT-TERM BORROWINGS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the third quarter of 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. borrowed loans with the total amount of RMB99,000 from China Merchant
Bank Co., Ltd. for a term of one year and at the interest rate of 4.79% per annum. To facilitate the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
borrowings, another subsidiary of the Company in Hong Kong placed cash deposits of US$16,015 (equivalent to approximately RMB104,783) with the bank. The use of such cash deposits and the interest
earned thereon are restricted by the bank during the period of the borrowings. The deposits have a <FONT STYLE="white-space:nowrap">one-year</FONT> term and bear interest at 2.00% per annum. The borrowings were fully repaid in 2018. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. borrowed a loan of RMB80,000 from China
Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.20% per annum. To facilitate these borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$13,500 (equivalent to approximately RMB92,653) with
the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a <FONT STYLE="white-space:nowrap">one-year</FONT> term and bear interest at 3.26% per annum.
The borrowing was fully repaid in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. ACCRUALS AND OTHER PAYABLES </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Staff salaries and welfare payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued external research and development activities related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payables for purchase of equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued travelling expenses, office expenses and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. INCOME TAXES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cayman Islands </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> is not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma
Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong
Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. For the years ended December&nbsp;31, 2017 and 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited did not make any provisions for Hong Kong profit tax as
there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax law, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited is exempted from income tax on its
foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Australia </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Australia Pty Ltd is incorporated in Australia. Companies registered in Australia are subject to Australia
profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is 30%. <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Biopharma Australia Pty Ltd has no taxable income for all periods presented, therefore, no provision for income taxes is required. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United States </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of 21%. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. is also subject to state income tax in Maryland of 8.25%. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. has no taxable income for all periods presented, therefore, no
provision for income taxes is required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>China </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
March&nbsp;16, 2007, the National People&#146;s Congress of PRC enacted a new Enterprise Income Tax Law (&#147;new EIT law&#148;), under which Foreign Investment Enterprises (&#147;FIEs&#148;) and domestic companies would be subject to corporate
income tax at a uniform rate of 25%. The new EIT law became effective on January&nbsp;1, 2008. Under the new EIT law, preferential tax treatments will continue to be granted to entities which conduct businesses in certain encouraged sectors and to
entities otherwise classified as &#147;High and New Technology Enterprises&#148;. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai has been qualified as
&#147;High and New Technology Enterprise&#148; and enjoys a preferential income tax rate of 15% from 2018 to 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s other PRC subsidiaries are
subject to the statutory income tax rate of 25%. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No provision for income taxes has been made because the Group and all of its subsidiaries are in cumulative loss
positions for all the periods presented. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Reconciliations of the differences between the PRC statutory income tax rate and the Group&#146;s effective income tax
rate for the years ended December&nbsp;31, 2017 and 2018 are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(401,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax computed at respective applicable tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,848</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses plus deduction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(946</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Effect of tax holidays entitled by the PRC subsidiaries on basic loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The principal components of the deferred tax assets and liabilities are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization of property, equipment and software, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrual expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Acquired intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Movement of the valuation allowance is as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance as of January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,931</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Business combination (Note 3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Decrease due to the change of tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance as of December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2018, the Group had net operating losses of approximately RMB462,148 which arose from the subsidiaries established in the PRC. The tax losses
carried forward in the PRC will expire during the period from 2019 to 2023. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A valuation allowance is provided to reduce the amount of deferred tax assets if it is
considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, the Group evaluates a variety of positive and negative factors including the
Group&#146;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group has incurred net accumulated
operating losses for income tax purposes since its inception. The Group believes that it is more likely than not that these net accumulated operating losses will not be utilized in the future. Therefore, the Group has provided full valuation
allowances for the deferred tax assets as of December&nbsp;31, 2017 and 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group evaluates each uncertain tax position (including the potential application
of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&nbsp;31, 2017 and 2018, the Group did not have any significant unrecognized uncertain tax positions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. ORDINARY SHARES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2017 and 2018, 500,000,000
ordinary shares had been authorized by the Company. Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. CONVERTIBLE PREFERRED SHARES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;18,
2016, the Company issued 5,141,587 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares with a consideration of US$11,282 (equivalent to approximately RMB74,742). In connection
with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares issuance, the Company also issued 2,246,744 warrant to purchase its Series <FONT STYLE="white-space:nowrap">A-3</FONT>
Preferred Shares (&#147;Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants&#148; and see Note 15). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On September&nbsp;6, 2017, in connection with the
Group&#146;s acquisition of Tasgen Group (see Note 3), the Company issued 16,723,646 shares of series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at a price of US$2.55 per share with a total consideration of US$42,645 (equivalent to
approximately RMB289,024). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Shares, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares
and Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares are also referred to as Series A Preferred Shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On September&nbsp;22, 2017, the Company
issued 15,894,594 shares of Series B Preferred Shares with a consideration of US$52,546 (equivalent to approximately RMB346,515). In connection with the Series B Preferred Shares issuance, the Company also issued convertible promissory notes that
are convertible into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares (&#147;2017 Notes&#148; and see Note 14) and 5,633,780 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares
(&#147;Series B Warrants&#148; and see Note 15). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Concurrently with the Company&#146;s issuance of Series B Preferred Shares, the Company also completed a round of
onshore financing with respect to the Group&#146;s subsidiary <FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin (&#147;Series B Onshore Financing&#148;). Series B Onshore Financing comprised 1) capital injection to
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin by a number of investors (&#147;Series B Onshore Investors&#148;) (see Note 14), 2) <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s issuance of convertible loans (&#147;Onshore
Convertible Loans&#148; and see Note 14), and 3) the Company&#146;s issuance of 2,620,842 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B Warrants&#148; and see Note 15). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On June 29, 2018, the Company issued total 8,361,823 shares of Series A-3 Preferred Shares upon exercise of Series A-3 Option held by its holder. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On June&nbsp;29, 2018, the Company issued 2,535,201 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of 2017 Notes and
issued 2,253,512 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B Warrant by Series B preferred shareholders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On June&nbsp;29, 2018, the Company issued total 5,938,640 share of Series B Preferred Shares upon exercise of Series B Option held by a Series B Onshore Investor and
issued 947,218 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 14), respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On July 6, 2018, the Company issued 1,455,549 shares of Series B Preferred Shares upon exercise of Series B Option held by a Series B Option Investor, issued 232,161
shares of Series B-1 Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 14) and issued 1,048,337 shares of Series B-2 Preferred Shares upon exercise of Series B Warrant by Series B Onshore
Investors, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Series B Preferred Shares, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares and Series
<FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares are also referred to as Series B Preferred Shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On July 6, 2018, the Company issued 31,046,360
shares of Series C Preferred Shares at a price of US$6.4419 per share with a total consideration of US$200,000 (equivalent to approximately RMB1,323,363). In connection with the offering of the Series C Preferred Shares, the Company incurred
issuance costs of RMB16,730. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Series A Preferred Shares, Series B Preferred Shares and Series C Preferred Shares are collectively referred to as Preferred Shares.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Key terms of the Preferred Shares are summarized as follows: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The holders of Preferred Shares are entitled to receive dividends, out of any assets legally available therefor, prior and in preference to any declaration
or payment of any dividend on the ordinary shares or any other class or series of shares of the Group at the rate of eight percent (8%) of the original issue price per share per annum on each Preferred Share, payable in US$ and annually when, as and
if declared by the Board. Such distributions shall not be cumulative. No dividend, whether in cash, in property or in shares of the capital of the Group, shall be paid on or declared and set aside for any ordinary shares or any other class or series
of shares of the Group unless and until all dividends have been paid in full on the Preferred Shares (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each Preferred Share may be converted at any time into
ordinary shares at the option of the preferred shares holders at the then applicable conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of (i)&nbsp;share splits, share combinations, share dividends or
distribution, other dividends, recapitalizations and similar events, or (ii)&nbsp;issuance of ordinary shares (excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion
price in effect on the date of or immediately prior to such issuance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Shares shall be automatically converted into ordinary shares immediately upon
the closing of a public offering of the Company&#146;s shares with an offering price (exclusive of underwriting commissions and expenses) that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
reflects a market capitalization (immediately prior to the public offering) of not less than US$1,000,000,000 or otherwise approved by all directors and certain preferred shareholders as
specified in the Company&#146;s memorandum and articles of association (the &#147;Qualified Public Offering&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group determined that there were no
beneficial conversion features (&#147;BCF&#148;) identified for any of the Preferred Shares during any of the periods. In making this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are
convertible with the respective effective conversion price at the issuance date. In all instances, the effective conversion price was greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as
described above, the Group will revaluate whether or not a beneficial conversion feature should be recognized. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any liquidation (unless waived by the preferred shareholders) including deemed liquidation, dissolution or winding up of the Company, holders of the
Preferred Shares shall be entitled to receive a per share amount equal to one hundred percent (100%) of the original issue price on each Preferred Share, plus an amount representing an internal rate of return of twelve percent (12%) per annum on the
original issue price as adjusted for share dividends, share splits, combinations, recapitalizations or similar events, plus all accrued and declared but unpaid dividends thereon, in the sequence of Series C Preferred Shares, Series B Preferred
Shares and Series A Preferred Shares. After such liquidation amounts have been paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed on a pro rata basis among the holders
of the Preferred Shares, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, together with the holders of the ordinary shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Accounting of
preferred shares </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Shares are redeemable by the holders upon a liquidation event, including a deemed liquidation event (e.g., change in control),
and as such are presented as mezzanine equity on the consolidated balance sheets. In accordance with ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99,</FONT></FONT> each issuance of the convertible preferred shares
should be recognized at the date of issuance after deducting fair value allocated to the detachable warrants and issuance costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company assesses whether an
amendment to the terms of its convertible preferred shares is an extinguishment or a modification using the fair value model. When convertible preferred shares are extinguished, the difference between the fair value of the consideration transferred
to the convertible preferred shareholders and the carrying amount of the convertible preferred shares (net of issuance costs) is treated as deemed dividends to the preferred shareholders. The Company considers that a significant change in fair value
after the change of the terms to be substantive and thus triggers extinguishment. A change in fair value which is not significant immediately after the change of the terms is considered <FONT STYLE="white-space:nowrap">non-substantive</FONT> and
thus is subject to modification accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s convertible preferred shares activities for the years ended December&nbsp;31, 2017 and 2018 are
summarized below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A PREFERRED SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B PREFERRED SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES C PREFERRED SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Balance as of January&nbsp;1,&nbsp;2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,141,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series A Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,723,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series B Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,894,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Balance as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,865,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,894,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series A Preferred Shares upon exercise of
<FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series B Preferred Shares upon exercise of Series&nbsp;B Option</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,394,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series B Preferred Shares upon conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,535,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series B Preferred Shares upon conversion of Onshore Convertible Loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series B Preferred Shares upon exercise of Tranche I of Series&nbsp;B Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,301,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series C Preferred Shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Balance as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. CONVERTIBLE PROMISSORY NOTES AND ONSHORE CONVERTIBLE LOANS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2017
Notes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;25, 2017, the Company issued US$11,520 convertible promissory notes (&#147;2017 Notes&#148;) to investors of Series B Preferred
Shares (see Note 13) at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of the 2017 Notes may convert the outstanding principal amount into Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the conversion price of US$5.38 per share or a lower price as may be agreed by the investors and the Company at any time from six months prior to the maturity date and prior to the repayment
in full of the 2017 Note. No interest shall be accrued if the 2017 Notes have been converted into <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As the fair value of the Company&#146;s ordinary shares on September&nbsp;25, 2017 was lower than the effective conversion price of US$5.38, the Company did not record
a BCF. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;29, 2018, the Company&#146;s 2017 Notes were converted into the Company&#146;s 2,535,201 Series <FONT STYLE="white-space:nowrap">B-1</FONT>
Preferred Shares at the nominal conversion price of US$5.38 per share. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2018 Notes </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;3, 2018, the Company issued US$9,000 (equivalent to approximately RMB59,704) convertible promissory notes (&#147;2018 Notes&#148;) to an investor of
Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at an annual interest rate of 0%, maturing on 36 months after the issuance date. Under the agreement, the holder of the 2018 Notes may convert the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
2018 Notes outstanding principal amount into Series B Preferred Shares at the conversion price being lower of US$10 per share and fair market value at any time prior to the maturity date.
Alternatively, the 2018 Notes shall be automatically converted into the Company&#146;s Series B Preferred Shares upon the maturity. As the fair value of the Company&#146;s ordinary shares on February&nbsp;3, 2018 of US$3.96 was equal to the
effective conversion price (being lower of US$10 per share and fair market value), the Company did not record a BCF. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Onshore Convertible Loans </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;25, 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin issued US$5,359 convertible loans to Series B Onshore Investors at a compound interest
rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of the Onshore Convertible Loans may convert the outstanding principal amount into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s
equity interest a stipulated conversion price at any time from 6 months prior to the maturity date and prior to the repayment in full of the Onshore Convertible Loans. No interest shall be accrued if the Onshore Convertible Loans have been converted
into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s equity interest. As the fair value of the <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s ordinary shares on September&nbsp;25, 2017 was lower than the effective
conversion price of US$4.31, the Company did not record a BCF. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In June and July 2018, the Company reached agreements with holders of Onshore Convertible Loans and
the principal amounts of Onshore Convertible Loans were then effectively converted into 1,179,379 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares of the Company and the accrued interests were waived, resulting in an
extinguishment loss of RMB8,548. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15. WARRANTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the
issuance of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares on October&nbsp;18, 2016, 2,246,744 <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Warrants were issued to
Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shareholder, which provided the holder the right to purchase Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares. The Series
<FONT STYLE="white-space:nowrap">A-3</FONT> Warrants were later terminated on September&nbsp;6, 2017 without being exercised. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the issuance of
the Series B Preferred Shares on September&nbsp;22, 2017, 5,633,780 Series B Warrants were issued to Series B preferred shareholders, which provided the holders the right to purchase <FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> Preferred
Shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Company&#146;s Series B Onshore Financing that took place on September&nbsp;25, 2017, 2,620,842 Series B Warrants were issued to
Series B Onshore Investors, which provided the holders the right to purchase Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the period
from June&nbsp;29, 2018 to July&nbsp;6, 2018, 3,301,849 Series B Warrants (representing Tranche I of Series B Warrants) were exercised to purchase 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares with proceeds of
US$20,000 (equivalent to approximately RMB132,332). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;6, 2018, the Series B Warrants holders agreed that the Series B Warrants shall be divided into two
tranches and exercisable in accordance with different time schedules, such that: (i)&nbsp;the holders have exercised part of the Series B Warrants in the total consideration of US$20,000 (&#147;Tranche I of Series B Warrants&#148;) and 3,301,849 <FONT
STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> Preferred Shares of the Company in aggregate have been newly issued to such holders on a pro rata basis; (ii)&nbsp;only when the Company fails to submit a Qualified Public Offering application at an
internationally recognized securities exchange by March&nbsp;31, 2019, the Warrant Holders may exercise the remaining part of Series B Warrants, in the total consideration of US$30,000 (&#147;Tranche II of Series B Warrants&#148;) and 4,952,773
Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares of the Company in aggregate will be issued to such holders on a pro rata basis; (iii)&nbsp;provided that the Company successfully submits a Qualified Public Offering application at
an internationally recognized securities exchange by March&nbsp;31, 2019, the holders shall unconditionally and irrevocably waive and cancel Tranche II of Series B Warrants; and (iv)&nbsp;the Tranche II of Series B Warrants may only be concurrently
exercised by all the Warrant Holders in one lump. This is considered to be a modification to Series B Warrants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the confirmations issued by the
Company&#146;s Series B Warrants holders in July 2019, the holders of Series B Warrants has unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accounting of warrants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The warrant is a freestanding instrument and
is recorded as liability in accordance with ASC 480, <I>Distinguishing Liabilities from Equity</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As the Company&#146;s issuance of warrants were bundled with other instruments (such as convertible preferred shares,
convertible promissory notes, etc.), out of total considerations, the warrants are initially recognized at fair value and the remaining were allocated to other instruments on a relative fair value basis (if applicable). The fair value changes of the
warrants (including the fair value changes arising from modification of warrants) up to the time of exercise or termination were recognized in earnings. Upon exercise, the total carrying value of the associated warrant liabilities was reclassified
into the carrying value of the Preferred Shares into which it was converted. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company determined the fair value of the warrants with the assistance of an
independent third party valuation firm. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group has measured the warrant liabilities at fair values on a recurring basis using significant unobservable inputs
(Level 3) for the years ended December&nbsp;31, 2017 and 2018. The Group used the binomial model to estimate the fair value of warrant liabilities using the following assumptions: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free rate of return</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.84%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.49%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Maturity date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Estimated volatility rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.3%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">6.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">6.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of underlying convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">5.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">6.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The model requires the input of highly subjective assumptions including the risk-free rate of return, maturity date, estimated volatility rate and fair value of
underlying preferred shares. The risk-free rate for periods within the contractual life is based on the US treasury strip bond with maturity similar to the maturity of the warrants as of valuation dates plus a China country risk premium. For
expected volatilities, the Group has made reference to the historical daily stock prices volatilities of ordinary shares of several comparable companies in the same industry as the Group. The estimated fair value of the preferred shares was
determined with assistance from an independent third party valuation firm. The Group&#146;s management is ultimately responsible for the determination of the estimated fair value of its preferred shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The significant unobservable inputs used in the fair value measurement of the warrant liabilities include risk-free rate of return, interval between valuation date and
maturity date, estimated volatility rate and fair value of underlying preferred shares. Significant decreases in interval between valuation date and maturity date, estimated volatility rate and fair value of underlying preferred shares would result
in a significantly lower fair value measurement. Significant increases in risk-free rate of return would result in a significantly lower fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>16. REDEEMABLE <FONT STYLE="white-space:nowrap">NON-CONTROLLING</FONT> INTERESTS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Company&#146;s acquisition of Tasgen Group (see Note 3), on September&nbsp;6, 2017, the Company also entered into an option agreement with the
third party investor of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, pursuant to which the Company granted the third party investor an option to subscribe for certain number of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred
Shares of the Company at a price that stipulated in the agreement, and at the same time, the third party investor shall transfer its equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin to the Company at the same price
(&#147;Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option&#148;). This Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option can be exercised at any time at the holder&#146;s own discretion or upon the request of the Company if the
shareholders of the Company approve an initial public offering. In addition, in the event that the exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option has not been completed within 6 months after the option holder delivers the
share purchase option notice, the Company shall purchase the third party investor&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option at a price that
stipulated in the agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the Company&#146;s issuance of Series B Preferred Shares (see Note 13), on September&nbsp;25, 2017, the Group&#146;s
subsidiary <FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin entered into a capital increase subscription agreement with Series B Onshore Investors, pursuant to which Series B Onshore Investors subscribed for additional equity in <FONT
STYLE="white-space:nowrap">I-MAB</FONT> Tianjin of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
US$24,444 (equivalent to approximately RMB161,196). On September&nbsp;25, 2017 and in tandem with the aforementioned <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s capital increase
subscription agreement, the Company also entered into option agreements with Series B Onshore Investors, pursuant to which the Company granted Series B Onshore Investors options to subscribe for certain numbers of Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Shares of the Company at a price that stipulated in the agreements, and at the same time, the Series B Onshore Investors shall transfer their equity interests in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin to the Company at the same price (&#147;Series B Option&#148;). The Series B Option can be exercised at any time at the holders&#146; own discretion or upon the request of the Company if the
shareholders of the Company approve an initial public offering. In addition, in the event that the exercise of Series B Option has not been completed within 6 months after the option holders deliver the share purchase option notice, the Company
shall purchase the third party investor&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and the Series B Option at a price that stipulated in the agreements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the accounting assessments, the Company considers that the aforementioned Series <FONT STYLE="white-space:nowrap">A-3</FONT> and Series B Options are embedded
features of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests that are not required to be bifurcated. Since the aforementioned <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin are redeemable at a determinable price, upon occurrence of an event that is not solely within the control of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, the aforementioned <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin are accounted for as redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in the Group&#146;s consolidated
balance sheets. Subsequently, the redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests should be carried at the higher of (1)&nbsp;the carrying amount after the attribution of net income of the Company and (2)&nbsp;the
expected redemption value. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option and Series B Option were exercised by respective holders on June&nbsp;29,
2018 and July&nbsp;6, 2018 to acquire 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares and 7,394,189 Series B Preferred Shares, respectively. The transactions were accounted for as equity transactions, and the
differences between the carrying amount of redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests of RMB305,708 and the fair value of convertible preferred shares of RMB615,393 that issued were recognized in additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group&#146;s redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest activities for the
years ended December&nbsp;31, 2017 and 2018 are summarized as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Capital injection by Series B Onshore Investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests arising from business
combination (Note&nbsp;3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of Series B Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(161,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>17. SHARE-BASED COMPENSATION </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(a) Restricted shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31, 2016, the Company issued 4,019,554 ordinary shares to Mr. Zang Jingwu Zhang, Ms. Qian Lili, Mr. Wang Zhengyi and Mr. Fang Lei
(collectively the &#147;Founders&#148;), including the 369,301 shares which represented the equity interests of Third Venture held by the Founders, and the Company recorded share-based compensation expense of RMB18.7&nbsp;million for issuance and
grant of 3,650,253 ordinary shares to the Founders in June 2016. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2016, the Founders entered into an arrangement with other investors of the Company, and
the 87,441 ordinary shares issued to the Founders in June 2016 were canceled and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to service vesting conditions, that shall vest 20%, 20% and 30%
over the next three years, respectively. There shall be no acceleration of the vesting schedule except </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
that, in case of a change of control of the Company or a Qualified Public Offering, or the termination of the Founder&#146;s employment with the Group without cause. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of the Company&#146;s ordinary shares of US$0.77 at the date of
imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the Group&#146;s Founders&#146; restricted shares activities: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBERS<BR>OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>GRANT&nbsp;DATE<BR>FAIR&nbsp;VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,752,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amounts of shared-based compensation expense in relation to the restricted shares recognized in the years ended December&nbsp;31, 2017 and 2018 were RMB7,039 and
RMB3,520, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shared-based compensation expenses related to restricted shares were included in: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(b) 2017 Employee Stock Option Plan (&#147;2017 Plan&#148;) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
October 2017, the Company adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued pursuant to all awards granted were approved. Stock options granted to an employee under the 2017 Plan will be
exercisable upon the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. Employees are generally subject to a three-year
service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant date, a vesting of the remaining 50% on the third anniversary of the applicable grant date. The stock option
under 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the Company completes a listing, all stock options granted to an employee shall be forfeited at the time the employee terminates his employment with the Group.
After the Company completes a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days after the date when the options become exercisable, or (ii) 30 days after the date of cessation of employment or
directorship, or such longer period as the Board of Directors may otherwise determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group granted 11,051,230 and 1,470,000 stock options to employees under 2017 Plan, all with an exercise price of
US$1, for the years ended December&nbsp;31, 2017 and 2018, respectively. No options are exercisable as of December&nbsp;31, 2017 and 2018 and prior to the Group completes a listing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the stock options activities for the years ended December&nbsp;31, 2017 and 2018: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED</B><br><B>AVERAGE</B><br><B>EXERCISE</B><br><B>PRICE</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED</B><br><B>AVERAGE</B><br><B>REMAINING</B><br><B>CONTRACTUAL</B><br><B>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE</B><br><B>INTRINSIC</B><br><B>VALUE</B><br><B>US$&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,051,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other addition <SUP STYLE="font-size:85%; vertical-align:top">(note)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,761,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,005,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercisable as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="right">note:</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Other addition represented the modified share options that originally granted to two senior management employees in October 2016 (see (c) Other share-based compensation) </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.34%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">61.32%-62.13%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.32%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.81%-3.06%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the
Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#146;s options in effect at the option valuation date.
The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee
exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any
dividend payments in the foreseeable future. Expected term is the contract life of the option. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of stock options granted to employees for the years
ended December&nbsp;31, 2017 and 2018 amounted to RMB99.0 million and RMB45.2 million, respectively. Since the exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, no
share-based compensation expense relating to the 2017 Plan was recorded for the years ended December&nbsp;31, 2017 and 2018. The Group will recognize compensation expenses relating to options vested cumulatively upon the completion of the
Company&#146;s listing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(c) Other share-based compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the year ended December&nbsp;31, 2016, the Group recorded share-based compensation expense of RMB3.3&nbsp;million for issuance and grant of 710,366 stock options to
two senior management employees in October 2016, as rewards for their services they had performed in the past and in exchange for their full-time devotion and professional expertise. Stock options granted to the two employees were exercisable once
granted, with an exercise price of US$0.06. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2017, in connection with the adoption of 2017 Plan, the Group amended the stock option agreement with the
two aforementioned employees, under which the stock options would become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control that defined in the stock option agreements. As the modification of
terms and conditions of share-based compensation were not beneficial to its employees, no further accounting impact was resulting from it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>18. LICENSING AND
COLLABORATION ARRANGEMENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a description of the Group&#146;s significant licensing and collaboration agreements entered into for the years
ended December&nbsp;31, 2017 and 2018. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with MorphoSys AG (&#147;MorphoSys&#148;) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November
2017, the Group entered into a license and collaboration agreement with MorphoSys, with respect to the development and commercialization of MOR202/TJ202, MorphoSys&acute;s proprietary investigational antibody against CD38 (the &#147;CD38
product&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under this agreement, MorphoSys granted to the Group an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human
therapeutic or diagnostic purpose in the licensed territory, namely mainland China, Hong Kong, Macau and Taiwan (collectively &#147;Greater China&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant
to this agreement, the Group granted to MorphoSys an exclusive license to its rights in any inventions that the Group make while exploiting the CD38 product under this agreement, solely to exploit the CD38 product outside of Greater China. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to this agreement, the Group paid to MorphoSys an upfront license fee of US$20.0&nbsp;million (equivalent to approximately RMB132.7 million). The Group also
agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate amount of US$98.5&nbsp;million (equivalent to approximately RMB653.5 million). Such
milestones include first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess of a certain amount. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the Group is required to pay tiered <FONT STYLE="white-space:nowrap">low-double-digit</FONT> royalties to MorphoSys on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis during the term, commencing with the first commercial sale of a relevant
licensed product in Greater China. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the expiration of the Group&#146;s last payment obligation under the agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the year ended December&nbsp;31, 2017, the Group paid a US$20.0&nbsp;million (equivalent to approximately RMB132.7 million) upfront fee to MorphoSys, which was
recorded as research and development expense in the consolidated statements of comprehensive loss. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining
milestones are still not probable as of December&nbsp;31, 2017 and 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Summarized financial information related to the above agreement is presented below: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEARS ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RESEARCH AND DEVELOPMENT EXPENSE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>UPFRONT&nbsp;FEES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MILESTONES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXTENSION/<BR>TERMINATION<BR>OF<BR>AGREEMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMORTIZATION<BR>OF PREPAID<BR>RESEARCH&nbsp;AND<BR>DEVELOPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INTANGIBLE<BR>ASSET&nbsp;BALANCE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with Genexine, Inc. (&#147;Genexine&#148;) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December
2017, the Group entered into an intellectual property license agreement with Genexine with respect to <FONT STYLE="white-space:nowrap">GX-I7/TJ107,</FONT> a long-acting <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine. Under this agreement, the
Group obtained an exclusive, sublicensable and transferable license to use and otherwise exploit certain intellectual property in connection with the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale
and distribution of GX-I7 to treat cancer in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the agreement, the Group made an upfront payment of US$12.0&nbsp;million (equivalent
to approximately RMB79.6 million) to Genexine which was recorded as a research and development expense in 2018. The Group also agreed to make milestone payments in the aggregate amount of US$23.0&nbsp;million (equivalent to approximately RMB152.6
million), conditioned upon the achievement of certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and new drug application (&#147;NDA&#148;) or biologic license application (&#147;BLA&#148;) approval in
Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, the Group agreed to make milestone payments in the aggregate amount of US$525.0&nbsp;million (equivalent to approximately RMB3,482.7
million), conditioned upon the achievement of certain cumulative net sales of <FONT STYLE="white-space:nowrap">GX-I7</FONT> up to US$2,000 million. The Group also is required to pay Genexine a <FONT STYLE="white-space:nowrap">low-single-digit</FONT>
percentage royalty in respect of the total annual net sales of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> The aforesaid milestones and royalties (other than the upfront payment) will be reduced by 50% following the entry of a generic version of
GX-I7 in China, Hong Kong, Macau and Taiwan without the consent or authorization of us or any of our sublicensees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless terminated earlier in accordance with the
terms thereof, this agreement will remain in effect until the later of (i)&nbsp;the expiry of the last to expire patent of the licensed intellectual property that includes a valid claim for Greater China and that covers the composition of GX-I7; and
(ii) 15 years from the date of the first commercial sale of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the year ended December&nbsp;31, 2018, the Group
paid a US$12.0&nbsp;million (equivalent to approximately RMB79.6 million) upfront fee to Genexine, which was recorded as research and development expense in the consolidated statements of comprehensive loss. Due to the uncertainty involved in
meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Summarized financial information related to the above agreement is presented below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEARS ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RESEARCH AND DEVELOPMENT EXPENSE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>UPFRONT&nbsp;FEES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MILESTONES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXTENSION/<BR>TERMINATION<BR>OF<BR>AGREEMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMORTIZATION<BR>OF PREPAID<BR>RESEARCH&nbsp;AND<BR>DEVELOPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INTANGIBLE<BR>ASSET&nbsp;BALANCE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with MorphoSys </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2018, the Group entered into a license and collaboration agreement with MorphoSys for MorphoSys&#146;s proprietary antibody (MOR210/TJ210) directed against
C5aR (the &#147;C5aR Agreement&#148;). Under this agreement, the Group obtained an exclusive, royalty-bearing license to explore, develop and commercialize certain anti-C5aR antibodies in Greater China and South Korea. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and South Korea, including all relevant
clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. MorphoSys retains rights in respect of development and commercialization of
MOR210/TJ210 in the rest of the world. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the agreement, the Group also agreed to make milestone payments conditioned upon the achievement of
certain development milestones and certain annual net sales of anti-C5aR antibodies. The Group is also required to pay to MorphoSys tiered <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalties on annual net sales of anti-C5aR antibody
products within the licensed territory. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the year ended December&nbsp;31, 2018, the Group paid a US$3.5&nbsp;million (equivalent to approximately RMB23.2
million) upfront fee to MorphoSys, which was recorded as research and development expense in the consolidated statements of comprehensive loss. Due to the uncertainty involved in meeting these development and commercialization based targets, the
Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Summarized financial information related to the
above agreement is presented below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEARS ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RESEARCH AND DEVELOPMENT EXPENSE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>UPFRONT&nbsp;FEES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MILESTONES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXTENSION/<BR>TERMINATION<BR>OF<BR>AGREEMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMORTIZATION<BR>OF PREPAID<BR>RESEARCH&nbsp;AND<BR>DEVELOPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INTANGIBLE<BR>ASSET&nbsp;BALANCE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition to the above arrangements, the Group has entered into other various <FONT STYLE="white-space:nowrap">in-licensing</FONT> and collaboration agreements with third party licensors to develop and commercialize drug candidates. Based on the
terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain contractually defined milestones. The Group made US$0.6&nbsp;million (equivalent to approximately RMB4.0 million)
upfront and US$0.3&nbsp;million (equivalent to approximately RMB2.0 million) milestone payment under these agreements for the year ended December&nbsp;31, 2018. Under the terms of the agreements, the licensors are eligible to receive from the Group
up to an aggregate of approximately US$164.4&nbsp;million (equivalent to approximately RMB1,090.6 million) in milestone payments upon the achievement of contractually specified development milestones, such as regulatory approval for the drug
candidates, which may be before the Group has commercialized the drug or received any revenue from sales of such drug candidate, which may never occur. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>B. <FONT
STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement among HDYM,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> and Hangzhou HealSun Biopharm Co., Ltd. (&#147;HealSun&#148;) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2017, one of the Company&#146;s
subsidiaries, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, entered into a technology transfer agreement with HDYM and HealSun with respect to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT>
humanized monoclonal antibodies. Under the agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai agreed to grant to HDYM exclusive, worldwide and sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold,
import, or otherwise exploit certain <FONT STYLE="white-space:nowrap">PD-L1</FONT> related patents, patent applications, know-hows, data and information of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, relevant cell lines as well as any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> monoclonal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
antibody arising from such cell lines for the treatment of diseases. Further, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and its cooperative party, HealSun agreed to provide
subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal
antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples, toxicological and pharmacological testing,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmaceutical experiment report drafting, and application for and registration of clinical trials. HDYM agreed to make milestone payments conditioned upon achieving certain contractually defined
milestones. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this
agreement, due to the early stage nature of the development, the Group determined the license to the intellectual property and research and development services are not distinct and thus were accounted for as a single performance obligation that is
satisfied over time. The Group would receive RMB51.0&nbsp;million (inclusive of VAT) milestone payments under this agreement, and considered that the achievements of milestone II, III, IV are constrained such that the transaction price shall
initially only include the milestones payment which have been achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction
price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group used a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method to measure progress as that method best depicts its performance under the agreement. For the year ended December&nbsp;31, 2017, the Group achieved
milestones I and II and received milestone payments totaling of RMB29.0&nbsp;million (inclusive of VAT). The cumulative percentage complete in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input
method related to this agreement as of December&nbsp;31, 2017 is estimated to approximate 42%, the Group recognized RMB11.6&nbsp;million (exclusive of VAT of RMB0.7 million) of revenue in the consolidated statements of comprehensive loss, and
RMB15.8&nbsp;million (exclusive of VAT of RMB0.9 million) were deferred as contract liability related to this arrangement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the year ended December&nbsp;31,
2018, the Group achieved milestones III and IV and received milestone III payment of RMB11.0&nbsp;million (inclusive of VAT) and recognized as contract assets as of December 31, 2018. As of December&nbsp;31, 2018, the cumulative percentage complete
in the <FONT STYLE="white-space:nowrap">cost-to</FONT> cost input method related to this arrangement is estimated to approximate 100%. The Group recognized RMB36.5&nbsp;million (exclusive of VAT of RMB1.3 million) of revenue in the consolidated
statements of comprehensive loss for the year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Collaboration Agreement with Everest Medicines Limited (&#147;Everest&#148;)
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2018, the Group entered into a collaboration agreement with Everest, which is controlled by the ultimate controlling party of a principal
shareholder of the Group. Under the agreement, both parties agreed to collaborate on programs to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary anti-CD38 antibody for all indications in hematologic oncology and
commercialize of MOR202/TJ202 in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A joint steering committee with equal representation from each party was established to coordinate and oversee the
development and commercialization of the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the agreement, the
Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38
product, including payments due to MorphoSys under the Licensing Agreement, dated November&nbsp;30, 2017, in the proportion of 75% by Everest and 25% by the Group. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The joint steering committee will decide which party shall be responsible for conducting the commercialization of the CD38 product pursuant to the commercialization
plan approved by the committee. If Everest is selected to be responsible for commercialization, the Group shall grant an exclusive royalty-free license to Everest to commercialize the CD38 product for all indications in hematologic oncology in
Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group and Everest will share the profit and loss and <FONT STYLE="white-space:nowrap">out-license</FONT> revenue derived from the CD 38 product
in proportion to the costs that each party incur in developing the product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon any termination of this arrangement, the terminating party has the right to continue the development and
commercialization of CD38 product. If Everest is the rightful terminating party, the Group shall (i)&nbsp;assign the MorphoSys license to Everest (subject to the terms and conditions of such license); (ii) grant to Everest an exclusive license to
all intellectual property rights that the Group owns or controls to further develop, manufacture, and commercialize the CD38 product; (iii)&nbsp;transfer the development, manufacture and commercialization of the CD38 product to Everest. The
terminating party shall be solely responsible for the cost and expense of such development and commercialization after termination. In the event that such continuing party successfully develops and commercializes the CD38 product, it shall pay to
the other party a percentage of the product profit and <FONT STYLE="white-space:nowrap">out-license</FONT> revenue generated therefrom in accordance with the terms of this agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The US$26.0&nbsp;million (equivalent to approximately RMB178.7 million) in aggregate proceeds from Everest under the agreement represented the full funding available
under the agreement, and was recorded as a research and development funding received liability on the consolidated balance sheet as of December&nbsp;31, 2018, in accordance with <I>ASC 730, Research and Development</I>. Because there is a
significant related party relationship between the Company and Everest, the Company is treating its obligation to make payments under the commercialization stage as an implicit obligation to repay the funds advanced by Everest (see Note 28). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with ABL Bio </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2018, the Group entered into a
license and collaboration agreement with ABL Bio, under which the Group granted to ABL Bio exclusive, worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibodies (&#147;BsAbs&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group agreed to share costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible for all costs and activities
following that time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In consideration of the license, ABL Bio agreed to pay the Group an upfront fee of US$2.5&nbsp;million (equivalent to approximately RMB17.2
million), and milestone payments in the aggregate amount of US$97.5&nbsp;million (equivalent to approximately RMB646.8 million) conditioned upon achieving certain research, clinical development and sales milestones. These include research milestones
of up to US$2.5 (equivalent to approximately RMB17.2) million, clinical milestones of up to US$30&nbsp;million (equivalent to approximately RMB199.0 million) and sales milestones of up to US$65&nbsp;million (equivalent to approximately RMB431.2
million). Further, ABL Bio agreed to pay the Group royalties at <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentages in respect of the total annual net sales of the licensed BsAbs product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, ABL Bio granted to the Group an exclusive, royalty-free, sublicensable license to use the BsAbs technology solely to exploit the licensed BsAbs product for
all indications in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope
of ASC 606. Under this agreement, the only one performance obligation was to grant the BsAbs license to ABL, considering that the achievements of milestones are constrained such that the transaction price shall initially only include upfront payment
and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction price when it is no
longer probable that a significant reversal of cumulative revenue would occur in future periods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2018, no milestone has been achieved, and
the Group recognized revenue of US$2.5&nbsp;million (equivalent to RMB17.2 million) of revenue in the consolidated statements of comprehensive loss for the year ended December 31, 2018, which was upfront fee related to the grant of the rights of
BsAbs to ABL Bio as mentioned above. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Collaboration Agreement with ABL Bio </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2018, the Group and ABL Bio entered into a collaboration agreement (the &#147;ABL Bio Collaboration&#148;) whereby both parties agreed to collaborate to develop
three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies by using ABL Bio&#146;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include Greater China and South Korea,
and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At contract inception, as both <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL participate actively in the
research and development activity. Also, they share the risk of failure of the <FONT STYLE="white-space:nowrap">bio-sequence</FONT> products and share the income of licensing, so this contract meet the criteria of the definition of a collaborative
arrangement, the Group categorized this agreement within the scope ASC 808. Prior to commercialization, the Group recorded the share of the expenses incurred by the collaboration for the development of three
<FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies products in research and development expense in the consolidated statements of comprehensive loss. For the year ended December&nbsp;31, 2018, RMB1.0&nbsp;million expenses were
incurred by the Group and ABL did not incurred any expenses. According to the terms set out in the agreement, the Group recorded RMB0.5&nbsp;million (50% cost sharing) of expenses in the Group&#146;s consolidated statements of comprehensive loss for
the year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Collaboration Agreements with Tracon Pharmaceuticals, Inc. (&#147;Tracon&#148;) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2018, the Group entered into collaboration agreements with Tracon, under which both parties agreed to <FONT STYLE="white-space:nowrap">co-develop</FONT> the
Group&#146;s proprietary CD73 antibody, TJD5 (the &#147;TJD5 Agreement&#148;) and <FONT STYLE="white-space:nowrap">co-develop</FONT> up to five BsAbs (the &#147;BsAbs Agreement&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given the early preclinical stage of development of these assets as of December&nbsp;31, 2018, there was no significant financial impact to the Group for the year ended
December&nbsp;31, 2018. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with CSPC Pharmaceutical Group Limited (&#147;CSPC&#148;) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2018, the Group entered into a product development agreement with CSPC. The Group granted to CSPC exclusive,
<FONT STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-irrevocable</FONT> and sublicensable rights in the PRC (excluding Hong Kong, Macau and Taiwan) to develop and commercialize TJ103 for treating type 2
diabetes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CSPC is responsible for developing, obtaining market approval and commercializing the licensed products. The Group is responsible for transferring the
manufacturing technology of the licensed products to CSPC and assisting CSPC in the continued optimization of such manufacturing technology thereafter. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
consideration of the license, CSPC agreed to pay the Group an upfront fee of RMB15.0&nbsp;million (inclusive of VAT) and milestone payments in an aggregate amount of RMB135.0&nbsp;million conditioned upon achieving certain clinical development and
regulatory approval milestones. In addition, the Group is also entitled to royalties of up to <FONT STYLE="white-space:nowrap">low-double-digit</FONT> percentages in respect of the total annual net sales of the products after its commercialization
in the PRC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this
agreement, the only one performance obligation was to grant TJ103 license to CSPC. Considering that the achievements of milestones are constrained such that the transaction price shall initially only include upfront payment and subsequently, once
another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a
significant reversal of cumulative revenue would occur in future periods. As of December&nbsp;31, 2018, RMB14.2&nbsp;million upfront fee received and was recorded as advance from customers in the consolidated balance sheets. The license was approved
by china intellectual property office subsequently in June 2019, and accordingly, RMB14.2&nbsp;million (inclusive of VAT) was recognized as revenue in the consolidated statements of comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>19. OTHER INCOME (EXPENSES), NET </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes other income (expenses) recognized for the years ended December&nbsp;31, 2017 and 2018: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(18,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(2,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from conversion of Onshore Convertible Loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(8,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1,196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from issuance of 2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(5,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(711</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">5,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">13,622</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">1,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net foreign exchange gains (losses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(3,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>20. NET LOSS PER SHARE </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted net loss per share for each of the
years presented are calculated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except for loss per shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average number of ordinary shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2017 and 2018, the effects of all outstanding convertible preferred shares, convertible promissory notes and restricted shares
have been excluded from the computation of diluted loss per share for the years ended December&nbsp;31, 2017 and 2018 as their effects would be anti-dilutive. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For
the year ended December&nbsp;31, 2018, the Company also has certain dilutive potential stock options. These stock options which can not be exercised until the Company completes its listing are not included in the computation of diluted earnings per
shares as such contingent event had not taken place. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The potentially dilutive securities that have not been included in the calculation of diluted net loss per
share as their inclusion would be anti-dilutive are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,811,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,389,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">673,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,623,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,134,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>21. EMPLOYEE BENEFITS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Full time employees of the Group in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care,
employee housing fund and other welfare benefits are provided to the employees. Chinese labor regulations require that the PRC subsidiaries of the Group make contributions to the government for these benefits based on certain percentage of the
employees&#146; salaries, up to a maximum amount specified by the government. The Group has no legal obligation for the benefits beyond the contribution made. The total amounts charged to the consolidated statements of comprehensive loss for such
employee benefits amounted to approximately RMB5,120 and RMB9,294 for the years ended December&nbsp;31, 2017 and 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>22. COMMITMENTS AND CONTINGENCIES
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating lease commitments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group leases offices under <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> operating lease agreements. Future minimum lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease agreements with initial terms of one year or more consist of the
following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The total amounts charged to the consolidated statements of comprehensive loss for rental expense amounted to approximately RMB3,127 and RMB4,659 for the years ended
December&nbsp;31, 2017 and 2018, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Capital commitments </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Contingencies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group is a party to or assignee of license and
collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (Note 18). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Group did not have significant capital and other commitments, long-term obligations, or guarantees as of December&nbsp;31, 2017 and 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>23. RELATED PARTY BALANCES AND TRANSACTIONS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table below sets forth the major related parties and their relationships with the Group as of December&nbsp;31, 2017 and 2018: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>NAME OF RELATED PARTIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>RELATIONSHIP WITH THE GROUP</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Everest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Controlled by the ultimate controlling party of a principal shareholder of the Group</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">CMAB Biopharma (Suzhou) Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Controlled by the ultimate controlling party of a principal shareholder of the Group</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Details of related party balance as of December&nbsp;31, 2017 and 2018 are as follows: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and development funding received </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Everest (Note 18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Details of related party transaction for the years ended December&nbsp;31, 2017 and 2018 are as follows: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Receipt of CRO services&#151;recognized in research and development expenses </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(NOTE&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">CMAB Biopharma (Suzhou) Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>24. CONCENTRATION OF CREDIT RISK </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments that are potentially
subject to significant concentration of credit risk consist of cash and cash equivalents, restricted cash, other financial assets, contract assets and other receivables. The carrying amounts of cash and cash equivalents, restricted cash and other
financial assets represent the maximum amount of loss due to credit risk. As of December&nbsp;31, 2017 and 2018, all of the Group&#146;s cash and cash equivalents and restricted cash were held by major financial institutions located in the PRC and
international financial institutions outside of the PRC which management believes are of high credit quality and continually monitors the credit worthiness of these financial institutions. With respect to the contract assets, other receivables and
other financial assets, the Group performs <FONT STYLE="white-space:nowrap">on-going</FONT> credit evaluations of the financial condition of its customers and counterparties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>25. SUBSEQUENT EVENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group evaluated subsequent events through July
29, 2019. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">On February 22, 2019, the Group adopted the 2018 equity incentive plan (&#147;2018 Plan&#148;). Under 2018 Plan, the
maximum aggregate number of ordinary shares which may be issued pursuant to all awards is 14,005,745, subject to further amendment. If the Group successfully lists on an internationally recognized securities exchange for a Qualified Public Offering
by December 31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. Accordingly, 10,893,028 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
stock options granted to a director of the Group under 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. </TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">On February 22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of the Company, pursuant to which
3,435,215 stock options held by a director of the Group under the 2017 equity incentive plan became fully vested and exercisable on February 22, 2019. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">In addition, the Group repurchased 3,890,155 stock options held by a director of the Group, including 3,435,215 stock options under the amendment and
restated 2017 equity incentive plan and 454,940 stock options under the 2018 equity incentive plan, at the total consideration of US$21,902 (equivalent to approximately RMB148,308). </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">In July 2019, the Group granted 640,000 stock options and 3,098,500 stock options to the employees under 2017 Plan and 2018 Plan, respectively. </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">On July 25, 2019, the Group entered into a share purchase agreement with certain third party investors, under which
these investors will subscribe for an aggregate of 3,857,143 Series C-1 convertible preferred shares of the Company for an aggregate purchase price of US$27.0 million. Up to the issuance of these consolidated financial statements, this transaction
has not been consummated. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">According to the confirmations issued by the Company&#146;s Series B Warrants holders in July 2019, the holders of
Series B Warrants has unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">In July 2019, the Group entered into an in-licensing and collaboration agreement with MacroGenics, Inc. for development
and commercialization of an Fc-optimized antibody known as enoblituzumab that targets B7-H3, including in combination with other agents, such as the anti-PD-1 antibody known as MGA012, in Greater China. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series C-1 Financing (Unaudited) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Out of the aforementioned
subscription of 3,857,143 Series C-1 convertible preferred shares by certain third party investors (see Note 25(b) above), 1,428,571 Series C-1 convertible preferred shares was issued to an investor on October 17, 2019, and the Company also received
the cash consideration of US$10,000 (equivalent to approximately RMB70,729). On November 6, 2019, the Group received cash consideration of US$17,000 (equivalent to approximately RMB119,387) for the remaining 2,428,572 Series C-1 convertible
preferred shares from the investors and the issuance of such 2,428,572 Series C-1 convertible preferred shares was consummated on that day. In connection with the offering of the Series C-1 convertible preferred shares, the Company incurred issuance
costs of approximately US$840. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2019 Share Incentive Plan (Unaudited) </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October 29, 2019, the Group adopted 2019 Share Incentive Plan (the &#147;2019 Plan&#148;), which will become effective immediately prior to the completion of the
Company&#146;s offering. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance shall initially be 100,000. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes to
share capital (Unaudited) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October 29, 2019, the Company&#146;s shareholders and board of directors approved that immediately prior to the completion of
the Company&#146;s offering, the Company&#146;s authorized share capital will be changed into US$80 divided into 800,000,000 ordinary shares of a par value of US$0.0001 each. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Termination of collaboration agreement with Everest (Unaudited) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
November 4, 2019, the Group and Everest have terminated the collaboration agreement (including all the supplements and amendments thereto) with respect to the co-development and commercialization of TJ202 in Greater China. Upon the termination,
Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its commercialization. All intellectual property rights in respect of TJ202 arising from its development under the collaboration
agreement are vested and owned by I-Mab, and the Group holds all intellectual property rights and have maximum flexibility to further develop, manufacture and commercialize TJ202 in Greater China. In consideration of the above arrangements, the
board of directors of the Group has approved the issuance of a total value of US$37.0 million of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing Everest&#146;s historical contribution to the collaboration and the associated
time cost. The CPP Shares will be issued concurrently with, and subject to, the completion of the Company&#146;s initial public offering within 180 days from termination of the collaboration agreement. The total value of US$37.0 million was
calculated based on the sum of (1) US$33.7 million, which equals cumulative paid-in contributions historically made by Everest under the collaboration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
agreement; and (2) a negotiated US$3.3 million time cost of the foregoing historical contribution in light of I-Mab&#146;s exclusive rights over the commercialization of TJ202 after this
termination. The issuance of the CPP Shares was approved by I-Mab&#146;s existing shareholders on December&nbsp;25, 2019. In the event that the initial public offering has not been completed within 180 days from the termination of the collaboration
agreement, the Company will issue 4,762,751 ordinary shares (the &#147;Subject Shares&#148;) to Everest on the 181st day. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Establishment of Biomaster Trust
(Unaudited)</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biomaster Trust was established under the trust deed dated October 23, 2019, between the Company and TMF Trust (HK) Limited, or TMF Trust, as
the trustee of the Biomaster Trust. Through the Biomaster Trust, the Company&#146;s ordinary shares and other rights and interests under awards granted pursuant to 2017 Plan and 2018 Plan may be provided to certain of recipient of equity awards.
Upon satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the advisory
committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by I-Mab.</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Modification of convertible preferred shares (Unaudited) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December
25, 2019, the Company&#146;s Preferred Shares were modified as a result of the Company&#146;s negotiation with holders of Preferred Shares. Prior to the modification, each Preferred Share may be converted at any time into ordinary shares at the
option of the preferred shares holders at the then applicable conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of (i) share splits, share combinations, share dividends or distribution, other dividends,
recapitalizations and similar events, or (ii) issuance of ordinary shares (excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect on the date of or
immediately prior to such issuance. On December&nbsp;25, 2019, the Company&#146;s shareholders and board of directors approved that, where the final offering price of a Qualified Public Offering is no less than US$4.176 per ordinary share, the
agreed provisions related to the number of shares to be converted into the Company&#146;s ordinary shares shall apply with respect to the Series <FONT STYLE="white-space:nowrap">C-1&nbsp;Preferred</FONT> Shares, Series C Preferred Shares, Series B-2
Preferred Shares and Series B-1 Preferred Shares, which will generally give rise to a one to multiple conversion of the such rounds of Preferred Shares, provided that unanimous consent of the directors on the final offering price needs to be
obtained in the event that the final offering price per ordinary share of such IPO is fixed at a price equal to or higher than US$4.176 per ordinary share but lower than US$5.22 per ordinary share. Up to January&nbsp;3, 2020, the Group is still in
the process of assessing the accounting impacts of such amendments. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Modification of 2017 Plan and 2018 Plan (Unaudited) </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December 25, 2019, the Second Amended and Restated 2017 Plan and the Second Amended and Restated 2018 Plan were approved by the shareholders and board of directors
of the Company, pursuant to which, in connection with the Company&#146;s IPO, the maximum aggregate number of shares that may be granted pursuant to all awards under 2017 Plan and 2018 Plan shall be adjusted in accordance with a formula <FONT
STYLE="white-space:nowrap">pre-approved</FONT> by the shareholders as below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For 2017 Plan, </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Max=9,941,650-B, and rounded down to the nearest whole number</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Q=1,446,875</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>M=1,371,973</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Z=2,000,000</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>If C&lt;=3,446,875, B =
0</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>If C&gt;3,446,875 but &lt;= 4,818,848, B = (C-Q-Z) &times; 37.90%</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>If C&gt;4,818,848, B =M &times; 37.90%</I> </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><I>Max:</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>The maximum number of ordinary shares in respect of which options may be granted under the Second Amended and Restated 2017 Plan</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><I>C:</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Total number of ordinary shares issued to all the holders of the convertible preferred shares of the Company immediately prior to the closing of the IPO less the total number of ordinary shares that would have been issued to all
the holders of the convertible preferred shares of the Company immediately prior to the closing of the IPO had the conversion ratio been 1:1 for each series of the convertible preferred shares</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For 2018 Plan, </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Max=14,997,680-Q-A, and rounded down to the nearest whole number</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Q=1,446,875</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>M=1,371,973</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Z=2,000,000</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>If C&lt;=3,446,875, then
A=C-Q</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>If C&gt;3,446,875 but &lt;= 4,818,848, then A=Z + (C-Q-Z) &times; 62.10%</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>If C&gt;4,818,848, then A=Z + M &times; 62.10%</I> </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><I>Max:</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>The maximum number of ordinary shares in respect of which options may be granted under the Second Amended and Restated 2018 Plan</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><I>C:</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Total number of ordinary shares issued to all the holders of the convertible preferred shares of the Company immediately prior to the closing of the IPO less the total number of ordinary shares that would have been issued to all
the holders of the convertible preferred shares of the Company immediately prior to the closing of the IPO had the conversion ratio been 1:1 for each series of the convertible preferred shares</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with above amendments to 2017 Plan, each of the Company&#146;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang
and Lei Fang, is willing to irrevocably surrender by him or her, for no consideration, of a portion of the unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to 130,000, 130,000, 130,000, and 130,000
ordinary shares of the Company, par value US$0.0001 per share, at an exercise price of US$1.0, respectively, under the Second Amended and Restated 2017 Plan (in respect of each individual, the &#147;Founder&#146;s Surrendered Options&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with above amendments to 2018 Plan, the director of the Company, Dr. Jingwu Zhang Zang is willing to irrevocably surrender by him, for no consideration,
of the right to acquire a certain amount of ordinary shares of the Company, par value US$0.0001 per share, at an exercise price of US$1.0 pursuant to the options granted to him under the Second Amended and Restated 2018 Plan (the &#147;Dr.
Zang&#146;s Surrendered Options&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December 25, 2019, the board of directors of the Company approved that the Company accepts the irrevocable surrender of
Dr. Zang&#146;s Surrendered Options and all Founder&#146;s Surrendered Options from each of the founders, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with effect immediately prior to the completion of the IPO and such
surrendered options be cancelled with effect immediately prior to the completion of the IPO. The Dr. Zang&#146;s Surrendered Options and the Founder&#146;s Surrendered Options shall be calculated in accordance with the specific formula set based on
the number of the additionally issued ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>26. UNAUDITED PRO FORMA NET LOSS PER SHARE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma net loss per ordinary share is computed using the weighted-average number of ordinary shares outstanding and assumes forfeiture of Tranche II of
Series B Warrants and the automatic conversion of all of the Group&#146;s outstanding mezzanine equity into ordinary shares upon the closing of the Group&#146;s Qualified Public Offering, as if it had occurred on January&nbsp;1, 2018. The Group
believes the unaudited pro forma net loss per share provides material information to investors, as the automatic conversion of the Group&#146;s outstanding mezzanine equity and forfeiture of Tranche II of Series B Warrants. The disclosure of pro
forma net loss per ordinary share provides an indication of net loss per ordinary share that is comparable to what will be reported by the Group as a public company following the closing of the Qualified Public Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The following table summarizes the unaudited pro forma net loss per share attributable to ordinary shareholders: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;for&nbsp;loss&nbsp;per&nbsp;shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Add back fair value change of Tranche II of Series B Warrants (Note&nbsp;15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Numerator for <FONT STYLE="white-space:nowrap">pro-forma</FONT> basic and diluted net loss per
share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(436,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series A Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,103,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,103,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series B Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,146,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,146,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series C Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,140,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,140,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Denominator for <FONT STYLE="white-space:nowrap">pro-forma</FONT> basic and diluted net loss per
share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,919,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,919,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma loss per share excluded the impacts of the Group&#146;s share-based awards that subject to IPO conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>27. RESTRICTED NET ASSETS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group&#146;s ability to pay dividends may
depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#146;s PRC subsidiary only out of its retained earnings, if any, as determined in
accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the
Group&#146;s PRC subsidiary. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the Company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its
annual <FONT STYLE="white-space:nowrap">after-tax</FONT> profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#146;s PRC statutory accounts. A domestic enterprise is also required to provide
discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#146;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not
distributable as cash dividends. The Group&#146;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the above mentioned restrictions on distributable profits. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2017 and 2018, no appropriation to statutory reserves was made because the PRC subsidiary had substantial losses during such
periods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of <FONT
STYLE="white-space:nowrap">after-tax</FONT> income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#146;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Foreign exchange and other regulations in the PRC further restrict the Company&#146;s PRC subsidiaries from transferring funds to the Company in the form of dividends,
loans and advances. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Since the Group has a consolidated shareholders&#146; deficit, its net asset base for purposes of calculating the proportionate share of
restricted net assets of consolidated subsidiaries should be zero. Therefore, the restrictions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
placed on the net assets of the Company&#146;s PRC subsidiaries with positive equity would result in the 25&nbsp;percent threshold being exceeded and a corresponding requirement to provide parent
company financial information (Note&nbsp;28). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>28. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with Securities and Exchange Commission Regulation <FONT
STYLE="white-space:nowrap">S-X</FONT> Rule <FONT STYLE="white-space:nowrap">4-08</FONT> (e)(3), &#147;General Notes to Financial Statements&#148; and concluded that it was applicable for the Company to disclose the financial statements for the
parent company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The subsidiaries did not pay any dividends to the Company for the years presented. For the purpose of presenting parent company only financial
information, the Company records its investments in its subsidiaries under the equity method of accounting. Such investments are presented on the separate condensed balance sheets of the Company as &#147;Investments (deficit) in subsidiaries&#148;
and the loss of the subsidiaries is presented as &#147;share of losses of subsidiaries&#148;. Certain information and footnote disclosures generally included in financial statements prepared in accordance with U.S. GAAP have been condensed and
omitted. The footnote disclosures contain supplemental information relating to the operations of the Company, as such, these statements should be read in conjunction with the notes to the consolidated financial statements of the Company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company did not have significant capital and other commitments, long-term obligations, other long-term debt, or guarantees as of December&nbsp;31, 2017 and 2018.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Balance sheets </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investments in subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Receivables due from subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,455,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>554,128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,058,282</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>287,964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deficit in subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143,642</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>98,028</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,714</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A convertible preferred shares (US$0.0001 par value, 21,865,233 and 30,227,056 shares authorized,
issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B convertible preferred shares (US$0.0001 par value, 15,894,594 and 30,305,212 shares authorized,
issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued and
outstanding as of December&nbsp;31, 2018)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>710,281</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>407,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2017 and 2018,
8,363,719 shares authorized, issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141,932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(133,623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities, mezzanine equity and shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>554,128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,058,282</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>287,964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Statements of comprehensive loss </I></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Share of losses of subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Other comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(292,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(349,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,848</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Statements of cash flows </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash (used in) generated from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(356,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,032,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,498,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Effect of exchange rate changes on cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net (decrease) increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents at beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash and cash equivalents at end of the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_10"></A>REPORT OF INDEPENDENT AUDITORS </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the Board of Directors and Shareholders of I-Mab Bio-tech (Tianjin) Co., Ltd. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying consolidated financial statements of I-Mab Bio-tech (Tianjin) Co., Ltd. and its subsidiaries, which comprise the consolidated balance
sheet as of July 15, 2017 and the related consolidated statement of comprehensive loss, of changes in shareholders&#146; equity and of cash flows for the period from January 1, 2017 to July 15, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Management&#146;s Responsibility for the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted
in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether
due to fraud or error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Auditors&#146; Responsibility </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An audit
involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the
consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the Company&#146;s preparation and fair presentation of the consolidated financial statements in order to
design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control. Accordingly, we express no such opinion. An audit also includes
evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the
audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the I-Mab Bio-tech (Tianjin)
Co., Ltd. and its subsidiaries as of July 15, 2017 and the results of their operations and their cash flows for the period from January 1, 2017 to July 15, 2017 in accordance with accounting principles generally accepted in the United States of
America. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ PricewaterhouseCoopers Zhong Tian LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shanghai, the
People&#146;s Republic of China </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">July 29, 2019 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> <FONT STYLE="white-space:nowrap">BIO-TECH</FONT>
(TIANJIN) CO., LTD. <FONT STYLE="white-space:nowrap">(&#147;I-MAB</FONT> TIANJIN&#148;) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_11"></A>CONSOLIDATED BALANCE SHEET
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>As of July&nbsp;15, 2017 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts
in thousands, except for share and per share data, unless otherwise noted) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NOTE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF JULY&nbsp;15, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>123,899</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>123,942</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,340</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,824</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>122,118</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,085</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>123,942</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,340</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> TIANJIN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_12"></A>CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>For the Period from January&nbsp;1, 2017 to July&nbsp;15, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD&nbsp;FROM</B><br><B>JANUARY&nbsp;1&nbsp;TO&nbsp;JULY&nbsp;15,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,882</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> TIANJIN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_13"></A>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>For the Period from January&nbsp;1, 2017 to July&nbsp;15, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">PAID-IN</FONT><BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL<BR><FONT STYLE="white-space:nowrap">PAID-IN</FONT><BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>SHAREHOLDERS&#146;<BR>EQUITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balances as of January&nbsp;1, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balances as of July&nbsp;15, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> TIANJIN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_14"></A>CONSOLIDATED STATEMENT OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>For the Period from January&nbsp;1, 2017 to July&nbsp;15, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE PERIOD FROM</B><br><B>JANUARY&nbsp;1&nbsp;TO&nbsp;JULY&nbsp;15,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Adjustments to reconcile net loss to net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation of equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income from short-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,758</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash paid for investments in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash received from disposal of short-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash received on income from short-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash generated from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net decrease in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents at beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents at end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>I-MAB TIANJIN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_15"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. PRINCIPAL ACTIVITIES AND ORGANIZATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. (previously known as Tasgen <FONT
STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd.) (the &#147;Company&#148;) and its subsidiaries, Chengdu Tasgen <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. and Shanghai Tianyunjian
<FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd., (together the &#147;Group&#148;) are principally engaged in the research and development of innovative medicines in the People&#146;s Republic of China (the &#147;PRC&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of July&nbsp;15, 2017, the Company&#146;s subsidiaries are as follows </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>SUBSIDIARIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PLACE OF<BR>INCORPORATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DATE OF<BR>INCORPORATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE<BR>OF DIRECT<BR>OR&nbsp;INDIRECT<BR>OWNERSHIP<BR>BY&nbsp;THE<BR>COMPANY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRINCIPAL&nbsp;ACTIVITIES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chengdu Tasgen <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">PRC</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">May&nbsp;30,&nbsp;2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR><BR></TD>
<TD VALIGN="top" ALIGN="right">Research&nbsp;and<BR>development&nbsp;of<BR>innovative&nbsp;medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Shanghai Tianyunjian <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">PRC</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">June&nbsp;28,&nbsp;2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR><BR></TD>
<TD VALIGN="top" ALIGN="right">Research and<BR>development of<BR>innovative medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. PRINCIPAL ACCOUNTING POLICIES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.1 Basis of presentation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of
America (&#147;U.S. GAAP&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Significant accounting policies followed by the Group in the preparation of its accompanying consolidated financial statements are
summarized below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.2 Basis of consolidation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying
consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.3 Use of estimates </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preparation of the consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used in determining items such as useful lives of equipment and software, impairment of other receivables, impairment of long-lived
assets, taxes on income, tax valuation allowances. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about
the carrying values of assets and liabilities. Actual results could differ from those estimates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.4 Fair value measurements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, other financial assets, other receivables, accruals and other payables.
As of July 15, 2017, except for other financial assets the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports other financial assets at fair value
at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group measures its financial assets and liabilities using inputs from the following three levels of the fair
value hierarchy. The three levels are as follows: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has
the ability to access at the measurement date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or
similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by
correlation or other means (market corroborated inputs). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3 includes unobservable inputs that reflect the management&#146;s assumptions about the
assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Assets measured at fair value on a recurring basis </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group measured its
other financial assets at fair value on a recurring basis. As the Group&#146;s other financial assets are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value. These
instruments are categorized in the Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
following table summarizes the Group&#146;s financial assets measured and recorded at fair value on recurring basis as of July&nbsp;15, 2017: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF JULY&nbsp;15, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTIVE&nbsp;MARKET<BR>(LEVEL&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OBSERVABLE&nbsp;INPUT<BR>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">NON-OBSERVABLE&nbsp;INPUT</FONT><BR>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.5 Foreign currency translation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Translations of balances in the
consolidated balance sheet, consolidated statement of comprehensive loss, consolidated statement of changes in shareholders&#146; equity and consolidated statement of cash flows from RMB into US$ as of and for the period ended July&nbsp;15, 2017 are
solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB7.1477, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New
York on September 30, 2019. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on September 30, 2019, or at any other rate. The US$ convenience translation is not
required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.6 Cash and cash
equivalents </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers all
highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.7 Equipment and software
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equipment and software are stated at cost less accumulated depreciation, amortization and impairment (if any). Depreciation and amortization is computed
using the straight-line method over the following estimated useful lives, taking into account any estimated residual value: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">Laboratory equipment</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3&nbsp;to&nbsp;5&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">Software</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2 to 5 years</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group recognized the gain or loss on the disposal of equipment and software in the consolidated statement of
comprehensive loss. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.8 Research and development expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Elements of research and development expenses primarily include (1)&nbsp;payroll and other related expenses of personnel engaged in research and development activities,
<FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to the Group, (3)&nbsp;expenses related to preclinical testing of the Group&#146;s technologies and clinical trials such
as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct the clinical studies (4)&nbsp;expenses to develop the product candidates, including raw materials and supplies, product testing,
depreciation, and facility related expenses, (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Group&#146;s research and development services
and have no alternative future uses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition
of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development in the period in which
they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent
obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be capitalized as intangible assets and amortized over the estimated remaining useful life of the
related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.9 Income taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group accounts for income taxes under the
liability method. Under the liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the tax income
rates that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some portion or all of a deferred income tax asset will not be realized. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group evaluates its uncertain tax positions using the provisions of ASC 740, <I>Income Taxes</I>, which prescribes a recognition threshold that a tax position is
required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the benefit of a tax position which is &#145;&#145;more likely than not&#146;&#146; to be sustained under examination based solely
on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax
benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#146;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. EQUIPMENT AND SOFTWARE </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equipment and software, net, consist of the
following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;JULY&nbsp;15,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The total amounts charged to the consolidated statement of comprehensive loss for depreciation and amortization
expenses amounted to approximately RMB22 for the period from January&nbsp;1, 2017 to July&nbsp;15, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating lease commitments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group leases offices under <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> operating lease agreements. Future minimum lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease agreements with initial terms of one year or more consist of the
following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD&nbsp;FROM&nbsp;JANUARY&nbsp;1</B><br><B>TO&nbsp;JULY&nbsp;15,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Within 1 year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Contingencies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group is a party to or assignee of license and
collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. RELATED
PARTY TRANSACTIONS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table below sets forth the major related party and its relationships with the Group as of December&nbsp;31, 2017 and 2018: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>NAME OF RELATED PARTY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>NATURE OF RELATIONSHIP</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Tasly Pharmaceutical Group Co., Ltd.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Controlled by the ultimate controlling party of a principal shareholder of the Group</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the period from January&nbsp;1 to July&nbsp;15, 2017, transaction with related party was as follows: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Receipt of CRO services&#151;recognized in research and development expenses </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD&nbsp;FROM&nbsp;JANUARY&nbsp;1</B><br><B>TO JULY&nbsp;15, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note 2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tasly Pharmaceutical Group Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_16"></A>Unaudited Interim Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>As of December&nbsp;31, 2018 and September&nbsp;30, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="16" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Pro&nbsp;forma)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Pro&nbsp;forma)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Note 26)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,224,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,224,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">92,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">56,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">7,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">56,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">7,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">2.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">11,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">11,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B></B><B></B>18<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>11,000</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B></B><B></B>2.7<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">88,972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">74,895</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">10,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">74,895</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">10,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">2.4,&nbsp;4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">255,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">63,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">8,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">63,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">8,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,483,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,483,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">13,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">13,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,839,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>257,375</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,839,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>257,375</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Short-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">67,674</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">105,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">14,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">105,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">14,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">2.4,&nbsp;15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">5,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Consideration received in advance from a preferred shares investor</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B></B><B></B>13 <B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>346,158</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>470,293</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>65,796</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>470,293</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>65,796</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">67,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">70,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">9,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">70,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">9,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Operating lease liabilities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">5,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">710</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">5,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">710</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">2.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">2,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">3,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">3,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>415,684</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>549,622</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>76,894</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>549,622</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>76,894</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Commitments and contingencies</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"> 22<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="16" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Pro&nbsp;forma)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Pro&nbsp;forma)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Note 26)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series A convertible preferred shares (US$0.0001 par value, 30,227,056 shares authorized, issued and
outstanding as of December&nbsp;31, 2018 and September 30, 2019, and nil outstanding on a pro forma basis as of September 30, 2019)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">687,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">687,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">96,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series B convertible preferred shares (US$0.0001 par value, 30,305,212 shares authorized, issued and
outstanding as of December&nbsp;31, 2018 and September&nbsp;30, 2019, and nil outstanding on a pro forma basis as of September 30, 2019)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued and
outstanding as of December&nbsp;31, 2018 and September 30, 2019, and nil outstanding on a pro forma basis as of September 30, 2019)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>407,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2018 and
September 30, 2019, 800,000,000 shares authorized on a pro forma basis as of September&nbsp;30, 2019; 8,363,719 shares issued and outstanding as of December&nbsp;31, 2018 and September&nbsp;30, 2019; 103,586,034 shares issued and outstanding on a
pro forma basis as of September&nbsp;30, 2019)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">366,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">51,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">3,282,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">459,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,117,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(296,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,117,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(296,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,625,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(227,393</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,290,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>180,481</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,839,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>257,375</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,839,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>257,375</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_17"></A>Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>For the Nine Months Ended September&nbsp;30, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note 2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(314,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(578,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,918</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(312,095</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1,131,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(158,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(277,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1,103,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(154,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1,635</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(279,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1,103,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(154,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total comprehensive loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(219,267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,037,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(279,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1,103,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(154,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average number of ordinary shares used in calculating net loss per share - basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">6,397,663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">7,184,086</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">7,184,086</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_18"></A>Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>For the Nine Months Ended September&nbsp;30, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY&nbsp;SHARE&nbsp;(NOTE&nbsp;12)<BR>(US$0.001&nbsp;PAR&nbsp;VALUE)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TREASURY<BR>STOCK</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL<BR><FONT STYLE="white-space:nowrap">PAID-IN</FONT><BR>CAPITAL</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>OTHER<BR>COMPREHENSIVE<BR>INCOME</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>SHAREHOLDERS&#146;<BR>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(299,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Transaction with redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests
(Note&nbsp;16)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250,369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(305,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of September&nbsp;30, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(887,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(821,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(955,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of September&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,117,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,625,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_19"></A>Unaudited Interim Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>For the Nine Months Ended September&nbsp;30, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS ENDED SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Adjustments to reconcile net loss to net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense of convertible promissory notes and onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from conversion of onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from issuance of 2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Amortization of <FONT STYLE="white-space:nowrap">right-of</FONT> use assets and interest of lease
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(651,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,390</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,617</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from disposal of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from disposal of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash paid for investments in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash received from disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash received on income from short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash received on income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash generated from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="12" COLSPAN="12" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS ENDED SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Consideration received in advance from a preferred shares investor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payment of initial public offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Repayment of bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Effect of exchange rate changes on cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net increase (decrease) in cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents, and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents, and restricted cash, end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,281,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Additional ASC 842 supplemental disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating
activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Right-of-use assets obtained in exchange for operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Other supplemental cash flow disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payables for purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued initial public offering costs payable</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin713200_20"></A>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. PRINCIPAL ACTIVITIES AND ORGANIZATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) was incorporated in the Cayman Islands on June&nbsp;30, 2016 as an exempted company with limited
liability under the Companies Law of the Cayman Islands. The Company and its subsidiaries (together the &#147;Group&#148;) are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and
immuno-inflammation diseases in the People&#146;s Republic of China (the &#147;PRC&#148;) and other countries and regions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the incorporation of the
Company, the Group carried out its operation in the PRC since November 2014 mainly through Third Venture Biopharma (Nanjing) Co., Ltd. (&#147;Third Venture&#148;), which was incorporated on November&nbsp;17, 2014 in the PRC. For the purpose of
introduction of overseas investors and in preparation for a listing of the Company&#146;s shares on the overseas capital markets, the Group underwent a reorganization (the &#147;Reorganization&#148;) in 2016. The Reorganization was approved by the
Board of Directors and a restructuring framework agreement was entered into by Third Venture, the Company, and the shareholders of the Company based on Reorganization framework agreement, pursuant to which on July&nbsp;7, 2016, Third Venture
transferred all of its assets and operations to the Company&#146;s wholly owned subsidiary, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;), which was a
transaction in which shareholders had identical ownership interests before and after the transaction and was accounted for in a manner similar to a common control transaction. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Reorganization, as described above has been accounted for at historical cost. That Reorganization was reverse merger of Third Venture and Third Venture is the
predecessor of the Company. As such, the assets and liabilities of Third Venture are consolidated in the Company&#146;s financial statements at historical cost. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As
of<B> </B>September&nbsp;30, 2019, the Company&#146;s principal subsidiaries are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>SUBSIDIARIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PLACE OF<BR>INCORPORATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DATE OF<BR>INCORPORATION OR<BR>ACQUISITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE<BR>OF DIRECT<BR>OR INDIRECT<BR>OWNERSHIP<BR>BY THE<BR>COMPANY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRINCIPAL&nbsp;ACTIVITIES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Hong&nbsp;Kong</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;8, 2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Investment&nbsp;holding</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">PRC</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">August&nbsp;24, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR></TD>
<TD VALIGN="top" ALIGN="right">Research&nbsp;and&nbsp;development<BR>of innovative&nbsp;medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin)
Co.,&nbsp;Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">PRC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;15,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR></TD>
<TD VALIGN="top" ALIGN="right">Research and development<BR>of innovative medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">U.S.</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">February&nbsp;28,&nbsp;2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR></TD>
<TD VALIGN="top" ALIGN="right">Research and development<BR>of innovative medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. PRINCIPAL ACCOUNTING POLICIES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.1 Basis of presentation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying unaudited interim condensed consolidated financial statements of the Group have been prepared in accordance with the accounting principles
generally accepted in the United States of America (&#147;U.S. GAAP&#148;) for interim financial information. Accordingly, they do not include all of the information and footnotes normally included in the annual financial statements prepared in
accordance with U.S. GAAP. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted consistent with Article 10 of Regulation <FONT
STYLE="white-space:nowrap">S-X.</FONT> In the opinion of management, the Group&#146;s unaudited interim condensed consolidated financial statements and accompanying notes include all adjustments (consisting of normal recurring adjustments)
considered necessary for the fair statement of the Group&#146;s financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
position as of September&nbsp;30, 2019, and results of operations and cash flows for the nine months ended September&nbsp;30, 2018 and 2019. Interim results of operations are not necessarily
indicative of the results for the full year or for any future period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended
December&nbsp;31, 2018, and related notes included in the Group&#146;s audited consolidated financial statements. The financial information as of December&nbsp;31, 2018 presented in the unaudited interim condensed consolidated financial statements
is derived from the audited consolidated financial statements as of December&nbsp;31, 2018. Significant accounting policies followed by the Group in the preparation of the accompanying unaudited interim condensed consolidated financial statements
are summarized below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.2 Basis of consolidation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.3 Use of estimates </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preparation of the consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and
liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as useful lives of property, equipment and software, impairment of contract assets and other
receivables, impairment of long-lived assets and goodwill, share-based compensation, leases, tax valuation allowances and revenues from licensing and collaboration arrangements. Management bases the estimates on historical experience, known trends
and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.4 Fair value measurements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial assets and liabilities of the
Group primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other financial assets, contract assets, accounts receivable, other receivables, short-term borrowings, accruals and other payables and warrants
liabilities. As of December&nbsp;31, 2018 and September 30, 2019, except for short-term investments, other financial assets and warrant liabilities, the carrying values of these financial assets and liabilities approximated their fair values because
of their generally short maturities. The Group reports short-term investments, other financial assets and warrant liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of
comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three
levels are as follows: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the
measurement date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are
not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market
corroborated inputs). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3 includes unobservable inputs that reflect the management&#146;s assumptions about the assumptions that market participants would
use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Assets and liabilities measured
at fair value on a recurring basis </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group measured its short-term investments, other financial assets and warrant liabilities at fair value on a recurring
basis. As the Group&#146;s short-term investments, other financial assets and warrant liabilities are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
value of short-term investments, other financial assets and warrant liabilities. These instruments are categorized in the Level&nbsp;3 valuation hierarchy based on the significance of
unobservable factors in the overall fair value measurement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the Group&#146;s financial assets and liabilities measured and recorded
at fair value on a recurring basis as of December&nbsp;31, 2018 and September 30, 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTIVE&nbsp;MARKET<BR>(LEVEL&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OBSERVABLE&nbsp;INPUT<BR>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">NON-OBSERVABLE&nbsp;INPUT</FONT><BR>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER 30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTIVE&nbsp;MARKET<BR>(LEVEL&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OBSERVABLE&nbsp;INPUT<BR>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">NON-OBSERVABLE&nbsp;INPUT</FONT><BR>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The roll forward of major Level&nbsp;3 financial assets and financial liability are as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHORT-TERM<BR>INVESTMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OTHER&nbsp;FINANCIAL<BR>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WARRANT<BR>LIABILITIES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of Level&nbsp;3 financial asset and liability as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Disposal of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Disposal of other financial assets due to Termination Agreement (Note&nbsp;4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(177,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Reclassified as other receivables due to Termination Agreement (Note&nbsp;4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of Level&nbsp;3 financial assets and liability as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><B>63,412</B><BR></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Refer to Note 15 for additional information about Level&nbsp;3 warrant liabilities measured at fair value on a recurring basis for the nine months ended September 30,
2018 and 2019. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.5 Foreign currency translation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group uses
Chinese Renminbi (&#147;RMB&#148;) as its reporting currency. The United States Dollar (&#147;US$&#148;) is the functional currency of the Group&#146;s entities incorporated in the Cayman Islands, the United States of America (&#147;U.S.&#148;) and
Hong Kong, the Australia Dollar (&#147;AUD&#148;) is the functional currency of the Group&#146;s entity incorporated in Australia and the RMB is the functional currency of the Company&#146;s PRC subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Transactions denominated in other than the functional currencies are translated into the functional currency of the
entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting exchange differences are recorded in
the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited interim condensed consolidated financial statements of the Group are translated from the
functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are translated at the average exchange rates
prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive income. The exchange rates used for translation on December&nbsp;31, 2018 and September 30, 2019 were US$1.00 =
RMB6.8632 and RMB7.0729, respectively, representing the index rates stipulated by the People&#146;s Bank of China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Translations of balances in the consolidated
balance sheets, consolidated statements of comprehensive loss, consolidated statements of changes in shareholders&#146; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the nine months ended September 30,
2019 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB7.1477, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve
Bank of New York on September 30, 2019. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on September 30, 2019, or at any other rate. The US$ convenience translation is
not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.6 Accounts
Receivable </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Trade accounts receivable are recorded at their invoiced amounts, net of allowances for doubtful accounts. An allowance for doubtful accounts is
recorded when the collection of the full amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including aging of the receivable, the customer&#146;s payment history, its current
creditworthiness and current economic trends. Accounts receivable are written off after all collection efforts have ceased. The Group regularly reviews the adequacy and appropriateness of any allowance for doubtful accounts. No allowance for
doubtful accounts was recorded as of September 30, 2019. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.7 Short-term investments </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Short-term investments represent the investments issued by commercial banks or other financial institutions with a variable interest rate indexed to the performance of
underlying assets within one year. These investments are stated at fair value. Changes in the fair value are reflected in the consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.8 Goodwill </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Goodwill is an asset representing the future economic
benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their
estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment
of goodwill assessment is performed on at least an annual basis on December&nbsp;31 or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group has elected to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Group&#146;s reporting unit is less
than its carrying amount, including goodwill. The qualitative assessment includes the Group&#146;s evaluation of relevant events and circumstances affecting the Group&#146;s single reporting unit, including macroeconomic, industry, market conditions
and the Group&#146;s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group&#146;s reporting unit&#146;s fair value is less than its carrying amount, then the Group will perform the quantitative
impairment test by comparing the reporting unit&#146;s carrying amount, including goodwill, to its fair value. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that
excess. For the nine months ended September 30, 2018 and 2019, the Group determined that there were no indicators of impairment of the goodwill. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.9 Deferred subsidy income </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred subsidy income consists of deferred income from government grants. Government grants consist of cash subsidies received by the Group&#146;s subsidiaries in the
PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized when all the obligations have been fulfilled. If such obligations are not satisfied, the
Group may be required to refund the subsidy. Cash grants of RMB3,920 was recorded in deferred subsidy income as of September&nbsp;30, 2019, which will be recognized when the government specified performance obligation is satisfied, which is expected
to be more than 12 months after September&nbsp;30, 2019. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.10 Revenue recognition </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group adopted Accounting Standard Codification (&#147;ASC&#148;) 606, <I>Revenue from Contracts with Customers</I> (Topic&nbsp;606) (&#147;ASC 606&#148;) for all
periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in
exchange for those goods or services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount
that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the
following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the
transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity
will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once a contract is determined to be
within the scope of ASC 606 at contract inception, the Group reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the
transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Collaboration revenue
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At contract inception, the Group analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,<I>&nbsp;Collaborative
Arrangements</I>&nbsp;(&#147;ASC 808&#148;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on
the commercial success of such activities.&nbsp;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines if the collaboration is deemed to be within the scope of ASC 808 and those that are
more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For the collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group&#146;s collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property
rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Group must develop
assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&nbsp;In developing the stand-alone selling price for a performance obligation, the Group considers competitor
pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective
obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When the timing of the delivery
of product is different from the timing of payments made by the customers, the Group recognizes either a contract asset (performance precedes the contractual due date) or a contract liability (customer payment precedes performance). The Group&#146;s
contractual payment terms are typically due in no more than 30 days from invoicing. In limited situations, certain customer contractual payment terms require the Group to bill in arrears; thus, the Group satisfies some or all of the performance
obligations before the Group is contractually </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
entitled to bill the customer. In these situations, billing occurs subsequent to revenue recognition, which results in a contract asset. For example, certain of the contractual arrangements do
not permit the Group to bill until the completion of the production of the samples. In other limited situations, certain customer contractual payment terms allow the Group to bill in advance; thus, the Group receives customer cash payment before
satisfying some or all of its performance obligations. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licenses of Intellectual Property</I>: Upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing the Group&#146;s intellectual property
are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from
<FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit
from the license.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Services</I>: The portion of the transaction price allocated to research and development services performance
obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Milestone Payments</I>: At the
inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of
cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone
selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the
probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative
<FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Royalties</I>: For arrangements
that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&nbsp;when the related
sales occur, or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.11 Research and development expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Elements of research and
development expenses primarily include (1)&nbsp;payroll and other related expenses of personnel engaged in research and development activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development
rights of drugs granted to the Group, (3)&nbsp;expenses related to preclinical testing of the Group&#146;s technologies under development and clinical trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and
clinical trial sites that conduct the clinical studies (4)&nbsp;expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, (5)&nbsp;other research and development
expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Group&#146;s research and development services and have no alternative future uses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <FONT
STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development in the period in which they are incurred, provided that the new
drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established
alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. The conditions enabling
capitalization of development expenses as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.12 Leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior
to the adoption of ASC 842 on January&nbsp;1, 2019: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Leases, mainly leases of offices, where substantially all the rewards and risks of ownership of assets remain
with the lessor are accounted for as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The Group had no capital leases for any of the years stated herein. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon and hereafter the adoption of ASC 842 on January&nbsp;1, 2019: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group
determines if an arrangement is a lease at inception. Operating leases are included in operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets, operating lease liability,
and operating lease liability, <FONT STYLE="white-space:nowrap">non-current</FONT> in the Group&#146;s consolidated balance sheets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ROU assets represent the
Group&#146;s right to use an underlying asset for the lease term and lease liabilities represent the Group&#146;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement
date based on the present value of lease payments over the lease term. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the
Group&#146;s leases do not provide an implicit rate, the Group uses its incremental borrowing rate, which it calculates based on the credit quality of the Group and by comparing interest rates available in the market for similar borrowings, and
adjusting this amount based on the impact of collateral over the term of each lease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group has elected to adopt the following lease policies in conjunction
with the adoption of ASU <FONT STYLE="white-space:nowrap">2016-02:</FONT> (i)&nbsp;elect for each lease not to separate <FONT STYLE="white-space:nowrap">non-lease</FONT> components from lease components and instead to account for each separate lease
component and the <FONT STYLE="white-space:nowrap">non-lease</FONT> components associated with that lease component as a single lease component; (ii)&nbsp;for leases that have lease terms of 12 months or less and does not include a purchase option
that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii)&nbsp;the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January&nbsp;1,
2019 to not reassess (a)&nbsp;whether an arrangement is or contains a lease, (b)&nbsp;the lease classification applied to existing leases, and(c) initial direct costs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.13 Share-based compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company grants restricted shares
and stock options to eligible employees and accounts for share-based compensation in accordance with ASC 718, Compensation&#151;Stock Compensation.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Employees&#146;
share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; or b) for share based awards granted with only service
conditions, using the graded vesting method net of estimated forfeitures over the vesting period; or c) for share-based awards granted with service conditions and the occurrence of an initial public offering (&#147;IPO&#148;) as performance
condition cumulative share-based compensation expenses for the options that have satisfied the service condition should be recorded upon the completion of the IPO using the graded vesting method.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense
of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation
cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining
requisite service period after modification. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Share-based compensation in relation to the restricted shares is measured based on the fair market value of the
Group&#146;s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#146;s ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex
and subjective variables, including discount rate, and subjective judgments regarding the Group&#146;s projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects
at the time the grants are made. Share-based compensation in relation to the share options is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of the Group&#146;s ordinary shares as well as the
assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. The fair value of these awards was determined with the
assistance from an independent valuation firm. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.14 Adopted accounting pronouncements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases (Topic 842). This ASU requires lessees to recognize lease assets and lease
liabilities on the balance sheet for the rights and obligations created by all leases with terms greater than 12 months. As we are not a lessor, other changes in the guidance applicable to lessors do not apply. Additionally, in 2018, the FASB issued
codification and targeted improvements to this guidance effective for fiscal years and interim periods within those years beginning after December&nbsp;15, 2018, with early adoption permitted. The Group adopted the new guidance on January&nbsp;1,
2019, using the alternative transition approach. For additional information, see Note 6&#151;&#147;Leases.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2016-18,</FONT> Statement of Cash Flows (Topic 230) (&#147;ASU <FONT STYLE="white-space:nowrap">2016-18&#148;).</FONT> This ASU affects all entities that have restricted cash or restricted cash equivalents and are required
to present a statement of cash flows under Topic 230. ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally
described as restricted cash or restricted cash equivalents. This update was required to be adopted for fiscal years beginning after December&nbsp;15, 2018, and interim periods within fiscal years beginning after December&nbsp;15, 2019, and early
adoption is permitted in any interim or annual period. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2.15 Recent accounting pronouncements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2016, the FASB issued
ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> Financial Instruments &#151; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;).</FONT> This guidance
requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable
forecasts that affect the collectability. In November 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-19,</FONT> Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#147;ASU
<FONT STYLE="white-space:nowrap">2018-19&#148;),</FONT> which clarifies certain topics included within ASU <FONT STYLE="white-space:nowrap">2016-13.</FONT> ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> and ASU
<FONT STYLE="white-space:nowrap">2018-19</FONT> are effective for the annual reporting period beginning after December&nbsp;15, 2019, including interim periods within that reporting period. The Group is currently evaluating the impact on the
consolidated financial statements upon the adoption of this guidance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. PREPAYMENTS AND OTHER RECEIVABLES </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepayments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">&#151;Prepayments to CRO vendors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">&#151;Prepayments for other services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Value-added tax recoverable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rental deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. OTHER FINANCIAL ASSETS </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Financial asset at fair value through profit or loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Note receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group placed the principal amount for investments through a contractual arrangement with a third party for the period from June&nbsp;30, 2017 to June&nbsp;30, 2020
(&#147;Principal Amount&#148;). The Principal Amount can be redeemed from the third party at the discretion of the Group from time to time whereby the Group is expecting to earn an income on the Principal Amount with an average yield in the range
from 4.50% to 5.25% per annum. The Group initially records these assets at cost, which approximates its fair value at inception and subsequently records these assets at fair value. Changes in the fair value are reflected in the interim condensed
consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On June&nbsp;22, 2019, the Group entered into an agreement with the relevant party involved for early termination of
the contractual arrangement (&#147;Termination Agreement&#148;). Pursuant to the Termination Agreement, the Group shall receive cash with an amount of RMB95,056 and commercial bills with a total face value of RMB160,944 (including those commercial
bills redeemed during the year ended December&nbsp;31, 2018 with a face value of RMB40,387). No material gain or loss was arising from such termination. As of September&nbsp;30, 2019, cash of RMB95,056 was received and an amount of RMB97,345 cash
was received upon the maturities of certain commercial bills. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Subsequent to September 30, 2019 and up to the issuance of these interim condensed consolidated
financial statements, all commercial bills have been collected upon maturity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. PROPERTY, EQUIPMENT AND SOFTWARE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property, equipment and software consist of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,390</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,225</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The total amounts charged to the interim condensed consolidated statements of comprehensive loss for depreciation and amortization expenses amounted to approximately
RMB2.4&nbsp;million and RMB6.8&nbsp;million for the nine months ended September&nbsp;30, 2018 and 2019, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. LEASES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As of September&nbsp;30, 2019, the Company has operating leases recorded on its balance sheet for certain office spaces and facilities that expire on various dates
through 2027. The Group does not plan to cancel the existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
lease agreements for its existing facilities prior to their respective expiration dates. When determining the lease term, the Group includes options to extend or terminate the lease when it is
reasonably certain that it will exercise that option, if any. All of the Group&#146;s leases qualify as operating leases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Information related to operating leases as
of September&nbsp;30, 2019 and upon adoption of ASC 842 on January&nbsp;1, 2019 is as follows (in thousands, except for percentages and years). </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information related to operating lease activity during the nine months ended September&nbsp;30, 2019 is as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;NINE&nbsp;MONTHS&nbsp;ENDED</B><br><B>SEPTEMBER&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease rental expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Amortization of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expense for short-term leases within 12 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Future annual minimum lease payments for operating leases as of December&nbsp;31, 2018 under ASC 840 were as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPERATING&nbsp;LEASES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(NOTE&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,935</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,089</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Maturities of lease liabilities were as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Remaining 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total undiscounted lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total lease liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,965</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,534</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. INTANGIBLE ASSETS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Intangible assets as of December&nbsp;31, 2018 and
September 30, 2019 are summarized as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">In-process research and development (&#147;IPR&amp;D&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">IPR&amp;D represents the fair value assigned to research and development assets that the Group acquired from business combination of I-Mab Bio-tech (Tianjin) Co., Ltd.
(referred to as &#147;Tasgen Group&#148;) in 2017 and had not reached technological feasibility at the date of acquisition. Upon commercialization, the Group will determine the estimated useful life and amortize these amounts based upon an economic
consumption method. As of December 31, 2018 and September 30, 2019, there was no impairment of the value of the Group&#146;s intangible assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. GOODWILL
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The goodwill of RMB162,574 (US$22,745) as of December&nbsp;31, 2018 and September 30, 2019 represented the goodwill generated from the acquisition of Tasgen
Group in 2017. The business of Tasgen Group was fully integrated into the Company post acquisition. As of December&nbsp;31, 2018 and September 30, 2019, the Group performed a qualitative assessment by evaluating relevant events and circumstances
that would affect the Group&#146;s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Group&#146;s reporting unit is less than its carrying amount and therefore the Group&#146;s goodwill
was not impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. SHORT-TERM BORROWINGS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2018, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. borrowed a loan of RMB80,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.20% per annum. To
facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$13,500 (equivalent to approximately RMB92,653) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the
bank during the period of the borrowing. The deposits have a <FONT STYLE="white-space:nowrap">one-year</FONT> term and bear interest at 3.26% per annum. The borrowing was fully repaid during the nine months ended September&nbsp;30, 2019. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2019, <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. borrowed a loan of RMB50,000 from China
Merchant Bank Co.,&nbsp;Ltd. for a term of one year and at the interest rate of 4.15% per annum. To facilitate this borrowing, another </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
subsidiary of the Company in Hong Kong placed cash deposits of US$8,000 (equivalent to approximately RMB54,998) with the bank. The use of such cash deposits and the interest earned thereon are
restricted by the bank during the period of the borrowing. The deposits have a <FONT STYLE="white-space:nowrap">one-year</FONT> term and bear interest at 2.63% per annum. The borrowing will be due for repayment in June 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. ACCRUALS AND OTHER PAYABLES </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Staff salaries and welfare payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued external research and development activities related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued initial public offering costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued travelling expenses, office expenses and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. INCOME TAXES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group has incurred net accumulated operating losses
for income tax purposes since its inception. The Group believes that it is more likely than not that these net accumulated operating losses will not be utilized in the future. Therefore, the Group has provided full valuation allowances for the
deferred tax assets as of December&nbsp;31, 2018 and September 30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. ORDINARY SHARES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2018 and September 30, 2019, 500,000,000 ordinary shares had been authorized by the Company. Each ordinary share is entitled to one vote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. CONVERTIBLE PREFERRED SHARES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;18, 2016, the Company
issued 5,141,587 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares with a consideration of US$11,282 (equivalent to approximately RMB74,742). In connection with the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares issuance, the Company also issued 2,246,744 warrant to purchase its Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares
(&#147;Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants&#148; and see Note 15). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;6, 2017, in connection with the Group&#146;s
acquisition of Tasgen Group, the Company issued 16,723,646 shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at a price of US$2.55 per share with a total consideration of US$42,645 (equivalent to approximately
RMB289,024). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Shares, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares and Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Preferred Shares are also referred to as Series A Preferred Shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;22, 2017, the Company issued 15,894,594
shares of Series B Preferred Shares with a consideration of US$52,546 (equivalent to approximately RMB346,515). In connection with the Series B Preferred Shares issuance, the Company also issued convertible promissory notes that are convertible into
<FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Shares (&#147;2017 Notes&#148; and see Note 14) and 5,633,780 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B
Warrants&#148; and see Note 15). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the Company&#146;s issuance of Series B Preferred Shares, the Company also completed a round of onshore
financing with respect to the Group&#146;s subsidiary <FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin (&#147;Series B Onshore Financing&#148;). Series&nbsp;B Onshore Financing comprised 1) capital injection to
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin by a number of investors (&#147;Series B Onshore Investors&#148;) (see Note 14), 2) <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s issuance of convertible loans (&#147;Onshore
Convertible Loans&#148; and see Note 14), and 3) the Company&#146;s issuance of 2,620,842 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B Warrants&#148; and see Note 15). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June 29, 2018, the Company issued total 8,361,823 shares of Series A-3 Preferred Shares upon exercise of Series
A-3 Option held by its holder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;29, 2018, the Company issued 2,535,201 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares
upon conversion of 2017 Notes and issued 2,253,512 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B Warrant by Series B preferred shareholders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;29, 2018, the Company issued 5,938,640 shares of Series B Preferred Shares upon exercise of the Series&nbsp;B Option held by a Series B Onshore Investor
and issued 947,218 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 14), respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;6, 2018, the Company issued 1,455,549 shares of Series B Preferred Shares upon exercise of the Series&nbsp;B Option held by a Series B Onshore Investor,
issued 232,161 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 14) and issued 1,048,337&nbsp;shares of
<FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> Preferred Shares upon exercise of Series B Warrant by Series B Onshore Investors, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Series B
Preferred Shares, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares and Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares are also referred to as Series&nbsp;B Preferred Shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July 6, 2018, the Company issued 31,046,360 shares of Series C Preferred Shares at a price of US$6.4419 per share with a total consideration of US$200,000
(equivalent to approximately RMB1,323,363). In connection with the offering of the Series C Preferred Shares, the Company incurred issuance costs of RMB16,730. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
July 25, 2019, the Group entered into a share purchase agreement with certain third party investors, under which these investors will subscribe for an aggregate of 3,857,143 Series C-1 convertible preferred shares of the Company for an aggregate
purchase price of US$27,000. Out of the aforementioned subscription of 3,857,143 Series C-1 convertible preferred shares by certain third party investors, the Group received cash consideration of approximately US$10,000 (equivalent to approximately
RMB70,729) for 1,428,571 Series C-1 convertible preferred shares from an investor in August 2019 and the issuance of such 1,428,571 Series C-1 convertible preferred shares was consummated on October 17, 2019. On November 6, 2019, the Group received
cash consideration of US$17,000 (equivalent to approximately RMB119,387) for the remaining 2,428,572 Series C-1 convertible preferred shares from the investors and the issuance of such 2,428,572 Series C-1 convertible preferred shares was
consummated on that day. In connection with the offering of the Series C-1 convertible preferred shares, the Company incurred issuance costs of approximately US$840. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Series A Preferred Shares, Series B Preferred Shares, Series C Preferred Shares and Series C-1 Preferred Shares are collectively referred to as Preferred Shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key terms of the Preferred Shares are summarized as follows: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of Preferred Shares are entitled to receive dividends, out of any assets legally available therefore, prior and in preference to any
declaration or payment of any dividend on the ordinary shares or any other class or series of shares of the Group at the rate of eight percent (8%) of the original issue price per share per annum on each Preferred Share, payable in US$ and annually
when, as and if declared by the Board of Directors. Such distributions shall not be cumulative. No dividend, whether in cash, in property or in shares of the capital of the Group, shall be paid on or declared and set aside for any ordinary shares or
any other class or series of shares of the Group unless and until all dividends have been paid in full on the Preferred Shares (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each Preferred Share may be converted at any time into
ordinary shares at the option of the preferred shares holders at the then applicable conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of (i)&nbsp;share splits, share combinations, share dividends or
distribution, other dividends, recapitalizations and similar events, or (ii)&nbsp;issuance of ordinary shares (excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion
price in effect on the date of or immediately prior to such issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Shares shall be automatically converted into ordinary shares immediately upon the closing of a public
offering of the Company&#146;s shares with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$1,000,000,000 or otherwise
approved by all directors and certain preferred shareholders as specified in the Company&#146;s memorandum and articles of association (the &#147;Qualified Public Offering&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group determined that there were no beneficial conversion features (&#147;BCF&#148;) identified for any of the Preferred Shares during any of the periods. In making
this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are convertible with the respective effective conversion price at the issuance date. In all instances, the effective conversion price was
greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as described above, the Group will reevaluate whether or not a beneficial conversion feature should be recognized. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any liquidation (unless waived by the
preferred shareholders) including deemed liquidation, dissolution or winding up of the Company, holders of the Preferred Shares shall be entitled to receive a per share amount equal to one hundred percent (100%) of the original issue price on each
Preferred Share, plus an amount representing an internal rate of return of twelve percent (12%) per annum on the original issue price as adjusted for share dividends, share splits, combinations, recapitalizations or similar events, plus all accrued
and declared but unpaid dividends thereon, in the sequence of Series C Preferred Shares, Series B Preferred Shares and Series&nbsp;A Preferred Shares. After such liquidation amounts have been paid in full, any remaining funds or assets of the
Company legally available for distribution to shareholders shall be distributed on a pro rata basis among the holders of the Preferred Shares, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, together with the holders of the
ordinary shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Accounting of preferred shares </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Shares
are redeemable by the holders upon a liquidation event, including a deemed liquidation event (e.g., change in control), and as such are presented as mezzanine equity on the consolidated balance sheets. In accordance with ASC <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99,</FONT></FONT> each issuance of the convertible preferred shares should be recognized at the date of issuance after deducting fair value allocated to the detachable warrants and
issuance costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company assesses whether an amendment to the terms of its convertible preferred shares is an extinguishment or a modification using the fair
value model. When convertible preferred shares are extinguished, the difference between the fair value of the consideration transferred to the convertible preferred shareholders and the carrying amount of the convertible preferred shares (net of
issuance costs) is treated as deemed dividends to the preferred shareholders. The Company considers that a significant change in fair value after the change of the terms to be substantive and thus triggers extinguishment. A change in fair value
which is not significant immediately after the change of the terms is considered <FONT STYLE="white-space:nowrap">non-substantive</FONT> and thus is subject to modification accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s convertible preferred shares activities for the nine months ended September&nbsp;30, 2018 and 2019
are summarized below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A<BR>PREFERRED SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B<BR>PREFERRED SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES C<BR>PREFERRED SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Balance as of January&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,865,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,894,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of Series A Preferred Shares upon exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT>
Option</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of Series B Preferred Shares upon exercise of Series B Option</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,394,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of Series B Preferred Shares upon conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,535,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of Series B Preferred Shares upon conversion of Onshore Convertible Loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of Series B Preferred Shares upon exercise of Tranche I of Series&nbsp;B Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,301,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of Series C Preferred Shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Balance as of September&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Balance as of January&nbsp;1, 2019 and as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. CONVERTIBLE PROMISSORY NOTES AND ONSHORE CONVERTIBLE LOANS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2017 Notes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;25, 2017, the Company issued US$11,520
convertible promissory notes (&#147;2017 Notes&#148;) to investors of Series B Preferred Shares (see Note 13) at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of the 2017
Notes may convert the outstanding principal amount into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the conversion price of US$5.38 per share or a lower price as may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
agreed by the investors and the Company at any time from six months prior to the maturity date and prior to the repayment in full of the 2017 Note. No interest shall be accrued if the 2017 Notes
have been converted into <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As the fair value of the Company&#146;s ordinary shares on
September&nbsp;25, 2017 was lower than the effective conversion price of US$5.38, the Company did not record a BCF. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;29, 2018, the Company&#146;s 2017
Notes were converted into the Company&#146;s 2,535,201 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the nominal conversion price of US$5.38 per share. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2018 Notes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;3, 2018, the Company issued US$9,000
(equivalent to approximately RMB59,704) convertible promissory notes (&#147;2018 Notes&#148;) to an investor of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at an annual interest rate of 0%, maturing on 36 months after the
issuance date. Under the agreement, the holder of the 2018 Notes may convert the 2018 Notes outstanding principal amount into Series B Preferred Shares at the conversion price being lower of US$10 per share and fair market value at any time prior to
the maturity date. Alternatively, the 2018 Notes shall be automatically converted into the Company&#146;s Series B Preferred Shares upon the maturity. As the fair value of the Company&#146;s ordinary shares on February&nbsp;3, 2018 of US$3.96 was
equal to the effective conversion price (being lower of US$10 per share and fair market value), the Company did not record a BCF. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Onshore Convertible Loans
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;25, 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin issued a US$5,359 convertible loan to Series B Onshore Investors at a
compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of the Onshore Convertible Loans may convert the outstanding principal amount into <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Tianjin&#146;s equity interest a stipulated conversion price at any time from six months prior to the maturity date and prior to the repayment in full of the Onshore Convertible Loans. No interest shall be accrued if the Onshore Convertible Loans
have been converted into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s equity interest. As the fair value of the <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s ordinary shares on September&nbsp;25, 2017 was lower than
the effective conversion price of US$4.31, the Company did not record a BCF. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June and July 2018, the Company reached agreements with holders of Onshore
Convertible Loans and the principal amounts of Onshore Convertible Loans were then effectively converted into 1,179,379 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares of the Company and the accrued interests were waived,
resulting in an extinguishment loss of RMB8,548. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15. WARRANTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
connection with the issuance of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares on October&nbsp;18, 2016, 2,246,744 <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT>
Warrants were issued to Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shareholders, which provided the holder the right to purchase Series <FONT STYLE="white-space:nowrap">A-3</FONT>
Preferred Shares. The Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants were later terminated on September&nbsp;6, 2017 without being exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
connection with the issuance of the Series B Preferred Shares on September&nbsp;22, 2017, 5,633,780 Series B Warrants were issued to Series B preferred shareholders, which provided the holders the right to purchase Series <FONT
STYLE="white-space:nowrap">B-2</FONT> Preferred Shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Company&#146;s Series B Onshore Financing that took place on September&nbsp;25,
2017, 2,620,842 Series B Warrants were issued to Series B Onshore Investors, which provided the holders the right to purchase <FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> Preferred Shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the period from June&nbsp;29, 2018 to July&nbsp;6, 2018, 3,301,849 Series B Warrants (representing Tranche I of Series B Warrants) were exercised to purchase
3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares with proceeds of US$20,000 (equivalent to approximately RMB132,332). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;6,
2018, the Series B Warrants holders agreed that the Series B Warrants shall be divided into two tranches and exercisable in accordance with different time schedules, such that: (i)&nbsp;the holders have exercised part of the Series B Warrants in the
total consideration of US$20,000 (&#147;Tranche I of Series B Warrants&#148;) and 3,301,849 <FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> Preferred Shares of the Company in aggregate have been newly issued to such holders on a pro rata
basis; (ii)&nbsp;only when the Company fails to submit a Qualified Public Offering application at an internationally recognized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
securities exchange by March&nbsp;31, 2019, the Warrant Holders may exercise the remaining part of Series B Warrants, in the total consideration of US$30,000 (&#147;Tranche II of Series B
Warrants&#148;) and 4,952,773 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares of the Company in aggregate will be issued to such holders on a pro rata basis; (iii)&nbsp;provided that the Company successfully submits a Qualified
Public Offering application at an internationally recognized securities exchange by March&nbsp;31, 2019, the holders shall unconditionally and irrevocably waive and cancel Tranche II of Series B Warrants; and (iv)&nbsp;the Tranche II of Series B
Warrants may only be concurrently exercised by all the Warrant Holders in one lump. This is considered to be a modification to Series B Warrants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the
confirmations issued by the Company&#146;s Series B Warrants holders in July 2019, the holders of Series B Warrants has unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. The fair value gain of warrants for the
nine months ended September 30, 2019 was amounting to RMB5,609. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accounting of warrants </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The warrant is a freestanding instrument and is recorded as liability in accordance with ASC 480, <I>Distinguishing Liabilities from Equity</I>. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As the Company&#146;s issuance of warrants were bundled with other instruments (such as convertible preferred shares, convertible promissory notes, etc.), out of total
considerations, the warrants are initially recognized at fair value and the remaining were allocated to other instruments on a relative fair value basis (if applicable). The fair value changes of the warrants (including the fair value changes
arising from modification of warrants) up to the time of exercise or termination were recognized in earnings. Upon exercise, the total carrying value of the associated warrant liabilities was reclassified into the carrying value of the Preferred
Shares into which it was converted. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company determined the fair value of the warrants with the assistance of an independent third party valuation firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group has measured the warrant liabilities at fair values on a recurring basis using significant unobservable inputs (Level 3). The Group used the binomial model
to estimate the fair value of warrant liabilities using the following assumptions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free rate of return</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.49%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Maturity date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Estimated volatility rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$6.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of underlying convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$6.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The model requires the input of highly subjective assumptions including the risk-free rate of return, maturity date, estimated volatility rate and fair value of
underlying preferred shares. The risk-free rate for periods within the contractual life is based on the US treasury strip bond with maturity similar to the maturity of the warrants as of valuation dates plus a China country risk premium. For
expected volatilities, the Group has made reference to the historical daily stock prices volatilities of ordinary shares of several comparable companies in the same industry as the Group. The estimated fair value of the preferred shares was
determined with assistance from an independent third party valuation firm. The Group&#146;s management is ultimately responsible for the determination of the estimated fair value of its preferred shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The significant unobservable inputs used in the fair value measurement of the warrant liabilities include risk-free rate of return, interval between valuation date and
maturity date, estimated volatility rate and fair value of underlying preferred shares. Significant decreases in interval between valuation date and maturity date, estimated volatility rate and fair value of underlying preferred shares would result
in a significantly lower fair value measurement. Significant increases in risk-free rate of return would result in a significantly lower fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>16. REDEEMABLE <FONT STYLE="white-space:nowrap">NON-CONTROLLING</FONT> INTERESTS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Company&#146;s acquisition of Tasgen Group, on September&nbsp;6, 2017, the Company also entered into an option agreement with the third party
investor of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, pursuant to which the Company granted the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
third party investor an option to subscribe for certain number of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares of the Company at a price that stipulated in the agreement,
and at the same time, the third party investor transferred its equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin to the Company at the same price (&#147;Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option&#148;). This
Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option can be exercised at any time at the holder&#146;s own discretion or upon the request of the Company if the shareholders of the Company approve an initial public offering. In addition, in the
event that the exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option has not been completed within 6 months after the option holder delivers the share purchase option notice, the Company shall purchase the third party investor&#146;s
equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option at a price that stipulated in the agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the Company&#146;s issuance of Series B Preferred Shares (see Note 13), on September&nbsp;25, 2017, the Group&#146;s subsidiary <FONT
STYLE="white-space:nowrap">I-MAB</FONT> Tianjin entered into a capital increase subscription agreement with Series B Onshore Investors, pursuant to which Series B Onshore Investors subscribed for additional equity in
<FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin of US$24,444 (equivalent to approximately RMB161,196). On September&nbsp;25, 2017 and in tandem with the aforementioned <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s capital
increase subscription agreement, the Company also entered into option agreements with Series B Onshore Investors, pursuant to which the Company granted Series B Onshore Investors options to subscribe for certain numbers of Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Shares of the Company at a price that stipulated in the agreements, and at the same time, the Series B Onshore Investors shall transfer their equity interests in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin to the Company at the same price (&#147;Series B Option&#148;). The Series B Option can be exercised at any time at the holders&#146; own discretion or upon the request of the Company if the
shareholders of the Company approve an initial public offering. In addition, in the event that the exercise of Series B Option has not been completed within 6&nbsp;months after the option holders deliver the share purchase option notice, the Company
shall purchase the third party investor&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and the Series B Option at a price that stipulated in the agreements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the accounting assessments, the Company considers that the aforementioned Series <FONT STYLE="white-space:nowrap">A-3</FONT> and Series B Options are embedded
features of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests that are not required to be bifurcated. Since the aforementioned <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin are redeemable at a determinable price, upon occurrence of an event that is not solely within the control of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, the aforementioned <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin are accounted for as redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in the Group&#146;s interim
condensed consolidated balance sheets. Subsequently, the redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests should be carried at the higher of (1)&nbsp;the carrying amount after the attribution of net income of the Company
and (2)&nbsp;the expected redemption value. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option and Series B Option were exercised by respective holders
on June&nbsp;29, 2018 and July&nbsp;6, 2018 to acquire 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares and 7,394,189 Series B Preferred Shares, respectively. The transactions were accounted for as equity transactions,
and the differences between the carrying amount of redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests of RMB305,708 and the fair value of convertible preferred shares of RMB615,393 that issued was recognized in additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group&#146;s redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest activities for the
nine months ended September 30, 2018 and 2019 is summarized as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of Series B Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(161,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>17. SHARE-BASED COMPENSATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(a) Restricted shares </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31, 2016,
the Company issued 4,019,554 ordinary shares to Mr.&nbsp;Zang Jingwu Zhang, Ms.&nbsp;Qian Lili, Mr.&nbsp;Wang Zhengyi and Mr.&nbsp;Fang Lei (collectively the &#147;Founders&#148;), including the 369,301 shares which represented the equity interests
of Third Venture held by the Founders, and the Company recorded share-based compensation expense of RMB18.7&nbsp;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2016, the Founders entered into an arrangement with other investors of the Company, and the 87,441 ordinary shares issued to the Founders in June 2016 were
canceled and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to service vesting conditions, that should vest 20%, 20% and 30% over the next three years, respectively. There shall be no
acceleration of the vesting schedule except that, in case of a change of control of the Company or a Qualified Public Offering, or the termination of the Founder&#146;s employment with the Group without cause. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of the Company&#146;s ordinary shares of US$0.77 at the date of
imposition of the restriction in October 2016, and was amortized to the interim condensed consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the Group&#146;s Founders&#146; restricted shares activities: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBERS<BR>OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">WEIGHTED-AVERAGE</FONT><BR>GRANT&nbsp;DATE<BR>FAIR&nbsp;VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2017 and September&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2018 and September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amounts of shared-based compensation expense in relation to the restricted shares recognized in the nine months ended September&nbsp;30, 2018 and 2019 were RMB2,970
and RMB1,556, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Share-based compensation expenses related to restricted shares were included in: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(b) 2017 Employee Stock Option Plan (&#147;2017 Plan&#148;) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
October 2017, the Company adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued pursuant to all awards granted was approved. Stock options granted to an employee under the 2017 Plan will be
exercisable upon the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. Employees are generally subject to a three-year
service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant date, a vesting of the remaining 50% on the third anniversary of the applicable grant date. The stock option
under 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the nine months ended September 30, 2018 and 2019, the Group granted 1,470,000 stock options and 640,000 stock
options, respectively, to its employees (all with an exercise price of US$1). No options are exercisable as of December&nbsp;31, 2018 and September 30, 2019 and prior to the Group completes a listing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the stock options activities of 2017 Plan for the periods presented: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED</B><br><B>AVERAGE</B><br><B>EXERCISE</B><br><B>PRICE</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED</B><br><B>AVERAGE</B><br><B>REMAINING</B><br><B>CONTRACTUAL</B><br><B>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE</B><br><B>INTRINSIC</B><br><B>VALUE</B><br><B>US$&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,761,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,005,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(351,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Repurchased (Note 17(d))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,435,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of September 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,859,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercisable as of September 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">61.32%-62.13%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.64%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.81%-3.06%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the
Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#146;s options in effect at the option valuation date.
The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee
exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any
dividend payments in the foreseeable future. Expected term is the contract life of the option. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There were 640,000 stock options granted to employees under 2017
Plan for the nine months ended September&nbsp;30, 2019. Since the exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense relating to
the 2017 Plan was recorded for the nine&nbsp;months ended September 30, 2018 and 2019. The Group will recognize compensation expenses relating to options vested cumulatively upon the completion of the Company&#146;s listing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(c) 2018 Employee Stock Option Plan (&#147;2018 Plan&#148;) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
February&nbsp;22, 2019, the Group adopted the 2018 Plan, which was subsequently amended on July 22, 2019. Under the amended and restated 2018 Plan, the maximum aggregate number of ordinary shares which may be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
issued pursuant to all awards is 14,005,745, and if the Group successfully lists on an internationally recognized securities exchange for a Qualified Public Offering by December&nbsp;31, 2019,
the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock options granted to an employee under the 2018 Plan will be generally
exercisable when the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. The vesting schedule shall generally be a
two-year vesting schedule consisting of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date. If a listing
occurs at anytime prior to any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding, any such option shall vest in full with immediate effect upon the listing. Except as otherwise
approved by the board of directors, vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however that in each case, no option of an employee shall become
exercisable until the third anniversary of such employee&#146;s employment commencement date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Board of Director&#146;s approval of 2018 Plan on
February 22, 2019, the 10,893,028 stock options granted to a director of the Group under 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of aforementioned total 10,893,028 stock options, 454,940 stock options were
repurchased by the Group (see Note 17(d) for further details). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amounts of shared-based compensation expense in relation to the aforementioned grant of stock
options to a director of the Group (except for those repurchased by the Group as described in Note 17(d)) recognized in the nine months ended September&nbsp;30, 2019 was RMB365,329, included in administrative expenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the stock options activities of 2018 Plan for the nine months ended September 30, 2019: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED</B><br><B>AVERAGE</B><br><B>EXERCISE</B><br><B>PRICE</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED</B><br><B>AVERAGE</B><br><B>REMAINING</B><br><B>CONTRACTUAL</B><br><B>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE</B><br><B>INTRINSIC</B><br><B>VALUE</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,991,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Repurchased (Note 17 (d))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(454,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of September 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,536,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercisable as of September 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,438,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock options granted to certain directors and employees of the Group were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the
following assumptions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">54.64%-56.31%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15%-2.75%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the
Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Group&#146;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide
to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as
the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except for the aforementioned grant of stock options to a director of the Group under 2018 Plan, since the exercisability is dependent upon the listing, and it is not
probable that this performance condition can be achieved until a listing, no share-based compensation expense related to the 2018 Plan was recorded for the nine months ended September 30, 2019. The Group will recognize compensation expenses relating
to options vested cumulatively upon the completion of the Company&#146;s listing. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(d) Repurchase of share awards held by a director </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On February&nbsp;22, 2019, the amended and restated 2017 Plan was approved by the Board of Directors of the Group, pursuant to which only the 3,435,215 stock options
held by the director (see Note 17(c)) under the 2017 Plan became fully vested and exercisable on February&nbsp;22, 2019. As a result of the performance condition being waived, the stock options held by a director of the Group were accounted for as a
Type III modification where a condition that the Group expects will not be satisfied is changed to a condition that the Group expects will be satisfied. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, on the same day, the Group repurchased such 3,435,215 stock options under the amended and restated 2017 Plan that was held by the director of the Group
along with 454,940 of his stock options under the 2018 Plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902 (equivalent to approximately RMB148,308) at an average share price of US$5.63 per
share. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the nine months ended September 30, 2019, the Group recorded the total payment of US$21,902 (equivalent to approximately RMB148,308) as share-based
compensation costs (included in administrative expenses) in the interim condensed statement of comprehensive loss. There was no impact to the overall shareholders&#146; equity balance as the amended shares vested immediately and were repurchased.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a
description of the Group&#146;s significant licensing and collaboration agreements entered into from January 1, 2017 to September 30, 2019. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A. <FONT
STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with MorphoSys AG (&#147;MorphoSys&#148;) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2017, the Group entered into a license and collaboration agreement with MorphoSys, with respect to the development and commercialization of MOR202/TJ202,
MorphoSys&acute;s proprietary investigational antibody against CD38 (the &#147;CD38 product&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under this agreement, MorphoSys granted to the Group an
exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in the licensed territory, namely mainland China, Hong Kong, Macau and Taiwan (collectively &#147;Greater China&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to this agreement, the Group granted to MorphoSys an exclusive license to its rights in any inventions that the Group make while exploiting the CD38 product
under this agreement, solely to exploit the CD38 product outside of Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to this agreement, the Group paid to MorphoSys an upfront license fee
of US$20.0&nbsp;million (equivalent to approximately RMB132.7 million). The Group also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate
amount of US$98.5&nbsp;million (equivalent to approximately RMB653.5 million). Such milestones include first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess
of a certain amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the Group is required to pay tiered <FONT STYLE="white-space:nowrap">low-double-digit</FONT> royalties
to MorphoSys on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis during the term,
commencing with the first commercial sale of a relevant licensed product in Greater China. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the expiration of the Group&#146;s last payment
obligation under the agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2017, the Group paid US$20.0&nbsp;million (equivalent to approximately RMB132.7 million) upfront fee to MorphoSys, which was
recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December 31, 2017. No additional payments were made in 2018. Due to the uncertainty involved in meeting these development and
commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018. In March and April 2019, the project achieved the first and second milestone and the Group paid
US$8.0&nbsp;million (equivalent to approximately RMB54.9 million) of milestone fees to MorphoSys, which was recorded as research and development expense in the interim condensed consolidated statement of comprehensive loss for the nine months ended
September 30, 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Summarized financial information related to the above agreement is presented below: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RESEARCH AND DEVELOPMENT EXPENSE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>UPFRONT&nbsp;FEES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MILESTONES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXTENSION/<BR>TERMINATION<BR>OF<BR>AGREEMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMORTIZATION<BR>OF PREPAID<BR>RESEARCH&nbsp;AND<BR>DEVELOPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INTANGIBLE<BR>ASSET&nbsp;BALANCE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with Genexine, Inc. (&#147;Genexine&#148;) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December
2017, the Group entered into an intellectual property license agreement with Genexine with respect to <FONT STYLE="white-space:nowrap">GX-I7/TJ107,</FONT> a long-acting <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine. Under this agreement, the
Group obtained an exclusive, sublicensable and transferable license to use and otherwise exploit certain intellectual property in connection with the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale
and distribution of GX-I7 to treat cancer in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the agreement, the Group made an upfront payment of US$12.0&nbsp;million (equivalent
to approximately RMB79.6 million) to Genexine which was recorded as a research and development expense in January 2018. The Group also agreed to make milestone payments in the aggregate amount of US$23.0&nbsp;million (equivalent to approximately
RMB152.6 million), conditioned upon the achievement of certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and new drug application (&#147;NDA&#148;) or biologic license application (&#147;BLA&#148;) approval
in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, the Group agreed to make milestone payments in the aggregate amount of US$525.0&nbsp;million (equivalent to approximately RMB3,482.7
million), conditioned upon the achievement of certain cumulative net sales of GX<I>-I7 </I>up to US$2,000&nbsp;million. The Group also is required to pay Genexine a <FONT STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty in
respect of the total annual net sales of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> The aforesaid milestones and royalties (other than the upfront payment) will be reduced by 50% following the entry of a generic version of <FONT
STYLE="white-space:nowrap">GX-I7</FONT> in China, Hong Kong, Macau and Taiwan without the consent or authorization of the Group or any of the Group&#146;s sublicensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&nbsp;the expiry of the last to expire
patent of the licensed intellectual property that includes a valid claim for Greater China and that covers the composition of GX-I7; and (ii) 15 years from the date of the first commercial sale of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No additional payments to Genexine were made in the nine months ended September&nbsp;30, 2019. Due to the uncertainty involved in meeting these development and
commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018 and September&nbsp;30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Summarized financial information related to the above agreement is presented below: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RESEARCH AND DEVELOPMENT EXPENSE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>UPFRONT&nbsp;FEES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MILESTONES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXTENSION/<BR>TERMINATION<BR>OF<BR>AGREEMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMORTIZATION<BR>OF PREPAID<BR>RESEARCH&nbsp;AND<BR>DEVELOPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INTANGIBLE<BR>ASSET&nbsp;BALANCE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with MorphoSys </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2018, the Group entered into
a license and collaboration agreement with MorphoSys for MorphoSys&acute;s proprietary antibody (MOR210/TJ210) directed against C5aR (the &#147;C5aR Agreement&#148;). Under this agreement, the Group obtained an exclusive, royalty-bearing license to
explore, develop and commercialize certain anti-C5aR antibodies in Greater China and South Korea. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group will perform and fund all global development activities
related to the development of MOR210/TJ210 in Greater China and South Korea, including all relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of
manufacturing processes. MorphoSys retains rights in respect of development and commercialization of MOR210/TJ210 in the rest of the world. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the
agreement, the Group also agreed to make milestone payments conditional upon the achievement of certain development milestones and certain annual net sales of anti-C5aR antibodies. The Group is also required to pay to MorphoSys tiered <FONT
STYLE="white-space:nowrap">mid-single-digit</FONT> royalties on annual net sales of anti-C5aR antibody products within the licensed territory. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2018, the Group
paid US$3.5&nbsp;million (equivalent to approximately RMB23.2 million) upfront fee to MorphoSys, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December 31, 2018. No
additional payments were made in the nine months ended September&nbsp;30, 2019. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are
still not probable as of December&nbsp;31, 2018 and as of September&nbsp;30, 2019. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Licensing Agreement with MacroGenics </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2019, the Group entered into a license and collaboration agreement with MacroGenics, Inc. for development and commercialization of an Fc-optimized antibody
known as enoblituzumab that targets B7-H3, including in combination with other agents, such as the anti-PD-1 antibody known as MGA012, in the Greater China. Under this agreement, the Group obtained an exclusive, sublicensable, royalty-bearing
license to MacroGenics&#146; patents and know-how to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In exchange for these rights, in addition to certain financial consideration, the Group will grant to MacroGenics a royalty-free, sublicensable, license outside of
Greater China, to our patents and know-how that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the enoblituzumab product or a product containing MGA012, and combinations thereof. The
license is (i) non-exclusive with respect to the enoblituzumab product, and (ii) exclusive with regard to MGA012. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the agreement, the Group paid an
upfront fee of US$15.0 million (equivalent to approximately RMB107.2 million) to MacroGenics, which was recorded as research and development expense in the interim condensed consolidated statement of comprehensive loss for the nine months ended
September 30, 2019. Under the terms of the agreement, the Group also agreed to pay MacroGenics development milestone fees of up to US$75.0 million and regulatory milestones fees of up to US$60.0 million, respectively, and tiered double-digit
royalties (ranging from mid-teens to twenty percent) based on annual net sales in the territories. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group is responsible for all development costs in Greater China. MacroGenics is responsible for all development
costs in the rest of the world, except that the Group is responsible for 20% of the costs incurred in (i) activities supporting global clinical trials in which we participate, (ii) certain CMC activities for material intended to be used in clinical
trials in Greater China, and (iii) companion diagnostic development and validation for indications being studied in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to the uncertainty involved
in meeting these development and commercialization based targets, the Group evaluated and concluded that no milestones are probable as of September 30, 2019. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED SEPTEMBER 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RESEARCH AND DEVELOPMENT EXPENSE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>UPFRONT&nbsp;FEES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MILESTONES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXTENSION/<BR>TERMINATION<BR>OF<BR>AGREEMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMORTIZATION<BR>OF PREPAID<BR>RESEARCH&nbsp;AND<BR>DEVELOPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INTANGIBLE<BR>ASSET&nbsp;BALANCE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition to the above arrangements, the Group has entered into other various <FONT STYLE="white-space:nowrap">in-licensing</FONT> and collaboration agreements with third party licensors to develop and commercialize drug candidates. Based on the
terms of these agreements, the Group is contingently obligated to make additional material payments upon the achievement of certain contractually defined milestones. The Group recorded US$0.6 million (equivalent to approximately RMB4.2&nbsp;million)
upfront fee and US$0.3 million (equivalent to approximately RMB2.1&nbsp;million) milestone payment under these agreements for the year ended December 31, 2018. The Group recorded US$0.4&nbsp;million (equivalent to approximately RMB2.9 million)
milestone payment during the nine months ended September&nbsp;30, 2019. Under the terms of the agreements, the licensors are eligible to receive from the Group up to an aggregate of approximately US$164.4&nbsp;million (equivalent to approximately
RMB1,175.1 million) in milestone payments upon the achievement of contractually specified development milestones and sales milestones, such as regulatory approval for the drug candidates, which may be before the Group has commercialized the drug or
received any revenue from sales of such drug candidate, which may never occur. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration
Arrangements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement among HDYM, <FONT STYLE="white-space:nowrap">I-Mab</FONT> and Hangzhou HealSun Biopharm Co., Ltd. (&#147;HealSun&#148;)
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2017, one of the Company&#146;s subsidiaries, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, entered into a technology transfer agreement
with HDYM and HealSun with respect to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal antibodies. Under the agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai agreed to
grant to HDYM exclusive, worldwide and sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <FONT STYLE="white-space:nowrap">PD-L1</FONT> related patents, patent applications,
know-hows, data and information of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, relevant cell lines as well as any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> monoclonal antibody arising from
such cell lines for the treatment of diseases. Further, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and its cooperative party, HealSun agreed to provide subsequent research and development services on such intellectual property to HDYM,
including the selection and examination of innovative <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal antibodies, cultivation and selection of stable cell lines, establishment of cell
bank, research and development of manufacturing processes and preparation of samples, toxicological and pharmacological testing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmaceutical experiment report drafting, and application for and
registration of clinical trials. HDYM agreed to make milestone payments conditioned upon achieving certain contractually defined milestones. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group determined
that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, due to the early stage nature of the development, the Group determined the license to the intellectual
property and research and development services are not distinct and thus were accounted for as a single performance obligation that is satisfied over time. The Group would receive RMB51.0&nbsp;million (inclusive of VAT) milestone payments under this
agreement, and considered that the achievements of milestone II, III, IV are constrained such that the transaction price shall initially only include the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
milestones payment which have been achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included
in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group used a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method to measure progress as that method best depicts its performance under the agreement. For the year ended December&nbsp;31, 2017, the Group achieved
milestones I and II and received milestone payments totaling of RMB29.0&nbsp;million (inclusive of VAT). The cumulative percentage complete in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input
method related to this agreement as of December&nbsp;31, 2017 is estimated to approximate 42%, the Group recognized RMB11.6&nbsp;million (exclusive of VAT of RMB0.7 million) of revenue in the consolidated statement of comprehensive loss, and
RMB15.8&nbsp;million (exclusive of VAT of RMB0.9 million) were deferred as contract liability related to this arrangement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December 31, 2018,
the Group achieved milestones III and IV and received milestone III payment of RMB11.0&nbsp;million (inclusive of VAT), milestone IV payment of RMB 11.0 million(inclusive of VAT) was recognized as contract assets as of December&nbsp;31, 2018 and
recognized as accounts receivable as of September 30, 2019. As of December&nbsp;31, 2018, the cumulative percentage complete in the <FONT STYLE="white-space:nowrap">cost-to</FONT> cost input method related to this arrangement is estimated to
approximate 100%. The Group recognized RMB36.5&nbsp;million (exclusive of VAT of RMB1.3 million) of revenue in the consolidated statement of comprehensive loss for the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Collaboration Agreement with Everest Medicines Limited (&#147;Everest&#148;) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2018, the Group entered into a collaboration agreement with Everest, which is controlled by the ultimate controlling party of a principal shareholder of the
Group. Under the agreement, both parties agreed to collaborate on programs to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary anti-CD38 antibody for all indications in hematologic oncology and commercialize of
MOR202/TJ202 in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A joint steering committee with equal representation from each party was established to coordinate and oversee the development and
commercialization of the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the agreement, the Group is primarily
responsible for carrying out the development, manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38 product, including
payments due to MorphoSys under the Licensing Agreement, dated November&nbsp;30, 2017, in the proportion of 75% by Everest and 25% by the Group. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The joint steering
committee will decide which party shall be responsible for conducting the commercialization of the CD38 product pursuant to the commercialization plan approved by the committee. If Everest is selected to be responsible for commercialization, the
Group shall grant an exclusive royalty-free license to Everest to commercialize the CD38 product for all indications in hematologic oncology in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Group and Everest will share the profit and loss and <FONT STYLE="white-space:nowrap">out-licensing</FONT> revenue derived from the CD 38 product in proportion to the costs that each party incur in developing the product. The parties will also split
<FONT STYLE="white-space:nowrap">out-license</FONT> revenue according to the proportion of development costs incurred, with the Group getting an additional five percent (5%) share and Everest receiving five percent (5%) less. Everest cannot share in
any profit from the commercialization of CD38 product until it has fulfilled its payment obligations under this agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon any termination of this
arrangement, the terminating party has the right to continue the development and commercialization of CD38 product. If Everest is the rightful terminating party, the Group shall reasonably cooperate with Everest to facilitate the following:
(i)&nbsp;assign the MorphoSys license to Everest (subject to the terms and conditions of such license); (ii) grant to Everest an exclusive license to all intellectual property rights that the Group owns or controls to further develop, manufacture,
and commercialize the CD38 product; (iii)&nbsp;transfer the development, manufacture and commercialization of the CD38 product to Everest. The terminating party shall be solely responsible for the cost and expense of such development and
commercialization after termination. In the event that such continuing party successfully develops and commercializes the CD38 product, it shall pay to the other party a percentage of the product profit and
<FONT STYLE="white-space:nowrap">out-license</FONT> revenue generated therefrom in accordance with the terms of this agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December 31, 2018, the US$26.0&nbsp;million in aggregate proceeds from Everest under the
agreement represented the funding available under the agreement, and was recorded as a research and development funding received liability (equivalent to approximately RMB178.7 million) on the consolidated balance sheet as of December&nbsp;31, 2018,
in accordance with <I>ASC 730, Research and Development</I>. Because there is a significant related party relationship between the Group and Everest, the Group is treating its obligation to make payments under the commercialization stage as an
implicit obligation to repay the funds advanced by Everest (see Note 23). During the nine months ended September&nbsp;30, 2019, an additional US$7.6&nbsp;million of funding was received and recorded as a research and development funding received
liability, resulting in a total balance of US$33.6&nbsp;million (equivalent to approximately RMB238.1 million) as of September&nbsp;30, 2019. No additional milestone has been achieved in the nine months ended September&nbsp;30, 2019. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with ABL Bio </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2018, the Group entered into a
license and collaboration agreement with ABL Bio, under which the Group granted to ABL Bio exclusive, worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibody (&#147;BsAb&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group agreed to share costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible for all costs and activities
following that time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In consideration of the license, ABL Bio agreed to pay the Group an upfront fee of US$2.5&nbsp;million (equivalent to approximately RMB17.2
million), and milestone payments in the aggregate amount of US$97.5&nbsp;million (equivalent to approximately RMB646.8 million) conditioned upon achieving certain research, clinical development and sales milestones. These include research milestones
of up to US$2.5 million (equivalent to approximately RMB17.2 million), clinical milestones of up to US$30&nbsp;million (equivalent to approximately RMB199.0 million) and sales milestones of up to US$65&nbsp;million (equivalent to approximately
RMB431.2 million). Further, ABL Bio agreed to pay the Group royalties at <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentages in respect of the total annual net sales of the licensed BsAb product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, ABL Bio granted to the Group an exclusive, royalty-free, sublicensable license to use the BsAb technology solely to exploit the licensed BsAb product for
all indications in Greater China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope
of ASC 606. Under this agreement, the only one performance obligation was to grant the BsAb license to ABL Bio, considering that the achievements of milestones are constrained such that the transaction price shall initially only include upfront
payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction price when
it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2018 and as of September&nbsp;30,
2019, no milestone has been achieved. The Group recognized revenue of US$2.5&nbsp;million (equivalent to RMB17.2 million) in the consolidated statement of comprehensive loss for the year ended December 31, 2018, which was the upfront fee related to
the grant of the rights of BsAb to ABL Bio as mentioned above. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Collaboration Agreement with ABL Bio </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2018, the Group and ABL Bio entered into a collaboration agreement (the &#147;ABL Bio Collaboration&#148;) whereby both parties agreed to collaborate to develop
three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies by using ABL Bio&#146;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include Greater China and South Korea,
and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At
contract inception, as both <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL Bio participate actively in the research and development activity. Also, the parties share the risk of failure of the BsAb products and share the income of licensing,
so this contract meet the criteria of the definition of a collaborative arrangement, the Group categorized this agreement within the scope ASC 808. Prior to commercialization, the Group recorded the share of the expenses incurred by the
collaboration for the development of three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies products in research and development expense in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
consolidated statements of comprehensive loss. As of December&nbsp;31, 2018, RMB1.0 million expenses were incurred by the Group and ABL Bio did not incur any expense. According to the terms set
out in the agreement, the Group recorded 0.5 million (50% cost sharing) of expense in the Group&#146;s consolidated statement of comprehensive loss for the year ended December 31, 2018. For the nine&nbsp;months ended<B> </B>September&nbsp;30, 2019,
RMB6.0&nbsp;million expenses were incurred by the Group and RMB6.6&nbsp;million expenses were incurred by ABL Bio. Accordingly, the Group recorded RMB6.3&nbsp;million (50% cost sharing) of expenses in the Group&#146;s interim condensed consolidated
statement of comprehensive loss for the nine months ended<B> </B>September&nbsp;30, 2019. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Collaboration Agreements with Tracon Pharmaceuticals, Inc.
(&#147;Tracon&#148;) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2018, the Group entered into collaboration agreements with Tracon, under which both parties agreed to <FONT
STYLE="white-space:nowrap">co-develop</FONT> the Group&#146;s proprietary CD73 antibody, TJD5 (the &#147;TJD5 Agreement&#148;) and <FONT STYLE="white-space:nowrap">co-develop</FONT> up to five BsAbs (the &#147;BsAbs Agreement&#148;). The Group
recorded US$3.4&nbsp;million (equivalent to approximately RMB24.3 million) of research and development costs in the interim condensed consolidated statement of comprehensive loss for the nine months ended<B> </B>September 30, 2019. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Licensing Agreement with CSPC Pharmaceutical Group Limited (&#147;CSPC&#148;) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2018, the Group entered into a product development agreement with CSPC. The Group granted to CSPC exclusive,
<FONT STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-irrevocable</FONT> and sublicensable rights in the PRC (excluding Hong Kong, Macau and Taiwan) to develop and commercialize TJ103 for treating type 2
diabetes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CSPC is responsible for developing, obtaining market approval and commercializing the licensed products. The Group is responsible for transferring the
manufacturing technology of the licensed products to CSPC and assisting CSPC in the continued optimization of such manufacturing technology thereafter. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
consideration of the license, CSPC agreed to pay the Group an upfront fee of RMB15.0&nbsp;million and milestone payments in an aggregate amount of RMB135.0&nbsp;million conditioned upon achieving certain clinical development and regulatory approval
milestones. In addition, the Group is also entitled to royalties of up to <FONT STYLE="white-space:nowrap">low-double-digit</FONT> percentages in respect of the total annual net sales of the products after its commercialization in the PRC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the
only one performance obligation was to grant TJ103 license to CSPC. considering that the achievements of milestones are constrained such that the transaction price shall initially only include upfront payment and subsequently, once another milestone
was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant
reversal of cumulative revenue would occur in future periods. As of December&nbsp;31, 2018, the amount received of RMB14.2&nbsp;million (net of VAT) was recorded as advance from customers in the consolidated balance sheet. In February 2019, an
additional amount of RMB0.8&nbsp;million (net of VAT) was received, and the license was also approved by China intellectual property office in May 2019. The first milestone was achieved in September 2019 and the amount of RMB15.0 million (net of
VAT) was received according to the terms of the agreement. Accordingly, RMB30.0&nbsp;million was recognized as revenue in the interim condensed consolidated statements of comprehensive loss for the nine months ended September&nbsp;30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>19. OTHER INCOME (EXPENSES), NET </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes other income (expenses), net recognized for the nine months ended September&nbsp;30, 2018 and 2019: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from conversion of Onshore Convertible Loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from issuance of 2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net foreign exchange gains (losses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value change of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">(16,985)</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>20. NET LOSS PER SHARE </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted net loss per share for each of the
periods presented are calculated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;for&nbsp;loss per&nbsp;shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,397,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">For the nine months ended September&nbsp;30, 2018 and 2019, the effects of all outstanding convertible preferred shares, restricted shares, warrants and certain stock
options have been excluded from the computation of diluted loss per share for the nine months ended September&nbsp;30, 2018 and 2019 as their effects would be anti-dilutive. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">For the nine months ended September&nbsp;30, 2018 and 2019, the Company also has certain dilutive potential stock options. These stock options which cannot be exercised
until the Company completes its listing are not included in the computation of diluted earnings per shares as such contingent event had not taken place. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as
their inclusion would be anti-dilutive are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,874,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,222,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,898,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">not&nbsp;applicable</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,445,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>21. EMPLOYEE BENEFITS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Full time employees of the Group in the PRC
participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to the employees. Chinese labor regulations require that the PRC
subsidiaries of the Group make contributions to the government for these benefits based on certain percentage of the employees&#146; salaries, up to a maximum amount specified by the government. The Group has no legal obligation for the benefits
beyond the contribution made. The total amounts charged to the interim condensed consolidated statements of comprehensive loss for such employee benefits amounted to approximately RMB6,649 and RMB9,987 for the nine months ended September&nbsp;30,
2018 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>22. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Contingencies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group is a party to or an assignee of license and
collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (Note 18). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Group did not have significant capital and other commitments, long-term obligations, or guarantees as of December&nbsp;31, 2018 and September 30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>23.
RELATED PARTY BALANCES AND TRANSACTIONS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table below sets forth the major related parties and their relationships with the Group as of December&nbsp;31,
2018 and September 30, 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>NAME OF RELATED PARTIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>RELATIONSHIP WITH THE GROUP</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Everest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Controlled by the ultimate controlling party of a principal shareholder of the Group</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Tasly Pharmaceutical Group Co., Ltd.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Controlled by the ultimate controlling party of a principal shareholder of the Group</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Details of related party balance as of December&nbsp;31, 2018 and September 30, 2019 are as follows: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and development funding received </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Everest (Note 18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Details of related party transactions for the nine months ended September 30, 2018 and 2019 are as follows: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Receipt of CRO services&#151;recognized in research and development expenses </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tasly Pharmaceutical Group Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Receipt of research and development funding </I></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Everest (Note 18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>24. CONCENTRATION OF CREDIT RISK </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments that are potentially
subject to significant concentration of credit risk consist of cash and cash equivalents, restricted cash, short-term investments, other financial assets, contract assets, accounts receivable and other receivables. The carrying amounts of cash and
cash equivalents, restricted cash, short-term investments, contract assets, accounts receivable, other receivables and other financial assets represent the maximum amount of loss due to credit risk. As of December&nbsp;31, 2018 and September 30,
2019, all of the Group&#146;s cash and cash equivalents, restricted cash and short-term investments were held by major financial institutions located in the PRC and international financial institutions outside of the PRC which management believes
are of high credit quality and continually monitors the credit worthiness of these financial institutions. With respect to the contract assets, accounts receivable, other receivables and other financial assets, the Group performs <FONT
STYLE="white-space:nowrap">on-going</FONT> credit evaluations of the financial condition of its customers and counterparties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>25. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Group evaluated subsequent events through January 3, 2020. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">On October 29, 2019, the Group adopted 2019 Share Incentive Plan (the &#147;2019 Plan&#148;), which will become
effective immediately prior to the completion of the Company&#146;s offering. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance shall initially be 100,000. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">On October 29, 2019, the Company&#146;s shareholders and board of directors approved that immediately prior to the
completion of the Company&#146;s offering, the Company&#146;s authorized share capital will be changed into US$80,000 divided into 800,000,000 ordinary shares of a par value of US$0.0001 each. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">On November 4, 2019, the Group and Everest have terminated the collaboration agreement (including all the supplements
and amendments thereto) with respect to the co-development and commercialization of TJ202 in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its
commercialization. All intellectual property rights in respect of TJ202 arising from its development under the collaboration agreement are vested and owned by I-Mab, and the Group holds all intellectual property rights and have maximum flexibility
to further develop, manufacture and commercialize TJ202 in Greater China. In consideration of the above arrangements, the board of directors of the Group has approved the issuance of a total value of US$37.0 million of ordinary shares (the &#147;CPP
Shares&#148;) to Everest, representing Everest&#146;s historical contribution to the collaboration and the associated time cost. The CPP Shares will be issued concurrently with, and subject to, the completion of the Company&#146;s initial public
offering within 180 days from termination of the collaboration agreement. The total value of US$37.0 million was calculated based on the sum of (1) US$33.7 million, which equals cumulative paid-in
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
contributions historically made by Everest under the collaboration agreement; and (2) a negotiated US$3.3 million time cost of the foregoing historical contribution in light of I-Mab&#146;s
exclusive rights over the commercialization of TJ202 after this termination. The issuance of the CPP Shares was approved by I-Mab&#146;s existing shareholders on December 25, 2019. In the event that the initial public offering has not been completed
within 180 days from the termination of the collaboration agreement, the Company will issue 4,762,751 ordinary shares (the &#147;Subject Shares&#148;) to Everest on the 181st day. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">On July 25, 2019, the Group entered into a share purchase agreement with certain third party investors, under which
these investors will subscribe for an aggregate of 3,857,143 Series C-1 convertible preferred shares of the Company for an aggregate purchase price of US$27.0 million. Out of the aforementioned subscription of 3,857,143 Series C-1 convertible
preferred shares by certain third party investors, 1,428,571 Series C-1 convertible preferred shares were issued to an investor on October 17, 2019, and the Group also received the cash consideration of US$10,000 (equivalent to approximately
RMB70,729). On November 6, 2019, the Group received cash consideration of US$17,000 (equivalent to approximately RMB119,387) for the remaining 2,428,572 Series C-1 convertible preferred shares from the investors and the issuance of such 2,428,572
Series C-1 convertible preferred shares was consummated on that day. In connection with the offering of the Series C-1 convertible preferred shares, the Company incurred issuance costs of approximately US$840. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Biomaster Trust was established under the trust deed dated October 23, 2019, between the Company and TMF Trust (HK)
Limited, or TMF Trust, as the trustee of the Biomaster Trust. Through the Biomaster Trust, the Company&#146;s ordinary shares and other rights and interests under awards granted pursuant to 2017 Plan and 2018 Plan may be provided to certain of
recipient of equity awards. Upon satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the
consent of the advisory committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by
I-Mab.</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">On December 25, 2019, the Company&#146;s Preferred Shares were modified as a result of the Company&#146;s negotiation
with holders of Preferred Shares. Prior to the modification, each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shares holders at the then applicable conversion price. The initial conversion ratio
is 1:1, subject to adjustment in the event of (i) share splits, share combinations, share dividends or distribution, other dividends, recapitalizations and similar events, or (ii) issuance of ordinary shares (excluding certain events such as
issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. On December 25, 2019, the Company&#146;s shareholders and board of
directors approved that, where the final offering price of a Qualified Public Offering is no less than US$4.176 per ordinary share, the agreed provisions related to the number of shares to be converted into the Company&#146;s ordinary shares shall
apply with respect to the Series C-1 Preferred Shares, Series C Preferred Shares, Series B-2 Preferred Shares and <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Shares, which will generally give rise to a one to multiple
conversion of the such rounds of Preferred Shares, provided that unanimous consent of the directors on the final offering price needs to be obtained in the event that the final offering price per ordinary share of such IPO is fixed at a price equal
to or higher than US$4.176 per ordinary share but lower than US$5.22 per ordinary share. Up to issuance of these interim condensed consolidated financial statements, the Group is still in the process of assessing the accounting impacts of such
amendments. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">On December 25, 2019, the Second Amended and Restated 2017 Plan and the Second Amended and Restated 2018 Plan were
approved by the shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#146;s IPO, the maximum aggregate number of shares that may be granted pursuant to all awards under 2017 Plan and 2018 Plan shall
be adjusted in accordance with a formula pre-approved by the shareholders as below. </P></TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">For 2017 Plan, </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>Max=9,941,650-B, and rounded down to the nearest whole number</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>Q=1,446,875</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>M=1,371,973</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>Z=2,000,000</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>If C&lt;=3,446,875, B =
0</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>If C&gt;3,446,875 but &lt;= 4,818,848, B = (C-Q-Z) &times; 37.90%</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>If C&gt;4,818,848, B =M &times; 37.90%</I> </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><I>Max:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>The maximum number of ordinary shares in respect of which options may be granted under the Second Amended and Restated 2017 Plan</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><I>C:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Total number of ordinary shares issued to all the holders of the convertible preferred shares of the Company immediately prior to the closing of the IPO less the total number of ordinary shares that would have been issued to all
the holders of the convertible preferred shares of the Company</I> <I>immediately prior to the closing of the IPO had the conversion ratio been 1:1 for each series of the convertible preferred shares</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">For 2018 Plan, </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>Max=14,997,680-Q-A, and rounded down to the nearest whole number</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>Q=1,446,875</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>M=1,371,973</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>Z=2,000,000</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>If C&lt;=3,446,875, then
A=C-Q</I> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>If C&gt;3,446,875 but &lt;= 4,818,848, then A=Z + (C-Q-Z) &times; 62.10%</I> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL"><I>If C&gt;4,818,848, then A=Z + M &times; 62.10%</I> </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><I>Max:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>The maximum number of ordinary shares in respect of which options may be granted under the Second Amended and Restated 2018 Plan</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><I>C:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Total number of ordinary shares issued to all the holders of the convertible preferred shares of the Company immediately prior to the closing of the IPO less the total number of ordinary shares that would have been issued to all
the holders of the convertible preferred shares of the Company immediately prior to the closing of the IPO had the conversion ratio been 1:1 for each series of the convertible preferred shares</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">In connection with above amendments to 2017 Plan, each of the Company&#146;s founders, namely Zheru Zhang,
Lili&nbsp;Qian, Zhengyi Wang and Lei Fang, is willing to irrevocably surrender by him or her, for no consideration, of a portion of the unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to 130,000,
130,000, 130,000, and 130,000 ordinary shares of the Company, par value US$0.0001 per share, at an exercise price of US$1.0, respectively, under the Second Amended and Restated 2017 Plan (in respect of each individual, the &#147;Founder&#146;s
Surrendered Options&#148;). </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">In connection with above amendments to 2018 Plan, the director of the Company, Dr. Jingwu Zhang Zang is willing to
irrevocably surrender by him, for no consideration, of the right to acquire a certain amount of ordinary shares of the Company, par value US$0.0001 per share, at an exercise price of US$1.0 pursuant to the options granted to him under the Second
Amended and Restated 2018 Plan (the &#147;Dr. Zang&#146;s Surrendered Options&#148;). </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">On December 25, 2019, the board of directors of the Company
approved that the Company accepts the irrevocable surrender of Dr. Zang&#146;s Surrendered Options and all Founder&#146;s Surrendered Options from each of the founders, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with
effect immediately prior to the completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of the IPO. The Dr. Zang&#146;s Surrendered Options and the Founder&#146;s Surrendered Options shall be
calculated in accordance with the specific formula set based on the number of the additionally issued ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>26. UNAUDITED PRO FORMA BALANCE SHEET AND
NET LOSS PER SHARE </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma balance sheet information as of September&nbsp;30, 2019 assumes 1) the automatic conversion of all of the
outstanding Preferred Shares into ordinary shares at a conversion ratio of 1:1 (except for 1-to-1.08 for Series B-2 convertible preferred shares and 1-to-1.11 for Series C convertible preferred shares), as if the conversion had occurred as of
September 30, 2019 and 2) the Company&#146;s authorized share capital had been changed into US$80,000 divided into 800,000,000 ordinary shares of a par value of US$0.0001 each as of September&nbsp;30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma net loss per ordinary share is computed using the weighted-average number of ordinary shares
outstanding and assumes the automatic conversion of all of the Group&#146;s outstanding mezzanine equity into ordinary shares upon the closing of the Group&#146;s Qualified Public Offering, as if it had occurred on January&nbsp;1, 2019. The Group
believes the unaudited pro forma net loss per share provides material information to investors, as the automatic conversion of the Group&#146;s outstanding mezzanine equity and the disclosure of pro forma net loss per ordinary share provides an
indication of net loss per ordinary share that is comparable to what will be reported by the Group as a public company following the closing of the Qualified Public Offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the unaudited pro forma net loss per share attributable to ordinary shareholders: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;for&nbsp;loss<BR>per&nbsp;share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Numerator for <FONT STYLE="white-space:nowrap">pro-forma</FONT> basic and diluted net loss per
share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series A Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series B Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,574,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,574,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series C Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,420,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,420,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Denominator for <FONT STYLE="white-space:nowrap">pro-forma</FONT> basic and diluted net loss per
share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,406,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,406,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma balance sheets and loss per share excluded the impacts of the Group&#146;s share-based awards that are subject to IPO conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>7,407,400 American Depositary Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g25k48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Representing 17,037,020 Ordinary Shares </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:19pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>CICC </B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>China Renaissance </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Huatai Securities
</B></P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">January 16, 2020 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g713200g00i34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g00i34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1WB4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M             %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I
M;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!2
M96-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC
M<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \     !
M  $X0DE-!"8       X             /X   #A"24T#\@      "@  ____
M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
M[0   [X          0                         !              .^
M   ![0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ![0    !29VAT;&]N9P   [X    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   >T     4F=H=&QO
M;F<   .^     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X
M=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI
M9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!
M;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#
M;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )
M=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O
M='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))
M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     !-3     0   *    !2   !X   F<   !,W !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !2 * # 2(
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MS)NW;<F_?B_^:ZEG[1R=]%VQ)3O=%MR3;U.B^]^2,;,].I]@8'!CJ,;)]/\
M05TLVLLR+-GL^@M-<2/K7=TKZQ9/2[<-K[^HYH+&MN$G]!B5;:#8RNM[O28R
MS],_'_2V_9_\'ZBV+?K)F8N?97G=,OQ\!K6[,LEA&\]KG!_V:JMWT&O^T_\
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M)Z))0JM9=4RVLRRQH>T^3AN:IIJPBC14DD@9V0<;#NO;JZMCG,'BZ/8W^T]
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M?SUGT.?I4_SW_=G_ +D?R_LZ^:$DE/TH[\W_ )/_ )[*Y^%OT?\ NS_Y8_\
M7U8;_3:OZ+_A./Y[Z3_YK_W8_P"$]5?,:22'Z3Q_H4?\G_S3_P";XX=_,?\
M ?Z5'POHXW]$^A7_ #''\V?Z-_P7^A_[K+YE224_1G0_^1\+^A?S+?YOZ'%'
M]'_[K_Z'_@/L2L8/_+F5_1_Z+1_-?SG\]F\_\#_[L>NOFM))3]5)+Y5224_5
M22^54DE/U4DOE5))3__9 #A"24T$(0      50    $!    #P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@    @
M" $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0
M   !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.3HU-CHP, !R<C4P.3$V-P
M Z !  ,    !__\  * "  0    !   #OJ #  0    !   ![0         &
M 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $
M @   @$ !     $   %& @( !     $              $@    !    2
M  $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P    $
M     1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$Y.C W.C(Q(#$Y.C4V.C P ')R-3 Y,38W       #H $  P    '_
M_P  H ( !     $   .^H , !     $   'M          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
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M3Q$\14 _*;U?\RM/4!.#O)O&,2:%QU@LPXRR*ZL/?INR4J^V>ED490/Y[S3
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M=H*[&0,3^+%))Y2#D/XFI^1^D(^DM_ Y'/5& "?:N^H5R_8LZ$?M31S:$4V
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M'19RLM*N;0VBP.)C+R'*U?R?+DHVZU7D-73F"Y+JZ4T<D5>.Q*<D89Y4H2G
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M$L_U+WJ+C':]UW,C=WE&6,QD<S]P"C=G=_(7$A$F]&>G7XIO5_TZTJ-JMO\
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MSG,;>I'IT?2=:L^A"P36.D[B;Q,2E/WHC5@T$?KN)#JVP]46V#,&(11]G?\
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M6VT20;H(Z;JK+*[ZII)Z;;[[:ZZYS@BJ=LCY%N'.CN4[JR.,6=;=363:T\X
MT'4S"RTBG5P6#,*P_D9$*I-DRT54/CU*]D160"IJKAD"4'A"1EHL[8)CEB1%
MN]IVSSE#^4H1;M220-84*:4/%[5BL5>6! :^FJ5%C<,8XZL62#K1D40?"0$4
MV0W&R9PNR5*:2-HM&F(I[(E$QFQ%-2$REO.(9$9JT%F@C681@!*6P62,,BI$
M(;R 4T+(BSXO*BV1IH>F[U:%6&55<LWR2[?*F^4_NR11AF'>G+T&Z*+<MGK(
M8ZVU%:8G-^6"/9)?O"*QK> ,8T8+O["+-U-DHX6> )2,DHF/JIKF',:V3/N6
MC,62!.BQ%H;B3J#C&3".A)O6D@F=5*3R^(S:-EANDQZM4&E9IT)7L(6J\S&!
MTP_C=-XI;$-CH$A7S)LZ>$23S0HRW;-RB:XQL13,Y[O8+T3!"4^ Q:9PUD-L
M.RZ[5!3\/B/RE,A6<W-P<B]( =UEG@;0H["*D68PMJT-L6;E!N:'#2B;I@W(
MG1_2%-\FT_+[TOB9CX/7<,8*.GY%WG*S\H^RBLHPCD:$H_5](90;41V:A (Q
M)=^0<_75-/"2:RJ1% NP.R>*1O4?*MK29>W=K*DG/4>%121!X4;)5E5U5]V6
M55@ZM'U[EQ[=T+@Y6RK,J>-0Z%N71%9)B0T-Z&$D!SUB62(I=T3UE#K[LNY*
MTC\9DX-[4CM;"9@WD/L,F8AC;-TT:5,!$QI)Z^'Z#[,H&Q!>6)UL/>.0VD>.
MMM-TS"S4:12IWWT3TV44VUTTTUVWWWWVQKIIIKC.VVVVVV<8UUUQC.=MLYQC
M&,9SG/T\14[W5WEP#U7SM9S)0U8MR5N%ZIK7FT2WI&*/I+*K9OT I";UBH"D
M<C]'.):)79#D2+N4([C0!*.A)0Y8%E0^S(J]^A(A[\2(?(7$O%W;R%_N+]?<
M7Z;MG^'Z3K_\?*E_#>XZALIUR8K6XV=3")]@L),3KZ?(15^'B4?2B\#ELZ=B
M9D\.ZCW(N7+)0L\'_H]!H[-CB T@H90&M6[=5Y\HI*1>LJW@Y:2GX77T(B!V
M9O-2,P-1>* @!:5D-5%U=7TD(BF#1X<>:JNG*NKDFLZ6PHY<*8W^]93.V;9T
MM"[%7@N7[MN"F'MU(;-J>>*K'T+>%>.4S" .A%O&)A'H1;KIF7P,48.1!& $
M;]F0@(N;_/R3LS.3_+_+]_=U$:ZNC^(YO>[7A*Y]X'9UA.:[E-WR>OI1&@TS
MBE?Q6O&00MN<L!8JFZ&14VY#R9N9CK%='8TL!W6+JHLA! :Z)\Y^GHY-AKF7
M>MYUI@*-K%*Q+6F]L^O,/<A,#\"Z;R%W\7=F=V[9EQ)%%,/A+&$H=L_C(+&/
M;?9^B9V[91<Y([/Y%KGD.PF_+T,M?6N.:Q[2U"$0MUB#I$HTJ+HJ43*WXY<@
MXQ:I"%Q_>F3C4C,S42>LU%#N0<>WC[.,NCB#5@[Q9999Y9)YY))IIC.6664R
MDEED,G(Y)#-W(S,G<B(G<B=W=W=W7VS,+,(LPB+,PBS,S,S-TS,S?#,S?#,W
MPS*QNMX+3$P(1OJ -3,;BMH67 XT7=2\] 0(.X&H20@!C]O'):63:JFVI0<P
MW9B2XQ4FXPU58?QVRJJ#1+&,TMC6/.CR#TKYY44CRQYI6YWHQR.3EYA5<_9$
MO(B/M@^"(B;]1.[];0PM*\S11M,[>+RL M([?;ISZ\G;IF;Y?[-TL0Z][-Y^
MX;JA:X>AIEK&(VH49@0(D>V_EI=,I ]V^J0*'QQ)5)X;((M=5R9#*6R;,2'9
MO2Y5VR'-%W&FN7:HZC.G.18U\B,_@;5S9NO0-E@ZCYFE$O5B1Q6B4IM5T1M;
MHV!TTVG'Z6H5C;CRN[>F,X>#=G*S1^#_ (@;AXV.MM1CLBE3SUT&VOMO:B"L
M"E5:2>GK3?U/,XC,'T4(E&AQK$H?-V[I%W#S\B%+LG .;B$METGV[;<HV*:B
M71D&F,/EB*1'B)XB>(GB)XB>(GB)XB>(GB)XB>(GB*&O3G,AB\;4XVL:/$XR
M#VYOZ2:W+,-RK5U_+RF+,J<N:N6D<#NF+-?.[YJ9M%(JV2*+MQR#30OLDKHZ
M<ZIKD40>$/C9LGEZUVTFM"R:YL&OJDH*9\O\_!(O%3PT^^K";WR[O(A(+@W/
MDB(A>9,56\9B31G%T=@J[,2]-++)O"?Z38BLWA5(T]6TKFLYKZL8-")?8V!6
M)W((K&1($E+,A%2C@8H=6&-6W[Z[9P;+./V%M=EUG#]PNX455V^_!%B'5E-.
M.A>:;^I(8L#82&U:4MNMXJ<D+51R,C<DL*N)1!AA]QENW=/FZ(_:1*9>+CD=
MW_\ '*/$&^BF5MDE"*KX_P#%O<KZV*O(A[;K-E39!C\>!CHH&1C<H?6"0G'Q
MVG'TFA.*F,MW[($SB]CD?X(=*-90.P3"L@Z[X7^VX*J,FI%;.:H>G9%/XM:1
MJNHP0G\*5W<1B2K#]=7@MWG4KJB_U12V39.R+#^>.["2+YJZ?!E#AE04X9J%
M7^S@BVJN@BY16;.44G#=PDH@N@NGHJBNBKIE-5%9)3&VBB2FFVVBB>^NVF^F
MV==L9QG./$5+\D^-R\!FDVF]3V+4(JV!'R=R?Y :693,)+7];Y R6A&=!N:U
ML%O']A!T<\U!$)*40)1C^1:M': -%/19)9YEJ12PH3@6K:\XRH_D:W60RXF%
M5QR*Z&) LW)1K4Y-H_*,V%_40O DHB8$,AUA*[2.,,<EUU!#EB(=Y64),$G>
MI%.D>Q;BQ[$8S_/^H.9MF+7]IV[?N?UVB.C=#]A\_7<OGJ_XD]?RNWKEP[<J
M?<LY756WW4V(J[.I>#U.D[\"V$K(@47@A#D#L7F.PF[)BOB9E"/3XNH8X.EP
M[=)KJ->[1F/5R[9N=BS])WMK@$T:X4:-M\-R+JN ^+;:YX?6]-^C9K5MB6)9
M<>YSKEDWK",R 3"Q,#Y>K=S7\$**MYB])%%)G)G!<_)9)^'.@P2Y>,Q@=5PW
M9_LJ$5B$7A\8A;4HQBH5D#:&I)))@508Z;:)OI/,#+R0R8TOC;;?.STT;(/"
M3W?&<:[N7"FVNNN,XUP1:QZ9J1:]^>KNI]@H&9G+*J*SX#&C!YKLY'1^0SF!
M2.'#3JWX6[EX@F/W/;[.5V"6S[#'=TDWUWRKE/<BJAGWQ6W-)SU5"0EN5B-J
MP]1OQ^T[U.-*1N5/YJ2_T ;:WN*+$Z3,-7[(0PTL0J[>10_K,!F=PH?1$T/3
M>$5=F#<BN(AE/UC7<DG,OA$)!1F2V4_1)SDP+:Y0=R%XW)R$XGLZSG?9-%'^
MH)?+Y(JT9Z-F:\FETKDBZ"AR2FR#XBV/MKKOKMKMKC;7;&==M=L8SKMKG'TS
MKMC/UQG&<9^F<9_MG']L^(J6YO\ &M<J9NU;%J6?U$"L-/Y'H-WE1 :5@I2Z
MKQL/BG+X#FAY6EB-8[_$EAB;P,I+R3!_$OY%$=O_ $[KJCOC]U% BFSR!R!'
M^;.<>:Z;E3T78\RY[9G"XZ>8%K"TDK!FZ<QS.Y!&AJCMTJ*8$-+!EP4<U=.7
MBZ  AJW75W<?<K@BF9XB@#T+Q:K>?3E37%DP!!0B-<]]<4G8PULV<(3"1N^D
M0=01D8>&.D&6[!=2/!*X=LW:Y9UJZT1W"MV>B[=MOH@11MY%^,*00T-/F':,
MAJV\?Y:J^/:%AH:MP\YAD?:5]Q&A+W-3S20;OY'L8_Q++RF9.9<43%/=0D=+
M!@NX-RX4;:.$2*X,:P;"A[ 6S_/^F-9-6#7]IX\(.OUF:&C=#]E^07=/WR_X
MD]?S/'SEP\<J?<LY766WW4V(H@_(#S(8[ Y'NCGV+%(U'9A8T9: XY*92U=+
MC 2R<ECYIXJNJ.9O2B"+MH&W:JX8H;[J[[HZJZY2USG4BB4\^..TG?<"ET_X
MHP#7FMQUD$[F<0O^FY%_C'B] /+W^C(VB*4@_D\Q#-9KL]4IZL]W'_U'H2TV
MC:;7+#?!70BLQJREZKI(24!U1!P<'%FRB)DLU"H*:?R!!H&$QH<HY7<*KN5$
M \9 @HR!8Y6_1 1H('CX9LQ#BV+) BV?XB>(GB)XB>(GB)XB>(GB)XB>(GB)
MXB>(GB)G/T_OG^V,?WSG/_T\1>>3ESY3[IGG7$@6M9>'.N-^C8OUU(.&?Z>"
M-&$Q)YXTFR4>D3<Z9W>[;DG-IPP3+;(C2)%)KJB+&HZLMU6NVZF"+*G/SAMI
MA1-C3ZN>3+NB4W<\%V3W+SNG;J]4:0NUH/6^HP7+'SC:)6T[.B1T*.&FQ<D(
M.Z1:13&&BB!"'H*O2T6;&2*-]U?+YTS!XM59Q&,'XG8TAHCX\K;F%,*U[6DP
MPZ']&=-&*KF;Z%2N.V6<R1D-E1$3A["H6[3:(1)L9 ;$SR$IV.!A)%8CM\NU
M=L0DKCL@YTZ# =11CHR&\L)<?N4ZH(6P?M>R(%M:D!V$RP/9I"FM8,<K5)],
M7DZ?V,S"A18@IEYMMO\ Q/\ +D7+W^6ZLWL$A:T6H.^Y3T1,NEYER)_HD-6]
M9BK<CEZUM%U)Y882124[8HZH&\7C,"PQF6)RQL4A'"80\!6:NL*.2*8DBC_Q
M;\O"\Q""T>KHQ((*XL*QOD"WA<X(A(Y&8_$HQQS+'I1_5$\'L#9!1C9H6ID7
MDB>N4%7PLMB*2?9$DLJQVVW(IRR+Y!X)#.+:E[(E]76F*2O)"J&5644U8Q]_
M<,NFMYE1XJIZ^9M%3K"+,Y)*,EQKU?8M)!PL&Q4=JE'Z.[%5+8BUZ?\ DP6C
M4;JX.9XUZI&=-W+:UA5#7?)I895H2PI(5JJ-XF,[G0JP#%EL:4)TZ&C&[<@E
M9PRQ'H,FX=(CA^B[I-YJT(M9._F4K<RTH9I4'-/1URSZ^8YTD18U1'FE7QB=
MUW*N4)&#C-S02S,3JQH[%@)F-OBC_;5VPDQ<>6U%)-X^J9?GX\T(D79I_,-6
M<R!4P3Y\YKZ?Z8-VKS:*ZX.P2IHW7V\WJ^BRDH<P= K(0TJL2.Z2R;.I>.-@
MP]=5J[F4C.;@"S]BGL-U'NR!%^7+\T/,5)])..>9-')ZLG%I%2\-MFQLD:QC
MXNJI=T W#.ZY#$Z[E]@QZZ)>BV:R( ZL0O7M<2D76R1AHG)7*+Q(BT8D765W
M\QD,LB?PJ%C.5^C!P:S[>Z&YWK"RBBU/-X+.K[YZ1G+\K78W.UGZRD<C*QL&
M=X S,]&14/1-/T@I LA_$R1\%(H^<I_-/:5D5=QRVL_C"WIA?G8*_01.# :1
M>5/O$WD.I2P@P4U,=MI);>58G%0@:2.!*ZDQ,-#[XW 32^@S+.311T4(M^3'
MYA8P%N>U><17.UG)7 !K7HZ:4\R-3?GUTUM(KS@!6-2(:9C,<NDE.ZD8R%KI
M_+PA[;H*")S("V?.1RK5VW4;)$4>*+^8XNTA=37%UP,DE;!2?Q>Y[0G< BT'
M@YX;)C#F\X15<9D]?R,-91V0M'=D.Y<*'0&JS[1#9LSD@Y>;2./R%B]&Z$4E
MIA\Q=?57 [H,79S-T93UL46MSZ2E'/TH;5B8L0_ .E;$'UM7-A00G"+#E,'D
MXO60NGHV1AM).SD4>/"'L=)C4".[3]@BEUR5V8'ZF<7Q&B%1V=0UG<VV*SKB
MV*PM16!$3@4@:AX2?1HHQ.5E,Y]#C LY%3[!XFH.D*ZS5WH[:JI;(Z-'KTBK
MQI_Y<IB2K+F*2F.?+1ORR>[,=96WSW6M(H5N%WBU,4;-&+*)@I4;LB<0@/DH
M]K8@*F):1/2V<O#;@L&%L5':\;!N2+0,[^:.:&.Q?CC-5*L.$<*]/T#%[8N)
MM8$5',IU$\65=;SG2,D",C:DG[2-IQBTY/ V1[]9Z0"+MVQ%1(BHS>:/,$6L
MN<?EY[#G',/<W6=C:0W^EN6N@.;+%!P5E"$!Q$MQE=*,:G1>,JO?V-77]=H4
MQ/Q$F"25?79760@D&KQJX8D'B.Y%ZHTE4UTDUT=]545D]%4E-,XVT434UQOI
MOIMC^VVN^N<;:YQ_;.,XSCQ%]/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1
M/$3Q%AMBQ#>P:_G$#TDD@AN\VB$DB6LNB2H]O*HOF1AW@?\ J&-."P\N+0/A
MOW/Y .N1%$F*)!NW4=,':&N[=0BJL1^#7@6.Q?GX;5==8I2><^&(J4&WA5H6
M! ;ELEN!A1B"2 );4P<PLA_6 FR YTBXGR7Z(]T4**:/F+H9LGC3)%GH7XE>
M=1,0JZ"N)=;1>.5;PK:WQ]CVSXY%$G!VFKA1CS:4GSCH?#62F+!0;QQJF(+"
M,"P;3+ETHO''2GZ^R!%J.5_"%0T\  1$UZ#ZF/E8]4?/-+,IK_5-7!)EK$>8
MKID5TU8X1*1VI1+5B?&/SZ4/7,#A[5?:*  BC?5O*DR$F($6QL_$32KN,294
MW=O2A^_9+T%$NG=NN2$P@:'0(>VH!!\UC!WP=P+K4?6"49C=<J.X6WAKRM'L
M<>@R+] DP=JJ-U6I%S5/B4I!"NX='X_;W0\7N.&]%2SJYOU:)ET+<= F[UG\
M=6AD[EDB?&Z]+5L182N$;M8:1BFE;MHNE'1 9DR%-MF.5EB*!W57Q1!G54<O
M?'M5TA-GH-/>L;.Z5LN^[CM1_K<X(&=6)*WO$(NQA-3HC9NYMNO[,G4.67DD
MEB39HF^35-YDV76RK$BNHZ9Y/J_J2ET*2F*LDAX8'((',J^E5:DFD9FM6SFK
MS8^05[,H 3<#BHX4:BI(8VRPU>""(U5GLX'O&#AFX52R112(_%A!BD<@KEWU
M%U\XONM[?G5V0[JU[9$,*W6"E-F11&#3H )'%ZW?TV'K:111JS%.ZW"U2.B>
MFS70D@/3*+OGCLBR:I/B]Y]I25<_S"&2*TE#7/\ #>E(NQ>R&1!3C^RC75YX
M%*;>L2T2CF-:DSLZ)R$'H38/A#H (9[/7+/(58>@.:,2+2[3X7:.CD(IZ'UI
MT'U?3A&J^=MN4#,]JN?P>-3BVJ%S+R,Y2AE@$UZT)LF3UA(C!=T(EU>#8++1
M215^W9&4TEM=4R+<1'XQ*HQT2\Z'A=Q]%5B]E+^I"]K5Q"YQ&MH+<ABDP+&*
MPHG/"$JA,GLG5RZC P<!FG]*V!&DYVQ9(JR?0@0RL^5(OK!_C#I"!)4$B*FE
MJ.]>=^K+KZ[B'\B4B*F2]@WK_B-_5,?DOZT-:X<PP9_B:;_@&8O HVAAD+_D
M3Q/\3O\ <(NCYF^*NG>79S1TTB5M7I,4N<A?1,;I^+3\Q7I !%(?TF:B$CEL
M2T4CU<1HX0$QX[$U"D3<$C#HRW7DAY(R4-,\B&PDBUQ5'PM<\U'9T-L03<'1
MDC%UT\Z9S!:SEDGKM[!8T%ZT$&QUQ@6^XRL1$R*X+O3*1MI(9'+C4M;.P0%@
MJ>< F2PIT1?&._"=S*RA;*OIS95^6U%AG&Q?AL4UG4C@+9Z*II>V8W<,2>#R
M,*KB(N4)K6LCB$;:0@]G*B* \0U5.CCI7\A)0BR4E\0=,RZ)6F,M6].EKFL6
MWR_/:\JO.RY77I*SVL3YDL4=9U85Q'<A:R PD'#-).Q</),FUAV3TH=F"A8N
M=7-J-230BFI4/+\&IJVNH;ACQF4E)!UA.H;/Y^,.NA*P,(4A-:QZKAK*)(CP
MXY^T&NP4;9O""9D@;=*%5W2K9TV:;),T2*!'$/Q\QZM$.>5);+##Z4_'D:[!
MH"F\QA^SUBLJJ*]I,'D4=<3D<6C/\RE+8G ,1"/:H@C340B9&EG6RIID[9Z-
M2+&2/P2\FEZ8#T:5GMY/XJ#X[=<6CWZYR ?SB4!5OT'T:RFN'&E=:L<6.(L"
M.BM1I+0?K'4A#?\ "M&EWV<$,$7QZ!^,> 1VD[FHFGI :&".\+/X^JRU_P"K
MBC'^-@]0T1$8+!3C.N6L>B;=VH>D%-U$X!MFL@>N&2DJ/9)9*"!3?4?J179)
MIII)Z))::II)::IIIZ:XUT33TUQKIIIKKC&-===<8UUUQC&,8QC&,?3Q%_?B
6)XB>(GB)XB>(GB)XB>(GB)XB>(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g713200g01c14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g01c14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1=.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/T
M   2 #4    ! "T    &       !.$))30/W       <  #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #*@
M!RH          0                         !              <J   #
M*@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M*@    !29VAT;&]N9P  !RH    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   RH     4F=H=&QO;F<
M  <J     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MNM:'OV.+ZZJX+W$?SK_6_P# %KJ+&-8"&\$EVI)U<=SN?Y124X_[0^L#F/\
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @    D   "PAVD !     $   "\    Z  MQL   "<0
M "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W
M.C(Q(#(P.C P.C(T ')R-3 Y,38W       #H $  P    '__P  H ( !
M  $   <JH , !     $   ,J          8! P #     0 &   !&@ %
M 0   38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M     0              2     $   !(     3A"24T#_0      "
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M     0   RH         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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M05%8=YBXUB0G56%Q@9&A\"4F,D=26=@I-6F'L?_$ !0! 0
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M6L:/2AZ]?F9(1Y5:)E=,FP728# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MQ(\J$)\B#+S\FMOD-O8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MUM7@<4=]MG7*(6*8# 8# 8# 8# 8# 8&C?2EUL//%(6!;;L6ZD1"."D&</B
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M7C49FT:/'T(T1:B7H^0+!Q9-T12"/F9X&[9E>V_+%RV,BET5^TB#3I8-D8#
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MUF[2201.3QTL2AU=U''5FR"":,DMN9P@822018A5RK_\J/5#K>F/R$W)O?!
MO2_C&$OT^/N3BO*WI/T,DU[^S?>DCLC%1*B(!(.-;4X[YZB'H &AWKGI%T^U
MO[^0[8!\?7GC983*[B9S+U7/@KK@@.FGJ>7/KA_2BB7?WI%8K7A5)G3->OTN
M_P"Z17K>M(A^%U_=<Z^_?7>PVUZ;].T7XRI"87W?\U$U[5\!%[</7KC[>GA!
MS]OX0J,18*CO3L[)#3G\(<# C$E'+MRIQSKE)NFLND&B?C<]EE_>?G+OT6_K
M\W6P>16),Q4(CQZ,F8X]4@HE0?\ LX2VX.D%GLI4=(.E4R4H0!Q(0[-MR@T
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M#A(:-];^(?1-^^B)%8\6YIP96[6'U^ ' 2-G6.#.71R/G<%EDYBMW(M*RE+
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M/B30L\F]NR&9FV??459Q]$,';?L?ZQ]--M&;DECSQK0[CE,KJHJKDO'/I60
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M$?AUF^0*/B#6SVDF V'+2DJ0"5BQDY^502:5U^O2@P]VX%<B&C$>D%_& P&
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M5U;'=FW'%TB2]1)5X%2D[D#MS/.R1QUVI7J#-48EP%R55?X+ZW_S"A_^KP[
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M]+[CXMFE3* ,O:/\);=66@X;V[/," =PX;6J23?I)LPN$JK_  7UO_F%#_\
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MWUUUO>PV)K6M?7>M:UOK?UZWK7T^N_IKGZ[_ .??TUK7UW_R:UK^36L#]P&
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MTZH\%^(9964"D44C4@ED=*Q($N*DC>W;_$<&6W ]NCM[V'=60@[".5%4N]/
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MCLS*F3 NV*/ Z W2SM,,"4^13QBFT7(:O$*N.0(LA_))G')N_'/$7B,]65D
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M6)2C<5D(D_J.RD7,8KT2CAS8IVZ_2CC#E='IX*??@/6VE4]JH<:[Y^H6+X#
M8# 8# 8# 8# 8# 8# 8# 8# 8# U;<5<.+1AJ<?''TXN=$RV!SN,'W C]H&
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MG'7)/ITJTZ[8\,W23OH)8X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M)+HZVC$AB UIN)VM-8N!5#!I5UV?T(>1D0%=,2)'?*I=-7]4Y323=\)\!*_
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MUZ%J6 P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P&!^;UK?\NM;^G\GUU]?I]=?3?\ \=;WK_V;^F!^;YYW_+SS
MO]WV_OUK_P##_P#I_P#9^[^3^3 ?9QO^7CG_ )O_ ,.OY/W_ +OY/_7O_P".
M_P#GP'V\_P#Z>?\ EU_)K^3>_KO7_OW^_?\ S[_EP'V\_7Z_;S]=_77U^FOK
M]-[^N]?^_?[]_P#/O^7 _/PT]<_;KCC[=?OUS]NOM^N_KK>_I]/I^_6]Z_\
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C QN2<P";RN+-BAQ@2<LAAMWPS[05_!52"9. P& P& P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g713200g02s93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g02s93.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $L< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,# W,# < @4
M(DUI8W)O<V]F="!7;W)D("T@5$I-,B!,051%4U1?1FEN86P .$))300E
M   0V:N'Y2'T3<WW. [ AX81:3A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!Q;ZX0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  $#P
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  +^   &Q          !                          $
M!L0   +^                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   +^     %)G:'1L;VYG   &Q     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "_@    !29VAT
M;&]N9P  !L0    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     0X0DE-! P     #FX    !    H    $<   '@  "%(   #E(
M&  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $< H ,!
M(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54%^9B,>6/OK:]
MNCFEP!&F[43^Z5C.QOMF)0]^']O?2^\2ZPTQ%NV&:,:_=L_XO]$KO3W[<_+H
MD,]QM]'<"[W';ZO[VU^S]])3;^W87_<BK_/;_>E]NPO^Y%7^>W^]'224T<KJ
M^)CL#V'[3)(+*"U[A#7/G9N_.<STO^,L8JX^L>.YCG#%R06AI+7,#7$.=L.Q
MKWCU'5?SMK&?X):R22FAB=9Q,D6%P?B['%H&0!67@?X2H%WNK5C[=A?]R*O\
M]O\ >CI)*<K)Q>BY60[(NR 7NK=46B\AFUPVN_1!_I[_ .7M0_V9TBRUI;G9
M&\D!H;G7>/T0T7_G+90<O^:;_P 95_Y\8DIJ#H6$UK6^IDRV0'?:;MYDO?[K
M/5]1VUUCOSO_ #W6B8M.)TRLT.R7NWN-@.5<;'ZPV&OO<7^FU4\IHOR,ZBRA
MV8QKL=PH:=G[SMWJ?HV^QS=_TUGYK*\<X+6WOZ$]OI>B'/WM>6F[]1R(>YCJ
MGM_TC_\ II?BK3J:>B^W87_<BK_/;_>E]NPO^Y%7^>W^]5J^HY5>+9?FXKF"
ME@>7TN;8U\5MML-30[U/YWU*:_WU:;E4.&KMAT$/EID_1^GM253FL^LE+]#A
MY3';2XA[&@ C\SU-Y9N_JIG_ %GQ@7BO$R[368(;6!)TX-CV?O+78]CQN8X.
M$D2#(D:$*22G(;]9*',>\8F4TLV^U]8:YP<[8[TFN?\ I/2_G+/^#5C$ZSB9
M(L+@_&]-Q:/M %9>!_A*I=[JE?224@^W87_<BK_/;_>E]NPO^Y%7^>W^]'0L
MK^BW?U'?D*2G_]#MCC_:\/'<[#.:6ON( M%0;^E=MUKVUO\ H_O*6(\5_61]
M(KVNMJM<XZ?198S;N>'%SM[[G/96YOZ/WJ#L+U<2C=A.RRU]SV[+C6 '6N<W
M\YFYVQV[WJ1&SJ0M;66OJO(W'<0&W$4NWN#_ $_?NKLK9]- I#O)*+7M>T.8
M0YIX(,A210I))))2DDDDE*0<O^:;_P 95_Y\8C(.7_--_P",J_\ /C$E-2J_
MT\[J3W N92VMVUH!.C'/=M:SW[G?RU2S[7Y>12ZAH;N#'.Q<I@;ZS0ZS=0SU
MQ[;_ &^LS;]#8M#$8[]I9UD>UWI ?%K7;E1S\3'ZUDU>E='HMJR:K&<R'6-;
M_*9ZC'/1 !-$T.Z0:-T#X'9-C-PJ\>_[):_ L+6AS;?\$[TZ_3_16[JG>G2U
MBT-M_IP=ETCN"T'CG^=_ZE4"[J%6!DMRF,R?39#9/IEX%;-^_P#,]]WJ>_U%
M:;Z0@^C97QJSC3_B'O1,3X%'IZ6$&'32*M:7,BVZ#4[0?I+'_P" <WZ;BY^W
M:I-+?VA>&93PX5,)IL@L:2ZYWJ#=M?[]KO[%2;$R6"HEMX'OL&V\%ID6.:?I
M['>WZ#45EQ.5;+"Z*FD[#N!!=:UOTG-;^;_HT"*W%)H]#:UN5E5NQPQK+Q=8
M6.<S< &['O#O\(UOZ2O9]-$R,QV/39:ZBPBMA>8VGAN_;[7.?_T$+*^S.LQ@
M^F0+3!+" TBNT[]VWV_2<GRPQ^+>ZFUQ/I.]K8LU(+FNV.^/[R"->R<9=.TN
M=N9 !.YKF\Z?GM:A9650:',:\/-K+ TM((]K2YW"*P9#:]"UVGM!!9'@UVMB
MJ=1;:YU+G5,(:V[<_1SFS4?YMSMCF[W?R$E/_]'N#BB_I>-9]F?F/!+7,;;Z
M9#=Q>ZPN)9NV65M^@K%-++GY>,6M_GVV&IYW:!S;/5_.]S]OZ+]Q_P#Q2":F
MW=(H:W&LO;7<YHJHMV$!C[:M[G[J]_\ PE:J[*V]>=8RRS%R1+8LCT;:R]I<
MSUY=^L-W6/93O_PG_!I:==$@2/RBZU^CJ57WX5&+3D<N+:S<\"28<YWJ-H_1
MUO\ 9_.?S2T 0X M,@Z@CA4FWW>C0<VAXM+P#Z$O:'0_W.]([O2;M]V]+)%-
M>+:^EQQR6N=P6M)VN^FQVSP_,]*S^6E2+'DWDE4QK;S72/T;PZMA)#B':@;G
M!CO5W?\ ;J>C-=8+39194*GE@D;]P&WWM]+?^\DIM)*N<[#%C:G6M98YIL#'
M^T[6D,>^'[?HO<B.R*&F'6,:20T N ]QX;_624D0<O\ FF_\95_Y\8BR/%!R
MR/3:._J5&/\ KC$E(,(G[=G@SH^OG^HWZ*FT!O4RUHAHH$ :#Z;E##+1U'.K
M#0(-3BZ9)+FGZ3?S=L>U2<YPZFXM:7?J\P"!J'.AON_>24W$D/?9,>F8F)D<
M1.[G][V)"RS2:B)VSJW2?I=_\&E2F3*VL:6MF"2=23J3N/TI5?[!C_:GY!8S
M<]C:Y AT,+W?3#O^$1?4MB?2,P3$MY!@-Y_.^DG-EDG]&2)(F1P!(//YZ.O=
M36R,4FW&++;6AEI<0(L'\W8WWNM;:YC?=^\H]0IO.%D&:[7"I^W<P@SM=M]S
M"_\ Z%:MBRS2:B/HSJWO]+O^8H/+[*W,?2XM>V'-W#N=KFZ._=]R-[72@48K
MM#1%4" (KM</Y7T7-K5;-]7U*MU=L;;I<X,<&S6[\]CM[/Y*O[[ (%1,;HU&
ML?0[_P"$0,P6OK+MD-8U^XDB8-;M1!_-=[4M.P39?__2]-=@8QQ#AAI90?S6
M.+3SO^FT[_I+)NZ#T[(ZQ=:XMLR0VNT"UMKRP;G;-KO593M]5GT?_1?IK>21
M!(V)'DIY^CI'3K;/L-3JC^SG-=74*[1Z9U<UV\W[+'>]W_HQ&HQ*<S[30S(#
MQ6YU5[0RUH]PVN;/KC?[?SZUM))6>Y^U-EPL*C&NPS?3D--&/+"=ES=K:A[6
M;;;M_P"CJVJ&-B88Z;;G8][?L]^Z^U[:[R'/,>I;Z+K_ %OS%9OS^H[S]ENP
M'L).TV6N:=OYNE8L4?MO52P.;=T\VR[=7ZKMH;[?3<VS;OW_ $MWZ-*SW4AN
MQ\.NAG5WY+6M%897>67&&/<UP#:FW[V^]K/ZB?J&#B-HJR,JT&HVUO:\UW.A
MS??4]PKOW-^C^=_;5AV=U/UAMLP?2@3-KMP='N_-^AO5_P"VX7_<BK_/;_>E
M9[E#DY.)BXEE&-;=76<I\,9Z5KMQ$?G,N]CM[Z_YQ+[#AXW5L9KK0W)LKV,
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MYWT]]?K?HO\ M.OGI))+](]/=4S%=8UN1NO.XT6FU[:R'.WLKMKK?M]V[?\
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z  JD:@  "<0 "J1J   )Q!!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#(P.C Q.C S(# Y.C4W.C0U ')R-3 P
M-S P       #H $  P    '__P  H ( !     $   ;$H , !     $   +^
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0              2
M  $   !(     3A"24T#_0      "           _^$!2$U- "H    (  @!
M$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $
M 0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,C Z,#$Z,#,@,#DZ-3<Z-#4 <G(U,# W,#        .@
M 0 #     ?__  "@ @ $     0  !L2@ P $     0   OX         !@$#
M  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (
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M 0$! 0$! 0$!_\  $0@!" )4 P$1  (1 0,1 ?_$ !X  0 " P # 0$
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MM2L'^5/O?J^7'A$_/EM2O6_0*(4X.\52:B2\(+'@".OUN&><%!B7,/108ZW
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M0^!1NP#)H0(6;C?>C@!F'B4#K=QDD G,Q!.-\ G^E37P? NZ7VI=7ON$VO\
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MF(L+G</HS**CIOL=V&LU"P58.]_7I@YM&JK'M&5U>U',(DB%0L.U3T1%:>;
M(KH,4_%1;H9HC7F(T.\A_P"6O^ONHJ0G&^/Q'R/C7$?VB?M(NZ75[NA)U*O6
MKM#&:049<F 0).@:CKB+&<,YDM3.J;!,:.G8^PTZK-)C\?%7BK9-/1);^)"0
MCY-I[WS\[](/2#B/"^+LM-)?%I .E;+80^H@%26G2RJ4HD"=1.8)2<C[S@O
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M>*XYVV[JJA2'T(&<&BX",@<GZ =R8R4K*B<DY\P1,$'V^-9XR.4X\#G!!\?
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M-J)S:'Q"NQMA189D.WPU>*V1"D]]048)A6" G5D+@S'0GG $Q&1Z@&-L01.
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M!*>9C ZG-9J\CXD9Y$[8F0=_9Y]':#99JT4&+LIT!*1<G("2) ,18P#*S,F
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M;#;=Z_9OM#2IMN\N.)V2T@0GZKB"$J3W8PUV)U=XJ4<U,6P[-M"B:_'DJI1
M]QWIEL,:0 "L$+JV"=)]V\#YYXJSR$[\&@VR$9><!8)LLP**XEL=$N\RI;O/
M;M,7#^A;AMFU&$]QQ]4G 2.S1J/B=/D#M7IWUS?V-EVK%HGB5P@)[1*'K>P0
M8]9S5<N:$H&^@N%0& I1S53.N_M ZQN1N:FK[%ZYT=48V9F:I'REKWG4Y21F
M[7 'I#D!111HD" 1#D-*]\A)7-I658 <CS$-$&UN0C)TWOON$&T2DMK>N%*2
ME8TVKK:="AO*\G_2#@$F!!/SG!O36VXD'7;MFWX/:M.N6W;7W$[$*<N&EAM6
ME"%E*&5J)[!UU;9?&E33:D+2JN@P,B!)BCFQQHAX1;:7A# B6"Q2F5?Z+HQ
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MM^N->[!%0%?:)3;N&VK*FQ+=6(2R#-J4GRJ4VQ,@FM(5E/Y.<I3C.<?+QY!
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M=8J14Q<BW!#Q*2\W 098)=3*EU3=:;!A:_.3R)<RO0<O%ZCU"F,:5&2$C?(
M.YY>\@8@UF?UO&/+D<'D<](QMFNE]R59D5B853I"M1-DP+CX;+7 (^2K,2KU
M6\$RDQ%Q<G"'RHL<%DDW$4/.P.9-UAH!<]"M$.2@F28U#5J(Z)C5MB)\8]E7
M,QC!\?GE[:H91.U.\3YWHK!7RFT")=[-SN_8*[$1+-E1AR-U=3+[;M>7_7PL
MC)Y(@Z]M.!JM?NC-?MF)V;K\);6( PQZ6CWY-RRTI25@3*2!DCV@B-P9Z1M%
M0#.9QTQOYGY/PK+=3.XMB[ V*C1UDK41# ;EZOU#MIK9,,-),F5ZBW"XRD -
M3;P](2)[)]J!ARJ;).2L8Q"AER!UFC4P@S4$,;)RM*4C!5(,&1@X!D8$1,09
MG!!BDF9Y=!DSM^.?(9C-:CNO?5%V=N'HO7*] [HCCF^VSDFX_L#K?V(U-!9%
M&ZN]FV'&D6?:>KJ;6GSUN%L^A$LRSDH6S@E\8-X<0MUBJ1 4<>J>8.Y _K4^
M'D1N-C._LV_I5#>V-JZ55?N906JA=].ZWM1T!UW@6;+KJ)UD9)P5H9[D5DA!
M+#1M<L=9C)R(B!K;(SD@7%^^!1(*$V%>8A0H[WS/$'[!CB+(6\W;O+3:(4I"
M4%PJ^GL%AM04D@:CJA4$H2"K  KZ6Q:O7N&O*[)QYH*O%)*E.:8^@.AP84#!
M)1$>LH0),UV+ZPXO\Q0PKI?-LV_89DZY8 DQD]!:RAHN(S!VZ=AV2H[Z"T"H
MR#A!(4>.@K$F?(C97A;@XXZE_+VK4.]DA;KRW5K0E1"DM!*51D([-M!B3]HJ
MP!!WGQ;LM=LI++";="%$!*5NK)Q]HNN+\Q$1L9JS'.FN6G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M@"6_E3:__4!M_P#O%T?RWV/]7]*5/_*TKE?VCN$C+;B'H<?L2NP$Y$Q=&S9Z
M:BH=A"'MG REXM9U.JI[E$/CH(ROC!MMH-;9DS$622D;+7[((742#*I([MX$
M1ZV9.G&(.=\GW0,$R*H>9'+'/?K[!^),\SU/Q]6/GX_+'S_G_IYA5Q7S%&AA
M89R86*)@DE@,?)3[0^""R7,-#"LY=6C#I)#JDML,(\SKKBL(;2I6<8XI7J9E
M(P@\R*'D0'Y2.;&=D(UDP=T\!HQ*EB.&!H<40*V4E"U#+?;0E]*%9:RK"<YP
M@[QCK2J<>T QC\7ZO9SCQSCMC[/_ ,O]&<]].M:?'_Q_Y<T;];>.ZN?+0H_T
M_K3N[J2%0%  _K*24I/^E1"O,"J*][?9@-;SE[#MPC;&L:"F(>L<X*M[3T0)
M,DO2KHQ$3$S6P)C:4!'R2VI9ORQSUBQ&PF)25?P^..&<4TOQ>*<&:XLMI:G
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MXI3BE.*4XI3BE.*5 $M_*FU_^H#;_P#>+H_EOL?ZOZ4J?^5I7+ON) PL_N^
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MUI]5:D^2B/P-1M^*UHH7Q^C5*?UUE7^EG4%NN^F,KQG/BI+F=462F^HVO/\
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ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE0!+?RIM?_J
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M_P N*@['R/X5!G77_5U*?KD['_XB=I<WN?\ -_\ Z3'_ -!NO#]'?_ASO_\
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M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4J );^5-K_P#4!M_^\71_+?8_U?TI4_\
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M7O<X+86'$75L75Y>VKP9NWD?1[%FZ:4S:6CMTYK6Y?VJTK4EE:$I#:TR4DK
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M2\^@E&JT<3M>O2,--SA\9<ZH)7&!WII%RH=PK3HOO&7,8]T=/A4@3[;/I_\
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M7&TY0VLX 4M;:,Y\V4(40TXI*<J^>4ISC&<_/P\>:(>=:D-.N-A7K:%J1JC
MG21,>-00#N ?,3OO7TA@A1S&!H\,4$;"E+P.&.T,QA:\^*U8:80AO"EY^:E8
M3XJS\\YSGE5K6XK4XM2U'&I:BI6-LJ).*  "  !T @?"L99961A(0Z5B:S+7
M&1$2SD:N015?"EI/+I++#B RK3-5Z!:R.TXLQ[)\R$E0X[J&%/%*8'>TMVFG
MWVVWKAFT0K5-R^A];;4))E2;9FX?.H@('9LK[R@50@*4!) , J/(",GVD#WD
M5 O7HC8<:'8:W==/W"BH-OFW+P)/3,_J^6BGA+SM*S6^&B,,T_8%FF42S418
M1\&Y=BFXMDD,QEJ2?Q@5PKW./IL'%V]Q9\5M;THLN%62V6F.)-.I59<,MK1Y
MV;NQMFBT7;<Z(<+I2M!+8[P3DT5Q"FRC*B)TF05*(]52LQ!,P!D3,39?P_\
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M0%*2"?LE0!VG8[XZ3'.,5TJ]&/2,,N7*>"<3?M&DI4[>VEHY>6384-0[2[M
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MRK*[4E*&YYW%L8W( ?05*C<)2D$J.P SO6EHDE3JH[HMKD$X'>+*PE.=RHF
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MC'S\N?%/C\O_ &<_/'\V?JY,GJ<3&=IW]_.FE)Y#W>,_ Y'0U\IL='R(ZQ)
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MQ2G%*<4IQ2G%*<4IQ2H EOY4VO\ ]0&W_P"\71_+?8_U?TI4_P#*TKE1*:T
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M_0TC"4I0A./+C"<82GZLXQC'U>'YO#^;\W/CSN9,F<G>?&><U^TIB ! Q@
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M3BE.*5 79EMK.GYQ:TISGZ1:S1G.?_<SM&F9SC^;Y^'S_H^7U<]ST=@\69!
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MI6K7EC-KS>W[-*UXAK64+U)AJU-"/@-Q\Q&%&;2D6[^HG$O8-F/NS9\J/H"
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M%Y2#@@:DK1/)2=OWE)U('B2J!UWIV2C&DH5/18!_A5"I\(_I4[@RL;) QLD
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M5'L[Z#1HJ$KO4G=URBRDJF$6RV>S8[)6Z=L>9=7OZ)0N=(ZW>F4PZT\TF.9
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M[UNE2B -2@R\@%4 "2)@#I71=7-Q>J2N]N'KM:!I2NZ=<N%)2<D)4ZI9 )Y
M@5ZF+]T5&:RR-TLVBPSGS^+3/LN>QK;6?4QG#G\&CK=A/Y>,YPOY?E8S^5X\
MASB?%7;E-X[Q*]<O$ !%TY?O+N4!((2$OJ>+J0 2  H0"0,&B;FX1;JM$7#R
M;56K5;)=<3;JUQKU,A0;.J!JE/>@3,56*IT[V:>DMV0N[XWK[VAKEI,MY3U
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MRWEL^5_"FF\(7C&58S(,3XB*5(O(I3BE.*4XI3BE.*4XI4=G:YCSMLUG;:Y
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M5X+:AV-K[BO1$QE:5/RL#("0SCS2(T-]N=9SW4Y_>Q,3'>Y@#>?"*B#C.?\
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M[;K?"Q52F+?:Y4M/J%'"52*DF5ENE21MFF;S/2TLL(F)"7*44L*"C]I2I,Q
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M$VABP%GV7<?9^=T)*LQ35*:+%S(U=6L6M8F89P3EA^D"UU*&AP/=+@$JG4D
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M,*S0;#6%0H85><B!&<G=P#ZP2 O]Z3N9,F(!/.I3/*-.?^.G+SVS!K/]//\
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MRESB9.JQS!4\"4 T[->3I,#?'@#^!%-0SX?'R_/:JV#[/ZU7_M[?ZOL#2--
MV-JO7VH+36MT6:%@I>5LL/=-H=FJ) QK#S<0])PXE.L77/8-F DY>0=B0(B:
M%L 9$5EXU?--+B4@(4HXE0 (TR 8ZS"A(&QFJXW5M./Z\R.GNP*MO5-CZ3[!
M0%O@JI::'M6NI"17;W7ABHJQ@_";A (/$C;3 /\ K^,)<ZE*,2T2F4"^%VRJ
M2HLO&*DH.1'*?R*5((D%)W'L/AT(JX((\-OA[ZSNO-4:TU+%/P>L:)5J'$%/
M)(*CZM"@PPY3[;>&FG24!,M9(6PSCT1\O97[NQX,L^1K&$8@J4=R3&T\IR8]
MII ]_P _/_-96S7RC4K(>+E<ZI4LR/KYC\6:Q1$#D[ N6<$Y#Q*F">]>[Y(8
MP_Z'G]++S/J>7U$>:I4E/K$)\R!^-6"5*PE)4? $_A6J?AWT?]LNJ?O#J/\
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MC!W@X\MLG?/7^M2!!=JYBT[$WMJ:M:2M,U?=,!Z_D6P@KOK0N"GA]CD7 :)
MFK%'V<X:@V>&:I,C-V>J6 =R: K$U3I>+'FWK,)'-BT  2L!)G.E4$@?9Q)D
MXF(YTU&8CS'3Y]D'>M0JW>Z!M7XJ1@VI+]&1?:N9DZM!-S,SKT6U5&RPT1=9
M::3)TQBVES%DJ==Q0Y5JP7JGYF:XT+,5*<A")^!FWI*,%J-7>DIR1I5@0""2
M1 D3 D[;QFIU'I@QS',Q C.-Y/EY3SJ?L!5]P7_?%#K<7,C.:$NE<I$S-R"!
M6XRS2%BHL!>4R%;2T^Z4[$!CSR(KWTUD3W\T,HJ/:)B7 )$RJD%&F3DB8Z3F
M#XP<CD<4!GRY=<8..GSX"*HWN=6)I&8R/H]F"O,MV@O/4ZDTBPR%= +M>Q->
MT^Q;#L4MF6A)*RQD35!Z!3;=<$F..&RN(F%]W=AFIHMN);D(!5&L0$ZBJ#'C
M',YQRYT), QSVYP1CX_T%;BSV;ZZ6_1VO=HW:VU6LZUWS6E8@(;:!,+&$6%J
M3J<M/V"D'0)A9@TO-QE>B;(BS5X!<NA+$-,XQDP)A;RP0O40D24&9$$;X,[>
M/]C0D:>][O;\Y_":T?6&XNA.KJC+':>OG7VHTUI^!=EB:!*5<6,>3,TH_8%?
M-6N$5GWZ)SKR-G+@)(L^\1$;3X&RS62!(>O3CX$E#Q.E042)P?$Y^)^-1*1D
M>'X''PY^%:-O?:'6:?W1H"(V+J+7FWH.X"V]JL[M+8K%NBJ2S':LM&ZI*-"6
MB.ECIB/L56I<!*X A2W@I%F;KTF0.]C$9@R4I6$#2I045=U !SL-4X'4<SC,
M8J#I,$[1OT\#_P <\3O%MJQN_3EJMS^N*QL2H25WCPY$E=-%EQ&Y](D 2)'6
M'(L.ZMHLKZ*2!T?$VQD)EYRI2QP,38FXR1+'%<S*%) )20#L3S^?CRJP4"8%
M2QRM6IQ2G%*<4IQ2G%*<4IQ2O!QM#J%MN(2XVXE2%H7C"DK0K'@I*DY^2DJQ
MG.,XS\LXSG&?EQ0B=ZUFHTBG4&+5!T>L051A,EDGIA:W&"0T0R69E"BWQ8P!
MI@$113B/7)P*PRE\E;Q3J5$/ONN64I2C*B2=L^']S[Z@ #85 W3S_4L7^O3M
M?_BIW/R#O[!^ J:M%R*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE0+VIAY:P]8>QU?@(N1G)Z=T
M/MZ&A(6(")DI:8EY37UA!C8N+C@FGS#Y&0-?8$""$9>)*)>:88:<=<0C,C!!
M\:5H<3VVU6S"Q8A-/[1)=9C 6'VL]'^Z2O*XT*TAQ&<IT I.?!:<ISG&5)SX
M?+.<< $9! (R"%#'QJ")!$ ^!R#[*Q..PO7/&/EJ/?6/GG.?#V?W;WYYS]><
M_P#HY_\ SCFG:O'=U?\ \T_[JXCPVP/K65H=\_1F<D[G+?@/ZSN<1;=[Z*M-
M-F**S5.U57@+#Y&)U%3Z/=RX(N1BWGQ_C45@L7KOAT!NP1C+T)(24;D2;%CR
MWG8:3BY-H.0%T:N'6W4O%16XVF&E*<DMJ&4*29/J*[P&!JSUJ'N'6KMHY9);
M0Q;/X?;8;0V'6U8=;5H"8[5'<6H=[2<$8C 4?:'6O7F)^+J>N^S411YQ,6XW
MK5CHKW$508.3C_>$ERU;KZ^N>6H-Z=1D!R:CP7&X4F2C&YYF,'GY.?E)>7+E
MYS2I2OKDZOKPN'%)(3"5$*R$D$@G/>/*LK;A-I:(<889;;LW @_00V@VC;B)
MEQIHITM=H-(6A*=!*0O3J*B=V_&%ZY^'A^"/?6,>'AY<>S_[>^'AX>'AC_T=
M/'P_Y?\ =S+M7M^U7/\ ZI_W5M^C.'DR;&TG'_\ #,\L#_\ =SM6R,=M]0C,
MM##4WLZ...TAE@=GHUW1:99::3A#333:.OZ4-MMH3A"&T)2E*<82G&,8QC%#
MJ425&23))4"23N229)KL2E*0$I2E*4C2E*0 $@0  !   &P$;=*I4$J@1U#[
M0T@"[=LHO':#<5EVI8)F,]G1VX][K\==H*HU"X44(6;T?.AFQ<Q4*FF)8F<H
M!G8LJ6/E0BDDM1Z [2)22D$ 1&L"8V,\OPH03N1Y1Y<]XW\8YUIUETOTRML9
M+T>?K7<"1U%8I4*U6+7+W23N=A$S= >JY/3=N;*L2.OR3TA.Z65$X>B6AT+^
MFU;@[0/)#MMGQ,A;7CU43UE.VH*B)SG$DR!MG-"">?G$^S\X^)Q67LU7TK=:
M7N:D7"6[366.['5GZ$;S*F?9R]L)$FT58#5T'JJL)K+16A' *?/UF+BY.RAR
MZQ)\%ZYVF>EW() *(*(A)#@"@0A.)@!8 DDDS!E0F,'E*?$1I/7,X_MU^><U
M(#5\%C=@3EP@-A]DHV+S4VZ718,[V97<6Q25'K0,,*%&P";1.:M,)F8=Z<%9
MMMI5\.BK)<9@6)'F+-F'@(*-CHURG24I.9]8 ZIDF1G(D020 21!S33&=SB<
MD B-MO[[':H9L>C.G%C@!([X;WBJLOGLI%=G9J1UUU<]HIK>$E+>-MJJ[8EX
M1BF4?6,!7@H:2D*C' QIY(\I9JT81(6^*G,721DIX^%+43. (B"H'D<F<$R2
M=JD"!^!Z3TWV]OGTL;OR[:5[$,0U9O,=V:=UQ&V'75R=JR?9\]PGYUJY:OV-
M![(K5AKEV>T/F0K!#\A7P(>74+'E'9B/7S R5>E'UR?(0K1. 3F#K@;1D B>
MHR(,'.Q$3!'X;^W/CR-0WV0@=1=A=BR&PG9WM54WR]5T368\6U[/3N7-L#_0
M/L/1>PX,ZX0]IJ-<(6=,T*/K949A#+>(LPLMLS!:6<-@8'78^L-X@C?;F.=,
MSR/CX<N7OY>55"/UWBC[O,DJ!4NQ-KJUHV!/[EQ;[%T)[?N0,9?IWM]N[N-%
MQFPZT+4:3892(U/L[;;LIJ:0 A-FJ&);]=V)JDBF8E;3JE:- !B9(([I.D)2
M!!.TQR(SG&]5A7ARC,"<"8^&?9TJ?MIZ\UC,;AE>PVNISM;$7D#K50>M<'2#
M^A/<I=0M6N==-;Q+>H]Y>(T0;&2$7L>4W88Y.RA-3/763:C2IF#CG%QDV#9*
MAPY"@(6O6KO")D$&!^KF!_:I*3 SL('N'//2=OCFMWZ$[+ T=4K?'; UOV6A
M\S2->CAKDNC7<M[8$B71*2#K?#]FEXRK[>AY*OATRIT*(IB1IZ.D6&HV;(FH
M84R02MV'2E>DI@>MCNI !/=VB3&Y.=ARJ4@@F?#.X\?C)]M7Z_&^U/\ [)=H
MOZCW=3_(#F4'P]X_.K5B9/M!HN;]',SKCL9+^[>I[MF3Z&]R#_0]7R>KZ/O?
M7IWTO4]-'J>GY?/Y$>;Q\N/"JD)5A24*'WM)_&I2I222E2DD_JJ(_ UBOQ@^
MM_V/[W__ *?G;S]W3D=BW^HW[D5?M73NXY_&K\ZJYL"/T)=[#L>=CYONI14;
M+BJY#2<=4O9[;PQB""J8;[<#]$IF?Z83MFKY,7,&R=KCS0YM)8%HDRY4)X=6
M!FQ^5RR*G%.M/&V4M"4$M-VA/=F#J=9<5.20)T@Y"1F>EN]4EM#;K*+A+:U+
M2'7;D E<2%);=0DCN@>K,8)(Q5J'NQV@35)(E]9]A9F0RRPV3)R703M\2<:M
MEE#.'B7E=<\>+BDHQXI0E#:,>"&D(;2E&.LMI405)0HC8G22/*:Y$N+2(2I:
M!T"B!\#7M"[(]?8PIHV-U9V!CS6?-Z)8707N$(4UYT*;7Z1#'7=MUOSMK6VK
MRKQYD+4G/BE6<9!M*3(2@'J- /O%%+6K"EJ4.BE$_B:B+L/M+66]JS1ZZ-GL
M_3L4O<^G-RI+5[/[NE8?B4AI?8<#LN!@W!U:7AO=@)6?K<8-+$MO.$_"LECA
MX&*?;,'T3@R0#@CU@-Q!^%4,\C'C\_/CR,1;4A-!;HV/=-E;"/[BRTI(U^D0
M&L@F.A7;4 74K>O]GZMWI72XY8W7-#EM?!W;I^H;!&7:,%D,K^)U]13\&\$-
M'V2H) A"2023*P9!!!$8 P=_ >,Q"I.<'Q./'>?8#X;9K3"]3]6I$N]R![/;
M\@S=A!BNPF?Q$^X^!]K1I&['=XA06&'-!.JJT5"RLA8J)%I#=D"TZVLTI$&%
M&61B(ML9?M.B$0(TY3B$E.>N\G:3DR<U70>N?SW_ +\_"MXFR:%(V78VT(NS
M]F:]O#9&NZMJ&5V;$^S=[C1^5:XJ]UL-O;!D82'U#$$REID![(?6G+<BP1Q4
M%&?]+I8-6E2##7X[2 D!([I)$K"L\L$Q R8(,J)Y8JVDG<[[CPB,$0>G3VU]
M9Q&J+D#IV#VF1V'MM<TE;]?;$H\97/9H]M=?OUZY:TF)Z0K'T5D8?2)I54J3
M$8? 5HFN1V73S8"MJBC+&_&V2R R,:X"H2 5""=>),2J)B3DX@"3&( :3.__
M ".8G?;YQ-9KKOCK+UHO.ZKG0@^]4DUN60H)3T!>.MOM'MA@U8/7]!@J%&1T
M.1L'65K+>]42$01\0)7\1%#<%KHQ"8"'B01:*)5O$Y),IR29^>M3'_&-OG^E
M:;"QVH(HXJQNRG: FZQ7:V\=MM<V-'L\.Z##-*NVQ*)9]76JOEQ3NH2T62NG
MZ\NUMKF,Y,AY%KXRJ007@H47+=@H#[((*=)!4D\YD=#/NY140KK[8\\?A\:R
M$B#H8;7O5#6=+5VQKU=ZH72+ND ]+=">YEDE+D:!JW8VJR\6,EO1D&RR7,@;
M/LEBDCX\5O"[&D0A@-@%#X#\%4J4HA/>Y I 'E'D!@9$[4@QOY?EY'WCQJ@%
MLZ^U?6E/TW7=:Q_;+:H-!U?H?19;S?0SMI6[8!2]#]?=P==(B69;-J.MQ9!5
M^I.YK&-L7X??8-X/(@CD#79?!JAXK5*T]XD)!.TZ5"2M*B8,C !Q'QBJJ2>1
MP3F,<MICY,>9M9LFB:VW)1^O85@L':+6MZTC/S6Q!)S6'0#NX(+';+=U_P#0
M77\K5&2M0-IC(75 PT$N&KLBB9AK2-6HZ'M0DA"&SD?+1VL*44@:=.D J&TR
M9S]HDD@1N1M4Z<08WD_ATZ 9ZYY"L+U<M!>L^QMZV'<-7;["BB[%OHEJ?_$6
M[C."FQ.[MBA['GW]8XAZ5)O5YV[6JM4ZT['BK#J^IY=EXY?A,W"6:>M,J6I*
MD  CNA$#NC(!!D[F)C?<SMFH2"")\<_/Y<]^5=0/QOM3_P"R7:+^H]W4_P @
M.80?#WC\ZTI^-]J?_9+M%_4>[J?Y <0?#WC\Z4_&^U/_ +)=HOZCW=3_ " X
M@^'O'YTI^-]J?_9+M%_4>[J?Y <0?#WC\Z4_&^U/_LEVB_J/=U/\@.(/A[Q^
M=*?C?:G_ -DNT7]1[NI_D!Q!\/>/SI3\;[4_^R7:+^H]W4_R X@^'O'YTI^-
M]J?_ &2[1?U'NZG^0'$'P]X_.E/QOM3_ .R7:+^H]W4_R X@^'O'YTI^-]J?
M_9+M%_4>[J?Y <0?#WC\Z5Y=.V)!K1@A,E!V:N.S6U.Q5I"B;A5[%2K(W!W#
ML3M2UULR3JMMBX6RP;DK79F+EF 9N)CY! AS"WQ6LK\O!W]P]PB@,U:#D4IQ
?2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g713200g02t31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g02t31.jpg
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MMM77(C5!='66LR,V47%WTB0X80HE,D-2@9&QM?_$ !T! 0 !!0$! 0
M       ! @,%!@@'! G_Q !9$0 ! P(# P4("!()! (# 0 !  (#!!$%$B$&
M$S$405&1T@<5(E-AHM'P%S)6<8&4H=46&",T-D)25%5S=).5L;*SP=0(99:E
MM+7AY/$S-7628M,E-W9R_]H # ,!  (1 Q$ /P#^XV62QX\>+L&"ZC=BW4S1
MRR1SO@H[4PO?%3/-3'JR[GM6RQ33QOV<\?Z>?:OECCAJV(XC+)*^&%Y9%&XM
M):;&1P-B2X:Y;W#6@V(\(WN WX)IG.<6M-FC33[8CCKT=',>/O8'>][WO>][
MWO?Y[WO\][_\[UB%\R_*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*C:D1[_-V
MFQ?,WF;!SFR?8-7*+C-D\3MCDHT=XHYYW;N<,<L<LT%K8*XVRQOEA:U[4M\N
MJ*LHBHVA$>_S=IL7S-YFP<YLGV#1T@XS9/$[8Y*-'>*.>=VSE/'+&^:"UL%<
M;98WRPM:]J6^75%641*(E$2B)1$HB41*(E$2B)1$HB414;XB/&(V<DGS,>WR
M520Q7?.D&B.2Z^=DT$;*N,T\+JK*7M@DG;+MJ9WMCA:][]5 "> O[R*LHB41
M*(E$2B)1$HB41*(E$5&P(CRC?%X,?,R+3+-5/%TP<HNV^2B*F22R>*[?-1*^
M:2N&::N-LNTFICEAE:V6-[6(JRB)1$HB41*(E$2B*C8$1Y1MB\&/F9%GGDIA
M@Z8.47C;/-%3));#%=OFHEEDDKAFDIC;*]\%,,L,K6RQO:RUN.B*LHB41*(E
M$2B*TJGP2&;]-<T)14%+CVI/!4BS3S'.2V2&(IN_QS6MDS7)Y.6V(])Q9-1[
MDX0LVQ4NJGVIL>@ZW/5QZN=%5,R(\A=W9@^9OKL'BPY]9FZ0<W9$&]L,G#%W
MW.>?AWB&*J62S5;L+I64POGAC;/'KA%641*(E$2B)1$HB41*(E$2B)1$HB41
M*(O=NZ<M%,5FJZS=7&_7;-%3-/*W5_ZXWMUV_P"-K]=KV^:]NJJF/?&X.C>Y
MCAP+26GK"D$@W!(/2#8J:(K*\"3)3 FJDD\:73PS5RO;#%S@I;+L*=FUK6LI
M:^&6*ML;=GK[.5K6[?9MM&'X@)XB)W!LL=@7< \&]G6&@=H0X#3@1:]A]\,X
M<TYS9PY^8@\_O]/-PMY(1O>][WO>_7>][WO>_P!^][_/>]_^=:JL>ORB)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HBXH\("9)UTO?3/#W)!\X8#<."?ES%=VNLS
M8>*T6;5=>";**9(M?$JVLHOW&"??*6MFIVLK==9"H Y#AQMJ>5W/3:9O%?5*
M!R:E-M3O[GIM(.*U;<\[Y_QZC'.&9:,T;Q["3;#IAQ_&9\F]9;&8B-CXSK
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MP2ETIFG:\M:,N[&27*[-H':MX 7\+B0-%9='&V&-Y+]Y('$#3(,KRTWY^ T
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M/!SMS83>$2F,988$AJK.K0E:U\3@\!AHI(R!S$QS-+' ?=3>$ >(<UQXJV'
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MV 03'2UI"SV)%^T?-T;2.-R0>)3N&3!D\'91:]-5QL9&V-K'O?AT5.Z0/=X
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M4</'1;P3"3$R@N"'VJI!W9(M@UE.625T+-T6*Z/B%*N^%S.7P-<)I63-:7N
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MXSF14F9AYD&5NM&45VH^Z93$<T<85<OSNFWT#)632-ER!SF97L;E;9PO<90
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M#8S&\9V;FP'#9]L:J'!,0[@]%M2)L8IJ2MH=F*^DCI:6FJJ*CI8*)\U%14I
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M&8;N1I-N/9Q=VR5AJ7H[<ESZ^];]2F2 :KB6MLSCB.6/N"$FN$SD)B3RJ23
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M>Q6\G9S!Z;'-L!4QU<V%;,1RRQ4<-2V&HJW&K@I*>*2K=#+NX[RE\LC8G/\
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MB]M+VNKD,FZFBEM?=R,DM>U\C@ZU];7M:ZY\N^#$J'<?>)>O8/ML6 V]P_)
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MU-.V0PNJ(&2-=-"V5H+HG2QAS!( 2PNS $A7(G1MEC=*PR1-D8Z2,.+#)&'
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M98\),-Q"AR+R-V!$PPL;YA(6A2/3Z_#P]*@\[R4Y3/(_($Q6HS4=,.89L%X
M(M=%[8DZP27!=/(;$'BC(XB]CS-TU#2NQ+5HTT$4D]MJ3-JRS QB.L'B;5<I
MTOT_#:^MNC3IYM#Q4K3C:NYH_P L-71-A'-B%-*'8<+8G7,:U>0+1V\YD)$_
M@B=D\LM'2&<0BP,4/3S(7O*6Y04>M'AQJ-91V5*S ,4<U_+Z/]5CA;=&\=?[
M$V8B\BVQ]F15L0+N MQFK99D$C ULJ]Q!!Q@X!JED=D1,JY( 6")B-S_ '..
M.#V)N1F&NHEFF$;?DZ/2/3Z/AXGP:;DY+B4%9(6UU,CC%H](%W\7;00DF]]'
M!$GY@%"8H.D.C:A8J=>PG7^E043:=Y@L2/R&"N%UE\IJOA(2:=/KI_KU*T8\
MF.4KQ>0-F?'LPQ=!8\$-*(%M;;$NAD6::EV5-Y7$1!5D14%RQ0I-(A%H%&)$
M-<#U1C^8H6?Q,XOD PDA+#IX^FUSI\-OE4L[IW%OF!S+%A!M47ET/R*0D4F5
M;1>:'G:C@V%V 9/+OEH[EE86$:.XS%8SY\R%2.X-_+[DB8E[FS$@)$0>7U]>
M*A!#EMR+(P@=+XQH]Y,<BL/2E@-N+UEMM@QDQ$G'H"4M#!Q%9!]B.O$L96=,
MJ3YV@ZB^TV,9RC>O6B<B6)Y!"6UL2!Z^OO? MQM.%]F$<MDL=H+CG)2/["S$
M UPT)/0X*K'<X;#BJ68A8Z4,7E+&Q@F93PD+%[FAWJ:H=S@B1$O44R'F]><_
MP4ST4)1$HB41*(E$2B)1%#X[16N(^H2?1$-E$SSQ ^D+D0Q;S-_$\Y$DZL\]
M$!\JPD4:!#D'3UT391A %E#T23M\YSCRMR1+!V16N"\;M.:Z%:_$1B(-VJ&L
MX+KW744RR<N\$VL;U;8GE!K.!C-9H"<DP#@X?=,BV0G%^W6/F\4%DFY-V@H3
MU]>=5PGCWIH"Z3=!X&+'V12AJ;=D@Y*V#ME-?N86ZB+]J"R?Y!6I@2KKC7^'
MG;=@F8?M85%F1-\]9@AJ#8BH#'&?1)YF,'D];A%&8B-,(8R;MEB@[#T.%C$A
M#*(O/+2#3(G%TF39CVH^2N[$+NQ88DX9JD0PIVS)=>V?&_2BI!0HM!6:[M=W
M)GKCQ!60.&CEQ+2<H-%LG0Y8MF/=)(&)O,RD>;N&JC>'D)=)GD22".#Q11T2
M_KZ^I5(VXQ:+:D!1;&!-G!0.Q.,&A @;DY1VO:28[#P-D2S@D:=J'Y"_PVWM
M#!24'<B,D3PV#,<$"J6,A*6<DN?7U\@ZE*<.AL<@0%O&8JP4'"&[LL1[M<@2
M+O71,\6>GCA4F7,O"!@N6,FB3\J5*E7[P@0?O'#IVY565RSN19/1$HB418H6
M@<'/GPTJ.PR*&I1'4UDH_)"T=$$3X))QV_$)AC#QFL1&)K]XIWV#)PABKV\^
MW;+M9=9%C;O2.F'Z1E!]J+6#U"1I!$)"B[@,4<)'D8U@DG'$3*:PG/ HD 31
M13")OK+X"L$DL&-D,4\;6(OQYH_2Q%0LL0U!J]\J>)H&SBKR 1-TH9,MLE\V
MQ<MFN)SR(DV^3IUD@_>76=)9.5[IJXW64OD2YZ5E@2&Q"-$#Y:.16-Q\K*WU
MBDI)! 8P40DI/&Z^6)$^\8-4')A]CDY<Y6=D5'+BUW"][*=:JG:(LDHB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*,,M,:RSE1":YQ-IG
M(R90:==NLW93-GYZ*6"N&QUJ%R?7",#BJL;CF1(PP'-B1FT?!X&'+[ 0/Q;D
M6%1OC!J( 'Q%N@:LD=+%MNFS1PNHV'$I21WK)<I;M'.4-(@SB\>,M9.;3&NE
MQSD'<<W5 1QTU:I/P8]X@3UZE?B_'O31UT]=DX&+<9E6$K%FD$W)5H/D(^:D
MI@9D+62BV;]N,DB:Q?84[*C;G6A#./D9C)GL>R%N31!5P154DT1J26*IN3D*
M'N'J!(X8:DVCHH(,,BDF)1\M(GP\P'?L"@]P=>1<%YMFR=H>8-&60UU94<[?
M-')%84N,.B&^#9%OKL:V:-+@,4!S8B>;"L6<;BT8A(T.H)0*IC5XZO%(1"PA
MR-+M5(_*&D/BWI,-+JQX0HS)?U]??XI?C%HO-VS?JP%LY>L#EI V=NS4F>+V
M>)N8F]9LEU71I;-W&Q3Z!P=\#B#NZ\3 /H=%G@4*P<@!2K4BD2%:YANNTC",
M/#>58GR6)8LHH0*E7#ITBQ:"V:.+LR^(.FPL6+8LQ@0(T60# QK9%@'8,6F%
MD:(LVHB41*(L5E$%A,X3&HS6'168)!G^)00E*(\)D"8HGAADE@1&X%FCO%B_
MP3SS3Q>-;).,<,\L+*6QRO:Y%:GNJ-6DB#PL1UK "!4B)- "!-[#HZZ(/P4D
M>$",B"O'JXY1RZ$GB!8J_-#5U,V91X3(.GR*Z[USFH2ZM>>C-)*8VQST[JS/
M'$&C&<<<]?1++'&-MT5VR$?M:XB]K T&[ERW1$V_\ FBX72P;XX*J8Y$60 ]
M<:\C!7 [&X'#(\<2 ,8FF9!Q<&)*IQ89@U3&QK BP8MW>  >FQ98,0V*UAS3
M!FUQ;MD\6Z5L"+,Z(E$2B)1$HBT#A_2=<+YI'FLF';9LP'O=@!-8M4R\;DC1
MXI,CZL+;L1:C=$8Z\):SB<C[*N'V;5#P869&4,UP,-D90<4V/1S7^!;A:SV;
M MQP<#LG6,G&S*#2=%XL"D8G):[)_B/(O Y!/'%PD@Y0<#RP]^-?M'2"#IF_
M9N6CE%)=%3#$HX:%9U1$HB41*(E$2B)1$HB\TDDD$DT44TT444\$DDDL,4TD
MDD\;8)IIIX6MC@GAC:V.&&-K8XXVM:UK6M:U$7I1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7
M.5/2W#O+6\UV+EQSU*Y,Z\.;(?M8=&,$RQ V>T2:0U;#WK-L.&HOG<L?!]7P
M(*"O@!(EP2A1.-"5B5B[Y4^4W/2;+/-6\AM/PC4)]C&M=R2$A])"-:HR.!M<
M!;>X$IM!VG@N$9/I>=CREG$9ESPZ'F#J:^B;]J2#EGR[3-!5JLZ(1KQN3?I]
M'/S65\/<M,(N!@TB.:QER#&4R;<#(TT:(O")B,Q36<S(P *;6:,!+IEF<FTG
M?:_;-(\:*1L>+;2DNHM)7)"-H"CQ+>NGI]>A?"7-_3SB6D(DT9RM[F/E2D.\
M^:X1%2.OC&>3_P KN+>WF&+E^Q/X#U% KQ!E=-WBX889V05?-T\RBWKZ^M]%
MZB>6K&7:JG>T89!72C:(2"'"&8J;S6"0/(NSD;N,,RY-R6)G7 8%Z.+ESK9-
M%\_S:R5_&LQ\=)/GA'!)H4VYOX>OJ5ENSN1#*$QF&R6,BA4T5F%BBC"+YR)U
M'I:0Q 6;9R-B%%K1TBDL<CN&1!N8"G'<>((R-FPA+=!S+3X\9@4>OK_P5A;[
ME4X9!+E,8Y"'RF &4'\W _9F3D#F)B.XHWJ\O)&93T/P=$(GB,D.4H:$V8Q9
MX1>B2,5'CG+CP15X4VUM_#GMPMT\RVEB!UQ*(E%Y*[#/XX[D4="'74>*VM8F
M"<%QK8@L&(VMCA:S\6HXR8O+6PPM9P@IU8X_>L4+(J(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HBTIU[_ .=O?'YCQK_^#K2B+=:B+'XS_5SG\X)9^]1FB+(*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
:2B)1$HB41*(E$2B)1$HB41*(E$2B)1%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g713200g05c03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g05c03.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!%@)@ P$1  (1 0,1 ?_$ !X  0  !P$! 0             #! 8'" D*
M!0(!_\0 8!    8"  ,#! H($08. P$  0(#! 4&  <($1(3%!4)(565%B(Q
M-CAWE-/4UA<9-4%4=+.U&",R45=8<7-UDI:QM+:WP]$T0E9XE[(D,S=#4F%B
M9':3Q-+7XB5&@8?_Q  = 0$  04! 0$              00%!@<( @,)_\0
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M_9+RQJXNLQ.EVBT4LY?QKE1M(&#H!(S4YC-E3]/+MBB'2'/S""N\ 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8!X<G6*W-%(29KT'+$3EV,^F23B6#\I)Z,312C9LA73=4"R\>DV;IL9
M(H \:)H(D063*D0"@2]M^X2_XY#_ )YC\ J3 & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M,%?67NM3=NG7Q2301(DV=0A&R9$B%3;D3EH],A4"%*!4BD( $(5,"@4@ 4
M/-@%58 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8!\G.1(AU53E333*8ZBAS 0A"$ 3'.<YA I2E* F,8P
M@!0 1$0 , Q^#BIT(,(-A]GR98HIU%#J'K=O3=(PR4&VLZUS7C#U\LHWUNC6
MWC2P+;/79IZ\2A'3:44LY6*Z2Y@+O6P0&"7$! 0%W#B AYP$!F8_D(#]\!P"
MI< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MSR9TX"<\N=>$AC#)"@Y0[_+\G*Q5C*!*.P72$HB;LVRW:=:"(\^1DDQ*00Y
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MXCS*')GDSIP$4W>_GQDOX*EW4[3O\STG<=X%;Q5YWHINCH[(CGM.U(WY>V[
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# -7,[P_7R4UI['!T)W^*93'&^QKFM'
MDOJU@R@+5O7;3R_Z4W4P%I;W5>A6M/@)"QP3N5AW1MFU)]<I5>MUB01,[77$
MHNW?=??DONY-9387/M)9K4HUJO)H/'3,U<0F'KAB<RLJJB_C4G+A J3QNFQ6
M=.2BY$QDWB9 ,*0(^X<!!:79'OL??O#'^B)9E%E])P^VB?;4L4]TR_<9]A"A
M,N!2# & 75U-]V9+^#/_ %3?+1;'Q$+NO]#BX6=\:_N?]331QY='_E!X?O\
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M+X(EC%3(FFWL<?H39W#)^?FV+^I1LDEWA-">-7'; BS98JW0]?QKQ$CDA"*
MU4!$X=H"QB%(H I]8F#SB"N\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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ME3ZP/CX/=8?VT+[[(]Z;[]_8_P!+2S'[+Z<A]K$^PI=Y[I=W;-Y3&K,H+&,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MD[DSE<7JS_B%[H[D:6@NWOJFOQO^Y2R]2/2D#M/2I;9KIB+VWH0I;*LIQ@#
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MQ1 W9^UYB C@@K; & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MFX-(BS.5T#;L# <0HNP5;;?N$O\ CD/^>8_ *DP!@# & , 8 P!@# & , 8
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MN146\XBU)QNHRE685V 3/)/CO4GR:,D#V((=5%4&$48TH9N1B0$A1(1ZW?.
M266 SDR@D4)W(DJ](LO%YMG') @I"=!5T#2IE4:YNG3")+H]8RJ[&583X3,9
MK:0T1%1>4%CL6'&9S-+HL6(L1L1$C:9!17([2H-8RL2&E%:FF,B/Q7*F/6BI
M/>RAIXDE(>PZI=DFQ[D,7W>;\-64[45/$%2>.][%]R'LNHCPC;L@ .[=?M\^
M7,$72'0?=.T<9T;34F,:4T]J8N+I+5YCTO2?\5'0G/QOUE+CZ<UP]-;%YAD\
M5(>EZ329TIRUKIKDYITS3-:Z(C*?X*WD@6;0+'M6/L?@3*-GY7II(R,B,@Z3
M*J=3P]T<),&IF!@."1B)-$7/9)D '(& QS?995ZQHD7FR;1KX*PD@(Z!I,-5
M1$TZ&BP%B)&2E45\1\.JK^C5*(GS2.U(3(?,TNJLB)$6*J1M-B(BJNE/_3(S
M2UK1<5C7T1.CRUFQLK47<DZ]B56*20:D;)LP0F.Z1AR)BF+R-*,T*Y'1Q'M3
MF=+NT!4 !*@4OM!^:2,1(<"'[HSZK!B+$=%5TKIDPBNKI<=>9<18:)T*)"9"
M=BY7JMY[6:8KXK^8I1$BLQ&L1)C$@K2FF0JS"NQ_\7Z1T1M?\-+CLKX#(U4>
M#G0!O%90 >:MKX$*"C3I8>U5'J8\V8B0WWO^$"Y#E][GY\XNT0-6F$F^D?\
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MIU4EVT<U72^+-?\ ZF:2R*KNXK!3:(688J1TYDEDTY:M5$CUE]J!6.J(B_\
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M)N5WW^-[ZI&D!!454Q>=?8IKF0#L! 14 P=(MT\WZQ7> , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# , N)S@!U[Q,;*@-DS:U0B'<&PATI.'=ZO@[''[+>Q\VT:NFNZ
M1<2D<IM.DFU2^V!JR"H,^!8:N([-LMQ:K.;+'5)>NB46G_-.]L;NU0SU:-&K
M!JV8L6S=DR9-T6C-FT13;M6C5LF5%NV;-T2D20;H(D(DBBD0J:29"D(4I2@
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MDTCK(D4.4HE(95,IA 3E 0(N , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MBT4LY?QCA1M(F*!01,U.8S=4XE .V((<@YX(*[P!@# & , 8 P!@# & , 8
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M7%,JTD;;E0VTH1A7Y>;H>VZ/97FYGH.I?<E<9<BUJB__ -+R4VZI0Z$,'@8
MP!@# & 4?L-L[>T"\LV""[I\[I]F;,FS5,ZKIP[7A7J39!LDD!E%%U5CD313
M3 3G4,4I $P@& <AW!GPB[5B?)Y\6==V?P:W'8MX/I_A/8</=+VAPV76A,83
MBGL6G7VF;S.Q>EKZE8+!(3>I[E8(>V[RXF6",16-N1YY2PM8JOQ=.?N5!]7*
MF,BHM$J[73)6J<"I<B9=TZA8>B;/X?\ 2NE-.<.-*UG>XK5E!J>M.6V-K6[5
MX-Z]1:O#UN">LGM7T]N1Q-R3]*.,>33?MX<$3]+@KU^JX4(DW,^)3YY555U[
M[D_NA@!Y1K6/%EM&Y<%,EJ!C&TZ]P-4XNU-E3L10KMQ ZSJ#JS<,TK$%K*QH
MV5TI)O3W"74<T_7EFFSUEPI8'<?(%J,BZ3-7%QZ:J)6NU2^F1=Q>\83\/FEK
M?%;Y\D_,Q?#)Q&4C=.I]4\/];XG[Q;M3[)C(2R4-#R?9J<9='B'DK'-4"A4C
M5NP79:=L'A/D*_2KSL#=+9.^+P29X0UEMPE:='>E*K1+NJV*5R:^LE4UZ%V^
M//AV-OZJ>5/K]CU#);9W?'[ X2[5P\1[6JR=FL:&CVNM]80$ ZUVW9-7#TZ4
M;M%_QEI3*<2"JC-2<L[A\1)K(I'."+3%ONOKNU]6+ZRC+7<?*$Z]NVT-#Z!J
M&^Z!JW5TQMZK:O3I7#FF6C5[7H<3'D_(/2"&MK-,:LE:9:T(/1%EXGEF*,>[
MLZ+.'96]]:FRSRH)GA@Z%4K=5::^O1U=>Z_%]!;)7:/E:X&G3+:VV'C2/75I
M+6"\S;ZCPU5JT;;KS0(_RCL#X=1JW7N'^85F6,[==7\#JFR' 4>T2<)7[Z:S
M/Y"M5>ZOYA .@KK;255*_!V536QJ7I7=,E(,_&)=&-;M7$6^V>VWFSX_^ 6!
MT#09"F5BN5"L5]GI+AIN_&/;Z2[@:;'V&6A).CVCC6IESFWESL-.;MH>1J$*
MWC9!HZ*['FY,F16NKMY:5[R:R&9%KL<ZAQH(,*KNS["$:E>J2SO%3<SVRMR%
MW\F_AX!%*I-M6V:KIZKX=RNBNV;4FR-;W)>S33A [FSP2)#"JL&M>B+L7HBI
MZ5X3!/:=^V)6(;>41M+?>^(71+3RT,1K_<>T#;.NM!F=?<+,KP@Z[NB5<8[1
MUXZJ$[J'4Y-U2-2@EI2D2=2;-_'GK*0E^\V*P/Y 2FLM$KBK1*(M]53(MRW%
MH*G-\:59T%I?B7>\1^_KJM;M#[B!KJ9NWOTKMAUH[63;92<AM)."F;>TU_,V
MA;6;O6UZHFV[;K=YM>:WY8=1U&QW$=:72QMT6>>MQ"[)1*W7K2E5I<NLB94R
MTI5<IOYX3=V1?$'HBG[+A:S-U2,=.K15FC";L(7,)!*@6J9HOLD@;V5=R&P*
MC:1KPV&IWL5C*VVOR+";<E2=O%TB#RJ46FXMVVE=HR.P0, 8 P!@# & , 8!
M9+B7A)>R\.6_J[7XUY,ST_I7:4+"1$<W4=R$K+2E'G&4=',&J)3*N7CYXNBV
M:MTBF4675(F0HF, 9?,&(\&6PEP>F9B*R#+R]N63'CQHKD9#A084_+Q(L6(]
MU$:R&QKG/<JHC6HJK<A:;?A18]A6U @PWQ8T:R;1@PH4-JN?$BQ).,R'#8U*
MJYSWN1K42]55$..W]!-Q>?M;-S_R L7T'.R_?O@?^\UB?6,M^(<R^]3"7L%:
MGB<;V1^@FXO/VMFY_P"0%B^@X]^^!_[S6)]8RWX@]ZF$O8*U/$XWLC]!-Q>?
MM;-S_P @+%]!Q[]\#_WFL3ZQEOQ![U,)>P5J>)QO9'Z";B\_:V;G_D!8OH./
M?O@?^\UB?6,M^(/>IA+V"M3Q.-[)UQ\&%9L--X5=$5:UPLE7;)!:[A(Z9@YA
MHLPE(M\@10%FCYFX*19NX3$0ZTE"%,7GYPSD'#::EIW"RWYN4CPIF6CVC&B0
M8\%[8D*+#6E'PWM56N:NLJ*J'2."TO'E<';(EYF%$@1X,E#9%@Q6JR)#>E:M
M>U:*UR:Z+>4DZ_REQ^_J_E#96L^ WM6\B%.N5=U>4@9Z(& , R(U;[VE/X4=
M?D6N8U:W32=R9RN+U9_Q"]T=R-+07;WU37XW_<I9>I'I2!VGI4MLUTQ%[;T(
M4ME64XP!@%Y]0^[8/W(K^>1RQVS^S?/?=%TLW]=\W]X<WOEJ/A<U_P")*G?U
MION=*:"6H^8W\G?-+/-&:*>J6#O5*^<39J*S<!K88 P#;3Y&#X7\A\3UU_/5
M0S46C7J.A[\R/D)PV-H7:IG;VS?E)<ZM\Y,.BA@%'EUY0"1Z402C4\L4A8 M
MB$86LPI8]&U Y,\"RI,@9 V3L .SG=!,D3"1!R8R_>>U,)A"OJ)RV_<)?\<A
M_P \Q^ 5)@# & 2CL[X@$[BV:.#"(]H#MZLS H<@Z1(9%@_$XB//F!BI@ <A
M QN?( )+MY_T9#^O'OU>P!V\_P"C(?UX]^KV .WG_1D/Z\>_5[ ';S_HR']>
M/?J]@#MY_P!&0_KQ[]7L =O/^C(?UX]^KV .WG_1D/Z\>_5[ ';S_HR']>/?
MJ]@#MY_T9#^O'OU>P!V\_P"C(?UX]^KV .WG_1D/Z\>_5[ ';S_HR']>/?J]
M@#MY_P!&0_KQ[]7L =O/^C(?UX]^KV .WG_1D/Z\>_5[ ';S_HR']>/?J]@#
MMY_T9#^O'OU>P!V\_P"C(?UX]^KV .WG_1D/Z\>_5[ ';S_HR']>/?J]@#MY
M_P!&0_KQ[]7L =O/^C(?UX]^KV .WG_1D/Z\>_5[ ';S_HR']>/?J]@#MY_T
M9#^O'OU>P!V\_P"C(?UX]^KV .WG_1D/Z\>_5[ ';S_HR']>/?J]@#MY_P!&
M0_KQ[]7L =O/^C(?UX]^KV .WG_1D/Z\>_5[ ';S_HR']>/?J]@#MY_T9#^O
M'OU>P!V\_P"C(?UX]^KV .WG_1D/Z\>_5[ ';S_HR']>/?J]@#MY_P!&0_KQ
M[]7L =O/^C(?UX]^KV .WG_1D/Z\>_5[ ';S_HR']>/?J]@#MY_T9#^O'OU>
MP"(DM-BH0%H^+32$Q04.E,.UE"$Y^V,1(\&@50P!S$I#+) 8?,)R@/, /4P!
M@# & , 8 P!@# & , LDKJ9VHJJH$RV %%#G !:*^;J,)N7_ !WWN>7UML-1
M$32'7(B?&)K)VI:ULY555TU+_P#\+[1#^Q&\]--OD:OSV3[LLZP[Z1/9(]S5
MZ\G@+[0^Q&\]--OD:OSV/=EG6'?2)[(]S5Z\G@+[0^Q&\]--OD:OSV/=EG6'
M?2)[(]S5Z\G@+[1<JI5]2MQ9H]5R1T8SM5SVJ:9DB@"A$2 7I,8P\P[(1Y\_
M/S]SS9:YR82:BZ:C59T"-HJUR*M]:)LE=+P=(AJQ78W1*ZM*941*4JNP8_W;
MWU37XW_<I9D<CTI [3TJ6::Z8B]MZ$*6RK*<8 P"\^H?=L'[D5_/(Y8[9_9O
MGONBZ6;^N^;^\.;WRU'PN:_\25._K3?<Z4T$M1\QOY.^:6>:,T4]4L'>J5\X
MFS45FX#6PP!@&VGR,'POY#XGKK^>JAFHM&O4=#WYD?(3AL;0NU3.WMF_*2YU
M;YR8=%'FS$Q&0$8^F9EZA'1D:T<OGKQR?H20:LVZKIRJ/+F8_9-T551(F4ZA
MBD-T$,(<L PH@^-V&M=/;6FH4IO:GCJIW/:9JM"WJ(<3<5J2BURC6:4F)Q12
M-1BVE\DV>Q:DTK%,8/Y6M6%S+(2++9 U4KBRMQ-.6G#R\1EI89:-?59I(-GB
M!VDPI7G46J8_9=]0=R,:Z;F036Z%#&4;G*J"?0"@%'VQ $! !!6N , 8 P#6
M=J3C)V=8MKT[4>Q(2DQ<U>^*/B IU,D(:-FFC.X<.^M([BE8QLK%IR%@?"GL
MZCW[1=<KNTA05D80D%;J?8T8FO*[)B8FN#U3D1>%:>N[TT,U97=U%AKTEKIZ
MVV&:R+24/$D58:=V]+54'<ZFR58&4OT51WM$29%)(-_$I-6QDC84X.DYEVP4
M8/BMQY+N8 P!@# & , 8 P!@# & , 8!83>=YN]#=:;=51Y6THJT;II%!N;"
M<K\A*R$A7[>X<1XFKLHSLL,VKTFQ<E3=F=R$19D':!3-",F9S]\*!82!XQV%
MNXV4^'NO6C58Z\C:3MN&DNWG6JVS+!O36L_J,LO#P#-*PIMV=0K$+>IN D$7
M,"_G;!>H"Y,T%(&/UT[4M FEVOZ#/;! P!@# & , 8 P!@# & , 8 P#'BBW
M79%BV5Q)4.2EZ<!:'(4XNM9%K4)A$D2SN-("9;(W)DI=UU+>XBY<#*NG,/(4
M@DHQ-W)!K#K #[!.LB[:UX*>O;/:X;+Y9=H\/^F=C7,T0>VW;6U1LUE/ 1[F
M)@SS<O#-'DFI$1;V3F7<=''=JJG9LG,O)KM4!(BJ_=G(*YP6Y53;+VX(& ,
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M3$/#!7[U1Y5G.RS%E#2C6Z5$T6_>#984KT,\I7].N5;O]?:VBIR7BD*[=2[
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M$1!6>L/ZKKWB)J-\-M%NJ+%Q)M-B['U]KRH+2S:0[R2,G$'M9;.HV'G;;+V
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M(>R78BNSCI$&BKA!0*7+M*GI*2XC9W8KV_[-K5<V"&NFU2X;*S=:P9_<AU]
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M# -M/D8/A?R'Q/77\]5#-1:->HZ'OS(^0G#8VA=JF=O;-^4ESJWSDPZ*& ,
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MZMWQ?]9S<^6H^%S7_B2IW]:;[G2N@EJ/F-_)WS2SS1FBGJE@[U2OG$V:BLW
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M1<-8:VV5<$?)X?HV-M6);:<M4U+! TNFTZ<F&<%$Q.EUHLM]OS68>R9XXK>
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M+8FDC:)JHZYFK4_UU2Y^Q))JISD_4JI"S,H1_,%>OEPFY@'PBNL7IP!@# &
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KK!6)Q-(V9Y:)NPB:W4IG=M5X_4;!\$# & , 8 P!@# & , 8 P!@# /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g713200g07g87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g07g87.jpg
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M 0$! 0$! 0$! 0'_P  1" &# EP# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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MV)>6-X U2WZ(TJBLW.CWJ/3YS$_H!7Z*6AR>;C>C#I0-,*DOVZQV0C#()%*
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M-M5H!BSVJU)>FUE^PA0Y>$)-RZY+D.R TLC#??B+4C6EK;8CH:VS$ZVU%A*
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M#YO-:@CQ=K.Y*ODRS5LNGLO-&Z6OBKT ;3J"**[%-<9/\E0V8V<$D-,W[IA
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M"#[TE;#*FXK*E[1&89:TE&HJ]D;F2?7DNSF=]6E4Q]<ED;.KIT86UZD $;&
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M$3")A$PB81,(F$3")A$PB81,(F$3"*20/W(U_*?TJ\D:_P T/:[XJ-L?//\
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M1E=99_(ZBS$O67,A,7\#2>IJUV^37IUFN)+*]6(-BC&Y<[A,DCGROD>[8>;
MM=3")A%)('[D:_E/Z5>2-?YH>UWQ4;8^>?\ T?V6KN9?5E,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PBBC_Y][]*Y^OO(E_GN^L[XE2L?S<?U&_LA<6>5
M[3")A$PB81,(F$3")A$PB81,(F$3")A$PB819P5^:<_2?U=9G5?,=];[@L&U
MY[?J_>5E,REBIA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+X<_-N?Q%
M?J[RA[C[#\%4=X]H^*B61"ETPB81,(F$3"+4O;^X<U\=.<E^L=<.2JW0P4^O
M#2IB(!/V1V+*M%@&U@,G8JLC"Y=U$DR7@1=N,074M;?TI>]:]/7TUI>>%O,G
M?8;@=PW\=O0O+G-8.)QV'+TGO]B\#_*_R-/=,NQ898^B%)K>^L\ZN7A:7XR*
MY@58JE<LY,!3.1^3W&R3Y.=>/*(TY;K!8.==S\? 0>Q.)$E3#C RMM#:T0LV
M7&P <F_HD2!W%YPW+HW>#!L 6O.WHW//;&D<7'F?T@8^';N.P:YH\YY)W#F\
M]ASY<M_6WP*X#T_QSX96^?\ 0[E/)1H 86R'YS-563T;ED]IXDY9Q5>Z&"KM
M4*7.IG2DA)RMM6P*NR5B!)^AD#9MQG3[6/*]KW$M&WKYCB[MB1N0#MW[<B>>
MP[E?B86- )W]7+8>G8]Y'HWW(6YNZ^1G,O'P!]6O!?WE9;+BP-2&;:DV0\XC
M>T>L2$IQM,:"AS6TR2T]R,/8WK;7QW):V(KV@ZWZ0]-:!H=JS=O>U*QQHXFL
M629&\X;C\U"7-ZN .&TEJ<QUXSY/&Z5S(G]!T'T;ZGZ0\AV/!5.&I"]HOY>T
M'QXS'M.Q_/3AKC).YIWBJ0-DL2>=P-B;)*SP \BO+/IOD22<9-2]UZC1I/QA
M%#$27?I3/PU[W'EF7_1IRP%D)TG_ !V8VB-&<^(H9 ')>>0Y\&](/2KJ7I!L
M.9<E./PD<G'4P=21W96<)WCEN2;,=?M-&WYZ9K8XSQ&M!7#WAWZ#]''1'I?H
MXK-?2A&1SLD?!<S]R)G:W\0_.0TH]WMQ],G?\S"XR2M#1:L62QCFQWB_C%V3
MO$EO=&JSR06GMLRK@<VX)JD/:5>QW7U-UIQ9%YA7IIZ$%C$Y[6E)4Y%2C?OU
M'Z.Z--8:YD;\B8MXH\?!+E[I=4Q4.QX7?RES'.L/8>3X:4=F=FX+H@WFI+6W
M2CHS0,3OEW*L-_@XX<-0X;>6FW'$S^2M>T5HY!YD]Z2K7?L0V4N\E;"\F_$"
MU^.DF@-:+*O$2[1E0$SQ8B1%2Q<69/H[78T33\U^0F1$DP7!#[BF915Q!'2(
M#'RFT9/])71+E.CR3 M%IV:BS,;H.T5J<D09EV2>5CXHA)/))UD,D#JCW%DM
MIPL!L#.J+5KO1?TQ8GI(BU"XU&X*7!RB<U[5R.4OPSXMV9&68QP1QF.:*=MR
M-H?%4::Q=8DZT.7L1X7>,D;Q]Y\F<>C,N=.N<>+-MDK\1U0:+K7QH%3AO)]R
M=,C??\4HXPI2)Q=3ROC2(<,;MKZZZ'.C6/0. $UZ-CM2YAD4V5E\EQIQ;<<&
M*A>-QP5M^*TYA+9[9>>.2*&L6_&O39TH2](>HC!CY7MTOA9)8,1%Y3!=EWX+
M&7FC.QX[/#P56O =!3#!P1S360^YV=B7%4PB81,(I) _<C7\I_2KR1K_ #0]
MKOBHVQ\\_P#H_LM7<R^K*81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%%'
M_P ^]^E<_7WD2_SW?6=\2I6/YN/ZC?V0N+/*]IA$PB81,(F$3")A$PB81,(F
M$4/NG0:/SD4HW>[8 J8O7OTB4=)Q8&I"T:]RF(33SB7Y\G>MZ]D6$T_)<WO6
MD-*WO6LB,SG\)IZJ;N<RM'%51OM+=LQ0"1P&Y9"U[@^>3T10M?([N:TE3.$T
M[G=26Q1P&(R&7M'AXHJ%66QU;7'823O8TQUXM^^:=\<3>9<\ +3/'_*&C]YN
M5BKO,!A\S7JD/:EG;W/A[# MS)TC; @6)AS-?69LJ>A@A*4J= $-1XP]Y>E/
MK<9;7I^DNDS":YS&0Q^F:UZYC\579+>SD\)IT>MGD+*M6K#,.V32SB.>4F:"
MJV..!YW>XM:=TUCT69W0.%QN2U39Q]+(Y>P^&A@*\PNW^IKQA]RW<FA/8H(J
MYDK1 06+CY);#&[,:U[FV6SHZYDF$3"+."OS3GZ3^KK,ZKYCOK?<%@VO/;]7
M[RLIF4L5,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?#GYMS^(K]7>4
M/<?8?@JCO'M'Q42R(4NF$3")A$PB81>*'D$)Z)6^J>1]!ZO0^]]]8\G]U^E\
M'BU2T=.E<37RRZG>?5FZ4J;50 H_SOB7:.!PH5IZ=4NJ60>$A6X9/E&YMSBD
MQL^",R6;%K'-+&<'-VX:'<0W(.YV+FO[BT;[;;;;%8[@0Y_$'.X]FM )X>$E
MH(]#7#OW.P.YYJY7B%X4T;QAI0N6?=3<NN2VU67I-[)'+(9 %^GSWC$FY=/J
MM=M1"<)Y^?NJ2GP;1)J4 "B>-&AQDAM4$3&3EJ:?<.<YP9&P$[NX6AD;1OY3
MN7DM WW<=AS)5V*$[M:T%\CR  .)Q<\G8<+>?E..PV:-R=@%J#R;_"+5JDZ(
M4SARQ]PMJ/BQ)MT<TF740#OWH7L3I._AV@DS]ZFWFU?0&'/A+4^7TF1 3\P]
M)7\(/'87M&&T48,OEAQQ39D[2XF@_P T]EVW;D[#.9#FGL$;N$E]O:2!OU5T
M7_P<,GG.SYK73;&&Q!X98<(W>',9!G)P[7N.+%5G\@YCF_*$C>-HCIDQV#Y2
MU'GG=?*:\$9PB#8+]8B$I#E@M19]:10WXG[118Y,VV.&QV6-;U!&,K2[\LSJ
M*('N):;CZ^6\3I_7'2?F[$]2"_G<A8E#K^4M/(JU^+;8VKLO#7K,8SYFLPAW
M5,ZNI7<&!@^LLOJ/0?15@JU>Y8QVG\;7B<W'8FI&#;L\/G"I0A#K-F1\AWGM
M/:6]:\RW+#2]TA]=."_@W><4/Y(_UN2QTRTM?#?T%TV]'HHU]/HKV;@NZ;F6
M7:%:WKXIA,<:^VKVN@=+3IS/K#0O\'73N#ZF_JN1FI,FWA?V+A<S!UW]_#U#
MPV;)<)Y<5L1UY&G9U#<!R^0-?_PE=2Y_K\?I"*33&*?Q,-TN9)GK,9Y;]>PN
MAQG$.?#2,EF-PW9D-B6KTAAPX8Z)'@#XL:#!ALMQXD.&PU&B18[*=(:8CQV$
MH989:1K2&VFD)0A.M)2G6M:UGT5##%7BC@@BC@AB8V.*&%C8XHHV#9K(XV!K
M&,:  UK0&@#8 !?-,TTUB62>Q+)//,]TLTTTCI999'DN?))(\N>][W$N<]Q+
MG$DDDKH%J^#/+$K-"8!50$Q&L ;<^,U)^F'(3,EB&5AZ=2K3,^(U,DIC24:T
MZQMU2VE)7[5:L6Z%*\:CKM6"T:-N._3,\;9.S7862,AM0\0/!/$V601R#RF<
M1+2#L1D4\C>QXN-HV[%07Z<N/NBO*^+M5&=\<DU2;@(+Z\KX8C)$[R7\ #@1
MN#F,RUAIA$PB81,(I) _<C7\I_2KR1K_ #0]KOBHVQ\\_P#H_LM7<R^K*81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A%%'_P ^]^E<_7WD2_SW?6=\2I6/
MYN/ZC?V0N+/*]IA$PB81,(F$3")A$PB_-[TG6U*WK6M:WO>][]-:UK[][WO?
MW:UK7W[WO\F"=N9Y <R3X(!OR',GD /%5%ZSYP>/?)OF8<FW(N=AC^]&Z[0]
M,6"2AY/JE34PJB0S7QZVG/1$AB463.9_&](3BD;1G)M5=-6@-*];#+EAF,A'
MN/D_!AE^0/'(LFM![,?7<UW*2.6V)V\]H7$$+L&D>@SI$U=U4T6'=A<=)L?E
M'/F3'1%AYA\-1T;\C8:YNYCDBJ&!_+>=H<'+S(ZS^$Q[#</F1W-Q8KF =SW-
MIG(TU9+6ZWOU3O>R1"*V)@Z=1^-I,(+\Y%7O?P2BU)2YGS9JK^$CJ[+=;7T[
M5JZ:J.XFB<<.1RKF'<;]HL1MJP<3>>T-/KHG'R+)(#E]0Z1_@Q:-PW56=2V[
M>J;C=G&!W%C<2UPV('9J\KK<_ [EO->ZF5H\NJ 2U>?-BL]HNI=TS:3QRTG)
MBM)<(FR,TN1?VI6_8UJ1,=??VG2E>UIE"O8CUTAM"=>FLX%D,ED\S;=<REZ[
ME+TQ =8NV)K=AY)\EG63.>\@$[,8#L-]F@#DOH;&XO%82FREB<?1Q5&$$MK4
M:T%.LP >4_JX61LW(&[WD<3MMW$GFOZ5_$#B">%<3KM=G1DLVX]K5JNJ]IU\
M9!TJPSM(M:OOW[0(]N&(VA*U,*E19DMK6OG%^OZ.=$FBAH?1F/Q\\89E;P^5
M,R[;RQ>M,816)Y\J-=L-38$L,D4LK=NM=O\ F7TQ:Y.O=<9+)02E^'H'Y)P8
M!/ ['U)'@VVCESR%ATUP$M$@BFAA?OU+=K0YTU<L3")A%G!7YIS])_5UF=5\
MQWUON"P;7GM^K]Y64S*6*F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MOAS\VY_$5^KO*'N/L/P51WCVCXJ)9$*73")A$PB81,(M'=J\BN4\$$?4+_8F
MF23["WA-5&?#GVDU[?=I/R(I+K:FHREI4VHF1=@BFG-?"=G(=4A"M)UETA:6
MT)4[1GL@UEA["^KBZW#/E+FVX'45>-I;&7 M-FP^"JUWDNF#B =ZT3T<:LU_
M<[/I_&ODK1O#+>6M<5?%4M]B>T6RQP=*&D.%6LV>V]IXV0.8'.'BQUGR?\@_
M,(^YSKF]>-C:I-4I#5$J'S$N:4A_$2C4R['6T1D.P4J4E3[<A0RM1-;:5+:?
M?81.5\;ZJZ2]?=+E]VGM.X^Y7Q4Y+6X/$\<LUJ'<#K<U> C:Z$$[R->:V.B'
M#UK9'QB<_;6D>BWH[Z&\>W4FI<C1LY:  NSV8ZN&"K-PD]3@Z#G2%DY (C?&
M+63F\L0OCCD=7%GN!_@R(,/Y*Q]^+))2->Q]'/JS,=;'M[^Y6F;#9&-M29BM
M:WM#\(#N(RAU&E-G)K"E-[Z7H3^#7!#U.0UY;%F3R7C 8V9S:[?'@R&19PRS
M'GL^&@8FM<-VW9F$M7+>D#^%!/-UV-Z/JAK1GBC=J+)PL=8<.8X\=C9 ^*$;
MC=D^0ZY[FN(=0@> Y>KM:J]<IH:%7:H#%5P$.;^%"$AH,<?!CI_*K:(\9MMO
M;CBO5;SRM*>?=VIUY:W%*5OZEQV,Q^(IPX_%4JN/HUV\,-6G#'7@C'B6QQM:
MWB<?*>\@O>XESW.<23\F9/*9+,W9\EEKUO)7[+N*>W=GDL6)#X!TDKG.X6CR
M6,!#(V@,8UK0 ,[F<L!,(F$3")A$PB81,(I) _<C7\I_2KR1K_-#VN^*C;'S
MS_Z/[+5W,OJRF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8111_\^]^E<_7
MWD2_SW?6=\2I6/YN/ZC?V0N+/*]IA$PB81,(F$3")A$PB81?S9^=/-^;\V[H
M7@\X-#'XQECZT?J0[6]HHQZ6ZI<H3I;2/DF8LY*DE(8QI[YD2W(7$=B1(6AN
MW_SHZ;].Z=TYK>W!IVY6?'<9VV_BJX)&$O3.+I:O$UO4LCG!%F&LU_656R&)
MT44/9N/]+^@?4NI=2Z#ISZDI6624I.PX_+V2-\[0A:&Q6^%SNN?+7(-6:TYG
M5VW1B9DLLYLB.F><>7:5>[\'[P[]ECM,6S%X?QZ?RWY.SD_BH]T>=8=O+^R@
ME7KZI5ZSXSQE]M25M.Q0ST5_6M2T>O<>@31/\:M919*W#QXC3'4Y*SQ-WCFR
M!>[Y+JG?D=YHWW'M(+71TW1O&THWX)_"%UU_%+1,N+IS=7F=5]=BZO"[:2#'
M<#?E>V/$;5Y64HW-+7LFO,FC.\+MOZ*L_0=?G$F$3")A%G!7YIS])_5UF=5\
MQWUON"P;7GM^K]Y64S*6*F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MOAS\VY_$5^KO*'N/L/P51WCVCXJ)9$*73")A$PBU7T[MO*^.#MD>C74+7/<T
MIV*->D;E'2*=>NO_ &:!A)DEYZ??KV*=CPUL-*WK;[K2?56M7U+K32^D*_:-
M0YJGCMVE\5=\G6WK '+^3481);G&_(NCA<QI(XW-'-;7I?0^J]9V>S:;P=[)
M;.#);+(^JH5SR/\ *<A.8J=<['B#)9VR/ /5L>>2\RKYYY]@[06D4'Q/YR?0
MM_U9<M4D4V7LJ6'-[:^;9@(^:KM3B;WZZ^IFY9#VMJ2[I0N0CU3\VYWISU;K
M&U)@NBO3U\.?Y#LI)5;;R(C<2WKF5V];C\5$>?\ *;LL^S2'?R:1NX^G\!T!
M:.T34CU!TMZDQY:SRVXF.VZGC#(T!W4OL'JLCEIAR/9:,-?=P+=K4;MC^\M_
M!N6NWEU7GR:O9"83)/)G$*X'+.&; 0>5I*MHL=SF[DM-KU[?@/Q@[9':V-I^
M4.1%H3K33'\'7*9:V<WTDYRQ-9L/$UC'T[;KE^P\]XR.8FZQK7<N!\=1MCB9
MMU=V(@;-5?PEL3AZ@P71A@:\-6M&8*V2NU&TL?78-P#C<+ (GN:0>..2ZZMP
MR ]=0E!._J=S_F5!Y6";K?/:J(JHA'LVXP,C:2_-=;3[$R2A!W;I M,]GXNY
MA*5*E;3Z)V]M.M:U]/8'3>"TO2;CL!BZF+J#8N96C DF<T;"2S.XNL6IMN77
M69992-AQ[ !?*>H=3Z@U7?=DM19:YEKCMPV2U*3' QQW,56NP-KU(=^8@K11
M1 [D,W)*F;<J,ZM334AAQQ/K[FVWFUK3Z?E]R$JVK7I^_P"NLF6R1N<6MD8Y
MP[VM<TN'M .X6OA[7'8.:2.\ @D>XKGSVO281,(F$3")A%C9A@0.F"AY J-@
MSSLI^$#@S)T6+,,S8L&23DQ!49]U#Q&5'&PYA!^/$0\ZS!B29;B$L,.N);?J
M[_4BQTFX5&%#L1"9::Y$@5!U;-LG238QB'5WFX<8BMJQ2792&0KJ!\R'.6V2
M7&6F'*C2MZTP^TM39-UV-V:MIKWVNW8 FJIH7]<W9]EH&J]H+\O\W]8^M;D?
M3?I?RG^-?4/F?E/E_P##?&^'^-C;P\44QKA0:;!C# 8C!+B2D1N>-*#)<>>.
M(P97J]%F09L5QV-+B265H=8D1W7&7FU)6VM25:WN1K_-#VN^*C;'SK_Z/[+5
MFLOJRF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8111_P#/O?I7/U]Y$O\
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M8>Y#*'G4M/;9^(VEUQ*%:TM6MU!(Y@D'U<D6F^OG/&SE<M'2.IAN<Q+9]"?
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M.LWD+TRR%^>]S[(*Y;)O],W!X;S^N;O'8ZGSJTL56#ZV.KD*MS&'3 K[K_R
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M9V;!XB;-PM:V'+RXVG)DX@QO P1WG0FRS@82QA;*"QA+6[-)!FXM2ZC@Q$N
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MG2CCBJM< '/(;+9+6ND$<;8:\%[3NFHL.)+EJ4W\U;W?=R$I+W%S]BZ* O\
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M]>L7OXMZ;#9,H]I-VZ3^9Q<)V#G.=LX"8!P).SC$2UC&/G>UK-Q\&\?:CP@
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M%^K $RXV:M8H\ AEE R1)H!\_7[%\R>6-B1*Z?FOQ@\VK=B>?K[O3L=OU_\
M,=ZH>[\?C\=Q[E5,3V;H5M>Y<&J'2B+E\8MA*O6RCRAO.CH\B*Y[WLUS7K5]
MZ!T6)5*N.W22 FI6$/Q*#1JKS&Z6BR-/2)X<Q])N(JA^^$<_)Y>!&^_-H( ;
MN?$@D[D;>/IIN>7/X'Q[R>7+8<N06L?+7S+N'+>BKK'+[9%+W&5/\>:_RWE
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M9,29#DH=CRHLAE:VGX[[:VG6U*0XA25;ULBK#Y"6?B7$:D#M1[G5).VH2W#
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M)0VVVC6DH0A*4H3K24ZUK6M9V)C&1,9'&QL<<;6L9&QH8QC&@!K6-: UK6@
M-:     -EMH : UH#6M #6@   #8  <@ .0 Y +ESTJIA$PB81,(F$3"+X<_
M-N?Q%?J[RA[C[#\%4=X]H^*B61"ETPB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3"*20/W(U_*?TJ\D:_P T/:[XJ-L?//\ Z/[+5W,OJRF$3")A$PB81,(N
MI/FL#8$TC)3)5&'Q),V0F%"F$IBF(K*WW4Q!PYB40GR=MMJTQ"@19,R4[[&(
MK#S[B&U$5 _%+\(UQKRMO1[GP&&Y2#Z:L#Z'S\?9KESLB7Z'SX\9ME=048 5
M:U&C-4MH(O3"S5RYO:8D"WU"-,!O'(45\B]$@MD7H/A%0CR/\D/A?/\ />>S
M_P#"_P"%AV6S0W/S7Y6WPX9]O?YW]LT0(-J_P7XT6(KXOQ7FN%=(G2)P=?@,
M!/Y7E19'(Q.\WO:^I4>T^=WMGG:?)YQQG?B<.^]&W1MQ]GU#J*OY'DS8S&3-
M\_N='<N1N'F=SJ]=P\OE+,.#@8^I'-.4VWJ9?0VN0_;$86W]5-R]+;%"F5[_
M &TA_2=[=D+3K>X\%C3DI_>MJTA+*'7FN4:;TME=47.S8^+:)A!M790X5JK3
MXR/ /%(X?-PLXI'\SL&![V]>U-JO$:5I]JR4V\L@=V2C%LZW;>/"-A(#8VG;
MK)Y"V*/D"XR.8Q_JCRKB]0Y..^&'C_/G9#*4%+)-;1LC,W^*I;,?6O<D</\
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M?1ID0P+D$I]**WXB(?8FTUAV#[[N/<#O(&XY[G]PW/J.WI7D\]MO;N#X#O\
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MUEMS=F"2-K&P2N81:DR37<9L5-,6;UAF1U/9[?8;Y4./9RQ]7?8\)8-A*1L
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MJ=P/?6XU#K!!P$XH,Q8+188S;#A6&)(S9XX,+ :E-O18\XS)#FU3C#K$EP1
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M_P#1_9:NYE]64PB81,(M.43N%/Z+T?JO,ZW%.N$N1HJVSE@DPH;=4..V:?=
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MN6!M^7KU]K:CK*=C'F][2K3FPBSDMKT]5PO3>MYU+!]#FK<E!\H9=M32>(8
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MXD2*N8F%/8E\^W)KQKZS!GJ=3\N[F37>9(Y(WO<)&R/C+A*'DEK6.)C=P-W
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M#Y":-J(Y2E)<W&&A(LO<G<5IS7LU'7/9$R&TIVH&QK>VM2&,Z$\=:M,RVO\
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M59DF@KMXYI8H6=_%+(R-H]>[R %B*V6\=N/"I@.K&^0<W#2S!6Q3Q8LW4:Q
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M0<=7O.81*+3A/B?X7BYIZQ0+><F#A,:%*,VP41E&!=H+2(US:>(V(:6FS2D
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M\I]!\?FZ=UG8(_ZVS6C:[[8LPTC_ #1^]\C?PD9O/U=T>U-_"O1MS$?9/@7
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MQSOJ8<RUBZ2&.8=5++8@=(W@D;Y8CX''<QN>S9QB?]\_\<O_ '-US_<5G_\
M3N2WY#=9_P#S&G_]:/\ ]E4%_=*='_\ \EJS_4D?^W)_?/\ QR_]S=<_W%9_
M_3N/R&ZS_P#F-/\ ^M'_ .RI_=*='_\ \EJS_4D?^W)_?/\ QSW^U!]>7O\
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M_O-/[YQPM7W-4+O#V_\ LM<^&J5__M:D_P"W?Y?R:WC\A^J1YV6THT>EV6G
M_P#\>4_ND-$^&#UP[U-P-?[\F%^_WS#CZOS/)_(V1^AYR&W^O<T?[?YN_P#9
MZT_(GJ']+4&C&?7S-K[L8?P57^Z-TD1NS2_2#+_]/3U0_'+M'_(I_?*>:K^Y
MCAGD^]O_ &<U ZUO_N]MW7O\FM_Y/[W^;[]/R*YL<W:IT.T>GY:M_?BQ\4_N
MB=.GYO1724_V:<I;?JS1/I\/!/[X[4E_N?QV\H'O_P#'(S7ZEF=_S;_\O^_T
M?D:R YOUAH=H]/RS/]]%OJ5/[H3%.^;T!TE/_P#Z>K?_ &Y)WK]R?WQ$<O\
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M. S5A@._?RG?; _7R3^Y*\:I7KLWV[R?/J5^W22FV);2_P#/^(GF.G?O_?\
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M,<KN98=_4T#W[ ;H)8A^FW_.6S_E)/\  .?S=Y3JI/H.]RKUL?TV^]/E)/\
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MT^4D_P  Y_-WCJI/H.]R=;']-OO3Y23_  #G\W>.JD^@[W)UL?TV^]/E)/\
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MFE2TV0B/,8=%<V[MT.>F*)CID-SFVF>-QH#/N*0UR%6!]Q6H_P!+;3/(!O\
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MZ5+_ +D7S+\O_(\C7KQ])\*.IUP\,YST6PU@@=>E$1+UKK=).GJL'FC_ +/
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MV7L?],&EBXRXDT2ZY<'!5D'PGV!L@;"J-$N<B&V<=9@/&WAD9U<F+(F""I%
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M$7&KK',&YI(<[T*F,RP\9$LHAZR"66X+"YLT<K<B2[+1&0Y'G#Y46;'^-N1
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+$PB81,(F$3"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g713200g11b01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g11b01.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19*4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
M\0  !T,          0                         !              =#
M   !\0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !\0    !29VAT;&]N9P  !T,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   ?$     4F=H=&QO
M;F<   =#     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,      N[     0   *     K   !X   4*    N? !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  K * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5))))2QF#&I[ Z(7
MK/VN?^CVLG<[U-!M^GN.S\U57];Z=.1778+;L9ECK*A(,U?SE<NAN]<^SZP=
M&JPG8C<"WT'O)>TN;)>(L=N=O_-]J!("0">CU>^_3V,UX]Y_])I]U_[C/\\_
M^DUR]GUNZ464;\%^R@M?00Y@VQ[*]D.'YOM_X13/UQP/M37_ &)_VC::P_<R
M=LA[F_2^BW_H)<0[JX3V>C%UCGNK:*R]D%[189$_1W-V>W<LUW3'VFR]V=<Z
ML[A[;]C:RUSO4VNJK'T/YK8_Z'I_I%BU_6KI;67L;B7N-C7"Q[K&%[66$GTV
MV;][6;[/T3%"WZU=+MQ&-=C9'H,=^E(LK_2$-VO^TNW?I/;[K+/](EQ#NGA/
M9ZFO*97ALN#ZCC-:(N=9H0/;N<_TU+(S1C;/7-=?J.#6R\ZDG;_H_P"5])<M
M;]:NE.LH=9AWMKK ]*@/K],D'<RST]W\[]+_ +^DSZT=+9FG(MQ;;LEL^D7N
MJ/IL)W>G5M=_-M=]"S_K:7$.ZN$]GJK<HU/KKL]-K[3MK:7F2?\ MM1R<]F*
MYC;]C76D-8T.<223M^BVO=L]WN>N7Q_K5TNO*?E'&NORI+?4>ZN6M)W>DW:[
M\W=_QGIIL7ZT]+JL.=939DY+F^[)>:Q#6^P%K0_TZ_;['NK2XAW5PGL]DPO,
M[P!X;3/_ 'UJ'E95&)5ZV0[97N8R8+O=8YM58A@<[W6/:J/0,W#S,6UV'2ZB
MMEK@YCC/O<&W/CW.V_SB;ZRL8_IK=Y(:,G%)+1N/\_3^;OJ16L;\C-P<;);]
MKJ=92:RR_+$,_2O.YMGH;/S/T=2;/ZJ_$R7L=E45L!T;8'APAC7[9:UWYSO4
MM=_HOW/YQ%JJR[[<NNZS[+<=A%F,0XAH=8ZK7(J<W<ZG8V[]%_I/31<GI]UU
MCWLS+: _\U@:?S=K?YQK_;N]Z2=$%?UCZ0VIGKYE1MVQ86;MNYK/5MVZ?1V^
M[W+1JNKMW>F9V.+'2"(<.1[EG_LC,VM'[3R!MXVMJ:/HBL0WTOHL^FS^6K]%
M3J@\.L=9O>YXW=@?HUM_DL20E4/5K]05;V^H6EP9(W;0=I?M^EMW% R,IOK?
M8:S^M6U/LK&L!K2RMUCG?R7VUJ.%@-I;3=?%N=70VFS())<1[38-Q_,=8S>A
M>M#ZK^$ 7*Q?RC][^M_=?__0]54;"YM;G,;N< 2ULQ)[-E4[W]9%[ACUT.JG
MV.L<X&(;^XU_NW^H@B[ZQ%K3]FQF$Q+38XF(W/X9MW;OT?TOY:2D&1E7686:
M']/=C%^/>ZRW0^YK&-;N]K'6>M_@_P#B/TOIKAPYHJL]@ ]0BSV<N W&SZ/N
M]7WL_P"'7?YKLX]+S?MC*V#[(\_HR3#R+O4;+MOM;7Z'YG^D7G>^_P"S/<Y@
M$. :V="-?1=MG]]J9/<,N,6#YCJJQU8QJ9K_ $< L;Z<1) ;[-O^"AKO^ 4K
M-OVFMCF^^ &/V< !NL[?\(W9L_TJ#:^X44D,:7NG<TNX/^%C]WV[%.PN^UM8
M TUD"7[A($>W_P S3+_8R5_W75=AW9%Q:S;:&N+O9&[1VYOT=OZ-F[?_ *%"
M::OLMKQ6?2&EE6SEL_N[?\(_Z'^D_P"N*3"XVVAX:UH!VN#N3KOG3][^;_?4
M&N><=[]K1:TZ,W:']S\W^KZG_F"']J*_9U9/+175+2]A?[?;]!\#=[H]NUOT
MGIGFH6 /G^;EEFW_  <^UN[^4_\ P>Y,\CTV.:UL$[;&D\ 1N>WV_G?F-3/?
MM>/8',<TD"?<UQT8SZ/NV?2>])7]O5(PGUW !S,@603$%SX^EN@;]K/SU&M]
M'V<EE9]/82ZK9IL!^CZ$?GO_ #-BB(]0U/#8W;66\^W\ZS;M^C_)3,?8YABM
MK;F@G;/)'\W6;=O[J2O[.KWOU(+3T_)V3'VC7<9U].K<K7UK%9Z6SU TM&5B
MF7.V[8OJ][7>U4_J(X.Z=E$-#1]H(@".*Z=5L=7Z<.IX1PW/].M[ZW6:3+6/
M;::]',V[]GTU-'8,$MRMA7>MEY3]CZ_HMVV#:?:;6;X_<LV^HS^0KRQ1F8N1
MG&ZCJ+<>H1N:TU_I8%E6QWKM>]GH6MW?HT]+]OH;^O>KL#_5_HP]6?H'VU?H
M_1_X-.H=PAV5&QXK87NX'8<GP:/ZRR*7[11OZ]ZNQCA9_1AZI.W9;[:O9Z7_
M  :C4VL/HLMZ\;GUU/:9.,&O<[9^L>FRMK=]>WV_\:D1XC\4CQ=3%%CJQ=<P
MUW6@%]9()9_P.YFYOZ/^1_A$=8]=@ KW==#]M)8X_JPWV';&5I7[=O\ HV_H
MO>BX5C1?2'=6&7^A],TGT!ZEDM/VK] QEF[VN_1,_0^]*A^\#]J";-T__]'T
M>_I^39>^QF=;2QYGTV!IB UNT>H+-K?9N]C/ST$=+ZB6@/ZI<7 @DAE;08''
MT?HN?[_I?\&M1))3FY&!E#!RV"]^7;9BFFMCR&R^+3OTV5-=;ZK*_H_0K7(_
M\U^OBM_ZN=[GRWW52&ND;3^FVN]#V_\ &+T!)-E75?'BZ5]7SMWU5^L7I,8W
M'=N_/=NI$P?W?7_PS?\ MM2?]5_K ;FN;C.]-H$MW4ZR!_PWM]-R]"23:CW*
MZY]AU[/G;?JM]8A8]SL9SFF=@WTZ?^#?X1#'U3^L?HO;]G=ZA^@_=3IK^[ZW
M^#7I"251[E5S[#IV?-W?57ZREK'#$+7M=+AOHAS0![?Y[Z5GYZ9WU5^LH=NK
MQ#JV'-+Z8W'\[^=]K6-^A[5Z2DE4>Y5<^P?-A]4_K&'N;]D<ZESICU*0X-';
M=ZWTW)F_5/ZT&OTW8QW!IVV;Z8W'Z)]/UOH,7I2251[E5S[#IV<+ZHX'4,'"
MR*\^HU6/NW-!<UTMV5LW?HG/;^8MQSMK2Z"=H)@"28\ G23QLQG=YXV_6#+>
M<C$:<6F^:L)CFC:QCOTC\[.JL].[U7_]IZ&U?HK?Y[V66>H2O'Z_8TOKL-+0
MW[-17:6^HUOT+NH9'I^M5D7^HWU*:F65?H?\-ZBW4D4.2,+K!-S_ +2*RQ@H
MQV/)L:Y@+?4RKWL^SV_:+J_W/Z/9_A;T:G#N-U@?EN?2*A34UAAX:6M:ZV]P
M.W[1ZC+/2NI91]/_  FRM5?K=Z/['=ZWV?9ZC/Z7ZOI<_P#=3]-ZG^B_X1"^
MJVSU,W;^S_I,G]G[IX?_ $OU/\)^Y_UQ)3I9'3[;:W-JR[J;'4BCU!M,:SZX
M9M&V_P#-WU^G_P"!U>G+'Q,BK*LNLRGW5.K9772X- :6?3MW,:W=9;_K_@_3
MMI)*?__9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, -@    $ .$))300B      %&34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    )    L(=I  0    !    O
M .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q.3HP-SHR,2 Q.3HS.3HR, !R<C4P.3$V-P       Z !  ,    !
M__\  * "  0    !   '0Z #  0    !   !\0         & 0,  P    $
M!@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !
M  $   %& @( !     $              $@    !    2     $X0DE- _T
M      @          /_A 4A-30 J    "  ( 1(  P    $      1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @    D   "PAVD !     $   "\    Z    \     !
M   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W
M.C(Q(#$Y.C,Y.C(P ')R-3 Y,38W       #H $  P    '__P  H ( !
M  $   =#H , !     $   'Q          8! P #     0 &   !&@ %
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M%:R*MIRA4865A7S]O:]J?O$RYITD=.N;)6_:F)K6Q!XE4X 6NQ++,DPRIR?
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M650TE!M>TT^;/L>S_36(YIC60W.8Z=S2XS3$C+CN09;CF,2,KQS%,HBX;/\
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M)1Z5H[418^8R$(O7CN-8[B%1&Q_%*&GQFBADFFB4M!6PZBJBEL9TFSL"1Z^
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M'%A;^R:LQRFFRUK]5DQND!C;<@I+!X<SR#'9N9Q4LWT46*,5>2R11MM;_?\
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M3Z8R"/H*38!R7,]O8"FWL<RV'EV/MM[/(M8CH]>[C%3Y$"FL 7$$ZG!5WRP
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ME<ULMMR-JT=;CEUEMW@LN;"UWZ^64.,86=D* D=UB1[]^^<(^K).W9.WX?\
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M+BEZ$&S>_6/L=Z7BJ?INT(96(-2:=UP]6(O=&*[$:ARM_P#ZJO;M_ESN,/\
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MQ"'$(<0AQ"'$(<0C"]BYYC>L,$R_8F73OL[%\)QZVR;()S1O.Z)4TT,LZ>=
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M1KP.)QAF85*42P%!@&  -J4]0+[1*FR]>W&*1\)NZX=S<8ID]%EA:+(+.!'
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MA[H[T=1Z\'Y-3LU?#%*I.[47Y[?'Y_/[_GGHN'_R)/\ _6CY"//\3_[B</\
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MP8D)# Z7<FAW^7EI+1/4ELY#!@.]MON/8UC%18G=R)L>^NSQ91B^I]CQ6&C
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MA&+^"HO_ ,OW=_\ )?\ P_?RA)! ;QOKR_BL 0;1Y-=W5R=V_"_@B_/;_/\
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MS%*5*58&C5I;YQ1ZMZZ=/&/>GRB+^_EX)(!,5A\_N3_>O_ARG>'^GUA'@4C
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ML;(F8>8626!:S5%&4W/?EX=[L9E92QZROB2(Y9$FN9);(B2EDQ;])C?<U\A
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MFG4\RXS^_CTY:R+^DZY/*I==STO:>KI)/F(J,*BOC[]_./IE9W[+W3MV^/\
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ML2G+6T/39=]..0XM;["S>;9YW8V1:[(YV54UK[,-:&5"@8\VGK:MWN(UY/\
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MP[(Q<DISOO-3TQA:\A$<OCZ;7>2>/?FOXH_Y&>PT36FX<^'AY7W7 /\ \MA
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MBA:,3PO:YBC[^:I(GE2I;W=[/MKXO$7#*"5L3E[M[D$"GF?2HC75ENL<]O\
M:53E\"W;%HQ'AG41)!1D"*&K5+%9&^&F:5K.SE>C>ZN<C_/X[<_,03,4JX#%
MMK'FVS$CJ[QZ7@^/\,D<$5A%RT]H4E*U4J5 ZY@[/M1G%6$6.=9&#, K))(B
MS7$ 9L9K_2(!4<20%S!.:K@,5!HP?Y.5J?Z;7 )[R<PM9WY'7V#:/..*2PE
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MP"(*4\@9,=33)H0%C]T(\SU<Y60%<.1,<J32[./L#1W]:1TR.-)35$TYB.\
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M4)/9*2@J+]]JN;$<P& IOK?WTU7:UDJ7+FR0.EF"Z*43?;G",)?3,K M$XS
MH14'YJ)RN16N&4G=R,Y)E24A(#$$6(I\J/K4T>U(A8B;VH$MW0BF7Y4#4/2F
MSWS<UODA,1EXL^PD'QR59CO15I"JD6%;":YB6$=%1&@*YCE&3Q[(1O;R3NB+
MR^:D+24*J*@FS^+..O(>,-".S45C]3N:_P  CK;QC!98\E'5EE1:V&V/%:R
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MKVZRMM&;;@;==F678ED&;X;7BU@?$$S&1!R_'<7NI6/7L6J-1S3P)D%]@"9
ML0Q&;](N5F8 $U94E(6M"F<@A)!J Z2"*&%2[?Z4J<LV59RI4'(<%5.M(Z:C
M^IITFWN.9+E@,HSJMQS%=7Y[MV==9-I_:N*5\_$]43(-;M:-C\K)<1JA9#E&
MLK>RA4V<8K3.FW=#;%?728GNHDX<85,E]#V>4N"%)FJ2A$P&CI*U!+TKU$&+
MLVI'_<$E67KE2I3;),9]2=<&F\EILOL<>H]W7-SA%UCM/=X#"Z?]QILQ@,PK
M9MQB62AU]+PR-E#L*R6KK+254YH6O!C1BULVM+9AMHQ:]K]+: *4FE<JD@*4
MA;U"BE04-&-":M0<B[@+'-).4%.X<-36.MK^OSIVO;?"Z3$Y^QLXL,\U/"W?
M3Q\%TUM?,20M:S2Y1#%>9$''</L)6-2DNL0N,9=C]Y'@Y&[)_9X\*J):RQQ>
M6NZIB7K+2A:F-,LQ)7+8@.<R10,[Q6K)+44I:4EQ4RR$KO;*35_G2(YS'ZDF
MM:.[U#0XYK3=&46^P^H->GS+L:/K#.\9S?5V0$U!D&X:^=D&&W6-#MY:7..5
MU-.IX@6Q@6%#:V>01[-X\8M87,B05+2G](4F80HD!+R@"L9C1P%!QHPO:**.
M5*BX[I0&>I[4E*&'^Y08<Z<QGAOJ%=,L6PRR+,R3+H57BU-M:Z!F4[6>P8.O
M\W%H^OM;+:U?K+.Y6.AQ78EUAD2BO#6%1BEK93)8Z6X-4,L05-B6+C"P4=H7
M8)[2HRJ,O,$=HD&Z"5)8[$*L03>$*4M,L %2EB70A@L_VJ/]ITKJ""Q$2U0[
MPG[9TQ*VEH'#+')+&R5@\%I=O5V:Z,@9&(TN$./D,H^3X3.RB%B,JKEK?5=S
M$P^R6\KQ,961R$DL<R];HN*O46:XJ]JB,:%!6]&% [E@:;W :E79XZ'I+W]D
M74/KS)<DRW"ZO",IP;;&S]/9)!QG)CYIA-O>:ORB7B]I?X-EDNAQB;>XU.FQ
M"@$>90UDN%:1+2ID@<:O(4@5"% ]V8DJ#AC12D^1RDC<,12*D$+4*.@@."6J
MD*9M%!P%#0^$19]30K0]&.UR$<U@T)B'FKF>HU6_IC1=V*SNWS1_^'P[_>54
M3Y_!8F/+86:>0^8ZQ,P*<^*DI_W?0Q\EN03#1J.B>:(@DIW3+,XYH0CEN?/4
M"R'S&.1HF/$P3&!"YCV1F.\58UWF]W(S,:&2D,&!O0"UG-B!\S5GCM\)PU<R
M8420N9,46RH!)=S2E;Z[:VC#L&K!YM<Q_:2)L6L?.2+/RFLCDFU6*K-<\,";
M:R@HX25H9GIMG1WD&YT9A2B7NWE94P3@QJ0'<>]Z'SO&;$R%X<F5B910H,R%
MAB2+W.C&SB,RNI.24LR;CUX]:674/F8]>BK7'(*]L@2"19,83HR--(AR?31X
M@,5@',<BG>K?'O=VO9$I9AN]WU)\ZW/SLD]G-E*.506 X)T\+4+"UQ&$7=C!
MB536J%D*!#F++0A2Q%#&(@V1I+G>H!?/W*^GV]P\@QHWMZ:/+Y<B8C&H9DD.
M^FY\J#TY1-PO"YT]BC-,-'RI)+7\ZT8.#'2T *RZO8,.!))7P92R2,MPO8]*
MH48836!&L&K02!0&/)8N@"5R3*Z/)>(:DCO5I"S/%*.UF_DBI87UK&3$82;A
MV$Q!24O10*:6Y:[TY;9[;.NL5EY#B=D=8A@/=09*.NDA+'O/9SV$:^%)&CW&
M@R5&*;#)'5JK#,UYGN$O+B#+JU?0UU/K6U&TB"2I>;ND . 15COZ>=AM'%[>
M KXP4:R/65,><DD<8AHQ/&41$$TISFCM_;N&U$<%SG [*OW7*O,7YI#MFJ+^
M_L:4B5)X7/F@*E(5,4;A(4[GI4/_ !RYN/51[QQKZ*WVV/1)B?:%O%>-S:Y)
M:J9/(+%8.0K8_K2D#'!X'& WI#5['>.0$3 'U+ZG5GI2C6^U,,V6O#'LUA25
M[+%QS=_7H6B2LK]_BY+3$2^,B@98UJ6]A3@%)]^K $D030+=B.4<*;#E>]&T
M1Q"E"(!9*.<)&LH#V3U%:]6LY.X-"&OK&)$CM.^:*JP-]7]T&H>CPO>6\>G&
M)AC AT26(I881BQ6(Z2BN:U'2U$I#2% WP^7D&U4<GH.^'+C., HHL-RSM72
M^MMZQ/P_",3."IDH3%@).;*Y &I+4#.U^5X[BDK#V8[3(:YT.+5U3??SFOD,
M"9T669!HD43&,%-,)GD?T6(-Q0QWN8USAJU*YC,% XU.A\^;-72(,U*I*BA0
M(4"Q=PQ%[Z^?/:,LS(YJM_Z//&)(40@#.LJUWFZS%91128R"E,7Y@&"K"B&[
MQ>CC*AO!.P^9BL2DJ2X_35_#[!C]HPR\.9BW2Y)/4@^SRNYWB*)61I3,!7O)
M'C1G6'O8X'>T88LL0_28]#.9ZQE:-ZIZ/WP.<Y5<U7=N\(\0"5Y34)_NH'T?
M3W7:-QAN!8E84N4B8MN\O(@E(U[QM0;WW:.RH_"]+=%,:-7.KVI/CPS%:TEW
M7%-XG]BH@A&:?6,<,\Z"@AN2*XD@/FP+U3,B>)M7II[8>-*4WB/B)"Y2B"A3
M@L2Q]MSIM$A9&)]:V-C[%$*O2)!FRY5>93K;1)K63()GN\D8,+6R1QU&QZ(A
MVJA$54[)4@ $D@$7VWUJ_EY5B&E!G%F=5$L!:XYW'RB$Y5NRNGAASYP"5Q;4
M<W[*8^/ ),]LXB!1AVC=,4B#<@GJUQ!^7=R-^$Y'F8T Y01<5-K;EOY\XV&&
MX3B)R%S$2IA1*JLI02 S7(%>?[&.;7.D3B7MC83JRN]N@9E6) JU;LKS(V16
M"?'"T(;*+&<*<-LM@A60 RO2*V4+TB294U,R@;<&@ZBONWC'6@!P+"BBQH;6
MYL-/VRC)H)B_8P989,"$:IB3F$20\\:X=91U.*8(@&-1(#1^$9@']W"F#DC,
M_P V]FYB,H!--?3FV]Q9GZ8DRPJ@)40"VC@/L]ATS O:(\#DZ4\C[/,^O> T
MA#AKD;#AK(D-$<,0ODC%EE43BN5&*5XG+\E;V3MR/,QB0 @*#:EWYOMLW2M7
MB4GA6,FH,]$I:I0U""S5J6%@SG4#6)8+38+-U@[,_P"T$<'9H,E6N/KT]&^.
M*;2.$CQW,&]C,;#>;S<@BQ9 &)V8Y4>UZ-861)F)4 "KD/%CIZT%:V#1J5I4
MF8X+.6)-+7KK6V];7C"+EIK*'7R7Q20*DL=CA1TDJUUQ*&KO54KD57""-6N$
M\/C\%:]'HBHG:DPA&8%G>GSO>K:\]X578N*$ 7(YL2WUY!C&+1LD=",M<K(3
M!&(THZQ/2$3S$PPXI>_B^418Q'J]&>?IE5$\V^"-Y%_.9%%#.!_=JW2S"FG2
M-A_A>,G2DS.PF(E90<V4@+LQ>A-M=J[1,P:K6]GJL64?IU+!MJ)E!H,[ )=(
MH($C%R1QNB9#4W41K(TD@);"1K*'-$A5]4!!>*(Y'20M*T@@OR;32O)V_@F(
M8EJDJR*#@$DJ-,I&]GK<UU&C1%%\R5:LB2)OE&QQH6.%& 1/6L[!"$ 1DCP?
MZ@O25CG-&_\ 9^AV,HW>352A( <G[1>^?]+TLS5^W6MCS$=;4Y *L).K!P:I
MP)T4HF02M8]XU[.]K+1QO*1YQ2^)V-8\+'O;W<-[?N\L_- '("X2Y!>[W3TZ
M]8S'A^(4@3>Q6$FW=(LSUJ3H/D(F"S;JL^K:2R@Y+D3-OALFBN:&34UT;'7T
M[7&5LB'.B/\ <GD1V,CE\SB1#L,YI1!])2ER"8%AS2]VZN&:PY^D81*F)4V@
MJ22;C?\ :V]X@RP-+R$C"2CN!CT)C$<P2N3WTA'HCE*K'-]5SB=FM U5&U55
M55WY7." :->^@T?7Z,PU O6!W4J[I51+G]1Y:/0]!YQS*V[AU/OZZLCQQMF0
MSUY8ST88H8Q5&1KA>IZBA*A6#(CPM"Y5<HWD<-5[QUXI,M12%6\>ONFO.)2N
M'XA$LSE2IB4$$!126--W:FQM6](EJRDZWEZZQA(LJ^B;/B6$N/?#+&KFX_*H
M"*_V$BM/&""6VQ 5[F20R'2VG:]I4<-$[<N$W.!H#JZ;Z.=7Y[ZF-=V),P9J
M ,2:VITOR;0Q ]O*L<CDQXZ2!LH8[7-/Z"N:DHS"N:]93D[=V^3/%HD(@6O:
MY%:JIVY31V&47VJ'OI\WZ #*0)2LI+E7Z4ZD4J!KM2.^H[.#3&+!J(\94?%F
MP2,(YAO%\L+F>Y:!['L%)8YR$89J(Y'-1C2=_P ;?SC?TQW@":I9];7+5?QZ
M1*7@9XE=N9<Q$LB[$4OF>Q%-14/SB5;"XPHN"8Q$$*R#EL"5+CWDPZ1'PYH'
MG>Z 2 (01F82,!R,FO+*(JL<UJ#7LA>9Y:PI"K@FK']M2S\RQ:L:Q2&6 H]V
MC:G-2U']-M3$86%I)LBJ $J4M:!JB<V.Q0/51D;Y%D&[H_Q3R:UC&_<<Q455
M\U[)D 8.UG+OZ<F\=CM%ZFS)1GJJP:JJ.S<]F(-!2,HQBVBT\P$@8DF>B.2Q
M GDN5Q7D$4<0GIO<K61QR'M)X%&I'.;V1S6]^8_S02Z0>;W/,7TL#0TB2OA\
M]$LS5R9B4D%(401XC8:N0*G4&)9S+,<-DXWBU9CM;:)=UM21<DM9"QFQKZP.
M1A6E!%8/UZ\L!5=",]9<D$H:"F,0+W(-TF3B$J*4JH7%:UM3W7UC3S,.05*#
MJ8$BFS\C;H0UH^WKI4(TW3)T]F8WP:72VLR-;Y>7BCL.IU1/+_I=N_;R^>_;
MOWYV4C_)E?\ !/RCDIK]HM[YB_G$^\RQ9#B$.(0XA#B$<8L.(<L>0>+&,>(]
MQ(IB@$0L8CV^#WQR/:KPO>S[KG#5JN;]U55/CB$1YMG9E/J+!,GS>T@6%Z>C
MH;NWJ<0QX8IF79K84U3+M&8QB-.\HC7F160HA!0*V(A#%=][P1C%5$4^OOY_
M.*T]*?6GC/4/?97K?+, R/1G4+A;[X^6Z@S"/+E23XYC^5V&)"R[#\V;2U6.
M;!Q@EB! 2+'&3S6T=A*^S+4<60\2G0;5WV\?7U;E9I;ZF=_1NGG4F<[$K\3M
M=I97B5#'O:K4>'RX:Y[F0I%Y6T38^/5A5(<Y'2[(0F%6/[59'A'+("XB.1"M
M/7R^\<OISW#I_?.NA;8TR^#]C9=;3I.514IQ4&4U6>P&Q:?):+8M&X4>TJ,^
MQ\E=&H\@KKP#;6*L",%[B1617*AJWCKO7W6I%*1$O5KU=3>G"FKYF'Z8S3J#
ML1R[ ^<T6N9<$DO \4IHE=-M[2Z&@; Y[Z7%MX28GA;(@[;+RK('6D8V*][D
M+G4-O0%^NT3?T_;1U%M_4V+9IHV5!)K5X)=%20(5!,Q']'"XQ-/066*S<1LJ
MZHL<4L<;GUYZB=CMA55TNI-%=%)$"C&IQ >_YU^[U,5KWCUY8!H[=>N,!S7$
MKJ;I7.<7-99#U+4Z N]3ZKRLF9,Q#&:'9-E%">)CU;>W I$']*)$Y*^AMV0(
MMVR &:R:-#GX>]V/2GA%[9%G6PZXMO+L(46I!$6>>SDRXX*\$%HO6=,--*1L
M8<1H?VSI#RH%!?M%?X_/$5C6K;=>.-Q.H*)K?=O3YFF%Z>/FD*ETAU'7N.VF
M68/DFRV7N/8?12I+ZO%)];K6ORZQS5(&KL^M\C'6Y6@;2-&F032XD>4AO7RT
MC9LU?NIW[(OX*G=%^>_RGQ\?[.(1K[Z4^M/7/4ELG-\-RC6-QI/J!P>9GU5C
MF.;"J0PK_9&E:/8%CC$?9NK[Z3"AR<CP"\N<<CDOJV&OKXY? B@N8OIDIK&<
MA%NMQY[:ZOUEF.>T6#Y%LJ\QRH)+IL"Q,7JWV56Q2BAUM/!51F;'23-D 25-
M>$[*^$DF<\!FQU$Y"*Z]*/6)C_40;)L%R7!;_3/4+@\1+;9&GLHJKX1XE2;(
M[O$ZC-</RFVQW':W9."7<O&I+*S+\<'(A)X"@RTBRVH#B*>.WMM']T:,MZNN
MIEW2EK&FV0FJ]@[D;8Y]B^'2L/U=6.N\U;67;ILBZR*HHA!*:\=C5+6V%R:F
MB^C*L11EBPR^Y()KT*^6NG2I>VKW\HF/4VS]>;GU[B^TM49/39CK_-JP=YCF
M1T16&@6,>40OKJJ-1A8TZ/+;(B6L"6,4ZOLP2X4\(9@#B8AJ:_M[\]XJGU:]
M80>GG)L:Q'(>GG96U=7Y!4Q).W<]QG'I.28[@F(9->.Q!%+BD"GN[K8DACR2
MK')L8H(!YE;B0I-O(%( Y([D5WK%MM>YU@>>ZXQ#8>O;VGN=;Y1BM1DF(9!4
MN''HIN*6%<&943X+G- R- =7/"YC7C![9B>#Q!4;F,10'>_R]^]HHOGWU'];
M:]ZC\DT=E^N\QC8/@-QKG&\^WJ\U!(Q+ LPVM7P[76TG),8;-7+Z_7&2%F#Q
MZ'N!E:3"8.;"-C-A-B2(YI0T [5/D+=+O&QJ1-APXRRY<J-%BM]-'2)!PA W
MU7-&)%,1[1)ZCWL8-//[[WM:WNKD145C7/H;ZC>NMW[A=K&TUQF6M WF9;*P
MC36<9::AF4.R\LU+;V]'L##2LJI<JQUSLNI93V5[$U]F0:[(+K#'#R.O::*\
MT<2*?QX5^='TC9%V_P"SYXBL?G9/W)_NXA'K.$<D)8YFM>(PWB*QR=VO&1JL
M>Q4_<YJJU?\ )5Y:M(6DI-B""10L0Q8AB"1J("E1<1K-@?3OR.)IZ[Z8S=3F
M9%Z9@8U-QS6FO@Z^PD69:]C1;./=X (FS9+9T[**[5MK!K#8E"F44"3,AU-=
M79599#%');+ * 0ZR5R^R*9@[JLTE22A1:Y9(2IWS!WJ8H  590 %F85I(<*
M[5*A,H?]145<C41EU!T*6)MF8MN_9^[;38FW:3;6!;&M,AB8+28;06=#K/6>
MV-<8A@5;B]?9V+::#'=N++<JL[L]K<6EC=RR :D6J;!A5X)"9@6D =Z>I0_U
M*G2DR7?_ &2TI2GI6\6K1G2$YE!A)2"Y-)4WMF(_WJ<*-*6M6&-^?3EM;GIN
MRW ]:9G,OL\K-,=<6$81!MHU520;V_ZO\Q3/NUE9GD'CU(\3M "J()WB/'FQ
M7K,GM"K%$L>9)S90@U1)PN'NS(DXG#3LX/\ U,LB@L2;AXS%;DJ(M.F3P'IF
M7*FRVL2P[4D4H0-GC(<H^G!D.PPW62["ZBK7+-H9!E&K)]M<6^LL837=]@>H
M,<SRAQ'6>;:GJ[>NI,RI1V.R<ISBRDS[4 )V>)16XZF+4T4&@;(* %*4FA7,
M5-F$USK,M,I*A8)*):0$T(W$8D#* X#IEHEH8ET)2K/E!!U43FW%'UCO-:_3
M8H=9:FR?5=#NG.ZW](>D^'TKQ,RQFNK,2RG&X$#+]JY=$SW'I%.9D:KOHY]H
MR(L>! #%@Q1TT9\4@/<*./68,Y67(SC#<_\ VTKL@39\P<FS$TI%R>[EH.Z9
MZK,YGK"STRLPC$<#^E['UT%EQBFXZ_',\A]2.%=2=/:8OIO%\=P:IR#%]*V>
MAK/'@Z\B7A!2*O(L(O+F5(L9>0FN@9-*%=&G3T ^&>XETRTD I0J>2/]0Q"4
MI4GEE">Z:FI?1B@% @B\N2AW_NDS%34S#1BIU5#-01V-A],>)=8O)UC>;VR6
MQT]B]#U#5NCL'3"L>B6&K[3J)Q/.\+NK:YRT$Q+#80<+QW9.7U6%5LZ)1M#"
MLA_;\J]GPHE@+%V8R!)+D2!ATKU$H&6P:Q.64A)4:EB=3%P6>U$TU_K">I-0
M%3 5$&AT*E%B#?I%SMN:<S'-^GN[TOK;;UWIG*K'#JG#:K;=#1P[G(,=B1&U
M\*SGU=9)G0 @L[.GC3:^/81["+/I#V"6M5+#808AF7S@)RBI5 I94I(=B"22
M@U!RDGV:Q:@!  J62P+LQ8 *ZAOEM'KZ8M+Y!H#5%)JRZR[%LN@8KVK\4?B&
MMHNKZBEQH,6**)3_ &%&R7*G3YK93)L^??2[1]A;2IY9$]"RU-*D5-6Y:7#6
M2$C^T)T H!04BT AZN[7 <G51(N57,5P^JK8/K.BG8DIIXD1GZ4:I!(F3Y*0
MX<.+)V?B8)$N1)5KFA%&$1QWO<GCXL5'?"\C8R4J=AYDM'ZE"G@7B9@IG98F
M4LA\JK>!CY0>HG [#,L8R_#HUF.IMI+BQQ6\,J28TH@9#3-.V0!ZI(KI[41O
MF%SFECO;(9Y-<B<\WQ$J8F8I!?,%E%;L "^E3IKTCU/X<Q\G!XV7B9X9!4&(
M(-" ]_%]QXQ%^AJC<73]J[(L'J\T$HMAOKL<R6%4PQE@/I)-LTCHTQTF/Y$.
M(Y)1O>-1A6L.H D8Q7+R9P\+02E7^FI.@V&AYZWVC8_%/%N&<2FH5ATLL*"B
MK<'1J..=*N3:)_VAKW*,2OM63_TA'?4N;41[2ER,\677";92 V-=-@2BD>AB
M6L*W$L(,A7/=)>2*\:)ZO?DO&AJN[I-=>6K^-=?#G<(43#EHFM0!_:"XIL"Y
MMUO%1]L:DR?:6$&I:"S#36<>='D+[IYQBF(#S&6')]%SG,:KGM(UWIO:A!HU
MRNYH<1+=+CKY EO'KL>4=9P+C6$X-B%#%I2L%PD$.&<G0$VL+BC$1ZL UUE>
M"4F+XK/F/M9S+RI/,+7CDD"! O*LDC1-\3N#$K"34^?2]=KWB(BM=V61@>U2
MH)-K#KIX'E4L8Q_$'$\+CYRL3A\J4%-$"F7K0: /3IK%D=BX5;878ZVN:RXD
M7%/GE#D(::\-"-7K[\<JPH95257'5"&<]K/3D"*\)/?1QM>C1-Y-Q 4D:[$\
MNAKU!&O*.;P,U,T+0X;,Y#/M9K/32O)XJ7M_4.1[2QJ'4T]G'J)D"T64\,I9
M'MY2+'((@9+A+ZC"!7]HUGBY$<B*J]N[N:J=+42XU+;,WU-OYIUG N+X3A*E
M?F0E85F9]JL* [[,+1(FN<#O\<J*S$+ LJV6-%ACM35L"5,021S!8DSVD5'$
M],2O\&*1?%4*K7.1"IWEX%,S,$U(!I3P.SZ4I47C0\=XC(Q^,5B9 0F600P[
MH=W?1M: 4U#5BPV>ZPN<5CXE.QFXFWN+YO29C'IY\JN-6'+;8W-:R91,"XY
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MIKN?'4?+>GF^.5*6E,R4P2I2E,U;[6-QSLXB>\XUI?U&K<,V="DOM\7R"Q=
MERQP?:BI[X-<V7(J2O8<K2'0+7$9W],A *TSQM<[MR=BT94NG:WO2C4TZB(N
M$6CMDI67=GZ:,[]0_P!*T(GZ.S"9MT&?"R*,RF2>":Z*A)+)B#8C4=6M9W4+
MP*O=7N\OO"5&J-7-\EY]065*40ST#FS':YH-69X]-/'^'R^$2,$H@S)2"D@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g713200g11t09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g11t09.jpg
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M*G3X\*?*I+$E*TB349,5EE^8BO6*UJW)K<I5*<^?+?EO'\GW4 4 4 4 4 4
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M?69(XR:8<=U^FE^77'9D[/)VNW76_L+/[U_P=C;\^NE 63H H H H H H H
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MIQ+5&%4Z"IK,.%WH1QWW":Z JAO1GYR;:8+*RFU P,\80.!NB,8YPZ+]1M^
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MV_ E1=UJ>YL6+M^7LP/$',!B!W"0=HAE-(6ZR^N?4JYAS<#H7"3U4WVY5.I
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M@3(DMF51FRY\EN#!CTOS9<F6[36^^Z[4#VJ * * * * * * * * * * * *
M* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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MD6@L==LMQ7BCU04 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
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MR6:2YH<KH5@&VS [W<S[M6O)I,)L.1,Z4C*;YU&''Y\B P12X<;S<3BL/O\
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MWI)B+>J=E;4(NG(M!8Z[9;BO%'J@H H H H H H H H H H H H H H H H
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MRMJ$73D6@L==LMQ7BCU04 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
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M"VJ; [49H 4V&V)L6+%!%7:,!!$B$6@M5$%:M<IM2I<6F=8I4*<NEV;-DON
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MC>,ORU1_TY .H,CUM=1-ZYG]GHGM*5&4UO7=@,:<;#,!:FJM)U"@'7-M/+E
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M1;U3LK:A%TY%H+'7;+<5XH]4% % % % % % % % % % % % % % % % % %
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M\=A=*AP% % % % % % % % % % 0RQ]P</R.[E[%9CRPF'*A0&RZ=+<&<0Q
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M%@!015ER2])'@L(M,&">8YH?5-S*I;V=QM\^HQXE+A8KCR"[CD<N)5CM5'V
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MM!8Z[9;BO%'JB-YD\4,J]&[YZL%*[61<-R;%9?M;DZ^;<%3/#XW9G@C_ %]
MR+PH!C'@O>)J7NDU'U5%U+E?/#TEPAO;'Y053W \UQ)C971LO6%&O"J?%6UU
M_MDO3Y]?JLPO^O\ ]L(JL6IQ$6@L!:B;\F6UO"8:T+W1>BP.SL&<GPZ_^NO_
M .=:U*Q.1/,AGI<[AZ:Z_P!LR"/GU^LA?_K_ /:3AKP=9R)XB4BS)O5QQ?\
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MI>ZBVFXIB(:>(\;B(IRK**YB7+.0C+AE4165:M5K])4L1*1_+,[C?V=0G_\
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MQH6I$*5,-N-?]7-O7GN1_8&;5"5!;ZI-H\KUD<8M7)O:0]/,-7"F %4H80%
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M4#4#4KO323'YQVC$ECT<N](L&E>PN"4G)]73_F4I[#GKIX7?,/T[K6,G:/\
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MT<N](L&E>PN"4G)]73_F4I[#GKIX7?,/T[K6,G:/_D'W1/.HHBC7T1(D"@&
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MAT6H-+!,]N*1R62;YWCWK^W*TVJ"_LIZ"9]FQ1X*LRYTRZ6 V^'%0*LLEP*
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MSD_-,>RXT;4J+BIS(WC+\M4?].0#J#(];743>N9_9Z)[2E1E-;UW8#&G&PS
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M[.OU'/?Q@;_'IX_TT^LDV]+>^\>)E%OH*7>CL>XF*.]G$41((6 (S,2@R I
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M'IT)5Q &]DOU<)P0*7#FQ<_DS<1+C*>;8D5GM9_LHO@/M!ZMX.ZFN;38U&'
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M)44$ ,1[RA8Z7*PY :[0=$;QNN&#GP^6 ZC[8' 9";#?5FP?;BK,7FTZ]$>
M& ^I$(?#$5XYL7\OO/R6[R(,&-TJX"JR1Q6<,[&0R5[,(PC,R63[3\E9-<;
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M.9K2M<6+7 DNRK+@>I#O;C4(+B/<NA)!W0%EG_*+[". V\_;N:&FC>)X&AH
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M#QZTHD19E&70<%26O%S_ (V=<2S6S(.E!PE6ZUMQK$DUGOA^0ODFQ\.6=7+
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MT-D)E(Z,LLO;;H;8@WF:T0 BE[G4%5!I2I2J2AI4.6EMLYF4W$MS,HFZ=*2
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L!A,S,[2".@G@6BB1Q*M)QT\C"9-WN4 5NI8<-QI!Q;N^5;=S\]TU:H<'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g713200g19d04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g19d04.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M3   !.<          0                         !              3G
M   "3                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "3     !29VAT;&]N9P  !.<    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   DP     4F=H=&QO
M;F<   3G     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    &.$))300,      O3     0   *    !+   !X   C*    NW !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !+ * # 2(
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ME2KZG8;/2;96^T<T7!U-OR:/5>_^QCI*=1,J@Z@0=MU%C2.=D6_]"HNO_P#
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M)25!R,<W^G^ELJ]-P?\ HS&Z#.Q_[U?\A&224__9 #A"24T$(0      50
M  $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D
M &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4
M   !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[
M  (    )    L(=I  0    !    O    .@ +<;    G$  MQL   "<0061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.3HU,#HR
M.0!R<C4P.3$V-P       Z !  ,    !__\  * "  0    !   $YZ #  0
M   !   "3          & 0,  P    $ !@   1H !0    $   $V 1L !0
M  $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M     $@    !    2     $X0DE- _T       @          /_A 4A-30 J
M    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@
M P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "P
MAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y.C4P.C(Y ')R-3 Y,38W
M       #H $  P    '__P  H ( !     $   3GH , !     $   ),
M      8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M     0 "   " 0 $     0   48" @ $     0             #P     $
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M]2F-E=4IM?)2M@GKTZMOLFULHS[,(P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@''XC^X/YC@'. , 8!%FVQI05H/KO%3DM'BJX!HC!0=OG7";ST+GA59O
M3F;Q\BB"7D**SHA6H',4@F\IB ($1]"@HCT<=-7IRG(W_(_2_ 10BJ:A$?A*
M'C*=-<"K)G*3M Q%B@J4P"50 , X(7]W_4M?@D8 P!@# & , 8 P!@# & ,
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MR&6E/?==T^Z:]SQYQ<6XR34HMQDGM-2B]--/NFFFFGW3]3O@@8 P!@# & ,
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M,QT"D\?15TO$ 2F FE*&4#$$IB& L&V !(8AU""40 !*)%%"B'':<P<&$/\
MG_G^9;K & , 8 P!@# & , 8 P!@# & , 8 P!@&*4^\4_C-_4. 97 & , 8
M!H*^E^J%S%70]J@XB?;C5]Z6782$BMM*UVF)<-:)I#9MJ>'2UP\\\'5TT&<2
MX>"YBTDS-BM3)>0B#UP.=WP[*I\@\:Z73'D<7(XV+]E9FQ5-3?RU8XO;U\M]
MRV>#)X[YB6#DRC"',X.;PD)S^["_E:OLE$Y/]6,+K(3DVXK47\7L\!=M4WC7
MD11.KS7+)I;J?-Z[KZ.P7.O8)_ W*!].DB:5/9(5S)VYA.).5'+N2G':L,>&
MCK(,W*RE=?PENG3%\RY7#MX?+OR:\>7YMR+-Y^-7![P\SJ<+<N,4GT1L[>>U
M!PC+SK+8RC;;&7KW@_EX>,^-Q/#7+9ZQ?'/AY6X'A_,S;7&SF.)IZ94^'<BR
M<J?M&3@W1MAQ]-F55DN$,+&X^ZF_$QKJ=E'3_P!4T%8VD"PFI9J\K5A;-PJ%
MU34.2/7=@5!%W 2Z;EP[=UZ88NE2I*P4R^>N&:*C=W'3=A@W))!AU,#/73&$
MK%95+7EV[3Z(]DE)[;4-N/KMU*46YV4V56E#\4^%+599D8^'+$Y"-DHY.!T]
M*R+-63;QX^73%Y+55CC&NFF.;Y5]<<;$Y/%S,$O8 @( (>X#[@/[!SN'F(P!
M@# & , 8 P!@# & , 8 P!@# & , 8!Q^(_N#^8X!S@# & 15MUC*OZT"<3'
M7.2735<**)4FR0U9D")>B< *CIW-.V:"[,#"4!;)*&6%44S@02D,( 1)T* <
MO1QTU%.58ARZ>I93$<*%57*8(E !*NJ03$56 ?950AA*<_<8HB A@A?W?]>_
M\RV&"1@# & , 8 P!@# & , 8 P!@# & , 8!BE/O%/XS?U#@$8[UV#+:RH#
MFU1$OJ6O*(2<6Q=V+=MZ6U_0()G(KBU&0D)E",D5'KT')VS:-@@/%?%W;DC?
MXS'_ '@@>>Z<=J6/;M0F;'.2&H[$S86=_ P=PTK;I.W4FTMHY%J#YXU<248U
M!FNPDU742LBQEK$T6.R,O\0;.3N(MD!83 & :V]]1.G)GJEZ68 =>E96:T[4
MV]7[=8'FJ9V!:6V/D^F/<:<G&?7Y]66,+:2O6I>]1JSG9(7"3518"*$9JF3F
M+<9*46XRBU*,D^\9+NFODTUM?B?49RKE&<).,X2C*$D].,HM.,D_9II-/YE#
M=+;=V5T [[L_3IN1Y*VG6Z"*3B#65;NG_P!<M6\E9P>PZ@V.DY64M5)CO3UB
M^T9FY>?%H2-:.*^U]9%-XY:SWT4<_5;G40JHY)R;S,6+2JODTV[H0D_A5[?Q
M3^*,+DX7:5M5AZ3;AXOC7%R>:XR%>%XIQY^?R?'T3Z*L^2^)\AAU]775;?/X
MK>EN,<E/KZ7E4SE*'4'T@EJ3A7?W32>:D]<VEL:RR;#7,H>>:MXF68.3$EHZ
MDAZB)MD&U]=\49(QZ;IP9H5*)58(M6J<VU\BY'A<KC+)W\9UUUPDY2Q7'KC5
M).77!42U*-:<I*=47Y<H2G7*%+<KWZ/X7_*#Q?BNNO@_'L(V\I*'V*7)6MXF
M5FN$:H0LOS([?YR3QZ7')N@LZO,Q\?(KOSE&KBZ_4]+_ %WR]76AZ5N%T-@U
M_+*"VI.R4C&7DH@@+HMD(2:/XFY[9' ==-&,F6K"+GT7!'-;=P$A+Q#U?-_C
M>;HM@HM]$H_#9BS?Z>AK6YXW5IYF)N7PRK3NJ^Y.+<7"NL>-/R9\G@WSR(U^
M=7;\>-SN/&/YJY)2<W&CF53U0\-<_&-;^T1S73QV=+655=5"R.3E[BXF8BIZ
M/;2T)),9>+>I@LTD(YTB\9N4C?(Z+A YTE"\\@/:8># )1X, @%DA.%D5.N4
M9PEZ2BU*+_8UV_PSQO)QLG#NLQLNBW&R*GTV4WURJL@_7XH32DMKNNVFFFFT
MTS)9]& 8 P!@# & , 8 P!@# & , 8 P!@# ./Q'\?8/;]?SP"H]8WSMJ4VC
M"4N?U3KN+@+#*3;%LX@][1-IO<.R@T%EW$Q/TYI46D4@W J:(.&<?;G[UJ9X
MBF";A5-=,@%N< 8!%VV34(M; ;^JX2C14< R%NM8D3"^]$XX QJX<CH2^'R#
MPN(M_P!8=_;@$0]"HH#T<]-0MO\ V8=/TL6_(J"(H?"4/"(BKRJ/*?:/YS\Y
M_I_:YP0O[O\ JRU^"1@# & , 8 P!@# & , 8 P!@# & , 8!BE/O%/XS?U#
M@%<>LRUJU7ISV;Z$MF).V"KSM=K$C6*[=9U6'LLA#2!X:3E'M#;GF*G%(.VY
M"+6]9_ Q\(X5;*N+!#F.D\3 \AT"S"$GTY5UJ:[U^]2T1-65I-R$!?U-C@Q=
M.)EU(-8^2G76U-RR2+]..=M%31LE>7KEFBJD0&48CXF2(%@-O[7B--5:.MT[
M"6.<C']WU_1E25IK'NG$8ZV)<H6CQ4S)%DI.+22@X^7GF!Y59!9P^(W.(,8]
M\Y,FW.!X#7/5/JO9$S?XEF\>UI+7RJAGTS;QBX.$E8U/8VRM3#+1CY235!%L
M:_ZCO<(DUF"14FJ2,:2*;$S"48+K!]?7\2A/TBO4KKG7&T?HV[LQO54EHV-Z
MWHN%LQH:SPTA\+KE[TEN*@/IB2*R>KG0BXY2T-W+E=4"(%,1(AS@)R@-@\.\
M?'E,CD<-1Z[Y<)RN3BKMOS^/QWR*44VMRG5B6UI1^)];233:>*ZQ5QC-]EYE
M<6_PLFJ_D]=Y+O\ S+\]1G3#KCJ6K+:)MI'D-9(14'],OU?](G9JE+)B8Z#M
MF+UN[CY-@H8YTI&#EVCR+E&+AVS<( 1TH?.%5;93.-M4Y0G![C.+::?I^]-=
MFGM23TTTS<Q<K)PLBK+P[K,?)HFIU752<)PDODU[-;C)/<91;C)2BVGJWU7O
MW8?0)M]_H7?</)K:9EY TG!VI@B_DH6$:R"P%5O5* QWKT:4]?"92YTA4Z\W
M2)MTLZ(I,$=$FKA8)55\[3*['C"'+TP<LC&BE%<A5%:=M$>R>3'MUU^MB^[N
M6MWO)HQ_&V-9GX%5>-XJQ:79R/&5*-=?-TUK<\_CH=E]N@N^3AQW.V.[*NO7
M2KQ;NZ,-8[SC%-A:FGV= N\\R-+Q]HKQ6MDUE?D)9F4>V^Z^757IUUA)QH9(
M'4DBV;32B'B60ECD+X5?.>4\.4YG5?B62X[/34E9&$;*)SBTW'(P[=T34NE1
ML<8PL?ZTGK1V_!OY6^8\.JKBN>QEXF\.JN6-;@Y-UN)RF)3*,H*7&\SBSIY"
MBW&<NO&INMNQZ9)JFO'E.5D=6$NGLOIVM[&OWV(WYJ*SOT5HQ(NK+K,/]-;'
M*U> Y2?492N$AG[FR+-DO(2E6M26M[M@DH@2Z0;5%X1W7X9>;QD]<AQ]V+*,
MG*=W&66VXUS7=W0IBIY,>M+KGCV4<C16FU*W'6SU"[B.!\98T+/#GBKB^<HG
M5"NC \7XN+@<CQRFNF''9F;9+'XUNJ4UCU<GC\AX1Y#*G%3IQ>8?3&6P;1G7
M; #"Q;.]V MRA/4$8%V#%MO#+0A3&(@V:W^ 5*T?I.T%.47<JE'L7:BIBE^"
MOT&[RP+6?!Y:&35"RFRO.IDFU9C]*OC%=GUX\92C;T/X9SQ)V?%M>3'6CQWQ
M+X"R.&RK<7,Q<CPYG5SC6\;DW;9Q-TYJ3K6/S$ZJ;>/E>EUX^)SV/BS535D\
M^<7&4MD<#8X*SL224!*LY5F?M_.M%BJ"D8Q"* DX2]EFJX$4(8S=RFDN0#!W
M)AR&=BJZJZ/55.,UZ/7K%_[9)Z<9+WC)*2]TB@9O'YO'6JG.QK<:R4>NOS(_
M!=7MI6T6Q<JLBF33Z+J9V53U\,V9K,AIC & , 8 P!@# & , 8 P!@# & =#
MG*F510X\$3()S" ";@I0,8P\% 3#P #[  B/R !' -.O2NWHUCZ^]VW[6L+3
MCTI>(FVD98J9!:\8LU%W[2ENY-*2<P#!G;&\V]G2S2LHULA$)%5Z@Y,_37%-
M!P>/W?O^O_'N#<;D@JP/6;H BL2@O:)=FO+WBTZ_2;R%0M4<Y93=-N-:U_/N
MI=L^B6[B*@6UPN=1A$9UZDC&O'%EAU6JZK5SYR 68D5$P8/P$Y $&;KD!,4.
M.$3\_C^'XX!6;H?]^D+IS]^?_5-4??\ ^FIX(7]W_7^_J6HP2, 8 P!@# &
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MTZL.ESJEJ01JDM!+MY0J"$M2=CL6+44) 5?S4:N+\SFOO)(BZ8+,TF$DY=F
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M6/#?929* "!@ 2B @(<@(#R @/R$!#V$,VS@-:[/LUV:?L<X P!@# & , 8
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M_P"1QTU>G,8[?\C]+\!SG54.='X2CXCG47$RQSF3[3&.L(JF,(F4$3B. O\
M/]2U^ , 8 P!@# & , 8 P!@# & , 8 P!@# ,4I]XI_&;^H< XG8&"M$0_K
M]FA8FQ0,J@9K)PD[',Y>(DFIQ 3-G\;((N&;Q PE*)D7"*B8B ")1X# $% 0
M57B&%?K,+$UV!BD"M8N$@HYG$1$:V*(F*V81L>BW9LT"F,82HMT4TP$PB!>1
M' ,M@$*TK>E4MBVWTY1J^H*6F-HN-66-[>'U=BV#^2+5*;<HZ<BGS2<D&@0<
MU"WF$4C DUXZ7\QU6[V*9." D($$[?OE&M/4%T4,JQ<ZG8WJ&X-EN5F<%8H>
M7=)-B]-^X4S.%&\>\<*D1(HHFF94Q (511,@F[CE 0+P8!\SQDSD6KAA(-&S
MYB[2.@Z9O$$G+5R@H E41<-UBG262.41*=-0AB& >! 0P#49U<_11T?<K64L
M.H;-+ZYMQGI)]A#&<EDJPULC5,Z;.7@$Y(%G5<<HD46(>.CWS**?MEG<0)XF
M+EI@'EGX'Q3F\+;0I=>5B43DX4^8Z[L=6?\ 5^QWN,U4K/\ WL:ZN_!R/_?Q
MI34+:\-E,;-_JR?OZIOOIRC[M;[26IKV?L46J/5O](ITM>MJ_490;4%8I;5^
MW=WE@[0O-6%JP6%K%3DTRA]>WS95*J;EL1$[F64:6>OG=^=O S"3-N#4GI,>
M(\$>*H.WB\SBZ>3MEN6!>[>(RFY1ZOT4<G,QN/R;I6.47"J]J$>F3MRIO9J>
M;D4-*R$W7K[\4K(I[UK48.S26FFTVWM:2TELJZ:OI)M>[ABX\M@<5]=TX:H*
MEL%#EV]A@WQU/84FS9!59P>2*(IE&LM5G%\$QE7+FCQC!(7&4SF/ G)\?.;C
MCW4Z<OT60W*'3%KXH97EU1\MI[5V11C8O;IAF7RUO9KR837JGV7IZ_\ ;KW]
M-)N6^VDS9! V2 M#()"O2\?,,^X4SK,'*:_@6+QWMG291\K1TD(]JS1T1%RB
M<!(JD0X"4*1?CWXT_+R*ITSUM1G%KJ3])0;[3@_6,XMQDNZ;1G33[I[%BK5=
MMT0\@+5!1%D@Y!,R+Z'G8YI*QKM(P" D<,GJ2[=4.!'CO3$0'W#@??,))K8W
MQ]%GI79R+I]0W\OK*;.54R*<8]=*Q29SJ@Z!-D<5#2$2F9T1,WA\DI$H)]Y4
M(,#'[@Z6%RV;@N*JMZZD]JF[JG6MZWY;4HV42>EN=%E<]=NK78[?&>(>4XIP
M6/D2G36]QQ[I62KAO74Z)PG7D8DI):=F'=CV/LI2<=Q>LZ7T!](MT9R*LIKV
M]2%GK22ZCW\W+$A6;Y4 (JN+Q\X3D]?R >P,V9[O",)Q^/"$1 ]Q@4RR1YKB
M^0@H9^+3YG2HJ.2DFM)=Z\^B$'"/JHT65T[[2MY!Z+Y5XOXGFJHX_-86)?/H
M5=<>1A#KBN[_ --RU%4+*DYR:C5=5B2:T\CF&]LG[5GTMFS(%,T5OS6L0UD8
MQ5%K)A(DE]>6,@'\12O7"0Q]FJ2+5P)Q%O(V"2H#!P42*>-L4X]GS+PWBYDI
M2P)Y%*UU1C:Z;8M:;;@Y3J5T4D]O"NY'7HY*1-G@GA^3<I\5;GX.X]<:[O(R
M:Y]WWI5]V*KZ%%-NSC.1YUI?>?5V=Y(WJ&Z/-Y"VL%HB"5B>02 $+XHV227A
M14#L,#/>>JY.9@X<WS 2C>X]7@/SJ!>>W*[F^&,B72YX]&6TWY4ZVX9*UVW5
M5=''SH^N]UUK?M+MM<JOP_XNX:-BX?,^UXUVU9B8MTHQRX[]+N#Y2O'LS8MI
M;B\')K?9IR3V34AK\+;!)?4S:-6W+1E"=J<!L]E!;/BSI%*/8E&7N%5:3[=0
MP_VI&?4NCLHB)B@(AVC7LCB[ZOT-K<TO_P!;DZ/-:?KN%LE#)A+?I.R5SC^J
MNR2UJ^>GQV1-Y_#YW \C))3S/#U^1X>R'Z+_ %/&3KMXVZG6]T8N-QL;-OKL
MTVR$+AT[ZR>-7IKQI:;HZSP4A=S=#:N-G5DZY%.6XIJUIK';48HMU"D<]Q(B
M#C&@@)E'1B%$1YF1BPE#HR\6U0;6TZUR^+O:UJ$X2S*XI)/=<*8Q??K4ELLO
M$\[?1D0R/#_-8$\A1DMPRY?D\Y[I<6['9D8^55X:S9SW*MO+OY&^]?>QVI:4
M$6+IF5LQU&VM=F:KV>X*9,QX"PSRE8O4>=N< (B@\22E+*R(R1.<$(PK^LNS
M+]@.IDH*G5+SG@[;?%YM5=TG\<:<NRN3Z5J,98UTIWJ*7;RXYN,NZWKVML?%
ML?+A#QIX;Y#,P*NKR;.3X/$SJ%YG>RVGF>-KP^,E.79/*N\.<O9*#VI;UU0)
M/Z;=Z,G6REEJU]UP5VX%V>XTU*U0"8+%-]A0;QJ&2B 6DES&%)%KL'8FPG:J
M'',.9N"J88+9\MC34LS E>EU;R:<:4[HP2:[3P92NJVO]V3D3[[;[O?6PL/\
MG_.43H\-^+8\199&#CPG(<O71Q=MNW+HG1XGI^P9SBVOT=/"\;6U%PKVM,F:
MO]0N\:2@F\A=OV*TUM!$SEPTV/KZ)W:Q9(&-WI-W5NU.;6.RXE<Z9B@9)W0-
M@/&11[UE'?88#;&-S74ET7W5Z7Q1LZ,^JN/OYCE]ERX36_\ INVR:]-2T<7F
MOR;3KE.5W&<;FJQI4W8*R/"^?ES].K#IH7-<#=BK6_M2P,&BSU5D=MO9CT\[
M3F-Q:W972;9TQJ[<2#]@"E"L\K::Z](Q4*D9RBO/U>G6")=@L*K=[ SD TD8
MUP@<IU'**B+A2U8MWVBBNY.,E--J4865QEJ3CM0NC&R/=--23T]ZE):;\-YS
MC9\1RN7Q\Z;J)8\H+RK[\3)MAUUPL497X,[,6WM-.-E,M2BUU1KGU0C..;!R
M1@# & <?B/[@_F. 0I2^GC5&O[Q*;"J\%)L['*$ETR%>6VW3$!!$L+Y&3L):
MC4YB<?5>G!/2+=%Y,?5B(BAD%R 9SW@)@$";, \#:]GT>D677U0L\X6,L.TY
MV0K5$8&82;KXY-Q<%(V5ZR]4R9N&4<9*&B7[LBTJX8MUQ0],@JJZ421.![*1
M_P![WW_,W/\ V)\ USZ%W@VUSTC]-=0@(>6M&T;1IBF%I5=CHU1VS<2DF0D3
M%'FGPKM6D7' Z([>.G+UVU0)'Q4DL=PD"/(B/\O^Y/C+5.]#D<V"2ZEK+!VF
M5;B4U?1JFOIF@0W/'IT6<6^K[68<.4!$0</DY]L#LYA**(E(F81)^;?_ "G]
M<@X5"/K>]XQ1N91<36A*F68) !( .HM@XK:D*A'JI@?SPQYAPHDH0JL>[$5#
MLS!]?7N9JL=2%:5<A#[ 32I4\;RF*D9.<58E*D(>5*0+*0</,0*[;D"G5G(E
MC%O2AZB(DY! 3&3 G:$LU<LJ'J:]/PTZWXY%:(DV<BF4/^,9HLJ!?W&X' ,Y
M@# & , 8 P!@# & , 8 P!@# ,4I]XI_&;^H< R*BJ27'E433YYX\ARDYX^?
M'<(<\<^_& 8J"L=?M#1R_K4Y$6!BSEIF!=O(629RC5K.5R4=P=@AW#ADLNDC
M*0<TP?1,NP4.5U'23-TQ=I(N4%4B@9G /#5K6M'I\E<9>N5]K&R.P9XMHN;D
M%WKH;#82,&4427?IO7+E$7Q(J-C8PJR2:0ECHR-8APUCV:2(&NB^12[/KPZ9
MW?BGT6BNV]JE0]4:VA B!NG;:!@+')2&HJU6"&^R;L")V3:% +Y?&@N3SK,A
M'[O_ #\S:A@D8 P#RMJI==N35)O.L?*LT%12-E&BRT?-PZZI!24<P\RR.C(Q
MJZB8BDL+5PF1R@8[9T1=LHHB<#4QU"?11T>XRLK>]8MXNMWJ0;N$Y&8JL=$4
MR1LR:Y !PE=*Q&%A]=7E60 #H.G[-KJRS'14$RUS6,4P*77@O'O/\)77B/(?
M)<;"4''!SI2M5/1VB\.]MVXK@M^76O,Q5)]4\6QZUKVXU=CZM=$_3JCV]?7J
M7HT_1^_?U-?CRW=2'11()-;A9+72V4:NDU;S]M972W4Y\R:%*"35K;HUN_V)
M385DF#@6,-:(79VIFRAE5%=@$02\25^Q^8\(^*X>5DXN/B9<U*4L>Z>+@S5D
MGU3G6\B5/&9UDFXIY&/?QG)SC'IIPIZ;-9POH]'U1]$TI26OQTG;'LEZ]</>
M4H^A?G4?TJK 2,FFVJXD]CW"K5JWNM&DX:T1+Q5V<GIQ;2=9<.X&;4.@<KAX
MHU+ (1@ *3H@+<E#B<M^3B"W;Q6:J]P=GV;.C=C?#K>]Y$8V5IOX:TW?*U:E
M'X=,R0RO]RW\Y1TTO^W>F_D]:[[>^RV?ZQWMJ7<3(CS7EX@K H/>"T8B\21F
M6IT@+YB+Q2YB/ !$3 !ETDE6IN0,DNH00,/G?)<+RG$2<>0PKZ(]M6N#E3)/
M>G&Z'57WUZ.2DO1Q3[&U"R%BW"2?]?X>I+1R$4(9-0I3D.42G(<H&(<I@X$I
MBF 0,40]A 0$!#V'.6?96_8727HK9#51K-4M@T(;S'31CF[,\.W7<&$Z[Q&I
M2S25I?KU3&.8[]2N*/>Y14X+@=0YAV,?+RL277BY-^/+L^JFV=;[=UOI:3TU
MO336_8W</DN1XZ77@9V5AR[;>-?95U:?4NI0DHS6UO4DT:^-H?14KEDPM&D-
M@LX"?(<$ "<"PQD@2,,'"B3"TP\J\D(Q\D'/H@AVD+%H%,HD1DB50QR]S%Y^
M3E)<A7*V%GWKL62Q;7-:U.^FOIQ,Q;2ZED4RG))+K+7Q_C&?7./,4.]7:=F;
MQTOS=E=:UJ>3C8_E\=R2W\4UFXT[IO6[VEITGGM*=4FE[ _*8^RZM.$.LLA8
MH2(4NZDVF@<#*2"]FU_)0FRG[ 4@%QVN+-8@8!RE)LT3E!(O5_/>/*,5?73F
M8W_^ZM1@GV4?T=;IHFD]/JXGXI?<NF_B=K7BFF5*>2Z>3XS;6\C$KR:*EV4:
M[553*&!/MIJ?AU.QMRJR;4NN4FT?K.ZX*RJLUA).A;VCX7P*2<4A-0ZUH8M2
M<^J;.:]9PHUR"1(0 \;=W8Y5Z*O<11-0QB\8XT^&,];:MP9N+?50Y704M_#V
MI5TTM/XM\?0DM-=FD:ZP? _-0Z_L]O'72@WYG%72R8*>UT[PH+*RU%[^)OBL
M."_!:9/[3Z1W1][!C7>I'1C&%FR." W:7NOEBCD5 %$Q>1JM]AV]>CSI'Y*1
M9*^&6(53D%2B'V]/)\'4Y:?V7(P^1@DY>6XU9%L/=*5,'/*4M=WO#@UKT(Q_
M"&=AW3M\+>*[*[>B3E5BY$\;-@I+O"ZO#R8YG5)/[DL)-[TX^J)FA=D=-LLF
MLZH>]-UZ52=HB<PR,G-W35ITU #A,'EX8[.U,BQ .Y-1K7+#%%!,2E*HD!FQ
MPKU_AC*Q9/RY64332Z*<Q*?9]U' S.J2?MVQ-^WL]<[+I\2X_35RG'<#S45*
M2Z<[#Q,3D+6_7>1&/#>(KGONMW2[_/XC\G>E[!:&Z+_7UMZ?-P,D4C.&!JDH
MTH+TJGD45450@6KK8VMAD')C_GIF+@J?, H8YDI1IW<AQLSB<J6UF4T973]Q
M9V'*FV+?ZT<BO_IRT^UE="DF^S]CXX_G;/#\U9C8WBOPA*S<;Y\-R5UG'7I:
MU&WB>4JC',I<MN5.3REM4UI-26V7$Z;JQ;*IK]2-N5?5K,M\:?*%BUK"_L9B
MMA(@)' .WEHMJ*15U16$B;&5!%0A2.%6C5RJL@3)@8T<6CRHUSJ2G)J$LF[*
M23U]VR_XU'Y)I/W>Y-E>\5<Y;S_)K.NRZ<V?V>JMY-?!\=P%D^E/MD8?&=6/
M.V*UNU6V[34(RC&"A&P&;I6A@# & <?B/[@_F. <X P"*-CZEC-E3VK9^1L-
MCA7&IKP&P(%M!GAR-)&<"OSE7\<V63B)-9=A\%LDTV].R68'[W@./-YF[<R0
M$#]3M CF-:";K83<;-2DP[-)NV%E=I"X36CWJRA/3S4F>-12,N!3]C)! Y!
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MR7W^T8]<I8=CT^]N+6G/'DWKX\12K^6+'O)UDLO1CTX315F!+1N#4)UUCG&
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M$3-QD6*#E9J<0X\K-R<@N&:P<_96:JI*E'W*<!]\ A.Q=,U0E%#O8.=M5:E
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M'$<J<JE8,6+(#>F9MDD@-?6Q8Y-#KEZ8WH0[UJHXV]M,II-6ER<2U=@/3KM
M>U&TN-05EA,B;M 03;;,M1E (*A6[@$#+L0-GV , 8 P!@# & , 8 P!@# &
M , \1;-=5"Z"1>;B2_%$4A0:6",7<0]C8I"(B*+2=C%6LFFU,)A%9B9P=@Y
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M9W3_ *;ZF:XB4 6F=86%"F691,!X.J.M]JIOX-1P).XWA8[#$#'$"D H"(E
MPU2WUTU1ULA8J?B-N=,]P6DFB+2L;&@[]K>K2SY58J:,<D^26>:GGDG*QRI
M1C+. 5$Q>PQ1$. -@P"!@ Q1 Q3  E, @(" AR @(>P@(>X"'L(8!S@&*4^\
M4_C-_4. 97 & , 8!KHW-$%;]6O2=(P[ZB'F'6XMG%4;HRL\\GD2#TY[7,I\
M8C#3BS%L7A,H',SC68E5,@'<!3G*H!?+MN/O^=K7S+V_H\I\N [^?TKY]W/;
MQ^''/O@#MN'_  M:^1O\WE/GW?9_SGY=O'=[<]WR'C ';<.0X5K7' <_H\IS
MSQ]KC]*^7=\OV?,.<#O]?+W_ +G %N/XJUGG[7R;RGZQ[?\ .OU<=W[>>/;
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M_ B'<  / B'/ X!6WH=*!.D'IR*4H%*74M0*4I0 "E*$8D!0* >P  <  !P
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MFXX#CN$>. X^6 ?"<I0.< *4  Q@       1    ]@  ^08!E\ 8 P!@# &
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MR:AG+Y1XH4/KZ_D7+P!@# & , 8 P!@# '[?_/X__G & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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1HD($MX P!@# & , 8 P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g713200g21v73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g21v73.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[25P4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %X< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(R-C0V,3<< @4
M-4UI8W)O<V]F="!0;W=E<E!O:6YT("T@25!/('!R;V1U8W0@9&EA9W)A;7,@
M,#<R,BYP<'1M.$))300E       0*]X2)5P^CK[\D2Y'K/^1]CA"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 \     !  $#P     $  3A"24T$)@      #@             _
M@   .$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     S4    &              -%   #>          !
M          $              W@   -%                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   -%     %)G:'1L;VYG   #>     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #10    !29VAT;&]N9P   W@    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     0X0DE-! P     &LX    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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M69&)914_TWO$!VOCJTQ^]]%8F?T?[)B->"ZYQ,6P!L#8/^#]SE+"=;J>.5C
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MOZ"V[WLM%OTE\Q))*?_9.$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C W.C(R(#$S.C$V.C(W ')R,C8T-C$W       #
MH $  P    '__P  H ( !     $   -XH , !     $   -%          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3DZ,#<Z,C(@,3,Z,38Z,C< <G(R-C0V,3<       .@ 0 #     ?__
M  "@ @ $     0   WB@ P $     0   T4         !@$#  ,    !  8
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M8I66H=,F-#=VDK*V_\0 ' $!  (# 0$!              $" P0%!@<(_\0
M21$  @$"! ,%!@4"! 0$ PD  0(1  ,$$B$Q!4%1$R)A<? &,H&1H=$40E*Q
MP2/A8G*2\0<5,Z*"D\+2%E3B)#1#4V-S@Z/3_]H # ,!  (1 Q$ /P#[^.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7A51$555$1$5555]$1$_BJJO\
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M7MC84X=*;I,9U]:/DH<K\CLK2%?J-MI;@&*:1S /N58GSEJL0[?Z\\J1K/\
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MZF^BATA]1TIGL_\ L[7D/&@U6L%L3R[U(G*QYH%0.95LK )7HJBH;(67./\
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M(@/O,6/3NB//\WE(/05NWYRZYE.*4XI3BE.*55OO3Q7Q?<DQ.AAGFS&Y<+'
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M$STC<URPHC7R21-DF9&V9^C@+F.N62W$+-NQ>%QP%MMF4VQ&1I#, 3W@1FF
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M5Q6.P^'Q%O"7+H1[]UQ8M93WV!((E5(7WE S%1) !,Q5@KLI@2JP3'+E4C6
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M:+*X[0":G.5+Z2B CKKL%2?MRON*O<A&%-;&:9!]L800,D!,L38FM5OMV+.
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M1ZRJ41TUUW),^1RJYTDKW9U5F>YRJYSI?>JJOJJ^O-L<1X@H@8_&@#0 8J^
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MHJO-]U9P$BP=E*V3-[. 6-TTPV>4LBQJ;OXF?O?9UAYMD/:2M:]T,-@(3*C
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MGK0]]D-=HJ+45172E'I,I@-#7&0'N&9I1,;K;_$WUL2&5)L<4?)D];'=4*-
M2.T:(F5[VA ([VX\I&8=#K2NQJO"7I>@DL9*$_M2F_:'."9C9-"[<WOIO@1[
MS:Z4HO</)NB)M+<W5]V-MK.^N#Y'GVQ&@,^ZF=&T>.&3<8[Y3T[HTT TTT@
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MN5<$F(DQTG3Y5CGERKNVM:QJ-8UK6I^$:U$:U/\ J1/1$Y%*XIM=7V4$@UB
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MB00HY9M5QLW(?$U2')[#2X:]#TN4N#*6Y"E26(L63T^5/<CGP&0N]T!HD_\
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MK+(P"8V]T.D[)[$GV=_;Z6:O.M4+N;<R>:XF0,F"X/:S)S@ =!#*1(F  JP
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M3BE.*4XI3BE.*4XI7A4]45$54545/5/3U3^]/5%3U3^*>J*G]J*G%*^>:O\
MIF^3?77U7.H_+:P[+G[[ZAN]UMM'K]%:04&7V&!-,ZEV6:H8M'E*,6GS-L"Q
M%H,Z#J,A6"3SO^!EOG:B&-IA70_$VFPC6<O9N%4 "2&AE)@ZD3J2K&!!(.H
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M4IQ2J_>2O?-)X]]:6.P.2$R_-<ZIQU%)(K77&@GB>Z%)$;ZO96UT;76%I/\
MNHP:'[>-_P!X6)%+FL63>N!!H-V/19$GZZ>-9;-HWG"C0;L>@^YV%?,CH-!<
M:J\MM)H+ BUN[RP*M+2Q+=\A!9QLKIR)I%7\)[GO5&1L1L<4:,BB:R-C&-]
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M$\NRLC%74JRF&4[@C<>MZS R)'.L%[9Z["[7Z]TN"/,?717PL#8+&.%"7 '
MG"V=>7]NLD/W$<1H<#IQTFA6>#Y86S0N>DC;6KAM7$N  E3L=)!!!'@8)@P8
M/*E8MT!TP)T;A%R45LMZ<9;F7EO:_:?8Q$&E0BB,C%$6<I\ XX0(D*)(1,^6
M9LQ"K&DR0Q6Q%XW[F<J%&4*%F8 DZF!,DGD(&G*E7JZ3[1H>O5O!;T$M\%K]
MI-$?70PD$QR").Q!9XI9AU4>1)UDC>R1WQRHY'QJV3Y(_*>T'!\5Q/L'PUQ
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MP3V$LW>Q-^VZ%BG<NI%M\TF267O2 1F[HBL]RT+65@9!,&=]CJ(Y>&^VM;@
MM3FK(,2Q OZ8L$X: P,J"R#DA)%)C;-!/$]LRH^.6-[7L<GX5JHO.4;=Q259
M&!4D$%3((,$'3D:BN5^N4O\ ZXJ__B G_P![D9'_ $M_I/VI3]<I?_7%7_\
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MBI7+QN+X8,@Q2"'0JEV![R$PIT_,I,=2"!K$5=#!CKMZ\OVJZ?.!66K>]/\
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M0"JY!U-=/C?^3P=7 68\^^\D=UJ:F.9KR*[*82BQ!A$35570I9VM_O&0^_\
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M7R_%%))[&N]C'.]$721@KHQDA75C&\!@3$Q^]*L%T5T/NNV2*W/9X5D0%0(
M)?Z<IDK:.I;"/#$]5E]K7EF2M:KPZP=%*G16OE085LQ4.CC<?9P:EKAEVDI:
M4C.V_P ED:LT <I;NU*J3_)K=1TST7B^E*1P&>@<=<G1Q?KFG.CC_5+61B(O
MQM]ON:#6QR(KA:T=RQ1?\Y/(46LI4OCL7C+V,N9[AA03DMJ3E0?^ICS8[\@
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MY/:0/4Q$RS1+_06PK_WDC,!L#\0?H(WT,3OS@UD6P-V/*8&OSZ1MK/E7TR>
MGA;/<6>;[+V.99G>LLA]H1A\R17H#'IC@4:M43#6NCB2++5+FQEQ3+$V"W+B
M'A'0@%AJOYV+Q0"FU;,LPAC/NCI.V8[:'0;ZQ&#%7U13:MD9CHQ4Z(/TB.?+
MP_?>USE5S*<4JLO<WBYC>Z=92:R[N+JG*K@(ZFQAJ$"_VO7#DSE"Q+,5!/\
M9D0R%DL4EL1'O@D;'\3711R-Z.#XE?P=I[5M48,V92^8Y&( ) ! ,@#0\QXF
M:E9YGU/WKE;+IC*9'I;<YKK+K^AEMILI;#5T$M<-8VMD;*))$D\QY[9S+&T8
MQ[Y0/N2'JI;!X8OC9[&MK:Q=V[B[-W$7W@74).8A57-,  @*O6(T))FD0" .
MM:-B!IPR)Q"X"!2AI7P$C$PO@('GC<K9(9X)49+%+&Y%:^.1K7M5%1R(O/<
MA@"I!! ((,@@[$'F#UYUAKT_C^U?\$_SY-*S?3==ZO(4&.TN@KG 5>[ -LL\
M][F_/,(#/%$^0@=520;YXB131/<BM("*@G8[]YS&:]K$VK]R];MF6L,%?0Q+
M"=#$&((/1@1XU)!$3SKL\+KNP,<#<6.3B/=3*L:6Y"T\EC4"$,8OPSD$+$\8
M(EL;_P .?+'\L:L25DK&QHW3XAP[A_$&MC& =HL]G%SL[A7FHC5E)UB#!VC6
M;V[CVYR'0[B)'GX'QK K*Q,MSS+2R*E,//(E*+)E1OOFGF<KGO5&^UC4]5]&
ML8UL<;$:R-K6-:U.A9M6[%I+5E0ENVH5%$P% TWU\23J3).I-4)))),DZDUP
M\#U<TNU.J.M,)');WI<MM9A9+/PL*L"G*C9[.R2N@9[U17I\QQBHQBR>KY6J
M_P#*]?2TH>_=RJ- ;C:#_"L^&RB21, U$3M4N7_0?<N8$4^ZZWU8X;6^^0D:
MN6TB@8B>JN)=4R'?:M:B+[G$?$UO^\J<U[?$,%<;*F(MSR!)2?+.%!^!/6K9
M6Z?S^U='D^S]EAP3:NALFCB%ROF? 2&.4@Q:L;"\@9"&N^&96QL;(Q4="Y8V
MK)"Y[?7FOC>$8#B-RW=Q%HL]ONYE=D+*"6"/E(E9),[P3!@BK)=>V"JF 9W$
MP=M)V]<ZLSX+6Q'^FVTCF$;93W62O)"[.=JR& OCL*PZ4Q)U5R^TTE&#%>Y$
M662>%WR)[%9+K\:MJN"M*AR):N(JVU@*1D90(_PC41MM&M0AU/.>?/T:W"\\
MG66G%*<4IQ2G%*<4IQ2G%*<4IQ2JIR>:/C^!V3W)UCH-:[*6G1\_7P.MOM,,
MRLR=G;]CR50E-19"X4B5^ENJZVT65H+X (-)*[1:W.T;5)LCU'AOD8A2!.:8
M U.D[CEL?@":5VG6OEUT7V_N;3"==; +2DU(-E83WPAE3%G#1*_+]);&(JB*
M)LX3])766?[^P18EU05EE1#3R&@7%G5G3T(]X*,HDB-8\=V'[J:>/KG]JCI?
M./-%5V#N*'HOR#TU/V[8 B=+W%3GNNAJ?M<.Q'O;(.WS]Q?]GTE7F13,_1/T
M];6=G&8+3W>=/$L:*@M/M+V*GGLSK+*,OO23W>7(&==)$B=)U%3'B--_G'+^
M-*Z_J/RBZ?J@^LNM:DW3Z[M7MD+N3L9,=79=M3I!M#2:W;6O8%)J0K:WCJ<3
M<LVM1M\=FZK0Z1L-K88O0AU=H<!FK2P%R7LSL7C*BBW;63,*B(B:@">Z%9B
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M[_@O&%NJ2Q_T:. ")VC3.@C-$ 0 PRD#X:"F]=)GO!3H#-KE60!;>U!Z];B
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K[TQEC:EVL$#"G3VMHC7MC.G8ZI8L "!I&PUTTB>E23/K;R^=6!Y6HK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g713200g22d25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g22d25.jpg
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M5G)S=Y27MQHD)291DZ;6USA"AI*5XE)35&%Q@:3_Q  < 0$  @(# 0
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M+(E'<>7U/)X! ;*E\Y]QYXTCM'0F-.*ZLZ<OP]6&K5MK#";S%NP#:#PB"JC
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M(0;_  @KN@MEF6$N7;!UA%=-1%7T#C?T:NFZ>_AOKMC")D/$1Q$<1'$3B5@
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M]O#PVTSC[W-G1UI;JJ*[!N1[55ADC()YC(((S\1!\1FOJG:O37V(=KI4[*<
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M>65"\J.(WEW"*+;,LP8CJ( PBL>WQ34MJQN<6<"UB =@TC@C<G$RLHUF&&A
M3-XWE,J^-U[LG&C[@@RUP68QYG,<O6JX211=Z8C8]4@@5=D!NW8KV+M "C*E
MM^"'7GNK[UL]84/G*LI*C.21K5,E3;R=S8<+LSFMN]"V=\ #R+%,'*L%8X(
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M0$OZQR[>X='^:Z?]37^[*A[MUGYS=^L;[8^VY:/XP9A_* E_6./<.C_-=/\
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MTK]V/"_\E91_\PG^O<D/Q!J/[>GT/^[-'\=Z?^RN_P#1^_'W8\+_ ,E91_\
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MMU-$G&[/#9ZCZ-VQ6<-%D5U+&K!QE<X!*\U93E3@\F /6.O&#UC(D Z-60&
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M EM JIQ)@HPIIW 8(Y/76^=I]YG=DIDA"=@9@ 3=7RJRR2$'=#]IUY_"9/\
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MR4F.(EGG5'X)6_R@-?SV_*=QOPX^:K_;+9P?P)?.6>L22G(B2DI\N?X5I_\
M*<G^?SR^</\  M+YE/5*5K_#-3YUIK+FY-22GZA?"@3^1A7Z6 \A>.^!I^D)
M]7;)?@OA;^8?VZY93RHRTQQ$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<
M1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$BMVM8Z/0M1^\84I(Z?:W.(=7P
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M7KYO).X09.3DA0!ULS'"J,D#))[2 !DD@ D:%:&QMH(&%9BQSM554LQ. 3R
MZ@"2<  D@21O1Z:C)Y8+$T-:DAN[5.:Q\P%-(-VQD#((ZY<AS0<FDT=/V67#
M-^T5PD['/R DFSW:E0Y$B)?,GSB)XPP?A[D9&+44@XRK*Y!!P2.L<B"01A@2
MI!,IPM#7KE4D'-3,&4Y5E9001D ]1ZB 0<@@$$2W+E/EID+^YG[@0C\L%?T)
MMRP]S_PFI^17[32"XY\'I_EO[*RI>$0*?1%>?.59A$""TUM!O.$_1P8RU3&
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M<1+%NG/X!R;Y7*_0PGE4X_X33Y@?6/+/P3P:WSY^KKDNN04F95'V4^&J9_\
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M^HXEI]-::K!9N ![U01AAD8.X>J8E]UQ5G_Z66__ $EC_:_._P#$6M_K4?\
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M+PMPY)8M6S!F+%2UH;9N))(3.P$G)"@GG-W0,K<34H%"!752JA P2HKOVJ
M;""Y & 6P.0$NMY4):)#?N7KKO$(EIOKKOIO('>NVNV,;:[:[#%L;:[:Y\<;
M:[8SG&<9QG&<9\,\G^ ?#ZCS2^W(3C?P-/G3[!E2$4HB$PO734$\EZ.6C*'@
MPBB\N-.%HW#X*>1D &# E]W'I6D4W<H^HG62N[EY* >V@.2$"@MF.;,[(M*(
M,+NY!0.^.51&W*@_\.>1'6R]ZQ(  @7U%C^^"')=F[Q>^>Q2K6-RYO@Y4\@C
M=\H!R3YH71\)@A@27#*R1QK& 96,PD.7D9(H"@T<-N13HF&C UPIG1NS5V!B
M&K/<CN2=AA3!((#<C NZ[!;*U(A!&[O5*H"Q(13C(4'Y( SDJHVKA<@X>][%
M(;;WQ#.P4!K&7."Y'6>^)/5D]\V6YSL-@/W""_DD=^AH\\^L^$L^6WM&7>OX
M.OY"^R)Q,]_ ::?).1_0[SG;I/"M-^D4_6+.-_P%WFK/8,I;YZ!*)'$2R3I_
M\&9GY;$_H2.\J7'O#*_T9/K;I:.">"V?I#_5U25G(23$J:[%?#--_P"$B?Z/
M">7?A/\ )^G\EGUUDIW$_#K_ "I]4DTIR1FA)'=5OA='_D4Y^BXY$\:\!?SE
M?M24X/X:OF[/4):%RFRV2%_<S]P(1^6"OZ$VY8>Y_P"$U/R*_::07'/@]/\
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M_L>.NN<X\?V/O?>_[>!S('QS!Y GXIU[NT'>:VQ\CLI;$K:P,M NOC"=T(#
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MU777!LA;*%KW 9*DJ"&QD9&0 >>=I)&2 #"QI4UC$ZRF%>D'D=B:UD'YW,)
M88/",G9B-)G9:DA>5YJ%21ASTF,.05X^C\EE V31PFW*O2;X"B@LNR(M-_HW
M-;(2JEV=F()8#=9N*8[TD,A*LP93DDK@X,TC=6+4L 9^B5$52 N=E6T69[\
MK9AE0JPP &/6#++R><$F%<S&-QN:DXJ4)*V3?4G'J0\$_CP=L!F\CL>9B&GL
M\@</*Z.=&Q[TJJ*3O1N-T62")Y(Y%[G"VAQ%'KX7J5<J3TFX;05&'U:N.19N
M>&\?+JYXR=O1.EG$M.R!@.C"G>0QW)I"AYA5[5QU<_?<L[1>-RG2U2(_<7\
M(W\L$/H4SR=X!X3=Y@_6)(;C?@U7GQ]79*E!5*5D$5(K"XUEKL2W8YVUP:D*
MJ(QL./IREJ)C3=<LJWB4>Q($4BKB-Q=(. >N4],O!KC37&G+.*JQG"]>.UB
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MZ6NRBSAPJFBDGKG=3?77&<\A%5G9416=V(554%F8GD JC)))Z@!DR8) !)(
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M#M5?VP\"-=GJL]NTON-;QP[1=.VK.A%71U]%[H77-H';I>@W&E;$>T$UAVK
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M#QS08-=N&RG).ZSN,JN:^OB.G6Y]^7&GUO+I&#V[1[GVITKJKVE IM<![-S
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MCE7O_)&*[^/#-/\ <4#_ /4_EK_[5=1_W+3_ .=?_P"--'\1I^<M^K'[\?\
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M4,D2$;'48QDDW2.M7TKFS]@?3FEMP1LLW5&1#."J3JOF"T.?6.F>7+[G';_
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M9=XVCH4.%U<$A#I3<<*'-5=E$F;?5-$R2PJTA5J!&L>G8;8T+8&A<C'IHE#
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MAR\$;@"\^:1"#M*?W5KG8^.6A4TE%!QL%%:CGTU05!;'GTOAXJ*1#*2H<^#
MF7\-AY&1@##N,!%62,_?R]?W/S3TF'22KH^TA8V+'YV% 0B/4P+TANYAB^AT
MQ-]<M&2U%S*>,LBV\A(R*ORHB/%?21B40]I+%8U&V<R;'1X *U'IC/W_ &??
M[96IY+6NHE/0UBP,?H7CL!IF7TYN;CV<Q-Z_GUV5/,F,O#7$ZE@R&QR3,TBC
MF%-F)N&2(C.-WC9QJO[UZODWCHDG)OVD?,,8$M+ =4@T3B"T&BEPWG'8V.8
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M=0Z*"7_UKI>72N93II7C>5!IS!J:'8K]E$HZ"K:PFLNK.*EUQE?"]W9.%S4
MX,ISZ ,JME4F%/F<6F2\@$"$-7",^GQ\_)]/_3$M=XF(XB.(CB(XB.(CB(XB
F.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB)__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g713200g25k48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g25k48.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X66^:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^24U!0BU,24=(5$)!0TM?0U,U/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT
M:71L93X*(" @(" @(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \
M<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR
M97!A:7(B/D9I;&4@3F%M93H@(" @(" @(" @(" @("!)34%"+4Q)1TA40D%#
M2U]#4S4N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(R.38T,3DF
M(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(W+4]C="TR,#$Y(# V.C T
M.C0V)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#(V+4]C="TR,#$Y(#(P
M.C,T.C0V)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL
M;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E
M.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@
M8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K
M<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03LM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF
M(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!)34%"+4Q)1TA40D%#2U]#
M4S4N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(R.38T,3DF(WA!
M.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(W+4]C="TR,#$Y(# V.C W.C0S
M)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#(V+4]C="TR,#$Y(#(P.C,W
M.C0S)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S
M=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @
M(" @(" @("!!<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE
M8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A
M<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03LM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!
M.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G,C5K-#@N86DF(WA!.U5S97)N
M86UE.B @(" @(" @(" @(" @<G(R.38T,3DF(WA!.TQO8V%L(%1I;64Z(" @
M(" @(" @(" @(#(W+4]C="TR,#$Y(# V.C,Q.C Y)B-X03M%4U0@5&EM93H@
M(" @(" @(" @(" @(#(V+4]C="TR,#$Y(#(Q.C Q.C Y)B-X03M38W)I<'0@
M5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ
M(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K
M)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N
M(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E
M<B!P<F]C97-S+BHJ*B8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM
M<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@
M(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3
M-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#
M<F5A=&5$871E/C(P,3DM,3 M,C=4,#8Z,S$Z,3,K,#4Z,S \+WAM<#I#<F5A
M=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C Q.2TQ,"TR-U0P
M-CHS,3HQ,RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,3DM,3 M,C=4,#8Z,S$Z,3,K,#4Z,S \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @
M(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM
M9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.FAE:6=H=#XQ,# \+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M
M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%1
M4VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311
M:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$
M:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W
M9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"
M451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O
M9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!6D%%04%W15(F(WA!
M.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'
M05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&
M0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A1
M5D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1
M>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q
M4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S
M8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L
M<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)
M1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!
M.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%
M9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K
M=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP
M-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV
M9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&
M5VYD555U-4-O;TI::6$F(WA!.T%!9%-4:4%P3$A:4'I%.&U2>G1!,G!P>E4X
M4U935FMR-T]%2T@W.'I",F9M279H*S4Q-3=5,#1.8V8S+T%(.&LR<SEB,&4Y
M9V4T=$PF(WA!.S)'94=.4SAJ;S9N9V\S2F)F-&9P>D=Y-#59+W%&3UAJ>G=M
M3&E16&HO=T-92#5H-FIR16MU;C9:23%T<$MK<7IP5EAN-U99.5%N9W8F(WA!
M.S,K,F@Q1W5->E5F<"LY=V12<41,66-N;6LQ<U902F%H:'5#3FIL35IU05%Q
M,G9M=GIB<$Q!-F9Q,3%!1C92:59M:C(X55EL1#DR6F4F(WA!.U!+4C%2-#)3
M4$M26G(U6"]!3V-H3F-G=6]B6'I$8E)8;'4W<6I8:U9)6E5$1VA:;"]U,D$X
M049Z3$=O249N9'E-4&%K<G%9*TPR+U,F(WA!.TYD,'96-&96<UIH2E0W8UHR
M9&8Y6E1V;&U$57=Y:31L,T5*:5A*2#5E>F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G,F(WA!.U9D:7)S5F1I<G-69&ER<U9D:7)S5E%U<6%P
M639867DS=#=+27)E259::C%*-T%$=50R1U=9<U5P>319.#)V3FUJ:FE:4TY!
M4$4O3T@F(WA!.VXS52]-17)1>&QR8E1&4'=7>6UH9B]+;$DV;C(V1#AC-EA3
M84=/25=D-60O-FYJ9&8R;E!/84AP:#-F<EET;6,V>$=A9D5X3%-!:T,F(WA!
M.VA863EA.69W>FQ087)T1'=S47A2*W%F4"MR*S,Y8G1/>DU.>4TK9U9*<E5%
M8D104&]Z9#)1;'0Q8E5R=&U40V)!:$HW=41R=&U80U0F(WA!.U9)2DAE43!R
M;6)#5&@U27939DM/<S-H,#9Z=C1*;6EU-'AW85)4.%A*1'A*4"MT4W!(=FUI
M,48T8WA-5%A53S P*U%M25!6-THU43@F(WA!.S5W-G=O=&)V:D9Q2T1O3FQL
M04<W3#<K27IF841T05IV5$QA9C-U>GA:=4Q9.#)56G,R.3)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8F(WA!.S)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9:
M3DY&0D1*3DTV>'=X2UAK:UDP5E955DI*4%%!66=+.$,X,69M069/17EZ,FA:
M3DAI95(F(WA!.V)/33=C*T1S;G)-4$9Q8D1S4'!Z<4]Z.4M-8TPO:4QX;F$K
M<T]82G<O=T%%9GAA45IN=7!D:7%D5W-00S)153-)<6$K2C-Z>50R9S$F(WA!
M.UAJ87E:-E)00U!H*S(S<71&:31-55(X5C=,;6]"8V=H03-C46]4;"M/5$%H
M23=Y4')M8FI,5DE*1&92.6-Z<UIC8DE'4BM12G$R9#,F(WA!.V(Y-#522B]Y
M35=N+T%"<&UU-U5J-F]N>2](,W0K:5!P23@R5GAY>7=Y<$Q%>%-20T=2,4Y#
M0TYW46,Q<UI%1WAZ8WIK.64X;BM:1C$F(WA!.W94955H07992TIC;TYQ:SE(
M03A'>G)T0G$O1VAV.5$U=7=X6D])96%F6FY.<G-65U1Z=U<X3%14>4Q&0V=Q
M.&MJ0E9!.%-4<TU11E$F(WA!.T@K2G9,9CA!,61B4"]P26DO=T-A<VQW2'52
M>$1V5$Q)<&1I<3)75T]+3C5:6%=/2TY3>G5X059607%34V1G04U64R\O04).
M-6(O-G4F(WA!.W1N+S!K4F8X,5I,9U!C:FE(96ER4%5D4'966G)+-FEU5E$P
M9&]85U%!;G-E2D]!9VIM;TYQ-TUQ<5=9:%955EIJ<T%",T]"2UAF-&TF(WA!
M.SAT+SE85WHO04]K:4PO;7)*8T(W:V-1-S!46C9P<&PV5U=Y=DE,:W!1=4E:
M16M)0C96-&LP=T=*2$Y145549U-H3'973DES-5)&95@F(WA!.S%V8E-K8VA(
M3DMI3GA/,6%-46%B65)%;$))6%=E<#9B9F,O<58S1&1E;E0Q4%)K5U1J>7)3
M=D5M;&%(16=J;6])2TIW2E%L-7$K;%<F(WA!.U5G:G9,,D,R:UEC;%-A5DEY
M4C!Q07A',D522C5)2D%54#A495<O.$%Q-C)F+U-21B]W03%994$Y>3A1-S%7
M,S%V4G)L*T9V9C(P>C$F(WA!.T$T>'I2=6%T,$9!5#%X350S3%E2=5)3.&,O
M-7E4.#=T<%!L<4AY-V%38V(S5W$O5T-P,U<P:E!X1"]N;S-W+TE.;69O35A&
M3&E04G<F(WA!.W1D;#1954]:95)E4G!L9E%X1U!T47E/<$AZ*TPK3V1&9T]Z
M>"MU:E4W.&U1-6,T8G-65&\V:EI52'@Q+S)*+W!N;6-V6EA7-4I'4C0F(WA!
M.T%38BMR=CA!9SE,+T%#;FA!<7HX:V9P5VUA:')0<69O,C-E-$58.31Y:6EJ
M,C5.458Y<W<Y5C=086Y!3&QW;C-(*WAY9%!M1V(V3$LF(WA!.T<Q8E-D5'-6
M+W="371*64(P1%-)>6<O26M53V$P-%IW4'%"1%I/0DA-35EV44XX>7-B4DI)
M3#=V;6)J8V9);E U9F9B,4@O;FHO>DTF(WA!.WI$-U8U4BM0-D=Z42]W05AW
M+U-Y-#5Q435P5%1Y=')B85!R54YY5%-">C9D>5!'3FIU9CEJ.7)-,U)A:G=S
M9U!4<C=M94MF1$LS=%$F(WA!.TE)<4YW8S=&,E1S5EED*V-0+VMT3F8X02M9
M8V8X;D9Y-U0O5T=J52\S8W9C*T]C,V)Z8C<S>FYN<3-9<6M(-6=F.&]&-6LO
M-UI6-R\F(WA!.T%.43<U6F@K<V4X3E=F.$%U-64T=FEF3C8X,#EK+S5X;#$S
M-G0U;S%(4C-E:V5O,G=L:E4Y-6):<6=$+T%'16IN-DUW9&1#-&<Y>G,F(WA!
M.W5Z6C%)>#<S<VXU=#8U*VAV>3<Q<3969TI:641A=RM03S5):7%09%$U8C9-
M=W102&EM03=(57HT8UI,-#-Z9'9/4&-F*V-7+RM/<'(F(WA!.R]W1'AG="\K
M2G9M0G)U461P,EIZ;#A(,$U304MN641Q8S%R=&YX9"M:4&UC*UIF3W5Q87%R
M8W)D-51&864P15AW4BM0,F=V22LU>F4F(WA!.UE)8TU!2&Y.5FLT.&A,2G8K
M8V9F33,V23@K4C)-<F-B6%=9>F%U1%=N<6HT-%0X*U$T+S=,2V1:0S18,TXO
M6BM4:&Y892MQ.#%,=D@F(WA!.WI8+WIK.2]Y;4]L+SES-68K5#AU8E!1+U-F
M939F=% V:#=N;C-L8CAV9DXO;7%'96)18D0V-49B37%4=#8P15A&;4912U-U
M:$]W-UHF(WA!.VLU33!98WDT94Q4>FU,:4Q69DUF-5HK979,;&UB,U=.2FMT
M<E%%0G)H6&EM4E-X;T]4479)1G%F2$)$4$-2;T9/5%1:24-Y3FU8+VLF(WA!
M.V0K6D]T-EHU;W-T074W;5,U,&95;D9U<TUH3"MJ2RLP8E)64'=G=%%-3VQ$
M6$MD5F=":GA$;4A*,%=P:TI#2C-"67HK9"MV=G)8-6PF(WA!.S9U,5-98D)X
M65%+5%AI3&(T2"LK6&UF<'I*,&-/2$=04&1H<EHX5U$K4T$X:#-N<%AC,6]X
M,FY536XK<VY8-W=C>CA*;S V9E=W=4XF(WA!.SEZ3CAY;E9U>%9K,VMJ>5IC
M95DW,&QY671.9TDK<WIG8FLY9E14='E0-%IH83-71$1(*VM86F1N9&YN55-S
M-U%(4#A!53EW,#=48DPF(WA!.U1B3T]Z<V]L:'0T:%)56#E:4&-N=6,U:DIK
M;$TS23)8<SA72T]/26I%54%I2%)(46\V:&M955I71E%2-V<U5U)B67<W>DPK
M5F9L=E<F(WA!.T5:-UI0,&)D;F-3=T%E;50O;%)B3"]W3DUX36UI:$QC8D9X
M<VUL:DQY3'=J>GHU3#$W>7I0=S%#1W1T25-)3'E/<E%V-V-V,E<O>5<F(WA!
M.S-Z1CA'541U-F9664I9*V9*9C5":$,R5C-C9#5*46XP271F*TXX,5AA:W96
M16539$504U0U<VY*>E=H>7EP:S5)35,Y;SAL-F=B-WDF(WA!.S%:4W-A>5)P
M-DUN>FE0169E;T)Z<CE";#0X350X4&LW3$1+-&A/.'I',6@S-7<O*U,P,2\O
M;4A(+TIX8W4P+S%H;S%0.3-,,U!J;DXF(WA!.S(X,BLP4%!0-6@V1C5,=')7
M-#%D2C-J=DAA3TPV=6EU86]!5%AK>65/85!&:$TK5# R8DY(1TQK>$0O;UI4
M.'9F.3AA:B]Y2FHO-G$F(WA!.S5D*U-N-4]0+TM'3'I4938X.&%.-7DO2S-Z
M5G%E:W)-;'1$6E@Y<S1U1E9'-7)A8WI12WHW56M(9DE$15E:26<Y-"LY;DQ.
M2$II:UDF(WA!.SEX*S4X=CA!:WDP:7903C)I,E5W<D)E6#%V8E1$>&IM;%=.
M+RM&635T8W!Q2E!K-E1".5DY-EHK5'(V9GEJ*UI&:$ID17A0<'0K8F$F(WA!
M.SDW551M64IU=BM35WE/46-E32M98DU*.%!+4$DP.6(O04]C;TYC.5!3.4<P
M3D<S=4IN=DHQ2%5,0W9P>#$Y;4UJ9F1M2&]9-VMU9C(F(WA!.VQ/;VE093A:
M=71(3G(U1G-D5&1A4'%D+T]K8F8X5C)K84-O*V)Z35!O>DY%<FU2,T(Q-6A7
M24AV:SE2+S5X8B]!3T]P<B\X07AG="\F(WA!.RM*=FU,<G518WIS>FY,-%!5
M4'IK.'IN>3DK6"MO,T5B8V)Q.%@V:F%(=GIN0D1%939X:#)(>7I%,#!/2UEC
M-U9:941'4RMC=GEE.'(F(WA!.W<K62]0=&A:,TUF<5=5064V=3%P549):%91
M9EIP0W$O5&UZ,4TK1T),<#E&:C0X9SAT,$A&-4XX,C)V;D<V,#-28DLT=3E1
M,&$X25,F(WA!.U="1UE+,$5N-W51<T)X54=G24IP:$]72FI:3WA9:D)-6DMI
M4'!,-GI0;3=33&4P:&952C!T-WAO,&$T=$595$Y(259"84UM3&U0:$\F(WA!
M.S%A-7I/8EA98UIO>4@S=2LX441M.#(X+S9*-4TX.&%Z8E@Y>3)Q1C=A05<T
M:7,P:4%:96).5W)I46<Q9BM825EV84-%05)#37!F1#DF(WA!.W)I6CAC37!"
M3C=D>5EF;'I9858U2&=V8F$P<SE7=4ER,3!K6G!O14Q+54)88FIW,F]C3UAT
M:GA$=FIM4&=Y=T%9:%%%;"\U<6$Q964F(WA!.UEF2U9X;VUI:4M#93A+:354
M54,Y=$E54C%F:D5757<Q67)U6&M79R]#+U,Y<%E"3S5K>#DT6%5Z-&]'361I
M93DU:BM4=C57*V%,:GHF(WA!.VY:-FYQ1FQ,66%D<$5W;FMM;55P-FMK93AA
M4E8K,U9Q17-.<60K;6)R4'%91TAP3C(T5VHP<RM/>4M!9518=# Q-7%&>F1U
M4UAU2E@F(WA!.VQ9;G)6,DQ'=C,U<V]I:%1H-4I826Q%86902F)816,X4F\X
M8D)L*VI*071:1FEI.4US<G5+-W19-VE-+T1)2S X1#-(,%IM>&Q9=# F(WA!
M.V541UE324MA84IP1C%Q*W%7*VY7=R]E>G14:V5I<4XR62MY:F9)6G-O>'=-
M:C!B3DYP-5IP:4$V=F]84CE*<SE*,#9'=W,Q-'=W<E,F(WA!.W9D:C-:=F-N
M3U)Z6EI:2D=2-6PW,T)H:FEG27@U0D=:5S)U>%8R2V]F561.<TY3<W!R1R]G
M4S5T2C$T>7=Y0W%K9C%(63ES0D%/>%DF(WA!.WEI2D-J>65&4S94<#)L4WHR
M96U&;7-)<'!04EIY0S-%=5-+:V1F635X97)Y:6574DA*,6YH:4<P95-K5&Q$
M1S%H3U-#2' O-594;'0F(WA!.TAU-$0P:G5/42\R84M0.$%J6$]J-TAL*S=)
M.#-/,' Y2EIT;3-C<&@S-7<O*U,P,2]W1#5H>"]Y8UA,=% Y66%.5"]D>3EZ
M-#5Z9'8F(WA!.TYV<S=Z-RM83VEE9#=A,'0Y5FYU645S,V%323)R4F]36$%"
M-65O:W9H;6IX6FI!-U!36CA%8V=O<TPO-D9J.&AF.'0K<2\X04DR,R\F(WA!
M.T%/>69,+WHP*S1/3B]*=5!V4#0K0V5495)D23AL+VQ:-7$P=E,U<FEA,VUS
M<BLV6G)P:V1W-S)F<&M!>'!'2U5J2&))1$M:-4EK.30F(WA!.RLY=$]!63A5
M9T\T+V,K62]*131G.#9A0D]2>457<%=J;%(S-'IO85IT36\Y2CEZ<$U(.35(
M,VAL6#4Y-D8K:79Z2'9:551J0G%A4C,F(WA!.W-8:%9X=VLO-4M)>'ER4U1U
M2'5C:EAW<DIF96MF-6<K8UIV3E=Q,E8W25-4839F83)P2C=Y2DAY;5 P>D\K
M5'<T*T%%96)8<6,S:44F(WA!.TAY6G@K8S)I<F]0:TAY1G!$1&A01$1C4$UH
M2"LW6%='4V(O:W!)8V\P,'5+8VDU5W1J=UDT4E1(+VY&=B]J<6$O=T0X64QF
M+T%);2LF(WA!.U(Q,TE-=7I/8W9G<B]N<3)U96)V3W5N*U1D0G1N=DID3VDY
M93923FQ75V5H-5--9FA65FHT+T54*S%G,'11:5I(<7DQ=D9K;4E2-DDF(WA!
M.S=Y1F]E;F9L<TQU5C=L3E<X>%AC87=Y<D155S%U<6YK53E1+T4U3%5R<T]M
M851T4'1U03E-4EI$3$)!66(S=5)2,G)A.65Z5T5U<38F(WA!.S=F<G!U:F-J
M5G%C56MC+W-24DHX57HO9C=N3DQH=S9R6%,U,40W4#)T:W!K:35';V]J.&]V
M369L1'I49F%N8G=A8U9M<U!493-E-UDF(WA!.U-34WA.54TU:D$Y3D],53)&
M96\S>F5$<U1&<'=#4GA(=DLV6$I$2F1$:WA0+VY*1%<Y6G-035=M-F99,S%X
M85=,,DEK93%G;&5+2FXF(WA!.TTP:3AI:45+5%%5>F,V2$A(:$]Z4C)J:VQ%
M9T$P;&XU32]L,W S;F5Z,4LX,6)5=%)H;G,U;S!I83%N5DLX,4Q%<UI%;$YD
M<VYQ8W@F(WA!.WAK04%-3DIH.%%%;55U9F5Z,WI$*U56-V]F;#(K=F9,9FUR
M5TEB:3!H931.=&1826MT-5)%0S56:U9)>'5!844Q>D=J;D5Z56]X;W4F(WA!
M.U904VU)2FI+5BMB>GIY1"ME,G-A5'%K15=T4G@S1VUY=49U6EE514UI<61U
M9D-0:D4S2'%F9T1(*V),2F1M-#0W=SE*-W5N>6-05#8F(WA!.S1G,4QK.&=1
M14Y1:6A'>$(V,7IC3T-56D-/;4M'4F58=%=.;$PV56@O=T)':U!X9C5*+VTO
M<FQU3V1/3'%C4$=.=6(V2R]*>E$P4W<F(WA!.VXQ='=#.3!F4G1M+S1Q53%9
M:B]78F(V33%F83)E-4-!-41D,FY95VPT66Y)95HR*T$O8CEZ,&9.3S<Y,DMU
M>%8R2W!"-3 Q=V%:<$0F(WA!.W!',4QU-D)J:$$V9T@W5"]!140X8S$S865Q
M.$Q&=#E5=&<Q-5HP2&LR8V,T4T9L56\Q3W@V6F9%,D=M47!4>51&-EHK5310
M-E!V>E0F(WA!.UEZ2T%F:W5D0C)..45V934R:S5&;E=B;'DR2&9N1"\U3%18
M+T%0;4A(+TIX8W4P+S%H;S%0.3-,,U!J;DXR.#(K.3@U-39T,DMP0BLF(WA!
M.UE(+TM"95I0*S)692]W1%5/*U=99G)(=D16;B]!3'58=4PT-CAR=7%E6G1)
M9&IX5F(R,TQ%.4%"2W5B<DHY2CEZ>C)(-C0K.%!D9BLF(WA!.V-N.4,Y6%-.
M23%Y3F9I=%IN=$HR2%5R379.2RMY=$=F*T-Z03!-.7E(861P475);#-01W9Y
M-#!,.4\K961',#!R>FEL=55E-%AX:&DF(WA!.R]E>68X26AZ3GI4-%E%=74P
M<T],24$Y62]W0V-Q4#A!<&U0*VHW+W-8>D0P2#A8=R]3-3-A9CA!1#AF,$E4
M+VY&,6Q8579-1$U11D4F(WA!.T5"2D]W041V:#$U,D-/>E T=F=Y=E@O359L
M8GHV:&$K6#$Y1DPK6C5T4C%!9C,Q=S=%-V,K=G!O1'A8,CEU=D@Y;V1Q4VXV
M24@P:G$F(WA!.S-:8W<S1558-4DX;$A59W5O-F=#=&=$*S9I-D=59R]G=C8X
M<#!(6C-I975F,"]F*WAL9W<S=653>B]N25AY,49E+VPK=#5B>$):3D8F(WA!
M.VU35D%O<%-&+W=",4EO03=F17)F4FY8-DEI37%(2D]U>#-J.7IW-SAO=DY(
M*TA04'5M,V-J.$Q3-68V;F5%;6<Y2V5I.&HW22]&+V\F(WA!.WI986E(1D%U
M<C!E5&=Y1'HR6FHO04TU4&8X<&IP9CA!,GIL+S50>352;V9P4'9C;G10-F@W
M;44K4V9Z4#AZ951B839T.4A&=C9D,C8F(WA!.WE4979'6$Y50D%P4FPX8WE-
M=4--*V)I-$Y63$=+1DIN-6@O4%!Z+W)M;'HV6F-814YT83-+;4\T*W)28TAE
M3G1M47-3>$%096Q+.4\F(WA!.VU1:'!94DYT;5186DI#=&=K2&MJ>51R6&TS
M5V]D4# K1GI#6%@V,V0P+V1W>%8K2FUB<%=N4614;&U82TE#>3 T345S:W%(
M2D%E8SDF(WA!.TIB4U!/1W,V85)15W0U36ME,4MP>DI1+U-P0GDO1$QI9T0U
M2C%%87E%96%":$]73DM/:3-)07E165-E-651+U!L,S5A:6DP-C1"=70F(WA!
M.TI10E)'4'1X*TQ2,3AE<%4U6'$K>GAK1FIA9C-T96DW5VQI;%5T.&8S4%IT
M2C%N5$Y7=%9U=%!N5V5).650,FQ09WEN9%0X.#4W3&@F(WA!.VQJ3E-&4%8T
M8SA-<V5+0G-),TLR,3)+;V)59%)T3D]S-4QU-F9H1$=.+T5N<T%/-4]66G,P
M8V-42UA)24I!1FPU0G)U=%A'<C9I.3,F(WA!.TXX2R]::&DV:$5(468Q>FDY
M6'%:6G!M4BM$:%1L>$<P=GI'64MC>6-O>C1R=5 T-4]",UEZ1WE&>35P970O
M;'!:;41Y>7-R0VAU<&XF(WA!.VQ(:E%5:D@O04)$3VXW2VA71RLX+W-D:G!H
M54=6-7-N25$K;V%F639J6E,R5CE!;'IA5&IJ3D))3U--2S%O4FA"24YH0D%)
M;W-E+S4F(WA!.U9:*UA8+U5U,E X07E*6$Q02&XS;'$O3#0O-6\K5$MC<6)N
M67%P6&1R8EAD<DYA6%5A>E<Q=VI25'A/2W$V3T-R2W<X0T140T17-D,F(WA!
M.TQ&1FIS9C59+VPY1DEK<V9L*WE74D-'4FA%=%%186=J3%!(;C-L<4=N>&HK
M14HS<3)J-E9R1FLQ:G%L<DAE5VIK33!%>6AL2E4Q0F\F(WA!.V9$25)K66UW
M,E-I2D-J=6PK:V52=DHK:C-G=F1,,&4Q<S=T5DMR4$9'<75!,GA!4'9K<%I:
M4T9%<UDT65).9T%+,G0K579,5W5V12LF(WA!.W-A8F(S-W=!<D,P-D)Y;V%H
M249F1VU#3U-595)44$A'6$U7<#98-4PX<6%5;'=M;3968E=I6&%H3&M24FA2
M26]R4E=P,4<K4GE337@F(WA!.U5T=VE/2TUE44%69CA+95=V*W)B8B\X04ES
M6FDO:SA0.#!,-%5E-4Y),%-.1FI247%)07%Q0E%!1%E!1$UG0W1G,DM6-UHR
M;#=A5%<F(WA!.V0S17,Y<F-)635O6D)Y5C!954MK2$I!,&)#0T%24EDU+W=!
M<70O3'(O<5AR2"]K575795!0=DQ6*UAX+WI2.&MW,6YY6C56,75E3V8F(WA!
M.U9T3'0W-F%*0D9(2D]G9&Q116YI0V4Q5&M9-4I2-49N4$9'6$U!<&8O=T%Q
M<R],<B]Q6&)(+VM3=5,X969E5T@U9D@O0412.&Q71#@F(WA!.W1F>2MG9FY(
M-60P.'0P*T\S:F8W9S1B134U.355869(+TY(>50V,',W3WIG5S-T24DW84)0
M<U%X27%)4&MQ9T1+>5-E8F%"5#5Q+S4F(WA!.WE9.')062MA-UAZ0D5N*VIA
M=$5)-3)(831T=T8S+S%O*TY0:V,R+UHK4S0X4&,V;G1(1E5H3'9E4U%T;64V
M,4YT231T<49Q<F)Q6F\F(WA!.W=W.751>55E8D1)849V46-Z;E))<E1T53%(
M5&)G6$9H8U!B>D0Y=4TP<5!!:F]2-TA)6DU56FEP0W<R-&,X.%IU0F]S-S!F
M.#0Y4F@F(WA!.U99.59T175G3FI00V949C5L9#%0,%5Z5EIU>4EN-D14=DU(
M8CAH=&MJ9FU'5'<O;7HU56MH6GDP.&-O1E)#.&1#5#1C9U=8-WIM='HF(WA!
M.SEN6F]22D$T=F0K,FY:-"LR9%!,<5(W,D8V+S5R;#%Q-3E7965.255R-DYU
M<FII;RLO8RLK8V9R3D1R.#!V5FEN6%%6<VEE=7A3+VDF(WA!.VHX,'-34TYW
M4VI"9T11:T=O<C%Z5F%R4EIT3U%-<U1%;G94:GEX;G9%,G5Z1F)(67%H-V4P
M;75,=4\Q:$A/5U9X2$=01FU.0FU80THF(WA!.VM10GI,4TDR864X861:4C).
M:&(R8V8R3&5.67=F2&E+5BMN<FY:-'-9:$522%(R,%DP2U)'5TI9:BMB3W%A
M:'!F-65A>&8V9$\Y<F4F(WA!.U%*15E:-'I2;$IM4E11+TEK6F1P-&=Z04Q4
M<4I'3TUK8S!O:CAH95EM,'AB=V5E=%=H8W=I8FY+,$II43AE5EAQ;RM%9#DX
M;C1S8G(F(WA!.VA$2'=:5CE:*WHY4U5A;#4P.'@S4"]/4&XK2G9R5#(K='1(
M141D>$%2=%9B.5E#=T,W1&UG,W T-4]/2U!J8U!4.6I44$Y,.'9X+W@F(WA!
M.V9T5"]!33=A:G)..35Z,$QY:' K;U1A5&(S,$9X9#9H95=W5#$R:FE(=U)X
M37=B:#A13E142SA106E:15<S6E-425)"<3=3+WI6-4XF(WA!.SAW95@O3#$O
M<FUJ96(Y86QV9$UG93=%3B]01F-W3VM).5(Q6D1';E963U-X-4EY:T%9:F1H
M:WAY:$5Y16IT,S$K<&(U-#%V5W12:3@F(WA!.VE*<"MO>C914$U5<697<$Q5
M:%A#>7=R2E%C=5@R4S)/2TE(1EEU;5=74E!$4G)I4#9%4#4P,&IZ6C5-.'58
M4&U7>C@S,SDU3'!Z4D\F(WA!.V)/*T55:T5Y=DMS8DEW0W%26&PQ1R\V.$]+
M55IY-%1%8G--=VQJ:5I#4C(W-E0W5TYC,4YF>DXX;S)-33AK3FAF,FPW3&17
M6DY!>DHF(WA!.T9Y5&U01E1L8UEJ=S5(<G,R>6UF16E/:$)42#AZ.5)V=$XX
M9S8Q9E=%-U<Q-4)">6AN:DY'53@Q1E%F<'E/04%Z04Q,4$EI0DDW:S(F(WA!
M.S!E.7 U8G-R-CAL+S0X-' W;61Z+W=!5D)N9&HK3U%K4%916F<W4$MV269N
M6'I62C5S,"]5.6%U;F)Y-S5W93EJ,&4R8R]$8G9B>2\F(WA!.W52-&IM;TMJ
M>')M6&QX4C130CE5871W.$]74FM#9G!L9&9O6FXK8FUO-FQP+VLU<'1.=35,
M2S5E-W194F-1;6IQ<W-Y;S%$.&IL3VXF(WA!.T%-=#(O55-):G1T=5!V44=O
M*U%F371N<#EZ9'=E961713%V13AS6FU-3%(Q4E-W-7)X1E8R,WE1>7A**VM)
M3T=69E=F<R]5:TAM4'HF(WA!.V@U<3%0.'!03$]R5VPT,FYA>G$Q.6(R<S%Z
M1#A&4S=3>$9Q1'-X44U136Y$2$5:0T1U03%4>7E/2TI";VUM8F9L9C5L=61F
M.&\R,#$F(WA!.SA33E=S5V5W,59'1DA&>F)N:7A99GI-2TUF;FQ/94A$3&)K
M,S9F25I2,S4X:C<S;C$S-3(X>C9J*V%L;$I9,SAK4&QC87%U:E)7.%HF(WA!
M.TAP>G9!;DLT63 V+T5W;V4T<&U13552:C-(<7$S1SA74GE#:C9B<C=(;W8U
M;65:6E!,=FMV56(K,V%L*S9I,C X1#=2=4IZ=U%R-&PF(WA!.V$X+V]Z1W=1
M-'!!3U1N>6--0U)Z4U@X<3E7.'=X6%=S*U9F33DR,35R96MY4E1R8T]A;5,S
M=5EW>3!09F<R>"ME5'IX:G1+4$ES344F(WA!.W!767E.:THW*UEV:WDS.#1E
M53=V4G!#16Y90U=X;6)P2&-2,31.=#).4W)E>$]2=UIF1&M#,EIS46Y%>&9'
M3C-:6&UN6# Y:&5X3D(F(WA!.V0R<VI25'=V<WEU:&]18S9#36=2665D;$5X
M3DAM:F1(:U5A;&%&:E)23DA5*S-)6DE':3%Z1F=H-E!M939&,DMU>%8R2W5X
M5D\Y2U$F(WA!.W):<6$O8EET5#A0-%HU9#=86BM05V-0.'E)2#9F,'94.6Q1
M-&-..35V.4@V15IN3'5X9&ER3F9Y-CAT;')T.6%U1G!';G=765!D:4LF(WA!
M.T\O,&1".5!H;E)D:V%7+S-H*T1D9WAB.%0P4$]G8W0R2W-)+T]Z+WE6,G9F
M.%DT9BMO:5!,.4XO94)X.58O9%,Y>D=:4$E(-6$S3VDF(WA!.TMT.35Q=6\T
M<$E637=F5E9+3%925W%31FPR4%EJ3&9';41S4'-94W=123-*+W="36LQ+V98
M5C,O04TT>EAB5&Q7:F=A3S-T6E914D,F(WA!.U-#2%59,&IB:4%",$9.=C$Q
M>6-25V8X04AC,%I$96U0-#9S=C@S,TYP<%@U="M6=%4Q1V5/,'-*<DLX=%)C
M>DU%:D5O2$E+>G-1<3@F(WA!.W57,65U531W5&IK0C-H>6-H16-K4V4T+V]2
M,S5L*V-F3%58:U!816HQ4WIL;G5R1V4S=#15;FI:,V%D1$=!:7%X6G9T,3)Y
M3T1(3&HF(WA!.T<S5D]O>5)'33<Y1TQE9#E&3GAA+VQJ;SDT,'1U>E-25S@U
M:&-X4V]28DER8UA'-FM%6F)I;%A'43$U;UAW03DO=T-H;%9V*U0S;$8F(WA!
M.TQQ1V4X92LQ45%-2DEO3"LW;&YH1$$Q0DU:259V:V1S<4]O;#!O3F\P.&5T
M;C-K<$PK66UI5RMT9FUJ-5(P-C1M;F=I;'1B.'1,87DF(WA!.W1$2T]#0FAX
M9&1X,#-Y>D1,:'AY4'5A.#!"3$I%95(O46=F>DHO3$A2.4LX:F%X<45/;S9R
M3DQB=V-K:G5,,E=726YM;RM*1'-W,W<F(WA!.S1C-4UW2TAY639J04)!;7IY
M-WEM9FXS5DQQ2#AS9$@P6%0R<'%N;4]/>C!Q,$%*0G!/:6E6:E0Y;FA65#@X
M:FAJ-GE4>6IU>GIY4$$F(WA!.T%/8W1K<S@T9FLO6390-55K,4Q1<C(O9E9.
M0E9,-U0P;G57:VA6<E5I4G5-4C)"-$LS2&HS>5=0545Y;S%265ID34)'-#-C
M9'AV,THF(WA!.VHK6FUR5VYM2#AQ3$Q5-V-L8F95<#E0:RM&=FE4,4IK-4QY
M2#=31V\K95)W>$UC:$AD8E!0251X9SDY9F5'+TTO=T-4=6=F-&0Q2B\F(WA!
M.S!N<7IV1F)3>7AI5SEK;&HU26A:95-054U+:F-9=S%%<D=W*U-Z,#!413=N
M-6Q)=%AV2'90>6HX:%A$;VMB2%9.3E5R16]24#-B4THF(WA!.U5+=$%+.&%M
M;5=21EI*931T8VIE2T(X-'%N;EA7-W8X=2].5W5Z,F-B;3(X,C):;3 Q27=4
M>#%A36E*:4LK26LY4G9(<&=X4D=3278F(WA!.RM(-VQY>D]+4G(K26)F,6PY
M.35:6'DP9GEW,&=J+U-)=%%:-WAQ9VQR:5)!.'!Q3W9X:V=E,D%4-'5-*U-4
M:C1/065F-D-M=FXR>50F(WA!.WIL*UE/:BM4:DQ+;6YA6D,K<F%S.$1L1T1K
M96YB2T<O6F-%,2M46DA%94-";#%/>DQ.2'A*:4A18FXY0T,Q6'DS82]L-S5Y
M.'9E67(F(WA!.T\V=34Y4#%#6G1),6E3.&YA8W%T=T%91S5T=496,7%F;&MO
M>D]32FEE63-$1U5":FU*0S9/>#8K-38U;4<U<GE,.#=F>650;5=*=DTF(WA!
M.T=H4F=A.4%L3&DS1S,Q<4Y2<T(O>%EO*WHT:F)W>D\P;7$T4%1,-EA",65L
M.%%74'$K.3AZ9G996E=J:U9O-5DR2W5J06AL6E119V<F(WA!.SE#1&TU0F1)
M4C!,,4\R;E<T=#1P,49&;%)8565!659Z3VEB1G5I>5(T6D5+;5-93WA6,DMR
M:U)N9%589&U)02MN2SAU5T]/0FY,84TF(WA!.U):6E%G6D5!8WEY3TY"2$=Q
M1&]O04@P6C1N<DY38RM75U$O>$5L-U!&:D5):4DV0F1M37I4+WER-59U3EIU
M0DQ+1$AP.%HO97DY0W@F(WA!.T@W0V4O:64R8DAS+W,K5V56;F%!+T9.=5!(
M>&4U-G1$1$9"0VM-2VA);W=&4D8R04$R04=D9D=):4M(24]9079Y4W5X5D1A
M;'!M;C8F(WA!.VY:4S)/;U<V6%9N3T%*64I2>5)G0T=&469C5G=X:U%B0TI2
M0D9&25DO=T%S4'DW4G<V*UAB06QD=T=G4F@Y25E%2$Q02&XS;'$O3#0F(WA!
M.R]W0V%0:VY.-6]7:EAM;$A33&UY:&LP=&=Q;7E+2TEE2TU'56-"455$2T--
M9TIK1RMR65E!:6E.;%A59$PP>E4W9C9T<4YN0F4R.6$F(WA!.RMJ8U)P2VQF
M2&DT65E"26IK;5514E)3=7HX:6538D]B,3=844Y0:&Y$8S%L4S%H1$LS*U,S
M1W$O4FMZ;&UE6DQ#3T=!,T%(>51+.3 F(WA!.VY43#(T=&)I-W1O-34W1B]6
M<S5(549O;DEP>5$Y:FM"26IK>DU155AG4VA*=$HP,F958F95<')A3C<K,%8P
M=')L;$)E3EI"4G=P-V,F(WA!.V@Q=VE2<6MC274Q*V]A9EDV:EI3,E8Y06QZ
M851J:DY"24]334LQ;U)I0U%B0VM!:6EO>39&;S!S,6A02EIX4$QP64DP-3)5
M17=";$,F(WA!.VXP+S5F:%5$1'A(9GI166IB>5)R2W)+5EE";%E56E1U0T0R
M3U):2EEV;&9Y.'5K4F%/=6YW1%,T5T5K5FYW2'!+=V8Q05%V:GI03#4F(WA!
M.S50:FQD,W5W-$DQ5F)*:DY$1E!$2D1-;V5+5E-K:4YU1U9H46<O35I!33!V
M4&QN>2MD3W1D3D]N=T=W<UI%;',W8F=/155K6DI2:T@F(WA!.UEG:S5,:DXS
M8DAG1E97>71Q3VDV5'%4,GHV:&%26%0R8V]N=%=L54U9-58V3W1E:$=):U)Y
M5U5195E86'5K-EIE,T9R8UAD=$A04%DF(WA!.W8V=&Y)-F=T135&3U-(<V-!
M:U)Y4UEG=6<P:E,W9E5B;E5O8E=/4%5,,$ET,61+;SE34EEX>%%-,U=I:D5Y
M3E8P55)&,S%D<75K85@F(WA!.W$Q;3%L<61R2&57:FQ784=:47DX;$Y63D0S
M0GAJ26<R1FQ%15556&=3-T98;D@U;69K<&]8;D1N<49O>39B<C%0.39L5W-C
M,4]G;E$F(WA!.U5Q9CAS8B]0<&U8<#E83$AS9#1U3'%.2DA*=GEK.&MT=DMN
M;6IY,T,K;6$U6E!#8F1I24QL9FIG;&IB8T9*4G-A13=J<4YQ-3!':S$F(WA!
M.T5C9V]&-51T3%)Z>'DT:4YI=GI-9%<W1EA9<7IR>5(K6'0W<71M*W!4=CA!
M5EDR1DQ)<W9,;B]-,4MI:3EH;DYE,$5J;7@K1$-66'HF(WA!.R]5.40R4#)E
M5"LY;'0O3B]7;59Z*UAV;5-&:4EO-#=H97I2>4M0.$%I9D104#AN62MC8V=*
M9D@Y9$\X3T=36C9"*UA5-T]*=%E0<'@F(WA!.W%D<E9'0EIV.5IL,D$K4BLW
M37939&I%;3AV>5IW=SDW4%E)25E):VAH45)X24M):6EG03EG339'35)%54YG
M-4E#+TI+-T9867$W1E@F(WA!.UEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T963S0K<BMG+W="6C1E:%$K<#9L3TA(
M=GDU8E4F(WA!.W=X=3EU84I65R]*-6@U;B]!3U938S)P>BMS8CAV,%I7;C!C
M=C-0,UIV3DXK8BM(.4PX5S@S<E!Y1BMF.40X8TQZ*R\O0452>5 V4"LF(WA!
M.W-C93,Q:FA8+VA-,C)0:B]!27$K1&]S=FAF=V-8>'!.4$I8*T9V,'5N*TE/
M9F\W96HP.4AN+WAD*S%X+T1X,GEJ5V5,=V9U*V8R+T(F(WA!.WEE>G9!.%0Y
M-SA/-S1V9EDO5#E.9E1P-F1"=S0P-#AA8E5P,GIL1#5V8T1Y6%E%=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C(F(WA!.TMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6+R]:/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \
M+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-C5%-C,Y,#8X-D-&,3%$0D$V
M13)$.#@W0T5!0T(T,#<\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HS,D(S-3@T-34U1CA%
M.3$Q.#E%-#DS03 Q,3-$-CE",CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HS,D(S-3@T-34U1CA%.3$Q
M.#E%-#DS03 Q,3-$-CE",CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @
M/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HS,4(S-3@T
M-34U1CA%.3$Q.#E%-#DS03 Q,3-$-CE",CPO<W12968Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HS,4(S-3@T
M-34U1CA%.3$Q.#E%-#DS03 Q,3-$-CE",CPO<W12968Z9&]C=6UE;G1)1#X*
M(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C8U
M138S.3 V.#9#1C$Q1$)!-D4R1#@X-T-%04-"-# W/"]S=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S
M<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X
M;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F4R9C)D96-C+3$X960M
M,&(T."UB8S)B+6)B.&-A9# Y86(X8SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TQ,"TP,U0Q.#HT-CHQ
M,2LP.#HP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0T,@,C(N," H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C,R0C,U.#0U-35&.$4Y,3$X.44T
M.3-!,#$Q,T0V.4(R/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3$P+3(W5# V.C,Q.C$S*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O
M<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R
M871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*
M(" @(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E=E8CPO:6QL
M=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @
M(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+V<O(CX*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E
M<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A
M;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @
M/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S
M5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ
M92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I
M;3IW/C4Y-2XR-S4S.3$\+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH
M/C@T,2XX.3 V,C4\+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET
M/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G
M95-I>F4^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @
M(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A
M=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^9S$\+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1I;G0^,3 P+C P,# P,#PO>&UP1SIT:6YT/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXT."XX-C(T
M,S@\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XR+C$W-3DS-CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^9S(\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1I;G0^,3 P+C P,# P,#PO>&UP1SIT:6YT/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU-BXW-S$Q.3$\
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XT+C,X.#0Y-#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^9S,\+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1I;G0^,3 P+C P,# P,#PO>&UP1SIT:6YT/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXX.2XV,3$V-38\+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XS,"XP-S@U.#4\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDX+C$Y,#(W-SPO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$Y
M+C(U,#<X,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/F(Q/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M:6YT/C$P,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-CDN.38W,3DT/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,3@N.3(T,C,X/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C,Q,3(X-#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P
M,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^8C(\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1I;G0^
M,3 P+C P,# P,#PO>&UP1SIT:6YT/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXY-2XX,S<S,S0\+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XV
M-"XQ.#0P,C$\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C,S+C0P-3 U,CPO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$T+C8V,#@V
M.#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/F(S/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT:6YT/C$P
M,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C<X
M+C$V-S,X.3PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,C@N,C4Y-S V/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3(N,S(S,3@V
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%10
M9SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @
M(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P
M9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIP9&9X/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9G@O,2XS+R(^"B @(" @
M(" @(#QP9&9X.D-R96%T;W)697)S:6]N/C(Q+C N,#PO<&1F>#I#<F5A=&]R
M5F5R<VEO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$
M1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( "\ > ,!$0 "$0$#$0'_Q  ;   " P$!
M 0             )"@ '" 8% __$ # 0  $$ @$# P,# P4!      0" P4&
M 0<(  D2$1,4%18A%R(C"C%A,C="47>V_\0 '@$  00# 0$!
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ME=69[Z/F*.-IB_'V+5%E(+2S<^NP.:Y]Q:>)A*1LGN$#,$B8WF-]J0[@G?\
M^0O&;EGNS1^DM5:1M^N=0V& I3MLN\5?SYDFW.UD.0LH)A->OM?BF, 6)JQP
MP(R0$ON,P)#SCCB_<PVH::]-L9EL+0R&0N9!%JZIEB$USK"$(AI"DAAM=ASR
M5*F%/+:)9$;1XW2=9^LF:P.H\KB<3CL39HXUR:LV;:[AM*S*!-X$2+B%CP=#
MU /#>824S,^=CU\W^7 W#[ACLODV6%$2%AK=,BG*;7Y/)7TJ=V);W8^%J,22
MP*6-)$Q*9Z6&-FF 31STUX"4?:,&4PHMJ.<!A9S>>J8D2,5-L'#VAMS751!&
M\XF1D(/MA(A)#(]T@B1G?:9@U9J0=,Z7OYXA4;D55S52SEVW7;,@JLLH$A82
M^\R#; $)]D&3!#MRC /9W[L6P.X3-[IU[N^DT'7>S->1%1NU5BJ*#:(L6QT*
MP>\'*2;X-KL5D.R]#2)%:<^8P4P&8!;8E;#"O%3[KDUQHRMIE="UC[%FU4M,
M?7<=@E'*K*]B ()*E#LP8;'&8DA))[S^(9OIEZBW=:-RM++5*=*_176M5UU
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MFHH)*?'#YQ])M^Z4##/+2EQ[#",9RAQW*)1RB_K-[5NERD>=O$T,A2@I^V+
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MU'ZY>N6&L+TXC&Z&T%C9?D59C.4DY;5F;8TK=NN>.QS2]K5&S)O!#; NJ\)
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M>D+*/,O$<CBJ[DD+,<J)U#2OF6/C+LYUD1=@VV_J LXDGW ]D*DC)2ZQW5'
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&U.CHZ__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g713200g27e81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g27e81.jpg
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M.4%"45-76'=XE[;2Y2364F%QAY.ET=<F,V*!D9*W_\0 '0$!  (# 0$! 0
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MHU=KM6CK'6JHK./BU68F+?74KA#6=S*3%V>VJ/&:]SBX<N6NY]F\9K8,# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?)S%(4QS#R*0HF,/^0I
M0$1'_P#8 P#"FO<:<#/5J+L8Z^L[ Q*Y*7J^0CXZD38-:4:(::WD'LE9X2S1
ME=ES3Y(K9\)8D*ZP8.$I&L1LW*0\U).1KT98AFGMEO7B]JF92,G&N7KR-;R#
M%>1CP1,_8(NVZKUB5P3N-S/&I%#+M@73]NB*R9 5)[8G4'IP8.]@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M_8TYXS!^X=EG[.'K=X\:-"Z'NY#.G*#8IQML"($%=4J0&$ CP$0*)N8@ \Q
M.6?+^83:3&.=^D$BN*USJ<YS"5HBK2NJK0^F\UV0<YK>@\XF,Y&UYY@W56GQ
M#W+S\'/UX8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M,)B.?Q,JS;R$9*,G4=(L':1%VKY@^04;/&;E$X"19NY;JJ(K)' 2*)G,0P"
MB& 8Y(\(ND(]17R%7Y"M,W[^77G8F!F7K*(LL3/^9!IFJ3; YETEJM(J:YIX
MN(UIX-7PL:]ATW9(*Q6>+F0K[>WMDWD(IX]FZ"7#KQ'K)H(IK.=$2YG"I$R$
M47,G-,TTS+'*4#*BFF $()Q,)2 !2\@#EGL>9][]<&_G.#H<>8PT]ZMN=H1=
M+337SM\Y.& 52#]VH?XTC_I:.:XVQ1<V_P U39!V6%G&><A_0$S^>9VH, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MKNY$4[^:S[& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MN(V4:$*+M;1LFX4!Z4LFS,HVF&220#&R0.XX$N@ !1 &@(+FYG734.(F'UN
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M943 82N79I873UOS#T-'JSAH4.92H@41 0.4\"P4/(G,K+=4J4I'0%L$\0A
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MKSSKGA[3.1DV2M24/7%_*7:FY2/L:J4 ]81IG+IK-JI12Z1'RA$# 8L\?/\
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M5I=NGHQGYL>Z& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M['M6(J.:YJJUS5145%5%N-R'.+SJ88 P!@# & , 8 P!@# & , 8 P!@# &
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MHER\9?61S>, 8!:(^OA?R1-]<DP"[L 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , MJ;N%:K<K4(2<EVT;*WZ>>UBGLW *]R>GX
M^JV.[O(MF8B9TBND*G4++.&!<Z)#,H9X)#F4(5,X%RX!C]Q9_P %CB5_V!;A
M_P#\]L.>AP1]]>#'\PV+_P#TI8I<)/>[;_S+:G^#'-&C.[SD$8 P#:6]E<_@
M$5'\KM4_\ORV<I\R3X0)SM.UO\B"=$\T?WF2W;-F\C$-6G.K#G88!EYP#?PR
MN'7_ &E0_P"C<YX[F@^\K"3YLC:6GI\"_?58?;\+0XVZMM_AL-^*NOTJ6<?6
M-U$?LH>AQTW:75PNQ=I0B'+HK1@$I:G]W9#XI4^F,\J;8VO#SR>8\L+.V5^;
M])I;U_\ 6Z8_EM/J]IDBS=I0?ZG*Q#3.[9B?0Y-A9V3B*, G[4_N%(?&RGT-
MGGG;8VQ#S*>>\N+.V)^<]%IHF37NS+?&;_Z4KG>L#8(.:A^8AQW&V6+G'^<I
M3,VFL8!M&3']Y@1_W?X/_F&/SE:#\-B_S#'_ ,:(=#1?@I3YE@\NPU<\ZI.>
M1@%STGUSJ/Y3P'UJTR+/;2G.U9CDGDB4VU+=L0>4:;S>V?<>,^,A^BK9PA8^
MSQ<UZ;3L"T=B9G/1<0+GH2G& 7IKWUOB?Z=]7.\@6GM.+QP^4:2I+;,/Z?)O
M*SM;UC:?$S;Z;(9ILC:S\^[DX1LM#9TS;=+B,LM2", F+47X1.?S+#\]UE+;
M/40.RB:&EG9N6-Q,TN(_MOK-.?&3G](.6,GM67S3-!"F-GC9Q^E2W<DFD8!D
M?K+U62_'7GYY<\Q:FVW=@S07DCM=O9.TD@Y7$PI$NC.K!&^0I*(CA2EF*TQY
M7A'DV#Z!3,?RE&QH,Y^ \E2SL@IE8S;H9EG'F*<SB DP.4B8'GZCPT[)<-:6
MB-1H<22$MEZ=5I M@*)=)-)KB;+M^(L]%195GPKB26UWV:PYBF'D<C*7K5?K
M9'*]1G9V5B!FOMEW,OMOF<**3DFQ'*BSOOH+5,@M6_833\&4DHF14G>*(G<=
MY0!5ZE  4^?;+S*'/!@OC & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# ,&^)/@5UWQ*[%J6PK*XA6"U9:13:5@EZ-#3L1LI)C/M
MP<Q.VDG;IM]T.GCK>5V9KB&IDZ5:#KX;5LER;).+/&5EQ#C*+3V]N#O(9Q$(
M1,A4TRE(0A2D(0A0*0A"@!2E*4H !2E   I0      #E@P6CL*E1.RJ%=]=3
MR[]M!WVHV2ES+F*5;MY1O%6B'>0D@M&KNFKUJB_2:/ECM%7+)V@FX*F=9LNF
M!DCS+.GHMF6A(VE+MAOCV?.2L]!;&1SH3HLI'9'AMBM8^&]T-7PVH]&O8Y6J
MJ->U:*D6=E(<_)3<C&5[8,[*S$I%=#5K8C8<Q"?!>L-7->U'HUZJU7,<U'45
M6N2Y?*W]Q.X4/AMOSYVT'_[89^L]/'"WY!@]XI:/^U/SGI2X-_++:\9DO]</
MW$[A0^&V_/G;0?\ [88Z>.%OR#![Q2T?]J.E+@W\LMKQF2_UP_<3N%#X;;\^
M=M!_^V&.GCA;\@P>\4M'_:CI2X-_++:\9DO]<5GV7^/0B>"B.BFQE3MXS8^O
M(]N=8Q3+&091DZV2,J8A$R&5,FF45#$3(43B(E(4.10T<QR(Z-AQ$BN1$=%L
MVT8CD;5&HY\67<J(BJJTJMU55:954W<TYB0L$F0VU5L.>D6-5:55&,BM2M$1
M*T2^B(E=Q#50SK(YQ& 9>< W\,KAU_VE0_Z-SGCN:#[RL)/FR-I:>GP+]]5A
M]OPM#C;JVW^&PWXJZ_2I9Q]8W41^RAZ''3=I=7"[%VE"(<NBM& 2EJ?W=D/B
ME3Z8SRIMC:\//)YCRPL[97YOTFEO7_UNF/Y;3ZO:9(LW:4'^IRL0TSNV8GT.
M386=DXBC )^U/[A2'QLI]#9YYVV-L0\RGGO+BSMB?G/1::)DU[LRWQF_^E*Y
MWK V"#FH?F(<=QMEBYQ_G*4S-IK& ;1DQ_>8$?\ =_@_^88_.5H/PV+_ ##'
M_P :(=#1?@I3YE@\NPU<\ZI.>1@%STGUSJ/Y3P'UJTR+/;2G.U9CDGDB4VU+
M=L0>4:;S>V?<>,^,A^BK9PA8^SQ<UZ;3L"T=B9G/1<0+GH2G& 7IKWUOB?Z=
M]7.\@6GM.+QP^4:2I+;,/Z?)O*SM;UC:?$S;Z;(9ILC:S\^[DX1LM#9TS;=+
MB,LM2", F+47X1.?S+#\]UE+;/40.RB:&EG9N6-Q,TN(_MOK-.?&3G](.6,G
MM67S3-!"F-GC9Q^E2W<DFD8!D?K+U62_'7GYY<\Q:FVW=@S07DCM=O9.TD@Y
M7$P8 P"T1]?"_DB;ZY)@%W8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8!Y2>S)_P.__ 'JTCZ)8<_6N8O[\_P#U
M,]Y\L?G'-3]ZR_.,GYL8U0LZV.;A@&7G -_#*X=?]I4/^C<YX[F@^\K"3YLC
M:6GI\"_?58?;\+0XVZMM_AL-^*NOTJ6<?6-U$?LH>AQTW:75PNQ=I0B'+HK1
M@$I:G]W9#XI4^F,\J;8VO#SR>8\L+.V5^;])I;U_];IC^6T^KVF2+-VE!_J<
MK$-,[MF)]#DV%G9.(HP"?M3^X4A\;*?0V>>=MC;$/,IY[RXL[8GYST6FB9->
M[,M\9O\ Z4KG>L#8(.:A^8AQW&V6+G'^<I3,VFL8!M&3']Y@1_W?X/\ YAC\
MY6@_#8O\PQ_\:(=#1?@I3YE@\NPU<\ZI.>1@%STGUSJ/Y3P'UJTR+/;2G.U9
MCDGDB4VU+=L0>4:;S>V?<>,^,A^BK9PA8^SQ<UZ;3L"T=B9G/1<0+GH2G& 7
MIKWUOB?Z=]7.\@6GM.+QP^4:2I+;,/Z?)O*SM;UC:?$S;Z;(9ILC:S\^[DX1
MLM#9TS;=+B,LM2", F+47X1.?S+#\]UE+;/40.RB:&EG9N6-Q,TN(_MOK-.?
M&3G](.6,GM67S3-!"F-GC9Q^E2W<DFD8!D?K+U62_'7GYY<\Q:FVW=@S07DC
MM=O9.TD@Y7$PM&[$LJD Y"KHMW;LO<,_C3+.64E+1(-7/C8FN2S>9@B0-FD!
M[3>%GGK\K"*=G*[=$Z$P42 \^H32F[$QKK\E0N4"Z?S$9*1<"-_@2UK0MF;V
MW5J\Q,Q*:.S+$^N%8EJ36I-M)R"CB2M%UM:VS7,M4*G7=TS<0V&;JK?O[F7V
M\AGVB1Z78CDSAPU5:GJ9!8HHLU4'#8@2B8+E=N3OG*;TRBW4HD=%HP!%(01.
M1<X"N88+XP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M"0]7WQY8!]$"P=V.[BD/V 2_ML!$7H*G7Y&],<(KB1-+GT^AR54_+J]MZ0Y
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MU3GU5D]2=1LUJVJZQ5="U)(%4HCDQ,98N+6]'(RM%I2X[0FJGC' @C8? "U
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MY;XD?P8?XHZ'1_C0O"?]PO2CTN5K4DZ>/UV"J2[$S8A6BKA0X',N@KS,"K5
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M3B\</E&DJ2VS#^GR;RL[6]8VGQ,V^FR&:;(VL_/NY.$;+0V=,VW2XC++4@C
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MW"FV(NO7F+JVKN&/AU$NNSSVPK.VF1BY4HJY$31W:TWKEJJ[R&P[@^!@# &
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M7$PCS:M_+K&B6.XEKEEMSR(B95W%UJJP$]/R<W*LHE_),(H2P,5+J1#:269
MQ//2B"$+&JN4#R#M$JB8' P.@.,^[3)X9J62UJ$@RE8*/E&Z\&R%+:DO/6+3
M[<]-TU)5#>=_K[N4A*YM!FJ^F4YVX@%BFH&+=P#%")EW$H,TIWN%-*)Q>U%S
M\1<*J[$<HG8NFZ;:J$*BZ6.R,W?@I*)J'4:%;NUW1"(&$4%0?-F1Q5*(H$61
MY*B,%\8!QJ]T4E00%,JXIG[)E2F.D57I'MBJ4AB',F!^0G*4Y#&+S IBB("
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MVSU$#LHFAI9V;EC<3-+B/[;ZS3GQDY_2#EC)[5E\TS00IC9XV<?I4MW))I&
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M5F5ZUZ&SI-M9%$5]+[![X^E2B=[=RUX,MU]^2[A0]0L'R, 8 P!@# & , 8
MP!@# , WG$5NJ%X=]HWA\PJ5CV;1>(TNDF:]'U3L6QP:D$\WY4M6A:RZG@[U
M/7VROJY5;,YL,G"P=S:J33R&64:J0C)P9NT&:)7@I7R5I]AD/P^;+=[-I<FZ
MG+%'SMRJEKE:?>6;35MMTP]JUC9M(R:1KDWKR[7*^ST3(EKD]7YQM(#9Y&)L
MT%.0UHKRRL#,QSA8%]KZ^5"=<&!@# & , 8 P!@# & , 8 P!@# & , 8!Y<
M./8?^#=TX7<JQFQNZX6574Z;TN!>XL<RA^D/)X\@ZC#R#GZ ]&?JK>;)AHQK
M6I$LRC6HU*R"9$2B?_+O(?GCN9A@LY5<L*>JY55?_,=E5:K^H</[COP9_P 6
M;'^?:_V=GUTYL->N69X@GXICI7X*]:GO''?<'[COP9_Q9L?Y]K_9V.G-AKUR
MS/$$_%'2OP5ZU/>..^X2#Q@ZYK6HO8ZMLZTIY'J58I>L6D'")R+L7SXC%M/Q
M(I Y=F(F+A7F<W4H)"B/H]&5V!MI3-L<TBR+4G58LU.VH^/'6&S4X:Q'2\:N
M(RJXJ79*J3<*)&7LS :TI"51R2\I9[8,%'NQWHQL>%3&<M,9;\M#3SSLHY>&
M 7/2?7.H_E/ ?6K3(L]M*<[5F.2>2)3;4MVQ!Y1IO-[9]QXSXR'Z*MG"%C[/
M%S7IM.P+1V)F<]%Q N>A*<8!>FO?6^)_IWU<[R!:>TXO'#Y1I*DMLP_I\F\K
M.UO6-I\3-OILAFFR-K/S[N3A&RT-G3-MTN(RRU((P"8M1?A$Y_,L/SW64ML]
M1 [*)H:6=FY8W$S2XC^V^LTY\9.?T@Y8R>U9?-,T$*8V>-G'Z5+=R2:1@&1^
MLO59+\=>?GESS%J;;=V#-!>2.UV]D[22#E<3"ASTRE#-V@'"0!S+R+6#C%6-
M:L%G0;2DD"B;%U,-J\U75CX1!4@'DIB3<Q,*Q2Y _F8\%DUL PB8<3NS2%:O
M'T?096"\JN9>/F&D38*^XV3KP^W*CIN*?T.)<6FQHHR<M*RTU;8&0&;LL78J
MW(:J:H,XQQL9=_5AE4WJ\6G>R<6_O&8*+Q)?8CEL0CHJC*ID(L99D\;MU!6E
M$UB"T=+H)MGY2E$"JG9*N"(*\T5C)K ) &"^, 8!#EUT1KO8L[:IFZQKBP-;
MMJ*8TA:*V]73&NR]#GI%S(RS1=LFW3?E?.S.UVIG:,BF";4X=E%-P4K@H$<U
M#@WTQ4*+K*@MU=H2<=JG6NOM5UV1=[FVG$2+VN:UJT54:^[G6U/ME7KSV=<1
MD0U6FI-O LO*L@=P[60**O049JMZW7K7(GJ,J<&!@# & , 8 P!@# & , A.
M]Z6)>MHZHVBILC85:<ZC=3#R(J-=2UR:I6!6P,%XB;\YS637MBMJA)&&<*11
MPKULKHMF_2Y8"TDP%^(=S3ZR.:OPAU&KVJGS"6Q=J2U-USLB[;:UWJ&7>4$V
MOZ9?+XC>D9>7CY*,U[&;1F&S0NS+V:%A+=LFQP48:?#M1IBPE:+##-?^>'VH
M998,# & , 8 P!@# & , 8 P#&6H\-1J=3-C5%CO7>#ISL2_O-F^>2CS5D/;
MJ=;9&P-[0_<596I:JKE>=Q4A+M41DZY=Z[<J_+1?B:_*QCV D)*,>#-<EVF^
MG=T4)&U1J:)U0PM16UAL]SLM^M[B^7Z]7-6 -9[C:E*]7*<TDY1O4Z_4JFP+
M%4RG5&I1;"N5>#C6\+6XWK:+2!GS]X,$J8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@&%_LB'\"KB%_(E/Z^A\]MS./?O@[V\O\ CQCRF''O3MOM1.6A
M&EOG;1RD, N>D^N=1_*> ^M6F19[:4YVK,<D\D2FVI;MB#RC3>;VS[CQGQD/
MT5;.$+'V>+FO3:=@6CL3,YZ+B!<]"4XP"]->^M\3_3OJYWD"T]IQ>.'RC25)
M;9A_3Y-Y6=K>L;3XF;?39#--D;6?GW<G"-EH;.F;;I<1EEJ01@$Q:B_")S^9
M8?GNLI;9ZB!V430TL[-RQN)FEQ']M]9ISXR<_I!RQD]JR^:9H(4QL\;./TJ6
M[DDTC ,C]9>JR7XZ\_/+GF+4VV[L&:"\D=KM[)VDD'*XF# +9<4NG.S5HSNI
MUER:F&3/3S.(&+6-5#HH(MD35H5&IA@C)-FZ#=,T7X42(((I%$$TR%*!UQ]?
M"_DB;ZY)@%W8!QK)%6251.*A2*IG3,**RK=4"G*)3"DN@=-=%0 $1(JBHFJF
M;D=,Y3@!@ H?FS'>^;!\[+5]LX \V8[WS8/G9:OMG 'FS'>^;!\[+5]LX \V
M8[WS8/G9:OMG 'FS'>^;!\[+5]LX \V8[WS8/G9:OMG 'FS'>^;!\[+5]LX
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MLNI:2E)' IDKD7V^VN]QGK;@P, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M6IC556.1$JQR)552F5:')M;UC:?$S;Z;(8LC:S\^[DX0M#9TS;=+B,LM2",
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MFH5=Z9HU*5LV,Y.H*"  BD)$P N =[SLJWPD@?E=A^T8 \[*M\)('Y78?M&
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M=E6^$D#\KL/VC 'G95OA) _*[#]HP!YV5;X20/RNP_:, >=E6^$D#\KL/VC
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MJ< >4)[X.E^6&OZG 'E">^#I?EAK^IP!Y0GO@Z7Y8:_J< >4)[X.E^6&OZG
M'E">^#I?EAK^IP!Y0GO@Z7Y8:_J< Y$7TT=5(BT$5!(RA2J+>56RO:()@ RG
M;*D!C] <S= " FY<@$.> 5S & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , Q1MOK-.?&3G](.>OD]JR^:9H/.S&SQLX_2I;N232, R/UEZK
M)?CKS\\N>8M3;;NP9H+R1VNWLG:20<KB81G-:FITO/UNS-V9J[,UN\?=$\96
M$H^'4L%G-5YFEK.[6=%@=2P%<5:P3$*KXTYEP:/ %)=)=LS6;@10IP?Z;49'
M9=BVIE-4D]:)N4;A,HOF^GDV$A%AIM!XFL5<FN_ 2KY/P!C&FBNSM9E.=)/1
M4/*1X5,FTFC1!59=!JW16< D5=9)%--5<$"=M$%E"% Z@(D]HD!Q,"9/:DY!
MZ, [& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP#YZ2CZ1*41_]@8 Z2?^B7_^ P!T$_\ 1+__ %#_ .F ?H  >@   _\ 5Z,
M_< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@%*CYV$EG4LQBY>,D7L"\)'S;1B^;.G,0^4;INDV<D@@J=1
MDY.V627*BY*FH9,X' O+ *K@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , P#XR.'K?NY;1JRP:7V6ZIS?7[Q>XR$6[G:JS9O+17RNX2
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M6/E$G+VK02YR/0 T<@   C"DO8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M= #DM;JGESS7IL<N=PK"U"'@X91V],P%VL/DR$P!@# & , 8 P!@# & , 8
-P!@# & , 8 P!@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g713200g27s64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g27s64.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1HF4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M3   !#P          0                         !              0\
M   "3                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "3     !29VAT;&]N9P  !#P    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   DP     4F=H=&QO
M;F<   0\     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    ).$))300,      ^7     0   *    !7   !X   HR    ][ !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !7 * # 2(
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M0_Z3FM]3V?G+(ZCU'HS>KV4YF VZRFME=N66,<6UV]GS^D;C[;/^W'^DRO\
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M2G__V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3DZ,#<Z,C$@,3@Z,C,Z-#D <G(U,#DQ-C<       .@ 0 #     ?__
M  "@ @ $     0  !#R@ P $     0   DP         !@$#  ,    !  8
M  $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !
M   !1@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0%(34T *@    @ " $2  ,    !      $:  4    !
M    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (
M   4    G $[  (    )    L(=I  0    !    O    .@   /      0
M \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR
M,2 Q.#HR,SHT.0!R<C4P.3$V-P       Z !  ,    !__\  * "  0    !
M   $/* #  0    !   "3          & 0,  P    $ !@   1H !0    $
M  $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !
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MY;^]=KFJ)Y#_ !XV/FBXU5D4""HNJFB0 $1.JH5,@ 4/481,<0  * "(B(^
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M)Z^:SQ-HU1;I-$FZ!&J"::*+8B*94$44BE(DDDB4H)D32(4I4R%*!2%*4I0
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M-GBD7D/V>-VY3[N+RTY;4FFUEZWGZ<FT)VJ#%O9%S&ZYFSP>N)F42VHZ+T=
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MZ<(G")PB<(G")PB<(G")PB<(G")PBU3]GXW7\<[HTKMQ7>K6@=N*6TZ^KXW
MQ.66.G)Z!A=S<7:=L%HM,-3+Y9:M%3$7K%<DZ]6Y^>@Y \Y#IT1DS>(FBI,>
M$]^_525\-O';WD63:DXN.4!U[A]6WZ]ZYF_7$+/%VL<,HEIAZFQ2J3A] .GU
M8C9"PVB$M&E2E:J[QU UN1O+J(:+"LV= 4BV'<(G"+6+\8W^SOVK_6'6S_=+
MBO"+9UPB]%)6BLPS@K28L4%$NCIE6(VDI>/8N#(G,8A%2HNG"2ADS'(<I3@4
M2F,0Q0$1*( 18OJQIP*!/*5IY;F,L1)FLV?4-WGC.SMTDI!HJ[5CG>J-W="1
M3!D5P+]2=0.0([YKY$22(M%"[QV#5D;.,>S*%AT*$CI&,L&3ZL F*U2DVPN$
MC0RS&7.:&Z>#R.CVGRL@>^"&:Q*W7)% ZNV5WB <6NM/C@'*TESN=X\((;XM
M!:QNK6ER^Z9+F>[]C]#GRY'28^L6P[W4%,XA&FB;NE#19W\C L<^A:_'N\US
MB>3D/P+ RZ$S9IG1W+AXZ!)W08(KR]\8V,9PA/FJD-2EAK4EG(42Z.Q8D-+
M,M3QUB^2U=NN&2S=412S=B^$Q8MT4)A;+>LQ0\Z&WS016;SG01"0-C$QBYK,
MY=V<78,KD]HV1_\ =X0'V'RN#2QLC Q4US[?=Y[ =\[%%C":/K/7FROIU-K5
MFM'@:@VM&.U1[;K)G#6:D[+%4]+\(C8)(AW1+-,M/Q2U<!79DTN9TG%*_FF#
M,2Y/-O%:2;,5)29&T:[J,<D^.BDGDJ\YE=58*K9) 29Y6B8'LI'2N+6'X,X7
MXYR'%\47&'"N8X&X,LVG8J;B+B#@WC*ABM8NM?OT:MZ88R]8=:OROC[U3;6+
MI'2,CFK5ZW:M&\8;KN;I R$=@D5')BW!("6#7XB*])E"&(4J)ZQ6K2HDBB4"
M^ZL0R*Z/D!:(KB7R%X-[/O:1'@((_#K5K-10^(]  :E.Z0UOZS@0X'[#7+V1
MN ^'E=S#/\1;<X:\'6+X'NVP&,(/B9ELKAF%S^HCC(?$[6IGQ@Z-"^H$)WGB
M=,UIQH]7>!#,EEHZO!J>JZ8[K;4YI-,19THKE_=D['&@T:IK)61Y&G=D(8R2
M4X OG;#GG/!4/Q!BRN<.6IN[NQYBJ_2N7RSZK#VH\&/$DM\68>1K7"V^(R=2
MUMD\[XQ^B_C9>_H^7>%>"H^%LO!W^>..UDOZH\'<*0969K:CAVV?,-? OQ=K
MMYG,?BH;382X![\?JO!86PL5.Q;@P #/%8<A0$1,,E>;&98PB'@H$")JH-0(
M "(F$[P51, >E$">3^E;XD=Y,P< '_NW[7-^SLJ?)K\9.;?DW77\UAGPQB!)
MGX\NDD: J\/XL1@;V2[OF7,Q<=:'+ & 'J_?3C59=D7'I(C9<1B/!A,=RI2;
MW8O64 $ 1*R+?ZQ[9C&$#_,B_4 @$%/Y4_N^ZCJZ/B=V@VW@8/4N=C\A:W_V
MB,9.GKY\W:.UK7(=[;NV?X71;<_%<?7=@!L3<_P]B^4[!+S8/#>7Y@ "T1"L
MS9<'=LT,Y'T7E,$[NO>Y49IA+MFR% 3@RLU;*QJC9.NM6/TPGS4.IG#ZSO+4
M\EW-@02D"29[>H "5%TG/,$44H)+S^7A[C]_',.5&1Q3<6VMV;K,=)C:S&&(
M%]<XN2W)=?8?9:V7MS>/3E<+$;6BL/T!5^(OP!A^!MOA-V XIDXE?D#.S%6,
MO*_)RV!<<(KS>*:^(@PT%&+&R/K.J#",)V^%V-L22/R+[Q%SC771!+*=A; @
M/M%3+^%L]S>( #& ?>5.-A@;F<RG]7Y;VC(%1 #>\1T)@$E_&,S+_P!-Q)99
MTT.YXW&0C?J3WJO?)Z?9 +>7];G.BO 7<3\&1$&I\-,9(.8N(S'$O%-WH-<C
M&_1F1P30WS[7G;(9-CLS" 0X?%)-X)OK.X;=*E4.05"(V.K5@IDTP+Z$2FI%
M+JZK<H&+ZS*-E47"XB9-PLJB84QS]"2OWVV>SLP)&P+%*KT Z-W0H5'- /4E
MA:YWDXN;T1O'=6  4> . *9:UP:YV+R^6(<[?,\CB#/9=LAT>5K9FR11Z#HX
MV/ <J==I.F77_0WU!'1MKT*JOHE\Y4*-IO\ .7%6PQLFY:E>1L<E<)"4:UYX
MNJS11;.X)J@0_I$'D9)'2;&;U3B3X98KB1U%]C)YF-U21Y>Z6_8R';0READB
M8+TLS:KCV;0U]=K&ZWVD4A#2WU+X<_TF>*OAU'G(L?PSP9-%EZ\+88Z> QW#
M[:=RJV9M>S,[!U:DV5B;V\A?7R$LLFS_ ,/:K-=*V6V[+!XYJS:FJFM[=#,Q
M:D%D9/2WUK0]@Y"JM%4BWYG<4E")^052]9#IJD/[+@J[4"(%M+>'VQ-#:N7S
MU8-;RC^TY+FAZ:^DF7AMIZC8._LNVW0'F4GQ%FMR/DR?!OP^R3I'A\A/"M;#
MN>>H?MW#4V#<.T:=.Y7 M([2(QS%TA[RF:ZPT+_Z+V&M*QBBIZ27"B9G.M_!
MOVB"<M;K%&>'.FI^SY^> AFPF3]L%A3<I9=B\NS9K\26W.ZZ%['XJPP ]>HJ
M5,=(2'>7U@'+MNN8A[?@SB?@Z;I>^&F'C;X=G!\1<68Z78\)T<KEN(80US3S
M:[N7"4-?S%G-$XG#]DV!S"%^QJQH#Y]*3O,+C6'11,0H@8SUGJ-B;G*0Y3%!
M$(LACD5 XN2BC[:V!!Q1&3_:.#M-ZZ#\1>J/&QTW(S,6FD ]-=B"0=\VVZ=L
M^[\+K#1_Z=XYQ<G3;X>+<'EH3IQVT5Y^$,7*TN:6GM#=>&EI A(?S,_%;!V-
MCS%!7,\HGDO( 96)UJR13GP9,?ZK&5RE9 ?0L >LPRH"*9P]"8G(('V-CB6/
MSQ>'L#?G%F+4+M:_Z)<.]NP[_P![J#L#8T3<;\,; )9Q9QCCGZZ,N<%XJY%L
M.];%/C*.3Q,/A IG3V^)P:[;26GZDV$@3/72\^D?0)U:S<\HG$R>HI@,'HEK
MO5G9S%5*4/!&IB^RH17U@8%$B!E<JS]-PWD'>6S4NX>=HWO8/;Y"G)L'7E&0
M00=CJT'\*<)2@]Q^)_#V_%IN6P7&6/<[1!!YJ7#^7A#2TG1=,#SM+=%I;(X?
M>XMCX"?S+<X(WI3,H!<DM=N*B!S"FH!ULX;75 YD% ]*@-U5A4+X7;?,-1!<
M<'B"&/7>,7GJY.B0,-=N\OH[9QD=YIY3T/*YV_M,YF>);-^'=NQLXWBSX?9$
M;<&$\:8?"%^AS-(9Q3+@9&"1G5O:LCY3]5+V<P,8\TNR>+_<9.X'J@!X]8WZ
MM6W.RI#[GM*%7->X*N@W,W4$I'A5A3,Q$Q/G 0 Y1$.*,%_SKW<]:)^D:MS&
M!O71YCD*];EY3T>':,9(#^7:U?\ "[CK_P"DP8S!)TT<.93#<3E_AYVF,<.Y
M')F02M!,!CYA8T[L#)RG63P^T8]8! ('5<WFA'\@BKQ6)$1\J>T'@&<HL(^5
M?Z(/ #Y4_8_K?;DN#.82R=5LQB[!/D(<A4E/4Z'1DKO,]!\SY+D7>!N-L:"<
MCP?Q30 WLW>'\M5UIO.=]O49K3/&?DSQ'P]5(J#ILY("C9R@X3-Y]*B"R:I#
M>D?2;P=,QBCX, E'P/V$/ _?G2:YKAMKFN!\BT@CY>8^_HJS)%)$XLEC?&\:
MVV1CF.&P"-M< 1L$$=/(@^2Y^;+1.$3A%@L_IE!JTLU@;%:HB'F7OM_)1KU<
M4G;L54UE4RM4O0(N#&2;KJ>E+UF!-!4X@!4SB!%G7")PB<(G")PB<(G")PB<
M(G")PB<(G"+4=\3^_P#:;#&^:;%E?:_] 6(/KK2LSUD3=787>([-X^</<)"2
MVRR2A5W%I0@ 4:5>BEB&D42)83,M%2TA+-&CA^)2>_?FI+^&%M&N;ICNIVS4
M=<7WV)B]ZMU6R+;BXN&$0NH9;%56CKL;)6J0=HT=GB&]K?VVO*3C@'24I+0<
MF>,?.8I-E[9%Y]X^RG8K!]5Z95S-*=2T\FVCM1BV.:CHUCF0?V 6NAREE0=4
MFFT=!D!D'9XN!-+25YDYA!O&D68QD1#RCQT^=Q!%@OQ .TO87,M,J^-]=)Z@
MTFP->KW9SMI9[5H5'>W^/FXCKTUIR$-F+&*:6BIA$)W.:MP?B"T%>O7\+$L"
MC%L#.G'N Z^_R14X[X=[J!V-ZF4[$25B^4VX;[0^M^Q2TW8:%>8.@UM(5,D[
M+-X2JWBPUR)IVENSQ[!2O2P5>S+*5A<'*TN07K)6*/F**S8F[&M5GLD0/L2.
M@B?-V,;9ZM9CI&Q@EK99[<,,;O(RO9&-N>T*-):CBM5JKP0ZS'9D8_\ 5'=N
MQ+@[H=;;*7!QT/!R_:>W=X*W\5/%)R 2>2M:NE2E7D V>LU744G8*ZK,R$<@
M\9-&S^'=IOW\:H#E)RD_&/CS/(X2.$44CKID#&G#H]CHWC8?&\%KV.'0L>UP
M:YKVGPO:X!S7 M(V%]V/;(QKVD.:]H<T@[!#AL$'UZ**X>%V[O)+T[7YZA0=
M'B<DNBL0_KR%AL]>E- :QC=27?PWB0;J)1QD')D8%-^Y21,'XBDT%E4463CT
MELLQ^)QMD%.=.;IG=5:23_1=0>Q=+3IA0(WMM-5B;)77UD?3\2DHJNW^G'4A
MJ_' @=1O8IVYTYI!.Y!M9(QRYZ%2U6PU>[Q5?K16Z?##(,G'4G89([V7988<
M)0:P.:Z626^R.TZ*/FD[I3MR-CD[/D/RDCR-I\&-PTPAS&5GAQN-+K4M-DEN
M](RM!7FM0@F"O;EE93FFEY:L<=@NNR15!/*RNOPJ^C*(Y >U[O V%VP0O<N[
MH]"N31=.-6C@BX1NK-N64@4%%(=Z_0=MDXAHSBHV7,S6<6 MD:EA4HFAR9*S
M\4\C-QIQ/C(Z+[9BB.*CQ\N.K7WTHFP,R%ZO8M6Y;'-$V.NV,OCKRMK-=/%8
MU$YE\;A^(/@W;LX3*6N#<UQ[6D[2KQEPOG+_ !'#POB[4,7+B>'._5JM/AW.
M&PVU:R>5QU=^3[&U5AKW:3A;;/OJ;M6[1%%NU02;-VZ1$&Z""94D$$4B FFB
MBDF!4TDDR%*0B9"E(0H 4H  !RUM:&@-: UK0&M:T !H T  .@ '0 = %2I'
MR2R/EE>^665[I)))'.>^21[BY[WO<2Y[WN)<YSB7$DDGJN4PF IA*!1,!1$H
M&,)"B;Q]@,8"G$I1'["8"&$ ^X%-X\#E:JN^.[NGJMGNU>2<98H%)=D8.U*3
MJ9;P^>**1L#($D48XE5@P2@2JS#F%6E%'7J3L$-(Q@-3F1.JF12I-:7G-<,)
M+#?Z7!G 2E%.7M,'&J>HWI])?0\?(G]1@.00#QY$#%$/L(<(L7/N6?*&]$0K
M;;4<?3Z#4[.M!M;0_J!,0'ZK UE]#I$ %2"*KB011*/D@J <!+PB@-UM791?
M?&%4@,5.\Q]W7CV4TC*Q;:!NXMF:+9@_8I.Y71&E<3>!8'K(4"2#1B]4BEW!
MT8MU\@J[5(I^&\Z2J8 ;8C8$2@'DYY:ZY\T 1$0 I4 BY^=,<0#R*@K V O[
M/H%41,!"(%JV!81%OD<&W3   0E]0:M7!C_?R*:<34IY 4@#T^#J.DE1/Z@]
M@"E*<Y%6KL-6^WU\5S4V<DJ=$;Q]WCEIQHQL[*UF*FDJ5VPLC]2<S-J$>C!*
M,UBJ%CUY7YD))$JL.Z%$?!%9<DEN)B$1&EYB@;P0AGBVE69Z)?3X ZIVB65Q
MP+'. #^P1PV*!S>0\%#T"1<WS&W?\IRO_N&V_P#C'")\QMW_ "G*_P#N&V_^
M,<(O $MQ4\G%]E#3U"(@V"*M\A[(>1\$%[]8C/F1\>!%3Z>U^XB'M?;R)%^_
M+[A_S;*?^WK?_P"3\(N)1CNR_I*E:,FC0+Y$RAJ+<)H5!^P%("(:)! B ?M&
M%45U_/@" D'D3@1<0PV]"'@= R00_P#M%</[OO\ OKX18C.Y/H%G!4+&]Z\S
MPK%5*H::Z_S$J)P73!);U_/Z^X _NIE*14#^05(4"* 8H>.0Y\?0M;%FE4L;
MY@>WK0S;YARNWVK';V.AWO8Z'HNQ0XBX@Q/+]%9W,XSD+"SZ/R=VGRF-Q?'R
M]WGCY>1Q+F:T6N)+=%8&IU*8")S-28G#J' Y3+UO!AJ[D 4  .!'-=TJ+<)@
M(E*H $5+Z5B$7+X6(50.?_5KA\$EF'Q\#COQ5:\=1_7S\=81.'7Q=#]K3OM
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M7B#F,>FG?*TC+YNB=@U$B%K6_0+%4J21!-8,<B9GW52G_I5CFC+572E!1+[
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M+\CKN=S*FC=?DINB1%X3T@*0Q:5323+M&#4**H1G3X]*"'W),@RW,=?R_/\
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MX%/8))GV?[#J-G=Y^6\S2B1ZOKC&N' %Q]!C0K5&-$Y3"T R7I.8BL)^IZZ
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M^9/.]U[$:'@'2;-].[5:]5TM%M7Q2IW4-ZKEP3H=ZM=BZR6W2_T5U\;0 +A
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g713200g29v69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g29v69.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2QJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
ME0   T<          0                         !              -'
M   "E0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "E0    !29VAT;&]N9P   T<    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   I4     4F=H=&QO
M;F<   -'     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    &.$))300,     "';     0   *    !^   !X   [$   "&_ !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1" !^ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MW_92*Z]FV_Z7^D56SI?6P,<V=:M(%C34/LY(+FV6/V6"MC'^G?C_ *+](_\
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M #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !#
M %, -@    $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M?@$R  (    4    G $[  (    )    L(=I  0    !    O    .@ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HP-SHR,2 Q.3HT-3HU-P!R<C4P.3$V-P       Z !  ,    !__\  * "
M  0    !   #1Z #  0    !   "E0         & 0,  P    $ !@   1H
M!0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %&
M @( !     $              $@    !    2     $X0DE- _T       @
M         /_A 4A-30 J    "  ( 1(  P    $      1H !0    $   !N
M 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0
M  "< 3L  @    D   "PAVD !     $   "\    Z    \     !   #P
M  %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y
M.C0U.C4W ')R-3 Y,38W       #H $  P    '__P  H ( !     $   -'
MH , !     $   *5          8! P #     0 &   !&@ %     0   38!
M&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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M$0$#$0'_Q  ?   " @$% 0$             "0<(!@$#!0H+! +_Q !D$
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MQ3JJ"Z"R9C)JHK)'*HDJF8Q%"&*<AA*("(#$- &@#0!H T : - &@#0!H T
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M-UJ:QQC]S$6&*D825;$<6MN9Q&RK-9@^0*NA.$71,JU753!5%0BB8F Z9R'
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M[P^R?2+/]M#OC\?2:6K=><KJ.G$%#KN5E 56<+1C-5=50$P2!114Z)E#G!(
M3 QC"8$P @#U0X:B0L8?,6GU(G4ZE8KQ>S A2=6&C@Z@)MRLTP)P;_2@1H0C
M8@!P K<A40X)@!=  T^I&  -6*\8 #J@!H:.$ +X.1IU0 6X@ >"))MN <O!
MTR(_R92E !=F]-HU8VJF,V39NS:(5U<J#9LBD@W1)XQ5.)$D4BD33*)A$1*0
M@!Q'K=X\^'X4^%6;9(?KO?\ $M-\G[Q/P@^M)'W2#XE+=<N6"-0[P]8?GUK%
MWL7DOL,/!\S&6;.8V.E<86)I*,6<BU/;W)C-7S5%VW,<L5% 4QD5R'3$0 Y@
M PE$0 P@'?PUWO!?P*;](BZ?F2_<5'X^VUPLL%/ZBD::.G=ENK[-'PMVI4ZL
MJ8QE:W J&.50IS*1# XG*L9 RQ3B9N(F!4S5J90#<0.+= 3<123ZO2D('X\C
MZD)C&&KU[K'%4QS>)H[B<RSA)TL8P^#\3&5=((.5!'B)UT4EC"*B93 !&F:Z
M] 1V&<PO(^$B6+LN*\CD*Y:1S1LX*1W6)-5T0%D42* 5PJF11<H&X*J$(<X&
M,4! #IF%[@]0:&CP?.W=L=]=-VM5P7,:Z&<;J8U6S3LNTK72F.BP6T[ZYW /
MPMT;]?LOR>G[V@6.O&_JI70WJ:T'<%5KE?674<K0<0JX6517574CF9UE5FRZ
MSENLHJ9$3G50<N'"Z*AC"9-9=94@E.H<PC8V"5*K)@F!*W D!$6ID0+$,"@D
M9B50C(R8 W^D,S(LJ1J)> H%54*D) .8! T)4:JD*1DZU IF0[#L1)$,"BCX
M*BJV:]D)6X"3P=NNL@AU>'9(JJ))]4AS%$#FV[=NT01:M$$6S9ND1%NW;I$1
M0012*!$TD4DRE3333(4"$(0H%*4 *4   #0% ND0P1EC.&)FD=A[<1";>K,"
M%LHB\E<7%E:TRTLLR0!\;MXER]J5MJ$Y$7-O-2\2KCV:8NY-TA/KFC&<.X>S
M#9RS#??VF9;#,-S6!,$'QC8<G5K)<O"9!O;EXE3)2V2U1QLI+2_C(,45QS?[
MI?[V6+IA7()I-[?9G4PBJ^6 K2+CA8QK4"Z.@-E<0[%8.(<>R4Y?ZAM +\Z*
M3['?M5^#I7Y33^BWH!A.@#0"7NE<_G;"_P#=UT_2:]J7.*]K,RO=_/LNEK^;
M.?P*T?* =+1P:K_0Y1]:S=8HC4K/'T-N[#KQ6BF-RU%=5Z=>%>?\+@ULL:::
M[*Z,=>-]&KE5JM1LW]/7T/4QWW14>UWE'W]1?R=#4)\9?C:Q?05]I%SEH^(+
MQ-ESZSL_1^HR^D:UJ-R?@T!A>2/:[OOO+M/ZC?:V@[^'RH>U'C:/!Y_F9OJ1
M'F$(_4A^;S#]+\P#4OQ=\^:#[. K;I?E1>LS? .?'U\.\>' 0Y<._ESX</<[
MM8!-VV/ZY3;R/G]G'$WQ^7T!W#[H#YO3R'AW>5I\#M2_V$[U-1]F3E_&%D^D
MV?1_MH??O4]+;42%C T : 6EO>_IE4?>^M^GJ</C^?'CKA^%/A5G\R_79:;Y
M/WB?A!]9R/ND&^[*2:Y<L$:AWAZP_/K6+O8O)?8'@QG6R@...+!R_K<[^/Q5
M$A_@/F#_ !UWO!=_J4Y:5:&^ARX*;XE1N/NOYV9.I_4<B_\ MEMNV<^S N;K
MI2$ T!%.=_:0S%\%M_\ DI+: Z6@=P>H/S:&E7?I^<UCA1Z=2]F-51&NAFBO
MUN_3H?.M/;3!%@]IOUSN ?A;HOZ_9:#3IP>B[%5Z=\3N.Z&P: - &@*)=(MM
MR7W/;;W6/HC&M%R=;VF0\66*GQ^16LA(UFKR,?D"O(3-\<Q$;;J*O8%*=47E
MCFR5H]HCF]B(U4AURO4W@L'0' ]&)C7*6)MK$53<P8BI.%;DUNMR>KU&AU*O
M4J'<M9!Z@Y"><05;O6261)"0>G?(GD7-QE)":9,F,PY1BP?)Q+$-(PH>8" =
M_ >[0"/=O.%.D1:9^WGSDED*UXL@[[/2;_%%HRXHXSK1X1DTS9D208141C@,
MO1<4]4F,3OZD2%GZ>WQ3$U& 1BZ;8ZO;[=#R=J?C&K3M>.!;'HETW*71Q[2D
MGKA-V\3QB1-V[20%JDZ<DL,X5=PFU%5<6R:RH'4(@*ZPHE,"?:J=7KB,C$M
M&@$O]*Y_.V%_[NNGK_\ >:[J7.*_O,K^79;KW7YLY=5+[M6LK1\H#PC@U?\
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MDV?I_2PW'I:ZB0L8&@#0"T][P?QRJ//^KZX?]_4$?C_)YM</PI\*L_F8KO\
MC+3?)^\3\(/K21]T@*1ZY<L$:AWAZP_/K6+O7S/L88SK9080QQ8.[G;W0_\
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MX/*A[4>-H\'G^9F^I$>80C]0'/EQ#U]W_G]_AJ7XN^?-!]G 5MTORHO69O
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MV/DZ'$OIF9A5+3-R%YKE?91+$\G-N^PC4^J!S&P>CX-KF'G=EPI@5A@=O;[
M^\HXL^0*/ENSV!Y J'8,I.RY/H^0LJ-+,<B"BI8]L_O$D]ADE5FZC5@=91(X
M:=]^G=7C$.("'I#AH!8%6Z+_ !M$Y3W'WR]Y(R#D^I;BHRL+V*FRC_R'G6%I
MK.2LGY)2FSY+Q2K1+G,,FQ\BDK$!%23U16)K$#'03N2EX=E"1\(!EW1,-$(_
MHY-I;!J4Q&S+&)6C<AU55SD0;6&<11*99PHJNL8J9"@95951500$ZBASB)A
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M%_9H [%+[4G^ 7]F@/V!2E#@4 *'H   /B#0&N@#0!H T : - &@-! # )3
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M4UIAU)6*8<LH=5Z1J88]NW8-JT,AH T!^3%*<HE.4IBF 0,4P 8I@'O 0'B
M@/G >6@$SU+HW,N5.K8DK(W3#=C:87V69VVW5]K-UVS'96:^9XO^/K1)VRQH
MCX2DUK-2C<<1)H-LR;.9EY-O5E5U&3=@V56;_B#%,?\ 1?YKK-EP=,63(6%[
M%%XOI^W@U@AC5VW*>45XVO[?LR[?*5!-G+U59)/&60(7)["RWQJ]9JR48^CI
MZ%BV$NSL0/X\!A^QO!-[VS[9\?X.R',4R?G*&K9VS>7H;:99P3N)FK3,69D
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g713200g30a67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g30a67.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1/F4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <T[QL
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
ME   !YP          0                         !              ><
M   !E                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !E     !29VAT;&]N9P  !YP    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   90     4F=H=&QO
M;F<   ><     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    %.$))300,      E8     0   *     A   !X   />    D\ !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  A * # 2(
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M(:UH)<3P .2@T9^%D"HT7-L%[0^HM,AS2)WL/R61TKZQ.ZEDOQ;&>BZ]@=C
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M)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V3A"24T$(0      50    $!
M#P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
M    L(=I  0    !    O    .@ +R.\   G$  O([P  "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.#HT-SHP,@!R<C4P
M.3$V-P       Z !  ,    !__\  * "  0    !   'G* #  0    !   !
ME          & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^
M 2@  P    $  @   @$ !     $   %& @( !     $              $@
M   !    2     $X0DE- _T       @          /_A 4A-30 J    "  (
M 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$X.C0W.C R ')R-3 Y,38W       #
MH $  P    '__P  H ( !     $   ><H , !     $   &4          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0             #P     $   /
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M 0$! 0$! 0$! ?_  !$( 'X"70,!$0 "$0$#$0'_Q  >  $  @(" P$
M        !P@&"00% @,* ?_$ %@0  $$ @( ! (#" P("P<%  4" P0& 0<
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M$6EZ?J\$K<=YV 8:VO7]AO5BND:T^S7J.;TN;"[!"K*B'[5,)E:LDW8</!Q
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M)H0?*5)4G.,I5C.,9QG&<9QG'GCGQ]J0[9O/$=",IE""/1_I<ZZ!C6AQH-<
MYKC5:X$;@@]V""#X@CH0OG(\*W>.Y]C[LWD'V!M?8MV$S^NNRK-.&6JY6 ]
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M?5SZ @]_*Y^ S?3M_P!^J_#Z[+6'>YR+[^/3\3UX]D_Q)OA[^7_USW;]7_\
MI-E_O_Q<:=]^37WR+A?HV.Z?B5UW[ 8K[M-_:G_0L![N_BZ/"8_F;V>_)_\
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M\LKWRRRN<^261SGR2/<2YSWO<2Y[G.)+G.)))))W*EP      -@!T  \ !Z
M%"'5+\&3K[_0WKG]4Q7E_F_OCDSJ;W1YWY7R'Q?]ZEW7E7_>(?N4?Q_R1LI_
MY!KV57]P7"I!]Z=8 9>S !AJ;;KPN$)(%X$,G+01UK:PP]<6#(?;DOIFEY#
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MN/&C/<-VD?>>*^<N?'^U6]O?\8[V*/RSK7Z+@U^=6_Q9/B'?QF=*?YK:+_\
M/^7_ #\:7][?M ^ZXCZ5%Z_\@J]K_P#&R]C)]XZ]_4MQ;6_ O_!,OW]/UI_4
M'6?.H]B/N5O_ "_:_5^,7QU_E"O?GTW_ $;8?_:35BU!>+-^-,$_R:#_ -$5
MR1U%[H9/YU/YJ%?B]VF^^6W^=@_[$"\M]_CU 7YV'7;]_/\ E:S_ /'R^WEM
MSW4CY6I_/P>E,U[]$7X5:>_X9Z5F ?'_ #^+_P!?_P P9C_9_,^O^_\ %^3G
MHSW6'Y5D^<=Z_E^'IEQ^_7_7\WT:18YU(_'F6;\XSME_J&V^4QWNJ_K/(?HN
M>OZ/2L;2OOR3?A)JGT?_  LTN#X-V/\ G*#F?_M7='^OQN4TQ]FV#_RV?FY/
MC]?TV]E/OAO^XY?_ 'E]CW.I+ZR3A$X1.$3A$X1.$7'EQ(L^+)@SHT>;"FQW
MHDR'+9;D19<60VIF1&DQWDK:?COM+6T\RZA;;K:U(6E259QDBT?^%Q.;?[1]
M\(+S%#@D1FT+Q 0-J(G6 F9 KL'=FS8%18*L:\UM3G_B36HPK"E';!9"3TG#
M[Y3T#;A)QTBOW>NB^F[[N"+NJ=,M@:SHO5&OQ,;7WZQ"KUB)T(G3SHV"<ARJ
MM.FR(1.P:_I9DY+C$8A^8Z!;@,FXH8@7&SR+J]\:KH=4F].XU5!JJPJA]E*[
M"K%;K!8W7JA$8LM?N\DMF=30Q*%53TA4II4P?,/ARDL+,E$)89^!))D793P\
M.F_BBSS;W3?0>Y3:KD<IS%<V2EM*8^SJ2B$ NB5M9PJ,LG(S"F!K8W$7C#D.
M#=@ME&Q7?VYB$V]A+B<[RYTM9E#(UJ>9QL9+HL?EZS+M>N7?7.I2.+;F,E=X
MF?&6J=CI^^J2Q6:S> FDLX#-9;!6)AM/)BKT]1EIHW^IWJ\;_)<A"=R'07H+
M$+P2UT9!(6I#M?I_Q':/V*ZPU/2978FY--2#4A%D)B[[L*BBF(N9T9HJ,VQ8
M46NU2:NR_6D2&EV81'9!2(TA^)2:6".HS")94&@- Z@Q^0S-C6.K=)6\'")J
M>F*V9==JY:8D.D9!/<:W(SPVV#R!E0WFR8[GY6ZX]G,KH>'[=,SIO%YC%S]F
M'9?K#):ACDC.I\GI#&4\EC3%7D]KWUH*%>+!06:>2=%DY;D^)F.2=$*]V.=K
M8^[V-U75G9S :"!.KIE'JT5'IHH6B;6WJT!F,ZM2WHY"SS->; V(_.4M2G'S
M]5M%"G2W5*?=CI>==5B%AR7M9&V#!Z*Q+(XM^YFS&<DLO8=_KV4Z>(@QXY=7
M217*V1#G'SI'G=QXUD\YK7/WYLEG&QW[UEP=/9M9Z>2:0 <6L,CL58D#(V@,
MB9%)"R*,-CB:QK0T5/N/3_:T'O-UZW52^L>C2==HU5M+%AO=KVI?KA;W+ 6?
MD9BG+!=;(TD^2/5Z*PTS59!*H7%3*K$;6J;A;0]X!*GM'UPW"W],OHR]QEI8
M)]Z&0Q\&!K0UF3MDJ2AF-J7*@M2.K22LQ^.?$X5HFGF)K'=:=;=JUF?QOD^F
M\9-2[J4SWSF'OCA=Y^PL2S58[@E_>^Y$-*VS=SPZ38ET&TG)??6/KQ0-3JSC
M&?+&=K6Q/G^3'G]R#/EY_E\OJ_)GFH=_J/\ ]V87_P#=W?\ ^#U_,MG,VH@/
M-QN%)V.P]NKH]'0;^T)\?#XEUA(YV-0.GK&ZWU"X13#E*@-O;;MBV5S<,+S%
M0ZC[D,7XFUO_  )<3[F/YHSG]O:_QTA8U$""[%8ES1U<&9NUS('B&<\(UO(C
MHWDX-WVW(&Y7@^SJD,<6XC"%P:XM!SUSJX [#K@&CJ?A<T?^8>*K=TU1W*K6
MGUA=U:OU9!LS-[O9**B+>BM<<<$6>R3;7EQT9 K^Q(F,MF3AF+$?P?9<?&1X
M*GH#;F%2YF59SF=S,QO-T\RAO%5K.KY3,L99)IU(:G?-%#&W81#*(0Y@?*)
M[F./ ,DDBM/7=93T>>5P&/I3BQ..ZGRW=3&/D'!_=TZ61@XN>Z3@3:#W, Y1
MM/G/L-?;/V+'TRURZ5J[7!"VQ:Z8D5B++V4:(PY1]J!(6)C2ARJ'6<S6'IR8
MZ'(N+ %]PA66?FL#*_=-8SKN<A#I9,'3LQQ-,CJ]3.O99L!O4PP/L81L+)9
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MT?=@"21"&-%7.N$EM#I,F,6A>V6^@BPCP\ZCLFC=7*C6MK@2M=MT"S[(_P
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M+NN^QGLYS=+B[5.;TSHYCANZ#*9:&WE8NO6.S@L'%G=1U7G?;C9PM, [@R-
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MP FQA\FD#OH-9&L3UB\3/?)A9<6AO$K+'H96I*<.?$K&.=[@NTQVVVYS;K"
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MYG%3UJF8UFZW8AR%26"JU]7"\'6)63.CA#N+N)D<T'B=O K\ZQ[*US#\-GQ
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M/%HV7U@[(,<;?@$XODM&%KC2F8LU$>1AZ'F?!'3U1U3!T%^.14D[(U/I/J"
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M;ILR[;XS$+;-0M'7;4FGXENBF*!:A<D8"9CA)X;9+#!\ZD+6"!"+7LT^<Y;
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M3%8<015&[?Q]Y61BJZOH^K!>S-,[>@6+6FZ$QS'R"VUN%;UB04.QPST@JW"
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M6>K&V(V].M^CMO1JF0H.-@ZPIUCE44H%EUV?2B<P+$P7J+X2=&AR1_T:*MS
MK;*HS366H3;D;"HRV5J(I\X1=+9, \UT_BS18DVMY"E<6&%/A))098/,%_YM
M%FCELR$3XDB![AJ3"5'?3*96MA3+N',H41:V?"C[4@.X^B=C;GCZ'8T#<7=_
M;7J-RKN=>NZ_*6*)5K%(BZ\LIM$N''GV UC6[]8KUE+2GI*8]S 6D1&3"CCD
M08Y/7Q6T#A$X18*-U?K4-9D741KVD"KBW -BD6P=5 4*RH%V6QS+A8AJ#L:
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M44*$(36"9Y%G'21$:9%=2]DBRD1W%ZH6!@3*!]D-)EXQYTPR%?&[*J<QHJX
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?B<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g713200g31j43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g31j43.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2*R4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
MQP   ^@          0                         !              /H
M   !QP                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !QP    !29VAT;&]N9P   ^@    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   <<     4F=H=&QO
M;F<   /H     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    (.$))300,     !@D     0   *    !)   !X   B.   !@( !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1" !) * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MCW6.D'>,=KCL_-_H57_HS?\ HTYC=-))))2DDDDE*22224I))))2DDDDE/\
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MF:-_\#_T;$E/_]/U5))))3Q%%E8Z#UX%[9^TVZ2/WRB]">W]JN&X?\EXW?\
MX)BZ*W^D#XG\J5_TQ_5;^1'5?W:/U*(/1)!D>O=Q_7*WD'$_F1\3^5&0[K3N
M5))))(4DDDDI22222E))))*4DDDDI22222E))))*?__9.$))300A      !5
M     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!!
M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-
M!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L
M!0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "<
M 3L  @    D   "PAVD !     $   "\    Z  MQL   "<0 "W&P   )Q!!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$X.C0T
M.C W ')R-3 Y,38W       #H $  P    '__P  H ( !     $   /HH ,
M!     $   ''          8! P #     0 &   !&@ %     0   38!&P %
M     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!2$U-
M "H    (  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,3@Z-#0Z,#< <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0   ^B@ P $     0   <<
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              /
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M @,! 0$            '" 8)! 4* 0(#_\0 5!    8" 0(# P,-"0P+
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MNS(W[0KHZJY-:LVR=&/B98\+9%.WU,V(B<=)JG#U!B?S5&<ET#J8",W*JX$
M3J()AU -_:*Z8M%:W?'245<^VW=^WP-=FLI*QS\;MIB7N@K,<PVGE?+P@N=$
MT XF*:OIJK C?AY_LW^*_P!@Y.[_ !2=MU8/-J+-3")A$PB81?A11-%,ZJRA
M$DDRB=110Q2)D(4.IC'.80*4I0#J(B(  =QSB][(V.DD<UC&-+GO>YK6M:-R
MYSG$-:T#<DD !%3G<_,2H:Z5<053:!=+:GXDQ:H*BG%L%>G89!RF!E \(_\
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M)\LCN!C6X'SW.:-MOT!1'5\<O5MW+B&C';EV!GGL/4?;LMWVAH)Y6M-ZYAI
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MM-VNEM%K@9!2TL;6-#6M:7EK6LXW<( R0T #DUH#1L K:QC8VM8P!K6C  V
M"D#)E<E\\(=>O3O]/Y_[<(ON$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A%Q'S!E*,G4=)-&S]@^05:O&3Q%-PU=-ER"FL@X0
M5*=-5)4AC$.F<HE,41 0$,Z:BG@JX)J6JABJ::HC?#/!/&V6&:*1I9)'+$\%
MDD;VN+7,<"UP)!"^$!P+7 $$$$$9!!Y@A:U-P\0K+3WKJWZ-%:0BA.9T\HBK
M@QI&/ZB)E/J=<+F$9!H4/XD<Y5&02 / W5?B8J2?D_6O0=>+!45%]Z,Y'RTF
M3-4:5GF/61Y)<[X'J9B1)&.8HZF3K6G/4S399"RO5EG(<9:/;?)B)W'>(W$\
MN6&D[;\)QAJK5';JF8E5:)G$GD;(,SF;NV3]%=H[;+D^:=%P@N5-5-0@AX3D
M53*<!]0S6M'TGUMNE?;;S#56VN@=U<]+6Q24\\3P,$/CF:QS=AMD;C!'-1'7
MS1'JY&N:X#<.;PN&_:#@XSVXWYY.%CENV*C,H'\2I3^(!#P@(#W !Z?'O_J]
M1[CZ0VI-<4M=!)\<QW$T@>,TG8=P)YG&/9R PNB24OVQ^@X&>TD[]_N%9KV>
M1)!2V;+=D35"(/"Q":ZGA'R!D?E!<[,OBZ>'S ;>_B  /4"B;KV$.NU?P58J
MPR:QK>"1MOJ7V]C7$$1NJ8G53R <<)<V*H =@D[C/8K!8@[@J'8\0N8&GLRT
M;_HPKP\CZ%+[(T_;:S $!::4;HOXUJ)BD]^<QRY'16)#G,4A%794S(HF.8I/
M.,F!S%()C!OCI>TO7ZNT#>[/:V];<3'#5TE."UIJIJ.9DXIFN>0T/F:US(^(
MM;UA8'.:TDJ6KH75%+-$SRW,\4<LN&X&?3C'=OOLM'U=MJU>45;+ =%PR76:
M.$S!T40=-%3MW+=4GJFLW<)J(K)G #)*)F3.4#E$"_G[9]0U.FY9+?<*:IHJ
MNED,,]/40R0S1/8<.9+$]K98GMQXS',![-E16N+22#N'$$%VX+=B,[C8[;GL
MQOV9!-[V4:E;L"O3>]OCD:L(]$JCB1D'*@]$VT='-BJOG[I0>R;9FW674-V3
M3,;TMS=?7F[.9162BK*ZID/"QE/"]WC$]IQAH[B>_<K,A965.T,;W]A+1EK?
MI2>*QO8?&>/K4VZIXE;GW<[;3FRB2NIM?*'*J=M($*CL:PMO$"GEL890JQ*D
MT<E^8=].])Y(AC^3",5P2=DVMH[H*U%J2HANW2!4/HZ'B$K+,QQZ^49#@VIQ
MY(R<%CBW! /"]F6&9I;* 0^J=QN_PV$\/9GB) ).1\WA;Z7!;<=?Z[IVKJRQ
MJ-'A&L'",2AX4$ ,==TN)2E5>R#M43N'SY?P@99TY444./0H"4A2$+ZXM5HM
MUDHH;?:Z6*DI(&AK(XFAO(!O$X@9<[  R>0 :,-: )UK6L:&M :T# #1@#U#
ML'H6;9)+DF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$4:7W3VM-G) 2[U"*FER$\M&1,FHRET"? J,LP4:R)" /
M<$@<BB(_QDQRLZBT;I;5<0BU#8[?= T89+/"!4Q _P"%51\%3%_W<K5TRT\,
MXX9HF2#_ ##?V'F/856QSP$TFNZ%PG)7UH@)_$#%"<BCMBAUZ^ IW4 X=^'X
M=3N3GZ?Y?7OFK'_@W]&#JCKFT-TC9GB\';=:AT&<Y ^,XY>'LX3*01LL,VB@
M+LF(_1ZR3A_6S^GU*+[KI]/A#\C[GTC<+JUUNML*B0V[=0VZS2-TJ]@@;Y:8
M:BN[O5W%B4?3U7NU>D)V-F@3BYA"ORT>R=Q2L.CYB!@] Z1L5AMUK;IBV6>A
MMT4-/4S6^HHH&T\[:FGIWS\%46894Q3,B<PF1G&QY:6/#<A5ZYT\NGI(KQ05
M=5X%X91P7*V5$SJBD=3UE3%2NJ*02ETM-50R3,EQ&\12M:YCF#8&?N9L]8H_
M336IU2:DJS/;?V9JC2C>RPZH(2T!';/OL)6;+*Q3D0$S24;59U-_)KT@ JS?
MG;.D3%62(8LA8XXG5QFG8V2.BI:NO,;AEDCJ2GDFB:\'9S#*UG&WYS06G8J0
MU3-.RUMIJ:5\$USK[=:FSQD"2%EPJXH)Y(W?->*=TO X;L<0X;@$9,CQ)XUM
MZQ7:<EIJCDK]5CTHR$:IQ)$G#9JGXC#Y\DB=.2D'#A4ZCEZ[D';IT^=K+.WB
MRSE914U,OVF[!J>L?<=06:VW:NE(,E764<$M0[ PUIE+.LX&# CCXN",>*P
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M[G<;&OWP.,!X&YY!V0-E5[D2U;+>R)X/$5;H*$+M*: I%$B'(0#2&VRB!2'
M2E#P]NW3MT#T],*C@@=<Q$Z&(QBIO&(S&W@;BIG(PS'",'E@;;X2"**2ZU3'
MQ1O8UKBV-S&N8TM,;00UP(;@$@8&P) VV5_>,^G]4R?#)_,R.M:(^EB0RQBR
M3NJ0;A^!P;G,!@=+,3K@8!_R@/U^CIZYW5%NM_AC3X%2YQG>GBYG'^7[>79Z
M.F>.-M4&-CC:SB X UH:1X@W:!CD3V>A5+]C@Q9,.8V^46+-LS1#5,J4$FJ"
M3=,"%O=/$A0(D4A?"7J/A#IT#KVSG<Z:G@J:+J((HOZ/6 ]6QK"?'H-CP@9
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4A$PB81,(F$3")A$PB81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g713200g31m68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g31m68.jpg
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M 0$! 0'_P  1" $  CH# 1$  A$! Q$!_\0 'P !  $% 0 # 0
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MI741C"O7'=^16F\K$D0*8=[@:?B3MHJM88F'L<8>9*OW-])_'YY%[;N4"1\
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MH2*BIPKNBI&SAL<80?Q Z$/B\BGKEPNV*-F3IJR,I/1;28!E+ED<8(F[U??
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M5\*68K YOJ)%K$XR9UCCQ,D70D\87$2AJJU:%T&NF(Q6.G;$#!3LBM,P"1H
M,C',DUM;1N=ARZG,T->+!UEE<.=4%YW^=\I=$26._P#3<',TO<W=E<,PLTM=
MF802+K:KS K+KC%\8N\('V@ZH=T:KKZDYF'CL7-]88C,B+(A#8O(EE3SZU+C
M".7.KPV,>NDDMQX 8EALFKJAINCNKJGA197;;<78]P7#\1P:JFJXG/D9B<T3
M2V61@#!2T;P+,< >$]VNW7O*,8WQF+H&^\D6@;_XT7A OPI1C\U]??\ L')Y
M_P *X+_=Y/WB;^M89;(O!#^%'[E7MX1SJ[4UDV !+PB9RN4,CXYI (8(<.F[
M*N)F6;Z)$1H=L^:YU?#VJF=VZZ>VVNFR>V<Z;[:YCNZW<_A='N=Q.I@A>V:*
M*(L<9I7 %U1"P\%SB#P7$:COJ^PWCU/XSO=O4@CS0:F2Y+/&UODU]3OGQEOU
M"6YM/L6?:.*>11>_"P>.=J@Z1W57"5S=JC:K"O/X?P?\L(S^FF7/*?M$W12=
M0KZ9]=OC-]H4RQSD13Y:;?&!?="]P?YOIC^\74/)=N$[J\)\:L_R^K5AB?$9
M_ SWK%&$\Z24.3A%*[>"1]V7T;^C?6OZ#0YR_NK[I,:\X5'74VHN)TW0Q]4+
M,*[_ .):WOFOG_U4+<Q-#QVC\JI_>L7O)VN3Q'=4J''YULH$G"*0U\5<]V[.
M?I8V;]G%,\T'V3>Z*'S73?$5:E."\4?T[^I&NE/FNUETX1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A%^9-XT6<.6B+ILJ[9>AR\:IKI*.&GK.F5&_K*.NV5$/6$]
M=MT?2ZZ>ETUSMIYVN,YX1?E9&PQ)X4'#BXQ^0"+(MC3%D_:NG@APY1]8;H%&
MJ"JB[!9PA_AT4G>B6ZJ/^$TUVT_;<(O3X1.$6$1+KE)].QF+DBD)IF+.FTZ+
MV$7LP6?ES>U+70<4,_J055%A#5(D[9#X.U.*1>4.'H^<&P6-Z\C;]A5S26N-
MI(,*MQ:VO-X-;W'SRG5?61ZLSPEV!KWL!FUW+9^UGPB96!#5QD<+BV(<-1<V
MJ]A *_D:\09R;,19R&;2&1-FAETRRB\FL[DC;#0V72:Z$OH1\[0>?O<BSAX5
M%\=\^;KMMC]W&N<X\O\ X8SGA%J!KSPE\CL=^.9#X&S!HR2)_#Z"$I$(W086
M#!<.QS1251CV3/3#YNP1]N1ITX82EE&Y W:2@$LL&3RY7T;2AF#4,A%GU8S-
MSL+G0@2,TX3;1$V%VW#@UPSMX.IM'9,4K8P26TCLK][D#6S$QOL3D?>0"YLX
M M+FDL<+Z*F6OA6B#O:P]M(,+PTKDH7 $'*2L:?O#,D&39>NV4>#Q85;;^;-
M24FES=43%U)3&(T-+;^B5P001<MMUOD810'/9]7^C):?TE.27!YC#0T,+P7/
M%FYFM!Y[+Z.)5PWO@TMY UP&]U #6EF^9G.+@PAK#F=E<XCFT*SZZE]BW_8V
M)S@N:C#B%R.!3Y6!R.*OF[)(@&(_!2*S%GH[7$R67@W_ +0C\O"&&KL+('[3
MU0B@U<Y;%6I%DUQ&(4T5+*V.(R_5N\3%A<U][@7C ;8L+7"Q/UM2#<#*44\M
M1$9)=Z-W'(Z$/#',  O:3A@AX>TW V: BQ.5G+!7BXU^[7A"^D])=W;UB4V/
M7\C(H/<;^0G(8!BT6?UZE9J<+:13,Q&KKY1DCARF'73<I#%36L4S(=?A/O&M
MI#C)/;:V![E,1J\,H*R%T(BFB$S&/E &8AS,Y;O3B#87RYRR_"RYM5$:^=PJ
MJAF5A.;>\Y#L^]Y@_)];+8G3-ESY>#FRZ+& QX6OHC(UPB<EF_:211\6I#7Y
M&'EX="UX[*)#!'+,D DQST>$3C8EJ<%B) _'1DU'8N1,BFSEW'E$W!)!]E3N
M,Q9V7,^!P&0EIGX+G,(+7']#<$.#76:6M) NW4WLVSEN8LCC:XYP'@.S,:^X
M<UO#RVRDM!<US@";.V6VU>!,[.]*KU[$W4.ZPQ261B2MJ3C:IUF7B@^-1]G%
M(M+&0H8T"),R;[9%7+N1)X7;>3T&6[5MZ'"&&WF*Q+=;N>J<'HZ>>9L#6S5+
M86B)Y=;+#*X#+D:&BPY#R#19K")Y999&R.+LL;G FY)+GLS$F^NP6TY^==+O
M("I H_'QKWW@U*_0Y@OVU7YS>_8N^P:SSO/\'0*,8WQF+H![R1<PO-DK#+;9
MX"?WLO33\MIG]DU@<BN[;N6Q?H8?BZ=7V&\>I_&=[MZE'.<TJ9+DL\;6^37U
M.^?&6_4);FT^Q9]HXIY%%[\+!XYVJ#I'=5<)7-VJ-JL*\_A_!_RPC/Z:9<\I
M^T3=%)U"OIGUV^,WVA3+'.1%/EIM\8%]T+W!_F^F/[Q=0\EVX3NKPGQJS_+Z
MM6&)\1G\#/>L483SI)0Y.$4KMX)'W9?1OZ-]:_H-#G+^ZONDQKSA4==3:BXG
M3=#'U0LPKO\ XEK>^:^?_50MS$T/':/RJG]ZQ>\G:Y/$=U2H<?G6R@2<(I#7
MQ5SW;LY^EC9OV<4SS0?9-[HH?-=-\15J4X+Q1_3OZD:Z4^:[673A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1?4OE?5!;9JFDJYU24RW276W;H*KXTSE)-9PF@Z402
MW4\W51;1LXW2TSG?5!7;7">Q%K;ZOU_?5-VW>4PN>NH\0*6H!Z]N)=.JMF4C
MG^TTM(M/;(!2%^R%R*M:_=#(-7("61]AZ)X2)O*^J*'Q,9JXE6[)TZ:%]&Q
ML>?;X!WSM]J_+URI"9PGLVV(BE-U:JK"L+^@)&0$:.*U)*)G+[-NJN)M'-Y/
M,#LJ*KWX4##X?,R[VSH_%(E&%GLQ5)MW)PY-)&PC!"=/#;EOL!]'@Y%LSX7R
MJ'LNP8[5$!EEDRYTFQB\*"NY ??++MFJ+$2PTPJ^>+N7BR#5!NT0QNX76763
M3313WVVV^+GK#$9I61!S69K\)Y(:T %Q+B ;"PYEYRR;U&Y^5S\MN"W5SB2
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MEG]? XHKM7)Z''99% TBM+,!@K@^W2Q#( F B39*'S0^W:,WF)$Z'C64/;!
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M.C%>1!!5E*W 9T1*').%'MSMD2-LP#,0( ^;+K:AXRX),FS'=X<+E7Y+_/\
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MY\W7RXUU\I:#Y\W7&<YSYN/W,>7.<^3]W.>13LE=S8\X4O4G5]@_'/\ "?\
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M8>TR$F\F0.L!P#;1Q+N$HE45K]]E ,HO*!)EG< 6QN(+8@&_HL]@7&[QF%P
M."J0W\,90'P]G$_T[3SA<T=#R0%!2Q:A;)+R&K!!02@@)$1AZXM72.^RD)$/
M$RB7HI1)@^L%T/;L3I))J-C?P>N/^!\5S2.WF@X8(;<1DQC+9H'"RFSN$[@
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MZ>;GR:&[)&&U<.,'%'L:*.K;!! \/:7.DA@:) 8P<[0+:%P /(I3@\T;J<0
MG?(\SG"QL YY(-]AV\BZ:^:X674/]V[^5AV?^D/=7VDR7G6.%?9>&^04?P\:
M@D_;YNEDZY6/'+]>2[7_ !1'^#G?7^>^MO\ P%X\TYV5NV8'XF(]:B4@P+_\
MK_ _^Y=DRF<ZI[[8_=UTVSC_ ,\:YSCFHE(%$:7A<'8GPAW8B8W'8S@'*K7D
M@0<]EIU).(UM$A<<@4<%QIJ6-D2+N/PR*BV(D8+8KE2Y$:T=$UVC;*ZI(DV0
M7ZKHZ3#\ H(J2G#XJ6.1S8HR9:B5TD\CI"QC6B2:5SG.<X-8UQ#0XV#6DB#2
M22U<KI'6<]P!<=&- : +DDAK0  +D@7[Y5CLU%8.EAK58X!H,9JV]84<,B1V
M.C!" ]L$WDRI]:6D"S:()17,9TS)D9=N=UC#F.;)'FQ=40NB\4O?I=.:<50>
M70FUG,9(]Y<7[V(Q$UAE,N^'>C#DWT27C+ \%J\][>'Y"+.YB0!:V:^:^7+E
MX6:^7+K>VJS#Z27-V&Z"]UZZ,P=<1$+&*$H;!"RKUI&)T((5[;KF(E/7@KYL
MN:CA89*8F2#FXW*03YZR>B2#(J(?KM722V^(QJCH,<P:H9.'RT[6S3M ,D#V
MU%()6Y7M(9(QT4K7LDB>UKFO:YCV@@A>]/)+2U#2VS7G*TWLX%K\IN-H(<VQ
M#@2"#<%2OG.7E-E&.>&OGUO7AX4N]*AE-DE3X"$7&I :E$SV8Z,856XR5-8K
MAVT'OS[U '#8VJ0PV?FGBJS(:U2;[/WRNB2&RFO2&XV"DHMS-%5Q4[8Y)J3?
MZI\$-YJAT1ELYS8VE\T@;=K  7$FP%RH?B+GR5LD9>2&O#8PYW!9F#;V+C9H
M)U)T Y= M55FU8^K3,0=YE$5FT<GT:<RN'RZ&[R34*:$L)5)(22SJRF,:A\I
M'N!\GB1X8L@7C@_T^&B;\?L\&.V;U>3TU2VHWT;W+#)!((I8IM[SL<8HYFZQ
M22Q.#HI8W@LD=;-E=E>'-%D]A9EU:X.%VN;>Q ):='!KA8@C4#9I<:JLIA7M
MP=4)?2LR5.XAMA%XK%;XK\I$3J^DJ@;II,I$+ [DG39)LK&)_')+!GCIX*07
M6(1MZDV:$E&1UJ1&#_&&HI,4BK(0S?J=LLM#.V5@,4X,,;I,H)(E@DCF :\@
M-D:26W86N=]%LD+HW7RN+1(TM/";PB!>WU7 MO;:.6QN!*B>#VF$IL'H?TTG
M<XD!:63.9=7Z,E$KDYYZN2-R&1':VCA(R:+D'.ZCA\2)D'+AX]=K[[JN'"RB
MJFV=MLYYS)CT44&-XO!#&V*&'$JV**-C0UD<;*F1K&,:- UK0  -  II2N+J
M:G<XESG01.<2;DN<QI))YR3=<7?C8'R_:-^A[#?MIO;FX.Q=]A5OG:7X.B4?
MQOC,70#WDBT6W%$*PCU4Q-^UA+NM[#+$(F]B0%]+'TBF$MJPA#G[T[8UK!G"
MFXR$O9))=XN3J,8#81GVS RY<F_#F12,3G$IFU)+4R54H,PJ*=K91+((FQPQ
M5+96M93TKQPIFQQ[ZVJ>]TF2=C&M>QQE@BQLC6!C>"6/):6C-=Q86\)SQL:2
MZQC #;M))!&5SOSR\37;/K#!Y2[K0'%+,F\YR-AAD+()TN^-UY78-R+L"9R<
M)))29!^CFD^- P\2?1H6(&H%(#:0[U5/5JQ0:UB?4.Q*>)M2^6F@AS3,?'
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M[Q#DDCWF+>Y7/=*S>V9)'2&[W2-M9[GG5Y<"7';=4S.N#F==H :;FX V 'D
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M-BK''OK@P.:USB&MS9]238 9&.]=@MQWB^$ZL.O?"T4E3L3MF09K2:'KG'V
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MI:>E:QN\QQ@\&!O]EK0T,:& M<^1++ON3@-:6M<"1F.8ND>\DYB?UO#>YOL
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M;G9)*6>:GD=5T\3GPR.C<Z.02!\9<P@ECQHYIT(VA9+"HV258;(QKP(WN <
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MN;^F(X_.3NCYZ+]V']:?D:DYY/VEN!Z?]%'W1^C@77NC[H>I5['2\C-CM);
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MF=2C]3?I2II[+][77_2_KT*I QVFOL5?Q00[;F4:R:V=**M^%[2*Q9UU]PZ
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M.%8-X;FAO") &NMQ;:OD/838.:3S!P)]%U:Z)]N*0FDZ:UX%*S5(T3L&R:I
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M?N^3&<X\N?\ QQ_W\(K(F.Q53!*/CO8MT=*NJGEP6M3T8,AH?,3QHZPM\G&
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g713200g36d33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g36d33.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19"4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M%   !SH          0                         !              <Z
M   "%                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "%     !29VAT;&]N9P  !SH    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   A0     4F=H=&QO
M;F<   <Z     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    %.$))300,      NT     0   *     N   !X   5D    N8 !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  N * # 2(
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3
M #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H "W&P
M)Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ
M,#<Z,C$@,3,Z-34Z-30 <G(U,#DQ-C<       .@ 0 #     ?__  "@ @ $
M     0  !SJ@ P $     0   A0         !@$#  ,    !  8   $:  4
M   !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("
M  0    !              !(     0   $@    !.$))30/]       (
M      #_X0%(34T *@    @ " $2  ,    !      $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@   /      0   \     !
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q,SHU
M-3HU- !R<C4P.3$V-P       Z !  ,    !__\  * "  0    !   '.J #
M  0    !   "%          & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M8^/"5%DRD&6+*,@2+(QZ R6'7AFDO-^(H4M\(G")PB<(G"+H2,7&2[#0TM'
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M&#5?*]S-6$/; T,<2UH@;)*V( =8)9 VP<0;J_H4LP)L1S=,/O:$%VBHV\6
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M322:0;?,1F =H(.W?GD=H-B"" 5Y->6$N&KV+V'78Q[;2,<PY2-<T. <2QX
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MX1.$3A$X1.$3A$X1.$3A$X1.$3A%J4ZS<6*W=0U)ITU<&Z1JRM1$?<"TRI3
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M*BGR!TH(3$20F52#2B<<<>==K8X)C^S]=R+.6,MP[X"FD^L1C4@EV2E\@%K
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MO)Q!]N;(E;(/:"<)-;A1(W+>#AD--HS%]TC94G*E.9\S%^.4#%QI?2Z9.IJ
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MOX^A2MZ4+ZP]Z-?_ #S2/\2MYY;:&>^IIW\7B/[VH?8IKQ_(N$7_ -)AZ/\
M$2^WR^%9E_J?#ZV#N?[]^QOS)UYS"<IOO@:._(*']X5RL7]RFDEO^QJ_+^11
M=&>W/+/);@^EC_""U?Z&9^7_ .VM=_T_8^+'PZWR@^Y:#Y3)Z(<>=:QR8=L,
M2^21>E/&W[/#UZ+7Z\GICY/G[;7_ &_8.P>WZ?M<[CIU[W^+[.U-'Z:CV=Y;
M+AW;&C^5>J15/TYGUUW=W^7T_P#B_L<4OY/?RGDR[A<$^+KOWC6*K&>V%?\
M"9]7A_AWE[=.I//]1:]^//LAS_X87;W_ &^</T$_K?HZH9YIKK7^4_\ 381\
MGJ?20+%[K]^MYQOW5T[\N2?-RY+_ 'W:WQ?B'U>E\/G6A\K8_,AAWC+#!_\
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MY"0)"0R/&(:4YZV1; >$3A%"]K^GCIW[D]N_PZ^X1:G-A:.W#(=6<Q; =:W
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MWD<-R_K+#=H_XJKR]H6(_1Q];2](/][[;O\ $I(\V'E?]\C0#X>'_OEJLO\
M!O[C--/&1_=C>,UIK_4SWU?%V_!TN_YWZ^Y7RR]R$7CJA^K5R[G@/;(?)9_V
MX%[Q^?*ZWA:G_22[0O>MK+IB0H^Q+Q4O4X794S8X6KD5X4:1KSHL%3RYP,2?
MW'J,>W7BOOW 4NEU%WYL&'9/&)=$.*9'#.E$6RS75XB-ET2I7^"9DA8BWP,=
M.@BS(S8<N(R>.A[(<F*P^4.R>(O*QRT#%%"X?:7D8DAC+;RR*].$4&VCZH;3
MWWM=V_EG3G"*<N$6)-SZ%.E#86P9':EQT]#3=_EI8*<D+&_,6EDDF5CFQ&@C
M%#B3HX*5L-@BH2AL5#6<,I\:%=U>+3J[0#1#$L1EQ:NP6"HQ":5D\M0Z>K:Y
M\K&L:QY8RH;&"T,;D& 7%R+DWVVBTZTKP[#H\*HL8F@H(8GPQT[8:5P9%(Y[
MGL#WP.DLXR/-R\D:V1&5O/QZ4G1.ZKKUM7"PT[4NQK3!2T501HN7@*;/R\;(
MD1M.B_:# 1H ! Y3H7JI'K3;+BUL>2[AW"? KM\[<J^CN/XAIS7U5#@N*UE,
M^'#@RHIJ"IGA<64<(>!+%$YA+""'6=D00<UWWDOQ[ Z#0S#Z>MQC#*.HCGKM
M>"IKZ:"9H=62O871R2-> YI#FD@ W!!._;MU44.[6"^U\J#J%FEQ6:#70W28
MR#D36&BF7I/+HZW1AW&T/M8<;RXTI6%H\:?$G'?'?L>EF'U]1B-.^GHZJ=@P
M^F871022-:]KIKM):P@.&1(.RXW67)]%,1H*>@J&3UE+"YV(5$C6RS,82QPA
M#7:KG EIL0#:QW9K4CZ9P<@78W36*4RX,2-T\PS! Q",LOL/LSLFVZRZVO"5
M-N-+2I#B%8PI*L93G&,XYQSEO#F8GHNQ[7-<W1FF:YK@0YKA43AS7"UP6D6(
M.PY+JW(V6OPW21S'-<UVD=0YCA8M<TT\):1;:'"Q%LK9K/)_ZD7H@^3YRP'O
M_P#55>YT$]QF@7B*+T-*M(B[K=./'+_35"QG]*1COT<=(><?%;[OW[_YH3CX
M\_!VQ\/?[7R8U7E8/\R-#!_QE=:UO^S>=GV+8N2_/3#3#Y+1;?C&\>Q8X;(^
ML]=/GX4-L^/X\Q^S/CYK.)^\MH]^ME1Z'$MRV/#<^5_2(7_S6I#<G+*3"KY^
M7+O+N5;&<^AKV;CO_P!]-"_'C_[+4,_#_L_V\JI/>3Q3];(,K?\ <I-RHJA^
M>+#!>Y^]6?/POK3ZUS=.N/[D]UOX[_\ =-UY]KWRFO/@^7][E>C)_-!I\?\
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M *@%W[^K-=\YSGOX?CSE6<_MY4K/X\\)9/9X7?OZLSW]_O\ #\N>_P##PH
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M;_U-$VVYU[71"T)6G'3M=%XQG'?'B;N.OEH5]M*DI5C]G&/DY/+*!]Z$-O\
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MJ,JRRAMMIOJ_JR4-H1A*4(3L.#2A"4X^APE.,)QC&,=L8[8QCY/+%O?<FO\
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MJ* V)3WK2[&DV>-Z<9T&L)G*S*UR<S=((:ION#*DTS)H]92,E_!S;S$F-AX
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'1.$3A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g713200g37e21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g37e21.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1_84&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/T
M   2 #4    ! "T    &       !.$))30/W       <  #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             "B
M L@          0                         !              +(   "
MB                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MB     !29VAT;&]N9P   L@    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   H@     4F=H=&QO;F<
M  +(     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MM%EA.YSW!H;ZKW_G>HP-?_Y@DIF[.>.KBCW>AL-9U9M]7V6M_1_TC^;?]/\
MF_\ @_\ "*SFVBK%L<2Z2TM8&?3+B-K!7_+5')9CM^L.+D0SUVT65.= W[+'
M5N;_ "]GJT-9_P!<5[-979AW-M;N9L<2..!ND$>YKF_FN24MT^[UL*EY+B[8
MT/WB'AP$/]0?O[D)N8T]6LP_6;[:6/%&F[<7/W.GZ7T/3]BCT&OTNCX=)DNI
MJ;4\DR2Y@V66.<?<YUCV^IN0VTL'77-WN+6TB]E6FT/+K:GV?1]3Z-C_ ,_T
M_>DITTDDDE*22224I))))3__T>[ZAD'$ZNRT,LM<YC26@P#6/4WBEK+*W9/V
M?])?96_'R=GK,_25^JMI9E]3OVQ78VROU"T ,(+BU@W\LVOV[W&_;<R[$_<_
M6/06BY[&"7N#02!),:N.UK?[3BDIDDH574W!QJ>VP-<6.+2##FZ/8[;^>U-7
M?1:UCJK&6-L!<PM<"'-$!SF;?I-]R2GF.K9M>+]<NE.L>[:69@>W98 UGI46
MNL]2U_H6M;]G_P"TU>__ ,%75KF^MX==WUHZ+9=-WIC)LK8Z(9/V7&?MV-98
MYKFW^]EK[&+I$E.5]77$8%51Y--%S1_)LJ:#_G7U7N1.J-<ZQNS5[,>ZQ@\7
MUOQK:_\ IL0>DEK<7I5C3++\-E4CNYK&74_]!N2KMD?M*@?\!=_U6,DIL;FO
MKW-(<UPD'L00L_H_L9Z79]-%P\MU8HVC^K]F_P"FK'3],%M9YHW4_P#;1=2'
M?VFLW*OB^QO3;.UE'HGXEC;V_P";]GL_STE+=3)%Q>/\#0;H\?2LJOC^UZ:N
MYDG#OVC<36^!,3[3W0GM#NI-:X2UV.\$>1<Q1QW./2MKC+ZZW5/)[NKW4V?]
M-B2F/2][-]+_ *193;$R '5BG;_VYC6*K9DLK^M==9X?A$/?K#'>JST&/]NS
M]/O?LW6?F?\ "L5MGZ/(PW\"VHU'S< VZK_-97D+)ZS795]9,+*HK?;%8;D5
M@M]/8;&!MKJWV4>ID,L]/T/YW_B?492DIZ1)18]MC&V,,L> YI\0=0I)*4DD
MDDI22222G__2[W(NGZPTUL(#FL:'M&S<&N]9S7/:#ZMM=NU_I_0^R^C99_AU
MI9.,S)J%;^ ^NP: ZUO9<SZ4_GUJADD'KM#7!P+6--9WEH)(O]3:PN-=OYGJ
M^RJW^:_27,_1K524YHZ)4<?[/9=::P;X#'N:"W(#VN;:S<^NST_4_1>WTZ_\
M'4HX_0JJLG[6^^Q]KJK*GAL5M_3/9=8ZGTQZV/\ I*_\%?\ G_I/4M]ZU$DE
M/%=?PLIW6ZL?'%MX.)G[<=UUP-H]+$C'KR+#^A>_(<QV]EWYGTUUV$XOQ*GE
M_J;VAP=J='>YGN<&N?M9^?M]ZQ<FO;]<NGOV.;OIR_>6U@.TPOHOK_6'?1_P
M_P#Z31^G]3M%MF(*0*VY ;CO<Z-U%@%WJ!C&V.K])UGH55V;/4]/\RSUJJDI
MLDEO2L6_O0VFTGP: UM[O^V'6HUG_*F/_P 1?_U>*GQ:F7=+IJ?JRRAK'#R<
MP-*KXUK[<G"?9_.?9KA9_7:_%9:/^W&N24V*/9DY=7B6W#PA[?2_\^8]CE7^
MCT;&N_T%=-Q/@U@8ZW_P'U&JQ=[,ZI_ MK?6?-S8MJ_Z'VA+"K;;TNBMXEKZ
M&-</(L *2ER!^T6GOZ)_ZIJ$WV-SZ> TNL8/Y-C-Y/\ :O\ 74<%[K+*"\S8
M,<ML/\MCA7;_ ."-<GS#Z>18X<78SP?C4=U8_P#9BU)3+(]N#3=WH-=A/@T0
MVX_]L.M5+KF(W+-K30,AU0Q;F-(!@U767;O>6_Z/](W_  C%IMJ;=A"E_P!&
MRK8[X.;M*J8>07/=D6R7#$J=: ).YIO]5H:/Y8<DIT&/:]C7M,M< 6GQ!4ED
M_5S)?9B/Q[#N?C66-:0]KP*O5M;BUE]0:WU*\>NO>W_IV;UK)*4DDDDI2222
M2G__T^^RGVU_6#&#"&MNJVN:0X%^TO=["S]'=Z+7/W^OZ?V?UM]?KVW?H]=9
M5QL_;++JMOI-#:,AT_GPZUE=FYPV[&Y#'T>C7;ZOK6>OZ7Z-:J2FL[J6 VPU
MG(K#VV>DYNX2UX:VWTW_ +CO3MJ=[O\ 2U?Z1/1U#"R'MKIN:][FEX:#KM!V
M./\ 9<J^7T3"RWO=>7EMI)M8'>U[7-IK=2[3<VO]4Q[?T>RSU*_YST[+*T]'
M1L:JQ[W/?>;0[UFV;2'O>!7;>]K&,_265,95M;^@]/Z%*2FEFU-9]:^E6 N)
M?1F;@7.+1 P_H,<=C/H_F*'5\(X>57G8P>'9654V[T?28XET8V/Z[GLW78M-
MUC\G_"7>H^S_  -ME:K''JH^NN"*FM8ST,R&-/&G3_\ ![W;/^VZUM=7:'45
MM<X,'J [G& "UKWL<X_R7M:DI-T_=]@QMT;O29.V0)VCZ,JG1%?6/0D#:S(>
MQLZEMCL2USX_=]=UR-T/+&;T?"R@ TVT5N<P'=M<6-+ZR2UCMU;O;[F,52[[
M4WZR56,!AU#JPS9+75A]#[+W9'^#?4Y]C?1_/_ZY^A2F_GPVNN__ $%K'_ $
M^C:?^V;;%+ !;@XS3H14P'_-"AU9CK.FY-36[O5K-;H:7PU_Z.VSTF^ZWTZW
M.L])G\[_ #:AT5SSTO&#M6MK8UC]IKW-#6[7^B[^:_JI*1XSZV=5NQ=P%C&.
MM#)&[9<YK_4V_N_:/M#47JK1Z#;3Q6[7X6-?C?\ H[>JWH9 ^L/K N ?3!=O
M'I^DPZ5_9OI?:/6M>[UOW/\ "_\ :9&Z_6^[HV90P[3?4^HV$%P8'M+/6V5_
MI'^ENW^Q)3<HTHK!YV-_(J.":V=4S,83OK:RPR'06W/ON:=\>G_.NN9MW?F(
M_2K'V=.QWO$$L ! +00-&OV6?I&;V^[8]5*L.QOUAMR9 +J:_4LWNE]8.3Z.
M/]G_ )EC:K+76>K_ .E;4E-;&M.'U!M;*K*Z;[\BS)+&-8P/WOJI==OVV6?:
M:OTM;Z/^XWK?S2WUF=3PJ,G,Q"YC1>S>ZBXMW&M[6S78WC=L<?\ J_WU=Q,@
MWU;G-V6L)9=7,[7CZ3>WM_/K=_A*O3M24F22224I))))3__4[_(LI9]8,:OT
MZA8^LN]0M#K"8L9_I:W4;6MVLN]#(]7U+:?T2UEB7WV/^LM%&Z&5M,,$6@^U
MUGJN:P.?A/\ YRGU<G]';6_T\:ZNVU]=NVDI22#D9>/C>GZ[M@M):UT$MEK'
MWNWO:-M3?2IL]]OL_MH5'5,+(?Z=;R'P7.#V/9MV_399ZC6>G<S=O]%_Z7T_
MTO\ -I*<S+;8/K=TQS@0PT9FTETCC"_P>WV?1_>6CU.MMK,>M_!OK,CD%LV5
MN']2QC'K/RV4?\Z^E6UP7/HS=S@9G^A#QV_FL6OD4&[TB'[/2L;9Q,@3[/[6
MY)37Z)2*^F8SB2^RVJNRQ[H!+O38SZ+ QC=K&,9[6HEC7_M*AX:2P47!S_S0
M2[&+6N_E/V/_ ,Q'JJJHJ932QM55;0VNM@#6M:-&L8QOM:UJFDIC8"YC@.2"
M!/BAX==E.'15;'J5UL:_:26[@T-=M<X,W-_L(R22D7V<'*&3O=(K-89IMU(?
MO^CZF[V_O[%*YKGTV,9 <YI#2>)(TF%-))2/'K=5CU5/(+F,:UQ'!($:2F&.
MT9+LG<[<]C:RW3;#2]^[C=N_2(J22D;Z*[+:[73OIDLAQ ]PVNW-:=K_ .VL
M;K;<NGJ.'DXM3K!OU8QH<7O%=[0YWJ%K*?0J+_?['W4V?X2ZC%Q[=U!NH]6R
MA^\M]"PV0 #NEEE.UV[_ (W?[4E,J;ZKZQ;2X/8[@CQ'M<UP/N:]KO:]COH(
MBJW8CQ:<G$<*\@_3:?YNV!MVW-'YVWVLO9^DK_X6K] IXV6VXNK<TU9#/YRE
MWT@#P]O^DJ=^9:S_ ,^>I6DI.DDDDI__U?4/LV/ZIN])GJDR;-HW2!L^G]+Z
M'M14DDE(K\:C(:&7,WM$G:9CW-=4Z?WOT=CT"CI6#0XO8PN<YI:_>YS]V[Z=
ME@L<YMESVM:Q]S_TGI_HOYM7$DE/,/HII^NV":@UNZC,]K8TTZ?^8UWM_P"V
MUTZP<NM[?K=TU[A#7T9FT^H]TZ8?^!?^BI_ZW_Y-;R2E))))*4DDDDI22222
ME))))*4DDDDI2SNN=)9U7#] AA>)+?4#BPR"TLL%3ZGNK_.=7OV/V?I%HI)*
M1X]1II947;MHB>!\&_2]C?S/<B)))*?_UO54DDDE*5"CK&+=M):^ECJ_4-EH
M#6M@"QU5ON_1VLJ?ZC_S%?0*\+$JM%U=366!GIAP$0V=VT)*>>ZIU/H6)]9.
MF9UF5BT5NJRVW9!>QH+B,7TV66S])S:_9O=^8M#_ )X_5/\ \N,+_M^O_P F
MK]C3]OH?N: *[6EI,.,FD^UGYVW9[D9E36/>\3-A#G221( 9I^[[6I*<K_GC
M]4__ "XPO_8BO_R:7_/'ZI_^7&%_V_7_ .36D,6D8]>,)].GT]FIG]$6OKEW
MTG?S;4-Y:<^JP6,VULLI>W<-WJ6&BRIFW^I6])31_P">/U3_ /+C"_[?K_\
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M22^54DE/U4DOE5))3]5)+Y5224__V0 X0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,C Z,#4Z,S@ <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0   LB@ P $     0   H@
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.3HP-SHR,2 R,#HP-3HS. !R<C4P.3$V-P       Z !
M  ,    !__\  * "  0    !   "R* #  0    !   "B          & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
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M 0$! 0$! 0'_P  1" #/ .0# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M      @)!@<#! 4* @'_Q ! $  !! ("  4# 0,* P@#   $ @,%!@$'  @)
M$1(3%!46(2(7(S(8)#$V-SAW>+:X,W:U&24U.5%A=;=!M,'_Q  4 0$
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M&%S,UH':\*$U,R141&IS+4N8CGB"CPHF<):2(,2\6VVU&$9*>8;$4L5#ZBV
MR.O/.5SL;:(4H1(.-H:AJEX'8#6L@$BTZUG3J=L YPI3 JGRL0-RT_%L$.C#
MNE 1+/FRU@?VT!M785B@JC1+A9K-*@P=?@ZW,R,O+R3Z!@@ A@'UO/OO+SC"
M4IQCR2G'FXZXI#32%N+0A05W^$#LUF[=%M'5.1<9#MFL:<U3)"!7 W"LGL5J
MMV"R4VHS^8V[0L'(FQ\^/49!#4S$L&U[,O%SE?'DG)>NS8806@<!P' <!P'
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M]$,59K3NN2Z4;*R=:GJM&VZ.EYU]HB=G%71O-M/GIUYA@494W.R4T9+R^!!
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MA4GX>^-?)[_^*1C6.OB=8U+Z=T;^)4BM82FH'A"OV4;&^:5FD2\!6C0L'/\
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M5&QLGC*OEWM=TGS4B$^IE +\\^Q&XQ\45@9I&&L!<UP' <!P' <!P' <!P'
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M%27DD%X8QI@AH,GV3X+'2PJJ.-:ZU_MP&TYL%*<003W,[D^UB!8NE??N3/\
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M2!$=S.Y/R!)9A-C^\G7_ &=^H-])2G:]['S"2&OW#GQ&V,>_[H2'ZG]9=/\
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,@. X#@. X#@.!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g713200g43c34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g43c34.jpg
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M:A\-6P%[C"[XQO+8K:5('X;1$5*4U$5:5I5=JN'4I]M<":A*Z!^0
M
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M&NC.W9$)#E!!:E%"[9E,B-R7'EEH2-4+(KP+4*"S%>2=)@>I*"G;3CYC=H'
M
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MRQ,#4P1V0V)+L;-L+<$T%0DGXF5ZCS'-6FI]B4V]6FS^6$F- X
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M@5J"%>L3CS80\O/?*XE*W]P0FX&$]^=]YZZDIS--05$V&J]JBG<@'Y
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MLI1(W5IU.9M%>3FC:QRG&=)
M                                       #"K$GS!6$.>)O)=5V;8T=
MX$%HFI)DX/+R\/;HB88W'&)OQR+U7O\ )Y$Z-4>84.II.*QW<T2;,\C W(W
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MD.4CR;TY*3 <-Z@
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M7"J)1%4F-$,*V
M                                              $6._[?79>TV;0.
M,P:*060(Y5%5KZN/EB9_/4IU*9W-;\"DNK._-!6)&11>F>6AQ1QG=-===#-,
M?\(L%VUW<IMI+YC%S",F$,W!QCN&=LP34,RPTPVY1ZK3?5X=^JM56B:%64IL
M5PDQMW;:966C8&&@86!?L14*V_;:BF7[33+3+U7:(QU%^Y1&:)5:HJUV3@3Q
MS>X3S:4U_P!OF_\ O44G2(LSNM/?^R7] /"Z;\_W.D__ %QO31XYO<)YM*:_
M[?-_]ZAI$69W6GO_ &2_H TWY_N=)_\ KC>FCQS>X3S:4U_V^;_[U#2(LSNM
M/?\ LE_0!IOS_<Z3_P#7&]-'CF]PGFTIK_M\W_WJ&D19G=:>_P#9+^@#3?G^
MYTG_ .N-Z:2)</O>U8V[=XL]NG<7A,>*A#;%EK;G$D[Z08J,?53X0IQ7:O#X
M[XY8%8MA.I'<,2,M,C#>Z9&::X:83"\NP$KL4XE#V71D?%+,'L8[>I&M0[2,
M)#L0[3"N^H0[A455>M:+1*UJ)2F&M L';*86J>S)W'0T$X2"=PK;M81E^RK2
MOVG[+2-]6?OJHG4V=#H=#JK6N"DFXDI2    K%<8+E5LO,]$>L4T&MKC\37^
M7(W-8 S=>UC.XR1"YS&D5@L1,     "PKP5O)_>GIC$O4CF,RW]ZY6=WC&YP
MY+Y<[K?.M^0O(O";,0$L@
M                                                      5UN-)Y
M6J;YNG;K*H&H+AM99[E1SFC!G^^'7649/>YRT0P"\$?     )QN"C])]P7Y#
M7?K"7#/E_G6=FM\S/DH(M-S?7,^\!+^4BBP$,U%W   "L5Q@N56R\ST1ZQ30
M:VN/Q-?Y<C<U@#-U[6,[C)$+G,:16"Q$P     +"O!6\G]Z>F,2]2.8S+?WK
ME9W>,;G#DOESNM\ZWY"\B\)LQ 2R
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M+$3      L*\%;R?WIZ8Q+U(YC,M_>N5G=XQN<.2^7.ZWSK?D+R+PFS$!+(
M
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MOF9\E!%IN;ZYGW@)?RD46 AFHNX   5BN,%RJV7F>B/6*:#6UQ^)K_+D;FL
M9NO:QG<9(A<YC2*P6(F     !85X*WD_O3TQB7J1S&9;^]<K.[QC<X<E\N=U
MOG6_(7D7A-F("60
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MH]_ NI<^@VG$&W%J\>1##Y&D9?.'.@1EETPJ*JOD:K54HRJ4PX)$1,#WX
M5UN-)Y6J;YNG;K*H&H+AM99[E1SFC!G^^'7649/>YRT0P"\$?     )QN"C]
M)]P7Y#7?K"7#/E_G6=FM\S/DH(M-S?7,^\!+^4BBP$,U%W   "L5Q@N56R\S
MT1ZQ30:VN/Q-?Y<C<U@#-U[6,[C)$+G,:16"Q$P     +"O!6\G]Z>F,2]2.
M8S+?WKE9W>,;G#DOESNM\ZWY"\B\)LQ 2R
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ME\N=UOG6_(7D7A-F("60
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M$!+(
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M>"MY/[T],8EZD<QF6_O7*SN\8W.')?+G=;YUOR%Y%X39B ED
M                                                     ,;F4E30
MR(2J8+$RA8CBD;?)*J2)--,E:I,Q-BIT/3)<<O\ #JH/*2Y%$Z:_PU,RQTU_
M@ .;:%MJUY++4T.MDRO'%=)*.KN[H^NKB/R%@0L>$K<GMJD,+>-7^8S#)_\
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M\8W.')?+G=;YUOR%Y%X39B ED
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MX<E\N=UOG6_(7D7A-F("60
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MFB0   @DXVGS/;9^)MS]JM!HFX'YRU7>27TIJ1&^7Y%G>^FOFEQ D-'D-
M  )=^#/RCK$YDGGKW7XB=^V*LL^L$/ZNF95[H,89AD9]GT"641E,T2   %=;
MC2>5JF^;IVZRJ!J"X;66>Y4<YHP9_OAUUE&3WN<M$, O!'P    "<;@H_2?<
M%^0UWZPEPSY?YUG9K?,SY*"+3<WUS/O 2_E(HL!#-1=P   K%<8+E5LO,]$>
ML4T&MKC\37^7(W-8 S=>UC.XR1"YS&D5@L1,     "PKP5O)_>GIC$O4CF,R
MW]ZY6=WC&YPY+Y<[K?.M^0O(O";,0$L@
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M?     )QN"C])]P7Y#7?K"7#/E_G6=FM\S/DH(M-S?7,^\!+^4BBP$,U%W
M "L5Q@N56R\ST1ZQ30:VN/Q-?Y<C<U@#-U[6,[C)$+G,:16"Q$P     +"O!
M6\G]Z>F,2]2.8S+?WKE9W>,;G#DOESNM\ZWY"\B\)LQ 2R
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MA7@K>3^]/3&)>I',9EO[URL[O&-SAR7RYW6^=;\A>1>$V8@)9
M                                         (O]N\+E=<R:F7)=3TU;
M'VG=N5CU=N"D""*)4A]KW)-;.HQ>@F#(Z9*$9=II9$XQ6V[:62M,K<<8PBG"
MPAY-;)=(W]@3CM?/5-FB84IYN#N'GN48CCS+KUE[SMEFIB&(QS<K&8W3S-5\
MM1+K]QL24MZBQ9/.[64->L?D"*W7..(<X#7S*Z.K>V01PU?)'@_/A[1!:M'=
MK#JTPU3!M8.ULK]G=ZLVHQ<ADBD]D)S<O9Y-9-D'SB;,^5:R:J(PSR'"!P*%
M)&F!127MK8^F19MBD-C*,Z2+"\\Y7*B9-(LB&3-QSC#$.+_C4_*IU(!P
M APXS_D0JCG5SZHOXN=P^,,YR-^NAB1WP:RRO*GZ2(*XPU*9[     )+.$WR
MP&/T%G/JX@2B^?$B(RC+^5:*-=9C8YWC&^@R6G!CXTT   $$G&T^9[;/Q-N?
MM5H-$W _.6J[R2^E-2(WR_(L[WTU\TN($AH\AH    !+OP9^4=8G,D\]>Z_$
M3OVQ5EGU@A_5TS*O=!C#,,C/L^@2RB,IFB0   KK<:3RM4WS=.W650-07#:R
MSW*CG-&#/]\.NLHR>]SEHA@%X(^     3C<%'Z3[@OR&N_6$N&?+_.L[-;YF
M?)01:;F^N9]X"7\I%%@(9J+N   %8KC!<JMEYGHCUBF@UM<?B:_RY&YK &;K
MVL9W&2(7.8TBL%B)@     6%>"MY/[T],8EZD<QF6_O7*SN\8W.')?+G=;YU
MOR%Y%X39B ED
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M+$3      L*\%;R?WIZ8Q+U(YC,M_>N5G=XQN<.2^7.ZWSK?D+R+PFS$!+(
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M\%;R?WIZ8Q+U(YC,M_>N5G=XQN<.2^7.ZWSK?D+R+PFS$!+(
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M8:E,]@    $EG";Y8#'Z"SGU<0)1?/B1$91E_*M%&NLQL<[QC?09+3@Q\::
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ME9W>,;G#DOESNM\ZWY"\B\)LQ 2R
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M*VPTHAR2IE1!ZEO..*T/))7$%&9&I#32<L3BBU&)>9A6NAF.FN&NFH ^T
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MB)@     6%>"MY/[T],8EZD<QF6_O7*SN\8W.')?+G=;YUOR%Y%X39B ED
M                    C*1UX^H;\;%F=7R3.S&C=G8%P2*XB(:JS:GBAG6E
M9G'8XD(L75)@V/.I3<Y0FER:NT>#92B?8ZGEOQ4+BK,WRS4=V%[B<-?\\/;H
M>9+H/))7:$N>&^J98GM2PMR&U.XJ>LYZ@2WL5[14*BE#XVA%W^Q.]C$]=*TI
M$5W#1EUJM6]H'=^66PM(;6=T0SJ1KDX[L)AV%1>[]FW@P]KM'L\/R&6C7;<A
MB4Q87SNB2EJWPMN42^I&&M'CY12)8]Z3QACLF:F9L<+FBZE4N=90MG[N\6/H
MI?W@]Z26M,%DQ>DD?'%6O#J;%/;_  E"2\#@    !P;Q-N0_=O\ IM_=V BC
M72_Z@R#[U]23(\/>1B7.?N[UK E2D;2,K@    '2.SOE5[=^>& ]8D \K;G$
MVT^0YEFKP]%9'&B096@>78+FXPB:^   "+_BY\DK7G.AG],_"N7*8ZIDF/\
M2AR:WK8J_>4'Z+\J[C7AFD     [=X<7+4HS\UEG]OI:)_>GB%:'P,%ZS@CV
MEWF.4E\)%^KXLMUC$YJP   (<.,_Y$*HYU<^J+^+G</C#.<C?KH8D=\&LLKR
MI^DB"N,-2F>P    "2SA-\L!C]!9SZN($HOGQ(B,HR_E6BC768V.=XQOH,EI
MP8^--   !!)QM/F>VS\3;G[5:#1-P/SEJN\DOI34B-\OR+.]]-?-+B!(:/(:
M     2[\&?E'6)S)//7NOQ$[]L599]8(?U=,RKW08PS#(S[/H$LHC*9HD
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M'QIH   ().-I\SVV?B;<_:K0:)N!^<M5WDE]*:D1OE^19WOIKYI<0)#1Y#0
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M$?     )QN"C])]P7Y#7?K"7#/E_G6=FM\S/DH(M-S?7,^\!+^4BBP$,U%W
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M8^--   !!)QM/F>VS\3;G[5:#1-P/SEJN\DOI34B-\OR+.]]-?-+B!(:/(:
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MA1RL^-DR>!16=LT!E*=%W\L3J$\BC+H0ZH%!K:[EKV_+O8#E?:B&Z
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@D2I6N*41Z.-9S<6N7H&S-&VKE:0X<K[40W0    #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g713200g49s71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g49s71.jpg
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M-4X"R#@_ P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MCMSRFILW<.$.=]=N45E4_:J;#!^V , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , P>P)4>B(%,C&J_DME&7))B,:1N,/HN+<:>_-M_=BY0K+ST>## 0I%)1T
M4=>_'1+E+75N($%R:[4>N!CU+VX)NRMAUD PAL(@[+S>./(^:4"+%!\CKJ;R
M2NY4.U?@C!B-EFB4HBA=(,>#''P(^*]XFAK]0>_15P/Z<^4_.C[:2NN!J3?2
M(2.!K-IS:D!(Q26.8V\/BC-3V?+ZM-\/7,0.R:-K:O"T/>/V>PH\3;^\G3?C
MESLKPIKJ'].?*;=P#\EED4-.5%U4D4_9XXYW64T3T]GG_P"7'.V_/&OL\_\
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M/.S=^.?-T'C%VDLU<HIK);Z<#!EN , 8 P!@# & , 8 P!@# & , 8 P!@#
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MGW@8*M-JF)Z*&S6,Q5(=90_2+D>0N5T<V/%@\GDC^FL%^]^<ZK<UCF$T"8[
MYW>CA*)TR!VQ5>RPR8Q@%Q#H;Y/Z"^@K?[Q(9#EXV-[2:Q;V3LK:Q&$Y%H+'
M3;)<9I1M1B<V-R./ '!.*0I_8!E)=LFC&AIH  =N4EEM='#C0E)7XT2GJT3Y
MY7W35=:*JZZ\Z(:[J<\:\@:4]+M\?),F?\UZ6_O' 'I=OCY)DS_FO2W]XX ]
M+M\?),F?\UZ6_O' 'I=OCY)DS_FO2W]XX ]+M\?),F?\UZ6_O' 'I=OCY)DS
M_FO2W]XX ]+M\?),F?\ ->EO[QP#7M@\R&VFHME:OA_,+-9!'2SX*TL&1]<I
MFU$/G*'+5P\%MY&?)),'2[;GELLX::)+*H<\H[[[)\^UP*TS'BO([\(MH.R(
M>'!%GS.L5.5JV:/'_61RVKU7EZT)<JP=!8QNE$U.2(]@_P"=P.C#;WZR:.O9
M]W;(J:!5>//G])[:^\C<V$SMMSX?[%Q:PY@J*'V:O(^N:MA,!B[18>L.9S10
M_M)&K!9@X<,E6:!+1NHT76;;I\HJ[Z; ?#"QY&N#QN55YX=X.!2>2ZKZ2.1P
MLSULBYZ0:.7^Q1SH;, SC$@5U<$]]R*^K]POPJ_VV=J<;.-N5.0J? 4C.AR=
M>E UX;L4,67\*!CGI$*/>L9"=?#4<;#F<>,?I:[+K'_A0"T#B&H8A\(>^Q;8
M6.08K(),6VJ0S5<U5H>N-1-AI-*IJ'\/@6*F4[:NF$WEHT]UO8R:9,7VR.[Y
MG*CS4\D5D+5YNW;[.FY=V\1<;(([+:;\I:<ZC%>;,>.'C.D>AL@KH!X;L3!U
M]+%DW$I@@=YUC&0V2N$=6NB*\@C#(N@$,K):,66J:I%BYWTU9M===N.&Z/&@
MS5<]5J?&?A R51>+0B4>&=!Y)"X-[\YA,0/[]7#$7A_PCS[8A^BP B4<"H_[
M^V_:\^"6C3WSS^U;V_.!5>-?I-IQZ=VQ$00F+Q3I>;C$: #VHD%'8]8E$A00
M44Q2U09#!(D;*VS :/9H::(M6;-NBV;I::II)Z::\<<#!['I=OCY)DS_ )KT
MM_>. /2[?'R3)G_->EO[QP!Z7;X^29,_YKTM_>. /2[?'R3)G_->EO[QP!Z7
M;X^29,_YKTM_>. /2[?'R3)G_->EO[QP!Z7;X^29,_YKTM_>. /2[?'R3)G_
M #7I;^\< >EV^/DF3/\ FO2W]XX ]+M\?),F?\UZ6_O' 'I=OCY)DS_FO2W]
MXX ]+M\?),F?\UZ6_O' 'I=OCY)DS_FO2W]XX ]+M\?),F?\UZ6_O' 'I=OC
MY)DS_FO2W]XX!KZ4;R.;R6*32:>'^QE\Q@CQ(A!Y9*)'US/R6&OT'.CQ%]%#
MI8^[*1UXB[33=).1#IFLFY3T7TWX5UUVX _AEP?&SDO9X[P_!S"RI S4'GK#
M92'KBUG)M@L@Q;*L2\M0/IGR3-5L,&MU&SP@LCN@/8I;:<IM$-4PKP<![021
MV#&N(YK'.C3D!K#XKI!(EJ$FO7\5Q%H0GP)X3AL<X8R9#@)%4^  +C2/#/>H
MC7@*)]JSX^#6?N('XR0W.9BSD Z7]$]Y4/EHX4'E3&23'KX<9R80">/" 07(
M&Q.2.D3(X._(/WPIB2T<MA[Q\\<M$D5G*V^X&1#+*N8*-'A@W3N2B1 EBT&"
MA0RS*/8#1@U@@FU8CQ[%K+DFK)BR:I)-FC1LDF@W033113T3TUUX ^[TNWQ\
MDR9_S7I;^\< >EV^/DF3/^:]+?WC@#TNWQ\DR9_S7I;^\< >EV^/DF3/^:]+
M?WC@#TNWQ\DR9_S7I;^\< >EV^/DF3/^:]+?WC@#TNWQ\DR9_P UZ6_O' 'I
M=OCY)DS_ )KTM_>. 21;J*JMT%5D-FRRB*2BK;?=-7=NKOIKLHALHCMNDILE
MMSRGMNEOLGOSKSMIMMKSQSR!^V , 8 P!@# & , 8 P!@'EG&Y9X%+M )-L%
M..A9!N&,O!OPRT$EEVBJ0XFZ#\/1OPLV8/-D72XWX18>_DDMFOOUK[K[NF!$
M^C^O]RTY"CT>WMZK)%+) ]!'#5FZ43+V4TFDM1?C-9?+K.?G>P\O4F1B21QB
MK'P: ]6+!X"W^"&,;%Z0Z-AH6W&55%7-3Z.;)WFXX_4VHRZK$NLR>V/&99%8
M77T1&;#.&36OX'%-BIH@(9+;/WW)(M,)O(3,ADQU% -\(BQT#CKD:X_09F6(
M#'%[^_ ;AP#Q9)\73_S*4^PKY_O"[YA_7NMHR?Y/_P! ^]4\Z"E%'/HB1(,
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M.&NJ$9?Q9^6'2G1ZMJ*<1UV3;%^-Q:SO3893/\R_P4AK:YH]8UBW^' 76&8
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M)[^^4_!WW [$[$WDA:CJ8"18S9\YJ&*0.>A9/$3,6.@^A\D[;B9#:%LNK!7
M#Q;&7QA>#RUHWK<4B+C+MP?Y,)OA>[9P,T3FK7_%3-R>DECU0N.5V]#YCI82
MC9&QJ^G/Z'34$W@K.";QM\]A<-G8D8Y;A+COR(2!1U&YF'.-9+#+2D %\,+L
M&RB0PTQ+,$1A?1[\R?P)2X,# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MGW@8*M-JF)Z*&S6,Q5(=90_2+D>0N5T<V/%@\GDC^FL%^]^<ZK<UCF$T"8[
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M7:W/*SI?5'A5=7GE17;??GGG ,EP!@# & , 8 P!@# & , 8 P!@# & , 8
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M4RHI3)]($\_][2[ZR&?][EW_ (MEWF$%]5<>S) _#HWSR*^L/?\ ./2!//\
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ME#](N1Y"Y71S8\6#R>2/Z:P7[WYSJMS6.830)CL#G=Z.$HG3(';%5[+#)C&
M7$.AOD_H+Z"M_O$AD.7C8WM)K%O9.RMK$83D6@L=-LEQFE&U# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M&, N(=#?)_07T%;_ 'B0R'+QL;VDUBWLG96UB,)R+06.FV2XS2C:A@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M*'Z1<CR%RNCFQXL'D\D?TU@OWOSG5;FL<PF@3'8'.[T<)1.F0.V*KV6&3&,
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M$2)?N"@;235?/)!!2!0&_=M&+M8#)=0:$H!I/6J1!D)-,QY+CDBU=<\C!NG
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M%O9.RMK$83D6@L=-LEQFE&U# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MR[NY_&]?Z@59_8^>GXJ+O_[OL_:4X_\ D#^#QCVS_7*_4)7_ "1TQ\,3MAV
M[!6A8D>MZP5)@'!P)$R+9[QJ'!.&I+:0C&.SGA>-QX.Y6]EJX62]R<+*H?\
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M , 8 P!@# & , 8 P")/< 8J[BM2&"($I**\AO8*L9C;,?$Q\E+7#J$AE2_
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MFA&XG/KQ1?)5:?SG7?\ 42,9TRZ''LH]3,^S(LT*\S!TR]; =?ARIYEF$N#
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MZEK2_ QW/7LKB>SFOI/VA#GFVA\@3S4\SZD_*4&7T1N, LG^#-Y<[&]=9?\
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MOY0S_P#7DX^TXWVX_P")+L3_ ![NG^:4Y_\ .X_)6S']W)#]CR_^7'Y0S_\
M7DX^TXWVY;DZL%2ASK50ADV2?F#!6HJ_($RI1XX($B3]W&!JSIZ_?.U%G3QV
MY6WW5<.7"JBRRN^RBF^V^W//,4VP<N8>U=I'$.Z=N'#F=S)VY<N6&73IT[8B
MWK+#MV[81EAAAEE$1EEE$991$1$1"J[,/7CZSDC?/GC;UZ]E4 \>/7K;3QX\
M;;AG;33;;;2JTVVTJJK332JJJJJJJIOO-;/=*'SK_P#4N/\ /5_[FV?19C^P
MS^RS_!"(6_[;7[37\5/PS]'Y.\/@E?\ U.RW^"GO_P"5H9.=_P!_LI^^_P#M
M)W"YK_:+]U?]Q.\^3F=P*SGC(>:&&>HR+?CJRLK&XO"$=\H8SL^5$XWN8FA-
M2PO79@<FL[.<M)"]2?-+UT]=M8_C(/FLVTPA:CY/S?J#\]^RN)K/ZYEO6W1=
M#R#2P3GUXHODJM/YSKO^HD8SIET./91ZF9]F19H5YF#IEZV Z_#E3S+,)<&
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MSH+V)J/BQLCYD_\ KL9[8?J:*-_B59'^D!_L,>..W/G\+]G07L1XL;(^9/\
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MTTTM:55I55<G!E4WUEA6&66&6J,LLHRRE*T1E*(E5RYD/)E-*6),XQ(X>?[
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MEL^:\*@;,UVUWUUWTVXVUVUXVUVUYXYUVUVX]GC;CGC]G/'/'/'/'/'[.>,
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M/0FN]AZ;7556G-2#39FTMMY]%M$Z[$QG=9*3$YJML4X2C3"-K-UT)"Z+[M$
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
'8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g713200g53f99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g53f99.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19@4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   " 0$< E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $!AXZ)PG9:$FP@U%<#"ZD0DX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              )8   %AP
M   !                          $             !8<   )8
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   )8     %)G
M:'1L;VYG   %AP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "6     !29VAT;&]N9P  !8<    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M9#LK'BRLM>'5$;F^D?3V._==]/<M7J->7;BFO#L%5[BW:XF._N]WTOH_N_\
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MP&7"1;]&?Y-EG^>N;SOH]3_].59/_@ZZT>K_ *-_!_-$S#O_ "2Y+.XZF?\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@
M   !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C(@,3,Z,34Z,C$
M<G(R-C0V,3<       .@ 0 #     ?__  "@ @ $     0  !8>@ P $
M 0   E@         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%(34T *@
M  @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,B Q,SHQ-3HR,0!R<C(V-#8Q-P
M     Z !  ,    !__\  * "  0    !   %AZ #  0    !   "6
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
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MH-DM/F9LCP+$+TV88]&=#H,J-;8_7SRY'20WJKXE1=DD.LZZ*]?./#DA"_\
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M9$3^'\HO[?C_ $?[>5J%6WC%&^DCVWN0/RK7([VYD$%W7VLG6!OMWL<O9SC
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MK>"H_+O\-<3Q7XW;_>=TITD^/_'\GR_^;FL_V^\4;[>?CQ_!Y.TT_E_@[?\
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M?;V[?7VR.]<T( . RMV4Y&0 64$KZ@IRA.K8&NRDJS)AC;[?JIU'_P 3Z?\
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M;Q7B5M/."2]:$6\$4LS)-N4FD5"((2D9$D@>=H^HD?JZ(D8$!2:^V_%K\O\
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M6VQ[*K.S'.%1?=FU!( R .Q)8JHRS '$O;R&QA,TNQRRQQ1( 99YG[1PQ*2
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M_'ZRS@H,@FI.?)<4 J  #   ^P&!W.3[?<]_YU)BS$LQ)/L2QR3@  =R2<#
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M+N[L%1$499F9B JJ 222 !W-21'D=8XT:21V"(B*7=V8X555069F)   ))[
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M, NQX.1.I8U';9'4LEW4>(%T84J9'0(1V! .5>TJ:!S#'*G;W]QD=Y/\B/\
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MQJKVE5J@5(JA&A!O42,)^4A'Q7',EZQN2PAD=5?=0(5"J07&/7ZB5+?*VNJ
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MGOZ,B-X)DQ_=_/,Z;E&%6WE9>E*0RQK&A>,.2%\C)(MPF?WL%Q(C?\[Y<(V
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M/2@N !HGDKB6,0KEHX"+*8')U9NLO4"DZ2K=%F9761:>O>2,DY;KQ(W4/9I
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MPP')"HT)CL(8U&$,71;L)F8T5E,4Y7Y3) >R]_)RLCNXP,L'VN'9N[!]P,E
M*Y2?50F6TG4>H4E :!'[!R.3D2" !GKS8D&X9;5\MXOXVK5PV0@4Y'JY+*H,
M.6PL@0A%YOW@5(5Y'DM&+8M;9+79F.; !##(@;L1,Y=IP,=*=2A"EB*V_P &
M-(;RXV&N;61I@%&/,FZ0.K$>VBA1%G/4C.V2!DR_T@%$C=I"E@%]NGWV(A)(
M?$"?V7-?#N;7'J\DAXWDB#5T:UM0/8HFOL*F$)QD*0()$?B-MI9,C-U(XKA@
MH=EQ!(4AN9 @(5R \4+9V(BFD.N S+E>+\><XW8#1HK@$E0<R(\,D2YP=1Z9
M'![>M%&<D \FM4JUN\=9N<\XVMVUA3G$C!=(DC1,RK%5\:.QKWR)#$3R"!K'
MN,5&C1CE=XKT"]_Y+N\!2?P^XP'8(A_N[]F<D!5/[S$@*,G(Q6W7_P#R9>=V
M']QN.Z@LP_N[]U !)8?0 $D]@*^MQT\#:@S:J-%*V1DEQ'+&!$$L.3/KZOV:
MW@R7-<T(*ZSJ8>*'@RV&&&:5:JO>1$M"Q7_/HC)F'6=@5M8&#LYW6.6;'*2+
MG):2*9[Q9$P3&O6E _)##CA8:'0 YFD!4*-694_NBM]D=%@*MD!B40G+ZU/V
M\JG;#JB17*2JG4:3P'CQRG255W5_4&S.Q[MCN>.1]IFOFRGME_-6/,LI0HSU
MBF?RU"DYDF5QB:.?ILK,%*306\ZV,7=P"O6C"*"FFZ1(6&ZBIR&/6,K\C1[
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M;-A0[MSG1)%7&O+J:]&/C2#P[@C?J7++CK^8G4*KY'Y4*3<;&F&(DC<I(]N
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M\XK2AT5LMZC:"V92IS(GEPI(93449-#J%*[VH[J >@0A#$8'83&4,#V5A*2
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M!UZ$<UVHVSMHL<15QKZ6U"@$95<L"#V-4,.PI;*6X@EA,-.MPQX$B5Y&;#?
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M.,Y1"[%$/W52<+_D!011*[R+'&KR#$CA%#./L[ 9;_,FH8,'Q./72:D5)#;
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MK'*]B#,XBF T;E5PV@(-K%_NHB<D;B<NDAFF,D8Q&YD<N@^R,6)4?H"!41!
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2*4XI3BE.*4XI3BE.*4XI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g713200g57c81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g57c81.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X>Y$:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S4W8S@Q/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @(" P,#$N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(S,C,Y-C(F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(#,P+4%U9RTR,#$Y(# Q.C$X.C(S)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(#(Y+4%U9RTR,#$Y(#$U.C0X.C(S)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!
M.^* HB Q-C$@8FQA8VL@=&5X="!C:&%R86-T97)S(&-H86YG960@=&\@;W9E
M<G!R:6YT+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S
M96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[0V%L:6)R:4)O;&0F(WA!
M.T-A;&EB<FE296=U;&%R)B-X03M#86QI8G)I271A;&EC)B-X03LF(WA!.RTM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<U-V,X,2YA:28C>$$[
M57-E<FYA;64Z(" @(" @(" @(" @("!R<C(V-CDQ."8C>$$[3&]C86P@5&EM
M93H@(" @(" @(" @(" @,S M075G+3(P,3D@,#DZ-# Z,S8F(WA!.T535"!4
M:6UE.B @(" @(" @(" @(" @,S M075G+3(P,3D@,# Z,3 Z,S8F(WA!.U-C
M<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R
M<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R
M='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP
M;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T
M960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N
M=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M#86QI
M8G)I0F]L9"8C>$$[0V%L:6)R:5)E9W5L87(F(WA!.T-A;&EB<FE)=&%L:6,F
M(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S4W
M8S@Q+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R,S4X-C4Q)B-X
M03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P-RU*86XM,C R," Q,CHS.#HS
M,28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P-RU*86XM,C R," P,SHP
M.#HS,28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU
M<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@
M(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H
M96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@
M87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03LF(WA!.U1R861E1V]T:&EC+4)O;&0F(WA!.U1R861E1V]T:&EC)B-X03M4
M<F%D94=O=&AI8RU/8FQI<75E)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP
M=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL
M;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG
M+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C M,#$M,#=4,3(Z
M,S@Z,SDK,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z
M36]D:69Y1&%T93XR,#(P+3 Q+3 W5#$R.C,X.C,Y*S U.C,P/"]X;7 Z36]D
M:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C M,#$M,#=4
M,3(Z,S@Z,SDK,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP
M.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\
M+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@
M(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX
M;7!'26UG.G=I9'1H/C$X.#PO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @
M(" @(" @/'AM<$=);6<Z:&5I9VAT/C(U-CPO>&UP1TEM9SIH96EG:'0^"B @
M(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG
M.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ
M+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU
M34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[05%"24%!04%!44%"
M+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="
M45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$
M0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H
M55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T)!04,X07=%
M4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%1
M1D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!
M0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&
M25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y
M9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH
M2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H
M<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#
M:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!
M24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%
M>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-0
M4TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0
M>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP
M=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y
M531Q-T9867$W1EAM6&Y6=DYA+R8C>$$[;51P:E=A87I*<&]T<EDR2V%C>DQ9
M;3<K=%,O5W9R-6]9=E0Y1# V*W!V5"LW*TQ&5T$V<C5T+S5Y1%A2=G)&:DAQ
M:'5O;U1)5B]2328C>$$[6$XU>71G<W-2:DYS5'=I;&YU:$=604Q+;DMR044T
M<&1F+VU(*V,P9S%".4HO4U8T.%9X<59S-G=A5W-S3G9083-4<F)22397:W!C
M3B8C>$$[1VA2+W0W.%%Z4C%,9V]29#DU=R]/*S(Q0C%K:W5B84,K,4=/>712
M8U=D=D5K674W>3ET22]Q-TY"5B]45DQE6#1Y,5)U5'AB1EAV3R8C>$$[;V97
M=G%&>CE5+S-Q.4HO<3EF.$%F;D4X3W8X06Q91F5(-DQQ,S5R,E9N-61I<TE.
M9&MA-'5O5C%V.4Q1*W9Y=4M74S-+2SAQ3DQ"828C>$$[9DAD34A*035,.$1C
M84M656M(;G(X.')#1D1Q."MP45%827-9>&-Y85A#2D5M=5@P+W="4T]%3&$P
M95$O5V)H1E1G>F9$4VA:5&EQ+R8C>$$[57906"]/460Q8W=*6C)/<3)0.$%O
M36HS84QP879X=3=7>4Q55G!,5U-0:F-82S%!5U)Y4E)2=T]X5794=GDV,79Z
M;G%0;6YZ4%HV-R8C>$$[8T(W4%-'=&]B84E2>$PK.75L83=A<%)623E+2U=+
M2VA*-E90>%EO579Z1E!M;V5B=$0O4C0Q539B-DQE;4Y+3$-0-B\Y870K2#$P
M9R8C>$$[1E!1*W(K<GDY5&%L869&5$971%(K6E!Z-'5&<U98.4M22WI2:35K
M3VU123-+439F2$]H1#)Z04I$2F-86'!T5#1L5&M3-F=K<7!,<"8C>$$[,S5K
M9FYL9"M8+W)503%7-S%%2F1X6'-C5VMX;$QE.6=N-'=W-U=P3S9Q>7E,4GE#
M04-9-FQW<6Y..35W+T\K,C%",6MK=6)A0RLQ1R8C>$$[3WET4F-79'9%:UEU
M-WDY=$DO<3=.0E8O5%9,95@T>3%2=51X8D-R-D%W2S=&57!G.'I712MT-G1O
M-G!+3&Y2;TQA-75N25@P>6PR2B8C>$$[4V=1:'5223E"=5913S-81E=%-EHO
M=T$U1&9L>F9M,DIL=7)73S1S2#%)>5-W1U%24G@S1%<W4GER8G1--G5#:D]F
M:#1H4&E,67%Y9B8C>$$[>3$K669L;GI&<58S<&UN>7EI*W1(=59A2V%*,%=2
M3$\T*W)34W=Y,$U5:6,V9EIE;W%/44A41E=3-'$W1EA9<3=&6%EQ-T9867$W
M1B8C>$$[5TDO;&QD6'1X;S)P:3A-5%1183%Q='5:64E%=#%K.4LY:U1M56I&
M3U1%5EIJ56LY4U1V:7)*<FY4=%!U<')E935T;W U<E)Z3&%3>28C>$$[27)T
M1355<5AJ6F=3:F-34E5D<U921TMU>%8U<"MD9FU&=$IT.49I:3%M,C R-W5R
M;FQ:5W0S0F)Y>%18141X4$A,3$QC:&MH:'1V="8C>$$[<U5P251X-$U'-G%V
M4SA654Q05#=#>45W<S=A2S)&>$LY>&-E:6EX*W!.2G4X<CA13U1T,UDW;D96
M9D96<VA94G-63D=!3D-15S-P+R8C>$$[2TM%+TQ&5T$O:S=Q.35Q3VUA,38Q
M,49F45<K<'EP8C,P3G1&86EC>5)2>E1Y.$E!22]J;FMC-VMY1'!*.&1C5EIX
M8S9D<#DQ3F)Z,R8C>$$[3G1&4$YA3UIB4U=21F1O;DML4SAB34-58FE32VIT
M:7%)>%8R2W-D=69)6&QU-S$R.#%Q.71X95AD-3E564Q/<4]K171G2E)$3D%#
M=B8C>$$[2DI".5EB-'%N=%-M2W-);2]W0V-A9DE4,C-O4C-M<#(V;4@V=DLP
M571V5U-0,%E)85-";T=6=CDU5F-B8D]3=V]E4$96;&9L6#AS="8C>$$[13AT
M-GI,<71N9#-C.'-I6%5C549W,$II:5<Y=49U<'=N<'A2=655:4Q4;7I502ME
M2W-U>%8R2W!4-G9M>B]L;'-0.$%P26TO-F\U:28C>$$[8U=O-V]F32\X4S5N
M1' K*V8K;$@O1D\Y6'I:+WEY,D@O4U).+W="56-E3%5D,%!M9BM*6&@P+V90
M+U-J+VEN97(U<R\U6F)$+W!);28C>$$[+W=#<4]01G%/-DAZ4"]%<G<V9G9N
M+W!2+W=!53<Q9DYN+TQ,668X05-23B\Q4G@T=%(S42M:+S1L94A4.3@O.4M0
M.$%I;F5R-7,O-28C>$$[6F)$+T%+4TIV*W%/4$9Q3S9(>E O17)W-F9V;B]P
M4B]X5'96.#)F.'-T:"\P:U1F.55C94Q59#!0;68K2EAH,"]F4"]!16\O-' S
M<28C>$$[*V)0*U=7=R\V4TIV*W%/4$9Q3S9(>E O04)+.$]N-S4O=T-L2"]&
M3SE8>EHO=T%S=&@O,&M49CE58V5,560P4&UF.$%I5C1D4#-Z+R8C>$$[04Y+
M4"M+9#9V;7HO04I:8D0O<$EM+S9O-#A7;S=O9DTO=T1%<G<V9G9N+W!2+WA4
M=E8X,F8X<W1H+S!K5&8X059(2&DQ2&1$-6XO:28C>$$[5C1D4#-Z+S!O+S1P
M,W$K8E K5U=W+S932G8X07%J:GAA:G5H.'HO>$LX3VXW-2\V568X049/.5AZ
M6B]Y>3)(+T%%:U1F.55C94Q59"8C>$$[,%!M9BM*6&@P+V90+U-J+T%)<#-Q
M*V)0*U=7=R]W0VMI8B]Q:FIX86IU:#AZ+WA+.$]N-S4O-E5F.%4W,69.;B],
M3%EF.4I%,R]62"8C>$$[2&DQ2&1$-6XO:58T9% S>B]W0DM0*TMD-G9M>B]L
M;'-0*VMI8B]Q:FIX86IU:#AZ+W=!4W9$<"LK9CA!<%(O>%1V5C@R9CA!3$Q9
M9B8C>$$[.4I%,R]62$AI,4AD1#5N+T%);&5(5#DX+W=$4VHO:6YE<C5S+W=#
M5U=W+S932G8K<4]01G%/-DAZ4#A!>$LX3VXW-2\V568X53<Q9B8C>$$[3FXO
M3$Q99CE*13,O0492>#1T4C-1*UHO-&QE2%0Y."\Y2U K2V0V=FUZ+VQL<U K
M:VEB+T%+;S0X5V\W;V9-+SA3=D1P*RMF*VQ(+R8C>$$[04)4=E8X,F8X<W1H
M+W="2D4S+U9(2&DQ2&1$-6XO:58T9% S>B\P;R]W0TMD-G9M>B]L;'-0.$%P
M26TO-F\T.%=O-V]F32\X4W9$<"8C>$$[*RMF*VQ(+T9/.5AZ6B]Y>3)(+U-2
M3B\Q4G@T=%(S42M:+S1L94A4.3@O.$%3:B]I;F5R-7,O-5IB1"]P26TO-F\T
M.%=O-V]F32\X028C>$$[17)W-F9V;B]!2U5F.%5I3V5U9E5U6&\R,S$W;"]D
M*W)*-EA(>#4K;GER+W-C<W9,=SAO.%AV3F9D*VAQ<D9X8S5C4'5&+V8K;$A:
M928C>$$[,$]"0DI!3E-.:C=(<FER9U%W0D)Q1'5#3VQ-5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<B8C>$$[<U9D
M:7(U+S%N.'0O>E,Q4%=037,W5W!G<V9-;6\R9#!22&17-W5K3VXS,W!X0U9*
M95-!;3!94VA6-40T04<S*T1#<6AO=C5:9FUX;R8C>$$[-S9E=6Y,8S)C35IS
M2G)P66(R1T)7;5-$4UDU>$Q(0DI':WEO26)T4&I6<6=%+T5Z07-&53E&.'1F
M;6)O3CDU6C!A.3%'.# O-B]D-B8C>$$[8F%*<#!6-'))3$<S<V]P3E%A2DE*
M0U9A3U,P-%--,W<P:RM(-V)62W9O=D%Q>61894-252LR>6M,=58S23(S6&-F
M35EQ.$<O3#-Y2"8C>$$[*V%U9U@K9WA83G!C5RMM45@W>F%Z2&$S,%5-8W-:
M=#=71DAE1EIP0DEF<D5,>D\Q45A8;%91>CA-5E@V+W=$;&(U>FQS<#=A,S!W
M,R8C>$$[:V)4-C)U:V\Q>D97>&UV3E%J;7-T44QY4V-V:&=2=#%,4W)8<%5N
M0W(P=GE0-4-N.'-A;G(Q+TYR12MQ=G)C-E1F=C0T-#)49UI'2B8C>$$[8WA"
M5FMK9'!45G5+9TM&4E9#<6]!5FPR2W9/9GIF.$%,2&YN6#1T3&HX=G!B>E=6
M;&,R.3-08E!C=&%Y=E!&9%)-:D4K;$EJ4E)X0R8C>$$[47-P64=P1$%-5D-S
M<6LR9V554%!S=#%P9#%R3G9E1V5X.'I09E%V9#9G;#$V5VM35U5Q4G@P16A8
M;$<U4DAO0U,Q5T))2D]+<$QO6"8C>$$[-4HK84Y4.'%A-35F,6$T;#AV2G%%
M96UP3DQ'8F4V5SAU<D]35C=Q-6M25TQ&6BM56D1&,&M*56-X46-3<3DT4F5+
M2W1384%#<#-*<"8C>$$[-#1Q:VYN;E1.4C%8>5IR;6UA6B]X,$PR>'5)3%-R
M;5 Y-TI'>7(X639B;D98;&9K>GE2*UI.;&115T]O,F1X839#,FU8.74Y<$)F
M2B8C>$$[2&)*9%A-.7I,03,Q5T]E6&=Q47E#37%J<T%X46EV1&QH5D5A5BM8
M4&YE4%A02TUZ;SEK3E P;E1,4V95-'!B9'!,2#9R65A51C5B228C>$$[:BMQ
M<G1,3E!#-$E2-'IW*TQO2VA75BM79GER6%$O4$UN;6QD54TT93!V8DU76&]#
M4"]E,U4U9%(U1C%C:C105S1C46=R5&QT.6Y&5R8C>$$[931Q-T98>C$U8R],
M:CAX.4)U.4YG,&Y3<G%W,#)'-G-4<7!I=DY/=#5R;4,S9&AC2S!T;CE8865.
M9S!B4FU997!14T%L961#5E1,>B8C>$$[8BM76&TR-W9T6F4S,&LV:&(S;"]Q
M.#EG<'5945EP-S9W<UER3R\X03-S:3 K<GI14SE0,VDO<W)1-$9:4'%8-4XS
M1V\K86)(>D9C-B8C>$$[.#AT,6)#>#ED2G)A3GEZ5U8R8G)N1SAB44MK;$M1
M2DE52D5824YY3$4T<3E->%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>"8C>$$[5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+;TPQ6E U
M:FER=E9K+VU/2W4Y5U0K631Q-S%:4#5J:7)V5FLO;4]+=3E75"8C>$$[*UDT
M<3<Q6E U:FER=E9K+VU/2W4Y5U0K631Q-S%:4#5J:7)V5FLO;4]+=3E75"M9
M-'$W,5I0-6II<G96:R]M3TMU.5=4*UDT<3<Q6B8C>$$[4#5J:7)V5FLO;4]+
M=3E75"M9-'$W,5I0-6II<G96:R]M3TMU.5=4*UDT<3<Q6E U:FER=E9K+VU/
M2W%N3B]1<GE.95A81EAZ0F9F;B8C>$$[1BM9.$56,G@Q57%5=C=I2S-4,$Q)
M4T52<F5#2D%(44%W=$IB>'(O=C%I2D97<#1J0W(P-SAU9DXK=6%X-7,Q;7@Q
M5%9F5FQT;G5L3R8C>$$[:6EZ.4IB84]'-%=/,VPY96EU4%=J4$QH3%5T.7!A
M0459<3E+>%8R2W5X5EIC6$9V8E%08UA%<5%W4DM7:VQK64MI<4]P6FI105E#
M428C>$$[0EI:46A+6D59:7EE9V-,:3-.=S%S2E5.=VE#4F]E435H1TI#<U8V
M,$I59T@R>'-84SA%=4AI<C X<C97=G=S6%EQ-T9633-6<TIN9R8C>$$[37E#
M84Y"3$I&>4A*63)*06-R,4-K<60O8DDX45HK2$MR;S!46'@W;31:;UHT634T
M2D9L:&Q54$9+:$1+>7-+<7ES3FE#3VAW9S)I8R8C>$$[1$5K1551=G=S6%EQ
M<W5,:3-T;TAU3&E625E);$Q34WE-1E)62%5S>&]!34))07-S;U%L36E-4EI0
M44].>&)I-%<R37%#-&1$27-0228C>$$[8WEI:T)M0SEA07-!5#<T,DQP94-8
M1'A6-F56.4Q8-%=,<U91,G!A;%IA8EIY6'0W2TEB5TQJ-FMH0DE(3F=G,E5%
M+V%96E!(:FQ/6"8C>$$[1$AC=&583$A(2&EK84-G9DU':DLX:4YD2VAI;6$S
M;%IG>7%S:V-2;6-->$%50EDQ2DIR5#9C;#1%*S=P9C(Q.3=!-FE!-CAJ6#)8
M.28C>$$[>E(X>6%!;S5.<4YU<UA&2$5Z4TM):4I'9%8T>44X1TY96#)"<G1H
M+TPU4#5P+T9F<D,O;7-8.#16-SEU=EAL,$MQ;71A3S5J0U@Q=28C>$$[-6U,
M3$-&;%%L,E0W455!+T56-V=:131::F]D=DIK33A$6'%'+VUI3%<U9W5R84<V
M=#(U=U1O<W-4,$EQ:FIK<&]A2&-(25-I66MG."8C>$$[=WIH35-!235&12\X
M93,K>7E,2C11=CA!>FM$-6AJ<SE#32MJ5VI8="]*64-D175*1FAK:C%'2V-2
M<W)'3C)G2U-W,5IE379W-T$Q-B8C>$$[1E9E-2]0-U9B;3)M=4Y/,'%#,FEI
M,&DT=G%Z>5!/-75O-U<Q=5510E)#=G!Q3'EH3F%T-$I4-&Q55G S+T]11GAE
M<%E2<#5D079D428C>$$[=4EO26]296QK<&-25W-K9$@K<FAM:R\P,&-K0V)+
M:G-#855X5C=$:7)S5E-N>E8U96HX=V%*8V%7.7A*82MS1'AL:EIH43!)2$Y6
M6B8C>$$[4%589F1384A+8S),>$DQ9$]B,F9R5'!S=WE!0U9D1"MJ;E(X,$IP
M,VMY,W-F34HQ;&(K.&U0,6%/,E='965A5#=(3W!D;6,X=U$K>28C>$$[:V).
M5G5P>45.4'=Z-'),9FXW56QK=V5&=W=(<4UR15%/9&-T='584'%.=6I)8WE8
M5G5X5C)+<UEV9DED<F0V,64V;2MO6'%F6$QD628C>$$[4%)J=4HP0T5--T=H
M5U%F0CAE,&1+1&9X>D5N<%)+4DYN9CA!2'DX;F(T=3)*47A2>&E%4%1+-TU9
M;G4X=64S,6-Z.$4P.'0V1VUH-B8C>$$[3&$V671X3&1F5C0Q47I3<WI%;%9#
M;FE'6G5#8F9#9TY&>3=&:C1),61U2')T5V12;&QK;U(T:GE(-#-0965Q6C5A
M-&IS5E-N>E8U928C>$$[:CAW84IC85<Y>$IA*W-$>&QJ6FA1,$E(3E9:4%58
M9F1384A+8S),>$DQ9$]B,F9R5'!S=WE!0U9D1"MJ;E(X,$1$-4ET;V1F=$Y8
M6"8C>$$[54PQ>F%W3D(V371Z3DIZ2EI'0EIM8R]$.$AX2E-J2&,Y37)';7%8
M1EHK9C0K5&M3-U=L3$),1G=1.55R<U)I2S4K6%!F63E/6%9K;28C>$$[6E1Q
M;EEQ9TYC,&E(5CE.97=M8FI$2SA44V)6<7-5<7E&96\K,$4T-6)H>6Y(3&E(
M;CDQ3D]O=VI,1&A03&(W1&)(-"]Y*T-A8DI:9B8C>$$[<$)M85=75V0U:DAU
M6&UT1W1N2DA0=7IM5#A09DUS-BLU8UA$,$$K57(O6311-T\Y0FIX8WE4>3<T
M.% W55I&-4]63E1&.3EB-55N928C>$$[9C O5"]M93=E;&588C8W-&9S*RLQ
M6C%D>#1A-E8O=68K2BLQ=&IO<6YX6#%V+V0O.%@Y:4%I+TQY5T]A,EEA;WAI
M=#-T<$1&-F)!1B8C>$$[<EI)638O1$M"5GA"*S!'<%AB,W1/=D)".5!/+W1V
M>3@R;5!:>$)(<35C4#)#23<K=&1B6E1P9&HY43!Y>G-E9G%F5DE)-%!5<'@U
M928C>$$[;6=8;%-P<%=M64]79DA)>3=Z8G--3U!G9TDO>E%".&MD+W@W9C=,
M2S)X24EF2E!K>4)%4TA13D]I4T]63&E.571)1D-Z4D-K8V=!5"8C>$$[6C!'
M>70Q1T96-BM4=DM+;&EU:#9E0SEV.51C:3%H0DYT440P1#A/.&1!0G<V67%K
M=FU,.'%02U=T1WE+4DA35%EL=E-/;7A7,$I02B8C>$$[230O=$Y$27E-<5%)
M<5!'5EI12T%J1E=9-'$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1E98+R8C>$$[04DY=CEL9U97*W)292M+=2MR4F4K
M2W4K<E)E*TMU*W)292M+=2MR4F4K2W4K<E)E*TMU*W)292M+=2MR4F4K2W4K
M<E)E*TMU*W)2928C>$$[*TMU*W)292M+=2MR4F4K2W4K<E)E*TMU*W)292M+
M=2MR4F4K2W4K<E)E*TMU*W)292M+=2MR4F4K2W4K<E)E*TMU*W)292M+=2MR
M4B8C>$$[92M+=2MR4F4K2W4K<E)E*TMR=E)4:'<W5G)I<C5H=B]!334O>DQG
M:79'3W)L4VPO8WA7>65H66E1:4YB,%))03A90FAA4S)J6"]F<B8C>$$[34I&
M5W T:D-R,5 X=%!/5W9A>C5V,7%W,5A6=E=L=%AU,4]I0WDY2F)73T,U5TLR
M;#EE:7E$,31J>313,4QF85=G0D="6' R2W5X5B8C>$$[,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8T>&1F;B]!
M2VA(2#5F=D)O='-L;G).-6%X1R8C>$$[15AY5#-(,5<Y4U523WE+<4Y"27)X
M9VQ84FQ95D-S9'EQ<3)Y+W=#8VI:8FTU=$90;'A5=&)N-G)Y;"MV17E*.5DK
M;S@V4B]69W)C4"8C>$$[,&MT4&I(3&EF<S1Q<%$O.#5%86IC<EEZ=S9&1D@V
M-CA:3$XW;'E'961T3BMR<TQK46IG1EA5;3E196DR-C=9<7E4>4HK8VMN;3=Z
M0B8C>$$[83948C9+8F%/5WA3*W5,:')J;3!184-+5VYP:4E6579C2VE/5UAK
M5F998V%&5C96:7%2961T0S%$6&9,9#5P9&AD+U4U-VA'6&M1<"8C>$$[4G=6
M23E/46Q:0W%K;F-Q3U=5-FI'6GAO1VY99&PV=4=N>GAY5&IX069:-6IC8BLO
M6D(V6C57,38Q.#)V<D8Q<E5L-6).6GA7>E).2"8C>$$[06I33D<P:$EC4GA+
M06]-;DY3<')5:T@T85I#1T=9;GA'5C=.,F98-%HV8G=O-'A'6$=:8S5B6%A+
M>GHR;S-T5DAM>6Y-;#%,<U9D:28C>$$[<4AV8F$T;D5)9W4U3%%X>7)*25DQ
M:F(Q15=T66TY4EAO<F5+,&)W3T%H0D8Y55)H4S=&6%EQ-T954%I7,7A!2FA0
M9'E86FML85-->28C>$$[3$=V<&\Q2U),-F%P5E8X5W$S:6-!0T%+-F]J0VPR
M2W5X5C)+<4%G;BMU;68V>35G369!5VY'4#!W,6$K<'DT*W!Y<'14;%0R>5A%
M3R8C>$$[1W$S-S)(0V5+-S(W=C Y-G9K5V)S5F1I<5)T-48X:U!$2D,S;#=4
M1VAL;$TX<U)S-V-Q.')+5DUJ3'=O6$MS4GE/.41I<7)(-4\X;R8C>$$[>#A0
M5#!05# Y4&HV9D<Q:$A(,"]3-%5O=3-(-G1&5'<T3"]+2TMO2'DY*UA0:S-1
M=$9S9$IT=$QT<#1B0E%)<#=I0T8U;69L1S5L9"8C>$$[=VDQ:UHT23),041D
M5E W27A64S!8.'0O3#)I*V%R<GI(<#-Q5S@Y,4-,9C9J1TE9-U9),5-+3E92
M230P9FEQ,C8X5EIY<2]%5D%,3B8C>$$[5E9L5TMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9#9E=*9D@X359D.5EL
M.&9W>%8S,6E8>"8C>$$[+T1&6&972F9(.$U69#E9;#AF=WA6,S%I6'@O1$98
M9E=*9D@X359D.5EL.&9W>%8S,6E8>"]$1EAF5TIF2#A-5F0Y66PX9G=X5C,Q
M:28C>$$[6'@O1$989E=*9D@X359D.5EL.&9W>%8S,6E8>"]$1EAF5TIF2#A-
M5F0Y66PX9G=X5C,Q:5AX+T1&6&972F9(.$U69#E9;#AF=WA6,R8C>$$[,6E8
M>"]$1EAF5TIF2#A-5F0Y66PX9G=X5F8V>BMJ>7)V5VU+=DHO*U8K*UAO4G%B
M6&5N,UAP,D]O5#)-2G1J1DM:66)E3U-2<F]I4B8C>$$[;T]#570U4&AQ>#(R
M<61S2W!Z-64O3FI13EHQ<#=!+S=J-%-I3&%46'I#,V5E-64X=6)4,$DP96EU
M>$YP>5AG>$IQ4E%&4TU66G9I<B8C>$$[<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%R+T%-93,K>7=+.%-,+T%0
M3TYI5U5%<5)X;28C>$$[1SEJ:&EJ*W)P<41Y5&97:W5O27<T:$1/.')"<FA'
M3%9E=C)J54IH5E O3&9M8CAM3$\K4RLP93572S8Q5U9B84UU;#<Y<5=16%,X
M628C>$$[-3$T=WAT2G%!8FY257))0EAT:7)/=$,Q,U,Y9#!U1%9D3&Q-.6AC
M<GEG;4UC:UA*9D5,2W%.5#9-5E(K2W5X5E)V<C(Q<V)35SAU;B8C>$$[.4\S
M9U5V3$I1;6EJ<6%+0U0Y1U-H07E)035L:&MM25)-:GE$:&4R<'98<U$O=T1P
M4U),3S!D1'1'-TUQ=%=L3W%(2&=01'AD3U,X628C>$$[-'5(<E8O:C5+,E):
M=7A6,DMO9'12<S%U<&)6<$M4=W=I-&M3:#)I67-O871+9%5/4SA-,691;6U(
M:5(T:DAQ0F9W+T%8,G0Q0F0R<R8C>$$[3C%B='IG=4575THV1592=T=5,$Y#
M2V<Y.$5O;4I)4$U*:$U3:4I$:U9807ED:7%J9EAT<EDR:W0U9% V9'9!<&57
M4VA.1DA5,%5%;B8C>$$[-DUL0T)K44)Z3$1*35%I6DAK2$<Y=%)E<%EL+SE+
M94IP,6IO9#0P6E9:<3!P,6-9.$(T94QP>5AJ2$9W.6%V.&9.5WE,3C)+=7A6
M,B8C>$$[2V]*3F$P>5-+,VQ397-D,4\Q<F)T>&(T<&M,:&PV8F8S5&)N8F),
M1&AK0U)825@X4'=7;UHT1VIF33!094PO555B;&)A-T966"]J,B8C>$$[+W="
M;&=6-6<O=T-19FQ*-61-8S,K<&-.3"MQ*VI&-FQV>&8V:3AR=V5O9E$U9D-S
M-THX3$-O<%@T=FEW<3%P+S5,*U%)<GE#,V=V<B8C>$$[<6$U,'<R='A,8FUE
M1FU-4TI!:TMZ2W-926IK8E1596]O4U9A:#0W67%Z4'EF<"MJ86(U6#!Y=S!7
M-2MU859B5SAC9&YD8S!L36M95R8C>$$[<75844MP-4$Q,D=+<'AI<G-644=T
M-DI983%P-S)..&Y+2CDQ654U23%#039%9V=-2VYT;'5(3DQ(3&EI,#4X16-S
M5$=82D176&Q(428C>$$[3$Q60G%6<F%R1F-,17-5655$:6=534]3-U9$1E<T
M;F9O0FLU-G)*2TA#5',Q=S!E3T4K34-J5DIX;4\U5'-69&EQ4C-0:W)Y,V,V
M:"8C>$$[8U@P.6]K:S%Y9U-1349+.'%S5$E.<3AZ>3-.97=Z2FIR36M9:4E/
M=V-35VAX4VM:15=3:CE',&5X,&I4-')'>51H1$5!0U14:S=!028C>$$[1C)O
M04-Z53,R>7).;6QK;'A3-70R1$1(1D52:GE#3GET=&1I<4$Q=E),1%=T4&5X
M=FLU4E!U<D-N2D=O44A1:T5":%4Y<W1W-7!9-28C>$$[8U57;E!G:FQI67DU
M25-(>6(U9&@Q3T1526).235R6D]%4W%!1D)Q<%8V57)Y6&I11W9C-5ED6&M-
M5$5N6719,%=)5$5W3G=N5UEZ;"8C>$$[3WA6,DMR2F]9<#1:25IK16M5<6Q*
M16)C37)#:$(K67=G:T=W:5514E(U3654.'902WEX,CAF,55-3&5D-7=70VMV
M>C5F02]W-V]/428C>$$[;U X04I'6EHQ*U=Z=GI&3T-/>F-)049C:50X+S!F
M<41*37<S4&1I<7(O>#=F-TQ!<G=I>B]*4'IN1U1*9&Y2-W=.8S-->3)%:W0R
M3"8C>$$[5THW:4LS45A59G!2>%-E<D<P1$5!34<K3&55=%9I5E@V4#A!:U!R
M.71E84I.9%AT<C9E;D14;TQX56QM;&%7,7,U<#=I84Y42D=#1B8C>$$[;&LK
M<FM*<T%!>3%O<3AL541:9FLS-6<P<E9V3#EV9$U,<' W>E0O<G-T<5HU259S
M<D,P:2MT4GES.&%2>$(U-T](9U%1,&=.2V9":28C>$$[<C,S1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<7$O.$%(
M="]S<T-Q9$0T659D42M'2W5O9B8C>$$[1$9855!H:7)Q2'=X5C%$-%EQ-F@X
M359D42M'2W5O9D1&6%50:&ER<4AW>%8Q1#19<39H.$U69%$K1TMU;V9$1EA5
M4&AI<G%(=WA6,28C>$$[1#19<39H.$U69%$K1TMU;V9$1EA54&AI<G%(=WA6
M5F]F<2\K>7=+:7-69&ER<U9D:7)(4'I".#!495=F3$4K<#)Y>%!D*W!&1&)*
M4"8C>$$[6#!I.&IG2&Y1<6%"3U(V-6HV;DXT8TQ(3C)F6D=G1W$Q07AY=FAO
M:S%Z,DA4-'-:4#5Y2510-E=L1V1&4TTR:GAZ37AL95$R;V]55R8C>$$[2C)5
M9C9A=$]026UN5$U982]W1&]U,2\P3FYA-3%U8C(U5G@Y94QF-D]T1'IB="]Z
M:3EF5G)A=R]21%)2,VY)4E103E=26%<Q4S5)928C>$$[2# Q+S,V1BLS-#0O
M;B]*6BMZ9D1J32]%<W@V5G0Y4FIS8CAR-4IR*U@S-6=0-6YR8E0R>5)834YP
M8C--:S!4;#0S855&6$%"56-E3"8C>$$[<61G>E4V13AG4FPR;3%0:4=I3C9C
M4'1F<V=A6#%!,T5Z:TM),T9C=F9T-41Y1E576C5L=6IE92M99GI2;3!N>FAD
M-DI(8E%8355%128C>$$[06E1>4Y(26)Q96%&84\T16Y'35)82$Q:0V%G+U)G
M6F1:=U1-835F93E*;RMW:&TP,&-P2FE36F1,2$-"3'!T=F-A-3E53D@K8S5M
M5B8C>$$[9E$P5FEZ4E=Z2WIZ<W-F<3-*9R]D;5%1<TM+3&]';W%443%58E9J
M*V8O;R]A,FXR831E951R3'!V565,975,*VHW=DTW=%=N-7981B8C>$$[>4AU
M0G P8U5-9'$X,S%D<&E795)M<WI#0DE%<G5L-U%Q<V)%<TYQ-&I813<Q*TYL
M>65Z<UDK;FI*2FQ6,7E(-WDY<C<T8RM)0W5B,"8C>$$[1%)T4UA63DAS9%12
M1$5L.6)X6$MX:S%+:5I!-%5N,C5:;G=L>%)"-S-N9%1H.$Q,3$=49D)):C5'
M:V\O34AZ4DXU6CAS5#9N8DQ%.28C>$$[,S9K54YS:SEF4TQY3T%E9$-P;T4U
M2')L3W!Z94A#>'IC>G-J441686=9-5AW,%-A-3=$<#A73FHX-&\R:VU74%-Z
M2V=34#9P26MR328C>$$[6EAK3G%+36E1=7ER+W!Q,#0X,DY0<S%P;4].9F94
M.&9*,F@Y;7E!3&Y83SEU5F-F57E!4#!D945B.#%T="MC4FXQ5S%S5'!":%,X
M1"8C>$$[0T]:<#9U:G)A>#-*1'AE;794,5%V,B](0BMF.'9T5% R8C1C8W K
M2F9$,'(K:UDW1R]+*U-A95-F>D4O>$1E,BMN=F)+2D@P-D\Y:R8C>$$[=DDR
M8C R;$%I13AA<59O3T5K,TAA4FE+8C!Y,U0V<FIL=S$P+U4T;F%N63,U84)M
M1'0T:&I2-3$V=44X*V](8T]E>DYC>DA22D8U9R8C>$$[,6I5=$\Q4%-)-UI9
M<')A*VMU25IO1U)Z2U=I=$IB:$1'-G-A9D9$>$DY3G$Q,GDS2$%%1RMN-C)R
M2DUI56$V+W%*4T=8.'A.6G1D128C>$$[1W!8,FA.8E-T3DM"6GIY4U%U<T9V
M64<Y;&)K,$HU="LW9$8K14M4=%5B-6%.4$5Y;T@X6%163%5%4G-X+T98,TM-
M=C5K86Y0-6IJ,"8C>$$[=7ES23!I:3%$-G9,8U-34U5M9SE/.$1&03!+55I8
M<WHY:W-/431C=G1C4TY/0D=Y96XV=C%S5'%36CA)2%@Y9C9L4%0O=T$Q3E%U
M628C>$$[<F%.9$E%='A.1%E!>FPU;TQC,U8X3$TX3U)H;5962#$X155D,F]P
M<4%/2EEY,&](6'8X07-V.$%5>&IQ>5)Y-W9D6G(Y861E479.928C>$$[;RM:
M13%#-G5,94\S=%5A,6%Z:E)Y-W%T>%IW,T1)-31)1'A-=7ID-FM5,D).969%
M255"-2]E,V%F36-L;71T=G5"6EAM3S5$<U9D:28C>$$[<G-69&EQ;%!A5W1W
M66IC47!-64A%<TIK54YW:T%+:#%Q4&AA:D562&IG35%E8D]'4U5B;VM72U!M
M3S5"1'DQ-6-%5%%J4W)-4D]N<"8C>$$[=D=,94QI>69!3TI(1VA(-VQ.=CAL
M9D%:1'=O9'<K5&8K97HS9DA/*V8Q2'HO5V9M93EE4$PK9VED3&=A8F%I94UL
M;S5V46HU<5=14B8C>$$[:VAU3E)614,O24%9*T9$=41(.#5M<F@T-55E;D5E
M*R]V,SDV-U0Y1#!45%=D.4\P*S)S;FQ#<DDQ=D1(15=#+UI$1D%T861S36-C
M628C>$$[.&=!:DYQ<W57:$]C<%8S:VXW,&)K,FA,<GI34$PO0C=M-W-,5FQI
M:TXT.'-K2TU22VEG1V%P56YM1E%F1C$R>4)X>%!13U)(5C59:28C>$$[:$]1
M,G)M95AD-W9*:#ET-38O2G%7,48W8GE75%%*2%%32EEV55(R;' K:V=+96IY
M06ET,#E11'-2>$AX-UE00F@S1#5*3W1Z;BM/6"8C>$$[6"M).65F>C9P.6]C
M4&M,6#E/;&XP=7AS<G%X5U-3>FPO=T)%5D8U=TUK8GAL6D57;U5W24]L4&A7
M;E%9*T1$=4AY5"ME>C-F:51V*R8C>$$[<V90.5HK6C<P-FQE>C!Z5%AC24E,
M2WEH3$-/2DYK:6E7=D9%461!<3=!1$IG5G,T.#5M4DI*<VQJ1VPK9B]+5W51
M,C!T>D)*0DE:8B8C>$$[95-W:G5O;S5Y>'5M149V4$1*8DYC>%5D<$=4:TAQ
M=$@U8U%R551%2&UM1U-58F]K5TM0;4\U0S)0;68X<6)T;TQ/,7195U,O0U%X
M5B8C>$$[,'5D24AJ;F%/3TAL23%U<U%I;6%/3EDR63A(2W%&2F]-:#1-3S1F
M2G8O4%HW=FIN63,K;RMF-GHX>C-T5TAN3#AP<G978F5Z<S!G9B8C>$$[56I)
M<3(P:39D3T9";E)9-'!&;DU!:D5C,&%Q<V-N4&A);TA%:T1(=UED=RM31')-
M,45C8W%0.$%34&9F,S<K.5(P<GIZ*U9.;')-:R8C>$$[3VTR,&1L8V5L8G%L
M+T)P,&M58S!6>3521$A+:U%:;T9+4FQP=C=N-#0O:BM,1$A(1U!)04QM,6UB
M24]'8S532$]J26YF-' U669M2B8C>$$[-5IV,S%!,C!L=SER<'E7<G9E9E9P
M:$9-8C4S4T)B6#1E9'AY2T1I,&%L5S5R>$Q6,G1J16LP2$5L25)&;$1A<C5T
M.&EY5#(Q>F-W1"8C>$$[54QY,&%&<E5I>F5794DS3'=+1$9Y5&QZ6#9X0WIO
M;C=W5E@T86M$3&\T<VY)8D0S*R\X06$P>GDT-W,W:V589E@V>#5O8E@O0412
M*R8C>$$[6$]O:E0W<E9,=C$W5WEK:G9,9%=T<'!92DAN9T-X27=-3&AP06PP
M:V=J2'AR<WA&36Q$1FM&9T1N*U P36-M6$9+:51Y,S5F:G8U8R8C>$$[,6%Y
M=G9)9'IP<VUV4S901&(K=F9Y4D5T649R;6$V9VYD16-2<D5:6DI#5EHY9U-U
M.61W,D-58V=01&94=C9*:6-:2$986'4S<T9$,B8C>$$[+VUN.'-H1&)A9S%P
M1F)3>5$R;VA*<T=A4E)32U,R=#%E2T]25$EN3TIL:5)I5C))1DXX2GA:958Y
M+U@U;T=81E8Q,V10:U R239,>B8C>$$[5#5!,'%A-5<Q161V8U)R2$9+;'1:
M>6E345)$:6MA96Y&5U@P9V%C57)W-S!Y0GA:2F,O=EHK2FIJ9&9D*TPO46TS
M*TDW2"]#,RM*928C>$$[16XQ1#9J*VMV5&]V<2MJ-E!R530X=5!0:C(U57(S
M>4AH;FHT970P>CA58TA(,'$P,7ET<V1I<G-69&ER<U9D:7)S5F1I<G-656(V
M,28C>$$[1C-:6$9Q5S1#94XT:7<S<'I5<E@X8U9E3E<S+T%$:DYP,$=H9F]G
M83(O<$9P6E,V=TY(*RML,# R4% T2C%.4%=0<FQE5D=(-W,W5B8C>$$[3TMS
M*R],-WE4<5!L2S,Q0WIL,5-054Q#-G5P8G4Q:49S64I)5VYK95-13DHV<W9Q
M5C5!1#16<%0S>%9K=6\R9C$R>&YT4%=L='984B8C>$$[:T9X8G8V8S!:655$
M>'1V4FPV:F%N:FER1')$.'!.2'-T6&)653%/+V$V;61:-W5V,4Y%;G5),&Y3
M2V0Q:71O*TQX+U<R2VE0:79)0B8C>$$[:7!.4U951&](-4TV9G R<39N4&18
M,7AC5T8S2D,P9&U$06E41T9(9%IP,6AG9T5B<%!C4VQ5:#1P,&1G>FLT<6EV
M3"]!3U,O;%121B8C>$$[6F)E5S1K1'EW>7EG<F%10B]Q.7908GA+-C)L=F)+
M94EU;69L5&U804IB<U96:U@U2RM7+W)6<&189#=E86A.6G-04V$W4WAC:$5J
M:"8C>$$[:6E24TQ65$8V671K-'1#565T951'=4MP='!F-65A9' K:UA';D,O
M=DQL-7!R5V1,-F(V=C8X4G-6:5<Q5U P-%DT=4U8;TM11VI.9"8C>$$[*U9A
M-4M%>D4R=VY!4T9.:CAV3DI.*W0Y3&0S8S V>5%Z:WE01V55,$PR>G1),4EW
M87EM=V@U-S R*T5,535B*UE.5E$O1B]R3%8K6"8C>$$[:F0W+T%)<CE14U12
M+TM0:TA5:%DR,FYA,4QD3&%,6C9J8C9E2F]0559O26]%:'5:26I'<WEL-%EO
M,%!+:3!B64%M=5=Z>35),E-/."8C>$$[9F9S,5%W-#5506561W9L4C<K4V$R
M=6TK6$QQ,G1T3G-T5756;6$K=G13,#)D1E%3=WI1,T12,UEJ3'=L3T-3,T1P
M4U)7<4<R2DA3<R8C>$$[>6M$6DA102]O*S5S15EK540Q2DAZ,S9E854R6&MJ
M>5AQ87DV4&%A:F5Y2EDX5F%"-#0O5#E70TYB1G P33ET=VUB:&(K:R](:V<S
M,B8C>$$[1$A,2EIP:C%%1&8K,W8X06EW:F=G9E-#9'8W3S<T9'E942]L3#5C
M='!J4&%4,TYT9$ME8TXP9W1J4$<U6&I)=VUE0G!(.5%6-4-2;28C>$$[1S4T
M9UI!-G%2-2]P+U=Z+T%#<U%B2% T9G$K.6M(*TA,2"]#,RM'=6-N,40V:BMJ
M9E5Q=G$K:C90;S$U8V504&HS-#!R,GER>$1X."8C>$$[6%<W8F9#2$)W9$MP
M:&MF-2LK4GAC1TLW:79R2TU44$-B;5=&6&HT4B]743!X145K>FE0;EEY<G5T
M4G-3079X6E<R36I(-6ME4VIQ8B8C>$$[85HK:V=,-4QY4%1Z05EP9U1C4RMP
M=U9356]Y;C!(*TU(:#A*,WA66#!V>G@U6C%B4G(W5CE*=6IF,F5N8R]R4&]X
M>6,V<$=*9F=2,28C>$$[5FTU;W=:0TYM0D)"27A634Y#,64R,7)23E Q:3%6
M,'1D4W1O8GE"2E%"24DU-'A);V-+5T%90G0V131Q:G-69&ER<U9D:7%6*V%B
M,R8C>$$[57)(>35Q3C-P:TQ81V]1,C=T87A):E-T-FQ.:4EK<3!N2#=80F0R
M-D1C-'%W1%-.42]->697<DI48S9G,FQ,9$I(13$U6E%1=&,R."8C>$$[:C-C
M<E-8:$9T1UEE349T148T2VA$4TMR:FXX3T95;FTX*V5F=%$X,%AK0U1896TR
M;&Q/65HW8E1R56%H0SES:W-.<E!06DTY;#E:=28C>$$[<$QE6G!V55I6-$DS
M<&=O=T0Q0W$X3C<K8FMT>4I(;#%'>FU33S%I;% Q84HP:V5T;W$X,6%*-%8K
M3RMU1&-V0T8R:'%'-$%%1E4O+R8C>$$[04-Z.#!A-35L,3-78C8U=F)H9$QH
M,G-T36YG:6A1>%1Z>71A,V-".4I*,FAE,FI12S=334AF,4M!04QG5C9,:7)S
M5F1I<G-69&ER<R8C>$$[5EEJ-5<O3#AA1&0R;'@Y9BMS+U996&@T*VQW-6,W
M87ET-C$U=%-N-E U9C=+;F)F27DV:FI"1F9I>BMT>'-/;C1#1&9,.552+W96
M828C>$$[=SAN,S%J9FTV:#%#26DS6%5"<&E.8G-413)P6$,S36AM26U(<D)(
M4VEH46TS53DX17-W27%U-B]H<VU/16<S9F98>$XO2#=&*VUE5B8C>$$[3#=4
M.6)V9%1G=C1G=#0Y6&=7,DM+-&%94T\P;U-6565B:%=.2D%I.6%S2$]#5U5'
M249C;55C6D)*=C=0>"M/.6MU571Z<U9E9EAN-28C>$$[2&533')31C!Z:E!!
M4%=V8FEA.&@Y1DQI6C<Y2C0S.6%4,'9J.4YB<&A(569#06\S1F%Q<4]M9FM4
M-55S2C)U0F8V;%!-,35:,S=34R8C>$$[>5%",FQS1VQA3&TX8T5B=GDY9'5B
M=5,W9GID87%S9SAO9FPQ-64X<6%&9#9,<%EK*W S<DTP<&8P9SE':D515W-3
M4F<X555F17=,2"8C>$$[<7A*>%9/9$,P:3(P6%).4#!E,5HS=&1.=&]B3T(U
M4T1)631)>$=P8W%&0EEH9#9!67%J<U9D:7)S5F1I<G-642MP6#A';C9D9%@Y
M=R8C>$$[85<Y;D1*4$UF0DEL3'0Q.6AI<GAA,"]/-WEN<$9H<#)V=V5624Q#
M.3AX4F%P3G%2='I'<W$S96YS46M-,&E12S!R6$UR2V]C.4=C8B8C>$$[2$98
M;VXU82MF4C4S,$]B5E!Q2#%!4E-X46U%>2MT6#%B3S-U-CAU1694-GIW-F1Q
M.39"5E Y23!(471':&5(4CE/=&1.:&QB;DI(828C>$$[47AW2WID3U1#3E9"
M4'9I<4]X5C)+=7A6,DMP2C5S,4,T<V)+,61,;S)&=$QD4GA8=6]!4FMW47-'
M*T]S<79'=%I!:6-M1D)Y>79*2R8C>$$[:#-.95=61&Y8;7<R.3@W*UE9231'
M<TQS6$MY-G9A,D5%,3%!<7$X1GA9;R].,&HY33!-:VYQ07%26&(Y;F)+1&QL
M,%!8.41J4WI32"8C>$$[3"MC0CEI2E!N<E<P=65-,#EP86]127!B;65.:&%X
M=D90<45B4S!$<30Y8C9L1V=5>4=H655Q9G13.%4K6#1V.5-F2&QE+S=/8W9V
M<"8C>$$[5G-04&5Q,S-M:V%71VA7,FHQ15<U35-J;5EH2&5":VM$4$EW264R
M43AU35I0.'9%9VQ'56U6968V,'AZ:WIR>B]8*W)Y43)P*V)0328C>$$[.7)Q
M;FUA>F=U-$-T:D9E,V-134I-,%-W,C%Q6593<VA1079C5G%Y1W!6=D=I:5=3
M44UH9C0R67IY>D)K0C!V-V@K='$T+TU,5VTQ<28C>$$[*W,W9#=54C)-.7=K
M45E"3UEI='(T:%HV>5--;U=7,%%K,&I*0C9C4T-5-6I:2#0V<$]O;'A%0W1V
M,5,O57E4+T%"5DHO9V8O04)"5B8C>$$[4%<Y2W9,,'@V9G%E<#9694AR8V5(
M3&5V<F-A8CAQ8C5B-&YO-&TW>%!2>&9J-R\P+T9K=5=T>G-69&ER<U9D:7)S
M5F1I<G-69&ER0B8C>$$[=DUN;G)Y4&9'8GDQ<4%U8G%Y=E1E5V5Q>7)"95)7
M,%5.<D9*.6%:-W!%4D]#36YP3U5F66LQ3WAX5FHX:T@U0G=H1$I:1S!J4U(U
M>B8C>$$[0V)857)E2S)C,T5.9E9I-$EL<GIN<V]W<75Q0FE.9V5B8VQ56C56
M,5@X;5!,9#%*2F]S,'5M>5-X2D1D4C-(-E-33T9)8F17:6$U:B8C>$$[=6@V
M9'579V=":F552UI&53A3,BM+<S(X=65A3D\X=W@S<W1H2&-X>%=.>6).,G5O
M2DQ6;FM72T]6:6MC=U-8:5!6-#%:4CA14&%H2R8C>$$[<6(T<3=&6%EQ-T97
M3V$Q-71M,#=813 T5V%Y=V5N8E!,8VU7:G$Q,TY*0D=&:#1(;4$X9%=0355"
M.7-Q;FMO,#!Y>3%+<3=V=%DO<"8C>$$[6#5Q6$8W2&)X3' P8W0S4$1A3DA)
M2EI)-$=M;FQG9VM1<UE8-"MN2F-J-TIF,V]C<FIQ3#9.361664<R*S,V4$QZ
M.#%E2#@P;64S828C>$$[-693-E).8G),045M85(R;$UD;2]P<VEW,4,O-VM&
M2$IE4C)0=S1F>D<Q,2M.=C%P:G%B-F10,658;6ET2C@Y86QQ97 V9D%.3E=Z
M="8C>$$[<')U5WAV4%AE5#$Q;6ES,G5I16EA3TEH4',O13(O.$%K1')H:FQ*
M23):4GIK:T-U=&9:9C0K-7$T.#(V,FMF<GA.6D\P.3@Y;&$V9"8C>$$[27-S
M8V\Y3%5%<VUA4U98:T9#2$1%:5 T4WDW3C-4:U!L>B]44VY,2W(R-3%8>'(X
M8DE'3#@P8G@T<$QH3DU34T)91W9757I'3F\T228C>$$[<D\P=4I"6&A)2E@U
M6%I#+UE',CE/=5(X8SDS-&]-0G%J>G)Z*W=(.4LS+VQB.78K;%!Q4#90.$%G
M-6,O<F9Q4RML.5<U8U!7<C9(."8C>$$[,RMW+WDX2#5N9FMN.#!/2W$K+VPX
M=C)E8C!037!Y,UEQ-T9867$W1EA9<3=&6%EQ-T970W0K54=G=F4S,3@K;U@W
M6&5O>%A-1C%+1"8C>$$[87)Y5S5-5%9+<&)Q<E!',75H5C)"63E(3&IB1E5M
M,6(X;4QI+VHQ>4DV<$LX97%T8G=L2E=I26UI1'9,8UA.>%,R<C8V>5AL>3!5
M8R8C>$$[9$EV<V)!54-+<')C9FMX-5IU=%%N,4LW=7)Q-#%'-FAE2S5V6DDW
M2#$S:V-/=G(K<4Q93VIH2F501D-)*TE!2T=M2W-S.'9A1D9O=28C>$$[;G1A
M2F-Z6&MK:S Q>F-8;'HV9G)3>7IY1U(R9C!5:&HR-6-11E%!04%9<6U72W5X
M5C)+=7A63%I03#)L4S8S*VUP;T9M=FQG4S-I928C>$$[4E5B,#%2<$=R1U-V
M2E=B,6E';V1X5$DX074R2&AJ:31U<F-(;'9Y.6)Y*W1"<&1P1DM/245I45)+
M,S=S<7EB:&$O0S!A:V5&0C19:28C>$$[15(P55DT:F]&46%(;V=J35DP*S)%
M6E%X;$)$2'A+37%)>3!P,$MX27!(9V](65DX03=K.$5E-6)B*U@Y0G1R:4LU
M=#E.=%EB:4)E128C>$$[33!C16%/:3!+.%992T-O;WA&0FE)4DA207AX1SE"
M9BMH9$<K=%-89C%#,RMT5$UJ>3-(<$HV:G1'=UI'6C962E9L0D9E:$=00T]D
M2B8C>$$[-$)D,'18471%5D-I-F9B0D=1>$UO:&I!36)+<49#2V9:2WAO=%!"
M44\R4$%/-65#4&-O9C14.'$K<C8S-D=S9E9R>3E4-G1$>356-28C>$$[5G)X
M<E=U*T1W-#EW62M&1&Y15%A*=&IS5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69"8C>$$[:7)S5E%N,6U8,BLW
M1EAF5UIF8C=S5F0Y6FPY=G5X5C,Q;5@R*S=&6&976F9B-W-69#E:;#EV=7A6
M,S%M6#(K-T989E=:9F(W<U9D.28C>$$[6FPY=G5X5C,Q;5@R*S=&6&976F9B
M-W-69#E:;#EV=7A6,S%M6#(K-T989E=:9F(W<U9D.5IL.79U>%8S,6U8,BLW
M1EAF5UIF8C=S5B8C>$$[9#E:;#EV=7A6,S%M6#(K-T989E=:9F(W<U9D.5IL
M.79U>%8S,6U8,BLW1EAF5UIF8C=S5E905V8P969E=$U6659"*V$S-6946$@Q
M9B8C>$$[.4UX=W8V-71G,7=K='5H:U@Q96MK>5)P>')B4TM(<GA,3'A"-6)9
M5E1X9DUF;#5R:#=D9%5T1W5)-3%T2DE24$585S5C17)#>3AQ:28C>$$[43A4
M4D]U2W%6>C5S.'0R*VM83W)T<4U-=6Y7:VYO,T9X8G0Y64-Y.'A(-E9)9E59
M>6,S0SA!3U944VU+;VY2.5DP,U=D3F@Q3%1:=B8C>$$[6',U*UAP>6-743%2
M:6IQ>4]&9%=6,4MS<D%%155/2W9.=GI)9GHV;FYZ4S,P36%M8DY9<DUW0S!%
M:'-Y-'5P4'(S,6],*S90*VIC3R8C>$$[4'$O-T0T<U93>7HX-&9M>EIF;#=Q
M9#ER545Q6&M4,DLR,2],0VMD*UAU>%I#4T-#=T9S:U5H-5A%<5)S5#ES8T=8
M66Y&541A*UE0>B8C>$$[8S%+>F=R2F0S,$4T,#8T831T8F169S1.8V%B3#9L
M=F-7.&-F<6-J3&1P2VY).%DP*TE$8W-Q:'1..#EF;7I"<69L+U1D9'9,=7E'
M;R8C>$$[,TU*=6)M-7-R94%I1C P+S%68VU"55)&:W5P63!01W9Q;$59;F9&
M6'8K2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5B8C>$$[,DMQ
M=B](="]S<T-V2F(O.&=T3'5.249R1G%443,W>3,P;#%F;4HU4%53.%,V5TM-
M4DY.>&I71#8V5%)+0FI5,$)A;TMU,#,X:C=Y,R8C>$$[,44V:F0K66ID6&AV
M-TA54%A&<55C;7IA9&Y(>'IY<7!M*W-K3G=654@X;2M+<'8U8B]+-C<X=&54
M9%,P2%)D84YT<48X-G1&<3=13B8C>$$[2S!3;VMC4R]U<$IM<31I:7!537%G
M-W%O04,T<7EN>7!O8F%&-65S=$IA4TM:<E)#:&QH:F5&2'%X8FQW:VMN9FMA
M,5IM:TI:<6YV:28C>$$[<D904%AN5%A.0S%Y84\R:VAH<V]B3WEB,4QL3U9U
M:EAT+SA!5G!R<69I56LT5VMA06M,26\K4#1U,49716%Z*V)0;4Q5;G5D1W5D
M228C>$$[,'$X='!6<T%%=6)A-'5)9CE+87E#>E-1>DY#>E)Y;3AC=W%Y;W<Y
M4&5P<E)62CE.+U!R>F=M;%<K;U<Y<G V;W1J8B]!1F9Y-T9!>28C>$$[:59V
M<FPQ8FLR;D=4,48T4E%P>5=J<E)D9W4K2W,K.&UE65IF3BMT-DYD-GA:5U8V
M9G%M;U114TQB>'1(1$I9,WE143-L<SAN<7EO3"8C>$$[<$I$=#9H+W4V:G9I
M<C%(1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&5E@O:C(O
M=T)L9U93=W$W1EA9<3=&5FAG:"8C>$$[37EZ;4Y436ES:5-K1&M&66=S;V)Q
M05-O<CAS5E@T<3=&5F=G:$5Z5&E.4D]Y:$=L;T]:4E-3<6QU=$%72D$Y.%98
M-'$W1EA9<3=&6"8C>$$[67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ<2]W
M1$AT+W-S0W8X02\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.C,W1#5#,3=&,4,S,45!,3%"0T1&0SDR149"-S$S-4(P/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED
M.C,W1#5#,3=&,4,S,45!,3%"0T1&0SDR149"-S$S-4(P/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L
M87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \
M>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C,V1#5#,3=&
M,4,S,45!,3%"0T1&0SDR149"-S$S-4(P/"]S=%)E9CII;G-T86YC94E$/@H@
M(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C,V1#5#,3=&
M,4,S,45!,3%"0T1&0SDR149"-S$S-4(P/"]S=%)E9CID;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R
M,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-#4U04-#-S0X.4-!13DQ
M,3A",D)#0S,U1#0U-#E$,#D\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM,#@M,S!4,#$Z,3@Z,3,K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C,W1#5#,3=&,4,S,45!,3%"0T1&0SDR149"-S$S
M-4(P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(P+3 Q+3 W5#$R.C,X.C,Y*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R871O<CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @(" @(" @
M/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O
M<CI3=&%R='5P4')O9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O
M<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X
M;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB
M;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^
M"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS
M93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX
M;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!4
M4&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" \<W1$:6TZ=SXV,3(N,# P,# P/"]S=$1I;3IW/@H@(" @(" @
M(" @(" \<W1$:6TZ:#XW.3(N,# P,# P/"]S=$1I;3IH/@H@(" @(" @(" @
M(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO
M>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@
M(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT3F%M93Y4<F%D94=O=&AI8RU/8FQI<75E/"]S=$9N=#IF;VYT
M3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^5')A
M9&4@1V]T:&EC/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9A8V4^3V)L:7%U93PO<W1&;G0Z9F]N=$9A8V4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT
M.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T
M<FEN9SXP,#$N,# Q/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I
M=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^5$=/
M7U]?7RY01D([(%1'3U]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1.86UE/E1R861E1V]T:&EC+4)O;&0\+W-T1FYT.F9O;G1.
M86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y4<F%D
M92!';W1H:6,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z9F]N
M=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG
M/C P,2XP,#$\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y41T)?7U]?
M+E!&0CL@5$="7U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$YA;64^5')A9&5';W1H:6,\+W-T1FYT.F9O;G1.86UE/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y4<F%D92!';W1H:6,\
M+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%C93Y-961I=6T\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P
M,3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/E1'7U]?7U\N4$9".R!4
M1U]?7U]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \
M+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#
M>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE
M<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.
M86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4
M>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y7:&ET93PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D)L86-K/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#35E+(%)E9#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+(%EE;&QO
M=SPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!'<F5E;CPO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#35E+($-Y86X\+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D--64L@0FQU93PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+($UA9V5N
M=&$\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],34@33TQ,# @63TY,"!+/3$P
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ-"XY.3DY.3@\
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXQ,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TY,"!9/3@U($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XY,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C@U+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STP($T].# @63TY-2!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M.# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXY-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/34P(%D],3 P($L],#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3,U(%D].#4@2STP/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C,U+C P,# P
M-#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^.#4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/34@33TP(%D].3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXU+C P,# P,3PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXY,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,],C @33TP(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,3DN.3DY.3DX/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M-3 @33TP(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P
M,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-S4@
M33TP(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^-S4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].#4@33TQ
M,"!9/3$P,"!+/3$P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXX-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,#(\+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXQ,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3DP($T]
M,S @63TY-2!+/3,P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXY,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XS,"XP,# P,#(\+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDU+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C,P+C P,# P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-S4@33TP
M(%D]-S4@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW
M-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-S4N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3@P($T],3 @63TT
M-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@P+C P
M,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C$P+C P,# P,CPO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-#4N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<P($T],34@63TP($L]
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-S N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,30N.3DY.3DX/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX-2!-/34P(%D],"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@U+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,],3 P($T].34@63TU($L],#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/CDU+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^-2XP,# P,#$\+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],3 P($T],3 P(%D],C4@2STR-3PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C(U+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C(U+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,]-S4@33TQ,# @63TP($L],#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-S4N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,]-3 @33TQ,# @63TP($L],#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],S4@33TQ,# @63TS-2!+/3$P/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXS-2XP,# P,#0\+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXS-2XP,# P,#0\+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,"XP,# P,#(\
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3$P($T],3 P(%D]-3 @2STP/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,"XP,# P,#(\+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXU,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3DU(%D],C @2STP/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDU+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,3DN.3DY.3DX/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3(U($T],C4@63TT,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C(U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C(U+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,SDN.3DY.3DV/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/30P($T]-#4@63TU,"!+/34\+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C,Y+CDY.3DY-CPO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C0U+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^-3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-2XP,# P,#$\+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/34P($T]-3 @63TV,"!+/3(U/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C8P+C P,# P-#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C(U+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,]-34@33TV,"!9/38U($L]-# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C4U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C8P+C P,# P-#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^-C4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,SDN.3DY.3DV/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STR-2!-/30P(%D]-C4@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXR-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XS.2XY.3DY.38\+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C8U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STS
M,"!-/34P(%D]-S4@2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,S N,# P,# R/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXW
M-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXQ,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3,U
M($T]-C @63TX,"!+/3(U/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXS-2XP,# P,#0\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XV,"XP,# P,#0\+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C@P
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C(U+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-# @
M33TV-2!9/3DP($L],S4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C,Y+CDY.3DY-CPO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C8U+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.3 N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,S4N,# P,# T/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STT,"!-
M/3<P(%D],3 P($L]-3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C,Y+CDY.3DY-CPO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C<P+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C4P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-3 @
M33TW,"!9/3@P($L]-S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C<P+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.# N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^-S N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A
M;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R;W5P3F%M93Y'<F%Y<SPO>&UP1SIG<F]U<$YA;64^
M"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ/"]X;7!'.F=R
M;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@
M(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP
M($T],"!9/3 @2STQ,# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @
M63TP($L].3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^.#DN.3DY-# U/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STX
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXW
M.2XY.3@W.34\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3<P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C8Y+CDY.3<P
M,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-C \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-3DN.3DY,3 T/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STP($T],"!9/3 @2STU,#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXU,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/3 @33TP(%D],"!+/30P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C,Y+CDY.30P,3PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-
M/3 @63TP($L],S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,CDN.3DX.# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @
M2STR,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXQ.2XY.3DW,#$\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3$P/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/CDN.3DY
M,3 S/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STU/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C0N.3DX.# S/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @
M(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y"<FEG:'1S
M/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O
M=7!4>7!E/C$\+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" @(" \
M>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3 @33TQ,# @63TQ,# @2STP/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3<U(%D],3 P($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XW-2XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,],"!-/3$P(%D].34@2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P,CPO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^.34N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/3@U($T],3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXX-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,#(\+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],3 P($T].3 @63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDP+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,]-C @33TY,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXV,"XP,# P,#0\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# S,#DY/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,#,P.3D\+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#;VQO
M<F%N=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^
M061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( ;0!0 ,!$0 "$0$#$0'_Q  >  $  04! 0$!            !@0%
M!P@) PH" ?_$ $00  $$ @(  @<$" 4# P,%  4" P0& 0< " D6$1(3%!54
MTQ=3DY0A(EASDIC1U2,Q,S6Q&$&R"B51)C)A&21"4H'_Q  = 0$  @,! 0$!
M             0(#! 4&!P@)_\0 1Q$  00! @,% PH% @0%! ,  0 " P0%
M$1(&$R$',5%AH10B0146,E=Q@9'1U.$CEI>Q\ A")#-2P25#8I+Q1%-4@C0U
MHO_:  P# 0 "$0,1 #\ ^_CA$X1.$3A$X1.$3A%R5\2+;O86%O#P_>IG7_<T
MSKO+[?[7W$'O&Y:_2Z;>[G7*MIO3A;9. E7#; %FJK'>M)%F-"GEI(M^? 8C
M-J@N)2Y*9DE=H&CB1KM Z:Z=Y ^'58ING>KMOT6UKI;2/836%>[K]O)>L>R>
MZ=A6K4=WK>F:7)Z_]=RD6?(V047;J<$'IV43I]EJ\69KVIUEH-,M4,\L<7@"
ME#\OD#0[4@[1[HZ]>I^'3[_N'BK'<O'"!#+2*AZ^ZK["V5128GH.=Q<&-C4.
MIE6H/B%!"1+4 ]-2L.&_:V*&0BPQA.)D^T ;:65($K0$P/&Q3Q-A\>[=K_\
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MLOVXBG\O^M_[GQ\Q.U;Z[;/\@\.?J4^?W9']1=;^H?$OZ5/L$[9?MQ%/Y?\
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MX_TBRBY5GD$MB>%7?+ ?:.W.VV41$GB^TVD*Q%8J8&PFB82BB%#0\1Z6!ID
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M*%K7F!'*"=22MC.%"<(L!ENK77<\%WA736GJ.5"]E)Z2>^AT\0W*8VM/;$0
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M)9M19COD%.BJW"C9415B.]KU9=MXXZ[ZZ#265I@)B95C."&0'7IWB,?^SO\
MQ7*/L)U"[+]?=TZ&IE0Z[WKLM5NO_4OI1KLB"K%8['535O;/8W7JXVZTB(MA
MM6I NQM<1V:$>Q7"PA/8.3K,4)E.HCON6(!&=F2BR->TAQ+MNY[SW@EH=IW
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M(0G*E9QC&<\D N(:T$DD  #4DGH  .I)/0 =Z@D-!<XAK6@ESB0  !J22>@
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M]B#ZH9WMYOS7&;)K7:P[9%CC:\KO7J;=!U$/[;S0Z\/NQBO6O!#_ .J8=?\
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M-+6C9"W#NINRO9ZP6/:UH,;L:CR)^M^]TL_09FUAI^P!"&J,V6/KDA4=,C:
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M_010K>J#I3=L.LO#-@48SM&PZUG2+"4C3=B5ER=LBKH71B%.AAJD4'XG3X?
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MW+%R>>"R'K6S_P!8V^/9V-Z16X0VO/O&D>@BZZ"'0 [CDA2QL*+#RRPWQ^+
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MT?@&'Q$>9P,A>P(K'(UIKF9;,WV70*3*O.8\")FZ2*J"?MF8@J2W,%Q<V)V
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MO&X'MB:^O$:Z:H$!]@;Z;US3I/V96.M[%Q2F]EQ![%G,RXYJ>M0Q_= X#7O
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M%.L"QA6.%DR^8X\K#[/5?I8M.DHU[LKX*_5E>9GN6)80\EG-+9"V"$S3?PY
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MDR,N-9:<5ZOLV4_K)QCT9]*&TJ_1Z?\ +T^CA6:XD@$_V\%$G_\ 7>_>N?\
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1T3^X>_X3PK,^D/O_ +%?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g713200g59k87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g59k87.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2%L4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
MS0   _,          0                         !              /S
M   #S0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #S0    !29VAT;&]N9P   _,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   \T     4F=H=&QO
M;F<   /S     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     !;=     0   *    ":   !X  !(,   !;! !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" ": * # 2(
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MB)CXF159OLS;\AL$>G8*0W7\[]!CTV?]-*A^\/\ G*OP;2I]5Z?^T<-V-O\
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MGH_I-59O1K[KCG^J\O\ 3S+:Z]WYK &;6-_DM6DC(4:4#>JD.^AE]3JW$MW
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MN$G:]VX R=WTF!W^8FZ?CY^0;\F\;=U9JJ&TLW207%C'^]E3=GL]3WV_I/\
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M_C15Q#L?L+HWWTX]+[\BQM5-8W/L>0UH'BYSEEXS;>L9E74;F.KZ?C$NP*;
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
ML(=I  0    !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q,SHU-CHP- !R<C4P.3$V
M-P       Z !  ,    !__\  * "  0    !   #\Z #  0    !   #S0
M       & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@
M P    $  @   @$ !     $   %& @( !     $              $@    !
M    2     $X0DE- _T       @          /_A 4A-30 J    "  ( 1(
M P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $
M  "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$Y.C W.C(Q(#$S.C4V.C T ')R-3 Y,38W       #H $
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M 0$! 0$! ?_  !$( 3<!1 ,!$0 "$0$#$0'_Q  >  $  @(# 0$!
M    !P@&"0$$!0,""O_$ %40   & @(! @,"!@T(!P4)  $" P0%!@ '"!$2
M$R$)%#$5(A88(S)!41<9)#A566%Q=9:7MM8T-W9W@;&TU24V0U)XD;4S1V)R
M\$)38X*AIK?1X?_$ !T! 0 " P$! 0$            %!@,$!P$"" G_Q !9
M$0 " 0,# @(%!081"0<#!0 ! @, !!$%$B$&,1-!!Q0B46$6,G&!D14C0G.A
M\#,T-3924U97=).4E;&SM-/4%R1B=;*UP=+50V-R=H+1\0C"X414@Y*C_]H
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MG@9\@?/X=OCY<YJH7)V:0H$>XV%#.RQ=EK3->RD=MSBBJL>O1KZ7 RXI^)U
M,2,:QBAC )A:2JR(^7J(@2D=53>H%=3M6,>H6#07,,B\.<"3="V,;HW C5E.
M1M=D(PY!PSL5.]?G(5(.?>.1]!['\GGG9;6)8\]6Z_-JHBW5F(6+E%$! 0]$
M[]D@Z.ET/N'@942AW[]![YV2WE\>W@F(VF6&.0J>ZET#%3\03@_14B.0#\*]
MS,U>UY9YR&3FD*X>5CB6!U&NIEM"&>MBRSB(9.6C-Y*(QPJ_-J1[5X_9-7#P
MJ(MTG+MNB=0JBR9391!,86N1#(;=)4@:<(W@K,ZNZ1&3&P2.D;NJ$[BJ,P&
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M*J)F(FY23<IK-E%$#F!4A'"*R!C% %4E"")1^U(5E9E#JK*Q1BP#@')4E2K
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M3^]II?\ +(_^GT^3^O\ [J+G^)D_Q-/Q&.9G\9#LO^ICK_'N/EYT3^]II?\
M+(_^GT^3^O\ [J+G^)D_Q5/Q&.9G\9#LO^ICK_'N/EYT3^]II?\ +(_^GT^3
M^O\ [J+G^)D_Q-/Q&>9G\9#LO^I;G_'N/EYT3^]II?\ +(_^GUY\GM?_ '47
M/\3)_BJ?B,<S/XR'9?\ 4MS_ (]Q\O.B?WM-+_ED?_3Z]^3VO_NHN?XF3_$T
M_$8YF?QD.R_ZF.O\>X^7G1/[VFE_RR/_ *?3Y/Z_^ZBY_B9/\37Z+P?YIH 8
M[?XC^Q#*"7H <4=95/OL!#LJEX6 /I^<!!-UV'T$<\/7?1#8W>C730,\[;U
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MKW)R+9<>N27+F/HFH=E[PTFXY.P?&;=VAVFOM0.-V;,_"F/UI<9^K7UO)OK
MZ:V.S6.*J\M&J=23I@I',%*Z7![X36S9RV:,C^<^FI-Q3==_#2B],'^T=E1T
MU&5OD.^Y ;]=32[2,J]Q=DE;7$ZBV,486Y.XQ]'1T;9Y".82*,@YD6*2E1EK
M/X>GQ(+%JTDUOZE2,AN'3&WOAX<:-/MVNR:<Z-8>)7$WD%%[#V1NUPY;VP8Y
M)?8K9XUF)6%E72=S=-*,W:'B'"ZR"+A2O5<?#YY_U%WR9I4?I*M[=TWQ2I'(
M.L?#WIU_OT0\KF[6G+G>]4V+:_P@@F6PZL_*OI+4\=9=?0T%?9^GQ-I<R2$
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MU';7=E=+JUN'>V6-HKM  Q6)Y#+O5<Y+12O--'Y,)IXW9#X0;!,C(YE495@
MPSV/;<>>1V\C]E119]Z+MX@$:G&,YN?<%#TSKR)XE@S(<1 B[XAF4A,H"?\
M-(5E$2(E-X*.OD6JI7J5<N^H72V<P>JM(5R9VN$2!5]X0++,7_[J*&27ON1!
MBL;2X!QL#=]Q( /EQW;GGR/GWQ5)B0-OY+[@@]-O)A&QOI)VPF-W24(U,E7-
M>:LBGX2@TX#?,R HS]_?H-(HZ$G)K3,G!C-/W ,HX8*,:5G3;2YZGU:&S:9K
MF+Q$GU.X1&BBCM8'WI!%[<C)O+;0\CF:61LR*B(B1X8U,T@7<6 ]IVP0!@C@
M \Y)\S@D^=;ZFC5NQ:MF31(B#1FW1:MD$P J:+=NF5)%(A0]BD33(4A0#V
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ME,4IBE,4IBE,4IBE,4IBE,4IBE,4K6'\7G]Y9:?].-?_ /KI,ZCZ'_UZVW\
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M3MNS04<NET6Z")#**K+JD22(0@=F.=102D*4OZ3&, !^D<QR2QQ(TLDD<<:
MM)([!41!RQ+=A@<\U](CR.L<:-([L%1$4LS,>RJHR22> /,U5^^;U^T)>,IF
MMCIO9IW(M#KRRJIT8QNV:KD<NA45(*9OD$T4E%'SLYR-CM2*(IE= L)<YSJ7
M6IO[^#1^F)%EG>8&XU26,-I\$$88R99B"6+!1G 7&>3Y]%TOHA[33[C7.IXI
M;2PBA98;)#F^N;N3"V\:1INQN8\CE@/:*8!Q92'>DD&+9VD\;/TED4S%>-1*
M9NX/X_E%$1)]T4S& 1+T(]![#[@.=#MY4EB219HY1M"M)&08WD7B1D/N+ X
M) \JYY-&\,TL4D;1.CMF*3Y\8)RJ-[]JX]K@GG->IF>L=,\R/>/M%*Z$I)L8
M9@XDI%<&[1J0#*'\3J',8QBII(HI)E,JNX75,1%NW1(=9PNHFBB0ZARE'XFF
MC@C:65MJ)C)P2220JJJJ"SN[$(B(&=W*HBLQ .2**2>18HEW.^<#(   +,S,
MQ"HB*"[NQ"(BL[D*"1"%HV;=6YVR4!78IG\\@#EG]K.CRT@+8XB"2SV-B%T2
MQHG#[Q2D=R8@4!!0$SAZ>5F_Z@EMBJ+%'!*_,4,JR7ER5_93V]JZ);J3G;FY
MD<@$.D; @6*PT&*Z5Y&EDFBC;;)-$T=G:AQR5AN+I7:X(& =MNB$\HSH0QQ1
M#;>VH@QW$Y1X^=C4A\USP0F9.4T0#LRB*;B2>/G1BA]X$$84ZAOS?(OU")'4
M^N02%I=+M;^W'+^IRRVMRB@98I#=AEF8>48="YX# X4R[=,Z+,FV'4[FRN#P
MINXHKFU9LX ::T.Z)3QF1D(7YQ3&34ZT6_5O8L&G/5I[\PW]0R#MLH!4WL<[
M)_[5H]0 QO263']1C)G#W3.8.^K7HVM:=KUDM]ILXFBWM%(C I-;SH<26]Q$
MWMPS1GAXW (X(R"#57UC1M0T*\-EJ,!AEV++$P(>&X@DYCGMY5RDL,@Y5U./
M(X((KT9ZRM8,S9J5NYDY:0$Y8Z'8>C\TY$@!YK**.%4&K)DD(E!9\\61;D,<
MB)#*.544%-NYNTM]B[))II,^'!"%:1@" SG<R)'$I*AI972,,RIN+NBMIV]L
M\^YM\<,,>/$GF+"-"V<*H17DEE8!BL42/(RJ[[0B.RP#8]D6^8%Q%%H=?D&B
M#I!92/?E;V9H=U&O$GK!8%CRL(@5TS?-6SU$%F1#M'*2*J:@+(%-E9DZKO8)
MF%@MNMQ'XD;B*6ZEV;T:.6)KB%88]S1NT<BH70AF0NP)%6:#I>UEB5KU[D0R
M;75I$MH,[2'1UMYI)9&4,%:-F\)BV/85A7?B]_*1;MJRV35GE20=K)-4+ 0Q
M7$+\PKWZ:;HZ*SU!GY 4P@5.3?+=%$YD2)$553U8NM4MF1=>L'TJ&61(H]06
M9+FQ\1SA!<,@$EIO/"F0-'G :16.VMB7HQ[E7.A7JZI-'&TLE@T+VU]L3)<V
MZ.2EWL4998F$@Y(C*^T;')*I+I)K(J$616(15)5(Y5$U4U"@8BB9RB)3D.40
M,4Q1$IBB @(@.7D$, RD$$ @@Y!!Y!!'!!'(([U22"I*L"""001@@C@@@\@@
M\$'M6%V2_15=^;1(SEIY^Q2*L\80+(7JC(BA?)+YYP<Z+-FHJ4042:JN/GET
MA!5LT7)[YHW.HV]LSIB2:6-=\B0J"(EQD&>9VCMX,@@@32HS+RJL*W;?3Y[A
M4?,<,<C;(Y)B096'<0PHKW%QMYW>#$X4C#$'BHC6Y"+HF*<=?S2S03?>59FF
M7+@A 'HQCH!5B(IB'7_;.TD__P 7KH<KDW5RQ-E=-GNHP<$V<\5Q+]4(50Q^
MB7:?)L<U8HNDFD&&U*"V?&0+R&6WC^N0LQ7_ -2 ]O9R0*E*C[/J5_(L2#>G
M3D6A0,]AGY"MI1H41\?,Z **IK) ;[AE6RRY$SB":HIJ#X9,:3K^F:R'6SF9
M;B( SV5RC6][ &[&6VDPX4]ED7=$Q^8[8J&U30]2TC8UW"#;S$K;WMNXGLYR
MOSA%<1Y0NN?:C;;(G&]%R*D+)JHBF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2H,Y$\?J5R:UF^U3?WMACZY(2L1+KN:N]8L)8',*Z!XT(FYD8R6;%
M1.J  N4S,QSD]B'3'[V3W3G4-[TQJD>K:?';27,<4T(2Z222$I.NQR5BEA?<
M!RIWX![@U':IID&KVC65RTJ1,Z.3"RJ^8SN'+HXQGO[.?C4TL6B<>R9L$3',
MBR:MVB1E! 5#)MDB(D$XE*4HG$I $PE*4O??10#H A)',CO(V 7=G('8%B6.
M,DG&3QDGZ:WU7:JJ.R@*,]\ 8&?CCO\ T"NUGQ7U3%*8I7'8!["( .>;@//\
M_P _LI01  \A$ #Z]]^W7\^,COD8I6+VBYU>FMVKBS3L5")/EC-V9I1XFU!T
MN1,53I-P/[K*$3*)SD( B0@"<WL&:=[J-EIT7C7UU!:Q_LIY @('?;YL?< #
MDD#OC.U9V%]J4I@L+66[E W&.)2[ $@#( X&2.3V\ZI+R1M&Q=@QI('5;-(\
M<9)1T:84EF,>S?K$;"HW*W6?>0% ZXE;-G"S!RU; +B360<"BT9NN8:GU#HN
MO:C'!=7-P.G=.87+I:1S2-K3H%?P'0+&+>)6# B64^,/F>T>;YI6FW73UI-=
M1PP/U'.IB2*X#,-'3LTBKC9<W#@@Q"/F-P"0QR*J5KO7DWHW4:5PY([1C7T^
MVD9$)U2M2:;QNL%HM*YH&JM;%*'B#&:L&K^,A0DWQ8L 09G=N7C=(IEB5RRT
M2RUSJL_<2UL[#3[S+6]I,6-K;(K+^F#;3R3RL?\ ]MN0MNWY)09L=]UIJ%AT
M_#8WT-WJ%]*?$DU.6W\%Q*4D&V-)(G1&PS%6V@A0>^2*G+6W/G6<M=:UIYM*
M0U6DY=@Y2I:$6\@;'&23>$C'$BNT!PPEG+MLY".8/7*+APU5CW/RJR9Y4KM9
MJBZZ)JQU[0--EN[;4M%:RLI%@>WM]*N[9HA[0W1K=R;F#8;:_MJ=N<D'GF-A
MX>JWH@?3KV>\NV9HW>Y#F0J1O+"")0H!<<G'<>562E=\Q[$ACFM!UC /CX(-
M(I(0[[]_OMW!_?H>N@$ Z_7]*,>O-;F<QVMQ)<,VT)';6,#R$D X8&.3')\@
M.,#FKM%T'< >+=V=O9PCGQKFZF*!>,GAX\$<Y!)Q[SQ64T6[7.T1#B62B)T6
M:DDNE'KNFZ387C--!J)72!#(-0.W.L=<A%2)>!S)G\3& ,NV@R=77=D\^H(8
M)7N)/"CF\."3P D80M$L*A=S;R.!D8/;%0&KVW3MC<I;P7"W.R!#+);*SQ>,
M7D+(KEGW%4V;CN/.1Y5VMO2#EW8*U62&\6RPIN%/O'#R=O4)Q1!8P$$O9&["
MOR[8P 8# ,D"Z9DUFZ*I)W6KEXV"HP5HX0\.2<>M7#O%!(0,;O5XH[J4*>TG
MA2*4>-7$9HUNDBLS#(>;9+@@'U6!5EGC!.=OCRR6L;'',9>-MR2.C==JR;LD
M@2;I 0@= )@ /(XE   3G  \A]@_^$ Z*4"D I0JL<:Q*0@/M$EW;F1R?PI'
M/)8^>??CM@59Y))7(+< 8"JO"(HX557YJJOD/+.>]=@1*!3";\WQ-Y?_ "]>
MX_H^GU^OZ/T?7/OCG/;!R/\ 1\\_#&?L\N]8U[KCYVX8XSSD8_X_T>=5CTM-
MFJW*R0IT684X:_:Z/9))@ ^"#:?B'SHBCU%+\T3.V(,""H'8%\3MT?%%$J9*
M?T7>&R](EQ80;EM^H.E_NO=Q9(C^Z-AJ4EFEVB]A)<6>Q9CGVF16.6S5TZQL
M4O/1Q#J4P1KC0.K!H]G-@&;[FZEI:WQLV;.3';7<<CQ9R%64@$+C,W&<&MML
MG)5RJHJV0=*MVY ,)2IH-W#MHP;D'\XB2D7\L_,!#%\7,O*$[,1V8"W_ %25
MKB9D+,%FEG,VUL-X-M-):VUKN7:1#(%ENW'F\Y!)4#% TN(01(X09BA@\#?@
MJ9KF*.XN;G:1CQ!NCM(R?FK I&&'.6D3(D4J::94B$  *1,H$*7KKZ%* !_Y
M9H !?9"A .RJ H'T #'Y]ZW6=B3O]IO-F.3]O]'N^-8??HB/GZXYAI5,%F<D
MLBS5(8 ,/2@B7U"@8IB"=$/RI/,IR"<A04(H03IGC-8BBN;)K:XC6:"[ECM9
M87[2QSDQR*>YX5BX;!*NJN.0:DM(EF@NQ=6[M#-:QO<13+WBE@V.CCMP6"JZ
MY]I"RD@$D8EQ3V5.2''%TZ>KC)2]/L<_1HER[,8PNCLY[[!@U7BACF55+\TN
MDHY$3>8(^29!$$RYF]%^LW5WT.$EE:[N=&U/4^GH)YR=USZC?M9V#S$\@M&]
MNLAR3@$Y->>E#1;6RZW#11K:6NM:7I/44\$ !6V.HZ>E[?QP@>R<2+.\8&!E
MU7R)K,JTV6>117;UV[<-I?PD3-%G*HINC+_ERN9 H"4KIVH)O4<'4 Q5G0J+
M"4$Q;MFLA<DSM)$TDC6:.46$L0MVZL#-=W0!^^23S LJME44 *  $6+ML6\<
M<JQHMXZ*YFV /:QLOWJTMCC[U'%$0K,@5W8DL=Q=GRLB9$R@1,A$RAT %(0I
M"AU].@* ![?S9C554!550., * !]   %?;2,QR2Q/F69F/UDGX_;55N04NYU
MS)U[;< Z,PFZU,5I"0*F)2IS$+*2H1K]D\*4/)P"#151X5,PE%5-OX*G,DW2
M2&@]9WTF@SVG5-K*T=YH,NG33[" +W2[R_AT^^TZ<=G0Q3BZA+9V31'& PQ?
M^C=/37XKGI:ZC$MKKT.IQ0[LDV6J6.G3ZA8:C"2<JPEM_59]N \,OM9*X.QZ
M->IR4<PD40$J,@S:O4@-^<";I BZ8#]/?Q4#OV#^8,_0J,'1''9U##Z&&1^0
MBOS\ZE'9#W1F4_2I(/Y17=SZKYIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE=%"4C73E9FVD&3AVV'IPV0=(+.&X]]=+(IG,HD/?M]\I??V^N8([FVED
M>**XADECXDB25&DC/N=%8LA^# 5]M%(JAVC=4;YKLC!6^AB,'ZC7>S/7Q3%*
MZKXKL[)V1@LBW?&;+E9KN$A701="D8&ZJR)3IF5235\3*)E.03D 2@8!'O/B
M02&-Q$RK*581LZEU5R/99D#*6 ."5W+GMD=Z^E*AE+ LH8%E!P2N>0#Y$CC/
ME51M@[4W;JB$/+VIKKQ\P%X@S1?1YWRCM4[@PE 21BK]@LMZ( =9T"2?Y!NF
M=3[X!UE!U[6.I^G].EO9I="N40[5)2[M[B5CDA8[<-*FX 8PTN">215\Z?T;
MIOJ*_BL84UNVF==S,#:R6B =V:5@LJKCW*Y)R!Q5>);E1LN6;J$9O$V7F7H3
MQ46V;J  B(^!%G7S3E,1#_N."'[#Q Y.LY5=^D[J>XC"+-;6@F;"-! 'E4\9
M4'+;6'8Y&./G5UR#T4],V3++.+N]  (,LR);MQW9P53G=V8KW^:.15';5SYY
MFT">=H,M7%L<"T=*IM_F[#,N7$DS3.?T522BU&EH))9=,I3*((F55:F'TU5C
MB41#I>B227=I;W,7I&CDE=&\6*^ATM4$N/839+)&Z!FP-RDGW8S7,=>L19W4
M\$WH[N+>"&01126,M].+A6(!GBGMXYX/9&6V,=V>-AJRU:Y<V'?NL6_[(5"8
M4=W(N7,0XB;O IN95J[67^RTG$.X(_0:G^TCN")PTJE%,W:XJI@G'I+]!E8Z
MAZOUV&4Z"IT;69),JNH:?;2W(]H8$8A)DA$OQ5G4GMS@U:]!Z&TAX4ZB(US1
MTB"^)97DZV1158$RFX*I)X3$<[]A((![<_NC0-+KBS-'9>RMB1Q%@%I TN,;
M0#-NW:,FS-!O\U*O8IJ[<J.#"NLQ:LBIG!LD(.'#A4AO4CK.QZ;T>TCN^JK'
M7)KV[+-(OJ%[9VJ!F]G9B2"+)/S2F>WO(K:O]6ZGU?4+B#I2ZT'U:WC"1NMS
M8WMW*4!.YB(IY@54??-^%Y[CO6![J?ZM=-IZD2TT^)2+*HWC6[;8JL#*P%H0
M5:F<J1Z7VBZAF+2<*Z;*+,T%)0'Y%VQ7K!BH"'K):,EQIQOA<])Z5K4,]OB9
M95FD:*&,-AI+F!X)V\%0R@G<"K; ""!F1%CK*V%N.K+S1'@N0T4D,UBD4LT[
M E(8+F.>V#2NBNP41E2,YSC)K]J'4/';0>QF$E#:/M#*=L'S3%G/2X2LRQ8)
M)L%W<DQ2F&$I(.JLQDF[)4ASJ2*:+KL(Q1RH"J#8\U?:YJCZ>;J]U?I77["-
ME>?2Y;J:*Z\< EXY()(H68@Y&/#*#Z" 8+3.GM/BOI+.PL.I>G[V3?X%[#9Q
MM9+&Y_1([E99A&&&"2'5N5SC'&UK6]KA["HS:T/3<:R=*KHM5[06(^VVD.7O
MM5VJK(@W ZA2@;I)653[.8AC&Z[ UAZ;ZIU+5S;)8]'6]C;/,J2W=M';I! F
M%SA!% S-C\++97 [U6>I.E;/1S<OJ'6+7UR(F>*UDEN)9IY,M[+R>),J9(&5
MVKWR,$Y-\D@Z(4.BAT'710 "AU^@.OT?J^@]?4 ^F=6';W_5C\_S[]ZY>/L/
MN[U ^[:Q+.6S.W0!C%DH-,AC& H* W^5,Y.T>*I&$ 49E1?RT;(D#KP9RQW1
MSIHM%5"U/JNSO9+07NG>U=6HWB(Y,<FS<RB51R\;*TUNX]D1BY]9+9MUJU=+
MW=FET;+4,BUNLH77&^,N%#&(X]F4,D,R=Q(UNMOM^_Y$,0.S'<D@L:0:-6KZ
M-41)+LB L0HH*CX%DF9E%3G1;&6[;+(.!<&9.#-R*N52/&ZAN;VW4CW%OZTT
M @-K*L&HVD@826KD\2JY"GP),,J&105DPK=Q70[CIU+>=;82M*+B$SZ?=( 8
M[E!G,13D&9,;V$;D%,LH(4BLJFKI#H,52-5SN'#A$Q$")IF$_DJF8/8@]'4.
M4!$0!(I@[ 1.<A ,8-R_UZQC@*0.T\\Z%(HXE+2$R+C"H 6=ANP @;+8S@<U
MJV6A7AG5YT$$$+!I7E8! J'));A5CX!+,5(7D#/%5^XFE+MOD-M#<[$@.*51
M*_&:?J<NETHPG)N.<.Y.XR,:Y+VB_9-)247@$I!H=5!=:$6,13Q$H!@]'5J=
M6ZEU'J0+NM--T>'INRN P>*>8W4E_?20,/9=(I9? $JEDF""9"(Y4 D/2-=#
M1^E=+Z79BM[JFLS]57UNR,DEO;M:0Z=ID<Z-[22RP0-="-@KPB81N"Z-4S7L
M;!JVTO'C-BG(5^4456,V.)TO5;F=NGC=PR= 4Y&SV.!ZI$.45DURK-644JJ9
M ':2J,QU5=WG3U\MTUO)=Z9.TIE://BP%YI;A9U)!5]@D>VDB9E 2*VD# S.
M*KW2]K:Z_9^K+<+;ZG!L$0<@QS!8HX3"RJ=Z*Q1)XI55SXDUS&581*:]R'NK
M&0%N==1$C5^U*]CW90.D"B1C"04UT%!.9%=!4JK5T3S$6SQ%1NH ' !'5BUB
M+QEBN)(5CFB%Q:W"$B.6%LE6VDL5\U;DA9$93W%;<VCR&$RP),SPR-#<P. 9
M(94X9=P"AN<%1W*$,.,XCO;VX:I0JQ)VN6>E+#U)LM.2*@AT*QFI!^48-TS>
M)U'LFX\(^.;CXG>/W*"*11*"BA(;6^HK& 1N'9X+)Q=W#JN1[)VQQJ#C,DS%
M8K=6V&>=TBCX)=9G0^G-0NG-NJ!;B_1K2U1^V9<B21V&=L4" SW3C*V]O%))
M)CV0?3XHZLLM;XG5Z.FV?I72R**;$?QRW2:J<K(3B%J)#JJF'Q^^JC\J1<QA
M(4JY5!^Z AEP]'VA7.E=#6<#Q[-0O9Y]<FCD.W==7=]]T(XW)!V;U6*,D %<
MD@!A56](VOVFK==WMQ ^_3+&&VT&VD4!_P#,;&Q733(@4D,0/$<8+9/X1[U^
MZS?3QYV]/E8\Y9!@D1C%/1.*2$P@U3$J!%B'2!6/ECH)"0S91,Z"[Q-9#UFK
MU1.-+ P:XJW,VE3P,-2ME8QHV8X[Z*/)\6 ^ULF* F6W<;DE66/.Z-P):;1<
MP1:E!,C:=<.@9D*RO92R!?O4PX\2$.=L5PC,KQ>%*0%D3,G,9V->M/G/F$VY
M 'I0JRB93)C^CZ&_* 8/<AB_G![ 'D @$G;ZA:SP>L>*L2@D,KL R$9^W/<8
M .,< GB.GTVXAF\ 1O(QP5,8+*P.1W"G;@C!R./KS5)>4LZG;2TK6D";YZQ[
M-VC3:]#LD/O.ABH116=M<@1( \BH,HAD=)PJ<"D16EF"1S HZ(7.==5E.HU;
M0K8>-)KFI:1ID( RPAMKVWO+R7:,L%BB@^^L0/#]9A4Y\0[>D]'A^GY#U!=?
M>H.G](UO4YRV<>/=V-QI^GP]Q[<UQ=;H4X,HM9V7'@G=MCBV)(R,CXU,QC)L
M&35F0QA$1$K9$B)1[,(C]">P=^P= 'L 9^F$01HB+V150?0H 'Y!7YG=B[N[
M?.=F<_2Q)/Y37?SZKYIBE,4K3O\ %;Y<[TXT6OA12=+6Z1HS?D+MS9%-O=CK
M''.P\I[XSA:?J6>O$82FZ<JCMM8;([<3,8W1E?LHJJ\=#G=S"W@QC'8'4KOS
MGQ-FVC-S<=^'FS]>;3V7O_D#2])2^F[@SI#36$3NP+H_>,-M6*6I4L]<R&DW
MND8N+?W+85)LYW4LSACMFL:#A^H+8BE8?J7XS=9V=8M>M'_%;=-'I>ZH7E$&
MB-A6"W:93A-KWWB0A9I':-$8HKWYB:DD6B*G-KUZX[+<TVKOWT=(-W+MC&,S
M3:BE8Y7?CBZVFZ;?)1'05PLU_H7(OCKQT6UYJ';>C=RM+58N43.27U7(4O9U
M/NQM:3"B[^(D(*?B75CC!@)I(&SZ0*W]5TBI7I?MU=/28ZHB97CC>Z?LZ^[[
MWCQSMU,V+M'3.OZGKC9F@I*K,;54W.Y;+;&>L[-;K2C<H1WK*MQ,TBI=P1G$
M6KYF:) [Q3\_?7QHWQ0;,QMNPM/US7>T^6F_)[F'S$UGK#640WT]J(*YJWC"
MC2'=M</;C+6&,K*];KAKG!0]8EK L>[W27G"-WC)LFR5<HJ5B=B^/?J5*F)[
M+UUQCW[L_74-QLUOROV;9XM[K.N&U9J2X[(O&J[3]OQ%FN,>]FKC1;=1WS(U
M9JGVV%D2^??QTDVC(E9\NI6^1JY1>M6SQN;S;NVZ+E X@)1,BNF55(PE'H2^
M1#E'H0 0[Z'WQ2NQBE,4IBE,4JJ?-:YW*A\<;_8*(H[;3A4(^//),3'3>Q,9
M)OD6<E)-5D_RC==!LJ8B;D@E4;"K\PF<ATRG+R[TRZOJ^B>CW7+[17EAO MO
M;O=0%EFL[6YG2&YN8F7VHW2-RJR+AHR^]2"H(M?15E9W_4FGV]\%:'=)((G
M*32Q1L\43J>&5G )4@AL;2""17\WNMMD;$J&P8"TU*>FBVDDTR52%%XZ55EW
M"CI,!8/DO4$9%!^8PMW#5<%"N2*F3,41-WG\^]#US6]&UFRU71[R\75([N%X
MC'-*[W<C3*?5YEW-ZQ'<$^')&X=75B""":_1M_IUA>V,]I>00&U:%U;=&BK"
MBH?OD> HC:)1N5E*E=O?&:_KD9*++,FBSE/TG"K9!1=+_P"Z642*95/_ /(<
M3%#OW]O?WS^J$#.\$+R+LD:*-G3]@Y4%EY_8G(K\DN%5W53E59@I]Z@D \<<
MCGBNUF6OFN!#L!#]8=>WM]?Y<'GC^BE5IF^,%1L$L\DI.QV]RFY<JNBLUGS!
MP"1E3B<42.GD>Y<F03[!-,JQSG*DFDF*I@3+U3[WH?0M1GDGO!J$YDE\8QOJ
M5UX D/[&$-@# 'G]N:M]CUUU%ID$=OI\UE:"*(0B6*P@\=HQGY[D%=W)]I44
M_::PB2H^F]96-G'6:ES8QRJ2!V5OD'+V4A7KE3S!5A(M68H-VYT#^/BD9DX]
M<@^LHB"8&..F^G],=/3+'+TW!':K[<&I&U2ZC\9\L_K#,C^KX)QXK@ G)&.Y
MVEU/JKJ&#>G4MQ+<Q%C)I?KCVK3+SM,$"LD4Q('S% (SCVC@5$VE)^O;IN6X
M("\:6J=3@Z5-@QI<M#E/&.K*P!U(H 3U4G+8DTNLT;,I1-_$E(S*232;JI H
M4ASU7H_J)>M-8ZKL];Z9TA-/T>\2'2+A[6"7UR EU(>23*2S$*I1K=512V.^
MTG9U>PU7IBRT2?3M;URWFU" R7T EN8(+60[2!L5O":/V_;)0@ '.>144;>B
MM5)M4Y35:MYKUF1D$D5(&32C)&$2*W<$.Y7>)2I9.2:.$_$2-4&<DS\'1A.Y
M3(1(PF@^JINBH;:0V.DWVE:K'=&%&A@ELHXW0X,D@&%\(@95QMP3G)[5T?I"
M+K:[E1=2UC3=0T&:#,P,T%Y-,".(XO8#^)G!92O 4C%82SVALM@JP/(*5VSI
ML%D#$1M$*M*HMD .0CPC="3=3Z#8RS7U4Q&.-$B!C"8JA$A,4*SI76FMV3*J
MWOKP4A((M1\*[B.<*J%Y6$T1;L"LB*,^V"N15EU#H'0KV.8BVDLG969I[ /:
MN"/:+D1Q^')CS#1NQ\N<$55N7(_1^RKA(Z]OT16&1I"9,#)E:*PVJ=>=/6SP
M2LR1[:99(U9T\9O2%*V6&?).^J0/3C >%4(-SU'2.MW@75KBTTZ"&[M3.T^F
MVUMXL%N2 R2_<YI)G@C7,KO.74>&&.6" 4[3M9Z*LYAIEO<WUW+8OX#6FI7=
MUX-W> A4,9U+PX(IR24C%LL;D2-&"%+"K@Q6MK\I&-'T(RFY6-61!-%U%)?:
MR8&$A1(@N2-%VLU.(?=!)XDB8AA #@4X=A4TZ UZXA6YL/4-5AN TD,MKJ$)
MCD\7_M)(KB2"3:64KQG:5?<H!&;2?2+TO:NT&HI>6$T+1QR)=V#+/'G=NAC:
M/Q8]L0V[G'SU=2">0*H;9V%RXT==SSU %FZC&*+15U4I6"E6<NDW!,OS!W#N
M*<-+$Q*[72441?N(Z;K9RG!-\FV(W*9U>NGM'TW2X5M+^ZU?I77PWAB274$^
MYMY(1P]HT:7FGW$Y)V&TE5)L(&+B,H6I'5&HZAJ<[WVEV>B=5=/N@66&ULS)
MJ.G1@Y:6Z/CV]["@!SXZ.T*D\1F0'.QWBIST3W3K!:QVRMR=6L\+99"K3L0_
MC7CD4G[".B)$56DG"LEHN99+(2R!T9)JC'"H;U&[F+8.VSA M_M[[6;97M[P
M6E_)$X5+N!H8?%B,4;J9HDNIUCN S,LH!C&0"(8P<5S6XT_29W6:Q:]LX9%)
M,%Q!-,4D61XW,4IMK8O VP-'E),9*F:0@FMEXAW[#[@/L(#^G+15:JNNP..-
M<MSDTK7)V:U_.CY_NZO&2,T'U"B53N,7Z03]0O1#@W.BF*7F3TORJAAHVN=!
MZ=JL[7UE=WNA:DRLK76FM%X<P;YRW-G<136LZM^$K1C=DY)R<W;1.N-0TJ%;
M.\L[+7-.5@RVNHK*'A8=FM[RWEANH77\%EE..!C: !7:4X/7&UE4A[9OZT(U
M-UY)2L94HR/KK^;8&$ 4CWTFT23=().4^R.%V"S9X4!_(.$S?>&GIZ)]1FD\
M/4>L)I=.;B:TTW0].T::Y0DEHI[VS/BM$X]F2-%2*125>,KD&Y'TKZ;;1B73
M.B[6/4X\-;WNJZUJ>MQ6LH'LRP6-Z? $B'VT>3Q&#X8$,-U7=UUKJG:IIT)0
MZ'",Z_6*^T39QT<R2*F0I"  &66,4 %=RL8/-==3M14XB)A^@!UG2]+L=&L+
M?3=-MTMK2V0)%$@^UW;N\CGVG=LLQY)KD^JZK?ZU?W.IZG<275[=.9)II#DD
M^2J.R(H]E$4!5   KWIV B++'+14TR2?,E@'M-3R*=,XE,4%6ZQ!*JW6*4QB
ME61.10"F,7R\3F*.>[M+:^@>VNX4G@D!#1R#(Y&,@]U;GAE(8>1K7M;NXLIT
MN+69X)HV#))&<$$$$9\F&0,JP(/F*J#;.*]K(NLMK79XPK55918D+;(%K8HU
MLHI[G61,'I*?,']B"L!$C^BFDB8YR$#KENH^C*[]I="ZB]4M2[.FFZQI5OK=
MG;L_SO5)&FM;NV4\>RL[#&0<Y&.GZ;Z2;/V6U[IXWEQL6-]0T?5+C1;N=4QM
M%S&L5S:SD<X8PJ0>>_?"JWP9=3EP@[9OK9"VR&%5E$)NNZ^AXLE<H*,VU[,T
MFY**2,964D&:GY1J1VJJS14!-RFW(]00=)_&C>BUTN[>\ZFUE-:6TF\>UTVS
MTV'2M)29?F326D+N+B1>VZX,LFTM&93$[HV?5_2E&;*YL>E=#;0C>PFVO-5O
M-3GU?69;9@-]O%=SQQK:PO@;H[:.-&(5V4R*KC820A$B$33(5--,I2)ID*!2
M$(0 *4A"E  *4I0 "E       .LZ\!C@< < #RKD)))))R3R2>22>Y)J%-FZ
M6B[X0[^,D%*U8RG*NE)-D2JH+.4Q Z2SE IDE4W '(3IZU627*)2*F!59%N=
M&H]1=(VFN[+B&=]-U.!@]MJ$"*[1N#D%X25$@SC=AXV8##,<"K7T]U9=Z'OM
MY8(]1TR<%+BPG8HKHPP1'( Q0XSMW(Z@]@,G-3)W3?*=HNNVB&.M;$50#=S*
MLY+P)55!^BQXI Q4 ,(_>5#T2^J;R,H*IQ,<_+[[HCKQ97\"UZ4U NP)N_NA
MK6F(Y)&99=-A5HA(?:9TM[J)&9BQ/G73K'K/H-H5-S=]66&P#%FNGZ+J;J!V
MBBU&=HW\,?-5Y[>1T48 QP,ZX\<3)>D7=WNG<]H9WS;"\:I!U]",8_9M1U[7
M5ER.E8FL10J+%([=N"E7E90YSJOG*97! 0 2HIW+H[H*31+MM:URZM]0UIH3
M! MI#X&G:9 W+16,!4;68YW2D"1]TC2/+([2&I]9=?QZU8IH.@V<^EZ"DPN+
MDW4_K&IZO<J-J7&HW"X5O#&!##&%AB4!8HXU&TWFSIE<RIBE,4IBE5%Y3\+M
M6\MWNH)J]6?;E%MFB;7/W+6-XTML>7UC<ZW-VBKOJ;.J-K!#$.[!&1KDD]C5
MTR>F84'*R8* FLL112H6M'PL>-5YO5.VS>YO==XW'K<=$&UMN&V[3E)W9-!'
MC_)3<Q7?P:LCYFHHB%VDK+8'6V0?H2 ;$-*JIS0"@UCDF2E5,XO_  -](T;5
MHU_DY8+MN>XNZ_ROI00;7;&PU]-T:M<J;A<AN\KJ6ER9XT-?W:RZRG8FJVJ;
MA46J9WZ,P]8(BYDG<F^4JRM%^$=Q5HQ@=%E-U6Z:/MGB]NAU8KSL][8YI[=.
M'JDF72 *KJQS=LW@8./DQAI&!CVC*/DHQDQ(*:#LKEXY4KN;(^$[Q?VG7KQ2
MK+-[P0UWM/=>P=[[7UO![8EX>C;-N&RYRIV&Q,K=!MV@E7A&\E38HT",6O%6
M"#:N)=BPL";26>HJ*5]+3\*#B]8':T_"2^[]8W[]FO=V]([:.I=NV"@[&@[+
MR+8P<=N&N1-CATRBG0[>TK, 5Q6G;5X5DM$LG<>\:O$O7%2OTK\)3A@37^P=
M70M/M-8HVR>+E+X@3T' 7&113;:?HEGM%RARQCM^G(/D[:[L=PG).<M+YS(/
MIETY%=Z51<ZZJZE;)F;5%BT:L6X&!!FV0:H@8WD8$6Z144P,8?<Q@(0O9OTC
M[XI79Q2F*4Q2F*5T)2+CIN.>Q$NQ:R<7)-5V4A'OD$W+-XT<IF27;N6ZQ3I+
M(JIF,0Z9RF*8!]PS!<VUO>V\]I=P17-K<Q/!<6\Z+)#-#(I22.2-P5='4D,I
M!!!K)%++!)'-#(\4L3J\<D;%71U.596'(((X(YJMU*X:\<M?VY.\5G73)O/M
MG)GD>J]?2<HSBW8G]0CF-CI!VX9M%T#?Y*J1'U&O0>@9,0 0YUH_H?\ 1[H6
MK+K6G=/Q)?12>+;F>YNKJ"UEW;EDMK:XFD@A=&&8V5,QG!CVD BR7O6?4>H6
M9L;G47:W9=D@CCBADF3&"DLL2(\BM^&&;V_P\U9\1 H"8P@   B(B/0  >XB
M(C[  ![B(_3.F$XY/ '))\JJ]4?L?Q"^-59NJM,=6.7?':O#Q[^PQ4,H^KC-
MTFKZ*I1>%7([=)(J=E.YCV+MN( )DE5"AWG%=0]/WH[T_5Y-)DOKZ<0S&WN-
M1M+%Y].AE5MK_?PXDECC8$/+;PS1Y!(8@ F\6_H]ZEN;(7JV\$>]!)';2SJE
MRZ, RD1X*HQ!!"2.C>\ \5=&)EHR>BX^:AGS:3B95FWD(Z09JE7:O&3I(JS=
MR@J01*HDJF<IRF ?H/Z_;.Q6EW;7UM;WMG/%<VEU#'/;7$+AXIH95#QR1NN0
MRNI!!%4N:&6"62"9&BFB=HY(W&&1T)5E8>1!!!KT,V*QU63:Z6\3/)EI5(NO
M3U8?M/!FDJR9N)%@J=(A%@6;R*Q6KM0JH*JMSF1>-_%4A%&I3(^1Z?KJ=7M)
M.NBMH\MG-"$V728N%;&""'D\)N?FMP><[15PZ??HK;;?=T:Y;WD4Q<SV3J;8
MKGV3G9XZ-@#<H4CR#50-;6NU(%)-)Y"6$B22@E SN(?"F0_9A33*J5 6_L ^
M!#)G'R+T!!Z I"\0NNB^LX)C*VDW$C$EI'LY4EXSDL192._&,C'M$=N>_>X.
MN.AKF%(EU.UC$?">MH]NY'DA]9@5=I['G;COD54O=&U]UZ7L2<TPUC7+96R(
MI*RC>2*^@)P5 Z^8!]-*-Y**9>8F3^62GX$&*W9!(^67.=!O;NE^G R&*[UG
M4-#ZE9O:L-52R.ERVHRP*I?[Q<R% -UNLR3#E@K,H4TSJS6_#99=+T.RUCI@
M@NNH:5=7(OH;PXW'.G\V2<D":6%8V/L!_;S5N.,G(_C7R-A71Y>ER-8L4/\
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M@/):?;"V5$HE,="0(R[%)43%*1BL"!2_-.O4SP+X@G@/*2VT^1Y QQ^(I [
MAHUP>,9[UO" &P\1N&:>6$>YD6!) 3Y91_,<^T,]AG:N ]@ _K !_P#/*Q4-
M7.*4Q2G0>P]?3Z?R?H]O]F*5QT'??0=]==_IZ_5W^K%*X\"_>^Z7[P]F]@^\
M/ZS>WN/\^*5SXE[[Z#OOOOH.^^NN_P"?KV[^O7MBE<>!/O#XE[-^</B'WO\
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M !>5G9AX=60EI)?H/5>/5U53_K#L>X:ZN[B]E,US(TCGMG 5!^Q1!A44>2J
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MU(Z][JRL/.+Z^J41.3=IJC*=1C#WV,2C5&*E&_"(\PYCX@CZ0:J5HVXV<O\
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&Q2F*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g713200g61j34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g61j34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2*$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M?0   I,          0                         !              *3
M   "?0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "?0    !29VAT;&]N9P   I,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   GT     4F=H=&QO
M;F<   *3     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X
M=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI
M9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!
M;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#
M;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )
M=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O
M='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))
M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    *.$))300,     !?V     0   *    ";   !X  !(J   !?: !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" "; * # 2(
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MJGS_ %O:JF1?B]9Z <IK0YI82^LZP1K;4[_-W,_ZVMI DQ(.THG_ **Z<A(
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MK&.QQ_XQO\W:W^NU2"4)?.*/[P0W@S'R6C(H>/>);=409']8;F6-_K(K0X-
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M[/3]?_ ?^#_;?M_VC_!)*>K22224I))))2DDDDE/_]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
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M     0   GT         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0%(34T
M*@    @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
ML(=I  0    !    O    .@   /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 R,#HQ,CHR-0!R<C4P.3$V
M-P       Z !  ,    !__\  * "  0    !   "DZ #  0    !   "?0
M       & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@
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M*7T4LL<L*XMU$XN:\2AVYE5O#58H;E5U:T4B"YD9;F(X/V:[[LIQV27'B1G
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M5,QRPF5=H.?"#'Q(F[YDM)6*>_@-&O:*N@=?Z?!='3^H-+B!L=6LS=PL@^!
MW\HM9,<";3YF:/GG[*T8X$%<1\-Z\R-=^(YSBJELE7 FW#*1KFN>[HJ-9%Q8
M=,5.C5V8KCTRINUY8X:&EA-*.D0\<H#-64;=4%0R=NX1??LTTBYB3=)H6OZA
M;7>W#&.#5(X[B&5@!E4:2,1 DXW\?B%<B.8=2VOP+JQCEB[X)AFFC<9/KAU.
M.V.:M8Y=Z7L.Q:E"WK69S1^YM220VJAR34_IWSU-,G^6:UYP^1T9EH40(U<
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M)=2MV#@6T38UFYG*4>1^B_C9ELD/:K(U692*FWGHXAODN"9$).-./IY>-CW
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MXXO8%PL<4C!+@*$W!F(I5-H5M]/MV$C[EINR@L9RV:K"T?#1Y.1/YUGL"_*
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M,I,WI9\&11*HJZ;NGY![XI(AZKI.HRBPU&U+922PN$=<!OAC)ADY#;2I)CW
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M^Y9BOH,C&X#Y-E9%]@^WN#6XW&8?X\<P/V<G9 /_ &?U"/\ U_Z_CE0ZC_\
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M_=F:5YQ2F*54[R?;1)>2/%5PD:)]Q-S(I8*@CH6>@9'YZ\V.!_-N%=((><_
M3@@H(ONH(DZBW/T4JV+%*8I7@Q2F*)3 !BF 2F*8 $IBB'00$!^0@(?(0'Y"
M'R'%*P#76L*7JB*F(2BQ!(2)G+5/W)ZP14.=N6;LKH'LJHU3-\FS95P'<BT3
MZ(MB=$D2E3*4A=_4-3O-4EAFOI3-+!:P6:.1YC#;+LB#'\3 'S.>6/)YKY5%
M0$*, LS$#W8Y)_6I S0KZIBE,4IBE,4IBE,4IBE,4IBE8A<Z+6;[%FBK)')N
MTR]QFCL@%3D(]8P=HK,77:8Z)C%^HLD(';.T1.W>(.&ZBB1MNSOKFPE\6VD*
M'C<IYCD _"Z'@CU!&&4^9&5@&&"H/<553N?AS+T1ZG8];VA*B^D?^X,CKGGV
M&JI!^J?O5.Y-4W36T:$LKP \+BW4!XUJ<KU\<Q$(IJ^A/T_2.KXKY#;:A:M?
M;X_#D51 ^J(BYP$^U(UMKMNGQ+:7T;7<1PT,K8WUI2VQ&&A;PR/PG/A$Y))&
MPAH6/\49YSA@2369Z^Y-;<U^5A#;3>LF"SDR+:(2VS*1?T,LHB($32H7)^EQ
MPT:<<. Z SA=AUJNVI53JFZ>.C =T;2O^F])OS)+I:NX3+RG2HY?MEN!DG[;
MTS>2"^@5>-TNGW%Q:@8*HH.RBSNF!+Y"> )&!1OZDZ (V?X7"O\ XG=&'Y(4
M,SQE#7Q&6U-/2!D4XYKL!!"/@9M5?^9+6KVR</J/8A7'^8;QT^>1.7H*D>B(
M]N4^;IZ^"/+8F'58(P3(U@QDG@"_$;FQ=4O;;'JTD'A@Y D.,UM>*O ;*$]M
M_ /]5OA;\@V?E4YO&,;,LCM'[5G*1[M,.]!TBB[:.$S!U 1(H51)0HAT$H]!
M#[A ?QR$!9&R"R.N1D$JP/KVP0<C\ZV(II8)%EAD>*1#E9(V9'4_)E((^?OZ
MU&[RB240*"M6<,Y6/9KE=MZE;^^28-7"9@.FI7YQ<CN5@%4Q#[!,_N+!'Y$;
MMFI?K![B97SXH968;3-#Y6(/?Q$!"R _B^%CZDU,QZI%<;EOED@FD4QOJ&GX
MAF=&X87=LIC@NU(^,@Q2L!R[GOG\)(NY-B5P_B'L&\*H=%Q'O3MECD43'H8Z
M+AFLNW<M5/Y2"Y#E$Y!#R)I* 9,O@ZA6P'5QW#+G!'S! (/N"./G45<PQP2[
M(KB*ZC*ATEB#J"&]&215>.0=F0C@]B00:Y?/FM>NM?R8XU5G8>YN7-TJ? Z@
M\A6Y]CV*J;$VK3N2=*9<B8>2NM$X_DN<72=?6;CJ_.RME<KM3K$Q1X^1V/).
M*TK8+&^JEJK7TB,WBL?7^>/]/;Y4KLG%#H4H  @ %   1ZB'0/N$>H]1_K'J
M/S_',TKVQ2F*57MRTB+\GLOB')/KC"/:<?F10!9UA"G*,Y5F!Z%LPB K6<;,
MZ([\*G>8_2!;^8%"D#Q=G<92K"<4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4KU,4IRB4Y2F*8! Q3 !BF ?O 0'J @/X@/RQ\_:E0Y;-#:XM2$@F,0$"K
M*)*)21H &[2/E2J@('+.UMPW=U6QIGZCWI6"#DB'#[P_')BUUS4;5HSXWCB,
M@Q_:-SR18.?N+E62ZMC\[>>(U\%%/IW&"/0Y]P<@_D01\JT$O/$7D9J%L]><
M9+C6K747*AE)W0>Q69'VLY]D8_<X:1M6G5I&*JSI5/N#I3Y2IPIU!*"<"W#N
M,-ZL^J^GM69%ZDM+FTNT&(-=T]RFHV[#X7DNH%CFN44_^[BNY0,DSM6HUO-'
MDVSC![POS$WR 8G9QCX&5<]U[U#6ON44=K^QHTBQ.;EP?V0*X]^N]L,Y2^\:
M+*H!NW^+TC)JL9;7[)T<!!!>N2\-7FG<(BA*G#M/+7_3,E_;->VZV?6FGXXU
M#2WBL>I+8=R9XXQ)#?N@[K<0RW#' S%GCR6?8P1BUJ^?@D\\#<GX3D;0?=2H
M]<&K+*+OBR/)2O5O9.M92#>6=0B%<ONOG*FS-064RB1E4%FMMA&A']<*[3(9
M1$EMAHEI]R2,H[,8AE.<WVB6R17%SIVI0SI; M<6.H+^[-6ML'!5[29FCN"G
M9C:32O\ B,2CMNK*20K(06[,OGC/Y.,8_P"X >@)-;,Y7:]J8I6@SOX9'"FP
M;0VEN786C:9M+9&U]CI;+F+3L"$C)J3AI1K5ZE56,/7G*;-HLT@(]M3V4@S:
M.SOG"4F^DUQ>&1710;XQ]9/^O/T*5OSF:4Q2F*57[RQHD2QV/Q(MR4G;5)%Y
MS$U_Y6#NY6AY6T_/1]CIG]+5W,HK7VG:!"F2%O'I>$XF.D)3',)E*L"Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5@&Q-5ZYVW .*QLJEUZZ0
M;@IBF8ST:W? B8Q1+YF:ZA/4L7)0$?&Z9K(.$Q^L10HAUS>T_4]0TJ=;G3;R
MXLIEQAX)&3..=KJ#MD7W5P5/M7RZ)(I5U5@?1@#\LC/8_.M)*1P;M7'W9%>L
MW&;=MIJFL#S[-:\:*NSEU:J4_@55Q]U"K/'1UWD#*%2-Y&:@HK+JK$*FM*)H
M"9,URO>M;77M.N+;J/1;:ZU,0.++7+-4M;Q)POW7VE0 LT61AP"%"G*Q$@5J
MI:F&0-!*R1Y\T+99,>NW)RO//'?G)JQK.?UN4Q2F*4Q2JV]6[(Y'MN2&TF&S
M$=@)ZO1/M*.1+] EGE>KSDVSJ?!:">4UY&0:B\NC.:^D+/.6Y=-[-LV:[$KN
M?-"B@5 ZGU_=^8^OUJ3.*USWA-<?B+V%*7O^S8;9VUZ^Y?;<:OM42<Q3X[9U
MP0H\VX384$R)O640E8=,1CZVBT=MERG4<)N"J%,I4!<A]NWR=W'Q(H-IUY&5
M\K'E]1A=3,3.7*:9>H:T;8RI$VSR3UG68-VDMW]OF2G!/W ()(+F*<"*5:KB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4JHSDM!H(<H.,$N",."J_,2F *J,CJ%23'OH&PBCYF415&NRB?=]8)2Q.N
MT.AGGD2%(A%/KZ^N.U6YXI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*K"Y:1#G],7%AY'7#4I9!;F'0P0B6E'9&O3(
MQJ+L0##+SB-Q!\_ B93^I*,0Q%0BB0&,F5/[13Z]*L)]NOWYJKO3_9!Y_BK'
MU]<_7O2GMU^_-5=_'^B#S_A_2K_GBE/;K[T'^-5=Z_A_%!Y_6']JOZNN8Y]^
M/R^O\*5X]MOWYJKG[H//O_'^E69I7GVZ^_FJN]?]D'GW?O5BE>/;K]^:JY^Z
M#S_%6/KZY]OKTI3VV_?/^-==_9_%!Y^W^U7]V*5Y]NOWYJKO[H//N_>K'U]<
M_7O3Z^OHT]MOWYJKO3_9!Y]WX_TI#%*>VW[\U5W[_P H//N_>K[\4I[=??QM
M5=_=!Y_BK^O'/T/]Z4]NOOX6JN_N@\^_]ZO[O_WYX_/Z_O-/KZX_U_T>W7W\
MU5S]O\4'G[?[5#^S_ECZ^N:5X]MOWYJKG[H//\58I7GVZ^_FJN_NB\_X?TIS
M'/R_3]?7Z^=*>W7W\U5W]T'G[/[5?W_^F9^OKZ%*#'7W\+57?^-0>?XJQ2GM
MM^_-5=^[\H//O_>K[L4KYWC:]LVCIX>T5\R;5LNY.4M0=]YBH)'5,4O6U '<
M(%Z!U$ Z_>(?AYR/X<;R,>$4N<#T49([^N*^D4NRH."[!0?0%C@'M\_8_P!M
M0$7?4J[ARR,3)QT@]=06MYJ,BAKK1H=Z;9ZKI&#9*OE[KZ1@+-5HH65=N3 U
M;=2 F=8Y@(.S+ \;.F58I<S6V < M! MP[[C@!#&WER 68;1R121?#4,W8J[
M<*S'RW'V8* !W,A!)^%4\S$ ''G3_(1UM2V-()J[:MFZ[&4?I"YAXU)V^&N+
MQ#6QLO2,KI)/XY-HZF6Z#"8<,58R7!-9RP.JW].=SYHI>/Q%.5,:S+E6!:*1
MVC5F!'W3;U(\.3#E1N (#8^3D%@< I-X#\C^=\/Q<)_U$\,9,B94'CU!.W&8
MI3%*8I3%*8I5<7*N3I*FW.)S!E2))E:T^8E#]7;%-=R$>Q>"6B[&%?QW56(2
M9/\ SIB4A!2DE1<"04R]W8( I5CN*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2O4Y"J%,0Y2G(<HD.0P 8IBF 0,4Q1Z@)3 (@("'00'H." 00
M1D'@@\@@]P10''(X(Y!'I4<MM.:E9D43::RH;9-6.4AU$T*G!I$4BEES.E8T
MY2,2E,Q.Y.9<S40%'S&,IV=XB./3'IQD>^"",^^" 1[$ T)).223EFR3ZN,.
M?^X$AO<'!XKF8W7U#AYWZ41%+JL79/:TH3W^/@(IG,^S(%2*C%>YMVJ;SVY(
MJ"!4V7F].4$40!, 2)VY!(WX)^\(:3GXV' +?Q$8&,YQZ<DYQ@'9D9\/.S/.
MS/?;_#[<8XX[5E^8K-,4J,=J;BUYI>$8V#8L][*PE)$\3%IH1\E,2,F_0BY*
M==MX^)AVCZ2>"Q@X>6FGYF[50C**C'SYP9-NV4."E8S8N2ND:K-4F F;]%I/
MMA1$+8*NHU2>R$>Z@K-(MH>L3+R48-G,=%1EGF7C:'KCV3<M$)N56*PCCN'/
M5,%*R_56UZ)NNDQ^P];3)Y^I2CZ>C&<DI&R<0J9]69V1K4VU6CIEFPDFJS":
MB7[%4CIHB83MS'(!DS$.92M=^7O_ '[P]_WP]<__ $K97_\ <4K<W%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*U_Y"<?83D#
M!5B-DK%,U24IL_)V"O3L,BP>*M7,Y2[3KZ:1<1\F@NR>(O*M<IUJEY2 9F]4
M:OTQ,=J"2BE0Q+\%*9*V6A3@WJV(,=>0&LJ?#00-851JM3=,6F$O6L()V\%F
M5\=2 N4*$M(2H*@_GFKUS%/3D;$;G14Q_G_?4J:IXX1NO-:/=93-RLUNC7=_
MO.P4Y1D\D-?RS>2O]QGKS,,0>4>5BG2L>C.624](@=R!/1"U;N2.#MBKF4J'
M^0O%O4=M_0O#3Y-BO62F[JVX)UW3N)%TT=-:O=%V[R/>HWHCN/>I')VD=LED
M'()*+(@IXUE"F4J/D/A^U0&D&5:2W@+E/<<\]EQ_6GW]]?5JDM9CPS7J79X%
M/V1JM?*+9+H_)XQ*H83D6[E*)_#]J8,XL#R6\1=%W%)O9$?UI]^B ZN/,3)X
M]KU_2?VF[8I2*+Z8G\.*).TYN\JG52O8/A_5(&;(ON.\/5%W(Z?.S?K3[^'K
MJTTV_4;-.OZ3NTP!$F9$],4 ?AT[1-Y ,./]_P#:E<# \(-?V2.=*1,QO-9:
M'Y"6"+E3GY/\@41)KZ#L\@U=1Q?)LT 5328D;HD(F NU #ZJ@F 1S'U_E_=]
M>]*Y\/A^U+TC8ON6\/4AN9T^<#^M-OX>NJS3+X[9IU'9_0>D49F3TP?P\.@E
M$PJ%,.9I0/A^U'T92C);Q]5^F(SXQOUI]_?Z+O>3G*TZAL_MZ>U]I/3?Y_\
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=6/7\@/[S_M5UF*S3%*8I3%*8I3%*8I3%*8I7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g713200g61p76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g61p76.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2JV4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
MI   !?0          0                         !              7T
M   #I                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #I     !29VAT;&]N9P  !?0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   Z0     4F=H=&QO
M;F<   7T     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     " H     0   *    !B   !X   M\   " , !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1" !B * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M5XJ079>(PV!UU;33'J@N V;OH>IK[-_YNY&6*1A#.ZF:O0;D?JYR'-Q2'_\
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M^54DE/U4DOE5))3_ /_9.$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y.C0U.C,Q ')R-3 Y,38W       #
MH $  P    '__P  H ( !     $   7TH , !     $   .D          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3DZ,#<Z,C$@,3DZ-#4Z,S$ <G(U,#DQ-C<       .@ 0 #     ?__
M  "@ @ $     0  !?2@ P $     0   Z0         !@$#  ,    !  8
M  $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !
M   !1@("  0    !              /      0   \     !_^%  &AT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B
M(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R
M92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @
M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z
M0W)E871E1&%T93XR,#$Y+3 W+3(Q5#$Q.C0U.C,W*S U.C,P/"]X;7 Z0W)E
M871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @
M(" \>&UP.DUO9&EF>41A=&4^,C Q.2TP-RTR,50Q.3HT-3HS,2LP-3HS,#PO
M>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P
M,3DM,#<M,C%4,3DZ-#4Z,S$K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R
M/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P9&8Z4')O
M9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB
M:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \
M9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @
M(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D
M("T@1V5N97-I<R!&+3$N9&]C>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A
M=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:3YR<C4P.3$V-SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI
M;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)
M1#YX;7 N:6ED.C-%.$$V,C%!0S%!0D4Y,3$X-D9!.4(R0S0S0S9"-T,S/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX
M;7 N9&ED.D4Y0S="0T4X.#A!0D4Y,3$X.3<Y0T4V0C!%-D$P-T9#/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z13E#-T)#13@X.$%"13DQ,3@Y-SE#139",$4V03 W1D,\
M+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI
M<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D4Y0S="
M0T4X.#A!0D4Y,3$X.3<Y0T4V0C!%-D$P-T9#/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 W+3(Q5#$S
M.C Q.C,T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,T0X038R,4%#,4%"13DQ,3@V1D$Y
M0C)#-#-#-D(W0S,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,3DM,#<M,C%4,3DZ-#4Z,S$K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T
M97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I
M;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C-%.$$V
M,C%!0S%!0D4Y,3$X-D9!.4(R0S0S0S9"-T,S/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 W+3(Q5#$Y
M.C0U.C,Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C-$.$$V,C%!0S%!0D4Y,3$X-D9!.4(R0S0S
M0S9"-T,S/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z
M9&]C=6UE;G1)1#YX;7 N9&ED.D4Y0S="0T4X.#A!0D4Y,3$X.3<Y0T4V0C!%
M-D$P-T9#/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z13E#-T)#13@X.$%"13DQ,3@Y
M-SE#139",$4V03 W1D,\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-
M;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MB<(L=/VZIU3X'VIL]>K6"DC,09D^:&A\$9>/1YQ8.2,F-\N1CW&_-B/[CO\
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MQ#]:?ES<S[Q9J?7(\8>QE<N4J:=BK]AI>(Z)#WH97J7K3TJLMEJ\UEHFY%%
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MX<-Z/*CO1FU\K!Z8U)&1 >GLV!@[B0EBKS.SM_\ 06TUNJ[;M9K[?/K1[?\
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MR093'EPLV*W![  ##/O7ZI0[.XPRPGR?GLT)_P ;^RA%"31<_JT@7OETN-$
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M6'EQ;Q*7(?8KMBSD=,02V;<QY? U@*2:<^(Y;&5P$B>21]QCRM>(6;F;=*^
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MY5);MJW0$N?#E7R%5Z,]0R<F<8+XW1E )&BG"0=GULM:R%"N!QS1&[FPL3
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MVGKO"O\ K]R^ZUK^E0.]H=TH)F_+V2;.FM<4.TN5ZSB]BTC[)3D$BMA*8.3
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MG?5HQLT.)KCQZ_6"DS#HV'.R\_B/";1EY[.459;:P"7V@#OV4S2:=KN^7VZ
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M20W\S8PM_0^EX-:T8^SO.5>4,7J.*#=AKUJNH[H[%-/U;(,9\\8SC\F<>?\
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MG=Y9;5S+2$,39I0NPM/M9QBBV:&8UAM5Q$C.=;7^,@.:)?#3E4R5327N+ [
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M:!"Y<:@VD4-G2QM8DA656 D[\"+';ER?8=>4-?2YR_6NH@TEK_ Z>RE:/JC
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M>(=BA7\0/(Z>R33$UOQ%Q&$?(YV]#Y5X:L>I\/4O8K'Y-QM-%-<U!#%;U"\
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MU'!$Z+MG7D"L9H([8 .YRHDZ6$L6$TJ/77R5B*P6R[L"!?\ 660T?A8\UH[
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ME<'LPQ,4]29GBLQ"[R02L\<H@;.RR?FPHM.$3A$X1.$3A$X1.$3A%"SQ#=E
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M;JM;H;X:<+80TCZ42-GK=- 5 */LLYU FL,3#_VALA9+XJOUXJ395"Y;]0Z
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MYQJI:XN(]FJ#]B!.J&$I]8+"9\B+AMM4GR:;])%]FF-,4'0- 'ZUUM!+0:S
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MLV@"]96UF+M_9X:MR*B!4]*KT,75@UJ@ Z_,KYQ]=M"%@4(<3&71+-NBRV[
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K$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g713200g61w04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g61w04.jpg
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M1.$3A$X1.$3A$X1.$3A$X1.$6/+3U"Q9(FB 0*K'0)DY(L2RU(*$E1([DA,
M:P^_&9>GR\MXCPVGI,=IR0XVAQ]I&<N)(N6 KU(K:0[A$>N*^N=X2"BQI;+:
M664KVDS+AUK%DR9G5MR8W7FP4E'B.RVDYA6(<B*604D.O)#YGP=-]VW^'O\
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M5\V>54E$1B2V0*E0M %UJNQI:W76(CI<RS$6N*^A^9'D(S&Q=R6(OXF4(,A
M]:60&D$#.(G<'\"^[D/;?Q;?9W9V=F=G9US]NC;H&,5R!X)"%C$'(#=Q?P?[
MLBVWW9VWZNW5FX=G>EG1_O7LK8?;/L=2;32MYV4#2V#REU.-"OM@):D4S:A8
M^"*LP:R2XXZ22)Q6Y$B+@2VX?^(R6^W1$NLYE_1LS(Z=RN,HT\A=KPPU+_#W
M.8;M"?O+.!'Q1QU[,LS@+"[2&X,$9N,<A#(0B5^WA\C0K5[MJ$ K6]N[F-JK
M,\N[.6X1PSR2.(L+L9\#"!; ;B1"*Z0;P[U:?TOJNW[$)S'A1.JP8\UNI[9
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M>G]'TI,?IW'!CJLTY69A:6Q8DEG(1!SDGM2SSGP@ @ O(X1BVP".[[[OB!A
M^81(0!0V%/+N-/%IT2#%C3";K",ML.D9++2'IKC+><H:7)6ZIM&<I1G"<YQR
M<56M#+/-#6@BFLD)698H8XY;! W")3R +'*0MT%Y')V;HW1=9->NV8:U:Q<M
M3UZ0F%.O-8EEAJ!(7%(%:(S((!,F8C&(08B;<F=UDN7UBIPB<(G")PB<(G")
MPB<(G")PB<(HZBH5-NRO7-NKUUNX2(*1<BUH"#4V5\8CV^P<\=3&P4=@H]B/
M;$7*5'3[$^&\>W'C!;&8T;Y94<?1;)G"U<\BU2!KYUVVV@*XT?>"A;9MHGD<
M&V;8>BV19K,%BPP99;)%A8K#VX\.5^T^+CM%OQ60Q[R]T"P7$6\PPM(_$^Y=
M765)#H)@=/$%(C,\84A2AQ&#)1AR/,@SF'(TN)(;S^#C,B.ZXRZC/X*;6I.?
MPSS.6M4'5J36CE@'6EVE 7CHFNYJ@Z8_#P^B( S"D"\P6H3REP,9R)ES _SF
M8N9WT:9,$?,_39<F*Z1>-/U#K.@"S 6G4P*"&6".S",1HK"U_/C8L-T>/$//
M27'Y& @D>^] "A&W4"0D%YV&)APXSBV\D68+42JF0(2LS!+: M;)50M7XD)Z
M2.R'GT@F.+UET>_!>CR([8Z6*AMJC)=^6G#\2!1!F4+FS(CY%@%:9U@X]?7I
M%/&S%;/>8DWU$]R;/CV25$;9:ARYD2;*?BM2X+<:(B!*ALQI$%,&!B(XS\A#
M^ 18J9U]TN0#B@,_7=?FBP[A]<=B4U(D/2TVR7&GV^,<FNR%SK+ N,^'"FW$
M=8I)2!;)<&#)L48D]#C+:(IS9*/4+@E]%HKHHZF36;/37TD8J)&':K=&QK-K
M +PK\QA]H.+03C?W)*8,;"_^'CA%H7;/4O7FV;5'ND@O:*78D1C;$LM2OMB$
M5D2ST2HCYE@A&2]:-&:[;61E%JPN#9ZU/$E(< 3$;;=^/$@R(A%LP]I#6%@K
M4BK2*H-AP'*Q5:C#DCF&F"(8-0I,^=0VP\MQM_Y-ZEDB<TE77,MNIA3)#RU-
MO-//-.$6O=3=5-?:F6,7!*6>QHKY&$5K TS(##*W624*KV&F?5!-3IH2K5GZ
MP0K=I-CS)B<*FD">)+*W7TX'C$0B+.;YJ[).%6++^L+>.ND\*7CUH79ZR9H3
M0(\2V"9K]>#UBQU;:=5NE%LDXS84A!-6<<!LVN"3(OCZN:'_ %\K&(OBBQ/6
M&?2+'2RUQH_9(]VEB'C\F*3V24M5).C6B8-M$-T"!#:RKU1U[5X<%#J)'RP.
MLPYI5F7$*EB)O+\(@LBU5V%%;C+;MTP7%T"VV37=$OU%GAW*B>"LPU&S;A^#
M=K1=Q<DQ!(?(UJN9@!:VM<18>(S8+G+)O2I<ZOI%$6!N*ME9]2SKVFP,T9&M
MD]:>VOZ/W@\H^Y>'IN;-TWS:<7&--B- 8\5LC[< %!)<IUV%Y412R_X1PI?D
M?VAW]Q_PN@_"BG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G"+G/ZGP^RE.N$2 '"U&Q!I>T=5Q;&#/A-W&3Y1F5?J]
M''P:(O010-?!EEGR'7!S<Q@H-B2(\QP7((PFB#CF:M]?+R_Y_OEU12_T^Q)@
M?IJTD#U0C48C9=JV8[FLQ-;;'U>P+A_0ZH&&PHP/:9L[:I0T>.#Q1@*2AZ!7
MQ%?@BJ;61 T%5H+&*(KT\(J8[*_;TZD_PY]U?YSZ;<*3?@+VA^1JYW"BG")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M"*B_J.,UUSJ=>WK9#I$RO0BU-EDD;$B:%FU-MMNT#&V'B#'929 U+E[$IUAL
M?]9DI)*GN1FZ^ATRY#:6_3Q103TL61Z.LDR2#A:FAUDAM&X3*S^AZ/H")7Y(
MG$&O0W'S,/K2I_5L:T-E8A.&1;A3R)=R%$&2"[\5YY H=5]_7\=_Y13[LI5<
M6;9NKY=?H9*9>*W?=,&46).H2]A>-U4)M00;)C*_O >_)"Z=A5V"U8REX@V!
MB#+O &0JLPV9T8PGXM$4>N4?9*/4KZ]2#Y:CR=;O]:NVV* )#UX]!NXR8W9N
MFZ;0Y<;#-LY$"=C3"/M= ,A:Q771L+S'(OE7_$G!2_*_M#\B70;A13A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%S
ME[^[-H-<E:,UGN)@A4]0W^QV"XV;>P\_L&M$]3VC3\BH6#7<2G%=?5D_(9V-
M:[&9P1 (L,T)7G:S2[PU)=)RUPQ<DBR7IL$QQK1=P,P!1A2R6[-@.S]BE[=?
M;PC=TF-'KX^+M838MDURIVJ2+G!X0NHH8?!18$*=3I\46]/@-,$)3^_W^_%%
M?J03&Q)<&!*(08TXFI](V%(EL,RR"HS?QI*8,=QQ+TM4=K.'7\,(<RTWGWN>
MU/X\(J?[*_;TZD_PY]U?YSZ;<*3?@+VA^1JYW"BG")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*G?9CL].ZZW[1<4W
M7I3.G[P[L1W9VS&:-M/8*JF]5QU;^SZ>,#:LJUHF0[)?9]A)$AYFRLQ:[&#4
M.R0O<^9(B4(?WQV^:+.]0MWW;?VL#%VN]6C@'86PK;6*R:'5N_TX)L.GAW(2
MPE]!5;: <'> @\AF;*"O1C4-:9!0 2(#)4@1,@+X_OFBBNYZS N.[*P&GZQ-
MLC&FM3GC6X!E'*VPL3=I&R2%QJ&NZN8A,R8.OX0>QP<'[_;I^6)60)V,* Q5
MDI2K91R*%7(?L=CU*^O1 _;:63UQ.ZU=MD4&I"=?FPESK$R-9NF[=GD6V_R]
MD'PMWC&2&4R@<01K>@.UR'C,&=,M#RL$$E+\C^T._N+9=!N%%.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7%KU@Y
M-D9':3^@[RL&H&(H3=9HM]N1NQ[\@-#$-:R7)WH9>ZZ2X4X?4]*"Y):%8R5_
M7-I42+LQMR4)FS/EW8=6_3?JW_SKY_WUHK-^F@/,CNO)A$XV1-U^5M:Z$* N
M0"WB"!0*5/C I4.!1OUBG9&U"](P9<.S0APS)DP)RILM(.0\(8B+S1%?.38
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M ##)SV&'(L"4;$1Y;K3Q*&AXBR?"+&#S08L\6C"BPPG( $\A3L<?/BS7@IG
M^ 6R)+-1G7%C2>!9462S F)9E?3R4"9\+Y>9'<<(AHT&K@DB>L)88!!"(;Y
ML:-3XHL2+@1D9=DSB)&<ZQ#A0X[:5./R9+S3+2,96XM*<9SPBR?")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*O.^>J77_LZBO-[TUU"OR*K M
MH&F4:LX;Y07=4A$6L8[]M&PV9XXZFM@TD()',N*[@;'\-)_K^]NBG&I=.:YT
M;554G5P!VMUE128:4.>.V.PKR2GMQFI<CZA:"YHGC#K<2.G$?$S$9OX>5-,H
M4MS*R*&;-&627N#KX5#40X?$UZR6^7:;4.D5)B!61I>A62MP<DFS%D%6"6VX
M5+Q75, 1!E3;"7GUMX<0EM9%7JY!;S$]2OKT:,WB 8HQ?K5VV;IM'9J$<7/I
MTJ#9NF[-@DS;>@S*D6E!^;E,V/'?#BL!4)^4;<FIS\7!2_*_M#\B70;A13A$
MX14QZ'?\D[Y_&=ZC/_Z"]G.%5_']F^3+Y]07]DG9W_N>K?\ K!0>%4/Q-^_R
M=7-X453&X_\ B&]<_P"#'NC_ -;^A'"DWX"]H?D:N=PHJF/4[_F+WR_C.D?_
M %8ZL\*K^#?I_+IZBO["/;?_ . ]D_RW-X1O%OU;YJYW"HG")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PBB1>_46O'PE4/W2I [19LX36ZV7L
M8<:?L"LN_ PD('FS&2)7.7_['&($:1GXO]G_ '_PX15>V5^WIU)_AS[J_P Y
M]-N%)OP%[0_(U<[A13A%"=ET:#L[7-]UN3)&0PZ_TRSTN<9KA*6&L0>+9PLT
M*^5 &(#T><)-C6YJIHDG"?8EP"#$>7&>:>90M)%PY_H^G3+L)U/Z_;]G]GKA
ML&R;-OO9#: & /NEILQV! J>J[O:ZQ)M8(?8B,U,![:FRI>R+^0.PFVE7@24
MJ]EERB?S$><X5R0F)VVZ-PM[W;Z;-^RF/]('ZI[P[0=%,XZVFK]"W'K':%"L
MH>M4*S'@$G8%<L)V%2[%6"4</.B1R,46^<"[!;600]D>[1\O0U-O.K2Z2-V8
MO2VV?=GW;?\ AUUCZYZF>T/H73VFI5H.7@CK37-3IYB[68J2.6"Y'@P:)%/V
MPR5+R)9&60LAE$XS)5)?5EMR;EEI+;+;;2"@[[N[^&[N_O7#3=_I];VM_K\=
M=>R(;86VHG6-[3!_;MY$P+W<8=.&[!U-)IM2<UK#&Q2R08T#L&Q/:*V <JF8
MS<&\KJEVFSATU8E^8P4V)N6[;-Q;LS=&WV\?W];?\;LOT5RHK$V+)AR4?$C2
MX[T60WA:V\N,2&U-.HPXTI#B/<VM2?>VM"T^?<A258QG!6U^=ST2.@>_>IN_
MO4:MN]=B[:N0A&^9.H]&IV'>;=8V;-KL<-!71&V),4\4G0RQJVU OJ>L_<7M
M=(0)%&L%=Q.=C1\M(*X9,3#LS>&[]-GW\';].F_[JQ?KW]9=M]F?3EVB-T,5
MOD3;.LB0;9@"O:_.G Q#80 ;F2#O]"*1PDV*H^+(T@\;.,@)C4R*1/5T(U\#
M"_:ZV5(W9B;=MV?H_3?]/<^RZ'=/-)F^N?5S1&DK3;3U]N&O-;5P->+K93Q2
MS&;5?'8F"5Y/2#1J3,)RXY.VSC,H<W*E/*A#'(<!M?P8K>,%%WW=W\-WW5DN
M%1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$5+-O:RV&<NFS(0
M&GR#H[;H_0D(;?VB]7B1=:.ZQO)@R5?-PBYR!9'4UYN<FZT/-2#V)R=;IY.&
M036D-MF91%K[M#U>[)7G:]2WWHKL[9*1<J<^%H%8HLC7^FRM1K&JMH[$TBQV
M+),$[12RITS8\4C7<VYU-HP0EH9M8Z(#BI;$$7H:BDSLS.SMNS]?W9GV]?AN
M_7_C]E.OU=^U?^8+M#_07K%_MAPJ;MY-\?JH/^@/O5^DGZ?^O;<?T6?8_P Y
M]?\ T(]:?NG]('U[X/TCZ?\ HS^6^@?;O_;?G?A?'^H_V'Q/A_U>$W;R;X_^
M2G'ZN_:O_,%VA_H+UB_VPX3=O)OC]5!]>Z#[USJ_-?V7WMN(.R(NNRHD"%6M
M)=:9XUVAC]C6J!JLL^_)UFXX@Z?U?&IYVTPTJPP.LY(N/BMM1HK32";MZF;X
M_5-CZ#[U0*<5EZN[W7$]>&G1. XJSZ1ZTCPDEETT.9-*F2XVLVGFEQ@+A.7"
MPA>,.SV(S*_<VXI.2;MZV;X_53C]7?M7_F"[0_T%ZQ?[8<)NWDWQ^J@\W0?>
MI&R:R/@=[;B]JR11[S,M9]_276E%H'[ AGM>,:^#BAR=9XC20!BNSMF33\UU
MI;\(B#K3##C;<^2ETJ[MMX=?WVV]ZG'ZN_:O_,%VA_H+UB_VPX5-V\F^/U4'
MHF@^]4V)8U;#[VW$-,CWBX0ZNU7M)=:9S,_7\4U)9I)@HJ1K->8Y\H!3%EFH
M364L1)SCK+*$(3A.";MY-\?JFR]!]ZA^OKE.U3WMN-@V5$KI1^C!+5I+K2.K
M96S-Q7%"()N?&UFU(B#)$O#;<N0RXAQMI2E)5C.//";MY-\?JIQ^KOVK_P P
M7:'^@O6+_;#A-V\F^/U4'*Z#[U-[!IL$/WMN,G6LNN7A^\FYFD>M+5D%6>'+
MIJ=?P <!&L\1Y8PQ#EWEP_(>;6Y">% TL*;Q+>PLJ[MMX-OT\_#KOZ_T4X_5
MW[5_Y@NT/]!>L7^V'"INWDWQ^J@],T'WJERKRF]=[;B)AP[Q/AZ^<!Z2ZTS'
MC.OT!@+HXQ8$O:S7B$?>.O6*)(A,8;8;@PA[R486^XI1-V\F^/U7LV3H+O,/
MUW?I^K>]]S/[.A4NTR]<@K1I'K0.K)J]Q@<YZH";$0C:S:DP01&P('PR\R.Z
MV_&'O2'FG$.(2K!-V\F^/U4P:Z\=K\M-Y>]0/9R7LMHRZE&ANL64)<RG'O2G
M.=8><IPKSA.?WX\9X3=O)OC]5"[#H/O4Q;]?1:SWMN,ZE3IMC1LDH2TEUICF
M@D!BNRWZP[6XC>LTLSWY]F3"@DT2$.)CC''I#>$N)PK!-V\F^/U5@]4ZFWA2
M;.X8V)VKNFYP"Q4N$BH6#5^F*?!:(/O1'(YG!:@TL <5(A-,2&&X:YV8#R9K
MCDAAQQEA39/V9O?_ "ZL?PJ)PB<(G")PB<(G")PB<(G")PB<(G"+P=6IMMQ:
M6EO*0A:TLM9;PXZI*<YPTWEYQIG"W,X]J,NNMMX5G'O<0GRK!%5'8^Q6Q^P^
MI$DX5.:H+WG;UQJ,K75INM9@2K&'<TMMZ8Q%)A*M;[#6+*YFX"*'*"NQ21>0
M.($0\)'R)0JN"X10?2VU+W;.S^T!=N:V2$&$-?C2%2U\>I5F"UFH!Z]>KC78
M)/!B<&AA2-DO$*(BSDRC1%]CX9*#3X$HDQ3?J4LBD>X5E+]/T]7QT?;&KMEW
MRWM,X&L[,) Y-6UC0B<6S[+MQL!JW8IJA&6R E(W7X8B16=<'6C9=+^JQ?E&
MY$%!%O/>9NUUG2>X;)0VWW;S7]6[ -TQJ*/26E.6L54RT^O(C"E-/I)R%%V(
M>&1ZF'L37,IC9:<P[[,D6J- V062OFSP%"V&0VEJ4/5-2EP=LG7>3LM$?8%D
M_2!]]5Z-=99 K(D(;K0?6-N< *(O, W;HI\=&'"RT&!'(I9V5FQAFK"D]'W%
M)L^9XH)KH-7+Y>-?/6+9=OFM5&B RIB@'Z\977Y=C.0%V#+LF1 $AF9]BE1O
M8&^88?WPW^:+:M&KLVHTJHU4E8C%O(UJL@@)"V6!]4D[9YPD9%@3+"9D*6O+
MI0U(8<(SU^_*<RI+OM_J^,<(J)@]LF)O7@U U]<+C?9L_?N^]:$]D5!XOMZT
M:UI0K;6T)+)QYT&W9C&2T2B"A-;U\_(ASH0@N>IAB=!?JL"4TLBRI#<E;5U5
MZR7#8U[O 8IL&OZ^;9%Q[6[J"S;2N$K6A$A,%'KN8F50M3:^W*BS=@&;'$/U
MQR=%KL.,Q+.P3K=5M!%*:M;GP6U>J55M6ZA=LM5IZZWAH^V-NL7-;V58 J]3
MNP[N&KC,B'!-R2#[]M?$6"();D21GU),5N+&1,C-D7U-@; !N=BX51KFWBL2
M\5DI32MLK\J]PQE7KE0R,65D:X!ZL8FQW=J;*VG!>5)85)"&2E,#E1MB8L0"
M1'IE:N1%J7I3M>[V L6:OEWC6&)/T)3+\\0KVTI>Y%/&6BIUFR72\"WVI$70
MM]L<.<'<;T73$V374-X38XU/L]D^UR2(A%@HET.F6=N5JO[WJT2D13?6PD)V
M 2[(7&X522#L]GO*;%/D[A#Q:G8*=L&_,5@3&+Z6K,ROTD,/=JN:E<H2]FD(
MPAX?WZHM_N;2M13K?39=1$72-+N%G/:WEW2EYNFXYE:J-<L5O!EMP5PR]#L%
MNLXZX@:DHGJ:R$H9QI1*\40P=P1KS!20LBT=4=R1KV%ZJPF]U68+N*RZ?ZW7
M(P/M]T3KROA1$TTVY=+'8:B7>"DMHV[>4<38Z76*]/$6N)'P,A6D-]C-D\V@
MZ1;CW!M2]"NT.@JPTWLBNZ[C;#Q6B#(2E6@G7]JEK;IC;)M;I2P"0LX6W6]?
M2@U;=C0'"K#TD[+LIPZ,A#*&(+SB+!=9+AL6;MQRF%[!)N+ /44V1NZS-[1'
M[)K,[=C%O!CP9FF#!TPA'UC7K8,QL65$I./M>0S%"0HDR@ , XIJTD6BW=N;
M!J56G@!M]JE\L-IE:ZE[$V=7>PFPB-4UD)*[@%T^SAK81M$6QP=-2[)",$8(
M,Q4*E6R0AJ!:X;8461UZ)L<HBZ$]=K>Q==6#2D6,ZRP/L-YK#<K[].[2'F,5
M.ZGZ[DX"V)9FVCUN %U#531),FWB0U%=0.][Z(*)#I%O#A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1>M332U(4MMM:F\^4*4A*E(SYQGRC.<9RG/G&,^<>,^<
M8S^['"+S\8\^?&//CQY\?CX_/QY_/QY_=PB>,><*\8\XQG&,^/QQC/C.<8S^
M>,9RE.<X_?XQY_+'"+YX1>MIEIA/L9:;91E2UY0TA+:<K=6IQQ?M1C&/<XXI
M2UJ\>5K4I2LY5G.>$7GG&,^/.,9\9\X\XQGQG_''G\L_CG\<?C^/"+YX1>I+
M;3*5?#;0VG\5*PVA*,9SC'XYSA.,8SGQCQYSPBH)J+U)>JNVJ:3NIVPSM&@!
M8#75OCN]AV*[K:.9I^V$6O&O+37",BQ% !<78UT:XL,-PRRBL%=<*9*#8++2
M'7*[/Y>;>[Q16&.]FNM-7AOE+#O/3H2$-P6;?G$K]4X;$7Z!.IPHPW\9XDA*
M<C26Q:".DMHSY;FW:J1?;\:PBD2Z(MQAR0&R"Q5E 3Q)X,<'03(0^(E0R@PN
M)(Q6I@PJ**0UOQ9X^=#>9E09T1]V-)C.M/L.K:6A62+)-,,,Y=RRRTUE]Q3S
MV6FT-Y>>5A*5.NY3C'Q'%)2G"G%^59PE.,Y\8QPB\/E(OPGF/EH_P)&752&?
M@M_"?4_G.7E/-^WV.Y>SG.7<KPK+F<YROSYX1>_&,8QC&,8QC&,8QC&/&,8Q
M^&,8QC\,8QC\L<(O5F/'4I*E,,J4C"<(5EI&5)PG^[A.<I\IPG_RXQX\?NX1
M>W.,9\><8SXSYQYQY\9\9QYQ_AGQG././W9SC]_"+P;999]^&6FVL..+><PV
MA*/B.N9\K=7[<8]SB\X\K6KRI6?SSGA%XXCQ\8?3AAG"9*E*DXPTC&)"EH2T
MI3^/;X=4IM*6U9<]V<H2E&?*<8QPB]B$(;0EMM*4-H2E"$(3A*$(3C"4I2E.
M,)2E*<8PE.,8QC&,8QCQPB\N$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1>*L>Y*D_E[DYQY_P\X\<(N*=?](^[ ]8L4-?;:1*)L475VFL
MEX6G9U:#R=):HJ&\  *G3!=8W,)M;A^98-X%+B8L[6P6!!IVNB:F=IA:DD;&
M ,5W^;O^[_QT\$6#UUT.B[(O/;.*-MHD(BO0>O&DJ:8. 3%@9@[ TU6=5R]E
M;-;KM:M.O+)4I&PXVK-&?2I5"VR!N5=.47-E@6V"33'4ZW\'\^NWJVW?IM[_
M #\478W5=.)Z[UCKR@&K:2OI>DTBK5,I>#,6+!+6\A7@D$3,LI*%"RJ+$FFY
M$1PC)CLN.H9=D*;^._E.7ET13WA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
*3A$X1.$3A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g713200g63r89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g63r89.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1\J4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $&9H976%ALX6Y+ 3M]'"\MPX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              *U   #,
M   !                          $              S    *U
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   *U     %)G
M:'1L;VYG   #,     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "M0    !29VAT;&]N9P   S     #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MAC^ED_K%OI*SB=3?U7I^-:ZD4G(OV@->+6.92\N=?1<UK/5HL;3^CL]-F_\
MXO98C#YAYW]B9_*?$5]K_]/U#*QZ\K&NQK9].]CJWQSM>"QT?YRPNJ?57I9H
MLO+++"QV]K=P 8"?4>*PQK?;O?;;[_\ 2?Z/TO3Z),0"(.H/(24^>UX.';8[
M96\.])];P7@S4\;"6;65^YE>UO\ I/S_ -+^F5YG2L2P/<;+0ZV2]P-8DN%,
MZ>CL;[L3'L]O_GOV+7R^D-Q+G9&/7+'<D22T<D;?W?Y?^>LK*+Z&^I206?G
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M1@XWN97N?W>[4JQD45Y%1KLF#J'#0M(^B]COS7-0*\M]+QCYL->=*[^&6?\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@
M   !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C(@,3(Z-3DZ-3@
M<G(R-C0V,3<       .@ 0 #     ?__  "@ @ $     0   S"@ P $
M 0   K4         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%(34T *@
M  @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,B Q,CHU.3HU. !R<C(V-#8Q-P
M     Z !  ,    !__\  * "  0    !   #,* #  0    !   "M0
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
M  $  @   @$ !     $   %& @( !     $              \     !   #
MP     '_X4 1:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K
M970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_
M/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L]
M(D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P
M-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*
M(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3DM,#<M,C)4,3(Z-#<Z,S<K
M,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4
M;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z0W)E871O<E1O
M;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$Y+3 W+3(R5#$R.C4Y
M.C4X*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A
M9&%T841A=&4^,C Q.2TP-RTR,E0Q,CHU.3HU."LP-3HS,#PO>&UP.DUE=&%D
M871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W
M<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^
M"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC
M<F]S;V9T(%!O=V5R4&]I;G0@+2!)4$\@<')O9'5C="!D:6%G<F%M<R P-S(R
M+G!P=&T\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @
M(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(R-C0V,3<\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C
M.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z
M9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @
M(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52
M968C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HQ-C<Q
M.$8W0C4R04-%.3$Q031"040Y-#5!1C1".40Y03PO>&UP34TZ26YS=&%N8V5)
M1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HQ-#<Q.$8W
M0C4R04-%.3$Q031"040Y-#5!1C1".40Y03PO>&UP34TZ1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C$T
M-S$X1C="-3)!0T4Y,3%!-$)!1#DT-4%&-$(Y1#E!/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ-#<Q.$8W0C4R04-%.3$Q031"
M040Y-#5!1C1".40Y03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C Q.2TP-RTR,E0Q,CHU.3HT-RLP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C$U-S$X1C="-3)!0T4Y,3%!-$)!1#DT-4%&-$(Y1#E!/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#$Y+3 W+3(R5#$R.C4Y.C4X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%
M=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^
M8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ-C<Q.$8W0C4R04-%.3$Q031"
M040Y-#5!1C1".40Y03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C Q.2TP-RTR,E0Q,CHU.3HU."LP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP
M+FEI9#HQ-3<Q.$8W0C4R04-%.3$Q031"040Y-#5!1C1".40Y03PO<W12968Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP
M+F1I9#HQ-#<Q.$8W0C4R04-%.3$Q031"040Y-#5!1C1".40Y03PO<W12968Z
M9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#YX;7 N9&ED.C$T-S$X1C="-3)!0T4Y,3%!-$)!1#DT-4%&-$(Y1#E!
M/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ
M1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N
M,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H
M;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R
M9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( -X!!0,!$0 "
M$0$#$0'_Q  >  $  @,! 0$! 0          !P@%!@D$ P(!"O_$ $80  $$
M 0,# P(#!04$"0,%  ,! @0%!@ '$1(3(0@4,2)!%5%A%B,R<8$)%R21\#-2
MP=%"0U>6H;'5X?$8)6(9-$13DO_$ !P! 0 " P$! 0             $!@$#
M!0<""/_$ $@1  (! P,!!@,$!P8$!0,%  $" P $$042(3$&$R)!46%Q@? 4
M,I&A!R-"4K'!T15#8G+A\18S@J(D)5-CDC1SLP@U5++2_]H # ,!  (1 Q$
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M=,;[A 4A#JV+5Q3"(P$2)U-<Q"B<HBRY*B1\PS'*]48@VLM\FGO'8O9:?/\
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MT^^JDFE<12NDM(8EBKB$7ZWN)(C"<]7<.5>I%3SKT#LF\5Q>JZ A8K>XV+@
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MP?>1)^YH^C(/4!7U&/@%FV1+A/J+I*_*8MA8.LSLR3,:/<ADH0+ <O#84Z7
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M!D6CMX<6XMA3K')H0:^751989$ET:N'UV4X$32LX_E[_ )]*R -^=II,O'X
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M>_O[LX"P0+DD!F\(DD"L$SG: \K I$]5[M'KL>AV0=4[^_NG^SZ?:#):>=L
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M:4KYD*(+%(8@Q,1417D>UC$5RHC45SE1.5541$Y\JJ(GG2E:GE>:0,56MB+
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M<\D@<UA=BLFVWR?-<LG;=Q/9A7$<52XHIXI$6WV_L66V2@)B25,EQ!8Y3SE
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M TGVFV ^Z(+C]8JK_AC8O"/>,CRK5V4U,ZMH5C<NV^=(S;7)/WC/;GNV9O\
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M[JM37L#NG,V93-L:D58JV]L7BC2+-L,+L@K!0D>A(<$[GLXBSGN&]SQO<-A
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M-<3/T2*),LQ)&>%7+,H,K5-2M]*LY+RXW,%PD,,8W37-PYVPVT"#)>65\*H
M.!EVPBL1K^UF,6>/X_)GY%T+EN76DO*LI[:M<.-9V2#:*K ].>8M-7AAU@41
MY&=48I!O<PJ+J5KE[!=W:16>?[/T^".PL-V0SP0;BUPX./'<S/+.V0&Q(JL
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M8E:1LGMZ?:;0+B0#<PS&#SM7]\^A(SCT7GSX\O[8Z^9I&TBS?]3&P^V2(?\
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M-W^T.R]IGU-NO8[A1\E]]9QK;*J60&^Q],;B08>(RP?AYG6A&606?F/H?Q^
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MQ(W X\)Z#G[U=:/2]3DM&OH["^>P0E7ODM+A[2,KC>'N5C,";<C=F12."0.
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MFZ@-&;>XR6$9P0>Y=FV <]WW3?MBJUIEY-V@[)7-L7ECU2PA:TN4#,D_VFS
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MM8QC4:QC41K6M:G"-:B<(B(B<(B>$35 )))).2>23R23U)->B@      8 '
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MR@EH]PX)WR3;?")D3,=;]/[)/-=+JG::[_MC4!AH[<C_ ,OM//9'"559 IY
M[N.')RT+R 2U91$1$1$3A$\(B?")JFU=Z_NE*:4II2FE*IAO)_=@#?JDD^H>
M)B!MK#;13(>!2]S(53,V\B9^[*BIG$.0_(A&QV+F5QBQ\2'C0Y:#N;.DA9E&
MH^]%%?BTK/7IFJXW=-M?)W W^CXO3X:GJ(?ZJ]D+':.344U=_>368W%VM]+P
MRV\"57Q/VCK-LXF/PLPAY6=Q 8J?%V910V/?!-EUTG'K[GC\!_2L\X'I@_#J
M?S]*\NY%E61<JWV_NPNH<C'IV'4$;)I51DF=6$:ER]V_N)0<HD>I1DYZVU!6
MK7WU\"2RI+&N*_8G'MPQB)'J(6*CKG]/KBL?'^'ESTY]^G2K&;!9@;%MDMUK
MROAT]I&I-RLSC;=PL,GRK#;')/QIE"_":':.?)"$QL4G9%>Q<1*HFI6AW 'E
MX*?L48J\(,_E3SQTZ9S^?UZ5;3"\9!AF)8[BL>26<VBJ(5<:QDI_B[68$+4G
MW$YW4]Q;"WG+(L[ [WO(>;+.8CWD(YZJQ7MN,<Q[(1M#?4=1="'SVV6M;#GM
M'SQSVTE!+V^>$Y5G3SPFL$ ]0#\0#602.A(^!Q4(;?5-'MCN+D^$/JJRL%EA
MY&48-;!AQXSYU>5!NNL122UC7N)C\UKID"O0C^*F2TK&-''5&V?4HQJFF6FM
M0C=<6<,.FZPH&75H1LLKU\#<8[B )"\C<">(+U855-+D_LG5;S0YSLMKR:;5
M-%9N(V6=N\OK&/.%$EM.7G6-<L8)=_13BQ.JS5JK7\LEU\'&,@EVL,5C6@I[
M%\ZN.QA03XWM2H6"896O&\4MJK'(PC'L<TBH]KFJJ+M@C:6:*-3M:21$#<^$
MLP&[CGCKU'3J.M.[6;,3*&20%'5@&5E888,#P5*DY!ZC(KC8.TR;9[+Q6N-S
M;.KAF2/71S02V#8=SAKYG'[,6LQB27LN,'4ON\<GSBO+/H&NK5,:0!XC6M[5
M%E57C2>)N3O"G8_&Z11T\>,L%'WB#MZD42/2;_L]V@C.GQ-<Z?= E@__ "Q:
M;AWD,\I5@L]FS![>0C=+'M0;BTB"SEWNWFUOCZXE$OR6#<S@.BN.8(7R8E!,
M%Q86+9*"')&TD(JQPJ9_4\QVM$G<:Y$[&E:5813_ -KRPJL&FLLRC<>[GO!X
MK6W"DD$]YMD? PL:$MP1GN]IIUN(8="LI +_ %K,+,A_^CTT'_Q][*/V%6$-
M!"&VF2>150ED(&SES3+#UL6I9=2H57!A@@1H-:@JX(XD4+(X(ZNA,"4@V"8U
MG00CT5J<+^G,-M:&:2X=4>:21YI))#WC&21BSMAR1N+$G@ Y)KO1K:VL,4,?
M=I%#$L4:;@=L<:A$4 $GPHH XZUI[H;%Y^E>5Y_->?*^>?*^?_?]=2UE4$X(
M(^0/ESYG'Y5IDO%'" D_O'C \L#J<CUQCWKQG@M<U>6_R\?;[<+_ /'.MRN#
M^7S^%?$=P>#[]23\P?3\_7WK0H^%4]1)LI\.+_C+.7)ERI1>'GYE'=(> ;NE
MO9CL>[Z!#1O5PUQ5,1.M<HJHS, -SDLS'DG.>,]1[8P/7/)KO3:U>7L5M;RR
MYAMHHXHHERJXCC"+(P\7>2$#Q.Q.,^$*"16+L('"+X_E]OG[?\OT_P M24?S
M'S'U^7^](Y PQ^/D1[\ ]1U]>F.F+D^DNNG1<:RN88;V5\V\BLA.<G2A3Q(;
MFSGL3CZFHAHHE(G+5>-[$7J&Y-53M*Z-<6R@@ND)+@>2NV4'SPQQ@=<^=1KP
M@L@X) .>!TSQT^!]JMIJM5#II2FE*:4K'V=35W40D"XK8%K!-QW8=C$CS8I.
ME>6]<>2,@G=*^456KPOE-;89Y[:19K>:6"5?NRPR/%(OKAT*L,^>#6F>WM[J
M,PW,$-Q$WWHIXTEC;XI(K*?F*A"Z],NT-N?W<>@DX],1>IDC'+*76]MW//(H
MKGG@"5%\HHHC%3A./'C5FMNVO:&W7NWNTNXR,%+V".?<.F&DPDK>^Z0YYJK7
M78;LY<MWB6;V<F<A[*>2'!\BL9+PKCRVQBL<+TYCAJC:S=[>.O SA1QQ9:Q1
MC5%Y^E&P!MXYX\='\U76YNV!DYG[/=G)7(P7;3SEOCF8G/KS6E>Q:1\0=HNT
MT*#&$74A@8]A"H_*OP_TVP)O+;G=3=ZXCKQS%EY:QP7?FCVOKR]353QPG2O'
M/GSK([92Q\VVA=GK9_\ U(]/(8=,8(F&,8SY_"L-V)AEXN=?[27*8QW<FH@K
MYYSF!LYSCR\^>:V''O3CL_CI$./$P6\I'(Y9&0R)%SU.1>4<Z)+(ZNZN?E6P
MF\_?46\[9=HKP%6U![>/&-EHB6V!TQWD8$WXRFIEGV*[-V1#+IZW+]=]X[W.
M3G.3'(>YS[]UFIJBQ(L&.*)"C B10,08(T4(P1PC;X:,01-:,;&IX1K&HU$\
M(FJR[O([22.TDCG+N[%G8GS9F)9C[DDU9XXXXD6.)$CC0!42-51% Z!54!5
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(2E-*4TI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g713200g67b87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g67b87.jpg
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M  (" P$               4& 00" P<(_\0 51$  0," P$("@P,!@$% 0$
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M]6!9N;6OI<:7X^CUXK\2]?(.I'5V5QEE#)-U\IZ01$=4S.AQ\:,5_&2 -C3
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MM8?)]1866.@Y5)\)]U%&@\H4!,RA9L>K[/7ULJ[1"4BIQ%8[,@7MF0<I##Y
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M!ZT#5Q*+.<1\>13CD*B<2/M0];@': , 4.QLJ]*I5L><IAHQE]5LFMIT*:Q
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MVZ.9;&I8%]G=ZX]2Y]<&66]5G/LZS=3P4P146^3_ #/Z679;_C_^90/[!/\
M[\(NN(TL>#BB!XOW&["BP8E@\*E3)$CUX8BA@L>W4=/R1 BYHA)FS8,6J*SE
MX\<K)MVS=)19931/3;;!%S\T%,<:95SVU[*83QKY\J95H#&F-,8\V=\[_4$\
MOE\O[[S>/AX?7\?#A%^OD_S3Z679;\907[!.$7\S0$RQG&,]M.RN,Y_O8RI0
M/CG_ /&/J"?7X1?S% S'.<ZX[:=E,[:YQC;7"M >.N=L>;&,X^H)XXSG'U\8
MS_?Q]?'UN$3% S'.WEQVT[*9VQKC;.N%: SMC7.<XQMX?4$\?+G.NV,9_O9S
MC.,?WL\(OU\G^:?2R[+?C*"_8)PB?)_FGTLNRWXR@OV"<(GR?YI]++LM^,H+
M]@G")\G^:?2R[+?C*"_8)PB?)_FGTLNRWXR@OV"<(GR?YI]++LM^,H+]@G")
M\G^:?2R[+?C*"_8)PB?)_FGTLNRWXR@OV"<(GR?YI]++LM^,H+]@G"+XM^NT
ML:)81:]J^R#9'&ZJF$F^.OR*6-UU=UUM\)IT%KIC=991197;P\5%=]U-\YWV
MVSDB^WR?YI]++LM^,H+]@G")\G^:?2R[+?C*"_8)PB?)_FGTLNRWXR@OV"<(
MGR?YI]++LM^,H+]@G")\G^:?2R[+?C*"_8)PB?)_FGTLNRWXR@OV"<(GR?YI
M]++LM^,H+]@G"+YJ]>9>NDJ@OVM[)+(+)[I+(J_)_42524USHHDJGO0>=%$U
M-,YUWTVQG7;7.==L9QG..$7ZTZ]S%+31)+M?V4333UUT33TVH#33333&-=--
M--:#QKKKKKC&NNNN,8UQC&,8QC'"+]?)_FGTLNRWXR@OV"<(GR?YI]++LM^,
MH+]@G")\G^:?2R[+?C*"_8)PB?)_FGTLNRWXR@OV"<(GR?YI]++LM^,H+]@G
M")\G^:?2R[+?C*"_8)PB?)_FGTLNRWXR@OV"<(GR?YI]++LM^,H+]@G")\G^
M:?2R[+?C*"_8)PB?)_FGTLNRWXR@OV"<(GR?YI]++LM^,H+]@G")\G^:?2R[
M+?C*"_8)PB?)_FGTLNRWXR@OV"<(GR?YI]++LM^,H+]@G")\G^:?2R[+?C*"
M_8)PB?)_FGTLNRWXR@OV"<(GR?YI]++LM^,H+]@G"*2**>R**26RJKC9))-/
M9=;U?KEMM-,:Y55]4FDEZU3./.IZM)-/S[9\B>FOAK@B^O")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*WAW'_AG%/YL;_G5YRU8!P>?
MPP\AJK6.>[P^"/EE0^Y/*$57:%^R_!/NOO\ T%WS0Q3@%3W@\MJW<.X;3]^?
M)<KN?*,KFJ$]HX\<EW67L5%(P-=&9+)Z)MV/1X0PT]8^*G#5?R :)&LT_''K
M'3Y^Y;M6^GCCS+*Z:^./'A!M"MM3J35?V1?*K1.;R<Y743]';<\#M^6U""(3
M21UL>L&84 ^%Q,M%V@P@Z<S[ :O)R]D%0D!:TNR&"DA)^--M3#)!\7+9H=MQ
M]O']OC46+P;U;(>D7;J)C']!@X/7BKB<"+<Z]UI*CO3&ZII(.OMF@5(O+:?:
M24S"JGD,91'BGQE<79K^'1NZG=%3TE*"-AK+0#<LCVPV\^NHUY?[;+Z6U5R2
M+S597T<-Q2&&5O$(A\4JB[,,H5%XR.5F542?2(M["1 22OX_+@#9$U5,]69H
M'(I$WL=7BN(T4;QN/ZR*$I!BY<N.UW'J1T_:C"Q[XT[*:(JSN0[UKGMR$H5&
MM-85!D(DE7#[T>0:_74EWD&D-^/VYM&ZEG"#8JG-6\>09JKQ5<*XWU;;-2SI
M;Q7\>:WT*)/I)(S%C_8*3Z20SU@!E''2@F/@&>Q]5JV.6,RU:?S3RBZ-=LY8
M#-1>S=-=V2C(I&HQ8QQ%^O'G3>'DMVB# B1IMRVN-GKQJNPXQ+)#9]2)%(Q(
M0C<-V%ZT/-6TH",-)ZTT*=*K$>F$+'DP\<U=2B1AS3SW07*%G#K5D2TV',]F
MK;U#74L'BMR:]9_LJ40.Q['K>J*G9C"&*V I]<>H3&:VQ\2XN[D-7Q>77K/H
MW84I<F)3'##/#*.QM%KG_P",FIF#5U[W?V*? [B&)[+L@Z.7Z/7I7=YOKL^7
MBTMEH.V90L$JVNY/.(:3'5U6BS3L$* =I[2KV#224K.:_=Z;@K%IV)1DR^<5
M3I VTDT,MYW G,7 EAS+8LV&G.=>;9Z2-;[%)3K5=-@2+L9=E53VQ,6/L.>6
M1((\E$%X*]A=;1F.6FI'XW#9B&85S ;5JRR5XV?#-6P"R"]H"++9Q.3SVOIQ
M@0R?CL$(T!^GCY^0CJYU<&X7%.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$45.WTY@$#KB.OK"E$K ,3%@A0  -%K.Q3.
MD\E+D-(WPR)RJTM2L;7AD*:MQK^:R4BUE<=6=LX=@1GXU($5J_EY9'1?Q75#
M)1,4(]UTIJ'F;Z0E+1D<I4C>EH0BRS6[L=34JF)L:WD"%K,"[:6X@KB4QYM7
MYBU'YUJ??PX;*))*S3%Y[])MB<9XN;Q[/4*0?4LP]-584=:GS$LB*%J6^/J^
M5GSI24DY'5X^Q9"TAQ'$I-NR!:5!-&22@^'RIZ1)J2>%L8[(-"YI$DD8?$/V
M#KMKZ^)2;X6%:\](1-6E?.8_)73!Z6WU$@ (H..V;)O3,CF$Y:P^*AD%WJS9
MDTV+R4Z)'9?/G"#)CHYV>.U4VR"N^+1@;PREG<=?Q[&@"URYX8QHU( NYP%R
M0!>Y("KN,,,E3 T$#\2]Q)V!K"][SSV:TFPU-K!0&1N=JU@=MRZ21YT#)TCK
M)$Y['D2+0HFDZCT&$V/K@(;TT:-R;$M$) ")L';EJ-71W(;,B;!@]9NFZ<UN
MHR2N<+&'-NC00;%K!)H= ;L<TB]MMB ;J(W&\D+&NS"?+N;K$&SGF/5O$0]K
M@1<@VN"0057GI;932T9_$S;7>*YV83!P)71B<U'SEHAOH 1(I>VDAS)@FR>+
MMR*3E-@JAG90:L/*H+KLB;7?.E7OW3#JH[W1H&]>'CVS#M&S0@VY+'80MNDB
M,5?3-WVKKW<PQ\3P; WO:UKCCN-H*OA\I2MR<(G"+K3(8/(PY:/2$4-.@#PU
M\&. S#%L3$&0Y1JJQ)BBHUZDLS(#2+)==H^8NT56SMJLJ@NDHDIOIDB['77&
MN,:ZXQKKKC&NNNN,8QKC&/#&,8Q];&,8^MC&/K8QPB_O")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB\<6L." 7ZPLW,(V))-L)9<,"!ABT=HX72T71RJ@LOHIIA5%1-5/S:X\R>^N
M^/'7;&>;#*6ID:'QT\SV.O9S(WN:;$@V(!!L00><$+H?4T\;BR2>)CQ:[72-
M:X7 (N";BX((YBNM^JW5W\H4._ZPB_ZSSEW#6?FM1^YD^ZN/=E)^<P?O6>E=
MP$G<+DKS8?'Y5'S3[1#=SLT%E63USJW3W3347V1;K*;X2TW52TV4SKY==E-,
M9SX[8\>N2FJ(FYI8)8VWMF?&YHN;V%R +FQTYESCJ()798YHY' 7RL>UQL+"
M]@2;7(UYUZOG2NY6O/2$0II8+J/QEV_>B=]Q($Z+,#L-MWH:1P^<-9?%33=%
MZ@Z8NMQ$E!"27L3YLX8OM6NS-X@JV75TVL^!L#Z6=IN/Q[' BUPY@8]I%P1H
MYH-B"#:Q!"KN,/,=3 ZP=^)>TM-[.:\O8]MQJ+M<1<:B]QJ% H'4Y42SEN%K
M *+&+#(R(Y.R[2/1=+0F=+0^.04(^#B2PX\-$-HA'(H#:BACU$XS**M-EY1J
M=W<N_7S@B(S;\WD+G/(:W5Q8U@(!#@,K6@ ',#;?9M;Q#IFDMM& (PUL8+W[
MUH>Z1P<6EKG%[GNN06D [W+86KUU'K]W$KO82([)5I9+)I(12AHO[J9@6*;*
M/1UR)"CAH9CNOHW202RZ>O'+MX_?/"1%YMAPW%)"1 O2Q%A;0U;B[,Y[6W-@
M!9KF   >,FY)N3K:P&W12!]92-:W(QCG91<N-W!Q)+CMX@+   #2]R;WW*2K
M<G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PBZ,S*(U'5PK602(&"<R0LB!CK<R68#%SYQPFHLW#!4
M7KA!0H6721651',=5WBJ:2F^B.VNFV<$71SBSJVK%FQ(6384'KU@3<J,QKZ<
M2P#$V9!VDEE=5JQ<GGX]%VY31QE91!#=171+&5-M<:?7X2U]B]4,)C30T>9#
M$&)8068M"8HJ,=H/QI,:_03=,2 ]\U45:O6+UJJDY:.VRJB#A!1-9%3=/?7;
M)%SN$5JGLS]FB6?\S'OT:$<NV$?DZG^5\_*J?BO#Y_DO,QJ@O))1ZE)U%^RB
M^_F>6_.03D-CO F^'9Y,BE\%X6_P#_+C5RSE05I5O#N/_#.*?S8W_.KSEJP#
M@\_AAY#56L<]WA\$?+*A]R>4(JNT+]E^"?=??^@N^:&*< J>\'EM6[AW#:?O
MSY+E=SY1E<TX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$48>TPV1%8U6:<7K^1STD,OFD92[2C:4=
MV= H]#K,C$JDQAPK(3@+1-!(((>:X28+.7KQ?U35-KOZSQP1<V^6UA6-7DOK
M"$1J3Q]],I>$J<I-EGX ;@164H'!7]FVI$'S&0.RC9P'AA*512%*NQ[&0IVV
MP&JJQ[XI:)25T12 #B!<?$"P ,>S$! @YB(#BA[=-HP&"QK9)D/'L6J.NB+9
MFR:(HMFS=+75-%%/1/37&NN,8(NQX169N[<[6AESX'BP2DED\\D0"(Q8/DB@
M'8K$T*U>S%^Y,&%D'F18IC'8D;=*N4!Q-TJ[39#VS%9=ZGG6Y86_)AU( W,Y
M[I6-%["^ZSO-SK8!K''0$WL+:JIXA'GKZHEV5D;8GO=8N(!CA8+ ;27/:+7
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MCCFS1PMJ*F*%Q+6R.();:XLTG2X(XN1=%3*8()96@%T;<P!O8ZC;:Q^=0?\
MEC3S^+,1_%&?[6Y8O8"F^&GZX_N* ]FZCX*'_P#?WT^6-//XLQ'\49_M;CV
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M!+'(AF36,RJ.MY?#%;&KTK(=(]AC/8*W>!F;B1!DPL@,D!NB&LGB;]89*6(
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M;;?;;.?F":9]1-+/*09)Y9)I"  "^1Y>\@#0 N<38:#8%=FM#6M:W0- :!S
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MF#-PFEJT<[;[:X05SJ1>PX1.$40[Q[)R6K#UF(Q^" Y)&:%I6/=@+C)&):_
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M)/6SI_ZPN5%"$MFR2FJA8J+%Z;;/R+)NN15"X1.$5&[4ORLJ859(3TJ;:K/
M$DERJ4?A<TFB@F&P[83I*YE(=(: /;1V*Q_<X)U)'36&+!/9YKA-97*+GU)/
M7K7;6#;\)K1O'UI I)";B5+/$HZ(@L(F=E2 JB.';ER9%M'Z_ R4S[G&C]-%
M7AA1EH,3</!0O5UN7-A6! GKMM]*]E&)*!FD:CTQBI5H=B\L!B9+&S;!3UK
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MW2/CR37<T7DBB=F ]L,E@=A*N])4,J86R,#@WVEG@ W;8'87"W)JL;+X7?\
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M1,XU2T$Z'L2'8@ ;-=]U32HWV-9?&K#"_JUM/%>V;C$[ZF+ C%"*:+N;$1*
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MLF#F@4X>7 WN[.8P+6%M,IVK7L<]Z573A%L1/@U72Z9]:>J,FNV2RZ,2$)W
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M5KQ;0[R]C<6<T$'Q%7&?0*>DQ[TW[WVK_KK<M_%YO3^T%MLFXA;F(UT,9J%
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M; 46<.'"FRJZZRFT@SLHJJKOLHIOMG.VV^V=LYSG/-H5]8T!K9Y UH  #W
M 6  OH - %KFBI7$N=#&7.)))8PDDFY).74DZDKX?(IHS_(6!^5*?_V_S/LC
M6_G$O[;O2L=PTGP$7[MGW5Z0!U:K>*ZNM(T;M@%J]V1V>:BKBLACASLWPIA#
M*^&\CT]9E+"RN$\[>/EPIOX>'FSSIEJ9I\N[/,N6^7.2ZU[7M<Z7L+]"[8Z>
M**^Y,$>:U\@#;VV7L!>UR@WKYE([)').SKD=@'>PCXLC4;FLU)T)U08[)F,/
M'.)%KL[]N?\ E<-_.HKZA+&4]?)C/EYU9OT6]2[,OZ3NM=:6Z@U">(+E3;JS
M"I-UZK#A^_MJPW3M?""*;='UJZLAV4W]4@DDCIYML^5-/33'AKKC'-B.MJHF
M!D<SV,;>S6N<&BY)-@#;4DD\Y70^DIY'%\D3'O-KN<QKG&P %R1<V  ',%UO
MR*:,_P A8'Y4I_\ V_SG[(UOYQ+^V[TKCW#2? 1?NV?=7<@^I=51EYN0CQ&T
M0KY1ONUW=C+=L5FXW;*;I*J(;*H2'3?*6ZB*6^VF<^7.R>F<X\=<<ZY:NHF;
MDEE=(T',&O<7"X! -B=MB>M<XZ6")V:.-L;B+9F-:TV-C:X -K@:<RY>_7S.
M94U>IV=<FL2TC[YJZ"YN:SLOUI$J2'*L"FCWXQ>?1HV&)$FBK7"N-55G:*N4
M]LI8VUZ,WZ+>I=V7])W6O@>ZH5=*%T'4C*6H<<MD<MVZY2W[&>JHH9WV4RDG
MNO(M]M$\J;;;^37.,>;;.?#QSSNBJZB$%L,CHP3<AA+03:US8\@75)30RD&6
M-LA L"]K7$#;87!LNB^131G^0L#\J4__ +?YV^R-;^<2_MN]*Z^X:3X"+]VS
M[JYPSIY3H9\V)B5[*&D6>^5&KYE;%A-W3=3.FR>=T5DI!JHGMG3?;3.==L9S
MKMG'][.><7UU5(TL?-(]CM'-<YQ!&W4$ZKDRCIHW![(HV.&QS6-!&EM"&W&A
M7;F.OF5RD46#6=<C$4R-/'$M9N+FLU=<T$4C9YHS'L5MI%OLR<H29R +*.--
MTME&8UTTSOMJYV24ULWZ+>KG'V77?EYW=:_1[J]7<H10;2,];9QNU5V7;HE+
MCLAZF@MMIE/95+1>1[ZZ;YTSG3.VN,9SKGP\?#G;%430DF%YC+A8EA+21ML;
M%=<D$4H E:) #<!X#@#LN+@V7F/D4T9_D+ _*E/_ .W^=WLC6_G$O[;O2NKN
M&D^ B_=L^ZOHETNI%!5-9'2PTED5-%4E4[4L#7=-1/;&^BFFV#^,Z[Z;8QMK
MMC.,XSC&<?7Y@XA6$$&HE(.A&=VP^-9%#2@@B",$:@AC 01L(.5>,[.=?7+S
MKY<*,+L6XFDAQ 9 NWV(6Y9AIJ[8-&6[HZ)V%JGW*;M8V!1)AFNFR"F-'3Y%
M7&,93QMC- \"NHR0T 55.2; 6_&LU).EAM/,NR5IW*2Q<3D=I?;O3HM917)7
MLS6D981P50$A,+QF1RB9UQ)3]8V0M(JMF4SCX&-2.50U04Z$"'!9Z/B<3<,\
M3,/+AX$O&A9N.L1!;+YV]^FZAN&U,CI'8A&P21Q0U$<=33".JAAD?)'%-G#W
MA@=+*';B^)TC)',D<]F4-IK#,P6$1-B7,<6/NQS@&ES;$"]@VV8. (! !790
M*2=C:[RUU#]8%'S8,<KV:Q-B9JBTG3*'6=7$:;QP79P1NV+LM7<E.[M]9!,P
MLES(*[E4@]0N5@ZPX8&&#>,[,.J+Y\3#2]D\,KF55*'34U1(9'4SR6.M&P$Q
MPOCW.HBCN&S!SG.<:96;(;V+7-NQ^]>P6#QKJ3M<'78X[6V  Y6LV[2Y"HL7
M77=\5D#@)!(?*YT=I^>R"2V'7]:R".26'5_.AYQ8A!C$:&/X7!VSA5M#A\B+
MB(9'@Y@^_'(.V[W&Y87GS#$&MC#YY8H&5<$<5//4QR1S3P.9EF9(YLTY%YG1
ML?-(]C&N((SFFM;<KFS6EQC<XN8P@M:X&["!E:/:W(: 395NZIQV^;,[I]$8
MVVI*1TM$H?V1J)A&&T.A]L"P<,=R:X(X3.3!:2S(O+)<D^]MRU>N2+R5*("V
M@EGJ,1')-MO/'8R^BAP+'R*^.JGJ,,K<SY9Z8R/RT<K(XVL@;%& T$Y0R(.+
MG$N+B5VTXD=54HW(QM;-'8-:^PN\$DEY<[DVNL+:65VOX2*H9ZY=R.B$]"G#
MLME\ K47/T7$]DTFF3!W*85:6IE#7&ALJL\:A'I,;KNZ&L7++51%53&N4E<X
M4UJG:UA958+C=,^[8ZBH,#RRP<&2TFYN+38[X!QL2" >);V,.,=33/&I8P/%
M^5LEQSVN.58[)6^HJS'0P#7-=G(>#K(]([%KO!JPD)<<#6]+)!6CLO,C!5&#
M1EB>!HQ2K(U$Q$/U""_8]T<'WQ\J^RZ0>>BMH97.E?45#)7U$<=/49*<PL?2
M11U(9$QN[2.CD,M5)*^;.ZX.YMC8VQ$296V:&-+0PE[+OS$2.++N)RM!&5C6
MAMA;;<E>X;]JX:*G]72:.T^4"16"WV3[(R"()66D[>2:PGSF,O&(81)'-?[:
M1BO8XM%FR( $] RR4:,3,C0+S@PZ=B7P/I.&2N@J8I*MKY9Z%N',E[G($=.T
M2ASW1B?\942"4E[P^*/,R,LA8 ]K^6[M#V.$9 ;*9BW/J7'+8 Y-ZP9=!8FQ
M-W'0BXI\'O"Q^<^E;AS,;M,HK'B$$NQ\-1'3=^SE0YGB)OG#5DZF$691!9^K
MIIG5)ZX9B@[5_P"&V=AJ">WJ=:YVP YG8K,'EKWMGH@YS6%C'$3-!(87R%H.
MT-+W$?ZCM6YA5C7-M< ME(UN0+$@7L+\YL+\@5[/X2+UJL];J;UN91E.Y[ME
MZ-_29<RD.(6/9C=B%7BTM5#NM0*BAK03NT8*C!*Y35HWV<N$U==EU,N<^>C=
MK.IIZ?$L1=/-#3M=0L#7321Q!SMW82 YY:"=IL.+6RD<88]T$.4.>=U-PT%U
MMZ[F)ZUBTREOW)F+-=H;ZBS%?<_(F$UL=YBB+9W<VU/ \5DL1 SB>ZN=G#/X
MQ!6,SEA)OM$&D2%$9'(BLB/BS!9SESKZK$<'A(+,6A&2-T-..[J6U+ ^6.:2
M& BSMS>Z&)IW4RN;'&V-CF,%E".W=VV ZD.?^+?OW %H<[G <3O<H))+@2N3
MN_[[MA#)"+4'=-?2_5A!A)VUJ_JJY(O9TL$5I%%H1!A9F0LMLLQ[,-%U$QC_
M !$1$87F2K-@7GJTI.,FQ-/ &!%[C)7T4\.:9\=+/54<M-$^HEW:9S(SOG%\
MN^;NKY1#=S8!$PEI7J;"T<C76:"]K) ]P8W*T$\5FZ;T-S6!=F(NI'=/H=W-
MNOTBO1:47O7_ &0<-8M='72&K2\Y%;6&*QR(1*2QH3@GF4D6WM )SJT:;ERY
MQ(@RSL55>&%-T5U=]\1N,28-2]CV.0451A[3/18C)N4,U-=\LT4KLK61N!=8
MNRQM ):T!HV+N@%1)5TSI&RG+)"W,6OT:UP%[F]M-2>74K8 7)U$/V+2G92N
MF5HV,\-6= [&B-8IR&XK0TC@-.5U<G%Q(^8X2)%%"0S$Q6+E2ZWNLPIN$(ZL
M]63W#?1EGY_P^JCI:^AJI&$QTU735$@8T%Y9#.R1P8'.:"XM;9H+F@NM<@:J
MU2QE\4K XW?&]K;DVNYI OIRG6W$L-L?\%<]).(=:O1-U]1!CS5-9'5V/M&[
MF3K5)RENW<):KMJ!25PFN@HHBMIC?RJI;[I[XVTVVQGVEW;-['7C*^CQ5S=#
M9U-1.&AN-#7$:$7'(=57A@M6-1+ #S/E'_$OVR^"P^DL'*MEQ]W]1V"[+"^&
M:S*U+P:JM,.L9U<X;*(4%INAAQKG.J_JLZ>MQG.%/-C.>#VS>QQUPZBQ5P-K
M@TM$;VV7O7:VXK[$&"U8V2P"VRSY=/\ ^2D'U$^#3][*2[74#=]D6WUJ?1"M
M[AA4_F>T%M"YM)\[#@I T+&-HR\<4Q'L8D:Z**VS!PM(!/\ PS;3?<DVSXK:
MQV+]L/ Z_"<0H*>EQ-DM51ST\1DIZ5L3721EC,Y96/<U@)%\K'$#8T[%VP81
M4Q3Q2ODA(9(U[LKY,Q -S:\8%^DA9?2'7S.LJ)O5[.N12)+1\&U%A=;FL[5^
MTD38E(53Q19[\8L;K-"(UU'&C5KE7;5LL+=K:IIY=;;*>-YOT6WZ.CGZ58,O
MZ3NM1"D/H6?1HRLN]/2#JW!21DDNL[(D5$W*+E^\<KJN73U[NV51]J>NG"RJ
M[IXOA1TY54V4754VSX\FH^R7'XF"./&,1:QH :WNRH(:  T-;>0V:   T6 X
M@M<T5*XW,$1)VG<V7/3O=5TG[AMZ+CZ)T$_SB7];YS_"GLB_WG$?XN;[ZQW#
M2? 1?NV?=7-'^A']&"+=)O6?4^O<+I8WQIERU6?HX\^N=-O%L_4<MM\^7.?+
MMNCMMIMX;Z9UWQC;&'=D_9"X6.,XE;FK*AIZVR _.LBAI!J((OW;/NJ93[KW
MYY#'G(^S;C:QIHT.)R$4I<UFJ.R;IQH.P!59NLR+;9HF-W2(Y<IZ*)X<8=(X
MVUW]5CRP>;]%O5]*V,IY3;CUU\7]U22\/1O=2NS'Q9SV%@9JZLPOWQB)9LV<
MS"9?%OXP^Z_?ON7WX9>>[O>_N0/[Q]E]7[7[L8^N\_LR7EWZ+%L1PW=>X*RH
MH]VR;KW-*^+=-SS9,^1PS9,[\M]F9UMJZY*>*:VZL;)EOESAKK7M>UP;7L+\
MM@J!_N&WHN/HG03_ #B7];YO?A3V1?[SB/\ %S??75W#2? 1?NV?=7H(GZ&'
MT;L$E$;F\+ZV1J+3"'G1,HBLF D#(PY'9&!?MR@0X&)-'Z3H>4%$FK9\/>ME
M$W#5V@DNCOHIIKMCKE[),>GBDAFQ:NEAE8Z.6-]3,YDD;VEKV/:7D.:]I+7-
M((()!T*R**E:0YL,;7-(<UP8T$$&X((;<$$7"EQ(.OF76H;$=LZY!FS>0"G1
MK+NY[.=8?QU!7?8L,;8VD2GL[MZEG31!UKY-D<XSG533.?'D-F_1;U+8R_I.
MZUXBX^B/7?L-$T8'>H>:6]"VYAG(4(K8EE3J6 43H]N]:,2Z8LR==M-"+1J2
M?MV[O"6%DD7CE/3?&JV^,[5)7UE!*9Z&HEI)BPQF6G>Z)Y8X@N87,():2UI(
MV$@'B"X20QRMRR#=&WOE> X7&PV((OJ5%[]PV]%Q]$Z"?YQ+^M\D_P *>R+_
M 'G$?XN;[ZZ>X:3X"+]VS[J?N&WHN/HG03_.)?UOC\*>R+_><1_BYOOIW#2?
M 1?NV?=4T9'UT1VB103![(N".G=0ZC&-/G-QV8Z&B'::&$1ZBC#,B435:M?+
MICV?U6VF4]<:8TSC'AR#+[FY ))N3;4WVGI6SEL-">87T^;D7%L#J+4EK0V0
M5W9;RSIY!)6Q]VR:(2RV[$.1T\/]<DX]B+"2$A79/FWKT$5O4N$M]/6))[^'
MFUQG';!4STLT=132.@GB=FCEB)9(QVS,US2"#8D7!V%<71M>TM?OFNT+76((
MYP18J''[AMZ+CZ)T$_SB7];Y+_A3V1?[SB/\7-]]='<-)\!%^[9]U/W#;T7'
MT3H)_G$OZWQ^%/9%_O.(_P 7-]].X:3X"+]VS[JF9!.I555A#X]7U=$;1A$&
MB8U$/&(E%[=L4+'@ IOG;* X0*82%%FP9HYWV]6W;I)I:>;/EUQX\AYZF:IF
MDGJ'F:>5Q?++(2^21QVN>YQ)<3RDKO;&UC0UMVM:+!K;  <@ %@OZ!ZW-%H2
M* 6!8ENRDTM&VHF9.TKBLM 1('ZP[1H=6T&9D*:*0\FKLYSAEE#1/5NMZG*>
M-?WO. D+7!S+-<UP<UPT<T@W:00;@@VL=NFU<LMQ8DZBQ%]#IKMY5#+]PV]%
MQ]$Z"?YQ+^M\F_PI[(O]YQ'^+F^^M;N&D^ B_=L^ZG[AMZ+CZ)T$_P XE_6^
M/PI[(O\ ><1_BYOOIW#2? 1?NV?=4IJ@Z+]?>OT1^(%'#)O4L(]Z/3?Q3KZS
M)W%8_P"^"6K?0@3]U!SK5G[<\T:MM7+GU7K5M4$L;[9QIKX1E77U=?+N];/)
M5396LW6=[I9,C;Y6YGDG*+FPV"Y7<R&.)N6,9&WOE99HN=IL  O8QWKYEH@4
MUDEG7(576D!QT*49W-9S35G'7)!94"+7UUD2>%G8X=LBU=.LXVV<JI[*[**9
MVSMG5S?HMZESR_I.ZU$.3>A;]&Q,Y)()A+>M$7DDJE9LK)9-(C3XP1,'I =?
MN"ADT6(.GRCE\3*$G3E\_>.%%%W3I=5=7?93?;;,U'V2X]#''#%BU?'%$QL<
M<;*F9K&1L:&L8UH?9K6M :T#0  !:YHJ5Q+G0QESB226,)))N23EU).I*Z3]
MPV]%Q]$Z"?YQ+^M\Y_A3V1?[SB/\7-]]8[AI/@(OW;/NJ0%(>CDZH=:$I(AU
M[A!VED9BH)5E:59SN90Y.1*@M2.@50SJ#,L\$-Q6A<IJPV<X4RUP0>82\N%U
M/-H5N*XAB1C-?5SUAAS"(U,KY=S#\N?)G<<N;(W-;;E%]@7;'3Q0WW)C8\UL
MV0-;>U[7L!>US;DN55<=U\RD?D;HE9UR.H^[U#_%H:C<UFI.A6S=HKH:R\<X
MD6NSOV]YLBNW\RBOJ$]-M-?)C;PSHYOT6]2[,OZ3NM1IM+T1_06[YP7LNX:,
M8V=84@T&IG)K.#\BDDF+)AQC,**T(&2I)R^=:CA ]B-9X66WPW9-&[9/RI):
M:XE:7'\9HH64U)B5934[,Q9##42QQM+W%[LK&N &9[G.-AJ23M*Z'TE/(XOD
MB8]QM=SFM<XV%A<D7T  Z%3[]PV]%Q]$Z"?YQ+^M\V/PI[(O]YQ'^+F^^N/<
M-)\!%^[9]U58IOT5O2#KQ*W$[HFH<U#,W05Y'',IKN4RB)GEP)!TQ>O@ZI,,
M5:.]QKMX,'.7#397**J[%JIOIG=%/.NK68WBV(1""NQ"JJX0\2"*HGDE8)&A
MS6O#7N(S .< =H#B.-<XZ6")V:.-L;B+9F-:TV-C:X -K@:<RD IU\SF5,WJ
M5G7)I$TX^2:O0N;FL[+Y>1+$12HPHF]^,6=TVC0:@7:+-<*ZZK+/4%<I[90Q
MMI&9OT6WZ%W93?VSK=.MU0ZZ_1A=,NR!L1);^K!Y<L@ "M@80U9,PE<O)B0V
M[M9_L+'O#99XNU8[/7+AWELCOHEEPLHKY?/OMG,C1XSBF',?'05U31QR.SO9
M3S21-<^P;F<UC@"[* +G6P XEU24T$I#I8VR$"P+VM<0-M@2#I<JC'[AMZ+C
MZ)T$_P XE_6^;GX4]D7^\XC_ !<WWUU]PTGP$7[MGW5[*OO0]>CSJ>9@+%K+
MK\&@,\BKS8C&IA$C)X%(P+[9NLUV>"BX\B@]8N-FSA=#*K=;3?*2RB><^7?;
M&>FH[(<;JH9*>IQ2MG@E&62&6HE?&]MP;.:YY!%P#8C: N3:.F8X/9#&US=0
MYK&@CH(;<*M%S]:;"D$9'LZ2O.SX!*$CK=R1+R.T[)D+)T T'DDG(U%FN;>Z
M).E2*PQUHYPEKMJDT62PIC"V==HEKFWWS01;8!;71=Q:>)Q\957^Q\JAL*I.
M?2:P)?+(/#QPYAJ;/P4QK'9AE%^:&#6P".R'S(*@"DO?/&L1;G&9( 2#Y.9(
MBY3$R39K)17!=@U(5M?661]LQAR]F]CSL?HN3Q+M%+8\_@G:*9GTX-8K%_1;
M>M*G=WY'YM\8;+L8+%B%GS$%79"42<2]/&Y4'BX:4QJLX85:%G9?ETXN8WTM
M\_I5>(':DE#V]"=9H7-';Q*]$!DYL"@!UA83?%K7!;1DF\&1>L#\J90V+2HF
MX7D0M(FT&QY-\AMKN=*[#!VKEF2VA[ZU^O\ LN^Z(R>US+OM"-N/2SU)<QO@
M(:<9GBN^\:CBDQZ]45)B]>U:U4-%,!:^ATE('-(X(;-V6J@LDSD!I0A,S\J>
MK%@VTZ->G53DDQ!@)C<A*E#6\;&# 98@1D27LOK +!FP<.79I/VYH09><6W3
M4?:>V,'K7S(8]H:.4?.CN6%9YAT]C!H3$9>([!RYGU?EUJU?'K$0.=HY3++
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MKA-PU:CTQZHP0BRT$,BX=*M:PVQ(U(HXE-XAV,FCKK?(YI04=L-^>[+'Y3;
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M @ZE#Z4677Q,/&39S6Q8M6,:LT&S9$0LD'1N.37:H( :\ J2$LBAJ/,"4.F
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6<(G")PB<(G")PB<(G")PB<(G"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g713200g69u35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g69u35.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4L6:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,C M,#$M,#=4,3$Z-#$Z,S,K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,#$M,#=4,3$Z-#$Z,S,K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#(P+3 Q+3 W5#$Q.C0Q.C,S*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,30P/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G06I!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ-T98
M67$W)B-X03M&6%EQ-T9867%W:E@Y2# S5F90:5%8.%!R4DQP66-,>5I0:5<T
M24)Q:%4Y1T]&0W8O9T1Y;"]Y=R]W1$IA8B]M=D9,=CA!955V*U=()B-X03LO
M:W1.+W=!,31Q-R]!04(U4R\U668K4S S+TYE2W-,=71B+TME,3%"-T=E=W5L
M;%)15UEE=7EC;6Q-2U(X;&Q.2%IW3FHP1$%M9W%1)B-X03MO6E9P9FQ0>4YQ
M;6Y7*V\R5F]:3%<V45-1=5I,:%-64'-Z9VI&2TLO=T(U4R]W0U=(+VMT3B]Z
M6&ER=CA!955V*U=(+T%*3%1F.#$T)B-X03MQ;&UR*U8Y0S!U.#!/-'-B8C!P
M5S%3,5)M3'E0.$Y3,4M/>D1Q;WA1.41W2F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I)B-X03MR<U9D:7)S5F1I<G-69&ER<U9D:7)S5EEL<44X
M35 U9W$P,&EX<61*;T=C:%)8-GHP,W=Q;78V4S W+VQQ:"\U1TPO6$96<VUO
M5T1))B-X03MY<F5227A"0W5(43!*-S!*>%9H8F%*-7)I;F=E>#@W4G=W=6]7
M.6IL:FIU1%99=V]E3G S:S,U3#!!545'<E995EI634Q7=S$Q5G9%)B-X03MV
M9D]+6%-4<D5,6&IB,CA$44Y'54QT>6ED4R]Q8U=Q1'1V-&1654AB-D@U;VIT
M56=L."M,359E2C-C,G-#;'5$4G1)=%)*>D%K2U K)B-X03LQ<TAP,$%X5FM(
M;#4S<TY+:71T53%M3%4W-5-X;79356HU;&U*<G=$14PO<6<P2%%B05EQ;5@V
M4S W+VQQ:"\U1TPO6$95:SAZ6&1P)B-X03M.4&]3=WI2>4U.5W135E)G>' X
M5RMX>%%Z4$%L,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU)B-X03MX5C)+=7A606%H;T=J-FA-2G(R,5-E54M%1'17
M=D5%:T19.6EX>%9#+W=#1&9,2"]!1F)O=BM'+W)J874O=T%'*U=0*W)D1B]W
M,SEC)B-X03MB5C,K1&9,2"]6=6DO=T-'+W)J87!D9&56+TQ-3W,R>79:>%(R
M,S%3-FQM-45H0C9B,CE'87!P.$E:=#A+<4E4.')7=79Q85A';E-8)B-X03MN
M<5)1;3%J;E(U4DIC8GA+63%C=%9X=4YU;2]167%M+RM$9DQ(+U9U:2\T8BMU
M0S%D+V<S>7@O,6)O=BM'+W)J87(T4$MN;#)#6DIO)B-X03MR0TY*63)6,%E6
M,EI31U4W;G-26$95,GA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A64VUU-U=!9U142D54=4$W
M0F$O96-652\P;G!V+T%#,7<O=T1)>&8V-'$W.4HV8B]Y,7<O.&I&+W)I<G8P
M;G!V+T%#,7<O=T1))B-X03MX9C8T<6M/;V$O<&\X-&%:64]H;6AU8D<Y1#-+
M*VTQ<V<U=T5R2WAB879';$MB,2MD1E9C84@U045Z>D14.4M%,')24U-Y*VIB
M8VUE)B-X03LS+W576G%62FIP.$(O6C=9<6TO-E0P,R]!2F$T9BM2:2]W0F-6
M9"MK.4XO-6$T9BM2:2\Q>%9F1F9757)H27)I3U)Z,%9856YB,D)X)B-X03M6
M5WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5D12+SA!2%-N+T%/34U0+T5P)B-X03MC5EEL9"]M1G)L
M=G%,,F\X;S9N4$%I:B]!17%&1UI$23!P:D,W;W5W2$8R659!56UL4W1#5F1,
M*UDY+T)C9S-(;&)613 T=U<P-75L)B-X03MH67-H=49*9%I56E564%%P*SA0
M33!X5G5,.'ER:#%J62M5=&5);59P27I(84MW.4UE;58U;'!%-'5F5BMZ+VMT
M,4%Q47%T8RMF<C9.)B-X03M9-6]F2RMR>E=T8FM4;C!/37EF5GE1<%='<$QI
M86XW=F9E=3E-5E$V9FUG='I(3SEH-64Q5S1A=VY%1W!7-6=P4$-7="]8*T=*
M1$E8)B-X03MB8U(P,DA).65.5T)65B\U5UAB>5AT>%E184QQ6G9B4EDU3&DS
M:W1Y2$5C>&Q73FQ74#%73E=I.$M!34-4:E-R5R]-:3971T=5*U5T)B-X03MD
M<$Y'-VE-5VY+4DA21V9H27%S=UAL>&]P1$=P3DU#<VQ795,T:3!U95-)=U-3
M<TAE0G$X:UIR9'E53E%.,39D3592*TMU>%8R2W5X)B-X03M6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMO85 O04DV
M52]W1'AH:"\T;$QI<4IX5C)+<V4X)B-X03MY*U@Y9C%/-FEM,'I86F1)155B
M0E9J:D5I;5AF:7IO>%5/=31012]Y*T))>%9+>#58+TU'839K:79F3DA+=U0P
M2DQ784="65IZ2VIY)B-X03M.2W-I4FA"-F)+>4PY<SE/;&0X2W)T4#AV+VU2
M1#5I<TI,+WI*1F9A1F))6'551G5L=E!.3U4T049),31E;4XR,V,W;G X2S1&
M6FYI)B-X03MR<U91,3,O9C)8+T=9+SA!2FU41E54:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9197-8:SEN<',Q)B-X03MZ
M07%V3D=&-$LY4713=UAE;2]F1E5R,4188FY46%9.4C%$4V).,E5U<3-%>&E*
M54%K:T)Y3F=&2BMG-'%V,#-6=%(Q3TM38E1R<E1R)B-X03MY1TM2;UI*65=K
M9$));$]A:&QQ<$LQ;V%D1'0Q0GA61B]W1$]Y9CA!3&XO>59X5C,O3WEF.'5F
M+T%#5GA64FUS.65L9C%'*W%H-D)3)B-X03MY4&-*54-P05!!<EAQ8U979F\O
M6&8U-&8K4CDS+W=!,3169"MJ.60O;F@O-4@S9B]!1%AI<G8P9G)V.$%01"]Y
M4'4O*V$X5E5)8EA5)B-X03M2<CET1&53:U%083-,.$E:-VUH9$I)04,S2BMW
M8S K94MP>BMJ-% U-78X06MF3B]Z6&=6,S909R]N;2\U2'IF.#$T<3<Y2'=F
M>GIF)B-X03LX:C5V*V$X5EA*63(V4TQ)4%5::TI+.#5:2$%*0D9A37A(431Q
M<C1Q-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T954&1Y)B-X03MZ
M;UE%:$MQ,#!N07,V;&=!15HK9TLO>2M/2W1E;G%8*R]W0T@O:U,S+U981E5.
M9#,O=T)3<#EC,4MZ='%G165S=G W1F=O*S%-4#)M)B-X03M!*V5+<6,K<U<X
M15!R>C9V65)18VM4,5AO<6-P44=J6&M:<59C149F2$953#5N.'9W*UED36)2
M9%-V23%I=6ES:6E%4$1-9E)D6'%J)B-X03M,3'EP,$15-T@S>%97,511.5!U
M67A.<7-/;E1X=TE6170S87$T4D-#<D1L2DEA06AI1&EQ:F\Y>F]V0U@Y1%@K
M;&-*6FXY9C9M:V1')B-X03MN5&EK;E P-60U1BM&5W)U3G-65%-&<GEE2EI9
M8G4S;&EC5E-226U:4U!%15,P3TMR8G1T56=T2G!L;6=,4E)S-$)H96A+9VXO
M9G5+)B-X03MO-T9867$W1EA9<6PP+SA!>6MD:B]W07=D,R]Y9'1S5E1(1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98)B-X03M9
M<6AR=BLO<W8K37@O=T-436U+;VY&56XX=RM4+TQN;4I&:C%M>D8S1V]!-$8U
M155G34A!64EY:'%-;UE6-S1Q=W)Z1BM8;6XR35IS)B-X03MF3"]L84\O=$QJ
M:$YC4GE857E"<$EP<$I60FME-%1H>&59;EE.6&PP4$=M1E5T+S56-C Y.'1R
M8V5314YH<55S:5@Q,BMP8VQT<F1L)B-X03M*8FI%<W%Y33!H=5IH5E@R*U9!
M1E904F9+,VU#>6M5>B]L-6)E<GEE1U,T=&14.4940F5-1G5'5T9P6F5,2W-5
M8F9B2DI(=S!)<FER)B-X03M+4$LS:U12-W)10D9Q,VPO.45Y4%!.3DIP-C-C
M.'9X4VA1-6526F8S;C)!2SE#5C5!0W5+<W8P9E-.4#!F5$QB5$Y/:4U.:F%)
M27)E)B-X03M)=3AN1D8V3'EK3$UA935W2W8Q4"]J;3-F+T='5"]I2GA6131Q
M-T9867$W1E5U;B]!3U5J<V8X06U$=2\K5'1T:7%9-'$W1EA9<3=&)B-X03M8
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T952TQY-#5+4'%--$1&05<U
M455(3'%4*SAR.$@W5E!O<FER6#$V-C1C=C!F8U8T)B-X03LX=5!+,W)8;G@T
M+S-T2S K4'=P+VQB67%P6$US:WEG4' Y>3-P<WI*=VMI4G%R.$EO4DUV,G=X
M<"M.35971TTX>78Q3SE)0EEC=G)!)B-X03MO94LX9V8W*W9X2#12=#$V,$<K
M2W5736UL8E,Y5W!18C-!,C5,>4HR;E R1#A*.2ML4G9I<E%J2D-K,F0V0V5.
M46)K5DA):T=T2B\R)B-X03ME<' Y1F-68CE-,'(Y5'9F<VQQ9E=2,40X95 Y
M+W="4U!I.$ME*S)+=6%-:FQ3,'97-&U10VQW4&DT531K5FY(.358-&$O-TMM
M2W4Y)B-X03M,-'%F5DPR;&%6*W-B530X<2\S+T%)+T0X+V)F1E<P:35%03)L
M-&]0<#%*=4YH>D97<E-C+W=",S!B+VAE5TMQ8G=#5T%R2EDS<%=2)B-X03M!
M2&I.>4LO17A5<6%81DMG9D5A2' P,S)X5D9.9EA156MA9F--84UE26$S<E5.
M441E540T:#A1.75U*S)+<FUV3&=-=T9J3W=5>4%-)B-X03M'9V\S04%Q4E=1
M9C-L84Q8+UI51TMU*W4S4#A!>7=4.5%0=%%D0W9+=CDW,E!W+U R,WA6>3-T
M>5-G3FA/;V)H56QO4&@U+V%R4U4O)B-X03M9+V%P.49C5E,R93EU9C Y6E X
M055*=W=S<F]I4&Q">4I.>&)R5"LY-#%!2$QR,#DY<U9423-T>4%X1FA/4T]6
M04=G<65*049+>2]T)B-X03MD4E@V85EQ,F)U-$)P.5-M27%W<E=';$98:T0O
M04AN-U(K164O5V<S>%9W=3=G;6XQ2UE#<6ET66%56F524#A!969S;C14-SE+
M:F9&)B-X03M7:&4S2D-K,D4T2C0Q0F%#;S5%9S%P3"MZ,4Y0;W)I<G9R='I3
M=C%#9C=*86Y+1'%(-#AF-S-Q4CA8:%0S,GA6>EAL=T]63$=D=4IK)B-X03M!
M;S!(>&-+8U-+>40K.'(X3F8X05I5>%9X=DQG9$Q'8S=K8DY",EAL6&58>"M(
M-2LR*TMU5SAU0WEG,DTV:&I'0WAA0VDX=U-X3DI$)B-X03LO9#!O,5 X05DQ
M1TMR5G9R;W%#9%!U1DY&4$5T8C%Q5V]2=$M2.$DK22LS5&9B1EA.9EA156MA
M9F--84UE26$S<E5.441E540T:#A1)B-X03LY=74K,DMR;79,9TUW1FI/=U5Y
M04U'9V\S04%Q4E=19C-L84Q8+UI51TMU*W4S4"]!0W=4.5%0=%%D0W9+=CA!
M93EJ.%!Z.70X5F-T)B-X03LW8VMO1%E4<4<T5DIA1#1E9C)Q,&Q0,E R<692
M6$973&5:4$PO;6962F)Q8E1T5C%$4TAM:%%7-GAI1C%H:TA/26YH.5E25U!X
M:5%J)B-X03LR-FLX47!65&<P6'HO8FQ!=78S56M%56E.-DPR9&DW4$A&3U=K
M:CE2<"M8-S9*=4-S5%9A5D\K>%9:8V)U-$)P.5-M27%W<E=';$98)B-X03MK
M1"]E9G1(-%(W.6%$9D%Q2GA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5E-M
M=DQ31F=S,#AC5$560W5Y<6%E3D-C5E4O,&YP=CA!)B-X03MY,7<O.&I&+W)I
M<G8P;G!V+TQ81"]W06I&+W)I<G8P;G!V.$%Y,7<O.&I&+W)I<D@Y53%E2B].
M96XR4TMX<S=I=W95;#%31U=.56=:)B-X03MM:&]#,TQK<FYJ.$9"-R]S;D95
M0W9K-U-H<45L-C-M-U9P0S@Q<&-,8E,S.&-L=6I79E)6:5I#;D=8<DE$5W S
M1D-!8U9:9"MK.4XO)B-X03LU831F*U)I+S%X5C,V5# S+VQR:"]W0U)I+S%X
M5F1(9C)-<FE/3S1I95)V<V]R<5-A0W5W0CA-5E8X5F1I<G-69&ER<U9D:7)S
M5F1I)B-X03MR<U99-W)0:VDP,4\Y=6(U9%,Q1%0W<39I5T8U8D<T.4)G<6\V
M0V@T="]V>FM+,4%90FA1,7%Q:$Y)+TQQ,S!Q-FEN9S$W5W!);V)P)B-X03MR
M<$Q/83@U,CE'5&=94%0T065J*S!%-TAP:7),8U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&EQ1VHO=T-/;% X03A9668K2E,T)B-X03MQ;#-M83DX,%=S
M2TA13E!J=C5M5U1K:W)Q:7$T-&Q+;&YJ,F(T:'-$=E1&5T\R+VU$.#-*3%15
M;S5V2S%T0F5W5V--;6Y4+U<T<$EB)B-X03MI.$E5>E)E;4I!-F]P2D-S>D1P
M-S1Q;THK6EAM039F2&-P;S%L8U-M<4UK97(R2V\P9VXY4#1*0S=$*S92-5-V
M='AQ5%A#<4QU4$YN)B-X03MM.51P,$%T.4]T<C8T:VU34T-794XO5V%";41X
M=VM44CA:3U!!,"M/;%18<%A&5FPU-3$X-C(Q<F-3,U!L,D-X;'0W45A-<U4Q
M.44V)B-X03MX9VHT<$=L2'!O>7AS1T)59&%F849C5E1J5#EC.'EY-FLS<C97
M<S)J5$%T83,Y<DQ%-$$K04I596]7;$0X;5!)2W9(:E-H*S%G5F)O)B-X03MM
M<2MD-VY566].5C!33WES<50K=F1I94YY5U0P+U(T>&\W:T-1=$HQ<E1J=E-U
M2W U9"\S.6PO>&U0.$%Y6FMX5D4T<3=&6%EQ-T98)B-X03M9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<6=N=4QE1%5:
M5%!+:U%E1TE+6%E,5VI35G!8=W)I)B-X03MQ<"MK.4XO-6$T9BM2:2\Q>%9B
M2F8V5DI',&(S54Q)-$MS<&M88T55238T<7@R*SAN9FPW<4,R9W9O-&)G,E%J
M1G57=5A&1$-P4DAO)B-X03MS:6=U050X5DLW;GAW<7 R2&MV.'1.3W1"<#%P
M1F)W=TUF5E=$-C%)5"LW5EDV:FQ+5V]Q.%(T67%P-DXK6#,U839-,7-D4&EH
M:6IS)B-X03MM1#)54G576EE7;V526&LU2C564$QK5%=P.&-66DIP.&UI,D9P
M2&%7.3%%26\V,#53<7A*66QM2DI057-38T-O:CE*-F(O>3%W+SA!)B-X03M)
M>&8V-'%P4S-D<%!C,F%W>E)Y<TI72E9'1$5$,%I"6%DK*TMO-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9)B-X03MQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&57%V,VQ46$Q6-%DO5FU7>'942$57-#AM16QT
M4F52<E-P-S1Q:S8K62]W07=',4-3)B-X03M!*U5F4W-K;71&5S@O4T9T27IW
M>3<S3')$.$9$0C!O6"M,<4LP-&Q6;'5+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6)B-X03LR2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%9">6U6-W564')$45)24DDU2VE/;GA--$I*9%<W2FEQ1D]O-EE*4%1/=4E*
M0D@V)B-X03MX5#%,6&PV9$%E9$](,F%-1%@S1TMQ:T9Z85A&-5!:46%X-G0U
M8E4K<S)Y4&).3$A506IM9U1K=&$Y>&EQ=$1%,#A3>7<V:$I,131Q)B-X03MK
M:65G>6ME24EJ;V-64UA5.4@X<D1Z3G K<C9J9GAX-B]A4E-7*VYY5%!B<$M%
M=6$X9W%&4GE,0TIU3S-4;%1V:7%D4U).155%;6]3)B-X03M)6D<T4FAV44A*
M:4-E2S%J,TY!9'-654AU<DY*5FEF5T]-<GDO5C!J3#)W67I5-65M0G=R>F]+
M.&5U2W%K>E)1<WE486\P8DEN<4]R)B-X03MM,U5H3B]I24MD4&A/+W1I<3<Y
M.4A.87-T,#@P8WIL4T=%9D5R-F)U0T-I2V5Q:G9I<4YX5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU)B-X03MX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5D-'3DIB-C9J8V-K93-I5FPX45=L0D=+<V,Q2#AP=GDO,4LU4S9V=$PY
M935J)B-X03MI84)*;75,;FU);FIA1F]W=VQ"-"MM-5=N8C9":7%8*V)V>7$X
M<S-T<F14,D=M2616=GI(0DIC=DIC3W%)-F96;6M-46Q13G=H9'5H)B-X03M(
M:C%'1E=-6"]K9E<T<C8U1G8U1G,W,GIL:E9(63-Z>$=2>%!)+TQI,7=W-'%*
M9E4S;WI'<3=B14MQ='HU4#%Q34MS6&MA1S9S1$5*)B-X03LU3DY/<$=.:&-Y
M<F-T3V]M33=+,5I*=U!I5&I1-V1":7%44RM3<FTT.'I&-T@X=C=I1DY,3#-%
M:U1A:WE7,7ID6&MY:W8V:V\T>6E+)B-X03M.4%50<'-+3E)A-'%Z-U$O>34P
M8U=D-7!7<&%9:3)+0EER8C!:8FU)1T)O=5!O:VUE4C)#2U%'6712;3-O2T-I
M<61A=#5".'(V>$-9)B-X03MD5G1P3'E->&U(:DIC6$$O9&MK:&9H:U=V2&MA
M13=J>'=+;7-K36-","M'2452>'EC14)*66=,0DE"=5-38U92;4MU>%8R2W5X
M5C)+)B-X03MU>%8R2W5X5C)+=7A6,DMU>%9*9CA8858O=FI59BLT6'%0.$$R
M5#1Q9V9+,S5G868U:3%J5F1,=')#+W0S,'55>%!C,TYT3$9"2E-N)B-X03LR
M6&16-'1V=6IG3FEQ6&5A+W=!=VXX=F5B;TY0=5IB94Q3>%EM.&MJ8U%I-6YF
M;$EN<'=V3F0R;UAJ=T1-,W!/;T93-U)J-'-644XO)B-X03LK94AL,4Q"8FEW
M=#5R<31&=6)Y4WI,5S9S<U Q2F)W96\O<D9)-G!)2TYU1'AA;&%$1E5Z+W=#
M5F]A6$QP>'8W87AV2D5J,5@Y1%!B)B-X03LX2696935%6$YL:E!R3$926D0V
M6EEV5&M'-V(T<6QC4#4U84,Q,&)78E-T46IL9$IP<EI65S-F;DA"67@S>$1S
M2F5#4T9*9T%H8G=*)B-X03M)0G)I<E0O;G U9%E82U=U;EAZ,T9R3DI$2D90
M.5AT:"LT;FAH;6)L3$M/25%82$]R,$9&3E--3DLY2G=+-T9867$W1E9#5S!,
M>D=:)B-X03M*-4E86E92=4A!9VA34U!T<3,X>'A68CE5;B\U8EIV=6@O-G T
M<3<V<% X03AT<S,S42\Y53A69#E5;B]!3U<R8C=O9BMQ94MU*W%4)B-X03LO
M=T1,8DXY,% O5E!&6&962B\X06QT;2LV2"]Q;FER=G%K+R]!0S)Z9F1$+T%.
M53A69#E5;B\U8EIV=6@O=T-Q94MU5WEB,5DU2DQM)B-X03M76#!M3$MR0TU#
M<%5R*WEI;F]X-S1Q:6-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M8TM5,C9E,DMU>%9!-D0K:78P3%IF)B-X03MO;B]J;65I;C%+;E K-C0O0CEV
M-"MN:G9I<6@U6B]19C9/:R]1,U V=#EA=698.5@Q=E8K<RMU+W(K<#E9+V4Q
M.5-T3UAA;D@T85EQ)B-X03MM=4MU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W8O+UH\
M+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z
M+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U
M8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T
M/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @
M/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @
M(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG-CEU,S4\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE
M/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I
M<B(^1FEL92!.86UE.B @(" @(" @(" @(" @('-T;7!?,38N86DF(WA!.U5S
M97)N86UE.B @(" @(" @(" @(" @<G(R.38T,3DF(WA!.TQO8V%L(%1I;64Z
M(" @(" @(" @(" @(#(Q+4IU;"TR,#$Y(#$R.C(V.C4W)B-X03M%4U0@5&EM
M93H@(" @(" @(" @(" @(#(Q+4IU;"TR,#$Y(# R.C4V.C4W)B-X03M38W)I
M<'0@5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I
M;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!&;&]W
M($-H87)T)B-X03LF(WA!.^* HB Q(&=R87ES8V%L92!O8FIE8W1S(&AA9"!G
M<F%Y('!E<F-E;G1A9V5S(&UO9&EF:65D+B8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C
M>$$[5&EM97,M4F]M86XF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @
M(" @(" @(" @(" @9S8Y=3,U+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @
M(" @(')R,CDV-#$Y)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" R,2U*
M=6PM,C Q.2 Q,CHS-CHT-"8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" R
M,2U*=6PM,C Q.2 P,SHP-CHT-"8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @
M(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!
M.T=R87!H:6,@='EP93H@(" @(" @(" @1FQO=R!#:&%R="8C>$$[)B-X03LJ
M*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS
M=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ
M*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I
M;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.U1I;65S+5)O;6%N)B-X03LF(WA!
M.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<V.74S-2YA:28C
M>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C(Y-34V-"8C>$$[3&]C86P@
M5&EM93H@(" @(" @(" @(" @,C$M2G5L+3(P,3D@,3<Z,C@Z,# F(WA!.T53
M5"!4:6UE.B @(" @(" @(" @(" @,C$M2G5L+3(P,3D@,#<Z-3@Z,# F(WA!
M.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@
M5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @
M($9L;W<@0VAA<G0F(WA!.R8C>$$[(" @(" @(.* HB R('!A=&@@;V)J96-T
M<R!H879E('1O=&%L(&EN:R!C;W9E<F%G92!O=F5R(#(X,"XF(WA!.RHJ*D9)
M6"!!3D0@4D5254X@4%)%1DQ)1TA4(%-#4DE05"HJ*B8C>$$[)B-X03M4:&4@
M9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF
M(WA!.R8C>$$[5&EM97,M4F]M86XF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA
M;64Z(" @(" @(" @(" @(" @9S8Y=3,U+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @(')R,CDU-38T)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" R,2U*=6PM,C Q.2 Q-SHR.3HU,B8C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" R,2U*=6PM,C Q.2 P-SHU.3HU,B8C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @1FQO=R!#:&%R="8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.U1I;65S+5)O;6%N)B-X
M03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<V.74S
M-2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C4P,3@U,"8C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,#<M2F%N+3(P,C @,3$Z-#$Z,C@F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#<M2F%N+3(P,C @,#(Z,3$Z
M,C@F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($9L;W<@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C
M:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS
M(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F
M;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C
M>$$[)B-X03M4<F%D94=O=&AI8R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I
M<'1I;VX^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C4P.3$V-SPO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O
M<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @
M("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @
M(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M9R\B/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S
M/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L
M<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \
M>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I
M<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ
M=SXV,3(N,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XW
M.3(N,# P,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0
M;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53
M:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F
M.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4
M<F%D94=O=&AI8SPO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%M:6QY/E1R861E($=O=&AI8SPO<W1&;G0Z9F]N=$9A
M;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/DUE9&EU
M;3PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# Q/"]S=$9N=#IV97)S
M:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E
M/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1FEL94YA;64^5$=?7RY01D([(%1'7U\N4$9-/"]S=$9N=#IF
M;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @
M(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE
M<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.
M86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4
M>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12
M968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @
M(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C)%,T8Y-#DQ,3 S,45!,3$X
M-#%$0SE#-# X-#1&,3)$/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C)%,T8Y-#DQ,3 S,45!,3$X-#%$
M0SE#-# X-#1&,3)$/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-3$P140W,D0X,D%"13DQ
M,4(Y1#E#1C$R0C Y,SA#,S$\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-
M.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C)$,T8Y-#DQ,3 S,45!,3$X-#%$0SE#-# X
M-#1&,3)$/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z
M9&]C=6UE;G1)1#YX;7 N9&ED.C)$,T8Y-#DQ,3 S,45!,3$X-#%$0SE#-# X
M-#1&,3)$/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-3$P140W,D0X,D%"13DQ,4(Y
M1#E#1C$R0C Y,SA#,S$\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F
M.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z-3$P140W,D0X,D%"13DQ,4(Y1#E#1C$R0C Y,SA#
M,S$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,3DM,#<M,C%4,3(Z,C8Z-3(K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C)%,T8Y-#DQ,3 S,45!,3$X-#%$0SE#-# X-#1&,3)$/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 Q
M+3 W5#$Q.C0Q.C,S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $_ E,# 1$
M A$! Q$!_\0 '@ !  (" P$! 0            <(!08#! D""@'_Q !.$  !
M! ("   (" @, PD! 0 %  ,$!@(' 0@)$Q05%QA8UQ$2%AE7EYC6-U56>):9
MN-@A.%-9<Y*5MK?1U-4B,S4*(R4Y='5YL;,D0?_$ !@! 0$! 0$
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M(" @(" @(" @(" @(" @(" @(" @(" @(" @(/S4?]H!_P"<#_\ C2\*K_\
M?3933&J>,-Y&?)_WR.,O>(;_ -.@?^BB_P#X-JO([J @("#2KOL*IZ[B"IUN
M*-B8IHI($P7W<,O$^/@5X];BTB4_\'#$(>%J=7LED*SI;K,>**"3G.,W'^&(
M[Q8BN9I]8WWK:QQ(LJ:4G41PD9# PH[:(F=K4K89UD@,E:TW71UP:$R3;A^
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M=E>?V&NXB.W^'^65_K'_ *9"]?@S?_+AZ _F5=6O\#Z,C<YYUSQ7=1! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MR3+M(X)5\E;P!84#:QOCM0<L=0/E\>BF.>ML9K9BNB_3,YU\$<Q 0$!!Y/\
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M%777]:EX.#W[)6+XVP>1]\>W+_$^?#KOT5==?UJ7@X/?LE8OC;!Y'WQ[<O\
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MC)\1&BQ8T6*QXN/'8;::PQX#>T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M9LMQ;"L:Q;**01Q;R4''ABHG'BQ/G,L=)$AWG5BH7@W:I4-<8:Z?N8<<.YJ
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M$! 0$! 05C[:?@TI7YSG3;]K32R+&?TGA*SB((" @(" @(" @(" @(" @("
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M 0$! 0$! 0$! 04:\'Y^"#;OY\OA$?VY=_H+RH" @(" @(" @(" @(" @("
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MNS>../''&./'=CN7QQQQQQ\'''''&^O@XXXX_@XXX_@XX0K.&R.C^^J1JO\
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MC7@_/P0;=_/E\(C^W+O]!>5 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 05CU1_&)[7_^Y:6_PS819S1JYRLXB" @X^&6>'LI
M'#3?$C-O!G-_AO'A[)EO+/-MK)WX/CY-X9NNYX-\Y<XXY.9Y8\<<YY<\AT'
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MG!M5=L]?'3"4[V]->"W*((" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M'#A]YB-D^_E':<<R;9R>=Y;QQY<S^$.X@(" @(" @(" @(" @(" @(" @("
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M4G1HG-71%=,RNXC(@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!6/:/\9+JO_0[T_N2'1=$ZXX2LXB"
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M/;8[.?HITS_=(0K%T;^IZ!-J>VQV<_13IG^Z0A6+HW]3T";4]MCLY^BG3/\
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M2H4LR0$1QD"SP8@HM.(TJ?*C7$</$%Y\X%'ABY[\<E.CXA]H=&3C\&KLW?/
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MZ65JT]@[C/@;8\DKYBAV%O8VKLZL(+G^:UO$OV/S(DQ5K*<27JO./6796R\
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MV[@^$5]M/P:4K\YSIM^UII9%C/Z3PE9Q$$! 0$! 0$! 0$! 0$! 0$! 0$!
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M @(" @(" @(" @(" @(" @(" @(" @(" @(" @("""/5:ZR>SGHCZHM?_=Y
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M:A;J!?-9FNT5WM)N00>R9L@ZVUS;%/=%F@=8P< DA<(^/LXLNLUV[:=\*O\
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M.%3['O*T]@)<PWU8J%G[)B;5>CTZ[W*M5SL(5MF<&#53.P"I4_!G3]6%;I6
M94A4J_9XF#=?-UP>*REMV>S9\HV+^#1MEL9[!SK)MO3U?MN[^OEUT<1L>F>M
M.>IH]X/6D[6[ ,W3V(KD#<1H1M_8]2<K& H#+!X:VXA"K;LB/#E0X5K%#*D*
MV1%M(IIT71996:SIT75GU-JC%KC5L,Q>2=>,V]J SA82E4!DJU6YQ/CCGRA\
M,!+V&V$Q4#+GX.&8DZR&)&'''/.<USG+X,3+84! 0$! 0$! 0$! 0$! 0$!
K0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g713200g75i90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g75i90.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $&9H976%ALX6Y+ 3M]'"\MPX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              )[   #80
M   !                          $              V$   )[
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   )[     %)G
M:'1L;VYG   #80    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   ">P    !29VAT;&]N9P   V$    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MYO-#B9?4+,AK,BCTZW&T3M.FWTO2W/W.9^=<W=_A=GL6@LW.LS,?*&0PN=1
MW-&K0!]/<!]'_C%8HZCCWV>DW<UQG;N$ QX) UH3]JIP) G$#AK7A_1_O-I)
M)).8E))))*?_T/54EAV9F7[FMSJ&$[I<YVHUV@^ZG;5_.,:QC]_^#_G_ -)Z
MKCJ&0X7!^;CM>-OI02T0TL?8??6=U=C'?SE?_J1.X"BW;26$.H9NVQPS,8-K
M@,<\^T@A@%CW-#MOO=^=_.6>I_8M.KZY6&EME=DN:'-[ALMWOW.#/S?]?42X
M?$*MTT$W.>2V@!T:&P_0'P_TCOZO^>F?-[S6TQ2TQ8X<N/\ HV_R?])_VVC
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M]WJ/_P".]=G\RNJ7RJDDHOU4DOE5))#]5)+Y5224_P#_V0 X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C(@,3,Z
M,#DZ-3$ <G(R-C0V,3<       .@ 0 #     ?__  "@ @ $     0   V&@
M P $     0   GL         !@$#  ,    !  8   $:  4    !   !-@$;
M  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M          !(     0   $@    !.$))30/]       (          #_X0%(
M34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4    !
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M 2@  P    $  @   @$ !     $   %& @( !     $              \
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M[59.AOF6&^W<&[\E1:?R3I=61N^K\//&J-+UC4]OU'>*NHK3J7>M?LJIMOK
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M+#..&L7PHX6P@)\:7G.Z2:K<_P!ET7@X>7NF#%4C-XPA5T:12<N/FU=US/\
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MVUNLUPAZX$T<0SVBL//5OHE>7TH $_?<HA'V2WJK<XCE$WJZ"OTG7(53JU;
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MBQMDUNBV^CL=;V6L%N*2V'<,?7EL5T,T:JCVN:YJMDAGAE:R<8F!\9(I$<1
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MHD[N-2ZU3#:=;QE<D:'"AQ&')C"LW-$+Z1KUX1SNS(%.-B:\87M4\.GWFLU
M-S;D"[1$8HUV_4]M#K:XAL_',5,VZ:?1BF5%5M,/*&K%Z]M=@,-J-A 7$C+U
M)2PHR,C<$X@L4TC1(#"5U1\^!G<8O#(8],I61X#8SK+ C&X0J?FL D6B]@+H
M@9CK!.K0X5<&+3JRH*AQ,A5R A&^JI?JW-ND;KMHVHZQ-:'F2 ;B4?*92VVO
MOIC-,EX\4ZJLZO8PJF[@+. Y,UNXJI4KG!&U,R'0E.@($?/@FX=<V\#3S!%4
M-;A0LD<O,6Y%WHD1XF>,JKV4T;C7J5QI*Y#8R+<1O((TU$E9"3I*Z3'RL@A@
M&R1*I&V"-\]*A.N=J'0]@ ;=$5M]KM$\K;!(C;=U"?8%2ZI::M1RP0:WJ%WM
M.QP6]C>;;648>H6];4[VRZ<RK+U6 TD6&;8EX-=1MRU:.:33 Q6/FJJB=)Y%
M)EN(H(C&L5N\K3QN]KR_+6<J&(QI>1N-6&1<N 7TDG0R*<+&SMG4X4(P5\[:
M:D%=VDN';=T;*S8[8Y\U2ZY@8-HG($CYX&5<ETZO@8FK=Z?9$J82+%-0B1^U
MN$%,E93.:&5X.)^$<0C!+PHH#Z#FYM1@\P1:S\_M#S"$\8.(-3*#)Y0S<MW;
MOLLA)P3LDG8"Q'F>=@$Z//V/D[5XLG:CXNCC6T4\I-38D9,NU/$*8&E6O&VP
M<G3V#*I!G; YP5)KAPQM9)50VT!S70*&LD,D:9/D:]V30.><J( 1KUB[BLPA
M?(B&J29"CARC*0=6X-4\<B))!\A>K]@'*:7./.V"D$8# ]FQJ65'/G%5Y>:W
MK=;L1TE[M1-@#55I.I[E7D0V%83N A59?^D=?%9J=HI/'^[0"5FU/IC[&35[
MEM<.5Y*7IADX7?11S3/"HB@5&D<3V[*4=;=E>+3*>>FF[MBSP<Q4$\>LKJ%7
MK<PNRJKY9B0!H<$%2ZE6RHT,#'(,/I)*' VJX'O9$Q\DCVQQQM<^1[W(UC&,
M17.>YRJB-:UJ*KG*J(B(JJO3(\ D@ 9)V &Y)/0 5GJJVO-Y.5SHI2JSCE'*
MULL#Y!++?&M]3G13,5I%?I\G56MDB=!8; C5?'(/2O:ZUE2$X7@$)+Q+J0P#
MQ\//I4Y62]'<<QVQ."'G'S6MO<="5@[QD--ZCU6+TC#2=F$\^S0PQ*\4<$ 8
M<(,6)D H@L,8XP\$349'###$UL<4;&HC6,8U&M1$1$1,C'=Y&9Y&9W<EG=V+
M,S'<LS,26).Y)))K8      &P & !W #I79RVJUX&T7T6LT%G=R0R%/#@3R@
M47]-86)$C!:RM@Z^KS%C83#!0=>B>+.SJJ)US8M;<W5Q% &"!V\N0^;%&H+R
MRM^S%&KR-Z%-62/RT9L9QT ZLQ.%4>EF(4>DUU=-H)-=HX!3)FEW!DLUKL%@
MUO=](7MB_P >Q)3_ ,20-E5!08G*[RU<,&(U?#'8B7WMP+F=G0%(4"Q6T9.>
M7;QC3$GVL>5(1YTC.YW8U2)-" '=B2SGO=MV/;MG8#L4 #85*<U*R4Q2F*4Q
M2F*4Q2H#>ZH7'82[3ILH]7L[FL\^-,KXZ3:X(&]V,._AA8]6E,C1(@+X>);*
MOZ1QO4RN;+7R[\%VAC%K>*TMJ,\MU -Q9LQR7MBQ&4)WDMF/*EW(T2D2C"\9
MSS(B%D[0?,E Z!P.WZKCRE_:7*G&OE3CS9N;+JMV+6B*NL?1UK=;V77-F-*
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M<<:M;,]['V#(^LF0G$.(P&.YM(IFCN NA7 95U@J3&)!YK$93)PH)\[:O5_
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MU^-W7JU,D;?,%C=W.VJ<I80GM <<ZZ=?2(DCA/[-R:P/Y<L:;X7,K8Z>3Y*
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MYC3XP^!)+*"=)97F#B4JY!=1)K<NBL$9F+%=6].1%DMH&2JJ>N"JXT@C.#C
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M>'DE3#R3_>2!@W.[P05.V]=CX,^$B>$D%U.EG)9BUF2$K)*)2Y="^H$1QX
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MK7& >9GEJ "0!_&N?C/M9Z1RKRV9Q3JU?*?,-J5?M\=_7W5):"K66&G<;;E
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MBE5PGL3\B?5F@>I]9^-=!6N4I6"H/(_/5'VFMWI+ZEWFUXM.L>4J7C6#WO\
M89=,(NHN/NQ>?QS'<[UJ6A;&3J^MD;7?=H@9VX[ Z6D&(9M$)TIJZO65];D
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M:GIE50V-4V2,$VO<9$1'%-J^L::1!)(I3G%#%:[I>I!F#%^/ 81KE/;%1S7
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M&4J<@#'3';7/DG6"F*4Q2F*4Q2F*5+M%_&BN_--^PDY8_3V_<:UKOZ!O6O\
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$%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g713200g78p43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g78p43.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( +P"70,!$0 "$0$#$0'_Q  >  $
M @(# 0$!            !@<%" ,$"0(!"O_$ %@0  $$ @$! P8'# @!"@(+
M  4" P0& 0< "!$2$PD4%1>2U!8A-E17=-<8(C$T<7)SE+&RL[0R,S=!5G65
MM2,D)5%356&1D]'24M,*&2<Y1&)C=GB!A__$ !P! 0 !!0$!
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M)?RTTXO#;:NZA6>S&8>YK&N>\AK6@EQ.H :R5ZCC?*]D<;2Y[W!K&BUW.<;
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M0I76$;:-SC:(.;]$(1@?N8QJ-HEBKS;^RZTW)=*991&G2,.N3X,K$N<F2-#
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M$2<B18HHI5M=; ,O23Q,,X"Q2K&(LS 6Q0%!UE-M_>_X]JFM=ZA-<6LMJH4
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M3,ZQM30048PX.V*_+;:VA-L]7@4,R2M=$#Z4.P:WM<W;!$!,CPAU.,%!D9.
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M^19&]*$FH;WA^:1O3L+SIIU,5_#A!H\_G%E3L/HGM8^Y39\>T4IZMV?9]=V
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M38%)&OS]C;_%[WQ?H+.OS >39K-$)!Q\0V"L$T<Q8R8JI&F;6"14$C3I3?\
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MJ,L\4%C*\,#B0TFYN1IW@56(L)K0.X7>@[UV(U.M/PC*W,\B1'A6&U7DHC6
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M[ NH*CUJ9KLP/$W:T$Y4"LUE53=O5AO)U%:/$0U1K@[)RL#1S3Q:%"*6^V6
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M@0$URPDX,:1!!E9$0BP\#=VIR8(19X-Z!/UVPVX)1*\<P\\V+L-JLKD)NMC
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M(L2BS-2%&)3NK50$GX>$MDT=K\/C[6TZUZ<\*%@;%:JO4(;)&V60#6!\F6W
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MO>N'3%\)'"+4%G6VOXX:7*'5H]3RAP^31HX=/CT"PM;_ )-]-EBZEM?<$NS
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M#R9C46/C"CX@FJ.J.P[%RPZRVM.)=C%*USFEL]VDM-F,U@V/[16_?48N+/\
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M$:YC&5E4UK6U=0UK6MG>&M:T2 -:T      6"U*>IJ!/,!/, )9  )7@ !Y
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MDU=N$:.VGVWKT?[0OFPWR";;>IUZ7ZF-&VZYQI@ZKPDZQWE;GMD)VOJ5.*R
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MWYSCL_NYD,.I(ZR21DCGM#&!P+"T&^<!ISFNX5B\5KI*"*)\3&/+Y"PA^=8
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M7QM+&$1LCLTG.(M&& Z=\@E9C#<(H,(CDBP^)T$<KQ)(TRR2W>&AH-Y7/(T
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MU785GR/*,QR6Y_)O^7MR*01>LZX%S *N!=%J0=)(A0R,6V7<Y2&X!LJ<ZC1
MIN/#.ZM1:E@9<7INL1U9(_5:O8(XNTU9.:@X047A#"6T7[;WM4JUUU99V/<6
MZ_7:AEX=(<J1HC.LEE$562!JMUJ.FB@-(2(N-/C7,XV7VJPV8%8*A7(3$;#$
M&66+EJL#-D(MVYQ^"[5]ZIL:NMNY1ME!H)A=?@+%9PRH$AH;(<A4S3$#:)@?
M/E37'F'II=]^1 %NM-1VXJ<(R^V_W%+42VKFN?*0OD!U=1"5]@TPQ2,"8M@V
M-L*B5@[#ML4PAR+K+8NS-960Y;8>0PU%3<D']</2@(I,\VDL)*..9)Q"0$V+
MC$MR[P/EMJX5GNGWJ>C[V(JANTN;1D$J)4]A4]LO.)3)MIKIT)7R1F?!D8K$
M"H3XM;GV<,((9J=QMQ 7(GPFKJ,I!4@.#RBCL>0Z="MC>-@/5/2NX+359"X=
MGK6K=@6"N2VHL><Y%/!JF6(AY#<&6Q*B3%L$(T=U$63%DQY"DX9>8>;6IM12
M-8YPM+]D]0._2,ZTZ^IC=>I4I\Q6JS6-@)$3+ ='J8NW2&%M1N<))1<5MQTR
M+ZD+$P'B(B/L 7:)DL^\8P9>&UHFCS'\;>WET!0JU==.P-<V K355@9?C\7/
M5T;:BD'X-<)MC]6GNL([K-CP(DE@M+KJP73K7Z*^6K]&M2'Y%G9+62RACL84
M+OI3;ET:-//;7P:SKX+*U&^I7>[1.+6IM-UTLQ8KT>H=?+Q$7%(@9FH[\%Z8
M-6DZ.=6J5-C$AYQBW!:["*0/#2'D#I=H=8,(* RBWM\5K\&OQ*M4=>VPQH/5
MTJT:^J4&Q;%/ZTEH P"<MMEJFW^K:'/$H4,E:R5300LM-D[K7&EJ$QS1\\Q6
M'9HC6>!6;86HA+#3P#?Y?[]BL/!ZY=N5O7@J23$:VV9?86GK5;YX@;-)U0I;
M+8!I>_+3*4.'0$V9L)6J6?TV$UQL!>8I A"LEUD.JC YP()6KV2WDX=?!>WE
MN-5QOK;O7VZ[_:[?NK6UDJ8\'8=&@!7PELXCTHY6[)8;F(DV>H.4=)6+WY(^
M%5F&G[0U/=>?'6";&%,YEL,OR%E'1O+5'6W7'LDK6]5#R<76=M.'6*= (7$6
M3GLB=AV,V/Z>6BU(I42 WB)C9E:F;IL9*RP&E.C'&-;2VF0];:/6+.JBDBQ/
M;M?>]BC\?RCFUBU?>*1^GUFI/QR@N(1EWBRP:Z#K@NQA+3BJ'3YN[DM<U2&.
M-[&T_N;6,K,RX#7PQ'&MR;3!N?:H55)E-@-_^_8:1O%>@>@+O:;_ %FU'+6T
M]$EM[$M \:,>2/RL,$8\P>'!\3!L>/&*)&XDNQL%<>.J?W,OYD/)4C."\J]>
M$3A$X1.$6FG4WLW?]7N^O:)T_P!?A62RVG66[[L@;,"5LK&DGM=E=."*I$.R
MK-L_5[(>ES)NQYK%HG@R!BU-8R,=#"'D,S<\)HW^PWU%)W6_@62NH,EK!Z"?
MU^/V-?;&#G68D,GXTUK0HR*(W0&LM1X VUV.U/NNKH%>JA W2+/D788'K6@&
MJT=%P"FW+P>4ZO[]"QLGKADCZJ7N9'73D!R32:+;Z52Y1Z>2('AMH(;T?5*5
M*I5*N)EDB]5-*G;2L9"K9F # ,QS%G+UT?'MDRL%';MI"Y4]<.26''!VLSS$
M],\S+K51D37&;%?*[%U!OS8028S-) (%/BM6(AIKS"%*IMMV R(EEH86WOUN
MT1+!5AA2!?\ 'RV_'D6WVI]@QMI4$)=HT5N HB\;'$!K?IY.11NLV K5K"(>
M9M5:IEGBRQ)T*1'38-BJ5:.P)D9^$6"#9[$B(T4*Q>$3A$X1:&=3._\ ;^L-
MO4&I:_&P)E>,!Z>Z8DDJZ(*!V#EYW/3M5 H]K-2]C4\[6*].>LV(C1VJ5J^3
MA)-YDF2K\X?$]&$B] :.73Y@#P?B%$'.NFS5<<:A6C4TBQ6S.PK#6Z3!I4NS
M%TV<"Q:>K!D0^5&UVCVLU6S+=9Z4[2E3<>#804LF;K$LT?J T@?<JA18</!?
MS:N'7R*T)/6%&FKJ8VI4!TO9+M9KI5P@LY:HU=B19-0W?.TGB?8)\,-8Y@P<
M2G#Y-APY##EI+$%EZ"Q%(3&_OB6Y=&CEUB_]E7H[R@$)^KTNQ$]8OBY-PLE$
MCHK[-F+'B<&D7^L:$LP^UNO :#/&QIP5'4/21%D@GIM>I\$XV\*A;%)SBU6C
MGB$6[;^GV&W0L3#ZYK;"UG&/WC78$98%ZT/6,Q-IMLDEH8ZU-ZLW=MRNQ 5?
MLE=#D#%?DU+21E)0U*G1D#[01B X<,Z.'68Z!);5;?-NCGX5L'KK?-CV%NLI
M36J\&$4&&!V[@5/49<)6LN?U)N=O3AR44&-P(D&M#'#0NP/!XK)"PO%Q3HLC
M+EA""" "*2VB^_H\]^W(MI^%"<(M3>JC;&Q-4#*Z9I$RM1A$,7>;5>LRA8JU
MVZ%6J6)@%9-B%40E?]=3;/2*\R_*E;(53BIC8$*(\ BU"L%IQ9UR&4BV_P!-
MOP/X* D>N02P:L0Z!KLM(%T*Z1ZMLRS3"1)(FAPGYM]((,FV*]4[28'MO:UK
MM$VUB2<& JH&I&WJ26NUPIX]_)!XENC1R\F]V!M=5]!Z_;$" ,KOFG79]C%:
M?LFW;H[KTA;2%3%0(D+?9.ICX5A-T.$":4>9T*7$$5V"PA)\$[8@20(FU#VK
M%,KI+7[<WM5E.]79V"\[!MFN&ZM(1=6JO$DUNV?#O!!RM]1NJ]$WA.8DFJ52
M1'BKD;3!3J](9;ED24=)U+PT3*&"LG"CMY!=3S.^[.6Z?IVWX=: 5THZJA3P
MHM%IB7J$NOWO%$+BY).2*8"K@EU5ZYMMSA+C?AQ"4?,L61L-;DB#I<I&OR^8
M$J)R^L1N6=&U*I4**4M!<RV(B1K)>H54#,YP]U8><R"9AH#8)$!"8G2;:7(V
M/1+Z'Y5E$QY#L**/*D&26X>VK5I%]?DTK#KZXQA:JUZPT?5]HLLZU"+4>$5Y
M]^<T:CB*K<].563++ *G7+S<G'5Q-O1C2Q54J5N.MIKY"#&%3LN^=126TZ=[
MQ[U[<^\MT*I9!EQJU:MX25&FAK4 #V01-AR$2X<L8<'1B<"5%EMXPW*C2(LI
MIUB0WC"'FEI<1C"58X4+63<.V-F4G:.0%/8&DX!*JZ?'C1YV$\H&.L6R-^#-
M9E+1-DBHR#9#%>KA?)?T T5@1".1J(SDT-B8\8C%.]RZ>@?W6MK74YNN*L=N
M.QDHHO71$)0;0_K2'7/'B A*NAO=?4!;X9"Q8!SK415(V(+K$?TA 8C2X\*M
M#A<46EXB9C&""W-_R-[F6:UUUB;KVKFMQZU1M>#,$# VKDC)>=-,P7IYK:O4
MOK6%9!2*-9;37'0T2!H43<71HZ_6.,39N;06';X\=B-9I93:U[Z_^/;XK'6N
M:N=9&YK1+K!>-K*FBJF>%UVP2H,R;:IEEA#'(_2F[8(2)3<""-<)R7>IDA'$
M+<B-1QK>L9,J:V55:WX=-*+"VOMI]GG'CK]'7QL4X0F'P BFIJE55L\CZ&=6
MTJ=LU@?IFP;'H51%S()\^6JEJCSZP69.03($??'(Z7$%]3U0H+F@G2G-MKT>
M/5IMIT;^]^*G<OK=V.&&WNYNZ]J5ZUGJ<%5)UAM.NR9Z?.V:]==O[;U(%,ZH
M'9BD!BZY!E:_ FSRYU@+JBLFCD0;/*0@<(Z<*+>4[WDZ=[AZ+7W/O;8FJMK:
M(!O2Z5YK=*26^%-$?D.XGW"YO;,T/36AVLISC#).4:!C;W;S<"+)2]$)C1JV
M# R$T^JU50G#VT:?[+7>;Y1>Z :[6K63U) LE<*QVSMK-TB982D/7(X-4Z1M
M[:-%L#+(HA,E[4U1IS.X9Q, VP/78K?1:L"3!KA2YR@-<*;<OX?CO^;3?4IG
M4>K7=EWM$>H'=>"M9F!.QM:URV"XMDJ%@L0/#VR:Y3[0,+U[TZ6MC->O@LE/
MLM+M)BE41+=8:B2A,NQ)(Q3C11VW_+Y=7G"]+^%"<(G")PB<(G"**FZ)2+*$
M=K5CIM5/UQ\BZ7? &Z\(*A'BSY%\P^4=%3H;\%PB\6DR2CLU;&9+A&0_-6[F
M2ZXZHB^X%(I@HI/.#*C6!QHJ50=*&(  5#*$CC8Z6'09GD(\1N7,*H$$)XM!
M&0\Y+2.FRX.'L1I+S2R*.2M,Z?GY+*G:IUK,4>%C 9U4JBU>1DT%"I%H#!RV
M7A:\D18E 0*D8/F>-$@)$"TQ66L0(F&B7/"LWG7M!45"'54>H*-UIR6]7#&:
MT%R5 /$(3 V>Z$(9A>=BG)HZ+%@2W(+S"I,*,Q%>RMAEM"2*7\(G")PB<(HG
M)KM-#0\DU58.VR #,1X_HVL-3IT,, &&H< 8('BQTDB\T.%'; .$!A49YU,8
MX5&C8:L%I,>21:2ENI7HG*P"LT+386QY5K*:LK5S% >GFY&2<B'/W7!T74\7
MN.[KA2V_@A>!\U 2N63"#F8]9=>J8F5C U;Q3I\Q\EK^=3NF]1W3B>Q"KKU;
M?KEA,7N1J&!35ZAN4N06(S).R*>*2+4.HJQYBH&:QT[W!^991ZY--!5>@N1[
M"9@#PL;.":?QUJ @.HCI-P",7,A0J74*]7[H!,F[7(U=8F@Q8]8NG!SJ,:N]
M%GHU=&FW LW4+D?C/RY,&OV5N//.2)C,2?9 X&R$L=7F\=OPWEME7:-IVT:^
M$CA.M*BG7AH-#6/J976L6O#/0SQ'-BB1)E'L%?&/BVTF'<F\"R86&ZP5<407
M%;FJR[DHNK-@P80R%#&C8<4<.'18\$>/@QVHD*#"B-(CQ8<.+'0VQ&BQF&VV
M8\=EM#3+2$-MH2A*4X(NUPB<(M&;5M#HG$W4W2I^1HZY"=J5*VV,%1M>; ;?
MN>UA=NK$>M3RB=?5;,7;)JM; M=/?G-+=M357N3X:78&QQ<:ER(4Z>W-^('C
M&A1NR=2'297,N2*EK*!=L/TG8F_)!&JZ:)^8M$X-2U20-NER&*3GS#8%QU]O
M.NN2,34)L$J&0S4C*$&S0X).*;'H&D\O1<*;,]2_1=06A0:-.KE+0.K-JL,
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52W7IDV0_*>=>619?A$X1.$3A%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g713200g83v20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g83v20.jpg
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M$S1256%B<7*5LE9V@;'!T=,4%B)4D]+A(]7Q)$)SA*(R_]H # ,!  (1 Q$
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M-BQ?MTU@?Y@
M                  !Z#HJ5(6QQ6H6Q4]+4:!6J1LR(Y"F6NRI.G,.3MB10
MZ*T#80J7FZ:)4YSBN1(2C3=-U:M.GU,.T CYX9KB^J)<'X_XW>^P /#-<7U1
M+@_'_&[WV !X9KB^J)<'X_XW>^P /#-<7U1+@_'_ !N]]@ >&:XOJB7!^/\
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MHEP?C_C?[ZP!)'7.<ZXSG7.N<XQG.N<XSG7.<?QUSG7.=<YQ_P#K.<9SC_\
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MF[P>.,?PL%C[9&1[8MJV)NHB9/;^&5=FW=.\HE&H[FO9D<[NR.(Q:V;*B.M
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M=_D1/7A\1^./;^X$O&LO/4J7-:K/S%S#]]E>H\783?L_%2U,#P
M      "H7E/:,OBW(BY)/*&N-/U;\;:-I>U(E ':[)[7,IF"M^E]G[2Q?5\/
MAJ8AKE]D/JR*,<*B*B7+G<D^1M#)7<?;HV794LD"L>IER>G9XONRV[&_N'LQ
M>0F[3^!3?6<R0_D._=0B^J@E,/-G\C.+54M&Y5>+='(>XUB8][1YIB;)QPCE
M>7(R[$QU%J:[X9[%T5'.4S7K7P/NL3OQY/1]A)>]9-#W*T> DZ8I_H<V26^Y
M,B95T>L=P*A4UB,AXI\B';0\UG:) 7#9P@.=FV*K61V<&YYW;E>R(QC6)-W(
MSXT";OL_%"-'(%NFU+VY*),[6Q-);#;0VV(E\*C+N_H'YHKN?6C441CK6I73
M"UFNIH2N-E6Q%'UN_,+?52E-!;0MNSW:1GR2K'U[?1ZF7)[<OL1=U,OIW=A-
M\LMJ>S&.X:]C=CQQ(Y-[3)"%NY2!WRU&."%4UNBYE<T9RM@='V.N>B5T;5A"
M9ZC3Z^QI\2EDN\=>WAD6H'%2/R=B
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M>'_>(;.N%2=.4400?A7\*424647OKIIKK@+&?*YE.=?2=ZB/]KW_ '7H[V
ML9\KF4?2=ZB/]KW_ '7H[V  L9\KF4?2=ZB/]KW_ '7H[V  L9\KF4?2=ZB/
M]KW_ '7H[V  L9\KF4?2=ZB/]KW_ '7H[V  L9\KF4?2=ZB/]KW_ '7H[V
ML9\KF4?2=ZB/]KW_ '7H[V  L9\KF4?2=ZB/]KW_ '7H[V  L9\KF4?2=ZB/
M]KW_ '7H[V  L9\KF4?2=ZB/]KW_ '7H[V  L9\KF4?2=ZB/]KW_ '7H[V
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MU'';'C<>4N$>4*GW=M=]5R<+,ENY_P ?GN_>35 \
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M
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MA"L* W0DF;OM;B":(X([
M                                                      ,C_4J[
M;5X?:H)^U\)%JU4W H_[DQZWCR5:Q;YSKWH'JR"(+C0SB0    #4GTE.R(W^
M<.;?FMPD"NF^SW1DO^5X4S57=-WG\;\S!9J,F-'   #%WRU[4G(OSW6AZYO(
MO*A=T*+_ %?E&H."/J57FI!IF9:V](]CICX     !KWZ>'8QHG[O/?KC)!$E
M9]_*19S#:A"%84!NA),W?:W$$T1P1V
M
M    9'^I5VVKP^U03]KX2+5JIN!1_P!R8];QY*M8M\YU[T#U9!$%QH9Q(
M !J3Z2G9$;_.'-OS6X2!73?9[HR7_*\*9JKNF[S^-^9@LU&3&C@  !B[Y:]J
M3D7Y[K0]<WD7E0NZ%%_J_*-0<$?4JO-2#3,RUMZ1['3'P     #7OT\.QC1/
MW>>_7&2")*S[^4BSF&U"$*PH#="29N^UN()HC@CL
M
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MC@  !B[Y:]J3D7Y[K0]<WD7E0NZ%%_J_*-0<$?4JO-2#3,RUMZ1['3'P
M #7OT\.QC1/W>>_7&2")*S[^4BSF&U"$*PH#="29N^UN()HC@CL
M
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M9,:.   &+OEKVI.1?GNM#US>1>5"[H47^K\HU!P1]2J\U(-,S+6WI'L=,?
M    ->_3P[&-$_=Y[]<9((DK/OY2+.8;4(0K"@-T))F[[6X@FB.".P
M
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M%G,-J$(5A0&Z$DS=]K<031'!'8
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M<031'!'8
M                          !F,ZPG:J8_,Y$O66;BM:C[G1.G8W5)>3=6
MU>=QHB%UF-*JAL9F     !HDZ+7]*[H\X#'ZN:B8*^MN9#HQ_K2F_P!3VU<X
MS]SJZ%T@P8V$   ,C_4J[;5X?:H)^U\)%JU4W H_[DQZWCR5:Q;YSKWH'JR"
M(+C0SB0    #4GTE.R(W^<.;?FMPD"NF^SW1DO\ E>%,U5W3=Y_&_,P6:C)C
M1P   Q=\M>U)R+\]UH>N;R+RH7="B_U?E&H."/J57FI!IF9:V](]CICX
M !KWZ>'8QHG[O/?KC)!$E9]_*19S#:A"%84!NA),W?:W$$T1P1V
M
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M!$E9]_*19S#:A"%84!NA),W?:W$$T1P1V
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M,&-A   #(_U*NVU>'VJ"?M?"1:M5-P*/^Y,>MX\E6L6^<Z]Z!ZL@B"XT,XD
M    U)])3LB-_G#FWYK<) KIOL]T9+_E>%,U5W3=Y_&_,P6:C)C1P   Q=\M
M>U)R+\]UH>N;R+RH7="B_P!7Y1J#@CZE5YJ0:9F6MO2/8Z8^      :]^GAV
M,:)^[SWZXR01)6??RD6<PVH0A6% ;H23-WVMQ!-$<$=@
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M@QL(   9'^I5VVKP^U03]KX2+5JIN!1_W)CUO'DJUBWSG7O0/5D$07&AG$@
M   &I/I*=D1O\X<V_-;A(%=-]GNC)?\ *\*9JKNF[S^-^9@LU&3&C@  !B[Y
M:]J3D7Y[K0]<WD7E0NZ%%_J_*-0<$?4JO-2#3,RUMZ1['3'P     #7OT\.Q
MC1/W>>_7&2")*S[^4BSF&U"$*PH#="29N^UN()HC@CL
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M([
M      ,_76M_FOC_ /=ZP/U*+"E:@_$Z2YS+.BC3!ZX_&I%F\=TD,4>"@S%P
M    "[?HJ_SW>_W2AOZP\C *^]KJ.Y['= X-EJ=\>G>:0G3/30B)F-[   #,
M9UA.U4Q^9R)>LLW%:U'W.B=.QNJ2\FZMJ\[C1$+K,:55#8S,     #1)T6OZ
M5W1YP&/U<U$P5];<R'1C_6E-_J>VKG&?N=70ND&#&P@  !D?ZE7;:O#[5!/V
MOA(M6JFX%'_<F/6\>2K6+?.=>] ]601!<:&<2     :D^DIV1&_SAS;\UN$@
M5TWV>Z,E_P KPIFJNZ;O/XWYF"S49,:.   &+OEKVI.1?GNM#US>1>5"[H47
M^K\HU!P1]2J\U(-,S+6WI'L=,?      ->_3P[&-$_=Y[]<9((DK/OY2+.8;
M4(0K"@-T))F[[6X@FB.".P
M                         #/UUK?YKX__ '>L#]2BPI6H/Q.DN<RSHHTP
M>N/QJ19O'=)#%'@H,Q<     NWZ*O\]WO]TH;^L/(P"OO:ZCN>QW0.#9:G?'
MIWFD)TSTT(B9C>P   S&=83M5,?F<B7K+-Q6M1]SHG3L;JDO)NK:O.XT1"ZS
M&E50V,S      T2=%K^E=T><!C]7-1,%?6W,AT8_UI3?ZGMJYQG[G5T+I!@Q
ML(   9'^I5VVKP^U03]KX2+5JIN!1_W)CUO'DJUBWSG7O0/5D$07&AG$@
M &I/I*=D1O\ .'-OS6X2!73?9[HR7_*\*9JKNF[S^-^9@LU&3&C@  !B[Y:]
MJ3D7Y[K0]<WD7E0NZ%%_J_*-0<$?4JO-2#3,RUMZ1['3'P     #7OT\.QC1
M/W>>_7&2")*S[^4BSF&U"$*PH#="29N^UN()HC@CL
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M<9((DK/OY2+.8;4(0K"@-T))F[[6X@FB.".P
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M27DW5M7G<:(A=9C2JH;&9@     :).BU_2NZ/. Q^KFHF"OK;F0Z,?ZTIO\
M4]M7.,_<ZNA=(,&-A   #(_U*NVU>'VJ"?M?"1:M5-P*/^Y,>MX\E6L6^<Z]
MZ!ZL@B"XT,XD     U)])3LB-_G#FWYK<) KIOL]T9+_ )7A3-5=TW>?QOS,
M%FHR8T<   ,7?+7M2<B_/=:'KF\B\J%W0HO]7Y1J#@CZE5YJ0:9F6MO2/8Z8
M^      :]^GAV,:)^[SWZXR01)6??RD6<PVH0A6% ;H23-WVMQ!-$<$=@
M                                             %+W6D_I/37G#>/5
MLX;Q4-MU/=%N=;8,>KAVKD^?OM74SL"H#      "TKI"=K!;YIYA^K148_7=
M<QUIJ!Z"--,JHO2WHN+Z6&-/PD<I0   ,_76M_FOC_\ =ZP/U*+"E:@_$Z2Y
MS+.BC3!ZX_&I%F\=TD,4>"@S%P    "[?HJ_SW>_W2AOZP\C *^]KJ.Y['=
MX-EJ=\>G>:0G3/30B)F-[   #,9UA.U4Q^9R)>LLW%:U'W.B=.QNJ2\FZMJ\
M[C1$+K,:55#8S,     #1)T6OZ5W1YP&/U<U$P5];<R'1C_6E-_J>VKG&?N=
M70ND&#&P@  !D?ZE7;:O#[5!/VOA(M6JFX%'_<F/6\>2K6+?.=>] ]601!<:
M&<2     :D^DIV1&_P X<V_-;A(%=-]GNC)?\KPIFJNZ;O/XWYF"S49,:.
M &+OEKVI.1?GNM#US>1>5"[H47^K\HU!P1]2J\U(-,S+6WI'L=,?      ->
M_3P[&-$_=Y[]<9((DK/OY2+.8;4(0K"@-T))F[[6X@FB.".P
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MP@  !D?ZE7;:O#[5!/VOA(M6JFX%'_<F/6\>2K6+?.=>] ]601!<:&<2
M :D^DIV1&_SAS;\UN$@5TWV>Z,E_RO"F:J[IN\_C?F8+-1DQHX   8N^6O:D
MY%^>ZT/7-Y%Y4+NA1?ZORC4'!'U*KS4@TS,M;>D>QTQ\      U[]/#L8T3]
MWGOUQD@B2L^_E(LYAM0A"L* W0DF;OM;B":(X([
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M,XD     U)])3LB-_G#FWYK<) KIOL]T9+_E>%,U5W3=Y_&_,P6:C)C1P
MQ=\M>U)R+\]UH>N;R+RH7="B_P!7Y1J#@CZE5YJ0:9F6MO2/8Z8^      :]
M^GAV,:)^[SWZXR01)6??RD6<PVH0A6% ;H23-WVMQ!-$<$=@
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M0B)F-[   #,9UA.U4Q^9R)>LLW%:U'W.B=.QNJ2\FZMJ\[C1$+K,:55#8S,
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MS&]@  !F,ZPG:J8_,Y$O66;BM:C[G1.G8W5)>3=6U>=QHB%UF-*JAL9F
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MU:.91BLW"J"17;?=>F6HEN5!;*B)586)7(E.O(4Z*2S=#RU9!9^#==OA->Z
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M  !D?ZE7;:O#[5!/VOA(M6JFX%'_ ')CUO'DJUBWSG7O0/5D$07&AG$@
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M   ,_76M_FOC_P#=ZP/U*+"E:@_$Z2YS+.BC3!ZX_&I%F\=TD,4>"@S%P
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M.<\CA^W#%12CA)7RI_V0>+EYD>1IT],QSVL&.VAO!SGD</VX8J*4<)*^5/\
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MP1E2\O:Z\&]OD!IAT%D3@HVK<V=H<M:=,H1+5IJY(G-"SOERV?9]]A)T#P
M    #H>X+[;::V-5/-=V=)(TT,.LIFLVBK/'=HG X[LYX;,+WE=)Y5&%DB78
M^#<%YD5K9OG4T(;F[X=1&RC7F+D/X'#2N6T/.<GA,77MM*&DG:WD4*DK='&!
M[;[:D='NC@RSR(5PR,,L=)PKDFCBRR#2.)Y1$HJ@ER&/.[Y&W%R8"4[HI ^<
MIYB1! E<D;E75DME@L]B'UHZ52XK:B1RQ ]):_AMH*717)3[8TJ--&4\,L*$
MK#'LZS2R?EF4,D/T+WF3FB8#P[]_O.<M-]J'ZTGRKF6F;7<#HB=$$DXF9:RG
M$T0AB^8QE%+$B!UT76ZDF+J<UM;@EP['1&(25#A5ODIK5NFFFYN![9D)! >
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MQZ4+H;,7&$N1+*V12T99.4OQIR:'):W&26'QXHQL2;&*MT:TY,@/'GVG?
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)M.X@/    __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g713200g84s38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g84s38.jpg
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M 0 ! P4         !08#! $"!P@4 !,5$1(6(2?_Q  6 0$! 0
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>DC=M"J-3$7""[K"\0+>CJ<DK9U*G[<4]F.8F%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g713200g85v78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g85v78.jpg
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MT? 5,C.!%!9358.2E*+!TM0C0E23PL3A\5)BTR2"0V.U_]H # ,!  (1 Q$
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M1M)X/D< < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < \\L6%@19(X<)#PP4.P=E"Y@L\;CA8H8/;J.GY$D0>*(M&+!DU25<NW;I
M9)NV;IJ++*:)Z;;8 I%6UJN1!P63K63 4HU:+J-,:SD*LQCJ8.Q'LT01=0YG
M!2VQ'#"7.I8V<MW,:;@'!!4Z@NBL+T=)JZ;;!8]:8SB%5V#6D]@3"+P:-MW#
M5JXD,QD F,@T'3Y;5LR;+%C3MDP2</'&^C=JCNXU4<+;ZI):[[[8UR![@XB/
M+CV)82^9E!91FV(C20YRB]'D1[U'1RS?,7C;=5N[9NVZJ;ALY;J*(KHJ:*I;
M[I[Z[9 ^S@&K'>]*>!5=V@S*>P$M<1*&=M&T-9:PR\O6IZZ=GV%=$A%0"[%D
M4S3*0(3*)<YD(Q=Q\N(*-A<?TDFVLIA$6 E'XD?5GJ=N"^M:M3>OS?-RJ#%D
M*QCJ/&Q[F^H^<D)>:08U)91#;=Q+BT5ZW2OMQ%HO8J[.UL$$I68C]+4_*2%:
MR;L$X<C#C%>,/+#+&P<HT5=-11:^#@?GM\> O_U4D63X>WFX26DK JV-74;C
MM,3DK*R,^<2.#HP>ORDAT2GY<@8*S1C%K?+6C!6!HB8+.TFD52#*DG?Q5A7(
M/5W^'Y[UC*?@H. . . . . . . . . . . . . . . . . . . . . . . .
M . . . . . . :0X[UB\2*GY5VQA5*$>O(RH+6M;NQV1B4Z,322J3^8S_L;
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ME!NF*/:[;. N/P#_ #R8_P#+'_TX \F,X\GDQY,X\F<>3'DSC/\ OQ_\,_\
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MFQ=OGCS#BY?^RC2U-:DXZ7I:MYT><T\<$&6KR+2\/UV52-3BONJ4TC8R5W.
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MW/CZ$[LIV56D[4,Z14; EE&C5<545JN]MKKD>RSY;6Y-NM7*[[->+%-:Y?\
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MXH66BX.2>N]XRBGR6[+T%="/6.NIRTE44&M6C9QE)6X>#T[-5WO6IW\5=?\
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MD&>'4)&[&&(CVG)D')1KZ#+;*TF?%UY2H.;JMF[I )L:R%2?(IO]!^KW3"^
ML^3SKXE6$IY4!;0GZY2O:7UHQ"05>$"[2J+_ !LA5B<:?D2@-DE)1VK20,R
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M>"Y?"*=A7TTMJEHR!C 9:JKSZTS3L##YTI)2&LOPI%3U$LD8^5@VT7T$L!Q
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MTYXXA8\$_1KFL(^YPV)SJ5Z&I& =N1^,I%%1H&(-95-SZ,?D&T?BI782ZTU
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M71X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M93 6X> K)T<"L"8D*^,"V9D]A_D&)=$&C<F9P*0T=%,B6"RVCHC@:V53</\
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M'?P6'V;,Q^M79_V J#F@NJ9W14O)F&Z;%$IR7>D^?G[%,Z3>:\,N. . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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M&7' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M:V>;5-8UG6$Q'2I.V*W?Y!1>31,>N+8QF-RR4LY0>#R!V9MZ7(28@M94H:/
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M 2'?P6'V;,Q^M79_V J#F@NJ9W14O)F&Z;%$IR7>D^?G[%,Z3>:\,N. . .
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M )#OX+#[-F8_6KL_[ 5!S075,[HJ7DS#=-BB4Y+O2?/S]BF=)O->&7' ' '
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MDM)2<=)N+3=SN6\+3L)KVJZ'4-?FD2V@NL^;V*IB*['<2785\G+<GT0SC)O
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M_F/$Z"?! [^13O8#['$(O7LA@.E:E:N9O4SY<:5V)[2IG/%T-VN1R*.$-6F
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MYW_9?ZMJ/O/A?-8=5+M3EWE'_;5C-9)OBKS/^N!WK<T<28C[?A7GM#*8^IK
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M;[UO3J]%S9_,W[*,5!*B2ED:0L?'ZX-O-K=.Y%&](HT%QERM]T4Q\9Z: R^
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MG +E6KA_X[]O7LM<MX:OGL.(ODL[<RXHYK)&X+"IW27#I'#$03\Q%>JIHYB
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M)0M%F-#=;IEE\*GT3A(.2&I1]UA?,I>5TWBN7$J;VZE&(J2<-0Q40+$LBNJ
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M\= ,(^@]:@6(4(,%LPC8DMJX(MQ#9BV01&H/U]=5WJ3+1%-TMKJHOJIOC&W
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M[(N;*IN,=@!=;1,#9(>("5%(7!71;TUJRRISEH*0$P::=@I/(*@DPQJ-568
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( < < < __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g713200g86o18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g86o18.jpg
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M 0$! ?_  !$( /\".@,!$0 "$0$#$0'_Q  ?  $   <! 0$!
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MZJ@]UBIXN#MFF%#,P5 A093\(O;94I3JF9L[,QU[VE[B4Y^,RLR*]7L$H)Q
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M:?&OC\!-@&*=/"L./2(DC!-AFOT>MS4DF$Q51F'')[D9,>7+2N*XXMIUE'Q
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M+#C(=DOM-KSA8*,L0HR!DD 9)  R>LD@#OD@#>8159CA06.YPH). "2<#?8
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M;?B=]0K+HJTKFHE1,JVEE;!&I2RGQJ2#U&3:Q[CMO(IZ(DV;O^PMM[[U]_\
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MK3PQK:<YI.A.VV"2/!F8/CGN5#RC>C-/K^S$^(G]/L?\DVEOZN^;<^YG@?\
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M7;PD?FR^C?X-^M?S&QSE_LK]\G&OTA<>G)M9=QVWD:?HB7A;O^PMM[[U]_\
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M.-(7GUBHXV R]/*2_+[*,@,NSI[T:(TMY.=>HE, NRKG.,G&<#)\PW)Y ;G
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MKZTMK%[AZ=>TZ=S<U$J,'Z:I3PI2E2 72@V()SG?JDLX;=U+ND[U0@*U-(T
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M]QU4W: NXM?T6TV6/JZ%=W):*[&J\5DD4M8@8\%%W*=<HX>TPRT^M1@OO*;
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M8QZ<YSG]W/.DNP=5/8KPDE5)Z.YW(!_];<R'<3[NK^-/HDF(3WT9_P"MB?\
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MH[-K<4-E44OM05<A0&%)EE=<LZ(G=B:X9:KIZTU<6.)V'7;0YZ0..W,2+KI
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M2J8+;-D!B%!TZ=1&H@$@$ D9QD3Z:R[<=?-QWB;KG7-^<L%MAQ+)/;A.5"]
MQQB#3C42NVV95[)8JR)K-PBU@\0@"#[]5,&6Q$^?"C3U,.2XZ7/"I;5Z(+5:
M;(,D9)&"5;2VD@]MI;9BN0"1G&1/=*]*H=*.&; ) SE0PU+J&,IJ&ZAL$@'
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M )&%85W0A*^,</<-K=7#U[=JE76EY4XC3-OHI@6PM*SK2*,J"J2JIT5STKU
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M/(;D,.(2ZTVYC&%H3G&@:=2I2=:E)WIU%.5>FS(ZG&,JRD,#@D;'E)60&!#
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M!]%?A?5']#&\>;*]2[\.WOZ)J_OEE,-QON:EY<?1U)S_ 'F]I&(XB=G"O?X
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M0[<QY"'9:![$=,AQ*5O86I.,X^E]4[A*/4J)P:Y2I5(-5U:V5ZA48!J,,,Y
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M@< ;LP6!%@VB$), XI=IVOU<1+4^R)/F(26W9#D;+<YQ2F5.I:6W?\.XM?\
M":SW'#K@VM:I2-%ZB*A+4F='*$.K#!:FAV&>UYXS/*K;4JZA*P+J&U $G8X(
MSMCJ)EDW['4\+?Z(+3^/93^9YF?NV[*/[6K?L[?^3+?V,LOR(_6;ZX_8ZGA;
M_1!:?Q[*?S/'W;=E']K5OV=O_)CV,LOR(_6;ZYE<8TR2C,,QF-V[I;8CM-L,
MMX,TG.$--(PVVC&54+*LX2A.$XSG.<_6^OG.>1<N222%).Y..LR]T_WF\\I]
MMOJ+4-[ZXMNHMM['V[==<7H9@/;:J1/U>-"-#<28\S$20^,ID&>TCVF+'>\T
M66PYYFL8\_ERK&;BUO+BRN*5U:OT-Q0;72JJH+(V",@,".1(W!&\^7I)41D?
M+(PPRD[$3')^QU/"W^B"T_CV4_F>2#[MNRC^UJW[.W_DRT]C++\B/UF^N/V.
MIX6_T06G\>RG\SQ]VW91_:U;]G;_ ,F/8RR_(C]9OKF1C4'4"FZ#UM4]0:AV
M+MVD:VHT!T74ZH./UB5""P'YTHD[&COE*;/(.(7.G2I&<R9CZ\*>5C"L(PE*
M8_=WMQ?7%6[NWZ:XK,&JU650SL%"@D*%7VJ@; <I=)22FBHF511A5!V Y]<J
M.O3A1Q"VU[NW4I"TJ0M.3%)]"DJQE*L9]%!]/U\9SCEOJ_NKYI]Z?[S>>8H,
M_!U?"WS]?.H;3Z<__OPI_,\E'W;=E']K5OV=O_)EE[&67Y$?K-]<?L=3PM_H
M@M/X]E/YGC[MNRC^UJW[.W_DQ[&67Y$?K-]<O4ZT^'1HKIY4#E"ZU'=H:GJ-
MELCMN.! =F#3XY"R/#!H9PJZ[8*N8E(>6,$#8F6V7VX^&XJ%89PXIQ:\/Q'B
MW$.+5DK\1N#=5J=,44=U0%:89G"@(J#&IV.XSOSQB7%&VI4%*T5**3J(!.YP
M!G?)Y 2XWY'R_P!-^ZO],4C^@/,?J_NKYIZZ?[S>>8X-K^!5X?&\=BV[;6UJ
M/=;EL6^%G3MNM!"ZO1IILL\VTR[-D,#!T& TXMMEI.4Q8C#7H1C.$8SG.<R"
MU[+.R"RMZ5K:\2JT;>@NBE26G1*HN2=(+4V;&2>9,M7X?:5'9WI:G8Y9BS9)
M[^QE/?V.IX6_T06G\>RG\SRX^[;LH_M:M^SM_P"3/CV,LOR(_6;ZY<CUH\)#
MJ/TZM1^[=:8NQ-3VFT5_XK'S .VQ9[Y*O^\89;W:\U8 1B,AGWB/ARO.RPT_
MYV$I];ZM2T*Q_$>R'C'%J5.CQ&\>ZI4JG2TT=*0"U-)34"B(<Z6(W.-^4]:-
MG;T"6HIH9A@D$[C.<;D]8EZ'R/E_IOW5_IBD?T!YA]7]U?-+C3_>;SRR3LIX
M073SN!=Q.R.R8_86UKN"JL.DB; ;MT>!*A54>6-'88=MD $$0U1V"UB-34N.
MQER<N3W4K?4TAE#>9X=V1<9X31>WX=>O:T:E4UGIHE)@:K(E,OVZ.02E-%P"
M!VHVSG-O6L[>NP:LFM@ND$DY R3C8CK)EO/['4\+?Z(+3^/93^9Y?_=MV4?V
MM6_9V_\ )GE[&67Y$?K-]<J;IOP..@?7W9=4W%IRFW>B[+H\R7/JEL&W1R5.
M#2YPR:'EOQXY4:0'N*>&$IL16),-]&&Y"U)2ES"%IMKOLKX_?VU6TN^(U*]M
M6 6K2:G1"N%97 )6FK;,JG8CE/NG86M)UJ4Z6EU]JP9LC((ZR>HF9%/D?+_3
M?NK_ $Q2/Z \P&K^ZOFEUI_O-YY;-V9\-GK]W' 5JK=F"VSMM *<8DGZT-.6
M<3 9$F)D+(Z3.877JR'?<<>A*S'4F0Z\UA.?2EO"_P!MS(\.XQQ'A%2I5X=<
MM:U*J"G49%0ET!U!3K5QL=]@#/&M;4:X K*:@4Y ).QY=6)9O^QU/"W^B"T_
MCV4_F>9?[MNRC^UJW[.W_DSP]C++\B/UF^N>J#\'A\,$;-AD8.IK7'FP)4>;
M#D(O9+*V)45U#\=Y.%QU(RIIUM"TX4E2<Y3CS8SCTXY1NS7LG8%6XM6(8$$=
M';[@C!'N7>@<-LAN*(R/[S?7,J_R/E_IOW5_IBD?T!Y&-7]U?-+W3_>;SRE6
M[>F-![':OM.E]VW[;6P-875 ENT5 I8:U$@&$ SHNS"4OR!%.'$6\0CH461;
M]FFLY4[#;0[E;*G&EW5G?77#[FE>6=3H+FCJ-*JBJ636C4VP&#+NCLIR#L3U
MSXJ44JHU.IED;&I2=C@@CEX0#,>?['4\+?Z(+3^/93^9YGONV[*/[6K?L[?^
M3+7V,LOR(_6;ZX_8ZGA;_1!:?Q[*?S/'W;=E']K5OV=O_)CV,LOR(_6;ZYDG
MUEU4KFFM?4_56LMG;?J6OJ !'U>GUF">JDB&# BV<1QXV,^0I4R<ZS&93A"%
MRI4AY6,>E;JL_7Y';FZKW=>K=7+=+7KU&JU:C :G=CEF.G &3U  =X2[2DM-
M51-2JH"J =@!L!)I,:)>/B2@(ON;<\X2:'31)2$X:IB&Y@XC&=AS8KBFJ(VZ
ME$B,\ZTI3;B',)7G*%I5C&<>:56INKII5T975@-PRD%2/$0#/HH"""6(.Q&>
MHS%?^QU/"W^B"T_CV4_F>2;[MNRC^UJW[.W_ ),LO8RR_(C]9OKC]CJ>%O\
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MV@=B/W\CVDLU?*4O?-DV*-I-5UIO^!7JU5[1K:6('U2CF(=8N5>JTEP \[(
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MN@)A3WXBY45,%W^VP\,.MXC.?MV?(KZ_$3S1]=:^B9)JB42FQ<FHST,SF/6
MC.2T20\B1(BD\MP4YGQGWVVWWF)7K6G7D(<6E2TI5A$C(.NU^L0U#JV"#5X>
MM]<I<$&,A"8:Y3B&VW)*HT!B.RI]QMEEM;V49<4AIM*E92A.,(G@@T>E#"4T
MT-I]7'F"29:"):#7Q,0E/1/=P]/3-G,1&Y4I,U[&'9:7W7,27<8<>PM6/3Q$
M\C^N=>RA0P%)H=,D! GK\!@[]7".BA&)2_62L#![D%42![2Y_;'_ &5EKUR_
MVSGF5]?B)%V:Q6HY2*<CUX&P:@BD@H1=D3 :*0P:%X<0&BD$1TRXXI+B4K2.
M9=1$2M.%89QG&,\1/."IE/J[TJ16:I6ZZ_.2A$U\$"%B'IB&U*6VF4X/BQUR
M$H6M:T)=4O"5+4I.,95G.43\RJ53IQMFRS:E69ECCKCNQ[!* BY!MAR)C&(K
MC)5V*N>TN-A*<1UH?2IG"<8;RG&,<1/R[2*6_%,PGZC5WH5C(8+6&(Z %.13
MI5*F5I)F8ZXF6BA!*X["L39R'Y.%,,JPYZ6T92B>\=7*\(&M!A($,+#QWTR6
M!(X7!A#69*)29R)#4&,PU%;?3-0B8EU#27$RDID85AY.%X1/&U3*>P>5:6:I
M6F;.M3BUV-H$+;/+6\QF*ZI1=$7!!2G8JE1G%9D9RMC.659RWG*>(G]/TVH6
MM455HJM;LBH.'DPE'P8PPJ&F1EO,C$7)&+)S'P_EEG+V&O)AW+3>5^;U:?0B
M?==7K+A!\LY703A22'S79))8@>HA(K^5Y<R"?F*CYD.A\N*4YD8XXJ%E><J]
M1YLYSQ$A3&N=>Q110%&HE-CA#>&,&@[%7",BB^(R\N1L%![<%,2?B.O.5L8E
MLNX:7G*F_+GZ_$3U$:12S$R 1+U"KE2 IJ.P+G$0 F=,&L1'5/Q68$J3$=?A
MM1GU*>CMQUMH9=4IQO"5YSGB)$C0$'9(*AEB"B3PU3C;RAYH=#*05/-9SEIU
M42<R^QEQK.<Y;<RWYD9SG*<X]/$3P,TRGQVP33%4K3#57D2)=9:9!"VVZ[*E
M^LQ*D@D(BI2(D2<//8D/#\1W'O6N>L4KUBO2B?B#2*6,*3#@VH5<>:(XEX(%
MX( 3$*3L3W?73L3"$>(W+DXFO8];+]<ZOVEW^V/>=7U^(GG=UY0'PT"N/4:G
MO5X4ZZ^+!.UD*X&&OOJ=6^] %KA9A0W7EOOK=<CL-K<4\ZI><Y<7G*),&1 E
M0K(%0P>H'D?[IR&S"C9%9%>S^Q^[,CLM>QY'^R?\%]B]3[-[/_:/5^J_:\1)
M=:UUKYD1-K[-%IK0$C(8ED C58"-B)\J*MIR-)FC4P<0I4B.XPRXP\^RMQE;
M+2FU)4VC.$3V2J539IIBQS:E69=ABKC.13TH"*D&HSD/R^QK8*.Q%SF5Q?*G
MV93;Z<L>5/JLI]&.(D0E@0<\9)"3PPF:&F*=7+$2QT.2,E+?E*G/JDP'F5Q7
MU/35*F.J=:5ER4I4A><O9ROB("@0=<@I&5X,) C4N./)'A1T,7!2\]G&774Q
M(++#&''<XQEQ>&_,O.,95G/HXB0F!0J,*D$98NF5,;*+QI,(M)@5T/#D%(<U
M:79D0B]'AMN38TMQ*7)+$E3K3ZTI6ZA:L8SQ$^,O7.O9\ 2*G42FS18%AR*#
M&RZN$DP L9WU678PF&]!7'',.^I9]8S#;9;7ZIKS)SZM/H1(FFJU=)C-A36P
M"3^1F N3B0X[!C(=.<92)R3Q']MR,3G&,X@9?]EQG&,X:^MQ$^8"GU*J>U_%
M:K5RM>W^H]N]P!!@?VSV;UWLWM?NZ+&]H]G]H?\ 4>N\_JO7/>K\OK%^9$_#
ME*IKQ[%I=J59=LZ7&G<6-P"*6>PZS'1#9<P75%R0PXU$0B*TO$CS-QT(81G#
M:<)PB?-VB4=^ 0%/4VJO#"Q5TZ5'.UX0Y )FWU)4^9(0UP\QYI5Y2$J=(26W
M);BDIRM[.<8XB?N+2:9!="/P:C6(;U91.;K;T4 *CNU]!3*\DT!'&8B%B4$<
MN.9G)@9CXEY<7F1AS*E>E$_46F4^":?LL&J5J'8I2GUR3\4$+CFI*Y7]]*?*
MLQ43GE2?_;J<?5E[_P!IE7$3^':53K0]&DV:I5FQ2(:%-1'SH$67>BMK7AQ3
M<9TA%D+80I>,+4AI24Y7C"LXSG'IXB1!L"":+RS[042V=(0F1L\TV.AH+S1T
M92EQX$LDEG$R3"CK6M;,5YY;#2E*4VVG*LYRB0O%%I":\JI)IM535%O9D+K.
M*\(Q7EOYEX(9?4%Q#]VJ>S/2F;ES,;*_:\8D^;UV,+XB?2?2Z<5+0SQ2IUDD
M='>RY'FIX(7,+0<P7LR8689&1%<F1?8Y"E/Q?4/(]G>SEUGR+SE7$29N(CB(
MXB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(
MEF&L/$1Z1[HVTSHC5?936EXW!(F6. SK\$3E2+ Y,J,,B0LL=,=R$TUEP-"$
M$Y,W'KO0AJ&]E.593C&<Q<\ XS9VIOKKAUS1M *;&NZ@4\52JTSG)]N74#;F
M1+=+NWJ5.B2LC5-QH!.<KDMU=6#YIZ9G<JO#]DV*CSM2;:CU:L;UIO7(IN#U
MFJ7:"C:-^!T,O5AK(1K:2MM21<^7LFJ 'C$76;\8<3F29Q+$2KC"=BAX>7./
MKQXODZN_*QM;\U)&?JPRS[%UY3;%>;+:*I2*Q8=C4%LY<B]6N,JD38=5BP;)
M-38)ZC3,6(\'%.2S0<B1BU\^/%V1$L1'2D@H3LWI8@/$3;!?*MKJ59=H[9U#
M40FQ[55*F=N5PTYMVQ:6LL>HCIIW+EA1/M]>PL(P,5()OCSE?Q/'#B9+ QI*
MX_A\L^I;LQHF$5M56%;<U39-@4QJ<[8M<BMJZX8N8C L@P,+8-"BUI'9 8%S
M9#<4@Z><&LQ):D0GG$S7F8[B4P>])@G;[T6+,76O$]T:G''];"7#^Q0<[8M/
MB%Z"":P/4Z:NHV08;FU82TDL*4X1.,P8:$DQ^5/8Q-C>M1CKZI.U3M]3OM>&
MVZC6BNW.J&FW7@]GJ9H;8J\59CR7H;[HTT(DS!LYMB9&D1'EQ9+J6Y+#S"\I
M=:6A*)&I<J/!BR9TQY$>)#CO2I3[F?0VQ'CMJ>?>7GZ_H0VTA2U9]&?0E.>5
M52S!5&68A5 YDDX 'C.TH2%!9C@*"23R  R2?$)*M;V%2KA*D0JQ9!IJ5%8]
MJD,0G5.+9C^L0UZU>%(3C"/6+0CT^G]U6.>]:UN*"AJU%Z:DZ06& 3@G'F!,
M\J5Q0K$K2JI4(&2%.<#ED_'*(-]H1\[8A*H M2;=LU+ [,AZ<LFZ*\*J1+7H
M+8TQ@;ZT5)%-W).SIH(*9,#*G:;L)U\0J-8L\F3%,%XPNOVXQ7+>>^/FS]OM
M\L]NKNW?7?;&M,[3![8U^* C*A5[I>8%AOE'AF=5"[?%5)#L;2CQ+'/ATB<Z
MMJ5"RV7G-1W)T&;&BR9*HSF<(P1\WC\4F<EV7ZXA854)&-_Z3$CKW$BSZ1/)
M;5HL&%<H,V?[JAS:K*E'FF+#$ED\9&QI(E<ME^?CV-I:I']KXE,9Y2(@]YZL
MMK=:(T>_4.\U>RN6YF/<*GL&B&:\P]28J9-@91)BV);Q5T9Z5MED HY3(#+2
MWC^!D;*'E(D'7V@ZT-T^)L-SL1HQ% GG7ZO!O*]M4%-/FV6-!R4DUZ)9E6#
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G.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g713200g90r82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g90r82.jpg
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M:2?%S72YK1\*I?$>[#^%E<0JZI K'1=#]O1'5^'.(L0<Q.I+(Z4"JRA+Z81
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M$#VS1L]>Z+I/'B#9%OHBBZ=I.G2;EPGIJLOHY7T5WVU64QL1?7$<CVKEJ\U
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MV/M![(A?4F!RJ,U *;16LNP4/[ 2@G*:V9RH$_./)3V KF6-@,7<Q%[#XR,
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MR*01:5LTRDX2>/F28P.YPL6;: \[B/%:WM]"LV0WHUO:D8KP=1-&D\%NT&U
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M=/K/3@4KJ",.(L>,(VY.2,#0D(UP!3$1,DR@TLG+58^@0,,S;E$NTB!$>PP
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ME65C2WNX7M*!_(@=].R/EMP'<Y/I+^RA58QO>8N@':2*J')M0RF7KY[8X/\
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M!F@D28DIDZ3<-'1!-@ CT:8%SQUY@:P(%5FX@:]5;B1Q$JXU2'#WCE'VY[6
M%QVFP !<2=MFM:"YQL"; &P!)T!*\,8YY(:-@NXDM:UH! NYSB&M%R!<D7)
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MP:7AA>;,-C*>.YXS$$DE>7R123<(YT@OD'>HS\V,-+\A?DL9&WX$#(&'*'
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M:WHF61JOR:\T[%.(F-@%>38G[R5A!J15M(;<*#;"-MA,J6B^T2@T.EKHWZO
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MPX11O</LLL#Y)FOF2O-N@WVEZ>/K!:M;N=3T,G5*3OR^JDHX1-=ZV>Q6&?\
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MX#;,91@C'S20MZ)?X1]<,,DCW-(X,N#@TAUW- -F&X#KDAHOEL^[792"!\S
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MENJ'M92^3IG_ .EY$8WN)Z6/[5*X/OGZI_\ E3.N4Y6M+E[V2V+Q4S5*<DD
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MGZFIX.DDJ82U]FAS";EANX-OH03M/*O.I[P=Q^T'A/)X[[,6Y 8WYRDZLB<
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MX<I*!I]/41M'<)Q4=#6!00XVR7U.IE_%)1KQOY(%04JTROC8JF[3PUWN6$/
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MEA-V3QGO$7XR1AHQL-C#>%0 ::7L)PQ7:(D&4@-Y*9CR+=(]()*_<L-$3+-
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MMTC@TE ]G['F9.2 R8:=QYID8"8Q=^+)@O>X.0&)8?GG$K+-3?I2"FVZF6X
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M%TH:[BSRL-VV-N,T_5JJ;B>_5'E,],;"J>_^W#Z*?]L6C^3MU]9<F?Z)8O\
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MQG,YD<3&1 ,_S(RUW$S .X221MP='-N\-=MV$V.@,L;7]3F>TD2OMX9)*9A
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MC\AO5"ACLU:%:5A4DL=V58D%KQJ=!&A01S.9: B3<P4]6KK^K12Q\@/3(/\
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M%76%E7:R9%11YLHKOMLLOOONME3RMO';#%&3&[(V\0(BL+9 YN4AH%@!ET\
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MLN5EK9;-:TZ-TU()TYU4?]BU=_/XWTS^,:W]WR5_K2PS^[:W]I#[5\/D2?\
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M5]'Z1B+\:%9.BA!^D]"SXOL&(O8HQD2+5R5R/S&8QW>XIC6&U.&5%)010U/
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M7\L,EY,!8&HY9<WN)_1+^OXS'6>I;2>'*SG@QVO9BZ)B/BF,5R@9A3^=O_3
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M[H1JLX6YL*[2[^= F+6,PUI;UH4QN=K%51ENE;S-X>IV;RD+NFK#/7T#WB)
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:$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g713200g93a29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g93a29.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1M&4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
MY@  !<T          0                         !              7-
M   "Y@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "Y@    !29VAT;&]N9P  !<T    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   N8     4F=H=&QO
M;F<   7-     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    (.$))300,     !"X     0   *    !0   !X   E@   !"< !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !0 * # 2(
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MCK['@"EC6$G'LQH:WZ3?YS^<W_3L5^OZU=&LO]$6EH):&6N:0QQ=_*_,V_\
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MJN=Z?IM4D<?I)D-:L+)3U%'KJ]E7TWT\AM_VK)<&DD5.LED'=[7-CW_2_/\
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MQ*B7 'Z&_P!NWV_R5KBBMN/]GI_0L#-C/3@;!&UOIZ;6[/S4M>IO^Q,I76@
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M.QZ]H#*7-V%@'M:ST_S-O[J,I&H__]DX0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,C Z,38Z-3D <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0  !<V@ P $     0   N8
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.3HP-SHR,2 R,#HQ-CHU.0!R<C4P.3$V-P       Z !
M  ,    !__\  * "  0    !   %S: #  0    !   "Y@         & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
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M 0$! 0$! 0'_P  1" #M =L# 1$  A$! Q$!_\0 'P !  $$ P$! 0
M      D&!P@* P0% @$+_\0 6Q   00" 0,# @,#!@<'#PP# P$"! 4&!P (
M$1()$Q05(2(Q019181<C)#(S<1@E)E*!D:$*&4)55M'6&B<T4UABDI26E[&V
MP=/P-SE$1D=7<G-V=X*$E=35_\0 '0$!   ' 0$               (#! 4&
M!P@!"?_$ %$1  (! P,# @,$!P0%" D#!0$" P $$042(083,2)!!Q11(S)A
M<0@50H&1L? S4J'!%B14T?$T8G*"DI32X1<E-D-356.BTX.3LG.CL[3"_]H
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MRD!6-<*IGS!L:UEV(B$;&)(1/GL<T?N>\QK7[IZ'ZU^>2/2M9G_]8%]EK<R
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M;M ::]BLA96DF?#K#8WAA,JC+!NZR\BV<BLJ\KE4<$'VYMXTSW)Q?-G&8_\
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MC@>V.53Z3>^\"PNKQ[5?49K6AM,@Z8=_]*NTIN2ZJN\DAR,*VYN#8.W<>R;
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M?$+I+0^HXS+HVL:O#IE[&LTENQ%\KVT!2:%TDC9;F2%E8-C(&X,N5,*FB?7
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M)Y (H"R91A1XX!O,<YR,$$(AM5Q"E*]6L&-C45SWO<C6M15<J(BKSPD*"6(
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M,83+8!^^S'G(-2\W%O6T%397ES-C5M13P95G9V$PK0184"$%\F7*D&>J,$$
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M'.2,!\-SOPL2$-.R[0Z?^(;V\<-GKT<UU%$@BBU*$AKR.-1MB2YC<A;N.(9
MDWQW 3TEY555&.7NB'<TNGLJ%B6:UD.("3RQA8 M 3Y*@-&S8]*9+B #*_3'
MZ]M.6TBLO-"Y9D42*9S!7N&!9D5/)8Q7>!F28:N1GFQGGXJY_MHO9[O)>W-B
M6_4&@W2J]OJ]B^[#!)KA;:49YPT-QV61AX(]?C@D<UCD^GW:9#VMRI\9$7<!
MS[[XBZX_(\Y&0&\RU>E5T&[_ (VZ,:VWMW![C ,0PGW;*#&R2,6%8V]HC4'&
M;&C/3NHVJYR*[R<G@I7O4:L"V1BO674>G)IMQ8VEU%<75TO:VP.LJQQG[\DC
M(VU#@E47RQ]L XJ]'TJY:[AGEB>.&!NYND5D+MA@JJK -Y()) &.1R:V<<CS
M;$L8M,8H+S(*RGO\[LY-#B$"65B3;RWC5DNU-&@QU[N.L6#"/)*KO$+&L8-[
MT(83'Z-FN[:WDMH9IXHI;R4PVL;L T\JQM*T<2Y!=EB1W('A5)-;0T_1=6U*
MUU34+#3;J]L="M8K_6+B"-F@L+26YAM(YKF0<1++<3Q0IY9F;(4JC%8_>D?,
MO4#RK=^X\<ZCX>!5&IM8Y)88[C]W7X7*J+?9#I(F3,?L\<E-MR1&5 ZF3%GV
MT]\>0U)KVU !,,DLL3%=#N>K+C5KZ+54LHM-L7DA5TM98YKR5CNADMW:5D^7
M$)61VVL=["/.Y7QNOXDZ3\$M+Z.T"]Z)DUJ[ZGZB@M[];=]9@N[30K16VWT&
MKVXM>\-0^:CGLK>WWVY=4>_/V!MEN+VOP[K'G]2F4Y(#;NOL7Z: Q\?CXW@4
MC#@Y5F5M)!41OV@F%M&)CZX\*1;NDLB^[;Y ]0B:;X,=I&#2YM;:^^K23)J-
MI!I [7;M&M1<7#[8U[Q[@,'8W/G!+SX7]@9K$(]7^%<'0EEITO2>L:CUVRWC
M7FN1:Q+I>GVSO>3FS7Y8MJ$6H+'9F#N(+*P9G&T77ECF(G]_?^/+_6KJ_>*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7E
MW5Y38W53KS(+2OI::LCOE6%I:2PPH$*.-.[S294AXPA&B?\ ">Y.ZJB)W543
MDN66*"-YII$BBC4M))(RHB*/+,[$*H'U)%55E97FI7=O8:?:W%[>W<JP6MI:
MPO/<7$SG"QPPQ*TDCL?"JI/OX%0Y=1OK :[P6988SI:G'FUO']Z.[)K=Q(]&
M*4-SFJ^%6B<.9/"G9.Q9DJL5?ZS(IQ^+G:IZ@^*FGV+/;Z3#\],,K\PY*P!A
MD9CC'KD''#.8E/!4.",]H_#7]#3J+7HK?4^N]3'3EG)LD_55F$GU)HF ;;/=
MMOM;67R#'%'>$#[SQMD"*K./4WZH\UD%(NQY^/Q7E>0<''5CTH@HY5\1-)3@
MKI)!,:OBULF1(<G9%<][OQKK&\^(_5%TS%;QX$.<) JP@?3!C57_ (N2/J3S
M776@?HN_!G0XD1NF[?590H5I]4DDOF<^2S1W<MQ"&)_^''&N, *N,UC+L_?>
M5;Q@0JG<]E(V96URF6 +)K2XD2ZY9+PO.M;8+/67"4SXX'$0)$:Y1-[M^ZJM
MCNNIM5U$Q_K*:2]$6[M]YG9E#8WA68DA6*J2,$$J&\C-;$T7X7=$=,Q7L/3&
MFV_3JZAV?G5TV"W@BNC;%F@,\*(JLT19MDG#J'=-VUL5A_FNCJ.ZB3+35DV9
M%MHPBR7X);R637SV#:XA!XU<]F%D26,15%5V+'2#HU4%,>_Q8L5K=6]R2NTQ
MR_W&QSSY0^&&"/8$8\50ZMH-]IRM-#*+NW&?7&I#+[_:)EMO'W3N(/.[;Q6'
M3YDU"*)T:4AD<K'"]@R$8]JJU6N8K4<CFN16JU>RHK514[HO*XQQ@$DJ,><E
M1_7_  K%_F+@G:(Y2Q\*$?=_#&?;'%7MT_T\=06_+J/0:FU3FV83))AA4]?1
MV"5L;S>UONSK,H$APXS/)JEDG(T06.0I%1GWY5VFG7-_((["SGO)"0,6L32J
MN2!ZY5^RC'/F21 .<D#)J@U;6+'I^V:^ZCU33^G;-4,AN==O(M.#JH)/R\,Y
M%U>N0I"PV-O<S,<!(V. =MOTP?24C]*TR%NC><JJR7<[XC74-%7]I=-@*G&G
MN&68Y/;LL@:Q[PH6.U8->Y7DCFF'2-(B;@Z0Z(_54J:IJNR34 N;:V7U16)8
M$,Y?Q+<E6V;A]G$-VPLQWCA_XW_I#1]5V%ST7T*UW!T]<,(]<UVX0VUWU%'$
MX9+.UM?[6PT8R*)G69_F]0(07,5M"K6KSF\V37)=.*4XI5ELRZD.G[7=_*Q7
M/=V:LPO)H0HQYF/Y1G>-45Q&#,"V1$*>NLK&-+$.2![3 >\2-*-R/8KFJB\G
M1VUQ*N^*WGE7.W='%(ZYXR,JI&1D9'L#FH6=%X9U4^<,P'\S5+?X8_29_P!T
MMHO_ ,Z6&?\ _8Y,^1O?]CNO^[R_^"H>[%_\6/\ [:_[ZCUZ^?5)P?IN9H7/
M-+;"USN:DE;(L:/;>"8AF&.7]E-PB7CTDS9T<M9+FGI[.NL8X9%3-*UD0\AK
MX$I'@E/\;YH/35UK5Q=6A6:UFCLI+BW>:)TB>9)856*1G48217<;ERRL <$
MU2W=]':I')E9%:54<(P+*K*QW #.<$#@_7'DBI/=%;VUEU'ZSQS;6I<CBY+B
M&216E"83F-G5DUC6_-I+N$CWEK+JL*Y8\^ ?L01$1[%( @BDL-U:W%E<2VMU
M$\%Q Y22-QAE8?Q!4C#*P)5E(8$@BJN.1)462-@R. RL.00?ZP1Y!R#S7C;Y
MZ<=7]1>.QZ#8E00Q:\Z2*>^K"CA7].153WF0I[@G3XTEB>$F&<1HQ5\"^VV0
M()AXWKG3VE]0VZVVI0=P(=T4R$)<0D\'MR@%E##(93E&]U) Q8>H^E]'ZILQ
M9ZO;=U4;=#-&>W<0-[F*4 E0P&&4Y1N"5) (M?K/H*Z8]9QG,C:\@9;.>Y5?
M;9SXY'+5%_)@X\D;:P#6)]FJ""Q_;NKB.55Y;-,Z%Z8TI<0Z9#</G/=O1\U)
M^0[H**/P1%'^=GTCX<=':.A$&CP7+GS-J ^=D./IW@8U_P"I&I^I-02>J_U2
M28V?S>E/ X%=B&JM>$J36=#20XU9"NLC&P5HR7(CQ! 3VZJ6\;8,=?(8Y<-;
M+LZ4\+X^L^N>L]6TK59-'Z>N&TBVLXI;6<6:B![@W=L5NT.U=ORSV]R;=D P
M^Z;.?V?JQ^BY\!^@HNA-,ZPZBT/3-5U#6IAJ&EP7,(%KH]O8ZBWR36ENFQ%N
MGNK(7K7B^O)6#A8Y!)#D_,2/<KG'\W*O=[R/<KW.7NJJYSE5RKW_ #[N7\_S
M_+FF2C,<ON+,2<GEB2>26/+<Y.3R/?R<=U#4XU 56  XP/ ]\# X'X>!7"_+
M5_[<G?\ 7\794_VK_M^_;GO8Q[G\?'\,$\>W^/O4/ZT7\/WGZ>/K_P ?XCW\
M7R:]/:B2D"6:5G9TL#?%T5\)5\9#;%S_ !CCA/&KF%)*>P3>_EY(]K5Y.@5T
M==F2"</NP%V$^H-C]D_4D8X(.<9D7-[#<Q-%(<_=9<'E)%.8VCX#+*&P5[8W
M9QC-73GAPN-*,Q]R^:Q'.48*F"PK1HKNZ!?-D21 >HT7P]X#)#7*WR[=E[+%
M*EJCL#.7P<A8ES@9\%V.#CW]S@'\JV&[U":*/%E%$^,/+>3%0Q'!=8(HB_JQ
MN*LT>,XR,5:W(-=:^R2ZG72W68U4NQ>-Y%9]&GQ@J( X[?"+[4 JL5HFJJ?.
M;V[JUKONB<J!=VNU4V2' ^]E"3]>./X9_P L6&ZZ>OKBXFNDO+7N2D,8@LR1
M9X& Q,K*, <D'\QFK:Y7K:ZQ6 :^I[4&6XY$1KYLR''-#MJ=CG(Q#7%,YYW1
MHGFYK/GQI,N$A'HTQ N5B.FE(I1NA<./=2 '7V&Y.<<^XR"3QG-6:X6\T^18
MKV(H#]R9#OADQY"L#Y Y((5@/*C!-49 R%?PHI?)/S5._P!U3^[[*OW_ +U^
MWY_;E.T)./;G^Z/RXQX/MQCSGZ5507I&"&^N/4?;D\9_W^?-24>G%T\Y/U.]
M0>)PHD&5^P>#V5?E.?WJA<M?#K*V0V5&JE.YJA=874D(X46-^-_BXTE1*".9
MX\EZ+Z:FUS7;5 CFSLY4NKZ8H3&D<;]Q(=W"EYV';"D%@I9\;5R-9?&_XIV7
MP]^'VL7CW"+K.K6EUI/3]GW%,]W?7D1A:X1 0ZP:='(UY//AD';CM\K-<0FM
MQ;=6XL%Z>]5Y;M_9$N;78-@M?&L+^765TBUF1H9Y\.L$^/71$61)\9,T".8)
MJN:/R?V5&KSK2VMIKNXAM;9.Y//(L,,8*KN=SA5!8A1D_4@5\:I) BO)(V%4
M,[L<G@#+,?)/N?<U&C_OZ/IZ_P#+W//T_P#LRRA>W?\ _K__ !^[F3?Z$=3_
M /RQO^\6O_YJHOUII_\ M*_]B7^']G3_ ']'T]?^7N>?^;'*/_\ 7_\ CNG'
M^@_4_P#\L;_O%K_^:GZTT_\ VE?^Q+^'_P!/^OX5CIU<>LYT@;$Z;=OX;IK9
M.?5VU;O$S!P">S",EH2PLHC3(<^KDBN"B8.O* \5"#D/>C6O:B.[H[LM78=$
M:]\]9_.Z6WR9N81=?ZQ;_P#)S(HF/IFW?V9;A<L?8$\5*FU6S$4G:N09-C]O
M$<A]>#M\IC[V//M5Z_2Q]4_'NKW'X.H]N3:['.H['JY$<CWQX-9M*MA!;[E]
MCXOYH8K\0VO-?4 6]VHPEG7-="<<$"FZJZ5N.G[@RQ[I],G<_+W&,F(GD6]P
M1P) /N/P)4PPPVY1'I^H)>)M8JMPBC?&"3D?WTR 2I]P>5)P<^3-'S$:N-.*
M5#OU2="G5KNGJXUWU'X9O[ Z3&]66U#)P?7]M4Y-&%35]7,%-MOD2:\DP5E8
MY(3Y(K64T</RANBQ&)[,5J.U]KO2NLZIKMGK,&IVJ#3IH'L+>2.=?ET0AILL
MA=9'G.]9&V(>VPCR0HKJ7X=?&;X==(?#C5>A;_I;J">7J*TOX>I;RV?29TU2
MXO(9+>&6(SO;26\-A"T?R4,@N!!<(]TK&25\R3;W#L>PTGLFNU)&AS=GVN'6
M]-AS36;:N%'R.VBK619QK0B?T./5EE.L2'\7':.(OLA(=6"=F.IB[?3KR.Q
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MLK:VAMYKYHP0>U-=/,D9D W]B,JK!7D5M<G]H_+[J]RJO=5557NOW^ZN7O\
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M!.^]3ZHTS1+'4M5US5]-TJPLXVNWEO;B*SAM;->W&V^:5E[K=UBP)9G/<2)
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MM"S&-&935T>,:9+F/16.9X,$CR-8,:%<5[.S^W@O?MW\>>K]4A!EEN([>WC
M#F5D1"6. "[E57G"@@Y)X %83T!UC\&= ^'NMZ-UE\()?B1UYJ74$UWH^IOK
MFI=-V>D:0-,L8K>)K[0[Q-2O-MZE_=2Z?\M;QX=&:^;=LCN!37PI4NZIX2K
MGUB]SO(#NT,F1W\G(-SV*>5&?XOD (X957MY-5J$5EKE168D $'!5_*29 (
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MLD0+3I$R;I_UW@72)@U7D\C5NR\%O(^O)<N9@F:8_D]BDK%9LW,6WSJ^P_:
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MLK*.>;]87\ MH9;F&XGMFCC@M+BXN(77>Z7(MI53TAA:?K:SOJ$K.D>JM=2
M-5]0=YENKZ^NK]?2294+ZZ#)H%ED%;4G9$']6I)<2ILHLY)44(WTQI0I[&(A
M42@ZHOM9M^G4GL+>7]<2SV"+!8DW)68SHTJHP51)#M1Q(754,6X287(K*?@_
MT[T1J/Q4O;'7[NW?H6QTOJ.ZGONI8H]+7]6BRDALI[V-Y)/D[W==0=GY>5YE
MO#$]FYD[1JX&[*KJ VCT6Y,RF2]U-U&V&NXUW!A8)?O=9TV=5B LGT]9:0W(
MDB/;$BE@+&(I6M#/^.9[WA4O*S4EUB]Z9F,2266MM9+,L-K<>M+R/;+V$F0J
M")2IC(SC#X)XW58>E)NA.GOB_9)-<V74?P^BZ@FL&U#7--C:VGT6[[ELFHW%
ME=Q2A6LNZEP)#"6;Y?NK$-_;K&BRJNM/1'0G%Q MML/J(ZI<^CRZV=D8P1K=
MFN6WT94.C9,2/&-(#C=6B18DV2LL\W))!I:R$@#$)MBO&ZHTKI0111WFL]07
MQV$H8Y5T_O)F0&5A&S);QJ4C=@Y:Y<'B/ &QM&;X0]:_&DW]S+TYT)\..G<7
M$:3H]@.J);&X9K=FLU9XH_UA=2*\T%NEND>D6Z1-$MR\KU;#TDM8]8>@*S)=
M6[OPG(X^K+ LB]Q6UR&TK2V&,WQ%0EA$2"2<MJE9=?<CFM 5H;!HRH,333#N
MMOPZM.I],6ZLM7T^6UT^3,]MW)(6,%QD"5 JR&0+.I#GTE5E1V  <DY1^E'K
M7PFZN32M?Z1ZKT_6.K;.0:?J7REO?$ZKI14]B2:Z:U2W>XTR5=L,DDO<DLYS
M 9'%M;()M>;3KC6G%*<4IQ2G%*<4J)WJH].S,>H78W4WFE9L'$Z2NWUK'I#P
M"MJ[>GM)Q*8W3AOFYV[?R[50/]B9#RBKM&TM8 #?*-,8\LU'1U1%0?8R*YYQ
MJVG:B<8^Y9"$-$,_MOVSM;[HR,BH9@94=5.TMI6IZ>#])+Y'5)<CG;&6&X#D
MC.*Y]C>G?E.:Y#U.7L'.,0K2;YZR^COJ<JE-26#I%'0=,O\ (@MQB]F8*HZ5
M;9$NK;GZ-+C.2'"^N@^4B?TOOY".TU@QY^3U:ZU%A_?CN+<0B(?1E;)8G@CC
MS4=P>\EXJY7YG1[?35_YDL-S+,TIQ^PR.B@ ;@5P<@ UQZP].K)L$ONE:YGY
MOAUE_@^=6_65U(73044]A\CK.IQ^ZG4%'6D-W^-=8LW9U0VUGRU4$M*0Z0U1
M%B^*WS!'8H>3::++I>1P&DDFMY3*![)B)U(^]A\9(+97)[[W[+PMYJ]MJ2@X
M]$<%O+#VB #ERSJP((4!?<C%8YU'I0]1&O\ ":K']5[_ -3T]OD73!U!=*FU
M).4ZYR3(('[&;:W!L3;V-93KQD')*0E?E%#)SL^.V4;( V-*:*JV@(IRP@P)
M<IT=[*6Q+?9S:9IEHY]_F--LYK4-NSD0SBXEW^DN@VE?5R)XG NS=*F&&K:G
MJ" GTB'4;M;GMLH_][!VH]I!V,2RGTCU7*R?TN\WO].]5>MA[*PP-KU!]-?2
M+HRDN34ELX&.6G3=C;J6WN[%B.=)D5N0RO&941HC_DP>WE)\BIW6MDFWW5Q.
M,A9NH4UI5/WEC5K!NP3X+CY1\,.!O7Q@FJ*W0P0641(9K70I-(9L>EW<WGVH
M!YV?ZTN1Y/;]N*J6]]/+<4#-).T->[3US"S6K]0^ZZT\9AY=BV2VV,GQ7*M!
MKH._P:_'47%1:MOX]-9W=_4VM=(? =8BK(DL'QRRB#DP$1/:NPRL+:PDH7.6
MM]5N9ISV_I-$KJ!NRC,&..17LR=Q;H#TM+'I)B/L)M+MX(@9/K'*\1)QZ@I'
MO5.=!&AK"RZO>JCJ8'0;#QC1$3+,RH^EW$]G8%<Z[MJZ]W-,Q3.^JC,\?QC)
M@0L@%BF5;0QFN'BUM95%2^8CLL?6 /33H\^P\MLI9@MC?*>U;\C?'IB3S7D4
M<J\E'EN[N;,;$.L%I:%@IX$VY.^[*KR(AON6'*2:@8H[1GB;.'6.UMH\NN4,
MUQ<A6;'$S_%>4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5PR#@B@-
M)DE&"/'$0QS%<C!"")JO(0CW*C6L8QJN<Y51$1%5>>@%B% ))(  Y))X  ^I
M->$@ DD  9)/  'DD^P%:]767ZN^+R;/.]&ZJUL/:6-%C7&&9I;6,UE;1V(I
M R5]Q61)BQ; IOP.D1#NBP/Z,1%]NP24QX@6R7JJTTB_$.G6=WK.JV%P#*UO
M,MM86EQ"XQ%\R$EEN)TD&'[2+'&PV[W.<;9T#X.7^LZ1;ZQU/K]GTAI6J6RS
M6%K)9/J>MWEI.N8[J6S^8M(+&&:(F6%9YGN7B9':W16%4[T6^IEB5/94^I#Z
MDQ;4P9Y61*G'JFFQZIH[LGMM18E7D&/5=$UMV5B/6)&OZ<S[-[4$RR-,*UBW
M.TZFL.H[WY758K[2-<N6*VSWMR;VUO'R2L"W4FQTD.?1$R(#R(RYXJS=5?"?
M5NEM,GU_I_5+'J_I^S7?J1M;+]7:QI]N" ;B6Q$D\<UI&2-\L,\K1[M\Z11Y
MD,K?0O\ 7J7"MA:^/CLRNU_A&R[T>F\A="-$K<DUSD@8F31V#67:64XEU09%
M:9!3Y$I4C0OG@3Z2)L'VP@N>HZ;9:7'I\%I(Q?Y3_7K>1@TEM>":7N+D(@,,
MJ&.:' +!'VM@KSJ708([2Q^4@1Q:PRS-;._WF2>5[B0.,\2)/+*C*%"I@*N5
MQ6<7+75[IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M'CU=:O*+OKI6[OQG^#+PWX50
MI!D0 B5N:9:&SBL<Y/:]^/[L!2H/\21R0W/3[L5>BNAVACZ>C2,C*OF0#&?7
M#%(F[R<$M(5/C=N\DFM9ZT[->3EL[VE<*#[ -M5<\$#: 1^_GZ6JU]6H*-'3
MQ1/PL^WW[??LB)]^_;M^]%7_ %<N\[$L?J1SR>//^_SXK&Y>#C."!]/)'/TX
M_+\?W5FAH UC V]KR34O,*:"_CF8\'DKF"&(SSN<B(O=C HY[NZ*S[?=/MWY
M9]36.33KQ)0I1H'!W?BIQC/\ZCT]I%OK5D+!NXGW>>00>1_TL?7.*W!H[G/C
M@>_^NX(G/^W;\3F-5WV_3[JOV_3\N<[G&3CQDX_+VK=@S@9\X&?SKFYY7M.*
M4XI7B9'D5/B=+/R"^F,@U=:'WI,AZ*Y?NY&#$(;>[S'.5S @"-%>4KVL:BJO
M)D,,D\B0PH7DD.U549)/^X#DGV'-022)#&TDC!40%F)^@_F3X ]SQ47V[?4K
MQG7$LL=LFCQX*.[Q8]A&GY'DLB,ODHY)Z>G<K*YAFM1S6R%(U.Z(V017(J9O
MIW1DMVF7>1G/'V91(@< X[DF2[#(X0>:Q>ZZD$<FV-8U7/!D)=W7^\%0KM\'
M +<>YK'N)UB]$77JYFGM\8_@N833->RJ*>MLL8SFK(-/=-8X\EHT%J4<=&I(
ME_LY9F<$0B$EU\B.CVI:^J/A:EW:-\Y9"[C0>EF(,D>?)BNH-DD#$?LMM#^"
M2#BLWZ!^,7570^H"\Z=U>;33(X%Q"NV?3KM0<JM]I=T);:=5P"LC*9H2!)"\
M;HKC/?H]Z3$Z2:G+,$UMG1\GT?ET@N78?&N%$>_PR]GB *0*'*CC2MNZ.TB(
M&:TRCAF%,BHI 2$F%,W5_3O3<G337MI#>27&G3R?,117*XNK2YPL<B;QA'A9
M$0X*(RNK;@^\D;9^*/Q3LOBK'H&LZAH%OI/56E0?JV^FTR1SI.LZ5OEN8'[<
MTCW5E=6UQ+,@42W,<D-R=LD1A5#Z[M?2^E;IPRS6^DI^6[%V-8Q<TO-?4V37
M<"PR&QR[+;0+[.P@B]JKAU^,TV0Y$R_M!QP!K*84PSR/&DD;7S'M9-!T6ZM=
M,:[U&^<7$MG%<2QO.]S<,JLR\1(EO%-*)Y0 $C#.?! J5#KEE\2_B+HVN=8P
M:-TOTW#)I-KKMSIMK=0Z=;Z1I-O(T,$S/)>W%QJ%Y967ZMM27>:X*01QIB,X
MQ:].#H.ZA>F"/*R'<O47EEY]9E6-F[3--9BNL$KYUJ\IY4^SM+R#)FFMB',X
MY4QSZ.!DA%0DZP \@WV7H_IG6-(!N-2U64M+N=M,AD$UH'D#;I)I)$]4Q+;B
M;981NSNDF'-9[\=/C'T5UX#I72_1]DZ6_:BAZPU2U%IK2P0.I2UTV&S>)TL%
M1.S''JLMXBP/B&PLI521<LL7PSJ(L.L/8NR[/-C4'3K6X)C."8QK1\:/,_;3
M)X8)-Q9YQW,CR4 :^=>2J@<J&44F^; "&0#X,&.8V0PP:N^OWEU)/VM'CMH+
M:WM>'-U,%[LESSGL"-Y7ARN&FV#=E44UK74=4Z$M_A7H.@VVF)J'7EUJU_K&
MHZVN^ :'8O.+6#2S*H4ZA)=VEI#.UJX>UL.ZTT;B[FD48W^H#F/7;D(XFK>C
MS6625(&3:JRRC;ORJ*$2<&))BV"8[B2S;4+HD4_MI'O+>6,1RB4U=!"T3BRB
MX]U=?=5LZZ=TYI5SM8*TVJ=R!%#9RL4 :3(4';WI'"G;E%7RU;)^!_3_ ,&;
M.W?JSXH=8Z&]WNFAT[H^XM]0NEBBP8I;S55@LY$DFE0R+96T3.L/INW<S&&.
M&2? 9^2VF$8C8YE5K29=-QRGDY/4>82)6WQ8 '6T-KXQY('L#.4[!N"<PU8C
M?$CD[+S-[1YY+6V>ZC[-R\$37$65/;F**94RI*D*^X J2,>#7/.OP:7;:YK$
M&B71OM&AU*^CTF\9)$:YTY;F064S)*J2JSVXC9Q(BMNSE0>*J[E15IJAZ+9V
MMLHR6^PO&=A8/D68XJI$RC$Z++*&WR7&U#(;$,E]15\^1:4ZBE/9&(EA%CJR
M0YH7=B.1JJ57'%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2L8.M.ZO\=Z5-[W6,%."^K]=WQJX\5?Z0(_Q_
M#S$G9?)R-<[LWLOE_5[+WX:22&&[F@_MX;&_F@QG/?ALYY(2N,G<)%5E('!
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MZI:0]37UAIEH7W_JUM3LI]2U+L?:-:PQ03RB-6V@2N[*Q0X526R+9J&O]/\
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MFHZS8]>=/W>F:-,BZE,T#+:7$B1N5AN(I)7C<;HY%C12S;"6&"&4'@ZLZ2Z
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M'FULMAZR+5R"R;41&.CQ9>"]>ZUIEKITFES0Q7M[=H#%;MXM1R4NY'7E&7S
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ME2FLV=TN]Y5@EP=\4C! I\_9EFY7'N?'^-3[FUG3D)O7)&Y<LI)/X<GS]/'
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M2WCW[],ZY=<Q#,D L?V6JDDM.*PQVU"9SDCHA2Q[+$L:GQGE1[H\JDKS@49
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I&,;6L&QB(UC&,1&M8UJ=D:UK41&HB=D1$1.*5]<4IQ2G%*<4IQ2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g713200g93m30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g93m30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2HP4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   " 0$< E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $!AXZ)PG9:$FP@U%<#"ZD0DX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _0      !( -0    $
M+0    8       $X0DE- _<      !P  /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              )-   $%          !
M                          $             !!0   )-
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   )-     %)G:'1L
M;VYG   $%     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   "30    !29VAT;&]N9P  !!0    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
M    (#4    !    H    %H   '@  "HP   (!D &  !_]C_X@Q824-#7U!2
M3T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A
M8W-P35-&5     !)14,@<U)'0@                  ]M8  0    #3+4A0
M("
M     !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T
M   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D
M;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $
M/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H
M=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M   2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V
M+3(N,0
M            6%E:(        /-1  $    !%LQ865H@
M     %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I8
M65H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
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M<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T
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M.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^)
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MIK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /4V,:QH8P!K&@!K0(
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MQ:+7N+7$#:#^D?9O8"75>ZO]'_@OTM?HI*?_T?0#EM9UZVJZXM97C>I74X@
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ML!#J]U9)]ON;ZMMG\YNM_1N_FO0_G?TR.>K]3K(%_3RP]S-K_P#VUQLJIO\
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M6XY CJ[ZF-(HLW;1)V/;^CLL;N9>[8ZWU-]O_GNQ7>F95#VNH&:W-N:YQ+A
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M>PN;[4=)3__3]$JJO_;EUQ8YM1I#"[\UT%CJW_RG>^^O]^OT?W+J%:R,+&R
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@    @
M" $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0
M   !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.3HP-SHR,B Q,SHQ,#HR,0!R<C(V-#8Q-P
M Z !  ,    !__\  * "  0    !   $%* #  0    !   "30         &
M 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $
M @   @$ !     $   %& @( !     $              $@    !    2
M  $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P    $
M     1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$Y.C W.C(R(#$S.C$P.C(Q ')R,C8T-C$W       #H $  P    '_
M_P  H ( !     $   04H , !     $   )-          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
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M*#,T0D=2T?_$ !0! 0                    #_Q  4$0$
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MMKC>1/N-6/2"Q7+=H[D2:L#^S-OVK''HA";[#=)1$/F"R3D6]17%MPY4'\K
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MD[J4P+8NUC[,V)DY.,2B*N8S'Y*:>O@(T,EF7DD8P"WKVA9Z"."<4JZ=677
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MWCJ^@:\73TG$B3TCT"IDT?D<O8:/5B#T60U:0L6J4$ADPVB=0^[&_;N362Q
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M%U@G+1SU0?U[)1<<01;*/G49%! NVC6'(1UP1"."]X^'XV.DK^.U3#I^OV4
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MQ?DFTDCL1^W!!=S%$UY(N$:1*V?$7*%(O7=9]<(F]JJ:JUX^86"2K"50VJI
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M]MS5N?28M):*W]UI*[QLDNWT'D!+IBJ<:Y"D [B.19T## D/''UW3KX'%'C
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M&>2V@_,30/5N+M8SWQ$6Y.\!ZJA,TBXCII74ID,&T/&8S&;!E-+R2N2%'L7
MBL@KLU)(JVE-.'W+H,!0'NXR1(N=$M0C.*=C_.#0$"G2<5Z5QSNA3543B5 8
M'-KKOE&@.WL_J(&P%FHY+)M%Y="1L%*F68(GF-E#K4NF:E,GBLD+J!-\/1RI
M,*[T3YX>\4+7T=]PO'S/I6-O"LX;VOHEAUB1D,Y,P"AK-=OPP"O[(VWA;4*T
MF,:<@4R1,S+S<*T5^V QH\^5SKHDW"V(7])8Z)HN]AMKUGVBH<JDLDW7'6-"
M*R(/O>4QZ[:M0]=W!.)(\VT]-OA;I </W&NN-FK);51+*@9?+_TD;Q<1TS7
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M4UB2EOUC#K#4C.AK9EDQH"4E(@IN+3)[#1^7^C/*.KK9DVV6QOLCIG4*+-?
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M:&<$SJA4(GL7QYUI*B; S"I9)*Y,."&&LR+LG1(T1D<$>3Z669(X2PRJ=',
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M74B'&)EIV.)CB$%3CV=(N@5:KL\!/0/J9Y/_ *1$G]S=X:COZP*_N(?9<$+
MJ.)=900@0TJBU(25BDG'0B4V*E80^3FIJ!46:F6+!N 9,'QIED@;:AD4 [B%
M]3.[U<10A"8_=XL['!<+ 0N!L3EMV:P4'"&,@B"S_!LVPA3N7/9:@,&2XFQL
M5I)FQ@FZE.D6D@PJ!%CW;0,\"=8NVQ>@[HK6V+I:2R96I4>L;;F&L^F[9@&L
M=U-;2<E28HL-C,>+1:+NZ],UE'MF\88--5GL=,[K L;.5RAP,;%=6.\"K%@S
MD/9!SC9D_)*.=H_9DO$,B.KN:U HN]8LAL!%/0#)_7<?M@6QA^Q@X*A9J7CM
MXH^;*HM3D=#&3_63R,R,_N:6O* B?D%XBX8)";)LW34DJRWL078"FB2\"V2A
M;F<PH[#X^FI%\_38\;%/)D#"CCK1!<J$KVEU<[+V$"JC"MI1IW.(!!C4?:S1
MZ[<,'H(](8Y%!!Z2$=&4)>ZS^8/]Q,A2"6#&$Z&<Q#8PW*,XD54T?CG@<TOU
MK[)9IF#P.O[!%5$8!V18<I?BX;8<PR$$0\ZZE+J%P8+)\PID7,!X\Y*"'B@Y
M['0PIOAID2W;/ [)!L\"O:="]]Y5,9M5LML,N[ARM:RL3BPW5@29K'-GR0JC
MR-/M0@Y*(HN7TB83*(6*G,IHF^6D1./RV7HRE'7=. (& GKK]!NWL-[$!P]O
MR@[.H*"KB:(EYVWDY1*'R,BY<UTVAVZD'<1X>#;2DD296/+G2X8INXAZ9]W7
M>HQ2#QVOI 9#91P-6_?6HK>NQ;,&;U9:4QK*0@34,=O:-7Z7%3:P:8#6[&0J
M3G';Z,,RT"U89U>("#%,R"5$UV[E,JZ#-RS%DBF&QJ"YD^8F#^V(<6 D6K!+
M0@&#2-[+V W*>VZ;9JG)2(2./#*R;+5M\Z^5"L<*OLN?:T50U3<+!EW <!P-
M T[\-O7;N1;#+MC)$PT N:(3+LS$X_:T( RIG;P<T+[/6L^B$Q:G\V6E6)E_
M#5D<C1HF?4Q-PQ>+%Y)%94V.B'P9&.A\TGC1[&]S>D?EP[0]<VL!J=M$H;(K
M*JT3 IF<D]$UI>4A&6,WTB\<Z\RB0GYE6%/3BU8LRQ-:>IDH_P U4R4%D(-&
MG4#U+O2*8?:+4?E$ZDVK8H6BW4CG-6]DGN$49-UTM>KI[&+0K@BX(# [1K8&
M[4"6@P,::-FA :'3%.9O('81$J,;0"4290@TPJ&P_&?7&,_W_?P' <!P' <!
MP&<>O _/PX_W_P!_K]_ U91GQ#=2F5_7->MAPT%=^MU+3]R<K:X8G'9]7PAY
M8TV;3H^]% 9.T+,LO%":"C9%RX;*+-6+MTT'[,FCAPV6# ;/\'G30XDZ(=<"
MU]] 9HJGOAM+NC-X3JA6:6^V_NZZNJV$$7U3/&N5<:>^GB#MW2R":;;5\DDF
MCJF%35^EOFHZPNW;^K?(!9/;R L]=MF<?.OJ6C%OZI8133T24#W_ %5:$-L)
M_G9+*ZN=^P-#LU%5U=6^S-#"*&@=@+\B?<&N30V)7-<_62I)<4<99C8-Y ^L
M%W=*'Q)]G3":# -V2@-N7_U9GCM5SKMC&M>DC&ZB:VGP-4MT\)K!?-WVT[TP
MZ+JR67^/D5:H9,,Z,)2GJ7VUJ.R03]B@,W(-RK1E? WK"27'.<IYQ[8U0NZP
MCNDHU^>SMMC4-9'C)\K$.C92?0[NE>@FMOMO()+.(L3M>NC5/P^,2&26C,MB
M49WMM>Q+4I0]@\L^U<C]V]B!7[-V*>#%V)%;9-SJ'TL@)''Y6''R&+G!$C %
MFR3T4< DF9<.39K:_&B['DAZSAD];*Z_>FNV652WQ]^NV<9]>!W'P:_W?Z_V
M_CP(SGM)TU:K+<;9]2UG8X]3.<[LIW!(O+FNVVVN=,[90/BR">=LZ;;:YV^'
MU^'.=?7TSG' IX_\3GCL5=[D8YU5KNK"NVVF^"]#+R?KR7263WV42<MRE&GZ
M^?MW:2F^VZ;M!=-SIMGUU5QP.,Y\=+,1\.:I[H>0*HMD5%%&R+'LZ8N8:CC?
M3&N$-AG:0#?+91LGMC7=%+&--T<X]M)5-'91/<(,M3QHW=8XU4?+^R=!]EV^
MB3?5JR[O^/OKY='KNBIA57=<M5#CKX\QNXVUT]54VWNH*ZX71SC;7&N0JTW\
M8?:>L5LN*IJ[JW&O;5S\2W4WN?W\Z :.FR2BCAOJC6L=SV#J;XL+;[:Y'%AI
M =KIOG"2B2.F&VX:Z>]I#S"5JM6=.USV!MBCRV[>8]BTW/:3LYTTM:%2]#JR
MF L"-UM"IM#*KIB_#3JP+2<UW!B;&>I: C0DZHV,[$&2Q[1H%WZC\LOD5S6-
M?6;8/5D-/XY,H9$9H@\8=9>[M8ID14ICC$ZV<@)?1->^0.M#S)3YU/9@:TD8
M5@_8;IO5&P[5337(9YI^D>=<X*_^E=C.N]_TNLDMJB[-8S7Y@&AC?9+75;2/
M3*5U==BR6WQJ[)Z?J93=K8;+)H-E7&44%0M;5_GP\0]KND1P;O#4\4*+.MF&
MK"V=)/3>WSVF^NBK-,A9X"*!72R.VZ>%<,2;I-/"B>^RGMJ:;[!LXKNXZCMX
M4F=J>T:[LX(JGHJF8KV:QJ:#-TE,>J:FK^-DR37.BF/]#;"OIM^S@2/C.,_A
MP// <!P(!K.66N?L^XH]+UZ^VB$ D#(%']8V%D;*2/,FX[&I@+<F'I.1$AFW
MR0@_N+?HLAK?YPDVU(MU&;93([0)^X#@:<O(]9%C06VJU<19Q-I9" 5-VK-K
M)KN!77V!I%[% ,?D<%V7O.3G>OU:S4T<BL3%[& 3F-DGJQ-ZH64?Q&)&EQAM
MRS#;^+73<C1SE%5-=%PQ:+I+).=WB2R:K=-315)VKKHHZ34UVQOHY4TUW7US
MA7?77;;.,!SN X#@0/UQ_LZ-?QN[.?XD[9X&7V33M4W#"996]I5W#9]!)T,<
M!Y?%)5'1AD+(1SI35=5 FR>-U$W&<.=$WB"^?1PU?(H/FRJ3M!%;0/B%\DWC
MX[[5MY5^J:-05[W([2=!X,PK689DM?JM#]X4L%"2\XZDT-@_9!=C'K);3& B
MX['RE9;RJSWDD/BQL)@LHDIP.BS9[!L<MWR6=H.N]21^6TUV<KKMA10>S8]
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MAL*Z>#GB?KZZ[Y0<;Y24UV25QHIKMK@,XX#@. X#@.!!/7S^JLW_ ([=@O\
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M;YQC'Q;;9]<Y#E\!P' <!P&<8SC.,_?C/W9Q_JSP*(W[XV.GW8>39LF15?\
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M>!/' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P'
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M&_*AW.<KLE.!G_T'L;^]6D_R G7\RW ?0>QO[U:3_("=?S+<!]![&_O5I/\
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M!'A:*]L5+1A1%I:=3YB#2#62S/;(4S,FX?61/SM7+17! !OV5^:*$<CQTO\
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M3"1;#];=<6)H*W<-\#-&VGRT7SB)MP2:86UX#@. X#@. X#@. X#@. X#@.
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MVHA$R.NX)8</#Q/6[G,4%P=NY,2Z'" :\MT,S^$Z2>OG!<9,8J)(F7YD8V(
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IHWTWT=,&CY#"2;HAL^0"V' <!P' <!P' <!P' <!P' <!P' <!P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g713200g93q99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g93q99.jpg
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M 0$! 0$!_\  $0@!+0&F P$1  (1 0,1 ?_$ !\  0 " @,! 0$!
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MQ^](U4.(^$-$PN[=MV;8T17GV7\8]1\$#/,QI[P^,"/E,..BX]E2>*B3G'N
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MB4=D37]_W_"F[!!]"#@>XDX[GU[Y./2I;]AO#Y[$T;5G;D[7M9U9?[]=-J[
MVUU0N.JM?J3V8C]U[/[G1/;G7Q.T]AVF3@8&K:GU'=8R)KD\U&R,^-,54+-G
M+3%JC\54]5 PR"?<#Z8"[>W.3Y_'ZUTEN\$S8L&N=C-+2_6]-7%CM90].C=B
M5^T8?. B?#TMG0^Y.W1<' 2"2).!(F1-TT.08<D'9BRGV6+G<0!)B;&^]:;^
M<G/<DX][!OY>GOK9+OA&[B!LVTA:[LG3<7K^YP/7=AO*:_;"+3;+AIW<'4R^
MRMYGEV#%J-UU,3%6ZZSU?LD1K>XXH.U)R<HMKL=$JE@HSLO-J;AZ')W?0@CY
MX)SV]U3;Z*=.MB]5;[V=EK'-:LS0-M7&/GM<4W7,18,NUI*+AM:V622D;#=L
M25UCXVSD["CB@-4$7:^4S7EB#N4Q09>'B+Z15H55"<X_G\O[SZ8JQ[BHTXI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*571XC&V[W&42@=5=#S3L)V5[L6@[3.N9
M\+U+.U9KT>,S*[][ +0A3:FQ]0:S6<5"/X>:6YL:?H$:UAUR1PWE4EQW/8<_
M'T'S/Y5MV\1<%TAZ+7\+0U>AH>%ZL]7KR=JVO2H[YL.A6I=93$K6V;"V$3&&
MRR3S80=^QDMFA24R^3(%N'-'%K*PJG<\^9Y^9JHJL^-9>-&P%AK7;/7D1MW:
M(1NL)NK%=9ZN508ZQT38?5>L]G)09^H;)V5=B_KY4QY<JE0T5$6TQ&Q)@J 4
M(#5FWI)T54]@/X<^?!Y\\=^.#\/=S4HK5XQNNJQ:]BUG] FVCVZF3>X*G2^)
M6A@C['N5&V[UATT37 @#+"B6JC1MF[::M?3+VL&/9%"8M"EC.KB6,2"J;#CN
M/ASZ,?3T4]LUIZ"\6O84IHVZR-FU/.0&QZ=1=L[5N%XJ0=%DZCKNGUSO!V#Z
MKT&O&4^P[)Q*6JZGL:6%'G7J]*R%:7)24C/LR$9'- QKRJ;>?=P/3.0/<<=Z
MR*-\6R=B#;/9=J:BMU6BZ:=XA,%'ZZKK%!F2MD+ZJ=LM$]:J')BVY6Q245>:
MDY[:[=8FXZ1&8@B)UFV6!HT>IPU1D+6JNWT.?P_4J2?+W5+3LGVXW'K?I+*[
MW@M0O:@W8;M#5>EXZ@;L8#M<93;/M#LW2>N35PE4:\MH@=ZJ(C-N_2)5_H"W
MPV;= _0[1)E?(/,9 50#)QW')],@ GY=O^M:)*\36:Z]7[3/6OLK 5G<N]+Q
M<9J LU\ZKX1G7D;4R.P;6B:+:SZ)9K5/VV$N+9$B',;CUK&S]N7K > N9R+%
M,L@QT82IMSDC@#U]PR>0/=CWDCCOC+^A/=_;W9S8H53V%$T,",(ZJUS=BW*K
M#34<9BW2W:?L]I4D1+LE9)EK$$FI:;JI3(>6,FIG2ILQ<BX&6''1ZA'&?>/S
M&:M?XJ-.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5_*T(<0IMQ*5MK3E"T+
MQA2%H5CR4E2<^>%)5C.<9QG&<9QGRSQ0''(X(Y!'E7]<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KX%
M%"@BDFFDL!A!L/%%EE/-CBBBCMJ>())(>4AIAAAI"W7GG5I;:;2I:U)2G.<*
M55;T.%*[2;@W!XEEH&?S7-EAD:(Z61I[3C2H#J31;$^\=LH<5Y++@DGV<V4$
M;L9UT@5);FN('5 V"'!V5)RJ3< +Z<M_O>GR''U]:LNO=(J^S*/<M;W>+Q.4
MO8-4L5(M\+DR0CL2]7M<09 S\7F0B2@)0'$A$GEB9,C3@Y ;W?>#*'(0V\A4
M:@V#X5'1&*HPVO8K3<Y&0HUE,M2Y@#=N_1=B2)TE0F-62<5.;:;VCC:=@ITG
MK04:@R%!F[C(4<NHCL03U>5'L,LH5+<V<Y_(?PQCX>GE6;6SPZ>F]V=LQ%AT
M][I5N>V&5,&1M_VA F(/VE:].WFYR<*3 W6-=K4J5;] :?L,+)UQ44=4)*D
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MEUKL):ZZ>9<86#*)A+%2)7944\;"SQ49.0ICM!@+!;BHB;C8Z8C8&NV*0DP
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M(,..$&!CQ1@01&6QQ PV&AA1AVDX0TR.PRE#3++:,82VVVA*$)QC"<8QCFZ
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M0K"IRYW2R,=TLK\Y>1SRS')] ,X4 <5=7VI7>HNAN' CA7P[:VB7P[:UB_\
M;MX1[*#S9CNDD;VY7=R6K YNK#V7>U0F)!E!0FO:3-2\:TZCW&Q++:)%F%!D
MT8SC*4$LP8%E"85_*]!Q"D_K-X5C'FV,NNK<.,K:Z<JQ9Y DN)Y0S#T8)&5R
M.X(Y[U>P7DMKT_>6T;%!J>H01S,IVF6"QB,QA.#ED\:XMY'!]G<D9(SC'][P
MUP-M*%H]:-&60$#MG7-R+4EKW&V&*'/M7+/Q"OWLL'+A$1*UXSCUYD4CYSY/
M9YD+J$7"Q(1D"XAE/&>(7$O/IG9MS_BKST74&TR:]N$;:\FE:A9J,X+&_@-G
M[(_::,3&8#G'A[OV:R+8VMH[8;=/?>/*A9RA7B O=6G@&F'3(Z2B5O!R87H?
M3E"XVT5B1G:E.,I4VX[#3IOP[K)26'FIS0K-X9)*M%*DJ,.X9<@CX.C,C#]U
MCYXJUL+^2Q-T%198;VRGL;F"0L$DCE"O&_LD8DMKF."ZA;D":!-P92RG9'/:
MK&G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KHF*S!#3A=E;C1U3YS#8C
M\L]ZR3DAM^G*017R%NJ!!]:<.K""^'%<?\R'&EOJ4YGR$,0E:8(OBLH4R'E]
MH[*"<E5SSM7"D\D9JY:\N7MX[0S/]UC8NL"X2+Q&[R.B!1)+CV?%DW2!0%#!
M0!71[.#/D-<WH"+PZJ3-J<^+'I93E;JC7XPEH5+:<8SE2U/J1C&,8\_//R^?
M+74[=KK3[NW3\<L+JO?DD=N/49'S\N]>VE2)%J>GR2,JQQWEL\C-^%469"Y;
MW!02:R6#B :_"Q$#%LI&C(6, B8\=&/)# ,<*T(*RG'\R6F&4(3C'RQA.,8Y
M>1HL<:1H,)&BHH]%4!5'R  JTFE>>:6>5BTDTCRR,>2SR,7=B?4L236+:\I(
MM&BIP-AH=!%AO-\NTBX/E2L/F7&V2T^E3RUH;4X\.$:& O.4YPG B6VU*:0C
M/(0Q")7& "\LLK8\S)(S>>.=I /O''%75_>->RPR$MM@LK"RC#8&U+.TAM^
M"0%9T>0<Y]LD^T37=5VI5VIYGLUV+9BDV:Q2-LFFAEO>P789= R9632.MQ;
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M(Y*6"!W\L.X0[AE]ES*?0ZA2E*Y/%*<4IQ2G%*<4IQ2J\]I?]9-U2_W"[_\
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MU^U;18\FO3-Q_1KJ.)H]!D$.U 6L5JI0$O6Y!BHM1,E+N'S\[)14E6U"V1C
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M7N3(<IM89:,Y+2, H!(8+;[TR[IPG4S8VRV;/7F=M:OO$&'$V'6WQ\:X Y;
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M>U5F;ZZG](=P[AL!]WW ?1-\6+;W7VRN?4'L,C6NS8C;-!U-NJLZ2CZZ'%3
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MYYU:O4\02^XX040XZ00ZX\ZM:N'7%Q-=SRW-Q(TL\[M))(V,LS')[8  [*H
M"J H  %:C)(\KO)(Q9W8LS'N2?X>X#@#M65<\:A3BE8];8%NU52S5AY:4-6.
MO34"ZM>%Y0AN8C28]:U8;6VYE*4D9RK#;B%YQC/H6E7EG"E4D:(\$^B:2W+K
M+;H%DKY)NN+I V\4<<.W(?>>A#FC6VVEF6<H5+BE-XPG) [S6,_RVU8^7%1V
M_P!X'\@*O8XJ5>?OM+UU[.QG=Z>[,43KO>]R4B#[<=$]L P^OK+J,"UVFF:D
MZK=QM:;$-@0]D[*U_$-D5JX;5H\:\)/S<&]((F,EPZ9$8(YT>GF?@/YU,$$
M9QP?(^H([ ^E3![CZ)[!]A^JFSJ]8H77^R[--[2T+LK1.N M91M$O&GXJO;@
MHMCG(NXV^R;KV;3[;L>J4Q-B"DKS2'-?1IC+,['P<.:Q-,,N#_,?QY_*J9 ^
MA!Y[\? ?GFM6SFJ-B7?Q.:S/3?3B[4?K_JR__IAKF^*)^@)^.WEV+EM"R6I5
M[9W=-E[=B=R05+UKK:1)U51J-6M:64^U6=\.S6R0C:Q78F,S6F?9_%SZ<\#.
M<#C'<9//YU<KQ4:<4IQ2G%*_SM]A5NQ4Z^W6IV]LAJUUJV6&!LB"L*P3B=B9
M8L&5R]Z\85EQ1K#ZU*S_ "_5ZL9SC.,\_1O3;FVO-/L;NS*FTN;.VGMBA!7P
M)84>+&.,!&4>[M7R?=Q3075S!< B>*>:.;=G=XJ2,KYSSDL"<^?>L/Y>U;UZ
M4-)ZAJ6_:;TPOL@J<QKZF]6S-6RFUZ'N^/UA+ZLVC$REB&=J4I'!E-6B:D+H
MZ>!708@10*2!)!XW*S1',#D?,NNZS>=/WO6MA&(/TC>]5)JL6D:AH<FJ0ZMI
M4L5LRWD,CH;6&.R$<ER\S;RKQJF$<%E[!IMA!JEOT]<N9?NEOHK63WMKJ2V3
MV5ZDDP,#HK":1[@LD2QKM!5RQ+ A6YW5:QZWF]*=7=5;4E!AJC%=?F>RHJWG
MAW4"V;K1V7LEM?CDCO.H0ERQ5&9G@9!O/I4_$L/9SAS++*%>?5=KJ<&N=5:M
MI43M>3=1-TPX4,I>UZGZ9MK1)"P&2MO>0V\D1Y F9>P9C4M#FM)--T6RO758
M(]+_ $P"Q4A9M'UB:<K@GO+!)*KCS0$_LBH0=P[UI+8]^ZV7_LM^EJ19N?2K
M7%H__9F2I;,RU<;%LK:$U)(F7;H%(!YCTLG%>30[;1N"%#J5G#.5)SO71EAK
MNFZ?U-IW3/Z(B:RZWU*U_P"^HKYH#96^FZ7!$8!921/XA,:>TQ,94-CVL5KG
M4-SIMW=:/=:O]^<7'3MG/_W>]L)!<2W5W(_B&X5EV^TW"@-NQY5MN T9:>S.
MB^@UHU3M%K5=#TK2MX06V]V#6:&"F-%$L663EP7;!%M6^HSZ"IV-9;&85%F,
M)=!DTGNN-QKS>2,/<:]:]+Z]]H-KJ^E-JU_K=]H5QI&AM:SO!KRM;10R+;RM
M9WEN4@D8L?%1L/$8U!D4[;Z+3)]9TWI>>QO196NG6VHQ7VHK,BR:8PE>13*@
MG@EW2)A1L8>R^XD(1GM^IFLY;=77Z@4;>#>J]P=4DXW&0-NN/MH].W!TVDVU
MRDH6]99&:?C2\QMVE$MRV:N\-88PYF2$,D9,V&'!C'?'J[4X=$ZBU"_T(ZMH
M_5A_0RMHDEFU[HW6<1$42+;1PK(GB6,68A= V\L;1.D<:2L\H]="LY-0TNUM
MM2^XZAH8%^RZBEP+>_T!_P!8[&9I"C;+A_;,1\9&#!G=D54,?=Z;!J-6\-WI
M%2G]?4C8,G:X[M6! WF<5,M6776(W> [GTK5Q )081@BQ#ECJ+:G0STX: %P
M.EO.'E.;%H&G7EW]I77-\NHWVG16DO2<EQ86XA-KJ1DT)AX5TTD3.5MF1@A@
M>,YD;<3P!B=4NK>#I'IRW-I;7;SQZTD5S*9!-:;-17VX55PH:4,-PD5OP#&.
M:J0YV"M#K^D(4XI*$)4M:U80A",94I:E9QA*4IQC.5*5G.,8QC&<YSG&,8\^
M"0 23@#DD\  =R30#/ Y)X 'G7^@EUTKL_4.ONBJG:D.MVBL:=UE7K&V_C.'
MFYZ%I4)'2[;WG\_=;D!B$.9S^ME>,YS\\YY^>'4=Q;W?4&NW=H5-K<ZQJ=Q;
M%?PF":]GDA*_X3&RD>ZOJC28I8-+TV&?/C0V%G%-GOXL=O&K@YYR&!!SSFMR
M<PU9"G%*<4IQ2G%*XQAH<>PHH\L8$5"V6UDF/M#,)<(>;'80IYY:&TK?(=:8
M93E6%.O.-M(PI:TIRI6'6JBZVV>"Y&W6HTN_QX9+HSH5DA(6S"AF,^G+S"F)
M$8UL8IK*DY<;RE#S?JQZL)\\>?M!<3VS^);SRP28QOAD>-L>FY"#CYUZ1S2Q
M',4DD9/?8[+GXX(S6BS^C'3^1=R\_P!==6M.9<P[E4?6A8G'KQGS_DQ>0T81
MG_M-83[:L?)2,XYDTZAUR/\ #JEYQVW3,_EC]O=Y5<KJ5^O:[F^)?<1GTW9Q
M\JW]2=?4;6T,W7=?U&NTV#:5EQ,96X@*($4[G&,*?>;#9:]\A>,8]9#^7'E^
M7Z[BL\QUS=W-Y(9KNXFN93QXDTC2-CT!8G"CR P!Y"K:6:6=B\TCRN?VG8L?
M@,G@>X<5E#Y0HRAT$DCCK,(P*(A]YMI1166G7\##I<4G+Y&6&'WL,M84YEIE
MUST^AM><6]>==>S8J^1(EP[$[#OR\>:S&GQ;,F$Y(A2),4B=' +!0^HD8U^$
M<;F&17FD/NQ2T2"&U"*P]E2NXXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI7YG&,_OQC/_?CSXI7[Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*HV\3GPO3]^2<AV Z_"AM[94&U]>:&Z\/'B[&;CQD#BS,(80ID,&Z,!LLA%
M#'.CQUB%8&=^*!EQG53G=OLN^U2/I^*/I[J%Y#I <_<+\*TCZ:9&+/!.B@O)
M9,[,Z,@:2V=F&QX6'@<VZRZ+;5';5-*"B^VC[S;$A%NPHPLD;'"K<!0%8,0D
MJ@'<LBGQ?+99:Q9*9.R=7M\#,5>R0I2PI> GXTN(F(PMOR]8QT<>RP6*]C&<
M*]#S2,Y2I*\8RE6,Y^JK6ZMKZWBN[.XANK6=!)#<6\J30RH>S1R1ED8>\$\\
M=ZXK-#-;RO#<120S1L5DBE1HY$8=PR, P/Q%='Y_S?S?O\O^[S\O_P >>?\
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M47HWJ9C@:1<#_>>!!]7E4?G6Z*AX-'>JS.-(EZ32J"TYE/F3;]BULEMI*O\
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MQLAH5[*?9=?&):96K KJ6['3K*ZU*[@A@CWRS,) 6[,H8$L22/97S)/ [9)
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M_N:O&C!1'''XCF1LX/ZV1O9#ODC;&B# "YN'M1>6]FWCRO+M=KJ*1 BQ$O\
MJTC?.7#( Y) 92  ?)?3GJO74-JB@UJ@P./^;J['-!MK\O3[KB<>;KF$YSG*
M495^JTE2E*0RAM*UK7A2U>-O"+>)8@<D9+-C&YF)9C]3@>X"LJB!$5%[* !\
MJV%SWJ5.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI53':?&>D
MO:ZC]]XG'P&B-V?4CK=WN%:_9QM>;>D\PO6_M'(H3[3+.=;VB:SJ38\T2ZYE
MO6MYAI%UG(U%;6TJ0]H%?,<K[_4?S'P/K5L^,XSC&<9\\9^>,X^>,XS^[.,\
M5&M-;_T#JKL[JBU:7W-6&+31;:,RDH;WG@):'E07T&P=IJTX&IJ3K-OK$JR-
M,UFRQ! TI"RP@QH;Z'&_)2J@D'(J#/77?NU>N&UZYT;[L6=^T6&P_%B]0^V<
MJRR!$]HZS$,*?_1SL5]E+497NU-+B6TYGHO'PX.W(<95VJK693$]%,*J1D;A
MV\QZ?SP?+S'8^1-I?%1IQ2G%*UWLW5U2VU6W:O;PU$@K7[K3K*DH(&=\L8];
M2U)6GTJ\D^M"DYPK*4+QZ7&VUH\9X$G"A\@HVY67 93C'&01@^8QS4)(UE4H
MXRIJOX[PJ="&VE4\XAUT/#S3S0!:2B,)RA"/=]:4G,M.*<=PM>,J3EO&%83E
MG.,9PK'OITCN3]X]D^L8+_4%1V]W?DYJP_1EOOWD9P>!D]L''GY$G^^*L(U[
MK6H:P@F("H10\<(TVVVMQ#32'R,-8\F\.*:0VA+:,9S[;#*&AVLJ4IMI*EKR
MJ_@MHK=2L8.2<L[<NQ]2<#Y 8 \A5_'&L:A5 &!C@?E6>\]ZG3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE0)WIX?6G]UR4K.%K/B)26);)(P,\
MXD1+F5)P3EMME;?I]UM/H1A:7<->><(\DX1A&/EL2P<0RF/<Q;8RAD!8Y;&,
M,,DDXS5C/803DL1M8]R//W8^O.>/+W=_UWZ)Z8Z\NK/@HIF3EEJ2O!AC.7/)
M:/+*%NY(=(=?4VK'J;0I:!4+PAW OOMH=3&#3D1@\S^,RG*+MVQJ<?B*DG<W
MF"3@>0J4%E#!^%1GU/.><Y)/\*FOS)5>4XI6.VJIUZ[0I5>M$6-+Q!GE[PA*
M<Y3E2?/TN(4G*5MN)QE6,+0K&<I4I&?-"E)SYR1)*NR1=PR".2"".Q!!!!'N
M-490PPP!!\CR*BRUT/ZW,V?-I:HP*#,/-/M,X'"4TRMI+>,>TM8JWV_4IOUY
M<;=0_P"M:E)>PKY\LCIL+.6,DQ4X]C>,8'<;L;L'SYSCL?.K465N&WB-<Y]!
MP,=AQY')'Q-2VB8B,@H\:*APAX^/$1Z&!1F\-M(Q^_.?+'S6XO/FIQQ>5..+
MSE:U*5G.>7T<:1($C4(B]E48'^I/F3R?.KH * !P!Q]*[+DZK3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6%;(UW3-NZ^NVK-BP -IH6Q
M:K.TJY5R21E8,W6K+&DQ$S&D83E+B$% EO-8>96V^PM27F'&WFT+2H..1W%0
M!\._8ESIB-E]!MXSYT]NSINY!P]3N,XO&)7>?52R8,1U]W1[BL(^DYMB$BC-
M7;2?%R7\'LFBRQ<@5[EA"PXJ1QW'8^7H?,?S^!Q5F?%1K2/8CKQJKM+JBQ:;
MW% +G*E/_"&#%@&/1%GJ-FB'TG5F]46RA91)U*]5&6;8F*Q9HEUD^+D1T+2I
MT=P@9]502#D<&H6];>Q&U=';6A>C'=R?1-;*D1CU]6NS[X;$/6.WU'@F?>?A
MIQ+.$1E8[/4B*PTK8E&;6TQ<P6\[!I31$65)A1:JD C(\L9'O]WN]//U]:M
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M#GH=;0XE2$JC67\4K0_9+K=JOM9JF:U#MR(+-@I J/FX*>@SWH*[:]N\"_\
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MH7X.O$X_P]>R7Y.XR/?]#_2FW_$OUI]Z10OP=>)Q_AZ]DOR=QD>_Z'^E-O\
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M1DLWJ<QC"<82G&$I3C&$IQC&,8QC'EC&,8^6,8Q\L8Q\L8Y\H5]9 8X' '
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'E.*4XI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g713200g93x36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g93x36.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ ]@)+ P$1  (1 0,1 ?_$ !\   (" P$! 0$!           )!P@&
M"@L%! ," ?_$ &00  $$ @(   @&"P@-"04'!04#! 8' 0( " D1$A,4%3=V
M"A88=9:U%R$U-CE8=+.TMM895G-W>)*WTR(C,3,X5W*5L;+4U=@:)3(T07&3
ME]<D456XPE)389&4IM%#1%1CTO_$ !P! 0 " @,!               %!@0'
M 0(#"/_$ %D1  $# @,!" P'#08% P4!  $  @,$$042(3$3-$%1<[&RLP8B
M,C-A<7)TD:'1\ <4%8&#P=(6(S4V1%-45763M,+3@H22P^'Q0E)BHJ,D0Y1C
M9+74XZ3_V@ , P$  A$#$0 _ -_CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$
M<(CA$<(CA$<(CA$<(CA$<(CA%XDFD ^)QN02DMY[ N-!"T@)9;IX6<>KPS!P
M1>>82SMIA5;T=LIYI/.^F-]_)USMKX_'@B4/"?"DVR_ZFV9VWLWI:8@$&0Z^
M5EV$ZY;![G&S<+?#*Z'KH+6E6FI)I7<>VJZVB)YW"6AZ/) Y^-#,9R+?LS)I
M9LH/7+L6@'+FX2#H1:VT\_H6.O?"\R^1P_KF9I'J._M:96MU>/\ :NUJZ=78
M$A!BKHI";%B-0SJOH20*04@SMNU UER$S'AD=?IUB.,:1===8R)=DD1S8A;:
M]SL-@1K?AOXK6]*RFLO"SHSWO&\Z?$*3!!ACGL%;G7.,S0/>8J364XD]24PR
MN]_,YC02D! '(A5QJ/.E(^PFS*8RIJTF3?(4BV;I*8?:ESE[6]^ &UM+$V%C
MQ^"W'KHG&<+HCA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$
M<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(EU#
M;F.1Y+OHQK"0&;8G4-[*QN,Q2-H%9!<#VK]; HWKIJ^)N(8+(&).SKN 3<]/
MYD4@L=08X5R"ED=CS5H945T2+DBUO"+^/4KPJGLR2RGI,? AKB-,+D:#.RB4
M<E=YEEJ[L4W$J>N O&STR(/Y8#'/A36/QTS$(\>LEO%G4>KN1R$&L39HN$$!
M*I.&_B.FHUX+?4I6Z2S>13<7>ZRV)#M6H"[U(]3:TKLW6Y#GQ4;535KV5LE[
M-2.S)M*T1=L$+!'J*(6%86D>+(F(7\94,1C6-1\AX/%[^_\ NKN<+A'"(X1'
M"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"+QI$!'2F/
MG8P7345$R,,3 E$DE-D55!Q=DN/>IIK:?V22F[9PKKHIK_9:;9QMC[>,<(DN
M!/ VE'M1QN@K;[K7?9]*PQ#J_!(G7(\?FK 0JC>JTQ*SJ(0O&M>2T2LE:,G.
M[Q-.6=@0VX2<JBH+'&(EF+49,W;(N^?6X ![8DG75WOLV:[%&5D^ &KN70%S
M6$3[%RV+0AX"["UGN)E]<1JZW3"D+XN\-V(0A84[:)HV>83^NK5&.C<8NIR3
M(S1=,JY5>)8/)I'^%R)+&]M=.&VP6V#34:6\"MC3_@L8;2O9AIVHB5H$$K)5
MNVZK$E:^(4*;8FU8W94M7UZ4I"1/FY?!!V#BLLJ.)VG$#ZBZNXB1X*LD@?HA
M@DLZ+J77%N  #;PCA]9]*:QPNJ.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1P
MB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$48
MW4Q!$ZBLD?)HXK+P3V%2)J1C",1(SU8XDL,<)Z#D8:($G2<C5<+;):IC&0@@
MNOOXO(;;^+[1$L>V0%]S.C^E^D8J2R)'"JVQT^FQR,M/2X-.W=J1*YJB8/V=
M@0:;)QB4CXI7<2$R\X]1*"W8IP:,BYR:VCX^L6Q(N7;2Y_M<Q_T4L^$ 9V_;
MU(S2)U;6T^ED6$Q*WW4S$@='\0FQRRH;&6RM31Z.C)"@"*32%YEY!2;[FZ]7
M+:2:00&*Q@7L> 'I,RW+@>.U]AOL]'HMX=;)D(YPZ=CV#I\P4%/7+-JX>"UE
MVSI8:Z60T4<,%7+-19FX49J[;MU%VBRK9;9/*B"FZ6VNV2X7V<(OG2:-4%%E
MD&S=%5QMY;A5)%--1?;Q[;>4MOIKC97;Q[;9\>^=L^/;;/C\><\+BXXQZ0OZ
MRW;[8\6R".V,Z+)9QE+3./-N-M=G"?BSK_T%]M==EM/^BKMKKG?&V<8X2XXQ
MZ0O]000:H)-FJ*39LW3T10;H)Z(H(I)ZXU32223QJFFGIKC&NFFFN-==<8QK
MC&,<+F]]B_7A$<(CA$<(CA$C*^/"97]6?A%2?4R$0VJ)Q$PDLZ>@$Z[0A]LD
M+ZFT>['DS["R9_')A'3)&N(T H42&UFDCQ-8F.&$(]LX;[R4:X2PZR7<-!;<
MZ=UK<6N!<"VW78LHA?AU.I-D,I.K7L$O*<EQ,ZIZ#16*Q%I2Q^2V,K>UF2BH
MJZ+@6;"[%6D/T(3>)O6Q*)W"_K*R H8I&Y&1A" 0ZT><)D<-NFV][BUM3>X\
M.EKWX%Z,E\+M6]-,;*<V3"[HL9]%+@[5#" .N*O@$<*U93_5(;5Q2VY?,,2/
ML _83 )7*%I1M-U(8R^93.;N""R<>IUIJ)<*."9"=EM@X]2=@&FE_#\Y4DPS
MPCR=M=X*\ZT5C7AI.KGKGMS$II;$R8!FS:46'UJ84&Z785'J%G[\[H#$.[=(
M"YB]L& @?6CQ$1M#'#QHU,.>%QE[4F^HRZ>.^WT)I?"ZHX1'"(X14-\)7VCG
M73?J'-;[K=C#W\N SBD(DQUGD>ETMB[-I:5VU]6!DL_C$"+@Y@?5"AI>_+#Q
M$?(ID7Y%FU;((/-E/1%R[- )L;VL3IMT!/#XE0VG_# )NZLK.YK^W"Q^-YK/
MPB,^G#&J*X+EV,ZC_2>R:[A;66@<3BS0-A4F=D+"5Z.&-*6' 93*7[\\FA*Y
M16N(VGI*"Y+=;#75@VC:X7MX? ;V]*E$QX6^,M); WA"M9?5D C6G=YOVJBU
MK PKJX:K,=0**@-[.1\>Q6MBS*OS.2\1G8TQE4<>E*!-B08,&RX<NB012+C+
ML&VY '$;W'#KP<-N-?T?\-?U_BD))2:341VA#2>+&)XG8E5+QNG5Y]7,*K6G
M*YOZ76E(UV=V.(&0AC"I[9@4E;LHA-Y-.B"QI0*RABQ<:29M2YR'C;X#KKJ1
M8:<8(62N?">B8?++,BIBIKXM6P]+Y!5%7O7JKZSK%"UA+O3IM".V<Z".#[WL
M82K^RW$,B)&0DBAX.<B#D@<W0KZ"1*>9'CII*U_?CTO[W7&7PZ6O?6QU(XKB
M]M ?'IP6&I_OO6UV=DYMUDBU;70(EE?0N)S"52*9QF,140$4F,%@UB"HZ=AQ
M&::W/&">P"P!#34O*JL!PI[*A,OAHN5/Y-%"PQ(N"+"]QKP7UVV\7H/AV$*\
MW"X1PB.$23$^]G=LWMW1N6*5CUY(=8>LLI[QU6W;O7,U:6Y'IKU)@18I%YQ+
MGBLM0CLYAMH3T(XCKN%Q"-QF01(,08%59:1]'>YP7:PT!O<V\1N?5_OX%YSC
MPZ/7Z 4R)F]U5C;<1L5I(@D(EE>8WI&/*+F%>M$'[2&9G%3DROD9!U82[K:=
M!7<1C96?)6^?.DQD%9U\[F;CU7E?2_OXESD/&-E[Z_\ -EXN/YK:K++%\-YU
ML@!&:HM:;[+3L!"0,IDCB:0^.5$G'#@J%==ZN[52I<&E+[HB<D\86CK5$RQ=
M,U'@JCMV',QL5H1D2H$8;>_O[_4N,ATV:^TMYQ;_ $67/O"A1:'2NUHIK7MX
M=B9:R['SFJJZK"BZAB+"=:Q:M^L-.]BIP_;8EEZ)L[*;1^.6)H1;DF6L(G<H
M,G6%>Q6G3#\*G(Y*3+LX+B]SLVD#8-+_ .M^+W+U\*)!:LGDXI-G5]IA;3UZ
M_7!<%22&QXY&P%?3DU5E%.[Q? 5HHM8(R]&HQ@(2R++R0A6<?AR\E#R>$C)I
MF5!7+-(@;<7N-MO%K:_%Z[[.!?)V&[C=BXSUN\'Q.*2#TJWN'NK;77ZL26;4
M"3HS6L3S;U#V%:I<@Q%1*8QZ4>(>:AS,<-](.D<HBW3G#I%\[\TX3)87-[V%
M]AL=MAP'F4*53X;&!%J-&V):="W!I*(GUD1['WBYJ1A"9%6L,$)6S<]';,@Q
M>9V)#I.^>R&P:,E&(\*6 *80%F0&2!M39,PY8%R6'CX2!MX #XAH>/CVJ8+-
M\,)0%;'I/&TZF["SHM!K!N*"SAO#0-6::Q=I2UJU32!^=/'$PMV)-GL0/6C=
M=>1F,Z!UB$KW2)OSL@B\> AWY%,N,IM>XM\_%>VSBU_U5D^M?=Z!=G[1OJJX
M=7=J1@EUYF!>!3*03-K7^D?>RV.'G\:D 1@C$K"ELH!O61,:NY&)3^-0O,QC
M*S&:0;XS1)\@9R7!%K>'Q_[>B_AU5T>%PCA$<(L#L]&SUX')$:8(0,79^[-+
M$0(6>'D)^!MB'IC;*V\D#Q4Y&Y"^9Y88=Z))"S@Y?5YLV4V6V1T524(+<.SP
M))M+>& F,0ZAT3V-[A5VVF<C[#U];=_ 8KU"@ZC1K5O7:B6,3^RS/++^S5=2
M.Y7:%O)0.=N$823)R VP+L6<=A)-X.)N.%Z%EW$-TL;:F]S>P&@X>"_SE2F^
M\,9$8/678FW[,ZY7<C *([+6Y22DCAFE;*!R$-JL$A(W-BD35C637(-B_)C-
M\Z":_9$B$YEI<@# 0"/RTR\>LQI=<MR "+D#CX>#A].SCLKG=5^S1KL)8W;^
M.N1X!M$J(NR"U_7)02T+-"DAB$QZV4A=FA:4:DR#M/8SZWM HR1]7L@[=(0T
M&H+L-WZ3MZZ+@BP;X1<_XG#ZE<WA<(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(
MX1'"(X1'"(X1'"(X1'"(X1'"(X15%[%/0HNY^DI1[@KH0;7Y-&F70]G(7C1I
M'SO6V\(XOL<P(0<#&HQY.#-=C$GAW5-ND9?"=6RZ2FZFW"Y'#XOK"@4(8 Q3
MN%);' )GMH&,J[L"O;;1A5EX#)S'C@:2UT<T.V@4DCF2)W ,??%R3->N(2'1
MR/$ ,/+DQU4AIO!B3QZ )P<%].+W\?KL=LS,ZKC\B[EN+ $P5M&F%00ARZ-3
M)H%W$.;,MVV6V6";1<PFBU7/,*MK04X5)-E5"0$B6N &KC.D@@><,2<&WYK_
M %>_,KG<+A>67.!8^TP_/%Q@5CE71##PL_:CFN5U,;;)HX</%44?.[ZZ;YT3
M\OR]L:;9UQG&N?%WCCDE=EBC?(ZU\L;7/=8;39H)L+C7PKH^1D;<TCV1MO;,
M]P:VYV"[B!<K&/LI5G_C$@WTL _[?SV^)UGZ)4_N)?LKR^-TOZ33_OH_M(^R
ME6?^,2#?2P#_ +?Q\3K/T2I_<2_93XW2_I-/^^C^TLT:NFKYJW>LG"#QF\01
M=-';59-PV=-G">JJ#ANNEMNDL@LEOJHDJGMLFHGMKOIMG7.,\QW-+26N!:YI
M+7-<""T@V((.H(.A!U!7N"' .:0YK@"UP((((N""-""-01H0OQ)?<Y_^1.OS
M"G.6=VWRF\X7#^Y=Y)YBD?>7O_\ :V_G9_\ YYL94*YXSZ2CR]__ +6W\[/_
M //"7/&?25?_ *:9SD!-_'G.?^>!7]W/C_\ [)SRK]D'?:?DW](*Q8&;QU%_
M^=G1<KG\KZG4<(CA$<(CA%!\+Z_06!WG>/80(O(-YWV! U!'9T@_(-5X^@PI
M(?,AL.VCX](>W=#W"S><FLFU'1$CH]4T8[-DV.J"FJY/![\'L5.Z]\%/UYK=
M@$!!IQ?9&(PVVJ:MNMX.<L0<[AM:/*+LTU;,)B<1 -8JQ:[QQ>5G7*4D,2;X
MQV2>C[,+'G,_U%@Q*#,NV8\0N003QWX3KM7G6[X)#K-<GQIV-RF[HVXG4][%
MS&:NX5.0H5S*0':]I 6-[5.4V=0\GIBM)JVK*')[-F*;*9!\C5-PLS8;O'6R
MI \CU>D7L?FOIP<8*E.M/!W4?5'8Q;LG%)#:.)"G([JE@&!$9(#=5E$CO89A
M7#.VWD=#IQ5O)$\2EQ5<2+9;E985;C"2+[(E)DQ>[L="9C:VFMK\9ML]%[>)
M7RX75'"(X1'"*O':;K3!^W%,&Z/L(Y-8U'#4CKV6:R"O"PT', \@K"P(S9D2
M(AB9<)(AS=5I*(D(67PZ#O-%FNBZ&-4]E-54RY!L;^/UBQ]151M_!&=3GL/W
MAT@7MF6HE(3VVA\UD$GG^24KL=[W6*P,W>$[FAS =!=Q.GA.N(PYC1$&F"#@
M<MUM-03I/=+1 N<QX--6GYVBP]^%?4.\$_UI]3.1DQD5RV>0/[=G%K!E,^FH
M=S)K.>]M*IBM)6L_F3N-Q.,L4W6E:PJ,1V+?%(;%4 F@I)ZH@_?J+N52%Q/%
MP6\%KVMZ3MNJ1]I/ JR.4Q6M@O7BU$I(<#6A,[=L>9]I7\"FDHF,X<U+6U,5
M>]>HE^M%M5F;AU?P2NV$?(U]O4T;=RH<FR4Q8 ,KDL2*ER'<8X+"U[#4F_=
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MC-^1+R#:UAR@FPB4LDC^VW,DF$@DX]79N\DLI+&)"AY*2K$FU60143+FY]_
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M!AB0:*ZO&K!UA@]E3\*/?NDO0&3I=_NFVW(@99$2,6'+*L9.BOQVA,>B<JD
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M000""(9""#J""&V((V%>)J:<$@SP@@V(,K 01M!&;0A?G]D>O/W^0SZ4 _\
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M/YDLSEO541PB<M5_LTKSW'BGU"PY0*S?E7YS/UKE>*3>M-YO#U;5EI+[G/\
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M&2M:UQ;:\.1IL6W(.8![A(T PM1#&(K1M&Z,?"US6L<"TNB<7 /)(GS/%\P
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MNDDB\'DQ=$8R;Q=\H.G-23,[/8PS=3"35P-DP@6U,P:)R8K*I1$$2B.H 4*
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M)9:1X2^Z+_\ +77Y]3FQF=PWR6\P5!?W;O*=SE?%SLNJO7TN_O=C_P"7$?\
M5DW*WV0_DG]X_P E6' ME3XX>:17EY6U/I9O;;VJ(^ZHC]**<N&![R^FDYFJ
MJXSOP<BSI/58>3"B5*U'>UN!_/R'YI;F%B.\:GDG?4LS#]^T_*#F*;URB*Z*
ML7;7V5)>](?]&)\F<"WZ[D']*-16,;S^E9_,EF<MZJB.$3EJO]FE>>X\4^H6
M'*!6;\J_.9^M<KQ2;UIO-X>K:LM)?<Y_^1.OS"G/!G=M\IO.%[/[AWDNYBD>
M<V,J"CA$P#IG]P)O\\"OT)SRK]D'?:?DW](*QX'WNH\MG1<KH<KZG4<(E>WL
MM9@WMRWD+B)QR=AQ;/K6RI>(2.FK'L!9RX,6E)6%PR2O;%#2%G J>G$5$.A\
M@ELD,1XR\UBH*(.)"X%Q)ONJZ+L-FWCOKZ-.'A7F]I'"DTDMNFA\;L$Y)'O7
M 0 Z7%&]?V)LM%^U("P;U#RHG'%M(^GK 9'Z^1H1V[ELE]1B3M>"7IMF5)5J
M/FKS4@X/'KXK#T\.GS<*:IPNJ.$4$7Q23>YF=;N47L9'RBHK-86O!'4UA6EB
M0]*4-8?-("IO((=Z_BCHJFG&; D:H9<;*0!$')TP4A;O5L"=QSXBC!+K79 "
MCOL*0"[V4*9*-66RAP?79-JX9OB]FG9_9@R,Z1JS8H6AD&DX4WO7,(C\3D(B
M35)%&Z*T7G;HVU$DQ1<WUOM]_%]6O"K#U=#G5?P./0QUB$Z8CS3<<T0KJ%.Z
M\A[4<DX6R/:"(D^EDW<C-6[39))UMO)'WISW5P_QJUPY]%1+A9_PB^5T^9,L
M:;/7C5IA3.<)Y=.$F^-\Z^+.V-,J[Z8VSKC.,YQKX_%X\>/^[SD-<[N6EUN(
M$\RX+FM[IP;?C('.OC]?@O\ XT)_SBS_ *[G;<Y/S;_\+O8NNZ1_G&?XF^U'
MK\%_\:$_YQ9_UW&YR?FW_P"%WL3=(_SC/\3?:O6QGQ_;Q]O&?MXSC_MYT7=8
M]+C>\9BLDD:;?5VH!!%C&C7=3*6CG<:Q7>:H;*ZZ[[)ZJY1QIG?&F^=<;>5C
M7;./%SU@CW:>&(G*)9&1EP%[9G!M[:7M=>4TFY0RRVS;G&]]KVOE:3:^MKVX
ME2?Y9Q;]X8[_ #ZY_P!V\L7W/Q_I+_W;?M*"^7'_ *,W]X?L(^6<6_>&._SZ
MY_W;Q]S\?Z2_]VW[2?+C_P!&;^\/V%:>H+$7L^(?&=R+1$*>M'H_T1!UN[T\
MEIJWVPKYY1%#;Q[^>SX]?(\6ODX^WGQ_:A:^D%'/N+7F09&OS$!I[8G2P)XE
M+T52:N'=2P,.=S<H.;N;:WL./B4I<PEEI3-S2$^VM.=-VQPPW02D#S1)! F]
M212TQY'BU3337UTTUQ_V:ZZXQC_W<O-!%&:*F)C8286$DL:2=.$V5.KY9!65
M $CP!(; /< -!L *C+XT2;]\1W_.Y#_:.9>XQ?FH_P# WV+$W:7\[)_C=[59
MCJD:,D+-=H/RQ-\AB*%5,(O'[IREA35^(QKOA-97?3&^N-ML8V\7E8QMMC&?
M%G/(?&XV-HVEK&-.[L%VM /<OX0%+8.][JIP<]SAN+S9SB1?/'K8E,;Y4U9E
M1;NE_=K;_NF'^F+\LG8]^5_W?_.5?QW\E^G_ ,E48Y9%7UZ(?[K"_G%E^DI<
MZO[AWDNYBN\??(_+;T@G?\URKZHHO/V23SYB5_/H<SL-W]3<I_*5AXAO*HY,
M\X2AN7I4M'")I?5WV.@OG$]];.N4O&?PA+Y,75M5NPG>,?E2=8Y6%Y%J22:;
M0]I=A^_$K^OG_+_1[SI/-H.J:J/5[ZJ?.)NL<L%YDK'5NNG/W^2;W15^N1/(
M/'MZQ><-ZN53>!]_FY(=,)BW*FK*E_=R_OAA/S,4_3D.6CL?[U4<HSHE5S'.
M^4_D/Z353#E@4$LJ@OW[P[WJCWUNSYXU&]Y^1EZ#E[4^^(.6BZ;4Z;FO5>E!
M_9#V+37^#!?K.%Y)81^$:?Z7J)5'XKO"?Z+KHUK;Q>W3NE[&4YTLDV'.[7G]
M8@&#>UUVV\/!PZNBLW9F9/4:8!B&3C9X%''$HWGAR3$Y,V(RZ.-V;1I#GK'T
M2UME=NQ#] 9'QM&Z6+ V,O!=%E RN:W,'ESGW>T#M#I7G0MW!NYBY$,<KCN5
M\[GR!A:V7,3G:7!NYA@:0QUR7C7T9!;TF==G:O!-G,Y$5ZL<)P\>R8P.7.XG
M92I:K3<T<3569MHT]C;N/AB"$="QK9C(&F6+L=.C!Q-P&<@WK,Z5WQB)H+PS
M,6V#'%DEXG/SY\I:0TY6MLX6(D)N+$=6PM%+*XB,R90\DR,SQ@2AFYY,P<'$
M9G.NTD@L:.V#@MCKKG[&(3_ &?UC,<J>+?A"H\<?4QJR89O&#Q/ZUZFWD<L]
M)4F?WX2SWE._6CKFPJ?>\'(Q=!JHM1OB?EI>FY8USV7BKI],_NW.?FH-^EO>
M5[L@[W3>7)T6J=P/OE1Y#.DY7]Y6%8TN7N)[08Y[FMOKLYRV8#O67SAW5Q*L
MXWOB+D?YWJI/)Q0JSZJO:=7GOM%_KIES&K-YU?FT_5.612;ZIO.(>L:G)<H"
MO"KWVA]CA[YP _6[3DK@V_X_(EZ!4;BV\9/*CZQJ5GRYJHHX1-]I'V30+W>:
M?Z5.43$=_5/*N^I76@WG3<DU2GS"66D>$ONB_P#RUU^?4YL9G<-\EO,%07]V
M[RG<Y7Q<[+JKU]+O[W8_^7$?]63<K?9#^2?WC_)5AP+94^.'FD5Y>5M3Z6;V
MV]JB/NJ(_2BG+A@>\OII.9JJN,[\'(LZ3U6'DPHE2M1WM;@?S\A^:6YA8CO&
MIY)WU+,P_?M/R@YBF]<HBNBK%VU]E27O2'_1B?)G M^NY!_2C45C&\_I6?S)
M9G+>JHCA$Y:K_9I7GN/%/J%AR@5F_*OSF?K7*\4F]:;S>'JVK+2>?$.(9S]K
M&&3O.<Y_[/[0ISP9W;?*;SA>S^X=Y+N8I%GK85_\3'__ *UM_6<V1D?_ ,KO
M\)]BH*/6PK_XF/\ _P!:V_K.,C_^5W^$^Q$PGI8Z;.H_.<MG*#C&AD3C?*"R
M:V-<Y9.<XQME/;;&N<XQGQ8SXO'RK=D (EIK@C[V_:"/^(*QX'WNH\MG1<KK
M\KRG5^:RR3=)5==5-!!!/=999;?5-)%)/7.ZBJJF^==$TT]-<[[[[YQKIKC.
MVV<8QG/.0"2  220  +DDZ  #4DG8$) !)-@-23H !M)*Q#[(]>?O\AGTH!_
M[=SW^*57Z-4?N9/LKP^-4WZ1!^]C^TC[(]>?O\AGTH!_[=Q\4JOT:H_<R?93
MXU3?I$'[V/[2]\4;#'F^[L&7%F6J2VS=1R*?M"+=-QKHFKLANLS563T6U352
M4V2VVQOC11/?.OD[ZYSY/CDB.62-\;B+AKVN82+D7LX VN"+[+@\2]&21R F
M-['@&Q+'!P!VV):2+V(T7J<Z+NJA65V>?0&;G8BE#VA-,.HR3U?*&5FNZ_I8
MUF_SG9#4<OJGY&764L8PKOY6-,;?:SMY.)VCP9M531SFH<PR9NU$8=;*]S=N
M<7OEOLX5"U6+.IJB2$0->&9>V+R+YF-=LRFVVVU8-\LXE^\!C](7'^Z>9/W/
ML_2G?NA_46/\N/\ T9O[P_84EU+V/>V7,6\67B;40FNQ?O/34BZKS?7+-+"N
M-/,;CV^,X4_Z.=O.X\G^[XL_W.8==A+:.G,PG,A#FMRF,-[HVO?.=GB651XH
MZJG;"80P%KCF#R[N1?9E&WQJU?(53"I5W-^XT$^<S?Z*PY8NQ_NZKR8N>106
M.=[I_+?T6J@G+,JXCA$\AI_U5M^3H_F]>:X.T^,\ZOXV#Q#F6$VK[,;#]R91
M]2O>9-#ORE\XAZQJQZS>E3R$O0*3;R_*D(X1,WZF^RC'O*9_-L>4_'-^_0Q\
M[E:\'WG]*_\ E5F>0ZE4H&[?:S/O>)Y_]'+YA^\J7D6<RI>(;]J.4/,%%O,Q
M8:M%U&]J3SW1+?6 ;D-CN\F\NSHR*7P7?;^0?TXTR[E05I5%NZ7]VMO^Z8?Z
M8ORR=CWY7_=_\Y5_'?R7Z?\ R51CED5?7HA_NL+^<67Z2ESJ_N'>2[F*[Q]\
MC\MO2"=_S7*OJBB\_9)//F)7\^AS.PW?U-RG\I6'B&\JCDSSA*&Y>E2T<(FE
M]7?8Z"^<3WULZY2\9_"$ODQ=6U6["=XQ^5)UCE87D6I)(_OR=0F!3Z<$IU,8
MK"QQ"QI4,8/Y9(1,<9/26Q0P]U'M'1AVS0<OMF3)X[PT1WW7RU:.G&$_-(*[
MZ7VE>QE'2%[FL!IX "YP:"=Q:; DBYL";<0)X%2:ACY*NJ#&.>1/,2&-+B!N
MKA<@ V%R!?C*PB03>&1,*A(Y5+HQ&H\Z4:I-3T@/B@P5RJ^3V59)(%"+MLQ6
M4>):;*M=$U]MG">NVZ6-]<9SC)<]C1F<YK6Z=LYP UV:DVUX.-8[6/>[*QCG
M.%[M:TN<+;= "=.'B5U.E!(<9EA<N(?LBHHI!4R PF-=(/AY$>])AG#-\Q>M
M5%6SMF[;J)KMG+=51%=%315+?;3;7;,)CQ!I(2""#.T@C4$&*2Q!X05-8("*
MB<$$$1V((L00\ @@Z@@[0F1\JBLB5[X25,JK"RR0(UM&S:M36,F&D6F2VNX
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M'JVJTT]^\::>Z<C^IWG(R#O\/*Q],+W.P^(\RXT?/KM4!'"+>9^"0^Q#N/\
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M)@*]KT'+)?'IU.)T)G-MLY 62)RERYF 44U"3A^,0<O)Y'@SD\^$Y(QEC)9
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M27$8F11OD>62D,C:Y[C:,DV:T$FPU.F@4;BV\9/*CZQJ3#\I[K5^,-1O_FU
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M4RC$S)N>HCRM9D%@W*+W&@V/!RNXV[+'58N[OW02V:9 YS\Y!)S.M8FY_P"
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M825$3#N9J)9980V.G;2M<UKGATS26EW;-C?&TMR^3Y(Y'-<6%H:V)N5A.H8
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M:#^N;7YKWX5N\8)RM?T*52V!]W4^3'SO6UAX0W_ "[R?R/>S']"TVYK'L?\
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M04TU.V0U!CDGD+'2U#7/=),\ @E^=K1&QNR*&("*)I<UC6@Z]97M>1D#@T7
M:0 &C@ L3<_\SG$N<=22NH)X*O\ !K]%?Y+-+?J,'Y\V=D_XQ8W^TZSKGJY4
M>]*;D(N@$@[X6=6UARJINI,]C,&ETA@]8'+I<V1, D<+E(Q 6\MWI@%%EYF=
M9-%AD91DAO&1 )0RY9Z%2>,L6.5W./-<O/P65$$55BL$D\4<U2RC%/"^1C99
MS%\<?*(6.(=(8V=N_(#D;VSK#51>.,>YD#VM<6L,F=P!(;FW,-S$;+G076F>
MAV"LIM$DH6W5AB(CU?'0I)SI6%:8D$FCL2/B91'8O,Y1\4_C#-(P./  +_8#
M*B1<:0]01YF5;OA\=!-!VWC04YE,QW8OS2/:/C-3N<<DK'QR20Q;KN<,CF22
M-SQ-8YNZ2.:6ND>70&ZORY>UM8 ]HRY#2' .=ES.%P#9Q(-@#H!;\-+YL5")
MFH8R5AXP6?:FQA!^'K6N0TIT R,YM(S<7'3$7%FDI$14@5W5RI'11=F)1&N7
MP!JU0CQ(B*=\_$:<RLF(F<YA8YK7U-0^+/&S<V2.A?*8G2M;LD<PO+@)"3(U
MK@W1V4M[4 W!(8P.L3<@.#<P:3P @6N-A(6Z+\$WK>PHG2_:R<2B"R^.0NS9
M-43ZN):<CA<5&YZRC*-J Y&[AIM\T0&R5L!,_P#-)A<.Y>)C27_L3S9%S_:^
M:?\ A2J*>6KPN"*>&2:FCJQ41,D8^2 R_%7QB9C271F1G;,#P"YO;"XU5@P1
MCVQS.<UP:]S"QQ! <!G!RG8;'0VV%;*O;FB%NT'6*]^N[>3I0M>YZPEE=I2Q
M81N?2CV\F%KCM2R@70D'W*:,\K>>RRU*,,KXU\C#I'Q^7C76%5PPS$J'$#%N
MPHZF*H,0?N9DW-P=DSY7Y;VMFRNMQ%2\\>[0RQ7R[HQS,UKVS"U[7%_2%R0[
M<@6]56M9U7JE-3BE;V%-($H:T9Y'Z%]X?)"4>W*:,-G+S9CJ0V'9=ZL]GCK+
M;"N$<N5\Z>=V^J:6?XS2TU3ER?&((9\E\V3=8VR9<UFYLN:U\HO:]AL5&>W(
M][+WR.<V]K7RDB]M;7MLN5'O/==5L4?!J^I3F^N\R-YHSI",(]1DA4]=1I6.
MJ%U9YI.Q,UA&@M MH:&ZQS89LMZRV>*#C>'>NOHF&S;.?2,4#X1,5%#@AHC
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M)-))+*]TDLKW222/)<Y\CW%SWN)U+G.)))U))*N[6AH#6@!K0&M V  6 '@
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M-8V-P7;3H0"=@N038 ; %["O8@PZ@!NM7E=56O&#$PD,[2;-@!X'D/)I $8
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ME53O>YQL&M;*PN<3P  $D\ 5AE!,<@ N2QX '"2TV"Y)#,_=O5::697Y(!I
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M;#T\*YQ_/H)5-'"+?)^"O=3CU<4):7;5Y+A!(!V2R*B(:(-A[U$Q&7%,S*P
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M=<8Y\HS32U$LD\\CYII7NDEED<7R2/<;N>]SB2YSB;DDW)VJ\M:UC0UH#6M
M#6C0 #8 . #@"4?\((_!"=P/R*D__F/I_EK[ _QLPGQUO_XZK6%B>\9_$SK6
M+F&<^D53D<(NH#X ?\$7T[^9+8_I]M7GS9V=?C7BWETO\#2JXX9O&#Q/ZUZ<
M/RI+/7( [??X6?:'^43=G])4FY]8X5^"\-\PH_X>-42?O\W*R=,JNW,]>2V^
M?@CWMB[G_P 6E2_K3+^:H^%7>>$><U751*=P/OE1Y#.DY;Q_-+*QK0)^%B?X
M=- _R38__3!<'-Z?!=^!:_\ :C_X2E58QO?,7(#K)%JV\V8H97>\&=^$7Z'?
MRPNM_P#2]$>0W9%^+^.?LC$?X.99-'ONFY>+IA=:KGRPKND1?"1OP3MU>_=)
M?TIQKEW^#S\::/D*W^&D4;BV\9/*CZQJYJG/HE5%'"+JO>!T_!?=(OXAXM_K
MO.?,/9;^,N,^?2_4KK0;SIN2:F5<KJRUQJ;%]H,[]\I/]=ON?75/O>#D8N@U
M4%_=N\IW.5AO/9=5NH?!#?N?X0'\LZM_F>PW-/?"OMP'Q8GSX>K#@6RI\</-
M(MSCFH%/KG8_"C_PF C^3/5?ZSV1S?\ \&GXN._:-5U=.JKC._!R+.D]:XO-
M@J)3-O S?A2.DO\ '8'^K"W*WV7_ (LXSYF[IL69A^_:?E!S%=5+GS&KHM<K
MX47^#,'_ ,I.JOU?L+FP?@T_&-W[.JNLIU$XSO,<LSHO7.LYO]55'"+K;>#=
M_!X=#OY&O6/^A6$\^5^R'\/XY^V,3_C9U>*3>M-YO#U;5::>_>--/=.1_4[S
MD9!W^'E8^F%[G8?$>9<:/GUVJ CA%O,_!(?8AW'_ (U:Q_5&0\TK\*F_<(\U
MJ>M8K'@?>ZCRV=%RV[^:I4ZE<^$(!=7NXO4^UZBL )(K&51C$BF5>1MH"N&-
MN5+8CD5D&:]=(O8^P *N5$#KU'30<3>J WNZVJ95HX;XSC6;P#$:G",4I:N"
M84X,L<-1(61R 4LDL?Q@%LC) +QM/;-;G%NT(*Q:J..>!['C/H7-;=P[<-.3
M9;A.R]CPZ+G2_N9??S\4^XOHUM_7\^@/NP[&?UO3>B;^DJK\GUGYAWI9]I'[
MF7W\_%/N+Z-;?U_'W8=C/ZWIO1-_23Y/K/S#O2S[2VRO@Z75R$]1*]M:Z.R=
M33BJ.UIF:2VL0A<^)LUTN\Z]E 5.2I <E' >"D'PBXL>-%7.II83K*M=QZK'
M)#41OHV4U;\('9 S%:BEH\.K8ZK"V0Q5+V1L: *]KZN(N,CXVS7%/(T9 _<N
MV#LN?43>%4WQ=KY)HRR8N+ 22?O1#'6LTEO=MVVS:6O9;,2G8JG54]TE#QC=
M-739-33: V%G7?3?7.N^NV/BK]O&VN<XSC_W9YK@-<-0-1X0I?.WC]1]BYXO
MA.?!O7(8[T7X2Z=]2YBCUN<E(9M62=?P5V#B&K).M88C(/4PIXD/<M$\RY.0
M9=:JLT<J/\NE]<;Z*ZJ;[][&^R["VX)0MQ;&&'$ V;XS\8,KYLWQB8LSN#'
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MIH35;I*^Y:S=**IB9<-#G=M(]K18'4ZZ:K#KVF6DFCC&9[@S*T:7M(PG;8;
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MAWI9]I;+GP;:F+>Z<V=VD-=F:NL&HQ<X@=<"XH\D$//NTS1 /()*[)MFV ;
MLIINT;O6JJF7&B.F=5M<:;;[8VQC77PAXSA>+4V&,PZLBJWPSU#Y1&'C(UT<
M8:3G:T:D$"USHI?"8)J=\QF86!S6!MR#<@DGN25MI_*.J#]\)GZ!6%^RO-5Y
M'<7K'M4WG;Q^H^Q:;7PC+KY>?;_MS3<_ZV5#8ML0^.]<@T/-'0$1-M6H^2MK
M,LPTN)6T-LQ3G9PF+-"WF=TD%$/-O$\85RIA333;GP?8YA.$X5608C70TLLF
M(/E8R3.2Z,TU.P/&1CA;,QPU-[@J!Q6GFJ)XWPQE[1"&D@@6.=YMJ1P$+7U_
M<R^_GXI]Q?1K;^OY??NP[&?UO3>B;^DHOY/K/S#O2S[2MAT-Z#]SJM[O=0++
MG_6NV(S!:^[-4;-)E(WL7=*,P,7C%EQHR>,.TV>7+O=N-%LW3Q;1LW77V31V
MPBBHIG73,7CG95V/5.#8M3P8I3R3SX;70PQM$N9\LM-*R-@O&!=SG "Y UU(
M"]Z6BJHZF![X7!K)HW.-VZ .!)T<3H%T?_E'5!^^$S] K"_97GSUD=Q>L>U6
MO.WC]1]B4)X<Y\IV=\'-:E04,$EUD62=E]4$!,3#0F8-W[UF"L($6+KI*E@8
MYCKHQ'-7#I7"CK3;9-+;">N^^==<VSL*K*7#>R"EJZZ9M/3LAJFNE?<M:7P/
M:P'*''MG$ :;2L'$6.FI)(XAG>7,(:-+V>"=MAH/"M$O]S+[^?BGW%]&MOZ_
MF[?NP[&?UO3>B;^DJW\GUGYAWI9]I'[F7W\_%/N+Z-;?U_'W8=C/ZWIO1-_2
M3Y/K/S#O2S[2Z(7@QI]'J5Z =3ZIM).30ZPX'4$?C\NBY&#3=9\#,M-W67#!
MTJPCSQGNJEC?3RMFSE=+/E8\E3/- ]DD\59CN*55,]LU//5R212MN&O8;6<,
MUC8^$!6FD&YTT#']J]L;0X<1'!I<*]ORCJ@_?"9^@5A?LKR$R.XO6/:LG.WC
M]1]BY?$W\&SWQ)S27DF/5:X'+$A*#[YFXTC*F-%VKLJ[7;K:XW6UWQJJBIIO
MKC;77;&-L>5KC/CQSZ4@[+^QML,+78M3!S8HP01-H0P CO7 53W4%67.(@=8
MN)&K.$^4L7_<R^_GXI]Q?1K;^OYZ_=AV,_K>F]$W])=?D^L_,.]+/M+:A^#4
M5A9G31GW,3[.5S/:AWL5UU]WA6LAATC=YD&D32NK619:>HAI;"?JO,D!X7]*
M]'\KUBCYGSODJ^;UE\(N+X;BYP?Y-JXZOXN*_=MSS#<]U^);G?.UO=;F^UK]
MR;J:PF&6G$^[,+,YCRWL;Y<]^Y)V7'I6T=\HZH/WPF?H%87[*\UGD=Q>L>U3
M&=O'ZC[%I*?"".LO8;MAWQ&VEUWI:R;2@"-#5[%E9,"B1AJRTD @_.71$9E,
MRU&///M6Y-@JIMAME'.KG3&BFVV-\:[E[ \?P?"\#=35]?#33_'JB3<Y!(79
M'LA#7=JQPL2UPV\"KV*4T\]2'Q1E[=R:VX+1J"ZXU(/"$CO]S+[^?BGW%]&M
MOZ_ET^[#L9_6]-Z)OZ2COD^L_,.]+/M*^W@N^C_;RD?""=4K8M7KM:D,KN"6
ML,.RV4DHL^68A!*# BDJ]<I#]7CW=+119/7.K=JLIG.^/%IG'C\4%V3=D^ U
MF XI2TN)P35$]*YD431+F>\N:0!FC V [2%DT='4QU4,CXG-8UX+G7:;"QXG
M$KH<_*.J#]\)GZ!6%^RO-!Y'<7K'M5ISMX_4?8D?_"!6I;M?T,9U;UXC,RM&
MP$[UKN4;QD'"I8U>Z@! ::MB1+*AD,,9^9:+DF*:FN'.5LY<:9T3VQC?.MT[
M Z^CPO''5-?.RF@-#41;H_,6[H]\):WM XW(:[@MHH[%(WSTP9$TO=NK76&F
M@#KG6PX0M)#]S+[^?BGW%]&MOZ_FY?NP[&?UO3>B;^DJ]\GUGYAWI9]I'[F7
MW\_%/N+Z-;?U_'W8=C/ZWIO1-_23Y/K/S#O2S[2Z1'1FUH96/2CJ!6T\7D4;
MG%?=7Z#A,RCKV"SI1X!E45JN* I &=J-(VY:;N1A9B[9+[MG"[?95#;**RJ>
M==]OGG&Y&5.,XM40.$D,^)U\T,C=DD4M5*^-XO8V<QP<+@&QU 5LINTIX&.T
M<R&)KAQ.:QH(TTT(MHK"3'L%5)"(RE@R-FW#Q]'#;-HAI K!QNLY<C'2*".N
M=HMKKC917?337.VV-?'MCQYQC[?,"$%LL3CH&R,)-QH X$GT+U+FV.O > KE
MY_N9??S\4^XOHUM_7\^E?NP[&?UO3>B;^DJ=\GUGYAWI9]I'[F7W\_%/N+Z-
M;?U_'W8=C/ZWIO1-_23Y/K/S#O2S[2VV_@W$#GO3JI^SP'LQ IU4A>;6) 2\
M68R"&R5VJ9&BHT:9D';;8&++)Z)M73E!'?#C='?.RF,Z:[:XSG&JOA#Q3#\6
MJL-?AU5'5LAIYV2NCS ,<Z1A:#G:W: 3I=3>$PR4[)A,PL+G,+;V-P 0>Y)6
MRI\HZH/WPF?H%87[*\UWD=Q>L>U2^=O'ZC[%)TNET<@48.3*7EFX.-1P<X*F
M2CG591-JS;:^5MG1!LDN[>.5MLZ-V3!BW<OR#Q5!DP;.7CA!!3JNRA5WVQHI
MB(P6=262)J)DI +(1K%6VNK8(%>*!P<ADSJ55BE"-[%B(8#'Y5$CI602>+B
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MK+I]8L1K(*@>F)!XS9O2S "+9B04@E<A.G">RF&0:.12)BSDHDA59)%T\V'
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MGG-SC)C5\OA[T5;$Q*0(;'*VMF/S]*E8^#7HN-JP.*E!(I9,G8'FYO,)!-T
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M9-K^B_%PV4FB>V5!'C<&!!)RX+J6,)A)F*'!L,GKV$+H64 4E-?,#-AMXNI
MXG(II']4"<9BDMD@.4&4"035B(66/A$R!+'G]6WQV6"1GOQU=EZT;2 S&;.$
MI:UJPD!)/:)OT*#<@KO/?%6H94ZD!NL!P,3"[%DNJP")S4N0810N7:$![8SL
MY'/DVY,IY^$<&WA65:]L:A&Y8,Y')-]BQ286I&T4(3#K2G3 ,QJ^XS=-%3DX
M(AJ_SI7P<?)Q6H:02B9IA(&U/MCR8"822-!MI.Y);WTXK_.O)LWN!6\%$VHD
M(;R$[.:RB$SF.(H=A]A0 3+QM?GP$6F*T-GLGA*,2F+",2*41X/(B4(?2I *
M^-"T'^$MG[?RR6X?K"R6_P"X9[61BBXG6L"B,]EMWVD8KEBWG-A&:VC@) %3
MEJV^^-.S8"M[1)NE5&M8*A&HU&-Z:;N#*;U8@BFRV;N7%X?83]2 ;?![0/!Q
MJ.(SWJIS9OJ$L]<A6]IBM+EVFM=, LRL?$7:4"46%V=+,R6'0YPTVK=BGD*9
M"3.0,(IDD*F,)9D@H*6R-K%="6XM??G\'U:J6)3V<I>'O%1921G"!S1[&1Z4
M9B%=V3/Y80>2^*GYP!0#1."1&1R0[LO$8M(9"]V#"W^@48)=N#6P_&NN-BX7
MGUAVNI"Y2P<16QZ5R90Z'#&V)5*J+:'11%K(H8.L6/LS$U+P<?#X](#< ,A)
MH+BD@.C)0\C)P(81#[,S Y5R7-C[^S:K&<+A'"(X1'"(X1'"(X1'"(X1'"(X
M1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X
M1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X11];5; ;EJ
MJS*?E3@HTB]K5],ZVDCH&X;-#38#.8X2BYAP'=/69%FV*(CRCA0>X=CWS9%W
MJBHNS=):[H;^]+4/I*JFJX@TR4L\-1&'@EA?!(V1@>&N:XM+F@. <TD7LX'5
M=)&"1CXW7 >QS"1M <"TVN"+V.EP?$EN="O X=7?!T2*TI30TMNPV5MJ%-X-
M(=;0E$-D3%F+:OE"*#@2WC5?0Q9%]ARIG"N[IV\1W1QY&J">_P#;.6#'^RS$
MNR*&GAKHJ.-E-(Z6,TL4T;BY[<A#C+43 BVP  WX5BTM!#2.>Z(R$O :<[FG
M0&^EFM^M2#&_!_$=:\1@=@W9B4YCW3Z5]+8*4BM9#H+@76TO'0%@0D,N;N)7
M+W\VF3+-:1I4(MZZCT=$8>2O#..Z+21PY;UA9]];VX;^_P#LLFF_19&>"+%@
MY:U7R-825OVD)P:,-(@RU/P>>]NA4\869*2LM4.;ZS(8&<VG9#R"QG "-8$I
MR]TS/&)/J)CBP8N+[#P^S9S*-.V74$J2J>^" ^QTOB,T0OVZ8E!'<8;(D8Q9
M=N5#/*VL0XYF^SPI\88RUC%D6A)HI"5(D*()3F3)>F3](",!- ) ;>_A!^KT
M<"AKJ-34;[@T1)GYR3R)Y5Y>1W)&6<C+I&4[SL!I:=!:4A/B5L2*3SRUO3).
M"'$DAT#D+:3F=4HA'XK'W0D>U!-V^Y+_ %>HWTM:RN+;?4VQKRK]"+6==,)D
MLC:EB+L1*5: #M-((F]C+>-M)55.[&>MY]75Q!-]"$@#V6+LQTR:FSI9'XD[
MQK J.BB7'%Z]OJMZE=P<TR/'L6&7;Q_EDS;-,OB"NJ[][ELCHCEV^7T32T6>
M.<Z>><JZI)ZJ+;[[ZIZ8SC7!<+'YO#14_C)"*FE7R TELSV74'*HH/-<L7K=
M^CYI5PW=):XRLV3U4\I#?QIYWUU\G;.-]?>FJ'TLS)XPTO9FL'@EO;-+3<-<
MT[";:C5>-1 RIB="\N#79;EA =VK@X6)#AM&NFQ0=)>K,0,U0>J\1))3']W\
MN@]BQZ6Z;B"1F)V%6,PB]@U_(V31R+3%$FX.8PR/$GH0FT78'&2#P.0SEB07
MUQZ5E9+6O:^5L;2QN0",. M<FYS.>;Z\=O NE)2QT;7,C+W!SLQSEI-[!I +
M6MTL.*_A7S@.OLR<2R"6%:=R/Y_,X5:!2R$$!,6S#Z_8MWE+S&F&L0AL,=2>
M6O8L'T:3(C,BY A*92=.RQ=[E<BW!;!@H#$65?W^>Z@2LO!R0&K)35L@$/Z]
MD.T$B5"A#!R<T/ IA:#T]U\KJ,UI%Y#7UFF5W#^KFLA PR+_ !G#-0\E69NA
MJQ2!&8-("I4X\+DF_KMKH+^#YUG0'H_'@40 1%.>FG" &GNBU0I/=P['15PQ
MZ.6E)K0CIK=+5WG31W/GDE6$FFNNV40S9JFY8J.U5-D]7A]^'VKB_.[UZ+UP
M74^00*3KRRK;A<0\O)#%M_']V1@8F5KEXM:'8BQNQ+-C%-'QAH.BLM@IRTYE
M' $F+C9I'R <LNXD4#*OFXE062_U>I1"IX.440G=JSHU9R+\I94&O^O=S:%;
MB4)^O'[XMBO;5Q\?;%?'RIZ?*5CFO1L"K08EI%8G&J^]#"L8RW=L%"3\E]+>
M(\/!<;-G#KPWX5:J]Z:E%IDJ9DT(L ;7DOI6RBEB@B1J$[3X,34-U/9=1DA)
M$$E*X8XQKZFLPB29/4#6N6Q,<R\\T>-=UT-B#A\(_P!?J47!.D\/&-)>@1FT
MJD!"QJINNN;$D9!L#;R&4%[\EJ<OG,UPNP8-A0ETW=:ZB8T 8A\!0<?9!1*2
M:S<0CA4E_JMX+< \"7QW?IV04-#8A=-EWA*R/E6_7CB3R>FXJ[K>5A4X=1UI
MU-#P\#'"[-$2)LR/MID]?3LBK<PIXIM@@U:-B$>+IQ<27+3X.#TV-^865OJ"
MZOFB)3K?V -%ZPA)6*UQ#\+1RFJOVA;PK'&M6%(+&*Q?3M*3)D#5("Q9UC-V
M-73:.S)_%K'&LG48L!N!%L1V2XOP:^_#;77P@_6F.\+A'"(X1'"(X1'"(X1'
I"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g713200g94p77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g94p77.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M9%>^16'I4?M@M3\1>4O;0PNWX"1NORB[VJ6!&6&':8R]KN'<DDDD&X8C3DT
MU%N7O6]_T#/E%Y2>1!=OJ[HV;MQQ6A/BKXS[#/B]_D=9$VPEMW;9'8A3/9&E
M)]>"J]Z/Q]:D@ .'04'8K>813P$*T)1X.Y$5H\14 !T WG=>UA86(/*.6VD[
M)G$ZXXB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB
M(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.
M(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB8>_Z^1-K)C'KK9J<L[
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MIVR6=MX;TU2!R()>W77MVI:]\[R7B17(+O:>U#QJ[+J?6T-;R%VZ3;"T0)D
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M4L\FL!FEHTYMV_=S\_>Z.2_/+.]:/BQLI-&M:A.7G#9W#R_G&P"S04^/-IC
M436@*=%L5:H9J&03, +AB>-Z'O*6[1FGAGM5I8;4R<=TSSB(XB.(CB(XB.(F
MM]M4;I5!.BQ;*U*Y:]A6Q%V$4JH@W(U:IVH2>2<MEWBI<7Q9)UJT;*KT3E^
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M)%?"Z[:'BDTCV:3A\\MGRXDR+U%$[EFP*L!KYA&N,,DI\-U2,32W<T?WA_\
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MORVMRD"_-Y1OU$V \&-GQ>4FDTK7^[FTB&<OI7M79*);7=27T59T<G 80<>
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MW/R/F]*,YO\ *R_RF?\ 2[YZ1* =Y[Y],\?$Q+#_  X_,QK^T^'W53Y5=O\
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MJRMGEME7CB)>$,_>T?\ S&I^SQ\\Y?NV\)O29?D[A?!7T":]W5]4[]]F[_\
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M'! N=-3>B"M43,JL ,Q([525)%B48@LA(L"4*DV%SH+>(YJA*8ZPRF5K'\X
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M ,RWMF !++R:.$;4=K<,!7:E$HN;A*;C-D;@R3E:V:Q)4*VE^VIEUT.NHO\
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M.\V )L"=P,J.T4:IC\0%%[9"22%50*5.Y9F(51N%V(%R!O(D?)=DI42;2?\
M UU<526%#L9>%CRABV3G*6XJ% >-""J-P]?,62$V _$)4&3&,;_4E*2CA:AE
MBPD>$3('O=3:Q ))N;   %B2=+6O?2UYH\$^<T\MG%[@D*  +DEB0H4#7,3E
MMK>TEYX/M %S=L61:(1E Q!18,:]K&*S6DPL43@X<1HW*5V&M?'$Q9*I<&%A
M1&M5(BB=.V.(5:UVK/!'#[:97P*LIN#73G&H6H""#8@@@@@@$$$$ B2FR%9,
M:RL+,*+:=!-,@@C0@@@@BX((()!EIO*E+1*T_2 QN$U4=#KZ<%5=IDP[$KVF
M;XOY!4-2V>L*5LKC1K7+<E2M+EU/)%#5FRF]WU%EA[&>7?5GV%F^38G)E#\(
M,I:^4')H3;6TKVV,GRC#<(&*9#G"VS%<VH%["YE:JIKIOH(IM1+ $N*RY2-?
M3X6*.S1L0BWVC2G 'KLI\ETFZSL$"%ZU7J!2( ?"OB02:+&!TZX('4A(0--K
M38(RE4!?-G)9JA>Z!<S'+3))L 5&550!4*@*JQ#U$-17#/9 G!@(M((%>^51
MGJV %V#',6<DN"26.U/"S59#76X!]^=?1T(<QL:%6HZZUI<O7TP387(;U:^U
MXV;ZXI9R,K9U?ITS7N@$&.(U77<9[Y6]U;N9:F)IE,%C.U1 :#VITR2@(0@M
MJJ]LV@/:C1%WFYFWAZHJ8O!C,]0K5N:E4 .<Q!"6#/VJ6NO;;V;0"PG8"Y2)
M;9%7R_\ JQ$?;87]RL7)O8/'*GU9_:T9#[;XK3^L)[.K*V>6V5>.(EX0S][1
M_P#,:G[/'SSE^[;PF])E^3N%\%?0)KW=7U3OWV;O_P!#KFUL_CN%ZY/3-;'\
M3Q/5-*?^7R4J.(EM/CU]3:/_ #(C]]D^4?:OX0Q/A)[-)<MF\1P_@M[1YN?D
M?-Z49S?Y67^4S_I=\](E .\]\^F>/B8EA_AQ^9C7]I\/NJGRJ[?XQ0ZD^NTL
MVQ.+U>N_<23!Y R:CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB
M(XB.(CB(XB.(CB(XB8DTOJ4D3+==O:@*U8<6,:HJE<R3JT)V)G+R]0# (:&Q
M)A(0)W9LL8X*E;&27+++'\G7KZ]:(<'U*U]2$D7AJ J=$\S+J6$LGR=49&8;
M6TG"'6EL9W:DC[O&C9.Q%4'#JW4EFQ)WEEA'[N*7/!$RWB(XB:_VMKZIMG6K
MUK$B?8%<8_JYA0+'%3Y!TPT@Y^E*-+="LV<"S@XK-L;8M4O?W@1#W$=F2:MA
M#<CKV843%RVC5IL !U38QA@V8L" JO1^1-T*I%0OL2@8@.!-@VOHHK+%FJZ5
MKU2EG%.&L"EZIE2K61R[2O1_%Y(^+SDM,:92-"HL&N]?5R%9<KG&A@PP*$)"
M5SL@VL)%D)>U:DQC]<$5PE)6I1]1X]Q4H*^$V=BSU/:G1-K<1(A>4>Q'-%LI
M>"F=L!L"<![.]U!!3F^(RJ2".J_>7Q5:QWC[KJQ-UU['L]=^\[]KU^KKU3NQ
ML)A\2,1P],5,AI9;EA;-PE^Y8;[#?S2%VMB:^'-#@:A3.*F:P4WRY+=T#NN=
MTBA^Z"W'_#DA_P#X0C_R[DW\U;/_ #9?UZG\<A_G+'?G#?JT_P""9:@[RVL6
M>DP41<KUH>2:UX?>K9U!6.%BG<+U*]F#+*.AA)CC+#)GAWEAGCGUUEZ\<L<N
MNN^NC%;-P-/#8ATPZATH5F4YJALRTV(-BY&A%]1.[#;0QCXB@C5V*O6I*PRI
MJK.H(T6^H-M)9_RG2V2-'EA]4\GVC#?]ESDQL/COZ&IZ5D5MCB?Z5/WI6-RX
M2J1Q$NO4?S46/L\%^[:W//<1QBOUU7UVE\H_14NK3U1.#VI]66P_L0T_<E[G
M/!\<PGUFA[59UXOBN)^KUO9M*;.7^4>.(EJOC+]3"K_+L/\ 6,KRE;8_"%?O
M4O8I+?LKB-'OU?:O-]\C)(R@_:>S$#7[-<A=&T*M2E2C#9I8%;F%?O.@,(11
ME2T_K]?5(&)D(CHRYV[W7#BI"(^,A>K9W:O4OH*5$2E1SLJWIJ1<VT55S'H5
M;C,QT%Q<BXE&-*I4J5>#1FL[7L.4EK <[&QLHNQL; VGX8F]84>@W;,<'!.F
M$\)5P?S"QC!V483MN.@($4L>_P#"FN$+DT5:O'CU_A2R88]]]>UUSM9E6V9@
M,S!1<[V)L .DF=2HSWRJ6RJ6:W(JBY)Z -98_P"&7[RO7Z4"_LE[E:[(/I,-
MX%3UEEAV']'B/#3U6DU.5Z3LI*\\ZNS+VQV.IJR$/B<L,2I$6+D+]0>57EG-
M%KXE2J?(2 L8C)MFS[J!!TAD98&#ZA@@8LU"_P MP EKELT5#LW#"G8$M5N2
M;%5X:K<I=6&;<!<6%R3>V4U3&FD-HXGA2<MDL "59N#I6#Y65LG]8Y2"2H%U
MOF$:(EYR!:]J)*KKL-3#4%\%3^5X;@:PK!8RO73T3?5J.HE>[/5V"E6P"GZ+
M?,6^8-YPR9KE;2W8J?2,A(!65,BHM@H%N%8,;YLW;A,V8=JP:]W8M<K;.=+,
MC5"[U226;MN!5E%@N0FFS92I[9<EK(%4@,.U$P/1H(QK7$E!0/YU^R% -LF]
MA' 6NL,E08P;&M,8,<39R=.B6;CXP(6'CV1Q-0R'&X_6),ANZ2*E+A&W#[60
MT]G(C6N,0#H2VC&LR@L0"S!2 SMVSM=B222939KK4V@[KN-"V[+<JM)20H)"
M*2"50&R+90   +C.56625]^97YRI?Z#(?M^'+3L#Z#$=:OJ2M[<^EH=6WK2&
M?)^0<V9IGZUD#[4"OVC'FIC^)8KJ*GJF;> XYANM67"<H4NLBKY?_5B(^VPO
M[E8N3>P>.5/JS^UHR'VWQ6G]83V=65L\MLJ\<1+PAG[VC_YC4_9X^><OW;>$
MWI,OR=PO@KZ!->[J^J=^^S=_^AUS:V?QW"]<GIFMC^)XGJFE/_+Y*5'$2VGQ
MZ^IM'_F1'[[)\H^U?PAB?"3V:2Y;-XCA_!;VCS<_(^;THSF_RLO\IG_2[YZ1
M* =Y[Y],\?$Q+#_#C\S&O[3X?=5/E5V_QBAU)]=I9MB<7J]=^XDF#R!DU'$1
MQ$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$CC
MY-!7-A3T@:D(YIXOT=W:-<R=4,43160U>UQM=0V >NSRN30KUYY)A2W;HC:@
M^:Y:L%;5*.>*K1RLD*J9'O'E%IQ7D=1V0X:X,@5C5YIC(B=TZ/*A*@AE1J]A
MD4$1_P!7;58F?#)I95<>)ZBD!,J?2#7B/96X:&T2'N8017YC20/L/GT_G_.2
M?ASRDBBDSBDKYR1X9YP2]Q92PY98]991290230=R1]]]X9]PS2Q=Y8]]QR9X
M>K+M,3R<1(5;I\A7G7K^26 =1<F'5*8R>+,C0O3VN\[E**Q+UG) 4JQ]X]29
M]]8==0X]]8^KKOO+O\O=BV?LK#8K"I6J&KG8N#E90O:N5%@4)W#GWR"Q^TL1
MAL0U*FM(J%0C.K$]L+G4.H\TU3^Z[VC_ )O3O]%%/_/.;OS%@OQJ_P"NO^'-
M/YZQ?XE#]1_\2;<TCY!/&Q'RLM'JB["/F&DK>68VA>KVNI:D.,D76,DY2U'U
MAWEW_A]=P]]]]?XLL>_R\T=H[+PV%PS5J1JEPZ+V[*19C8Z!!Z9NX#:6(Q6(
M%*HM(*59NT5@;@::EV'FDS^5Z3D@=YH?\\UY_-F?_P"*"Y9>Q_=B^_1]%65[
M;N_#=ZMZ:<A!RQR F<ZP^LK7OVW5/OVAS6QG$\7]6K^R:;&$XUAOK%'VBRY?
ME EXD:/+#ZIY/M&&_P"RYR8V'QW]#4]*R*VQQ/\ 2I^]*QN7"52.(EUZC^:B
MQ]G@OW;6YY[B.,5^NJ^NTOE'Z*EU:>J)P>U/JRV']B&G[DO<YX/CF$^LT/:K
M.O%\5Q/U>M[-I2=BTK&3+FF8L0+)PC#]L.:IB7']LF #&W%0[.9@^K'9/$/U
M>L04NR657JE\7-%7]][Z3'#N^YES9,RY[9LMQFRWMFR[[7TO:U])2<CY<^5L
MF;+GRG+FM?+FM;-;6U[VG&DMA((9E&IAAW4!3@9PKR"%0DRAJ+(5CN2V8*F8
MX':NQ$[N%J:E<AK95JLO4\M2S'%WGG7EZP%T#!"Z!S:REE#&][64FYO8[AR&
M9%.HREUIN47NG"L5%M]V L+7&\\LN%\9?J85?Y=A_K&5Y3-L?A"OWJ7L4ELV
M5Q&CWZOM7F^^1DD9UMO)9><FUPMJ]%$NL>MS]9N%;*MK1!,'MQ\7<*1P8Z[^
M.;#03,0GGZ4A+-IO!\[1NW!\./#V %F24MU?"KO2HKDS4VH@5,I4.P*KVEV9
M;*POFMJ=P*[Y2T9$>JQJ!:BU2:88.44@M]\LBM=U-L@-@#J<PTGYW)3>V9/J
MC0:)9*$!^X]3'8*M1A78>[2IKS:"3L(@;SF+WA->M,0H+-\70$=2V+71.>CW
M9SAH2V;E3NJAF4 *215I-H5[E*B5"VI'(I &^Y&X:SKHFFCDFH #1JJ25;1Z
ME)Z870&]BP);06O;726[^&7[RO7Z4"_LE[E>[(/I,-X%3UEDWL/Z/$>&GJM)
MJ<KTG95#Y)?74Z_]9?\ ZJ@^7;9'X.P_Z7V]64[:?'J_?3V231O)*:$E%XC?
M6E<^R);[P#<AMN\27KT]6I);8W'#U+^LDLNY4):I7WYE?G*E_H,A^WX<M.P/
MH,1UJ^I*WMSZ6AU;>M(9\GY!S9FF?K60/M0*_:,>:F/XEBNHJ>J9MX#CF&ZU
M9<)RA2ZR*OE_]6(C[;"_N5BY-[!XY4^K/[6C(?;?%:?UA/9U96SRVRKQQ$O"
M&?O:/_F-3]GCYYR_=MX3>DR_)W"^"OH$U[NKZIW[[-W_ .AUS:V?QW"]<GIF
MMC^)XGJFE/\ R^2E1Q$MI\>OJ;1_YD1^^R?*/M7\(8GPD]FDN6S>(X?P6]H\
MW/R/F]*,YO\ *R_RF?\ 2[YZ1* =Y[Y],\?$Q+#_  X_,QK^T^'W53Y5=O\
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M1YS3339XQQ0Q1X]YR2RR9]XX1QQX8]YYYY]]8XX]=Y9=]===]\R 20 "238
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ML/K*U[]MU3[]H<UL9Q/%_5J_LFFQA.-8;ZQ1]HLN7Y0)>)&CRP^J>3[1AO\
MLN<F-A\=_0U/2LBML<3_ $J?O2L;EPE4CB)=>H_FHL?9X+]VUN>>XCC%?KJO
MKM+Y1^BI=6GJB<'M3ZLMA_8AI^Y+W.>#XYA/K-#VJSKQ?%<3]7K>S:4V<O\
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M3$V-Q$QMB<%92QJ9LQ\6#QO938T\B5N.KU9RK]1=S]0^\[Z]ON+J:+O/U?\
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M1\X5N R<)PW"8;@<EKY^$R9,EM<V:UN6:^5LV7*V:]LMCFOS6WWZ-\V+IO\
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MKH&PLARKG=VY.EA1:_2J7*U5SVAT1A551B>I[,@+60+KYQFUM,5==NVE\@9
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M1+77&FI?CNSDZ%\![]C\7B:3XA<.U)!@]GOCWX5"_#L&JA*((=.#I@4*G"N
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M+.G"_.6)?@\RY\G 809LE\V6^F:UKZ7E=VR#\J!L;<$@O;2]WTONO*2]D>3
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MILN8*H<@AE50.V7*26LVZ0E/9>(5$):GPE):RH 24;A0UBS90RY68D@*V8
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M AQ!"\-#+4T\BZ(IVIH!HNKAGWUR47;.SUT%+$;P=54G06 N:Q-@"0%[D#0
M2.;9FT&-S5H:@C1B!VQ#,;"D &9@"S 9B1<DS)M6^)6QM4'JA=7\<FH?UU:7
M([F?>PM;F;D8!9NSV@ZT(E/;:O9"%L)\>3[ *PN8>N!I"-WL:/I_%V,L^+;8
MP/!U5ITZX+TV0752!VK!5N:K%44L;*HRK<Y5UG(;,QQJ4WJ5*+!*@<@$BYNI
M9K"DH+L%%V;5K"YEE;#O-G51N)8[X^;<I#\R@$-C/T<T=9]9)F.CEL+7]U4W
M%/-U\89+4*?<W<?4%?J?XBU)#5BFFCK%ND>?W2PWMR'S>^83N,SM/8B$350_
MCULRI?NVAD\4Y)GT;'4QQI7X+4O4F=7;UN;K+*.++&/V8,NN\^^NLN\<?7EU
MN[/Q%/"8E:U3,RJK@A!=NV4@:,5'?UFICJ#XG#/1IV#,4(+FR]JP)N1F.X::
M2&?XC/(3_P!R+-^N&H?[2.6#Y]P?XF(_4I_XL@OF7%_CT/UW_P ./Q&>0G_N
M19OUPU#_ &D<?/N#_$Q'ZE/_ !8^9<7^/0_7?_#D]%_8S^H)(2D6\>-J_P#R
M75AM4G9K,6BYJ_\ ZE$PPW9X.OQQ8V)8?_1I)(NO<8S9X>SU[GK/OV.5?$.M
M6O6JJ;+4K5*B@WN [LP!L"+@'6Q(ORRR45-.C2IL+FG31"01:ZJ%)%R--.6T
MZZOX3=LHQL'T<6F2$FK'I. %_*?5S )868CKB>@0KW],[QL4*L=)5?64Y7MW
M*=SXS#JZ)JUXHJT\5JQ!:[KUY_0ON8"W9!B]1^",1S_GF Z)&;9-\(FA^G3F
M_$J=,ZE:#M/6-#7FNCI-]H!3&K_&WRFT>1U3*$=+#"[-NZA^]:BJZ@+XU:MH
M'0GKK="K29IV=O7SU =JRW)1'E9OHI4O^N5\-B37Q"+09TQ.T=F8U<4'HBG1
MI8-L":M&HK5%KYO_  =4TQ2I5$9L2H+)]]*P"N@1"6L4HUJ12S79JG"Y6!"Y
M;??%OF8'M-QT$Y?56PM1(P#5V!+;JY)WH-\WZRD5N@N;/RAW6+V7KU%%C*B?
M),B04JTK7*M7-<O$6QID>&@M5Q%^MVP5)[=.EPQ6'Q=>IB<N%J6Q]# 4EJ-4
MPU\$V'Q%=G-4"N2>"%5<11^3"L6JEU/!D!SFF]- GWP?>GJDK9_O@=5 R]K8
M9K9&#Y0  =;D2W_\%>832YY5^25D(B,S[//X^4X)AZQ?3*%JE%UL=6D^,LR.
MK6I4LZ_>>.,/6%.W:M>\DQR[K]1=9RXT_P"ZE^"=G?\ Y ZZ_FU;F!^!)#8G
MT];E^\]'XZ\Y$[,'I4MR&WGT97F['3TKLL2+AU3L57*'RQ74?RX.47"_80WU
M<K#-GDC5B"@3H6:W<HH21^)]CJ:EC9@SPER\Q[$A;LEV-J./4N?IZ)-8XWP>
M)T/T;#D]\Z OB8XD@24>%(NUU[3S[CO;1S<P'C[X,UYB5U(M#]C0LF.!0H2%
MXLP=:.E09-BUJ+D+GG3Y@%MBE%FS6)NQ/T#M6BKUD:MA:F+H?(<;2II3H-B"
MN*J-AS3[55;@WJ(KK3Q#Y*=+*X:K3X09ZI08A6RU!3?A*9)+A+TP'S:FUP"0
M2@N6N+*;3FD@W"/J;ZRT%L=5TZZ[1?TU_P!4%.MKK>K"8710/8&Y1;)K<FX$
M&$!336/(]AJ!Z^A!0R/*FUA1&'AU6_%V+AN<*R%C@?E^'JXNCAJ%6ABE^2U,
M4KXYZ&#:GB%I*E0U:83Y71X=$9:=6JR,R]N1E3;A>"<4V=E9.W5"*8:H"A8L
M,IOD;*3<A01?22T]&0WKI+TZFMG?50"PU)YCR-\A#Z""5*X9>S**AE6VW: =
M!:#/>51 :IB%MUK=<:2N"O@*,?5'&/JS''6SB.RA*M/L'Q5/$7%>GL_9Z5LS
M9SPJ5L(M3,P+9FS@W8$ACK?6;&#*G::,G<FM5*VT[4BIEL#:VEI]$*IO-GOG
MC2S5\>]N2FEZF&OEZ?SO1V'56JP?,NA,O5B3<.-6?XKY00]>%:::2#W'_I&$
M7O8?>?.UND>?W2VWY+'S>^?*7U0SJXMDW^K-3'40OQJZZ:4(*\E:)TB,4#>.
MQTAYRR,0J EC9,1K0&2C.N[U@$%+2PPN.<ERMF&Z(R8?5N)IU&I8"I2IFO\
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M<-'FAH;"H8&*CL9]8TAM?WL]PH9(1SV<*(&FQ,01,6\7\YI-;\RE5LM R@A
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M:<XKL(W7]:FDSFRVG1&S++W#>=X-P4O&R[ON._<UI^+ZJ#G2(,*5A4S8\7'
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MQ9!\ %\]E9+8YI+ 4Q87L#]GQ?O^+=><*@R#W)35V\3<$D134NA6080 EZK
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MBZ08.*>)Q>(KTPX#*'"5:C*&"LP# 7 9@#8F=:4:-,YJ=*FA(L2B*I(T-KJ
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B.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g713200g95b62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g95b62.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[13R4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <Q(,4
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
MQ   !X0          0                         !              >$
M   !Q                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !Q     !29VAT;&]N9P  !X0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   <0     4F=H=&QO
M;F<   >$     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X
M=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI
M9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!
M;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#
M;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )
M=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O
M='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))
M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    '.$))300,      IC     0   *     F   !X   1T    I' !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  F * # 2(
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MGI5O#M_M]C*_S+/^FMB^QU5+WM;O>![&3$N_-;N_-24MDUWV5;:+?1?N82^
M3M#VNM: \.;^DJWUJKB5=9&6ZS-OH=C;2UE5+'-.Z6EMCWV.?^;O:B69%K++
M8?6YS*P_T"8(_G/?ZCC]%^S]QGT/YQ&#[W-!#&B1.KI_ZEJ->(5:5)#C(/+F
M#^R3_P!^3U->RIC7NWO:T!SXC<0-7;?Y2"FAUFRNREV%8[*QF6^G.9B^TLE_
MM'K#=MW.K].SV?0N6DL#(MR[\1]EF2W8,AS11L;N<UF2]E7O#OW&,_-_P/\
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M"F)AK-K8U_X)2^WX'_<FK_/;_>E]OP/^Y-7^>W^]"AV1^Q?T;/S'/9\7[O\
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M QNUUN[>1&AL]7;9O_KHR^54DE/_V0 X0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H "Z/$   )Q  +H\0   G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,3@Z,S(Z,C, <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0  !X2@ P $     0   <0
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.#HS,CHR,P!R<C4P.3$V-P       Z !
M  ,    !__\  * "  0    !   'A* #  0    !   !Q          & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
M @$ !     $   %& @( !     $              \     !   #P     '_
MX4  :'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G
M:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM
M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E
M(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU
M-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @
M(" @/'AM<#I#<F5A=&5$871E/C(P,3DM,#<M,C%4,3$Z-#4Z,S<K,#4Z,S \
M+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$Y+3 W+3(Q5#$X.C,R.C(S
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C Q.2TP-RTR,50Q.#HS,CHR,RLP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z
M4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W<RD\
M+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @
M(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S
M;V9T(%=O<F0@+2!'96YE<VES($8M,2YD;V-X/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @
M/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/G)R-3 Y,38W/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z
M9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@
M(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I)
M;G-T86YC94E$/GAM<"YI:60Z,$)!.3,V.#="-D%"13DQ,3A%-T-!,# P,S5&
M1C,X,C,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/GAM<"YD:60Z-T9&1C,V140X,T%"13DQ,4)!13 X,$0P,4,U03=%
M-T4\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^>&UP+F1I9#HW1D9&,S9%1#@S04)%.3$Q0D%%,#@P1# Q
M0S5!-T4W13PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z-T9&1C,V140X,T%"13DQ,4)!13 X,$0P,4,U03=%-T4\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM
M,#<M,C%4,3(Z,C(Z-3,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP04$Y,S8X-T(V04)%
M.3$Q.$4W0T$P,# S-49&,S@R,SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-RTR,50Q.#HS,CHR,RLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z,$)!.3,V.#="-D%"13DQ,3A%-T-!,# P,S5&1C,X,C,\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM
M,#<M,C%4,3@Z,S(Z,C,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,$%!.3,V.#="-D%"13DQ,3A%
M-T-!,# P,S5&1C,X,C,\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-T9&1C,V140X,T%"13DQ,4)!
M13 X,$0P,4,U03=%-T4\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HW1D9&,S9%1#@S
M04)%.3$Q0D%%,#@P1# Q0S5!-T4W13PO<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO
M<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" ". ET# 1$  A$! Q$!_\0 '@ !  (" @,!
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M<YVW-'8M6;$-=E6*>>66.M&YSXZ[)'ES88W/]8LC!#&EW4@#?59F@AK07<Q
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M82M^7,?9CLH6ZXE.<U>O+:FC@A&Y)#H;(:UH )<][CT9'&T%\CW>JQC7.<=
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MVPA<WMG@#Z\FW=3UZE5XJT,//R-_G'F1W,2_UG=Y'-O7LT-!2BA#1PQE$<=
MA#X[>,);8A16(C*$X_!*&F&VT)QC\L)3C&.<RY\DA+I)'R./4ND>Y[B?:2XD
MJQK]%]O/*)PB<(G")PB<(G")PB<(G"*F_KA(VS7O:/;UILDB @:K-.;7N^*4
M,W-FR2QYR?8:U\&>GZ\=W2=P$FVF)(39'XT+3E69$N%93+Y-,I,AXZ\^?/\
M@\^=_GXJY#A%7][5G^YL]X/]&K:O^[$[A%-2@_VB4K_-*N?['A\(LMX1.$3/
M"*IK2/:O71?NSVRUU6:9M2QE*HL&PDN&%0R8DK(KG@->D1XKR1,IOY%8Y4,=
M"1&?).SV/BY2&L,,>]5]#RG!UVMPIPQE+&8K,99;:>ZG:NN'H[;[Q:H'E:)
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M)E;*%I^)9\^\3DA:'RQ,+'RATC&F.,\LD@<X#D8[DDT]^^5IY'Z)'JN[C!Z
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MFB_IG_)PBG[PB]5J]"%K]*E^A*E>A&/4M7IQG/I0GZ>I2O'A././.<XQP.I
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M4QR9G*0/,9!]61M;!V6.'K07V]'*">I>HXRE]R^P>RZ3M&_3]@$:W6W9.+#
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M+;9V=F2O$^=A;R%LCF@N!9L\A![V[Z'HNAH"^*5891L+,B(6"ZR"2*6!MD-
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M1CQX\)0E./'X>/&,8_+FRT/9KX=/R6L+G.ZN<YQ/>7$DG[R5U0RMUT(X4>#
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M=OV/YA[ %'GM=UB+;BT)L'75;NVSWC]E%M0X&57^3&8<>;EL/X;FLR78HMV
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M6F-1;/L97[?8ME VF"R*OAD.)P=AY/?&CX6&LMR!BA,1"8XW]:GW&7LO>_\
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MZ_G_ &00B?=_P<_CG^^2CDJ//GR%Y19CV?/O->VAOZ_3P1I:_./SS]VU>?\
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M9IIQN,A+>?=X+5W,Y""_=R^3?<^:\A3N4XMF*"OB;T3,-<C;4C;'7B;1%/#
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M:S^2AL,AI3/%[MVL#)HZK86UZE>2%D+2VY9G$3G<G/"^6P_;F0;7VO\ TH>
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M=OB_\=\(G],6D_Q#?:+?NWQ/_O>^$4Q=$;FK'834M,W'3AUD#UV[P9DR")N
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M]7; LNNU$Z&]\$/\U$UFM?-@3>8C>8\&8U&RI[W/OW2*47"*+';W?=IZY:Q
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M < R2ACCLV#& DB>?A_!:HZ6=K(^W=E[AT@#UEK_ %[1=2(,/:_A:^GYQ\J
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M;H$C\@VOU]:>&4#3\':^U]APD7"J3OL@*L&O7++=!>N2M:ES8S135-\QL^N
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MQEA&%MJ:(BWW%OP)2%I=BO\ I?94AU"%I(ODHFB--:PL=@N&O=94RH6NUCQ
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BQ_DQPB\\(G")PB<(G")PB<(G")PB<(G")PB<(G")PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g713200g95n07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g95n07.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X:[@:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,C M,#$M,#=4,3$Z,S,Z-#4K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,#$M,#=4,3$Z,S,Z-#8K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#(P+3 Q+3 W5#$Q.C,S.C0V*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,30T/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G06M!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X06HQ=F)W96A(*S=8-TLO<VIW
M>G)G)B-X03M"5&]I53,P3'ET8S8S2F-X,DM197)B4D-::VM+<'E":U-)2W)%
M8V%L<$(Y;V=E*U8U8VM95F96;D-%<&-K,$@U6"M:9E9N9V5Y:%,V)B-X03MG
M9T9Z.5A-:U1/,&9.:TI"475Q.%-J5C5L96Q0=%5"<2].671J,'5U5%!W2G%S
M9C5596%*46]J<V]8;$UN<$Y#<GAL;%E">6%N-TA3)B-X03M);EIJ,G!V9T]R
M>$0K>% U96%(6#AT9DU$4EA:1FY%6G)*;5<U="M3.&PT0FUB-"\W;S!%6DY!
M.6%D='AK=GI/4&)Z4C1%,5=0.'$O)B-X03M.8EA8,60Y3VEI;WI#4U)P64=6
M06A13U1W6GEE4'%R<V]*-T%%-UE$<3A66"MH27=:1TQ',V="<#9A9F-->7%$
M4EID.5AG+S,R=CA!)B-X03MW27@T471L84QE1&UF,V$Y0BMY4&9),$Q497E)
M:#!X<%EP3&A,579B44928U1,1U-K9DUN:GE90VDX<4=L8U1W:F)A,49L:V<X
M=69L)B-X03LQ27I)=FU$,%!I1$Q,2EI3=4]"-#%4:6DQ-4Q6=FDV3E1O=&-X
M*U!+4#10=$1D=W<O;D\Q1'EP-4QT-#5:3%!66F(V5TY*6&5Z5W=L)B-X03MI
M9$9%8F5L23!J:FIX85@P*U<S,E<V,39I1U-:-7A!*TDO2&5S;U)(26XU358K
M<G=F-S=8+V=2;5AW:&]S=71,0T\T,4)B9$5J1'I')B-X03M/3E-W055&;4E&
M5#)'4DY#>6M79&U54R]L6#5R4DAL5%1O-6)D6&MJ5UI:259$1TEU1TE34FMK
M2#DR,4%Y02LR630Q94QV.$%S8FIG)B-X03MM=5 U5F5A;#5'5W=G:E=.=45R
M971B=45)2W$S3# R8VII6%=O-C<Y369Z94PX0F9Y.#)R6#AR4$TQ,6)P4$):
M,C=I4FI(2$=*-$]:)B-X03MD4U9:86-T:7!!<EAX2#!-=%AI0F\O8V\P.'EX
M43(X2'%$.3)V42]S:GA'6D9#,FUZ5$MD4"],2%@Y4RMP;E1O3%<W1C-#2GE9
M-5EG)B-X03M95DI885I72W-R0EA6<4%';T\Q8W@U-G)(1S<R<GDK-71'0UIQ
M;E%F;&0U;FYQ,%=N>'1%<D9:6E$X9D9&04QC,S-Q1F]P-V4S56EQ)B-X03MD
M5FE#9D%M>%=3,FA7-5941VQ1<F<W1'-6>DEO5S R5U$R6&M056(W4TDY4W-K
M='!W-&M:<E98551P2$9Y-5-/<D)60R]U,G X5SE-)B-X03MP;&YH1UA#43)2
M>%-)<TEF5V9**V\V2UI5,4\R:G0U-%AJ4U-#<4]W.59'9$=Q;DI+14EF,G-L
M:GEW;CE+2C0U4C5P3$AB=V,U9C-A)B-X03LO84@W22]L6$Q103%K<W1L+TLW
M>D8Y4G1R-C%T<F$Y=&)I1EHK8T5K9%DV>&U5>'E++T)G-F]P2F]#4&5U67<Q
M5T]Y1'-2-4XU=U1Q)B-X03MX=6LK<V573&I34%)&-T9%:W-X;55X059+3D)-
M,$1Q>'!X4'AX;F1723DX='AZ:E!L*T]R6$]":GI15FAP>5AD,41A>'!'2DHU
M4D5H)B-X03M904M#-SA253!/,BM3,D%*.39.>6%:1F4O;&PU:'1P=45D<F(S
M:TI$=D9D5SAS5%)32DA%2FUD0WA6:6]2:#(K5U5X,5=-:G4K1%EC)B-X03M%
M=VM/=F%'9$QL:W1*,6EA5#!)-7%O<'!X;FA76E(X4W$Q47)I=3-83%EY16\R
M4% W1T5G66UI;E!K6%$P,4A7<$E5<S=7-4-7;'DW)B-X03M1,THT2E0P;51K
M0T5L*TI#-%ID=6\V:G)L97!K27@W='AY6C1!5$HV0E U0S!'3%A:-T5E53=*
M1G0T4DM&:S%#-D%L5U)3>%I$-F)L)B-X03MU0F=K5V]!*S!T84A.94TU34PT
M:B]P4BM/;V-R=VAD8U R;#5Z-3@P5F)#+TA04V]T2U,U<V]:-&)+37,T5E=I
M-#%*9%9F:U=1;&=A)B-X03MK2&%P>E!W15-G9"M+:60S1GEG:5$R<$QB9E1.
M4TYV15)B=%1G=C=59F@O<EIR:#=185%F>$@U1G%-5U(R,S589FU$8S(X5GI"
M;WI0)B-X03M$36EY4DXY671"5EA&5DY$340P3UIO-U)W:UAF,D9U+TMZ-VM4
M3BM6+W=#844V>$Q.<$TP<7=*-F-)93=T5T-)0U-%5W,K>3%9;6=X)B-X03M'
M=G=J:V9S4V1.:TML+WEQ8CAX+RMR23,O4U1:+W=$5F)$+TM'2'8K=V\O2S5/
M-3,O2W!V>D@O-G-J9CE*3FXO04Y6<V8U47<Y+S)&)B-X03MF>754=60O>7%B
M.'@O=T1Q>4XO,&LR9B]!1E=X+VQ$1#,O658O2S5/-3,O2W!V>D@O=T-R23,O
M4U1:+SE6<V8U47<Y+S)&9GEU5'5D)B-X03LO=T%Q;2]-9B]Q>4XO=T)*3FXO
M,5=X+VQ$1#,O04=&9GEU5'571#AQ9GI%33=X:E)7-7%Q<U(Y671/:D9G4#A!
M9#,K4V-(.&]9<C4O)B-X03M952]L6C%Y5&91=DIF-7AA1DTX,FLV83ET2DI4
M;7=M<TAR>$)!,F56:"LP8W)Y-G)4>D93,RMB2T=(3$AL*VA.:W,O>C=3,6IT
M:W-I)B-X03M%:DM&5S5A85132F<X83=U4E)',T<S-%5Y;S5.3&0O<F)/2%!8
M.6E&9E%V>GEC<WI75%9E2U-!;FYP;R]D>6E*6$%O*WAP8G@P23-&)B-X03M.
M=2M3.&949FDO4#E:4G=:=GA35C9R*UAN-7(V=&1T95@K:W1.8W98;$HV,6EL
M951&>G-K<6HW5$A,66$S0D%51'0X5W571$Q),E5U)B-X03M8.'%0>D9.,4EN
M-D9B:T51:V973%1O4SE0.3-E,E,O;$1&9E W0VHX<E!U5F8K5E1F;5 O04Y7
M4G8K:VUZ+S9R668U47<Y+S)&2#58)B-X03M*,T\O-59.*UDO.$$Q6D<O-E-B
M4"]Q=&HO2T=(=BMW<BM6>61Y<2\U6"]M9SA%9'4K:WI.8G=L;6AH3C-A;$5,
M,#5&5DTY05<T:71-)B-X03M(-2]$9#,Y:69Y,E1K:#(O2VXX>$)/:UHP5G5B
M2WI!9E=,5&]P54@O04AD+VQ$2"M5358X+W-++VQ:,7E8+SA!2W!V>D<O-G-J
M9CA!)B-X03M35%HO.59S4#AO664O=T-W;R]+-4\U,R]!0W%B.'AV*W)),R]!
M16LR9B]68D@K54U09CA!658O2S5/-5-B.'%F>D5&,4=N-D9B:U5C)B-X03MG
M9E=,5&]#;&8Y,V4K1"M5358X+W-+9GES*S56+W=#5E1F;4XO=T)74G8X07!*
M<R\K<3)(*U5-4&8Y:%(K5GED>G8X06Q5,S5J9CA!)B-X03M6:V(O04M38E O
M<71J+TM'2'8X07-++VQC;F-P42]L5"M9:E-49V%+>$MU03,K:U=M>#1+9CDO
M94)W1'1$1C,O04=&4#579F-Q+SA!)B-X03M+<'9Z1R\V<VIF.$%35%HO.59S
M4#AO664O=T-W;R]+-4\U,R]!0W%B.'AV*W)),R]!16LR9B]68D@K54U09CA!
M658O2S5/-5I$*U90)B-X03LU:4]H2V%+>$%:,2\S;W1/<7-64"LW=D590C)H
M:3<O<TM4<%HY>2\O04I63BM9+R]!1EI'+W=#:VUZ+S9R668U47<Y+S)&2#58
M2C-+)B-X03M6,2M62#5I<&%Z3S)I<T961TQ(-GAA9$%$+WAD9U!A1TMU9C)&
M23!S*S56+S563BM9+SA!,5I'+S938E O<71H+VQ$1#,O655F;&-N)B-X03MC
M>78O04%2<71Y<E(S9FM)=V9U,T5-.79F5W169C S0VQO>$Y%2')+>7-A='-"
M='1T;4HK8D$U6E!S8VIW8C5X*S%H.3$K5D@U:7!A)B-X03MZ3S)I<T961TQ(
M-GAA9$%$+W=!6%IL2'1$1EA0-T,P1%-Z-VPQ<"]V3$0O<4PK;UHU9DQM,6Q0
M+T%$:#59<W16=7)7-&LX=#9X97-D)B-X03M*9W1:3#-40D5%:U8W5#!Y4UIB
M854X:U,T25)K8SE'0D$R1&1::BMK934S1653:G%N:WIY-7%&:F(R,$]J961,
M3C=+-4XS1&-24E)7)B-X03LW;#53,7IY1$I(3'9(2G18:4@U54I**S%K,&]T
M+TQ$87!F86@V-F5D,RMV0S1J;&EN:T5D=CE5:W1*2W=0-F=N5UAI=V(P,'!X
M16IG)B-X03M$8F-Q<B]+;&YR3VPV9T5V=$(Q=EAJ4%!%65ID4FQM93-T4%-V
M26YH.4%3,GEY<6M7.&DX,TE!445C4S=Q<7)/-5!Z2W91=TUF;$A8)B-X03M4
M14I05&M,,G!6*T\O=T,X4E9,:&QP,EIL4&E"9U9.9DPS;D4V>G$Y-W!Z85)F
M86,Q;DA&3C9L-T=S9DI:96YW:&U)*TE-0C0X5WA6)B-X03MK5TMO85 X030V
M52\O1T=(+VE5=4MV2&13<W)+6'I0<6MV-D8X,WA81GAQ3'=Y>E=I,',U06E3
M;4=:0S!E,$I-:DYY569#-%AC-%92)B-X03M/:V%C=&\P:VIR-31%;#)S=G%S
M46]64E!/;VIJ05)P1U@P1E@T2TAI<6QJ,S)643A7;GI.<#EP9GIN>C%024)D
M;C!Y5VEU;UER95(K)B-X03M-65%E;WI037-Y<40V;C=W24<R27A6:TAK+U=O
M1C%M1D1P6&TV4U=5>%)2,T]T5S5A1T589'1(23-X:S%54B]607-H,S1Y368U
M<T-V)B-X03M162\K3VQ0+T%-65EF*TI3-'%X6%AV2TAN;38Q1SEV3D,X-7EA
M3W0R,%)7,VMS;S<Q26QJ:EI'5D9M:T-R>5IG,5959EHS<G53<7%P)B-X03LU
M5#@T>5<Q,T)F96)*2B]6=5!7=%1$86DR34U164U):3!5;VQE;$]V34$Y0T-V
M=S1Q:61'.'8X06TR>#%3,VYV4$TW86AP<V-$4GHR)B-X03M%;'!#:E-416=R
M3C8V;FUP1R]W:C1C5F$X-7A8:VHR4716:UIW2E-W:7%44W%E1UI/;4U15'A/
M4'%"26=5>'8V;G(O*RMB;C=N>DPT)B-X03LX6&LT=D)K.#-F53EF+S-Z8R]C
M*U!(:3AL-$UN;71.<')F<4M$1F-E;U%3;V\Y84%I=CA!1$AJ>&53.$=4>EAF
M53EF+T%..#-0,U!J)B-X03MX-'9*941*-74K<#8O=T0W-75F=69(:GAE4SA'
M5'I7<F%A,E=C3$9C8V=A4%%0,6]$=CA!4E1(:GAE4SA'5'I89E4Y9B]W0C@S
M4#-0)B-X03MJ>#1V2F5$2C5U*W V+SA!-S5U9G5F2&IX95,X1U1Z6#).<C5I
M37EM,%=:2#5%0C)$0D%W86@U5F]0=&1C<GEZ>&-,6FIJ:S1M62M7)B-X03MK
M.'EP64]034UL=DIE*V]X43)O64E),BM)03AV-6$X96Y19"MU66UB9W8P6%AM
M-6-/2W95:F14+T%/3V)D+SA!1T=4+T%):6-Q6F]N)B-X03M&6%EQ:'14+T%/
M3V)D+SA!1T=4+T%):6-69DXY<"]V3$0O<4PK;UIY375B<&DY170Y5B]-<3)V
M<E<S,&YY+T1Q+VPK2WES94I8569Q)B-X03LQ,7IM:5%U-T8U>4973VI56#!F
M:3=(3W-H.4ED>$AK:7)N>E(K6E9V87).2C5$36)L875K;FU+2D9$.'!"=T1K
M8FMQ:45D4'15-TA*)B-X03M*5DEV34@U:VTO=')36'E236ET0S@P.7E.6$)4
M:VMH:CE-56%I<WEL6D)6:G1553)*0E92,5169GI*=&17;'0T3%=W87E3-D%E
M5V$V)B-X03ME3U-/>F4X16%Y;%1F5EDO5FTU8FAA=G-&-D)L5CDQ<68U=#)M
M<'@K;C565%4Y3F$R3%-#2%5V<3!Q6$ET;VY#.#5B:5%&1% V<V8R)B-X03M0
M03E&<316975U+VUH2E!D<"]G85=#2EA32WIL8E=O<$]3=$E6861L5U)D;%-J
M96YS5# U8C=+<S5T3$9M=%E7=795:G541W!N4DQI)B-X03M9<7-H035"5'HS
M05!41E9/4%0T4#!J3T]5,SEZ1"]U*V(K85@O3'A62DYF;3AZ=S,Y;2]L,G=4
M5CE.1&U053!..4I&3W)E<7%(,#-A)B-X03M8:"LV57,W2W=Q86-2431Q;&1P
M<78U:B]!1E1N92M65$A.1W!A5VUR04LQ230S;W8W,2M0>',X935P.%!,;V%9
M5E=Y96)036LR;S,Y)B-X03MT<%AL<5,X9W,U4D1(8WEA=CE8.55/:V)W>6]R
M+V%J:SE29T-#9G,Y-C=+<VLX=5(V,617<W)A-5EV<#EW<B]U;S0W>5-536A5
M2&-Q)B-X03LU;U99;&9E;&4Y34-O,E!4-% P:D]/53,Y>D0O04QV;2]M;"]Y
M.%99<G(S-6YF;#DU93%'.7-D9'9R<E0R<VUI:F%743-5:4\P,&)3)B-X03MQ
M13E%>4XY;$0Y<%(W5G%-5E9%+TU4>5!08EAC.6ID,U8Y.5)U4'%L,4A#.#1+
M4SAG<$)E5C0T='569G0Q4%%68F)#<4LP8GIR-4PQ)B-X03MF5DQF4W)/*W5F
M,&QD44YD45=S:'9%6F]5241.>6(T061X.$IB;#=91E)8;4<U9S!Q-'1:=44P
M,TY*530O5UIL<'9'83%Q,VAL,DA&)B-X03MX;7)A<W589T-7+S1T9R\U635V
M*VMY8DUJ.&XU+UDP9FTO2C,K3%E0*U=/8B]P36UX+THK9C),*V(X;$IV33A"
M=45M*W%49D%J<'@K)B-X03MT>F(X>7!R6"]962]K+U W1B].*U-R+VDR1"]L
M:FTO-E1*<V9Y9FXY:2]M+THS*TQ94#A!;&IM+S942G-F>69N.6DO;2]*4VDX
M>G=2)B-X03MV33,Q4UDK<31E;C%U655O:7)4,RMZ:BM4."]S6#@S-4MV.$%I
M,D0O04I9-78K:WEB2#AN-2]9=C5V>6)4>EIA;&=(=$IW;&9I274U)B-X03MI
M45!98EE$;R].4G$O2DU03'5Q95AT5&UU<DMZ=35:3'$R:VME94PQ6G=65C5'
M2VYD:#)/63@X36]G16I9=51'64IO2C4K:C10-35V)B-X03LK4C@S+TYE5DTP
M3G%7;G=$5')O.'!V-VU4+V0X,SAP+WDX5E1,1EA9<6AT5"]W0T]B9"\X65I0
M*TEN1EAJ4TQA:CAQ-T%X2#DX,3AR)B-X03M49T]Z04XV5&=65V=65'A!,C,R
M,W(R2%!402],-V9Z+T%.8G)P5C1F>%I)9DHO;$1Z3EI7=&IE<&)Y83!T:F(S
M0E-,54I6=6]!645I)B-X03M3-5-!0FA',T9102]$-S@S*U V43=#4$I-3$PX
M=F9+179!=S)53C%,8GAP0UI6,4<U6G5-24U+:&A'06]#*VUY:%%!05%104UM
M;&IS)B-X03LO:W8X<DQ&-$Y0,4Q53$@P8DM782M45&)Z5EDQ569715(Q9&=9
M,&LT>%(R;SE).'1L0C-)<FEQ8S)0:W8X=&A*3D):,E=M=$YR4U-1)B-X03M3
M2DAQ37I08W%J<3AQ3#%:=4Q7-#5C96Y';E-U2W%L>BM79C5F9U-36$]J5U%Q
M571*6DI,-C1"3%-S1E-&,E!5>4Y-0490,FDS*U9I)B-X03MR22],+VPV,CAV
M5V(R5VHV9D1A,C!K;G%T2#E:;6LK4&=S9&%Y235(=WAQ2V1.<T-P;C9M<&8W
M-&@O-4A.+S%3>%9$4GEA:BMK6B\S)B-X03M%3F92:"\S8S,X,'8O1E=+<UEV
M+T%#3#5(,4173&<S=6U733)Q,U1L-31M=G!V55IY035B,&=/=$%$<W94,G=Q
M=E U8F55579:2FIP)B-X03M&=70S9#(X.6Y)5&986$M30S1*95I+9#9K:S$V
M:G141E9#-2],5'E.1$4P3GIP5G1$2&1I-&I:6#%'-U0Q4')B8S5G2VM63$5B
M9#$O)B-X03M:;TU64G5H*U-T03!J5GAF-E):=W<S4$=A67=R95-Y2WAU>6Y+
M8FDV3U)8,&%,>&]U-V)63TMP.4A*<5 V4FXO04A%3F92:"\S8S,X)B-X03LP
M=CA!>%9G5F9&<4TP='I.87AF5EI,;3(T+U=)1G53,&MF36-K-7%)-G)Y1S1R
M,7A68F,V;SER8B]78G!R4T,S1$)05VQU94-C;6)G)B-X03MQ.&UJ07%73D%0
M2$9684\U=EI5-7A2,CAI9$]3>G-2=#=I3$95<3%U,2MU6%9Q;"]&0VMA>'EL
M4V)H:TA+<V9F,'AK-$=1-4U:04AM)B-X03MG=C!$;S-H8B]W1%-A,R]64$HX
M951V3$1G:#5/+U%/:F5&=B]!3DIR9CE5.&502C-L94-(:V]V;V5K+UA);$%G
M.4UX>49V.$%41W!5)B-X03M-;$XO5#EZ:G@U3SAO-$EE4W0K9V1'.$QF+W!.
M8B]Q;FIX-4\X<#1)951V,$1O,VAB+SA!4V$S+T%&5'@T.&YE5C1)95-J0F]E
M:VU7)B-X03LT1$-#:7E!2E<X8G V84AB.3,T:S0X951V2T]#2&MI;W9,3VUZ
M5CE+1TM3;EAJ9'4S-F\X0GEZ2%5P1T]"-D)52&Q',4)"*W%)861J)B-X03MC
M>550+TI006-S:C%33552,%)E:C)45WEZ5%<R;C)K37,P<V]M;%(K3'5%;&-+
M1UE25F)J,G)K5$EK55-Z04-9*W!Q6"LK268K4GIF)B-X03LY57-I;$1A;$IQ
M4#9/=7%W43 Y1U-V-S5V-50O04U667%M5TMU>%9$86XO>'IB=B]!27=Y9CA2
M3TMV1&]7;F8X=F)0,#1V5'19<G-,)B-X03M+-&Q*.5-:;V%H:D56,F]L04-'
M.&1J,C5U9"M&-6-89C$Y>G)$.4AX5$A7=DE",65A4%5'.&U1-C)S,FU78V-6
M-3EE93!K9&QT:D=W)B-X03M:1G5),5EC2E-G*T933GI5+T1N4EDO<$AU9&Q(
M:VQ6>"M6,FXR*VA8>5@O-6-Y0EDW25=T:VUN-FQ02DTS3SA745)"4%9U869'
M-6U,)B-X03MK14M&23-R:S!P,7%N:T173EAV3$]/-#AN,G-7;G)%8E9K;'9*
M;4U516MC9DI#,$XU2#9O16MK-#5'3V](1FQ"26]6561*-4EU3#(Q)B-X03MS
M<F$U.&U7.&%7>GIV53-0.3-(1S5U8EI)6&IU9R].-VA6-4UA0F%K531K-'%X
M,C4O3%!724Y3<W14,&YY2D1B5&%:4$AC,G1Q3E-8)B-X03LP2EI)0DXV4FU$
M4U!123AN<41H5#=81G511S9R,F92<G)7<FA*+S!P64I:3D9*-F-*4UE3*W-Q
M:F552T(X0W-F<W%35SAA64942$95)B-X03M.2"]X,' O*TU-4"]!0DM81EAM
M4&U042]-5W5A<G%-5W!E43%V8E<T=6IB0R]85G9Q,W%78UE*:&XY1T]937)$
M:GAD459:='5W;T-Q)B-X03M(="]Y.719-T@V9V9Y-%-/>FMJ0U-X4C8P>F)K
M>'A(8W-H3DEO54IA=%14>#9Q<C X;3-+-F)A>7 K6#13-%-#-VEN<T@Q;'!$
M>%99)B-X03MO;UDQ;DUO2#<Y25903FQ*6&IV=7AX5D]F2F$K63E,=F9Q,%AK
M3#E$5U8S2D0Y8G4O=T)+=S-255-P3&-43G=*6FE)8FE6:V]$.%A,)B-X03MK
M3G-#<S9J+T%/3VQ0+WAH:"\T;$QI<D104#A!*U8O;&Y865IB>'1$6%4Y4W5,
M:3)A6D=U2C11>4LS<%-.*S=N=#%(1T=743=(8SEM)B-X03M/2W!39DM.,W!6
M,7)+-F8U2U<K=')U4U,X9VM853)I;&MK-$E1:G9.3DE5859U4VM*>%%+;S8X
M<4%Q>4QY;C5),$<P=6].8T]G9F]8)B-X03M78E9*<DM"0F108V-B6#%#12MY
M-6I):U)696A&5C991E(O;793-W)56G)/2S(T.#!75GIY3DYQ>&HK3U@T36]G
M5&)4;7AM63)34#A!)B-X03MW6G)8:$@O=V8Y;5I0-7E08S0S-5=893<O0FUT
M945F+T%!9CEM4#5Y4&-V-5=897!N>6QR06Y32&I(>6178TAL=%)#;U!B+TQX
M+T]2)B-X03LW;"]+>3<Q5"]";71E168O04%F.6U0-7E08W8U5UAE-R]";71E
M168O04%F.6U0-7E08W8U5UAE<'@K5719:V5647-D66U#3CA88W%R)B-X03ME
M2&<R4#5Y4&-V-5=896TR9V56.5)S-SE,;31K16%X+W-)83AQ9VEH.7-O>C5X
M355!,S1C2F=B2EI8;4TU0T<P+W=$=4@O-'I4+SA!)B-X03M*-3A64D]+;V)5
M+RM/8F0O.%E:4"M);D959S@V955T83$K4WEB5&9-1GAO471Q*W(Y5SE5;5=S
M.$5U+T=A2E!S=TUN>$LR>FYT54UQ)B-X03MK5C<K5W9N1S0P3TA3-"]/,3-B
M>5)68CE)4G!C+U=#>E=H='E#-79$>51N4U5"=51"<3!A<#5"5DYF3#-L8EAD
M0C S5E)Q;FU#8EA%)B-X03MM=%EK=#%N5C$Y17=1<W-H1%-45',S<7-E4C5'
M=FE4=%)6-6EM=5=R*U-B2%)O,&-42DEL>$MX,U1K1F-656QZ,58Q2$5)3VA/
M.6,U)B-X03MQ95EE2'=E9"]E-G55>'=C2UI8,G)E8G)455E.3C!7+S!"8F%A
M>'-J.5=V-V$U:W5,6E1A1C5*564S=#)J0DEJ9#9Z338W1%IF,G5J)B-X03MX
M+U-(6G@U2T9H-6TX*SA*6D<Q:GE9,%)I5V1R:2]H=DQE0D1+,&MC4U)31T\R
M4C!E84IK56QI=U56*TQV3DM.:SAY95HU6F)S>38Q)B-X03LU4'-R83)T<FYM
M62]6:FQ$=D1-.$5O*W-X>4MF5%I9:E5";'!Z2E9V:$=+;WI13D@O4$%A1DA)
M.3$U5#%A96-2>E<Y-TY"8T)7:6%.)B-X03MZ5#EX2&)Q95(Y3F=E039T-$QG
M5D=184(K9&-&<UE7:SAR,U5I3$EY6%4P1G=R>5-'6C)J5FQJ:E9%:4581D-!
M0S-8-&EF:7A6;5AL)B-X03LO4G(V2WA),35,1S5V,FM,8S=705)X2W!!;W%Q
M=TQ50G)3<$IP<U-E<%944#E'86(O=T%S:U X07E,6"MM2W!4<2MJ>7I,9E)A
M46QR)B-X03MB86E925!Q.# P2W9'<#E35&M76&EA+T-$+UHQ=W%K15=J9FUH
M.5EP3$@U8RMR4E<Q=TEY235Z2DID5F-7<E1$9V\Y4&IW855*>%!+)B-X03MV
M2&)!<593-C=R<B]!2U0K<F%H-55I=7)93$A"8C-I>G=22WE02S!R>6-W:VA8
M,#%52S9%<CA,;G1H5D4V9G%M=6%J3&-W-F)E*U9R)B-X03MQ*VU6<$Q/>$IK
M3'AQ;VU11C0Q5EIA96]K9DMO-U-E04=+<&UM:R]M3DDX,&,P4&PR1T9H3TE:
M;UER:'!6<44K<G1X8V-+:7(X+VMP)B-X03M(56=+<VQI,'I4:'%%>6TQ:4Y)
M661Z1VXX,'4K=W=+>%A8=D]53VEA:F4R,#-K<E9.471R9&]K=#=N4S=%6&9Q
M*W!'>G-E3DEW;U5R)B-X03MX<4=B8VET1%5"5E54>E9&8U<Q,TIA950W.%,R
M;'@Y6$LS9&UB9$I!1T%-:U)#4U-/=$1S4DA3=E5H9FEW<6ET1SAW5V5O87!B
M-F1.)B-X03LU5G8W0C4T1VXK=%A&;6=T62M*2#=Q4UE(85$Q,D9+92M"5F)Z
M4DIB85I.85,R.6QB37IR2W!$>$%I;%508FHT6FMA9D5*:S(P6CAH)B-X03MG
M3FML+W=!5%-F.$%6=G-F*U)0+T%$9&U4*U5J,VQX+WI5=DHS*TIP4"MR9EDO
M.$%);B]M-T@X<$AV2R]M<&53=RM96$UY>2]53$QK)B-X03MI<V=(;S=567%4
M*S$O:S1F>6ME.'(K86PU3"\X5%-F.5<K>"\U12\X,UE0>6ME.'(K86PU3R]X
M3DHO,6(W2"]K5"]Z9&HK56HS;&9Z)B-X03M5=DI8='9-3G-K85-,;TIV<$QQ
M.%=#65=K55I7265L1T]48VE+0W9J.$DW<TUO+TQJ:4DT9TMC:4]5,$183FU8
M-DTP,R]L:V@O=T-2)B-X03MA+S!Z1F(S9F]Z5&8K5U-(+VM7=CE-5E$R;C9B
M<'AG871R1"]!2# O*S8Q+S,X+W1I<4HO4FUM+SAS:U O271F-EEQ:'13,#-4
M:' Q)B-X03LP4F%W9VE'4V@Y3F8U5#=9<6U72W5X5D1A;B]X>F)V+T%)=WEF
M.%)/2W9M*S O,VQH+S%&+U5--4=83C!X96XV9C5J+T%#+VIU8E11)B-X03LY
M4W9.2VDQ,E=X=$=U:W4W36=S:&IJ.4536$5H151%.&M#2U=Q5#!'9%IJ*VME
M-3-%95-)=69.2#55=#A%=7)E6$QG5'-J14I&1$]()B-X03M)1&]J2&A).6%6
M6D%F1G505F=$3DM',6)64'EP=%=M=$QV.$%2:6EA>6$W864S,'E::V5Z341Z
M1U=+-70V<7DK;$5X<D<O:#-P:7%A)B-X03M1+VUH-4]75S)T4G)L=&)#9C%6
M='I.6C-.=D-&=&M,=7AL:TM226=24U9:;4-S4'-K-$940E!06&QL,E99+TTK
M:U-&;6I3<V-K8F=.)B-X03M/3U5167)/479Q069"6#=88D95>#!J5E8Q;7=4
M54Y,,4,R=3=+4FY33S1J:6-O-6EC>'-64'%F179*5'A98DU.=U-#1&EQ3CE0
M578Y)B-X03LO=T%0+TEL=BMQ=4MO84]0568P:E K+VAR-DU0*S97+VUL+S1T
M>%9$,RMV5S)N,VMD;F9A<&%7<SAY8S!%<U1O=DAK1498379!1FU.)B-X03M&
M0DY4,GA6:C$Q<5 U6D(U2DQY+SAU3#8O3U8U<&]R8TQ+6$II:UE34$QX:TY7
M2U!1;G)1.6-+<6--2#5B-DXU;4=R5SDU<$9N<F-L)B-X03MT3&)H-&%Q0D%Z
M=&-Y1#!K;CE*4WI2=DI8:GEA:FXK8D9756%8<DU/<2MS9$TQ3WIV5F=+0U=3
M0D1)9TUK87EP4C%L2VYK:G$R>#<T)B-X03M&5EDT.5(O4TTO-RM'=F]W+W=#
M-E<O;6PO=T-,8U98>%A-,'1Z3F%X6#ER2F,R,T@V>$%Q1G!)*UDU2GI54S%8
M:TYX6')I<3(U=DAT)B-X03MB9C9Z9&%H85%7-%E*-C!Q8T4U33-"5C5.34)5
M<V%!94]+<3!:=EI5-7A85G9);E1K<U1%8F4T;'A62SE::FHK=%<S-E1M='93
M.4]8)B-X03MH-FM,:V-Q>"]W1$9N:&LT4DHU34I3035O4# O3%@K+W)(+VM1
M+SA!,55Y9F<U3S1S4$9H,W4Y4'DQ+W8V>"\U15 X03E6369">61X)B-X03M8
M>%ED-F<X6&PW-C5%=VUS=E1%8V=9*V<Y2VQK<"]U>C)/2'=:.7A8>%ED-DMH
M='9,.#!Q>%)Y,DQ336%+=F]/2VXV6F-I8V-W3$E3)B-X03M-:T1S0VIV.$TR
M=BLK<E0O04I%3B]W0E9C<G-T;$MM;5=6>F).9'A7-S(X56%Z0VER0W='.%5:
M+S,W9U-J9E0Q3"]F.% O26QV*W%U)B-X03M+=3E0578X068X4"]!0TIB+W%R
M:7%',"M0569186LX4#DY4"]!3'!B+V9Z+T%01G5+;VXP.5,O,R]$+WE*8B]Q
M<FEQ1S%+4%5F,&1D)B-X03M6;FAP-DUL9C-,9GEN+VDS1E5Y>%8R2V]B52\K
M3V)D+SA96E K26Y&6'IT85=&.3E6:"\P85@K-U@Y:'9!93)C<V--<F11649N
M56XU)B-X03MD:E9P<F)7-'(R3T-79E0W84DR.7IO=W951'=X4BMK-3E7;DQI
M-D4Y2SE!<DQV>39E2#!H,C!E4T=N+THV3S)S<F8X05$Y,6%X,S%R)B-X03M%
M+W<S1VAX4$).33!X;D9694]8,$DK9DAA26)%5DAH:S!P;DPK6#$U9'=7<V0U
M<49R=V=T57-X06UH2GA725)E;3AA3T9J8F<Y5'E5)B-X03M!25)S155B67%P
M5R\U8WI89'!:2G)S;&ID>C9B9#-5<T$O46]A1U,S=4%09V%.23=F:#9J8W!*
M44-1>DXQ<'1I<DE.1SAH95%T3G,S)B-X03MG3V@R.7I*3DM:-VEA5%1I>%IW
M-65-1&Y'-4-X5C1X<E@T44U#<VDP.&%0<'1N2%DV9%IM>7-O45)$83(Y<$I&
M16=*3$AI:5)Q;W%3)B-X03M4<TU64D@V46<O:VTO=T-213,O3D=+;V%054E0
M,&I/94TS.7I$+W5I8BMA6"])>%9+=D]E;'<V-6]L,T):;W-/<RMK5C V+VYS
M-4IF)B-X03M2:T1",39X<V5*6D)Y2#1(1EAN+T%*;"]*3TQ8<E)B0V)566)E
M,70K8VQH2D1O8U5B=WEU-FYI16EJ:4)J0W%A9W-E6$QF9%%C2W!H)B-X03M.
M*U=6-V5C,W5T4W19>3EQ,$-W2C5E='!&:FLU4SA*3V)1<7IQ:U4S<&A#07!(
M2V\K231Q>B]28E12=$AS:W1R1WE7,BM&0DUB5WAA)B-X03LS4C-21FI$8TDT
M=T(X2T%!9&A16496;SE19R]3334T>F8S35 K-DIV-7!F.&I&5TXK62]Y-2],
M;GI*8U183W,V4DYC>EA$<$I-=TXO)B-X03M&5F\P6D8R:5I!4&AK871/=&%N
M9D9687HX:2M1-TU8670Y3G5&3C=-8FTU8VTK9#)K86Y):#),36])5VA64T)4
M86Q-2W%U;"M49DDK)B-X03ML871"<2MN-EI,8C9H87=.85%42W0T47-$57%N
M0G%O4CA)-FI!<2]Z4D%D5&UT26]0559K5U9Y6&AN1S%9>#)1*T]866-V05=R
M3&DT)B-X03MW:W8K1C<S*V(O:VIC9CA!5E!,+T%--&4U;R]+1'9D+VAE.2]M
M+S5),T@O5E!(.#1E-69Y9S<Q3G9,;#9,:$EE6#(P9#8K;&-F<T92)B-X03LO
M=G8O04-S9GIH-VPO2T1V5F8X04,Y.%-0,VA8>%E1,T))*VHP.$5T5U-/5$M/
M;$%03FUS1C5$1D)(1V988V]O57592G%M9W!5+T)M)B-X03M'-5-J839H0C8Y
M-3A-,CAW+W=",%1F-S5J+WE-5E)0-E%G+VMM+S5%5&8X04Y'2W4O4T5(.&LS
M+T%#26TO=T-A3591,FXV:$%)1RM')B-X03MB*RMN+W=",%1F-RMF+TEX5D4O
M<$-$*U-B+VM23B]Z4FEQ1S%,54E$<#$P3TTS.7I*+W5I8BM5+S5'2V]N.4E1
M9GE49CAI2G8K84U6)B-X03MD*VM)4#5*=BM213,O3D=+;V)5=%%G3VY8431Z
M9C--;BLV2G8U5"]K67$X,'-F.$%E2S,O04]-868X4D=A13@S6$UF.#DS>7EE
M64Y')B-X03LP*S(X,S9X;TUS:T9H1F,R;&Q(4$IB='IJ<'E-:3-50U<V.$IA
M=2]!1&]W2DMM;3EJ>41S0GE:-S56+TU84F\W3WDP6C-V=%%M,"MX)B-X03M6
M<C=72D56:TUD=D=W:W5P;4TP,&DX=E,U14U3,5A!4'A604Y*4DLO;DPU0V%7
M1E9V2G93;C5"2FIB5'%!>6HW3%)S9VU"-V)P:E-P)B-X03LY-6(X,V%(-6I7
M-V)3<$AK5WEL345X94HT>'E"27%V34-O3E X-FI&535X5C)+=7A6:B]M8GI2
M<&YL:4,X,6I5+U4K<%%2465S,%-H)B-X03MI<6PU87-14W5Y:F9X4%%!<U%#
M<3AZ:3@X4E=D4F1E9C=J-G)9>3-8,756=$EK;T)$3'=E2U)I,&MN2TM5<G5/
M<6UG*T5.47%V,50X)B-X03MX3&)4;G1P8FXX>DAI=$1B<DQ,2V1':EI85S=J
M95,Q:U5H03-*9W!+.%999D-1=T)X5EAM."LV8DU,1RM8.'A74DQ54U142VUK
M>6=4)B-X03MX,T4Y=DY#<&E#.59T<FU/1F9H2DIF:U!I1TMQ1VYE8TQQ3%9.
M2V<Q8CAY6F)U17EY4GI7<39(-D18<'1:>5A95%<O27=,.&%X3E=L)B-X03M1
M=CA!;%9X5C9P;V5R-F1R2W)Q=6UZ9E=,0SAT64IB86-+>3AK6G!A2&DT5F@Y
M27=+;4YW,#8R.')12TAN0TU9:UDP5794-%%4,D)/)B-X03M+<T9(;50X,T5M
M=&]7.&]W5')*8G$Q>F1R97=22DA/.&=5<4EZ2DLW:4Y+<U)8-'5G65EQ>G5%
M>6U'37I+1FQ+9WE+3V=A;31(,#1Q)B-X03MX+WID<58U65,R8W1Q-%(R5U93
M4T$R,550979H;5)P-%)K5'A.1V5C;V=5:T@K3'1E+S5A0B]W0V8P>DLX1$@K
M0S0S:EI(9C1U,3<O)B-X03M!2F%"+W=!06XY369!>"]G<C0R4EEF3E=T1U9:
M1&-$,496;%4X139-450R+WE2:C1'4#A!0EAX<VET1#5V,7=3;U1)2E)59G4K
M0R]&)B-X03LW9D-+-4=E2$=!>6IL>45S.6AD;FE2,E5O>DM#55!516IP;79C
M-5%T4#<K.2]W0TUW+S5->#1Q:6-69&EQ1S O*S1F+T%)>E0O=T1*)B-X03LU
M.%923TMO8E4O.$%J;3-F+T='5"]I2GA6131Q-T953G%F.$%X>F)V+VI$2B]W
M05)/2W9+-T@O94LS+S1X<"]X15IO5'ID8VIT5B].)B-X03MV5'9+67-D3#%/
M2V9N*VHP=6\U;V]);FIA3T\R95HV8W)P2'%Q=VMF64<Y33-S95%D9T]4,$]"
M<C9E0T]A3S5G84]6439-26U)2W-+)B-X03MG,45U1DLO,#E3+S,O1"]Y2F(O
M<7)I<7E/,'4T;6ME3C=D1VUB,4IM5T)G6&9I135-4DIU94MG5E!91$96+W V
M;"]V*T@O:U,S+U98)B-X03M&6&5N<5@K+S1F.$%K4S,O0496>%8S<#9L+W8K
M2"]K4S,O5EA&54<Y<&0S1C-D=U1V8GI1>3(X4U-X4U%&:UI7855&5U5Y54E0
M975+)B-X03MP4C5Z.#@R;FLK,W1R;E=*:4QE-6-O2DE,5C519UAJ>6%10U=O
M5E$Q4V%D0FEQ6%,O;3$U86AA4F)J54)$-DMY>7I&<E-7:5)12T=K)B-X03MK
M4$=2=&Q$<'-0:5!)54A7:'!682]W1'I(.&YX,V$R5C=Q,74P-EA%8V%).6AD
M3T9U1$Q*1DA2=#%$97)!=T)R,7 T:7%Q9F%&<F-E)B-X03MV86)&<65L6#!.
M>EEZ9TY$3CE7;6I$0FQ$06=33VID1SA-0W$X8V5O+W!'9CDO1%@P668Y,'0O
M3DPO>&)I<4E:9%%64WI814-Q;W%3)B-X03M9;4%!2"]06$953$)Q:V,X6')1
M87!9>7<X1VPY4D%'6# P<'EE;VUP>$9D>FEQ2U9D45I1>3-%1$MW<4-);4E)
M4"]06$95<S%7-DYP)B-X03ME5S!L.6-W3$<P8W%Q5&)Y3TLX;WHP16@X36Y$
M1UIC;44U:5!.1"]P-U-0*U=Y,B\V435V*V%S<R],5#=M2#5I2&4W.5!A4B]Y
M,E<S)B-X03LO4TA.+W=!,5DO;' Y>2]M260V;75Q-F),<45(0S9T86-*17%B
M5U)2>5IK24(U3U U5&=/0UE&,&]Z=THU<#1T;F1!9W$Q<T-/:$9U)B-X03MF
M*W%M571Y<#9E<&8W+V@O-45T+S%6>%9$5W-E;RMV969V-&8W-%8O8W0O=FU0
M.$$T='A612MN<5@K+S1F*U),9CE68U9D-F5P9C<O)B-X03M!268K4DQF.59C
M5E$R;G@V:C9$56YH+W9P+SA!9$QF-RMF.$$T='A612MN<5@K+S1F*U),9CE6
M8U91,G!2-FHK:G)Q<SA.4%)K<BLU)B-X03MB*U4O.%<T<6U72W5X5D1A;B]X
M>F)V.$$T=WEF.%)/2W9+-T@O94LS+W=#36%F.$%%4FUH4$XQ>6(S2&QR6#E4
M:G1R>7@X,#9H<$U,)B-X03LR='5Q,FM&<DTV1&A%9W)U,T@W45DQ54Q8;'97
M:3 S<V519&=/4TEB46903'%Y>2MD3&PQ2E9L0S91239&67EP,VHT3E%S961#
M974S)B-X03M48DI*5EED1#@S97(O<%AM*SAM9TA*;&I45%!28FU9;E)36%%6
M245J<DIX-F9$5&]C5E$K;BM4.6%H,49:-WIZ5G%L>EI$:GES56AV)B-X03M9
M:%9*56132E1,2DHY:5 P,D)*0E5K,#5K<U97-5!,=FYE4F<W961B=C%%:SE2
M1T=L8T9#-VXP>6E&15ID+S)G5%1U8U946'DY8659)B-X03MR1%8W,C0Q8E<W
M:E9B2V5/25<X3%=443A*1C)C.%5J;T)2461J=5=.4G--0W-I+U-%2#AK,R])
M:6(O;6I&54Y(<45(-E)N4$=B*S5H)B-X03LO=T(P5&9Z4R]W0U)I<7!D,V%4
M5W,P3514=U-Y4G-K8W=T-6E56F=11T$T:C=*,WA6:#AN;'IZ8V11;'8T+TYS
M-GIT8DYB449T241E)B-X03MN>4UR8V=.;&(T;FE/-"\S6%-V>$A#<4MT9$HX
M,U%82TUF3F1Z3&%Q.%1.8G9P45ES:7E).'%M46=T*SA25U-V-U!+;T=W>%9L
M9C91)B-X03MG+VMM+W=#4D4S+TY'0E5.2'%%2#92;E!'8BLU:"\S4DXO3DPO
M:UEQ<E185FY01$I$3$9+.%5Q;$I%344Q0W)#:$(K1'5-5EEF3BM6)B-X03LS
M-5I46&1V9'DV3D\Y>&%2<$1B<WIA9U%I4E-#5D%&-6-D;E5'=$LT<7I'3SAT
M26\P:E-/6E510E98,$IT9T)11#='2W!*-6MT,#%3)B-X03ME,&AJ85-);VMR
M:W1B>D=U.%DV0F9F3&-757<U3F541THX,' O=T%*>68X04Q1,R]!16EZ+W=$
M3D]8+VY*9'=A9GES93DS*T4U4#A!)B-X03ML;V(O04M26B]W1&UN2#@U3'5#
M+VQ9.39W95=71C-&0SEW+W!U<G5X5S)N-69!5D<Q5B]Y<T(Q8VE%:E-X0EIN
M1&57,%534DMS-59&)B-X03M#:7-%,6%!52]K>D5C;&8K:TE0-4IV.$%K4DXO
M>E)I<4=T9%%G.64X*T=B95EF-V]M+S-Z2"]K67%I9C!H0B]*3B]Y26TO-6]X
M5C,V)B-X03M19R]K;2\U151F.$%.1TMO8E0Y46=%1&9$3B]F5"\W;VTO,S@O
M=T1K67%I9C!H0B]*3B]Y26TO-6]X5D1A;'%%0C V-DA'8BLU:R\S)B-X03M2
M3B]+9CAJ1E5Y>%8R2V]B52\X06IM,V8O1T=4+VE*>%8X,#9*3%!**V-C-&%:
M2DEO3D)J:5=0-G4P8G@Q:VEK-"MS5DEK2'A&<6AU)B-X03LO1VYW-7%*9C-F
M>&-!.&U4*V0Y4E-05G).679.3W(V37-/;G=,8S)D;DA04$$W=&%K2S,W<3=H
M.4QI2C%:=F=5='-687%K<G1O.&<U)B-X03MW-4TX<W9Z8CAH,CEH0F)J5C5B
M*V$R:FEI;&UA,VY2-40V6% Q4UI%4E1Y5E-443ED=74R4U-J269Z63AK,T5V
M;S)T,4YC5&IK5VE3)B-X03LS;41"16EE6FY03E9&0DA%>#8Q-U5R=&=P5D-$
M.#(Y075*23!H<V(V5#%*;S=F:VDR-TM*2EI5:4,X;&U)2C532#=.9FA2;496
M;U-A)B-X03M6,&XU>2M155EC8C)74U Q4%)E55<X>7%J8C=K3W%/>3=6-4MP
M1DU&2VY(;"]W03@K6$YF,4,V<TY,;6ML;G1%4U-5=$1,1W!6=T-+)B-X03M&
M,5@K640O84]+<"]I<4=J+W=#3VQ0.$$X65EF*TI3-'%K2&XW4DY:,4A456XP
M>GI"8V58,S X4UA%<S%V1TIV54-!3T9E375G6E)W)B-X03LS2&9P=&ER>C8T
M.#(K;&945W-F;C9E2TLR<S=M-F4W;3 U-5!4;60U5VDO9&=+6D9H4T=9:&0Q
M64)A,2M(0W%A9C1W:W9.46QG="]0)B-X03M4,FLP-W!&8E=C;6M":$<Y>$TP
M8T%:<69&53-%2S!,1#=&5%0T<U9E:39$639T6F%:1&(V='%2,6$K44%46'AH
M:G1U6D-G16E+4#16)B-X03MQ450Q-S1&5C0O.$%J<%0O05!'1T@O:55U2W%T
M=S V,CAR44M(;D--66M9,%5V5#115#)"3TMS1DAM5#@S16UT;U<X;W=4<DIB
M<3%Z)B-X03MD<F5W4DI(3SAG57%)>DI+-VE.2W-26#1U9UE9<7IU17EM1TUZ
M2T9L2V=Y2T]G86TT2# T<7@W>FA.9GA35UIS;6M746E535DV,30Q)B-X03M4
M=WI),"]$6C1M:E!X54]&:C,V43AY+S<Y=69U8DUQ<U!K-#$U9DXS-E$X>2]W
M0R]B;C=M>')$-4QE6'ID2&8K6E!R569&-3)N;U)')B-X03M'0D]X2SAU;S96
M<%A)>D=+;55$;'0V1D%::D)'6F="3'A(<4%D3U9.-EIR,T]8-'%H<E0K+W9F
M*TUW+S5->#1Q:6-69&EQ1S O=T1U)B-X03M(+S1Z5"\X04HU.%923TMO8E4O
M*T]B9"\X65I0*TEN1E54:7)S5E$R<"\X04A.=2\K34UN+T54:7(U,3!6;VPO
M33):6GEZ,W(V4$5B)B-X03M8;D1!06QQ<G@Q16-S8S5L2W1-5S5#5TAR,%E!
M9D9P-692.%A!4$HV5&5E8F9.,FM3-F1P.6QO5C=Q;&Q*67A3>%@Q=7A+8VA!
M>D=.)B-X03MG;&Q+<4YY44M+>6(Q.&1J=#0X9S5W-4EB5B]Z33@U86-G:TAK
M-UA,>5 V.4YA3CE64EI8.4-'66],:%5&<E5H-#$U<4<T9S=$;%0T)B-X03MS
M2U97-2].4%5H8S,Y=%IE5V9-;# Y;4IO,&LK<5%I3G)M1T5Z:4]1>'!->4I)
M<%%)=U9M2DY/2%-Q<6,K4R]/9#$U<'5,;$DW1%9T)B-X03M.9W11>79C,S!-
M36-B>6\O<'-S1&E.;S55<4=O>71863AL6&%Q<DQ0<6LO+T%#,GIF9$0O04Y5
M.%973'!P5UHU,75:0E!)<7!*2T5G)B-X03M$<W%&:7%L=E1Q47!D<69--'%V
M*W%4+SAT<S,S42\X05901E5.2&%Z+W!'9B]42G8W;4AE:U X04Y,+WA8:7%8
M87IQ,G V8F9W44IA)B-X03LV:F97<VMF3U,U=$DT6D-J1U)9=T](<&=';DQK
M,WA6<#!$8C!667IQ9C5R2G!7;3-/<#9L<$AM1S!S665#>$Y*6G=,2DEZ<VDX
M46I")B-X03M13C5.=FEQ84YT='565%A69DYU<C9C3D]9-E!R3C!,*U<U:4M7
M<T55>G=E9WA%5%0X675+3$Y463AT=F9&53<P4SEM,5<P831",4-X)B-X03M:
M2DAI94,Y9VIG:W%H<'E51T]J23-65T(V92LR0E9E3S%N+U--+SA!<&LS.7I$
M=E-(*V%8+VEV1E=+-CDU-C%44DY2=F)A8E%F34=O)B-X03M7,74P4U<Y>G!D
M<$AD*W(V:V)/>#0K;D=&0VQE3E%Z8FM6;V%G2W%I96-T5G5,83=K=$Y',7-3
M,FQX.5A+,V1S='5K9T1!1U-):4=3)B-X03M2,6]D:4DV5C9K3#A71E56;S-M
M;3DQ1%9,9E1P=$TQ=7=E94)P+W)6>&%W:3%J-&MF=7!*9W4P:')S2U4Y.$-O
M-U<W>CE&,U9R3DYC)B-X03LS16=D2E5!55%6-GAN=6<X371X66I0:S$U36=H
M>E%0*TPW8B]!2#=D+V1B+T%03D=8+VLU9#1A9GI5935.9$HQ1TA5,%EW6',V
M>4HY)B-X03MU2C%G1$0S,FIY:DQI341U,UDX9VU.;&53,&XO045J0B]P:S,Y
M>DYV4T@K84PO:79+;7A%+U9*+RM7,F(W;V8K<65+=2MQ5"]!4$QB)B-X03M.
M.3!0+U901E5.83)S+W(S;BMM5&8S=S=1+S<U:B\T<GA612]62B\K5S)B-V]F
M.$%Q;FER=G%K+R],8DXY,% O0494>%9$869A>BMG)B-X03LS*VU41#DY4#)H
M+S,X+SA!>%AI<4HK<50O=T1,8DXY,% O5E!&54YQ5G)0*VIR<B]!17E9+W5:
M3G%1+WEN+VEV1E5Y27%#4$A&6&U7)B-X03MN9FQB-3AS8G5Z=48O34,X=5!Q
M<W=M:VAU67 U635K0U%$,%A5,V8Y,D=G66HY=C1Z>5IQ<U=696EA;%@Y1UA6
M979O>68X44]+=FYF)B-X03M19$$Q<%!Z1W5D8VQS;TED2VLP>4\R:'4T>49E
M6C91=%=24DEE5&II-FQJ1U!H5E%#8S P<$1G<G)B9T4W4%,W:CAU9$PQ-D\R
M,4LV)B-X03M/<7=Z>E=T=6A&<F-7.$M54TI&6'9Y86Y';S5K,'$Q2V-J6&-2
M-4)Z:'E21&9L,7I6;&PQ:GI,3W)&5S1Z6#A%:6AL:DU9241603).)B-X03MF
M.6)F<FMK<7-0-69X2DQZ;'8X05@W<%!I2W=Z,S!4>&@R:65,;4)Y2'A$,651
M4#AW0GA61%=V-5=A3&$S9W4T5'%Y>6]794)24&)+)B-X03MK57)1;4%3>&]V
M1E9:15!W8E579V]+8EEQ<5A(-6-2>G5K:W5P*UE7;&I:2&EL3C=B<S9&1C1J
M:7I6665*.%1V:7%B*U9F3#@S;#18)B-X03LV<DIQ3V]*950K=7!V2F\U5VI"
M5598:S!P<5,S23%O3G%$=%A!<69F5S4O*U=+8C<T9CA!<7!I<4=J=7 O=T))
M>B\V2$XO8W<W5F@O)B-X03MM;"\T<WA606$U;W(V=%!B>D8Y57-8="]S+U5B
M:4M$:TLQ;SE(4$EE,U1&56YG.&A447)29&(X>E!3651+6DY2:6-G0C!K369X
M13%1)B-X03MM3VQ'<CA,34%11&EQ:3,U8FET,EE.63AY,G!V2&ML;#E#*V=J
M;SAN<C%:861X.5HR4#A!>%A(+T%#-W%P-355,%,U.'9A93EK8G)6)B-X03LY
M6C5Y96],:E9B:4,U;55C1EAG<F=X+T0X3F0K-4]+<&I(9%0O<$=F+U$U=C=M
M2&%S4#A!3DPO>%II<D8Y5R],<7<Q2%<W-U9Z3G)&)B-X03MR8U@T:E=E3S)U
M3&%.4#-336DP<GEF<7=F-&U.1U9A530T5E<S2#5B861C4U=S,#!U<U!D5V0U
M3F9W,UIU3%E497!/-G9W36<K27AP)B-X03LV87%Q+W=!=7AR:7%)<V9*0G1B
M*W=V2DY2,2LY+U(O<$=+,W4W,D=A2C)H:FQJ1'E+5%9M651663$S2W(T8G%P
M<G).;4Y4=3=A2V4P)B-X03MU1E9)-5A(0F]!83AO>#-C*T]3:&M-951#8T),
M;6<O.$I76"]!0WHS;B]",B]W1'I6;&XU;69E=R],=S=K>#!R5$E.335M0WEU
M1V0O)B-X03MT3S=1:S!(8F%16EA/6FMB3%I'06E+0TEK=7 O,&I"+V]C,SEZ
M3G172"MA3"]I>DE-:U0Y8FXO-5EP=G9H+S9Q67$W-C-0.$$X<U4S)B-X03LS
M=R\Y5DU643%R9%0K=F5F-DA.+V9$=D0O=FU0+VEZ1E54.6)N+S59<'9V:"]W
M0W%M2W4K='HO.'-5,S-W+SA!5E1&54YP.3%0-D1F)B-X03LV2$UF,S O94@O
M9GHO=T1&;4MO;C8S4"]!37-5,S-W+SE63591,G!852\V3W5V.$%1-6@K-6LS
M<D0O2V8K3$U65$Q&6%EQ:'14+S0U)B-X03MT,R]X:&LO-&EC5F56,E K.%9V
M+T%-63 O=T-):DY#96)R:W X,RM63D(Q;E=,5V)5.4(Q<5=/3%190S)O85AA
M,CDQ2$TP54$T9WA4)B-X03LR,'=::U=99V9&5W5Y<69I-#<R4$E/=TA*;E,K
M9$Y4,"]4-T=(5"]+5V]',3E&5G0W9&ML5U=/3D<Y3D5D4D9)<4UQ<%9G-VIB
M:E1L)B-X03M885-66F905W933%II4'EZ9$Y,8U-'2V1'1GI'<U9*;UEU9DXW
M6E%62U-34T%T>"M&3C9&=&=Q;DHK6E8V1T)J.&\V-EEH2C9C:&4Q)B-X03M+
M=G@S+V5)<6QW>3 W37EN>$%X5D]V3%!M;'1D;C%'4#E'6&5N2G X:V-82SA6
M15HS:VE%<D%)<D]6-$(Q<EAX>%908U9D:7%':B\T)B-X03LV52\O04)H:"]W
M0TI3-'%X2U<S+T%$:D=O,T%H=61%3VU.95-',DUG=51C3%I/1'=5.%564%92
M9TMD45%46'!U<6DT>"MA=S0K;S)H)B-X03M0.$E$:%9V12M,;CA20DQ0=#9F
M465096U+<5)J+TYT<D-":DQO86%I:3-0<G%G=79Q,&HQ071F=$)P079'<&MO
M83%P43!X5F1P4#A!)B-X03MY='HV+T0K;'AO2#90-5%F5U!Q:'9F5S1E:3,Q
M;F@V9S0Q.69J-F1F,DLQ,WA6:W-F+TA3;B\T=W<O.$%%<&-65F)H6C)T-59G
M64I/)B-X03M565)/=W%O96YW:VIU06-664M,3#@W16UT;S!V.49K=&AB<6PS
M3DU*:D]:>DE/8GAI3TM/36-9-CA+:6Y,<71-5EHS0TI21$=*;413)B-X03MH
M44I'2%%T5&-J-F-6634U>FEV6DAS;'1&:UIW2E-W:G)7;G=E1UI';FY'2DYT
M1V5%<$%5>'8V;G(O.$%V;34K-3AY=DAX=4XT3U)L)B-X03M(;$9D85-/5DQX
M6%<S0DAP*W)8;%AV4W4Y37A-.#1Y4'!C<D1'44<V8WEF.&1+1"]!27=Z9CA3
M:7EH=5)/2W5X5D17;CDO92\X6F@O)B-X03MY6FIX5D4T<3=&54YP+SA!8U X
M03A:<"\K5'HT<6EC5E$R<"\X8S(W+W=#34UN+T54:7%*>%8R2V]B52\K3V)D
M+W=$1T=4+VE*>%8U)B-X03M862\W>%<O+T%":E0O:4EZ46YM-C51,5A6=D]M
M:GDS<S)M-C-P3#)Q85I:4'!M:C9L9%A-3'AY:$5--V9U;%9P3V%M9TAQ,%AK
M<&)I)B-X03M/=3EJ>41S0GE7>&599GI!;C%20F,K6G9+,6Y:5WEX+U=H0F58
M>$QY*VY(2DY',&MZ1T]N2&UY.$A$055*<E$U2DMT<6UR+VU,8U%$)B-X03LV
M:#5I.'176D9U<G97-G8O049Z3#E66&UY2DE8+V1M-D5H5#1#5$AX-S1Q;"MM
M965V4#%X6C,Q,DQV4TPW:'!R,T5,5W(V;TQD3&E+)B-X03M:5TQL6E1(8T=*
M8E5Y1U-N23@P-$Q2<7%Y<6)7,G0K86YU>F)A.35Q.'8V4D1B+U=,9E5:3$\W
M=55U67)G=W)&1G=J=C)+34DW;"M7)B-X03LK>F9#3CEW5E=984YR4&QP-44P
M-&$W2G%D.4Q*3S!59VQK0F1"3S8X5CE,:D=Y=S Y3&M0-69I,W)I<DEF,&9"
M+U!.+WE0;2\U<G=+)B-X03MH;SE09R]3330U5&8S35 K-S5V-7!F.$%,>%9*
M9D]E=%A8;#(S=' W4%).4S$Q6EA);FIS2EHS:VE294Y8-&=T>2M%;6<V:VEM
M2W!8)B-X03M,-39A1S1E,VPX=#8T,'-C8W1W56DK<U--,%5)56XP,35!<S='
M4E9696A03&9B8W%J8G)Z9$)B,VXQ8B]!03DU:FU(<7)$.5EI:&UA)B-X03M+
M<E-Y4F,V*W-$=T)I-49Q54-S<#96;T94<E%P-$Y8,#)++RMQ86IP-&Q!271R
M.7!O6C%"54XX8V9Q3GAP5VTO9D9695!4-% P:D]/)B-X03M5,SEZ1"]U*V(K
M85@O3'A65G5,3TM+,VQL451Y=D=J37-3>GIC;4E&46]Q+U4Y35992U!0.3AS
M,71B>2M4+TU";75,9%II.$EU6&=J)B-X03MK95%2<DA*2R]P57!5<SE&<7%J
M;V-+<S=H<V]P25DU1SEE3FY533!:;FUQ<$ER42]&,G=+;%=U6$9N<&0Q87I3
M0S1K5C!L44):-6$Q)B-X03MR1V4W*S)7-'-2;GEA.&U1435O2E!.5VML=T=I
M=6Q5;F1V6&Q.4&8W95=N4U1(8S%$5E):1&(R,6YC47!.1DI-,&-G1$MF6&TV
M2"]:)B-X03LU:753<%-A9D(K:UE">6TO=5IV.3-Z9GI29C5E2V]N.4AW9GIZ
M9CA!22MB+T%*<GA6,S909R]N;2]W0U(X,R].94MO83$P*T0Q-WHT)B-X03MP
M='!H+W4K8B]F368K6&EQ2B]2.$@X.#,O22MB+VUV1EAF;RM$*V5B+VMF3B]W
M03$T<6AT4# K07=..%4S.3E0+W4K8B]F>B]!3UAI)B-X03MQ2B]2.$@X.#,O
M22MB+VUV1E5.<5=N=T14<F\X<'8W;50O9#@S.' O>3A65$Q&6%EQ:'14+W=#
M3V)D+SA96E K26Y&6&U&;EHV:71N)B-X03M!<'-,=T52;T-0<7,O=T1+4#AJ
M3DMC32LT=41W4S=K5&1A6#5P=6(R2C=B43E#;G-5=$Q14C-'<#).,#DR>BMM
M16U6,U-.=G-H04(X)B-X03M04VTU,T$S3654;6IK:%E02F5T4$AB,G5R85)O
M9#EA1V4R835.=EHS5FY+:5)Y3'EA07=W25)W45965UDQ<%%M;5-3;4XS-6(Q
M-SE,)B-X03MA;&0R:T=N:4ME4T]05#)K<W%3=S)A44-*-&51<U=*175Y<W)-
M,457:6MC=FA64WEY.' K9E<Q6F)V5E)O5GIB;4]6-W5)85A)6DQI)B-X03LT
M945G8W!$8DMY>'9.>%HK<F9A,S-#:%9'42M53EEN=#54<4]N-DA(4%=!>'!9
M85<V4GE&2DAA8C%$8S(Y>7DK<$AX455R>'%X-C!X)B-X03M6=5AY>C5Q83@P
M-E=&9$UT:W1O-$9L;%14>3!I3V=%:WAH<EHY2'5':V,O17114G@T3E9I<6ET
M2FDO3FQ.95-85F19=$ID144V>5!B)B-X03MW5V-W;3E(9V555E=T>%@T>5!I
M-41P.4=+<WI3*VA';U1.=VTT;4M)02MH3C%$4U8O63DX0W(W=31T8G$Q;71N
M1G=I>GAT1WIP1$U')B-X03M!8T935E!!-S<W67%X2U1Y1G!Z6&,Q,G5V95EO
M-35O1&)E;VMS;UI%4'%N-$=-2EIF:6YQ3C965E U8TMQ.7(U3G-B835384A7
M.696)B-X03M%94M15S-Q>F5I9E-K4U%Q53E,8U-'3VHY>4-W<G5C5EI8*VM)
M4#5*=BM213,O3D="54]L.4-.46UB:$YX35510CE#8G%':W(K>#<T)B-X03MQ
M:U=Q*U9D3#%$5C4Y5EA53E=S3'$T4T]+8C9L-FM!6DEK:U)14W-032\S>&)D
M=6]"1T95=F8X04PK=VMG=$EP4$U8;58S<VQU;&AU)B-X03M$8U0K=%<W2$5S
M>BMJ5FUI56Q9:BMZ-VUH=TMM96PK5S=+=S%O87,K<6%Z9E-O2E9I=#=W>7EW
M;TIL:59U2RMI<$@Y=T-.*W).-#1Q)B-X03MJ.5=H,"]5<G$S4S1J=41&1VMP
M<7--=RM);4]N-TAH6$Q)6D1(:W=N:D5U84=8>3DU9$1!*VQD1VY9>'HP+S1H
M:WIQ6FYQ=T=N9T]I)B-X03MC=S-6;D1%<U5557%2;TM+;V=M;T%0.$%96E$S
M2U0S,$HQ0T9U13-%4E-G;C!*=7!A3VXW2'1I<4DO4T5(.&LS+TEI8B]M:D98
M9G!#)B-X03M$*U-B+VM23B]W03!9<6@W82MH13DR4VMW1%-G<BLT;3-(<%)J
M*U1X1TMO:CE)469Y5&8X:4IV*V%-5F0K:TE0-4IV*U)%,R]!1%)I)B-X03MQ
M2'-B-D991T1*340V<W@O=4IU:&Q9:CEJ=WA6169P0T0K4V(O:U).+W=!,%EQ
M:#E2=F]8,"LU5E5M3$Y%-$%%13(U2VXO27A6169P)B-X03M#1"M38B]K4DXO
M>E)I<G8P:$(O2DXO>4EM+S5O>%9$-FIF479P.7EQ<$U784IW04E*='E64"M2
M:7(O+UH\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB
M;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F
M.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C
M97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z
M9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @
M(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/E!A=6P@46E?2&5A;'1H8V%R93PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O
M<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*
M(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG
M.35N,#<\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @
M(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @
M(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL
M86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @(')I9&5R
M7S$Q+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R,CDV-#$Y)B-X
M03M,;V-A;"!4:6UE.B @(" @(" @(" @(" R,2U*=6PM,C Q.2 Q,CHP.#HS
M,B8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" R,2U*=6PM,C Q.2 P,CHS
M.#HS,B8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU
M<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@
M(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H
M96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@
M87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03LF(WA!.T-E;G1U<GDC,C!';W1H:6,F(WA!.T-E;G1U<GDC,C!';W1H:6,F
M(WA!.T)O;&0F(WA!.T-E;G1U<GDC,C!';W1H:6,F(WA!.TET86QI8R8C>$$[
M)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!R:61E<E\Q
M,2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C(Y-C0Q.28C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,C$M2G5L+3(P,3D@,3(Z,#DZ-38F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C$M2G5L+3(P,3D@,#(Z,SDZ
M-38F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C
M:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R
M92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M)B-X03M!<FEA;$U4)B-X03M!<FEA;"U";VQD350F(WA!.T%R:6%L+4ET86QI
M8TU4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @
M(&<Y-6XP-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C(Y-34V
M-"8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C$M2G5L+3(P,3D@,3<Z
M,3,Z,C(F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C$M2G5L+3(P,3D@
M,#<Z-#,Z,C(F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[
M26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y
M<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H
M="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE
M8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H
M92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[)B-X03M!<FEA;$U4)B-X03M!<FEA;"U";VQD350F(WA!.T%R:6%L
M+4ET86QI8TU4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @
M(" @(" @(&<Y-6XP-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R
M<C(Y-34V-"8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C$M2G5L+3(P
M,3D@,C Z,CDZ,#DF(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C$M2G5L
M+3(P,3D@,3 Z-3DZ,#DF(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N
M-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P
M:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R
M969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU
M86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X03M!<FEA;"U";VQD350F(WA!
M.T%R:6%L+4ET86QI8TU4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @
M(" @(" @(" @(" @(&<Y-6XP-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @
M(" @("!R<C$S,#@S-R8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C(M
M2G5L+3(P,3D@,3(Z,#@Z,S F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @
M,C(M2G5L+3(P,3D@,#(Z,S@Z,S F(WA!.U-C<FEP="!697)S:6]N.B @(" @
M(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X
M03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ
M5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R
M92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ
M)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@
M=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X03M!<FEA;"U";VQD
M350F(WA!.T%R:6%L+4ET86QI8TU4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.
M86UE.B @(" @(" @(" @(" @(&<Y-6XP-RYA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!R<C,R,SDV,B8C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,C(M2G5L+3(P,3D@,3@Z,S Z,#8F(WA!.T535"!4:6UE.B @(" @(" @
M(" @(" @,C(M2G5L+3(P,3D@,#DZ,# Z,#8F(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C
M>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E
M(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E
M<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X03M!<FEA
M;"U";VQD350F(WA!.T%R:6%L+4ET86QI8TU4)B-X03LF(WA!.RTM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[
M1FEL92!.86UE.B @(" @(" @(" @(" @(&<Y-6XP-RYA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!R<C$Y,C X,R8C>$$[3&]C86P@5&EM93H@(" @
M(" @(" @(" @,C,M2G5L+3(P,3D@,30Z,#0Z,S<F(WA!.T535"!4:6UE.B @
M(" @(" @(" @(" @,C,M2G5L+3(P,3D@,#0Z,S0Z,S<F(WA!.U-C<FEP="!6
M97)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@
M(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF
M(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@
M4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R
M('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X
M03M!<FEA;"U";VQD350F(WA!.T%R:6%L+4ET86QI8TU4)B-X03LF(WA!.RTM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<Y-6XP-RYA:28C>$$[
M57-E<FYA;64Z(" @(" @(" @(" @("!R<C$Y,C X,R8C>$$[3&]C86P@5&EM
M93H@(" @(" @(" @(" @,C,M2G5L+3(P,3D@,30Z,C(Z,3,F(WA!.T535"!4
M:6UE.B @(" @(" @(" @(" @,C,M2G5L+3(P,3D@,#0Z-3(Z,3,F(WA!.U-C
M<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R
M<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R
M='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP
M;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T
M960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N
M=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA
M;$U4)B-X03M!<FEA;"U";VQD350F(WA!.T%R:6%L+4ET86QI8TU4)B-X03LF
M(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<Y-6XP-RYA
M:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C4P,#4U,R8C>$$[3&]C
M86P@5&EM93H@(" @(" @(" @(" @,C0M2G5L+3(P,3D@,#@Z,#8Z,3DF(WA!
M.T535"!4:6UE.B @(" @(" @(" @(" @,C,M2G5L+3(P,3D@,C(Z,S8Z,3DF
M(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T
M;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @
M(" @($9L;W<@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C
M:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R
M92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M)B-X03M!<FEA;$U4)B-X03M!<FEA;"U";VQD350F(WA!.T%R:6%L+4ET86QI
M8TU4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @
M(&<Y-6XP-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C4P,#@U
M,"8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C0M2G5L+3(P,3D@,#@Z
M,SDZ,# F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C,M2G5L+3(P,3D@
M,C,Z,#DZ,# F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[
M26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y
M<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H
M="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE
M8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H
M92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[)B-X03M!<FEA;$U4)B-X03M!<FEA;"U";VQD350F(WA!.T%R:6%L
M+4ET86QI8TU4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @
M(" @(" @(&<Y-6XP-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R
M<C$S,#@S-R8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C0M2G5L+3(P
M,3D@,#DZ,S Z,#@F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C0M2G5L
M+3(P,3D@,# Z,# Z,#@F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N
M-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P
M:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R
M969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU
M86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X03M!<FEA;"U";VQD350F(WA!
M.T%R:6%L+4ET86QI8TU4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @
M(" @(" @(" @(" @(&<Y-6XP-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @
M(" @("!R<C4P,#4U,R8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C0M
M2G5L+3(P,3D@,3 Z-#$Z-3,F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @
M,C0M2G5L+3(P,3D@,#$Z,3$Z-3,F(WA!.U-C<FEP="!697)S:6]N.B @(" @
M(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X
M03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($9L;W<@0VAA<G0F(WA!.R8C>$$[
M*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N
M<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N
M*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X03M!<FEA;"U"
M;VQD350F(WA!.T%R:6%L+4ET86QI8TU4)B-X03LF(WA!.RTM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL
M92!.86UE.B @(" @(" @(" @(" @(&<Y-6XP-RYA:28C>$$[57-E<FYA;64Z
M(" @(" @(" @(" @("!R<C(Y-C,T-R8C>$$[3&]C86P@5&EM93H@(" @(" @
M(" @(" @,C4M2G5L+3(P,3D@,3,Z,S,Z,38F(WA!.T535"!4:6UE.B @(" @
M(" @(" @(" @,C4M2G5L+3(P,3D@,#0Z,#,Z,38F(WA!.U-C<FEP="!697)S
M:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @
M,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!
M.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE
M87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R
M;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R
M97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X03M!
M<FEA;"U";VQD350F(WA!.T%R:6%L+4ET86QI8TU4)B-X03LF(WA!.RTM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C
M>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<Y-6XP-RYA:28C>$$[57-E
M<FYA;64Z(" @(" @(" @(" @("!R<C(Y-34V-"8C>$$[3&]C86P@5&EM93H@
M(" @(" @(" @(" @,C<M075G+3(P,3D@,#$Z,#,Z-3DF(WA!.T535"!4:6UE
M.B @(" @(" @(" @(" @,C8M075G+3(P,3D@,34Z,S,Z-3DF(WA!.U-C<FEP
M="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO
M;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O
M<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T
M92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@
M<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@
M87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4
M)B-X03M!<FEA;"U";VQD350F(WA!.T%R:6%L+4ET86QI8TU4)B-X03LF(WA!
M.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<Y-6XP-RYA:28C
M>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C,U-C4T-28C>$$[3&]C86P@
M5&EM93H@(" @(" @(" @(" @,#,M1&5C+3(P,3D@,3 Z-3 Z-34F(WA!.T53
M5"!4:6UE.B @(" @(" @(" @(" @,#,M1&5C+3(P,3D@,#$Z,C Z-34F(WA!
M.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@
M5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @
M($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C
M;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP
M;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!
M<FEA;$U4)B-X03M!<FEA;"U";VQD350F(WA!.T%R:6%L+4ET86QI8TU4)B-X
M03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<Y-6XP
M-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C,U-C4T-28C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,#,M1&5C+3(P,3D@,3$Z,# Z,S@F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#,M1&5C+3(P,3D@,#$Z,S Z
M,S@F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($)A<B!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H
M96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@
M87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03LF(WA!.T%R:6%L350F(WA!.T%R:6%L+4)O;&1-5"8C>$$[07)I86PM271A
M;&EC350F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @
M(" @9SDU;C W+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @('!R;V9I
M;&5U<V5R)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q-BU$96,M,C Q
M.2 Q,CHU.#HT."8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q-BU$96,M
M,C Q.2 P,#HU.#HT."8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU
M)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" R,RXP+C(F(WA!.T=R87!H
M:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E
M9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A
M;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03LF(WA!.T%R:6%L350F(WA!.T%R:6%L+4)O;&1-5"8C>$$[
M07)I86PM271A;&EC350F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @
M(" @(" @(" @(" @9SDU;C W+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @
M(" @(')R-3 V,C,X)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P,BU*
M86XM,C R," Q,SHP-#HU,B8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P
M,BU*86XM,C R," P,SHS-#HU,B8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @
M(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!
M.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4
M:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E
M(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R:6%L350F(WA!.T%R:6%L+4)O;&1-
M5"8C>$$[07)I86PM271A;&EC350F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA
M;64Z(" @(" @(" @(" @(" @9SDU;C W+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @(')R-3 Q.#4P)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" P-RU*86XM,C R," Q,3HS,SHT,"8C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" P-RU*86XM,C R," P,CHP,SHT,"8C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X
M03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@
M96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S
M<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.U1R861E1V]T:&EC)B-X03M4
M<F%D94=O=&AI8RU";VQD)B-X03M4<F%D94=O=&AI8RU/8FQI<75E)B-X03LF
M(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*
M(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @
M(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \>&UP5%!G
M.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DAA
M<U9I<VEB;&54<F%N<W!A<F5N8WD^5')U93PO>&UP5%!G.DAA<U9I<VEB;&54
M<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P
M<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @
M(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=$1I;3IW/C4Y-2XR-S4S.3$\+W-T1&EM.G<^
M"B @(" @(" @(" @(#QS=$1I;3IH/C@T,2XX.3 V,C4\+W-T1&EM.F@^"B @
M(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @
M(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z
M1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1.86UE/E1R861E1V]T:&EC/"]S=$9N=#IF;VYT
M3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^5')A
M9&4@1V]T:&EC/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9A8V4^365D:75M/"]S=$9N=#IF;VYT1F%C93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z
M9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R
M:6YG/C P,2XP,#$\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y41U]?
M+E!&0CL@5$=?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$YA;64^5')A9&5';W1H:6,M3V)L:7%U93PO<W1&;G0Z9F]N=$YA;64^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/E1R861E($=O
M=&AI8SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&86-E/D]B;&EQ=64\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT
M5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^
M,# Q+C P,3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/E1'3U\N4$9"
M.R!41T]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M3F%M93Y4<F%D94=O=&AI8RU";VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^5')A9&4@1V]T:&EC/"]S
M=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# Q/"]S
M=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^5$="7RY01D([(%1'0E\N4$9-
M/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O
M;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @
M(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L
M="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I$
M;V-U;65N=$E$/GAM<"YD:60Z,D(S1CDT.3$Q,#,Q14$Q,3@T,41#.4,T,#@T
M-$8Q,D0\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I);G-T
M86YC94E$/GAM<"YI:60Z,D(S1CDT.3$Q,#,Q14$Q,3@T,41#.4,T,#@T-$8Q
M,D0\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^>&UP+F1I9#HQ04$P0C4W,S8U04)%.3$Q0CE$.4-&,3)"
M,#DS.$,S,3PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N
M0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$
M/GAM<"YI:60Z,D$S1CDT.3$Q,#,Q14$Q,3@T,41#.4,T,#@T-$8Q,D0\+W-T
M4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$
M/GAM<"YD:60Z,D$S1CDT.3$Q,#,Q14$Q,3@T,41#.4,T,#@T-$8Q,D0\+W-T
M4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^>&UP+F1I9#HQ04$P0C4W,S8U04)%.3$Q0CE$.4-&,3)",#DS
M.$,S,3PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N
M0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @
M(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#HQ04$P0C4W,S8U04)%.3$Q0CE$.4-&,3)",#DS.$,S,3PO<W1%=G0Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q
M.2TP-RTR,50Q,CHP-SHU-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T
M;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z0S)$,30Y13DW
M1D%#13DQ,4(R,C$X130S-C(W,3 T,C \+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM,#<M,C)4,3@Z,C<Z
M-38K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]P;W-T<V-R:7!T
M('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YI;&QU<W1R871O<CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z0S-$,30Y13DW1D%#13DQ,4(R,C$X130S-C(W,3 T,C \+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM
M,#<M,C)4,3@Z,CDZ-3@K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R
M($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D0S-3 Q-S8T.#$Q
M-45!,3$X.$5%13-!,S5&044R,#0W/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3$R+3 S5#$P.C4Q.C R
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO<&]S='-C<FEP="!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N:6QL=7-T<F%T;W(\+W-T179T.G!A
M<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.D0T-3 Q-S8T.#$Q-45!,3$X.$5%13-!,S5&044R,#0W/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3$R
M+3 S5#$P.C4S.C$T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HR0C-&.30Y,3$P,S%%
M03$Q.#0Q1$,Y0S0P.#0T1C$R1#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP,2TP-U0Q,3HS,SHT-BLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-
M33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!4P)> P$1  (1 0,1 ?_$ !X  0 "
M @,! 0$            &!P4( P0) @H!_\0 81   00" 0$ "P@/! <$" ,)
M!0,$!@<! @ ("1$2$Q05%A=6E=<8-U=8E):7U!DA(C4V575V=Z>UMM/5UC%4
MM+<C)$%1DK+1,C,TDR4F87%TD;&S0E)3H2>!@X;$Q^'P_\0 '0$!  $% 0$!
M              $#! 4&!P(("?_$ %L1  $# @$$"@T'"0<# P,% 0$  @,$
M$042(3%1!A,40561E*'3\!465&%Q=(&3L;/1TM0'%R(T-5+!(S(S4W.2E>'Q
M)$)B=:2RM$-$PV1RQ$5CM5>"EJ/"XO_:  P# 0 "$0,1 #\ U'C,9C>\;C^^
M\?";[[A!.VVVPEAMMMMLP;YVVVVRWSG;;;.<YSG.<YSG/;SS]#L.P[#SA] 3
M049)HZ4DFE@)),#+DG(7RS65E6*NJ JJ@ 5$X $\H  E=8 92S?DO&?1T%ZH
M'_5^7O8W#NX*+DL'1JVW96=UU/GY?>3R7C/HZ"]4#_J_'8W#NX*+DL'1INRL
M[KJ?/R^\GDO&?1T%ZH'_ %?CL;AW<%%R6#HTW96=UU/GY?>3R7C/HZ"]4#_J
M_'8W#NX*+DL'1INRL[KJ?/R^\GDO&?1T%ZH'_5^.QN'=P47)8.C3=E9W74^?
ME]Y/)>,^CH+U0/\ J_'8W#NX*+DL'1INRL[KJ?/R^\GDO&?1T%ZH'_5^.QN'
M=P47)8.C3=E9W74^?E]Y/)>,^CH+U0/^K\=C<.[@HN2P=&F[*SNNI\_+[R>2
M\9]'07J@?]7X[&X=W!1<E@Z--V5G==3Y^7WD\EXSZ.@O5 _ZOQV-P[N"BY+!
MT:;LK.ZZGS\OO)Y+QGT=!>J!_P!7X[&X=W!1<E@Z--V5G==3Y^7WD\EXSZ.@
MO5 _ZOQV-P[N"BY+!T:;LK.ZZGS\OO)Y+QGT=!>J!_U?CL;AW<%%R6#HTW96
M=UU/GY?>3R7C/HZ"]4#_ *OQV-P[N"BY+!T:;LK.ZZGS\OO)Y+QGT=!>J!_U
M?CL;AW<%%R6#HTW96=UU/GY?>3R7C/HZ"]4#_J_'8W#NX*+DL'1INRL[KJ?/
MR^\GDO&?1T%ZH'_5^.QN'=P47)8.C3=E9W74^?E]Y/)>,^CH+U0/^K\=C<.[
M@HN2P=&F[*SNNI\_+[RPDFC,;TC<@WTCX/7?4&6VUVU$L-=M=M6#C.NVNV&^
M,XVQG&,XSC/;QG[>.66(X=AXP^O(H*,$4=4012P @B!]B#D*YHZRK-72@U50
M0:B $&>4@@RMN",I9OR7C/HZ"]4#_J_+WL;AW<%%R6#HU;;LK.ZZGS\OO)Y+
MQGT=!>J!_P!7X[&X=W!1<E@Z--V5G==3Y^7WD\EXSZ.@O5 _ZOQV-P[N"BY+
M!T:;LK.ZZGS\OO)Y+QGT=!>J!_U?CL;AW<%%R6#HTW96=UU/GY?>3R7C/HZ"
M]4#_ *OQV-P[N"BY+!T:;LK.ZZGS\OO)Y+QGT=!>J!_U?CL;AW<%%R6#HTW9
M6=UU/GY?>3R7C/HZ"]4#_J_'8W#NX*+DL'1INRL[KJ?/R^\GDO&?1T%ZH'_5
M^.QN'=P47)8.C3=E9W74^?E]Y/)>,^CH+U0/^K\=C<.[@HN2P=&F[*SNNI\_
M+[R>2\9]'07J@?\ 5^.QN'=P47)8.C3=E9W74^?E]Y/)>,^CH+U0/^K\=C<.
M[@HN2P=&F[*SNNI\_+[RP1B,QO5[&<:Q\'C&Y[?7?&!+#&-M?$!W;N=L8;_=
M:]UKKMVL]O'=:ZY_MQCEC68=AXFPVU#1B]<0;4L N-PUIL?H9Q< VU@'>5U3
M5E68ZR]54&U+<7GES'=-,+CZ68V)'E6=\EXSZ.@O5 _ZOR^[&X=W!1<E@Z-6
MN[*SNNI\_+[R>2\9]'07J@?]7X[&X=W!1<E@Z--V5G==3Y^7WD\EXSZ.@O5
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M(8+N(S@$9UP(U):SG9KJWK*PE]GQMQ&F6J,,D:NSR1M-RB;H UQH-VRX-ME
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MW5U2USOCVW%\-?40TD59!///-4T[&4[Q.&U%'&):F"5\.6R"6*,ASHYG,?G
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M?_N_F?XEWA=36$3F J!JQE['I,9&+'&;.:[MH(WT -A#V0.9"])S%<(,'@$
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M*Z;)[Z9QC.NVN<9^WCG2F/;(QKV.#F/:U['#.'-< 6N!WP001WEJ#FN8YS7
MAS26N!TAP-B#WP195#</X,L?RZV_9Y/FM;+/LZ'QV/U%2LU@/UR3Q9_K85.H
MO^#,=_(0C]GM^9K#?LZ@\2I?41K&UGURK\9G]:Y9WEZK9.$4L@,L<0*=0N=-
M&B)!U"Y9')8V8.%-TF[UQ'##,PBT752QE1-%RHSU1543QG?33?;;3&=L8Y9X
MA2-Q"@KJ![W1LK:.II'2- +F-J87PN>T',7-#RX YB18JO2SFEJ:>I:T/-//
M#.&DV#C#(V0-)&< EMB1HNMQC'709*O1K=&M0@N(BM33%K&&4D.[J[A)%!+-
MA9ED[,N]7"KE\NO:\GD#4ELSPDQ>ZCVB0[9FWVU4TR'8'#$R5QQ2>6LFVE[Z
MI]+  )Z:OPNMA>R%A:&1AN$TM,^(/N^,R/,H>X$;#)LGD>6-%'&R!FVM;"V:
M4DQ34M932-=(X$EQ-=-,U^39KPT!F2++M=1G5A![YI4+'O$\U!6?M8Q^:R-H
MBC&<UOLR,SVZ)HQ',B"BKR:/EHWYV'K8,HOL-:J[E9%DFU=Y0!KI>-C>Q&OP
M#')JC;J&HPL8;3T5-(XU/9(20X?@E"^1T8#**-M2,(8Z<-$C@(:?:GM#IVGU
MB^.4N)X;'$&5,5::N2HF8!#N3)DJL1J&L:\DU#C#NYPC)R =LERVN(8X?._7
M$TUEMBSMC1$)&RVSQ\J5E)M V9=N7<JG?E=Y6'M="J!!!LS<>5JN@,:P29%(
M^V&HCT)*Y&%)"R,2-@C]QX;028_72T>%24@I('00L:RDH-Q[DIR8G1N<]NXP
M9Y9"^*H?*Z1U,V6&F?!';*!/5U3<,IF5%:V8S2B60ET]1NC;Y+/#P&G=!$;&
MALD36!@F<Q\S9.P2Z_),79RAH^KH%OY0B90P;*I'BJ6PQY)A]XAMWFV.\;^'
M-60B^90@D-WRAHJ\%@7F[G";=TS=^(OD]I874KH\2G&YI:61P-/"1*REDP*8
M,_.&0Y\VQ^E<9!E$,EJ&!MW,>ST_95-(V9KZ.(B6.9K;2O!8Z5N)1Y6@Y0;'
MB<X##8%S(G7S.:[D=]?!$MAU@Y4T=):O9+(#KE/8^0PURW+.+7)#VFH]V/?#
M7+@*:MXZ1[Z79E1!I 4$$&X^]%8+-BIGR?QPY&T8O4Q;72T].TBGCR\J%N$1
M2/,C)&2M;-!@U/':%\,T#I9YH*B.8PNB'90YX=ME!"_*FEE<-M?DV>:][&Y#
MF.83')B$K[O:^.0,BCDB<S;!)D))V1*7R-I/$5:]",W4Y"30.L[0./5L"]I7
M-;SF#5PQ2>#W"C?49KU S0.\U'N1KLVP'QQ!<@T8-C(TY3IODXHZ9] 6XC.]
ME!/13-8ZG8W;124. T3FR%DC0XR]KU#,PR-D9!))5.;&Z1\$M/ZFV6SS"J!I
M(V.JHZB,N;*[Z&W5.)5#2S*82-K[*U$;LDM=(UL(+VM$C9*,AW44* 5@[K61
M5[K+&9*OCE8OW'E.[ 8\FG%LQ>[(TX:X9#W"R1<).A!K9\LJLLV,A2S(?WAB
MH+W</L[6[&YJC%6XG38CN-\>(08I&W<K*@[J;A%5@=2UVV2-:89Z"6#:P '0
MSPODO()<EF-I\6BBHC1S4FWAU++1..WNB_(NKH<1B<,EA(DBJ8WY1)+9(Y&M
M(;D7=;33KT.H$PAQ:M@RY<(;-.$5=95(TA2T:DH140<"O(SG96-ERJFSEPZ%
MG9&+.M!?=)(ZQYQLGNNMB'[ ('1S0-Q.9L,U/ T@TE,Z5M32S-F@G959JF&(
M9#6RT]-+3NEL2:AMPT7XV42Y<<IHXS)')(0=OE$9AEC,<L;H<\3Y#<EDLS90
MP6&U&USSX[(#+U""3IY!1;AOK(G9EPA@\]RH[9OG]WKNA+KPM@^&/F[L;=Q4
M02;%1!($98AD&1J/D Q0D'4\_-Y1B,L97R-=N=D+7;F8 Q\<>!-9*W(D9+&Y
MDF!0S1.AFBGADF=)!41S113!VU3E^4ZE81MID+=M=G:YV(ES#E-<QP<S$7QO
M#V/CD;&&R1/8][#@Y%UQR(Y"BD/9U['X_J:"RT"^>BSD@W3:CSV)8W#(A6;U
MPY4'8 #ID59N=EWY!8]LBP<NEFJB*^KJXIM@E-!715C\1J*G:9J2>..6"G!?
M)3FD=,9WL:T2;HDHHGMR8XVT^5(UC7-<W(\3;)II:=].*2*+;(YXW.CEELUL
MHF;'M;7%Q;M3)W@W>XRD,<XM(.5JQ:$W3L*9.I&V&[B!J(2'10&,6=:OG3.-
MP"&@('&47[[1NT3>D\1^-#=B;Q)HU2=$-G*Z39!-35+3:\*H3AU$RF=*)I3/
M65<\H9M;'U.(5M17U3HXRYY9%NBIEVIA>XLCR6ESB"3@ZVI%74.F:PQL$=/!
M&PNRG-AI:>*EA#G -#G[5"S+<&@%UR !F5?<R*M$X1.$3A%@I1^#,B_(1?\
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M7L?DMNUPS+6\3HAAU=/1B0RB$QV>YFUN+9(F2C*9=V2X!X:X7-B"JBYF%8+
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M3]&GN ^ASXG_ $T_0G7?]/<=L>R'AW&?XI7=.G8K"^#:#D=/T:>X#Z'/B?\
M33]"==_T]QVQ[(>'<9_BE=TZ=BL+X-H.1T_1I[@/H<^)_P!-/T)UW_3W';'L
MAX=QG^*5W3IV*PO@V@Y'3]&GN ^ASXG_ $T_0G7?]/<=L>R'AW&?XI7=.G8K
M"^#:#D=/T:KBXN@_HF'U':;]CTD=.#-ZRKB<.V;MM3%?(.6KIM&2BS=RW63
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MI^C3W ?0Y\3_ *:?H3KO^GN.V/9#P[C/\4KNG3L5A?!M!R.GZ-/<!]#GQ/\
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MNJ]E"'B8LZ"ELGEY6#0N/PH1=MM-H+3U?D^HKK-M^5Q=:5E0K$P5KF&0FZ:
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MEWU#A$[N[_[M57RV7?4.$3N[O_NU5?+9=]0X1.[N_P#NU5?+9=]0X1.[N_\
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MK5>I*RR15ZKI90)!-E:Q,FNX&!K;H>M0(.,/1L/=QV078>CETE+94K=L;P;
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MCY\Z7^%>N_GB ^O\)8ZCQ%//G2_PKUW\\0'U_A+'4>(IY\Z7^%>N_GB ^O\
M"6.H\13SYTO\*]=_/$!]?X2QU'B*>?.E_A7KOYX@/K_"6.H\13SYTO\ "O7?
MSQ ?7^$L=1XBGGSI?X5Z[^>(#Z_PECJ/$4\^=+_"O7?SQ ?7^$L=1XBGGSI?
MX5Z[^>(#Z_PECJ/$52LNLJB)!<=?K$K+KMTT;UA;K??;:6@<IZ+N972*K?7;
M?P[.FN^VC1SE/3;[K?&BFVO;PGMV@)&A"VXS@Z=7>/E4I\H^F3X0*T^=\?\
MKW/66[7S#V+SM8^Z>=/*/ID^$"M/G?'_ *]QENU\P]B;6/NGG3RCZ9/A K3Y
MWQ_Z]QENU\P]B;6/NGG3RCZ9/A K3YWQ_P"O<9;M?,/8FUC[IYT\H^F3X0*T
M^=\?^O<9;M?,/8FUC[IYT\H^F3X0*T^=\?\ KW&6[7S#V)M8^Z>=5)=9?IM?
M0X,@TL"M^^Z6W0#S?N)6!4SX,.O>MR#WMZZONWC7P-JOW:F?N4M.Z5W^XTVX
MRG:^8)M?^$[^M6WY1],GP@5I\[X_]>XRW:^8>Q-K'W3SIY1],GP@5I\[X_\
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M!F)!TEJB4TU1W'/V;I1!\U5;:DL=_-X<RIE/LF%&+5NPLM&"7XL.)4I!^H=
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MGO?OG3FU 6SKVB'2,"6>O1@TNP=DQJ"#L@,2<I^,F+-T2-!V3YV/VVU>-V)
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M-6SB\< M9*;/Z 8>%BT>#88-A2^[\E^9; <*%YI=<V<^5%>Z]O[6!<M[6/\
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M^/I%5%>. -=5HQ8ZDA$9;L)(]9EMATQV  "9M_KUZ]^TKVZ;)]>I8FH5ED;
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MX1/(J1?& LWU;1GL=X1/(J1?& LWU;1GL=X1/(J1?& LWU;1GL=X1/(J1?&
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M7,\=A6H^J74^@S<;TE-619VUB_8_F]CCE2*8#)-H[+FI9UT/'2XN2MAS0O"
MF0"K  A&V,E@WWNN<?A=/H^G/G_Q6_\ \[RZE%A^RR/KKZ?9[:XVW6C%*1$H
ME/MI 0Z:' O:H3DSK:6$V5HL8:/CHYV4$1[6P!\4EU:0J)2IR6# F1AB+:DE
MPKF4.3GT;UM(S]Z]_+<[^;1F^^KZ@^O&=VE*I?T\)6"PGT4N:]=QIQ>5KQJO
MR\.N.I>EJE("3'MR)@>+/@:PK"37',FP9@U<(L+DK&4/]DA\FDK L7*06C3G
MT;VHDD>C/X+BPLHY$ /9::Q 5U6,* W@+K:O.GZFH/)7BQWI@GTG(%!<XZ;7
M%E2JM2T\9OY,YMMI4[SJ*CXO2SI#-HF=F01D44',4UXADJ3Z.?1I.\?\5M&:
MU[:-"MN88[+>D*\=Q(S;ZSY_:-1"0D5?ANC/5\-B(_I"ITB9+3[9 )N+3C\H
MZJ3EO"KV7A\G(EAF(N'3I1*-0?/AQTGT>]H-S]+3E;W_ .W.+CPY]&L\4KCL
MN58(60/JB$6/!C!F[(8]EEC$9-6=PEK1RJEU7/)-)Q,.MN\)##F$(=2IUT[I
M%S<?0I>6D(45#QQT#'-J^-&=27!M<W\EK?FV&8>'>(W\][*^Y,%[+@Y<30RS
M1,2,Z$/WM(JA<& O3-A>(J/JVZV(O7(^**^)QC?7"CC3IAV%K3!4DX<%9&JW
MF15Q&'DV'M"CZ/HOI_PW_'O:EEI^CV0\V/F )P,ZF)'#)#TOGF]9+S 3TQQ^
M10OJC:7$]]SW-)SO12!:2G9"FJK7)^;J EJ[K:NHK'"YR6!9)H^D2L4)]'-H
MTY].BPU^7-ISKW7X7E.$3A$X15A=WO,6[^C"??NH6X18[J%"RN24%>$=@:;U
M:<'Z?LL+#$1KW0:05E96%FF,=38$57+),>]W+KL]6KU1XTT:KYT7W<H:IY5T
M(M+9@#ZZHS8,G?QHTS."9'(HMMF0PB'1X<SQH*@X]H(&*0:QI[.<I1%P?R<;
MSM\)D\1/O7VT:4''XL(P=/I%.KP>U0:3N.O68QFW !@):8>/2B*V"WA;6/:T
M)O-QLR-@DQD5@I&2IL@[)>JV2NLA5-S46$C]@-3.X+2/RXJ!U0DALF;^O\N;
M3WUL!U)F^KYM9HT;0 <_Y':5;-G3\JFC5I..OYPZK*]-HDWPUE+%I)PIN/V6
M(I?.'6#9F.2-K+$A[F*M!0>8'M"9K=?991@H(ZL7LNCL:/D+(.1$);,"(!3X
MIO30Y"41<#U"F3,I(6X[%"@11BR&5.P@FT195\/C*D@76/LY4./[Y>(HD%O3
MF\AMSK/W!OUFLI98Q.K'I5[&E3K83$P&6%5Y8BX8B$Z=WIF5QQP4!+2-Y-LN
MWO4"T"-)20.@%R(\8W7B:[;4+N[*.M^O7T*O7[3K;D<0*#'.\H<V U+T.3@^
MLA$UA&JE=, $YZ?I!(I+83R%/MK'1EGC,=;6)?%8X13C16$,W+5C%8^^)1U%
MT4YM?7/X.O$-@WA&_%!W3DHX;6,,T=1=JK<B4;8TX9E6MC)+USAD#F6YIHVB
MZ4%?,][1VF1NMFX-]H[9 5(J2%).6C!^4+7.$$NR '="C^1IS&*HL'4CDH(&
M38T*_(/U4\=/&0M:R R,CJ#<Q'6SA[?C)62! D#/E/%F'+0UD:G$3!@I-M[\
M<W7OW\F@9Y4IUO;)5?AEF>).USBRMOJ%(S1;D>/E*:U?YTBL(;#O!'I.AUDL
M63HF>+/1=D)Z^3BBEA94RMIDH_FK_B<?N8I573V$LDL8-3@F:@TNN\SNC%P3
MN.O(^(<V,Y L4(DW&A<BF]EA8M ]VS1(LY(Q1V3R]($=]W);A3KYNO@\"LRQ
MOPEI+]*KK_*6U.%"M7A%#I_. M<1(M,3^KY=@+\ ;HL!3;#TP:,&2;,%'8Z$
M9[*H:.SDDD!(8 "M57#9%P4(M$5W+9+?==,FE5^WZA:W8HMT+"(YIR4KZ'%\
M0.TW\=!2W=A'WH]@^+C$19XZ%DX'9P8!MVQ^'FY"%5(G!@'9^G)%E Z)+=?P
M72D75)T_QIHP>/+5AKW4GM!%&*(4Z.,.7(^QI1#8C&32"#!RMNL%5)V##5WQ
M%+OB(X5(@Q-UW#4J-W=DL?3S:5)V%[4N4.,XR-M6 /Y&0/OHL. M)4&7,$9"
M,247(B!XY-WL[?/6*"#I=TDT26R@@S?+*9U38O-D"* &^J6"1YV><%XY/6D%
MCTKU@[JVM@PC>M%)8A.XQ6YP1L7TD&Q<3K&99)=QQ@O(P(0"LK&I8W!%33T+
MNT6*;=>O'X%*274;2 5JU*'+0@H6/DAP D&D9281AH(-)2)K-2+1,?G<QXP[
MMN)KV7&'BSQ@T8IBP)QX@[<)QV2^)BBW7KX5/P$^A$K,R6.QJ61\Z=AKA!K*
MA HHT>D "[ET48-]"C5!7=5KA4B#.C-=U-<)^-01P7G?! .2;-2*7<(O.GK4
M/%P\MKM801>BG6@2:-</!SE9FZ\$=.X4NY:^$-U$U?!EUF3)99'NN]J*M&ZF
M^N=D$\Z[]L HJ.MKJYE92T]4QE(US&U$+)@UVW,&4T2-< ;&UQ8K1]G-754=
M#1OI*F>F>ZKR7.@E?$YS=ID.271N:2VXN6FXO;4M,_+^=>F4H]?$_K7.J=@<
M$X(PWD5/T:YEV:QCA7$>6U'2)Y?SKTRE'KXG]:X[ X)P1AO(J?HT[-8QPKB/
M+:CI$\OYUZ92CU\3^M<=@<$X(PWD5/T:=FL8X5Q'EM1TB>7\Z],I1Z^)_6N.
MP."<$8;R*GZ-.S6,<*XCRVHZ1/+^=>F4H]?$_K7'8'!.",-Y%3]&G9K&.%<1
MY;4=(GE_.O3*4>OB?UKCL#@G!&&\BI^C3LUC'"N(\MJ.D71(2V4ED$VI21G"
M+9)\,)I-WQ5\Z13(A230P(?:)++[Z:O!99@R)CW&N,*LW[1L[;[IKH)[ZNP.
M"<$8;R*GZ-.S6,<*XCRVHZ1=[R_G7IE*/7Q/ZUQV!P3@C#>14_1IV:QCA7$>
M6U'2)Y?SKTRE'KXG]:X[ X)P1AO(J?HT[-8QPKB/+:CI$\OYUZ92CU\3^M<=
M@<$X(PWD5/T:=FL8X5Q'EM1TB>7\Z],I1Z^)_6N.P."<$8;R*GZ-.S6,<*XC
MRVHZ1/+^=>F4H]?$_K7'8'!.",-Y%3]&G9K&.%<1Y;4=(L@+M"?"GB;Q*5G'
M.R?;QWE^2>O6V^,]KMXV177VU[?VL=K?3.BF/MXQOC&VV,V.([%<&KJ26GCH
M:2CE<+Q5%/3Q121R#\PDL:TO9?,^,FSFZ+.#7-O*#9+BU%51SR5E35QM-I:>
MIJ)98Y(S^<!MCGY#[9V2-%VNM<.;E-=LK5O6#%*TK>R[ LH1,G0-C8I->1%(
M5%B4OUCB>L=BZ>7Y]H*RL1&B=\I;]LNJUR,;[:XT>NVVZ[75?D=#L3Q+$<8G
MP."7#X\1BDR(X*NMBI15.-B&TLDMHY7N:YKFQ939BUV:,EL@9UV3'Z*'#8<5
M<VJ?131AYDAIWS&$#*#C.UEW1AKFN:Y]C&'-/T[%I=P]%G9)X;U2OBT,TC$Y
M<SU*=3;9FB"A9)Y'Q-9+29^X@)N621+N04?60C*[$.1R1>(+D3 MSNR07=$&
M[7?:]FWR9UNQ2.&M-50-P\T-"'NGK8V5$N)BFC;B$%)2NO45 =5-DFCVMCFQ
MPRM#W-;&YPP^QW9?3XT]].(:DU0J:G)$5.]T3*/;GNI9)YA^3B(A+8WY;@72
M,.2"7@'U#YRQ;HG")PB<(H39?O<3_P#,F5?L)_PBST>^\ /\CC/\$APBS'")
MPB<(G")PBK&1>^I6?Y!L;_EB'"*SN$3A$X1.$3A$X1:)=D)]YB,_I/"_NI->
M$7Y-83^!D1_-@!^RFG/SKQ'[0KO'*GUSU\W57UFH_;R^L<I/RS5!>V_87?OM
MU/?DZBO\3=7/J/Y OL;'_P#,Z?\ XJZM\GOU+$/&H_5+9D1?=J'>HZUM75FK
MC*.AK^[EB(.(ZPJ8R6!QNHXA&*[V9R:$)TPK,HM*Y=;JDOLFKRY*R9SY=  F
ML;&U82#DTR@/OJZ'FMW\WXF_%;KILY])>IR"4HDT>YE\KN&>3* +QX]+_-"Q
M"P1A9%NQ*+>:T@YKV+J.'$@KNM'I23RZ9;U1)XPJ69R0H,,/QJ82+LR9K_U_
MKG5<&[KO0ZT%MTIFU@=FR+J1VBPZK(Z2CQ55C5(JY!%"&C463F5$8-7(%"OH
M!/K:E:3%_7!>.P:8/#):3C032$)<)FYN?C%M6_X,ZLJW^K*7Q&Z7=15O!V4U
M(#Q3<81T(=VP2&S:3,@6D-7)D&AER=9Q-:13ZKPKT@C7[X$_:2.7OA\X;&JR
MD$5>$MUZ]1OJ$->IVW,R\QI(=PN ((7%NZCT2BA%J:*Z,+<Z@B<FGZ:Y8C(2
M#"-2'I_H#QT&C.XUVJZ,SIB%82W0HBB[W)FZ\P\/X*)P;K+N5A%(8,DX6(V1
M*6:$!4*2*&,"CG>[F+H;3R%EITP)#*X&2625H_F5E$IX;!97C(GS9ICUHO'M
M)204@!",_46SYKW[W@TJ4USU6V_*;,#BLBX;,H]9QAM"X,K!O#W<,C9>-12H
M;0FYEU+L(.MSS,7#+4L,$_-.B(<+();1(2/@PD/DD^?"$"6ZW[_77K7I3PH3
MA$X1.$3A$X1.$3A$X15A=WO,6[^C"??NH6X16?PB<(G"+H%%GS<81<#&FC\D
M@P>+#V*BN$$WKY)NINT:;K[?<HZ.'&J:.RNWVD\;YWS]K'"+RPA_4M>(\,U<
M1N4XNY<M7E<F9*4F<4&CFE:6OO4O4E9MIUIL-KF/1!TS+CUZF@<=<0"6.59G
M6[Z:,E9,2(JF XA<IMH\.?O#-X>/TJSCG6!-F((X;T8UF#50G!V,K I&M*]R
MU7CX\+M\D"?6EAGH@GKI=V];15G5CE#6/.>^VJ!R.!S[9@,1F) /#Y.N>W6V
MD0HYUJ6G7L6DT@D4):/78!K;\O;0^4)N ,TE08/9?4 .9Q^+JBV: A!M1\/K
M&(D[+++C3Z[R+RX:7=/1I/Q<K," 7]N\/#^"LNBNJZ=6?/8-"7X&(&F$X&SF
M8#YI$?"6PI.#5R;E43E.Y)FA)9NT 31H:-=.A3>%EY(F<:B+D*LEV&7M?F'3
M@A S]ZVG7J].]O=];]<*$X1.$556-^$M)?I5=?Y2VIPBM7A%"["@@>RH@5AQ
MM<BQ:D=QCUH5#+H-C0 ]'R["11B3 W#MJ^9)&XQ)1(F0!]W[ @/P2&M?#Q[]
MGW]HL1:MMNA"H]14['ECLQD;FPC2<D.$C VJ4TTS[>75U.FA)E% M7AZ]SA*
M55=%C#P80AI )('GC=>4C#JQAZHH4Y1XLWI]I73;= ]7,Y0RE[*:V&P,"!,6
M%1WQ8-IH0QBR<1D].S,=B,#A-0LF8,4O*J3C<@=PM@BE7>AH_."P^'L"4G<.
MT27WK;]]_P!O\^^I_4O2'55,2QG+H?A]H]%CS08.V4!5N*38A#"R"B0MX6B<
M!C<IE?B5)#+4.7G4AE,DT1=$5"!H@\)OW3DH65<=,\<<&7SGR]LYM$W5A,K4
M:UBR+QII!!<\0L2-6H1.-DT(EI*R.AZ;1]X9)B)'*S@-NZE<F= AH9\J%=A"
M*,F>C*J3HXJ,>%9QHW,1^0QMULW+!M%=&$E!W_'WZB&V\=5UT=)L>I">;M5-
M]%$TW+",**HK)CR21@IN>+1S>Q3FK.G>)U/8MM6>(D,M/R6XW+!:2;RC>*N=
M6+83+;%EX@8-(AXH$D;\>&<689!!-)<=E+D)$148C(ARR%!$4%"$WMWNO6RO
MWA0O.+K3#EC,WKP<)&/B+O:+3XQA-HAE;'@@PI7;!SC[G/==^RL<9Y3U[GN,
MIZKYW4TVT3T5V_8ACE'@=5535C*A[)J<1,%.R-[@X2,?=PDEBLVPM<$F^]I(
MU795@U5C5+3PTKX&/AJ!*XU#I&-+=KD;9ICBEN;N&D 6OGOF.F/D3./0R2^K
MMOXG-]^</!>Y<4\Q2?&K1^T/&.Z<-\]5?!IY$SCT,DOJ[;^)Q\X>"]RXIYBD
M^-3M#QCNG#?/57P:>1,X]#)+ZNV_B<?.'@O<N*>8I/C4[0\8[IPWSU5\&GD3
M./0R2^KMOXG'SAX+W+BGF*3XU.T/&.Z<-\]5?!IY$SCT,DOJ[;^)Q\X>"]RX
MIYBD^-3M#QCNG#?/57P:>1,X]#)+ZNV_B<?.'@O<N*>8I/C4[0\8[IPWSU5\
M&H_)1LGB@YL4)PJ6;-G4@B<;2PV%Z;J>,)E*0T0$9VPLZ0TPWU*G66SK;&^R
MNC7"VZ"+A?5-NJ^</!>Y<4\Q2?&IVA8QW3AN_P#]:JWL_<:D'D3./0R2^KMO
MXG'SAX+W+BGF*3XU.T/&.Z<-\]5?!IY$SCT,DOJ[;^)Q\X>"]RXIYBD^-3M#
MQCNG#?/57P:>1,X]#)+ZNV_B<?.'@O<N*>8I/C4[0\8[IPWSU5\&GD3./0R2
M^KMOXG'SAX+W+BGF*3XU.T/&.Z<-\]5?!IY$SCT,DOJ[;^)Q\X>"]RXIYBD^
M-3M#QCNG#?/57P:_F:^L1]_JK"(G6[E?.$]'#H?OJDAC;[6RN<:]\[K;7'_8
MUSCN>Z[6=NWKC.NUEB/RA4;J25N&T]6RK>,F.2JC@9%%E9C(-KJ)BY[1G8TM
M#"ZQ<2!DNO*#8)5-JHG8A/2OI6G*DCII)W2RVSB.[X(@QCC^>X.+@VX: 2'-
MVMZ=NF58O4=[UT=D!V.Z3Z1&HA(RHC=#0XB%, 8QI)6XY=VBLFR(E KP@+1(
MJ(N<CU7N'^C=PHWU24YMAV+28=BU+BYBCK:BCJMVQLJB]\4E5&3)!)/9P?*U
ME2&S/87@RAN07-#B1T:JH&55#+AX>ZFAFIQ3$P!K71T[AM;XX@06LRH;QM-C
MM9(=DFUELE0G1M2W3%+)!(:/&%84)E\5 QV5P[4P0,1\R0BJV^8]+<Y-.'Q)
MI(FS-\98D54'V&1;4GL\79ID$U73K+;(-FF-[**2GI\=EBKIJ.KGJ:2M,,<-
M3#'5M&Z*/\BV.-],Y\<$D8<S+B,60UYC(:RSPS8_AV#3RRX:Q]-'/!'%/3B1
M\D4CX3^2G_*%SVRAKI&O(=DR9>46AP)=M;S4UG$X1.$3A%";+][B?_F3*OV$
M_P"$6>CWW@!_D<9_@D.$68X1.$3A$X1.$58R+WU*S_(-C?\ +$.$5G<(G")P
MB<(G")PBT2[(3[S$9_2>%_=2:\(OR:PG\#(C^; #]E-.?G7B/VA7>.5/KGKY
MNJOK-1^WE]8Y2?EFJ"]BNQ!R,P!,]2>HJ RV:ZN1E([+*1EY!6N@_*3JY<)Z
M/,3*:1)3?9SA3?9#+#1]IKA!7PG9OME'"WU'\@7V-C_^9T__ !5U;Y/?J6(>
M-1^J7MCYPY=\!-J^MZ0]LG.^KH2><.7? 3:OK>D/;)PB><.7? 3:OK>D/;)P
MB><.7? 3:OK>D/;)PB><.7? 3:OK>D/;)PB><.7? 3:OK>D/;)PBPV9 ^S(=
M9;GING^93H&VCNDCV7H7)Q, H]T)*A$RN;?R^3$K$4TGRP_1?5JL\10<JI;K
M(([Z$69\X<N^ FU?6](>V3A$\X<N^ FU?6](>V3A$\X<N^ FU?6](>V3A$\X
M<N^ FU?6](>V3A$\X<N^ FU?6](>V3A$\X<N^ FU?6](>V3A$\X<N^ FU?6]
M(>V3A$\X<N^ FU?6](>V3A$\X<N^ FU?6](>V3A%6ET6!+%*=MA/>CK10TWK
M2=Z;+JEJ5RDCKM%BNNRJF$+@66RFGC.=]\(HJJYUQG":>^_:UR167YPY=\!-
MJ^MZ0]LG")YPY=\!-J^MZ0]LG")YPY=\!-J^MZ0]LG")YPY=\!-J^MZ0]LG"
M)YPY=\!-J^MZ0]LG")YPY=\!-J^MZ0]LG"+&F947D0@I'Y!TZ6&= G![P0:"
M&'5#$Q)<41;J-" PH->V^NS?CWS195J\9.T56SINJHBNGNGOMKDBBD2'@8"Z
M</H/TD2&(/G;3#!V^C3#IW"/7;+#M5_X*Z=CK8;N'"&SY=5YNFLIOJHZ4V<;
MXV6SW?"*>^<.7? 3:OK>D/;)PB><.7? 3:OK>D/;)PB><.7? 3:OK>D/;)PB
MJZP[ EF\DI?.U'VBEE.T76^FNY:E<[+[>:FT-.\I=[M]37"F-=]ENVOLBEWM
M%3&%<K9225(K1\X<N^ FU?6](>V3A$\X<N^ FU?6](>V3A$\X<N^ FU?6](>
MV3A$\X<N^ FU?6](>V3A$\X<N^ FU?6](>V3A$\X<N^ FU?6](>V3A$\X<N^
M FU?6](>V3A$\X<N^ FU?6](>V3A$\X<N^ FU?6](>V3A%4YZ82%[<L!6=43
M9ZFR-8VXCHV4*TIMNIJO*Z2WW7TSYW]D<:H9;)I[XW634SESIWI);7"VZ!-Z
MWEYB/Q*G_E$5^+Q9GK2C_;)PB>417XO%F>M*/]LG")Y1%?B\69ZTH_VR<(GE
M$5^+Q9GK2C_;)PB>417XO%F>M*/]LG")Y1%?B\69ZTH_VR<(JFNDL0?0\,@M
M0-EM=-+9H-YA7).D_NE1UZUR00;_ .BMUQMVWBS5-ICMIZI]M?\ TR[9+NW*
M1/YJV?*(K\7BS/6E'^V3A$\HBOQ>+,]:4?[9.$3RB*_%XLSUI1_MDX1/*(K\
M7BS/6E'^V3A$\HBOQ>+,]:4?[9.$7UI)2VFV-M>GFS,;8_LSXTH_VR<(H+6T
MYE+0A:::-'6BIKO9Q!;.NA:E,90W6BD/4V0W[Y;Z6N=M<Y[K&4<JI=[WTQWW
M93"FNA%:/G#EWP$VKZWI#VR<(GG#EWP$VKZWI#VR<(GG#EWP$VKZWI#VR<(G
MG#EWP$VKZWI#VR<(GG#EWP$VKZWI#VR<(H98]@RW>O)YIM1MI):[0R4:[*J%
MZ3SHGC8&^QE3?"5PJ*9TTQGNML)IJ;YQC/<:;;=K7)%G(_84MP!"8Q1=J;8P
M(&XQMJ7I+N=L89HXQMCNKBUV[6?[<=UKKMVO[<8S]KA%E_.'+O@)M7UO2'MD
MX1/.'+O@)M7UO2'MDX1/.'+O@)M7UO2'MDX1/.'+O@)M7UO2'MDX1/.'+O@)
MM7UO2'MDX11/24&SEO5TW*5S,X:BC&;'63?R1]7KIHZ4[J&Z>"(:1">2M]JX
MSKOLMC9RS;M.]I*8RZPME))0BV!X1.$3A$X1.$3A%HEV0GWF(S^D\+^ZDUX1
M?DUA/X&1'\V '[*:<_.O$?M"N\<J?7/7S=5?6:C]O+ZQRD_+-4%[;]A=^^W4
M]^3J*_Q-U<^H_D"^QL?_ ,SI_P#BKJWR>_4L0\:C]4HK(^RD]3L=K656<]@5
M<)QQE<O73$&3M"M#Z^P" =','ZD#[<KJW(]10-2RS,T*5  PL18;5V-%[,YI
M&\!U5W0.2LN^]>OE71+#OY@#QV[V;3WU>,[[,A7\#,SP MT[7C*2L.M*0UX/
M&P4>.F966"X?/^MN 2B7BP\=V(E&+1B]Z#K;=MV19HT1PV-1!Z>*QT"K(CT?
M)D]\6U^1IYLH?@NL7[+Z(;6(XB(^A)'@+'R=S:R8\<L"N0*:D?JY#J4#BRHA
MP9D P6T=RJ>=,,X#)##;YJHQ"O0)517=\2P(0)DGT:^]Z+CG\L";]F99R W9
M@,55QJ*+ ^F K?L96E,:(N58^4@4QM*OK'B4K:O9'"V\E/J2F#,EX5"AI*&R
MES$V$VDLE\1Z@_%^A,D][3;T9_!G'E6YU:]:Y3J'C_5(,J:':UY.Z%:G-H^8
MM%LC,(?)<"+(O&K]"[H%#95'3>K%S)>GZ;9P+W/B"&@M_'R&SK59=X.:E%K6
MW[^3>!_%:KB^R']2+>A7U@%XO19R=-.Q_=.O6KN@+&3R,1=L\OBP)^S<Q/<>
MZE\P,.FT4@<>#)-,Y+#U9)+$BC]0C'PQ%J-#E.2+VWKD<0T_RYUGIAU]7BRM
M>[HTT*4%7M<0()U@'1<EE\#GLY.P@+T2.NGU6PY#/V >W8 TE ^Q@ERER$:9
MAMH/O!?$0+8B0GB<A6U&$L+#23FYP<VC2+#7>^\K,O'K3O*@^EJK[5F%=P7-
MQ.>D.\NIVWX;NG(Q\6'FJ,Z<5++/5C$U-S#PL/*/K+.Q<0B_+NCFZ,+!S1SX
M N3RR=,"  DZK@9N^;>#1X%10?LP0^&:O(=9%?&;BFT,$WR9LB?=/M;6I$JP
MCK6HW5N^)FAT+;PO4W!#4@\T)L$3;&92;CB1IP-(0J7SP(\(+ 2%I\AM;.#I
MMJZYE,VG9@X:^DVL.:=.-T+GF40N.4RIPCD"M#X8I5AOJC"#1LHL-)QO!X[K
M-W?298+882DIT$V;/346U;Z%Q:<Q,1 F3WQO9O" ?+^<-%]![U\,IV86(M40
M$LUJB7'(98,)J>PX:+8;Q8=(0$*L*+VA.]CTJ,+S0BP(DU87 FK[,+8 PY:+
M2!YO%2Y HYR^?@2D,)OG&8D=<W7TW)3/9&T[[FT"81"I9M#H:?ZCI%0;]]9$
M:+A7\H'>:.Z[&B=C5N0W4:#S S0K2!@+*1K=@<'(##J!H?+,[ B#%V4$6WQF
M&]X;+T_X7E.$3A$X15A=WO,6[^C"??NH6X16?PB<(M0K7O2>0VR388 WAODE
M 4.F]Q*19P89=RZ98ZAKAD56))1 JRD8L;&E8UH R^#X(QV8>7DA77BFF(EA
MCX[=%.]UWO)GOS;ZQ]?]8PZQR,6" :GG:9V4QH38B L@8K]GX#590/71?,W>
M$5I;J*PJT3LZ/:K1A)[N:WT2)*I)[;MDT%RCRJ+(=<0\B7A:0^O9 @QF47 R
M0**(. .3A]K:<BJ.-TB^9/V4@< P;21D;,4;RU@<4P8C.1:KK#9RPR/<FRFV
MGO&W,3X=[5Z%Q-^R"5XH3-IO(3+1$=A*H]O9\H)D8CHQK394K6@8T3E*#0\\
MV0B8%Y9[1529IK;1TJ.@MI% [UXRB+58Z2W/H[_@]FG1F4UEW65&H@+BQ%U5
MEONG!VM9/9)H1B);#"D20C2%9M_)ITV-N!NTGD):36S$8BPU@?E4+1+[E%B1
M)B-%NWNA1UZW4$DG7<-A;4[(I35\^'!14'BTIWB*T<?C[08=HWU&-+!)/(J4
MV:E'4<$!J)3,@7NH<?C8<?9'92YCL>=N"0(IMX.O?T+XTZ\F0#>2MIW3UEZ*
M0Q>XB\P*00"O,8[%8/7UFWG 8L;-FFFVHP>\E&U%2)!RW)D!B3,LY';H[K"W
MCAR+);1;?L/+FNMGZ;L:2V(E8N93%M(<0A=D/X4D$\.9DW2;1G%8B=T<OB U
M\0&NUW*\A<*(JLE$-/%_@6CEFT?Z.T=2A7+PBJJQOPEI+]*KK_*6U.$5J\(G
M"+C161<))KH*IKH*Z:J)+([ZJI*I[8[>NZ:FF=M-]-L9[>NVN<XSC[>,\(N3
MA$X1</A#?ONZ'?T>_)ZI;J(]]T[[IHOONFAONGW7=ZZK*)J:);;8QA3?3?73
M.=M<XP1<F-],[[)XWURIIKIOOIC;&=]=5,[XTVVU[?=:Z[Y3WQIG.,8VSIOC
M&<]SGM$7UPB<(M2K[MIO4ED5U(UARAC3:%V8!W'H+Z-U<*ES=5DD'F55-=],
MIM](^NALGVL;;;/--L9[2>W;V#8_@$NR">>"*HCIS!")BZ1CGAP+PRP#2"#G
MO<YE@L=QR/ X(9Y*=]0)IMI#6.#"TY#GWNX$$6;;O%5Q[N8?Z"OO6;?^#S:_
MFUK.%*;S$OOK6/G#I>#:CS\?N)[N8?Z"OO6;?^#Q\VM9PI3>8E]]/G#I>#:C
MS\?N)[N8?Z"OO6;?^#Q\VM9PI3>8E]]/G#I>#:CS\?N)[N8?Z"OO6;?^#Q\V
MM9PI3>8E]]/G#I>#:CS\?N)[N8?Z"OO6;?\ @\?-K6<*4WF)??3YPZ7@VH\_
M'[B>[F'^@K[UFW_@\?-K6<*4WF)??3YPZ7@VH\_'[BA%@]7B4Q L!#&*NABS
M2;UG*MW*KY%;51G!;(BDV(#\::I8SA0LPCSD4DKG/<H*O=%M\;:)[:Y?-K6<
M*4WF)??3YPZ3@VH\_'[JF_NYA_H*^]9M_P"#Q\VM9PI3>8E]]/G#I>#:CS\?
MN)[N8?Z"OO6;?^#Q\VM9PI3>8E]]/G#I>#:CS\?N*;PKK BDH?:L20U2/+J*
MZIHX>N-%$E]=NUVMM'.F-4]=\;=UKLDIC7;..YVTSOV]\:8#'=B.(8'$RH<]
ME72N.3)-"US=H>39HE:XDM:_,&R7+2[Z!R7%@=G,%V54.,R/@:Q]+4-^DR&9
MS7;<P"[C$YM@YS=+F$!P;](90#LG;A@_:DFJ+MHLFLBLGHIINEOKOKG&^N-L
M=K;7.<?V9QS4R++9P0="[O"E.$585S]];7_2>[_<R$\(K/X1.$3A$X1.$4)L
MOWN)_P#F3*OV$_X19Z/?> '^1QG^"0X19CA$X1.$3A$X15C(O?4K/\@V-_RQ
M#A%9W")PB<(G")PB<(M$NR$^\Q&?TGA?W4FO"+\FL)_ R(_FP _933GYUXC]
MH5WCE3ZYZ^;JKZS4?MY?6.4GY9J@O;?L+OWVZGOR=17^)NKGU'\@7V-C_P#F
M=/\ \5=6^3WZEB'C4?JEM(O,.BJ(V[<E<$>F&I8NLYFN&TWG'FKKA$):F9?3
M%N3*QY:0W'@%"TP>!A<>LNMITT?-"IHB5E'B1QATUF:J"_?5T//FS\^CV;RG
MLCF_8]R@QR_F4+J)T@YES0F]&2[I_<^/E)V.LBXE1I)]%3U=ZR/$K;W"\N;4
M4]="<%O.C-3R#!7,OLQLG)29]?/X-_BOJ'@4%B4#Z#DZCNJ2QCIXK2QZLB0Z
M5=1LKD,LK6-R0C-II9@*R+/F3<@C/8_F19EK2&3AT/V1E"*#P-$[$0@VJ+$4
M@]&8)<YLY&]OYAHZ^!3 E,NQ^0\&29EJRK$6+B:*H\@*#]-)@T,:,<QZ\7Y!
MQ'T8_5KQI(X>@"B74"D[E,71(Q/#72<LUR6FTC<-BA,_'W_3_-7K7<LZ<'<O
ML.&UN CHN1M6ZOE_@351:*C)"BO-[(8+(;29:(B8Y/=UK 0M?OK0.7/JJ2-6
M;/-TLO'Q9=P4=>OX*I8I9?0N0'2S2%PN&K#RX(7#+)8Q_IPE6N48K5XER)B<
M:M46RK+5<%&(T)9/P-=C)ZU'AE4QY(!"$G*H]ZQ0*<_?]M]6M84?9G1C(MSM
MDRFH(@%DMW0B,B[.7/=/Y8M99X,ZB=?25_#KP2'UL2(;QF( K'JU%^[EY8C$
M&BDE%,U'#/5%KX03/HOSYO9Y5:$KM?IPLF*3:=&!>T\$=.\5,VPZ<'(%+!H[
M6/GJXGHMP:B)&5@! &=1^:5XM-!&KV.NY#&#H$KMW]9=D08JK$SYL]K]_P!-
MM"PE75!TI2!L59,.EBB80UJ,^=JD"ABK:O1&C\S.N8DZL@'#]Q\?0;#A)#>6
M%:SF(X?JW;R%U&C;%^@['*)I9)<Z^=?$4KJG+$M2R8U)^E3I]W2JUL5CK:?,
MH]$YALNI;_CH]-X(Y2+5C'G $U)(R;'R^T + B<$$V]CC4RA(XY*$MTR;PSG
MT:/+G_DKU4H*B5ME]UJ5J57=RL[<.=E*XAV^SAP0<'';]=?;8-G*JSUU)Y*Y
M=JJ9VW<N)"<66VW4+/\ 9P47.M ="TG%Y"C*HM4]>Q:0HRR2S[)2,1,+'5W4
M]F(A4!*)T2U#,V2)6:&P3EX%?RPFD[D"HH@3'>,<-"9!%R2_L5M<(G")PB<(
MJPN[WF+=_1A/OW4+<(K/X1.$4/,U[ 9%(P$PD$'AYV6Q3.^8O*3,9"DY'&\J
M;]]WR -O62Y,/G=3_2;Y'.FW=;_=Y[>WV^$NM79/:?25'3$W V3%(''7%$GP
M6PY,M7+<XIHA%:XC4O&2B#,A48)N=O(*-FLLUM(^DN4A D7J0>)" ;\6NX*<
M_'[?:NFWM;HK;CI*(3@PT<S>&"3"01IQTNV**=R4])II!*ZD+1.*NZH:D9B6
M(2\U7(>5(#1A=VGJ\BA"0:I"M1S[0HZZ?QT+7Q,9T!RZ=6<76 ' .3@F*Q)?
M0##9ZPB]EP:05-T_AF<,CJ$;AVJC]L:B5B5S6#BAF[Q0VBKWUV+@(PL\5+<*
M<^;R[^CB/ENMJCW4]THG&A):5&61,;@42A)%W):IG;@6Y\KH\#E!JI,O"\'V
M8D)G(P>H5R9I=)9Q-R:PS XA$%B0)TS8DSC^O7R<R@!.S>A4U%-V:4,K ^#C
MD7+R$,..469:0H;M#8K8\X7C^Y1[6+P''),$!MK0*/(;JWVFX1%2;[8BVSQ<
MNT<$S[YY[]X[_D[ZN2)(=,%@V!.(]'8) 'UD5,9(/9BW)U-H"D,=*V>_DNI0
M^V>R.)BUB*-C/0<G<O90!<D&$QU0=D%29)N[3<."A75$81"X )\00.(Q>$@L
MNEWV0L1 "HV)R]<X3PY>>+@S1DS\*<822PNX[SWY7":>%-]NXU[1+WTJ4<(J
MJL;\):2_2JZ_REM3A%:O"*FNH&$'+%J.5Q"/MV)%\2WCKIS'2CK#$3-@025!
M#THKDP\V1<I-0UE1H86@)=PX;.6B(V1NMW;9PUU61W(M(&E-=5.HJ;KPH<QI
M4$@:-$H#5\1>A(RQ(!9#/*K,RC>21R!V"B!:6(4@K2XHZ%4BMHQ&-)223,)>
MY. 9CNWG(0O0MFZY\_\ +>/EW\"1IGK&E)U@RF[F6'*^ AZ<(N6@VQ<QB2RT
MU ;5Z6YYJL@H+MY4:(F#(+%+\%%-4,@F;XH_"+$[0L=$L+=PDFC0<_@S#>.D
M9]ZWE5S4M6'54VL<04M^P9$O$Q#^4$I"-&&F[$%+97V]$1)4<V\L)H<\@B:3
MA(@SC2.U:"Q;T&BQS6PEB\-JRTH-LW7V==\J.2/INEIL_*F&U6!=Y.6NYK8#
MWJ4;RH2#EIFN']^5A8K2&#E1NVTUV,PB#Q5I#TF9[1E'1K&KH22BI,B4((,(
MX2_?\G7K?6OY+*;ZM" )RT!34J.+,H@J/$E&,Z\7FB)J,1?JQ1K_ $D,B3Q@
MT<:-I3*NG<F7P8(.T3JX8EM)=2S+:3M3!+C5X>;1SV]NB]:'!W^/M2_BUK[J
M(0 V5$9JP7N=W-)H;,YM;N2I)AHK+9.H/&E("\J!+1JB.@+-(D-*-M8*W(M"
MDLEY#;-S];#\=[.MJ^%"\TNN7M^5->_V]KQ7+?\ W?\ ?Q3_ /WSI'R;_:&(
M>)M]?&N?_*#]GT7CG_@F6CG.P+DZ<(G")PB<(G")PB<(G"+JKNE4-T$6B*SH
M@X4QHS:H:[;***=O&.[V[C&<Z):=O&=]\X_W:Z]O;;&.:_LCQJAPBADW4QE1
M)41OCAHG6(J+BSML!!R8!?\ *.(T?1:"X@+/;'\(K<4K6&F>^GCIWLDEK&W&
MT6-V[61;*F=;\FT'_$ZS02O8_IK;29M ANLEPIASEFU[G"NFVF<8[UIVL8QM
M]O[6.UC[?V_]_P!OGSW*07N(:&@DG);?);<W#1E$FP&8$N)(TDFY/=8@0UK2
MXNL+%QR<IQ%AE.R0T7=G)LUHU "P&Q?*:JIPBK"N?OK:_P"D]W^YD)X16?PB
M<(G")PB<(H39?O<3_P#,F5?L)_PBST>^\ /\CC/\$APBS'")PB<(G")PBK&1
M>^I6?Y!L;_EB'"*SN$3A$X1.$3A$X1:)=D)]YB,_I/"_NI->$7Y'(7(H_K#H
MGKL=#:[:QD#KMKL398VUVP+:XSC.,K]O&<9^UG&?MXS]K//SZQ#"L4-?6D8;
M7D&KJ2"*.H((,S[$':\X*^=ZFCJ]TU']EJ?T\O\ T)?UCO\ "I-Y21W\?A?6
MC'^/RT[$XKP9B'(JGHU0W'6=R5/F)?=7KIV)?J!H:KC/47I9EVU%76YL92VX
M;2=63#8CL7U'NKAP_P!AFL@-#\O]6.7K/#S+7"N&V7;;"V=,KI=W]-?(32U-
M+A&.MJ:>>G<[$J=S6SQ21%P%+:[1(UI(OFN,UUU'8!#-%1UXEBDC)JHR ^-S
M"1M6D!P%UZ*2>8=C"F#H.1.]1'30X+QU:U'<=-M^IJ&LC  C<TS&6!/"@DBS
MGZ+AH3>2T,+*"7NN^5XWJS38 -APW=9FKW9= L[4=[>U:%@BK[L6)E=X_?\
M43TZKF'T<CD85/*=5486-:,XS;1.]6C]-^XL5;?QZ4MDLYF<L-J:J$)F^39,
MI6L8$,6H](EG:CQ=ZWHXMY68SNOL=;"*RB%-^IWIMS')HZ!NI2Q<]3$*?*FM
MX_%(=!V";\@^GS@DN@M%8'&@Y5)1WMJ;1:O%C'AKHL57>%%CJ/$H(TDG8P6C
M,BPVZDNGE^U)1$S7^Z9;JKC)7+*!F1[X/F'"-W]C.-Q$>$!RQT5'6 [+;4"S
MDDFP,V;K2(RL]*;.TV/%_)5Q4R78]()"[,A<TZP^EBQ&MJ[$W$H>[7%78,BY
M.2)E)6DPGB1I_:<KE(FQ)KF5E'!\W%9)&H^/729KPB(PYSN8<&"?2S9CF[VK
MR==:G(LOV,0(./"175+2C ?*XA((/*VK;K%%HI2<!(G$_<KH'=4[.UP04$[V
MA.-(ULK_ **-(%!S<*BS1BD.TCY18ZCQ*1&K&['07V)D=>JWIW;2DAW+G25;
M]25>OR")INO4+UB979/)JH))*-WU#5.JN/?L5A)%K%,"G[)<68.-")+'4>(J
M"T:=[']4%*2ZBW_6'TP2>&39V[4.BV5ZPX(/5'$(T!C)49JX-6[-)H\3/H!%
M'T@<')P95>NS!-JSP-![- [0IL;WL>OD"MF,7+V/&*.S[AGU5=/)5I(9@<GZ
MP.5=34"EL<%3&1RHM-"Q^. I%-B(Z.OUI&<)/FZHA!ID?HOJS'^"LD$&Z919
MVH\7\E.(AU4="<%"Z@(UU5],S(?DD:,N,K]0M:OWC\U)##Z02 P2(/YBY>OR
M1DV3?DW[MTNHJJY=*9QG5/&FFA+'4>(J3^[8Z,_C;],?T]U7_5?"6.H\13W;
M'1G\;?IC^GNJ_P"J^$L=1XBGNV.C/XV_3']/=5_U7PECJ/$4]VQT9_&WZ8_I
M[JO^J^$L=1XBGNV.C/XV_3']/=5_U7PECJ/$4]VQT9_&WZ8_I[JO^J^$L=1X
MBJWN3K/Z/'M0VJR9=5_34[>.ZWG+5HT:WK5SARZ<N(P420;MT$I3NJLNLKOH
MFDDGILHHIMKIIKMMMC&26.H\15D>[8Z,_C;],?T]U7_5?"6.H\13W;'1G\;?
MIC^GNJ_ZKX2QU'B*>[8Z,_C;],?T]U7_ %7PECJ/$5K#.I3V..QK!4FTJZI>
MEYZT= [28$A*=_01L_?E[?K^(U),2N3R%DZ98,G-90T9&VX@4,890>;KG]2/
MC'O?<%/TM1XN_?5K7=L2;]COGZ:"R?5Y046-I31E,_**/]3,'9E='6;2JVUY
M"V9JH3]#5EY0G:BB*&[A+&?%K9NX2:(9:/2#)Z46.H\17UI)^Q@(BVHEIU']
M.K%$>\%E!KIIU4QA(H.- PU8@PQ]J6S8VY')T:A3E=OD2KARN[6- =C3U1T2
M+&7! EG:CQ%0MFV[&)A66(FNJNAY #D$F'2X5'W_ %61O#",R4= 8U!M)@TV
MULO99_8ZN0A(]O93[;:8Y*2,BJH35631=<)8ZCQ*>.)EV,MZ <1LAU+=/!(<
M\U(^&[O^JB*N7SS<M6\RJ8BHL_4L/PK7+B"S^5"$TD%$6S+)!%T/0:.1HM1F
M4V=J.K1W[^E26M+A['549^=R:#=4?3L/+6.^\/E"C[J?A9IJLMY5SN<9U'#R
M\]>L R2DILN:EU]13=ILZ7,YT=;+(,AR30HL[4>+^2N+W;'1G\;?IC^GNJ_Z
MKX2QU'B*>[8Z,_C;],?T]U7_ %7PECJ/$56-@=9W1ZYD5.*M^J_IK7396<Y=
M/5$;UJ]71HUS5MFM,.76^DIVU;M\NG35MA97.B>7#E!'NN^+)Z[$L=1XBK.]
MVQT9_&WZ8_I[JO\ JOA+'4>(I[MCHS^-OTQ_3W5?]5\)8ZCQ%/=L=&?QM^F/
MZ>ZK_JOA+'4>(I[MCHS^-OTQ_3W5?]5\)8ZCQ%/=L=&?QM^F/Z>ZK_JOA+'4
M>(I[MCHS^-OTQ_3W5?\ 5?"6.H\13W;'1G\;?IC^GNJ_ZKX2QU'B*>[8Z,_C
M;],?T]U7_5?"6.H\13W;'1G\;?IC^GNJ_P"J^$L=1XBM<;0ZA^B&P[8@.3'5
M3TUN1#6M[62=.-;XJ_P5$@O)Z9W&I++8E.4DW*[9L6W:Z;[:JJI-WF4L9U26
MSBI'-+"28GO82+$L<YI(N#8EI!(N-!S*G) R4 21M> ;@/8'@&Q%P' @:=(S
MK&^5O8ZOC4],OT_U;_5G*^[JSNF?STOOJCN&F[FB\S'[B>5O8ZOC4],OT_U;
M_5G&[JSNF?STOOIN&F[FB\S'[B>5O8ZOC4],OT_U;_5G&[JSNF?STOOIN&F[
MFB\S'[B>5O8ZOC4],OT_U;_5G&[JSNF?STOOIN&F[FB\S'[B>5O8ZOC4],OT
M_P!6_P!6<;NK.Z9_/2^^FX:;N:+S,?N)Y6]CJ^-3TR_3_5O]6<;NK.Z9_/2^
M^FX:;N:+S,?N*K+BE/0&K$A&H+JCZ;UGN+3HQ1?1G?M8[+:AT;LKY61+;X2E
MG=>"MX_H37?9S_HM62;C9;M(X4SR#75?=,^]_P!:77_[U(H:8?\ ;1:"/T,>
M^+?<5I^5O8ZOC4],OT_U;_5G)W=6=TS^>E]]1N&F[FB\S'[B>5O8ZOC4],OT
M_P!6_P!6<;NK.Z9_/2^^FX:;N:+S,?N++!+!['<%()$4.J7I@V71SC.FV]]U
M5MG':SC.,?=2K/VNW]OM?[^4I)YI3>21SSHN]SGFPOFNXG-G*JLIV1C)CC#&
MWN6M:&B^NS0,^89]06P37K.Z+&2";=OU9],*226FNFNNM\U5C&-=,=SC[6)7
M_NQRBJ@:0+ 'B*['NV.C/XV_3']/=5_U7PIL=1XBGNV.C/XV_3']/=5_U7PE
MCJ/$56]?]9_1XW)VANXZK^FI#5W9#ITUV6O6KDM7+;,0AR.'#?.\IUPLAE9%
M9+"J>=D\J)*Z8V[I/?&"6.H\15D>[8Z,_C;],?T]U7_5?"6.H\13W;'1G\;?
MIC^GNJ_ZKX2QU'B*>[8Z,_C;],?T]U7_ %7PECJ/$4]VQT9_&WZ8_I[JO^J^
M$L=1XBGNV.C/XV_3']/=5_U7PECJ/$5#K$ZTNCES7\Z;-NK+IH<.'$.DZ"""
M%[U:JLNLJ$?)I(HI)RK;=153?;71-/37;???;&NN,YSC'"6.H\16; ]:O1LF
M""IJ=6O3+HIH)':;Z;WS5FN^F^K-'7;7;7:58VUVUVQG&VN<8SC.,XSCM\)8
MZCQ%9;W;'1G\;?IC^GNJ_P"J^$L=1XBGNV.C/XV_3']/=5_U7PECJ/$4]VQT
M9_&WZ8_I[JO^J^$L=1XBGNV.C/XV_3']/=5_U7PECJ/$4]VQT9_&WZ8_I[JO
M^J^$L=1XBJX/]9_1XI9E=.D^J_IJW;-@=@:.7&EZU=L@WW<:Q3P?1=;64Y32
MV7[TKWG53;7*O>E.XQMW&W:)DG4>(JQ_=L=&?QM^F/Z>ZK_JOA+'4>(I[MCH
MS^-OTQ_3W5?]5\)8ZCQ%/=L=&?QM^F/Z>ZK_ *KX2QU'B*>[8Z,_C;],?T]U
M7_5?"6.H\13W;'1G\;?IC^GNJ_ZKX2QU'B*>[8Z,_C;],?T]U7_5?"6.H\16
MD_7CU=])\AJ&.,@'4_T\''B5D"'2C01=5;$G*;;2,3!+=QN@RDJRNB&BJR*>
MRNVF$]5%4M,[8V4TQDECJ/$5I76/O;5[^8\3_8+#GR?5_6JGQB;UCEQN?]/-
M^UD_WE3CENJ2W=Z!/PXO;\U*4_:]U\[1\E_V?BGCD7J5OFQ+ZK5>,-]6U;<!
M.JOI>DRA]*-]2-"2!6*%,!)2F$N&O"RD:-;#909U$']&$B<;!BFP>$30K@>1
MPV=Y&Q"4/L)>"@"RK3J"VVQU%=DQU/\ 35'0ZLAD'4-1H( A&X;,ESABVH",
M#HP^QE%TJ]E:I-[($&2<;G:K9RE#3NZ^!<H4;KZ!'3[9)3&I+'4>+5IXE=;5
MTV>MF[QFX0=LW:"3IH[:JIKMG39=/55!PW72VW26062WU4253VV343VUWTVS
MKG&<E"Y^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$587=[S%N_HPGW[J%N$5G\(L
M,ZD<>8G \8?'@S.22%F7( (\Z*,6YPXPC^1V#[X.)67T?DV83)@1@NY9-UT1
MN2@[#W='+YMWTBR&[UFF\0';NVVA!TV=O6S'==+5XY9L%62#YV@VSOA=9LR7
M)#D7:Z>FR395^R36WTW=(84(OXB^8N7+QFW>-5W8[=%,@U1<(JN6.[E'5RWT
M>(:;[*MMUV^^CA'5?73*J.^JNF-M-L;9(NUPB<(G"+$*2  B6T JFQ"1Q7P3
M*050DRT+*>,&QMXP[@=LMAYOX:TC,D=-.Y1SX2VCYM='NTA3_9N19?A$X1=-
MN1'O'!!HT?,W3L2X2:%&K=T@NX&NEV;8B@V((I;[*,W"P]XS?)(N-4U%&;IL
MYTURBNEOL15M8WX2TE^E5U_E+:G"*U>$3A$X1.$3A$X1.$3A$X14W)S0X3=-
M>^,'2#312KK@VPJX631TQMI+*-QC3MJ9UQG;?"F<Z]K/]FFW_OQ(:7: 3X 3
MZ%!(&DVWL^CC4X\N(K^/1?RYO_$Y.0_[KOW3[%&6S[S?WA[4\N(K^/1?RYO_
M !.,A_W7?NGV)EL^\W]X>U/+B*_CT7\N;_Q.,A_W7?NGV)EL^\W]X>U/+B*_
MCT7\N;_Q.,A_W7?NGV)EL^\W]X>U/+B*_CT7\N;_ ,3C(?\ ==^Z?8F6S[S?
MWA[4\N(K^/1?RYO_ !.,A_W7?NGV)EL^\W]X>U5%=T_B[>&A5-"XY?.UN]/R
M&=$WS?NM=7-]5LVW6SVMMON&^BNSA7[7:[VEOV\ZX^ZPR'_==^Z?8F4S[S=_
M?'M5N^7$5_'HOY<W_B<9#_NN_=/L3+9]YO[P]J>7$5_'HOY<W_B<9#_NN_=/
ML3+9]YO[P]JR#"2 R>_>V)-DYW__ "HN4E,_[/\ \FV<]O[>/M=K_;CD$$:0
M1X192' Z"#X#=9SD*4X1.$585S]];7_2>[_<R$\(K/X1.$3A$X1.$4)LOWN)
M_P#F3*OV$_X19Z/?> '^1QG^"0X19CA$X1.$3A$X15C(O?4K/\@V-_RQ#A%9
MW")PB<(G")PB<(M$NR$^\Q&?TGA?W4FO"+RDK'WMJ]_,>)_L%ASY/J_K53XQ
M-ZQRXY/^GF_:R?[RIQRW5);N] GX<7M^:E*?M>Z^=H^2_P"S\4\<B]2M\V)?
M5:KQAOJVJJ[M['E;5CZVB$C<BJH0"LSJQN+J06+OW<E1,BQDKZ&WW2["(G@.
MPBBS-Z[5FI\S)9,1W-MVX..M&VXAI(RQ9TR&=06VWS>2W/?T9EJQ"^Q$=2-,
MA[:Q6LWH&82"Q=XG!8N4G^Q\27INC8>M,(I'XW4<C4JNR$(?/8O2QI.OH=,5
M(B91 /9=/3N!CK"R#$G%N?T:NN_G4Y5SG\O?.LZ-_.<Z]^:VBC*!UU 8,-"#
M(T.AD*BT481P(3(&PT?91T&P#M0@@R69CRI<8*09IL&!,FP8D'[5!)T]9MG*
MJB.DKRIKPB<(G")PB<(G")PB<(G")PB<(G")PBK"[O>8MW]&$^_=0MPBL_A%
MI/<_3/8=EW0(N0%9ODRZ@S"( H!&.\LEPFC$@VLR,W >-O-XVXDS$X:A=HKI
MQH?%Y"+&N9'7\((2-PJDEK@44WS6_KWNOALJC6Z4;\-R$?.9*9@KB4-1A(&H
MT0M*R%T$XQN+Z/&Y"'M)'F!#WZ(>S]^GNSQ<U<H@VJD?:6ZL;:,IB2;DF+XE
M]X>C3I]JRA#I$N@]%S 8Q;"R*ZX"=9BK8;8EG-TH1(C<'W"UZW82!ID8;+L:
MJ.[M=@4F?II'7OB,7-%!S.6;=Z9DOHS+)..C:9$9 DN3G;A>+#WYYN' (SZR
MVB#&)$)?U='A\?RU:/6[51LV%W'1@E=JKLLWW:51J*SLL* 1E%T3>T>7B]G.
MN5OTTW^6V# )G8PTE%1+@:L5(M;#L/)R;HO[DZ<;'E(XV,3!C$QK1O&*KL>#
MC\:24UI(1L[4:DFX,2:D [4F;>_I[?#F4AZ>NG&XZNLQM+[ M(O.!2-30^$8
M;;SXB0&IDP=<4Y%"J"L2+5YH3*:JR^OYE.Q<S)6>H[;N[$DK;$);/I%(#+PA
M-]ZW]2JU:](5U8'E4W$Q&L"Q$'$X_(SL>MJ?-9#9KF,55U&P\E-C9TQ 32,,
M,S.:V_%)H[BB8*PHL">@";Q7,J<]Y0)$OH\)/H]BQ#?I)ZH$MSKYY:S$J^*1
MH!&AP_-H'A\7$11FI !1:"*B%*7,.##S<-%I#)&%@O""</WG,K*(.NG;6&$S
M,?($OWAUZVZBV'3Z,^I[4>*8.+@4?-L1"NADY2<7$?V(V":A,-B$2U9,3CNC
M"*,$CNKH8;F)3<E'K/WE4J09OPX>L=Y?.U")+C5?3WO0>O?7H!2->G:[A[EC
M+C6TEF9HX]+R:1J$5RK@WLQ:#XE%73]^X&!MG9=O7T7AXTZ]3%,$R)MB1)ZM
M\;/-M]R@]>OA7<L;\):2_2JZ_P I;4X16KPB<(G"+5FP.H(K$+:0@S<3$48R
M,(4<&D1V42,P()D#5\S64PZ/"HNT81HL.T<"/)?9^DN>?LF,M+DV<-&NQ)77
M+U4BK!/KG#KPB$&V5<2HG*)6K0PS80Q< D@3F6V^YHM^5@D>.%3 QR\DT<A=
MZ1^5,')X5'8B:T0<#\RED['FTQ)3;KUZ[]EG)'UQUP.65!B QMS+O$Y9W@,4
M=QAO@9(XU(7<=E4&DK8/(SDA"2 &[#R/7!10 M!CBL>*(1J8&E4<:[$MS=>N
M^MV>%"<(G"+S5ZYU5,R6O$L[9[WJ-ENV-?\ 9C;OT4QV_P#Y9[7.D?)O]H8A
MXFWU\:Y_\H/V?1>.?^"7KY5HSSL"Y.G")PB<(G")PB<(G")PBFL(GQR E4B@
MIYLDCIOC=VVWV_U=9/':[O.VN=M<:[XUUQ_I,;:Y[6N-=LYU^US7-DF!4>,T
M;W3NCIJBF8]\%:ZP$0:"YS9CFO3FUW7-XS^49GN'9_ ,:J\)JVB%KZB"=[63
M4;;DREQ#6NA;GM.,P80/IYF.N+%OL74\]3L&+,#.J>4]U6K=13&==M?NMTM,
M[=K&W;__ !9S_MSSY]D9D/<T.:X D!S;EKK$B[;@')-KBX!M:^==UC=E-!(+
M20#DN RFW S.L2+C0;'3?.1G5H<\*HG"*L*Y^^MK_I/=_N9">$5G\(G")PB<
M(G"*$V7[W$__ #)E7["?\(L]'OO #_(XS_!(<(LQPB<(G")PB<(JQD7OJ5G^
M0;&_Y8APBL[A$X1.$3A$X1.$6B79"?>8C/Z3PO[J37A%Y25C[VU>_F/$_P!@
ML.?)]7]:J?&)O6.7')_T\W[63_>5..6ZI+=WH$_#B]OS4I3]KW7SM'R7_9^*
M>.1>I6^;$OJM5XPWU;5AY55M]2Z:V"@K5)9"0RC7J&CR]WKR$,/=C(Q-9<A6
M5+C827"V\D44A<=I"6Z6(?K@Q62 1M8U=&YDFZVM(D#<&^H+;<WHS>3/O'2=
M'A7)1]4]8T.B-@S1^R$(6^0Z=:BJR% IK,]3(6/&*KBMGM&VP=02X,"73Z32
M(U$)/*B1W1ONY/E) +5*DX_'@"^Y-5]?IMOY_1QK#6+1LJ+5\,:UET[V8'-K
MJY<N 5B3" 2>-V9*XS"%00D[U$1YC<#%PW,2TA/).^<W1!ID^M$9+:WBLW+[
M'-P\$!OB>$[W?OY-[\,_%LS5-52ZO_/G<\AA,?F%MR.36L5A A$9'A]B.XL%
M/GP]9PUQ:Y,Z73<,YA HQ6^6S<CL''1I^NXW.IN'GARJ)0JFKQAUXDG UU,I
M-*Q# 38,4(:,2 CI^3>RJ"&[%KAM+ 4IW""">J",0@$/M,@,)QK,0D)[SL1=
M1PR&F0"L?BA3FU=<_P#+?WE5;>O^LS6!5:JDC;B<^%B I0E(MW_3NO,<68K3
M]ND3>TQ=E&RT;=U\M<5[- 3,8F&DND7&U"H7"!]532!TF3-_3KJWS?3HO=3F
M3O\ L@&S&;+BV4]T7?-Y S"M(ZVZ;$G0F7BT;G4C&83F3JO&R-6G\[TVD;D4
M_=R2;J.&K_#",19%\869$S:O3G\.?F%K:RK^Z1O.9O&Y"UE4BV.5U##1>MZ;
M);:AW2TZ@T5E$CR"LEP89-4WKM!Q%W\8KP;ARNMDQM79.?*D#VLZ:$="&W7>
M[WD/A6WO"A.$3A$X1.$3A$X1.$587=[S%N_HPGW[J%N$51=2T++2LA73AY6L
MAN:MQ6L[0EE:1<O'!)5Q)RX!LW@$QV\JI7"Q3MM&54)&*9[X.8?QR3RR-3E@
MW;+1/Q^!*1U]GEZG7J+WWK3E9=V?C1R6N!M83*SJTC;&%E:K.B96Q\ES$D8S
M)Y(9N)9:RPW%TY4*HIDL861$ZW131 ],6:8B2R!QJ4YAO=;_ (C/Y<UEG(Q'
M>N7$[,%#XET2@$FD(#O.IU:I74SW;@K>CB\;.38(WU\D139A1H@G@OY ZCS.
M+-(H.D0RB:#5Z++RLDS:=D+8O:J;O))(GXITS@YJQR6T<Z?BYAK+'H*KW$IA
M:S!GO!QVE:L2B-ILR)(*XWFB#AR)4"R8BTPRWT*<V?-;5IS=='E4\MACUK)V
M7(B5=RDZE73NQ&;2.!!,8I4WXIBPVLZI<CW2S:5N(X<(1B36,_N1C/%7DQ:R
MUIL'@R$.UBX#<P>(E'7KUYE3 D9V0*)#5P#%&98!C817,>BXZ/MJ&*K"U5F=
M.(2N5.I)-3+PL8E\>.:V]N]B[YLX 2J(X;,AL@B)]P EC,IS9O+?\%C6[SLG
M>P8&U=[RQ(L]$P8G*#Z,9Z9E%(_)UJY.ZFXD!@^)+LP.1O2P]A2\FE#FRFSY
MWIN&&@!\."-97('13FOK[V]QYCS>57?U,3GJHK2:R.95H@6D\ &Q.+O@4->8
MJH#'CDL&2D0Z)P,.0?H';&ELVMT3A_ (FT24A3&+R,J-())29%;+D64"V_U[
M_DU;ZQC<3UR1W:,('9I/9R(<%)FSL8I$@G3>-F#$3'I;(!=>EJO%G  R-I.I
MT)S%#TQ93520ZCHQD^D%Q'I4DQ8J$S>C7JS\_757]<QGK\A=>4Z'>EIJ[*LQ
MD<"%(]WOI^?BHRUCI:H0C@?,C;YHI("@U[7[6TS34T /&) [EV$6S]XFGY.L
M293FS[^;OZ;>WR6[ZR[H+V0T,)=J,IS,9(Y6$QY%QL3#=-RI$;OG3I)(28C'
M68B*1=D]/I."O56):M2Z[H0H+ ,LLF#@OY%NS91FU6'A_KH\"VW2Q+]8]TIZ
MV"NLZGNL@ :S9TX'!A#AS+L438V)(X7$QTL?CXM9<SAZJH.!G3(=EOMEL-*D
M&22+M4H*V+X1.$3A%5TPI6K)])0DOF$+$G)''W48>#B3GPI/;=S")+K,X0H5
M;-G*#,_B$S#&TKAJ9UN23BLD6<G &@\F[<NE2*/+=-5$KXWUVK..IZ[!@ )+
M1MH\9Z,F46VB6T><"]&CM#00:$X@,"3:207AI(M$(-#&^Q39"*@4QY$:]-%#
MLW:+YM6,:3<(-]4$\Y2=*(]\R.0#N22C55UNU6/%!;,>/.R-9%0_(&@L0@;)
M$-! S#0BO+A$X1.$7GWU=0J1S2P:[#Q]EX4OM#+'.=UW6<?>@U5X[*'<]K^Q
M7R@PIE3NNWIE#77&FV%<[:;'L<Q]V 5%1.VF;4[?"(BUTIB#;2,?E7#'W_-M
M;-IO?>6O[(,$;CE/# ZH=3[3-MH<V(2Y7Y-[;6+V6_.O?O+57W/UM^CFO_FY
M_P"G-P^<F3@J+EKOAEJ?S?Q<*2<D;TZ>Y^MOT<U_\W/_ $X^<F3@J+EKOAD^
M;^+A23DC>G3W/UM^CFO_ )N?^G'SDR<%1<M=\,GS?Q<*2<D;TZ>Y^MOT<U_\
MW/\ TX^<F3@J+EKOAD^;^+A23DC>G3W/UM^CFO\ YN?^G'SDR<%1<M=\,GS?
MQ<*2<D;TZ>Y^MOT<U_\ -S_TX^<F3@J+EKOAD^;^+A23DC>G4/G%56S# K(O
MO$TW6KR85[%,);.]D<:[SR?1F#IN<;X24[K9FI(M7>B/<XPXW0U0RHEA3*NC
MYR9."HN6N^&0?)]$?_JDF_\ ]HW>%^Z%,/<_6WZ.:_\ FY_Z<?.3)P5%RUWP
MR?-_%PI)R1O3I[GZV_1S7_S<_P#3CYR9."HN6N^&3YOXN%).2-Z=3*$=+<XD
M!QFG*6>P\0COA59!/;MX<;:[Z=SW[?/W6=-<=O.J>,8USMVMMNZSC7N-?Q[9
MA68U"RF$;:.E_.EBBE,AG<#=NV/R8_R;<Q;&&V+_ *3BZS<C.X)L4I,(E=4F
M1U74Z(I)(Q&(6D6=M; Y_P"4=<ATA=<,^BT-N[+]4(;$AL-"M! U+"23=NBE
MG&/]O>]-=?\ =C_=S37&YNMM:+#OGK92SD+TG"*L*Y^^MK_I/=_N9">$5G\(
MG")PB<(G"*$V7[W$_P#S)E7["?\ "+/1[[P _P CC/\ !(<(LQPB<(G")PB<
M(JQD7OJ5G^0;&_Y8APBL[A$X1.$3A$X1.$6B79"?>8C/Z3PO[J37A%Y25C[V
MU>_F/$_V"PY\GU?UJI\8F]8Y<<G_ $\W[63_ 'E3CENJ2VTZ)Y 7"3JZ]1<'
MD\PPYB5-Y6WCSR&-=6&4C%SX3U=8EDMC&^^SG"F^4? ='FNN$5/"-D,Y1PKV
MCY+_ +/Q3QR+U*WS8E]5JO&&^K:O0[R\EGP*65ZWIWVK\Z@ML3R\EGP*65ZW
MIWVK\(GEY+/@4LKUO3OM7X1/+R6? I97K>G?:OPB>7DL^!2RO6].^U?A$\O)
M9\"EE>MZ=]J_")Y>2SX%+*];T[[5^$3R\EGP*65ZWIWVK\(GEY+/@4LKUO3O
MM7X1/+R6? I97K>G?:OPB>7DL^!2RO6].^U?A$\O)9\"EE>MZ=]J_")Y>2SX
M%+*];T[[5^$3R\EGP*65ZWIWVK\(GEY+/@4LKUO3OM7X1/+R6? I97K>G?:O
MPBK2Z9S*E*=ME/>F;'0TWK2=Z;+*EJAV31UVBQ77953"-IJK9T3QG.^^$DE5
M<ZXSA-/?;M:Y(K+\O)9\"EE>MZ=]J_")Y>2SX%+*];T[[5^$3R\EGP*65ZWI
MWVK\(GEY+/@4LKUO3OM7X1/+R6? I97K>G?:OPB>7DL^!2RO6].^U?A$\O)9
M\"EE>MZ=]J_")Y>2SX%+*];T[[5^$3R\EGP*65ZWIWVK\(GEY+/@4LKUO3OM
M7X1/+R6? I97K>G?:OPBJZPYS*=Y)2^=J9L9+*=HNM]-=RU19V7V\U-H:=Z2
MRG:2FNJF-=]ENVMLBEWM)3&%.^Y224(K1\O)9\"EE>MZ=]J_")Y>2SX%+*];
MT[[5^$3R\EGP*65ZWIWVK\(GEY+/@4LKUO3OM7X1/+R6? I97K>G?:OPB>7D
ML^!2RO6].^U?A$\O)9\"EE>MZ=]J_")Y>2SX%+*];T[[5^$3R\EGP*65ZWIW
MVK\(JO+S22J7+ EE*6L7*J=8VVCHCL6J'*FZ:TJI/=533.+3RAA-+9NCJIA1
M717.RJ7>4U-,+[)$5E>6DE^ ZQO6M-^U;A$\M)+\!UC>M:;]JW")Y:27X#K&
M]:TW[5N$3RTDOP'6-ZUIOVK<(GEI)?@.L;UK3?M6X1/+22_ =8WK6F_:MPBJ
MBYI4=>1 .DYI&PM$]+7H=UKE4K47<Y78WC7;UKKCO%I[[]\W=-T=$>ZUPCWW
M;3PG=-OWU34BM?RTDOP'6-ZUIOVK<(GEI)?@.L;UK3?M6X1?6LXE&G_8I&R-
M?_<6IS'_ /E;A%R>7DL^!2RO6].^U?A$\O)9\"EE>MZ=]J_")Y>2SX%+*];T
M[[5^$5:5Y.I5J4M/.M,V.IW=EN]]L:%JAQE+;R.AFO>E.^6GIC.^,:XW[:65
M$^YWUQA3N\;ZZ$5E^7DL^!2RO6].^U?A$\O)9\"EE>MZ=]J_")Y>2SX%+*];
MT[[5^$3R\EGP*65ZWIWVK\(GEY+/@4LKUO3OM7X10NQYU*MZ\GNNU+V0EKM"
MY1KLIN7J#.B>,@WV,[[X3M113.NF,]UMA/3??.,9[G3;;M8R19V/SN5X A,8
MI6R=L8$#<8VP7I[M;8PS1^WCNK5UV[6?[<=UKC/:_MQC/VN$67\O)9\"EE>M
MZ=]J_")Y>2SX%+*];T[[5^$3R\EGP*65ZWIWVK\(GEY+/@4LKUO3OM7X1/+R
M6? I97K>G?:OPBB/E(:-6[72!.OY9$4DHU8RR;V0/H*Z;.5.ZANG@J.D5F<E
M>:K]SMLKW3AJ@V[VGOCPCON4T]R*_.$3A$X1.$3A$X1:)=D)]YB,_I/"_NI-
M>$7E)6/O;5[^8\3_ &"PY\GU?UJI\8F]8Y<<G_3S?M9/]Y4XY;JDMW>@3\.+
MV_-2E/VO=?.T?)?]GXIXY%ZE;YL2^JU7C#?5M5(3WLC-^TP#O.5V16U02$-4
MW5).>GP6/A!>:#2AL=7_ $=V)U9%#S]V>2>M6;XHV#PN'CT6[5P@U76E!)PF
MNGJ)0YU!;=8&VFY'_P#H#VKLO.R?R:"2KITJ6S!G3^XM.T;BA<5LA]!+1?NH
M9":ZL%P)8115DT+L$SWGA?E#NB3^MW:SI&.1R.D)C)3(E&75Z#D1+ W(WA<7
MM<Z_)I\N9>S/"\IPB<(G")PB<(G")PB<(G")PB<(G")PBK"[O>8MW]&$^_=0
MMPBL_A$X1:T]2M^*]/K:F3KD<)=16;W8#KN?EB[Y4<E#803A%@2,M.DW>,>!
MHMXFXBS L?6*[)#FL20D+Q5=!=NW5T*0+W\'X@*IJ;ZU&\ZJ]C*IM"2D6FKT
MCL@K&6".KA@*1DUXW14$"8D71)^S(:EFWFB<N9UKABFD/=N^V'3?:;Y:-"$6
M[_\ 0'\=:Z<8ZW<NA;XM+JRE K#!T 8,!X',3,N)HY/5%1%B)[@73V=AVX+&
MA:ZFPELC)M&VKH<W:/GCP0Z\/:-2BW75ULNS(.O&'Q4P^0+UY9+QM@>*;,(Q
M&P@8_8B4M82[J9BMBB" EA*%0+UK%7'3F118J1<^?=R%Z6;H@6Y?1TUVP4V\
MGA[ZV&FMXAH3*9!&7,5E)5&'5XG9TWE+)]  T1A<7>MK#6"N)$6FLYB:C?)I
MS6,G')/&C-Z&"KZL7LM*QT*X4*H%%N?,J":]?U5K"?*%[ ;B"1]F(/%I*6,Q
M^(L\0_($W?,?W''!&LZ6D;I\3(=.L]R*4C(:0BUFCJ,O'1)FW++J,"FW?'7R
M6XUG9UUK0^M"+T+.*FO ,<"UP=M*4AVT>A,D<Q.*BFEHO!2QIS$["/"UEY?K
M4DG0CNP,@98-W+H&E*G\9\8*;-2 7WQY5MR%(.2H<63>A2<<>$![1ZZCYI00
MJ8"+N4-%E1110 5. U"##??9L[W$&BHW9=/?+(@\;][7W*%D^$556-^$M)?I
M5=?Y2VIPBM7A$X1.$3A$X1.$3A$X1.$6F'4A;#ZJ+%KJ0CF"!1?R-L@#LR<+
M;MD^]F357DLN^_:)JYSLWVCFJ&$>]=I3#S;?ONG>>X5V78SL?&R"IJ('51I!
M! )LL0B;+O(UF38RQ6ME7O<ZK+7MD6.G J:"<4PJ3-/M189=JR0(WORLH1RW
M_-M:PUY[*FO=N2ST0$^LG'U/FY?-I'PP_D+?BUJ7SB/X(;RX_")[MR6>B GU
MDX^I\?-I'PP_D+?BT^<1_!#>7'X1/=N2ST0$^LG'U/CYM(^&'\A;\6GSB/X(
M;RX_")[MR6>B GUDX^I\?-I'PP_D+?BT^<1_!#>7'X1/=N2ST0$^LG'U/CYM
M(^&'\A;\6GSB/X(;RX_")[MR6>B GUDX^I\?-I'PP_D+?BT^<1_!#>7'X10V
M=]5LIFX1B&W #1FK*95S+\.4G:[C97:OK"B\]3'Y3RBAW*9;>-:BE5^[V\%2
M>[N<(.<I>#JOFTCX8?R%OQ:?.*_@AN__ -\?A%NG3W4($LG7+5SE :4T2UV4
M9**=SOC;NL:[8USMVM5-<=O&<;:?:VQGMY[6>WKC0,9P2LP6K=2U+;@W=!,T
M':ZB*^9["=\:'Q_G,=F-P6D[OA.,TF+TK:FG-B+-FA<1MD$MKECP-(.ECQ]%
M[<XSAP&R6,XVQC.,XSC..WC./MXSC/\ MQS#K+K^\(G")PB<(JPKG[ZVO^D]
MW^YD)X16?PB<(G")PB<(H39?O<3_ /,F5?L)_P (L]'OO #_ ".,_P $APBS
M'")PB<(G")PBK&1>^I6?Y!L;_EB'"*SN$3A$X1.$3A$X1:)=D)]YB,_I/"_N
MI->$7E)6/O;5[^8\3_8+#GR?5_6JGQB;UCEQR?\ 3S?M9/\ >5..6ZI+=WH$
M_#B]OS4I3]KW7SM'R7_9^*>.1>I6^;$OJM5XPWU;5*)O*^F,?9,E?33IIC+Q
M&,V5:#-C<9>)UF1!%[A4Z9-)?9[E/9P]<2QJ6.TM%RM:')@X *ID](:5@15Z
MFPP+;E>H+;1?>.K-GU^W/SZU@:WL[I!AFX6DH)TWHUQ74,L.QI''&8BB'L?A
M8>;538@RNMI7&8Z&A_=NYW*+>)$XY7B$?'O)4?4CALHAX+N@R8NB9]-^<7Z^
M%;0M.K#I^([;8&V(V*))J1C5=V+C\L)#VJ4NCT9E8I\]),0+@>R%-(Y-H28E
M!AVY1%0AE-(>I-'@#,I X($L>O7K8ZBL:\ZO*,:O8VU0/'R:$C/. NI=A!YC
MD&'9H0:=V!K,3)9X$9M$J_=!:YDZ#*;L-R,>=D&:R:+W9H/-O11+'KQ+F/=5
ME3QA4:+,K2GRI>DZX%+Q<7"I84?,U+'(^+FY5-_H&0#%(Q$_!S+Z=2021>#8
MJRCY9(GND7U9B7A0N,OU;TJQ%-WPHV:DY!_)(_$1\="Q"6^.U3TL*0H/%M"3
M8@$9:1H+)'=C0;<!+)0J&BIQI*0CP.9?-R3/=8ENIS+.RB^F$=E,C#-85+)%
M&J^6%MK6L 2I'$XW7+DN TE*:!1J2.L3Y38-&'@"32O8()>I 8[*H^3[M]WT
MFW%D51D>MF-1N RJ4S2K;+BLOCD*B$\'50OY%EIK, DZ!RP]']8YL%EKX'J_
M0;0.:HR0>=*!7L=WBY)V[;JB70$B9*;=_-KS^R^^-[?5ZM+5?.KJ?T[Y"F<:
MCX9F<.YJ@7CSL(/%N23</'VY@<@0V.B7TN(I2A*+HN1^=":$%ESG*B"8Y+#D
MH6!5ZHJ-0=N1Z\S<HOV4@=QIZQ4A\YT>,GK%.'+NB#QKM&L+M8JDVL&%/,SA
M?1.%[,I*+>Z']FB_?M2*'>[&JY5@D08B;"?;;3=W!% 2,"E.\SR_:V1,J\T,
MCH4@+<20Y&WZ=:65,1Q$*P?.746A1=7##0JBX%MBFWHOS7_$>53-'JBHEWE+
M R>)G,OF:+\!Y.1Z623RU04PTV=:5UXA D?.4\!ZOVFTJ'0'RD(0_5;7,J:A
M\8WSJ4+*U!?U;7:!BYF%F.^NY1$64TTCSI)30X%$/F$>(I:2!!+55L+>>#RD
M-WI!9SVG^RKK85N_0&D%FQ%=/")PB<(JPN[WF+=_1A/OW4+<(K/X1.$44F,$
MA5AB% $]B4;F@)9$NV6#2D*./"UF\@CAN''6ZK HW=-5$3,3DLAC11+=+9-\
M".%A3G55D0=(JD5-V@#Z<J]4 3JQ8+7+#06_G!QM*2<7$K.(\H-!V!=,SD3;
M9,:Y?*/L8&S>4O5F2>Y'=Z6D1)+.[@H3P\)GZ\7\E1%@2+HR,@VD=S"V9'6R
MBH@$6: JW+ GHI.-/GE?I(SY0Q&6*,&:)9HM_7:@B6IB2AL77C^-"QI)M&5F
M[$IS\77\>?OJ9NR_1D3B3[4G X:5C<3%@7CUJRIXW*QB+=OK(7G>03@-#2;:
M7[QK>R)GI-=8NH:WC&)M+TIMJ,3D9U-V3/OZ>^=6N^CRK@(6QTFVR^(2.60T
M-(M!B-AUZD?F%:.BKV3C!)V'5N0$P=BH"*$[&B\S?7>/CL8WBZ!AJ?VF;L,+
M:KKR5XU<$L>IT>S1GU;Z^!L_Z&0H]8*&$5VB(T8A'W@(FJ"SL657E;MD=#!6
M&&,.<,Y',SI#J/3+XA8_8E-'C^WB;UR$V=24LHL3/?O]\V]/@5V#*'Z?"P@&
M]94]7:HS< ^;B=7<#%ME=0,M:D52;)RR)"T7J295O(3."# FWT<:;&C"3E!)
M8@0T5)<ZRKQX4)PBJJQOPEI+]*KK_*6U.$5J\(G")PBT)N^L[0(7]'9Y&*E"
M66WW-=,[4%,3:X+.*BC,2MJ3$;Q5$*N;1KJ7Q$X4AT@$R%D:A0ZP6EBZQY6M
M['A9.,HBD')2-%O#Z,WASCR75'[U%U@IPB%01PUG"H2'B^F=5T/C\MJ)%ID-
M5[OI>.R0+#G)8NT*:VV/F,1NXDF<DKMO!3,;(,!C@Z3<*1IK'R>77Y-[4LV9
MAO7++"6 AAH=Q"'4?)B'#0N<JIQD@)R_4/PMZ?*@I0.=#K-#IZ"(U-FH&*&H
MP4*CRY\'8C@"7:1L:3-GYNN?TZLR]2^%"<(G"+S1ZY<?^M->Y_V>*Y;_ /?B
M?.D?)O\ :&(>)CUT:Y_\H/V?1>.?^&9:.\[ N3IPB<(G")PB<(G"*TZ3"RR0
MSECM%TG2;=CG;=\0TQMJEOCNL:>#Z9SG&JNF-L]UOMVMM<;:8QK]O&<\Y-LW
MV0TE6.Q-*R*?:)0^:L(#A%*PV,5,[7I;-(#DG]&+_2(ZAL.P&JI#V3J7R0;=
M&6Q4H);EQNSB6H;Q.BC(N,SS8V"]K!*2Z UDDYVSLOHV1U5VSVNWG?5/7&V<
M]K_?MC.><P/>T+HXO;/UYA99'A2G")PB<(JPKG[ZVO\ I/=_N9">$5G\(G")
MPB<(G"*$V7[W$_\ S)E7["?\(L]'OO #_(XS_!(<(LQPB<(G")PB<(JQD7OJ
M5G^0;&_Y8APBL[A$X1.$3A$X1.$6B79"?>8C/Z3PO[J37A%Y25C[VU>_F/$_
MV"PY\GU?UJI\8F]8Y<<G_3S?M9/]Y4XY;JDMW>@3\.+V_-2E/VO=?.T?)?\
M9^*>.1>I6^;$OJM5XPWU;5M"ETKUCL^)/"[B72-%Y-)'.Q@H[(E%PL9,3"P=
M;)EB8(6S;,6N4)"=PL,?.C6ADVA#7Y2#C2["*%B0EUU!;;?KS>CK==&3](5,
MRP1D23&D]LX\FE4WZ[@>:6T?QF26-*M"RPZ4"ST=)$C1>UYTO(5C 0BD14+(
M/-46Y,0&?L"7/7KW@BW1_1ZK^M"&L>635J@S,#$536W8%4]/+:4Q>8EA[C<X
M.*N4FC<U!X;H*="7 LT/!1QK%$BV8L_.!RI+G/W[<W\E\YZ0J@P(0 HIR9 /
MI!B=;.6.#GA.K^%DZG TYD,LX?LWCQIX#%8ZR<C"0AR,+,S;T^\U?[-)-(&!
M(HOUX_:L#OT/T@J=F4C<)RIP5GTB)'I6Y4,M-%"S4N-N@,2CCA9 4BZ4$.0]
M^V(,\/4<*2U!FO'4VTF0S$HYL.*;GBT=[1HXEE8MT>5+#G =P#4D;+5B]AI,
MZQ8+Q\((FY.N)<ZG%>OI2%CD;"B-%8=)'SH@.2C#*--":JB2DF;'EV0]9H2_
M7F]"D,TZ8Z_G3RT%2Y>=M!=OC#C:;1H-*W V//CDAJQ&E2$P39I-]G&3^*S:
MCXZT9.WCR(M'(P=)T8OK+VB9_A0L>;Z0J(E[/&+ B*5D2!0X/D#^;SK+8[,B
M+IB4AA-4=N5W:(HC(N5\W\4'&(;'F0:)/Q@W+7<+KEV[57*;D=>NM7($K^.@
M,37<=H_3>V":>GI26R2=Z%WKYR+9 &>&Q!!1%<:W!1X6)!@$1VS7 QB,:JI9
MV(;.GSDH5!0/HKHZNV:#4&--*;I&1Y]5RY(MFN7A5@5I(ONX<L08X.&[@FZZ
M>JOT+MFXQNV(H"'Z:Z.=C93=R4WZ\>;G7?\ <D5SHTBZ320V*,*1!$$Q#285
M)T!LCT$1X/;T;'BW#]F)226_]7+TLH2X-Y:ZRM9<TWD_E!K-A(R3-2CKUZ\V
M98K/173S=JQ:@GDXBNL=*RE_ E8W(TAZE9L9TE.$IS'8#KN,<-PH66XL>7[E
M-UD'QIMNZ ^)3 G2!5YI%"F_77X>ME85+T)&:;)61(1F&*\CL\Y&GYUT,'O1
M D>!@<(C]<P") !+\W(5A86.Q:.(.G*&A11N3F)V82A)J,\HMA;(H5[\(G")
MPBK"[O>8MW]&$^_=0MPBL_A$X1.$5:V?4T-M\*B FK5ZZ'((RI!/1B_7'JX3
MF4 EU9G,950^ZSE:*S<^W0SG[;=VLW>I_P"E;)\(JQ(=*%6/SFQO"LL8Y>%R
MITX*8R#9,3)"9";6=8318PBLT<.L: 91<ECO1#<6\&-]TY D@92+I@8WXH)?
M\.98HMT=528C.\(<D9QI"-"[4\,ANL@;.(P&,=PMX\(- Y$4^:/W<E<N71=V
MXD&AI:.R5QO+J_WALJU2-)E-]_KUYEV&'2%58L6Q$C7DQ9I >[4A[A(VTV=P
MQWF25%-47P5182JF_7;36D8/*4TI4C(V2KU,L*=M',7)J $RA?>O2#3B(!U'
MV3,XU;.T7>BSA8F@;676?PVNH*0=$FDF8' Q_8F#JZ+>.64D%&1)YUDSL<'$
MFYPDU7(KZA$0#5]#(G XYHY3C\*C8.* TWKI1Z[3$1X8V$C4W+M;.5'*VC-H
MCJHMOVL[[8SMC77&<:X(I1PB<(JJL;\):2_2JZ_REM3A%:O")PB<(G")PB<(
MG")PB<(M9K5K0%8=PUXS.-M5VNE76_MMKG;./]+K+*-PEV\8SC.?N=EOM_V8
M_P!OV\XQGTUQ:;@^GO:O O+FM<,^L>@Z]&E8SW(U7?BE/_CW_P"O/>VGO_O%
M>-J'>_=">Y&J[\4I_P#'O_UXVT]_]XIM0[W[H3W(U7?BE/\ X]_^O&VGO_O%
M-J'>_=">Y&J[\4I_\>__ %XVT]_]XIM0[W[H3W(U7?BE/_CW_P"O&VGO_O%-
MJ'>_=">Y&J[\4I_\>_\ UXVT]_\ >*;4.]^Z%45V])5=)PT+LQ$)]^\[W3]I
MO_I=M?\ 5%+ZK9,A]O;;&,_ZALY^YQGNM_\ L:XSMMC&8,KN^-!TG>-U(B;?
M>W][O>5;AP:L(O 6V$ C!%#[C&G=8U^ZQC&<9QC&<_;_ +<?[^>"XG25Z#0.
MO7>\G>5C<A>DX1.$3A$X15A7/WUM?])[O]S(3PBL_A$X1.$3A$X10FR_>XG_
M .9,J_83_A%GH]]X ?Y'&?X)#A%F.$3A$X1.$3A%6,B]]2L_R#8W_+$.$5G<
M(G")PB<(G")PBT2[(3[S$9_2>%_=2:\(O**M-L:5I7^^W;[G6"Q3;/:QG;/:
MU ,,Y[6NN,[;9[6/M8UQG.?[,8SGGR?5_6ZGQB;UCEQR?]/-^UD_WE4KT[=7
M-9=3+N0,H"QD+)6/@HQ*-\FG<&?:O8_+U3"01[W,(FTR5 /5M@CSPJ-31*+R
MUCCN,/ ".VKC5OD,4P6KPD1FI=$[;))H?R8J&Y,L 89&_P!HIX!*T;8VTM.9
MH'?W93FO=UN&ST 89BPY;WQ_0$HL^,-+Q^5BB#P,L6?$9(SO/.:_JQT3P:%3
M"=77O+H?%I3NPB5-ZL=Y''Q)O9EJY,7/EQJTV)M'66VJ^44<K81SIA7*26=^
MZRGKVNH?)?\ 9^*>.0^I6V;$OJM5XPWU;5< V^NQOE]9?NPD?3<MI )(O#IG
MOO%XRVTCDJ;1683AS'R>[H"CJB5;PZ 3*3+L\9V52"Q]\_4UU;X1W5Z@MML?
MQZ\:YXM>/8Y9P]@ V&2'IMEC^T7CP=!&<<C46-.#S\<::QT@RU2' W&XYTQ-
MOF8YX@6PP4:N';;"^NFJR>VQ+'5H6T_F3IGX(ZQ^845_E/"A/,G3/P1UC\PH
MK_*>$3S)TS\$=8_,**_RGA$\R=,_!'6/S"BO\IX1/,G3/P1UC\PHK_*>$3S)
MTS\$=8_,**_RGA$\R=,_!'6/S"BO\IX1/,G3/P1UC\PHK_*>$3S)TS\$=8_,
M**_RGA$\R=,_!'6/S"BO\IX1/,G3/P1UC\PHK_*>$3S)TS\$=8_,**_RGA$\
MR=,_!'6/S"BO\IX1/,G3/P1UC\PHK_*>$5:733%/(4[;*Z%45JBLC6D[5162
M@L735253BQ7=-1-305C?133?&-M-]<XVUVQC;7.,XQGA%9?F3IGX(ZQ^845_
ME/")YDZ9^".L?F%%?Y3PBBTDA737#WD182F"TZ!>3V4I0B&H$X9$FN\CERX,
M[)4(\+RH*QJX*+@XR>(H-<;8W60%N<)=VKC1/<BX8G$NF6=QCRTAL)IJ2Q/P
MV2#\2$1#8B\%;O(>>+1B3(INTQ64E,ACX(N+>;IYV3U=,'&NF^^NN-LD7( A
MG35*LI^34$I\]JHF@KE03"(J_1;X= H]*&B;U9N(418.'D;ED:.LFKW=NY>"
M33!^V25;+ZJ<(LLC5]!.#9"-HUI4ZIX2*#'"0G2#13+UD(D+LZP"$7"/BGMZ
M-2;R,2!LS4S]I540^UQ]M';A%E?,G3/P1UC\PHK_ "GA$\R=,_!'6/S"BO\
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M5H:>>H);!#-.YHNYL,;Y"T7M<AC7$"^:YS75*6>"!H=/-%"UQL#+(V,.-B;
MO(!-KYKW4I\1]*_HO17S=@GU'E?L;B/<%;R6?HU0[(X?W=1\IA]]/$?2OZ+T
M5\W8)]1X[&XCW!6\EGZ-.R.']W4?*8??3Q'TK^B]%?-V"?4>.QN(]P5O)9^C
M3LCA_=U'RF'WT\1]*_HO17S=@GU'CL;B/<%;R6?HT[(X?W=1\IA]]/$?2OZ+
MT5\W8)]1X[&XCW!6\EGZ-.R.']W4?*8??3Q'TK^B]%?-V"?4>.QN(]P5O)9^
MC3LCA_=U'RF'WU5EPANF9.)"-AL.IAVXS:=&:*)#XW"MW&C!2[*^3*N5,(#]
MM\,60O9X\)[[8[RF-0=[N-M4-5=L.QN(]P5O)9^C3LCA_=U'RF'WU?@^K:$*
M:XV'UE4[O&=<;XRA"(BIC.N?MXVQG47GMZ[8SC.,X^UG&?M9Y9D%I(<""#8@
MBQ!&D$'."KL$.%P;@V((S@@[X(S$>!93S)TS\$=8_,**_P IY"E/,G3/P1UC
M\PHK_*>$3S)TS\$=8_,**_RGA$\R=,_!'6/S"BO\IX1/,G3/P1UC\PHK_*>$
M5:5Y3%/*%+3PI5%:J82LMVDEC>"Q??"26(=#-\)IXV%9[A/&^^^V-->UKC;?
M;;M=O;.<D5E^9.F?@CK'YA17^4\(GF3IGX(ZQ^845_E/")YDZ9^".L?F%%?Y
M3PB>9.F?@CK'YA17^4\(GF3IGX(ZQ^845_E/"*%V/2U.)5Y/54JFK--1.%RC
M=-32"1;3?3?0&^VTWTWU%8VUVUVQC;7;7.,ZYQC.,XSCA%G8_2E-[ 0FVU2U
MEMML(&[;;;0.*YSMG+-'.<YSD5V\YSG[><Y^WG/"++^9.F?@CK'YA17^4\(G
MF3IGX(ZQ^845_E/")YDZ9^".L?F%%?Y3PB>9.F?@CK'YA17^4\(GF3IGX(ZQ
M^845_E/"*(^;^!1&W:Z>Q.$1&,/7,:L9JY=QZ-A@KIPUSM#5O!EW UDV550[
MZFFKWE3?9/OB>F_<]UIKG!%?G")PB<(G")PB<(M$NR$^\Q&?TGA?W4FO"+QV
M&C#I>B8NQC!!L*D.\ AK@._?+FF[!!^Q&"'[?QCO'7XPRJ-5W;81(M&+]ON^
M9*+LE=MF[A5/?Y5>^-F(S.F:Y\6Z9Q(UHC+BQSWM=D;:U[ ^QNQSFG)=9PS@
M+D)<QM6\R-+F;=*'- 8202X?1VP.9E9[M+FFQL;7"T@['=/F$P+69HUEY.1Y
M>1V"2]EH0-6.9P\!R1S)L#9(GK-[+L/0;L7\!6PHQ<I1J4:]YUP:&9UT1U;;
M#LHIC RDO V+)EJ8'%K*5EI(A#E1?V>DI<O(RA])IEAS_DWYS?+8U$8VP7B;
M'9\L9LV!MGL$=V?DJ>#*R<K2#)'G^B[7^B+H$_#B]OS4I3]KW7S>?DO^S\4\
M<B]2LYL2^JU7C#?5M4.O3L=4LMUI:0!I<,5CT=LGJ3N/J0+9=PLD3-BG,^Z*
MW/2?%(RV72E@]CHS#/RI><R$JY9JJ%&20\ -:#%O"3&>H+;@;;VBW^ZZJV#=
MBTL*-R2N966O"HWDY877#+6GTUCE23"-S44C!)12)]"#4X6Q<Y#2/!9_ J39
M5[9J4Q82W!L)-9<38M6(Y]O&G!,H6M8\>;?WK=_F7MMPO*<(OG3?5377?3;7
M?3?7&^F^F<;:[Z[8QG7;7;&<XVUVQG&<9QG.,XSC.,]KA%_<YQC&<YSC&,?;
MSG.>UC&/]^<Y_LX1?.RJ>NZ:>RFFJBO==Z3VWUQNIW&.ZW[WKG/=;]QK]O;N
M<9[G'V\]K'"+XRY;X3PKE='"6=NYPIE73">=OM_<XW[KN<[?:S]K&>W]K/\
MNSPB^M5D=]\IZ*I[*:IZ*Y3UWUVWPDKG?":N=,9SMA-3*>^--\X[G?.F^-<Y
MSKGM$7)PB^,J::[8TVWTUWVQG;77.V,;;8QMIIG.-<Y[><8W43USG&.UC;?3
M7^W;7&2+[X1?S&<9QC.,XSC/]F<9[>,_^[..$7]X1.$3A%6%W>\Q;OZ,)]^Z
MA;A%9_")PBUGZHJ&-W[%(6,B\U;U_+*[GWG2ADH= ?*5N)GH" 3X)7I9R%V(
M#$B;&-SJ31V5E!*SM)$\* /H]NLS\;8?M"D=\7Z[V8JB(KT3FZ\&QN&PRPQ#
M*"#BK'=4<3#EG)A$+%[NNJWHP&$.$3R#55VY&6[K'Y&4?H+=\UAJ3MN/5U.[
M8 E.5WM?. -7>4--=#<ECT8FS>(/:_(O9 QC+3([>-ZB6TI<H0CIA@1M>;XV
M(-FQ4?IBB9#(%&JKM1R3935Z'RJB[27>%"C^7XYN=<\RZ Y!+@C-FWL< )2_
MU/OL9'QMTC$!S':3=4\@:!H]A(CX>+&5XEU'B6-<KB?$S\:RK9LB'<1!Z;%%
MX84+8JX: D%@3P[,@)JOF94Q3Q"O(Z2FL'S,S%;F]!%JCO*F%M791$0LWE"U
MGB6L^$E&2HTT"A(L,3:F4R;52/E/7-IWNH6N@'L>Q0?%\C5;*$BI0W$2$+&9
M< B[I,O7XZ4RSJHD)-E#WVQIH\&()C^H< &41#J1X<0TKEKND*#C7HH-'2DN
M/HS;V]IUZ%VYST&G9PZ\*;26O:[9+U/-:X8Q6N(D7CL9KY]*&%RL7,@@>K,T
MU+,G$HTMM'RW0'$8P-*;Q(:X7$D5566 Q1?TWZ^#VKT="A0\;#BX_'Q; (""
M#V@H.'%M$6(T6,8(:-F3!@R;:)MVK1HW330;MT4]$TDM-=--<:XQCA0LGPBJ
MJQOPEI+]*KK_ "EM3A%:O")PB<(M2;(ON21"W](BV7B :'@2'3T'/J2*-6 <
M,R<KU#V)+8"&;BC4*2),*[8AU8OHD&D<PC9N+3::%F\%*'*V32Q*W!3;\>;K
MS*ID.NI=U!X"18UB<)3"4NNGP,YU:KQU"*D9=;"O3R9DT/CBA&7M#:!$;![\
M&%H\8D;0=%U28UX.+&TE6[9(N2WH)MO[^O-Q+.2+KLBJ"CD''X1+L25)H=:+
M.##8&]BT?G,1..1,KKB5EHO)2^!,L'(BS1!@WVW\$/C&2)X [*1U^/*O"6S7
MZZO2M\^%"<(G"+S6ZYUE-I+7:.=L][U&RW;&O^S&V5HICM__ "SSI'R;_:&(
M'_T;?7Q^U<_^4'[/HO'/_!*/P6C'.P+DZ<(G")PB<(G")PBNRG[>D$(DXIBF
M^5<L7N?!=6"F-G&VFFF==L;HXQGN]$D^UC3;&<Y3U[M/77N/M8VY7L]P?#80
MS$XY(Z>LGDR9*;NN_P"=.QK1]"1F8RO-F27%R)B-LZ7L)Q6OF+\.DCDGI(69
M3*DGZKF(; ]QMELDSB)@)>RSK Q [7[(AGN2(QD]VU[G9RV15SKVLX[65$]=
MLX[6?_;G^S_Y\Y6NFA9/A$X1.$3A%6%<_?6U_P!)[O\ <R$\(K/X1.$3A$X1
M.$4)LOWN)_\ F3*OV$_X19Z/?> '^1QG^"0X19CA$X1.$3A$X15C(O?4K/\
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M)8=:(;2&IQ47=LYB4$@4M)"3+\,>/,G)61G$B Z/(*ZMW-;6$@W,.D6<4>3
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M=PS DK3/R+EGH\7^0.?X?.C]NVQSNY_)*OH%SWM/V0=Q-Y52=.GD7+/1XO\
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M-#P$K%7) 8T:2R+G1%<3Y\%F,;7*Q,LE#9+J/-.5 [[1$G7KQJ1OK2@XTC-
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MZ8,1(SRY5;-2S;M)'K8 $V1J+]542>Q2RX7);Z:0*<* -.JZ0E*S?QV,5VS
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MLV$OE"Q>)AM4T!Q(E\UNNCJ-[1O[W(%K6T2G3O6592ZH,XEK>WJIF]FJNY+
MRX=T79W$ N^WIJ,SXXWRZ&R"3Z2IB,8;HH2#9(SJNLPTUTWT4*.OL_FL]=E5
MWW,+.@DCCC\<OI$V<U1B\CCLB/5BUBV91/:A.MDIJ*1DDG<3[<9#*[E@7=3
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M#FH\ DC3P"1 PY]CW+W3P(T,9%6G<$A1 $1U\&?(+H]R_"%BH9[KW':="B9
M<OA1H]<HJ$5)V\_HVK](]/;%B$&11#+6"5:R-W"%3LA -Q,+G-PSDC%VX&(2
M(PN6?,XD?/E&;902X..,/G#=R6DJPT*:(J!GUI=)4C$)1SS<-I%K8)@6!ES3
M%5RV)9$MXU(I57[?6QRWD0BZ"-1YBBY'#6@0]WIP:%0O8*+8D16PIF_*;$?U
M'>]JEA.V.D76M29F10@"XK2"BHSL2>H4-*SM:BTP[A=(<PCQ?:N$X\32A!>3
M%6*B(Q)-:)$R1UF^9!BGCMF@2QT<U^NGG76QU#=-=E._*>20T:91'*61"(^;
MDM82 _)9&/2E-8UBZ;5ZTW@A->01*PR%SQH"I@>50T+Z'&K1,6<&*2-W'2?U
M_'C7&SZC^BJ(AETA;4%'(V!&!7FNS"D96"CK3QFE$S@L(S7Q!&(A.0MO/Z$?
MOXTDIH9CCB<R!4ZQ%+HRW+,HZZ>O7P+8D%5=)D0D1?AZGK]L(8 2'D>W7K4,
M$6CX*;-%ECHY@&(@6)",)R%L4=IR0+NQ&KNMWCUH;9974=(\)GZ]Y6UPB<(J
MJL;\):2_2JZ_REM3A%:O"+C64RDBJKJDHOLDGNIJBCW&5ELZ:YVPDEA3=-/*
MBF<=QIWQ1/3NLX[K?37M[8(M-Z\ZT8'(8QXYL$?M7IO1R\W*0\?M)IQ(H0(&
M!HP8D)"V03*%AI54*L'\K0[&P-K"C(*/QQ5\,(MI,9CQ@6:=$6(D/4MT7R@H
M)F<X8LGSZ##EI9&)U/J$G2>(^R9Q^36&U+1"62BO4_!UR(>MI8=CV8\^\,..
M8@OXFT>/_%6CPIMZ;:1U\NA9YY8W1R0@40LUS'H*9B-NEDZ*C;Y&HUSC^4/8
MR1D"6*V<!6D2>F5!L=*UL=T;A7S'Q.@1C""0I-9YL'T=%'7C_JH&TZ@.C4"
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MD9G+5;'#5(^*1:':#HA,7Y0R\86EM'I4,B9"&"8/N3BWO#O:-'@X_"J6)O\
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M0=])M'O&6@O(*6,Q3<JU.C1 FU[9"B09QJQ7';F8X,$3=DRC9<BV=OLFB@)
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ME:]]'F/_  ;?]>,MVOF'L3(;JYS[5WQM3P<6YT=LP3-)9/[>N^NFW;QG_?\
M]K__ +_Y=IE.U_AZ$R6ZE8R:>B6FJ:>N-=--<:ZZX^UC&,8[6,?_ "YY7H #
M0OOA$X155<GX(B/TJT3_ )WUYPBM7A$X1.$3A$X1.$585S]];7_2>[_<R$\(
MK/X1.$3A$X1.$4)LOWN)_P#F3*OV$_X19Z/?> '^1QG^"0X19CA$X1.$3A$X
M15C(O?4K/\@V-_RQ#A%9W")PB<(G")PB<(M$NR$^\Q&?TGA?W4FO"+\(T;[(
M'U=C8Z ',K;[RS8!1;)HCY!5DIWILU8H(()]\5ABBJG>TD]->[4WW4V[7=;[
M[;9SG/)9=C6"OED>ZBNYTCW..Z:L7+G$DV$X N3O9EJTF#8:9'DTV<O<3^6G
MTDDG_JK-?9$.L3X7_P!7]7?T3RGVLX'W%_J:OXA>.PN&]S?_ -U1TJN^@NR?
M]<T).3MY&+P\6.3(J%-B2GFTJ![X2@(>354=IW!" .TT?!U"Y';NF^J6ZOA'
M:7V5U20PENNQ;#J/#J>J91P[2V29CWC;)9+N#+ WE>\C-O @=Y9W"J.FI896
MP1[6UTF4X9<CKD- O]-SB,VI;+9[+[V1+.^JN>H33*FFFZ>BF:CHO.^NBF4]
ME--=_-EW6NBFR26V^N,XQME-/.V,YTU[6TK*Y#=7.?:OO[,!V17XP_ZI:,]F
M?"9#=7.?:GV8#LBOQA_U2T9[,^$R&ZN<^U/LP'9%?C#_ *I:,]F?"9#=7.?:
MGV8#LBOQA_U2T9[,^$R&ZN<^U/LP'9%?C#_JEHSV9\)D-U<Y]J?9@.R*_&'_
M %2T9[,^$R&ZN<^U/LP'9%?C#_JEHSV9\)D-U<Y]J?9@.R*_&'_5+1GLSX3(
M;JYS[4^S =D5^,/^J6C/9GPF0W5SGVI]F [(K\8?]4M&>S/A,ANKG/M3[,!V
M17XP_P"J6C/9GPF0W5SGVI]F [(K\8?]4M&>S/A,ANKG/M3[,!V17XP_ZI:,
M]F?"9#=7.?:GV8#LBOQA_P!4M&>S/A,ANKG/M3[,!V17XP_ZI:,]F?"9#=7.
M?:HQ-NRW]D),0R7"2/4#X0/*1@^.?-_-32*/?V;T4[;.D>^H5LDNEWU!7?3O
MB*B:NG==TGOIOC&V"9#=7.?:I/\ 9@.R*_&'_5+1GLSX3(;JYS[4^S =D5^,
M/^J6C/9GPF0W5SGVI]F [(K\8?\ 5+1GLSX3(;JYS[4^S =D5^,/^J6C/9GP
MF0W5SGVI]F [(K\8?]4M&>S/A,ANKG/M3[,!V17XP_ZI:,]F?"9#=7.?:GV8
M#LBOQA_U2T9[,^$R&ZN<^U/LP'9%?C#_ *I:,]F?"9#=7.?:GV8#LBOQA_U2
MT9[,^$R&ZN<^U/LP'9%?C#_JEHSV9\)D-U<Y]J?9@.R*_&'_ %2T9[,^$R&Z
MN<^U161]EN[(0_)0EP[Z@>^K!Y4J2';^:FDD_!WNT3E(O9;N4ZVTU6[;$D]0
M[VOJJECOW?<)]^3243)D-U<Y]JE7V8#LBOQA_P!4M&>S/A,ANKG/M3[,!V17
MXP_ZI:,]F?"9#=7.?:GV8#LBOQA_U2T9[,^$R&ZN<^U/LP'9%?C#_JEHSV9\
M)D-U<Y]J?9@.R*_&'_5+1GLSX3(;JYS[4^S =D5^,/\ JEHSV9\)D-U<Y]J?
M9@.R*_&'_5+1GLSX3(;JYS[4^S =D5^,/^J6C/9GPF0W5SGVI]F [(K\8?\
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:*#QQIWO=79+/?.ZV3SOHGMJ3(;JYS[5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g713200g95p44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g95p44.jpg
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M)ER.Y$6%:BVS8F2S=/5;RWDU(M8WM87ONUMSZJ.KI\6;M]$:DZEG $$I^O;
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MW'M:4=K+RG,TOEZ&J/L3U'NV\.JE:R"2"A0 4"BUT9I6BCD %OLH9>2.SH-
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M=OY%D6E W)2UH#Y'URKO1A#]BFT'8#)'+D[ )"(LP^"47L>.&;*M/<S&ZYF
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MW(+GOVOX O+E?7*EYI):QE1^!!%R-0R>93&$M6K?4>#;2.?0XW!)63+1]EA
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M%6TF@LE0MY9\[ "!+]V51< -Z9DS9=F82'OGZRC;9FT]6W2<+E6V[KZ>??6
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MD.-JZ8KIW-C8XVS.D?&2&.>!D=(+B-KL[KY +!QRW+B;-*R1$TR/:,UFQM>
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M93&4WA9D.I>1Q8!+F<0F+A5Q=3RC"DJ1C[_V-5IBT5HO,H^\5A^SXJ7UZW_
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MM8#'$(H6DR-C<YL>=['. N=7"]G.LHW$")=@6SLG-+200S2ASB))3+,ZS'/
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M_J:B_-G[R?A-C_\ 6M7\L?=3Z)J_?MJ2O^&)?U''X(\&OZFHOS9^\GX38_\
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M;1)1^ZV5M_ CA+<GT)%W -)Z<PVY#22T$]-W(:7.(!T!<2-Y51PNP( -&)D
M$N %-7@ N#0X@"FWN#6@GE#1?<%_2'8;K"U?M2K:4@FY1D.>"&9%"!R])\T$
MD'C4@_&-72<0U7;CWS]DR>O&:6^C=R[9M7"Z>ZS='?1^!'"4$$82 0"T'IS#
M;@$@D ]-W ) )&XD \B'A=@1!!Q,D$AQ!IJ\@N (!(Z6L2 2 =X!(W+V/HIZ
M ^V*C_)6=_\ :W+OP*X3_P!5GY[AW\8K?PKX/_UB/FM=_"K9IT7L:$V1"YL1
MA!W0\R'RAJR>+Z#3(WT#K82@OJEE,T.&K*>5+?7?ST4U$L>7S<[XVQG7'+.'
M^$XAA%=00XC3=+22TKY(V[6";,S;%N:]/+*T<8$6<0>6UET;@7B5#B='624,
M^W9'4M8]VSFBRN,37 6FCC)TUN 1U[J\G-!6YIPB<(G")PB<(G")PB<(J =_
M[>AE00V %)FC)UFI>3$6#/$8%"BKC#A(5ZQOETF5D,>321]'C.-=TEW&^=_U
M.4M=?U?.C=#G :_'J[$8:!](Q\%)%+)TW+-"TM=-E&0PTU22Z^\%K1;E)T6B
M\.L8HL'HZ&6M;5.9-4R1LZ5BBE=F;%F.82U-, VVXASC?D&]:M/HVJ)^P+:_
MD=#OTF\ZY_X=<(O=L%^>UW^U+FGX;X#[GB_S*C_W1/HVJ)^P+:_D=#OTF\?^
M'7"+W;!?GM=_M2?AO@/N>+_,J/\ W1/HVJ)^P+:_D=#OTF\?^'7"+W;!?GM=
M_M2?AO@/N>+_ #*C_P!T3Z-JB?L"VOY'0[])O'_AUPB]VP7Y[7?[4GX;X#[G
MB_S*C_W1/HVJ)^P+:_D=#OTF\?\ AUPB]VP7Y[7?[4GX;X#[GB_S*C_W1/HV
MJ)^P+:_D=#OTF\?^'7"+W;!?GM=_M2?AO@/N>+_,J/\ W1;(O#VNZ"7%O;>(
M4A+4,Q[2"Y)>^D,&$^=[5S,/4_4?9,GD?K'D]G.?6?3^I^B\J'HO6/2*>AY=
MT2>#F(X!Z#&O?1/Z;]$=ETG//-;8=([3:;:DI<OKS,F7/?C7RV&;H7 /&Z#&
M3BAHFU;>EA1;3IJ&&&^UZ:R9-C55.:VS=FS9+7;;-<VV4<Y<NAIPB<(G")PB
M<(G")PB<(G"+0-XT?U5T'][T^_*48Y])= ?J+A'VUAWBJM<'Z,?56!=KUWC*
M9:2.=^7%TX1.$3A$X1.$71[X-_UO=C_+*2^9$(Y\M='/^<V%_D*+_4,07T1T
M(/8#$?RQ)^A42VY\XHNL)PB<(G")PB<(G")PB<(G"+3OXRWQ+51\J"WS4-<[
MCT"O9[&?R0W],@7(NC![#85^4S^BS+G7Y]/KY\3A%9#J>BFO=8+3> ;65G .
M9[)1EJVBA4WJMK$C.4C\6C,VPK&YE*XOOY)#'X>_9D,R$B-18-V2CE1)1+5>
M&;BW *@C$AA/\HH :M[ZR&G+36P7IJRKH"VJH:.L'\EJ:Z.2+I6*5TKI P.!
MV+@J <:@O0>B/I%813-;2R3 BDFM44M/67IZNJINJ*>D>R3IB2-K&L+B+;+6
M]1LA@&UV,C@56GXJWLF[\6E-!]4QJ-(1$(CU1A4S@GHEG3=Z4J>0,9\19:/H
MY'S;-!C.G1P*T;J(9]7UY2[&WS5.#24N(XQ35C\*X/'!Z"7&:NK=6SNX9XA0
MXCF:UT<.-4TF&Q/,=554\CI,.93U#W \9=)&$LBAQ6.HH<+J*48EC/HG61X5
M3TPI(6\%J.LHK%S7R854,KY&;2G@F8UE:Z:%C2TY5I1(BR8=PFT+#GPMVJQ%
MDTFQ!HNS<*#38QH:#$-$7"::FS(L'?L2HUUKKE!\.>M7K;=5LX24W[Y%-%.T
MOAECF8))H2^)[9&B6GE?!/$7-) DAGCDAE9?-'+&^-X#VN XQ)%+"X,EC?$\
MLBE#9&ECC'/$R:&0!P!R2PR,EC=N?&]KVDM<"?@YZ+S3A%T0>#/\4-O?*0/^
M;##GS%T=?9O!/R5)^ERKZ!Z#WL3BWY1C_1F+<ASABZ^G")PB<(G")PB<(G")
MPBTS>,U\5M-??^:^;NW.[= GV8QW\FT_Z4N/=&'V+P?M^;]'*@FD]F!6)=37
M\A=P>* XU.*G'I MG=<'HQ/4W6DVP_D0EUEJA-(7/1"N5$[?!%5784MML'?;
MOF^Z34?ML6/[6&MX:1TT>(5M158?C4AJ!'BE-5X:6=(&*EGC#W4%?AL[;.P.
MIB:RHA&WC$;@Y\HA<%$<M+P5DJ'4-+!3UF%,$)?A\]-6YA6!\\3\K:NBKXC?
MT6AE+XI/27F1O$8:2]LA!<@9@98@@!>34#2<'^')[&UHNJFSGI&4R]HSR?WB
MJF1"AY:,YB+=_LTPJKKMZMJ^SJX\_.=_X&3P108C!$ZH905./XA^#T=6VL#I
M,-BHZ)\G2PK!MQ3MJ^GG19[ C,8[MLM*X5PRR34,KVP/K*?!J+T;?3FF(972
M556V/;FF.R=4&FZ4;(67-\N<YKKYUF AY10=L(=2X,#;UR0.R0TRD(IK 3%B
M-+!)92B<LC*(CV@9EKP>@&2 JNY$F29B-09-K']H^R>%7EPDGCX13/G913U#
ML4CIZ2"2FF?B5/A<F&19JVBJW3;."B9*Z<U+64IBDF-1$^J%3(R&.CHX7X%"
MV)U7# W#I)ZB=E1$V@FQ!M?):EJJ81;2:K?&(6PEU0)&1"&1D&P:^5_L&]F5
MNQDB2V6'0P^[!(/"3;SVIU=C%,E9=* K4FZ55CZD:A"1=GHVSMHQ-.HI%VE,
MB!Z1E,P\6QX4^?!*N&'++74S*ET<3[/IVR5FQHJ.H?$QK:D5>(&&0NMM(&5E
M8_'II33N@C:O:8MQ>FEDO'1SO@:^1MV3N92&:KJH62/<ZGZ6HA,P-T9,ZEIF
M81"P3"9[A7P'KZ.H)XZ8Z:Y(^_BNF9-;337+M&/*C9V\T1UVQC*N!3J0,0ZI
M/SO_  V";"-84SA?=KKOLU0;XWAK)/6O0_%)(FDG(ZJ$N'1YB/4[9E-+.V*W
M'V4E7;BA]M?@N,(KW1CTSI[#F2N !<*<QUKPW=?9.J(X3)^+M(Z:^I:ILDH\
MYK;I/WVL'Z:)CK<-=R7<RU42]96%]<!>%7KK+E/778@,L<&T30V4SA32:C&S
M#?\ ^HZ>@S 4DM/Z"0])21ET'"J5E*('@Y6S<*9K1LR$G93874/+K7!H)7RC
MTHYE-5$<XQ:4U<;PV;@[&ZI,S2,QBX.Q!SW9AZY'B$+ W<>G(VQ^KXJV*>"K
M^R]D?N=1?C6;SE_1[W<%>SCG@PA=!Z#7_P"8O_VK_P#T5O<Y\[+N"<(G")PB
M<(G")PB<(G")PBT#>-']5=!_>]/ORE&.?270'ZBX1]M8=XJK7!^C'U5@7:]=
MXRF6DCG?EQ=.$3A$X1.$3A%T>^#?];W8_P LI+YD0CGRUT<_YS87^0HO]0Q!
M?1'0@]@,1_+$GZ%1+;GSBBZPG")PB<(G")PB<(G")PB<(M._C+?$M5'RH+?-
M0USN/0*]GL9_)#?TR!<BZ,'L-A7Y3/Z+,N=?GT^OGQ9B-B6I*%R:7:&&B:L:
M) F2X+9L]R]<-CFSM),CH[PC@?HBBNV]#Z#+C=TIG*F^R22>B>Z^#+6[*OI*
M(P/(JXJB1M0'1[-KJ?(3$69MH7.:_-FRA@T&8DD-S(Z3:4535B9@--) QT!:
M_.YLY>!('VV8:'-MES%QU-@ "9*1HLFL_;"1TK#JR4>;B(65"O5BZ*D6?RYN
MJX'Y1=)M%MC:@IXA@$:0%H>NI25=B,!MSJ3M)]R*=PAB;&^>6BG%))3UM11S
M9H'"LCHG!LN9I>!3B9CNF*=TSLCJ1LDM0ZF+#&I-N!2F1L457":F.:DAJHLL
MS32OK&ET=GAA,QB>-A,V)N<5#F1PMG#P]8A8-<E:]4RW,DTE5GCQ'U!GEN09
MOW3-0.-+N"!$:11;/!2[)8LW!/6CM'=5*1CI()]+LM'W6RF;AF*0XFW/!$6A
MC';5^:*2-CQ/+ V.*6)SV3-D;"^HC>QP:ZEEI9[9:E@&'B&'38><LTH)>\9&
M99&2/88HY7221R!KXG,=*V!['MN*B.HBN74[U_>L25*-HH<ELQ'!$9$$*O6Z
MQ--V[=H1.%)IQ8.JU;M4]MB#@J0!DXI'A2.R>^C@!NL3<C1.WM%-TZ(75M/1
M4,M0ZEJ(8W-A+&,=6UY-7.'N>0(FPQU$5953.!!;4@0LFF]*(4AE;2SU=9'
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M&R;,\/&]IZ#8L3;-+;;=)J7:-;:20)-D]]]]DT'J:R6FV^VVNN,[9SGT?C^
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M2^1K@VY)M<DGMG0T?GP:M.S@C_\ ,Y!:"G@IFG^2TFI93QQ,+M;9BTN( %[
M ;R^<H714X1.$3A%C<GAT2FK'4;+XR!E##393=)H?$L"R""BJ.[=19OH^07P
MW7V14W2].AZ-;&FV<8WQC/"*"-NG?7K5G#A;*$O@P.$PZ$UZPCD>FT\CT:/P
M:N"KL["(I8$?#29B(LL)'C)(N1:LY^SD>KE8_)D2&7C.42-L4*MSS^7=;>LU
MGM 5=9;PB3EP@VL9(J@%/? !F\XA<F&:QD7+@HAO'Y/"I''I!'&N@JP)X/>M
M@9)@B593.3-"NCQL7=HJ%3SW*51 D8 $BP01BU%A@HYD)$C&26J#,<,&MDF;
M!BT0TQC1%JT:HI-T$M,8U323TTUQC&,<(O1X1.$7.K[H^^MJH3Y<G'S!DW-\
MX ^R%;VF/'1J4PKUV3XO]8+CQYU13B<(KY^&Z[C(WLU[7ERJ+<(#I'LJ=4>J
M!8](W0UZ%H&Q2@PH'!2M1&/%I -(M6SZ/CRRZ#-V909(K.$-=\JZ0N/ME=AQ
M9$"7OK,/9ESR1M<U]=3M<U[XKR-C<#:1S02&DD E8U6"8;#>9(AO(WR-!N6Z
M@6O<C6UUMEKBUNO-U=?;AE$?@4?'/IE)NQPV-5G(()3PU]>4AK?HW439<I*G
M8T2JG6DF,2UG(KKC@^KFS9LXGC)V$9E4WK[9Z]UBHIJ^DKZ2-\\A$4= Z2HC
MGJG"BCJ,9JB&Q!S@:F-D1CHY'51<1 0]S2UN5N"]DL<L;2X\5L1+VN>1&'5$
MF@!/& !;&2_\0W(*YP3T=.1=^B,D(QT((. \=D"#1XGZ-94++8^,E<:)::^7
M/E:FHX:%&&*GE_MK)^W5\F//\F-^9(R0%T;@]H?)&2#<!\4CHI&]EDC',<.1
MS2%+ @Z@W%R.ZTEI'<((/87B\O54X1=@/N;[ZWOL+\LHCYD"^<LX?=74/:CO
M'.4'BOKL?Q?ZQ6TCHW^V7=G\.^Z?FI6'-"48=_<'@"O?PJ)PB^5ZR9$FJ[$B
MT:OV3G3*3EF];I.FKA/.<9RFNW7T415TSG&,YT4TVUSG&/I?2X10:2ZPT>08
MD&*$*WCFQ&PLVKL6@TGF%?25A8.T:6ABLE RN#GX_)HVZ<Q%V0C#QK'RPP<^
M %S8EXS78G"Z#TB]E7K_ % O#(Y7CF%M'D)BD;DD4"1MZ1-/1R0J7QU_$I,N
M^U=DEEC)\U'#!X4_E9E9_*5V\EE&VQCT\F/*D"++8!7D4K&/^]J(-": Y0D3
M,O')V2R:9R$L7,.MWA$J>ELS,2"52 BX5WU2P].&B#E%D@S'-U$A[%FV0(LV
MX1.$7-W[I%^(SKA\K$G^9^W-_P" '5F(=K1>-4IA7KLGQ?ZP7(7SJ*G$X1.$
M3A$X1.$74O[FD_9^YOW+KY^/=G.<=$'=A/9KO!1J'Q;^C_WO[-;L.H/Q]>)W
M^'#"_P"CUZ)<YLHEVYGP3]=ROCPK4X1.$3A$X1.$3A$X1.$7*![I%^KWJG]Z
M%J?EF%<[YT&.I<?[8H/%U2X[T4NJ,&^)K?KTZYGN=L7*5_N/U\?_ -XY0[CV
M"BZ7[F[_ '5R6ZW(O'[!:J26VW1\;-S6 \C1:R(/278J)/\ KHLVRJ$3<YU(
M5!-YQG9!QYNK76!)X=IM'CD:V6XEAW!+':<8>)J-PAH&Q/I8MI"7128G@]0S
M& ;2$#)B%+2ZCU739RES6O(ZM6\(\(FZ<,=2W:UAD;429) )(Z#$H789:[+\
M>BJ)]#:W2W& <6!42\0ZX*H[0N!1*DY7$1<7KF6]NIU(8V^<SQ4D4,S"^&*[
M*>B3,H;D-E6=SQ1] S$<A;?(45$C8B8#L-!.KX6V=[7P/PZOP(2,Q.GJ7SUL
M'!ZEAF8VD$<<=/A3@ZDDC@+.-AL[:J*>J=M9*B.2G?FDR2.;KW":MH\7R/H)
MX&0TLV-5,L3C49WR3XBRU0Q\H=<5\3J>2* ;-D+V3L#6 L:=1G.AK2DX1=C?
MN=/ZTFY/PBS'^[2M.?.71B_G#AWY&B_3JY=PZ&/L+7?E23]$I%T"\Y(ND)PB
M<(G")PB<(G")PB<(G"+G5]T??6U4)\N3CY@R;F^< ?9"M[3'CHU*85Z[)\7^
ML%QX\ZHIQ3G7=41>>QPPOBP7 ^;,8U8\O;Q=M$%20)@!K:)K2IRYFDQ6/"L1
ME65>J.@$02% )9H\/Y'LS*P),JS7WPYZF2"1@V+3"Z2GB,AF#7F2HE$0$40C
M=M!'</E+GQ69F+ _*0O-SRTCBW;=H)O8W<;<5N4YK;SJ-+VO99:PZTN-HI3<
MA.S@3'W]M3/ %:/NV&?68?'7XP<7B\A+O'1)@UV)2\8Z5+ 8ZX]FHK WD4-+
M'TF$I24'>1Q ;6JC9"Z04T.</!TED:YS)(V -)RQ.;E?(,Q#Q*P,+HN-;MAF
MD :3LVWN/QB-' :$\4Z$ZFX<+7&N&V]3J=3*-DW$FP46,.6Z\?'JBD1QC8!D
M&,?DG\D9(&B[< 6#2,B\@!$*S?GT4)I#Y^)4,)YC2*A;VI:KID$B/*&@A[LQ
M<S/G<&B,EK2]KXP)VO+8R898'Y/3"&7,DS[AH!J;W%[FP&@O=H#[Z<5S3;73
M-('0Y2T"%;8-RTSH0G<!LJ<)HCH^WDQ,36U-@CH4$]1V*2J,#5]RIBNI1#VP
MT@6!#8J(CS$T]+;CG>K9GXS5K*=M1DC9E@FIX>,\QM?45;V/>WBQ2.&5E1'*
M7-8]TKY',#<PNZU\H8'V;HUS&[[ OD()W!QT#FNN 222 +A89*J:7 ,K.<H/
M)"B]K(K"L/X]+8JVC$A=Q":-EL-)GLV82:4#$1R)9>,LD-&1<JU+CIE'3PHF
MY8N%]6_K%5AYIP6LM4-F(?%(9(Q+$1>*[HXW9BW:$YF,+'121N:' 7N;)?)Z
MGCYK%KKC,TZMU:TDV#CN%LI!"A#F8O1=@/N;[ZWOL+\LHCYD"^<LX?=74/:C
MO'.4'BOKL?Q?ZQ6TCHW^V7=G\.^Z?FI6'-"48=_<'@"O?PJ)PB<(G")PB<(G
M")PBYN_=(OQ&=</E8D_S/VYO_ #JS$.UHO&J4PKUV3XO]8+D+YU%3B<(G")P
MB<(G"+J7]S2?L_<W[EU\_'NSG..B#NPGLUW@HU#XM_1_[W]FMV'4'X^O$[_#
MAA?]'KT2YS91+MS/@GZ[E6;Q,>\W8?J[*?85!L:BPA773[L=W7LG>U8K+98K
M-XKU]EU.1?%3Q!2+3N#ZP@O*]+,)/59V41F: I04.12BCK15WON56M!WW]4U
MNG]J^NXWM;=IV51R0^,EV@'V7WPB\:CU,RQCULK'OQ8("-J4Y<4<)UH&ZN H
MTZJ&9V%9Q.RE(!<X2T)5(%H7*(A6@V&R6)OQ[<@])#VA-!'A5#!Q=_&+1O!O
M<ZV%M+=?>MHOAB]N;0[B5-:<ULA*(%V\"NLW5T0LF$5A9%(A+)'1Z'PDE)W:
ME/V[)9=8<&,P>P3<NK,XW.&UT"Q*'+EAJ#1LY]73*UP /V7!MW1H=+&XY[<B
MV4<*U.$3A$X1.$3A%R@>Z1?J]ZI_>A:GY9A7.^=!CJ7'^V*#Q=4N.]%+JC!O
MB:WZ].N:P8H-1(L53#-Z0$INV^Y)B.((B7[QCJKKERV9DW TPW'N5D<;IHO%
MA1)-NIMJKNR<ZZY2V[3('ECQ$YK)"TACWL,C&NMQ7.C:^,O:#J6B1A(TS#>N
M5L+ ]ID:YS X%[6N#'.;?4->6O#21H'%CK;\IW*T,DJNNP\][E0]!A)=]*<<
M33>LWFTB9XT'M(M=8""ZH2AKF/[*R1P[CYK&FCIH^CR39\@J[49O-7"2#."@
MKZR2DX-5)?#_ .9-IA7-V+KO=/ADU7>!VV A:V:+5KF2ES2&AS;$NEYJ.ECJ
M<=@#93TBZ?I1VU%F-AKXZ>TK=G>4NBDT(=&&N!<6NN WVHQ2M5SBOF)N"O)9
M+IJ'!HKR2+B5"3AZ_DA2-&UD@Z[)U! P>,HA9&.5,(J#9O-\2&K8Q.)00<PP
MN*:!'/E/BE?2UCXJMM/34LLKA!/(&!K(8YHP90YM5+).987B,B2EI3%7STL#
M&U,<CI&^L.'T=13-DIS--/'&#+"PN+GROAD(C+3 QD(CE;G!;//M:2*HF<8'
ML$9A&#0%N[6MAQ-&19AI4\ /GS #.NXHU[Y-Y-'*SCXQXF[;[K,]1,\FX%_)
M&*K=)XJ&%&!J2K!ZND\:RE75N:,/;2NC<<0K(88YM'Q['835LTC2TV<9*2EF
M; X$M$LD;R'M!:Z.IJ9I-8:AKVBBII97Q^H?M=K%21,=<7:&U-1&Z5MLQ8Q[
M06..9LI*PRE&%?PB9G(]8@%J^EE>,4LE),&U.VM%E&)=.Z)!%HRB!VVCH6,2
M,>W#0B3*/RXMTY<*AGR4C,L3^(W@"IQ1U754T4U',YE/6/(C@D,5!.'L.&0U
M$YF].EG@>7U4 9'(UH$K##&Z+;9A@P]M-3SR15,8=-3-&>9FTK(2V05TD,(C
M]*CAE:&4\I<]CB<CA*\2"* ;"B#JO9].("_<HO7T'E\EB#QXWUSJ@[=1HT]"
MN'*.N=MLZHKK,MU4]<[;9QIOKC.V<_3Y+T=2VLI*6K:TM;54T%2UIWM;/$V4
M-.[4!UCH%&U,!IJFHIG$.-//+ 7#<XQ2.C)'6);<+KL]SI_6DW)^$68_W:5I
MSY[Z,7\X<._(T7Z=7+M/0Q]A:[\J2?HE(N@7G)%TA.$3A$X1.$3A$X1.$3A$
MX1<ZONC[ZVJA/ER<?,&3<WS@#[(5O:8\=&I3"O79/B_U@N/'G5%.*= ]MQ\=
M3SVJ5X*[PJ1)%#)62 Y@N!4DI-5%#2,YEXW ,AO(1<,5;X<@06Q-F);NG1-^
MBV;E2;PBIANII'50J1,"&M:UL;XL^S:+[39.SM$;Y@;/DR.>0&M)+&AJ\C&3
M)M,PT  !;?*/QLIN+%W*;$[N067USGLA8%CU]K ):UA3W3WUH2E61L*[KV/2
M5PHT #XZR8K&([%1)'=)LQ&MT\N=GF7;INFBQ=JKLFS=%.V&@@IY]O$9F^E;
M(1NGG?& 7ND)#))'-N7..EK W( )))L36/SMS#BY;9G$;R;V)/*>_KO7LE>S
M!TE64KJO2,"V<=/+-FXE)$F8PVCX%CB!:#1^XC1RD(.EPZ->L-1$F)L\DVKJ
M56&35U=$Y;L\'6MP]C:B*I,CG2Q@YB6LO(]VWS.S6SL:XSNS1M=E(BIVBS8K
M.H(0'M?F-QJ=!J3FN0=X!S&[1IHT;FV6(M;0CK@%6@F5PCWT>\ #-H0KIB0D
M@*;^&28Z5EP;V>X%8U6'RF-RN7S@DD2(IG01)L0","<:=M1+E(GZFGD#ZA\4
MVSV[X9O4-?:6-C8GW#M\4D44+2UI8]I:]S9&EXRW%AN\M=ES%KAH#9P :;WW
MM(:W06(L;.%]/5EEX8DH2=,&\:2"O)>+J>#L<M2"SIF"JZI0K0>,C6^7FBCP
MN8-$8]"3)8\JNS3U>1UUAF,0:&-&8JV.DV;H29"\1.J9G7 !?45+BYTG%(#6
ML;),QL=G<607<7,NZC8[%I)OESNW6)>\ZNTT  +@!U]22+F .9J]5V ^YOOK
M>^PORRB/F0+YRSA]U=0]J.\<Y0>*^NQ_%_K%;2.C?[9=V?P[[I^:E8<T)1AW
M]P> *]_"HG")PB<(G")PB<(G"+F[]TB_$9UP^5B3_,_;F_\  #JS$.UHO&J4
MPKUV3XO]8+D+YU%3B<(G")PB<(G"+J7]S2?L_<W[EU\_'NSG..B#NPGLUW@H
MU#XM_1_[W]FMFW7+/9_Z.+Q#,5_K0N>O'T8M8>_W:8[V%BY\27Z!#IA[X\1#
M0(GM!\@\1OWKY"9,J8?[&\G\/]=6&!VV>;**-K-O?U)M;X3K?;?N*0._U<>'
M)-C50;=ZYS$(*:*HRR 0!$Y>DLI5:Q8=*BD+<V!6TH;Q&:1'6PZI-F@\ 5F,
M:F6A:%ID4X_H1T:JDT]'Q4;FUR]DZ;M]CUCKH=]]VJA^2UMX0,ZG5]UX;GU5
M_" )%=P7W84$A>DECI>.QF^0D?#]L$)THTF [0!%E6<4C3XDQ>+-!$ *@V!Z
M.)1\FWR\R2[A;?R6TYMW(KJ]:&?4R/;G2W6:4Q,JS[(D#5Z.]8?.7TN 2XA#
MF$&IV7S<(TV+%1 11LX"Q*-S+00F+]>F#=ZY-M5Y1L=<9*AOR\FGV_:K;<*B
M<(G")PB<(G"+E ]TB_5[U3^]"U/RS"N=\Z#'4N/]L4'BZI<=Z*75&#?$UOUZ
M=<U8U^L*(L";9-DLX'/&KY!(D.'F!RJS1?1PDF_$E6ST649[[IZZNAY)FZ8/
M4,[MG;9=NHHEMVI[!(Q['%P#VN:2Q[XW@.!!+)(W-D8X7XKV.:YIL6D$ KE;
M'%CFO :2QP< ]K7M):00',>',>TVU:YI:X7#@02%,#OL+9SZ1VC+'CF&N#MS
M,G#"Q72E65=E T@](H&'RC(=[SL#8V](&&K4P0(Q=H&?OBS9N3=N5GJ"2^L:
MW!Z%D-#3M%4V+#7!]&T5]=>(M88F!S^F,\S61N=&QD[I&,C<YC6AI(6<[$ZM
MTM9,XTYDKVEM4XT=)9X<X2.+6[#+$YT@$CG1-8YSP'.)< 1BL3M.:PELU91Y
M^.1'MG)YTJ+)QR-R(05WD@M@&*)2 -(Q)45(VGJ UKJ.9'69!H&=87(AT6)%
MTY=*^]1A]+5.<^9CR]S86B2.::&2,02/EC,,D,D<D+L[W9W1.8Z5MF2%S&M:
M/&&LJ*=K6Q.:&@R$L=%%*Q^U8UCQ*R5CV2MRL :V1KA&;N8&N<2?Y'V;*F<E
MF<K>+M3I6PALQ&S+!E#95H?Q-M'*I1Z\;,E6.,/FAI9M*!"J.R20^1BA1#5#
M?1GAOO5]#3N@IJ=H=%'1OIGTVS-G1=*Y1&UKGA_%=$'02 W+X9)&7!=F!E7,
MV6>8ELCZID[)]H+MD%1<O+@TMXPD(E818-E8QUN+99@1[!SP\5AY:3CJZD:L
M*<PI07H\JVOA*SQC7X]B(C $R9BL=CTE*1YF)&L1BXA<YZJ^9MD='>JNZ>F^
MN.S!Z2*.HC@DK814MJ1)EKZN0-=5O?)/+'%/-+#',Z1[I!(V+,USB6V!(/L_
M$ZF5\#YFTLIIS 69J2F87-IFM9%'))#'%*^-K&M:6&2S@!FNH<)DWYHD0,%7
M:Y H6?.R9)^ZWRJY>OW[A1T\=N%,_347<N%5%E=\_3W4WVVS]//))C&1,9'&
MT,CC:UC&-%FM8P!K6@<@:T  <P6"][I'N>]Q<][G/>XZESG$ESB>4DDD]==A
MON=/ZTFY/PBS'^[2M.?.G1B_G#AWY&B_3JY=NZ&/L+7?E23]$I%T"\Y(ND)P
MB<(G")PB<(G")PB<(G"+G5]T??6U4)\N3CY@R;F^< ?9"M[3'CHU*85Z[)\7
M^L%QX\ZHIQ.$3A$X1.$3A$X1=@/N;[ZWOL+\LHCYD"^<LX?=74/:CO'.4'BO
MKL?Q?ZQ6TCHW^V7=G\.^Z?FI6'-"48=_<'@"O?PJ)PB<(G")PB<(G")PBYN_
M=(OQ&=</E8D_S/VYO_ #JS$.UHO&J4PKUV3XO]8+D+YU%3B<(G")PB<(G"+J
M7]S2?L_<W[EU\_'NSG..B#NPGLUW@HU#XM_1_P"]_9K=AU!^/KQ._P .&%_T
M>O1+G-E$NW,^"?KN5(?%(ZH=L+8N>-VKUFC,PE1 GU,M_KR.4A]@U!#A4)LN
M5636<Y@TINT%<6?4;"Z^J>]HCM8<,B#&42,WD*.%KP\RR?Z;M"-R_C;K@GKC
M4$:<NNGE&OR1+I;<LF[83V.2RF;4KOK)8A?MF][*EW7;@C,Z)['B+EU!NJR(
M5+2PF>-I)2-EC)7L5FALVRK: &(.Y0?B UIV$D]%/T"7TY+Z6TL18<_-R;]=
MY 7^0#KKWXZ\VX@:ZXP:,M(/9JTP)R1I;<R"6"ZCC?2<7%)F0:ZK$-STG:Y8
MQ+34Q3O)N3J=*<Z.+LN2WXS-C+:M8O7CA$A(/+J.MH>O]F[<!V%O;X5J<(G"
M)PB<(G"+EH]T2ST[#)SU<2#LX<ZU?Q.T%%\RBNJ^G*FFS<Q#-4\,UIM&) L.
MTSA7;TR0_=JFXVPGLXT5V22SIT_H?/E9!B>SJ*J"\M+<4]74TP=Q)K%X@EC#
MR.0NN1<VM<KVBP3",6!=B>'4E<Z$Y834PLE,;7ZO#,P.4.+6DVWV',N;_P"'
M.;_N34G_ *?Z&_1MSHFVJO?^)_XIB'\2O7\#>"O_ *?PKYG%]U/ASF_[DU)_
MZ?Z&_1MQMJKW_B?^*8A_$I^!O!7_ -/X5\SB^ZGPYS?]R:D_]/\ 0WZ-N-M5
M>_\ $_\ %,0_B4_ W@K_ .G\*^9Q?=3X<YO^Y-2?^G^AOT;<;:J]_P")_P"*
M8A_$I^!O!7_T_A7S.+[J?#G-_P!R:D_]/]#?HVXVU5[_ ,3_ ,4Q#^)3\#>"
MO_I_"OF<7W4^'.;_ +DU)_Z?Z&_1MQMJKW_B?^*8A_$I^!O!7_T_A7S.+[JZ
ME_!5@H;M)TJM(#93Z61IL'[/O2P][U]F\PZI'$WS"JH2V;;.Y!UA-U$9+M?1
MFWNSD69>D1)!9,8N18NU0@;=AR;A\Z1V*4ADFGF=T@T!U1435#P.F*CBA\\D
MC@V]SE!#;DFUR2?&3#,/PEP@PVBIJ*&0;5\5/$R-CI"2PR%H%B\M8UN:U[-
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M*AHK=1,9%W9!VX(KZ#3D!KR>G!J1%RHJHX8@YW,9@#&M-5,H1\>-;19JFW;
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M;-\P]2R\C9 ;%K7,(Y'!Q:>X6EHL=18N%KD$5Z_GR>11B*H-X.@S6 O;"*2
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M&"&2(]@W\_;R[;>A:MTD_.V^GMYOES]//,IC&QL9&P6;&UK&CF:T!H'< "O
ML !N MWENE\.GXI)C\HSWYLQGG/>%_LA3]IM\=.HC$?76?%_K.7H^&W]:XI^
M$WWQ_P".OLAS4U@'?W!X KX\*B<(G")PBB><7E5-;R(/%)K,&80X:2'N4FV[
M(N];BAY@QK'0I>6$Q@]Z*A (Y(MO>\#/3)Z!#&CVBH86^=DT56NA+>?GO7YC
MKYJ N6D8(9/0CTO$Y,$AQU@AEUNLUD<AE;V""Q[?_P -C0IA2;"C41=O16ST
M>+DD?D@0JZ9$8X<;CR*7.$3A$X11!;W[7!_]-<?_  8YG4/JY/@CPKW@WN[
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MMQ\AGD3Z!3KQ^X!_^5);^MX_"7&??3?F]/\ NDZ>J?;CY#/(GT"G7C]P#_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g713200g99a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g99a02.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2,.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M!   !=P          0                         !              7<
M   "!                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "!     !29VAT;&]N9P  !=P    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   @0     4F=H=&QO
M;F<   7<     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    (.$))300,     !A_     0   *     W   !X   9R   !AC !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1"  W * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M7](VA?,J22GZ<ZQ1TB_%#.KFL8V\$&Y_IMWP[;[]S/=MWJ>95TZSISZLPUC
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M(IQ-G2#4<7=/Z!P>W=#?SFN?^9L7S&DDI^JDE\JI)*?_V0 X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,3@Z
M,S Z,30 <G(U,#DQ-C<       .@ 0 #     ?__  "@ @ $     0  !=R@
M P $     0   @0         !@$#  ,    !  8   $:  4    !   !-@$;
M  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M          !(     0   $@    !.$))30/]       (          #_X0%(
M34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4    !
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M 2@  P    $  @   @$ !     $   %& @( !     $              \
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M P$! 0             !!0($!@,'"/_$ %D1  $# P(#! 8&! 8+$ (#  $
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M#.?=&H%(#A@Z(4Q3%([=@>W<9\YZ?BJD7/G_ ,O..FN[PBUG:/=Z-KOF1/\
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MBK#UI/5QZ22@)AE,5:5AI=J^B)))%^R.B]*0CM!%4Q#BF7HG0Y[5K+Y5\/\
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MR6RW4_;;1+>%:VU,P58F]<W'BI-ZFJG%B!U'(%5&M5"M[5D(J>B!?B:KQ4/
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M[64\D[\]N TGI@'(4\P'H'G_ #'CYD!>$MVVU]X@C..6[E# 82D&61UO I*
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MFZ'T QS"'J81&MM[&B:Z$-:";B>@ /\ $Z/'SR?:2NUXOEEDH>!Q))(\#@Z
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M3/BNXP/]S8G S_9P!G&^/J$G&>N,]BS"W:TU[?D01NE*K%G*3KRE)J%8/G*
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M>_U0U=6U-951$^UE0YAQ[L++ZYLH(#JRFA.X#9P:8^/JSLC(\<A3+ V;6D@
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MM8\A=T<K[]4M,,;&L]@^-.K'-1MR?*G:>A*WJ:\V6[[K:HW=2CT.$G8G:#I
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M.TL: UHS@ 8&%DUIO]5IPMT)F3+\4>@;X9 1R#B5L4L8@=B2+@HY-S)O>AZ
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MLJ<W3@BIP*CA.Z6\]K[1Q(2W)[>3=K9<'$#L8*AI/36.J!*[Q8=^]T[7=A3
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MIJ&Y5]#!=(?1:^"DJJFGAKZ?5JY%8R![65$.=^7,',W.VY4QB4HAT)2B'XA
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M8B**KA\JY8F7(91!MXR@Y4(K'$(5,I2$*4A"% I"$ "E*4H=%*4H  %*
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M!5!,XI@KX!/X#^'OPCU*+),(F$3")A$PB81,(F$3"*!>2.C$>0NL5*&6W2M
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M].6*=)9Y_5FH]>Z^FK"GY_DS4I4:K%P3^20]Z$7/N[MRQ45;^\#Y_DF)YO\
M">+)4%3=A%JQ]J7P^Y%\Q-;4BI:/V!KV 8T^U1%TE*-L&,L_PNX6F%M-6D*M
M,KS]:GXPS5"F,6=CD&\+*Q4Y%2TH[8K*M47S"-?,GGSL5(('49^'GX'9=+Q"
MX6;ETORTV?MZ]HZ[:5!:-WU&P5DI\W(/+3MUQO?D 7>#.6O<&[KT>:O'U?'
MI2(9NYLEM4=)N7#EBZCV/\74)MC8=WR&-O;U*VT84+U.!A(8"" &$I@*(]B
M&$!Z$0 0$0 >A'H0'_/A%^:I/V6O*N$IEECX6D:-DHJ/VI)VB'TE:-SWBX4>
M\S-NU3R'UI>=RJ6FY:_FI.EOIF0W+4K6VUHM&V"/8K4B7.SF6LK,H.ACW?EO
MY[NBRS[>F,X'801MGP7Z"=)T62U?IO4^M9F:/9)C7VMJ/296PJ&4,><DJM68
MR$>RQC+ 54?B#EBJ[ 52@ITJ'F !^\E8J3L(M3OM'.'.^^1U^T!L'1,O4$)7
M6[.YUI^SNTG&M8*%6MUHUE8V-[?P4U0M@1M[C( E >QTK1DF]5EIQ.9;>XW&
M+2;NTURD8Z'SU\1WKQPIX8;AT1R7VYL^^M->QE3<UK8M+JLO3IU[*6/;H;!Y
M(;!WRVO>P8UU7(@8":JT-<&5(09+S-I<.%T)5VWDDHQ1FB9Y\_O0G./A\/.>
M@Z]JVQX4)A$PB81<=VW*[:N6AS&*1TW6;G,0>CE*LF9,QBB/H!@ PB4?Q]81
M:T/9^\)ME\59*T2&S;C1[,,;JC5''C6Q:*VGFP/=7::F-A3-?MMX3G$TBM[]
M8E]A.D9>+AS/86*1BD",I1\#H_D%)\-O?GN6S?"A,(M6W*[V>[_D)M+<=SK$
MQ1Z$PV_PRV%Q\F91.%6-9'NR;'>*99:W<+$FP9MDYZ"C8NGLH5^9S+A, R31
M8LB%0(11(I!QCP\]58WAOHJ_Z0I>RG>UY:HR.S=T;JN^[;JRU^>96HM<D[6V
M@X=G7*L[L+9C-2#&/A*U%'>2<A'QZ\C,N)-V#)NDJF0"CY?/SGJK>810%R@K
M>Z[?HR^UOCJ^US$;EEF#1M1I_:S1V_IE:E/B3-0]F<L64-8%'<M -2+RM:25
MB7;,+$UC%7R9FB:Q#$'CT6J?6_LQMXUR[Z2E7\[I^LT^+EM%VK=L=%V78-]N
M3ZX<=-L[7VU!V"I6Z?K-7^DDMN6Q;,7DMHRMGCH1:%D_BZD WE&C]!HUC [A
M^[R%.?QW]H Z=G3';MW+>KDJ$PBU4\ON#N[^5VYTGCW8>LZCIJ/UKMJI04Y'
M0EH4W!&I[@TK:]36RAR,:9[]!K!3I*<FX'8PVA=5C:8Y>K-:E'L4V3MS,GCS
M\OG[U(./;^T'S[5.O![CELW05=VO+;DG*-+;(W%L2&N<ZQUH$^:D0+.I:KUY
MJ& 8Q+NSH,YI^ZD(;732?F'#MDU*C)RZ\:V*X;,$7CF4/W?O\>]7APH4'\DM
M36#>NCMCZ@K&QI'4\IL& /6S7N)B$IR0AXM\Z;!.MV\<K(1/F!-0I7\$LLA)
ML7C1O)*NV+I!XB@J4GGN6E35'L@>0&NH?6U/?;>TS*50DTWAMEA"U&P5-S7=
M;TKF2^Y;41OJ2*C?.C"3DL]>/*M.,YM6-CZLTDFXP+Z82KR)9<LB<_O\ /P_
M8OT-X6*81:E.67L]]B\B.4L'MZN7&C42J/J'$T:X71F\V0UW(RK$7$;0C)C7
ML7#,)SZL+;1KZ;8B#B7"R1D=(P2L4X6:A,N'3!6+;^?(^_\ ;.V.WV=BFC@+
MQ6VAQK@=COMQV2ASMYOR^J(<&^M4[ 6J1]5TEIRF::JKOS;,BVE%;!96%2/9
M+ E[N#*,=224,Q<R*$<$BZ*//S6P/"*#^3&G"\A^/&[M$FG#UGZW]6WC7);"
M1M[Z,(I;J\_A4I068*H"Z(Q5>$<*-BKH'733,F19(Q@.44Z;K2JC[)/DBZJC
M>$>[3U-&M[RRV#K&^U!.5VI;J]J/2E]NVD+N];Z1LEO!U:I^U%FM03$N2/N8
MP\$RF-D/UV+I-M7&Z$N\^>U3GP[B?G^>/<OT,%*!"E*'R*4"AWZCT =!V/\
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MGM'J7VYP$A19^'LR-PU-7M)W3<M<9OD[^^^++66M6O:B-'7/5*Y&J2%9B'<
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E!2@&$7881,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g713200g99f98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g99f98.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[17>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <NEPH
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M;   !W0          0                         !              =T
M   ";                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ";     !29VAT;&]N9P  !W0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   FP     4F=H=&QO
M;F<   =T     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,      M0     0   *     T   !X   88    LT !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  T * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#T?[.W%ZA;G/R;G_:V
MLJ;C'W5M-8<]OH5M;O8_^??;[OTG_6JU8^TL_<L_[;=_Y%5\C(HMR,/TK&6;
M,IU;]K@8>VG(WUNV_1L;^XKR2D/VIG[EG_;;O_(I?:F?N6?]MN_\BC))*0_:
MF?N6?]MN_P#(I?:JY$A[9(:"6. DG:W\W]Y&0<O^:'_&5?\ GQB2DR2222E)
M)))*<W.QW8V8[K3#DY#JL?T/L-)!:^7A_J-J?M;ZS?W]_P#-H^!U#[8'!U%N
M+:P!SJK@ [:XV,8[V.>WW>B]$S,NK"QGY-P>:ZX+A6USW:G;[:ZPY[N53Z;F
MTYV;?D4A[6&BD1:QU;M+,MOT+&M24Z:2222E))*GGL9>:L8B3O;;NYV>FYKJ
M[&M_TGJ[/3W_ */_  GZ3T_32*FTVQC]P8X.V':Z#,']TH;\JMF37C%MA?8U
MS@X5O-8#8TLO:WT:W_N,>]1PZ;*?6#[?5W6%S26D$-AHV.<YS_5X_G/9_P 6
MHVM><^EP9<6"MX<]KVBH$[=HMJWML?9_HWMK]B%^"AXZ,*>ILMN93]GR&.?H
M2^LAK3M-OZ1XW-;QZ>[Z'K?HU=7-NQ\L -%74@8 BG(J@>Q_M#7/9M_XU[&?
MID?&HRVV6%U&<1(VB[(8YGTZM6^F][F[8_[:]7_2HJ?_T.LZ4YI],U0]G[9R
MBTM=NEIKRG-=N_JN709&1E,;^@Q'7.[2]C&_YV]SO^@L;I[7V"L4VG(&-U7(
M#O4 :YK6LR*S5N#K?7]/?_.O]]GYZV[;LAH_1T%Y\"YK1_WY.W 4X.3;UO#R
M7=6S-M&-5!M8;1Z8K^CL#)]UG[GM]1]RW\?*JRJ*\G'/J4W-#ZWC@M<-S3JN
M8^L'2?K5ULMJ+<7'PZW;VTBYY<YWYK[W>CM]G^#8S_P15>EGJ71>J=*Z3G.K
MV5FT-%+RX%F23Z3+=[*_<S)J_1_R'HY!"&,2,@9F0'"#^C)?AQRRS,8CY83G
M?^SCQ_\ .^5[7<?W3^']Z%E$FH:$?I*O#_2,1-[_ /1G[Q_>@Y+G&MLL(_25
M:R/](SS3%B-N%ECU _,<X.:YC/: 6@_0=I^>S]Y$JQKF7>J[(<\=ZR/;$-:W
M^J[<W?\ VT"KHXJN98W+R88\/%9LEI@.'IND?S3O4]S?WU#]B35Z1S<H#=OE
MMFTSM-7TPW=L]WJ>E_->I^8G5'][\%.FDHUM+*VL+B\M !<8DP/I.VPU235-
M+)ZO@8E]M.38*112,BVQY 8&%QJ;J3N^FW]U"Z=FXF=G7Y.):VZEU%(#VG26
MV9;7!6;<; JR'=2N:QES:O1?>\P!5N]38[<=FW>@XEM%O4;WX[VV5&BF'5D%
MLA^7N@M]OTDE-]))))2EFAV3DY5[:R:"+6!MHVNFFK;N]K]^U]N5]KH]WYE?
MJ_Z-7LB^K'I??<X,KK!<YQT0.FX[J<??9/JWD66!Q)@D-;L:#]#Z/N;_ *7U
M$V6I ^U='0\7[NW7U)J*&4!X87NWN+W;WN?J0![?4<[8WV_S;/8AV=/PK<VK
MJ%E0=EX['5U6ZRUKX]1O[ONV*RDG 4@DDV3;5PNF86 '#%K]/?\ 2U)[N</I
M%WT=ZM)))(?_T>S^KKJS5::(>S]J94/DPX1;W.YWM_F_["Z";/W1]_\ L53+
MK^S4UV8M;&-IL-CVM8XR"VQA].J@;GV.>]J@^_JC#67LJV6>V&M>YX<1[ \,
MW5M9_I+'6[&))OP;KC='M8TGS<1_WURX7KW3LX]6#LS)J9?F$$.9N#:6M/IX
M_N=M^A9[]_\ P?J+K+KNKUO:P"DBSVL+6VOAVD&S;#&5;-[GN?;_ "/\(L3-
M^KO5<K,WY>578_($!S*7D -_,=[_ $Z:F,=[-UOJ6?\ "/4.>$I "(,M>]!1
MSY\4?U '&3 \6G^2G'-$>O\ KXXO2XOVP8[&Y08Z\ "QU9.TD?GM#FC;N_<3
M91?Z;9  ]2KO_P (SR5/&=UBCTL3(=5<_: V]K+((:#O?D.<=E;OYK_"/?;9
M9_->FB;NH69#<:]M8;++-];7D;6'<[<]^RMK][6M:QKK/WU*-AO]5&5ZT!>M
M=ESTENTAN5DL\-MD1\H]W]M.>E Z_:\J1)GU?'Y*7[,IV[1;<WL-MCA'R'M3
MGIM1@^M?(DSZKN_S3> ?N_BGW\W\O_15.Z=6YKFFVV'%A^GJ#7M U_E[/TN_
MZ:573JJKFW,LMEF@:7DMC:*MKF_G>UK?[:=W3Z'!P<7D/+"?<0?T8 9[Q[_S
M?WDJNGT4VMM:7[FP!+B1 :*ML?U6I<(OY0KWLNUZ'0Z]-DUU%.14ZF]C;:GZ
M.8X2T]_<TJGAXN-B]1R*L:EE%?H4'96T,;)?E3[6 +0631T-K<O(LL%7V>UV
MYC:_5:_W.LN?ZK_7]/\ GK['^RM/6NF^VIAA[VM/,$@(5G4,"IKG6Y-3&LC<
M7/:(G1LZKG<W&^K='4<EG6'X+FAE>VNQKW7>D?5+&V/MMM_/%COT;/Z_^#0Z
M,7ZGW9>3O=TRW&<QCPQC(?Z;=W\^]UCJ]S;'?FL_K_F(:]_P2ZV7EX_4'78M
MX%6!C6U&[*>]K6/(-=U%5?NW>[(]-EF_\S^;_GO85^==FO?5@6#'91<QEV5:
MT%KY%=IIQ6.<WU?59;Z7VC^;9_@_76)Z?U.=EWV9%O3;,.P,+:PV;'/8-P?:
M\VN98YG^#VU?^>D]57U/MZA9O?TZRBTU&FL-_2FT_0?98^S99;JS8YM?J_S?
MJ?S=:,:%G<]S_P!ZIZ3#Q_0%P^T6Y)LM+W&UP=L)#1Z->QK&UU-V[O35E<QT
MQGU?LZM?AX-V+Z3QZHQ<<6LL+X_377/;:*'6_P#6O6L9_.?S"V,3 R,;-M>Q
M[&X;FM#*@'FR1,^I9;:]G?\ P=?_ )[2)M#?22224__2]527RJDDI^H\_?\
M8<C9ZF_TG[?1_G)VF/1_X7_1K$^K7[3^TV?;OM\[';OMGI^GNFO;Z/H>W=_/
M?1_,7SNDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J=WHZ[]OG,>7
M_F*@?LF\3Z>_:[;]&=NGJ1_(^AO7RVDDI^IOT$_F3&G'"3?0D;=D]HB5\LI)
M*?J5GV7]'L]/C]%MCB/\''\G]U%7RJDDI^JDE\JI)*?_V3A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@ +BOL   G$  N*^P  "<0
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.3HS
M,SHQ.0!R<C4P.3$V-P       Z !  ,    !__\  * "  0    !   '=* #
M  0    !   ";          & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 4A-
M30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y.C,S.C$Y ')R-3 Y
M,38W       #H $  P    '__P  H ( !     $   =TH , !     $   )L
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0             #P
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ,4"70,!$0 "$0$#$0'_Q  >  $
M @(# 0$!            " D&!P0%"@$# O_$ %D0  $$ @( ! ($!@P("@@'
M  0" P4& 0< " D1$A,4(146%Y8B,4%65]4C-3<X475XM+:XU-88&21387>2
MEPHF)W%S@9'1V/ E,C-&6)BQP31'8G*%X?'_Q  > 0$  00# 0$
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MYYA1%*KI/U.I/1WK!JCJ[KV<L%FK&K(B2"9L=H6-F:G92>GY:TV"5*8!:8!
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MZ.Z+]T8#]7\(GV7ZS_1W1?NC ?J_A$^R_6?Z.Z+]T8#]7\(GV7ZS_1W1?NC
M?J_A$^R_6?Z.Z+]T8#]7\(NHL&L-:)@9M2=>4;"DQ$DI*L5* QE*L!/9QG&?
MH_SQG&?Q9QPBZ+K-^]OZ^_ZD=4?T#@>$6[N$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A%PY&.CYB/.B98$.4BI0,F.DXR1&9- D #65C& G!DH<'+#+
M'<<8)&?;<9?9<6TZA2%*3DBTK'=7>M41!TRLQ77W2L;7=<VAR[:_@@=84H6(
MI%R>=P^[:ZG',0J!*_8W7DH=<FHIH616XVVM1.5-HRDBSJK:LUE1[#<[=2]>
M4BHVK8T@-+; LM:JL'!SUWE TO($D;;+1@(Q]B.&221A@J6?+?:^(?\ 0O&7
M7/410Z\-_P#<;W1_+M\0?^N;NOA%8#PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G"+H9FTUBNOQ0M@L<#!%3QN(V#&F9>/C'YF05Z?2!%,FD,.2)JO4GR%#2\
M_GU)\D?/'*4DT,3@TLL43R%QC:20 >0NWL@Q.SD7=NP[OW;XJA-:K5RB"Q8@
M@*<^G ,TL<132=OHXF,A>0^[>R#.7=NW==]RJJZB)*63>C7;> UR'L*E,ZKE
MM<3FSG:\[K,HBT-AUF>IM3+KR;?B]LCY=E#[(1,-2_U:Q]'LL-1F8XS*E'8P
M1RY%LW'4&W$U0ZIW7B\HSFP1200%#UGF9]Y#E>3J\?89F!HR^LT2DLYUM6P8
MX,A1'%2XZ?)O7?&F5I@K3TJAUVN>?$>4LMDIFF>M]&+-%T3?Z12[YG5+4X1.
M$6'W?7U#V9!JK.Q:95KY7%E#G*@;A Q=CAU&B>O(I>8V7%+#R2-[CGL/Y9]U
MKUK]"D^K/G=TK][&SM9Q]RU1L,!1M/4L2UY6 ]N0=2$P+B6S<FWV?9MUT.,)
M!X2 $@OL[B8L0OMW;L3.W;W=E R$\)CHK!;XF=_CZ6A2YV8%);Q1)1L21U)%
M2)S&13IJ(UX2$N&%/*'4XA([GOPP+KJS(N)!.P@I$WE\4];SX2'!'F)0@A(7
M\]$YQY:6,'Y!#-D!,92 2V=R9AFD9F"64PW%\>.'QXV"LM7%S)G;@^SPB[^K
MC%MQ9W_([-ONS,ZL J5/J=!K\?4Z/68&GU>)2^F+KM8B (*#CDE$O&DI!BHQ
M@8(7!!A!!3V&&$8=(?=>7ZG'%JS!;5NU>GDM7;,]NS+Q>6Q9FDGGD<18!<Y9
M2(SX@(BW(GV$6%NS,LB(" L "("/9A%F$6]_9F9F;\S+3]VZ[5VZ3NXK,FX7
MZIV'<>LM;ZRD)RFS0L++5(;5=@V19ZG9:@;]&DK%L#,QLR5?.3+IF(.18C8T
M R&> <E!9&W79:7A^BT144 SVO=[[IU_MI][82[UN:"9U&?;=G,[.O)^Q[,+
M;ZY9]5S^M&F@K?)&RE.<K='@2:<DHT"'>;CI:;$DR+Y >'5UNJNU-/;EKT?>
M K_J":D+&B<,V+<ITC8$^?K!W4ZIW8N)V8D&9Z:16\BN.2C#(!9Q<<$U(.%1
MK68]1%.SA$X1.$3A$X1.$3A%7EVL<PWW \-[.<>?KV=OAOY?D]S1\RGS\_X,
M>?GG'Y?^KA/]W^[]JL-X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M%T]A_:"<_B>3_F3_  BU3UF_>W]?O]2.J?Z!P/"+=W")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PBK^\-_P#<;W1_+M\0?^N;NOA%8#PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G"*K'O[X;&.[FQ=.7Q.X)C7;>N&7HB6BQX
MM<L@N(?F&)E<C6G,2(3<%9\N-J%</>9,9(:;C'%MXS%(:)C&<T^>7L5YPM=%
MHX^C(!"1^QS(W.+8A89'Y.+[]BX@[O[&SZTUQX>_=ED,5=;+2X]J %!-&,75
MY1%*TKR5GZD;06O4>H32"_&%W%NGL4KKAV>HU2GB=94*%NV]MGP30XDK2-61
MS%A,KKWM80QB_P!PD3(FCTA][TH<6S:+''RKJ'/B6(PA&?/-_/EZ\,CU*T<^
M1MQML<%,6D>)V[-YB8G""#=^S\S8V]>"DMS4U*K.>-HP7<YDX&8):.+C"Q)7
M+9F;S]N22&E2)]V=QLV(Y7;<AB)EI^@6';EC[HP)^U-=UW6F%=9-@XK<'%7O
MZ\S2Q%;1U:HU=E)%K\-"1QB'<CH'$ACY]A6/B%KD/)+7N6-:6[+GXCN58Z;_
M #19:.,++6#<?.5-^J0@ ,7)VV$'-MN_)UB*$^6LZR@DRF.KXUON9R'EH(K_
M )^9Q?*XMS>R05X88S9^+"$,E@=N7TG9M[ .293U.$3A%@VPK7/4VO*F:YKR
MT[.DDF##8K%0,JH,PME_*\.G)?N-AK$-@83"4Y?2J422KW$?#L/9POTV5^U/
M4@>6O0LY&1B$?+5#JA,[%ON?*Y8K0\0V]K>7EW;B+J0:9P^.SF4&AE-38C2=
M1X)I7R^;@S-FB,D;#PKO%@\9EKSRS\G:-VJ=)N)=20.V]3=4\1KLI.=PK5H<
MKJ/:W:Q# 2#S-5COHIC:L4R$$V4+9)N?E+<-J]^%DGEH8;2)+L K2:(F,GI<
MS#8INK:OB#J.;5MK!GI.WY6*,R&M'T1RD;"#$-B:>:W'C'AD=]F8)F!V(&BG
MF+L?LG,_)>\*\?X(8?Q&A\:\.&6O6:\9Y>UYN31UV2>P<,N*H8ZGA)M71Y"H
M E(;S4I;#/!.]S&TH'*:M;G2;!+6FL1D[.4V>H$H>DA152LQ, 9.1&62WQFT
MG$5>8GX)Q13++9K/P,L7A(Y+*7\LDX>8:VM3GELUHIYJD]&21B<JMDH"GAV(
MA9I"K36('<F9C;A,;<2;?8MV;Q;GL;3Q&6MX['YS':DIUBB:'-8F+)08^ZTD
M,<I%7BR]#&9$6A,RKR>8I0N\L1O'SB<)#JTJVV:J_>9FW;*[4;*K78R([77W
M6X/6FMV]$FT;3(O95DKVLM:,]<!Q#DFP5_TZ'6=H'[>(KSMEC@9P[9#=]AZ+
M'9! N5A_^/\ P^WQ[=UJJI>)#V#V!:-%T"F9ZQSEC[!%ZH/:F(1F]V.(Z_M[
M,I&][0=JS;D0#=!39?:=1?U,(TWEF4HJK X)<HV3I]*^!C99\N?M]O>N'$^)
M+V+6#HM%U<ZJ:U<[!1>@++$7*U?7L6AZUA=PUCLP4:!:BY*[0JK+--3NBH+%
M;6Q)4T&0(MZZD3E!(XMI((N"YXM&P/KMUY@V*]J<L?8UGTU1;S!@?2RS'C-M
MVZQU2,V-1K-8+Q52RJ'-@1\'?J$%7=<;3<G:E,839;/3"4K('(ORD/%&WA46
M.K";:QH.2L6[:EU,V!<J=78&T0QL)6^V6Q6Z="BQ4O==LP^''Z=%M2<FD^IP
M6UY2SG1,JW.TO64 &+8I0BXVH_$4WS!T"CB7>WZ)N=I@H6@S%F#G1IJO[$[!
M2FS^R>Q-/FZ_T?$QUO*""O&I0JJ"-81B(NW8DK//5^O2<-007LSCI%9EUNO^
MZ^P76Q&PK)8:)1;AL;ZR/4:2HM2DY :C0#4D5!1)$E'VZS2PMIM368XN842I
M$97VGS HYZ#DAXPDB8(N]Z1V2S7'J#UKM5TL<M<+;/Z8H$K9+5//,D35BF3*
M\$[(34J\.P,.Y(2)*G"BE#C##Y>=7[ [+7H;212CX1.$5<O;IS+7;WPUU8SC
M&5;;W6U\_P J7=+RJ%8Q_ISC.<8_+PBL:X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A%T]A_:"<_B>3_F3_"+5/6;][?U^_U(ZI_H' \(MW<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*O[PW_W&]T?R[?$'_KF[
MKX16 \(G")PB<(G")PB<(G")PB<(G")PB<(G")PBAGM*T7#=^QY+KEJFPR51
MKM7& +[$[5@'_AYNN!3 Z3(74U#D/3G 5_MT6OZ4G+ QZGJ)5'A2Q\(L$]"N
M"8&Y--D+1XJG*4,40B63N1OL<8&VX4ZY>C6)1W>4_P#$1.SMO(3"T/R5NWFL
MC)I[%69*E>H,1ZARE<F:>N$X\X<31D_Q=^U%]-8L#N5&HX$'T]B%PDGKO6U&
MU/5(ZE:\K495ZW&)5\/'QK.4*?(<\LDR$D8ZITZ6ESW,9?DIF4)+E)(I;A1Y
M9!#BW59:M4KTX1@JPA#$/?B#;<BVV<S+N4AEZD9N1D_<B=^ZD>/QU+%58Z6/
MK1U:T6_&.-OK$_<Y)#?<Y9I"W*6:4CEE-W.0R)W=5<VKJ+W(EO$YKO9J)V^*
M'U]C HH5<)FQ2J2A*@Q!!BV'6B::ECZ.+9LEC$S-NR2GLBMNOCS+CGTQ%!,8
MC,N)RI:B#(#-_!&*-^IU=G&N(CU*G1]7:0A)]MGC]MIG/JMQ6MK6E=62^(T&
MHHLH(X.,8FZ?F)&*.FT !8QGDV;@8V+ /,\COP8C&9WZT("K?^2Y;63A$X1.
M$7XX;8]S+F&V_>RG"5+]"<.90G.<I3E7EZLIQG*LXQY^6,^?E^7G&S;[[-OZ
M._OV^#^_;\3KGD[BP\G<=^3#N[BQ.S-R9O1G=F;NWP9?MSE<*.;_ & ZR,[J
M9UN_?=>8W7DI%0;%R@=4RS,D _3;5"<M. U1PUJ)B_3,LT-Z::LA$:I$FU"K
M$6A_)%O(>MUT1Q;PD!"C/.RBYUQT>+!9<<FW6'!7)A;C;"5+E'!GG1UR"LY+
M6PZXRI[+:U)R18)=M)ZPV&502K74HR1SK.T-6ZIC)92,"-*L5.XTEEDX$?#8
MLK$-5Z^VD5N$D6B(M#TCDQ(N"F674/M^E%G#]7K)1;,@378(@\848-@U^)CW
M2V PBVI ,1DEP=3S0HAX[!HS"%I:8+9:):2AYM"TD7\.U.K/K!=?K5?><BPD
MQD8X[#1SBXZ.0MAQ$>"M8V5"!)<%&<2(/EMA*QV%8;PIEO*2+J*VUKFU1\1;
M:F/3I^,R9+R4#8X,:'D!/CS#"1IV0B90-MQO!1IS1;,F8(]ATLA#^"7'%^OA
M$N=TH6H:7*7"YS4+2:16V6%'R1>$!QP7QQK  (@XPS2G"#Y24.%CHJ+ '?D)
M:5.%CX\4HXMAAPB_#6%_UWLZDP]PU7/PMCI!GQH$6= I]D(=^$/)AI2'> 4R
M,1$24'* F1$M"'"!2,/(ADQQX8I0[K*"+/N$3A%6OW)5A';?PTLYSCS^VG;>
M,)_+GW-2FM9SC_\ ;ASU?]7E^7CX]G[>O9]OT^G^_LBLHX1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A%T]A_:"<_B>3_F3_"+5/6;][?U^_U(ZI_H
M' \(MW<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+2W8_=$3UQZ_P"Z
M]_SL47.P^E]67O9\A" O-C&3(U(K4C85Q(I3K;K0K\E\!@-LIUIQH93V'W&U
MH;4G)%2C&>-?L,[6-?NK&@=;RTW68C=&SM^0L?L[8T'BG:;TS9- P<IBJ15\
MTI4KF7M:6%[$5>;B:I=:O4*_(P4*[/QMG.A;76S5$4M.MWB< [3ONP!]SUK7
M.B=-HINS-HZDVE.[2;:'.UQJ3L;,]9+07M[ZT5^J5W7D_*742 FZV"!8[%'D
MP]I'BR9!J:C"&R2+97A?V& MO7W9UJJDY#V:L63NQWXG:]8Z_)!3,#/0DKW#
MW,=%S$-+QSQ,?*1<D$^R8!( D/B&"O-$#O.-.(7DBL9X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$6DNPVU"-/:JL%KAXY,[<C'8NIZXK/KRE=HV/<)(:NTJ"Q
MZ<^Y\.5.R CTHZWC.0X8>1/7Y,B.K3C\G<>E3DFC%CG)Q@JQ^O5M3DT< ;>K
MMS)B/;TC$W]RPNH,H6(Q=BU#&T]PWCJ8VL[[>:R5R0:]&OV[\3GD!Y7;ZD(R
M2/L(.[8CJ^#A.MM%I]!E46JV6RRFG35NN,?79*9*O.S;$B1L-PGY0L(=W#1D
MD2%)$B"OJ2B/A X^,&P@401E-K5:+#P5ZL@V)Y[!')+-'!)*]BY*QS3F9B.S
M$73-Q8G9VC 6]S;R#1FB;3X6<8+^+>6@!7\S:R63J4K%JS:L5X[60<+!QG+'
M+=N0P@XL31B4<+,P1>S)E*O4G"O+.,9QC/DK&4JQYX\_+.,^6<9Q^7&?Q9YF
ME1?MV^'P??\ :W9_RLL'?O\ %L6UFEKB[-F6(9<*:(;KLFY#J"9<":?-^F$,
MJ 2,P]("L/.*>Q[;SF4Y3GVW/3:/<C:R-7IS]0F<F=H)'B<1<&(NKMP81<Q9
MW=_5]O5GVS\>G;<F%DSHV\2U.*083B+*5!O-/(,YQP>1>3S#RRQUII(Q8/:
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M9N\0, %&#%Q:/5-30.KX=7V\T>KIQJS1F+70:*2_,!"PA5EQ\M5\6$<1=V<
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M-6<^9FMP[2EK1L)-B;U\Q-53;-E.M;TQLZ@'AZEU;'NT6XE2M:Q'Z\J@2(]
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MX)N<PM/D=[J91E6?<+:&(K%>$3A$X1.$3A$X1.$3A$X1.$73V']H)S^)Y/\
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M]CO^?NK"[]>C_IH>GXHI5:CG767'B2"+WL8ATE[+RLXLR0F6OP&VTLC!Q8
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M\3SY6&:..**2%N/4FH!&#R1M7W<Y([$TI20B4@D!#TGP-#/>;M]":$81E?C
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MIXDLPPE;8XPP[2%NOOO.(::;2I:U)2G.>=XXY)3"*&,Y99"8(XHQ(Y)#)]A
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M88)]-ZERV(;ET*]ESJ.;NY%3L"T]5W)_4FAD #?O[8%WWW6S*-GSE2"QV9Y
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MI.H/Q?\ HE^Y??M2J?\ FKA_NXV)_P#3ZK>?./FRU\:GZQQ_^OS6R=0?B_\
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MF4/=[=!#UN+L#I%^27*7Z:U9]3$ZWM[NPH_8L' .64FGR=(9C7)\68(BL,O
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MAK[)D]ZU)K76X]B0@LY.":57L$&RQ>864ASS9S7,4[*3,7#IEPQ,23+Z4('
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MLC=/J6[LYV)S;?;D?U0#EW:.$.,,3=MHP%MF]%]T--:=Q.D-/872V!K^6P^
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M@H ] B&$26"%NRKD@",V60Z\,)EAWS:2EW&<N9DF(P$.'NY.U!,9QY"/%1!
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MJD/GX:F-KGAZU*V30A6,)-^43 >LZ1U7N\!M*<WC<=TCWS:J=6R^J:+*XUA
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M"C06F P11PPQ0@!6&FF\N*0X2\00]5TWIG&Z6HG0QO7();!V9IK,C2SS32"
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M^/O3UQY3PU+,L+;;[RQPF4;<??N3-V]_I[U@-5WKV,TSJ#(XV/JY"CALE;I
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M1.T5BNUN2-Y(^FTL;$YAC=)[C]@2Z_7+3;X[5JXV^:9["VVM UZ*LS)L/:]
MLDL/&S!$A./,GQ-GD!2'OHD5@5^.$4,TF3==;><=H5\_E'BBFL!1<;..R\\0
MP!.SQV<3L+N922DQQ3EN_381*)MAZLGUE98KQ*UA+1HY')5\ \&7TOK+)48J
M<%YI:V0TB!B\MHY;3C+6ORQF7EXPC."-P'S!$)$7+KG=#9K<98E7*Q:?]R5T
MIK/;M0L%.KULLD=5)+8=I#J[&O;#!!V-T^R61QPMM<3@>0KK;LAAQ,A\-&X<
M>%[Q:@M[3>8EQ[,>-H9"O-7AL3! =ZPU<*DT0SN<\CD3=(@.NQEV,0'=U4H^
M)V<:"X^4N:9WL:5P6I<=<Q=/(WH<=-F<A%CQPUVI%=*:_=,I&>KTYJ3',Q-,
M(0,YA^M-[7]AK^YKVD08^N8R\6;=^Y-22L_9*M/A1S4?K*G1-R9G,U6/MLB1
M'3#X1)P)$1FP2 GQJ1U?%L-I>QE7SF4M/5K -,+,N4R&.DEEAG&-AIUAM-*U
M<9S(9'$G!XGG(>3;]5M]F[XSQ!UCERP^*J1X2#*W=5:ETY8N7J-R.!H<%C*^
M3&WY"'(SR0VCBDEBDJO<FCZK#]* ,ZQ:S]O-R6->TZY3[/42(F2T[NVY4.[Q
M6O[/750I>K#QPRTPI4K<BR[2I\+Z3"1-/PM>8 LC#$@*+)Q@S@9-*?.WY2NP
M5IJY1GC<K:J6@J31=(L=($9,+R6C*P[\S%I&BA!I09Q:0-V?'W_$;4MU\_2Q
ME[''6L:8U5E<1EH,/D*GE9=/RQQGY8Y\F<M]CB>>)K)5J(PW0&:..Q #PGV*
M^U>]J_2H0(:W:>D)BE]6HCL+9[):(F<S]H[9I)S =/@&1+>S@.7'"CD"S]A^
M(DOBK*8PD:% 8>RRGM)F\E#7%AGQY25L&&8GEFBE8;C&4O"O S6?8,0BXS3N
M<S/+)&XPBQ.+5G\0-6T\55C#(::FM8OP^K:TOWLC6MLV;:4Y@CQM08LD/1L!
M%"T=R[SGZE^0&"K$!N#26TONO;6W=U7>&R'3J]K&B5S5LT?%DQ\R_>RSMIZO
MB[@+'8D?I!J(&;K\NZ8V6\N,]XT9QL5+##K"B7,O0R%V]D;47&O#3JQTS(""
M1[1%=I16!!RYM&'1D<V)^F[F+B+,+BY%.-,ZIU#J/5&5J]+&TL%B:& M30'#
M:++23:@P4&2CAZSRA6 :5AY&D-X.<@$T; !"YEJ'>KC$IVSU57]9[:NT7L>/
MN%6M^U B-C&!ZTJ&JHX- SE0)J+A8T,18MBOY8S%1*13Y<I9!DF6L:+=&<;L
M,E])G:$5*[:"W'/!8OCYN0:4&/$79X#KN30E-=+BT0<"E^O*Y"''>.:J*.QX
MAZ?IX+464KYR#)8_):@A/-R18/':>AC8'QLF->0:LES-GQ\M6:*6T;R2V)7C
MKD!#+9<SL>R:YW8W'6?6Z+A'R&QX#7TO494@F.KB@XM;=5;O)$CE]N-M\0<Z
MV_9QFV_@ L894ACT^XC.=YVYJN08):GF&>U%4. B((G:/:NUERY<9XS=GF$6
MXBW'8>ZV(]C-7<+J@8+V$;)139NIA[&.L')!2>.!VQXY4Y^H,&1KRD)7XQ%X
M8O9=@=MQ57=$VUN34!.X8-@'9)$P'IW484F--78W?J*[N"VV"3@)78S"ZJ?;
MRXN&>B4GVI=8$PT04Q$ XS%#-G!(3#:MW(T3OPB%XI QV/8QFLGEGAR%B:2$
M[HM =DPB*/E8*N.SN$(NT4?-M]#XG46IM-2:DJC#G)+,6F=,Q6 M92;6 TM2
MY&W9I6<T/S?-DI*]8J[29$J$?$Y0K0N\$8RQLTI>B>V(QW3UJB9B^V>SR\3N
M39-6JI^SR)P2SVA Q!1]=B G+4T(9)RRXD%T@R%CTN%Q+F"!R@@G6U,XS6FK
M@'0FC*S8G.+(WJ\)WGE&>9AED*(&><1,SZ8[N MN'<7%MME//"74->33>1KV
M,Q?OV*VJ<[CL?-GSMQ7[[1R234ZT99$(I)[+UHB.2K Q25GYA)%$8N#1@T1<
MMD;7B2*^1*V(#<&^M2WVY1>PU;TMDM!1J8&_QC$S7YC7T> *!J-G##:J[ 2]
M=:D9&+#62AMQ9;K[+6&QEFW>!XG.8,AE,?:LA;^=)Y8PZ-F(983I@+!C]N30
MPR5P,P%I'WZC.SP72.4SFH:ITY)[D.H]7Z=S&5KYE]69&S3@:GF:\=JE9Q$,
M,<6G!X-Y*I9I#/-7B>01=Y',!V1I+<TK%7W6<+L:3N5AJT0<=&:Z.@YPV6@#
MG=E;%G*A W&S2MCD(>T7:K1Y+V-;Z[)5"R3BP(B4OTH&$'+5]X:^Q]^0;%4+
M<D\L $X5)(Y#DA-[ER2O#--),4<UF%G(:5(^D;N$4ER5A&6)QSFE]36*^7P=
M3-39.Y2K2S08:6I;ELTYGSF:MXRGE+]B]/6OY/'PR%\Q88WJSD\->QF+$445
MBD06X<FB]#)PB<(G")PB\^W2;J_W%U9N?L)9*]KV'TSL0BE[BKULW!N*,$NV
MM>RFV;GW&NFU=8[0<A==[*A[M<HVF]?I8BK-R$])4J8K9-JBZ@,V5&5@B/9(
ML[Z9:O\ %;JFM]E !7WIO1FY#M5V^LCD9LGK/V#5,RI-H[*;-GRK?"^QV.KR
M,4.Z/R#EIUZE0AKR:7*PB7YVP/87,FD4N,5;Q9_R[P\/?_JZR=BO_%9P^_N_
M:B^?5;Q9_P!.'A[?_+)V*_\ %9PBB?WCZ\>)UNWJON.FW/9_3.VQ -3.O+%3
MUAUS[!1]_M,QKUO-TA:O5""^Q]G%S-623A!X,%I^NS277Y!"41Q+WM)Y8Y*A
M'DJDE24S 3<"8PVY"0$QB^S]B;=MG%_5O1Q)F)L1GL+4U#B;F'O/,-:[&(&<
M!L$T91R!-%)&3L0N4<L8'Q,2 MN)B[.ZA)I'P/MUA:RJA=@*Z<S\M8(F.LY6
M-L:P[??7>OJGHT,_ZI3":;VVH$(E^MY=S%NX;J\<3DE@A9*/=7E*,I0M34JP
M0'6P5PA?=Y[.E=+G(_;;CN6()^+,S;,1&3ON3D[N[J:XG67B%B<?6Q[>)GB-
M=:M&T;6+FM-0=8A;ZHL->_!!''&/&.*.*(&",1%W,N4A?OL_P"]W["#BA8#8
M_3K4CT<24^2=KK5G:IXB99(&]I 4HS?^V-Y!^'&?2T6PX ("9AQ"VU%*8>6W
MSO9N2V!%@KX>F8%N,M'3.EH)-G;B0D[X0Q(7%W[<=V+NQ;<F+C*ZP\0<K6\L
M7B;XE4?I!D>>AK?/!,7#?Z,FM6[<!Q$^SDQ0.3.+%&<9>TMFUSP3MM05>@X(
MP+PZ[._#Q0$:_8K%I/N$_.SKX0K0[TQ,.1_<^.CERDBXVHLY0$> '\0\Y\*&
M,QZ&49"'/7J[#T8<,)"+ Q_<YISJD+,S>W(V)9R)]MR?9N3]]F7=]7:Q*((9
M-9ZQF &%FZ^JL]*Y.#;,9\LAL1OW<BV[N[O[U#OM1X&/9'ZWZAOE1L76P*-D
M=E:IUE8]9Z5T?V!53T0E@NCF)S9%U3:-^7RTB0L-&F99N)L+8ZXUBO"#J9/A
MSF$RN+UM593E!(4@!-6,CC\I2PU6M-N/L!>KCB3\Q%$3,48PR53]HPE.4'$0
MYCU3FVK6J]F_=R+V>3A9R.5S=BQ4,XSBDDKNV4CA,C$V)ANPVXX9@CLU@AL@
MTRL(QX3.]\8:PF&\-''L>K#/_(+W$Q[.%YQZL-XQW6_8_7Y8RKT>G"LXQYX^
M6.70:^U:&_#+</\ ,HXT=^VW?:FWY/R*,S1#9=WL'/.[ON[S6;$N[_'VY24,
M(K_@Y^[HWLO)]C']U=39@"1D)653H>6TEO%[3()\O$KC'G!6A^P8VR'&1WW7
MI8,,W8I8S4@XE+C;T>PR BY?Q$U0X?\ IWT[@$;S>4QNVPNVYB'D>33$S.Q$
M4A![<A#&)D)!0\C6VX\'X,[DP]27;D[,SOMU-M]F9M]MW9FW?MWF#_B@]N?+
M*J+X5KN<>6/4_P!8^U!"U8Q^1:G^XSBG/E\L^YE>,X^6<9Q\N4/\(&L=]_GN
M=N^[<:],=OR<:S;;>YQV=ERU"HS;= ?SN3_M<MU$/4G@T;ZZK;ZBZO6*GTKW
M1$=A@]D3<Q<]L]>.QNS-=Z##H*:Y)0U,B@9'L9\#"M7LFSF#P9<O(/V$Q%8(
M%S*2;([K3=Q;\2-860C&/,6Z7$N<A4K-N%YI.[<RY6)!B;N3]*N,,+D^_3]D
M.'#8^DWK7B/X<XP+9O<V[CW_ "ON_P"/NI-[C\&3;.Z-<737,O3O"CI[=S@S
MH;-TUWTVW54M@5A\M.,LSM2LXO9EY^(FP"$MD#/Y9)%?RC(T@&: ^2(]@[6J
M=37F=KFH<U99_49LG<,/?M[#R\=N[]N.S;[>BJA5K1_4KP _Q&(!?]+"RTQU
M4_X/UL7JSK-S7/M>&IV ,+L$C89#8?8SJ)MG8E]*>/;%':C&9!GL+"QD9"1H
MH;#049&10C675$FE*(-+(?7@7<B=R)]R?N[N[N[O\7)^[[_;=5UVW93P";GV
M7UUG7DI6O#"U%EJ9!G ;OH/J1NC6-] +!;)8^&3-@]D#A3HDT<M]D^(EXV1
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M.  AGS7<*:97C-C>O1T CEF%^@\@C/-R$1K1D3 TTG)VW!I"!B8=R87(V9V
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M]@1,=I?::2:N;812S84>0R551VLKD10#'F/AG'T^AA?K4C/EC/!7*@")'9@
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M.G<)''D1X7P#%40"X')CX61&!AF#F+'Q-B'FS'MR[KNXG5VMH$.NQ\)0J?$
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M>\;UOOPFQG]A:DHV].W6OMC[47.Z^B M[:?U_==GZYTS>#*K7M=-QUDEK/\
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M<.^).BM73=4C&]FXBB!]/T+K@.V+U7K9-V-=8G.TX9RM<1EAL$C/BB/I'==
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8B<(G")PB<(G")PB<(G")PB<(G")PB__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
